"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,GB,A,GB 2441564 A,062-669-522-173-800,2008-03-12,2008,GB 0617698 A,2006-09-11,GB 0617698 A,2006-09-11,APPARATUS FOR TEACHING SYNTHETIC PHONICS,"Apparatus for reaching Synthetic Phonics comprising a plurality of modules 1, each having a visible indicia provided thereon. The apparatus further comprises means for recognizing the relative positions of modules placed adjacent to one another 7, means for associating a sound with each module according to the relative positions of the module, the sound relating to the indicia on the module; and sound generation means 6 for generating the sound associated with each module. The sound may be selected from one of a set of predetermined sounds, each predetermined sound being a phoneme.",TTS GROUP LTD,DAVIES GARETH,,https://lens.org/062-669-522-173-800,Patent Application,no,4,0,2,2,0,G09B5/04;;G09B17/006;;G09B1/40;;G09B1/04;;G09B1/34;;G09B5/04;;G09B17/006,G09B5/04;;G09B17/00,G5G G10           G10;;G5G G5P           G10,0,0,,,,DISCONTINUED
2,US,A1,US 2008/0208184 A1,164-487-874-909-253,2008-08-28,2008,US 531607 A,2007-12-27,US 531607 A;;US 88307407 P,2007-01-02,Cardiac electrosurgery,"A method of accessing a pericardial cavity of a heart is disclosed, comprising delivering electrical energy to a pericardium in a manner which creates a channel substantially through a parietal pericardium and does not substantially affect myocardial tissue.",DAVIES GARETH,DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2011-07-26);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/164-487-874-909-253,Patent Application,yes,14,35,2,11,0,A61B18/1492;;A61B2018/00083;;A61B2018/00702;;A61B2018/00875;;A61B18/1492;;A61B2018/00702;;A61B2018/00875;;A61B2018/00083,A61B18/14,606/34,0,0,,,,ACTIVE
3,WO,A1,WO 1998/045557 A1,010-983-621-880-26X,1998-10-15,1998,GB 9800703 W,1998-03-09,GB 9707281 A,1997-04-10,JOINTS FOR MODULAR SUPPORT STRUCTURES,"A joint for a modular support structure, comprising a plurality of connector arms at least one of which is provided with a plurality of differently sized mating surfaces (4a, 4b, 4c) to enable the joint to mate with one of a number of different supports.",SECR DEFENCE;;DAVIES GARETH,DAVIES GARETH,,https://lens.org/010-983-621-880-26X,Patent Application,yes,5,3,6,10,0,E04B1/585;;E04B2001/5856;;E04H15/34,E04B1/58;;E04H15/34,,0,0,,,,PENDING
4,GB,A,GB 2585910 A,039-058-316-310-409,2021-01-27,2021,GB 201910514 A,2019-07-23,GB 201910514 A,2019-07-23,An apparatus for securing a bicycle,"An apparatus for securing a bicycle apparatus comprises a structure 110 configured to be mounted to a secure surface. The structure 110 comprises an internal cavity 115, a door 117 moveable relative to the structure 110 between an open position in which the pedal can be received into the internal cavity 115 of the structure and a closed position in which the pedal is retained in the internal cavity, and a locking device 120 configured to lock the door 117 in the closed position.",BISON SECURITY PRODUCTS WALES LTD,GARETH DAVIES,,https://lens.org/039-058-316-310-409,Patent Application,no,4,0,4,4,0,B62H3/00;;B62H5/10;;B62H5/10;;B62H3/00;;E05B71/00,B62H3/00,,0,0,,,,DISCONTINUED
5,GB,A,GB 2294405 A,136-794-135-908-382,1996-05-01,1996,GB 9421533 A,1994-10-26,GB 9421533 A,1994-10-26,Sports or athletics frame,"A sports or athletics frame e.g. a goal for football or mini-rugby comprises a base member (1) which has a tubular extension (17) which can either extend downwardly into the ground or can be inverted so as to extend upwardly (e.g. when the frame is set up indoors). In either case an upright tube (12) is supported by an internal clamp (2) which engages the bore of the extension and is optionally connected to the clamp by a close coil spring (4) which provides some flexibility in the event of a collision by a player. The arrangement includes small diameter tubes (11, 11a) telescoped within larger diameter tubes (12, 12a) and located by rubber rings (6) and tubular T brackets 20 (Fig. 1B) or alternatively flexible connections (Fig 1A) e.g. comprising rubber bands (8) between the uprights and cross-pieces. <IMAGE>",DAVIES GARETH,DAVIES GARETH,,https://lens.org/136-794-135-908-382,Patent Application,no,8,5,2,2,0,A63B63/004;;A63B71/028,A63B63/00;;A63B71/02,A6D D108B         D108B;;A6D D11E          D11E;;A6D D11F          D11F;;A6D D120B         D120B,0,0,,,,DISCONTINUED
6,AU,A,AU 1998/064080 A,196-569-168-400-927,1998-10-30,1998,AU 1998/064080 A,1998-03-09,GB 9707281 A;;GB 9800703 W,1997-04-10,Joints for modular support structures,,SECR DEFENCE,DAVIES GARETH,,https://lens.org/196-569-168-400-927,Patent Application,no,0,0,6,10,0,E04B1/585;;E04B2001/5856;;E04H15/34,E04B1/58;;E04H15/34,,0,0,,,,PENDING
7,GB,A,GB 2483234 A,078-300-308-651-331,2012-03-07,2012,GB 201014410 A,2010-08-31,GB 201014410 A,2010-08-31,An apparatus for securing a vehicle,"An apparatus 2 for securing a vehicle is provided and in particular, a vehicle lock suitable for temporarily preventing movement of a vehicle such as an all terrain vehicle (ATV). The apparatus comprises: a frame 4; a pair of opposing side elements 6 defining a span therebetween; a forward frame element 10; and a ramp arrangement 8. The ramp arrangement 8 comprises 2 rotatably mounted ramp elements 16 which are secured to a member 18 extending from the side element 6. A lock 20 is provided for securing the member 18 to the ramp member 16. An actuation arrangement is also provided for moving at least one of the side elements 6 towards the opposing side element for reducing the span therebetween and securing the vehicle therebetween.",DAVIES GARETH,DAVIES GARETH,,https://lens.org/078-300-308-651-331,Patent Application,no,3,0,3,3,0,B60R25/00;;B60R25/00,B60R25/00,,0,0,,,,ACTIVE
8,GB,B,GB 2483234 B,175-591-696-087-769,2017-04-05,2017,GB 201014410 A,2010-08-31,GB 201014410 A,2010-08-31,Vehicle lock,,GARETH DAVIES,GARETH DAVIES,,https://lens.org/175-591-696-087-769,Granted Patent,no,5,0,3,3,0,B60R25/00;;B60R25/00,B60R25/00,,0,0,,,,ACTIVE
9,GB,B,GB 2343608 B,131-250-062-859-200,2003-05-14,2003,GB 9819536 A,1998-09-09,GB 9819536 A,1998-09-09,Animal restraining device,,DAVIES GARETH,DAVIES GARETH,,https://lens.org/131-250-062-859-200,Granted Patent,no,4,1,3,3,0,A01K15/00;;A61D3/00,A01K15/00;;A61D3/00,A1M MAS           MAS,0,0,,,,EXPIRED
10,US,A1,US 2020/0352647 A1,052-750-143-246-833,2020-11-12,2020,US 202016939264 A,2020-07-27,US 202016939264 A;;US 201816124684 A;;US 201514933356 A;;US 201414257053 A;;US 201213656173 A;;US 531607 A,2007-12-27,Electrosurgical Pericardial Puncture,"Devices and methods for providing access to the pericardial cavity while reducing risk of myocardial damage. One method comprises the steps of: (a) advancing a puncture device towards a heart, the puncture device including an energy delivery device at a distal end of the puncture device; (b) delivering a single pulse of a pulsed energy through the energy delivery device to a parietal pericardium of the heart to create a void relatively close to the energy delivery device while maintaining the distal end of the puncture device in a substantially stationary position relative to the parietal pericardium; (c) advancing the puncture device a short distance into the void; (d) checking if the puncture device has accessed the pericardial cavity by measuring pressure on the distal end of the puncture device; and (e) repeating steps (b), (c), and (d), if necessary, until the energy delivery device is located at least partially within the pericardial cavity. The methods may include a step of confirming that the puncture device is at least partially within the parietal cavity by injecting or aspirating fluid through a lumen in the puncture device or measuring the pressure or electrical impedance at the distal end of the puncture device.",BAYLIS MEDICAL CO INC,DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2019-02-26);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/052-750-143-246-833,Patent Application,yes,18,1,1,11,0,A61B8/12;;A61B6/12;;A61B8/0841;;A61B8/4455;;A61B8/445;;A61B8/0883;;A61B8/4494;;A61B8/481;;A61B2017/00247;;A61B18/1815;;A61B17/3478;;A61B17/2202;;A61B2018/00577;;A61B2018/00708;;A61B2018/00839;;A61B2090/3966;;A61B2017/00026;;A61B2090/376;;A61B2017/00084;;A61B2017/00154;;A61B2090/378;;A61B2090/3925;;A61B18/1492;;A61B2018/00791;;A61B2018/00875;;A61B2018/00982;;A61B2018/00994;;A61B2018/167;;A61B2562/0247;;A61B2018/00363;;A61B2018/00601;;A61B2018/00196;;A61B2018/1475;;A61B18/1492;;A61B2090/064;;A61B8/12;;A61B8/0883;;A61B8/445;;A61B8/4494;;A61B8/481;;A61B17/3478;;A61B90/37;;A61B2017/00154;;A61B2090/378;;A61B17/2202;;A61B2017/00026;;A61B2017/00243;;A61B2017/00247;;A61B2017/00353;;A61B2017/22014;;A61B2018/00083;;A61B2018/00291;;A61B2018/00363;;A61B2018/00601;;A61B2018/00702;;A61B2018/00839;;A61B2018/00875;;A61B2018/1861;;A61B8/0841,A61B18/14;;A61B8/00;;A61B8/08;;A61B8/12;;A61B17/34;;A61B90/00,,0,0,,,,PENDING
11,US,B2,US 8308720 B2,080-387-518-073-716,2012-11-13,2012,US 531607 A,2007-12-27,US 531607 A;;US 88307407 P,2007-01-02,Cardiac electrosurgery,"A method of accessing a pericardial cavity of a heart is disclosed, comprising delivering electrical energy to a pericardium in a manner which creates a channel substantially through a parietal pericardium and does not substantially affect myocardial tissue.",DAVIES GARETH;;BAYLIS MEDICAL CO INC,DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2011-07-26);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/080-387-518-073-716,Granted Patent,yes,14,8,2,11,0,A61B18/1492;;A61B2018/00083;;A61B2018/00702;;A61B2018/00875;;A61B18/1492;;A61B2018/00702;;A61B2018/00875;;A61B2018/00083,A61B18/18,606/34;;606/41;;606/45,2,2,036-718-453-837-479;;121-269-922-471-239,10.1016/s0735-1097(00)00606-9;;10807445;;10.1016/j.hrthm.2004.03.073;;15851176,"Eduardo Sosa, Mauricio Scanavacca, Andre D'Avila, Flavio Oliveira, Jose Antonio F. Ramires, ""Nonsurgical transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia occurring late after myocardial infarction"", ""Journal of the American College of Cardiology "", May 2000, pp. 1442-1449, vol. 35, No. 6, Publisher: Elsevier Science Inc. , Published in: US.;;Miguel Valderrabano, David A. Cesario, Sen Ji, Kevin Shannon, Isaac Wiener, Charles D. Swerdlow, Hakan Oral, et al. , ""Percutaneous epicardial mapping during ablation of difficult accessory pathways as an alternative to cardiac surgery"", Sep. 2004, pp. 311-316, vol. 1, No. 3, Publisher: Heart Rhythm Society , Published in: US.",ACTIVE
12,US,A1,US 2019/0008588 A1,116-052-884-939-559,2019-01-10,2019,US 201816124684 A,2018-09-07,US 201816124684 A;;US 201514933356 A;;US 201414257053 A;;US 201213656173 A;;US 531607 A;;US 88307407 P,2007-01-02,Electrosurgical Pericaridial Puncture,"Devices and methods for providing access to the pericardial cavity while reducing risk of myocardial damage. One method includes using an apparatus to apply pressure to a parietal pericardium, retracting the apparatus, and puncturing the parietal pericardium by delivering electrical energy using a puncture device. Another method includes moving a portion of parietal pericardium away from a surface of myocardium of the heart and puncturing the parietal pericardium by delivering electrical energy using a puncture device. The methods may include a step of confirming that the puncture device is at least partially within the parietal cavity by injecting or aspirating fluid through a lumen in the puncture device or measuring the pressure or electrical impedance at the distal end of the puncture device.",BAYLIS MEDICAL CO INC,DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2019-02-26);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/116-052-884-939-559,Patent Application,yes,0,5,4,11,0,A61B17/2202;;A61B17/3478;;A61B2017/00026;;A61B2017/00243;;A61B2017/00247;;A61B2017/00353;;A61B2017/22014;;A61B2018/00083;;A61B2018/00291;;A61B2018/00363;;A61B2018/00601;;A61B2018/00702;;A61B2018/00839;;A61B2018/00875;;A61B2018/1861;;A61B2090/064;;A61B90/37;;A61B2090/378;;A61B18/1492;;A61B2017/00154;;A61B18/1492;;A61B8/0841;;A61B8/12;;A61B8/0883;;A61B8/445;;A61B8/4494;;A61B8/481;;A61B2017/00154;;A61B2090/378;;A61B17/2202;;A61B17/3478;;A61B2017/00026;;A61B2017/00243;;A61B2017/00247;;A61B2017/00353;;A61B2017/22014;;A61B2018/00083;;A61B2018/00291;;A61B2018/00363;;A61B2018/00601;;A61B2018/00702;;A61B2018/00839;;A61B2018/00875;;A61B2018/1861;;A61B2090/064;;A61B90/37,A61B18/14;;A61B8/00;;A61B8/08;;A61B8/12;;A61B17/00;;A61B17/22;;A61B17/32;;A61B17/34;;A61B18/00;;A61B18/18;;A61B90/00,,0,0,,,,ACTIVE
13,CA,A1,CA 3146937 A1,127-781-887-678-250,2021-02-18,2021,CA 3146937 A,2020-08-14,US 201962886534 P;;IB 2020057685 W,2019-08-14,MEDICAL SHEATH AND SYSTEMS AND METHODS FOR USING MEDICAL SHEATH,"A medical sheath includes an elongate member having a sidewall extending longitudinally between a proximal end portion of the elongate member and an opposed distal end portion of the elongate member, and radially between an outer surface of the elongate member and an inner surface of the elongate member. A lumen is defined by the inner surface and extends through the elongate member from the proximal end portion to the distal end portion. At least a first echogenic band is associated with the distal end portion and is secured to the sidewall.",BAYLIS MEDICAL CO INC,DAVIES GARETH,,https://lens.org/127-781-887-678-250,Patent Application,no,0,0,3,3,0,A61B8/12;;A61B8/08;;A61B8/4245;;A61M25/0108;;A61B17/12136;;A61B17/12109;;A61B34/20;;A61B2034/2063;;A61B18/1492;;A61B2018/00351;;A61B2018/00601;;A61B2018/0038;;A61B2017/00336;;A61M25/0662;;A61B2090/3784;;A61B2090/3983;;A61B34/20;;A61B2034/2063;;A61B8/445;;A61B18/1492;;A61B2017/00247;;A61B2018/0038;;A61M25/0108;;A61M25/104,A61B8/12;;A61B8/00;;A61B8/08,,0,0,,,,PENDING
14,EP,A1,EP 3770050 A1,072-956-329-607-587,2021-01-27,2021,EP 20187117 A,2020-07-22,GB 201910514 A,2019-07-23,APPARATUS FOR SECURING A BICYCLE,"An apparatus for securing a bicycle, the apparatus comprising a structure (110) configured to be mounted to a secure surface, wherein the structure (110) comprises an internal cavity (115), a door (117) moveable relative to the structure (110) between an open position in which the pedal can be received into the internal cavity (115) of the structure and a closed position in which the pedal is retained in the internal cavity, and a locking device (120) configured to lock the door (117) in the closed position. This provides a simple, convenient and secure apparatus which reduces the risk of bicycle thefts, particularly from within a building.
",BISON SECURITY PRODUCTS WALES LTD,DAVIES GARETH,,https://lens.org/072-956-329-607-587,Patent Application,yes,5,0,4,4,0,B62H3/00;;B62H5/10;;B62H5/10;;B62H3/00;;E05B71/00,B62H5/10;;B62H3/00,,0,0,,,,DISCONTINUED
15,US,A1,US 2013/0046305 A1,132-549-045-310-876,2013-02-21,2013,US 201213656173 A,2012-10-19,US 201213656173 A;;US 531607 A;;US 88307407 P,2007-01-02,Cardiac Electrosurgery,Devices and methods are disclosed for providing access to the pericardial cavity while reducing risk of myocardial damage. The methods include maintaining the positions of a puncture device and of a portion of a parietal pericardium relative to one other while delivering energy from the puncture device to create a channel through the pericardium. Additional embodiments disclosed include delivering a pulse or pulses of energy to the parietal pericardium and attempting to advance the puncture device through the parietal pericardium between deliveries of energy pulses.,BAYLIS MEDICAL COMPANY;;BAYLIS MEDICAL COMPANY,DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2012-09-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/132-549-045-310-876,Patent Application,yes,10,18,2,11,0,A61B18/1492;;A61B2018/00083;;A61B2018/00702;;A61B2018/00875;;A61B2018/00363;;A61B2018/00351;;A61B2017/00353;;A61B2017/00154;;A61B2018/00589;;A61B2018/00601;;A61B17/3478;;A61B2017/00243;;A61B2017/22014;;A61B2018/00291;;A61B2018/00839;;A61B18/1492;;A61B2018/00702;;A61B2018/00875;;A61B2018/00083;;A61B2018/00363;;A61B2017/00353;;A61B2018/00601;;A61B2018/00589;;A61B17/3478;;A61B2018/00351;;A61B2018/00839;;A61B2017/00243;;A61B2017/00154;;A61B2018/00291;;A61B2017/22014,A61B18/14,606/45,0,0,,,,ACTIVE
16,EP,A1,EP 3409569 A1,058-839-791-264-086,2018-12-05,2018,EP 18151185 A,2018-01-11,GB 201700550 A,2017-01-12,BIKE LOCK,"An apparatus (10) for securing a bike, the apparatus (10) comprising a base (1) configured to be attached to a secure surface, a first structure (2) attached to the base (1), wherein the first structure (2) is arranged to receive at least a portion of a wheel (20) of the bike, and a second structure (4), wherein the second structure (4) is moveable relative to the first structure (2) between an open position in which a bike wheel (20) can be received in the first structure (2) and a closed position in which the second structure (4) retains the bike wheel within the first structure (2). A locking arrangement is also provided to lock the second structure (4) in the closed position.
",DAVIES GARETH,DAVIES GARETH,BISON SECURITY PRODUCTS (WALES) LIMITED (2020-03-04),https://lens.org/058-839-791-264-086,Patent Application,yes,8,0,5,5,0,B62H3/04;;B62H3/04;;B62H5/14,B62H3/04,,1,0,,,"ANONYMOUS: ""Motorcycle Front Wheel Tire Shoe Stand With Self Locking Clamp"", 25 October 2018 (2018-10-25), XP055519177, Retrieved from the Internet <URL:https://www.wmastore.com/DIRT-BIKE-MOTORCYCLE-MX-TRAILER-WHEEL-CHOCK-TIRE-BIKE-STAND-AMDBIKEC.htm> [retrieved on 20181025]",ACTIVE
17,BR,B1,BR 112014031843 B1,123-668-400-246-641,2022-01-18,2022,BR 112014031843 A,2013-06-18,IB 2013055013 W;;US 201261661664 P,2012-06-19,Sistema de controle para o controle bidirecional de um cateter orientável,"sistema e dispositivo de controle de um cateter orientável, dispositivo de cateter orientável e método de utilização do dito sistema de controle. são providos um sistema e método de controle (40,42) para controlar um cateter (90) orientável, o cateter (90) incluindo pelo menos dois fios de controle, uma extremidade distal de cada um dos fios de controle (40,42) sendo acoplada ao cateter (90) em uma região distal deste, o sistema de controle (100) compreendendo: um alojamento (20) acoplado ao cateter; uma montagem deslizante (30) posicionada no interior do alojamento (20) e operável para se deslocar linearmente em seu interior; uma parte proximal de cada um dos pelo menos dois fios de controle (40,42) sendo posicionada através da montagem deslizante (30); e um botão (10) de controle acoplado de forma rotativa ao alojamento (20) para deslocar linearmente a montagem deslizante, possibilitando assim que a montagem deslizante (30) manipule separadamente cada um dos ditos pelo menos dois fios de controle (40,42) para efetuar uma alteração em uma deflexão do dito cateter. a rotação do botão (10) de controle em uma primeira direção de rotação provoca o deslocamento distal da montagem deslizante (30) em uma primeira direção linear fazendo com que a montagem deslizante (30) aplique uma tensão em um dos ditos pelo menos dois fios de controle (40,42) efetuando assim uma alteração na deflexão do dito cateter (90) em uma primeira direção de deflexão e onde a rotação do botão (10) em uma segunda direção de rotação provoca o deslocamento proximal da montagem deslizante (30) em uma segunda direção linear fazendo com que a montagem deslizante (30) aplique uma tensão no outro dos ditos pelo menos dois fios de controle (40,42) efetuando assim uma alteração na deflexão do dito cateter (90) em uma segunda direção de deflexão.",BAYLIS MEDICAL CO INC,GARETH DAVIES,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (IE) (2023-06-06),https://lens.org/123-668-400-246-641,Granted Patent,no,0,0,16,16,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/01,,0,0,,,,ACTIVE
18,US,B2,US 11298184 B2,156-509-675-534-625,2022-04-12,2022,US 201816124684 A,2018-09-07,US 201816124684 A;;US 201514933356 A;;US 201414257053 A;;US 201213656173 A;;US 531607 A;;US 88307407 P,2007-01-02,Electrosurgical pericardial puncture,"Devices and methods for providing access to the pericardial cavity while reducing risk of myocardial damage. One method includes using an apparatus to apply pressure to a parietal pericardium, retracting the apparatus, and puncturing the parietal pericardium by delivering electrical energy using a puncture device. Another method includes moving a portion of parietal pericardium away from a surface of myocardium of the heart and puncturing the parietal pericardium by delivering electrical energy using a puncture device. The methods may include a step of confirming that the puncture device is at least partially within the parietal cavity by injecting or aspirating fluid through a lumen in the puncture device or measuring the pressure or electrical impedance at the distal end of the puncture device.",BAYLIS MEDICAL CO INC,DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2019-02-26);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/156-509-675-534-625,Granted Patent,yes,17,0,4,11,0,A61B17/2202;;A61B17/3478;;A61B2017/00026;;A61B2017/00243;;A61B2017/00247;;A61B2017/00353;;A61B2017/22014;;A61B2018/00083;;A61B2018/00291;;A61B2018/00363;;A61B2018/00601;;A61B2018/00702;;A61B2018/00839;;A61B2018/00875;;A61B2018/1861;;A61B2090/064;;A61B90/37;;A61B2090/378;;A61B18/1492;;A61B2017/00154;;A61B18/1492;;A61B8/0841;;A61B8/12;;A61B8/0883;;A61B8/445;;A61B8/4494;;A61B8/481;;A61B2017/00154;;A61B2090/378;;A61B17/2202;;A61B17/3478;;A61B2017/00026;;A61B2017/00243;;A61B2017/00247;;A61B2017/00353;;A61B2017/22014;;A61B2018/00083;;A61B2018/00291;;A61B2018/00363;;A61B2018/00601;;A61B2018/00702;;A61B2018/00839;;A61B2018/00875;;A61B2018/1861;;A61B2090/064;;A61B90/37,A61B18/18;;A61B8/00;;A61B8/08;;A61B8/12;;A61B17/00;;A61B17/22;;A61B17/34;;A61B18/00;;A61B18/14;;A61B90/00,,0,0,,,,ACTIVE
19,EP,A1,EP 0972123 A1,164-491-843-730-05X,2000-01-19,2000,EP 98909588 A,1998-03-09,GB 9800703 W;;GB 9707281 A,1997-04-10,JOINTS FOR MODULAR SUPPORT STRUCTURES,,SECR DEFENCE,DAVIES GARETH,,https://lens.org/164-491-843-730-05X,Patent Application,yes,0,2,6,10,0,E04B1/585;;E04B2001/5856;;E04H15/34,E04B1/58;;E04H15/34,,0,0,,,,DISCONTINUED
20,GB,A8,GB 2336862 A8,004-664-431-500-849,1999-11-15,1999,GB 9921059 A,1998-03-09,GB 9921059 A;;GB 9800703 W;;GB 9707281 A,1997-04-10,Joints for modular support structures,,SECR DEFENCE,DAVIES GARETH,,https://lens.org/004-664-431-500-849,Patent Application,no,0,0,4,10,0,E04B1/585;;E04B2001/5856;;E04H15/34,E04B1/58;;E04H15/34,E1D DLFF          LFF;;E1D DTN           TN;;E1D D172          LFF;;E1D D194          LFF;;E1S SX            SX,0,0,,,,EXPIRED
21,GB,A,GB 2558631 A,154-234-065-559-013,2018-07-18,2018,GB 201700550 A,2017-01-12,GB 201700550 A,2017-01-12,Bike lock,"An apparatus for securing a bike, the apparatus comprising a base 1 configured to be attached to a secure surface, a first structure 2 attached to the base 1, wherein the first structure 2 is arranged to receive at least a portion of a wheel 20 of the bike, and a second structure 4, wherein the second structure 4 is moveable relative to the first structure 2 between an open position in which a bike wheel 20 can be received in the first structure 2 and a closed position in which the second structure 4 retains the bike wheel within the first structure 2. A locking arrangement is also provided to lock the second structure 4 in the closed position.",GARETH DAVIES,GARETH DAVIES,,https://lens.org/154-234-065-559-013,Patent Application,no,5,1,5,5,0,B62H3/04;;B62H3/04;;B62H5/14,B62H3/04,,0,0,,,,INACTIVE
22,US,A1,US 2022/0273374 A1,000-077-434-195-016,2022-09-01,2022,US 202017632610 A,2020-08-14,US 202017632610 A;;US 201962886534 P;;IB 2020057685 W,2019-08-14,MEDICAL SHEATH AND SYSTEMS AND METHODS FOR USING MEDICAL SHEATH,"A medical sheath includes an elongate member having a sidewall extending longitudinally between a proximal end portion of the elongate member and an opposed distal end portion of the elongate member, and radially between an outer surface of the elongate member and an inner surface of the elongate member. A lumen is defined by the inner surface and extends through the elongate member from the proximal end portion to the distal end portion. At least a first echogenic band is associated with the distal end portion and is secured to the sidewall.",BAYLIS MEDICAL CO INC,DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2021-09-05);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/000-077-434-195-016,Patent Application,yes,6,0,3,3,0,A61B8/12;;A61B8/08;;A61B8/4245;;A61M25/0108;;A61B17/12136;;A61B17/12109;;A61B34/20;;A61B2034/2063;;A61B18/1492;;A61B2018/00351;;A61B2018/00601;;A61B2018/0038;;A61B2017/00336;;A61M25/0662;;A61B2090/3784;;A61B2090/3983;;A61B34/20;;A61B2034/2063;;A61B8/445;;A61B18/1492;;A61B2017/00247;;A61B2018/0038;;A61M25/0108;;A61M25/104,A61B8/00;;A61B34/20;;A61B18/14,,0,0,,,,PENDING
23,US,A1,US 2022/0151687 A1,069-892-986-437-399,2022-05-19,2022,US 202117527490 A,2021-11-16,US 202117527490 A;;US 202063115927 P,2020-11-19,SYSTEM OF MEDICAL DEVICES AND METHOD FOR PERICARDIAL PUNCTURE,"A medical device includes an elongate shaft extending between a proximal portion and a distal portion defining a distal end. The shaft includes a puncture device having a puncturing tip at the distal end, a distally facing camera in the distal portion, and a lighting system comprising distally facing light emitter in the distal portion.",BAYLIS MEDICAL CO INC,DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2021-10-01);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/069-892-986-437-399,Patent Application,yes,0,0,1,1,0,A61B18/1477;;A61B90/30;;A61B2018/00351;;A61B2018/00982;;A61B2018/00363;;A61B18/1482;;A61B2018/1425;;A61B2018/1412;;A61B2090/306;;A61B90/37;;A61B2090/373;;A61B1/07;;A61B1/3137;;A61B1/3132;;A61B1/05;;A61B18/1477;;A61B18/1206;;A61B2018/00351;;A61B2018/00982;;A61B90/30,A61B18/14;;A61B18/12;;A61B90/30,,0,0,,,,PENDING
24,GB,A,GB 2343608 A,090-345-023-487-826,2000-05-17,2000,GB 9819536 A,1998-09-09,GB 9819536 A,1998-09-09,Animal restraining device,"The device comprises a cradle 14 having an elongate, generally upright channel-section back portion 16 for receiving the body of the animal to be restrained and an elongate front portion 17 which can be retained in a raised position in which it extends axially in front of the channel-section back portion 16, to retain the animal therein, the front portion being pivotable downwardly from the raised position to a generally horizontal loading and unloading position. The device may comprise a plurality of cradles and a rotatable stand 12,13.",DAVIES GARETH,DAVIES GARETH,,https://lens.org/090-345-023-487-826,Patent Application,no,4,0,3,3,0,A01K15/00;;A61D3/00,A01K15/00;;A61D3/00,A1M MAS           MAS,0,0,,,,EXPIRED
25,GB,A,GB 2336862 A,108-217-231-692-918,1999-11-03,1999,GB 9921059 A,1998-03-09,GB 9921059 A;;GB 9800703 W;;GB 9707281 A,1997-04-10,Joints for a modular support structures,"A joint for a modular support structure, comprising a plurality of connector arms at least one of which is provided with a plurality of differently sized mating surfaces (4a, 4b, 4c) to enable the joint to mate with one of a number of different supports.",SECR DEFENCE,DAVIES GARETH,,https://lens.org/108-217-231-692-918,Patent Application,no,5,2,4,10,0,E04B1/585;;E04B2001/5856;;E04H15/34,E04B1/58;;E04H15/34,E1D DLFF          LFF;;E1D DTN           TN;;E1D D172          LFF;;E1D D194          LFF;;E1S SX            SX,0,0,,,,EXPIRED
26,EP,A1,EP 0579929 A1,100-381-239-270-799,1994-01-26,1994,EP 93108475 A,1993-05-26,GB 9215322 A,1992-07-18,Improvements relating to supporting brackets.,"A supporting bracket for cable trays, cable ladders etc., wherein the bracket has a U-shaped cradle for receiving the tray. At least one of the cradle arms is bendable and provided with hook means for retaining the side of the cable tray. The bracket may be fixed to a wall or the like, and may co-operate with means, such as screws or clips, for retaining the tray more permanently in position. The bracket is best used in vertical disposition, but may also be mounted horizontally or otherwise.",SWIFTS OF SCARBOROUGH LTD,DAVIES GARETH,,https://lens.org/100-381-239-270-799,Patent Application,yes,2,13,2,2,0,H02G3/263,H02G3/30,,0,0,,,,DISCONTINUED
27,CA,A1,CA 2284980 A1,019-274-534-298-613,1998-10-15,1998,CA 2284980 A,1998-03-09,GB 9707281 A;;GB 9800703 W,1997-04-10,JOINTS FOR MODULAR SUPPORT STRUCTURES,"A joint for a modular support structure, comprising a plurality of connector arms at least one of which is provided with a plurality of differently sized mating surfaces (4a, 4b, 4c) to enable the joint to mate with one of a number of different supports.",SECR DEFENCE,DAVIES GARETH,,https://lens.org/019-274-534-298-613,Patent Application,no,0,0,6,10,0,E04B1/585;;E04B2001/5856;;E04H15/34,E04B1/58;;E04H15/34,,0,0,,,,DISCONTINUED
28,GB,B,GB 2336862 B,024-164-055-236-662,2001-08-29,2001,GB 9921059 A,1998-03-09,GB 9921059 A;;GB 9800703 W;;GB 9707281 A,1997-04-10,Modular support structures incorporating joints,,SECR DEFENCE,DAVIES GARETH,,https://lens.org/024-164-055-236-662,Granted Patent,no,7,0,4,10,0,E04B1/585;;E04B2001/5856;;E04H15/34,E04B1/58;;E04H15/34,E1D DLFF          LFF;;E1D DTN           TN;;E1D D172          LFF;;E1D D194          LFF;;E1S SX            SX,0,0,,,,EXPIRED
29,EP,B1,EP 3409569 B1,061-296-851-881-95X,2020-11-11,2020,EP 18151185 A,2018-01-11,GB 201700550 A,2017-01-12,BIKE LOCK,,BISON SECURITY PRODUCTS WALES LTD,DAVIES GARETH,BISON SECURITY PRODUCTS (WALES) LIMITED (2020-03-04),https://lens.org/061-296-851-881-95X,Granted Patent,yes,8,0,5,5,0,B62H3/04;;B62H5/14;;B62H3/04,B62H3/04;;B62H5/14,,1,0,,,"Anonymous: ""Motorcycle Front Wheel Tire Shoe Stand With Self Locking Clamp"", , 25 October 2018 (2018-10-25), XP055519177, Retrieved from the Internet: URL:https://www.wmastore.com/DIRT-BIKE-MOT ORCYCLE-MX-TRAILER-WHEEL-CHOCK-TIRE-BIKE-S TAND-AMDBIKEC.htm [retrieved on 2018-10-25]",ACTIVE
30,US,B2,US 8702692 B2,133-826-641-746-878,2014-04-22,2014,US 201213656173 A,2012-10-19,US 201213656173 A;;US 531607 A;;US 88307407 P,2007-01-02,Cardiac electrosurgery,Devices and methods are disclosed for providing access to the pericardial cavity while reducing risk of myocardial damage. The methods include maintaining the positions of a puncture device and of a portion of a parietal pericardium relative to one other while delivering energy from the puncture device to create a channel through the pericardium. Additional embodiments disclosed include delivering a pulse or pulses of energy to the parietal pericardium and attempting to advance the puncture device through the parietal pericardium between deliveries of energy pulses.,BAYLIS MEDICAL COMPANY;;BAYLIS MEDICAL CO INC,DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2012-09-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/133-826-641-746-878,Granted Patent,yes,14,0,2,11,0,A61B18/1492;;A61B2018/00083;;A61B2018/00702;;A61B2018/00875;;A61B2018/00363;;A61B2018/00351;;A61B2017/00353;;A61B2017/00154;;A61B2018/00589;;A61B2018/00601;;A61B17/3478;;A61B2017/00243;;A61B2017/22014;;A61B2018/00291;;A61B2018/00839;;A61B18/1492;;A61B2018/00702;;A61B2018/00875;;A61B2018/00083;;A61B2018/00363;;A61B2017/00353;;A61B2018/00601;;A61B2018/00589;;A61B17/3478;;A61B2018/00351;;A61B2018/00839;;A61B2017/00243;;A61B2017/00154;;A61B2018/00291;;A61B2017/22014,A61B18/18,606/34;;606/41;;606/45,2,2,036-718-453-837-479;;121-269-922-471-239,10.1016/s0735-1097(00)00606-9;;10807445;;10.1016/j.hrthm.2004.03.073;;15851176,"Eduardo Sosa, Mauricio Scanavacca, Andre D'Avila, Flavio Oliveira, Jose Antonio F. Ramires, ""Nonsurgical transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia occurring later after myocardial infarction"", ""Journal of the American College of Cardiology"", May 2000, pp. 1442-1449, vol. 35, No. 6, Publisher: Elsevier Science Inc. Published in: US.;;Miguel Valderrabano, David A. Cesario, Sen Ji, Kevin Shannon, Issac Wiener, Charles D. Swerdlow, Hakan Oral, et al, ""Percutaneous epicardial mapping during ablation of difficult accessory pathways as an alternative cardiac surgery"", Sep. 2004, pp. 311-316, vol. 1, No. 3, Publisher: Heart Rhythm Society, Published in: US.",ACTIVE
31,US,A1,US 2021/0053635 A1,139-354-075-219-752,2021-02-25,2021,US 202016936898 A,2020-07-23,GB 201910514 A,2019-07-23,APPARATUS FOR SECURING A BICYCLE,"An apparatus for securing a bicycle includes a structure configured to be mounted to a secure surface, the structure having an internal cavity. A door is moveable relative to the structure between an open position in which a pedal can be received into the internal cavity of the structure and a closed position in which the pedal is retained in the internal cavity, and a locking device is configured to lock the door in the closed position.",BISON SECURITY PRODUCTS WALES LTD,DAVIES GARETH,BISON SECURITY PRODUCTS (WALES) LIMITED (2020-07-31),https://lens.org/139-354-075-219-752,Patent Application,yes,18,1,4,4,0,B62H5/10;;B62H3/00;;B62H3/00;;B62H5/10;;E05B71/00,B62H5/10;;E05B71/00,,0,0,,,,DISCONTINUED
32,GB,B,GB 2558631 B,125-906-693-595-581,2019-06-12,2019,GB 201700550 A,2017-01-12,GB 201700550 A,2017-01-12,Bike lock,,GARETH DAVIES,GARETH DAVIES,,https://lens.org/125-906-693-595-581,Granted Patent,no,12,0,5,5,0,B62H3/04;;B62H3/04;;B62H5/14,B62H3/04,,0,0,,,,INACTIVE
33,WO,A1,WO 2021/028882 A1,159-937-513-781-666,2021-02-18,2021,IB 2020057685 W,2020-08-14,US 201962886534 P,2019-08-14,MEDICAL SHEATH AND SYSTEMS AND METHODS FOR USING MEDICAL SHEATH,"A medical sheath includes an elongate member having a sidewall extending longitudinally between a proximal end portion of the elongate member and an opposed distal end portion of the elongate member, and radially between an outer surface of the elongate member and an inner surface of the elongate member. A lumen is defined by the inner surface and extends through the elongate member from the proximal end portion to the distal end portion. At least a first echogenic band is associated with the distal end portion and is secured to the sidewall.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DAVIES GARETH,,https://lens.org/159-937-513-781-666,Patent Application,yes,5,0,3,3,0,A61B8/12;;A61B8/08;;A61B8/4245;;A61M25/0108;;A61B17/12136;;A61B17/12109;;A61B34/20;;A61B2034/2063;;A61B18/1492;;A61B2018/00351;;A61B2018/00601;;A61B2018/0038;;A61B2017/00336;;A61M25/0662;;A61B2090/3784;;A61B2090/3983;;A61B34/20;;A61B2034/2063;;A61B8/445;;A61B18/1492;;A61B2017/00247;;A61B2018/0038;;A61M25/0108;;A61M25/104,A61B8/12;;A61B8/00;;A61B8/08,,0,0,,,,PENDING
34,GB,B,GB 2404344 B,122-572-311-811-845,2005-06-29,2005,GB 0317689 A,2003-07-29,GB 0317689 A,2003-07-29,Golf practice brace,,DAVIES DAVID GARETH,DAVIES DAVID GARETH,,https://lens.org/122-572-311-811-845,Granted Patent,no,4,0,3,3,0,A63B69/0059;;A63B69/0079;;A63B69/0086,A63B69/00;;A63B69/36,A6D D109T3        D109T3,0,0,,,,EXPIRED
35,GB,A,GB 2371410 A,010-599-808-705-756,2002-07-24,2002,GB 0101511 A,2001-01-20,GB 0101511 A,2001-01-20,Platform with collapsible antenna support structure,"An antenna support system mounted on a platform comprises a pivotally connected antenna support pole and base. The pole is usually upright but may be pivoted into a horizontal position to allow for maintenance of the antenna elements which are located at the end of the pole. The platform is suitable for mounting on a sloping bank and may be supported by ground engaging feet, preferably at the corners of the platform. A counterbalance may be included, which may incorporate springs and/or hydraulic rams. Typically the platform might be located in a road or rail cutting, and may extend longitudinally in a direction parallel to the road or track. The antennae may be suitable for various radio communication systems.",MOTT MACDONALD LTD,DAVIES PETER GARETH,,https://lens.org/010-599-808-705-756,Patent Application,no,8,1,3,3,0,H01Q1/12;;H01Q1/08;;H01Q1/1207,H01Q1/08;;H01Q1/12,H1Q QKC           KC,0,0,,,,EXPIRED
36,AU,A,AU 1992/025103 A,001-272-272-560-139,1993-04-05,1993,AU 1992/025103 A,1992-09-10,GB 9119521 A,1991-09-12,IMPROVEMENTS RELATING TO SHELF BRACKETS,,SWIFTS OF SCARBOROUGH LIMITED,GARETH JOHN DAVIES,,https://lens.org/001-272-272-560-139,Patent Application,no,0,0,4,4,0,A47B57/565;;H02G3/263,A47B57/56,,0,0,,,,PENDING
37,GB,A,GB 2352421 A,012-794-764-404-754,2001-01-31,2001,GB 9917217 A,1999-07-23,GB 9917217 A,1999-07-23,Scratcher,A device with a profiled end 1 which allows scratchcards to be effectively scratched. The device may be attached to a key ring.,DAVIES GARETH JON,DAVIES GARETH JON,,https://lens.org/012-794-764-404-754,Patent Application,no,6,2,2,2,0,A63F3/068,A63F3/06,B4B B63B          B63B,0,0,,,,DISCONTINUED
38,FI,A0,FI 914800 A0,169-179-963-225-088,1991-10-11,1991,FI 914800 A,1991-10-11,GB 8908818 A;;GB 9000044 W,1989-04-19,FOERBAETTRINGAR BETRAEFFANDE KABELSTEGAR.,,SWIFTS OF SCARBOROUGH LTD,DAVIES GARETH JOHN,,https://lens.org/169-179-963-225-088,Patent Application,no,0,0,6,8,0,H02G3/0608;;H02G3/0456,H02G3/00;;H02G3/04;;H02G3/06,,0,0,,,,DISCONTINUED
39,US,B1,US 7043749 B1,008-870-632-237-568,2006-05-09,2006,US 62305800 A,2000-11-13,GB 9804071 A;;GB 9828513 A;;GB 9900570 W,1998-02-27,Audio-video packet synchronization at network gateway,"A method and apparatus for synchronizing sound and images in a real-time multimedia communication, such as an audio-video telephone call, through a network gateway, when the source and/or the destination of the audio signals, and optionally also the video signals, are from and/or to separate audio and video communication devices.",TANDBERG TELECOM AS,DAVIES STEVEN GARETH,CISCO TECHNOLOGY INC (2011-11-10);;RIDGEWAY SYSTEM AND SOFTWARE (2000-10-18);;TANDBERG TELECOM AS (2004-12-15),https://lens.org/008-870-632-237-568,Granted Patent,yes,17,72,6,9,0,H04L12/64;;H04L12/66;;H04N7/152;;H04Q11/0435;;H04Q2213/13098;;H04Q2213/13196;;H04Q2213/13204;;H04Q2213/13209;;H04Q2213/13213;;H04Q2213/1322;;H04Q2213/13248;;H04Q2213/1325;;H04Q2213/13296;;H04Q2213/13337;;H04Q2213/1336;;H04Q2213/13389;;H04L65/104;;H04L65/80;;H04L65/103;;H04N21/64784;;H04N21/43072;;H04L65/613;;H04L65/756;;H04L65/104;;H04Q11/0435;;H04Q2213/13248;;H04N7/152;;H04Q2213/13196;;H04Q2213/1325;;H04Q2213/1322;;H04Q2213/13296;;H04Q2213/13213;;H04Q2213/13209;;H04L12/66;;H04Q2213/13389;;H04Q2213/13204;;H04Q2213/13337;;H04L12/64;;H04Q2213/1336;;H04Q2213/13098;;H04L65/103;;H04L65/80;;H04N21/64784;;H04N21/43072;;H04L9/40;;H04L65/613;;H04L65/1101,H04L12/64;;H04L12/66;;H04L29/06;;H04N7/15;;H04N7/52;;H04Q11/04,725/120;;725/62;;725/91;;725/114;;725/120;;725/136;;725/138;;455/3.01;;455/403;;455/550;;455/553.1,2,1,044-136-481-974-913,10.1016/0923-5965(95)00050-x,"Willebeek-Lemiar M H et al.: ""On Multipoint Control Units for Videoconferencing"": Oct. 2, 1994, pp. 356-364.;;Civanlar M H et al.: ""A practical system for MPEG-2-based videoon-demand over ATM packet networks and the WWW"": Signal Processing, Image Communication., vol. 8, No. 3, Apr. 1, 1996, p. 221-227.",EXPIRED
40,NO,L,NO 913594 L,124-374-848-403-505,1991-10-17,1991,NO 913594 A,1991-09-12,GB 8908818 A;;GB 9000044 W,1989-04-19,KABELSTIGE.,,SWIFTS OF SCARBOROUGH LTD,DAVIES GARETH JOHN,,https://lens.org/124-374-848-403-505,Abstract,no,0,0,2,8,0,,H02G/,,0,0,,,,PENDING
41,CA,A,CA 975774 A,143-660-667-073-208,1975-10-07,1975,CA 151642 A,1972-09-13,GB 3169172 A;;GB 4604771 A,1971-10-04,BORON COMPOUNDS,,ICI LTD,DAVIES GARETH M,,https://lens.org/143-660-667-073-208,Granted Patent,no,0,0,16,19,0,C07D307/56;;C07F5/025;;C07D307/56;;C07F5/025,C07D307/56;;C07F5/02,260-239.02,0,0,,,,EXPIRED
42,GB,B,GB 2371410 B,011-149-152-920-178,2004-11-24,2004,GB 0101511 A,2001-01-20,GB 0101511 A,2001-01-20,Antenna system,,MOTT MACDONALD LTD,DAVIES PETER GARETH,,https://lens.org/011-149-152-920-178,Granted Patent,no,8,0,3,3,0,H01Q1/12;;H01Q1/08;;H01Q1/1207,H01Q1/08;;H01Q1/12,H1Q QKC           KC,0,0,,,,EXPIRED
43,NO,D0,NO 913594 D0,146-237-578-059-309,1991-09-12,1991,NO 913594 A,1991-09-12,GB 8908818 A;;GB 9000044 W,1989-04-19,KABELSTIGE.,,SWIFTS OF SCARBOROUGH LTD,DAVIES GARETH JOHN,,https://lens.org/146-237-578-059-309,Patent Application,no,0,0,2,8,0,,H02G/,,0,0,,,,PENDING
44,GB,A,GB 2404344 A,064-563-511-251-954,2005-02-02,2005,GB 0317689 A,2003-07-29,GB 0317689 A,2003-07-29,Golf practice brace,"A golf practice brace includes a measured length of cord 1 and two balls 2, and a cord toggle 3 slider adjuster 4 to adjust the position of the balls on the cord. Preferably the (3, Fig 3) slider adjuster (4, Fig 3) is limited in its movement outwards by a toggle-stop (5, Fig 4) so that the brace is contained as one piece with no loss of performance. The balls are secured (7, Fig 1) to prevent ball slippage on the cord ends when the brace is in use. The stated use is for putting practice swings each ball being placed under respective armpits of the player.",DAVIES DAVID GARETH,DAVIES DAVID GARETH,,https://lens.org/064-563-511-251-954,Patent Application,no,4,0,3,3,0,A63B69/0059;;A63B69/0079;;A63B69/0086,A63B69/00;;A63B69/36,A6D D109T3        D109T3,0,0,,,,EXPIRED
45,GB,A,GB 2436516 A,145-339-728-850-86X,2007-10-03,2007,GB 0606164 A,2006-03-28,GB 0606164 A,2006-03-28,A power cable guide to secure the cable to the operator,"A power cable guide 1 includes a shaped clip 4 for securing the cable of a power tool whilst the tool is in use. The guide also includes attachments 2 and 3 for fixing the guide to the belt of the operator. The device thus secures the cable, preventing it from being cut or damaged by the power tool in use. The cable may be released from the clip when required.",DAVIES DAVID GARETH,DAVIES DAVID GARETH,,https://lens.org/145-339-728-850-86X,Patent Application,no,8,0,2,2,0,A62B35/00;;A01D34/822;;A45F5/021,A62B35/00,A3V V9B2X         V9B2X,0,0,,,,DISCONTINUED
46,DE,A1,DE 2248690 A1,178-676-779-757-950,1973-04-12,1973,DE 2248690 A,1972-10-04,GB 3169172 A;;GB 4604771 A,1971-10-04,BORVERBINDUNGEN,,ICI LTD,DAVIES GARETH MORSE,,https://lens.org/178-676-779-757-950,Patent Application,no,0,0,16,19,0,C07D307/56;;C07F5/025;;C07D307/56;;C07F5/025,C07D307/56;;C07F5/02,,0,0,,,,PENDING
47,WO,A1,WO 1993/004612 A1,089-261-454-840-771,1993-03-18,1993,GB 9201655 W,1992-09-10,GB 9119521 A,1991-09-12,IMPROVEMENTS RELATING TO SHELF BRACKETS,"The invention provides a shelf bracket which is made up from a stamped sheet metal blank, which can be folded and welded to form the bracket. In doing this, a flat rear mounting plate for connection to a slotted channel member is defined, and this plate has a fixing aperture at the top end for a bolt which engages the slot of this channel member and is shaped at the lower extremity to define a narrow tang which can be bent out of the plane of the plate to define a projection which, in practice, engages in the said slot to prevent the bracket from rotating on said bolt.",SWIFTS OF SCARBOROUGH LTD,DAVIES GARETH JOHN,,https://lens.org/089-261-454-840-771,Patent Application,yes,5,11,4,4,0,A47B57/565;;H02G3/263,A47B57/56,,0,0,,,,PENDING
48,CA,A,CA 911884 A,166-475-336-807-22X,1972-10-10,1972,CA 911884D A,,CA 911884T A,,ANTIBACTERIAL COMPOSITIONS,,ICI LTD,DAVIES GARETH M,,https://lens.org/166-475-336-807-22X,Granted Patent,no,0,0,1,1,0,,A61K31/00,,0,0,,,,EXPIRED
49,WO,A1,WO 1990/013164 A1,004-864-873-805-750,1990-11-01,1990,GB 9000044 W,1990-01-12,GB 8908818 A,1989-04-19,IMPROVEMENTS RELATING TO CABLE LADDERS,"A cabble ladder system comprises a plurality of parts comprising cable ladder sections and accessories. Each part is made up of spaced side rails connected by support rungs. Adjacent pairs of rail ends form coupling ends so that ladder sections may be connected end to end or to accessories. The rail ends have male and female integral and complementary coupling formations so that the ladder sections and accessories may be coupled without the use, as in conventional or separate connector pieces.",SWIFTS OF SCARBOROUGH LTD,DAVIES GARETH JOHN,,https://lens.org/004-864-873-805-750,Patent Application,yes,3,3,6,8,0,H02G3/0608;;H02G3/0456,H02G3/00;;H02G3/04;;H02G3/06,,0,0,,,,PENDING
50,DE,A1,DE 2264363 A1,045-011-260-164-455,1973-05-17,1973,DE 2264363 A,1972-10-04,GB 3169172 A;;GB 4604771 A,1971-10-04,BORVERBINDUNGEN,,ICI LTD,DAVIES GARETH MORSE,,https://lens.org/045-011-260-164-455,Patent Application,no,0,0,16,19,0,C07D307/56;;C07F5/025;;C07D307/56;;C07F5/025,C07D307/56;;C07F5/02,,0,0,,,,PENDING
51,GB,A,GB 2315205 A,134-998-620-550-849,1998-01-28,1998,GB 9714356 A,1997-07-09,GB 9614746 A,1996-07-12,Scoop for removing pond sludge,The scoop has an inlet 10 for sludge and an outlet pipe 3 through which the sludge can be emptied from the container 8 when the scoop is inverted. Figs 1 and 2 (not shown) illustrate a scoop comprising a single pipe having an angle and an opening at a single point along its length and a container is mounted on the pipe with the angle and opening inside and near the upper end of the container.,DAVIES GARETH COLIN,DAVIES GARETH COLIN,,https://lens.org/134-998-620-550-849,Patent Application,no,3,0,3,3,0,E04H4/16;;E02F3/02;;E02F5/28,E02F3/02;;E02F5/28;;E04H4/16,A4F FSSC          FSSC,0,0,,,,DISCONTINUED
52,AU,A,AU 1970/020527 A,105-966-093-644-238,1972-04-13,1972,AU 1970/020527 A,1970-09-30,GB 5046969 A,1969-10-14,ANTIBACTERIAL COMPOSITIONS,,ICI LTD,DAVIES GARETH MORSE,,https://lens.org/105-966-093-644-238,Patent Application,no,0,0,10,10,0,A61K31/00;;A61K31/00,A61K31/00,87.1-6,0,0,,,,DISCONTINUED
53,GB,A,GB 2268838 A,143-450-345-516-605,1994-01-19,1994,GB 9310093 A,1993-05-17,GB 9215323 A,1992-07-18,Cable tray connector,"A cable tray accessory, particularly for connecting cable trays (58, 60 fig 2) at an angle, is provided with fish plates (62, 64) and wherein at least one of the fish plates (62, 64) is attached to the remainder of the accessory which is a one-piece blank (10). In this way, the fish plates (62, 64) need not be laterally cropped in order to accommodate the coupling tongues (28-32) which are formed in the blank, but can have the full width of the cable tray (58, 60). The cable tray (58, 60) may be of either the single- or return-flange type and may be a reducer. <IMAGE>",SWIFTS OF SCARBOROUGH LTD,DAVIES GARETH JOHN,,https://lens.org/143-450-345-516-605,Patent Application,no,2,2,3,3,0,H02G3/0608,H02G3/06,H2C CCD           CCD,2,0,,,"Cable Tray, Swifts, p26, Feb 1984 (Trade Catalogue);;Cable Tray, Swifts, pp 16 & 17, Feb 1990 (Trade Catalogue)",DISCONTINUED
54,US,A,US 3681493 A,004-828-447-300-700,1972-08-01,1972,US 3681493D A,1970-09-28,GB 5046969 A,1969-10-14,ANTIBACTERIAL COMPOSITIONS,"The invention provides pharmaceutical and veterinary compositions including as active ingredient a known derivative of di-(2-thienyl)borinic acid or phenyl-2-thienylborinic acid, for use in the treatment of bacterial infections, particularly those caused by Gram-negative bacteria.",ICI LTD,DAVIES GARETH MORSE,,https://lens.org/004-828-447-300-700,Granted Patent,no,0,1,10,10,0,A61K31/00;;A61K31/00,A61K31/00,424/185,1,1,006-638-815-207-565,14341914;;10.1002/ardp.19642970902,"Roth et al., Archiv dev Phavmazie, Vol. 297, No. 9, 1964, pages 513 523.",EXPIRED
55,US,B2,US 11666377 B2,042-847-786-272-849,2023-06-06,2023,US 201916532980 A,2019-08-06,US 201916532980 A;;US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 82745206 P;;US 88428507 P,2006-09-29,Electrosurgical device,"An electrosurgical device for puncturing tissue comprises an electrically conductive elongate member which is capable of force transmission from a distal portion of the electrosurgical device to a proximal portion of the electrosurgical device to thereby provide tactile feedback to a user. The proximal portion comprises a handle or hub which includes an electrical connector configured to receive, in a releasable manner, an electrically conductive component operable to be electrically coupled to an energy source.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;MIRZA MAHMOOD,BAYLIS MEDICAL COMPANY INC (2019-08-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/042-847-786-272-849,Granted Patent,yes,340,0,4,113,0,A61B18/1492;;A61B2018/00601;;A61B2018/00357;;A61B18/1482,A61B18/12;;A61B18/14,,63,44,022-286-573-136-47X;;063-832-404-449-689;;090-845-072-200-001;;113-591-253-296-335;;061-080-657-413-13X;;079-220-343-462-372;;027-249-765-633-859;;044-496-843-651-986;;013-298-075-588-774;;035-621-526-377-948;;023-749-888-124-005;;012-647-127-487-753;;030-041-321-743-550;;015-569-231-826-071;;007-454-134-946-40X;;007-454-134-946-40X;;102-284-308-414-898;;007-454-134-946-40X;;053-709-812-994-938;;012-193-495-831-569;;015-569-231-826-071;;013-523-269-156-951;;026-941-827-483-484;;020-214-294-476-433;;012-193-495-831-569;;016-249-543-201-808;;041-100-996-150-282;;056-565-923-253-058;;066-004-459-025-109;;003-336-720-517-736;;038-743-504-882-104;;114-217-294-103-276;;096-535-125-477-640;;006-495-373-391-557;;022-127-515-170-102;;080-511-818-680-898;;087-966-302-747-022;;064-062-639-916-470;;104-863-760-253-161;;006-495-373-391-557;;126-172-010-773-649;;126-172-010-773-649;;043-109-600-839-627;;041-155-588-518-082,11094817;;10.1007/bf02345756;;15129792;;10.1007/bf00595842;;10.1136/heart.86.5.e11;;11602562;;pmc1729980;;10.1017/s1047951103000398;;12887081;;12885744;;10.1161/01.cir.0000084548.44131.d1;;16473163;;10.1016/j.jvs.2005.10.059;;12772256;;10.1002/ccd.10560;;10.1583/1545-1550(2007)14[158:ivafoa]2.0.co;2;;17484531;;10.1177/152660280701400207;;15056015;;10.1583/03-1180.1;;14656175;;10.1583/1545-1550(2003)010<0946:rfoegf>2.0.co;2;;10.1177/152660280301000518;;11979539;;10.1002/ccd.10213;;10.1583/1545-1550(2001)008<0016:fiegfa>2.0.co;2;;10.1177/152660280100800103;;11220463;;8504569;;10.1002/clc.4960160502;;11733820;;10.1590/s0066-782x2001001100008;;11733820;;10.1590/s0066-782x2001001100008;;10.1002/ccd.10602;;12929108;;11733820;;10.1590/s0066-782x2001001100008;;9768726;;10.1016/s0735-1097(98)00357-x;;11329224;;10.1002/ccd.1135;;8504569;;10.1002/clc.4960160502;;12652210;;10.1097/00001573-200303000-00002;;10.1177/152660280100800101;;10.1583/1545-1550(2001)008<0001:sbpdea>2.0.co;2;;11220462;;12838844;;11329224;;10.1002/ccd.1135;;10.1583/09-2903c.1;;20426637;;8489867;;10.1136/hrt.69.4.343;;pmc1025049;;10.1002/(sici)1097-0304(199710)42:2<219::aid-ccd30>3.0.co;2-g;;9328715;;10700071;;10.1002/(sici)1522-726x(200003)49:3<335::aid-ccd24>3.0.co;2-n;;10216007;;10.1002/(sici)1522-726x(199904)46:4<425::aid-ccd7>3.0.co;2-r;;12410514;;10.1002/ccd.10358;;10.1016/0002-9149(93)90687-8;;8342519;;12112899;;10.1002/ccd.10222;;11553955;;10.1002/ccd.1244;;1764747;;10.1002/ccd.1810240318;;10.1161/01.cir.85.2.565;;1735152;;12929107;;10.1002/ccd.10605;;12772255;;10.1002/ccd.10506;;10.1583/1545-1550(2001)008<0003:eagwra>2.0.co;2;;11220465;;10.1177/152660280100800102;;11553955;;10.1002/ccd.1244;;10.1023/a:1009870227401;;11248781;;10.1023/a:1009870227401;;11248781;;10.1583/09-2903.1;;20426636;;10.1177/000331978703800704;;2956910,"Medtronic Inc. “http://www.medtronic.com/epsystems/diagnostic.sub.—catheters.html”. Diagnostic Catheters. 7 pages (Date of Printing—Apr. 2005).;;N Shimko, P. Savard, K Shah. “Radio frequency perforation of cardiac tissue: modeling and experimental results”. Med. Biol. Eng. Comput. 38:575-582 (2000).;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2015/052118, dated Sep. 27, 2016.;;Patent Cooperation Treaty, International Search Report for International Application No. PCT/IB2015/052118, dated Jun. 26, 2015.;;Pressure Products, Inc. http://www.pressure-products.com/Downloads/Education.sub.—PDFs/Using.sub-.—CSG.sub.—v2.pdf. 4 pages. 2005.;;Shyam S. Kothari, Sanjeev K. Sharma, Nitish Naik; Radiofrequency Perforation for Pulmonary Atresia and Intact Ventricular Septum; Indian Heart J Jan.—Feb. 2004;56(1):50-3 (Actual publication after Feb. 2004).;;Suhonen M. et al. Recanalization of arterial occlusions using a specially designed steering catheter. European Radiology: 2, 264-265(1992).;;Supplementary European Search Report, EP 15 76 8911, dated Nov. 1, 2017.;;Szili-Torok, T et al. (2001) Transseptal Left Heart Catherisation Guided by Intracardiac Echocardiography, Heart 86:e11.;;T Abdel-Massih, Y Boudjemline, P Bonhoeffer. “Unusual Interventional management in an adult with tetralogy of Fallot”. Cardiol Young 13(2):203-205 (Apr. 2003).;;T Humpl, B Soderberg, BW McCrindle, DG Nykanen, RM Freedom, WG Williams, LN Benson. “Percutaneous Balloon Valvotomy in Pulmonary Atresia with Intact Ventricular Septum: Impact on Patient Care”. Circulation. 108(7): 826-832 (Aug. 2003).;;Timothy A.M. Chuter, “Branched and Fenestrated Stent Grafts for Endovascular Repair of Thoracic Aortic Aneurysms”, Oct. 27, 2005, pp. 111A-115A, vol. 43, No. A, Publisher: The Society for Vascular Sugery, Published in U.S.;;Tsung O. Cheng. “All Roads Lead to Rome:Transjugular or Transfemoral Approach to Percutaneous Transseptal Balloon Mitral Valvuloplasty?”. Catheterization and Cardiovascular Interventions 59:266-267 (2003).;;Abstract of European Patent No. 0315730 to Osypka. May 1989.;;Abstract of Leonard W.H. Tse et al., “In Vivo Antegrade Fenestration of Abdominal Aortic Stent-Grafts”, “Journal of Endovascular Therapy”, Apr. 2007, pp. 158-167, vol. 14, No. 2, Publisher: Journal of Endovascular Therapy, Published in: U.S.;;Abstract of Richard G. McWilliams et al., “In Situ Stent-Graft Fenestration to Preserve the Left Subclavian Artery”, “Journal of Endovascular Therapy”, Apr. 2004, pp. 170-174, vol. 11, No. 2, Publisher: Journal of Endovascular Therapy, Published in: U.S.;;Abstract of Richard G. McWilliams et al., “Retrograde Fenestration of Endoluminal Grafts From Target Vessels: Feasibility, Technique, and Potential Usage”, “Journal of Endovascular Therapy”, Oct. 2003, pp. 946-952, vol. 10, No. 5, Publisher: Journal of Endovascular Therapy, Published in: U.S.;;Benson, Lee N., David Nykanen, Amanda Collison, “Radiofrequency Perforation in the Treatment of Congenital Heart Disease”. Catherizations and Cardiovascular Interventions; 56: 72-82, 2002.;;Boston Scientific Corporation “http://www.bostonscientific.com/med.sub.—specialty/deviceDetail.jsp7tas-k=tskBasicDevice.jsp&sectionld=4&relld=2,74,75,76&deviceld=11026&uniqueID=-MPDB2799”. PT2 Guide Wire. 2 pages (Date of printing—Jun., 2005).;;Boston Scientific Corporation. “http://www.bostonscientific.com/med.sub.—specialty/deviceDetail.jsp?tas-k=tskBasicDevice.jsp&sectionid=4&relld=1,20,21,22&deviceid=488&uniqueID=MP- DB58”. Explorer ST Catheters. 2 pages. (Date or printing—Jun., 2005).;;Brendan M. Stanley et al., “Fenestration in Endovascular Grafts for Aortic Aneurysm Repair: New Horizons for Preserving Blood Flow in Branch Vessels”, “Journal of Endovascular Therapy”, Feb. 2001, pp. 16-24, vol. 8, Publisher: Journal of Endovascular Therapy, Published in: U.S.;;C.R. Conti. “Transseptal Left Heart Catheterization for Radiofrequency Ablation of Accessory Pathways”. Clin. Cardiel. 16, 367-368 (1993).;;CA Pedra, LN De Sousa, SR Pedra, WP Ferreira, SL Braga, CA Esteves, MV Santant, JE Sousa, VF Fontes. “New Percutaneous Techniques for Perforating the Pulmonary Valve in Pulmonary Atresia with Intact Ventricular Septum”. Arq. Bras Cariol. 77(5):471-478 (2001).;;CA Pedra, LN de Sousa, SR Pedra, WP Ferreira, SL Braga, CA Esteves, MV Santant, JE Sousa, VF Fontes. “New Percutaneous Techniques for Perforating the Pulmonary Valve in Pulmonary Atresia with Intact Ventricular Septum”. Arq. Bras Cariol. 77(5):479-486 Nov. 2001.;;CA Pedra, RM Filho, RS Arrieta, R Tellez, VF Fontes. “Recanalization of a discrete atretic right pulmonary artery segment with a new radiofrequency system”. Catheter Cardiovasc. Interv. 60(1):82-87 (Sep. 2003).;;Carlos A.C. Pedra Luciano N.L. De Sousa, Simone R.F.F. Pedra, Waldinai P. Ferreira, Sergio L.N. Braga, Cesar A. Esteves, Maria Virginia T. Santana, J. Eduardo Sousa, Valmir F. Fontes; New Percutaneous Techniques for Perforating the Pulmonary Valve in Pulmonary Atresia with Intact Ventricular Septum; Arq Bras Cardiol. Nov. 2001;77(5):471-86.;;Christodoulos Stefanadis. “Retrograde Nontransseptal Balloon Mitral Valvuloplasty: Immediate Results and Intermediate Long-Term Outcome in 441 Cases—A Multicentre Experience”. Journal of the American College of Cardiology. 32(4): 1009-16 (1998).;;Christophe Fink, Mattias Peuster, Harald Bertram, Gerd Hausdorf; Transcatheter Recanalization of the Left Main Pulmonary Artery After Four Years of Complete Occlusion; Catheterization and Cardiovascular Interventions Jan. 2004;2(1):117-26.;;Conti “finite element analysis of self-expanding braided wirestent” 2006-2007.;;Conti C. R., “Transseptal Left Heart Catheterization for Radiofrequency Ablation of Accessory Pathways”. Clinical Cardiology; 16: 367-368, 1993.;;Daniel S. Levi, Juan C. Alejos, John W. Moore; Future of Interventional Cardiology in Pediatrics; Current Opinion in Cardiology Mar. 2003;18(2):79-90.;;DG Nykanen, J Phikala, GP Taylor, LN Benson. “Radiofrequency assisted perforation of the atrial septum in a swine model: feasibility, biophysical and histological characteristics”, Circulation. 100(Suppl 1):I-804 (1999).;;Edward B. Diethrich, “Side Branch Preservation During Endovascular Aortic Aneurysm Repair”, “Journal of Endovascular Therapy”, Feb. 2001, pp. 1-2, vol. 8, Publisher: Journal of Endovascular Therapy, Published in: U.S.;;F Godart, C Francart, GM Breviere, C Rey. “Pulmonary vavulotomy with the Nykanen radiofrequency guide in pulmonary atresia with intact interventricular septum”, Arch Mal Coeur Vaiss. 96(5):517-520 (May 2003), Article is in French with an English summary.;;Fink, Peuster, Bertram, Hausdorf. Transcatheter Recanalization of the Left Main Pulmonary Artery after Four Years of Complete Occlusion. Catheterization and Cardiovascular Interventions. May 2001;53(1):81-4.;;First Office Action for Chinese Application, Application/Patent No. 2015800262435, Issue Serial No. 2018122001954460, dated Dec. 25, 2018.;;Frank R. Arko III, “In Pursuit of an Off-the Shelf Fenestrated Stent-Graft: Radiofrequency Perforation for In Vivo Antegrade Fenestration”, “Journal of Endovascular Therapy”, Apr. 2010, pp. 199-200, vol. 17, No. 2, Publisher: Journal of Endovascular Therapy, Published in: U.S.;;G Hausdorf, I Schulze-Neick, Pe Lange; Radiofrequency-assisted “reconstruction” of the Right Ventricular Outflow Tract in Muscular Pulmonary Atresia with Ventricular Septal Defect; British Heart Journal, Apr. 1993:69(4):343-6.;;G Veldtman, A Peirone, LN Benson. “Radiofrequency perforation of the atrial septum: Preliminary experimental evaluation and development” Pics VII Abstracts. Catheter Cardiovasc Interv. 60(1):132 (Sep., 2003).;;George Joseph, Dibya K. Baruah, Sajy V. Kuruttukulam, Sunil Thomas Chandy, Shanker Krishnaswami. “Transjugular Approach to Transseptal Balloon Mitral Valvuloplasty”. Catheterization and Cardiovascular Diagnosis 42:219-226 (1997).;;George Joseph, G. Rajendiran, K. Abhaichand Rajpal. “Transjugular Approach to Concurrent Mitral-Aortic and Mitral-Tricuspid Balloon Valvuloplasty”. Catheterization and Cardiovascular Interventions 49:335-341 (2000).;;George Joseph, K.P. Suresh Kumar, Paul V. George, Subodh Dhanawade. “Right Internal Jugular Vein Approach as an Alternative in Balloon Pulmonary Valvuloplasty”. Catheterization and Cardiovascular Interventions 46:425-429 (1999).;;George Joseph, Oommen K. George, Asishkumar Mandalay, Sunil Sathe. “Transjugular Approach to Balloon Mitral Valvuloplasty Helps Overcome Impediments Caused by Anatomical Alterations”. Catheterization and Cardiovascular Interventions 57:353-362 (2002).;;Gero Hausdorf, Martin Schneider. Peter Lange; Catheter Creation of an Open Outflow Tract in Previously Atretic Right Ventricular Outflow Tract Associated with Ventricular Septal Defect; The American Journal of Cardiology, Aug. 1, 1993;72(3):354-6.;;Gideon J. Du Marchie Sarvaas, Kalyani R. Trivedi, Lisa K. Hornberger, K. Jin Lee, Hoel A. Kirsh, Lee N. Benson. “Radiofrequency-Assisted Atrial Septoplasty for an Intact Atrial Septum in Complex Congenital Heart Disease”. Catheterization and Cardiovascular Interventions; 56: 412-415 (2002).;;H Justino, LN Benson, DG Nykanen. “Transcatheter Creation of an Atrial Septal Defect Using Radiofrequency Perforation”. Catheter Cardiovasc Interv. 54(1):83-87 (Sep. 2001).;;Hector Biddogia, Juan P. Maciel, Jose A. Alvarez et al. “Transseptal Left Heart Catheterization: Usefulness of the Intracavitary Electrocardiogram in the Localization of the Fossa ovalis”. Catheterization and Cardiovascular Diagnosis 24: 221-225 (1991).;;Holzer, Hardin, Hill, Chisolm, Cheatham. Radiofrequency Energy—A Multi-Facetted Tool for the Congenital Interventionist. Congenital Cardiology Today. Jun. 2006; 4(6): 1-.;;Hugh Calkins, Yoon-Nyun Kim, Steve Schmaltz, Joao Sousa, Rafel El-Atassi, Angel Leon, Alan Kadish, Jonathan J. Langberg, Fred Morady; Electrogram Criteria for Identification of Appropriate Target Sites for Radiofrequency Catheter Ablation of Accessory Atrioventricular Connections; Feb. 1992;85(2):565-73.;;HW Kort, DT Balzer. “Radiofrequency perforation in the treatment of acquired left pulmonary atresia following repair of teraligy of Fallot”. Catheter Cardiovasc Interv. 60(1):79-81 (Sep. 2003).;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2007/061203, dated Oct. 26, 2007, 8 pages.;;IntraLuminal Therapeutics, Inc. “http://www.intraluminal.com/products/catheter.html”. Safe Cross Support Catheter. 1 page. (Date of Printing—Jun. 2005).;;J. E Della, “Notice of Allowance in the case of U.S. Appl. No. 11/520,754”, dated Jul. 2, 2010.;;J. Thompson Sullebarger, Humberto Coto, Enrique Lopez, Dany Sayad, Hector L. Fontanet. “Transjugular Percutaneous Inoue Balloon Mitral Commissurotomy in a Patient With Inferior Vena Cava Obstruction After Liver Transplantation”. Catheterization and Cardiovascular Interventions 59:261-265 (2003).;;John Lennon Anderson et al., “Endoluminal Aortic Grafting with Renal and Superior Mesenteric Artery Incorporation by Graft Fenestration”, “Journal of Endovascular Therapy”, Feb. 2001, pp. 3-15, No. 8, Publisher: Journal of Endovascular Therapy, Published in: U.S.;;Johnson & Johnson Gateway, LLC. “http://www.jnjgateway.com/home.jhtml;jsessionid=JNSFHTWOAOIC0CQPCCECPJYK-B2IIWNSC?icc=USENG&page=viewContent&contentid=IC0de00100000524&nodekey=/Pr-od.sub.—Info/Specialty/Cardiovascular.sub.—and.sub.—Thoracic/Cardiac.su-b.—Diagnosis.sub.—lnterventions/Diagnostic.sub.—Wires&.sub.—requestid=- 228905”, Diagnostic Guidewires, 4 pages.;;Johnson & Johnson Gateway, LLC. “http://www.jnjgateway.com/home.jhtml?loc=USENG&page=viewContent&contentld=lc0de00100001435&nodekey=/Prod.sub.—info/Specialty/Arrhythmia.sub.—Management/Electrophysiology/EPsub.—Diagnostic.su- b.—Catheters”. EP Diagnostic Catheters, 2 pages (Date of printing—Jun., 2005).;;Justino, Henri, Lee N. Benson, David G. Nykanen. “Transcatheter Creation of an Atrial Septal Defect Using Radiofrequency Perforation”. Catheterization and Cardiovascular Interventions. 56:412-415 (2002).;;Kamal K. Sethi, Jagdish C. Mohan. “Editiorial Comment: Transseptal Catheterization for the Electrophysiologist: Modification with a ‘View’”. Journal of Interventional Cardian Physiology. 5, 97-99, 2001.;;Kamal K. Sethi, Jagdish C. Mohan. “Editorial Comment: Transseptal Catheterization for the Electrophysiologist: Modification with a ‘View’”. Journal of Interventional Cardiac Physiology. 5, 97-99, 2001.;;Lake Region Manufacturing, Inc. “http://www.lakergn.com/jmc.htm”. Paragon Guidewire. 2 pages (Date of Printing—Jun. 2005).;;Leonard W. H. Tse et al., “Radiofrequency Perforation System for an In Vivo Antegrade Fenestration of Aortic Stent-Grafts”, “Journal of Endovascular Therapy”, Apr. 2010, pp. 192-198, vol. 17, No. 2, Publisher: Journal of Endovascular Therapy, Published in: U.S.;;Lepage, Lewis, Ruiz, Yamanishi, Padron, Hood. Angiopyroplasty using Electromagnetically Induced Focused Heat. Angiology. Jul. 1987;38(7):520-3.",ACTIVE
56,US,S,US D0600988 S,045-791-803-551-911,2009-09-29,2009,US 33776409 F,2009-05-29,EM 11305610001 F,2009-04-28,Craft stapler,,TONIC STUDIOS LTD,DAVIES GARETH;;BATHARD SIMON,TONIC STUDIOS LIMITED (2009-05-22),https://lens.org/045-791-803-551-911,Design Right,no,0,0,1,1,0,,,1902;;D 8 50;;D8/49,0,0,,,,EXPIRED
57,EP,A1,EP 0557486 A1,179-060-819-336-968,1993-09-01,1993,EP 92919018 A,1992-09-10,GB 9119521 A,1991-09-12,IMPROVEMENTS RELATING TO SHELF BRACKETS.,"L'invention se rapporte à un support de rayonnage, fabriqué à partir d'un flan métallique embouti pouvant être plié et soudé pour former le support. On réalise ainsi une plaque de fixation arrière plate, destinée à être fixée sur un montant à fente, et possédant un trou de fixation à son extrémité supérieure destiné à recevoir un boulon venant se loger dans ladite fente du montant. La plaque de fixation est mise en forme de façon à présenter une languette étroite à sa partie inférieure pouvant être pliée par rapport à son plan, de façon à former un épaulement, qui lors de l'utilisation, pénètre ladite fente afin d'empêcher la rotation du support autour dudit boulon.",SWIFTS OF SCARBOROUGH LTD,DAVIES GARETH JOHN RAINCLIFFE,,https://lens.org/179-060-819-336-968,Patent Application,yes,0,0,4,4,0,A47B57/565;;H02G3/263,A47B57/56,,1,0,,,See references of WO 9304612A1,DISCONTINUED
58,US,A1,US 2021/0338318 A1,189-231-836-646-075,2021-11-04,2021,US 202117377613 A,2021-07-16,US 202117377613 A;;US 201916532980 A;;US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 82745206 P;;US 88428507 P,2006-09-29,Connector system for electrosurgical device,"An electrosurgical device for puncturing tissue comprises an electrically conductive elongate member which is capable of force transmission from a distal portion of the electrosurgical device to a proximal portion of the electrosurgical device to thereby provide tactile feedback to a user. The proximal portion comprises a handle or hub which includes an electrical connector configured to receive, in a releasable manner, an electrically conductive component operable to be electrically coupled to an energy source.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;MIRZA MAHMOOD,BAYLIS MEDICAL COMPANY INC (2019-08-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/189-231-836-646-075,Patent Application,yes,19,0,4,113,0,A61B18/1492;;A61B2018/00601;;A61B2018/00357;;A61B18/1482,A61B18/14,,0,0,,,,ACTIVE
59,US,A1,US 2016/0283312 A1,014-666-746-569-359,2016-09-29,2016,US 201615079580 A,2016-03-24,GB 201504975 A,2015-03-24,LOGGING EVENTS WITH TIMESTAMPS,"A logging unit is used to log entries for events in a computer system. Each entry includes an n-bit timestamp field and a payload. The payload includes information about the event and the timestamp field includes the n least significant bits of an N-bit timestamp for the event, where N>n. If the n least significant bits of the timestamp have wrapped compared to the corresponding n bits of the timestamp of the preceding entry then a timing entry is logged which includes other bits of the timestamp. Therefore, an N-bit timestamp can be determined for an event, but only the n least significant bits of the timestamp are stored in the timestamp field of an entry for the event. Therefore, the time flow of events in the store is better maintained (by having a larger timestamp) without increasing the number of bits (n) in the timestamp field of each entry.",IMAGINATION TECH LTD,MURRIN PAUL;;DAVIES GARETH,IMAGINATION TECHNOLOGIES LIMITED (2016-03-31);;NORDIC SEMICONDUCTOR ASA (2020-12-31),https://lens.org/014-666-746-569-359,Patent Application,yes,2,6,9,9,0,G06F11/3086;;G06F11/3476;;G06F11/3636;;G06F11/3636;;G06F11/3466;;G06F11/3466;;G06F11/3476;;G06F11/3476;;G06F17/40;;G06F17/40;;G06F2201/835;;G06F2201/835;;G06F2201/86;;G06F2201/86,G06F11/07,,0,0,,,,ACTIVE
60,US,B2,US 11759190 B2,113-290-612-056-642,2023-09-19,2023,US 202017070442 A,2020-10-14,US 202017070442 A;;US 201962923051 P,2019-10-18,"Lock for medical devices, and related systems and methods","A lock for positioning a first medical device with respect to a second medical device includes a spacer for preventing advancement of the first medical device towards the second medical device. The spacer is movable between a lock position and an unlock position. In the lock position, the spacer is moved transverse to the longitudinal axis with respect to the unlock position. The lock further includes a rotary stop integral with the spacer for fixing the rotational position of the first medical device with respect to the second medical device. The lock further includes a clip integral with the spacer and removably securable to the first medical device in a first position to secure the spacer in the unlock position, and removably securable to the first medical device in a second position to secure the spacer in the lock position.",BOSTON SCIENT MEDICAL DEVICE LIMITED,ARNETT JEFFERY;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2020-02-10);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/113-290-612-056-642,Granted Patent,yes,315,0,2,2,0,A61B17/3478;;A61B2017/0046;;A61B2017/00469;;A61B2090/08021;;A61B17/3494;;A61B2017/00243;;A61B2090/034;;A61B2090/035;;A61B17/0057;;A61B2017/00619;;A61B2017/00584;;A61B17/3417,A61B17/34;;A61B17/00,,0,0,,,,ACTIVE
61,CN,A,CN 106021058 A,177-878-442-499-983,2016-10-12,2016,CN 201610170236 A,2016-03-23,GB 201504975 A,2015-03-24,Logging events with timestamps,"A logging unit is used to log entries for events in a computer system. Each entry includes an n-bit timestamp field and a payload. The payload includes information about the event and the timestamp field includes the n least significant bits of an N-bit timestamp for the event, where N>n. If the n least significant bits of the timestamp have wrapped compared to the corresponding n bits of the timestamp of the preceding entry then a timing entry is logged which includes other bits of the timestamp. Therefore, an N-bit timestamp can be determined for an event, but only the n least significant bits of the timestamp are stored in the timestamp field of an entry for the event. Therefore, the time flow of events in the store is better maintained (by having a larger timestamp) without increasing the number of bits (n) in the timestamp field of each entry.",IMAGINATION TECH LTD,GARETH DAVIES;;PAUL MURRIN,,https://lens.org/177-878-442-499-983,Patent Application,no,3,0,9,9,0,G06F11/3086;;G06F11/3476;;G06F11/3636;;G06F11/3636;;G06F11/3466;;G06F11/3466;;G06F11/3476;;G06F11/3476;;G06F17/40;;G06F17/40;;G06F2201/835;;G06F2201/835;;G06F2201/86;;G06F2201/86,G06F11/30,,0,0,,,,ACTIVE
62,CA,A1,CA 3173410 A1,172-967-407-150-906,2021-10-28,2021,CA 3173410 A,2021-04-15,US 202063013646 P;;IB 2021053119 W,2020-04-22,SHEATH ASSEMBLY AND/OR DILATOR ASSEMBLY,"An apparatus is for an elongated sheath assembly configured to receive, at least in part, an elongated dilator assembly. The apparatus includes a dilator-receiver device configured to be installed to the elongated sheath assembly. A dilator-receiver mover is configured to be mounted, at least in part, to the elongated sheath assembly. The dilator-receiver mover is configured to be operatively connected to the dilator-receiver device. The dilator-receiver mover is also configured to selectively move the dilator-receiver device along a predetermined distance.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;DAVIES GARETH,,https://lens.org/172-967-407-150-906,Patent Application,no,0,0,5,5,0,A61M29/00;;A61B2017/00247;;A61M25/0662;;A61B17/3478;;A61M29/00,A61B17/00;;A61B17/34;;A61B90/00;;A61M29/00,,0,0,,,,PENDING
63,US,A1,US 2021/0113198 A1,076-540-204-670-271,2021-04-22,2021,US 202017070442 A,2020-10-14,US 202017070442 A;;US 201962923051 P,2019-10-18,"LOCK FOR MEDICAL DEVICES, AND RELATED SYSTEMS AND METHODS","A lock for positioning a first medical device with respect to a second medical device includes a spacer for preventing advancement of the first medical device towards the second medical device. The spacer is movable between a lock position and an unlock position. In the lock position, the spacer is moved transverse to the longitudinal axis with respect to the unlock position. The lock further includes a rotary stop integral with the spacer for fixing the rotational position of the first medical device with respect to the second medical device. The lock further includes a clip integral with the spacer and removably securable to the first medical device in a first position to secure the spacer in the unlock position, and removably securable to the first medical device in a second position to secure the spacer in the lock position.",BAYLIS MEDICAL CO INC,ARNETT JEFFERY;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2020-02-10);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/076-540-204-670-271,Patent Application,yes,3,1,2,2,0,A61B17/3478;;A61B2017/0046;;A61B2017/00469;;A61B2090/08021;;A61B17/3494;;A61B2017/00243;;A61B2090/034;;A61B2090/035;;A61B17/0057;;A61B2017/00619;;A61B2017/00584;;A61B17/3417,A61B17/00;;A61B17/34,,0,0,,,,ACTIVE
64,WO,A3,WO 2012/167281 A3,014-376-515-596-83X,2013-01-31,2013,US 2012/0040808 W,2012-06-04,US 201161492795 P,2011-06-02,CLINICAL APPLICATION UTILIZING GENETIC DATA FOR EFFECTIVE MEDICATION MANAGEMENT,"The present disclosure relates a predictive method, based on a subject's genetic profile, which defines variability in a specific disease or condition to determine medication response, including determining select VNTR and SNP occurrence combinations which are associated with specific responses to medications, kits and DNA chips/arrays containing such combinations so as to effectuate better medication management.",DAVIES GARETH;;HANSEN RYAN,DAVIES GARETH;;HANSEN RYAN,,https://lens.org/014-376-515-596-83X,Search Report,yes,3,0,3,3,10,A61K31/135;;A61K31/135;;A61K31/137;;A61K31/137;;A61K31/445;;A61K31/445;;A61P25/00,A61K31/445;;A61K31/135;;A61K31/137;;A61P25/00,,3,2,017-955-349-238-345;;097-784-696-852-313,10.1542/peds.108.5.e83;;11694667;;18568102;;pmc2416755,"NATIONAL INSTITUTE ON DRUG ABUSE: ""DrugFacts: Stimulant ADHD Medications-Methylphenidate and Amphetamines"", NIDA INFOFACTS, 2009, pages 1 - 4;;DAVID MICHELSON ET AL.: ""Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study"", PEDIATRICS, vol. 108, no. 5, 2001, pages E83;;FREDERICK W REIMHER ET AL.: ""Bupropion SR in adults with ADHD: a short- term, placebo-controlled trial"", NEUROPSYCHIATRIC DISEASE AND TREATMENT, vol. 1, no. 3, 2005, pages 245 - 251",PENDING
65,US,A1,US 2020/0353215 A1,164-422-362-335-949,2020-11-12,2020,US 202016867132 A,2020-05-05,US 202016867132 A;;US 201962843883 P,2019-05-06,System and Methods for Left Atrial Access,"A method and apparatus are disclosed for puncturing tissue within a patient, comprising accessing a hepatic vein within the patient using an access device and inserting a flexible puncture device into the hepatic vein. The flexible puncture device advances from the hepatic vein to an inferior vena cava, and to the patient's heart. The next step is advancing a supporting catheter comprising a lumen over the flexible puncture device, whereby the flexible puncture device is positioned within the lumen and supported by the supporting catheter. The distal tip of the flexible puncture device and supporting catheter are positioned against a target tissue site and creating a puncture in said tissue, and the flexible puncture device is advanced through the puncture in the tissue.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;MORIYAMA EDUARDO,BAYLIS MEDICAL COMPANY INC (2019-05-02);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/164-422-362-335-949,Patent Application,yes,9,0,1,1,0,A61B2018/00357;;A61B2090/064;;A61B2090/378;;A61B2090/3966;;A61B2090/376;;A61B18/1492;;A61B2018/144;;A61B2018/00285;;A61B17/3478;;A61M25/0133;;A61M2210/125;;A61M2025/0687;;A61M2025/0681,A61M25/01,,0,0,,,,PENDING
66,US,B2,US 11660137 B2,118-811-194-726-924,2023-05-30,2023,US 202117377613 A,2021-07-16,US 202117377613 A;;US 201916532980 A;;US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 82745206 P;;US 88428507 P,2006-09-29,Connector system for electrosurgical device,"An electrosurgical device for puncturing tissue comprises an electrically conductive elongate member which is capable of force transmission from a distal portion of the electrosurgical device to a proximal portion of the electrosurgical device to thereby provide tactile feedback to a user. The proximal portion comprises a handle or hub which includes an electrical connector configured to receive, in a releasable manner, an electrically conductive component operable to be electrically coupled to an energy source.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;MIRZA MAHMOOD,BAYLIS MEDICAL COMPANY INC (2019-08-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/118-811-194-726-924,Granted Patent,yes,339,3,4,113,0,A61B18/1492;;A61B2018/00601;;A61B2018/00357;;A61B18/1482,A61B18/18;;A61B18/14,,57,36,013-298-075-588-774;;035-621-526-377-948;;023-749-888-124-005;;012-647-127-487-753;;030-041-321-743-550;;102-284-308-414-898;;007-454-134-946-40X;;012-193-495-831-569;;015-569-231-826-071;;013-523-269-156-951;;026-941-827-483-484;;020-214-294-476-433;;012-193-495-831-569;;016-249-543-201-808;;056-565-923-253-058;;066-004-459-025-109;;003-336-720-517-736;;038-743-504-882-104;;114-217-294-103-276;;006-495-373-391-557;;022-127-515-170-102;;080-511-818-680-898;;087-966-302-747-022;;064-062-639-916-470;;104-863-760-253-161;;006-495-373-391-557;;043-109-600-839-627;;041-155-588-518-082;;063-832-404-449-689;;090-845-072-200-001;;113-591-253-296-335;;061-080-657-413-13X;;079-220-343-462-372;;027-249-765-633-859;;044-496-843-651-986;;040-553-861-085-191,10.1583/1545-1550(2007)14[158:ivafoa]2.0.co;2;;17484531;;10.1177/152660280701400207;;15056015;;10.1583/03-1180.1;;14656175;;10.1583/1545-1550(2003)010<0946:rfoegf>2.0.co;2;;10.1177/152660280301000518;;11979539;;10.1002/ccd.10213;;10.1583/1545-1550(2001)008<0016:fiegfa>2.0.co;2;;10.1177/152660280100800103;;11220463;;10.1002/ccd.10602;;12929108;;11733820;;10.1590/s0066-782x2001001100008;;11329224;;10.1002/ccd.1135;;8504569;;10.1002/clc.4960160502;;12652210;;10.1097/00001573-200303000-00002;;10.1177/152660280100800101;;10.1583/1545-1550(2001)008<0001:sbpdea>2.0.co;2;;11220462;;12838844;;11329224;;10.1002/ccd.1135;;10.1583/09-2903c.1;;20426637;;10.1002/(sici)1097-0304(199710)42:2<219::aid-ccd30>3.0.co;2-g;;9328715;;10700071;;10.1002/(sici)1522-726x(200003)49:3<335::aid-ccd24>3.0.co;2-n;;10216007;;10.1002/(sici)1522-726x(199904)46:4<425::aid-ccd7>3.0.co;2-r;;12410514;;10.1002/ccd.10358;;10.1016/0002-9149(93)90687-8;;8342519;;11553955;;10.1002/ccd.1244;;1764747;;10.1002/ccd.1810240318;;10.1161/01.cir.85.2.565;;1735152;;12929107;;10.1002/ccd.10605;;12772255;;10.1002/ccd.10506;;10.1583/1545-1550(2001)008<0003:eagwra>2.0.co;2;;11220465;;10.1177/152660280100800102;;11553955;;10.1002/ccd.1244;;10.1583/09-2903.1;;20426636;;10.1177/000331978703800704;;2956910;;15129792;;10.1007/bf00595842;;10.1136/heart.86.5.e11;;11602562;;pmc1729980;;10.1017/s1047951103000398;;12887081;;12885744;;10.1161/01.cir.0000084548.44131.d1;;16473163;;10.1016/j.jvs.2005.10.059;;12772256;;10.1002/ccd.10560;;15038419;;10.1586/14779072.2.1.117,"Abstract of Leonard W.H. Tse et al., “In Vivo Antegrade Fenestration of Abdominal Aortic Stent-Grafts”, “Journal of Endovascular Therapy”, Apr. 2007, pp. 158-167, vol. 14, No. 2, Publisher: Journal of Endovascular Therapy, Published in: US.;;Abstract of Richard G. McWilliams et al., “In Situ Stent-Graft Fenestration to Preserve the Left Subclavian Artery”, “Journal of Endovascular Therapy”, Apr. 2004, pp. 170-174, vol. 11, No. 2, Publisher: Journal of Endovascular Therapy, Published in: US.;;Abstract of Richard G. McWilliams et al., “Retrograde Fenestration of Endoluminal Grafts From Target Vessels: Feasibility, Technique, and Potential Usage”, “Journal of Endovascular Therapy”, Oct. 2003, pp. 946-952, vol. 10, No. 5, Publisher: Journal of Endovascular Therapy, Published in: US.;;Arrow International Brochure Super Arrow-Flex Transseptal Sheath Introducer, 2002.;;Benson, Lee N., David Nykanen, Amanda Collison, “Radiofrequency Perforation in the Treatment of Congenital Heart Disease”. Catherizations and Cardiovascular Interventions; 56: 72-82, 2002.;;Boston Scientific Corporation “http://www.bostonscientific.com/med.sub.-specialty/deviceDetail.jsp?tas-k=tskBasicDevice.jsp&sectionId=4&relId=2,74,75,76&deviceId=11026&uniqueID=-MPDB2799”. PT2 Guide Wire. 2 pages (Date of printing—Jun. 2005).;;Boston Scientific Corporation. “http://www.bostonscientific.com/med.sub.-specialty/deviceDetail.jsp?tas-k=tskBasicDevice.jsp&sectionid=4&relId=1,20,21,22&deviceid=488&uniqueID=MP-DB58”. Explorer ST Catheters. 2 pages. (Date or printing—Jun. 2005).;;Brendan M. Stanley et al., “Fenestration in Endovascular Grafts for Aortic Aneurysm Repair: New Horizons for Preserving Blood Flow in Branch Vessels”, “Journal of Endovascular Therapy”, Feb. 2001, pp. 16-24, vol. 8, Publisher: Journal of Endovascular Therapy, Published in: US.;;CA Pedra, RM Filho, RS Arrieta, R Tellez, VF Fontes. “Recanalizationof a discrete atretic right pulmonary artery segment with a new radiofrequency system”. Catheter Cardiovasc. Interv. 60(1):82-87 (Sep. 2003).;;Carlos A.C. Pedra Luciano N.L. De Sousa, Simone R.F.F. Pedra, Waldinai P. Ferreira, Sergio L.N. Braga, Cesar A. Esteves, Maria Virginia T. Santana, J. Eduardo Sousa, Valmir F. Fontes; New Percutaneous Techniques for Perforating the Pulmonary Valve in Pulmonary Atresia with Intact Ventricular Septum; Arq Bras Cardiol. Nov. 2001;77(5):471-86.;;Christophe Fink, Mattias Peuster, Harald Bertram, Gerd Hausdorf; Transcatheter Recanalization of the Left Main Pulmonary Artery After Four Years of Complete Occlusion; Catheterization and Cardiovascular Interventions Jan. 2004;2(1): 117-26.;;Conti “finite element analysis of self-expanding braided wirestent” 2006-2007.;;Conti C. R., “Transseptal Left Heart Catheterization for Radiofrequency Ablation of Accessory Pathways”. Clinical Cardiology; 16: 367-368, 1993.;;Daniel S. Levi, Juan C. Alejos, John W. Moore; Future of Interventional Cardiology in Pediatrics; Current Opinion in Cardiology Mar. 2003;18(2):79-90.;;DG Nykanen, J Phikala, GP Taylor, LN Benson. “Radiofrequency assisted perforation of the atrial septum in a swine model: feasibility, biophysical and histological characteristics”, Circulation. 100(Suppl 1):l-804 (1999).;;Edward B. Diethrich, “Side Branch Preservation During Endovascular Aortic Aneurysm Repair”, “Journal of Endovascular Therapy”, Feb. 2001, pp. 1-2, vol. 8, Publisher: Journal of Endovascular Therapy, Published in: US.;;Entire prosecution history of U.S. Appl. No. 11/905,448 from Oct. 1, 2007 to Aug. 22, 2012; Inventor: Biadillah, Youssef et al.;;Entire prosecution history of U.S. Appl. No. 13/286,041 from Oct. 31, 2011 to Aug. 14, 2013; Inventor: Biadillah, Youssef et al.;;F Godart, C Francart, GM Breviere, C Rey. “Pulmonary vavulotomy with the Nykanen radiofrequency guide in pulmonary atresia with intact interventricular septum”, Arch Mal Coeur Vaiss. 96(5):517-520 (May 2003), Article is in French with an English summary.;;Fink, Peuster, Bertram, Hausdorf. Transcatheter Recanalization of the Left Main Pulmonary Artery after Four Years of Complete Occlusion Catheterization and Cardiovascular Interventions. May 2001;53(1):81-4.;;First Office Action for Chinese Application, Application/Patent No. 2015800262435, Issue Serial No. 2018122001954460, dated Dec. 25, 2018.;;Frank R. Arko III, “In Pursuit of an Off-the Shelf Fenestrated Stent-Graft: Radiofrequency Perforation for In Vivo Antegrade Fenestration”, “Journal of Endovascular Therapy”, Apr. 2010, pp. 199-200, vol. 17, No. 2, Publisher Journal of Endovascular Therapy, Published in: US.;;G Veldtman, A Peirone, LN Benson. “Radiofrequency perforation of the atrial septum: Preliminary experimental evaluation and development” Pics VII Abstracts Catheter Cardiovasc Interv 60(1):132 (Sep. 2003).;;George Joseph, Dibya K. Baruah, Sajy V. Kuruttukulam, Sunil Thomas Chandy, Shanker Krishnaswami. “Transjugular Approach to Transseptal Balloon Mitral Valvuloplasty”. Catheterization and Cardiovascular Diagnosis 42:219-226 (1997).;;George Joseph, G. Rajendiran, K. Abhaichand Rajpal. “Transjugular Approach to Concurrent Mitral-Aortic and Mitral-Tricuspid Balloon Valvuloplasty”. Catheterization and Cardiovascular Interventions 49:335-341 (2000).;;George Joseph, K.P. Suresh Kumar, Paul V. George, Subodh Dhanawade. “Right Internal Jugular Vein Approach as an Alternative in Balloon Pulmonary Valvuloplasty”. Catheterization and Cardiovascular Interventions 46:425-429 (1999).;;George Joseph, Oommen K. George, Asishkumar Mandalay, Sunil Sathe. “Transjugular Approach to Balloon Mitral Valvuloplasty Helps Overcome Impediments Caused by Anatomical Alterations”. Catheterization and Cardiovascular Interventions 57:353-362 (2002).;;Gero Hausdorf, Martin Schneider. Peter Lange; Catheter Creation of an Open Outflow Tract in Previously Atretic Right Ventricular Outflow Tract Associated with Ventricular Septal Defect; The American Journal of Cardiology, Aug. 1, 1993;72(3):354-6.;;H Justino, LN Benson, DG Nykanen. “Transcatheter Creation of an Atrial Septal Defect Using Radiofrequency Perforation”. Catheter Cardiovasc Interv. 54(1):83-87 (Sep. 2001).;;Hector Biddogia, Juan P. Maciel, Jose A. Alvarez et al. “Transseptal Left Heart Catheterization: Usefulness of the Intracavitary Electrocardiogram in the Localization of the Fossa ovalis”. Catheterization and Cardiovascular Diagnosis 24: 221-225 (1991).;;Holzer, Hardin, Hill, Chisolm, Cheatham. Radiofrequency Energy-A Multi-Facetted Tool for the Congenital Interventionist. Congenital Cardiology Today. Jun. 2006; 4(6): 1-.;;Hugh Calkins, Yoon-Nyun Kim, Steve Schmaltz, Joao Sousa, Rafel El-Atassi, Angel Leon, Alan Kadish, Jonathan J. Langberg, Fred Morady; Electrogram Criteria for Identification of Appropriate Target Sites for Radiofrequency Cathetei Ablation of Accessory Atrioventricular Connections; Feb. 1992;85(2):565-73.;;HW Kort, DT Balzer. “Radiofrequency perforation in the treatment of acquired left pulmonary atresia following repair of teraligy of Fallot”. Catheter Cardiovasc Interv. 60(1):79-81 (Sep. 2003).;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2007/061203, dated Oct. 26, 2007, 8 pages.;;IntraLuminal Therapeutics, Inc. “http://www.intraluminal.com/products/catheter.html”. Safe Cross Support Catheter. 1 page. (Date of Printing—Jun. 2005).;;J. Thompson Sullebarger, Humberto Coto, Enrique Lopez, Dany Sayad, Hector L. Fontanet. “Transjugular Percutaneous Inoue Balloon Mitral Commissurotomy in a Patient With Inferior Vena Cava Obstruction After Liver Transplantation”. Catheterization and Cardiovascular Interventions 59:261-265 (2003).;;John Lennon Anderson et al., “Endoluminal Aortic Grafting with Renal and Superior Mesenteric Artery Incorporation by Graft Fenestration”, “Journal of Endovascular Therapy”, Feb. 2001, pp. 3-15, No. 8, Publisher: Journal of Endovascular Therapy, Published in: US.;;Johnson & Johnson Gateway, LLC. “http://www.jnjgateway.com/home.jhtml;jsessionid=JNSFHTWOAOIC0CQPCCECPJYK-B2IIWNSC?icc=USENG&page=viewContent&contentid=IC0de00100000524&nodekey=/Pr-od.sub.-Info/Specialty/Cardiovascular.sub.-and.sub.-Thoracic/Cardiac.su-b.-Diagnosis.sub.-Interventions/Diagnostic.sub.-Wires&.sub.-requestid=-228905”, Diagnostic Guidewires, 4 pages.;;Johnson & Johnson Gateway, LLC. “http://www.jnjgateway.com/home.jhtml?loc=USENG& page=viewContent&contentId=lc0de00100001435&nodekey=/Prod.sub.-info/Spec-ialty/Arrhythmia.sub.-Management/Electrophysiology/EP.sub.-Diagnostic.su-b.-Catheters”. EP Diagnostic Catheters, 2 pages (Date of printing—Jun. 2005).;;Justino, Henri, Lee N. Benson, David G. Nykanen. “Transcatheter Creation of an Atrial Septal Defect Using Radiofrequency Perforation”. Catheterization and Cardiovascular Interventions. 56:412-415 (2002).;;Lake Region Manufacturing, Inc. “http://www.lakergn.com/jmc.htm”. Paragon Guidewire. 2 pages (Date of Printing—Jun. 2005).;;Leonard W. H. Tse et al., “Radiofrequency Perforation System for an In Vivo Antegrade Fenestration of Aortic Stent-Grafts”, “Journal of Endovascular Therapy”, Apr. 2010, pp. 192-198, vol. 17, No. 2, Publisher: Journal of Endovascular Therapy, Published in: US.;;Lepage, Lewis, Ruiz, Yamanishi, Padron, Hood. Angiopyroplasty using Electromagnetically Induced Focused Heat. Angiology. Jul. 1987;38(7):520-3.;;Medtronic Inc. “http://www.medtronic.com/epsystems/diagnostic.sub.-catheters.html”. Diagnostic Catheters. 7 pages (Date of Printing—Apr. 2005).;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2015/052118, dated Sep. 27, 2016.;;Patent Cooperation Treaty, International Search Report for International Application No. PCT/IB2015/052118, dated Jun. 26, 2015.;;Pressure Products, Inc. http://www.pressure-products.com/Downloads/Education.sub.-PDFs/Using.sub--CSG sub-v2 pdf. 4 pages. 2005.;;Shyam S. Kothari, Sanjeev K. Sharma, Nitish Naik; Radiofrequency Perforation for Pulmonary Atresia and Intact Ventricular Septum; Indian Heart J Jan.-Feb. 2004;56(1):50-3 (Actual publication after Feb. 2004).;;Suhonen M. et al. Recanalization of arterial occlusions using a specially designed steering catheter. European Radiology: 2, 264-265(1992).;;Supplementary European Search Report, EP 15 76 8911, search completed on Nov. 1, 2017.;;Szili-Torok, T. et al. (2001) Transseptal Left Heart Catherisation Guided by Intracardiac Echocardiography, Heart 86:e11.;;T Abdel-Massih, Y Boudjemline, P Bonhoeffer. “Unusual Interventional management in an adult with tetralogy of Fallot” Cardiol Young 13(2):203-205 (Apr. 2003).;;T Humpl, B Soderberg, BW McCrindle, DG Nykanen, RM Freedom, WG Williams, LN Benson. “Percutaneous Balloon Valvotomy in Pulmonary Atresia with Intact Ventricular Septum: Impacton Patient Care”. Circulation. 108(7): 826-832 (Aug. 2003).;;Timothy A.M. Chuter, “Branched and Fenestrated Stent Grafts for Endovascular Repair of Thoracic Aortic Aneurysms”, Oct. 27, 2005, p. 111A-115A, vol. 43, No. A, Publisher: The Society for Vascular Sugery, Published in US.;;Translation of JP407303703.;;Tsung O. Cheng. “All Roads Lead to Rome:Transjugular or Transfemoral Approach to Percutaneous Transseptal Balloon Mitral Valvuloplasty?”. Catheterization and Cardiovascular Interventions 59:266-267 (2003).;;Veldtman, Hartley, Visram, Benson. Radiofrequency Applications in Congenital Heart Disease. Expert Rev Cardiovasc Ther. Jan. 2004;2(1):117-26.",ACTIVE
67,US,A1,US 2012/0232546 A1,119-324-641-903-987,2012-09-13,2012,US 201213468939 A,2012-05-10,US 201213468939 A;;US 90544707 A;;US 82745206 P;;US 88428507 P,2006-09-29,Radiofrequency Perforation Apparatus,"A radiofrequency perforation apparatus for creating a channel at a target location in a body of a patient, the radiofrequency perforation apparatus comprising: a substantially tubular member defining a tubular member lumen; an end member partially positioned within the tubular member lumen at a distal end of the tubular member, the end member including an electrode; and an electrical insulator extending along the substantially tubular member.",MIRZA MAHMOOD;;DAVIES GARETH;;BAYLIS MEDICAL COMPANY,MIRZA MAHMOOD;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2012-04-12);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/119-324-641-903-987,Patent Application,yes,1,27,4,113,0,A61B18/1482;;A61B18/1492;;A61B2018/00011;;A61B2018/00083;;A61B2018/00351;;A61B2018/00839;;A61B2218/002;;A61B2090/064;;A61B18/1482;;A61B2018/00083;;A61B2018/00351;;A61B2018/00839;;A61B18/1492;;A61B2018/00011;;A61B2218/002;;A61B2090/064,A61B18/18,606/33,0,0,,,,ACTIVE
68,US,S,US D0594308 S,183-128-762-140-827,2009-06-16,2009,US 29786107 F,2007-11-20,US 29786107 F,2007-11-20,Hand-holdable cutting device,,TONIC STUDIOS LTD,DAVIES GARETH;;BATHARD SIMON,TONIC STUDIOS LIMITED (2007-11-13),https://lens.org/183-128-762-140-827,Design Right,no,0,8,1,1,0,,,0803;;D 8 98,0,0,,,,EXPIRED
69,US,A1,US 2011/0281852 A1,194-653-730-821-198,2011-11-17,2011,US 201113069375 A,2011-03-22,US 201113069375 A;;US 34072810 P,2010-03-22,Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs,"The compositions and methods disclosed herein are of use for the treatment and prevention of weight gain and obesity. In particular, the compositions and methods include treatment of weight gain and obesity with berberine and/or berberine analogs alone or in combination thereof to cause a reduction in an individual's weight or prevent weight gain or obesity. In certain embodiments, the weight gain and obesity are associated with administration of anti-psychotic drugs. In an alternative embodiment, the compositions and methods provide berberine or berberine analogs alone or for coadministration with an anti-psychotic agent. In an additional embodiment, the compositions and methods further include a natural product. The usefulness of the present invention is that berberine and berberine analogs do not have synergistic effects with other drugs and administration results in few side effects. Such characteristics of berberine or berberine analogs are a great improvement able to support the widespread use of the compositions and methods of the present invention as therapeutics for the treatment and prevention of weight gain and obesity.",DAVIES GARETH;;HU YUESHAN,DAVIES GARETH;;HU YUESHAN,,https://lens.org/194-653-730-821-198,Patent Application,yes,0,3,3,3,26,A61K31/4375;;A61P25/00;;A61P25/18;;A61P25/24;;A61P3/00;;A61P3/04;;A61K31/4375,A61K31/4375;;A61K31/519;;A61K31/551;;A61P3/04,514/220;;514/280;;514/259.41,0,0,,,,DISCONTINUED
70,US,A1,US 2023/0166090 A1,053-459-979-488-683,2023-06-01,2023,US 202117920214 A,2021-04-15,US 202117920214 A;;US 202063013646 P;;IB 2021053119 W,2020-04-22,SHEATH ASSEMBLY AND/OR DILATOR ASSEMBLY,"An apparatus is for an elongated sheath assembly configured to receive, at least in part, an elongated dilator assembly. The apparatus includes a dilator-receiver device configured to be installed to the elongated sheath assembly. A dilator-receiver mover is configured to be mounted, at least in part, to the elongated sheath assembly. The dilator-receiver mover is configured to be operatively connected to the dilator-receiver device. The dilator-receiver mover is also configured to selectively move the dilator-receiver device along a predetermined distance.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2021-09-05);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/053-459-979-488-683,Patent Application,yes,0,0,5,5,0,A61M29/00;;A61B2017/00247;;A61M25/0662;;A61B17/3478;;A61M29/00,A61M29/00,,0,0,,,,PENDING
71,US,A1,US 2021/0393246 A1,144-841-058-735-578,2021-12-23,2021,US 202117340615 A,2021-06-07,US 202117340615 A;;US 202063040577 P,2020-06-18,ELONGATED MEDICAL ASSEMBLY HAVING SELECTIVELY EXPANDABLE-AND-CONTRACTIBLE ASSEMBLY,"An elongated medical assembly has a distal region configured to be positioned, at least in part, proximate to a biological feature of a patient. A puncture assembly is configured to be located proximate to the distal region. A selectively expandable-and-contractible assembly is located proximate to the distal region.",BAYLIS MEDICAL CO INC,LEUNG CHARLENE;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2021-09-05);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/144-841-058-735-578,Patent Application,yes,2,0,1,1,0,A61B2017/00247;;A61B17/3478;;A61M25/104;;A61M25/0606;;A61M2025/0024;;A61M25/10;;A61B2017/3486;;A61B17/3209;;A61B2017/3488;;A61B17/00234;;A61B17/0057;;A61B2017/00247;;A61B2017/00672;;A61B2017/00592,A61B17/00,,0,0,,,,PENDING
72,US,A1,US 2013/0345554 A1,132-981-706-899-319,2013-12-26,2013,US 201313912244 A,2013-06-07,US 201313912244 A;;US 201261657371 P,2012-06-08,Methods for recanalization of vessels,"A method for advancing a medical instrument along a desired trajectory or path in one dimension while remaining within a particular area defined in an orthogonal dimension. For example, a method of traversing an occlusion within a body vessel using a medical instrument, the method comprising steps of positioning a target object at a first side of the occlusion, imaging the target object along an imaging plane substantially parallel to a longitudinal axis of the occlusion and advancing the medical instrument within the body vessel through an opposite side of the occlusion, thereby traversing the occlusion.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;LEUNG RAMSEY,BAYLIS MEDICAL COMPANY INC (2013-06-03),https://lens.org/132-981-706-899-319,Patent Application,yes,5,2,1,1,0,A61B17/3207;;A61B2017/22044;;A61B2017/22094;;A61B6/487;;A61B6/504;;A61B2090/376;;A61B2090/3966;;A61B6/12;;A61B17/32056;;A61B6/4441;;A61B6/12;;A61B6/485;;A61B17/32056;;A61B6/4441;;A61B2017/22094;;A61B17/3207;;A61B2017/22044;;A61B6/504;;A61B6/487;;A61B2090/3966;;A61B2090/376,A61B6/12;;A61B6/00;;A61B17/3205,600/424,1,0,,,"McGuckin et al., A new Pathway for Central Venous Occlusion, Endovascular Today, 1-3 (July 2009).",DISCONTINUED
73,US,B2,US 8192425 B2,167-418-081-612-468,2012-06-05,2012,US 90544707 A,2007-10-01,US 90544707 A;;US 82745206 P;;US 88428507 P,2006-09-29,Radiofrequency perforation apparatus,"A radiofrequency perforation apparatus for creating a channel at a target location in a body of a patient, the radiofrequency perforation apparatus being usable by an intended user having a hand, the radiofrequency perforation apparatus comprising: a handle graspable by the hand; a distal portion, the distal portion defining a distal portion length, the distal portion including an electrode and an electrical insulator extending from the electrode; and a force transmitting portion extending between the distal portion and the handle, the force transmitting portion defining a force transmitting portion length, the force transmitting portion length being larger than the distal portion length, the force transmitting portion having a force transmitting portion flexural rigidity of at least about 0.016 Nm 2 ; whereby the force transmitting portion has a force transmitting portion flexural rigidity allowing the transmission to the handle of contact forces exerted on the distal portion when the distal portion contacts the target location to provide tactile feedback to the intended user.",MIRZA MAHMOOD;;DAVIES GARETH;;BAYLIS MEDICAL CO INC,MIRZA MAHMOOD;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2011-06-17);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/167-418-081-612-468,Granted Patent,yes,8,60,4,113,0,A61B18/1482;;A61B18/1492;;A61B2018/00011;;A61B2018/00083;;A61B2018/00351;;A61B2018/00839;;A61B2218/002;;A61B2090/064;;A61B18/1482;;A61B2018/00083;;A61B2018/00351;;A61B2018/00839;;A61B18/1492;;A61B2018/00011;;A61B2218/002;;A61B2090/064,A61B18/18,606/41;;606/40,0,0,,,,ACTIVE
74,WO,A2,WO 2012/167281 A2,005-460-266-390-720,2012-12-06,2012,US 2012/0040808 W,2012-06-04,US 201161492795 P,2011-06-02,CLINICAL APPLICATION UTILIZING GENETIC DATA FOR EFFECTIVE MEDICATION MANAGEMENT,"The present disclosure relates a predictive method, based on a subject's genetic profile, which defines variability in a specific disease or condition to determine medication response, including determining select VNTR and SNP occurrence combinations which are associated with specific responses to medications, kits and DNA chips/arrays containing such combinations so as to effectuate better medication management.",DAVIES GARETH;;HANSEN RYAN,DAVIES GARETH;;HANSEN RYAN,,https://lens.org/005-460-266-390-720,Patent Application,yes,0,0,3,3,10,A61K31/135;;A61K31/135;;A61K31/137;;A61K31/137;;A61K31/445;;A61K31/445;;A61P25/00,A61K31/445;;A61K31/135;;A61K31/137;;A61P25/00,,0,0,,,,PENDING
75,US,A1,US 2007/0185522 A1,046-365-192-807-619,2007-08-09,2007,US 72738207 A,2007-03-26,US 72738207 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 74372206 P,2003-01-21,Dilator,"A dilator, the dilator being positionable substantially adjacent an aperture in a tissue and usable to enlarge the aperture, the dilator comprising a substantially elongated member, the substantially elongated member defining a member proximal end section, a substantially longitudinally opposed member distal end section and a member middle section extending therebetween, the member middle section including a tube defining a tube lumen extending substantially longitudinally therethrough and a reinforcing component located, at least in part, within the tube lumen, the member middle section being substantially less mechanically deformable than the member distal end section; whereby having the member distal end section substantially more mechanically deformable than the member middle section reduces risks of injuring the tissue with the member distal end section when positioning the member distal end section substantially adjacent the aperture while allowing for the transmission of substantially longitudinal forces from the member proximal end section to the member distal end section to enlarge the aperture by pushing, at least in part, the member distal end section through the aperture.",DAVIES GARETH;;AMANDA HARTLEY,DAVIES GARETH;;AMANDA HARTLEY,BAYLIS MEDICAL COMPANY INC (2007-03-22),https://lens.org/046-365-192-807-619,Patent Application,yes,14,52,1,113,0,A61M29/00;;A61M29/00;;A61M25/0041;;A61M25/0041;;A61M25/0054;;A61M25/0054;;A61M2025/0046;;A61M2025/0046,A61M29/00,606/191,1,0,,,translation of JP407303703,DISCONTINUED
76,US,A1,US 2021/0186365 A1,185-166-145-506-117,2021-06-24,2021,US 201916720190 A,2019-12-19,US 201916720190 A,2019-12-19,"METHODS FOR DETERMINING A POSITION OF A FIRST MEDICAL DEVICE WITH RESPECT TO A SECOND MEDICAL DEVICE, AND RELATED SYSTEMS AND MEDICAL DEVICES",A first medical device includes an elongate member having a lumen extending longitudinally therethrough from a proximal end to a distal end. A second medical device includes a needle advanceable through the lumen from the proximal end towards the distal end. A capacitor is configured so that the capacitance of the capacitor is a measure of a longitudinal position of the needle with respect to the elongate member. A capacitance sensor is configured to sense the capacitance of the capacitor as the needle is advanced through the lumen. A processor is in communication with the capacitance sensor. An output device is in communication with the processor and is configured to generate an output indicative of the longitudinal position of the needle with respect to the elongate member.,BAYLIS MEDICAL CO INC,KINIO STEVEN;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2019-12-17);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/185-166-145-506-117,Patent Application,yes,1,0,1,1,0,A61B90/06;;G01D5/241;;A61B2090/062;;A61B5/065;;A61M25/0612;;G01R27/2605;;A61B2090/0811;;A61B90/08,A61B5/06;;A61B90/00;;A61M25/06,,2,1,109-486-569-175-055,10.1016/j.measurement.2005.12.012,"Bentley (Principles of measurement systems. Harlow: Pearson/Prentice Hall, 2005) (Year: 2005);;Kim et al. (“A new linear encoder-like capacitive displacement sensor,” Measurement 39 (2006) 481–489) (Year: 2006)",PENDING
77,US,B2,US 9179932 B2,070-494-946-066-978,2015-11-10,2015,US 201414257053 A,2014-04-21,US 201414257053 A;;US 201213656173 A;;US 531607 A;;US 88307407 P,2007-01-02,Cardiac electrosurgery,"Devices and methods are disclosed for providing access to the pericardial cavity while reducing risk of myocardial damage. One method includes advancing a puncture device towards a heart, the puncture device including an energy delivery device; measuring an electrical impedance at the energy delivery device; delivering energy from the energy delivery device to at least partially puncture a pericardium; and repeating one or more of the above steps, if necessary, until the energy delivery device is located at least partially within the pericardial cavity. Some embodiments of the method include using supplemental means of monitoring, including measuring voltage to plot an ECG, medical imaging and using contrast fluid, using tactile feedback, and aspirating fluid.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;KLEIN GEORGE,BAYLIS MEDICAL COMPANY INC (2014-10-04);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/070-494-946-066-978,Granted Patent,yes,15,6,2,11,0,A61B17/3478;;A61B18/1492;;A61B2017/00154;;A61B2017/00353;;A61B2017/22014;;A61B2018/00083;;A61B2018/00291;;A61B2018/00351;;A61B2018/00589;;A61B2018/00702;;A61B2018/00839;;A61B2018/00875;;A61B2017/00026;;A61B2017/00247;;A61B17/2202;;A61B2018/1861;;A61B2090/064;;A61B90/37;;A61B17/34;;A61B2017/00243;;A61B2018/00363;;A61B2018/00601;;A61B2017/32007;;A61B2017/320069;;A61B17/34;;A61B2017/00243;;A61B2018/00363;;A61B2018/00601;;A61B2017/32007;;A61B2017/320069;;A61B17/2202;;A61B2018/1861;;A61B17/3478;;A61B18/1492;;A61B2017/00154;;A61B2017/00353;;A61B2017/22014;;A61B2018/00083;;A61B2018/00291;;A61B2018/00351;;A61B2018/00589;;A61B2018/00702;;A61B2018/00839;;A61B2018/00875;;A61B2017/00026;;A61B2017/00247;;A61B90/37;;A61B2090/064,A61B18/18;;A61B17/00;;A61B17/22;;A61B17/32;;A61B17/34;;A61B18/00;;A61B18/14;;A61B19/00,,2,0,,,"Entire Prosecution History of U.S. Appl. No. 12/005,316 from Dec. 27, 2007 to Oct. 24, 2012.;;Entire Prosecution History of U.S. Appl. No. 13/656,173 from Oct. 19, 2012 to Jul. 15, 2014.",ACTIVE
78,US,B2,US 11744638 B2,133-497-732-110-07X,2023-09-05,2023,US 202117399720 A,2021-08-11,US 202117399720 A;;US 202017074084 A;;US 201916532980 A;;US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 82745206 P;;US 88428507 P,2006-09-29,Electrosurgical device,An electrosurgical device for puncturing tissue comprises an electrically conductive elongate member which is capable of force transmission from a distal portion of the electrosurgical device to a proximal portion of the electrosurgical device to thereby provide tactile feedback to a user. The proximal portion comprises a connector system for connecting a source of energy and a source of fluid to an electrosurgical device. The connector system includes a hub which includes an electrically conductive lengthwise member having a lengthwise member distal region and a lengthwise member proximal region. The lengthwise member defines a hub lumen therebetween and is configured to be operatively coupled to an electrosurgical device.,BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;MIRZA MAHMOOD,BAYLIS MEDICAL COMPANY INC (2021-10-01);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/133-497-732-110-07X,Granted Patent,yes,340,0,3,113,0,A61B18/1492;;A61B2018/00357;;A61B2018/00083;;A61B2018/00172;;A61B2018/00178;;A61B2018/00077;;A61B2018/00309;;A61B2018/00142;;A61B2090/064;;A61M5/007;;A61B2018/00029;;A61M2210/125;;A61B18/1482;;A61B2018/00083;;A61B2018/00351;;A61B2090/064;;A61B18/1492;;A61B2018/00011;;A61B2218/002;;A61B2018/00839,A61B18/18;;A61B18/00;;A61B18/14;;A61B90/00,,61,44,013-298-075-588-774;;035-621-526-377-948;;023-749-888-124-005;;012-647-127-487-753;;030-041-321-743-550;;015-569-231-826-071;;007-454-134-946-40X;;007-454-134-946-40X;;102-284-308-414-898;;007-454-134-946-40X;;053-709-812-994-938;;012-193-495-831-569;;015-569-231-826-071;;013-523-269-156-951;;026-941-827-483-484;;020-214-294-476-433;;012-193-495-831-569;;016-249-543-201-808;;041-100-996-150-282;;056-565-923-253-058;;066-004-459-025-109;;003-336-720-517-736;;038-743-504-882-104;;114-217-294-103-276;;096-535-125-477-640;;006-495-373-391-557;;022-127-515-170-102;;080-511-818-680-898;;064-062-639-916-470;;104-863-760-253-161;;006-495-373-391-557;;126-172-010-773-649;;126-172-010-773-649;;043-109-600-839-627;;041-155-588-518-082;;022-286-573-136-47X;;063-832-404-449-689;;090-845-072-200-001;;113-591-253-296-335;;061-080-657-413-13X;;079-220-343-462-372;;027-249-765-633-859;;044-496-843-651-986;;040-553-861-085-191,10.1583/1545-1550(2007)14[158:ivafoa]2.0.co;2;;17484531;;10.1177/152660280701400207;;15056015;;10.1583/03-1180.1;;14656175;;10.1583/1545-1550(2003)010<0946:rfoegf>2.0.co;2;;10.1177/152660280301000518;;11979539;;10.1002/ccd.10213;;10.1583/1545-1550(2001)008<0016:fiegfa>2.0.co;2;;10.1177/152660280100800103;;11220463;;8504569;;10.1002/clc.4960160502;;11733820;;10.1590/s0066-782x2001001100008;;11733820;;10.1590/s0066-782x2001001100008;;10.1002/ccd.10602;;12929108;;11733820;;10.1590/s0066-782x2001001100008;;9768726;;10.1016/s0735-1097(98)00357-x;;11329224;;10.1002/ccd.1135;;8504569;;10.1002/clc.4960160502;;12652210;;10.1097/00001573-200303000-00002;;10.1177/152660280100800101;;10.1583/1545-1550(2001)008<0001:sbpdea>2.0.co;2;;11220462;;12838844;;11329224;;10.1002/ccd.1135;;10.1583/09-2903c.1;;20426637;;8489867;;10.1136/hrt.69.4.343;;pmc1025049;;10.1002/(sici)1097-0304(199710)42:2<219::aid-ccd30>3.0.co;2-g;;9328715;;10700071;;10.1002/(sici)1522-726x(200003)49:3<335::aid-ccd24>3.0.co;2-n;;10216007;;10.1002/(sici)1522-726x(199904)46:4<425::aid-ccd7>3.0.co;2-r;;12410514;;10.1002/ccd.10358;;10.1016/0002-9149(93)90687-8;;8342519;;12112899;;10.1002/ccd.10222;;11553955;;10.1002/ccd.1244;;1764747;;10.1002/ccd.1810240318;;10.1161/01.cir.85.2.565;;1735152;;12772255;;10.1002/ccd.10506;;10.1583/1545-1550(2001)008<0003:eagwra>2.0.co;2;;11220465;;10.1177/152660280100800102;;11553955;;10.1002/ccd.1244;;10.1023/a:1009870227401;;11248781;;10.1023/a:1009870227401;;11248781;;10.1583/09-2903.1;;20426636;;10.1177/000331978703800704;;2956910;;11094817;;10.1007/bf02345756;;15129792;;10.1007/bf00595842;;10.1136/heart.86.5.e11;;11602562;;pmc1729980;;10.1017/s1047951103000398;;12887081;;12885744;;10.1161/01.cir.0000084548.44131.d1;;16473163;;10.1016/j.jvs.2005.10.059;;12772256;;10.1002/ccd.10560;;15038419;;10.1586/14779072.2.1.117,"Abstract of European Patent No. 0315730 to Osypka. May 1989.;;Abstract of Leonard W.H. Tse et al., “In Vivo Antegrade Fenestration of Abdominal Aortic Stent-Grafts”, “Journal of Endovascular Therapy”, Apr. 2007, pp. 158-167, vol. 14, No. 2, Publisher: Journal of Endovascular Therapy, Published in: US.;;Abstract of Richard G. McWilliams et al., “In Situ Stent-Graft Fenestration to Preserve the Left Subclavian Artery”, “Journal of Endovascular Therapy”, Apr. 2004, pp. 170-174, vol. 11, No. 2, Publisher: Journal of Endovascular Therapy, Published in: US.;;Abstract of Richard G. McWilliams et al., “Retrograde Fenestration of Endoluminal Grafts From Target Vessels: Feasibility, Technique, and Potential Usage”, “Journal of Endovascular Therapy”, Oct. 2003, pp. 946-952, vol. 10, No. 5, Publisher: Journal of Endovascular Therapy, Published in: US.;;Benson, Lee N., David Nykanen, Amanda Collison, “Radiofrequency Perforation in the Treatment of Congenital Heart Disease”. Catherizations and Cardiovascular Interventions; 56: 72-82, 2002.;;Boston Scientific Corporation “http://www.bostonscientific.com/med.sub.-specialty/deviceDetail.jsp?tas-k=tskBasicDevice.jsp&sectionId=4&relId=2,74,75,76&deviceId=11026&uniqueID=-MPDB2799”. PT2 Guide Wire. 2 pages (Date of printing—Jun. 2005).;;Boston Scientific Corporation. “http://www.bostonscientific.com/med.sub.--specialty/deviceDetail.jsp?tas-k=tskBasicDevice.jsp&sectionid=4&relId=1,20,21,22&deviceid=488&uniqueID=MP- DB58”. Explorer ST Catheters. 2 pages. (Date or printing—Jun. 2005).;;Brendan M. Stanley et al., “Fenestration in Endovascular Grafts for Aortic Aneurysm Repair: New Horizons for Preserving Blood Flow in Branch Vessels”, “Journal of Endovascular Therapy”, Feb. 2001, pp. 16-24, vol. 8, Publisher: Journal of Endovascular Therapy, Published in: US.;;C.R. Conti. “Transseptal Left Heart Catheterization for Radiofrequency Ablation of Accessory Pathways”. Clin. Cardiel. 16, 367-368 (1993).;;CA Pedra, LN De Sousa, SR Pedra, WP Ferreira, SL Braga, CA Esteves, MV Santant, JE Sousa, VF Fontes. “New Percutaneous Techniques for Perforating the Pulmonary Valve in Pulmonary Atresia with Intact Ventricular Septum”. Arq. Bras Cariol. 77(5):471-478 (2001).;;CA Pedra, LN de Sousa, SR Pedra, WP Ferreira, SL Braga, CA Esteves, MV Santant, JE Sousa, VF Fontes. “New Percutaneous Techniques for Perforating the Pulmonary Valve in Pulmonary Atresia with Intact Ventricular Septum”. Arq. Bras Cariol. 77(5):479-486 Nov. 2001.;;CA Pedra, RM Filho, RS Arrieta, R Tellez, VF Fontes. “Recanalizationof a discrete atretic right pulmonary artery segment with a new radiofrequency system”. Catheter Cardiovasc. Interv. 60(1):82-87 (Sep. 2003).;;Carlos A.C. Pedra Luciano N.L. De Sousa, Simone R.F.F. Pedra, Waldinai P. Ferreira, Sergio L.N. Braga, Cesar A. Esteves, Maria Virginia T. Santana, J. Eduardo Sousa, Valmir F. Fontes; New Percutaneous Techniques for Perforating the Pulmonary Valve in Pulmonary Atresia with Intact Ventricular Septum; Arq Bras Cardiol. Nov. 2001;77(5):471-86.;;Christodoulos Stefanadis. “Retrograde Nontransseptal Balloon Mitral Valvuloplasty: Immediate Results and Intermediate Long-Term Outcome in 441 Cases—A Multicentre Experience”. Journal of the American College of Cardiology. 32(4): 1009-16 (1998).;;Christophe Fink, Mattias Peuster, Harald Bertram, Gerd Hausdorf; Transcatheter Recanalization of the Left Main Pulmonary Artery After Four Years of Complete Occlusion; Catheterization and Cardiovascular Interventions Jan. 2004,2(1):117-26.;;Conti “finite element analysis of self-expanding braided wirestent” 2006-2007.;;Conti C. R., “Transseptal Left Heart Catheterization for Radiofrequency Ablation of Accessory Pathways”. Clinical Cardiology; 16: 367-368, 1993.;;Daniel S. Levi, Juan C. Alejos, John W. Moore; Future of Interventional Cardiology in Pediatrics; Current Opinion in Cardiology Mar. 2003;18(2):79-90.;;DG Nykanen, J Phikala, GP Taylor, LN Benson. “Radiofrequency assisted perforation of the atrial septum in a swine model: feasibility, biophysical and histological characteristics”, Circulation. 100(Suppl 1):I-804 (1999).;;Edward B. Diethrich, “Side Branch Preservation During Endovascular Aortic Aneurysm Repair”, “Journal of Endovascular Therapy”, Feb. 2001, pp. 1-2, vol. 8, Publisher: Journal of Endovascular Therapy, Published in: US.;;F Godart, C Francart, GM Breviere, C Rey. “Pulmonary vavulotomy with the Nykanen radiofrequency guide in pulmonary atresia with intact interventricular septum”, Arch Mal Coeur Vaiss. 96(5):517-520 (May 2003), Article is in French with an English summary.;;Fink, Peuster, Bertram, Hausdorf. Transcatheter Recanalization of the Left Main Pulmonary Artery after Four Years of Complete Occlusion. Catheterization and Cardiovascular Interventions. May 2001;53(1):81-4.;;First Office Action for Chinese Application, Application/Patent No. 2015800262435, Issue Serial No. 2018122001954460, dated Dec. 25, 2018.;;Frank R. Arko III, “In Pursuit of an Off-the Shelf Fenestrated Stent-Graft: Radiofrequency Perforation for In Vivo Antegrade Fenestration”, “Journal of Endovascular Therapy”, Apr. 2010, pp. 199-200, vol. 17, No. 2, Publisher: Journal of Endovascular Therapy, Published in: US.;;G Hausdorf, I Schulze-Neick, Pe Lange; Radiofrequency-assisted “reconstruction” of the Right Ventricular Outflow Tract in Muscular Pulmonary Atresia with Ventricular Septal Defect; British Heart Journal, Apr. 1993.69(4):343-6.;;G Veldtman, A Peirone, LN Benson. “Radiofrequency perforation of the atrial septum: Preliminary experimental evaluation and development.” PICS VII Abstracts. Catheter Cardiovasc Interv. 60(1):132 (Sep. 2003).;;George Joseph, Dibya K. Baruah, Sajy V. Kuruttukulam, Sunil Thomas Chandy, Shanker Krishnaswami. “Transjugular Approach to Transseptal Balloon Mitral Valvuloplasty”. Catheterization and Cardiovascular Diagnosis 42:219-226 (1997).;;George Joseph, G. Rajendiran, K. Abhaichand Rajpal. “Transjugular Approach to Concurrent Mitral-Aortic and Mitral-Tricuspid Balloon Valvuloplasty”. Catheterization and Cardiovascular Interventions 49:335-341 (2000).;;George Joseph, K.P. Suresh Kumar, Paul V. George, Subodh Dhanawade. “Right Internal Jugular Vein Approach as an Alternative in Balloon Pulmonary Valvuloplasty”. Catheterization and Cardiovascular Interventions 46:425-429 (1999).;;George Joseph, Oommen K. George, Asishkumar Mandalay, Sunil Sathe. “Transjugular Approach to Balloon Mitral Valvuloplasty Helps Overcome Impediments Caused by Anatomical Alterations”. Catheterization and Cardiovascular Interventions 57:353-362 (2002).;;Gero Hausdorf, Martin Schneider. Peter Lange; Catheter Creation of an Open Outflow Tract in Previously Atretic Right Ventricular Outflow Tract Associated with Ventricular Septal Defect; The American Journal of Cardiology, Aug. 1, 1993,72(3):354-6.;;Gideon J. Du Marchie Sarvaas, Kalyani R. Trivedi, Lisa K. Hornberger, K. Jin Lee, Hoel A. Kirsh, Lee N. Benson. “Radiofrequency-Assisted Atrial Septoplasty for an Intact Atrial Septum in Complex Congenital Heart Disease”. Catheterization and Cardiovascular Interventions; 56: 412-415 (2002).;;H Justino, LN Benson, DG Nykanen. “Transcatheter Creation of an Atrial Septal Defect Using Radiofrequency Perforation”. Catheter Cardiovasc Interv. 54(1):83-87 (Sep. 2001).;;Hector Biddogia, Juan P. Maciel, Jose A. Alvarez et al. “Transseptal Left Heart Catheterization: Usefulness of the Intracavitary Electrocardiogram in the Localization of the Fossa ovalis”. Catheterization and Cardiovascular Diagnosis 24: 221-225 (1991).;;Holzer, Hardin, Hill, Chisolm, Cheatham. Radiofrequency Energy—A Multi-Facetted Tool for the Congenital Interventionist. Congenital Cardiology Today. Jun. 2006; 4(6): 1-.;;Hugh Calkins, Yoon-Nyun Kim, Steve Schmaltz, Joao Sousa, Rafel El-Atassi, Angel Leon, Alan Kadish, Jonathan J. Langberg, Fred Morady; Electrogram Criteria for Identification of Appropriate Target Sites for Radiofrequency Catheter Ablation of Accessory Atrioventricular Connections; Feb. 1992;85(2):565-73.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2007/061203, dated Oct. 26, 2007, 8 pages.;;IntraLuminal Therapeutics, Inc. “http://www.intraluminal.com/products/catheter.html”. Safe Cross Support Catheter. 1 page. (Date of Printing—Jun. 2005).;;J. Thompson Sullebarger, Humberto Coto, Enrique Lopez, Dany Sayad, Hector L. Fontanet. “Transjugular Percutaneous Inoue Balloon Mitral Commissurotomy in a Patient With Inferior Vena Cava Obstruction After Liver Transplantation”. Catheterization and Cardiovascular Interventions 59:261-265 (2003).;;John Lennon Anderson et al., “Endoluminal Aortic Grafting with Renal and Superior Mesenteric Artery Incorporation by Graft Fenestration”, “Journal of Endovascular Therapy”, Feb. 2001, pp. 3-15, No. 8, Publisher: Journal of Endovascular Therapy, Published in: US.;;Johnson & Johnson Gateway, LLC. “http://www.jnjgateway.com/home.jhtml?loc=USENG&page=viewContent&contentId=Ic0de00100001435&nodekey=/Prod.sub.-info/Spec-ialty/Arrhythmia.sub.--Management/Electrophysiology/EP.sub.Diagnostic.su- b.-Catheters”. EP Diagnostic Catheters, 2 pages (Date of printing—Jun. 2005).;;Justino, Henri, Lee N. Benson, David G. Nykanen. “Transcatheter Creation of an Atrial Septal Defect Using Radiofrequency Perforation”. Catheterization and Cardiovascular Interventions. 56: 412-415 (2002).;;Kamal K. Sethi, Jagdish C. Mohan. “Editiorial Comment: Transseptal Catheterization for the Electrophysiologist: Modification with a ‘View’”. Journal of Interventional Cardian Physiology. 5, 97-99, 2001.;;Kamal K. Sethi, Jagdish C. Mohan. “Editorial Comment: Transseptal Catheterization for the Electrophysiologist: Modification with a ‘View’”. Journal of Interventional Cardiac Physiology. 5, 97-99, 2001.;;Lake Region Manufacturing, Inc. “http://www.lakergn.com/jmc.htm”. Paragon Guidewire. 2 pages (Date of Printing—Jun. 2005).;;Leonard W. H. Tse et al., “Radiofrequency Perforation System for an In Vivo Antegrade Fenestration of Aortic Stent-Grafts”, “Journal of Endovascular Therapy”, Apr. 2010, pp. 192-198, vol. 17, No. 2, Publisher: Journal of Endovascular Therapy, Published in: US.;;Lepage, Lewis, Ruiz, Yamanishi, Padron, Hood. Angiopyroplasty using Electromagnetically Induced Focused Heat. Angiology. Jul. 1987;38(7):520-3.;;Medtronic Inc. “http://www.medtronic.com/epsystems/diagnostic.sub.-catheters.html”. Diagnostic Catheters. 7 pages (Date of Printing—Apr. 2005).;;N Shimko, P. Savard, K Shah. “Radio frequency perforation of cardiac tissue: modeling and experimental results”. Med. Biol. Eng. Comput. 38:575-582 (2000).;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2015/052118, dated Sep. 27, 2016.;;Patent Cooperation Treaty, International Search Report for International Application No. PCT/IB2015/052118, dated Jun. 26, 2015.;;Pressure Products, Inc. http://www.pressure-products.com/Downloads/Education.sub.--PDFs/Using.sub-.-CSG.sub.-v2.pdf. 4 pages. 2005.;;Shyam S. Kothari, Sanjeev K. Sharma, Nitish Naik; Radiofrequency Perforation for Pulmonary Atresia and Intact Ventricular Septum; Indian Heart J Jan.-Feb. 2004;56(1):50-3 (Actual publication after Feb. 2004).;;Suhonen M. et al. Recanalization of arterial occlusions using a specially designed steering catheter. European Radiology: 2, 264-265(1992).;;Supplementary European Search Report, EP 15 76 8911, search completed on Nov. 1, 2017.;;Szili-Torok, T. et al. (2001) Transseptal Left Heart Catherisation Guided by Intracardiac Echocardiography, Heart 86:e11.;;T Abdel-Massih, Y Boudjemline, P Bonhoeffer. “Unusual Interventional management in an adult with tetralogy of Fallot”. Cardiol Young. 13(2):203-205 (Apr. 2003).;;T Humpl, B Soderberg, BW McCrindle, DG Nykanen, RM Freedom, WG Williams, LN Benson. “Percutaneous Balloon Valvotomy in Pulmonary Atresia with Intact Ventricular Septum: Impact on Patient Care”. Circulation. 108(7): 826-832 (Aug. 2003).;;Timothy A.M. Chuter, “Branched and Fenestrated Stent Grafts for Endovascular Repair of Thoracic Aortic Aneurysms”, Oct. 27, 2005, pp. 111A-115A, vol. 43, No. A, Publisher: The Society for Vascular Sugery, Published in: US.;;Tsung O. Cheng. “All Roads Lead to Rome: Transjugular or Transfemoral Approach to Percutaneous Transseptal Balloon Mitral Valvuloplasty?”. Catheterization and Cardiovascular Interventions 59:266-267 (2003).;;Veldtman, Hartley, Visram, Benson. Radiofrequency Applications in Congenital Heart Disease. Expert Rev Cardiovasc Ther. Jan. 2004;2(1):117-26.",ACTIVE
79,US,A1,US 2024/0033011 A1,058-186-951-932-181,2024-02-01,2024,US 202318361021 A,2023-07-28,US 202318361021 A;;US 202263369692 P,2022-07-28,METHOD FOR DETERMINING PUNCTURE ENTRY LOCATION USING FLUOROSCOPY,A method and apparatus are disclosed for ensuring safe dilation after puncture. The method includes puncturing the target tissue via a distal tip with the puncturing device. The flexible puncturing device is advanced through the puncture into a cardiac space and visualizing the flexible puncturing device using a visualization system. The user checks the constraints imposed on the flexible puncturing device within the new cardiac space.,BOSTON SCIENT MEDICAL DEVICE LIMITED,KOON LAUREN;;DAVIES GARETH,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2023-07-26),https://lens.org/058-186-951-932-181,Patent Application,yes,0,0,1,1,0,A61B17/00234;;A61B2017/00247;;A61B2090/3966;;A61B34/20;;A61B2034/2055;;A61B2017/00247;;A61B17/00234,A61B34/20;;A61B17/00,,0,0,,,,PENDING
80,US,B2,US 10255161 B2,062-257-357-402-866,2019-04-09,2019,US 201615079580 A,2016-03-24,GB 201504975 A,2015-03-24,Logging events with timestamps,"A logging unit is used to log entries for events in a computer system. Each entry includes an n-bit timestamp field and a payload. The payload includes information about the event and the timestamp field includes the n least significant bits of an N-bit timestamp for the event, where N>n. If the n least significant bits of the timestamp have wrapped compared to the corresponding n bits of the timestamp of the preceding entry then a timing entry is logged which includes other bits of the timestamp. Therefore, an N-bit timestamp can be determined for an event, but only the n least significant bits of the timestamp are stored in the timestamp field of an entry for the event. Therefore, the time flow of events in the store is better maintained (by having a larger timestamp) without increasing the number of bits (n) in the timestamp field of each entry.",IMAGINATION TECH LTD,MURRIN PAUL;;DAVIES GARETH,IMAGINATION TECHNOLOGIES LIMITED (2016-03-31);;NORDIC SEMICONDUCTOR ASA (2020-12-31),https://lens.org/062-257-357-402-866,Granted Patent,yes,6,2,9,9,0,G06F11/3086;;G06F11/3476;;G06F11/3636;;G06F11/3636;;G06F11/3466;;G06F11/3466;;G06F11/3476;;G06F11/3476;;G06F17/40;;G06F17/40;;G06F2201/835;;G06F2201/835;;G06F2201/86;;G06F2201/86,G06F11/00;;G06F11/34;;G06F11/36;;G06F17/40,,4,4,061-841-368-218-032;;061-841-368-218-032;;029-674-956-317-488;;040-032-749-543-021,10.1007/978-3-642-16612-9_24;;10.1007/978-3-642-16612-9_24;;10.1109/fccm.2012.11;;10.1109/secon.1991.147891,"Kraft, J., Wall, A., & Kienle, H. (Nov. 2010). Trace recording for embedded systems: Lessons learned from five industrial projects. In International Conference on Runtime Verification (pp. 315-329). Springer, Berlin, Heidelberg. (Year: 2010).;;Kraft et al “Trace Recording for Embedded Systems: Lessons Learned from Five. Industrial Projects” Runtime Verification, published 2010, Springer, pp. 315-329, vol. 6418, Kraft et al, ISBN 978-3-642-16611-2 ; ISBN 3-642-16611-3.;;Arcas et al “A Low-Overhead Profiling and Visualization Framework for Hybrid Transactional Memory” IEEE 20th Annual International Symposium on Field-Programmable Custom Computing Machines (FCCM), published 2012, IEEE, pp. 1-8, ISBN 978-1-4673-1605-7 ; ISBN 1-4673-1605-9.;;BAKER K.F. JR., CRILLY P.B.: ""A priority event monitor for an interrupt-driven microprocessor"", PROCEEDINGS OF SOUTHEASTCON. WILLIAMSBURG, APRIL 7 - 10, 1991., NEW YORK, IEEE., US, vol. -, 7 April 1991 (1991-04-07) - 10 April 1991 (1991-04-10), US, pages 905 - 909, XP010045035, ISBN: 978-0-7803-0033-0, DOI: 10.1109/SECON.1991.147891",ACTIVE
81,US,A1,US 2021/0307671 A1,093-401-203-443-188,2021-10-07,2021,US 202117223088 A,2021-04-06,US 202117223088 A;;US 202063006391 P,2020-04-07,ELECTRO-ANATOMIC MAPPING SYSTEM,"An electro-anatomic mapping system is configured, in accordance with a preferred embodiment (and not limited thereto) to: (A) receive a first reference response signal from a first medical device, in which the first reference response signal is configured to be utilized by the electro-anatomic mapping system for formation of a first medical image; and (B) receive a second reference response signal from the first medical device, in which the second reference response signal is configured to be utilized by the electro-anatomic mapping system for forming a second medical image, and in which the second medical image, in use, depicts image noise interference resulting from activation of a second medical device.",BAYLIS MEDICAL CO INC,LEUNG JACKIE;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2021-03-29);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/093-401-203-443-188,Patent Application,yes,5,2,1,1,0,G16H40/67;;G16H30/40;;A61B5/4836;;A61B5/339;;A61B5/367;;A61B5/7203;;A61B5/367;;G06T11/00;;A61B5/4836;;G16H40/67;;G06T2207/30048;;G06T2210/41;;A61B5/7203;;G06T5/70,A61B5/367;;A61B5/00;;A61B5/339;;G06T5/00;;G06T11/00;;G16H40/67,,0,0,,,,PENDING
82,WO,A2,WO 2011/119649 A2,115-810-034-132-47X,2011-09-29,2011,US 2011/0029485 W,2011-03-22,US 34072810 P,2010-03-22,PHARMACEUTICAL COMPOSITIONS CONTAINING BERBERINE FOR TREATMENT OR PREVENTION OF WEIGHT GAIN AND OBESITY ASSOCIATED WITH ANTI-PSYCHOTIC DRUGS,"The compositions and methods disclosed herein are of use for the treatment and prevention of weight gain and obesity. In particular, the compositions and methods include treatment of weight gain and obesity with berberine and/or berberine analogs alone or in combination thereof to cause a reduction in an individual's weight or prevent weight gain or obesity. In certain embodiments, the weight gain and obesity are associated with administration of anti-psychotic drugs. In an alternative embodiment, the compositions and methods provide berberine or berberine analogs alone or for coadministration with an anti-psychotic agent. In an additional embodiment, the compositions and methods further include a natural product. The usefulness of the present invention is that berberine and berberine analogs do not have synergistic effects with other drugs and administration results in few side effects. Such characteristics of berberine or berberine analogs are a great improvement able to support the widespread use of the compositions and methods of the present invention as therapeutics for the treatment and prevention of weight gain and obesity.",WLST LLC;;DAVIES GARETH;;HU YUESHAN,DAVIES GARETH;;HU YUESHAN,,https://lens.org/115-810-034-132-47X,Patent Application,yes,0,3,3,3,26,A61K31/4375;;A61P25/00;;A61P25/18;;A61P25/24;;A61P3/00;;A61P3/04;;A61K31/4375,A61P3/00;;A61K31/4375;;A61P3/04;;A61P25/00;;A61P25/18;;A61P25/24,,0,0,,,,PENDING
83,US,A1,US 2013/0029862 A1,188-576-158-934-939,2013-01-31,2013,US 201213488397 A,2012-06-04,US 201213488397 A;;US 201161492795 P,2011-06-02,Clinical application utilizing genetic data for effective medication management,"The present disclosure relates a predictive method, based on a subject's genetic profile, which defines variability in a specific disease or condition to determine medication response, including determining select VNTR and SNP occurrence combinations which are associated with specific responses to medications, kits and DNA chips/arrays containing such combinations so as to effectuate better medication management.",DAVIES GARETH;;HANSEN RYAN,DAVIES GARETH;;HANSEN RYAN,,https://lens.org/188-576-158-934-939,Patent Application,yes,0,2,3,3,10,A61K31/135;;A61K31/135;;A61K31/137;;A61K31/137;;A61K31/445;;A61K31/445;;A61P25/00,C40B30/04;;C40B40/06,506/9;;506/16,0,0,,,,DISCONTINUED
84,WO,A3,WO 2011/119649 A3,102-171-902-724-097,2012-02-23,2012,US 2011/0029485 W,2011-03-22,US 34072810 P,2010-03-22,PHARMACEUTICAL COMPOSITIONS CONTAINING BERBERINE FOR TREATMENT OR PREVENTION OF WEIGHT GAIN AND OBESITY ASSOCIATED WITH ANTI-PSYCHOTIC DRUGS,"The compositions and methods disclosed herein are of use for the treatment and prevention of weight gain and obesity. In particular, the compositions and methods include treatment of weight gain and obesity with berberine and/or berberine analogs alone or in combination thereof to cause a reduction in an individual's weight or prevent weight gain or obesity. In certain embodiments, the weight gain and obesity are associated with administration of anti-psychotic drugs. In an alternative embodiment, the compositions and methods provide berberine or berberine analogs alone or for coadministration with an anti-psychotic agent. In an additional embodiment, the compositions and methods further include a natural product. The usefulness of the present invention is that berberine and berberine analogs do not have synergistic effects with other drugs and administration results in few side effects. Such characteristics of berberine or berberine analogs are a great improvement able to support the widespread use of the compositions and methods of the present invention as therapeutics for the treatment and prevention of weight gain and obesity.",WLST LLC;;DAVIES GARETH;;HU YUESHAN,DAVIES GARETH;;HU YUESHAN,,https://lens.org/102-171-902-724-097,Search Report,yes,4,0,3,3,26,A61K31/4375;;A61P25/00;;A61P25/18;;A61P25/24;;A61P3/00;;A61P3/04;;A61K31/4375,A61K31/4375;;A61P3/00;;A61P3/04;;A61P25/00;;A61P25/18;;A61P25/24,,0,0,,,,PENDING
85,US,A1,US 2019/0374281 A1,006-699-761-390-85X,2019-12-12,2019,US 201916532980 A,2019-08-06,US 201916532980 A;;US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 82745206 P;;US 88428507 P,2006-09-29,Electrosurgical device,"An electrosurgical device for puncturing tissue comprises an electrically conductive elongate member which is capable of force transmission from a distal portion of the electrosurgical device to a proximal portion of the electrosurgical device to thereby provide tactile feedback to a user. The proximal portion comprises a handle or hub which includes an electrical connector configured to receive, in a releasable manner, an electrically conductive component operable to be electrically coupled to an energy source.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;MIRZA MAHMOOD,BAYLIS MEDICAL COMPANY INC (2019-08-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/006-699-761-390-85X,Patent Application,yes,16,13,4,113,0,A61B18/1492;;A61B2018/00601;;A61B2018/00357;;A61B18/1482,A61B18/14,,0,0,,,,ACTIVE
86,US,S,US D0582733 S,105-385-464-240-65X,2008-12-16,2008,US 29713207 F,2007-11-05,GB 0795356 F,2007-09-25,Hand-holdable pruner,,TONIC STUDIOS LTD,DAVIES GARETH;;BATHARD SIMON,TONIC STUDIOS LIMITED (2007-10-23),https://lens.org/105-385-464-240-65X,Design Right,no,0,8,1,1,0,,,0801;;D 8  5,0,0,,,,EXPIRED
87,WO,A1,WO 2021/214607 A1,174-288-076-817-910,2021-10-28,2021,IB 2021053119 W,2021-04-15,US 202063013646 P,2020-04-22,SHEATH ASSEMBLY AND/OR DILATOR ASSEMBLY,"An apparatus is for an elongated sheath assembly configured to receive, at least in part, an elongated dilator assembly. The apparatus includes a dilator-receiver device configured to be installed to the elongated sheath assembly. A dilator-receiver mover is configured to be mounted, at least in part, to the elongated sheath assembly. The dilator-receiver mover is configured to be operatively connected to the dilator-receiver device. The dilator-receiver mover is also configured to selectively move the dilator-receiver device along a predetermined distance.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,LEUNG JACKIE;;DAVIES GARETH,,https://lens.org/174-288-076-817-910,Patent Application,yes,7,0,5,5,0,A61M29/00;;A61B2017/00247;;A61M25/0662;;A61B17/3478;;A61M29/00,A61B17/34;;A61B17/00;;A61B90/00;;A61M29/00,,0,0,,,,PENDING
88,US,B2,US 8679107 B2,096-605-827-934-798,2014-03-25,2014,US 201213468939 A,2012-05-10,US 201213468939 A;;US 90544707 A;;US 82745206 P;;US 88428507 P,2006-09-29,Radiofrequency perforation apparatus,"A radiofrequency perforation apparatus for creating a channel at a target location in a body of a patient, the radiofrequency perforation apparatus comprising: a substantially tubular member defining a tubular member lumen; an end member partially positioned within the tubular member lumen at a distal end of the tubular member, the end member including an electrode; and an electrical insulator extending along the substantially tubular member.",MIRZA MAHMOOD;;DAVIES GARETH;;BAYLIS MEDICAL CO INC,MIRZA MAHMOOD;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2012-04-12);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/096-605-827-934-798,Granted Patent,yes,3,8,4,113,0,A61B18/1482;;A61B18/1492;;A61B2018/00011;;A61B2018/00083;;A61B2018/00351;;A61B2018/00839;;A61B2218/002;;A61B2090/064;;A61B18/1482;;A61B2018/00083;;A61B2018/00351;;A61B2018/00839;;A61B18/1492;;A61B2018/00011;;A61B2218/002;;A61B2090/064,A61B18/18,606/33;;606/41,0,0,,,,ACTIVE
89,US,S,US D0581455 S,146-499-164-297-649,2008-11-25,2008,US 30365408 F,2008-02-14,GB 0795364 F,2007-09-25,Cutting apparatus,,TONIC STUDIOS LTD,DAVIES GARETH;;BATHARD SIMON,TONIC STUDIOS LIMITED (2007-11-19),https://lens.org/146-499-164-297-649,Design Right,no,0,2,1,1,0,,,1804;;D18/34.8,0,0,,,,EXPIRED
90,US,S,US D0680219 S,012-079-400-232-071,2013-04-16,2013,US 201129402621 F,2011-09-25,US 201129402621 F,2011-09-25,Curved electrosurgical device,,DAVIES GARETH;;MIRZA MAHMOOD;;BAYLIS MEDICAL CO INC,DAVIES GARETH;;MIRZA MAHMOOD,BAYLIS MEDICAL COMPANY INC (2011-05-26);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/012-079-400-232-071,Design Right,no,0,2,1,1,0,,,2402;;D24/144,0,0,,,,ACTIVE
91,US,A1,US 2008/0086120 A1,046-368-254-959-786,2008-04-10,2008,US 90544707 A,2007-10-01,US 90544707 A;;US 82745206 P;;US 88428507 P,2006-09-29,Radiofrequency perforation apparatus,"A radiofrequency perforation apparatus for creating a channel at a target location in a body of a patient, the radiofrequency perforation apparatus being usable by an intended user having a hand, the radiofrequency perforation apparatus comprising: a handle graspable by the hand; a distal portion, the distal portion defining a distal portion length, the distal portion including an electrode and an electrical insulator extending from the electrode; and a force transmitting portion extending between the distal portion and the handle, the force transmitting portion defining a force transmitting portion length, the force transmitting portion length being larger than the distal portion length, the force transmitting portion having a force transmitting portion flexural rigidity of at least about 0.016 Nm 2 ; whereby the force transmitting portion has a force transmitting portion flexural rigidity allowing the transmission to the handle of contact forces exerted on the distal portion when the distal portion contacts the target location to provide tactile feedback to the intended user.",MIRZA MAHMOOD;;DAVIES GARETH,MIRZA MAHMOOD;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2011-06-17);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/046-368-254-959-786,Patent Application,yes,8,71,4,113,0,A61B18/1482;;A61B18/1492;;A61B2018/00011;;A61B2018/00083;;A61B2018/00351;;A61B2018/00839;;A61B2218/002;;A61B2090/064;;A61B18/1482;;A61B2018/00083;;A61B2018/00351;;A61B2018/00839;;A61B18/1492;;A61B2018/00011;;A61B2218/002;;A61B2090/064,A61B18/18,606/41,0,0,,,,ACTIVE
92,EP,B1,EP 3098733 B1,055-081-249-050-058,2020-01-15,2020,EP 16160332 A,2016-03-15,GB 201504975 A,2015-03-24,LOGGING EVENTS WITH TIMESTAMPS,,IMAGINATION TECH LTD,MURRIN PAUL;;DAVIES GARETH,,https://lens.org/055-081-249-050-058,Granted Patent,yes,1,0,9,9,0,G06F11/3086;;G06F11/3476;;G06F17/40;;G06F11/3466;;G06F2201/835;;G06F2201/86;;G06F11/3636;;G06F11/3476;;G06F11/3476;;G06F17/40;;G06F11/3466;;G06F2201/835;;G06F2201/86;;G06F11/3636,G06F11/34;;G06F17/40,,3,0,,,"JOHAN KRAFT ET AL: ""Trace Recording for Embedded Systems: Lessons Learned from Five Industrial Projects"", 1 November 2010 (2010-11-01), RUNTIME VERIFICATION, SPRINGER BERLIN HEIDELBERG, BERLIN, HEIDELBERG, PAGE(S) 315 - 329, XP019156250, ISBN: 978-3-642-16611-2 * abstract * * sections 2.1-2.3, 4.1, 4.3 *;;ORIOL ARCAS ET AL: ""A Low-Overhead Profiling and Visualization Framework for Hybrid Transactional Memory"", FIELD-PROGRAMMABLE CUSTOM COMPUTING MACHINES (FCCM), 2012 IEEE 20TH ANNUAL INTERNATIONAL SYMPOSIUM ON, IEEE, 29 April 2012 (2012-04-29), pages 1-8, XP032202814, DOI: 10.1109/FCCM.2012.11 ISBN: 978-1-4673-1605-7;;BAKER K F JR ET AL: ""A priority event monitor for an interrupt-driven microprocessor"", PROCEEDINGS OF SOUTHEASTCON. WILLIAMSBURG, APRIL 7 - 10, 1991; [PROCEEDINGS OF THE SOUTHEAST CONFERENCE], NEW YORK, IEEE, US, vol. -, 7 April 1991 (1991-04-07), pages 905-909, XP010045035, DOI: 10.1109/SECON.1991.147891 ISBN: 978-0-7803-0033-0",ACTIVE
93,US,A1,US 2014/0228841 A1,131-696-726-986-349,2014-08-14,2014,US 201414257053 A,2014-04-21,US 201414257053 A;;US 201213656173 A;;US 531607 A;;US 88307407 P,2007-01-02,Cardiac Electrosurgery,"Devices and methods are disclosed for providing access to the pericardial cavity while reducing risk of myocardial damage. One method includes advancing a puncture device towards a heart, the puncture device including an energy delivery device; measuring an electrical impedance at the energy delivery device; delivering energy from the energy delivery device to at least partially puncture a pericardium; and repeating one or more of the above steps, if necessary, until the energy delivery device is located at least partially within the pericardial cavity. Some embodiments of the method include using supplemental means of monitoring, including measuring voltage to plot an ECG, medical imaging and using contrast fluid, using tactile feedback, and aspirating fluid.",KLEIN GEORGE;;BAYLIS MEDICAL CO INC,DAVIES GARETH;;KLEIN GEORGE,BAYLIS MEDICAL COMPANY INC (2014-10-04);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/131-696-726-986-349,Patent Application,yes,8,18,2,11,0,A61B17/3478;;A61B18/1492;;A61B2017/00154;;A61B2017/00353;;A61B2017/22014;;A61B2018/00083;;A61B2018/00291;;A61B2018/00351;;A61B2018/00589;;A61B2018/00702;;A61B2018/00839;;A61B2018/00875;;A61B2017/00026;;A61B2017/00247;;A61B17/2202;;A61B2018/1861;;A61B2090/064;;A61B90/37;;A61B17/34;;A61B2017/00243;;A61B2018/00363;;A61B2018/00601;;A61B2017/32007;;A61B2017/320069;;A61B17/34;;A61B2017/00243;;A61B2018/00363;;A61B2018/00601;;A61B2017/32007;;A61B2017/320069;;A61B17/2202;;A61B2018/1861;;A61B17/3478;;A61B18/1492;;A61B2017/00154;;A61B2017/00353;;A61B2017/22014;;A61B2018/00083;;A61B2018/00291;;A61B2018/00351;;A61B2018/00589;;A61B2018/00702;;A61B2018/00839;;A61B2018/00875;;A61B2017/00026;;A61B2017/00247;;A61B90/37;;A61B2090/064,A61B17/32;;A61B17/34;;A61B18/04,606/45;;606/169;;606/185,0,0,,,,ACTIVE
94,US,A1,US 2021/0121227 A1,198-003-630-455-136,2021-04-29,2021,US 202017074084 A,2020-10-19,US 202017074084 A;;US 201916532980 A;;US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 82745206 P;;US 88428507 P,2006-09-29,Connector system for electrosurgical device,An electrosurgical device for puncturing tissue comprises an electrically conductive elongate member which is capable of force transmission from a distal portion of the electrosurgical device to a proximal portion of the electrosurgical device to thereby provide tactile feedback to a user. The proximal portion comprises a connector system for connecting a source of energy and a source of fluid to an electrosurgical device. The connector system includes a hub which includes an electrically conductive lengthwise member having a lengthwise member distal region and a lengthwise member proximal region. The lengthwise member defines a hub lumen therebetween and is configured to be operatively coupled to an electrosurgical device.,BAYLIS MEDICAL CO INC,DAVIES GARETH;;MIRZA MAHMOOD,BAYLIS MEDICAL COMPANY INC (2021-10-01);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/198-003-630-455-136,Patent Application,yes,0,3,3,113,0,A61B18/1492;;A61B2018/00357;;A61B2018/00083;;A61B2018/00172;;A61B2018/00178;;A61B2018/00077;;A61B2018/00309;;A61B2018/00142;;A61B2090/064;;A61M5/007;;A61B2018/00029;;A61M2210/125;;A61B18/1482;;A61B2018/00083;;A61B2018/00351;;A61B2090/064;;A61B18/1492;;A61B2018/00011;;A61B2218/002;;A61B2018/00839,A61B18/14,,0,0,,,,PENDING
95,EP,A1,EP 3098733 A1,018-757-793-911-515,2016-11-30,2016,EP 16160332 A,2016-03-15,GB 201504975 A,2015-03-24,LOGGING EVENTS WITH TIMESTAMPS,"A logging unit is used to log entries for events in a computer system. Each entry includes an  n -bit timestamp field and a payload. The payload includes information about the event and the timestamp field includes the  n  least significant bits of an N-bit timestamp for the event, where  N  >  n . If the  n  least significant bits of the timestamp have wrapped compared to the corresponding  n  bits of the timestamp of the preceding entry then a timing entry is logged which includes other bits of the timestamp. Therefore, an  N -bit timestamp can be determined for an event, but only the  n  least significant bits of the timestamp are stored in the timestamp field of an entry for the event. Therefore, the time flow of events in the store is better maintained (by having a larger timestamp) without increasing the number of bits ( n ) in the timestamp field of each entry.
",IMAGINATION TECH LTD,MURRIN PAUL;;DAVIES GARETH,,https://lens.org/018-757-793-911-515,Patent Application,yes,1,0,9,9,0,G06F11/3086;;G06F11/3476;;G06F11/3636;;G06F11/3636;;G06F11/3466;;G06F11/3466;;G06F11/3476;;G06F11/3476;;G06F17/40;;G06F17/40;;G06F2201/835;;G06F2201/835;;G06F2201/86;;G06F2201/86,G06F17/40;;G06F11/34,,3,3,061-841-368-218-032;;029-674-956-317-488;;040-032-749-543-021,10.1007/978-3-642-16612-9_24;;10.1109/fccm.2012.11;;10.1109/secon.1991.147891,"JOHAN KRAFT ET AL: ""Trace Recording for Embedded Systems: Lessons Learned from Five Industrial Projects"", 1 November 2010, RUNTIME VERIFICATION, SPRINGER BERLIN HEIDELBERG, BERLIN, HEIDELBERG, PAGE(S) 315 - 329, ISBN: 978-3-642-16611-2, XP019156250;;ORIOL ARCAS ET AL: ""A Low-Overhead Profiling and Visualization Framework for Hybrid Transactional Memory"", FIELD-PROGRAMMABLE CUSTOM COMPUTING MACHINES (FCCM), 2012 IEEE 20TH ANNUAL INTERNATIONAL SYMPOSIUM ON, IEEE, 29 April 2012 (2012-04-29), pages 1 - 8, XP032202814, ISBN: 978-1-4673-1605-7, DOI: 10.1109/FCCM.2012.11;;BAKER K F JR ET AL: ""A priority event monitor for an interrupt-driven microprocessor"", PROCEEDINGS OF SOUTHEASTCON. WILLIAMSBURG, APRIL 7 - 10, 1991; [PROCEEDINGS OF THE SOUTHEAST CONFERENCE], NEW YORK, IEEE, US, vol. -, 7 April 1991 (1991-04-07), pages 905 - 909, XP010045035, ISBN: 978-0-7803-0033-0, DOI: 10.1109/SECON.1991.147891",ACTIVE
96,US,A1,US 2021/0308425 A1,160-924-922-620-049,2021-10-07,2021,US 202117222549 A,2021-04-05,US 202117222549 A;;US 202063006363 P,2020-04-07,MEDICAL SHEATH ASSEMBLY,"A medical sheath assembly is configured to be positioned in a patient, and is also configured to convey, at least in part, an electromagnetic-transmission signal through the medical sheath assembly. The medical sheath assembly includes a sheath-support component being sympathetic, at least in part, for transmission of electromagnetic energy traveling through the sheath-support component, dispatched toward, or dispatched away from, the medical sheath assembly.",BAYLIS MEDICAL CO INC,LEUNG JACKIE;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2021-03-29);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/160-924-922-620-049,Patent Application,yes,0,0,1,1,0,A61M25/0662;;A61M2025/0681;;A61M25/005;;A61M2025/0059;;A61B2562/18;;A61B5/287;;A61B5/367;;A61M25/0158;;A61M2205/02;;A61M2025/0166;;A61B5/367;;A61B2562/18;;A61M25/0662;;A61B5/062;;A61B5/6852,A61M25/01,,0,0,,,,PENDING
97,US,A1,US 2021/0369336 A1,051-077-859-118-788,2021-12-02,2021,US 202117399720 A,2021-08-11,US 202117399720 A;;US 202017074084 A;;US 201916532980 A;;US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 82745206 P;;US 88428507 P,2006-09-29,Electrosurgical device,An electrosurgical device for puncturing tissue comprises an electrically conductive elongate member which is capable of force transmission from a distal portion of the electrosurgical device to a proximal portion of the electrosurgical device to thereby provide tactile feedback to a user. The proximal portion comprises a connector system for connecting a source of energy and a source of fluid to an electrosurgical device . The connector system includes a hub which includes an electrically conductive lengthwise member having a lengthwise member distal region and a lengthwise member proximal region. The lengthwise member defines a hub lumen therebetween and is configured to be operatively coupled to an electrosurgical device.,BAYLIS MEDICAL CO INC,DAVIES GARETH;;MIRZA MAHMOOD,BAYLIS MEDICAL COMPANY INC (2021-10-01);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/051-077-859-118-788,Patent Application,yes,16,0,3,113,0,A61B18/1492;;A61B2018/00357;;A61B2018/00083;;A61B2018/00172;;A61B2018/00178;;A61B2018/00077;;A61B2018/00309;;A61B2018/00142;;A61B2090/064;;A61M5/007;;A61B2018/00029;;A61M2210/125;;A61B18/1482;;A61B2018/00083;;A61B2018/00351;;A61B2090/064;;A61B18/1492;;A61B2018/00011;;A61B2218/002;;A61B2018/00839,A61B18/14,,0,0,,,,ACTIVE
98,EP,A1,EP 4138691 A1,107-826-239-595-503,2023-03-01,2023,EP 21793062 A,2021-04-15,US 202063013646 P;;IB 2021053119 W,2020-04-22,SHEATH ASSEMBLY AND/OR DILATOR ASSEMBLY,,BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;DAVIES GARETH,,https://lens.org/107-826-239-595-503,Patent Application,yes,0,0,5,5,0,A61M29/00;;A61B2017/00247;;A61M25/0662;;A61B17/3478;;A61M29/00,A61B17/34;;A61B17/00;;A61B90/00;;A61M29/00,,0,0,,,,PENDING
99,CN,A,CN 104903563 A,010-898-840-771-796,2015-09-09,2015,CN 201380069327 A,2013-11-05,EP 2013073079 W;;EP 12195315 A,2012-12-03,Method and arrangement for controlling fuel supply for gas turbine,"It is described a method of controlling a supply of a fuel (105) to a combustor (101) of a gas turbine comprising a compressor upstream of the combustor, the method comprising: supplying the fuel (105) to the combustor (101); obtaining a property value of at least one physical property (PT8, PT7, Tinlet, THBOV) of air used for burning the fuel (105) in the combustor (101); estimating a heat input (HIengmodel) of the fuel (105) supplied to the combustor (101) based on the prop- erty value; measuring a Caloric Value (LCVmea) of the fuel (105) upstream of the combustor (101); adjusting the estimated heat input (HIengmodel) based on the measured Caloric Value (LCVmea); and controlling a fuel valve (103) regulating the supply of the fuel (105) to the combustor (101) based on the adjusted estimated heat input (HIexpected) and a demanded heat input (FFDEM).",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,,https://lens.org/010-898-840-771-796,Patent Application,no,0,4,12,12,0,F02C9/40;;F05D2260/80;;F02C9/40;;F02C9/28;;F02C9/32;;F02C9/48;;F02C9/40;;F05D2260/80,F02C9/40,,0,0,,,,INACTIVE
100,BR,A2,BR 112022006264 A2,041-381-829-990-739,2022-06-28,2022,BR 112022006264 A,2020-10-15,IB 2021074860 W;;US 201962923031 P,2019-10-18,CONJUNTO DE FIO-GUIA MÉDICO E/OU CONECTOR ELÉTRICO,"CONJUNTO DE FIO-GUIA MÉDICO E/OU CONECTOR ELÉTRICO. É revelado um conjunto de fio-guia médico flexível configurado para ser inserido em um espaço confinado definido por um corpo vivo. Um conjunto de sensor é suportado de modo seguro pelo conjunto de fio-guia médico flexível. Isso é feito de modo que o conjunto de sensor e o conjunto de fio-guia médico flexível sejam móveis ao longo do espaço confinado definido pelo corpo vivo quando o conjunto de fio-guia médico flexível é inserido, e movido ao longo do mesmo, no espaço confinado definido pelo corpo vivo. É também revelado um conjunto de conector elétrico que tem um terminal conector. O terminal conector é configurado para ser eletricamente conectável com uma porção terminal de um conjunto de fio-guia médico flexível. A porção terminal é conectada eletricamente, através de um fio elétrico, a um conjunto de sensor do conjunto de fio-guia médico flexível.",BAYLIS MEDICAL CO INC,JOHN PAUL URBANSKI;;GARETH DAVIES,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (IE) (2023-06-06),https://lens.org/041-381-829-990-739,Patent Application,no,0,0,1,9,0,,A61M25/09;;A61B18/00;;A61B18/14;;A61B18/18;;A61M25/01,,0,0,,,,PENDING
101,US,A1,US 2016/0058504 A1,061-797-254-054-863,2016-03-03,2016,US 201514933356 A,2015-11-05,US 201514933356 A;;US 201414257053 A;;US 201213656173 A;;US 531607 A;;US 88307407 P,2007-01-02,Electrosurgical Pericardial Puncture,"Devices and methods for providing access to the pericardial cavity while reducing risk of myocardial damage. One method includes advancing a distal end of a puncture device towards the heart from a subxiphoid region of a patient wherein the distal end of the puncture device is atraumatic and comprises an energy delivery device; positioning the energy delivery device at a target site on a pericardium of the heart using ultrasound for imaging; and delivering energy from the energy delivery device to a tissue of the target site to create a channel to the pericardial cavity. The method may include repeating one or more of the above steps until the energy delivery device is located within the pericardial cavity. Some embodiments of the method include using supplemental means of monitoring, including medical imaging and using contrast fluid.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,BAYLIS MEDICAL COMPANY INC (2015-11-27);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/061-797-254-054-863,Patent Application,yes,11,11,4,11,0,A61B17/2202;;A61B17/3478;;A61B2017/00026;;A61B2017/00243;;A61B2017/00247;;A61B2017/00353;;A61B2017/22014;;A61B2018/00083;;A61B2018/00291;;A61B2018/00363;;A61B2018/00601;;A61B2018/00702;;A61B2018/00839;;A61B2018/00875;;A61B2018/1861;;A61B2090/064;;A61B90/37;;A61B2090/378;;A61B18/1492;;A61B2017/00154;;A61B18/1492;;A61B8/0841;;A61B8/12;;A61B8/0883;;A61B8/445;;A61B8/4494;;A61B8/481;;A61B2017/00154;;A61B2090/378;;A61B17/2202;;A61B17/3478;;A61B2017/00026;;A61B2017/00243;;A61B2017/00247;;A61B2017/00353;;A61B2017/22014;;A61B2018/00083;;A61B2018/00291;;A61B2018/00363;;A61B2018/00601;;A61B2018/00702;;A61B2018/00839;;A61B2018/00875;;A61B2018/1861;;A61B2090/064;;A61B90/37,A61B18/14;;A61B8/00;;A61B8/08;;A61B8/12,,0,0,,,,ACTIVE
102,EP,B1,EP 1960637 B1,127-860-148-218-512,2009-09-09,2009,EP 06830548 A,2006-12-12,EP 2006069596 W;;US 74946905 P,2005-12-12,VALVE ASSEMBLY,,SIEMENS AG,BURKITT EDWARD;;DAVIES GARETH HUW,"SIEMENS ENERGY GLOBAL GMBH & CO. KG, DE (2020-12-15)",https://lens.org/127-860-148-218-512,Granted Patent,yes,5,1,6,6,0,F01D25/32;;F02C7/232;;F05D2260/602;;F02C7/232;;F01D25/32;;F05D2260/602,F01D25/00,,0,0,,,,ACTIVE
103,EP,A1,EP 2925985 A1,007-300-281-613-005,2015-10-07,2015,EP 13811130 A,2013-11-05,EP 12195312 A;;EP 2013073083 W;;EP 13811130 A,2012-12-03,GAS TURBINE FUEL SUPPLY METHOD AND ARRANGEMENT,,SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,"SIEMENS AKTIENGESELLSCHAFT (2017-08-30);;SIEMENS ENERGY GLOBAL GMBH & CO. KG, DE (2020-12-15)",https://lens.org/007-300-281-613-005,Patent Application,yes,0,0,12,12,0,F02C9/40;;F05D2260/80;;F02C9/26;;F02C9/28;;F02C9/40;;F05D2260/80,F02C9/28;;F02C9/40,,0,0,,,,ACTIVE
104,JP,A,JP 2001077149 A,044-045-180-571-463,2001-03-23,2001,JP 2000242828 A,2000-08-10,EP 99306444 A;;EP 99309842 A,1999-08-17,INTEGRATED CIRCUIT DIE,"PROBLEM TO BE SOLVED: To apply an integrated circuit die to both a flip-chip assembly and a wire bonding assembly by forming a passivation layer exposing a first set pad alone or first and second set pads. SOLUTION: A first set of a conductive pad 2 and a second set of a pad 3 are fixed on a surface of an integrated circuit die 1. The pad 2 of the first set is made larger than a pad 3 of the second set and is installed for flip-chip assembly. A wire bonding connection 4 is provided to all the pad 2 and the pad 3, and a passivation layer 5 of passivation metal is fixed on a surface of the integrated circuit die 1 leaving an exposed region for the wire bonding connection 4 on each of the pad 2 and the pad 3. As a result, the integrated circuit die can be applied to both a flip-chip assembly and a wire bonding assembly.",LUCENT TECHNOLOGIES INC,ADDINALL ROSS;;DAVIES GARETH RHYS,,https://lens.org/044-045-180-571-463,Patent Application,no,0,0,9,10,0,H01L2224/04073;;H01L2224/06153;;H01L2224/13099;;H01L2924/01004;;H01L2924/01005;;H01L2924/01013;;H01L2924/01015;;H01L2924/01033;;H01L2924/01075;;H01L2924/01079;;H01L2924/01082;;H01L2924/014;;H01L2924/14;;H01L24/13;;H01L2924/00;;H01L24/06;;H01L2224/0401;;H01L2224/13;;H01L2224/04042;;H01L2224/0616;;H01L24/05;;H01L2224/06051;;H01L23/485;;H01L21/60;;H01L24/02;;H01L2924/01004;;H01L2924/01013;;H01L2924/01015;;H01L24/10;;H01L2924/01005;;H01L2924/14;;H01L2224/04073;;H01L2924/014;;H01L2924/01082;;H01L2224/13099;;H01L2924/01079;;H01L2924/01033;;H01L2224/06153;;H01L2924/01075;;H01L24/13;;H01L24/06;;H01L2924/00;;H01L2224/0401;;H01L2224/13,H01L23/485;;H01L21/60,,0,0,,,,EXPIRED
105,JP,A,JP 2021180874 A,074-852-787-094-113,2021-11-25,2021,JP 2021126774 A,2021-08-02,JP 2018188330 A;;US 201261653967 P,2012-05-31,RADIOFREQUENCY PERFORATION APPARATUS,"To provide a medical device having improved visualization of a portion of the medical device insertable into a patient's body while minimizing obstruction of a fluid flow through a lumen of the device and while minimizing an increase in the outer diameter of the device attributed to the feature providing the improved visualization.SOLUTION: The device can include, for example, an imaging marker 6 distal to lumen 9 openings (exit ports) or, if the device comprises a tube such as a metallic tube 12, an imaging marker embedded into a wall of the tube. Another embodiment includes attaching a marker to the surface on the inside of a lumen of a medical device without embedding the marker. Various alternative embodiments, methods and applications of using such devices are also disclosed.SELECTED DRAWING: Figure 10b",BAYLIS MEDICAL CO INC,GARETH DAVIES;;JOHN PAUL URBANSKI,,https://lens.org/074-852-787-094-113,Patent Application,no,3,0,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61M25/00;;A61B18/14,,0,0,,,,ACTIVE
106,US,B2,US 11684447 B2,105-588-335-347-952,2023-06-27,2023,US 202017130691 A,2020-12-22,US 202017130691 A;;US 201414404518 A;;IB 2012056315 W;;US 201261653967 P,2012-05-31,Radiofrequency perforation apparatus,"Medical devices are disclosed having improved visualization of a portion of the medical device insertable into a patient's body while minimizing obstruction of fluid flow through a lumen of the device and while minimizing an increase in the outer diameter of the device attributable to the feature providing improved visualization. The device can include, for example, an imaging marker distal to lumen openings (exit ports), or, where the device comprises a tube, such as a metallic tube, an imaging marker embedded into a wall of the tube. Another embodiment includes attaching a marker to the surface on the inside of a lumen of a medical device without embedding the marker. Various alternative embodiments, methods and applications of using such devices are disclosed as well.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL,BAYLIS MEDICAL COMPANY INC (2014-11-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/105-588-335-347-952,Granted Patent,yes,369,0,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61B18/14;;A61B5/06;;A61B18/00;;A61B90/00;;A61M25/01,,6,0,,,"Japanese Office Action from corresponding JPO application 2021-126774, dated Jun. 29, 2022, Japan Patent Office, 5 pages.;;Japanese Office Action from corresponding JPO application 2021-126775, dated Jun. 29, 2022, Japan Patent Office, 5 pages.;;Extended European Search Report from corresponding EPO Application No. 21215791.1, dated Apr. 4, 2022, European Patent Office, 8 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/IB2012/056315, dated Jul. 30, 2013, 12 pages.;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2012/056315, dated Dec. 2, 2014.;;Search Opinion for European Patent Application No. 12877833.9.",ACTIVE
107,CN,A,CN 104919160 A,194-560-066-819-424,2015-09-16,2015,CN 201380070376 A,2013-11-05,EP 2013073083 W;;EP 12195312 A,2012-12-03,Gas turbine fuel supply method and arrangement,"The invention provides a gas turbine fuel supply method and arrangement. It is described a method of controlling a supply of a fuel to a combustor of a gas turbine comprising a compressor upstream of the combustor, the method comprising: supplying the fuel (105) to the combustor (101); obtaining an inlet air pressure (PT7) at a compressor inlet; obtaining an inlet air temperature (Tinlet) at the compressor inlet; obtaining an outlet air pressure (PT8) at a compressor outlet; estimating a heat input (HIengmodel, HIexpected) of the fuel (105) supplied to the combustor (101) based on the inlet air pressure (PT7), the inlet air temperature (Tinlet) and the outlet air pressure (PT8); comparing the estimated heat input (HIengmodel, HIexpected) with a demanded heat input (FFDEM) to derive an error signal (121); and controlling a fuel valve (103) regulating the supply of the fuel (105) to the combustor (101) based on the error signal (121).",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,,https://lens.org/194-560-066-819-424,Patent Application,no,4,2,12,12,0,F02C9/40;;F05D2260/80;;F02C9/26;;F02C9/28;;F02C9/40;;F05D2260/80,F02C9/40,,0,0,,,,ACTIVE
108,DE,D1,DE 602006009140 D1,192-934-122-417-843,2009-10-22,2009,DE 602006009140 T,2006-12-12,US 74946905 P;;EP 2006069596 W,2005-12-12,VENTILANORDNUNG,,SIEMENS AG,BURKITT EDWARD;;DAVIES GARETH HUW,,https://lens.org/192-934-122-417-843,Granted Patent,no,0,0,6,6,0,F01D25/32;;F02C7/232;;F05D2260/602;;F02C7/232;;F01D25/32;;F05D2260/602,F01D25/00,,0,0,,,,ACTIVE
109,EP,A1,EP 3425574 A1,198-742-064-352-325,2019-01-09,2019,EP 18181720 A,2018-07-04,GB 201710719 A,2017-07-04,A SYSTEM AND METHOD FOR UTILITY MANAGEMENT,"A utility management device, comprising: 
input for receiving a utility consumption signal for a premises; 
an output for outputting utility management information; 
and 
a processor configured to: 
monitor the input utility consumption signal for a change in magnitude; 
if a change is detected: 
identify an appliance event corresponding to the change; 
obtain information relating to the projected utility consumption of the appliance for an upcoming time period; 
update a projected utility consumption of the premises based on the obtained information; 
determine whether any projected stored and/or generated utility amount at the premises is sufficient for the projected utility consumption of the premises; 
if not sufficient, cause the device to output a request to receive a utility amount from one or more other premises connected to the premises via a communication network. 
  
  
",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,,https://lens.org/198-742-064-352-325,Patent Application,yes,4,0,7,7,0,G06Q10/06315;;G06Q50/06;;Y04S20/30;;Y04S20/222;;Y02B70/3225;;G06Q10/06315;;G06Q40/04;;G06Q50/06;;Y02P90/90;;Y02E70/30;;Y04S50/00;;Y04S10/14;;Y04S10/50;;G06Q50/06;;G06Q10/06315;;Y04S50/12;;Y02B70/30;;G01D4/004;;H04L9/0637;;H04L67/1042,G06Q10/06;;G06Q50/06,,0,0,,,,DISCONTINUED
110,US,A1,US 2022/0257313 A1,049-884-644-488-406,2022-08-18,2022,US 202017627739 A,2020-07-17,US 202017627739 A;;US 201962876192 P;;IB 2020056759 W,2019-07-19,"Medical Dilator, and Systems, Methods, and Kits for Medical Dilation","A medical dilator includes an elongate member having a proximal end portion, an opposed distal end portion, and a lumen extending through the elongate member from the proximal end portion to the distal end portion. A dilating tip is at the distal end portion. The dilating tip has a first end of enlarged cross-sectional area and tapers going in the distal direction to a second end of reduced cross-sectional area. At least a first electrode is associated with the dilating tip. An electrical conductor is electrically connected to the first electrode and extends proximally from the first electrode towards the proximal end portion for electrical connection with an electro anatomical mapping system.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,BAYLIS MEDICAL COMPANY INC (2021-10-14);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/049-884-644-488-406,Patent Application,yes,0,0,10,10,0,A61B18/00;;A61B2018/00351;;A61B2018/00613;;A61M29/00;;A61B5/06;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2018/00601;;A61B2018/0038;;A61B2018/00357;;A61B2018/00839;;A61B2017/00053;;A61B34/20;;A61B2034/2051;;A61B2034/2072;;A61B2090/3925;;A61B2090/3966;;A61B18/1492;;A61B18/1487;;A61M29/00;;A61B5/367;;A61B5/06;;A61B2018/00357;;A61B2018/0038;;A61B2018/00839;;A61B2018/00601;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2017/00336,A61B18/14;;A61B5/367,,0,0,,,,PENDING
111,CN,A,CN 110622013 A,069-733-144-636-393,2019-12-27,2019,CN 201880028166 A,2018-02-28,GB 201703178 A;;GB 2018050516 W,2017-02-28,AN APPLIANCE OPERATION SIGNAL PROCESSING SYSTEM AND METHOD,"An appliance operation signal processing system comprises: an input for receiving an appliance operation signal, the appliance operation signal comprising information relating to operation of an appliance; an output for outputting information relating to degradation of the appliance; and a processor configured to determine a probability that the appliance or a component of the appliance is in theor each of one or more degradation states, by applying a classifier to a feature vector comprising information relating to frequency data extracted from the appliance operation signal.",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,,https://lens.org/069-733-144-636-393,Patent Application,no,4,1,10,10,0,G01R19/2513;;G01R21/00;;G01R21/133;;G01R22/06;;G05B23/0227;;G06N20/00;;G01R19/2513;;G01R21/00;;G06Q50/06;;G06N20/00;;G01R21/00;;G01R22/06;;G01R21/133;;G01R19/2513;;G01R19/252;;G05B23/0227;;G06N20/00;;G06Q50/06;;Y04S20/30;;G01H1/00;;G01H1/003;;G01M99/005;;G01R21/133;;G06N3/04;;G06N3/084;;G06N20/00,G01R21/00;;G01D4/00;;G01R19/25;;G01R21/133;;G01R22/06;;G05B23/02;;G06N20/00,,1,0,,,"卢胜: ""《基于差频法和最小二乘法的XLPE绝缘检测分析》"", 《陕西电力》",DISCONTINUED
112,GB,A,GB 2563860 A,132-944-460-271-675,2019-01-02,2019,GB 201710244 A,2017-06-27,GB 201710244 A,2017-06-27,A system and method for identifying appliances under recall,"System and method for processing appliance operation signals to identify recalled appliances by: receiving an appliance operation signal; monitoring the signal for a change in magnitude; and, if a change is detected: identifying a component event, determining whether the event is a designated sequence start component event, if it is: extracting one or more features from the signal between the sequence start component event and a sequence stop point, determining a probability that the appliance corresponds to a model designated as recalled by applying a first classifier to a feature vector containing the one or more features, and outputting information relating to the recall status of the appliance. Also claimed is a method of training a machine learning classifier for determining a probability that the appliance corresponds to each of a set of models designated as recalled, using a corpus of data comprising appliance operation signals annotated with information relating to whether the devices correspond to recalled models, by applying the method of processing appliance operation signals to the corpus of data, where the first classifier is the machine learning classifier, and training the classifier using the annotations.",GREEN RUNNING LTD,PETER GARETH DAVIES;;CONRAD SPITERI,,https://lens.org/132-944-460-271-675,Patent Application,no,4,0,9,9,0,G01D4/00;;G06Q50/06;;G06Q10/20;;Y04S20/30;;G01D4/00;;G01R19/2513;;G01R21/133;;G01R31/2825;;G06Q30/014;;G06Q50/06;;G01D4/002;;G01D4/02;;G01D4/10;;G06Q50/06,G01R31/28;;G01D4/00;;G01R19/25;;G01R21/133;;G06Q50/06,,0,0,,,,DISCONTINUED
113,EP,A1,EP 2854927 A1,171-918-093-800-04X,2015-04-08,2015,EP 12877833 A,2012-11-09,US 201261653967 P;;IB 2012056315 W,2012-05-31,RADIOFREQUENCY PERFORATION APPARATUS,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,"BAYLIS MEDICAL COMPANY INC. (2022-06-22);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2023-03-30);;BAYLIS MEDICAL COMPANY INC., MISSISSAUGA, CA (2022-06-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2023-03-28);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED; IE (2023-03-24)",https://lens.org/171-918-093-800-04X,Patent Application,yes,0,0,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61M25/095;;A61B5/06;;A61B18/12;;A61M25/098;;A61M25/14,,0,0,,,,ACTIVE
114,WO,A1,WO 2021/161149 A1,175-354-714-278-544,2021-08-19,2021,IB 2021051008 W,2021-02-08,US 202062972810 P,2020-02-11,MEDICAL DILATOR,"An apparatus includes an elongated medical dilator including a cautery device configured to selectively form, by cauterization, a tissue passage through a tissue portion of a living body. The elongated medical dilator also includes a dilation device configured to dilate the tissue passage once the cautery device selectively formed the tissue passage.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,URBANSKI JOHN PAUL;;DAVIES GARETH,,https://lens.org/175-354-714-278-544,Patent Application,yes,5,0,3,3,0,A61M29/00;;A61B17/3478;;A61B2017/003;;A61B2017/00946;;A61B18/1487;;A61B2018/1497;;A61B18/1492;;A61B2018/1435;;A61B2018/142;;A61B18/082;;A61B2017/00247;;A61B2017/00331;;A61B2018/00351;;A61B18/1487;;A61B2018/0022;;A61B2018/00595;;A61B2018/00625;;A61M29/02,A61B18/14;;A61B17/00;;A61B17/34;;A61B18/00;;A61M29/00,,0,0,,,,PENDING
115,GB,A,GB 2564389 A,116-869-952-231-795,2019-01-16,2019,GB 201710719 A,2017-07-04,GB 201710719 A,2017-07-04,A system and method for utility management,"An apparatus and method involves receiving information regarding appliance events for a premises 3, determining projected utility consumption for the appliance 4, and updating a projected utility consumption of the premises. It is then determined 5 whether the premises has, or will have, sufficient stored and/or generated utility amount for the projected utility consumption of the premises. If not sufficient, a utility amount is requested 8 from at least one other premises. Energy may be traded with neighbouring systems to ensure energy is available at the required time. The trading negotiation, contract, and proof of supply and consumption may be handled by an underlying blockchain framework. If the stored and/or generated utility amount is determined to provide an excess then a utility amount may be provided to other premises.",GREEN RUNNING LTD,PETER GARETH DAVIES;;CONRAD SPITERI,,https://lens.org/116-869-952-231-795,Patent Application,no,3,0,7,7,0,G06Q10/06315;;G06Q50/06;;Y04S20/30;;Y04S20/222;;Y02B70/3225;;G06Q10/06315;;G06Q40/04;;G06Q50/06;;Y02P90/90;;Y02E70/30;;Y04S50/00;;Y04S10/14;;Y04S10/50;;G06Q50/06;;G06Q10/06315;;Y04S50/12;;Y02B70/30;;G01D4/004;;H04L9/0637;;H04L67/1042,G06Q10/06;;G06Q40/04;;G06Q50/06,,0,0,,,,DISCONTINUED
116,CA,A1,CA 3167407 A1,107-929-083-852-893,2021-08-19,2021,CA 3167407 A,2021-02-08,US 202062972810 P;;IB 2021051008 W,2020-02-11,MEDICAL DILATOR,"An apparatus includes an elongated medical dilator including a cautery device configured to selectively form, by cauterization, a tissue passage through a tissue portion of a living body. The elongated medical dilator also includes a dilation device configured to dilate the tissue passage once the cautery device selectively formed the tissue passage.",BOSTON SCIENT MEDICAL DEVICE LIMITED,URBANSKI JOHN PAUL;;DAVIES GARETH,,https://lens.org/107-929-083-852-893,Patent Application,no,0,0,3,3,0,A61M29/00;;A61B17/3478;;A61B2017/003;;A61B2017/00946;;A61B18/1487;;A61B2018/1497;;A61B18/1492;;A61B2018/1435;;A61B2018/142;;A61B18/082;;A61B2017/00247;;A61B2017/00331;;A61B2018/00351;;A61B18/1487;;A61B2018/0022;;A61B2018/00595;;A61B2018/00625;;A61M29/02,A61B17/00;;A61B17/34;;A61B18/00;;A61B18/14;;A61M29/00,,0,0,,,,PENDING
117,US,B2,US 9909509 B2,112-900-307-162-771,2018-03-06,2018,US 201314647223 A,2013-11-05,EP 12195312 A;;EP 2013073083 W,2012-12-03,Gas turbine fuel supply method and arrangement,"A gas turbine fuel supply method and arrangement is provided. The method of controlling a supply of a fuel to a combustor of a gas turbine having a compressor upstream of the combustor, the method including: supplying the fuel to the combustor; obtaining an inlet air pressure (PT 7 ) at a compressor inlet; obtaining an inlet air temperature (Tinlet) at the compressor inlet; obtaining an outlet air pressure (PT 8 ) at a compressor outlet; estimating a heat input (HIengmodel, HIexpected) of the fuel supplied to the combustor based on the inlet air pressure (PT 7 ), the inlet air temperature (Tinlet) and the outlet air pressure (PT 8 ); comparing the estimated heat input (HIengmodel, HIexpected) with a demanded heat input (FFDEM) to derive an error signal; and controlling a fuel valve regulating the supply of the fuel to the combustor based on the error signal.",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,SIEMENS AKTIENGESELLSCHAFT (2015-06-08);;SIEMENS INDUSTRIAL TURBOMACHINERY LIMITED (2015-06-01);;SIEMENS ENERGY GLOBAL GMBH & CO. KG (2021-02-28),https://lens.org/112-900-307-162-771,Granted Patent,yes,27,1,12,12,0,F02C9/40;;F05D2260/80;;F02C9/26;;F02C9/28;;F02C9/40;;F05D2260/80,F02C9/28;;F02C9/40,,1,0,,,"RU Official Decision of Grant dated Nov. 1, 2016, for RU patent application No. 2015121116.",ACTIVE
118,US,B2,US 11067482 B2,184-485-806-719-497,2021-07-20,2021,US 201816489535 A,2018-02-28,GB 201703178 A;;GB 2018050516 W,2017-02-28,Appliance operation signal processing system and method,An appliance operation signal processing system including an input for receiving an appliance operation signal. The appliance operation signal includes information relating to operation of an appliance. The system further includes an output for outputting information relating to degradation of the appliance and a processor configured to determine a probability that the appliance or a component of the appliance is in at least one degradation state by applying a classifier to a feature vector including information relating to frequency data extracted from the appliance operation signal.,GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,GREEN RUNNING LIMITED (2019-10-30),https://lens.org/184-485-806-719-497,Granted Patent,yes,19,0,10,10,0,G01R19/2513;;G01R21/00;;G01R21/133;;G01R22/06;;G05B23/0227;;G06N20/00;;G01R19/2513;;G01R21/00;;G06Q50/06;;G06N20/00;;G01R21/00;;G01R22/06;;G01R21/133;;G01R19/2513;;G01R19/252;;G05B23/0227;;G06N20/00;;G06Q50/06;;Y04S20/30;;G01H1/00;;G01H1/003;;G01M99/005;;G01R21/133;;G06N3/04;;G06N3/084;;G06N20/00,G06N3/04;;G01H1/00;;G01M99/00;;G01R21/133;;G06N3/08;;G06N20/00,,5,3,039-079-663-941-902;;109-908-687-501-680;;026-843-183-842-445,10.1109/globalsip.2015.7418189;;10.1007/s12652-016-0431-y;;10.1061/(asce)cp.1943-5487.0000108,"International Search Report for International Application No. PCT/GB2018/050516, dated May 29, 2018 (4 pages).;;Written Opinion of International Searching Authority for International Application No. PCT/EP2018/057172, dated May 29, 2018 (7 pages).;;GAO JINGKUN; KARA EMRE CAN; GIRI SUMAN; BERGES MARIO: ""A feasibility study of automated plug-load identification from high-frequency measurements"", 2015 IEEE GLOBAL CONFERENCE ON SIGNAL AND INFORMATION PROCESSING (GLOBALSIP), IEEE, 14 December 2015 (2015-12-14), pages 220 - 224, XP032871650, DOI: 10.1109/GlobalSIP.2015.7418189;;FERRÁNDEZ-PASTOR F. J.; MORA-MORA H.; SÁNCHEZ-ROMERO J. L.; NIETO-HIDALGO M.; GARCÍA-CHAMIZO J. M.: ""Interpreting human activity from electrical consumption data using reconfigurable hardware and hidden Markov models"", JOURNAL OF AMBIENT INTELLIGENCE AND HUMANIZED COMPUTING, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 8, no. 4, 22 November 2016 (2016-11-22), Berlin/Heidelberg, pages 469 - 483, XP036272790, ISSN: 1868-5137, DOI: 10.1007/s12652-016-0431-y;;Berges, M. et al.; “User-centered non-intrusive electricity load monitoring for residential buildings”; J. Computing in Civil Engineering; Amer. Society of Civil Engineers, Bol. 25, No. 6, pp. 471-480; Nov. 1, 2011; XP0091182171 (11 pages).",ACTIVE
119,EP,A1,EP 2925984 A1,039-299-854-019-851,2015-10-07,2015,EP 13792286 A,2013-11-05,EP 12195315 A;;EP 2013073079 W;;EP 13792286 A,2012-12-03,METHOD AND ARRANGEMENT FOR CONTROLLING FUEL SUPPLY FOR A GAS TURBINE,,SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,SIEMENS AKTIENGESELLSCHAFT (2017-08-30),https://lens.org/039-299-854-019-851,Patent Application,yes,0,0,12,12,0,F02C9/40;;F05D2260/80;;F02C9/40;;F02C9/28;;F02C9/32;;F02C9/48;;F02C9/40;;F05D2260/80,F02C9/28;;F02C9/40,,0,0,,,,ACTIVE
120,US,A1,US 2015/0315978 A1,041-836-044-646-231,2015-11-05,2015,US 201314647199 A,2013-11-05,EP 12195315 A;;EP 2013073079 W,2012-12-03,METHOD AND ARRANGEMENT FOR CONTROLLING FUEL SUPPLY FOR A GAS TURBINE,"A method of controlling a supply of a fuel to a combustor of a gas turbine having a compressor upstream of the combustor is provided. The method includes: supplying the fuel to the combustor; obtaining a property value of at least one physical property (PTB, PT7, Tinlet, THBOV) of air used for burning the fuel in the combustor; estimating a heat input (HIengmodel) of the fuel supplied to the combustor based on the property value; measuring a Caloric Value (LCVmea) of the fuel upstream of the combustor; adjusting the estimated heat input (HIengmodel) based on the measured Caloric Value (LCVmea); and controlling a fuel valve regulating the supply of the fuel to the combustor based on the adjusted estimated heat input (HIexpected) and a demanded heat input (FFDEM).",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,SIEMENS AKTIENGESELLSCHAFT (2015-06-08);;SIEMENS INDUSTRIAL TURBOMACHINERY LIMITED (2015-06-01),https://lens.org/041-836-044-646-231,Patent Application,yes,6,9,12,12,0,F02C9/40;;F05D2260/80;;F02C9/40;;F02C9/28;;F02C9/32;;F02C9/48;;F02C9/40;;F05D2260/80,F02C9/28;;F02C9/40,,0,0,,,,INACTIVE
121,BR,A2,BR 112022000536 A2,136-040-581-580-494,2022-03-15,2022,BR 112022000536 A,2020-07-17,IB 2020056759 W;;US 201962876192 P,2019-07-19,"Dilatador médico, e sistemas, métodos e kits para dilatação médica","dilatador médico, e sistemas, métodos e kits para dilatação médica. um dilatador médico inclui um membro alongado que tem uma porção de extremidade proximal, uma porção de extremidade distal oposta e um lúmen que se estende através do membro alongado a partir da porção de extremidade proximal até a porção de extremidade distal. uma ponta de dilatação está na porção de extremidade distal. a ponta de dilatação tem uma primeira extremidade da área da seção transversal ampliada e se afunila na direção distal até uma segunda extremidade da área da seção transversal reduzida. ao menos um primeiro eletrodo está associado à ponta de dilatação. um condutor elétrico é conectado eletricamente ao primeiro eletrodo e se estende proximalmente a partir do primeiro eletrodo em direção à porção de extremidade proximal para conexão elétrica com um sistema de mapeamento eletroanatômico.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;JOHN PAUL URBANSKI,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (IE) (2023-06-06),https://lens.org/136-040-581-580-494,Patent Application,no,0,0,10,10,0,A61B18/00;;A61B2018/00351;;A61B2018/00613;;A61M29/00;;A61B5/06;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2018/00601;;A61B2018/0038;;A61B2018/00357;;A61B2018/00839;;A61B2017/00053;;A61B34/20;;A61B2034/2051;;A61B2034/2072;;A61B2090/3925;;A61B2090/3966;;A61B18/1492;;A61B18/1487;;A61M29/00;;A61B5/367;;A61B5/06;;A61B2018/00357;;A61B2018/0038;;A61B2018/00839;;A61B2018/00601;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2017/00336,A61M25/01;;A61B5/00;;A61B18/00;;A61B18/14;;A61M29/00,,0,0,,,,PENDING
122,CA,C,CA 2891183 C,151-444-466-886-679,2017-06-27,2017,CA 2891183 A,2013-11-05,EP 12195315 A;;EP 2013073079 W,2012-12-03,METHOD AND ARRANGEMENT FOR CONTROLLING FUEL SUPPLY FOR A GAS TURBINE,"It is described a method of controlling a supply of a fuel (105) to a combustor (101) of a gas turbine comprising a compressor upstream of the combustor, the method comprising: supplying the fuel (105) to the combustor (101); obtaining a property value of at least one physical property (PT8, PT7, Tinlet, THBOV) of air used for burning the fuel (105) in the combustor (101); estimating a heat input (HIengmodel) of the fuel (105) supplied to the combustor (101) based on the prop- erty value; measuring a Caloric Value (LCVmea) of the fuel (105) upstream of the combustor (101); adjusting the estimated heat input (HIengmodel) based on the measured Caloric Value (LCVmea); and controlling a fuel valve (103) regulating the supply of the fuel (105) to the combustor (101) based on the adjusted estimated heat input (HIexpected) and a demanded heat input (FFDEM).",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,,https://lens.org/151-444-466-886-679,Granted Patent,no,0,0,12,12,0,F02C9/40;;F05D2260/80;;F02C9/40;;F02C9/28;;F02C9/32;;F02C9/48;;F02C9/40;;F05D2260/80,F02C9/40,,0,0,,,,INACTIVE
123,US,A1,US 2019/0013669 A1,170-628-989-681-598,2019-01-10,2019,US 201816026668 A,2018-07-03,GB 201710719 A,2017-07-04,SYSTEM AND METHOD FOR UTILITY MANAGEMENT,"A utility management device, comprising an input for receiving a utility consumption signal for a premises, an output for outputting utility management information, and a processor configured to monitor the input utility consumption signal for a change in magnitude. If a change is detected, the processor is configured to identify an appliance event corresponding to the change, obtain information relating to the projected utility consumption of the appliance for an upcoming time period, update a projected utility consumption of the premises based on the obtained information, determine whether any projected stored and/or generated utility amount at the premises is sufficient for the projected utility consumption of the premises, and, if not sufficient, cause the device to output a request to receive a utility amount from one or more other premises connected to the premises via a communication network.",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,DURIAN RESEARCH LLC (2023-06-01);;GREEN RUNNING LIMITED (2018-10-04),https://lens.org/170-628-989-681-598,Patent Application,yes,6,8,7,7,0,G06Q10/06315;;G06Q50/06;;Y04S20/30;;Y04S20/222;;Y02B70/3225;;G06Q10/06315;;G06Q40/04;;G06Q50/06;;Y02P90/90;;Y02E70/30;;Y04S50/00;;Y04S10/14;;Y04S10/50;;G06Q50/06;;G06Q10/06315;;Y04S50/12;;Y02B70/30;;G01D4/004;;H04L9/0637;;H04L67/1042,H02J3/14;;G01D4/00;;G06Q50/06;;H04L9/06;;H04L29/08,,0,0,,,,ACTIVE
124,WO,A1,WO 2019/002851 A1,071-582-719-690-566,2019-01-03,2019,GB 2018051789 W,2018-06-27,GB 201710244 A,2017-06-27,A SYSTEM AND METHOD FOR IDENTIFYING APPLIANCES UNDER RECALL,"An appliance operation signal processing system comprises: an input for receiving an appliance operation signal, the appliance operation signal comprising information relating to operation of an appliance; an output for outputting information relating to a recall status of the appliance; and a processor configured to: monitor an input appliance operation signal for a change in magnitude; if a change is detected: identify a component event corresponding to the change; determine whether the component event is a designated sequence start component event; if the component event is determined to be a designated sequence start component event: extract one or more features from the input appliance operation signal between the sequence start component event and a sequence stop point; determine information relating to a recall status of the appliance by inputting the one or more features into a first algorithm.",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,,https://lens.org/071-582-719-690-566,Patent Application,yes,3,3,9,9,0,G01D4/00;;G06Q50/06;;G06Q10/20;;Y04S20/30;;G01D4/00;;G01R19/2513;;G01R21/133;;G01R31/2825;;G06Q30/014;;G06Q50/06;;G01D4/002;;G01D4/02;;G01D4/10;;G06Q50/06,G01D4/00;;G06Q50/06,,0,0,,,,PENDING
125,US,B2,US 10855077 B2,068-928-984-084-441,2020-12-01,2020,US 201816026668 A,2018-07-03,GB 201710719 A,2017-07-04,System and method for utility management,"A utility management device, comprising an input for receiving a utility consumption signal for a premises, an output for outputting utility management information, and a processor configured to monitor the input utility consumption signal for a change in magnitude. If a change is detected, the processor is configured to identify an appliance event corresponding to the change, obtain information relating to the projected utility consumption of the appliance for an upcoming time period, update a projected utility consumption of the premises based on the obtained information, determine whether any projected stored and/or generated utility amount at the premises is sufficient for the projected utility consumption of the premises, and, if not sufficient, cause the device to output a request to receive a utility amount from one or more other premises connected to the premises via a communication network.",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,DURIAN RESEARCH LLC (2023-06-01);;GREEN RUNNING LIMITED (2018-10-04),https://lens.org/068-928-984-084-441,Granted Patent,yes,14,2,7,7,0,G06Q10/06315;;G06Q50/06;;Y04S20/30;;Y04S20/222;;Y02B70/3225;;G06Q10/06315;;G06Q40/04;;G06Q50/06;;Y02P90/90;;Y02E70/30;;Y04S50/00;;Y04S10/14;;Y04S10/50;;G06Q50/06;;G06Q10/06315;;Y04S50/12;;Y02B70/30;;G01D4/004;;H04L9/0637;;H04L67/1042,H02J3/14;;G01D4/00;;G06Q10/06;;G06Q50/06;;H04L9/06;;H04L29/08,,0,0,,,,ACTIVE
126,US,A1,US 2005/0242431 A1,180-213-219-730-304,2005-11-03,2005,US 15843505 A,2005-06-22,US 15843505 A;;EP 99306444 A;;EP 99309842 A;;US 63928800 A,1999-08-17,Integrated circuit dies,"An integrated circuit die carries conductive pads and thereon, the larger pads being suitable for flip-chip assembly and the smaller pads being suitable for wire bond assembly. The pitch between pads is at least the minimum required for flip-chip assembly, whereas the pitch between each of pads and the adjacent pad or pads is at least the minimum required for wire bond assembly. For wire bond assembly a passivation layer exposing all pads is provided, whereas for flip-chip assembly a passivation layer exposes only certain pads so that conductive bumps may be provided. The provision of pads complying with the minimum spacing requirements for both flip-chip and wire bond assembly enables a “dual purpose” (e.g. one set of pads being for normal production and another set for testing purposes) die to be produced without any increase in die size.",AGERE SYSTEMS INC,ADDINALL ROSS;;DAVIES GARETH R,BELL SEMICONDUCTOR LLC (2017-12-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04),https://lens.org/180-213-219-730-304,Patent Application,yes,13,2,9,10,0,H01L2224/04073;;H01L2224/06153;;H01L2224/13099;;H01L2924/01004;;H01L2924/01005;;H01L2924/01013;;H01L2924/01015;;H01L2924/01033;;H01L2924/01075;;H01L2924/01079;;H01L2924/01082;;H01L2924/014;;H01L2924/14;;H01L24/13;;H01L2924/00;;H01L24/06;;H01L2224/0401;;H01L2224/13;;H01L2224/04042;;H01L2224/0616;;H01L24/05;;H01L2224/06051;;H01L23/485;;H01L21/60;;H01L24/02;;H01L2924/01004;;H01L2924/01013;;H01L2924/01015;;H01L24/10;;H01L2924/01005;;H01L2924/14;;H01L2224/04073;;H01L2924/014;;H01L2924/01082;;H01L2224/13099;;H01L2924/01079;;H01L2924/01033;;H01L2224/06153;;H01L2924/01075;;H01L24/13;;H01L24/06;;H01L2924/00;;H01L2224/0401;;H01L2224/13,H01L23/485;;H01L21/60,257/734,0,0,,,,EXPIRED
127,US,B2,US 10166070 B2,184-474-345-864-849,2019-01-01,2019,US 201514933356 A,2015-11-05,US 201514933356 A;;US 201414257053 A;;US 201213656173 A;;US 531607 A;;US 88307407 P,2007-01-02,Electrosurgical pericardial puncture,"Devices and methods for providing access to the pericardial cavity while reducing risk of myocardial damage. One method includes advancing a distal end of a puncture device towards the heart from a subxiphoid region of a patient wherein the distal end of the puncture device is atraumatic and comprises an energy delivery device; positioning the energy delivery device at a target site on a pericardium of the heart using ultrasound for imaging; and delivering energy from the energy delivery device to a tissue of the target site to create a channel to the pericardial cavity. The method may include repeating one or more of the above steps until the energy delivery device is located within the pericardial cavity. Some embodiments of the method include using supplemental means of monitoring, including medical imaging and using contrast fluid.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,BAYLIS MEDICAL COMPANY INC (2015-11-27);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/184-474-345-864-849,Granted Patent,yes,16,5,4,11,0,A61B17/2202;;A61B17/3478;;A61B2017/00026;;A61B2017/00243;;A61B2017/00247;;A61B2017/00353;;A61B2017/22014;;A61B2018/00083;;A61B2018/00291;;A61B2018/00363;;A61B2018/00601;;A61B2018/00702;;A61B2018/00839;;A61B2018/00875;;A61B2018/1861;;A61B2090/064;;A61B90/37;;A61B2090/378;;A61B18/1492;;A61B2017/00154;;A61B18/1492;;A61B8/0841;;A61B8/12;;A61B8/0883;;A61B8/445;;A61B8/4494;;A61B8/481;;A61B2017/00154;;A61B2090/378;;A61B17/2202;;A61B17/3478;;A61B2017/00026;;A61B2017/00243;;A61B2017/00247;;A61B2017/00353;;A61B2017/22014;;A61B2018/00083;;A61B2018/00291;;A61B2018/00363;;A61B2018/00601;;A61B2018/00702;;A61B2018/00839;;A61B2018/00875;;A61B2018/1861;;A61B2090/064;;A61B90/37,A61B18/18;;A61B8/00;;A61B8/08;;A61B8/12;;A61B17/00;;A61B17/22;;A61B17/32;;A61B17/34;;A61B18/00;;A61B18/14;;A61B90/00,,3,0,,,"Entire Prosecution History of U.S. Appl. No. 12/005,316 from Dec. 27, 2007 to Oct. 24, 2012.;;Entire Prosecution History of U.S. Appl. No. 13/656,173 from Oct. 19, 2012 to Jul. 15, 2014.;;Entire Prosecution History of U.S. Appl. No. 14/257,053 from Apr. 21, 2014 to Oct. 22, 2015.",ACTIVE
128,WO,A1,WO 2021/074860 A1,015-495-697-433-115,2021-04-22,2021,IB 2020059729 W,2020-10-15,US 201962923031 P,2019-10-18,MEDICAL GUIDEWIRE ASSEMBLY AND/OR ELECTRICAL CONNECTOR,"Disclosed is a flexible medical guide wire assembly configured to be inserted into a confined space defined by a living body. A sensor assembly is securely supported by the flexible medical guidewire assembly. This is done in such a way that the sensor assembly and the flexible medical guidewire assembly are movable along the confined space defined by the living body once the flexible medical guidewire assembly is inserted into, and moved along, the confined space defined by the living body. Also disclosed is an electrical-connector assembly having a connector terminal. The connector terminal is configured to be electrically connectable with a terminal portion of a flexible medical guidewire assembly. The terminal portion is electrically connected, via an electrical wire, to a sensor assembly of the flexible medical guidewire assembly.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,URBANSKI JOHN PAUL;;DAVIES GARETH,,https://lens.org/015-495-697-433-115,Patent Application,yes,5,3,8,9,0,A61B18/12;;A61B18/1492;;A61B2018/00351;;A61B2018/00595;;A61B2018/00982;;A61B2018/00839;;A61B18/1492;;A61B2018/00577;;A61B2018/00839;;A61B2018/00595;;A61B5/6851;;A61B18/1492;;A61B5/6851;;A61B2018/00577;;A61B2018/00595;;A61B2018/00839,A61M25/09;;A61B18/00;;A61B18/14;;A61B18/18;;A61M25/01,,0,0,,,,PENDING
129,JP,A,JP 2019030693 A,065-731-105-994-29X,2019-02-28,2019,JP 2018188330 A,2018-10-03,US 201261653967 P,2012-05-31,RADIOFREQUENCY PERFORATION APPARATUS,"To provide a radiofrequency perforation apparatus having improved visualization of a portion of the medical device insertable into a patient while minimizing obstruction of a fluid flow through a lumen.SOLUTION: The device can include an imaging marker 6 distal to lumen openings 7 (exit ports), or, where the device comprises a tube, such as a metallic tube 12, an imaging marker embedded in a wall of the tube. Another embodiment includes attaching a marker to the surface on the inside of a lumen 9 of a medical device without embedding the marker.SELECTED DRAWING: Figure 10b",BAYLIS MEDICAL CO INC,GARETH DAVIES;;JOHN PAUL URBANSKI,,https://lens.org/065-731-105-994-29X,Patent Application,no,7,2,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61M25/00;;A61B17/34;;A61B18/14;;A61M25/098,,0,0,,,,PENDING
130,US,B2,US 8567174 B2,081-265-576-762-561,2013-10-29,2013,US 8570006 A,2006-12-12,US 8570006 A;;US 74946905 P;;EP 2006069596 W,2005-12-12,"Valve assembly for draining oil, moisture, or water from a gas turbine engine","A valve assembly is provided for a gas turbine engine with at least two drain valves connected to the gas turbine engine to drain oil and moisture from the engine, an actuator for opening and closing the at least two drain valves, a solenoid valve connected to the actuator and to a regulated air supply for driving the actuator and a safety valve connected to an exhaust of the solenoid valve and to a compressor air supply, the compressor air supply driving the safety valve to prevent the actuator from being vented during engine operation. A method of securely operating a plurality of drain valves is also provided.",BURKITT EDWARD;;DAVIES GARETH HUW;;SIEMENS AG,BURKITT EDWARD;;DAVIES GARETH HUW,SIEMENS AKTIENGESELLSCHAFT (2009-03-10);;SIEMENS ENERGY GLOBAL GMBH & CO. KG (2021-02-28),https://lens.org/081-265-576-762-561,Granted Patent,yes,17,2,6,6,0,F01D25/32;;F02C7/232;;F05D2260/602;;F02C7/232;;F01D25/32;;F05D2260/602,F02C7/232,60/39.094;;60/779;;251/94,0,0,,,,ACTIVE
131,WO,A1,WO 2002/102469 A1,114-287-295-182-424,2002-12-27,2002,EP 0206499 W,2002-06-12,GB 0114510 A;;GB 0116587 A,2001-06-14,EXERCISE APPARATUS,"Physical exercise apparatus comprises an exercise machine, such as an exercise bicycle, and a data processing device which runs a computer game program. A user controls the computer game with a game controller, such as a joystick, while exercising on the exercise machine. The data processing device varies a parameter of the computer game in dependence on the rate of exercise of the user. The relationship between the user's rate of exercise and the effect on the computer game is non-linear, such that the user receives a greater reward for increased effort at higher rates of exercise.",EXERTRIS LTD;;DAVIES GARETH;;DRAGE KARL JOHN,DAVIES GARETH;;DRAGE KARL JOHN,,https://lens.org/114-287-295-182-424,Patent Application,yes,9,0,3,9,0,A63B71/0622;;A63B22/0605;;A63B2071/0641;;A63B2230/06,A63B24/00;;A63B21/00;;A63B22/08;;A63B69/00;;A63B71/06,,0,0,,,,PENDING
132,EP,A2,EP 4273784 A2,137-830-757-440-499,2023-11-08,2023,EP 23185229 A,2018-07-04,GB 201710719 A;;EP 18181720 A,2017-07-04,A SYSTEM AND METHOD FOR UTILITY MANAGEMENT,"One or more tangible, non-transitory, computer-readable media (2) storing instructions that, when executed by processing circuitry (3), are configured to cause the processing circuitry (3) to: 
receive an input indicative of a utility consumption at a first premises; 
detect a change to the utility consumption based on the input; 
identify an appliance event based on the change; 
determine a projected utility consumption at the first premises based on the appliance event; 
compare a projected utility capacity at the first premises with the projected utility consumption; 
in response to determining that the projected utility capacity exceeds the projected utility consumption, transmit an offer to provide an excess utility capacity to one or more second premises; and 
in response to determining that the projected utility consumption exceeds the projected utility capacity, transmit a request to receive additional utility capacity from the one or more second premises.",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,,https://lens.org/137-830-757-440-499,Patent Application,yes,1,0,7,7,0,G06Q10/06315;;G06Q50/06;;Y04S20/30;;Y04S20/222;;Y02B70/3225;;G06Q10/06315;;G06Q40/04;;G06Q50/06;;Y02P90/90;;Y02E70/30;;Y04S50/00;;Y04S10/14;;Y04S10/50;;G06Q50/06;;G06Q10/06315;;Y04S50/12;;Y02B70/30;;G01D4/004;;H04L9/0637;;H04L67/1042,G06Q50/06,,0,0,,,,PENDING
133,CA,A1,CA 3155072 A1,138-448-785-221-567,2021-04-22,2021,CA 3155072 A,2020-10-15,US 201962923031 P;;IB 2020059729 W,2019-10-18,MEDICAL GUIDEWIRE ASSEMBLY AND/OR ELECTRICAL CONNECTOR,"Disclosed is a flexible medical guide wire assembly configured to be inserted into a confined space defined by a living body. A sensor assembly is securely supported by the flexible medical guidewire assembly. This is done in such a way that the sensor assembly and the flexible medical guidewire assembly are movable along the confined space defined by the living body once the flexible medical guidewire assembly is inserted into, and moved along, the confined space defined by the living body. Also disclosed is an electrical-connector assembly having a connector terminal. The connector terminal is configured to be electrically connectable with a terminal portion of a flexible medical guidewire assembly. The terminal portion is electrically connected, via an electrical wire, to a sensor assembly of the flexible medical guidewire assembly.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;DAVIES GARETH,,https://lens.org/138-448-785-221-567,Patent Application,no,0,0,8,9,0,A61B18/12;;A61B18/1492;;A61B2018/00351;;A61B2018/00595;;A61B2018/00982;;A61B2018/00839;;A61B18/1492;;A61B2018/00577;;A61B2018/00839;;A61B2018/00595;;A61B5/6851;;A61B18/1492;;A61B5/6851;;A61B2018/00577;;A61B2018/00595;;A61B2018/00839,A61B18/00,,0,0,,,,PENDING
134,EP,B1,EP 2925985 B1,149-956-843-551-24X,2016-09-28,2016,EP 13811130 A,2013-11-05,EP 12195312 A;;EP 2013073083 W;;EP 13811130 A,2012-12-03,GAS TURBINE FUEL SUPPLY METHOD AND ARRANGEMENT,,SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,"SIEMENS AKTIENGESELLSCHAFT (2017-08-30);;SIEMENS ENERGY GLOBAL GMBH & CO. KG, DE (2020-12-15)",https://lens.org/149-956-843-551-24X,Granted Patent,yes,5,0,12,12,0,F02C9/40;;F05D2260/80;;F02C9/26;;F02C9/28;;F02C9/40;;F05D2260/80,F02C9/28;;F02C9/40,,0,0,,,,ACTIVE
135,AU,A,AU 1970/020537 A,159-713-986-960-813,1972-04-13,1972,AU 1970/020537 A,1970-09-30,GB 5047069 A,1969-10-14,BORON COMPOUNDS,,IMPERIAL CHEMICAL IND LTD,DAVIES GARETH MORSE;;LEIGH THOMAS,,https://lens.org/159-713-986-960-813,Patent Application,no,0,0,10,10,0,C07D333/08;;C07F5/025,C07D333/08;;C07F5/02,09.610;;87.1-9,0,0,,,,DISCONTINUED
136,US,A1,US 2023/0277276 A1,015-375-804-689-620,2023-09-07,2023,US 202318315151 A,2023-05-10,US 202318315151 A;;US 202017130691 A;;US 201414404518 A;;IB 2012056315 W;;US 201261653967 P,2012-05-31,RADIOFREQUENCY PERFORATION APPARATUS,"Medical devices are disclosed having improved visualization of a portion of the medical device insertable into a patient's body while minimizing obstruction of fluid flow through a lumen of the device and while minimizing an increase in the outer diameter of the device attributable to the feature providing improved visualization. The device can include, for example, an imaging marker distal to lumen openings (exit ports), or, where the device comprises a tube, such as a metallic tube, an imaging marker embedded into a wall of the tube. Another embodiment includes attaching a marker to the surface on the inside of a lumen of a medical device without embedding the marker. Various alternative embodiments, methods and applications of using such devices are disclosed as well.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01);;BAYLIS MEDICAL INC (2014-11-18),https://lens.org/015-375-804-689-620,Patent Application,yes,0,0,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61B90/00;;A61B5/06;;A61B18/14;;A61M25/01,,0,0,,,,PENDING
137,GB,A,GB 2536655 A,056-532-728-832-352,2016-09-28,2016,GB 201504975 A,2015-03-24,GB 201504975 A,2015-03-24,Logging events with timestamps,"Logging entries 604-610, 614 include n bit timestamp, ID, and payload fields. The ID indicates the processing element causing an event, while the payload informs about the event. The n-bits of the timestamp field are the least significant bits of an N-bit timestamp for the event, where N > n. The timestamp is determined from the clock value when an event logging indication is received. A timing entry 602 is stored for the first entry including timestamp most significant bits k = N-n. An ID field of zeros, IDt, identifies the timing entry. The next timing entry 612 is generated when the k most significant bits of an N-bit entry, e.g. 614, differ from the k most significant bits of the previous timing entry 602, indicating wrapping for the least significant bits of the entrys timestamp. Unambiguous timestamps over a greater length of time are thus determined storing fewer bits.",IMAGINATION TECH LTD,PAUL MURRIN;;GARETH JOHN DAVIES,,https://lens.org/056-532-728-832-352,Patent Application,no,1,0,9,9,0,G06F11/3086;;G06F11/3476;;G06F11/3636;;G06F11/3636;;G06F11/3466;;G06F11/3466;;G06F11/3476;;G06F11/3476;;G06F17/40;;G06F17/40;;G06F2201/835;;G06F2201/835;;G06F2201/86;;G06F2201/86,G06F11/34,,2,2,061-841-368-218-032;;029-674-956-317-488,10.1007/978-3-642-16612-9_24;;10.1109/fccm.2012.11,"Runtime Verification, published 2010, Springer, pp 315-329, Vol 6418, Kraft et al, ""Trace Recording for Embedded Systems: Lessons Learned from Five Industrial Projects"" ISBN 978-3-642-16611-2 ; ISBN 3-642-16611-3;;IEEE 20th Annual International Symposium on Field-Programmable Custom Computing Machines (FCCM), published 2012, IEEE, pp 1-8, Arcas et al, A Low-Overhead Profiling and Visualization Framework for Hybrid Transactional Memory, ISBN 978-1-4673-1605-7 ; ISBN 1-4673-1605-9",ACTIVE
138,KR,A,KR 20190131046 A,056-169-665-885-233,2019-11-25,2019,KR 20197028450 A,2018-02-28,GB 201703178 A;;GB 2018050516 W,2017-02-28,기기 동작 신호 처리 시스템 및 방법,"기기 동작 신호 처리 시스템은, 기기의 동작에 관련이 있는 정보를 포함하는 기기 동작 신호를 수신하기 위한 입력부; 기기의 열화에 관련이 있는 정보를 출력하기 위한 출력부; 및 기기 동작 신호로부터 추출되는 주파수 데이터에 관련이 있는 정보를 포함하는 피처 벡터에 분류기를 적용하는 것에 의해, 기기 또는 기기의 컴포넌트가 하나 이상의 열화 상태 또는 그 각각에 있을 확률을 결정하도록 구성되는 프로세서를 포함한다.",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,,https://lens.org/056-169-665-885-233,Patent Application,no,0,0,10,10,0,G01R19/2513;;G01R21/00;;G01R21/133;;G01R22/06;;G05B23/0227;;G06N20/00;;G01R19/2513;;G01R21/00;;G06Q50/06;;G06N20/00;;G01R21/00;;G01R22/06;;G01R21/133;;G01R19/2513;;G01R19/252;;G05B23/0227;;G06N20/00;;G06Q50/06;;Y04S20/30;;G01H1/00;;G01H1/003;;G01M99/005;;G01R21/133;;G06N3/04;;G06N3/084;;G06N20/00,G01R21/00;;G01R19/25;;G01R19/252;;G01R21/133;;G01R22/06;;G05B23/02;;G06N20/00;;G06Q50/06,,0,0,,,,PENDING
139,WO,A1,WO 2021/161154 A1,118-862-642-411-951,2021-08-19,2021,IB 2021051013 W,2021-02-08,US 202062972844 P,2020-02-11,SYSTEM AND METHOD FOR CARRYING OUT A MEDICAL PROCEDURE,"A system for carrying out a medical procedure includes a medical device for advancing into a patient's body towards an anatomical volume, and a medical imaging system. The medical imaging system is configured to generate a graphical representation of the anatomical volume and to provide in the graphical representation real-time information about the position of the medical device within the anatomical volume. The medical imaging system includes a safety module configured to select one or more regions within the graphical representation for designation as a non-target region, and to monitor the position of the medical device within the anatomical volume and take a safety action if the position of the medical device within the anatomical volume corresponds to one of the non-target regions.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/118-862-642-411-951,Patent Application,yes,5,0,1,1,0,A61B18/1477;;A61B90/37;;A61B2017/00119;;A61B2017/00243;;A61B2018/00613;;A61B2034/105;;A61B2090/374;;A61B2090/3762;;A61B2090/3782,A61B34/20;;A61B18/12;;A61B18/14;;A61B90/00,,0,0,,,,PENDING
140,KR,A,KR 20010050075 A,164-556-288-574-573,2001-06-15,2001,KR 20000046915 A,2000-08-14,EP 99306444 A;;EP 99309842 A,1999-08-17,Improvements in or relating to integrated circuit dies,"PURPOSE: An integrated circuit die is provided to be applied to both a flip-chip assembly and a wire bonding assembly by forming a passivation layer exposing the first set pad alone or first and second set pads. CONSTITUTION: The first set of a conductive pad(2) and the second set of a pad(3) are fixed on a surface of an integrated circuit die(1). The pad(2) of the first set is made larger than a pad(3) of the second set and is installed for flip-chip assembly. A wire bonding connection(4) is provided to all the pad(2) and the pad(3), and a passivation layer(5) is fixed on a surface of the integrated circuit die(1) leaving an exposed region for the wire bonding connection(4) on each of the pad(2) and the pad(3).",LUCENT TECHNOLOGIES INC,ADDINALL ROSS;;DAVIES GARETH RHYS,,https://lens.org/164-556-288-574-573,Patent Application,no,0,0,9,10,0,H01L2224/04073;;H01L2224/06153;;H01L2224/13099;;H01L2924/01004;;H01L2924/01005;;H01L2924/01013;;H01L2924/01015;;H01L2924/01033;;H01L2924/01075;;H01L2924/01079;;H01L2924/01082;;H01L2924/014;;H01L2924/14;;H01L24/13;;H01L2924/00;;H01L24/06;;H01L2224/0401;;H01L2224/13;;H01L2224/04042;;H01L2224/0616;;H01L24/05;;H01L2224/06051;;H01L23/485;;H01L21/60;;H01L24/02;;H01L2924/01004;;H01L2924/01013;;H01L2924/01015;;H01L24/10;;H01L2924/01005;;H01L2924/14;;H01L2224/04073;;H01L2924/014;;H01L2924/01082;;H01L2224/13099;;H01L2924/01079;;H01L2924/01033;;H01L2224/06153;;H01L2924/01075;;H01L24/13;;H01L24/06;;H01L2924/00;;H01L2224/0401;;H01L2224/13,H01L23/485;;H01L21/60,,0,0,,,,EXPIRED
141,KR,A,KR 20220079875 A,187-925-516-992-300,2022-06-14,2022,KR 20227013243 A,2020-10-15,US 201962923031 P;;IB 2020059729 W,2019-10-18,의료용 가이드와이어 조립체 및/또는 전기 커넥터,"생체에 의해 한정된 제한된 공간 내로 삽입되도록 구성되는 가요성 의료용 가이드와이어 조립체가 개시된다. 센서 조립체가 가요성 의료용 가이드와이어 조립체에 의해 견고하게 지지된다. 이는, 일단 가요성 의료용 가이드와이어 조립체가 생체에 의해 한정된 제한된 공간 내로 삽입되고 그를 따라 이동되면, 센서 조립체와 가요성 의료용 가이드와이어 조립체가 생체에 의해 한정된 제한된 공간을 따라 이동가능하도록 하는 방식으로 행해진다. 또한, 커넥터 단자를 갖는 전기 커넥터 조립체가 개시된다. 커넥터 단자는 가요성 의료용 가이드와이어 조립체의 단자 부분과 전기적으로 연결가능하도록 구성된다. 단자 부분은, 전기 와이어를 통해, 가요성 의료용 가이드와이어 조립체의 센서 조립체에 전기적으로 연결된다.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;DAVIES GARETH,,https://lens.org/187-925-516-992-300,Patent Application,no,0,0,8,9,0,A61B18/12;;A61B18/1492;;A61B2018/00351;;A61B2018/00595;;A61B2018/00982;;A61B2018/00839;;A61B18/1492;;A61B2018/00577;;A61B2018/00839;;A61B2018/00595;;A61B5/6851;;A61B18/1492;;A61B5/6851;;A61B2018/00577;;A61B2018/00595;;A61B2018/00839,A61B18/14;;A61B5/00;;A61B18/00,,0,0,,,,PENDING
142,ES,T3,ES 2914993 T3,005-691-826-976-665,2022-06-20,2022,ES 12877833 T,2012-11-09,US 201261653967 P;;IB 2012056315 W,2012-05-31,Aparato de perforación por radiofrecuencia,"Un dispositivo médico que comprende: un elemento alargado metálico (2) que tiene un extremo proximal y un extremo distal, definiendo el elemento alargado metálico (2) un lumen (9) que se extiende sustancialmente entre los mismos y definiendo al menos una abertura (7) desde el lumen (9); un marcador (6) de obtención de imágenes asociado con el elemento alargado metálico (2) en una localización del marcador, siendo el marcador de obtención de imágenes un marcador radiopaco, siendo un diámetro exterior del dispositivo en la localización del marcador, sustancialmente igual al diámetro exterior del dispositivo adyacente a la localización del marcador, estando el dispositivo médico configurado de forma que, en uso, un flujo de fluido a través del lumen no es sustancialmente obstruido por el marcador (6) de obtención de imágenes; y una punta funcional (15) situada en el extremo distal del elemento alargado metálico, un extremo distal del lumen está cerrado por la punta funcional, comprendiendo la punta funcional el marcador radiopaco y un electrodo para suministrar energía eléctrica, en donde la energía eléctrica se suministra al electrodo a través del elemento alargado metálico.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/005-691-826-976-665,Granted Patent,no,0,0,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61M25/095;;A61B5/06;;A61B18/12;;A61M25/098;;A61M25/14,,0,0,,,,ACTIVE
143,EP,B1,EP 2925984 B1,024-755-308-850-287,2016-12-28,2016,EP 13792286 A,2013-11-05,EP 12195315 A;;EP 2013073079 W;;EP 13792286 A,2012-12-03,METHOD AND ARRANGEMENT FOR CONTROLLING FUEL SUPPLY FOR A GAS TURBINE,,SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,SIEMENS AKTIENGESELLSCHAFT (2017-08-30),https://lens.org/024-755-308-850-287,Granted Patent,yes,5,0,12,12,0,F02C9/40;;F05D2260/80;;F02C9/40;;F02C9/28;;F02C9/32;;F02C9/48;;F02C9/40;;F05D2260/80,F02C9/28;;F02C9/40,,0,0,,,,ACTIVE
144,EP,A1,EP 2738374 A1,079-305-548-461-368,2014-06-04,2014,EP 12195315 A,2012-12-03,EP 12195315 A,2012-12-03,Method and arrangement for controlling fuel supply for a gas turbine,"It is described a method of controlling a supply of a fuel (105) to a combustor (101) of a gas turbine comprising a compressor upstream of the combustor, the method comprising: supplying the fuel (105) to the combustor (101); obtaining a property value of at least one physical property (PT8, PT7, Tinlet, THBOV) of air used for burning the fuel (105) in the combustor (101); estimating a heat input (HIengmodel) of the fuel (105) supplied to the combustor (101) based on the property value; measuring a Caloric Value (LCVmea) of the fuel (105) upstream of the combustor (101); adjusting the estimated heat input (HIengmodel) based on the measured Caloric Value (LCVmea); and controlling a fuel valve (103) regulating the supply of the fuel (105) to the combustor (101) based on the adjusted estimated heat input (HIexpected) and a demanded heat input (FFDEM).
",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,,https://lens.org/079-305-548-461-368,Patent Application,yes,10,0,12,12,0,F02C9/40;;F05D2260/80;;F02C9/40;;F02C9/28;;F02C9/32;;F02C9/48;;F02C9/40;;F05D2260/80,F02C9/40,,0,0,,,,DISCONTINUED
145,US,A1,US 2021/0106400 A1,069-939-630-890-024,2021-04-15,2021,US 202017130691 A,2020-12-22,US 202017130691 A;;US 201414404518 A;;IB 2012056315 W;;US 201261653967 P,2012-05-31,Radiofrequency Perforation Apparatus,"Medical devices are disclosed having improved visualization of a portion of the medical device insertable into a patient's body while minimizing obstruction of fluid flow through a lumen of the device and while minimizing an increase in the outer diameter of the device attributable to the feature providing improved visualization. The device can include, for example, an imaging marker distal to lumen openings (exit ports), or, where the device comprises a tube, such as a metallic tube, an imaging marker embedded into a wall of the tube. Another embodiment includes attaching a marker to the surface on the inside of a lumen of a medical device without embedding the marker. Various alternative embodiments, methods and applications of using such devices are disclosed as well.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,BAYLIS MEDICAL COMPANY INC (2014-11-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/069-939-630-890-024,Patent Application,yes,6,0,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61B90/00;;A61B5/06;;A61B18/14;;A61M25/01,,0,0,,,,ACTIVE
146,EP,A1,EP 3999163 A1,098-109-777-430-478,2022-05-25,2022,EP 20844214 A,2020-07-17,IB 2020056759 W;;US 201962876192 P,2019-07-19,"MEDICAL DILATOR, AND SYSTEMS, METHODS, AND KITS FOR MEDICAL DILATION",,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-21),https://lens.org/098-109-777-430-478,Patent Application,yes,0,0,10,10,0,A61B18/00;;A61B2018/00351;;A61B2018/00613;;A61M29/00;;A61B5/06;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2018/00601;;A61B2018/0038;;A61B2018/00357;;A61B2018/00839;;A61B2017/00053;;A61B34/20;;A61B2034/2051;;A61B2034/2072;;A61B2090/3925;;A61B2090/3966;;A61B18/1492;;A61B18/1487;;A61M29/00;;A61B5/367;;A61B5/06;;A61B2018/00357;;A61B2018/0038;;A61B2018/00839;;A61B2018/00601;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2017/00336,A61M29/00;;A61B5/00;;A61B18/00;;A61B18/14;;A61M25/01,,0,0,,,,PENDING
147,GB,B,GB 2536655 B,114-566-047-657-701,2017-09-20,2017,GB 201504975 A,2015-03-24,GB 201504975 A,2015-03-24,Logging events with timestamps,,IMAGINATION TECH LTD,PAUL MURRIN;;GARETH JOHN DAVIES,,https://lens.org/114-566-047-657-701,Granted Patent,no,1,0,9,9,0,G06F11/3086;;G06F11/3476;;G06F11/3636;;G06F11/3636;;G06F11/3466;;G06F11/3466;;G06F11/3476;;G06F11/3476;;G06F17/40;;G06F17/40;;G06F2201/835;;G06F2201/835;;G06F2201/86;;G06F2201/86,G06F11/34,,2,2,061-841-368-218-032;;029-674-956-317-488,10.1007/978-3-642-16612-9_24;;10.1109/fccm.2012.11,"Runtime Verification, published 2010, Springer, pp 315-329, Vol 6418, Kraft et al, ""Trace Recording for Embedded Systems: Lessons Learned from Five Industrial Projects"" ISBN 978-3-642-16611-2 ; ISBN 3-642-16611-3;;IEEE 20th Annual International Symposium on Field-Programmable Custom Computing Machines (FCCM), published 2012, IEEE, pp 1-8, Arcas et al, A Low-Overhead Profiling and Visualization Framework for Hybrid Transactional Memory, ISBN 978-1-4673-1605-7 ; ISBN 1-4673-1605-9",ACTIVE
148,CA,A1,CA 2891183 A1,065-525-734-780-529,2014-06-12,2014,CA 2891183 A,2013-11-05,EP 12195315 A;;EP 2013073079 W,2012-12-03,METHOD AND ARRANGEMENT FOR CONTROLLING FUEL SUPPLY FOR A GAS TURBINE,"It is described a method of controlling a supply of a fuel (105) to a combustor (101) of a gas turbine comprising a compressor upstream of the combustor, the method comprising: supplying the fuel (105) to the combustor (101); obtaining a property value of at least one physical property (PT8, PT7, Tinlet, THBOV) of air used for burning the fuel (105) in the combustor (101); estimating a heat input (HIengmodel) of the fuel (105) supplied to the combustor (101) based on the prop- erty value; measuring a Caloric Value (LCVmea) of the fuel (105) upstream of the combustor (101); adjusting the estimated heat input (HIengmodel) based on the measured Caloric Value (LCVmea); and controlling a fuel valve (103) regulating the supply of the fuel (105) to the combustor (101) based on the adjusted estimated heat input (HIexpected) and a demanded heat input (FFDEM).",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,,https://lens.org/065-525-734-780-529,Patent Application,no,0,0,12,12,0,F02C9/40;;F05D2260/80;;F02C9/40;;F02C9/28;;F02C9/32;;F02C9/48;;F02C9/40;;F05D2260/80,F02C9/40,,0,0,,,,INACTIVE
149,WO,A1,WO 2021/014316 A1,162-890-347-543-613,2021-01-28,2021,IB 2020056759 W,2020-07-17,US 201962876192 P,2019-07-19,"MEDICAL DILATOR, AND SYSTEMS, METHODS, AND KITS FOR MEDICAL DILATION","A medical dilator includes an elongate member having a proximal end portion, an opposed distal end portion, and a lumen extending through the elongate member from the proximal end portion to the distal end portion. A dilating tip is at the distal end portion. The dilating tip has a first end of enlarged cross- sectional area and tapers going in the distal direction to a second end of reduced cross-sectional area. At least a first electrode is associated with the dilating tip. An electrical conductor is electrically connected to the first electrode and extends proximally from the first electrode towards the proximal end portion for electrical connection with an electro anatomical mapping system.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/162-890-347-543-613,Patent Application,yes,9,9,10,10,0,A61B18/00;;A61B2018/00351;;A61B2018/00613;;A61M29/00;;A61B5/06;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2018/00601;;A61B2018/0038;;A61B2018/00357;;A61B2018/00839;;A61B2017/00053;;A61B34/20;;A61B2034/2051;;A61B2034/2072;;A61B2090/3925;;A61B2090/3966;;A61B18/1492;;A61B18/1487;;A61M29/00;;A61B5/367;;A61B5/06;;A61B2018/00357;;A61B2018/0038;;A61B2018/00839;;A61B2018/00601;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2017/00336,A61B5/00;;A61M29/00;;A61B18/00;;A61B18/14;;A61M25/01,,1,0,,,See also references of EP 3999163A4,PENDING
150,SG,A,SG 11201907912Y A,171-148-115-633-96X,2019-09-27,2019,SG 11201907912Y A,2018-02-28,GB 201703178 A;;GB 2018050516 W,2017-02-28,AN APPLIANCE OPERATION SIGNAL PROCESSING SYSTEM AND METHOD,"Exttactpre t and nest cent Fig. frequen,,vciOrr p•e- , ttt 'Analyse ham harr through Ma L. arninn , 1 1 7,., nomaNcr. W O 20 18/ 15 857 0 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) W I PO I PCT ~~~~~ 11111111011101010VIIIOH olo onm ioo moilowo oimIE (10) International Publication Number WO 2018/158570 Al (51) International Patent Classification: GO1R 21/00 (2006.01) GO1R 22/06 (2006.01) GO1D 4/00 (2006.01) GO5B 23/02 (2006.01) GO1R 19/25 (2006.01) GOON 99/00 (2010.01) GO1R 21/133 (2006.01) (21) International Application Number: PCT/GB2018/050516 (22) International Filing Date: 28 February 2018 (28.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1703178.2 28 February 2017 (28.02.2017) GB (71) Applicant: GREEN RUNNING LIMITED [GB/GB]; Carpenter House, Innovation Centre, Broad Quay, Bath BA1 IUD (GB). (72) Inventors: DAVIES, Peter Gareth; Carpenter House, Innovation Centre, Broad Quay, Bath BA1 IUD (GB). SPITERI, Conrad; c/o Green Running Limited, St Magnus House, 3 Lower Thames Street, London EC3R 6HD (GB). (74) Agent: SIBLEY, Lara; Marks & Clerk LLP, 90 Long Acre, London WC2E 9RA (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (54) Title: AN APPLIANCE OPERATION SIGNAL PROCESSING SYSTEM AND METHOD (57) : An appliance operation signal processing system comprising: an input for receiving an appliance operation signal, the appliance operation signal comprising information relating to operation of an appliance; an output for outputting information relating to degradation of the appliance; and a processor configured to determine a probability that the appliance or a component of the appliance is in the or each of one or more degradation states, by applying a classifier to a feature vector comprising information relating to frequency data extracted from the appliance operation signal. [Continued on next page] WO 2018/158570 Al MIDEDIMOMOIDEIREEM311011HINEMOINVOIS GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,,https://lens.org/171-148-115-633-96X,Unknown,no,0,0,10,10,0,G01R19/2513;;G01R21/00;;G01R21/133;;G01R22/06;;G05B23/0227;;G06N20/00;;G01R19/2513;;G01R21/00;;G06Q50/06;;G06N20/00;;G01R21/00;;G01R22/06;;G01R21/133;;G01R19/2513;;G01R19/252;;G05B23/0227;;G06N20/00;;G06Q50/06;;Y04S20/30;;G01H1/00;;G01H1/003;;G01M99/005;;G01R21/133;;G06N3/04;;G06N3/084;;G06N20/00,G01R21/00;;G01D4/00;;G01R19/25;;G01R21/133;;G01R22/06;;G05B23/02;;G06N20/00,,0,0,,,,PENDING
151,US,B2,US 7541674 B2,043-418-220-052-469,2009-06-02,2009,US 15843505 A,2005-06-22,US 15843505 A;;EP 99306444 A;;EP 99309842 A;;US 63928800 A,1999-08-17,Integrated circuit die for wire bonding and flip-chip mounting,"An integrated circuit die carries conductive pads and thereon, the larger pads being suitable for flip-chip assembly and the smaller pads being suitable for wire bond assembly. The pitch between pads is at least the minimum required for flip-chip assembly, whereas the pitch between each of pads and the adjacent pad or pads is at least the minimum required for wire bond assembly. For wire bond assembly a passivation layer exposing all pads is provided, whereas for flip-chip assembly a passivation layer exposes only certain pads so that conductive bumps may be provided. The provision of pads complying with the minimum spacing requirements for both flip-chip and wire bond assembly enables a “dual purpose” (e.g. one set of pads being for normal production and another set for testing purposes) die to be produced without any increase in die size.",AGERE SYSTEMS INC,ADDINALL ROSS;;DAVIES GARETH RHYS,BELL SEMICONDUCTOR LLC (2017-12-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04),https://lens.org/043-418-220-052-469,Granted Patent,yes,15,1,9,10,0,H01L2224/04073;;H01L2224/06153;;H01L2224/13099;;H01L2924/01004;;H01L2924/01005;;H01L2924/01013;;H01L2924/01015;;H01L2924/01033;;H01L2924/01075;;H01L2924/01079;;H01L2924/01082;;H01L2924/014;;H01L2924/14;;H01L24/13;;H01L2924/00;;H01L24/06;;H01L2224/0401;;H01L2224/13;;H01L2224/04042;;H01L2224/0616;;H01L24/05;;H01L2224/06051;;H01L23/485;;H01L21/60;;H01L24/02;;H01L2924/01004;;H01L2924/01013;;H01L2924/01015;;H01L24/10;;H01L2924/01005;;H01L2924/14;;H01L2224/04073;;H01L2924/014;;H01L2924/01082;;H01L2224/13099;;H01L2924/01079;;H01L2924/01033;;H01L2224/06153;;H01L2924/01075;;H01L24/13;;H01L24/06;;H01L2924/00;;H01L2224/0401;;H01L2224/13,H01L21/60;;H01L23/485;;H01L23/48;;H01L23/52;;H01L29/40,257/737;;257/738;;257/780,1,0,,,"Parent case U.S. Appl. No. 09/639,288, filed Aug. 15, 2000, entitled ""Improvements in or Relating to Integrated Circuit Dies""; to Ross Addinall, et al., allowed on Apr. 7, 2005.",EXPIRED
152,EP,A1,EP 3589962 A1,033-573-772-424-993,2020-01-08,2020,EP 18709733 A,2018-02-28,GB 201703178 A;;GB 2018050516 W,2017-02-28,AN APPLIANCE OPERATION SIGNAL PROCESSING SYSTEM AND METHOD,,GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,,https://lens.org/033-573-772-424-993,Patent Application,yes,0,0,10,10,0,G01R19/2513;;G01R21/00;;G01R21/133;;G01R22/06;;G05B23/0227;;G06N20/00;;G01R19/2513;;G01R21/00;;G06Q50/06;;G06N20/00;;G01R21/00;;G01R22/06;;G01R21/133;;G01R19/2513;;G01R19/252;;G05B23/0227;;G06N20/00;;G06Q50/06;;Y04S20/30;;G01H1/00;;G01H1/003;;G01M99/005;;G01R21/133;;G06N3/04;;G06N3/084;;G06N20/00,G01R21/00;;G01D4/00;;G01R19/25;;G01R21/133;;G01R22/06;;G05B23/02;;G06N20/00,,0,0,,,,PENDING
153,EP,A1,EP 1077489 A1,071-556-015-666-913,2001-02-21,2001,EP 99306444 A,1999-08-17,EP 99306444 A,1999-08-17,Integrated circuit die including conductive pads,"An integrated circuit die (1) carries conductive pads (2) and (3) thereon, the larger pads (2) being suitable for flip-chip assembly and the smaller pads (3) being suitable for wire bond assembly. The pitch between pads (2) is at least the minimum required for flip-chip assembly, whereas the pitch between each of pads (3) and the adjacent pad or pads is at least the minimum required for wire bond assembly. For wire bond assembly a passivation layer exposing all pads (2) and (3) is provided, whereas for flip-chip assembly a passivation layer 6 exposes only pads (2) so that conductive bumps (7) may be provided. The provision of pads (2) and (3) complying with the minimum spacing requirements for both flip-chip and wire bond assembly enables a ""dual purpose"" (e.g. one set of pads being for normal production and another set for testing purposes) die to be produced without any increase in die size.",LUCENT TECHNOLOGIES INC,ADDINALL ROSS;;DAVIES GARETH RHYS,,https://lens.org/071-556-015-666-913,Patent Application,yes,5,0,1,10,0,H01L2224/0401;;H01L2224/13099;;H01L2924/01015;;H01L2924/01033;;H01L2924/01075;;H01L2924/01079;;H01L2924/01082;;H01L2924/014;;H01L2924/14;;H01L24/13;;H01L2224/13;;H01L2224/04042;;H01L2224/0603;;H01L24/48;;H01L24/05;;H01L24/06,H01L23/485,,0,0,,,,DISCONTINUED
154,EP,A4,EP 3999163 A4,133-230-651-456-244,2023-07-26,2023,EP 20844214 A,2020-07-17,IB 2020056759 W;;US 201962876192 P,2019-07-19,"MEDICAL DILATOR, AND SYSTEMS, METHODS, AND KITS FOR MEDICAL DILATION",,BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-21),https://lens.org/133-230-651-456-244,Search Report,no,0,0,10,10,0,A61B18/00;;A61B2018/00351;;A61B2018/00613;;A61M29/00;;A61B5/06;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2018/00601;;A61B2018/0038;;A61B2018/00357;;A61B2018/00839;;A61B2017/00053;;A61B34/20;;A61B2034/2051;;A61B2034/2072;;A61B2090/3925;;A61B2090/3966;;A61B18/1492;;A61B18/1487;;A61M29/00;;A61B5/367;;A61B5/06;;A61B2018/00357;;A61B2018/0038;;A61B2018/00839;;A61B2018/00601;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2017/00336,A61B5/00;;A61M29/00;;A61B5/06;;A61B5/367;;A61B18/00;;A61B18/14;;A61B34/20;;A61M25/01,,1,0,,,No further relevant documents disclosed,PENDING
155,AU,A1,AU 2020/317077 A1,190-696-586-977-845,2022-01-27,2022,AU 2020/317077 A,2020-07-17,US 201962876192 P;;IB 2020056759 W,2019-07-19,"Medical dilator, and systems, methods, and kits for medical dilation","A medical dilator includes an elongate member having a proximal end portion, an opposed distal end portion, and a lumen extending through the elongate member from the proximal end portion to the distal end portion. A dilating tip is at the distal end portion. The dilating tip has a first end of enlarged cross- sectional area and tapers going in the distal direction to a second end of reduced cross-sectional area. At least a first electrode is associated with the dilating tip. An electrical conductor is electrically connected to the first electrode and extends proximally from the first electrode towards the proximal end portion for electrical connection with an electro anatomical mapping system.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-22),https://lens.org/190-696-586-977-845,Patent Application,no,0,0,10,10,0,A61B18/00;;A61B2018/00351;;A61B2018/00613;;A61M29/00;;A61B5/06;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2018/00601;;A61B2018/0038;;A61B2018/00357;;A61B2018/00839;;A61B2017/00053;;A61B34/20;;A61B2034/2051;;A61B2034/2072;;A61B2090/3925;;A61B2090/3966;;A61B18/1492;;A61B18/1487;;A61M29/00;;A61B5/367;;A61B5/06;;A61B2018/00357;;A61B2018/0038;;A61B2018/00839;;A61B2018/00601;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2017/00336,A61M29/00;;A61B5/00;;A61B18/00;;A61B18/14;;A61M25/01,,0,0,,,,PENDING
156,US,B2,US 11248933 B2,187-144-515-400-711,2022-02-15,2022,US 201816626657 A,2018-06-27,GB 201710244 A;;GB 2018051789 W,2017-06-27,System and method for identifying appliances under recall,"An appliance operation signal processing system comprises: an input for receiving an appliance operation signal, the appliance operation signal comprising information relating to operation of an appliance;an output for outputting information relating to a recall status of the appliance; anda processor configured to: monitor an input appliance operation signal for a change in magnitude;if a change is detected: identify a component event corresponding to the change;determine whether the component event is a designated sequence start component event;if the component event is determined to be a designated sequence start component event: extract one or more features from the input appliance operation signal between the sequence start component event and a sequence stop point;determine information relating to a recall status of the appliance by inputting the one or more features into a first algorithm.",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,DURIAN RESEARCH LLC (2023-06-01);;GREEN RUNNING LIMITED (2020-03-10),https://lens.org/187-144-515-400-711,Granted Patent,yes,11,0,9,9,0,G01D4/00;;G06Q50/06;;G06Q10/20;;Y04S20/30;;G01D4/00;;G01R19/2513;;G01R21/133;;G01R31/2825;;G06Q30/014;;G06Q50/06;;G01D4/002;;G01D4/02;;G01D4/10;;G06Q50/06,G01D4/00;;G01D4/02;;G01D4/10;;G06Q50/06,,4,0,,,"International Search Report for International Application No. PCT/GB2018/051789, dated Oct. 24, 2018 (3 pages).;;Written Opinion of International Searching Authority for International Application No. PCT/GB2018/051789, dated Oct. 24, 2018 (8 pages).;;Examination Report in European Patent Application No. EP 18 739 585.0, dated Oct. 12, 2020 (5 pages).;;Search Report in Great Britain Patent Application No. GB 1710244.3, dated Oct. 25, 2017 (5 pages).",ACTIVE
157,EP,A1,EP 3987622 A1,194-872-411-463-282,2022-04-27,2022,EP 20733971 A,2020-06-18,GB 201908684 A;;NL 2023933 A;;EP 2020067017 W,2019-06-18,AN IN-LINE DEVICE AND A METHOD FOR CONTROLLING AN ELECTRICAL APPLIANCE,,GREEN RUNNING LTD,DAVIES PETER GARETH;;DIMITROV KONSTANTINE,,https://lens.org/194-872-411-463-282,Patent Application,yes,0,0,3,5,0,H02J13/0005;;H02J3/14;;H02J2310/58;;H02J13/00002;;H02J13/00001;;H02J13/00006;;Y02B70/30;;Y02B70/3225;;Y02B90/20;;Y04S20/242;;Y04S10/30;;Y04S20/222;;Y04S40/12;;Y02E60/00;;H02J13/0005;;H02J13/00006;;H02J2310/58;;H02J13/00001;;H02J13/00002;;H02J3/14,H02J3/14;;H02J13/00,,0,0,,,,PENDING
158,CA,A1,CA 2891736 A1,195-926-426-279-901,2014-06-12,2014,CA 2891736 A,2013-11-05,EP 12195312 A;;EP 2013073083 W,2012-12-03,GAS TURBINE FUEL SUPPLY METHOD AND ARRANGEMENT,"Gas turbine fuel supply method and arrangement It is described a method of controlling a supply of a fuel to a combustor of a gas turbine comprising a compressor upstream of the combustor, the method comprising: supplying the fuel (105) to the combustor (101); obtaining an inlet air pressure (PT7) at a compressor inlet; obtaining an inlet air temperature (Tinlet) at the compressor inlet; obtaining an outlet air pressure (PT8) at a compressor outlet; estimating a heat input (HIengmodel, HIexpected) of the fuel (105) supplied to the combustor (101) based on the inlet air pressure (PT7), the inlet air temperature (Tinlet) and the outlet air pressure (PT8); comparing the estimated heat input (HIengmodel, HIexpected) with a demanded heat input (FFDEM) to derive an error signal (121); and controlling a fuel valve (103) regulating the supply of the fuel (105) to the combustor (101) based on the error signal (121).",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,,https://lens.org/195-926-426-279-901,Patent Application,no,0,0,12,12,0,F02C9/40;;F05D2260/80;;F02C9/26;;F02C9/28;;F02C9/40;;F05D2260/80,F02C9/40,,0,0,,,,ACTIVE
159,EP,A1,EP 4000677 A1,013-976-455-329-31X,2022-05-25,2022,EP 21215791 A,2012-11-09,US 201261653967 P;;EP 12877833 A;;IB 2012056315 W,2012-05-31,RADIOFREQUENCY PERFORATION APPARATUS,"Medical devices are disclosed having improved visualization of a portion of the medical device insertable into a patient's body while minimizing obstruction of fluid flow through a lumen of the device and while minimizing an increase in the outer diameter of the device attributable to the feature providing improved visualization. The device can include, for example, an imaging marker distal to lumen openings (exit ports), or, where the device comprises a tube, such as a metallic tube, an imaging marker embedded into a wall of the tube. Another embodiment includes attaching a marker to the surface on the inside of a lumen of a medical device without embedding the marker. Various alternative embodiments, methods and applications of using such devices are disclosed as well.
",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,BAYLIS MEDICAL COMPANY INC. (2022-07-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-05),https://lens.org/013-976-455-329-31X,Patent Application,yes,20,0,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61M25/095;;A61B5/06;;A61B18/12;;A61M25/098;;A61M25/14,,0,0,,,,PENDING
160,JP,A,JP 2021180875 A,103-826-444-961-394,2021-11-25,2021,JP 2021126775 A,2021-08-02,JP 2018188330 A;;US 201261653967 P,2012-05-31,RADIOFREQUENCY PERFORATION APPARATUS,"To provide a medical device having improved visualization of a portion of the medical device insertable into a patient's body while minimizing obstruction of a fluid flow through a lumen of the device and while minimizing an increase in the outer diameter of the device attributed to the feature providing the improved visualization.SOLUTION: The device can include, for example, a marker 6 distal to a lumen 9 or, if the device comprises a tube such as a metallic tube 12, an imaging marker embedded into a wall of the tube. Another embodiment includes attaching a marker to the surface on the inside of a lumen of a medical device without embedding the marker. Various alternative embodiments, methods and applications of using such devices are also disclosed.SELECTED DRAWING: Figure 10b",BAYLIS MEDICAL CO INC,GARETH DAVIES;;JOHN PAUL URBANSKI,,https://lens.org/103-826-444-961-394,Patent Application,no,4,0,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61M25/00;;A61B18/14,,0,0,,,,ACTIVE
161,WO,A1,WO 2018/158570 A1,115-644-765-215-446,2018-09-07,2018,GB 2018050516 W,2018-02-28,GB 201703178 A,2017-02-28,AN APPLIANCE OPERATION SIGNAL PROCESSING SYSTEM AND METHOD,"An appliance operation signal processing system comprising: an input for receiving an appliance operation signal, the appliance operation signal comprising information relating to operation of an appliance; an output for outputting information relating to degradation of the appliance; and a processor configured to determine a probability that the appliance or a component of the appliance is in the or each of one or more degradation states, by applying a classifier to a feature vector comprising information relating to frequency data extracted from the appliance operation signal.",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,,https://lens.org/115-644-765-215-446,Patent Application,yes,12,2,10,10,0,G01R19/2513;;G01R21/00;;G01R21/133;;G01R22/06;;G05B23/0227;;G06N20/00;;G01R19/2513;;G01R21/00;;G06Q50/06;;G06N20/00;;G01R21/00;;G01R22/06;;G01R21/133;;G01R19/2513;;G01R19/252;;G05B23/0227;;G06N20/00;;G06Q50/06;;Y04S20/30;;G01H1/00;;G01H1/003;;G01M99/005;;G01R21/133;;G06N3/04;;G06N3/084;;G06N20/00,G01R21/00;;G01D4/00;;G01R19/25;;G01R21/133;;G01R22/06;;G05B23/02;;G06N20/00,,3,3,109-908-687-501-680;;026-843-183-842-445;;039-079-663-941-902,10.1007/s12652-016-0431-y;;10.1061/(asce)cp.1943-5487.0000108;;10.1109/globalsip.2015.7418189,"FERRÁNDEZ-PASTOR F J ET AL: ""Interpreting human activity from electrical consumption data using reconfigurable hardware and hidden Markov models"", JOURNAL OF AMBIENT INTELLIGENCE AND HUMANIZED COMPUTING, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 8, no. 4, 22 November 2016 (2016-11-22), pages 469 - 483, XP036272790, ISSN: 1868-5137, [retrieved on 20161122], DOI: 10.1007/S12652-016-0431-Y;;BERGES M ET AL: ""User-centered non-intrusive electricity load monitoring for residential buildings"", JOURNAL OF COMPUTING IN CIVIL ENGINEE, AMERICAN SOCIETY OF CIVIL ENGINEERS, NEW YORK, NY, US, vol. 25, no. 6, 1 November 2011 (2011-11-01), pages 471 - 480, XP009182171, ISSN: 0887-3801, DOI: 10.1061/(ASCE)CP.1943-5487.0000108;;GAO JINGKUN ET AL: ""A feasibility study of automated plug-load identification from high-frequency measurements"", 2015 IEEE GLOBAL CONFERENCE ON SIGNAL AND INFORMATION PROCESSING (GLOBALSIP), IEEE, 14 December 2015 (2015-12-14), pages 220 - 224, XP032871650, DOI: 10.1109/GLOBALSIP.2015.7418189",PENDING
162,EP,A1,EP 1960637 A1,147-860-659-229-702,2008-08-27,2008,EP 06830548 A,2006-12-12,EP 2006069596 W;;US 74946905 P,2005-12-12,VALVE ASSEMBLY,,SIEMENS AG,BURKITT EDWARD;;DAVIES GARETH HUW,"SIEMENS ENERGY GLOBAL GMBH & CO. KG, DE (2020-12-15)",https://lens.org/147-860-659-229-702,Patent Application,yes,0,0,6,6,0,F01D25/32;;F02C7/232;;F05D2260/602;;F02C7/232;;F01D25/32;;F05D2260/602,F01D25/00,,0,0,,,,ACTIVE
163,EP,A1,EP 2738373 A1,145-755-890-400-35X,2014-06-04,2014,EP 12195312 A,2012-12-03,EP 12195312 A,2012-12-03,Gas turbine fuel supply method and arrangement,"It is described a method of controlling a supply of a fuel to a combustor of a gas turbine comprising a compressor upstream of the combustor, the method comprising: supplying the fuel (105) to the combustor (101); obtaining an inlet air pressure (PT7) at a compressor inlet; obtaining an inlet air temperature (Tinlet) at the compressor inlet; obtaining an outlet air pressure (PT8) at a compressor outlet; estimating a heat input (HIengmodel, HIexpected) of the fuel (105) supplied to the combustor (101) based on the inlet air pressure (PT7), the inlet air temperature (Tinlet) and the outlet air pressure (PT8); comparing the estimated heat input (HIengmodel, HIexpected) with a demanded heat input (FFDEM) to derive an error signal (121); and controlling a fuel valve (103) regulating the supply of the fuel (105) to the combustor (101) based on the error signal (121).
",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,,https://lens.org/145-755-890-400-35X,Patent Application,yes,8,0,12,12,0,F02C9/40;;F05D2260/80;;F02C9/26;;F02C9/28;;F02C9/40;;F05D2260/80,F02C9/40,,0,0,,,,DISCONTINUED
164,US,A1,US 2015/0315979 A1,004-408-130-578-842,2015-11-05,2015,US 201314647223 A,2013-11-05,EP 12195312 A;;EP 2013073083 W,2012-12-03,GAS TURBINE FUEL SUPPLY METHOD AND ARRANGEMENT,"A gas turbine fuel supply method and arrangement is provided. The method of controlling a supply of a fuel to a combustor of a gas turbine having a compressor upstream of the combustor, the method including: supplying the fuel to the combustor; obtaining an inlet air pressure (PT 7 ) at a compressor inlet; obtaining an inlet air temperature (Tinlet) at the compressor inlet; obtaining an outlet air pressure (PT 8 ) at a compressor outlet; estimating a heat input (HIengmodel, HIexpected) of the fuel supplied to the combustor based on the inlet air pressure (PT 7 ), the inlet air temperature (Tinlet) and the outlet air pressure (PT 8 ); comparing the estimated heat input (HIengmodel, HIexpected) with a demanded heat input (FFDEM) to derive an error signal; and controlling a fuel valve regulating the supply of the fuel to the combustor based on the error signal.",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,SIEMENS AKTIENGESELLSCHAFT (2015-06-08);;SIEMENS INDUSTRIAL TURBOMACHINERY LIMITED (2015-06-01);;SIEMENS ENERGY GLOBAL GMBH & CO. KG (2021-02-28),https://lens.org/004-408-130-578-842,Patent Application,yes,5,3,12,12,0,F02C9/40;;F05D2260/80;;F02C9/26;;F02C9/28;;F02C9/40;;F05D2260/80,F02C9/28;;F02C9/40,,0,0,,,,ACTIVE
165,EP,A1,EP 3645976 A1,026-675-499-182-738,2020-05-06,2020,EP 18739585 A,2018-06-27,GB 201710244 A;;GB 2018051789 W,2017-06-27,A SYSTEM AND METHOD FOR IDENTIFYING APPLIANCES UNDER RECALL,,GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,"DURIAN RESEARCH LLC, WILMINGTON, US (2023-07-19)",https://lens.org/026-675-499-182-738,Patent Application,yes,0,0,9,9,0,G01D4/00;;G06Q50/06;;G06Q10/20;;Y04S20/30;;G01D4/00;;G01R19/2513;;G01R21/133;;G01R31/2825;;G06Q30/014;;G06Q50/06;;G01D4/002;;G01D4/02;;G01D4/10;;G06Q50/06,G01D4/00;;G06Q50/06,,0,0,,,,ACTIVE
166,EP,A1,EP 0468964 A1,148-156-282-184-547,1992-02-05,1992,EP 90901619 A,1990-01-12,GB 8908818 A,1989-04-19,IMPROVEMENTS RELATING TO CABLE LADDERS.,"Le système de gaine technique en forme d'échelle décrit comprend plusieurs parties formant des sections et des accessoires de gaine technique en forme d'échelle. Chaque partie est constituée par des rails latéraux espacés reliés par des échelons de support. Des paires adjacentes d'extrémités de rail forment des extrémités d'assemblage, de sorte que les sections de gaine en forme d'échelle peuvent être raccordées bout à bout ou raccordées à des accessoires. Les extrémités de rail présentent des configurations d'assemblage complémentaires et solidaires mâles et femelles, de sorte que les sections et les accessoires de gaine en forme d'échelle peuvent être assemblés sans l'utilisation, comme c'est le cas dans les systèmes traditionnels, de pièces de raccord séparées.",SWIFTS OF SCARBOROUGH LTD,DAVIES GARETH JOHN MAIN STREET,,https://lens.org/148-156-282-184-547,Patent Application,yes,0,0,6,8,0,H02G3/0608;;H02G3/0456,H02G3/00;;H02G3/04;;H02G3/06,,1,0,,,See references of WO 9013164A1,DISCONTINUED
167,GB,A,GB 2492578 A,005-034-527-363-930,2013-01-09,2013,GB 201111572 A,2011-07-07,GB 201111572 A,2011-07-07,Fastener supporting tool,"A tool 100 for supporting a fastener 108 until it is fully secured during aircraft construction comprises a receiving portion 102, which includes an open end 104, and an associated support body 106. The support body 106 may be arranged within the receiving portion 102 opposite the open end 104 and may be movable towards the open end 104 by means of a handle 210 and may be biased by a spring (310 fig. 4) towards the fastener (312 fig. 4). The open end 104 may be plastic and positioned against a surface of a component 112 and may be attached by at least one adhesive pad or suction pad (306 fig. 4). The receiving portion 102 may be transparent or include a window to allow the fastener 108 to be viewed. Such a tool 100 may eliminate the risk of fingers being trapped in a zone (22 fig 1A) between a fastener and a component during the installation of the fastener. The fastener 108 may be a lightning strike protection fastener such as a radially expanding lock bolt (RXL) or sleeved taper lock fastener (STL) used in carbon fibre reinforced plastic components such as an aircraft wing bottom cover 112. The tool may support a plurality of fasteners (406 fig. 5) positioned according to a pre-configured template by means of a plurality of receiving portions (402 fig. 5), each of which may include an open end and an associated support body (404 fig. 5).",AIRBUS OPERATIONS LTD,KERFOOT-DAVIES CHRISTOPHER;;TOWLSON GARETH,,https://lens.org/005-034-527-363-930,Patent Application,no,1,5,2,2,0,B25B23/005;;B21J15/022;;B21J15/32,B25B23/08;;B21J15/32,,0,0,,,,DISCONTINUED
168,US,A1,US 2020/0003659 A1,023-005-642-302-412,2020-01-02,2020,US 201816489535 A,2018-02-28,GB 201703178 A;;GB 2018050516 W,2017-02-28,AN APPLIANCE OPERATION SIGNAL PROCESSING SYSTEM AND METHOD,An appliance operation signal processing system including an input for receiving an appliance operation signal. The appliance operation signal includes information relating to operation of an appliance. The system further includes an output for outputting information relating to degradation of the appliance and a processor configured to determine a probability that the appliance or a component of the appliance is in at least one degradation state by applying a classifier to a feature vector including information relating to frequency data extracted from the appliance operation signal.,GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,GREEN RUNNING LIMITED (2019-10-30),https://lens.org/023-005-642-302-412,Patent Application,yes,4,16,10,10,0,G01R19/2513;;G01R21/00;;G01R21/133;;G01R22/06;;G05B23/0227;;G06N20/00;;G01R19/2513;;G01R21/00;;G06Q50/06;;G06N20/00;;G01R21/00;;G01R22/06;;G01R21/133;;G01R19/2513;;G01R19/252;;G05B23/0227;;G06N20/00;;G06Q50/06;;Y04S20/30;;G01H1/00;;G01H1/003;;G01M99/005;;G01R21/133;;G06N3/04;;G06N3/084;;G06N20/00,G01M99/00;;G01H1/00;;G01R21/133;;G06N3/04;;G06N3/08;;G06N20/00,,0,0,,,,ACTIVE
169,EP,A4,EP 2854927 A4,043-266-496-216-399,2016-03-02,2016,EP 12877833 A,2012-11-09,US 201261653967 P;;IB 2012056315 W,2012-05-31,RADIOFREQUENCY PERFORATION APPARATUS,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,"BAYLIS MEDICAL COMPANY INC. (2022-06-22);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2023-03-30);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2023-03-28);;BAYLIS MEDICAL COMPANY INC., MISSISSAUGA, CA (2022-06-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED; IE (2023-03-24)",https://lens.org/043-266-496-216-399,Search Report,no,6,0,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61M25/095;;A61B5/06;;A61B18/12;;A61M25/098;;A61M25/14,,0,0,,,,ACTIVE
170,CA,A,CA 913627 A,047-366-847-375-089,1972-10-31,1972,CA 913627D A,,CA 913627T A,,BORON COMPOUNDS,,ICI LTD,DAVIES GARETH M;;LEIGH THOMAS,,https://lens.org/047-366-847-375-089,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
171,AU,A1,AU 2020/366719 A1,053-831-060-321-261,2022-04-07,2022,AU 2020/366719 A,2020-10-15,US 201962923031 P;;IB 2020059729 W,2019-10-18,Medical guidewire assembly and/or electrical connector,"Disclosed is a flexible medical guide wire assembly configured to be inserted into a confined space defined by a living body. A sensor assembly is securely supported by the flexible medical guidewire assembly. This is done in such a way that the sensor assembly and the flexible medical guidewire assembly are movable along the confined space defined by the living body once the flexible medical guidewire assembly is inserted into, and moved along, the confined space defined by the living body. Also disclosed is an electrical-connector assembly having a connector terminal. The connector terminal is configured to be electrically connectable with a terminal portion of a flexible medical guidewire assembly. The terminal portion is electrically connected, via an electrical wire, to a sensor assembly of the flexible medical guidewire assembly.",BOSTON SCIENT MEDICAL DEVICE LIMITED,URBANSKI JOHN PAUL;;DAVIES GARETH,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-22),https://lens.org/053-831-060-321-261,Patent Application,no,0,0,8,9,0,A61B18/12;;A61B18/1492;;A61B2018/00351;;A61B2018/00595;;A61B2018/00982;;A61B2018/00839;;A61B18/1492;;A61B2018/00577;;A61B2018/00839;;A61B2018/00595;;A61B5/6851;;A61B18/1492;;A61B5/6851;;A61B2018/00577;;A61B2018/00595;;A61B2018/00839,A61M25/09;;A61B18/00;;A61B18/14;;A61B18/18;;A61M25/01,,0,0,,,,PENDING
172,CA,A1,CA 3144440 A1,085-738-159-931-70X,2021-01-28,2021,CA 3144440 A,2020-07-17,US 201962876192 P;;IB 2020056759 W,2019-07-19,"MEDICAL DILATOR, AND SYSTEMS, METHODS, AND KITS FOR MEDICAL DILATION","A medical dilator includes an elongate member having a proximal end portion, an opposed distal end portion, and a lumen extending through the elongate member from the proximal end portion to the distal end portion. A dilating tip is at the distal end portion. The dilating tip has a first end of enlarged cross- sectional area and tapers going in the distal direction to a second end of reduced cross-sectional area. At least a first electrode is associated with the dilating tip. An electrical conductor is electrically connected to the first electrode and extends proximally from the first electrode towards the proximal end portion for electrical connection with an electro anatomical mapping system.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/085-738-159-931-70X,Patent Application,no,0,0,10,10,0,A61B18/00;;A61B2018/00351;;A61B2018/00613;;A61M29/00;;A61B5/06;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2018/00601;;A61B2018/0038;;A61B2018/00357;;A61B2018/00839;;A61B2017/00053;;A61B34/20;;A61B2034/2051;;A61B2034/2072;;A61B2090/3925;;A61B2090/3966;;A61B18/1492;;A61B18/1487;;A61M29/00;;A61B5/367;;A61B5/06;;A61B2018/00357;;A61B2018/0038;;A61B2018/00839;;A61B2018/00601;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2017/00336,A61M29/00;;A61B5/00;;A61B18/00;;A61B18/14;;A61M25/01,,0,0,,,,PENDING
173,EP,A1,EP 4045126 A1,094-757-227-673-344,2022-08-24,2022,EP 20876144 A,2020-10-15,US 201962923031 P;;IB 2020059729 W,2019-10-18,MEDICAL GUIDEWIRE ASSEMBLY AND/OR ELECTRICAL CONNECTOR,,BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;DAVIES GARETH,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-07),https://lens.org/094-757-227-673-344,Patent Application,yes,0,0,8,9,0,A61B18/12;;A61B18/1492;;A61B2018/00351;;A61B2018/00595;;A61B2018/00982;;A61B2018/00839;;A61B18/1492;;A61B2018/00577;;A61B2018/00839;;A61B2018/00595;;A61B5/6851;;A61B18/1492;;A61B5/6851;;A61B2018/00577;;A61B2018/00595;;A61B2018/00839,A61M25/09;;A61B18/00;;A61B18/14;;A61B18/18;;A61M25/01,,0,0,,,,PENDING
174,WO,A1,WO 2013/179103 A1,100-957-054-561-564,2013-12-05,2013,IB 2012056315 W,2012-11-09,US 201261653967 P,2012-05-31,RADIOFREQUENCY PERFORATION APPARATUS,"Medical devices are disclosed having improved visualization of a portion of the medical device insertable into a patient's body while minimizing obstruction of fluid flow through a lumen of the device and while minimizing an increase in the outer diameter of the device attributable to the feature providing improved visualization. The device can include, for example, an imaging marker distal to lumen openings (exit ports), or, where the device comprises a tube, such as a metallic tube, an imaging marker embedded into a wall of the tube. Another embodiment includes attaching a marker to the surface on the inside of a lumen of a medical device without embedding the marker. Various alternative embodiments, methods and applications of using such devices are disclosed as well.",BAYLIS MEDICAL INC,DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/100-957-054-561-564,Patent Application,yes,21,28,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61M25/095;;A61B5/06;;A61B18/12;;A61M25/098;;A61M25/14,,0,0,,,,PENDING
175,EP,A3,EP 4273784 A3,132-160-828-425-949,2024-02-14,2024,EP 23185229 A,2018-07-04,GB 201710719 A;;EP 18181720 A,2017-07-04,A SYSTEM AND METHOD FOR UTILITY MANAGEMENT,"One or more tangible, non-transitory, computer-readable media (2) storing instructions that, when executed by processing circuitry (3), are configured to cause the processing circuitry (3) to: 
receive an input indicative of a utility consumption at a first premises; 
detect a change to the utility consumption based on the input; 
identify an appliance event based on the change; 
determine a projected utility consumption at the first premises based on the appliance event; 
compare a projected utility capacity at the first premises with the projected utility consumption; 
in response to determining that the projected utility capacity exceeds the projected utility consumption, transmit an offer to provide an excess utility capacity to one or more second premises; and 
in response to determining that the projected utility consumption exceeds the projected utility capacity, transmit a request to receive additional utility capacity from the one or more second premises.",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,,https://lens.org/132-160-828-425-949,Search Report,yes,4,0,7,7,0,G06Q10/06315;;G06Q50/06;;Y04S20/30;;Y04S20/222;;Y02B70/3225;;G06Q10/06315;;G06Q40/04;;G06Q50/06;;Y02P90/90;;Y02E70/30;;Y04S50/00;;Y04S10/14;;Y04S10/50;;G06Q50/06;;G06Q10/06315;;Y04S50/12;;Y02B70/30;;G01D4/004;;H04L9/0637;;H04L67/1042,G06Q10/0631;;G06Q50/06,,0,0,,,,PENDING
176,US,A1,US 2022/0120586 A1,189-984-349-140-970,2022-04-21,2022,US 202117646192 A,2021-12-28,US 202117646192 A;;GB 201710244 A;;US 201916626657 A;;GB 2018051789 W,2017-06-27,SYSTEM AND METHOD FOR IDENTIFYING APPLIANCES UNDER RECALL,"An appliance operation signal processing system comprises: an input for receiving an appliance operation signal, the appliance operation signal comprising information relating to operation of an appliance;an output for outputting information relating to a recall status of the appliance; anda processor configured to: monitor an input appliance operation signal for a change in magnitude; if a change is detected:identify a component event corresponding to the change;determine whether the component event is a designated sequence start component event;if the component event is determined to be a designated sequence start component event: extract one or more features from the input appliance operation signal between the sequence start component event and a sequence stop point;determine information relating to a recall status of the appliance by inputting the one or more features into a first algorithm.",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,DURIAN RESEARCH LLC (2023-06-01);;GREEN RUNNING LIMITED (2020-03-10),https://lens.org/189-984-349-140-970,Patent Application,yes,3,0,9,9,0,G01D4/00;;G06Q50/06;;G06Q10/20;;Y04S20/30;;G01D4/00;;G01R19/2513;;G01R21/133;;G01R31/2825;;G06Q30/014;;G06Q50/06;;G01D4/002;;G01D4/02;;G01D4/10;;G06Q50/06,G01D4/00;;G01D4/02;;G01D4/10;;G06Q50/06,,0,0,,,,DISCONTINUED
177,US,A1,US 2015/0216620 A1,195-469-564-672-145,2015-08-06,2015,US 201214404518 A,2012-11-09,US 201214404518 A;;US 201261653967 P;;IB 2012056315 W,2012-05-31,Radiofrequency Perforation Apparatus,"Medical devices are disclosed having improved visualization of a portion of the medical device insertable into a patient's body while minimizing obstruction of fluid flow through a lumen of the device and while minimizing an increase in the outer diameter of the device attributable to the feature providing improved visualization. The device can include, for example, an imaging marker distal to lumen openings (exit ports), or, where the device comprises a tube, such as a metallic tube, an imaging marker embedded into a wall of the tube. Another embodiment includes attaching a marker to the surface on the inside of a lumen of a medical device without embedding the marker. Various alternative embodiments, methods and applications of using such devices are disclosed as well.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,BAYLIS MEDICAL COMPANY INC (2014-11-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/195-469-564-672-145,Patent Application,yes,19,14,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61B19/00;;A61B5/06;;A61B18/14;;A61M25/01,,0,0,,,,ACTIVE
178,US,B2,US 10898291 B2,020-992-992-849-47X,2021-01-26,2021,US 201214404518 A,2012-11-09,US 201214404518 A;;US 201261653967 P;;IB 2012056315 W,2012-05-31,Radiofrequency perforation apparatus,"Medical devices are disclosed having improved visualization of a portion of the medical device insertable into a patient's body while minimizing obstruction of fluid flow through a lumen of the device and while minimizing an increase in the outer diameter of the device attributable to the feature providing improved visualization. The device can include, for example, an imaging marker distal to lumen openings (exit ports), or, where the device comprises a tube, such as a metallic tube, an imaging marker embedded into a wall of the tube. Another embodiment includes attaching a marker to the surface on the inside of a lumen of a medical device without embedding the marker. Various alternative embodiments, methods and applications of using such devices are disclosed as well.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,BAYLIS MEDICAL COMPANY INC (2014-11-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/020-992-992-849-47X,Granted Patent,yes,44,4,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61B18/14;;A61B5/06;;A61B18/00;;A61B90/00;;A61M25/01,,13,0,,,"Search Opinion for European Patent Application No. 12877833.9.;;International Search Report for PCT Application No. PCT/IB2012/056315, dated Aug. 1, 2013.;;Office Action for Japanese Application with serial No. JP2015-514606 dated Nov. 29, 2016.;;Corresponding Japanese Patent Application EP12877833, Office Action dated Jul. 26, 2017 and the English translation.;;Corresponding Japanese Patent Application EP12877833, Office Action dated Mar. 27, 2018 and the English translation.;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2012/056315, dated Dec. 2, 2014.;;Patent Cooperation Treaty, Written Opinion of the International Searching Authority, International Application No. PCT/IB2012/056315, dated Jul. 30, 2013.;;Applicant's Reply to Japanese Office Action for counterpart Japanese Application No. JP2015-514606, dated Aug. 1, 2017.;;European Patent Office, Communication pursuant to Rules 161(2) and 162 EPC, for counterpart European Application No. 12877833, dated Feb. 4, 2015.;;Applicant's Reply to Communication pursuant to Rules 161 (2) and 162 EPC for counterpart European Application No. 12877833, dated Aug. 5, 2015.;;European Patent Office, Communication pursuant to Rule 70(2) and 70a(2) EPC for counterpart European Application No. 12877833, dated Feb. 18, 2016.;;Applicant's Reply to Communication pursuant to Rule 70(2) and 70a(2) EPC for counterpart European Application No. 12877833, dated Aug. 24, 2016.;;Applicant's Reply to Japanese Office Action for counterpart Japanese Application No. JP2015-514606, dated Nov. 25, 2016.",ACTIVE
179,EP,B1,EP 2854927 B1,045-945-770-069-748,2022-03-23,2022,EP 12877833 A,2012-11-09,US 201261653967 P;;IB 2012056315 W,2012-05-31,RADIOFREQUENCY PERFORATION APPARATUS,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,"BAYLIS MEDICAL COMPANY INC. (2022-06-22);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2023-03-30);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2023-03-28);;BAYLIS MEDICAL COMPANY INC., MISSISSAUGA, CA (2022-06-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED; IE (2023-03-24)",https://lens.org/045-945-770-069-748,Granted Patent,yes,13,0,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61M25/095;;A61B5/06;;A61B18/12;;A61M25/098;;A61M25/14,,0,0,,,,ACTIVE
180,EP,A1,EP 1077490 A1,057-433-277-951-004,2001-02-21,2001,EP 99309842 A,1999-12-07,EP 99309842 A;;EP 99306444 A,1999-08-17,Improvements in or relating to integrated circuit dies,"An integrated circuit die (1) carries conductive pads (2) and (3) thereon, the larger pads (2) being suitable for flip-chip assembly and the smaller pads (3) being suitable for wire bond assembly. The pitch between pads (2) is at least the minimum required for flip-chip assembly, whereas the pitch between each of pads (3) and the adjacent pad or pads is at least the minimum required for wire bond assembly. For wire bond assembly a passivation layer exposing all pads (2) and (3) is provided, whereas for flip-chip assembly a passivation layer 6 exposes only pads (2) so that conductive bumps (7) may be provided. The provision of pads (2) and (3) complying with the minimum spacing requirements for both flip-chip and wire bond assembly enables a ""dual purpose"" (e.g. one set of pads being for normal production and another set for testing purposes) die to be produced without any increase in die size.",LUCENT TECHNOLOGIES INC,ADDINALL ROSS;;DAVIES GARETH RHYS,ALCATEL-LUCENT USA INC. (2013-03-27);;LUCENT TECHNOLOGIES INC. (2013-06-12),https://lens.org/057-433-277-951-004,Patent Application,yes,5,1,9,10,0,H01L2224/04073;;H01L2224/06153;;H01L2224/13099;;H01L2924/01004;;H01L2924/01005;;H01L2924/01013;;H01L2924/01015;;H01L2924/01033;;H01L2924/01075;;H01L2924/01079;;H01L2924/01082;;H01L2924/014;;H01L2924/14;;H01L24/13;;H01L2924/00;;H01L24/06;;H01L2224/0401;;H01L2224/13;;H01L2224/04042;;H01L2224/0616;;H01L24/05;;H01L2224/06051;;H01L23/485;;H01L21/60;;H01L24/02;;H01L2924/01004;;H01L2924/01013;;H01L2924/01015;;H01L24/10;;H01L2924/01005;;H01L2924/14;;H01L2224/04073;;H01L2924/014;;H01L2924/01082;;H01L2224/13099;;H01L2924/01079;;H01L2924/01033;;H01L2224/06153;;H01L2924/01075;;H01L24/13;;H01L24/06;;H01L2924/00;;H01L2224/0401;;H01L2224/13,H01L23/485;;H01L21/60,,0,0,,,,DISCONTINUED
181,EP,A4,EP 4045126 A4,065-426-873-321-302,2023-11-15,2023,EP 20876144 A,2020-10-15,US 201962923031 P;;IB 2020059729 W,2019-10-18,MEDICAL GUIDEWIRE ASSEMBLY AND/OR ELECTRICAL CONNECTOR,,BOSTON SCIENT MEDICAL DEVICE LIMITED,URBANSKI JOHN PAUL;;DAVIES GARETH,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-07),https://lens.org/065-426-873-321-302,Search Report,no,5,0,8,9,0,A61B18/12;;A61B18/1492;;A61B2018/00351;;A61B2018/00595;;A61B2018/00982;;A61B2018/00839;;A61B18/1492;;A61B2018/00577;;A61B2018/00839;;A61B2018/00595;;A61B5/6851;;A61B18/1492;;A61B5/6851;;A61B2018/00577;;A61B2018/00595;;A61B2018/00839,A61B18/14;;A61B5/00;;A61B18/00,,0,0,,,,PENDING
182,TW,B,TW 490834 B,061-873-456-458-999,2002-06-11,2002,TW 89111993 A,2000-06-19,EP 99306444 A;;EP 99309842 A,1999-08-17,Improvements in or relating to integrated circuit dies,"An integrated circuit die (1) carries conductive pads (2) and (3) thereon, the larger pads (2) being suitable for flip-chip assembly and the smaller pads (3) being suitable for wire bond assembly. The pitch between pads (2) is at least the minimum required for flip-chip assembly, whereas the pitch between each of pads (3) and the adjacent pad or pads is at least the minimum required for wire bond assembly. For wire bond assembly a passivation layer exposing all pads (2) and (3) is provided, whereas for flip-chip assembly a passivation layer 6 exposes only pads (2) so that conductive bumps (7) may be provided. The provision of pads (2) and (3) complying with the minimum spacing requirements for both flip-chip and wire bond assembly enables a """"dual purpose"""" (e.g. one set of pads being for normal production and another set for testing purposes) die to be produced without any increase in die size.",LUCENT TECHNOLOGIES INC,ADDINALL ROSS;;DAVIES GARETH RHYS,,https://lens.org/061-873-456-458-999,Granted Patent,no,0,0,9,10,0,H01L2224/04073;;H01L2224/06153;;H01L2224/13099;;H01L2924/01004;;H01L2924/01005;;H01L2924/01013;;H01L2924/01015;;H01L2924/01033;;H01L2924/01075;;H01L2924/01079;;H01L2924/01082;;H01L2924/014;;H01L2924/14;;H01L24/13;;H01L2924/00;;H01L24/06;;H01L2224/0401;;H01L2224/13;;H01L2224/04042;;H01L2224/0616;;H01L24/05;;H01L2224/06051;;H01L23/485;;H01L21/60;;H01L24/02;;H01L2924/01004;;H01L2924/01013;;H01L2924/01015;;H01L24/10;;H01L2924/01005;;H01L2924/14;;H01L2224/04073;;H01L2924/014;;H01L2924/01082;;H01L2224/13099;;H01L2924/01079;;H01L2924/01033;;H01L2224/06153;;H01L2924/01075;;H01L24/13;;H01L24/06;;H01L2924/00;;H01L2224/0401;;H01L2224/13,H01L23/485;;H01L21/60,,0,0,,,,EXPIRED
183,US,A,US 4486426 A,066-786-096-839-152,1984-12-04,1984,US 39987582 A,1982-07-19,EP 81401179 A,1981-07-23,Unsaturated cephalosporin derivatives,"An antibacterial cephalosporin derivative of the formula I: ##STR1## in which X.sup.1 is sulphur, oxygen, sulphinyl or sulphonyl; R.sup.1 is a variety of radicals defined in the specification; R.sup.2 is any one of the C-4 substituents from antibacterially-active cephalosporins known in the art; R.sup.3 is hydrogen or methoxy; X.sup.2 is nitrogen or a radical N.sup..sym. R.sup.8 ; R.sup.4 and R.sup.8 are a variety of radicals described in the specification; --A-- is of the formula V or VI: ##STR2## in which R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13 and R.sup.14 are a variety of substituents described in the specification; and the pharmaceutically-acceptable acid- and base-addition salts thereof. Pharmaceutical compositions and manufacturing processes are also described.",ICI PLC,JUNG FREDERICH;;DAVIES GARETH M,IMPERIAL CHEMICAL INDUSTRIES PLC (1982-07-06);;ICI PHARMA (1982-07-06),https://lens.org/066-786-096-839-152,Granted Patent,yes,4,0,4,4,0,C07D505/00;;A61P31/04;;C07D505/00,A61K31/545;;A61K31/546;;C07D501/16;;A61P31/04;;C07D501/18;;C07D505/00,424/246;;544/21;;544/22;;544/26;;544/27;;260/245.3,0,0,,,,EXPIRED
184,EP,A1,EP 1399225 A1,085-146-308-372-667,2004-03-24,2004,EP 02743189 A,2002-06-12,EP 0206499 W;;GB 0114510 A;;GB 0116587 A,2001-06-14,EXERCISE APPARATUS,,EXERTRIS LTD,DAVIES GARETH;;DRAGE KARL JOHN,,https://lens.org/085-146-308-372-667,Patent Application,yes,0,0,3,9,0,A63B71/0622;;A63B22/0605;;A63B2071/0641;;A63B2230/06,A63B24/00;;A63B21/00;;A63B22/08;;A63B69/00;;A63B71/06,,1,0,,,See references of WO 02102469A1,DISCONTINUED
185,US,A1,US 2020/0225060 A1,117-826-712-543-489,2020-07-16,2020,US 201816626657 A,2018-06-27,GB 201710244 A;;GB 2018051789 W,2017-06-27,A SYSTEM AND METHOD FOR IDENTIFYING APPLIANCES UNDER RECALL,"An appliance operation signal processing system comprises: an input for receiving an appliance operation signal, the appliance operation signal comprising information relating to operation of an appliance;an output for outputting information relating to a recall status of the appliance; anda processor configured to: monitor an input appliance operation signal for a change in magnitude;if a change is detected: identify a component event corresponding to the change;determine whether the component event is a designated sequence start component event;if the component event is determined to be a designated sequence start component event: extract one or more features from the input appliance operation signal between the sequence start component event and a sequence stop point;determine information relating to a recall status of the appliance by inputting the one or more features into a first algorithm.",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,DURIAN RESEARCH LLC (2023-06-01);;GREEN RUNNING LIMITED (2020-03-10),https://lens.org/117-826-712-543-489,Patent Application,yes,0,1,9,9,0,G01D4/00;;G06Q50/06;;G06Q10/20;;Y04S20/30;;G01D4/00;;G01R19/2513;;G01R21/133;;G01R31/2825;;G06Q30/014;;G06Q50/06;;G01D4/002;;G01D4/02;;G01D4/10;;G06Q50/06,G01D4/00;;G01D4/02;;G01D4/10;;G06Q50/06,,0,0,,,,ACTIVE
186,US,A1,US 2021/0366066 A1,114-872-198-645-471,2021-11-25,2021,US 202016880397 A,2020-05-21,US 202016880397 A,2020-05-21,METHOD AND SYSTEM FOR SCHEDULING A VIRTUAL CLASS,"A method and a system for matching a student with a tutor for a virtual class are presented. Candidate tutors for the virtual class are identified in real-time based on a student's preferences and desired class times. The desired class time may be “now” or “immediately.” Once a match is made, the virtual class proceeds at the scheduled time.",KELLYNKAI CORP,DAVIES JOHN GARETH;;SHI YUQI,KELLYNKAI CORPORATION (2020-05-22),https://lens.org/114-872-198-645-471,Patent Application,yes,10,8,1,1,0,G06Q50/205;;G06Q10/063112;;G06Q30/0284;;G06Q10/1093;;G09B5/14;;G06Q50/205;;G06Q10/1093;;G09B5/02;;G06Q30/0284;;G09B5/14;;G06Q10/063112,G06Q50/20;;G06Q10/06;;G06Q10/10;;G06Q30/02;;G09B5/02;;G09B5/14,,1,1,056-797-605-495-054,10.1109/vlhcc.2015.7357201,"Guo, Philip J., Jeffery White, and Renan Zanelatto. ""Codechella: Multi-user program visualizations for real-time tutoring and collaborative learning."" 2015 IEEE Symposium on Visual Languages and Human-Centric Computing (VL/HCC). IEEE, 2015 (Year: 2015)",DISCONTINUED
187,US,A1,US 2023/0079488 A1,148-436-724-684-693,2023-03-16,2023,US 202117760337 A,2021-02-08,US 202117760337 A;;US 202062972810 P;;IB 2021051008 W,2020-02-11,Medical Dilator,"An apparatus includes an elongated medical dilator including a cautery device configured to selectively form, by cauterization, a tissue passage through a tissue portion of a living body. The elongated medical dilator also includes a dilation device configured to dilate the tissue passage once the cautery device selectively formed the tissue passage.",BOSTON SCIENT MEDICAL DEVICE LIMITED,URBANSKI JOHN PAUL;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2021-09-13);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/148-436-724-684-693,Patent Application,yes,0,0,3,3,0,A61M29/00;;A61B17/3478;;A61B2017/003;;A61B2017/00946;;A61B18/1487;;A61B2018/1497;;A61B18/1492;;A61B2018/1435;;A61B2018/142;;A61B18/082;;A61B2017/00247;;A61B2017/00331;;A61B2018/00351;;A61B18/1487;;A61B2018/0022;;A61B2018/00595;;A61B2018/00625;;A61M29/02,A61B18/14;;A61M29/02,,0,0,,,,PENDING
188,US,B1,US 6972494 B1,150-889-674-022-635,2005-12-06,2005,US 63928800 A,2000-08-15,EP 99306444 A;;EP 99309842 A,1999-08-17,Integrated circuit die for wire bonding and flip-chip mounting,"An integrated circuit die carries conductive pads and thereon, the larger pads being suitable for flip-chip assembly and the smaller pads being suitable for wire bond assembly. The pitch between pads is at least the minimum required for flip-chip assembly, whereas the pitch between each of pads and the adjacent pad or pads is at least the minimum required for wire bond assembly. For wire bond assembly a passivation layer exposing all pads is provided, whereas for flip-chip assembly a passivation layer exposes only certain pads so that conductive bumps may be provided. The provision of pads complying with the minimum spacing requirements for both flip-chip and wire bond assembly enables a “dual purpose” (e.g. one set of pads being for normal production and another set for testing purposes) die to be produced without any increase in die size.",AGERE SYSTEMS INC,ADDINALL ROSS;;DAVIES GARETH RHYS,AGERE SYSTEMS INC (2002-08-22);;BELL SEMICONDUCTOR LLC (2017-12-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04);;AGERE SYSTEMS GUARDIAN CORPORATION (2002-02-25);;AGERE SYSTEMS LLC (2012-07-24),https://lens.org/150-889-674-022-635,Granted Patent,yes,9,14,9,10,0,H01L2224/04073;;H01L2224/06153;;H01L2224/13099;;H01L2924/01004;;H01L2924/01005;;H01L2924/01013;;H01L2924/01015;;H01L2924/01033;;H01L2924/01075;;H01L2924/01079;;H01L2924/01082;;H01L2924/014;;H01L2924/14;;H01L24/13;;H01L2924/00;;H01L24/06;;H01L2224/0401;;H01L2224/13;;H01L2224/04042;;H01L2224/0616;;H01L24/05;;H01L2224/06051;;H01L23/485;;H01L21/60;;H01L24/02;;H01L2924/01004;;H01L2924/01013;;H01L2924/01015;;H01L24/10;;H01L2924/01005;;H01L2924/14;;H01L2224/04073;;H01L2924/014;;H01L2924/01082;;H01L2224/13099;;H01L2924/01079;;H01L2924/01033;;H01L2224/06153;;H01L2924/01075;;H01L24/13;;H01L24/06;;H01L2924/00;;H01L2224/0401;;H01L2224/13,H01L23/485;;H01L21/60,257/778;;257/780,1,0,,,"European Search Report, dated Nov. 24, 1999.",EXPIRED
189,WO,A1,WO 2014/086540 A1,152-187-314-314-593,2014-06-12,2014,EP 2013073079 W,2013-11-05,EP 12195315 A,2012-12-03,METHOD AND ARRANGEMENT FOR CONTROLLING FUEL SUPPLY FOR A GAS TURBINE,"It is described a method of controlling a supply of a fuel (105) to a combustor (101) of a gas turbine comprising a compressor upstream of the combustor, the method comprising: supplying the fuel (105) to the combustor (101); obtaining a property value of at least one physical property (PT8, PT7, Tinlet, THBOV) of air used for burning the fuel (105) in the combustor (101); estimating a heat input (HIengmodel) of the fuel (105) supplied to the combustor (101) based on the prop- erty value; measuring a Caloric Value (LCVmea) of the fuel (105) upstream of the combustor (101); adjusting the estimated heat input (HIengmodel) based on the measured Caloric Value (LCVmea); and controlling a fuel valve (103) regulating the supply of the fuel (105) to the combustor (101) based on the adjusted estimated heat input (HIexpected) and a demanded heat input (FFDEM).",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,,https://lens.org/152-187-314-314-593,Patent Application,yes,12,0,12,12,0,F02C9/40;;F05D2260/80;;F02C9/40;;F02C9/28;;F02C9/32;;F02C9/48;;F02C9/40;;F05D2260/80,F02C9/40,,0,0,,,,PENDING
190,EP,B1,EP 3645976 B1,158-568-246-528-721,2022-08-31,2022,EP 18739585 A,2018-06-27,GB 201710244 A;;GB 2018051789 W,2017-06-27,A SYSTEM AND METHOD FOR IDENTIFYING APPLIANCES UNDER RECALL,,GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD,"DURIAN RESEARCH LLC, WILMINGTON, US (2023-07-19)",https://lens.org/158-568-246-528-721,Granted Patent,yes,3,0,9,9,0,G01D4/00;;G06Q50/06;;G06Q10/20;;Y04S20/30;;G01D4/00;;G01R19/2513;;G01R21/133;;G01R31/2825;;G06Q30/014;;G06Q50/06;;G01D4/002;;G01D4/02;;G01D4/10;;G06Q50/06,G01D4/00;;G06Q10/00;;G06Q50/06,,0,0,,,,ACTIVE
191,US,B2,US 9938905 B2,183-316-265-407-04X,2018-04-10,2018,US 201314647199 A,2013-11-05,EP 12195315 A;;EP 2013073079 W,2012-12-03,Method and arrangement for controlling fuel supply for a gas turbine,"A method of controlling a supply of a fuel to a combustor of a gas turbine having a compressor upstream of the combustor is provided. The method includes: supplying the fuel to the combustor; obtaining a property value of at least one physical property (PT 8 , PT 7 , Tinlet, THBOV) of air used for burning the fuel in the combustor; estimating a heat input (HIengmodel) of the fuel supplied to the combustor based on the property value; measuring a Caloric Value (LCVmea) of the fuel upstream of the combustor; adjusting the estimated heat input (HIengmodel) based on the measured Caloric Value (LCVmea); and controlling a fuel valve regulating the supply of the fuel to the combustor based on the adjusted estimated heat input (HIexpected) and a demanded heat input (FFDEM).",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,SIEMENS AKTIENGESELLSCHAFT (2015-06-08);;SIEMENS INDUSTRIAL TURBOMACHINERY LIMITED (2015-06-01),https://lens.org/183-316-265-407-04X,Granted Patent,yes,30,1,12,12,0,F02C9/40;;F05D2260/80;;F02C9/40;;F02C9/28;;F02C9/32;;F02C9/48;;F02C9/40;;F05D2260/80,F02C9/00;;F02C9/28;;F02C9/32;;F02C9/40;;F02C9/48,,1,0,,,"RU Office Action dated Jun. 21, 2016, for RU application No. 2015126553.",INACTIVE
192,WO,A1,WO 2020/254525 A1,199-780-323-481-644,2020-12-24,2020,EP 2020067017 W,2020-06-18,GB 201908684 A;;NL 2023933 A,2019-06-18,AN IN-LINE DEVICE AND A METHOD FOR CONTROLLING AN ELECTRICAL APPLIANCE,"A control and monitoring device integrated in an intermediary coupling unit, said intermediary coupling unit being configured to couple an electrical appliance to a power supply, said control and monitoring device comprising a control module configured to change a status of the electrical appliance; a sensor configured to monitor a condition of said electrical appliance and/or an environment thereof; and a processor configured to instruct the control module to change a status of the electrical appliance based on an output of the sensor. Complementary devices and methods of operating such devices are also presented herein.",GREEN RUNNING LTD,DAVIES PETER GARETH;;DIMITROV KONSTANTINE,,https://lens.org/199-780-323-481-644,Patent Application,yes,4,0,3,5,0,H02J13/0005;;H02J3/14;;H02J2310/58;;H02J13/00002;;H02J13/00001;;H02J13/00006;;Y02B70/30;;Y02B70/3225;;Y02B90/20;;Y04S20/242;;Y04S10/30;;Y04S20/222;;Y04S40/12;;Y02E60/00;;H02J13/0005;;H02J13/00006;;H02J2310/58;;H02J13/00001;;H02J13/00002;;H02J3/14,H02J3/14;;H02J13/00,,2,0,,,"DRAPER TOOLS LTD: ""24 Hour Mechanical Timer"", 30 September 2007 (2007-09-30), XP055722332, Retrieved from the Internet <URL:https://www.tooled-up.com/artwork/ProdPDF/44914ins.pdf> [retrieved on 20200813];;DARRELL MORRIS: ""PowerMaster Plug-in Mechanical Timer"", 23 November 2016 (2016-11-23), XP055722336, Retrieved from the Internet <URL:https://www.sitebox.ltd.uk/docs/toolstream/pdf/manuals/148232_Z1MANPRO1.PDF> [retrieved on 20200813]",PENDING
193,GB,A,GB 2560032 A,031-263-037-859-812,2018-08-29,2018,GB 201703178 A,2017-02-28,GB 201703178 A,2017-02-28,An appliance operation signal processing system and method,"Methods and appliance operation signal processing systems for monitoring domestic appliances for the detection and prediction of potential future failures, and a method of training a machine learning classifier. The system comprises an input, for receiving an appliance operation signal; an output, for outputting information on degradation of the appliance; and a processor. The processor monitors the input signal for a change in magnitude 2; if the change is detected it extracts a section for the signal from prior to the change to after the change, extracts a pre-event potion and a post-event portion 3, then subtracts the pre-event portion from the post-event portion, or may transform them into the frequency-domain and then subtract the frequency-domain pre-event portion from the frequency-domain post-event portion 4, and determines a probability the appliance is in the or each of one or more degradation states by applying a classifier to a feature vector comprising time-domain signal or frequency spectrum. The appliance operation signal may be electrical current/voltage/power signal, water consumption signal, gas consumption signal, an auditory signal or a vibration signal.",GREEN RUNNING LTD,PETER GARETH DAVIES;;CONRAD SPITERI,GREEN RUNNING LIMITED (2018-05-23),https://lens.org/031-263-037-859-812,Patent Application,no,1,9,10,10,0,G01R19/2513;;G01R21/00;;G01R21/133;;G01R22/06;;G05B23/0227;;G06N20/00;;G01R19/2513;;G01R21/00;;G06Q50/06;;G06N20/00;;G01R21/00;;G01R22/06;;G01R21/133;;G01R19/2513;;G01R19/252;;G05B23/0227;;G06N20/00;;G06Q50/06;;Y04S20/30;;G01H1/00;;G01H1/003;;G01M99/005;;G01R21/133;;G06N3/04;;G06N3/084;;G06N20/00,G01R21/00;;G01R19/25;;G06N20/00;;G06Q50/06,,0,0,,,,DISCONTINUED
194,KR,A,KR 20220038345 A,071-360-261-911-131,2022-03-28,2022,KR 20227001917 A,2020-07-17,US 201962876192 P;;IB 2020056759 W,2019-07-19,"의료 확장기, 및 의료 확장을 위한 시스템들, 방법들 및 키트들","의료 확장기는 근위 단부 부분, 반대편의 원위 단부 부분, 및 근위 단부 부분으로부터 원위 단부 부분까지 관통하여 연장되는 루멘을 갖는 세장형 부재를 포함한다. 확장 팁은 원위 단부 부분에 있다. 확장 팁은 확대된 단면적의 제1 단부를 갖고, 감소된 단면적의 제2 단부까지 원위 방향으로 가면서 테이퍼진다. 적어도 제1 전극은 확장 팁과 연관된다. 전기 전도체는 제1 전극에 전기적으로 연결되고, 전자해부학적 맵핑 시스템과의 전기적 연결을 위해 제1 전극으로부터 근위 단부 부분을 향해 근위방향으로 연장된다.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/071-360-261-911-131,Patent Application,no,0,0,10,10,0,A61B18/00;;A61B2018/00351;;A61B2018/00613;;A61M29/00;;A61B5/06;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2018/00601;;A61B2018/0038;;A61B2018/00357;;A61B2018/00839;;A61B2017/00053;;A61B34/20;;A61B2034/2051;;A61B2034/2072;;A61B2090/3925;;A61B2090/3966;;A61B18/1492;;A61B18/1487;;A61M29/00;;A61B5/367;;A61B5/06;;A61B2018/00357;;A61B2018/0038;;A61B2018/00839;;A61B2018/00601;;A61B5/367;;A61B18/1487;;A61B18/1492;;A61B2017/00336,A61B18/14;;A61B5/06;;A61B5/367;;A61B18/00;;A61M29/00,,0,0,,,,PENDING
195,BR,A8,BR 112014030643 A8,155-022-263-470-433,2018-05-15,2018,BR 112014030643 A,2012-11-09,IB 2012056315 W;;US 201261653967 P,2012-05-31,aparelho de perfuração por radiofrequência.,,BAYLIS MEDICAL CO INC,GARETH DAVIES;;JOHN PAUL URBANSKI,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (IE) (2023-06-06),https://lens.org/155-022-263-470-433,Patent Application,no,0,0,21,21,0,A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B2218/002;;A61B90/37;;A61B90/39;;A61B2090/3925;;A61B2090/3954;;A61B2090/3966;;A61M25/0108;;A61M25/0127;;A61B5/064;;A61B18/1492;;A61B2217/007;;A61B90/39;;A61B2018/1412;;A61B2218/002;;A61B2090/3954;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61B2018/00077;;A61B2217/005,A61B5/06;;A61B18/12;;A61M25/095;;A61M25/098;;A61M25/14,,0,0,,,,DISCONTINUED
196,CA,C,CA 2891736 C,156-107-409-314-054,2017-06-27,2017,CA 2891736 A,2013-11-05,EP 12195312 A;;EP 2013073083 W,2012-12-03,GAS TURBINE FUEL SUPPLY METHOD AND ARRANGEMENT,"Gas turbine fuel supply method and arrangement It is described a method of controlling a supply of a fuel to a combustor of a gas turbine comprising a compressor upstream of the combustor, the method comprising: supplying the fuel (105) to the combustor (101); obtaining an inlet air pressure (PT7) at a compressor inlet; obtaining an inlet air temperature (Tinlet) at the compressor inlet; obtaining an outlet air pressure (PT8) at a compressor outlet; estimating a heat input (HIengmodel, HIexpected) of the fuel (105) supplied to the combustor (101) based on the inlet air pressure (PT7), the inlet air temperature (Tinlet) and the outlet air pressure (PT8); comparing the estimated heat input (HIengmodel, HIexpected) with a demanded heat input (FFDEM) to derive an error signal (121); and controlling a fuel valve (103) regulating the supply of the fuel (105) to the combustor (101) based on the error signal (121).",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,,https://lens.org/156-107-409-314-054,Granted Patent,no,0,0,12,12,0,F02C9/40;;F05D2260/80;;F02C9/26;;F02C9/28;;F02C9/40;;F05D2260/80,F02C9/40,,0,0,,,,ACTIVE
197,WO,A1,WO 2014/086541 A1,170-139-308-621-796,2014-06-12,2014,EP 2013073083 W,2013-11-05,EP 12195312 A,2012-12-03,GAS TURBINE FUEL SUPPLY METHOD AND ARRANGEMENT,"Gas turbine fuel supply method and arrangement It is described a method of controlling a supply of a fuel to a combustor of a gas turbine comprising a compressor upstream of the combustor, the method comprising: supplying the fuel (105) to the combustor (101); obtaining an inlet air pressure (PT7) at a compressor inlet; obtaining an inlet air temperature (Tinlet) at the compressor inlet; obtaining an outlet air pressure (PT8) at a compressor outlet; estimating a heat input (HIengmodel, HIexpected) of the fuel (105) supplied to the combustor (101) based on the inlet air pressure (PT7), the inlet air temperature (Tinlet) and the outlet air pressure (PT8); comparing the estimated heat input (HIengmodel, HIexpected) with a demanded heat input (FFDEM) to derive an error signal (121); and controlling a fuel valve (103) regulating the supply of the fuel (105) to the combustor (101) based on the error signal (121).",SIEMENS AG,DAVIES GARETH HUW;;SMITH MICHAEL,,https://lens.org/170-139-308-621-796,Patent Application,yes,10,1,12,12,0,F02C9/40;;F05D2260/80;;F02C9/26;;F02C9/28;;F02C9/40;;F05D2260/80,F02C9/40,,0,0,,,,PENDING
198,US,A,US 4504478 A,133-763-711-802-543,1985-03-12,1985,US 41554182 A,1982-09-07,EP 81401458 A,1981-09-18,Cephalosporin-1-oxide derivatives,"An antibacterial cephalosporin derivative of the formula I: ##STR1## in which X.sup.1 is sulphinyl; R.sup.1 is any one of the C-3 substituents from antibacterially-active cephalosporins known in the art; R.sup.2 is any one of the C-4 substituents from antibacterially-active cephalosporins known in the art; R.sup.3 is hydrogen, 1-6C alkoxy or 1-6C alkylthio; X.sup.2 is nitrogen or a radical N.sup..sym. R.sup.5 ; R.sup.4 and R.sup.5 are a variety of radicals described in the specification; --A-- is of the formula II or III: ##STR2## in which R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are a variety of substituents described in the specification; and the pharmaceutically-acceptable acid- and base-addition salts thereof. Pharmaceutical compositions and manufacturing processes are also described.",ICI PLC;;ICI PHARMA,JUNG FREDERIC H;;DAVIES GARETH M,ICI PHARMA A CORP. OF FRANCE (1982-08-09);;IMPERIAL CHEMICAL INDUSTRIES PLC A CORP. OF GREAT BRITAIN (1982-08-09),https://lens.org/133-763-711-802-543,Granted Patent,yes,2,1,4,4,0,A61P31/04;;C07D501/18;;C07D501/18,C07D501/16;;A61K31/545;;A61K31/546;;A61P31/04;;C07D501/18,514/202;;544/22;;544/25;;544/27;;544/28;;514/203;;514/205;;514/206;;514/207,1,0,,,"de Koning et al., Stereospecific Synthesis of Biologically Active Cephalosporin R Sulphoxides Chap. 17 in Recent Advances in the Chemistry of B lactam Antibiotics pub. by Chemical Society, London in 1977 as Spec. Pub. 28.",EXPIRED
199,CN,A,CN 101449039 A,161-436-243-216-427,2009-06-03,2009,CN 200780018665 A,2007-02-27,EP 2007051822 W;;EP 06010534 A,2006-05-22,Gas turbine engine starting method and control device,The present invention provides a method of starting a gas turbine engine (1) by use of a start sequence (105). Turbine speed and fuel delivery are coordinated so as to provide a fuel/air mixture at an ignition device allowing a successful ignition. If a successful ignition has not occurred by end of the start sequence (105) the gas turbine engine is purged (111) and the start sequence (105) is repeated after the purging of the gas turbine engine.,SIEMENS AG,GARETH DAVIES;;JOHN WILKINSON;;RICHARD WOODS,,https://lens.org/161-436-243-216-427,Patent Application,no,0,6,8,8,0,F01D19/00;;F02C7/26;;F02C9/26;;F05D2260/85;;F02C7/26;;F01D19/00;;F02C9/26;;F05D2260/85,F02C7/26,,0,0,,,,ACTIVE
200,EP,A1,EP 4120935 A1,081-844-119-790-029,2023-01-25,2023,EP 21772212 A,2021-03-15,US 202062992215 P;;IB 2021052140 W,2020-03-20,NEEDLE ASSEMBLY FOR FORMING HOLE THROUGH BIOLOGICAL WALL,,BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DAVIES GARETH;;UHM YUN,,https://lens.org/081-844-119-790-029,Patent Application,yes,0,0,9,9,0,A61B18/14;;A61B2017/00247;;A61B2017/00867;;A61B2218/002;;A61B2218/007;;A61B2018/00351;;A61B2090/064;;A61B2018/1425;;A61B2018/00601;;A61B17/3415;;A61B17/3478;;A61B2017/3454;;A61B18/14;;A61B18/1477;;A61B17/3478;;A61B17/00234;;A61B2018/1425;;A61B2018/00071;;A61B2018/00107;;A61B2018/00351;;A61B2018/00613;;A61B2017/00247;;A61B2017/00867;;A61B17/00234;;A61B17/34,A61B17/00;;A61B17/34;;A61B18/00;;A61B18/14,,0,0,,,,PENDING
201,EP,A3,EP 3089027 A3,089-210-003-863-261,2017-12-20,2017,EP 16160320 A,2016-03-15,GB 201505053 A,2015-03-25,SIMD PROCESSING MODULE,"A SIMD processing module is provided, comprising multiple vector processing units (""VUs""), which can be used to execute an instruction on respective parts (or ""subvectors"") within a vector. A control unit determines a vector position indication for each of the VUs to indicate which part of the vector that VU is to execute the instruction on. Therefore, the vector is conceptually divided into subvectors with the respective VUs executing the instruction on the respective subvectors in parallel. Each VU can then execute the instruction as intended, but only on a subsection of the whole vector. This allows an instruction that is written for execution on an n-way VU to be executed by multiple n-way VUs, each starting at different points of the vector, such that the instruction can be executed on more than n of the data items of the vector in parallel.
",IMAGINATION TECH LTD,MURRIN PAUL;;ANDERSON ADRIAN;;DAVIES GARETH,NORDIC SEMICONDUCTOR ASA (2021-07-21),https://lens.org/089-210-003-863-261,Search Report,yes,6,0,9,9,0,G06F9/3887;;G06F9/30036;;G06F9/3887;;G06F9/3012;;G06F9/381;;G06F15/8007;;G06F9/3887;;G06F15/8007;;G06F9/30036;;G06F9/3887;;G06F9/381;;G06F9/3012;;G06F15/8007,G06F9/38;;G06F15/80,,0,0,,,,ACTIVE
202,NO,L,NO 814372 L,131-973-348-571-076,1982-06-23,1982,NO 814372 A,1981-12-21,FR 8027254 A,1980-12-22,ANALOGIFREMGANGSMAATE FOR FREMSTILLING AV ANTIBAKTERIELLE CEFALOSPORINDERIVATER,,ICI PHARMA;;ICI PLC,JUNG FREDERIC HENRI;;DAVIES GARETH MORSE,,https://lens.org/131-973-348-571-076,Abstract,no,0,0,23,23,0,C07D207/34;;C07D209/48;;C07D487/04;;C07D505/00;;C07D463/22;;C07D463/20;;A61P31/04;;C07D209/48;;C07D505/00;;C07D207/34;;C07D487/04;;C07D463/20;;C07D463/22,A61K31/545;;A61K31/546;;A61P31/04;;C07D207/34;;C07D209/48;;C07D463/00;;C07D487/04;;C07D501/16;;C07D501/18;;C07D505/00,,0,0,,,,DISCONTINUED
203,EP,B1,EP 0055099 B1,186-828-677-049-195,1984-10-24,1984,EP 81305957 A,1981-12-18,FR 8027336 A,1980-12-23,PENICILLIN DERIVATIVES,,ICI PHARMA;;IMPERIAL CHEMICAL INDUSTRIES PLC,"JUNG, FREDERIC HENRI;;DAVIES, GARETH MORSE",IMPERIAL CHEMICAL INDUSTRIES PLC (1985-01-23);;ICI PHARMA (1985-01-23),https://lens.org/186-828-677-049-195,Granted Patent,yes,2,0,6,6,0,A61P31/04;;C07D499/00;;C07D499/00,A61K31/43;;A61P31/04;;C07D499/00;;C07D499/10;;C07D499/21;;C07D499/42,,0,0,,,,EXPIRED
204,CN,A,CN 106021175 A,187-189-842-310-894,2016-10-12,2016,CN 201610170137 A,2016-03-23,GB 201504979 A,2015-03-24,CONTROLLING DATA FLOW BETWEEN PROCESSORS IN A PROCESSING SYSTEM,"In embodiments, the application relates to a controlling data flow between processors in a processing system. A processing system includes a program processor for executing a program, and a dedicated processor for executing operations of a particular type (e.g. vector processing operations). The program processor uses an interfacing module and a group of two or more register banks to offload operations of the particular type to the dedicated processor for execution thereon. Whilst the dedicated processor is accessing one register bank for executing a current operation, the interfacing module can concurrently load data for a subsequent operation into a different one of the register banks. The use of multiple register banks allows the dedicated processor to spend a greater proportion of its time executing operations.",IMAGINATION TECH LTD,ADRIAN ANDERSON;;PAUL MURRIN;;GARETH DAVIES,,https://lens.org/187-189-842-310-894,Patent Application,no,7,0,8,8,0,G06F15/825;;G06F15/167;;G06F15/167;;G06F15/167;;G06F9/30098;;G06F15/76,G06F15/82,,0,0,,,,ACTIVE
205,GB,A,GB 2489739 A,186-926-473-162-419,2012-10-10,2012,GB 201105936 A,2011-04-07,GB 201105936 A,2011-04-07,Improved flanged transportation drum,"A drum 10 suitable for transporting cable, wire, rope or tube comprises two substantially parallel, circular end pieces 12a, 12b connected by a substantially cylindrical crosspiece or barrel 14, the circular end pieces each comprising an outer flange or wheel (13a, 15a fig. 2), an inner flange or wheel (13b, 15b fig. 2) and a liner 19 secured to the inner flange (13b, 15b fig. 2), each outer flange (13a, 15a fig. 2) being formed around two centre members or spokes (25, 125 fig. 3) of comparable dimension to the diameter of the drum 10 set at 90 degrees to the other to form a cross and the outer flange (13a, 15a fig. 2) and the inner flange (13b, 15b fig. 2) are each comprised of a layer of circumferentially arranged planar segments (40a, 40b, 41a, 41b, 42a, 42b, 140a, 140b, 141a, 141b, 142a, 142b figs. 4 & 5), with each layer offset by 90 degrees to the other layer and forming the circumference of the drum 10 and wherein the circumferentially arranged planar segments link the two centre members to form the wheel or flange. The liner 19 may be made from plywood and may include a central cut out (22 fig 6) by which the barrel 14 is secured to the liner 19. The end pieces may be assembled using bright wire nails and screws. The barrel 14 may be made by joining the ends of a rectangular sheet of plywood and the flanges may be made from timber. Four steel tubes 95 may pass through the barrel 14.",MARLIN IND WREXHAM LTD,DROOG JOHN;;WILLIAMS GARETH;;DAVIES MARK,,https://lens.org/186-926-473-162-419,Patent Application,no,4,1,2,2,0,B65H75/14;;B65H2701/5116;;B65H2701/5132;;B65H2701/51522;;B65H75/14;;B65H2701/5132,B65H75/14,,0,0,,,,DISCONTINUED
206,US,A1,US 2021/0290200 A1,050-977-949-223-052,2021-09-23,2021,US 202016824776 A,2020-03-20,US 202016824776 A,2020-03-20,MEDICAL DEVICE ASSEMBLY AND RELATED METHODS,"A method for carrying out a cardiac procedure includes a. engaging a shaft of an ultrasound catheter with an elongate member of a medical sheath; b. positioning an ultrasound tip of the ultrasound catheter outside of a lumen of the elongate member; c. intravenously advancing the elongate member of the medical sheath towards a heart of a patient, to position a distal end of the elongate member adjacent a target anatomy within the heart; d. using the medical sheath as a guide to intravenously advance the ultrasound catheter towards the heart of the patient and position the ultrasound tip proximate the target anatomy; and e. using the ultrasound tip to image the target anatomy.",BAYLIS MEDICAL CO INC,MORIYAMA EDUARDO;;LAU KAYLIE;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2020-02-13);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/050-977-949-223-052,Patent Application,yes,0,0,1,1,0,A61B8/445;;A61B8/445;;A61B8/02;;A61B8/02;;A61B8/0883;;A61B8/0883;;A61B8/12;;A61B8/12;;A61B18/1492;;A61B18/1492;;A61B2018/00351;;A61B2018/00351;;A61B2018/00357;;A61B2018/00982;;A61B2090/3784,A61B8/00;;A61B8/02;;A61B8/08;;A61B8/12;;A61B18/14,,0,0,,,,PENDING
207,WO,A1,WO 2021/255604 A1,124-317-167-463-229,2021-12-23,2021,IB 2021055171 W,2021-06-11,US 202063040027 P,2020-06-17,PERFORATION DEVICE AND SYSTEM,"A perforation device for use in medical procedures includes an elongate shaft extending between a proximal portion defining a proximal end and a distal portion defining a distal end. The shaft includes an electrode assembly at the distal end, a wire extending between the proximal end and the electrode assembly, and an electrically resistive coating cladding the wire between the proximal end and the electrode assembly. A first coating clads the electrically resistive coating along the proximal portion. The first coating is relatively stiff. A second coating clads the electrically resistive coating along at least a first section of the distal portion. The second coating is relatively flexible.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,SAMIEE MAHBAN;;DAVIES GARETH;;LEUNG LINUS,,https://lens.org/124-317-167-463-229,Patent Application,yes,5,0,1,1,0,A61B2018/00107;;A61B2018/00136;;A61B18/1206;;A61B18/1477;;A61B2018/00083;;A61B2018/00613,A61B18/14;;A61B18/00,,0,0,,,,PENDING
208,US,B1,US 6674457 B1,045-642-872-096-693,2004-01-06,2004,US 89014901 A,2001-07-25,GB 9901859 A;;GB 0000203 W,1999-01-29,Audio-video conference system with parallel networks,"
    An apparatus for communicating video frames from a source having a video input means to a destination having a visual display unit during the course of a telephone conversation. A first user can use a first computer communication means to make a first connection to a service provider. The service provider or first user then initiates a telephone call from the first to the second telephone via the service provider and the first and second communication paths. A second user can then use the second computer communication means to make a second connection to the service provider. Caller-id data is communicated between each of the first and second users and the service provider so that the service provider can correlate both the call and the first and second connections with each other. At least one video image is uploaded from the video input means to the service provider, and then downloaded to one of the computers. 
",DAVIES STEVEN GARETH;;ROE STEPHEN JOHN,DAVIES STEVEN GARETH;;ROE STEPHEN JOHN,RIDGEWAY SYSTEMS AND SOFTWARE LIMITED (2004-03-26);;CISCO TECHNOLOGY INC (2011-11-10);;TANDBERG TELECOM AS (2005-01-16),https://lens.org/045-642-872-096-693,Granted Patent,yes,2,58,7,7,0,H04M3/567;;H04M2201/50;;H04N7/15;;H04N7/15;;H04M2201/50;;H04M3/567,H04M3/56;;H04N7/15,348/14.01;;348/14.12;;379/93.02,0,0,,,,EXPIRED
209,US,S,US D0631916 S,048-478-773-690-678,2011-02-01,2011,US 35614610 F,2010-02-19,EM 16709280001 F,2010-02-17,Hole punch,,TONIC STUDIOS LTD,DAVIES GARETH;;BATHARD SIMON;;RILEY GRANT,TONIC STUDIOS LIMITED (2010-02-24),https://lens.org/048-478-773-690-678,Design Right,no,0,0,1,1,0,,,1902;;D19/72,0,0,,,,ACTIVE
210,EP,A3,EP 0055562 A3,110-000-596-527-127,1982-08-11,1982,EP 81305958 A,1981-12-18,FR 8027254 A,1980-12-22,CEPHALOSPORIN DERIVATIVES,"A cephalosporin derivative of the formula :-
  in which R 0  is a hydrogen atom or a methyl radical; R' is any one of the C-3 substituents from antibacterially-active cephalosporins known in the art; R 2  is any one of the C-4 substituents from antibacterially-active cephalosporins known in the art; R 3  is a hydrogen atom or a 1-6C alkoxy or 1-6C alkylthio radical; X 1  is a sulphur or oxygen atom, a CH 2  radical or a radical of the formula NR 7  in which R 7  is a hydrogen atom, a 1-6C alkyl, formyl or benzyl radical; X 2  is a nitrogen atom or a radical of the formula
  R 4  and R 7 , and R 5  and R 6  are a variety of substituents which are described in the specification; and the pharmaceutically-acceptable acid- or base- addition salts thereof. Pharmaceutical compositions, manufacturing processes and intermediates are also described.",ICI PHARMA;;IMPERIAL CHEMICAL INDUSTRIES PLC,"JUNG, FREDERIC HENRI;;DAVIES, GARETH MORSE",IMPERIAL CHEMICAL INDUSTRIES PLC (1985-05-15);;ICI PHARMA (1985-05-15),https://lens.org/110-000-596-527-127,Search Report,yes,4,0,23,23,0,C07D207/34;;C07D209/48;;C07D487/04;;C07D505/00;;C07D463/22;;C07D463/20;;A61P31/04;;C07D209/48;;C07D505/00;;C07D207/34;;C07D487/04;;C07D463/20;;C07D463/22,A61K31/545;;A61K31/546;;A61P31/04;;C07D207/34;;C07D209/48;;C07D463/00;;C07D487/04;;C07D501/16;;C07D501/18;;C07D505/00,,0,0,,,,EXPIRED
211,AU,A,AU 1981/078786 A,187-211-114-059-142,1982-07-01,1982,AU 1981/078786 A,1981-12-22,FR 8027254 A,1980-12-22,"CEPHALOSPORIN ANTIBIOTICS AND THEIR OXYGEN, NITROGEN AND CARBON ANALOGUES",,ICI PHARMA;;ICI LTD,JUNG FREDERIC HENRI;;DAVIES GARETH MORSE,,https://lens.org/187-211-114-059-142,Patent Application,no,0,0,23,23,0,C07D207/34;;C07D209/48;;C07D487/04;;C07D505/00;;C07D463/22;;C07D463/20;;A61P31/04;;C07D209/48;;C07D505/00;;C07D207/34;;C07D487/04;;C07D463/20;;C07D463/22,A61K31/545;;A61K31/546;;A61P31/04;;C07D207/34;;C07D209/48;;C07D463/00;;C07D487/04;;C07D501/16;;C07D501/18;;C07D505/00,,0,0,,,,DISCONTINUED
212,WO,A1,WO 2000/045579 A1,018-416-585-273-330,2000-08-03,2000,GB 0000203 W,2000-01-27,GB 9901859 A,1999-01-29,AUDIO-VIDEO CONFERENCE SYSTEM WITH PARALLEL NETWORKS,"An apparatus for communicating video frames from a source (102) having a video input means (110) to a destination (202) having a visual display unit (204) during the course of a telephone conversation comprises: first and second telephones (122, 222) connectable to a telephone network (8); an audio-video service provider (6) that can communicate over the network (8) with both telephones along first and second communication paths (130, 230); first and second computers (102, 262) in proximity with respective telephones (122, 222), at least one of the computers having a video input means (110) and each computer having a data input means (106, 206), a visual display unit (104, 204), and communication means so that the computers can connect to the service provider respectively along third and fourth communication paths (116, 216). A first user can use the first computer communication means to make a first connection to the service provider (6). The service provider or first user then initiates a telephone call from the first to the second telephones (122, 222) via the service provider (6) and the first and second communication paths (130, 230). A second user can then use the second computer communication means to make a second connection to the service provider (6). Caller-id data is communicated between each of the first and second users and the service provider (6) so that the service provider can correlate both the call and the first and second connections with each other. At least one video image is uploaded from the video input means (110) to the service provider (6), and then downloaded to one of the computers.",RIDGEWAY SYSTEMS & SOFTWARE LI;;DAVIES STEVEN GARETH;;ROE STEPHEN JOHN,DAVIES STEVEN GARETH;;ROE STEPHEN JOHN,,https://lens.org/018-416-585-273-330,Patent Application,yes,2,6,7,7,0,H04M3/567;;H04M2201/50;;H04N7/15;;H04N7/15;;H04M2201/50;;H04M3/567,H04M3/56;;H04N7/15,,0,0,,,,PENDING
213,EP,B1,EP 0055562 B1,031-969-018-792-514,1986-02-12,1986,EP 81305958 A,1981-12-18,FR 8027254 A,1980-12-22,CEPHALOSPORIN DERIVATIVES,,ICI PHARMA;;IMPERIAL CHEMICAL INDUSTRIES PLC,"JUNG, FREDERIC HENRI;;DAVIES, GARETH MORSE",ICI PHARMA (1985-05-15);;IMPERIAL CHEMICAL INDUSTRIES PLC (1985-05-15),https://lens.org/031-969-018-792-514,Granted Patent,yes,0,0,23,23,0,C07D207/34;;C07D209/48;;C07D487/04;;C07D505/00;;C07D463/22;;C07D463/20;;A61P31/04;;C07D209/48;;C07D505/00;;C07D207/34;;C07D487/04;;C07D463/20;;C07D463/22,A61K31/545;;A61K31/546;;A61P31/04;;C07D207/34;;C07D209/48;;C07D463/00;;C07D487/04;;C07D501/16;;C07D501/18;;C07D505/00,,0,0,,,,EXPIRED
214,EP,A1,EP 1860302 A1,065-808-146-372-051,2007-11-28,2007,EP 06010534 A,2006-05-22,EP 06010534 A,2006-05-22,Gas turbine engine starting method and control device,"A method of starting a gas turbine engine (1) by use of a start sequence (105) is provided. Turbine speed and fuel delivery are coordinated so as to provide a fuel/air mixture at an ignition device allowing a successful ignition. If a successful ignition has not occurred by end of the start sequence (105) the gas turbine engine is purged (111) and the start sequence (105) is repeated after the purging of the gas turbine engine.
",SIEMENS AG,DAVIES GARETH;;WILKINSON JOHN;;WOODS RICHARD,,https://lens.org/065-808-146-372-051,Patent Application,yes,3,13,8,8,0,F01D19/00;;F02C7/26;;F02C9/26;;F05D2260/85;;F02C7/26;;F01D19/00;;F02C9/26;;F05D2260/85,F02C7/26;;F01D19/00;;F02C9/28,,1,0,,,"FRÖTSCHEL, JOSEF: ""FLUGZEUGTURBINEN im Betrieb"", 1973, HOLSTEN VERLAG, HAMBURG, ISBN: 3-87356-030-5, XP002411516, 92240",DISCONTINUED
215,EP,A2,EP 0075434 A2,125-783-408-105-188,1983-03-30,1983,EP 82304844 A,1982-09-14,EP 81401458 A,1981-09-18,"Cephalosporins, their preparation and their pharmaceutical compositions.","An antibacterial cephalosporin derivative of the formula I:
  in which X' is sulphinyl:
 R' is any one of the C-3 substituents from antibacterially-active cephalosponns known in the art; R 2  is any one of the C-4 substituents from antibacterially-active cephalosporins known in the art: R 3  is hydrogen. 1-6C alkoxy or 1-6C alkylthio; X 2  is nitrogen or a radical NR 5 ; R 4  and R 5  are a variety of radicals described in the specification: -A- is of the formula II or III:
  in which R 6 , R 7 , R 8 , R 9 , R 10  and R"" are a variety of substituents described in the specification: and the pharmaceutically-acceptable acid- and base-addition salts thereof. Pharmaceutical compositions and manufacturing processes are also described.",ICI PHARMA;;ICI PLC,JUNG FREDERIC HENRI;;DAVIES GARETH MORSE,ICI PHARMA (1985-01-23);;IMPERIAL CHEMICAL INDUSTRIES PLC (1985-01-23),https://lens.org/125-783-408-105-188,Patent Application,yes,0,4,4,4,0,A61P31/04;;C07D501/18;;C07D501/18,C07D501/16;;A61K31/545;;A61K31/546;;A61P31/04;;C07D501/18,,0,0,,,,DISCONTINUED
216,EP,A2,EP 3089027 A2,131-448-052-779-913,2016-11-02,2016,EP 16160320 A,2016-03-15,GB 201505053 A,2015-03-25,SIMD PROCESSING MODULE,"A SIMD processing module is provided, comprising multiple vector processing units (""VUs""), which can be used to execute an instruction on respective parts (or ""subvectors"") within a vector. A control unit determines a vector position indication for each of the VUs to indicate which part of the vector that VU is to execute the instruction on. Therefore, the vector is conceptually divided into subvectors with the respective VUs executing the instruction on the respective subvectors in parallel. Each VU can then execute the instruction as intended, but only on a subsection of the whole vector. This allows an instruction that is written for execution on an n-way VU to be executed by multiple n-way VUs, each starting at different points of the vector, such that the instruction can be executed on more than n of the data items of the vector in parallel.
",IMAGINATION TECH LTD,MURRIN PAUL;;ANDERSON ADRIAN;;DAVIES GARETH,NORDIC SEMICONDUCTOR ASA (2021-07-21),https://lens.org/131-448-052-779-913,Patent Application,yes,0,0,9,9,0,G06F9/3887;;G06F9/30036;;G06F9/3887;;G06F9/3012;;G06F9/381;;G06F15/8007;;G06F9/3887;;G06F15/8007;;G06F9/30036;;G06F9/3887;;G06F9/381;;G06F9/3012;;G06F15/8007,G06F9/30,,0,0,,,,ACTIVE
217,EP,A1,EP 2021601 A1,186-707-036-827-427,2009-02-11,2009,EP 07726521 A,2007-02-27,EP 2007051822 W;;EP 06010534 A;;EP 07726521 A,2006-05-22,GAS TURBINE ENGINE STARTING METHOD AND CONTROL DEVICE,,SIEMENS AG,DAVIES GARETH;;WILKINSON JOHN;;WOODS RICHARD,"SIEMENS AKTIENGESELLSCHAFT (2013-03-13);;SIEMENS ENERGY GLOBAL GMBH & CO. KG, DE (2020-12-15)",https://lens.org/186-707-036-827-427,Patent Application,yes,0,0,8,8,0,F01D19/00;;F02C7/26;;F02C9/26;;F05D2260/85;;F02C7/26;;F01D19/00;;F02C9/26;;F05D2260/85,F02C9/26,,0,0,,,,ACTIVE
218,GB,A,GB 2472996 A,024-301-064-308-400,2011-03-02,2011,GB 0914830 A,2009-08-26,GB 0914830 A,2009-08-26,Hole Punch Drive Mechanism,"A drive mechanism for a paper hole punch is disclosed. The mechanism comprises a frame 11 and a lever 12 comprising a first end and a second end. The lever is pivotally coupled to the frame at a pivot point disposed intermediate the first and second end thereof. The frame comprises a lever engaging portion for engaging with a frame engaging portion disposed at the second end of the lever, such that as the first end of lever is pivoted about the pivot point, the frame engaging portion is arranged to move along the lever engaging portion to cause the pivot point to move with respect to the frame. The pivoting action is carried out using pivot rod 17 which moves in slot 15.",TONIC STUDIOS LTD,RILEY GRANT;;BATHARD SIMON;;DAVIES GARETH,,https://lens.org/024-301-064-308-400,Patent Application,no,5,0,5,5,0,B26D5/10;;B26F1/36;;B26F1/36;;B26D5/10;;B26D5/10;;Y10T83/885;;Y10T83/885,B26D5/10,,0,0,,,,DISCONTINUED
219,AU,A,AU 2000/023034 A,096-326-950-093-347,2000-08-18,2000,AU 2000/023034 A,2000-01-27,GB 9901859 A;;GB 0000203 W,1999-01-29,Audio-video conference system with parallel networks,,RIDGEWAY SYSTEMS & SOFTWARE LT,DAVIES STEVEN GARETH;;ROE STEPHEN JOHN,,https://lens.org/096-326-950-093-347,Patent Application,no,0,0,7,7,0,H04M3/567;;H04M2201/50;;H04N7/15;;H04N7/15;;H04M2201/50;;H04M3/567,H04M3/56;;H04N7/15,,0,0,,,,DISCONTINUED
220,WO,A1,WO 2021/186327 A1,093-484-630-402-360,2021-09-23,2021,IB 2021052140 W,2021-03-15,US 202062992215 P,2020-03-20,NEEDLE ASSEMBLY FOR FORMING HOLE THROUGH BIOLOGICAL WALL,"A needle assembly is configured to be movable into a cavity of a patient having a biological wall. A distal tip section extends from the needle assembly. The distal tip section is configured to form a pass-through hole extending through the biological wall of the patient (as, or while, the needle assembly is urged to move toward the biological wall). The distal tip section is also configured to prevent (at least in part) the removal of a free-floating tissue core from the biological wall as the pass-through hole is formed by the distal tip section.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,BALKOVEC CHRISTIAN;;DAVIES GARETH;;UHM YUN,,https://lens.org/093-484-630-402-360,Patent Application,yes,5,0,9,9,0,A61B18/14;;A61B2017/00247;;A61B2017/00867;;A61B2218/002;;A61B2218/007;;A61B2018/00351;;A61B2090/064;;A61B2018/1425;;A61B2018/00601;;A61B17/3415;;A61B17/3478;;A61B2017/3454;;A61B18/14;;A61B18/1477;;A61B17/3478;;A61B17/00234;;A61B2018/1425;;A61B2018/00071;;A61B2018/00107;;A61B2018/00351;;A61B2018/00613;;A61B2017/00247;;A61B2017/00867;;A61B17/00234;;A61B17/34,A61B17/34;;A61B17/00;;A61B18/00;;A61B18/14,,0,0,,,,PENDING
221,US,A1,US 2011/0048208 A1,167-800-574-842-576,2011-03-03,2011,US 70608310 A,2010-02-16,GB 0914830 A,2009-08-26,DRIVE MECHANISM,"A drive mechanism for a hole punch includes a frame and a lever having a first end and a second end. The lever is pivotally coupled to the frame at a pivot point disposed intermediate the first and second end thereof. The frame includes a lever engaging portion for engaging with a frame engaging portion disposed at the second end of the lever, such that as the first end of lever is pivoted about the pivot point, the frame engaging portion is arranged to move along the lever engaging portion to cause the pivot point to move with respect to the frame.",DAVIES GARETH;;BATHARD SIMON;;RILEY GRANT,DAVIES GARETH;;BATHARD SIMON;;RILEY GRANT,TONIC STUDIOS LIMITED (2010-03-15),https://lens.org/167-800-574-842-576,Patent Application,yes,10,3,5,5,0,B26D5/10;;B26F1/36;;B26F1/36;;B26D5/10;;B26D5/10;;Y10T83/885;;Y10T83/885,B26D5/08,83/633,0,0,,,,DISCONTINUED
222,GB,A,GB 2600143 A,177-448-787-105-695,2022-04-27,2022,GB 202016813 A,2020-10-22,GB 202016813 A,2020-10-22,Nanoparticles for use in anti pathogenic applications,"A dispersible nanoparticle 200 comprises a core 210 made of a metal or a metal alloy compound coated with at least one of a carboxylic acid and a water-soluble polymer 220. The core may comprise zinc, copper, a rare earth compound or a lanthanide such as cerium. The core may be combined with an oxygen-based non-metallic compound, such as oxygen or an anion such as a carbonate ion, nitrate, nitrite or hydroxide. The coating may include an organic compound selected from an amino and a peptide. The organic compound may comprise a carboxyl, hydroxyl or an amine functional group for bonding to the core by electrostatic bonding. A nanoparticle dispersion comprises a concentration of said nanoparticles and may have anti-viral, anti-bacterial or anti-parasitic properties. A membrane coated with said dispersible nanoparticles may be used in a face mask or an air filter of an air conditioning unit. A method of coating said membrane comprises dipping the membrane in the nanoparticle dispersion or spraying the membrane with the dispersion and heating the membrane to bind the nanoparticles to its surface.",PHARM 2 FARM LTD,GARETH WYNN VAUGHAN CAVE;;KAREN DAVIES,,https://lens.org/177-448-787-105-695,Patent Application,no,8,0,5,5,0,B22F1/102;;B22F1/0545;;A61K33/244;;A61K33/30;;A61K33/34;;A61P31/12;;A62B23/025;;C23C18/00;;A41D13/1192;;B82Y30/00;;A01N25/28;;A01N59/20;;A41D13/1192;;B82Y30/00;;D01D5/0985;;D10B2321/022;;D10B2321/08,C23C18/00;;A41D13/11;;B82Y30/00,,0,0,,,,PENDING
223,US,A,US 4492692 A,069-799-343-974-67X,1985-01-08,1985,US 33357081 A,1981-12-22,FR 8027254 A,1980-12-22,Cephalosporin derivatives,"A cephalosporin derivative of the formula: ##STR1## in which R.sup.0 is a hydrogen atom or a methyl radical, R.sup.1 is any one of the C-3 substituents from antibacterially-active cephalosporins known in the art; R.sup.2 is any one of the C-4 substituents from antibacterially-active cephalosporins known in the art; R.sup.3 is a hydrogen atom or a 1-6C alkoxy or 1-6C alkylthio radical; X.sup.1 is a sulphur or oxygen atom, a CH.sub.2 radical or a radical of the formula NR.sup.7 in which R.sup.7 is a hydrogen atom, a 1-6C alkyl, formyl or benzyl radical; X.sup.2 is a nitrogen atom or a radical of the formula N.sup..sym. -R.sup.7 ; R.sup.4 and R.sup.7, and R.sup.5 and R.sup.6 are a variety of substituents which are described in the specification; and the pharmaceutically-acceptable acid- or base-addition salts thereof. Pharmaceutical compositions, manufacturing processes and intermediates are also described.",ICI PLC;;ICI PHARMA,JUNG FREDERIC H;;DAVIES GARETH M,ICI PHARMA (1981-12-08);;IMPERIAL CHEMICAL INDUSTRIES PLC (1981-12-08),https://lens.org/069-799-343-974-67X,Granted Patent,yes,2,1,23,23,0,C07D207/34;;C07D209/48;;C07D487/04;;C07D505/00;;C07D463/22;;C07D463/20;;A61P31/04;;C07D209/48;;C07D505/00;;C07D207/34;;C07D487/04;;C07D463/20;;C07D463/22,A61K31/545;;A61K31/546;;A61P31/04;;C07D207/34;;C07D209/48;;C07D463/00;;C07D487/04;;C07D501/16;;C07D501/18;;C07D505/00,424/246;;544/22;;544/25;;544/27;;544/28;;544/90;;544/92,0,0,,,,EXPIRED
224,US,A1,US 2023/0233253 A1,106-160-514-027-187,2023-07-27,2023,US 202318192369 A,2023-03-29,US 202318192369 A;;IB 2021057726 W;;US 202063084686 P,2020-09-29,SURGICAL PERFORATION BETWEEN THE AORTA AND LEFT ATRIUM,"Apparatuses and methods are disclosed for the perforation of a communication between the aorta and left atrium. The method includes introducing the apparatus, positioning the apparatus at a location along the aorta, and energizing the apparatus to create a perforation. For example, one method may include: introducing a flexible wire into the left atrium, advancing a dilator along the flexible wire to position the flexible wire adjacent a selected location along the aorta and energizing the flexible wire to create a perforation from the left atrium into the aorta.",BOSTON SCIENT MEDICAL DEVICE LIMITED,MORIYAMA EDUARDO;;DAVIES GARETH;;DICICCO MATTHEW,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2023-03-23),https://lens.org/106-160-514-027-187,Patent Application,yes,0,0,2,2,0,A61B2090/064;;A61B18/1492;;A61B2018/144;;A61B2018/00351;;A61B2017/22044;;A61B2017/00358;;A61B90/39;;A61B2017/00022;;A61B90/39;;A61B18/1492;;A61B2017/00022,A61B18/14;;A61B90/00,,0,0,,,,PENDING
225,US,S,US D0683452 S,123-869-126-345-700,2013-05-28,2013,US 201229424606 F,2012-06-13,US 201229424606 F;;US 201129394865 F,2011-06-22,Electrosurgical device handle,,DAVIES GARETH;;HARFIELD ELLEN;;MIRZA MAHMOOD;;BAYLIS MEDICAL CO INC,DAVIES GARETH;;HARFIELD ELLEN;;MIRZA MAHMOOD,BAYLIS MEDICAL COMPANY INC (2012-04-19);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/123-869-126-345-700,Design Right,no,0,10,2,2,0,,,2402;;D24/144,0,0,,,,ACTIVE
226,US,A1,US 2021/0187248 A1,181-286-389-535-943,2021-06-24,2021,US 201916720212 A,2019-12-19,US 201916720212 A,2019-12-19,"METHODS FOR DETERMINING A POSITION OF A FIRST MEDICAL DEVICE WITH RESPECT TO A SECOND MEDICAL DEVICE, AND RELATED SYSTEMS AND MEDICAL DEVICES","A system of medical devices includes a first medical device, a second medical device, an RLC circuit, a processor, and an output device. The first medical device includes an elongate member having a lumen. The second medical device includes a needle advanceable through the lumen. The RLC circuit includes an excitation voltage source, a resistor, a capacitor, an inductor, and an output voltage sensor. The inductor includes a coil that is supported by the first medical device and wound around the lumen. As the needle is advanced through the lumen, an output voltage of the RLC circuit is an indicator of a longitudinal position of the needle with respect to the elongate member. The voltage sensor is configured to sense the output voltage, and the processor and output device are configured to generate an output that is an indicator of the longitudinal position of the needle.",BAYLIS MEDICAL CO INC,KINIO STEVEN;;DAVIES GARETH;;MURTESCU LAURENTIU,BAYLIS MEDICAL COMPANY INC (2019-12-19);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/181-286-389-535-943,Patent Application,yes,1,0,3,3,0,A61B2090/0811;;A61B18/1492;;A61B17/3403;;A61B17/3494;;A61B5/6852;;A61B5/061;;A61B5/742;;A61M25/0606;;A61M2205/50;;A61M2205/0238;;A61M2205/0288;;A61M2205/587;;A61M2205/502;;A61M2205/3306;;A61M2205/3317;;A61B17/32;;A61B17/34;;A61B17/3403;;A61B2090/0811,A61M25/06,,0,0,,,,ACTIVE
227,GB,A,GB 2536069 A,121-706-861-815-562,2016-09-07,2016,GB 201505053 A,2015-03-25,GB 201505053 A,2015-03-25,SIMD processing module,"A Single Instruction Multiple Data (SIMD) module 102 has multiple n-way vector processing units (VUs) 108. The units execute an instruction on respective subvectors within a vector having N data items. Memories 104 and 106 are RAM storing data and instructions in assembly language. Control unit 112 determines a vector position indication to mark the starting or ending position of the subvector on which a processing unit 108 executes the instruction. The control unit manages the assignment of subvectors to respective processing units. This makes the system simpler to operate compared to systems where the partitioning is assessed by the program providing the instructions. Moreover the system allows an instruction written for execution on an n-way VU to be executed by multiple n way VUs, each starting at different points of the vector, such that it is executed in parallel on more than n data items of the vector.",IMAGINATION TECH LTD,PAUL MURRIN;;ADRIAN ANDERSON;;GARETH DAVIES,,https://lens.org/121-706-861-815-562,Patent Application,no,4,0,9,9,0,G06F9/3887;;G06F9/30036;;G06F9/3887;;G06F9/3012;;G06F9/381;;G06F15/8007;;G06F9/3887;;G06F15/8007;;G06F9/30036;;G06F9/3887;;G06F9/381;;G06F9/3012;;G06F15/8007,G06F15/80;;G06F9/38,,0,0,,,,ACTIVE
228,US,S,US D0662588 S,169-476-376-730-259,2012-06-26,2012,US 201129394865 F,2011-06-22,US 201129394865 F,2011-06-22,Electrosurgical device handle,,DAVIES GARETH;;HARFIELD ELLEN;;MIRZA MAHMOOD;;BAYLIS MEDICAL CO INC,DAVIES GARETH;;HARFIELD ELLEN;;MIRZA MAHMOOD,BAYLIS MEDICAL COMPANY INC (2011-05-27);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/169-476-376-730-259,Design Right,yes,8,8,2,2,0,,,2402;;D24/144,1,0,,,"Transseptal Needles. TZ Medical, 2011 [retreived on Sep. 12, 2011]. Retrieved from the Internet: <URL:http://www.tzmedical.com/product.php?product—id=34>.",ACTIVE
229,EP,B1,EP 2021601 B1,163-774-305-561-627,2016-06-15,2016,EP 07726521 A,2007-02-27,EP 2007051822 W;;EP 06010534 A;;EP 07726521 A,2006-05-22,GAS TURBINE ENGINE STARTING METHOD AND CONTROL DEVICE,,SIEMENS AG,DAVIES GARETH;;WILKINSON JOHN;;WOODS RICHARD,"SIEMENS AKTIENGESELLSCHAFT (2013-03-13);;SIEMENS ENERGY GLOBAL GMBH & CO. KG, DE (2020-12-15)",https://lens.org/163-774-305-561-627,Granted Patent,yes,3,0,8,8,0,F01D19/00;;F02C7/26;;F02C9/26;;F05D2260/85;;F02C7/26;;F01D19/00;;F02C9/26;;F05D2260/85,F02C9/26,,1,0,,,"FRÖTSCHEL, JOSEF: ""FLUGZEUGTURBINEN im Betrieb"" 1973, HOLSTEN VERLAG , HAMBURG 92240 , XP002411516 ISBN: 3-87356-030-5 pages 92-93",ACTIVE
230,BR,A2,BR 112022018281 A2,013-554-693-410-439,2022-10-25,2022,BR 112022018281 A,2021-03-15,IB 2021052140 W;;US 202062992215 P,2020-03-20,CONJUNTO DE AGULHA PARA FORMAR UM ORIFÍCIO ATRAVÉS DE UMA PAREDE BIOLÓGICA,"CONJUNTO DE AGULHA PARA FORMAR UM ORIFÍCIO ATRAVÉS DE UMA PAREDE BIOLÓGICA. Um conjunto de agulha que é configurado para ser móvel em uma cavidade de um paciente que tem uma parede biológica. Uma seção de ponta distal se estende a partir do conjunto de agulha. A seção de ponta distal é configurada para formar um orifício de passagem que se estende através da parede biológica do paciente (à medida que, ou enquanto, o conjunto de agulha é impelido para se mover em direção à parede biológica). A seção de ponta distal é também configurada para evitar (ao menos em parte) a remoção de um núcleo de tecido flutuante solto da parede biológica à medida que o orifício de passagem é formado pela seção de ponta distal.",BOSTON SCIENT MEDICAL DEVICE LIMITED,CHRISTIAN BALKOVEC;;GARETH DAVIES;;YUN UHM,,https://lens.org/013-554-693-410-439,Patent Application,no,0,0,9,9,0,A61B18/14;;A61B2017/00247;;A61B2017/00867;;A61B2218/002;;A61B2218/007;;A61B2018/00351;;A61B2090/064;;A61B2018/1425;;A61B2018/00601;;A61B17/3415;;A61B17/3478;;A61B2017/3454;;A61B18/14;;A61B18/1477;;A61B17/3478;;A61B17/00234;;A61B2018/1425;;A61B2018/00071;;A61B2018/00107;;A61B2018/00351;;A61B2018/00613;;A61B2017/00247;;A61B2017/00867;;A61B17/00234;;A61B17/34,A61B17/34;;A61B17/00;;A61B18/00;;A61B18/14,,0,0,,,,PENDING
231,EP,A1,EP 4232221 A1,040-612-181-497-659,2023-08-30,2023,EP 21807205 A,2021-10-21,GB 202016813 A;;GB 2021052733 W,2020-10-22,NANOPARTICLES FOR USE IN ANTI PATHOGENIC APPLICATIONS,,PHARM 2 FARM LTD,CAVE GARETH WYNN VAUGHAN;;DAVIES KAREN,,https://lens.org/040-612-181-497-659,Patent Application,yes,0,0,5,5,0,B22F1/102;;B22F1/0545;;A61K33/244;;A61K33/30;;A61K33/34;;A61P31/12;;A62B23/025;;C23C18/00;;A41D13/1192;;B82Y30/00;;A01N25/28;;A01N59/20;;A41D13/1192;;B82Y30/00;;D01D5/0985;;D10B2321/022;;D10B2321/08,B22F1/0545;;A61K33/244;;A61K33/30;;A61K33/34;;A61P31/12;;B22F1/102,,0,0,,,,PENDING
232,US,B2,US 11724070 B2,103-393-210-094-290,2023-08-15,2023,US 201916720212 A,2019-12-19,US 201916720212 A,2019-12-19,"Methods for determining a position of a first medical device with respect to a second medical device, and related systems and medical devices","A system of medical devices includes a first medical device, a second medical device, an RLC circuit, a processor, and an output device. The first medical device includes an elongate member having a lumen. The second medical device includes a needle advanceable through the lumen. The RLC circuit includes an excitation voltage source, a resistor, a capacitor, an inductor, and an output voltage sensor. The inductor includes a coil that is supported by the first medical device and wound around the lumen. As the needle is advanced through the lumen, an output voltage of the RLC circuit is an indicator of a longitudinal position of the needle with respect to the elongate member. The voltage sensor is configured to sense the output voltage, and the processor and output device are configured to generate an output that is an indicator of the longitudinal position of the needle.",BOSTON SCIENT MEDICAL DEVICE LIMITED,KINIO STEVEN;;DAVIES GARETH;;MURTESCU LAURENTIU,BAYLIS MEDICAL COMPANY INC (2019-12-19);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/103-393-210-094-290,Granted Patent,yes,313,1,3,3,0,A61B2090/0811;;A61B18/1492;;A61B17/3403;;A61B17/3494;;A61B5/6852;;A61B5/061;;A61B5/742;;A61M25/0606;;A61M2205/50;;A61M2205/0238;;A61M2205/0288;;A61M2205/587;;A61M2205/502;;A61M2205/3306;;A61M2205/3317;;A61B17/32;;A61B17/34;;A61B17/3403;;A61B2090/0811,A61B17/34;;A61B17/32;;A61B90/00;;A61M25/06,,0,0,,,,ACTIVE
233,EP,A3,EP 0075434 A3,031-776-135-659-009,1984-08-22,1984,EP 82304844 A,1982-09-14,EP 81401458 A,1981-09-18,"CEPHALOSPORINS, THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS","An antibacterial cephalosporin derivative of the formula I:
  in which X' is sulphinyl:
 R' is any one of the C-3 substituents from antibacterially-active cephalosponns known in the art; R 2  is any one of the C-4 substituents from antibacterially-active cephalosporins known in the art: R 3  is hydrogen. 1-6C alkoxy or 1-6C alkylthio; X 2  is nitrogen or a radical NR 5 ; R 4  and R 5  are a variety of radicals described in the specification: -A- is of the formula II or III:
  in which R 6 , R 7 , R 8 , R 9 , R 10  and R"" are a variety of substituents described in the specification: and the pharmaceutically-acceptable acid- and base-addition salts thereof. Pharmaceutical compositions and manufacturing processes are also described.",ICI PHARMA;;IMPERIAL CHEMICAL INDUSTRIES PLC,"JUNG, FREDERIC HENRI;;DAVIES, GARETH MORSE",IMPERIAL CHEMICAL INDUSTRIES PLC (1985-01-23);;ICI PHARMA (1985-01-23),https://lens.org/031-776-135-659-009,Search Report,yes,3,0,4,4,0,A61P31/04;;C07D501/18;;C07D501/18,C07D501/16;;A61K31/545;;A61K31/546;;A61P31/04;;C07D501/18,,0,0,,,,DISCONTINUED
234,FI,L,FI 814132 L,039-877-615-581-822,1982-06-23,1982,FI 814132 A,1981-12-22,FR 8027254 A,1980-12-22,KEFALOSPORINDERIVAT,,ICI PHARMA;;ICI PLC,JUNG FREDERIC HENRI;;DAVIES GARETH MORSE,,https://lens.org/039-877-615-581-822,Abstract,no,0,0,23,23,0,C07D207/34;;C07D209/48;;C07D487/04;;C07D505/00;;C07D463/22;;C07D463/20;;A61P31/04;;C07D209/48;;C07D505/00;;C07D207/34;;C07D487/04;;C07D463/20;;C07D463/22,A61K31/545;;A61K31/546;;A61P31/04;;C07D207/34;;C07D209/48;;C07D463/00;;C07D487/04;;C07D501/16;;C07D501/18;;C07D505/00,,0,0,,,,DISCONTINUED
235,US,A,US 4490382 A,114-082-096-859-659,1984-12-25,1984,US 33356781 A,1981-12-22,FR 8027336 A,1980-12-23,Penicillin derivatives,"A penicillin derivative of the formula I: ##STR1## in which R.sup.1 is any one of the C-3 substituents from antibacterially-active penicillins known in the art; X is a nitrogen atom or a radical of the formula N.sup..sym. --R.sup.3 ; R.sup.2 and R.sup.3, which may be the same or different, are hydrogen atoms or 1-6C alkyl, 1-6C alkanoyl, hydroxy, 1-6C alkoxy, amino, 1-6C alkanoylamino, 1-6C alkylamino, 1-6C aminoalkyl, 1-6C hydroxyalkyl, 2-6C carboxyalkyl, 2-6C alkenyl, 3-6C alkoxyalkyl, 3-8C alkoxycarbonylalkyl, furylmethyl, phenyl or 7-11C phenylalkyl radicals, in the latter two of which the phenyl ring is optionally substituted by a halogen atom or by a methyl, methoxy, nitro, hydroxy, amino, carboxy or methoxy-carbonyl radical; A&lt; is a radical of the formula II or III: ##STR2## in which R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are as described in the specification; and the pharmaceutically-acceptable acid- or base-addition salts thereof. Pharmaceutical compositions and manufacturing processes are also described.",ICI PLC;;ICI PHARMA,JUNG FREDERIC H;;DAVIES GARETH M,ICI PHARMA (1981-12-03);;IMPERIAL CHEMICAL INDUSTRIES PLC (1981-12-03),https://lens.org/114-082-096-859-659,Granted Patent,yes,5,3,6,6,0,A61P31/04;;C07D499/00;;C07D499/00,A61K31/43;;A61P31/04;;C07D499/00;;C07D499/10;;C07D499/21;;C07D499/42,424/270;;X2602452 R;;X2602452 T;;424/251;;X424273R,0,0,,,,EXPIRED
236,FR,A1,FR 2496666 A1,198-214-123-615-430,1982-06-25,1982,FR 8027254 A,1980-12-22,FR 8027254 A,1980-12-22,NOUVEAUX DERIVES DE CEPHALOSPORINE ET COMPOSITION PHARMACEUTIQUE LES CONTENANT,"<P>L'INVENTION A TRAIT AU DOMAINE DE LA CHIMIE PHARMACEUTIQUE.</P><P>ELLE CONCERNE DES DERIVES NOUVEAUX DE CEPHALOSPORINE DE FORMULE:<BR/>(CF DESSIN DANS BOPI)<BR/>DANS LAQUELLE R ET R SONT DES SUBSTITUANTS QUELCONQUES DES POSITIONS RESPECTIVES C-3 ET C-4 DE CEPHALOSPORINES CONNUES DOUEES D'ACTIVITE ANTIBACTERIENNE, X EST UN ATOME DE S OU DE O OU UN RADICAL ORGANIQUE; X EST UN ATOME D'AZOTE OU UN RADICAL ORGANIQUE; R, R ET R SONT DES ATOMES DE H OU DES RADICAUX ORGANIQUES ET R ET R SONT CHOISIS ENTRE DES ATOMES DE H ET D'HALOGENES ET DES RADICAUX ORGANIQUES, ET LEURS SELS D'ADDITION D'ACIDES OU DE BASES ACCEPTABLES DU POINT DE VUE PHARMACEUTIQUE; AINSI QUE DES COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES ET DES PROCEDES PERMETTANT DE LES OBTENIR.</P><P>AGENTS ANTIBACTERIENS.</P>",ICI PHARMA,JUNG FREDERIC HENRI;;DAVIES GARETH MORSE,,https://lens.org/198-214-123-615-430,Patent Application,no,0,0,23,23,0,C07D207/34;;C07D209/48;;C07D487/04;;C07D505/00;;C07D463/22;;C07D463/20;;A61P31/04;;C07D209/48;;C07D505/00;;C07D207/34;;C07D487/04;;C07D463/20;;C07D463/22,A61K31/545;;A61K31/546;;A61P31/04;;C07D207/34;;C07D209/48;;C07D463/00;;C07D487/04;;C07D501/16;;C07D501/18;;C07D505/00,,0,0,,,,DISCONTINUED
237,WO,A1,WO 2022/069961 A1,066-670-168-817-813,2022-04-07,2022,IB 2021057726 W,2021-09-09,US 202063084686 P,2020-09-29,SURGICAL PERFORATION BETWEEN THE AORTA AND LEFT ATRIUM,"Apparatuses and methods are disclosed for the perforation of a communication between the aorta and left atrium. The method includes introducing the apparatus, positioning the apparatus at a location along the aorta, and energizing the apparatus to create a perforation. For example, one method may include: introducing a flexible wire into the left atrium, advancing a dilator along the flexible wire to position the flexible wire adjacent a selected location along the aorta and energizing the flexible wire to create a perforation from the left atrium into the aorta.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,MORIYAMA EDUARDO;;DAVIES GARETH;;DICICCO MATTHEW,,https://lens.org/066-670-168-817-813,Patent Application,yes,5,0,2,2,0,A61B2090/064;;A61B18/1492;;A61B2018/144;;A61B2018/00351;;A61B2017/22044;;A61B2017/00358;;A61B90/39;;A61B2017/00022;;A61B90/39;;A61B18/1492;;A61B2017/00022,A61B18/14;;A61B17/00;;A61B18/08;;A61B18/18,,0,0,,,,PENDING
238,AU,A1,AU 2021/238998 A1,078-847-194-222-932,2022-09-22,2022,AU 2021/238998 A,2021-03-15,US 202062992215 P;;IB 2021052140 W,2020-03-20,Needle assembly for forming hole through biological wall,"A needle assembly is configured to be movable into a cavity of a patient having a biological wall. A distal tip section extends from the needle assembly. The distal tip section is configured to form a pass-through hole extending through the biological wall of the patient (as, or while, the needle assembly is urged to move toward the biological wall). The distal tip section is also configured to prevent (at least in part) the removal of a free-floating tissue core from the biological wall as the pass-through hole is formed by the distal tip section.",BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DAVIES GARETH;;UHM YUN,,https://lens.org/078-847-194-222-932,Patent Application,no,0,0,9,9,0,A61B18/14;;A61B2017/00247;;A61B2017/00867;;A61B2218/002;;A61B2218/007;;A61B2018/00351;;A61B2090/064;;A61B2018/1425;;A61B2018/00601;;A61B17/3415;;A61B17/3478;;A61B2017/3454;;A61B18/14;;A61B18/1477;;A61B17/3478;;A61B17/00234;;A61B2018/1425;;A61B2018/00071;;A61B2018/00107;;A61B2018/00351;;A61B2018/00613;;A61B2017/00247;;A61B2017/00867;;A61B17/00234;;A61B17/34,A61B17/34;;A61B17/00;;A61B18/00;;A61B18/14,,0,0,,,,PENDING
239,EP,A2,EP 0055562 A2,085-002-331-131-682,1982-07-07,1982,EP 81305958 A,1981-12-18,FR 8027254 A,1980-12-22,Cephalosporin derivatives.,"A cephalosporin derivative of the formula :-
  in which R 0  is a hydrogen atom or a methyl radical; R' is any one of the C-3 substituents from antibacterially-active cephalosporins known in the art; R 2  is any one of the C-4 substituents from antibacterially-active cephalosporins known in the art; R 3  is a hydrogen atom or a 1-6C alkoxy or 1-6C alkylthio radical; X 1  is a sulphur or oxygen atom, a CH 2  radical or a radical of the formula NR 7  in which R 7  is a hydrogen atom, a 1-6C alkyl, formyl or benzyl radical; X 2  is a nitrogen atom or a radical of the formula
  R 4  and R 7 , and R 5  and R 6  are a variety of substituents which are described in the specification; and the pharmaceutically-acceptable acid- or base- addition salts thereof. Pharmaceutical compositions, manufacturing processes and intermediates are also described.",ICI PHARMA;;ICI PLC,JUNG FREDERIC HENRI;;DAVIES GARETH MORSE,IMPERIAL CHEMICAL INDUSTRIES PLC (1985-05-15);;ICI PHARMA (1985-05-15),https://lens.org/085-002-331-131-682,Patent Application,yes,0,6,23,23,0,C07D207/34;;C07D209/48;;C07D487/04;;C07D505/00;;C07D463/22;;C07D463/20;;A61P31/04;;C07D209/48;;C07D505/00;;C07D207/34;;C07D487/04;;C07D463/20;;C07D463/22,A61K31/545;;A61K31/546;;A61P31/04;;C07D207/34;;C07D209/48;;C07D463/00;;C07D487/04;;C07D501/16;;C07D501/18;;C07D505/00,,0,0,,,,EXPIRED
240,DE,D1,DE 3173789 D1,146-501-481-969-111,1986-03-27,1986,DE 3173789 T,1981-12-18,FR 8027254 A,1980-12-22,CEPHALOSPORIN DERIVATIVES,,ICI PHARMA;;ICI PLC,JUNG FREDERIC HENRI;;DAVIES GARETH MORSE,,https://lens.org/146-501-481-969-111,Granted Patent,no,0,0,23,23,0,C07D207/34;;C07D209/48;;C07D487/04;;C07D505/00;;C07D463/22;;C07D463/20;;A61P31/04;;C07D209/48;;C07D505/00;;C07D207/34;;C07D487/04;;C07D463/20;;C07D463/22,A61K31/545;;A61K31/546;;A61P31/04;;C07D207/34;;C07D209/48;;C07D463/00;;C07D487/04;;C07D501/16;;C07D501/18;;C07D505/00,,0,0,,,,EXPIRED
241,CA,A1,CA 3171227 A1,015-715-858-517-937,2021-09-23,2021,CA 3171227 A,2021-03-15,US 202062992215 P;;IB 2021052140 W,2020-03-20,NEEDLE ASSEMBLY FOR FORMING HOLE THROUGH BIOLOGICAL WALL,"A needle assembly is configured to be movable into a cavity of a patient having a biological wall. A distal tip section extends from the needle assembly. The distal tip section is configured to form a pass-through hole extending through the biological wall of the patient (as, or while, the needle assembly is urged to move toward the biological wall). The distal tip section is also configured to prevent (at least in part) the removal of a free-floating tissue core from the biological wall as the pass-through hole is formed by the distal tip section.",BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DAVIES GARETH;;UHM YUN,,https://lens.org/015-715-858-517-937,Patent Application,no,0,0,9,9,0,A61B18/14;;A61B2017/00247;;A61B2017/00867;;A61B2218/002;;A61B2218/007;;A61B2018/00351;;A61B2090/064;;A61B2018/1425;;A61B2018/00601;;A61B17/3415;;A61B17/3478;;A61B2017/3454;;A61B18/14;;A61B18/1477;;A61B17/3478;;A61B17/00234;;A61B2018/1425;;A61B2018/00071;;A61B2018/00107;;A61B2018/00351;;A61B2018/00613;;A61B2017/00247;;A61B2017/00867;;A61B17/00234;;A61B17/34,A61B17/00;;A61B17/34;;A61B18/00;;A61B18/14,,0,0,,,,PENDING
242,GB,A,GB 2362291 A,033-342-842-191-411,2001-11-14,2001,GB 0117887 A,2000-01-27,GB 0000203 W;;GB 9901859 A,1999-01-29,Audio-video conference system with parallel networks,"An apparatus for communicating video frames from a source (102) having a video input means (110) to a destination (202) having a visual display unit (204) during the course of a telephone conversation comprises: first and second telephones (122, 222) connectable to a telephone network (8); an audio-video service provider (6) that can communicate over the network (8) with both telephones along first and second communication paths (130, 230); first and second computers (102, 262) in proximity with respective telephones (122, 222), at least one of the computers having a video input means (110) and each computer having a data input means (106, 206), a visual display unit (104, 204), and communication means so that the computers can connect to the service provider respectively along third and fourth communication paths (116, 216). A first user can use the first computer communication means to make a first connection to the service provider (6). The service provider or first user then initiates a telephone call from the first to the second telephones (122, 222) via the service provider (6) and the first and second communication paths (130, 230). A second user can then use the second computer communication means to make a second connection to the service provider (6). Caller-id data is communicated between each of the first and second users and the service provider (6) so that the service provider can correlate both the call and the first and second connections with each other. At least one video image is uploaded from the video input means (110) to the service provider (6), and then downloaded to one of the computers.",RIDGEWAY SYSTEMS & SOFTWARE LT,DAVIES STEVEN GARETH;;ROE STEPHEN JOHN,,https://lens.org/033-342-842-191-411,Patent Application,no,2,4,7,7,0,H04M3/567;;H04M2201/50;;H04N7/15;;H04N7/15;;H04M2201/50;;H04M3/567,H04M3/56;;H04N7/15,H4K KF56          KF56,0,0,,,,EXPIRED
243,EP,A1,EP 0055099 A1,116-390-472-675-595,1982-06-30,1982,EP 81305957 A,1981-12-18,FR 8027336 A,1980-12-23,Penicillin derivatives.,"A penicillin derivative of the formula I:
  in which R 1  is any one of the C-3 substituents from antibacterially-active penicillins known in the art; ⊕
 X is a nitrogen atom or a radical of the formula N-R 3 ; R 2  and R 3 , which may be the same or different, are hydrogen atoms or 1-6C alkyl, 1-6C alkanoyl, hydroxy, 1-6C alkoxy, amino, 1-6C alkanoylamino, 1-6C alkylamino, 1-6C aminoalkyl, 1-6C hydroxyalkyl, 2-6C carboxyalkyl, 2-6C alkenyl, 3-6C alkoxyalkyl, 3-8C alkoxycarbonylalkyl, furylmethyl, phenyl or 7-11 C phenylalkyl radicals, in the latter two of which the phenyl ring is optionally substituted by a halogen atom or by a methyl, methoxy, nitro, hydroxy, amino, carboxy or methoxycarbonyl radical; A<is a radical of the formula II or III:
  in which R 4 , R 5 ,  R 6 , R 7 , R 8  and R 9  are as described in the specification; and the pharmaceutically-acceptable acid- or base-addition salts thereof. Pharmaceutical compositions and manufacturing processes are also described.",ICI PHARMA;;ICI PLC,JUNG FREDERIC HENRI;;DAVIES GARETH MORSE,ICI PHARMA (1985-01-23);;IMPERIAL CHEMICAL INDUSTRIES PLC (1985-01-23),https://lens.org/116-390-472-675-595,Patent Application,yes,3,1,6,6,0,A61P31/04;;C07D499/00;;C07D499/00,A61K31/43;;A61P31/04;;C07D499/00;;C07D499/10;;C07D499/21;;C07D499/42,,1,0,,,"CHEMICAL ABSTRACTS, Volume 70, No. 3, 20th January 1969, page 279, Abstract 11622a Columbus Ohio (US) & Int. Congr. Chemother., Proc. 5th 1967, 1(2), 811-15 F. BONATI et al. ""Partial Synthesis of Penicillins: Triazinylaminopenicillanic Acids"" * Abstract *",EXPIRED
244,EP,B1,EP 3089027 B1,116-183-404-691-903,2021-08-04,2021,EP 16160320 A,2016-03-15,GB 201505053 A,2015-03-25,SIMD PROCESSING MODULE,,NORDIC SEMICONDUCTOR ASA,MURRIN PAUL;;ANDERSON ADRIAN;;DAVIES GARETH,NORDIC SEMICONDUCTOR ASA (2021-07-21),https://lens.org/116-183-404-691-903,Granted Patent,yes,1,0,9,9,0,G06F9/3887;;G06F9/30036;;G06F9/3887;;G06F9/3012;;G06F9/381;;G06F15/8007;;G06F9/3887;;G06F15/8007;;G06F9/30036;;G06F9/3887;;G06F9/381;;G06F9/3012;;G06F15/8007,G06F9/38;;G06F15/80,,0,0,,,,ACTIVE
245,EP,A1,EP 3073387 A1,136-778-355-869-434,2016-09-28,2016,EP 16160319 A,2016-03-15,GB 201504979 A,2015-03-24,CONTROLLING DATA FLOW BETWEEN PROCESSORS IN A PROCESSING SYSTEM,"A processing system includes a program processor for executing a program, and a dedicated processor for executing operations of a particular type (e.g. vector processing operations). The program processor uses an interfacing module and a group of two or more register banks to offload operations of the particular type to the dedicated processor for execution thereon. Whilst the dedicated processor is accessing one register bank for executing a current operation, the interfacing module can concurrently load data for a subsequent operation into a different one of the register banks. The use of multiple register banks allows the dedicated processor to spend a greater proportion of its time executing operations.
",IMAGINATION TECH LTD,MURRIN PAUL;;DAVIES GARETH;;ANDERSON ADRIAN,NORDIC SEMICONDUCTOR ASA (2021-07-21),https://lens.org/136-778-355-869-434,Patent Application,yes,2,0,8,8,0,G06F15/825;;G06F15/167;;G06F15/167;;G06F15/167;;G06F9/30098;;G06F15/76,G06F15/167,,0,0,,,,DISCONTINUED
246,WO,A1,WO 2022/084685 A1,197-355-090-039-299,2022-04-28,2022,GB 2021052733 W,2021-10-21,GB 202016813 A,2020-10-22,NANOPARTICLES FOR USE IN ANTI PATHOGENIC APPLICATIONS,A dispersible nanoparticle (200) for use in anti-pathogenic applications is presented. The dispersible nanoparticle has a core (210) made of a metal or a metal alloy compound. The core (210) is coated with at least one of a carboxylic acid and a water soluble polymer (220). Also presented is a membrane coated with the dispersible nanoparticles and a corresponding method of coating the membrane. The membrane may be used is various products including a face mask and an air filter for use in an air conditioning unit.,PHARM 2 FARM LTD,CAVE GARETH WYNN VAUGHAN;;DAVIES KAREN,,https://lens.org/197-355-090-039-299,Patent Application,yes,4,0,5,5,0,B22F1/102;;B22F1/0545;;A61K33/244;;A61K33/30;;A61K33/34;;A61P31/12;;A62B23/025;;C23C18/00;;A41D13/1192;;B82Y30/00;;A01N25/28;;A01N59/20;;A41D13/1192;;B82Y30/00;;D01D5/0985;;D10B2321/022;;D10B2321/08,B22F1/0545;;A61K33/244;;A61K33/30;;A61K33/34;;A61P31/12;;B22F1/102,,2,2,186-703-285-522-183;;054-242-560-828-609,10.1016/j.ceramint.2015.02.016;;10.1016/j.diagmicrobio.2020.115176;;pmc7428768;;33069048,"HU JIAN ET AL: ""Coating of ZnO nanoparticles onto the inner pore channel surface of SiC foam to fabricate a novel antibacterial air filter material"", CERAMICS INTERNATIONAL, ELSEVIER, AMSTERDAM, NL, vol. 41, no. 5, 11 February 2015 (2015-02-11), pages 7080 - 7090, XP029208973, ISSN: 0272-8842, DOI: 10.1016/J.CERAMINT.2015.02.016;;A.A. CORTESJ.M. ZUNIGA: ""The use of copper to help prevent transmission of SARS-Coronavirus and Influenza viruses. A general Review"", DIAGNOSTIC MICROBIOLOGY & INFECTIOUS DISEASE, 2020, Retrieved from the Internet <URL:https://doi.rg/10.1016/j.diagmicrobio.2020.115176>",PENDING
247,KR,A,KR 20230002384 A,015-632-681-194-111,2023-01-05,2023,KR 20227035110 A,2021-03-15,US 202062992215 P;;IB 2021052140 W,2020-03-20,생체 벽을 통해 구멍을 형성하기 위한 바늘 조립체,바늘 조립체는 생체 벽을 갖는 환자의 체강 내로 이동가능하도록 구성된다. 원위 팁 섹션이 바늘 조립체로부터 연장된다. 원위 팁 섹션은 (바늘 조립체가 생체 벽을 향해 이동하도록 가압되는 때 또는 동안) 환자의 생체 벽을 통해 연장되는 통과 구멍을 형성하도록 구성된다. 원위 팁 섹션은 또한 통과 구멍이 원위 팁 섹션에 의해 형성되는 때 생체 벽으로부터의 자유-부동성 조직 코어의 제거를 (적어도 부분적으로) 방지하도록 구성된다.,BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DAVIES GARETH;;UHM YUN,,https://lens.org/015-632-681-194-111,Patent Application,no,0,0,9,9,0,A61B18/14;;A61B2017/00247;;A61B2017/00867;;A61B2218/002;;A61B2218/007;;A61B2018/00351;;A61B2090/064;;A61B2018/1425;;A61B2018/00601;;A61B17/3415;;A61B17/3478;;A61B2017/3454;;A61B18/14;;A61B18/1477;;A61B17/3478;;A61B17/00234;;A61B2018/1425;;A61B2018/00071;;A61B2018/00107;;A61B2018/00351;;A61B2018/00613;;A61B2017/00247;;A61B2017/00867;;A61B17/00234;;A61B17/34,A61B18/14;;A61B17/00;;A61B17/34;;A61B18/00,,0,0,,,,PENDING
248,FR,A1,FR 2496665 A1,062-006-249-740-781,1982-06-25,1982,FR 8027336 A,1980-12-23,FR 8027336 A,1980-12-23,NOUVEAUX DERIVES DE PENICILLINE ET COMPOSITION PHARMACEUTIQUE LES CONTENANT,"<P>L'INVENTION A TRAIT AU DOMAINE DE LA CHIMIE PHARMACEUTIQUE.</P><P>ELLE CONCERNE DES DERIVES NOUVEAUX DE PENICILLINE DE FORMULE:<BR/>(CF DESSIN DANS BOPI)<BR/>DANS LAQUELLE R EST L'UN QUELCONQUE DES SUBSTITUANTS EN C-3 DE CEPHALOSPHORINES CONNUES DOUEES D'ACTIVITE ANTIBACTERIENNE, R EST UN ATOME D'HYDROGENE OU</P>",ICI PHARMA,JUNG FREDERIC HENRI;;DAVIES GARETH MORSE,,https://lens.org/062-006-249-740-781,Patent Application,no,0,0,6,6,0,A61P31/04;;C07D499/00;;C07D499/00,A61K31/43;;A61P31/04;;C07D499/00;;C07D499/10;;C07D499/21;;C07D499/42,,0,0,,,,DISCONTINUED
249,CN,B,CN 101449039 B,191-885-762-061-086,2012-03-21,2012,CN 200780018665 A,2007-02-27,EP 2007051822 W;;EP 06010534 A,2006-05-22,Gas turbine engine starting method and control device,The present invention provides a method of starting a gas turbine engine (1) by use of a start sequence (105). Turbine speed and fuel delivery are coordinated so as to provide a fuel/air mixture at an ignition device allowing a successful ignition. If a successful ignition has not occurred by end of the start sequence (105) the gas turbine engine is purged (111) and the start sequence (105) is repeated after the purging of the gas turbine engine.,SIEMENS AG,RICHARD WOODS;;GARETH DAVIES;;JOHN WILKINSON,,https://lens.org/191-885-762-061-086,Granted Patent,no,0,0,8,8,0,F01D19/00;;F02C7/26;;F02C9/26;;F05D2260/85;;F02C7/26;;F01D19/00;;F02C9/26;;F05D2260/85,F02C7/26;;F01D19/00;;F02C9/28,,0,0,,,,ACTIVE
250,US,A1,US 2023/0130473 A1,014-047-042-517-646,2023-04-27,2023,US 202117910551 A,2021-03-15,US 202117910551 A;;US 202062992215 P;;IB 2021052140 W,2020-03-20,NEEDLE ASSEMBLY FOR FORMING HOLE THROUGH BIOLOGICAL WALL,"A needle assembly is configured to be movable into a cavity of a patient having a biological wall. A distal tip section extends from the needle assembly. The distal tip section is configured to form a pass-through hole extending through the biological wall of the patient (as, or while, the needle assembly is urged to move toward the biological wall). The distal tip section is also configured to prevent (at least in part) the removal of a free-floating tissue core from the biological wall as the pass-through hole is formed by the distal tip section.",BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DAVIES GARETH;;UHM YUN,BAYLIS MEDICAL COMPANY INC (2021-09-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/014-047-042-517-646,Patent Application,yes,0,0,9,9,0,A61B18/14;;A61B2017/00247;;A61B2017/00867;;A61B2218/002;;A61B2218/007;;A61B2018/00351;;A61B2090/064;;A61B2018/1425;;A61B2018/00601;;A61B17/3415;;A61B17/3478;;A61B2017/3454;;A61B18/14;;A61B18/1477;;A61B17/3478;;A61B17/00234;;A61B2018/1425;;A61B2018/00071;;A61B2018/00107;;A61B2018/00351;;A61B2018/00613;;A61B2017/00247;;A61B2017/00867;;A61B17/00234;;A61B17/34,A61B17/00;;A61B17/34,,0,0,,,,PENDING
251,WO,A1,WO 2007/134886 A1,042-960-255-846-801,2007-11-29,2007,EP 2007051822 W,2007-02-27,EP 06010534 A,2006-05-22,GAS TURBINE ENGINE STARTING METHOD AND CONTROL DEVICE,A method of starting a gas turbine engine (1) by use of a start sequence (105) is provided. Turbine speed and fuel delivery are coordinated so as to provide a fuel/air mixture at an ignition device allowing a successful ignition. If a successful ignition has not occurred by end of the start sequence (105) the gas turbine engine is purged (111) and the start sequence (105) is repeated after the purging of the gas turbine engine.,SIEMENS AG;;DAVIES GARETH;;WILKINSON JOHN;;WOODS RICHARD,DAVIES GARETH;;WILKINSON JOHN;;WOODS RICHARD,,https://lens.org/042-960-255-846-801,Patent Application,yes,3,1,8,8,0,F01D19/00;;F02C7/26;;F02C9/26;;F05D2260/85;;F02C7/26;;F01D19/00;;F02C9/26;;F05D2260/85,F02C7/26;;F01D19/00;;F02C9/28,,1,0,,,"FRÖTSCHEL, JOSEF: ""FLUGZEUGTURBINEN im Betrieb"", 1973, HOLSTEN VERLAG, HAMBURG, ISBN: 3-87356-030-5, XP002411516, 92240",PENDING
252,EP,A3,EP 0071370 A3,050-352-200-374-270,1984-05-16,1984,EP 82303739 A,1982-07-16,EP 81401179 A,1981-07-23,"CEPHALOSPORIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM","An antibacterial cephalosporin derivative of the formula l:-
  in which
 X' is sulphur, oxygen, sulphinyl or sulphonyl; R' is a variety of radicals defined in the specification; R 2  is any one of the C-4 substituents from antibacterially- active cephalosporins known in the art; R 3  is hydrogen or methoxy; X 2  is nitrogen or a radical  R 8 ; R 4  and R 8  are a variety of radicals described in the specification; -A- is of the formula V or VI:-
  in which R 9 , R'°, R 11 , R' 2 , R 13  and R 14  are a variety of substituents described in the specification; and the pharmaceutically-acceptable acid-and base-addition salts thereof. Pharmaceutical compositions and manufacturing processes are also described.",ICI PHARMA;;IMPERIAL CHEMICAL INDUSTRIES PLC,"JUNG, FREDERIC HENRI;;DAVIES, GARETH MORSE",ICI PHARMA (1985-01-23);;IMPERIAL CHEMICAL INDUSTRIES PLC (1985-01-23),https://lens.org/050-352-200-374-270,Search Report,yes,4,0,4,4,0,C07D505/00;;A61P31/04;;C07D505/00,C07D501/16;;A61K31/545;;A61K31/546;;A61P31/04;;C07D501/18;;C07D505/00,,0,0,,,,DISCONTINUED
253,GB,B,GB 2362291 B,102-324-601-981-529,2004-01-21,2004,GB 0117887 A,2000-01-27,GB 0000203 W;;GB 9901859 A,1999-01-29,Audio-video conference system with parallel networks,,RIDGEWAY SYSTEMS & SOFTWARE LT,DAVIES STEVEN GARETH;;ROE STEPHEN JOHN,,https://lens.org/102-324-601-981-529,Granted Patent,no,2,3,7,7,0,H04M3/567;;H04M2201/50;;H04N7/15;;H04N7/15;;H04M2201/50;;H04M3/567,H04M3/56;;H04N7/15,H4K KF56          KF56,0,0,,,,EXPIRED
254,GB,B,GB 2536069 B,122-745-718-845-96X,2017-08-30,2017,GB 201505053 A,2015-03-25,GB 201505053 A,2015-03-25,SIMD processing module,,IMAGINATION TECH LTD,PAUL MURRIN;;ADRIAN ANDERSON;;GARETH DAVIES,,https://lens.org/122-745-718-845-96X,Granted Patent,no,4,0,9,9,0,G06F9/3887;;G06F9/30036;;G06F9/3887;;G06F9/3012;;G06F9/381;;G06F15/8007;;G06F9/3887;;G06F15/8007;;G06F9/30036;;G06F9/3887;;G06F9/381;;G06F9/3012;;G06F15/8007,G06F15/80;;G06F9/38,,0,0,,,,ACTIVE
255,US,A1,US 2023/0338710 A1,144-038-360-985-380,2023-10-26,2023,US 202318342353 A,2023-06-27,US 202318342353 A;;US 201916720212 A,2019-12-19,"METHODS FOR DETERMINING A POSITION OF A FIRST MEDICAL DEVICE WITH RESPECT TO A SECOND MEDICAL DEVICE, AND RELATED SYSTEMS AND MEDICAL DEVICES","A system of medical devices includes a first medical device, a second medical device, an RLC circuit, a processor, and an output device. The first medical device includes an elongate member having a lumen. The second medical device includes a needle advanceable through the lumen. The RLC circuit includes an excitation voltage source, a resistor, a capacitor, an inductor, and an output voltage sensor. The inductor includes a coil that is supported by the first medical device and wound around the lumen. As the needle is advanced through the lumen, an output voltage of the RLC circuit is an indicator of a longitudinal position of the needle with respect to the elongate member. The voltage sensor is configured to sense the output voltage, and the processor and output device are configured to generate an output that is an indicator of the longitudinal position of the needle.",BOSTON SCIENT MEDICAL DEVICE LIMITED,KINIO STEVEN;;DAVIES GARETH;;MURTESCU LAURENTIU,BAYLIS MEDICAL COMPANY INC (2019-12-19);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/144-038-360-985-380,Patent Application,yes,0,0,3,3,0,A61B2090/0811;;A61B18/1492;;A61B17/3403;;A61B17/3494;;A61B5/6852;;A61B5/061;;A61B5/742;;A61M25/0606;;A61M2205/50;;A61M2205/0238;;A61M2205/0288;;A61M2205/587;;A61M2205/502;;A61M2205/3306;;A61M2205/3317;;A61B17/32;;A61B17/34;;A61B17/3403;;A61B2090/0811,A61B17/32;;A61M25/06;;A61B17/34;;A61B90/00,,0,0,,,,PENDING
256,ZA,B,ZA 818594 B,103-623-638-168-52X,1982-12-29,1982,ZA 818594 A,1981-12-10,FR 8027254 A,1980-12-22,CEPHALOSPORIN DERIVATIVES,,ICI PHARMA;;ICI PLC,JUNG FREDERIC HENRI;;DAVIES GARETH MORSE,,https://lens.org/103-623-638-168-52X,Granted Patent,no,0,0,23,23,0,C07D207/34;;C07D209/48;;C07D487/04;;C07D505/00;;C07D463/22;;C07D463/20;;A61P31/04;;C07D209/48;;C07D505/00;;C07D207/34;;C07D487/04;;C07D463/20;;C07D463/22,A61K31/545;;A61K31/546;;A61P31/04;;C07D207/34;;C07D209/48;;C07D463/00;;C07D487/04;;C07D501/16;;C07D501/18;;C07D505/00,,0,0,,,,EXPIRED
257,AU,A,AU 2001/025372 A,023-844-210-478-868,2001-07-31,2001,AU 2001/025372 A,2001-01-17,GB 0001346 A;;GB 0100161 W,2000-01-21,Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin,,ASTRAZENECA AB,LARGE MICHAEL STEWART;;DAVIES GARETH MORSE,,https://lens.org/023-844-210-478-868,Patent Application,no,0,0,6,6,0,C07D413/12;;A61P1/04;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P29/00;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D413/12,A61K31/423;;A61K31/4439;;A61K31/513;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P29/00;;A61P37/06;;A61P43/00;;C07D413/12,,0,0,,,,PENDING
258,US,A1,US 2023/0380525 A1,119-101-137-195-581,2023-11-30,2023,US 202118032493 A,2021-10-21,GB 202016813 A;;GB 2021052733 W,2020-10-22,NANOPARTICLES FOR USE IN ANTI PATHOGENIC APPLICATIONS,A dispersible nanoparticle ( 200 ) for use in anti-pathogenic applications is presented. The dispersible nanoparticle has a core ( 210 ) made of a metal or a metal alloy compound. The core ( 210 ) is coated with at least one of a carboxylic acid and a water soluble polymer ( 220 ). Also presented is a membrane coated with the dispersible nanoparticles and a corresponding method of coating the membrane. The membrane may be used is various products including a face mask and an air filter for use in an air conditioning unit.,PHARM 2 FARM LTD,CAVE GARETH WYNN VAUGHAN;;DAVIES KAREN,,https://lens.org/119-101-137-195-581,Patent Application,yes,0,0,5,5,0,B22F1/102;;B22F1/0545;;A61K33/244;;A61K33/30;;A61K33/34;;A61P31/12;;A62B23/025;;C23C18/00;;A41D13/1192;;B82Y30/00;;A01N25/28;;A01N59/20;;A41D13/1192;;B82Y30/00;;D01D5/0985;;D10B2321/022;;D10B2321/08,A01N25/28;;A41D13/11;;A01N59/20;;D01D5/098,,0,0,,,,PENDING
259,DE,D1,DE 3166875 D1,155-454-169-356-262,1984-11-29,1984,DE 3166875 T,1981-12-18,FR 8027336 A,1980-12-23,PENICILLIN DERIVATIVES,,ICI PHARMA;;ICI PLC,JUNG FREDERIC HENRI;;DAVIES GARETH MORSE,,https://lens.org/155-454-169-356-262,Granted Patent,no,0,0,6,6,0,A61P31/04;;C07D499/00;;C07D499/00,A61K31/43;;A61P31/04;;C07D499/00;;C07D499/10;;C07D499/21;;C07D499/42,,0,0,,,,EXPIRED
260,EP,A2,EP 0071370 A2,191-481-376-009-115,1983-02-09,1983,EP 82303739 A,1982-07-16,EP 81401179 A,1981-07-23,"Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them.","An antibacterial cephalosporin derivative of the formula l:-
  in which
 X' is sulphur, oxygen, sulphinyl or sulphonyl; R' is a variety of radicals defined in the specification; R 2  is any one of the C-4 substituents from antibacterially- active cephalosporins known in the art; R 3  is hydrogen or methoxy; X 2  is nitrogen or a radical  R 8 ; R 4  and R 8  are a variety of radicals described in the specification; -A- is of the formula V or VI:-
  in which R 9 , R'°, R 11 , R' 2 , R 13  and R 14  are a variety of substituents described in the specification; and the pharmaceutically-acceptable acid-and base-addition salts thereof. Pharmaceutical compositions and manufacturing processes are also described.",ICI PHARMA;;ICI PLC,JUNG FREDERIC HENRI;;DAVIES GARETH MORSE,ICI PHARMA (1985-01-23);;IMPERIAL CHEMICAL INDUSTRIES PLC (1985-01-23),https://lens.org/191-481-376-009-115,Patent Application,yes,0,0,4,4,0,C07D505/00;;A61P31/04;;C07D505/00,C07D501/16;;A61K31/545;;A61K31/546;;A61P31/04;;C07D501/18;;C07D505/00,,0,0,,,,DISCONTINUED
261,US,A1,US 2007/0123964 A1,072-107-020-163-694,2007-05-31,2007,US 62740607 A,2007-01-26,US 62740607 A;;US 52075406 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 59629705 P;;US 74318106 P;;US 82745806 P,2003-01-21,MAGNETICALLY GUIDABLE ENERGY DELIVERY APPARATUS AND METHOD OF USING SAME,"An energy delivery apparatus for delivering electrical energy at a target location, the energy delivery apparatus being usable in combination with a magnetic field. The energy delivery apparatus includes an electrical conductor, the electrical conductor having a substantially elongated configuration; an electrode for delivering the electrical energy at the target location, the electrode being electrically coupled to the electrical conductor and located at a predetermined location therealong; and a guiding element mounted to the electrical conductor in a substantially spaced apart relationship relative to the electrode, the guiding element including a magnetically responsive material. The energy delivery apparatus is constructed such that a movement of the guiding element causes a corresponding movement of the electrode. The magnetic field is used to move the guiding element in order to position the electrode substantially adjacent to the target location.",BAYLIS MEDICAL COMPANY,DAVIES GARETH;;ALBERT KELLY;;MUNGER GARETH T;;PANDEY ASHWINI;;VISWANATHAN RAJU,BAYLIS MEDICAL COMPANY INC (2007-04-30);;STEREOTAXIS INC (2011-11-01);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/072-107-020-163-694,Patent Application,yes,57,33,5,113,0,A61B5/062;;A61B18/1492;;A61B2017/00252;;A61M25/0127;;A61N1/05;;A61B34/73;;A61N1/05;;A61B5/062;;A61B2017/00252;;A61B18/1492;;A61M25/0127;;A61B34/73,A61N1/05,607/116,0,0,,,,EXPIRED
262,WO,A2,WO 2007/090075 A2,126-688-544-637-972,2007-08-09,2007,US 2007/0061203 W,2007-01-29,US 74318106 P;;US 82745806 P;;US 62740607 A,2006-01-27,MAGNETICALLY GUIDABLE ENERGY DELIVERY APPARATUS AND METHOD OF USING SAME,"An energy delivery apparatus (10) for delivering electrical energy at a target location, the energy delivery apparatus (10) being usable in combination with a magnetic field. The energy delivery apparatus (10) includes an electrical conductor (16), the electrical conductor (16) having a substantially elongated configuration; an electrode (22) for delivering the electrical energy at the target location, the electrode (22) being electrically coupled to the electrical conductor (16) and located at a predetermined location therealong; and a guiding element (26) mounted to the electrical conductor (16) in a substantially spaced apart relationship relative to the electrode (22), the guiding element (26) including a magnetically responsive material. The energy delivery apparatus (10) is constructed such that a movement of the guiding element (26) causes a corresponding movement of the electrode (22). The magnetic field is used to move the guiding element (26) in order to position the electrode (22) substantially adjacent to the target location.",BAYLIS MEDICAL CO INC;;STEREOTAXIS INC;;DAVIES GARETH;;ALBERT KELLY;;MUNGER GARETH TORREY;;PANDEY ASHWINI;;VISWANATHAN RAJU,DAVIES GARETH;;ALBERT KELLY;;MUNGER GARETH TORREY;;PANDEY ASHWINI;;VISWANATHAN RAJU,,https://lens.org/126-688-544-637-972,Patent Application,yes,0,4,5,113,0,A61B5/062;;A61B18/1492;;A61B2017/00252;;A61M25/0127;;A61N1/05;;A61B34/73;;A61N1/05;;A61B5/062;;A61B2017/00252;;A61B18/1492;;A61M25/0127;;A61B34/73,A61N1/05,,0,0,,,,PENDING
263,WO,A8,WO 2007/090075 A8,067-275-579-597-76X,2007-10-04,2007,US 2007/0061203 W,2007-01-29,US 74318106 P;;US 82745806 P;;US 62740607 A,2006-01-27,MAGNETICALLY GUIDABLE ENERGY DELIVERY APPARATUS AND METHOD OF USING SAME,"An energy delivery apparatus (10) for delivering electrical energy at a target location, the energy delivery apparatus (10) being usable in combination with a magnetic field. The energy delivery apparatus (10) includes an electrical conductor (16), the electrical conductor (16) having a substantially elongated configuration; an electrode (22) for delivering the electrical energy at the target location, the electrode (22) being electrically coupled to the electrical conductor (16) and located at a predetermined location therealong; and a guiding element (26) mounted to the electrical conductor (16) in a substantially spaced apart relationship relative to the electrode (22), the guiding element (26) including a magnetically responsive material. The energy delivery apparatus (10) is constructed such that a movement of the guiding element (26) causes a corresponding movement of the electrode (22). The magnetic field is used to move the guiding element (26) in order to position the electrode (22) substantially adjacent to the target location.",BAYLIS MEDICAL CO INC;;STEREOTAXIS INC;;DAVIES GARETH;;ALBERT KELLY;;MUNGER GARETH TORREY;;PANDEY ASHWINI;;VISWANATHAN RAJU,DAVIES GARETH;;ALBERT KELLY;;MUNGER GARETH TORREY;;PANDEY ASHWINI;;VISWANATHAN RAJU,,https://lens.org/067-275-579-597-76X,Patent Application,no,0,0,5,113,0,A61B5/062;;A61B18/1492;;A61B2017/00252;;A61M25/0127;;A61N1/05;;A61B34/73;;A61N1/05;;A61B5/062;;A61B2017/00252;;A61B18/1492;;A61M25/0127;;A61B34/73,A61N1/05,,0,0,,,,PENDING
264,WO,A1,WO 2017/118948 A1,024-931-953-693-202,2017-07-13,2017,IB 2017050065 W,2017-01-06,US 201662275907 P,2016-01-07,HYBRID TRANSSEPTAL DILATOR AND METHODS OF USING THE SAME,"A method and apparatus are disclosed for an optimized transseptal procedure for providing left heart access, that reduces the number of devices that are used in order to minimize procedural time, complexity and cost. The apparatus comprises a hybrid dilator that comprises the combined functionality of a transseptal sheath and dilator assembly. The hybrid dilator comprises: a dilator shaft defining a lumen for receiving a crossing device therethrough, the dilator shaft being structured to provide support for the crossing device when the crossing device is used to create a puncture in a tissue; and a distal tip having an outer diameter which tapers down to an outer diameter of the crossing device for providing a smooth transition between the crossing device and the distal tip when the crossing device is inserted through the lumen and protrudes beyond the distal tip.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,THOMPSON SMITH MELANIE;;DAVIES GARETH;;LEUNG LINUS,,https://lens.org/024-931-953-693-202,Patent Application,yes,5,0,10,10,0,A61B17/3478;;A61M25/06;;A61B2017/00247;;A61B2017/22038;;A61B2017/22042;;A61B2017/22047;;A61B2090/033;;A61B2090/062;;A61B2090/0807;;A61M29/00;;A61B2017/22038;;A61B2017/22047;;A61B17/3478;;A61B2017/00247;;A61B2017/22042;;A61M25/06;;A61B2090/062;;A61B2090/0807;;A61B2090/033;;A61M29/00;;A61B17/3415;;A61B18/1477;;A61B2018/00351;;A61B2018/1425;;A61M25/09;;A61M2205/32;;A61M2205/582,A61B1/00,,0,0,,,,PENDING
265,GB,A,GB 2559389 A,036-979-610-553-927,2018-08-08,2018,GB 201701835 A,2017-02-03,GB 201701835 A,2017-02-03,Smarter power plug,"A self-contained, in-line electrical plug encapsulates a number of miniature printed circuit boards (7, 9, Fig 3) assembled into the plug body. These circuit boards may contain power supplies, microcontrollers, voltage and current sensors, electronic switches such as relays, illuminated indicators and communications devices. The invention is able to read voltage and current at high frequency to store, analyse and communicate the performance of the said appliance. The invention may also be capable of turning the appliance on or off when instructed by the internal microcontrollers or external sources. As a result the plug is able to monitor the performance of the appli­ance over time detecting whether the appliance is operating efficiently and turn the appliance on or off depending on demand response capabilities imposed or suggested through various energy providers.",GREEN RUNNING LTD,PETER GARETH DAVIES;;STEVE WILLOUGHBY;;CONRAD SPITERI,GREEN RUNNING LIMITED (2018-05-23),https://lens.org/036-979-610-553-927,Patent Application,no,2,1,9,9,0,H01R13/665;;H01R13/6683;;H01R13/6691;;H02J13/0005;;H02J13/00002;;G01D4/002;;H01R13/6658;;Y02B70/3225;;Y04S20/222;;G01R21/133;;H01R13/6683;;H02J2310/70;;H02J2310/14;;H02J13/00004;;H02J13/0005;;H02J3/14;;H02J13/00002;;H01R13/665;;H01R13/6683;;H01R13/6691;;H01R13/70;;H01R13/717;;H02J13/00002;;H02J13/0005;;H02J3/14;;G01D4/002;;H01R13/6658;;Y04S20/222;;Y04S20/242;;Y02B70/3225;;G01R21/133;;Y02B70/30;;Y02B90/20;;Y04S20/00;;Y04S20/30;;H02J3/00;;H02J13/00002;;H02J13/00004;;H02J13/0005;;H01R13/6683;;G05B15/02;;H01R13/6691;;H01R13/70;;H01R13/7175;;H01R24/28;;H01R2103/00;;H04L12/10,H01R13/66;;H01R13/70;;H01R13/717,,0,0,,,,PENDING
266,GB,A,GB 2257255 A,054-468-144-525-133,1993-01-06,1993,GB 9213196 A,1992-06-22,GB 9114024 A;;GB 9205164 A,1991-06-28,MONITORING THE CONCENTRATION OF CARBON DIOXIDE,"An apparatus for monitoring the concentration of carbon dioxide gas in a gaseous mixture, eg. from a beer cellar or vehicle exhaust gases, comprises a transmitting transducer 2 and a receiving transducer 3 positioned within the gaseous mixture to be monitored. A counter timer is provided for determining the time of flight of an ultrasonic pulse from the transmitting transducer to the receiving transducer. In order to correct the measurement for variations in temperature a temperature sensor 5 is provided for measuring the temperature of the gaseous mixture along the line of flight between the transducers 2, 3. The concentration of carbon dioxide in the gaseous mixture is then determined on the basis of the time of flight and the temperature. <IMAGE>",HYCONTROL TECHNOLOGY LIMITED,MITCHINSON JAMES COLLIER;;DAVIES CHRISTOPHER;;JONES GARETH,,https://lens.org/054-468-144-525-133,Patent Application,no,4,8,2,4,0,G01N29/326;;G01N29/024;;G01N29/341;;G01N29/348;;G01N2291/011;;G01N2291/0212;;G01N2291/0215;;G01N2291/102,G01N29/024;;G01N29/32;;G01N29/34,G1G GPP           GPP;;U1S S1502;;U1S S2192,0,0,,,,DISCONTINUED
267,BR,A2,BR 112020015961 A2,044-498-776-195-819,2020-12-15,2020,BR 112020015961 A,2019-02-14,EP 2019053726 W;;GB 201802486 A,2018-02-15,inibidor de gremlin-1 para o tratamento de uma fratura óssea ou defeito ósseo,a presente invenção se refere a métodos para o tratamento de uma fratura óssea ou defeito ósseo. a invenção divulga o uso efetivo de um anticorpo antigremlin-1 para acelerar a cicatrização e ligação em ponte de tecido ósseo nos defeitos intersticiais segmentares; e demonstra que os inibidores da atividade de gremlin-1 podem prover terapias melhoradas para tratar ou prevenir não união de fratura.,UCB BIOPHARMA SRL,GARETH CHARLES GLYNDWR DAVIES;;SCOTT JOHN ROBERTS,,https://lens.org/044-498-776-195-819,Patent Application,no,0,0,22,22,0,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,C07K16/22;;A61P19/00;;A61P19/10,,0,0,,,,PENDING
268,US,B2,US 8590317 B2,198-177-067-894-358,2013-11-26,2013,US 22747007 A,2007-02-27,EP 06010534 A;;EP 2007051822 W,2006-05-22,Gas turbine engine starting method and control device,A method of starting a gas turbine engine by use of a start sequence is provided. Turbine speed and fuel delivery are coordinated so as to provide a fuel/air mixture at an ignition device allowing a successful ignition. If a successful ignition has not occurred by end of the start sequence the gas turbine engine is purged and the start sequence is repeated after the purging of the gas turbine engine.,DAVIES GARETH HUW;;WOODS RICHARD;;WILKINSON STUART;;WILKINSON MARIA HELEN KATHALIN;;SIEMENS AG,DAVIES GARETH HUW;;WILKINSON JOHN;;WOODS RICHARD,SIEMENS AKTIENGESELLSCHAFT (2009-03-27);;SIEMENS ENERGY GLOBAL GMBH & CO. KG (2021-02-28),https://lens.org/198-177-067-894-358,Granted Patent,yes,7,1,8,8,0,F01D19/00;;F02C7/26;;F02C9/26;;F05D2260/85;;F02C7/26;;F01D19/00;;F02C9/26;;F05D2260/85,F02C7/26,60/778;;60/790,1,0,,,"Josef Frötschel; ""Fluzeugturbinen Im Betrieb""; 1973; pp. 92-93; XP002411516; ISBN: 3-87356-030-5; Holsten Verlag, Hamburg 92240.",ACTIVE
269,US,B2,US 8092450 B2,075-098-580-778-002,2012-01-10,2012,US 62740607 A,2007-01-26,US 62740607 A;;US 52075406 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 59629705 P;;US 74318106 P;;US 82745806 P,2003-01-21,Magnetically guidable energy delivery apparatus and method of using same,"An energy delivery apparatus for delivering electrical energy at a target location, the energy delivery apparatus being usable in combination with a magnetic field. The energy delivery apparatus includes an electrical conductor, the electrical conductor having a substantially elongated configuration; an electrode for delivering the electrical energy at the target location, the electrode being electrically coupled to the electrical conductor and located at a predetermined location therealong; and a guiding element mounted to the electrical conductor in a substantially spaced apart relationship relative to the electrode, the guiding element including a magnetically responsive material. The energy delivery apparatus is constructed such that a movement of the guiding element causes a corresponding movement of the electrode. The magnetic field is used to move the guiding element in order to position the electrode substantially adjacent to the target location.",DAVIES GARETH;;ALBERT KELLY;;MUNGER GARETH TORREY;;PANDEY ASHWINI;;VISWANATHAN RAJU;;BAYLIS MEDICAL CO INC;;STEREOTAXIS INC,DAVIES GARETH;;ALBERT KELLY;;MUNGER GARETH TORREY;;PANDEY ASHWINI;;VISWANATHAN RAJU,BAYLIS MEDICAL COMPANY INC (2007-04-30);;STEREOTAXIS INC (2011-11-01);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/075-098-580-778-002,Granted Patent,yes,67,12,5,113,0,A61B5/062;;A61B18/1492;;A61B2017/00252;;A61M25/0127;;A61N1/05;;A61B34/73;;A61N1/05;;A61B5/062;;A61B2017/00252;;A61B18/1492;;A61M25/0127;;A61B34/73,A61B18/18,606/41;;607/116;;606/38,9,8,041-155-588-518-082;;041-100-996-150-282;;114-217-294-103-276;;012-193-495-831-569;;087-966-302-747-022;;102-284-308-414-898;;013-523-269-156-951;;040-553-861-085-191,10.1177/000331978703800704;;2956910;;8489867;;10.1136/hrt.69.4.343;;pmc1025049;;10.1016/0002-9149(93)90687-8;;8342519;;11329224;;10.1002/ccd.1135;;12929107;;10.1002/ccd.10605;;10.1002/ccd.10602;;12929108;;12652210;;10.1097/00001573-200303000-00002;;15038419;;10.1586/14779072.2.1.117,"Lepage, Lewis, Ruiz, Yamanishi, Padron, Hood. Angiopyroplasty using Electromagnetically Induced Focused Heat. Angiology. Jul. 1987;38(7):520-3.;;Hausdorf, Schulze-Neick, Lange. Radiofrequency-Assisted ""reconstruction"" of the Right Ventricular Outflow Tract in Muscular Pulmonary Atresia with Ventricular Septal Defect. British Heart Journal. Apr. 1993;69(4):343-6.;;Hausdorf, Schneider, Lange. Catheter Creation of an Open Outflow Tract in Previously Atretic Right Ventricular Outflow Tract Associated with Ventricular Septal Defect. The Americal Journal of Cardiology. Aug. 1, 1993;72(3):354-6.;;Fink, Peuster, Bertram, Hausdorf. Transcatheter Recanalization of the Left Main Pulmonary Artery after Four Years of Complete Occlusion. Catheterization and Cardiovascular Interventions. May 2001;53(1):81-4.;;Kort, Balzer. Radiofrequency Perforation in the Treatment of Acquired Left Pulmonary Artery Atresia Following Repair of Tetralogy of Fallot. Catheterization and Cardiovascular Interventions. Sep. 2003;60(1):79-81.;;Pedra, Mont'Alverne Filho, Arrieta, Tellez, Fontes. Recanalization of a Discrete Atretic Right Pulmonary Artery Segment with a New Radiofrequency System. Catheterization and Cardiovascular Interventions. Sep. 2003;60(1):82-7.;;Levi, Alejos, Moore. Future of Interventional Cardiology in Pediatrics. Current Opinion in Cardiology. Mar. 2003;18(2):79-90.;;Veldtman, Hartley, Visram, Benson. Radiofrequency Applications in Congenital Heart Disease. Expert Rev Cardiovasc Ther. Jan. 2004;2(1):117-26.;;Holzer, Hardin, Hill, Chisolm, Cheatham. Radiofrequency Energy-A Multi-Facetted Tool for the Congenital Interventionist. Congenital Cardiology Today. Jun. 2006; 4(6): 1-.",ACTIVE
270,US,A1,US 2024/0027229 A1,028-044-492-718-538,2024-01-25,2024,US 202318351942 A,2023-07-13,US 202318351942 A;;GB 201710244 A;;US 202117646192 A;;US 201916626657 A;;GB 2018051789 W,2017-06-27,SYSTEM AND METHOD FOR IDENTIFYING APPLIANCES UNDER RECALL,"An appliance operation signal processing system comprises: an input for receiving an appliance operation signal, the appliance operation signal comprising information relating to operation of an appliance;an output for outputting information relating to a recall status of the appliance; anda processor configured to: monitor an input appliance operation signal for a change in magnitude;if a change is detected: identify a component event corresponding to the change;determine whether the component event is a designated sequence start component event;if the component event is determined to be a designated sequence start component event: extract one or more features from the input appliance operation signal between the sequence start component event and a sequence stop point;determine information relating to a recall status of the appliance by inputting the one or more features into a first algorithm.",DURIAN RES LLC,DAVIES PETER GARETH;;SPITERI CONRAD;;STEPHENSON SEAN,,https://lens.org/028-044-492-718-538,Patent Application,yes,0,0,9,9,0,G01D4/00;;G06Q50/06;;G06Q10/20;;Y04S20/30;;G01D4/00;;G01R19/2513;;G01R21/133;;G01R31/2825;;G06Q30/014;;G06Q50/06;;G01D4/002;;G01D4/02;;G01D4/10;;G06Q50/06,G01D4/00;;G01D4/02;;G01D4/10;;G06Q50/06,,0,0,,,,PENDING
271,EP,A1,EP 4132626 A1,049-965-690-934-942,2023-02-15,2023,EP 21784298 A,2021-04-06,US 202063007662 P;;IB 2021052851 W,2020-04-09,CATHETER AND PERFORATION SYSTEM INCLUDING CATHETER,,BOSTON SCIENT MEDICAL DEVICE LIMITED,LUK MARIA;;DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/049-965-690-934-942,Patent Application,yes,0,0,5,5,0,A61M25/0108;;A61B2090/3966;;A61B18/1492;;A61B2018/00351;;A61B2018/00601;;A61B2018/00089;;A61B2090/3966;;A61B18/1492;;A61B2018/00101;;A61B2018/00357;;A61B2018/00601;;A61L29/085;;A61L29/126;;A61L29/14;;A61M25/0045;;A61M25/0108,A61M25/00;;A61M25/01,,0,0,,,,PENDING
272,US,A1,US 2004/0011398 A1,130-442-553-244-577,2004-01-22,2004,US 34439203 A,2003-07-30,GB 0019552 A;;GB 0103000 W,2000-08-10,Dosing valve,"
    A dosing valve apparatus for introducing a metered dose of a second fluid to a first fluid comprises a first, or main body, portion ( 1 ), a second ball valve portion ( 3 ) and an end cap ( 2 ). The main body ( 1 ) and ball valve ( 3 ) contain first and second chambers ( 13, 14 ), respectively, into which flow the first and second fluids. An orifice jet ( 8 ) and needle valve ( 11 ) control flow of the second fluid from the second chamber ( 14 ) to the first chamber ( 13 ). Within the first chamber ( 13 ) is a pivotable paddle ( 7 ) which is adapted to act upon the needle valve ( 11 ). In this way, flow of the first fluid into the first chamber ( 13 ) acts upon the paddle ( 7 ), which in turn causes the needle valve to at least partially open the orifice ( 8 ) allowing the second fluid into the first chamber ( 13 ) to mix with the first fluid. 
",DAVIES DAVID GARETH HARVARD;;NORMAN EDWARD LESSELS,DAVIES DAVID GARETH HARVARD;;NORMAN EDWARD LESSELS,,https://lens.org/130-442-553-244-577,Patent Application,yes,8,2,5,5,0,G05D11/006;;G05D11/006;;Y10T137/2572;;Y10T137/2572,G05D11/00,137/114,0,0,,,,DISCONTINUED
273,CA,A1,CA 3178089 A1,152-323-710-142-256,2021-12-23,2021,CA 3178089 A,2021-06-01,US 202063040632 P;;IB 2021054816 W,2020-06-18,SUPPORT ASSEMBLY FOR FLEXIBLE MEDICAL ASSEMBLY,"An elongated support assembly is positionable, at least in part, in sliding relationship with an elongated flexible medical assembly. The elongated support assembly is configured to support, at least in part, the elongated flexible medical assembly after the elongated support assembly is positioned, at least in part, in sliding relationship with the elongated flexible medical assembly. The elongated support assembly is, at least in part, selectively maneuverable via an elongated ancillary medical assembly toward a distal portion of the elongated ancillary medical assembly.",BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/152-323-710-142-256,Patent Application,no,0,0,9,9,0,A61B2017/00247;;A61B2017/00336;;A61B2017/00867;;A61B2017/00858;;A61B2090/034;;A61B2018/00196;;A61B2018/00285;;A61B2018/00577;;A61B18/1492;;A61B2018/00357;;A61B18/1492;;A61B90/03;;A61B2018/00196;;A61B2017/00247;;A61B2017/00336;;A61B2017/00858;;A61B2017/00867;;A61B2018/00357;;A61B2018/00577;;A61B2090/034;;A61B18/1492;;A61B2018/00357;;A61B2018/1425;;A61M25/0113;;A61M25/0136;;A61M29/02,A61B17/00;;A61B18/00;;A61B18/14;;A61M29/00,,0,0,,,,PENDING
274,EP,A1,EP 1307799 A1,174-001-408-085-867,2003-05-07,2003,EP 01945523 A,2001-07-04,GB 0103000 W;;GB 0019552 A,2000-08-10,DOSING VALVE,,DAVIES DAVID GARETH HAVARD;;NORMAN EDWARD LESSELS,DAVIES DAVID GARETH HAVARD;;NORMAN EDWARD LESSELS,,https://lens.org/174-001-408-085-867,Patent Application,yes,0,0,5,5,0,G05D11/006;;G05D11/006;;Y10T137/2572;;Y10T137/2572,G05D11/00,,1,0,,,See references of WO 0212971A1,DISCONTINUED
275,AU,A1,AU 2021/291162 A1,185-513-442-406-941,2022-12-22,2022,AU 2021/291162 A,2021-06-01,US 202063040632 P;;IB 2021054816 W,2020-06-18,Support assembly for flexible medical assembly,"An elongated support assembly is positionable, at least in part, in sliding relationship with an elongated flexible medical assembly. The elongated support assembly is configured to support, at least in part, the elongated flexible medical assembly after the elongated support assembly is positioned, at least in part, in sliding relationship with the elongated flexible medical assembly. The elongated support assembly is, at least in part, selectively maneuverable via an elongated ancillary medical assembly toward a distal portion of the elongated ancillary medical assembly.",BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/185-513-442-406-941,Patent Application,no,0,0,9,9,0,A61B2017/00247;;A61B2017/00336;;A61B2017/00867;;A61B2017/00858;;A61B2090/034;;A61B2018/00196;;A61B2018/00285;;A61B2018/00577;;A61B18/1492;;A61B2018/00357;;A61B18/1492;;A61B90/03;;A61B2018/00196;;A61B2017/00247;;A61B2017/00336;;A61B2017/00858;;A61B2017/00867;;A61B2018/00357;;A61B2018/00577;;A61B2090/034;;A61B18/1492;;A61B2018/00357;;A61B2018/1425;;A61M25/0113;;A61M25/0136;;A61M29/02,A61B18/14;;A61B17/00;;A61B18/00;;A61M29/00,,0,0,,,,PENDING
276,US,A1,US 2023/0172658 A1,099-105-426-422-757,2023-06-08,2023,US 202117917636 A,2021-04-06,US 202117917636 A;;US 202063007662 P;;IB 2021052851 W,2020-04-09,CATHETER AND PERFORATION SYSTEM INCLUDING CATHETER,"A catheter includes an elongate shaft extending longitudinally between a proximal portion defining a proximal end and a distal portion defining a distal end. A lumen extends through the shaft from the proximal end to the distal end. The shaft includes a heat-shielding layer and an outer layer adjacent the heat-shielding layer. The heat-shielding layer includes an inner liner layer adjacent the lumen and a heat-shielding layer adjacent the inner liner layer. In the distal portion, at least a section of the outer layer is radiopaque.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LUK MARIA;;DAVIES GARETH;;URBANSKI JOHN PAUL,BAYLIS MEDICAL COMPANY INC (2021-09-13);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/099-105-426-422-757,Patent Application,yes,0,0,5,5,0,A61M25/0108;;A61B2090/3966;;A61B18/1492;;A61B2018/00351;;A61B2018/00601;;A61B2018/00089;;A61B2090/3966;;A61B18/1492;;A61B2018/00101;;A61B2018/00357;;A61B2018/00601;;A61L29/085;;A61L29/126;;A61L29/14;;A61M25/0045;;A61M25/0108,A61B18/14;;A61L29/08;;A61L29/12;;A61L29/14,,0,0,,,,PENDING
277,AR,A1,AR 114105 A1,064-264-333-401-568,2020-07-22,2020,AR P190100349 A,2019-02-13,GB 201802486 A,2018-02-15,INHIBIDOR DE GREMLIN-1 PARA EL TRATAMIENTO DE UNA FRACTURA ÓSEA O DEFECTO ÓSEO,La presente se refiere a métodos para el tratamiento de una fractura ósea o defecto óseo. La presente describe el uso efectivo de un anticuerpo anti-gremlin-1 para acelerar la cicatrización y el puente del tejido óseo en defectos de brecha segmentaria; y demuestra que los inhibidores de la actividad de gremlin-1 pueden proporcionar terapias mejoradas para tratar o prevenir la fractura sin unión.,UCB BIOPHARMA SPRL,ROBERTS SCOTT JOHN;;DAVIES GARETH CHARLES GLYNDWR,,https://lens.org/064-264-333-401-568,Patent Application,no,0,0,22,22,0,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,C07K16/22;;A61P19/00,,0,0,,,,PENDING
278,EP,A1,EP 4167887 A1,082-813-014-787-020,2023-04-26,2023,EP 21824881 A,2021-06-01,US 202063040632 P;;IB 2021054816 W,2020-06-18,SUPPORT ASSEMBLY FOR FLEXIBLE MEDICAL ASSEMBLY,,BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/082-813-014-787-020,Patent Application,yes,0,0,9,9,0,A61B2017/00247;;A61B2017/00336;;A61B2017/00867;;A61B2017/00858;;A61B2090/034;;A61B2018/00196;;A61B2018/00285;;A61B2018/00577;;A61B18/1492;;A61B2018/00357;;A61B18/1492;;A61B90/03;;A61B2018/00196;;A61B2017/00247;;A61B2017/00336;;A61B2017/00858;;A61B2017/00867;;A61B2018/00357;;A61B2018/00577;;A61B2090/034;;A61B18/1492;;A61B2018/00357;;A61B2018/1425;;A61M25/0113;;A61M25/0136;;A61M29/02,A61B18/14;;A61B17/00;;A61B18/00;;A61M29/00,,0,0,,,,PENDING
279,CA,A1,CA 3010700 A1,083-746-329-064-571,2017-07-13,2017,CA 3010700 A,2017-01-06,US 201662275907 P;;IB 2017050065 W,2016-01-07,HYBRID TRANSSEPTAL DILATOR AND METHODS OF USING THE SAME,"A method and apparatus are disclosed for an optimized transseptal procedure for providing left heart access, that reduces the number of devices that are used in order to minimize procedural time, complexity and cost. The apparatus comprises a hybrid dilator that comprises the combined functionality of a transseptal sheath and dilator assembly. The hybrid dilator comprises: a dilator shaft defining a lumen for receiving a crossing device therethrough, the dilator shaft being structured to provide support for the crossing device when the crossing device is used to create a puncture in a tissue; and a distal tip having an outer diameter which tapers down to an outer diameter of the crossing device for providing a smooth transition between the crossing device and the distal tip when the crossing device is inserted through the lumen and protrudes beyond the distal tip.",BAYLIS MEDICAL CO INC,THOMPSON SMITH MELANIE;;LEUNG LINUS;;DAVIES GARETH,,https://lens.org/083-746-329-064-571,Patent Application,no,0,0,10,10,0,A61B17/3478;;A61M25/06;;A61B2017/00247;;A61B2017/22038;;A61B2017/22042;;A61B2017/22047;;A61B2090/033;;A61B2090/062;;A61B2090/0807;;A61M29/00;;A61B2017/22038;;A61B2017/22047;;A61B17/3478;;A61B2017/00247;;A61B2017/22042;;A61M25/06;;A61B2090/062;;A61B2090/0807;;A61B2090/033;;A61M29/00;;A61B17/3415;;A61B18/1477;;A61B2018/00351;;A61B2018/1425;;A61M25/09;;A61M2205/32;;A61M2205/582,A61B1/00,,0,0,,,,PENDING
280,US,S,US D0529539 S,114-379-156-233-285,2006-10-03,2006,US 22537905 F,2005-03-16,US 22537905 F,2005-03-16,Guillotine,,TONIC STUDIOS LTD,BATHARD SIMON DAVID;;DAVIES GARETH WILLIAMS HUMPHRE,TONIC STUDIOS LIMITED (2005-02-20),https://lens.org/114-379-156-233-285,Design Right,no,0,1,1,1,0,,,1804;;D18/34.7,0,0,,,,EXPIRED
281,CL,A1,CL 2020002040 A1,164-591-622-264-233,2020-12-18,2020,CL 2020002040 A,2020-08-05,GB 201802486 A,2018-02-15,Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos.,La presente invención se refiere a métodos para el tratamiento de una fractura o defecto óseos. La invención revela el uso efectivo de un anticuerpo antigremlina-1 para acelerar la cicatrización y la formación de un puente de un tejido óseo en la brecha de los defectos segmentarios óseos; y demuestra que los inhibidores de la actividad de la gremlina-1 pueden proporcionar terapias mejoradas para tratar o prevenir la no unión de fracturas.,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,,https://lens.org/164-591-622-264-233,Patent Application,no,0,0,22,22,0,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,A61P19/00;;A61P19/10;;C07K16/22,,0,0,,,,PENDING
282,EP,A2,EP 2295210 A2,197-549-257-680-076,2011-03-16,2011,EP 10153313 A,2010-02-11,GB 0914830 A,2009-08-26,Drive mechanism for a hole punch,"A drive mechanism for a hole punch is disclosed. The mechanism comprises a frame and a lever comprising a first end and a second end. The lever is pivotally coupled to the frame at a pivot point disposed intermediate the first and second end thereof. The frame comprises a lever engaging portion for engaging with a frame engaging portion disposed at the second end of the lever, such that as the first end of lever is pivoted about the pivot point, the frame engaging portion is arranged to move along the lever engaging portion to cause the pivot point to move with respect to the frame.
",TONIC STUDIOS LTD,DAVIES GARETH;;BATHARD SIMON;;RILEY GRANT E,,https://lens.org/197-549-257-680-076,Patent Application,yes,0,0,5,5,0,B26D5/10;;B26F1/36;;B26F1/36;;B26D5/10;;B26D5/10;;Y10T83/885;;Y10T83/885,B26F1/36;;B26D5/10,,0,0,,,,DISCONTINUED
283,MX,A,MX 2020007431 A,007-808-403-000-571,2020-09-14,2020,MX 2020007431 A,2019-02-14,GB 201802486 A;;EP 2019053726 W,2018-02-15,GREMLIN-1 INHIBITOR FOR THE TREATMENT OF A BONE FRACTURE OR BONE DEFECT.,The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,,https://lens.org/007-808-403-000-571,Patent Application,no,0,0,22,22,0,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,A61P19/10;;A61P19/00;;C07K16/22,,0,0,,,,PENDING
284,GB,A,GB 2392126 A,008-383-665-947-701,2004-02-25,2004,GB 0219537 A,2002-08-22,GB 0219537 A,2002-08-22,Improvements in and relating to scissors,"Scissors are provided in which each blade 1, 2 has a handle 3, 4 and respective finger rings 5, 6, all formed from metal sheet. Each handle 3, 4 and finger ring 5, 6 has moulded thereover a relatively hard plastics material 9, 10 and at least the portion around the finger rings 5, 6 has moulded thereover a relatively soft plastics material 11, 12. With this arrangement the scissors' mechanical strength is primarily derived from the metal sheet, the relatively rigid plastics material is moulded thereover, following which the relatively soft plastics material then provides a soft covering which is protected from the metal part of the finger ring by the layer of relatively hard plastics material.",TONIC STUDIOS LTD,DAVIES GARETH WILLIAM HUMPHREY;;BATHARD SIMON DAVID,,https://lens.org/008-383-665-947-701,Patent Application,no,4,0,3,3,0,B26B13/20,B26B13/20,B4B B80E2         B80;;B4B B80X          B80;;B4K KAA           KAA;;B4K KAG           KAG,0,0,,,,EXPIRED
285,CN,A,CN 108390217 A,040-669-607-109-930,2018-08-10,2018,CN 201810116831 A,2018-02-05,GB 201701835 A,2017-02-03,Power plug,"A power plug for coupling an electrical appliance to an electrical power supply, comprising: a current sensor, configured to measure current supplied through the plug to the electrical appliance; a voltage sensor, configured to measure voltage supplied through the plug to the electrical appliance; a processor configured to: determine power consumption data from data relating to the current and voltage measurements made by the current and voltage sensors; and monitor the performance of the electrical appliance using the power consumption data; and a transmitter, configured to transmit information relating to the performance of the electrical appliance.",GREEN RUNNING LTD,STEVE WILLOUGHBY;;PETER GARETH DAVIES;;CONRAD SPITERI,,https://lens.org/040-669-607-109-930,Patent Application,no,13,4,9,9,0,H01R13/665;;H01R13/6683;;H01R13/6691;;H02J13/0005;;H02J13/00002;;G01D4/002;;H01R13/6658;;Y02B70/3225;;Y04S20/222;;G01R21/133;;H01R13/6683;;H02J2310/70;;H02J2310/14;;H02J13/00004;;H02J13/0005;;H02J3/14;;H02J13/00002;;H01R13/665;;H01R13/6683;;H01R13/6691;;H01R13/70;;H01R13/717;;H02J13/00002;;H02J13/0005;;H02J3/14;;G01D4/002;;H01R13/6658;;Y04S20/222;;Y04S20/242;;Y02B70/3225;;G01R21/133;;Y02B70/30;;Y02B90/20;;Y04S20/00;;Y04S20/30;;H02J3/00;;H02J13/00002;;H02J13/00004;;H02J13/0005;;H01R13/6683;;G05B15/02;;H01R13/6691;;H01R13/70;;H01R13/7175;;H01R24/28;;H01R2103/00;;H04L12/10,H01R13/66,,0,0,,,,ACTIVE
286,BR,A2,BR 112022025311 A2,072-182-322-258-293,2023-01-03,2023,BR 112022025311 A,2021-06-01,IB 2021054816 W;;US 202063040632 P,2020-06-18,CONJUNTO DE SUPORTE PARA CONJUNTO MÉDICO FLEXÍVEL,"CONJUNTO DE SUPORTE PARA CONJUNTO MÉDICO FLEXÍVEL. A presente invenção se refere a um conjunto de suporte alongado que é posicionável, ao menos em parte, em relação deslizante com um conjunto médico flexível alongado. O conjunto de suporte alongado é configurado para sustentar, ao menos em parte, o conjunto médico flexível alongado após o conjunto de suporte alongado ser posicionado, ao menos em parte, em relação deslizante com o conjunto médico flexível alongado. O conjunto de suporte alongado é, pelo menos em parte, manobrável seletivamente através de um conjunto médico auxiliar alongado em direção a uma porção distal do conjunto médico auxiliar alongado.",BOSTON SCIENT MEDICAL DEVICE LIMITED,CHRISTIAN BALKOVEC;;GARETH DAVIES;;JOHN PAUL URBANSKI,,https://lens.org/072-182-322-258-293,Patent Application,no,0,0,9,9,0,A61B2017/00247;;A61B2017/00336;;A61B2017/00867;;A61B2017/00858;;A61B2090/034;;A61B2018/00196;;A61B2018/00285;;A61B2018/00577;;A61B18/1492;;A61B2018/00357;;A61B18/1492;;A61B90/03;;A61B2018/00196;;A61B2017/00247;;A61B2017/00336;;A61B2017/00858;;A61B2017/00867;;A61B2018/00357;;A61B2018/00577;;A61B2090/034;;A61B18/1492;;A61B2018/00357;;A61B2018/1425;;A61M25/0113;;A61M25/0136;;A61M29/02,A61B18/14;;A61B17/00;;A61B18/00;;A61M29/00,,0,0,,,,PENDING
287,GB,B,GB 2559389 B,109-697-193-003-844,2022-09-14,2022,GB 201701835 A,2017-02-03,GB 201701835 A,2017-02-03,A smart plug with current and voltage detection,,GREEN RUNNING LTD,PETER GARETH DAVIES;;STEVE WILLOUGHBY;;CONRAD SPITERI,GREEN RUNNING LIMITED (2018-05-23),https://lens.org/109-697-193-003-844,Granted Patent,no,11,0,9,9,0,H01R13/665;;H01R13/6683;;H01R13/6691;;H02J13/0005;;H02J13/00002;;G01D4/002;;H01R13/6658;;Y02B70/3225;;Y04S20/222;;G01R21/133;;H01R13/6683;;H02J2310/70;;H02J2310/14;;H02J13/00004;;H02J13/0005;;H02J3/14;;H02J13/00002;;H01R13/665;;H01R13/6683;;H01R13/6691;;H01R13/70;;H01R13/717;;H02J13/00002;;H02J13/0005;;H02J3/14;;G01D4/002;;H01R13/6658;;Y04S20/222;;Y04S20/242;;Y02B70/3225;;G01R21/133;;Y02B70/30;;Y02B90/20;;Y04S20/00;;Y04S20/30;;H02J3/00;;H02J13/00002;;H02J13/00004;;H02J13/0005;;H01R13/6683;;G05B15/02;;H01R13/6691;;H01R13/70;;H01R13/7175;;H01R24/28;;H01R2103/00;;H04L12/10,H01R13/66;;H01R13/70;;H01R13/717;;H02J13/00,,0,0,,,,PENDING
288,US,A1,US 2005/0283980 A1,174-217-910-971-699,2005-12-29,2005,US 87840704 A,2004-06-29,US 87840704 A,2004-06-29,Scissors,"Scissors are provided in which each blade 1, 2 has a handle 3, 4 and respective finger rings 5, 6, all formed from metal sheet. Each handle 3, 4 and finger ring 5, 6 has moulded thereover a relatively hard plastics material 9, 10 and at least the portion around the finger rings 5, 6 has moulded thereover a relatively soft plastics material 11, 12. With this arrangement the scissors' mechanical strength is primarily derived from the metal sheet, the relatively rigid plastics material is moulded thereover, following which the relatively soft plastics material then provides a soft covering which is protected from the metal part of the finger ring by the layer of relatively hard plastics material.",TONIC STUDIOS LTD,BATHARD SIMON D;;DAVIES GARETH WILLIAM H,TONIC STUDIOS LIMITED (2004-06-01),https://lens.org/174-217-910-971-699,Patent Application,yes,19,11,1,1,0,B26B13/20;;B26B13/20,B25F3/00;;B26B1/00;;B26B13/20,30/131,0,0,,,,DISCONTINUED
289,SG,A,SG 11202005735S A,031-691-503-418-020,2020-07-29,2020,SG 11202005735S A,2019-02-14,GB 201802486 A;;EP 2019053726 W,2018-02-15,GREMLIN-1 INHIBITOR FOR THE TREATMENT OF A BONE FRACTURE OR BONE DEFECT,,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,,https://lens.org/031-691-503-418-020,Unknown,no,0,0,22,22,0,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,C07K16/22;;A61P19/00;;A61P19/10,,0,0,,,,PENDING
290,GB,B,GB 2392126 B,071-718-262-786-559,2005-03-16,2005,GB 0219537 A,2002-08-22,GB 0219537 A,2002-08-22,Improvements in and relating to scissors,,TONIC STUDIOS LTD,DAVIES GARETH WILLIAM HUMPHREY;;BATHARD SIMON DAVID,,https://lens.org/071-718-262-786-559,Granted Patent,no,4,0,3,3,0,B26B13/20,B26B13/20,B4B B80E2         B80;;B4B B80X          B80;;B4K KAA           KAA;;B4K KAG           KAG,0,0,,,,EXPIRED
291,KR,A,KR 20200121833 A,065-940-980-413-909,2020-10-26,2020,KR 20207026431 A,2019-02-14,GB 201802486 A;;EP 2019053726 W,2018-02-15,골절 또는 골결손의 치료를 위한 그렘린-1 억제제,"본 발명은 골절 또는 골결손의 치료 방법에 관한 것이다. 본 발명은 분절 간격 결손에서 골조직의 치유 및 연결을 가속화하기 위한 항-그렘린-1 항체의 효과적인 용도를 개시하고, 그렘린-1 활성 억제제는 골절 불유합의 치료 또는 예방을 위한 개선된 요법을 제공할 수 있음을 입증한다.",UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,,https://lens.org/065-940-980-413-909,Patent Application,no,0,0,22,22,70,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,C07K16/22;;A61K39/00;;A61P19/00;;A61P19/10,,0,0,,,,PENDING
292,EP,A1,EP 3399900 A1,186-975-095-036-095,2018-11-14,2018,EP 17735911 A,2017-01-06,US 201662275907 P;;IB 2017050065 W,2016-01-07,HYBRID TRANSSEPTAL DILATOR AND METHODS OF USING THE SAME,,BAYLIS MEDICAL CO INC,THOMPSON SMITH MELANIE;;DAVIES GARETH;;LEUNG LINUS,BAYLIS MEDICAL COMPANY INC. (2022-07-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-05),https://lens.org/186-975-095-036-095,Patent Application,yes,0,0,10,10,0,A61B17/3478;;A61M25/06;;A61B2017/00247;;A61B2017/22038;;A61B2017/22042;;A61B2017/22047;;A61B2090/033;;A61B2090/062;;A61B2090/0807;;A61M29/00;;A61B2017/22038;;A61B2017/22047;;A61B17/3478;;A61B2017/00247;;A61B2017/22042;;A61M25/06;;A61B2090/062;;A61B2090/0807;;A61B2090/033;;A61M29/00;;A61B17/3415;;A61B18/1477;;A61B2018/00351;;A61B2018/1425;;A61M25/09;;A61M2205/32;;A61M2205/582,A61B1/00,,0,0,,,,PENDING
293,JP,A,JP 2023133590 A,150-647-646-085-514,2023-09-22,2023,JP 2023127649 A,2023-08-04,JP 2021196970 A;;US 201662275907 P;;JP 2018535115 A;;IB 2017050065 W,2016-01-07,HYBRID TRANSSEPTAL DILATOR AND METHOD USING THE SAME,"To provide a method and apparatus for an optimized transseptal surgical operation for providing left heart access, which reduces the number of devices that are used, in order to minimize surgical time, complexity and cost.SOLUTION: The apparatus comprises a hybrid dilator 100 that comprises the combined functionality of a transseptal sheath and dilator assembly. The hybrid dilator comprises: a dilator shaft defining a lumen for receiving a crossing device, the dilator shaft being structured to provide support for the crossing device when the crossing device is used to create a puncture in a tissue; and a distal tip 130 having an outer diameter which tapers to an outer diameter of the crossing device for providing a smooth transition between the crossing device and the distal tip when the crossing device is inserted through the lumen and protrudes from the distal tip.SELECTED DRAWING: Figure 1A",BOSTON SCIENT MEDICAL DEVICE LTD,MELANIE THOMPSON SMITH;;GARETH DAVIES;;LINUS LEUNG,,https://lens.org/150-647-646-085-514,Patent Application,no,0,0,10,10,0,A61B17/3478;;A61M25/06;;A61B2017/00247;;A61B2017/22038;;A61B2017/22042;;A61B2017/22047;;A61B2090/033;;A61B2090/062;;A61B2090/0807;;A61M29/00;;A61B2017/22038;;A61B2017/22047;;A61B17/3478;;A61B2017/00247;;A61B2017/22042;;A61M25/06;;A61B2090/062;;A61B2090/0807;;A61B2090/033;;A61M29/00;;A61B17/3415;;A61B18/1477;;A61B2018/00351;;A61B2018/1425;;A61M25/09;;A61M2205/32;;A61M2205/582,A61B17/34;;A61B18/14,,0,0,,,,PENDING
294,US,S,US D0501884 S,075-548-156-788-565,2005-02-15,2005,US 20356904 F,2004-04-16,GB 3014838 F,2003-10-18,Paper punch,,TONIC STUDIOS LTD,DAVIES GARETH WILLIAM HUMPHREY;;BATHARD SIMON DAVID,TONIC STUDIOS LIMITED (2004-07-19),https://lens.org/075-548-156-788-565,Design Right,yes,9,3,1,1,0,,,D19/72;;D8/50,0,0,,,,EXPIRED
295,CN,A,CN 111683965 A,157-913-310-693-560,2020-09-18,2020,CN 201980012164 A,2019-02-14,GB 201802486 A;;EP 2019053726 W,2018-02-15,gremlin-1 inhibitor for the treatment of a bone fracture or bone defect,The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.,UCB BIOPHARMA SPRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,,https://lens.org/157-913-310-693-560,Patent Application,no,4,0,22,22,0,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,C07K16/22;;A61P19/00;;A61P19/10,,3,0,,,"MARC FAJARDO等: ""Levels of Expression for BMP-7 and Several BMP Antagonists May Play an Integral Role in a Fracture Nonunion"", CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, pages 3071;;ELISABETTA GAZZERRO等: ""Skeletal Overexpression of Gremlin Impairs Bone Formation and Causes Osteopenia"", ENDOCRINOLOGY, pages 655;;HANS-JÖRG SEBALD等: ""Inhibition of endogenous antagonists with an engineered BMP-2 variant increases BMP-2 efficacy in rat femoral defect healing"", ACTA BIOMATERIALIA, pages 3816",PENDING
296,CO,A2,CO 2020009731 A2,157-160-974-810-260,2020-08-21,2020,CO 2020009731 A,2020-08-06,EP 2019053726 W;;GB 201802486 A,2018-02-15,Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos,RESUMEN La presente invención se refiere a métodos para el tratamiento de una fractura o defecto óseos. La invención revela el uso efectivo de un anticuerpo antigremlina-1 para acelerar la cicatrización y la formación de un puente de un tejido óseo en la brecha de los defectos segmentarios óseos; y demuestra que los inhibidores de la actividad de la gremlina-1 pueden proporcionar terapias mejoradas para tratar o prevenir la no unión de fracturas.,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,,https://lens.org/157-160-974-810-260,Patent Application,no,0,0,22,22,0,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,C07K16/22;;A61P19/00;;A61P19/10,,0,0,,,,PENDING
297,WO,A1,WO 2021/255566 A1,171-811-248-587-432,2021-12-23,2021,IB 2021054816 W,2021-06-01,US 202063040632 P,2020-06-18,SUPPORT ASSEMBLY FOR FLEXIBLE MEDICAL ASSEMBLY,"An elongated support assembly is positionable, at least in part, in sliding relationship with an elongated flexible medical assembly. The elongated support assembly is configured to support, at least in part, the elongated flexible medical assembly after the elongated support assembly is positioned, at least in part, in sliding relationship with the elongated flexible medical assembly. The elongated support assembly is, at least in part, selectively maneuverable via an elongated ancillary medical assembly toward a distal portion of the elongated ancillary medical assembly.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,BALKOVEC CHRISTIAN;;DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/171-811-248-587-432,Patent Application,yes,5,0,9,9,0,A61B2017/00247;;A61B2017/00336;;A61B2017/00867;;A61B2017/00858;;A61B2090/034;;A61B2018/00196;;A61B2018/00285;;A61B2018/00577;;A61B18/1492;;A61B2018/00357;;A61B18/1492;;A61B90/03;;A61B2018/00196;;A61B2017/00247;;A61B2017/00336;;A61B2017/00858;;A61B2017/00867;;A61B2018/00357;;A61B2018/00577;;A61B2090/034;;A61B18/1492;;A61B2018/00357;;A61B2018/1425;;A61M25/0113;;A61M25/0136;;A61M29/02,A61B18/14;;A61B17/00;;A61B18/00;;A61M29/00,,0,0,,,,PENDING
298,US,A1,US 2023/0181244 A1,190-917-326-057-766,2023-06-15,2023,US 202117924212 A,2021-06-01,US 202117924212 A;;US 202063040632 P;;IB 2021054816 W,2020-06-18,SUPPORT ASSEMBLY FOR FLEXIBLE MEDICAL ASSEMBLY,"An elongated support assembly is positionable, at least in part, in sliding relationship with an elongated flexible medical assembly. The elongated support assembly is configured to support, at least in part, the elongated flexible medical assembly after the elongated support assembly is positioned, at least in part, in sliding relationship with the elongated flexible medical assembly. The elongated support assembly is, at least in part, selectively maneuverable via an elongated ancillary medical assembly toward a distal portion of the elongated ancillary medical assembly.",BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DAVIES GARETH;;URBANSKI JOHN PAUL,BAYLIS MEDICAL COMPANY INC (2021-09-13);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/190-917-326-057-766,Patent Application,yes,0,0,9,9,0,A61B2017/00247;;A61B2017/00336;;A61B2017/00867;;A61B2017/00858;;A61B2090/034;;A61B2018/00196;;A61B2018/00285;;A61B2018/00577;;A61B18/1492;;A61B2018/00357;;A61B18/1492;;A61B90/03;;A61B2018/00196;;A61B2017/00247;;A61B2017/00336;;A61B2017/00858;;A61B2017/00867;;A61B2018/00357;;A61B2018/00577;;A61B2090/034;;A61B18/1492;;A61B2018/00357;;A61B2018/1425;;A61M25/0113;;A61M25/0136;;A61M29/02,A61B18/14;;A61M25/01,,0,0,,,,PENDING
299,US,A1,US 2016/0283235 A1,071-889-125-314-471,2016-09-29,2016,US 201615079269 A,2016-03-24,GB 201504979 A,2015-03-24,CONTROLLING DATA FLOW BETWEEN PROCESSORS IN A PROCESSING SYSTEM,"A processing system includes a program processor for executing a program, and a dedicated processor for executing operations of a particular type (e.g. vector processing operations). The program processor uses an interfacing module and a group of two or more register banks to offload operations of the particular type to the dedicated processor for execution thereon. Whilst the dedicated processor is accessing one register bank for executing a current operation, the interfacing module can concurrently load data for a subsequent operation into a different one of the register banks. The use of multiple register banks allows the dedicated processor to spend a greater proportion of its time executing operations.",IMAGINATION TECH LTD,MURRIN PAUL;;DAVIES GARETH;;ANDERSON ADRIAN J,IMAGINATION TECHNOLOGIES LIMITED (2016-03-31);;NORDIC SEMICONDUCTOR ASA (2020-12-31),https://lens.org/071-889-125-314-471,Patent Application,yes,0,2,8,8,0,G06F15/825;;G06F15/167;;G06F15/167;;G06F15/167;;G06F9/30098;;G06F15/76,G06F9/30;;G06F15/76,,0,0,,,,ACTIVE
300,US,A1,US 2015/0374431 A1,066-157-306-249-168,2015-12-31,2015,US 201514850545 A,2015-09-10,US 201514850545 A;;IB 2014059641 W;;US 201361787617 P,2013-03-15,Electrosurgical Device having a distal aperture,"A method and apparatus are disclosed for providing forward fluid delivery through an energy delivery device that avoids coring when it delivers energy to a tissue. The device has a distal face defining an opening, with the distal face including at least one electrically exposed portion and at least one electrically insulated portion. An embodiment of the energy delivery device includes an elongate member defining a lumen structured to receive a fluid, and a distal face defining an aperture in communication with the lumen. The distal face includes an electrically exposed conductive portion and an electrically insulated portion. The electrically exposed conductive portion is configured such that the energy it delivers while the energy delivery device is advanced into a tissue punctures the tissue without the tissue substantially occluding the lumen and without creating embolic particles.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;MIRZA MAHMOOD,BAYLIS MEDICAL COMPANY INC (2015-09-10);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/066-157-306-249-168,Patent Application,yes,22,3,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14,,0,0,,,,ACTIVE
301,EP,A1,EP 3752527 A1,116-851-853-000-427,2020-12-23,2020,EP 19706471 A,2019-02-14,GB 201802486 A;;EP 2019053726 W,2018-02-15,GREMLIN-1 INHIBITOR FOR THE TREATMENT OF A BONE FRACTURE OR BONE DEFECT,,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,,https://lens.org/116-851-853-000-427,Patent Application,yes,0,0,22,22,0,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,C07K16/22;;A61P19/00;;A61P19/10,,0,0,,,,PENDING
302,WO,A1,WO 2002/012971 A1,106-566-336-606-281,2002-02-14,2002,GB 0103000 W,2001-07-04,GB 0019552 A,2000-08-10,DOSING VALVE,"A dosing valve apparatus for introducing a metered dose of a second fluid to a first fluid comprises a first, or main body, portion (1), a second ball valve portion (3) and an end cap (2). The main body (1) and ball valve (3) contain first and second chambers (13, 14), respectively, into which flow the first and second fluids. An orifice jet (8) and needle valve (11) control flow of the second fluid from the second chamber (14) to the first chamber (13). Within the first chamber (13) is a pivotable paddle (7) which is adapted to act upon the needle valve (11). In this way, flow of the first fluid into the first chamber (13) acts upon the paddle (7), which in turn causes the needle valve to at least partially open the orifice (8) allowing the second fluid into the first chamber (13) to mix with the first fluid.",DAVIES DAVID GARETH HAVARD;;NORMAN EDWARD LESSELS,DAVIES DAVID GARETH HAVARD;;NORMAN EDWARD LESSELS,,https://lens.org/106-566-336-606-281,Patent Application,yes,6,0,5,5,0,G05D11/006;;G05D11/006;;Y10T137/2572;;Y10T137/2572,G05D11/00,,0,0,,,,PENDING
303,CN,A,CN 106020776 A,041-138-904-021-007,2016-10-12,2016,CN 201610176658 A,2016-03-24,GB 201505053 A,2015-03-25,SIMD PROCESSING MODULE,"A SIMD processing module is provided, comprising multiple vector processing units (VUs), which can be used to execute an instruction on respective parts (or subvectors) within a vector. A control unit determines a vector position indication for each of the VUs to indicate which part of the vector that VU is to execute the instruction on. Therefore, the vector is conceptually divided into subvectors with the respective VUs executing the instruction on the respective subvectors in parallel. Each VU can then execute the instruction as intended, but only on a subsection of the whole vector. This allows an instruction that is written for execution on an n-way VU to be executed by multiple n-way VUs, each starting at different points of the vector, such that the instruction can be executed on more than n of the data items of the vector in parallel.",IMAGINATION TECH LTD,MURRIN PAUL;;DAVIES GARETH;;ANDERSON ADRIAN J,,https://lens.org/041-138-904-021-007,Patent Application,no,8,0,9,9,0,G06F9/3887;;G06F9/30036;;G06F9/3887;;G06F9/3012;;G06F9/381;;G06F15/8007;;G06F9/3887;;G06F15/8007;;G06F9/30036;;G06F9/3887;;G06F9/381;;G06F9/3012;;G06F15/8007,G06F9/38,,0,0,,,,ACTIVE
304,US,S,US D0505446 S,102-198-418-674-630,2005-05-24,2005,US 20429304 F,2004-04-28,EP 00140918 F,2004-02-24,Guillotine for cutting paper,,TONIC STUDIOS LTD,DAVIES GARETH WILLIAM HUMPHREY;;BATHARD SIMON DAVID,TONIC STUDIOS LIMITED (2004-07-19),https://lens.org/102-198-418-674-630,Design Right,no,0,2,2,2,0,,,1804;;D18/34,0,0,,,,EXPIRED
305,CL,A1,CL 2021002176 A1,123-689-534-876-641,2022-04-22,2022,CL 2021002176 A,2021-08-17,GB 201802486 A,2018-02-15,Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos (divisional de la solicitud n° 202002040),La presente invención se refiere a métodos para el tratamiento de una fractura o defecto óseos. La invención revela el uso efectivo de un anticuerpo antigremlina-1 para acelerar la cicatrización y la formación de un puente de un tejido óseo en la brecha de los defectos segmentarios óseos; y demuestra que los inhibidores de la actividad de la gremlina-1 pueden proporcionar terapias mejoradas para tratar o prevenir la no unión de fracturas.,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,,https://lens.org/123-689-534-876-641,Patent Application,no,0,0,22,22,0,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,A61P19/00;;A61P19/10;;C07K16/22,,0,0,,,,PENDING
306,EP,A4,EP 3399900 A4,160-858-703-465-541,2019-10-16,2019,EP 17735911 A,2017-01-06,US 201662275907 P;;IB 2017050065 W,2016-01-07,HYBRID TRANSSEPTAL DILATOR AND METHODS OF USING THE SAME,,BAYLIS MEDICAL CO INC,THOMPSON SMITH MELANIE;;DAVIES GARETH;;LEUNG LINUS,BAYLIS MEDICAL COMPANY INC. (2022-07-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-05),https://lens.org/160-858-703-465-541,Search Report,no,6,0,10,10,0,A61B17/3478;;A61M25/06;;A61B2017/00247;;A61B2017/22038;;A61B2017/22042;;A61B2017/22047;;A61B2090/033;;A61B2090/062;;A61B2090/0807;;A61M29/00;;A61B2017/22038;;A61B2017/22047;;A61B17/3478;;A61B2017/00247;;A61B2017/22042;;A61M25/06;;A61B2090/062;;A61B2090/0807;;A61B2090/033;;A61M29/00;;A61B17/3415;;A61B18/1477;;A61B2018/00351;;A61B2018/1425;;A61M25/09;;A61M2205/32;;A61M2205/582,A61B1/00,,0,0,,,,PENDING
307,US,A1,US 2016/0283439 A1,157-323-673-491-562,2016-09-29,2016,US 201615081007 A,2016-03-25,GB 201505053 A,2015-03-25,SIMD PROCESSING MODULE HAVING MULTIPLE VECTOR PROCESSING UNITS,"A SIMD processing module is provided, comprising multiple vector processing units (“VUs”), which can be used to execute an instruction on respective parts (or “subvectors”) within a vector. A control unit determines a vector position indication for each of the VUs to indicate which part of the vector that VU is to execute the instruction on. Therefore, the vector is conceptually divided into subvectors with the respective VUs executing the instruction on the respective subvectors in parallel. Each VU can then execute the instruction as intended, but only on a subsection of the whole vector. This allows an instruction that is written for execution on an n-way VU to be executed by multiple n-way VUs, each starting at different points of the vector, such that the instruction can be executed on more than n of the data items of the vector in parallel.",IMAGINATION TECH LTD,MURRIN PAUL;;DAVIES GARETH;;ANDERSON ADRIAN J,IMAGINATION TECHNOLOGIES LIMITED (2016-03-31);;NORDIC SEMICONDUCTOR ASA (2020-12-31),https://lens.org/157-323-673-491-562,Patent Application,yes,15,2,9,9,0,G06F9/3887;;G06F9/30036;;G06F9/3887;;G06F9/3012;;G06F9/381;;G06F15/8007;;G06F9/3887;;G06F15/8007;;G06F9/30036;;G06F9/3887;;G06F9/381;;G06F9/3012;;G06F15/8007,G06F15/80;;G06F9/30,,0,0,,,,DISCONTINUED
308,CA,A1,CA 3173132 A1,153-056-787-169-652,2021-10-14,2021,CA 3173132 A,2021-04-06,US 202063007662 P;;IB 2021052851 W,2020-04-09,CATHETER AND PERFORATION SYSTEM INCLUDING CATHETER,"A catheter includes an elongate shaft extending longitudinally between a proximal portion defining a proximal end and a distal portion defining a distal end. A lumen extends through the shaft from the proximal end to the distal end. The shaft includes a heat-shielding layer and an outer layer adjacent the heat-shielding layer. The heat-shielding layer includes an inner liner layer adjacent the lumen and a heat-shielding layer adjacent the inner liner layer. In the distal portion, at least a section of the outer layer is radiopaque.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LUK MARIA;;DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/153-056-787-169-652,Patent Application,no,0,0,5,5,0,A61M25/0108;;A61B2090/3966;;A61B18/1492;;A61B2018/00351;;A61B2018/00601;;A61B2018/00089;;A61B2090/3966;;A61B18/1492;;A61B2018/00101;;A61B2018/00357;;A61B2018/00601;;A61L29/085;;A61L29/126;;A61L29/14;;A61M25/0045;;A61M25/0108,A61M25/00;;A61M25/01,,0,0,,,,PENDING
309,WO,A1,WO 2019/158658 A1,143-386-389-955-737,2019-08-22,2019,EP 2019053726 W,2019-02-14,GB 201802486 A,2018-02-15,GREMLIN-1 INHIBITOR FOR THE TREATMENT OF A BONE FRACTURE OR BONE DEFECT,The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.,UCB BIOPHARMA SPRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,,https://lens.org/143-386-389-955-737,Patent Application,yes,4,4,22,22,35,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,C07K16/22;;A61P19/00;;A61P19/10,,4,4,080-784-865-336-364;;060-126-066-099-876;;098-322-700-973-135;;071-630-416-006-425,10.1016/j.actbio.2012.06.036;;22750247;;15539560;;10.1210/en.2004-0766;;10.1007/s11999-009-0981-9;;pmc2772945;;19597895;;20298438;;pmc2871998;;10.1111/j.1469-7580.2010.01214.x,"SEBALD H -J ET AL: ""Inhibition of endogenous antagonists with an engineered BMP-2 variant increases BMP-2 efficacy in rat femoral defect healing"", ACTA BIOMATERIALIA ELSEVIER SCIENCE LTD. UK, vol. 8, no. 10, October 2012 (2012-10-01), pages 3816 - 3820, XP002790675, ISSN: 1742-7061;;ELISABETTA GAZZERRO ET AL: ""Skeletal Overexpression of Gremlin Impairs Bone Formation and Causes Osteopenia"", ENDOCRINOLOGY, vol. 146, no. 2, 1 February 2005 (2005-02-01), US, pages 655 - 665, XP055576723, ISSN: 0013-7227, DOI: 10.1210/en.2004-0766;;MARC FAJARDO ET AL: ""Levels of Expression for BMP-7 and Several BMP Antagonists May Play an Integral Role in a Fracture Nonunion: A Pilot Study"", CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, vol. 467, no. 12, 14 July 2009 (2009-07-14), US, pages 3071 - 3078, XP055576712, ISSN: 0009-921X, DOI: 10.1007/s11999-009-0981-9;;DANIEL B. DEAN ET AL: ""Distinct functionalities of bone morphogenetic protein antagonists during fracture healing in mice"", JOURNAL OF ANATOMY., vol. 216, no. 5, 1 May 2010 (2010-05-01), GB, pages 625 - 630, XP055576692, ISSN: 0021-8782, DOI: 10.1111/j.1469-7580.2010.01214.x",PENDING
310,US,A1,US 2023/0174635 A1,170-081-579-389-993,2023-06-08,2023,US 202218062608 A,2022-12-07,US 202218062608 A;;GB 201802486 A;;US 202016970391 A;;EP 2019053726 W,2018-02-15,GREMLIN-1 INHIBITOR FOR THE TREATMENT OF A BONE FRACTURE OR BONE DEFECT,The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,CELLTECH R&D LIMITED (2019-02-12);;UCB BIOPHARMA SRL (2019-02-12),https://lens.org/170-081-579-389-993,Patent Application,yes,0,0,22,22,0,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,C07K16/22;;A61K39/395;;A61P19/08,,0,0,,,,PENDING
311,EP,A3,EP 2295210 A3,028-359-021-420-82X,2011-06-01,2011,EP 10153313 A,2010-02-11,GB 0914830 A,2009-08-26,Drive mechanism for a hole punch,"A drive mechanism for a hole punch is disclosed. The mechanism comprises a frame and a lever comprising a first end and a second end. The lever is pivotally coupled to the frame at a pivot point disposed intermediate the first and second end thereof. The frame comprises a lever engaging portion for engaging with a frame engaging portion disposed at the second end of the lever, such that as the first end of lever is pivoted about the pivot point, the frame engaging portion is arranged to move along the lever engaging portion to cause the pivot point to move with respect to the frame.
",TONIC STUDIOS LTD,DAVIES GARETH;;BATHARD SIMON;;RILEY GRANT E,,https://lens.org/028-359-021-420-82X,Search Report,yes,4,0,5,5,0,B26D5/10;;B26F1/36;;B26F1/36;;B26D5/10;;B26D5/10;;Y10T83/885;;Y10T83/885,B26F1/36;;B26D5/10,,0,0,,,,DISCONTINUED
312,US,B2,US 10387155 B2,035-712-095-506-982,2019-08-20,2019,US 201615079269 A,2016-03-24,GB 201504979 A,2015-03-24,Controlling register bank access between program and dedicated processors in a processing system,"A processing system includes a program processor for executing a program, and a dedicated processor for executing operations of a particular type (e.g. vector processing operations). The program processor uses an interfacing module and a group of two or more register banks to offload operations of the particular type to the dedicated processor for execution thereon. While the dedicated processor is accessing one register bank for executing a current operation, the interfacing module can concurrently load data for a subsequent operation into a different one of the register banks. The use of multiple register banks allows the dedicated processor to spend a greater proportion of its time executing operations.",IMAGINATION TECH LTD,MURRIN PAUL;;DAVIES GARETH;;ANDERSON ADRIAN J,IMAGINATION TECHNOLOGIES LIMITED (2016-03-31);;NORDIC SEMICONDUCTOR ASA (2020-12-31),https://lens.org/035-712-095-506-982,Granted Patent,yes,15,0,8,8,0,G06F15/825;;G06F15/167;;G06F15/167;;G06F15/167;;G06F9/30098;;G06F15/76,G06F9/30;;G06F15/167;;G06F15/76,,0,0,,,,ACTIVE
313,KR,A,KR 20230026320 A,102-548-413-791-907,2023-02-24,2023,KR 20227043454 A,2021-06-01,US 202063040632 P;;IB 2021054816 W,2020-06-18,가요성 의료 조립체를 위한 지지 조립체,"세장형 지지 조립체는 세장형 가요성 의료 조립체와 활주 관계로 적어도 부분적으로 위치가능하다. 세장형 지지 조립체는, 세장형 지지 조립체가 세장형 가요성 의료 조립체와 활주 관계로 적어도 부분적으로 위치된 후에, 세장형 가요성 의료 조립체를 적어도 부분적으로 지지하도록 구성된다. 세장형 지지 조립체는 세장형 보조 의료 조립체의 원위 부분을 향하여 세장형 보조 의료 조립체를 통해 적어도 부분적으로 선택적으로 조종가능하다.",BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/102-548-413-791-907,Patent Application,no,0,0,9,9,0,A61B2017/00247;;A61B2017/00336;;A61B2017/00867;;A61B2017/00858;;A61B2090/034;;A61B2018/00196;;A61B2018/00285;;A61B2018/00577;;A61B18/1492;;A61B2018/00357;;A61B18/1492;;A61B90/03;;A61B2018/00196;;A61B2017/00247;;A61B2017/00336;;A61B2017/00858;;A61B2017/00867;;A61B2018/00357;;A61B2018/00577;;A61B2090/034;;A61B18/1492;;A61B2018/00357;;A61B2018/1425;;A61M25/0113;;A61M25/0136;;A61M29/02,A61B18/14;;A61B17/00;;A61B18/00;;A61B90/00,,0,0,,,,PENDING
314,US,S,US D0504908 S,119-784-316-883-529,2005-05-10,2005,US 20429204 F,2004-04-28,EP 00140918 F,2004-02-24,Guillotine for cutting paper,,TONIC STUDIOS LTD,DAVIES GARETH WILLIAM HUMPHREY;;BATHARD SIMON DAVID,TONIC STUDIOS LIMITED (2004-07-19),https://lens.org/119-784-316-883-529,Design Right,no,0,3,2,2,0,,,1804;;D18/34,0,0,,,,EXPIRED
315,US,S,US D0528590 S,147-258-472-283-029,2006-09-19,2006,US 22537505 F,2005-03-16,US 22537505 F,2005-03-16,Swing out guillotine,,TONIC STUDIOS LTD,BATHARD SIMON DAVID;;DAVIES GARETH WILLIAMS HUMPHRE,TONIC STUDIOS LIMITED (2005-02-28),https://lens.org/147-258-472-283-029,Design Right,no,0,7,1,1,0,,,1804;;D18/34.8,0,0,,,,EXPIRED
316,US,A1,US 2021/0107973 A1,151-419-081-196-154,2021-04-15,2021,US 201916970391 A,2019-02-14,GB 201802486 A;;EP 2019053726 W,2018-02-15,GREMLIN-1 INHIBITOR FOR THE TREATMENT OF A BONE FRACTURE OR BONE DEFECT,The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,CELLTECH R&D LIMITED (2019-02-12);;UCB BIOPHARMA SRL (2019-02-12),https://lens.org/151-419-081-196-154,Patent Application,yes,0,1,22,22,35,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,C07K16/22;;A61P19/08,,0,0,,,,ACTIVE
317,CA,A1,CA 3090404 A1,154-722-919-185-32X,2019-08-22,2019,CA 3090404 A,2019-02-14,GB 201802486 A;;EP 2019053726 W,2018-02-15,GREMLIN-1 INHIBITOR FOR THE TREATMENT OF A BONE FRACTURE OR BONE DEFECT,The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.,UCB BIOPHARMA SPRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,,https://lens.org/154-722-919-185-32X,Patent Application,no,0,0,22,22,35,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,C07K16/22;;A61P19/00;;A61P19/10,,0,0,,,,PENDING
318,WO,A1,WO 2021/205342 A1,177-549-228-015-522,2021-10-14,2021,IB 2021052851 W,2021-04-06,US 202063007662 P,2020-04-09,CATHETER AND PERFORATION SYSTEM INCLUDING CATHETER,"A catheter includes an elongate shaft extending longitudinally between a proximal portion defining a proximal end and a distal portion defining a distal end. A lumen extends through the shaft from the proximal end to the distal end. The shaft includes a heat-shielding layer and an outer layer adjacent the heat-shielding layer. The heat-shielding layer includes an inner liner layer adjacent the lumen and a heat-shielding layer adjacent the inner liner layer. In the distal portion, at least a section of the outer layer is radiopaque.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,LUK MARIA;;DAVIES GARETH;;URBANSKI JOHN PAUL,,https://lens.org/177-549-228-015-522,Patent Application,yes,7,0,5,5,0,A61M25/0108;;A61B2090/3966;;A61B18/1492;;A61B2018/00351;;A61B2018/00601;;A61B2018/00089;;A61B2090/3966;;A61B18/1492;;A61B2018/00101;;A61B2018/00357;;A61B2018/00601;;A61L29/085;;A61L29/126;;A61L29/14;;A61M25/0045;;A61M25/0108,A61M25/00;;A61M25/01,,0,0,,,,PENDING
319,US,S,US D0529538 S,199-036-695-238-172,2006-10-03,2006,US 22537605 F,2005-03-16,US 22537605 F,2005-03-16,Guillotine with ruler extension,,TONIC STUDIOS LTD,BATHARD SIMON DAVID;;DAVIES GARETH WILLIAMS HUMPHRE,TONIC STUDIOS LIMITED (2005-02-28),https://lens.org/199-036-695-238-172,Design Right,no,0,1,1,1,0,,,1804;;D18/34.7,0,0,,,,EXPIRED
320,US,S,US D0530169 S,102-543-171-800-328,2006-10-17,2006,US 22153805 F,2005-01-19,US 22153805 F,2005-01-19,Soft handled scissors,,TONIC STUDIOS LTD,DAVIES GARETH WILLIAM HUMPHREY;;BATHARD SIMON DAVID,TONIC STUDIOS LIMITED (2005-01-10),https://lens.org/102-543-171-800-328,Design Right,no,0,1,1,1,0,,,0803;;D 8 57,0,0,,,,EXPIRED
321,US,S,US D0530170 S,111-366-424-272-087,2006-10-17,2006,US 22154005 F,2005-01-19,US 22154005 F,2005-01-19,Children's scissors,,TONIC STUDIOS LTD,DAVIES GARETH WILLIAMS HUMPHRE;;BARHARD SIMON DAVID,TONIC STUDIOS LIMITED (2005-01-10),https://lens.org/111-366-424-272-087,Design Right,no,0,1,1,1,0,,,0803;;D 8 57,0,0,,,,EXPIRED
322,EP,A1,EP 3358692 A1,032-595-428-116-108,2018-08-08,2018,EP 18154814 A,2018-02-02,GB 201701835 A,2017-02-03,POWER PLUG,"A power plug for coupling an electrical appliance to an electrical power supply, comprising: a current sensor, configured to measure current supplied through the plug to the electrical appliance; a voltage sensor, configured to measure voltage supplied through the plug to the electrical appliance; a processor configured to: determine power consumption data from data relating to the current and voltage measurements made by the current and voltage sensors; and monitor the performance of the electrical appliance using the power consumption data; and a transmitter, configured to transmit information relating to the performance of the electrical appliance.
",GREEN RUNNING LTD,DAVIES PETER GARETH;;SPITERI CONRAD;;WILLOUGHBY STEVE,,https://lens.org/032-595-428-116-108,Patent Application,yes,4,3,9,9,0,H01R13/665;;H01R13/6683;;H01R13/6691;;H02J13/0005;;H02J13/00002;;G01D4/002;;H01R13/6658;;Y02B70/3225;;Y04S20/222;;G01R21/133;;H01R13/6683;;H02J2310/70;;H02J2310/14;;H02J13/00004;;H02J13/0005;;H02J3/14;;H02J13/00002;;H01R13/665;;H01R13/6683;;H01R13/6691;;H01R13/70;;H01R13/717;;H02J13/00002;;H02J13/0005;;H02J3/14;;G01D4/002;;H01R13/6658;;Y04S20/222;;Y04S20/242;;Y02B70/3225;;G01R21/133;;Y02B70/30;;Y02B90/20;;Y04S20/00;;Y04S20/30;;H02J3/00;;H02J13/00002;;H02J13/00004;;H02J13/0005;;H01R13/6683;;G05B15/02;;H01R13/6691;;H01R13/70;;H01R13/7175;;H01R24/28;;H01R2103/00;;H04L12/10,H02J3/14;;G01D4/00;;G01R21/00;;H01R13/00;;H02J13/00,,0,0,,,,PENDING
323,US,B2,US 11524997 B2,047-288-034-270-094,2022-12-13,2022,US 201916970391 A,2019-02-14,GB 201802486 A;;EP 2019053726 W,2018-02-15,Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect,The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,CELLTECH R&D LIMITED (2019-02-12);;UCB BIOPHARMA SRL (2019-02-12),https://lens.org/047-288-034-270-094,Granted Patent,yes,71,1,22,22,35,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,A61K39/395;;A61P19/08;;C07K16/22,,167,151,112-504-073-213-534;;049-928-993-608-092;;127-732-134-407-287;;080-784-865-336-364;;060-126-066-099-876;;098-322-700-973-135;;071-630-416-006-425;;027-840-251-594-854;;148-647-852-252-502;;056-201-471-905-934;;080-856-085-597-555;;181-448-152-035-827;;033-401-440-963-789;;011-553-054-044-973;;098-724-633-703-400;;087-448-981-335-707;;076-897-757-672-092;;043-729-032-107-483;;041-863-374-864-841;;035-081-115-342-527;;012-007-448-024-359;;008-583-847-621-717;;041-701-093-712-495;;001-646-542-312-05X;;148-750-828-583-42X;;095-834-903-970-444;;000-769-593-092-070;;008-061-699-775-635;;067-024-105-019-398;;010-735-642-089-466;;053-699-924-523-691;;013-703-966-633-758;;097-901-796-209-229;;029-486-847-477-02X;;070-238-365-351-890;;066-141-497-990-023;;111-604-378-852-726;;075-789-057-546-584;;056-289-795-899-023;;082-151-267-963-934;;081-004-119-263-171;;060-522-017-672-204;;008-017-695-084-433;;051-036-594-306-992;;077-587-097-220-826;;076-252-023-764-678;;060-918-425-739-173;;008-693-687-336-286;;030-797-864-869-467;;006-574-942-364-256;;023-907-179-348-058;;018-280-468-055-668;;063-266-551-840-350;;046-951-095-213-650;;037-436-870-995-452;;038-728-499-086-588;;077-532-829-551-519;;023-860-693-372-071;;018-199-486-626-091;;002-880-498-827-946;;020-398-976-665-441;;034-499-526-956-496;;040-842-346-948-061;;113-446-080-346-814;;047-308-646-101-537;;029-970-218-339-139;;092-175-386-389-524;;019-779-601-634-917;;064-667-501-146-970;;055-542-669-483-094;;088-935-349-526-045;;013-337-877-638-381;;106-753-778-592-300;;024-205-497-164-000;;020-026-345-586-213;;057-051-348-154-974;;037-310-319-433-702;;028-671-261-063-506;;026-361-471-680-127;;083-861-682-427-488;;001-062-843-030-532;;040-363-636-264-022;;016-392-744-492-623;;082-522-923-505-342;;050-133-270-638-85X;;095-576-636-997-853;;064-781-969-527-647;;042-222-591-554-811;;061-154-078-727-141;;028-188-258-692-969;;072-971-856-375-322;;099-142-413-754-43X;;064-741-687-897-846;;028-716-741-713-711;;007-711-535-660-589;;010-655-350-435-62X;;054-899-454-772-257;;042-204-626-457-327;;012-113-132-303-756;;026-553-044-527-677;;034-489-784-615-708;;036-648-857-259-985;;053-688-298-868-719;;017-537-377-374-676;;044-958-492-431-511;;044-380-745-789-522;;001-135-333-260-455;;101-640-792-825-42X;;015-238-057-914-589;;017-186-900-863-545;;067-290-214-184-650;;042-623-879-457-954;;051-322-618-006-677;;025-662-361-226-516;;065-274-506-678-30X;;012-265-598-126-264;;016-507-178-023-87X;;021-221-160-658-727;;020-469-639-093-468;;038-014-138-403-715;;006-335-336-242-955;;027-348-187-303-025;;083-455-473-700-78X;;051-782-236-917-368;;020-290-815-800-919;;012-276-537-847-635;;013-047-685-206-757;;085-551-195-221-254;;010-638-827-530-479;;015-637-470-440-119;;029-618-245-313-265;;039-435-352-120-718;;098-133-538-052-633;;029-090-460-937-086;;109-846-005-988-815;;049-744-251-457-065;;047-464-834-398-90X;;052-497-936-393-263;;049-595-479-088-060;;026-297-055-190-870;;021-868-921-062-221;;027-477-313-726-928;;020-367-308-901-689;;046-845-561-202-870;;062-761-744-997-508;;075-555-351-927-589;;013-332-497-462-190;;023-512-772-502-769;;121-507-867-661-339;;051-621-009-816-906;;139-263-323-698-622,32572171;;pmc7493948;;10.1038/s41416-020-0945-0;;10656818;;10.1006/jmbi.1999.3444;;20098328;;10.1097/gim.0b013e3181cd68ed;;10.1016/j.actbio.2012.06.036;;22750247;;15539560;;10.1210/en.2004-0766;;10.1007/s11999-009-0981-9;;pmc2772945;;19597895;;20298438;;pmc2871998;;10.1111/j.1469-7580.2010.01214.x;;10.3892/mmr.2017.6253;;pmc5364878;;28260028;;10.2174/1567269053828800;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1007/bf00160485;;8483166;;7658022;;10.1016/0022-1759(95)00086-p;;8417368;;10.1016/0161-5890(93)90432-b;;10.1002/mc.22378;;26293751;;10.1182/blood-2011-09-380410;;pmc3382938;;22394600;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1016/j.jacc.2009.04.011;;19555859;;18751803;;10.1007/s11420-005-0111-5;;pmc2504134;;10.1016/0022-1759(95)00016-4;;7769243;;10.1016/s0065-2776(08)60674-4;;7872158;;pmc5119705;;10.11138/ccmbm/2016.13.2.101;;27920804;;22247494;;10.1161/circulationaha.111.038125;;25706628;;10.1038/ng.3225;;pmc3132213;;10.1002/jcp.22730;;21412775;;10.1107/s0907444909042073;;20057044;;10.1107/97809553602060000884;;pmc2803126;;10.1007/s00535-012-0614-z;;22706573;;10.1038/cddis.2017.533;;pmc5775406;;29095438;;25637218;;10.1016/j.yexcr.2015.01.006;;pmc3398763;;22451422;;10.1182/blood-2012-02-412783;;10.1164/rccm.201206-1028oc;;23087024;;24160323;;10.1016/j.ajpath.2013.07.017;;pmc5691347;;22182508;;10.1016/j.cellsig.2011.12.008;;10029599;;10.1182/blood.v93.5.1697;;10.1182/blood.v93.5.1697.405a17_1697_1706;;pmc5093055;;27118403;;10.1038/leu.2016.96;;25419707;;10.1038/nm.3750;;pmc4594755;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;19335218;;10.1359/jbmr.090210;;10511457;;10.1016/s0163-7258(99)00018-2;;25266456;;pmc4464690;;10.1038/nrrheum.2014.164;;20383002;;pmc2852313;;10.1107/s0907444910007493;;10.1056/nejmra035488;;15483284;;10495271;;10.1016/s0925-4773(99)00142-2;;pmc3775476;;22374979;;10.1158/0008-5472.can-11-2067;;10.1385/1-59259-890-0:571;;17785465;;10.1074/jbc.m701317200;;10.1182/blood-2012-01-379024;;pmc3390959;;22535658;;10.1097/00003086-199706000-00011;;9186204;;27862197;;10.1111/1440-1681.12697;;10.1016/0021-9673(94)01255-d;;7620566;;10.1201/b14193-19;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1016/j.neo.2017.09.004;;pmc5678743;;29091798;;10.1038/nrc2189;;17646864;;11154231;;10.1182/blood.v97.2.516;;10.1110/ps.9.3.487;;pmc2144561;;10752610;;10.1038/leu.2011.263;;21941367;;10.1038/nbt1142;;16151406;;10.1126/science.280.5366.1086;;9582123;;09582123;;10.1038/88919;;11381269;;10.1016/s1097-2765(00)80067-2;;9660951;;28299802;;10.1002/path.4891;;pmc5488238;;25706627;;10.1038/ng.3224;;22561515;;pmc4594751;;10.1038/ng.2263;;2406013;;20124692;;pmc2815665;;10.1107/s0907444909047337;;23659962;;pmc5528431;;10.1016/j.molonc.2013.04.002;;25153376;;10.1515/hsz-2014-0221;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;15848072;;10.1016/j.ymeth.2005.01.003;;10.1002/eji.1830240426;;8149964;;10.1371/journal.pone.0035100;;22514712;;pmc3325980;;10.1371/journal.pone.0174565;;pmc5367809;;28346486;;1172191;;10.1038/256495a0;;25834571;;pmc4365323;;10.1155/2015/834137;;25291284;;10.1016/0167-5699(83)90123-8;;10.1016/j.molimm.2006.03.020;;16697465;;15509819;;10.1056/nejmra041875;;pmc3693206;;23826422;;10.1002/path.4537;;25810250;;26632274;;10.1038/ncomms9983;;pmc4686867;;10.1016/j.celrep.2014.07.020;;pmc4471812;;25131200;;19461840;;pmc2483472;;10.1107/s0021889807021206;;20660291;;10.1182/blood-2010-06-291930;;22870311;;pmc3411619;;10.1371/journal.pone.0042264;;pmc3069751;;10.1107/s0907444911001314;;21460454;;10.1186/1471-2407-6-74;;16545136;;pmc1459871;;10.1038/nprot.2007.279;;17703211;;10.1016/j.str.2013.06.005;;pmc3749838;;23850456;;pmc4335214;;25561725;;10.1074/jbc.m114.628412;;pmc4007935;;10.3324/haematol.2013.090977;;23935020;;25117979;;pmc4198825;;10.1016/j.neo.2014.07.002;;pmc4595141;;10.1186/s13045-015-0209-2;;26445238;;10.1016/s0378-1119(96)00627-0;;10.1016/j.stem.2015.02.015;;pmc4355577;;25748930;;15014901;;10.1007/s00259-003-1441-5;;10.1385/1-59259-666-5:443;;14970513;;15608286;;10.1093/nar/gki088;;pmc540042;;3127726;;10.1038/332323a0;;10.1038/nature07935;;19329995;;10.1089/ten.tec.2013.0612;;24738624;;pmc2688661;;10.1002/dvdy.21882;;19235733;;10.1053/j.gastro.2008.01.079;;18325394;;10.1038/s41586-018-0084-4;;pmc5966331;;29720649;;10.1016/j.jacc.2009.04.012;;19555858;;10.1073/pnas.0606857103;;17003113;;pmc1578503;;pmc3759128;;23978876;;10.1038/oncsis.2013.29;;10.2353/ajpath.2009.080565;;pmc2630548;;19116361;;7042536;;10.1111/j.1600-065x.1982.tb00392.x;;21655089;;pmc3107194;;10.1371/journal.pgen.1002105;;pmc232332;;10.1128/mcb.17.8.4801;;9234736;;10.1007/s10585-007-9108-4;;17952614;;9624683;;10.1038/nbt0698-535;;18594511;;10.1038/nature07085;;pmc2840222;;10.1016/s0022-1759(98)00077-5;;9760222;;10.3892/or.2011.1463;;21935575;;25594183;;10.1016/j.cell.2014.11.042;;pmc4436082;;10.1007/s13277-015-4093-8;;26392110;;10.1016/j.bone.2009.11.005;;19913648;;10.1016/j.tcb.2010.01.008;;20188563;;28223433;;10.1158/1055-9965.epi-16-0858;;10.1080/14737159.2018.1439382;;29424261;;10556075;;10.1242/dev.126.23.5515;;16707453;;10.1158/0008-5472.can-05-4610;;10.1038/s41467-018-05366-3;;pmc6065368;;30061695;;27651036;;10.2217/fon-2016-0261;;pmc3492335;;10.1371/journal.pone.0048262;;23144859;;10633215;;10.1530/eje.0.1420009;;10.4172/1948-5956.1000554;;28109670;;10.1016/j.cytogfr.2017.01.002;;25209345;;10.1007/s00264-014-2512-x;;pmc5491097;;10.1016/j.semcancer.2017.03.009;;28408152;;10.18632/oncotarget.9286;;pmc5085234;;27174917;;25108577;;10.1016/j.eururo.2014.07.020;;10.1158/1078-0432.ccr-07-1036;;17975152;;10.1093/annonc/mdu260;;25190710;;pmc3400017;;22692129;;10.1038/emboj.2012.166;;pmc2289373;;1541640;;10.1083/jcb.116.6.1517;;9311916;;10.1126/science.278.5335.120;;10.1002/gene.20042;;15282745;;10.1111/j.1365-2184.2006.00391.x;;16987142;;pmc6495875;;21889923;;10.1053/j.gastro.2011.07.050;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;1961196;;10.1016/0161-5890(91)90003-3;;10.1016/j.intimp.2004.01.010;;15120653;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;10.1126/science.2426778;;2426778;;26530461;;10.3892/or.2015.4367;;10.1182/blood.v82.12.3712.bloodjournal82123712;;8260708;;10.1182/blood.v82.12.3712.3712;;20042676;;10.2353/ajpath.2010.090442;;pmc2808066;;30272371;;pmc6203161;;10.3892/ijo.2018.4573;;10.3390/cancers12082149;;32756430;;pmc7464474,"Park et al., Br. J. Cancer, 2020, vol. 123(6):988-999.;;Knappik et al., J. Mol. Biol., 2000, vol. 296(1):57-86.;;Dabrowski et al., Int. J. Mol. Sci., 2021, vol. 22(8):4255.;;Cao et al., Genet. Med., 2010, vol. 12(2): 61-76.;;Sebald, H.-J. et al. “Inhibition of endogenous antagonists with an engineered BMP-2 variant increases BMP-2 efficacy in rat femoral defect healing” Acta Biomaterialia, Oct. 10, 2012, pp. 3816-3820, vol. 8, No. 10.;;Gazzerro, E. et al. “Skeletal Overexpression of Gremlin Impairs Bone Formation and Causes Osteopenia” Endocrinology, Feb. 1, 2005, pp. 655-665, vol. 146, No. 2.;;Fajardo, M. et al. “Levels of Expression for BMP-7 and Several BMP Antagonists May Play an Integral Role in a Fracture Nonunion: A Pilot Study” Clinical Orthopaedics and Related Research, Jul. 14, 2009, pp. 3071-3078, vol. 467, No. 12.;;Dean, D. B. et al. “Distinct functionalities of bone morphogenetic protein antagonists during fracture healing in mice” Journal of Anatomy, 2020, pp. 625-630, vol. 216, No. 5.;;International Search Report and Written Opinion in International Application No. PCT/EP2019/053726, dated May 17, 2019, pp. 1-19.;;Hu, K. et al. “Gremlin-1 suppression increases BMP-2-induced osteogenesis of human mesenchymal stem cells” Molecular Medicine Reports, 2017, pp. 2186-2194, vol. 15.;;Adair, J. R. et al. “Therapeutic Antibodies” Drug Design Reviews, 2005, pp. 1-11.;;Altschul, S.F. et al. “Basic Local Alignment Search Tool” J Mol Biol., 1990, pp. 403-410, vol. 215.;;Altschul, S.F. “A Protein Alignment Scoring System Sensitive at All Evolutionary Distances” J Mol Evol., 1993, pp. 290-300, vol. 36.;;Ames, R. S. et al. “Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins” Journal of Immunological Methods, 1995, pp. 177-186, vol. 184.;;Angal, S. et al. “A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody” Molecular Immunology, 1993, pp. 105-108, vol. 30, No. 1.;;Attar-Schneider, O. et al. “Multiple Myeloma and Bone Marrow Mesenchymal Stem Cells' Crosstalk: Effect on Translation Initiation” Molecular Carcinogenesis, 2016, pp. 1343-1354, vol. 55.;;Azab, A. K. et al. “Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features” Blood, Jun. 14, 2012, pp. 5782-5794, vol. 119, No. 24.;;Babcook, J. et al. “A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities” Proc. Natl. Acad. Sci. USA, Jul. 1996, pp. 7843-7848, vol. 93, No. 15.;;Badesch, D. B. et al. “Diagnosis and Assessment of Pulmonary Arterial Hypertension” J Am Coll Cardiol., Jun. 30, 2009, pp. S55-S66, vol. 54, No. 1, Suppl. S.;;Bostrom, M. P. G. et al. “The Clinical Use of Allografts, Demineralized Bone Matrices, Synthetic Bone Graft Substitutes and Osteoinductive Growth Factors: A Survey Study” HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery, 2005, pp. 9-18, vol. 1.;;Brinkmann, U. et al. “Phage display of disulfide-stabilized Fv fragments” Journal of Immunological Methods, 1995, pp. 41-50, vol. 182.;;Budd, D. C. et al. “Targeting TGFβ superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders” Pharmacology & Therapeutics, 2012, pp. 279-291, vol. 135.;;Burton, D. R. et al. “Human Antibodies from Combinatorial Libraries” Advances in Immunology, 1994, pp. 191-280, vol. 57.;;Buza, J. A. et al. “Bone healing in 2016” Clinical Cases in Mineral and Bone Metabolism, 2016, pp. 101-105, vol. 13, No. 2.;;Cahill, E. et al. “Gremlin Plays a Key Role in the Pathogenesis of Pulmonary Hypertension” Circulation, Feb. 21, 2012, pp. 920-930, vol. 125, No. 7.;;Calon, A. et al. “Stromal gene expression defines poor-prognosis subtypes in colorectal cancer” Nat Genet., Apr. 2015, pp. 320-329, vol. 47, No. 4, Online Methods, pp. 1-3.;;Canalis, E. et al. “Gremlin1 is Required for Skeletal Development and Postnatal Skeletal Homeostasis” J. Cell Physiol., 2012, pp. 269-277, vol. 227.;;Chen, V. B. et al. “MolProbity: all-atom structure validation for macromolecular crystallography” Acta Crystallographica Section D, 2010, pp. 12-21, D66.;;Chen, M.-H. et al. “Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors” J Gastroenterol, 2013, pp. 101-108, vol. 48.;;Chen, J. et al. “BAFF is involved in macrophage-induced bortezomib resistance in myeloma” Cell Death Dis, 2017, pp. 1-12, vol. 8, No. 11, e3161.;;Cheong, C. M. et al. “Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo” Exp Cell Res, 2015, pp. 24-38, vol. 332.;;Chesi, M. et al. “Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy” Blood, Jul. 12, 2012, pp. 376-385, vol. 120, No. 2.;;Cho, T.-J. et al. “Differential Temporal Expression of Members of the Transforming Growth Factor β Superfamily During Murine Fracture Healing” Journal of Bone and Mineral Research, Nov. 3, 2002, pp. 513-520, vol. 17, No. 3.;;Ciuclan, L. et al. “Imatinib Attenuates Hypoxia-induced Pulmonary Arterial Hypertension Pathology via Reduction in 5-Hydroxytryptamine through Inhibition of Tryptophan Hydroxylase 1 Expression” Am J Respir Crit Care Med., 2013, pp. 78-89, vol. 187, Issue 1.;;Ciuclan, L, et al. “Treatment with Anti-Gremlin 1 Antibody Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension in Mice” Am J Pathol., Nov. 2013, pp. 1461-1473, vol. 183, No. 5.;;Curran, S. P. et al. “Deletion of Gremlinl increases cell proliferation and migration responses in mouse embryonic fibroblasts” Cellular Signalling, 2012, pp. 889-898, vol. 24, No. 4.;;Dallas, S. L. et al. “Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease” Blood, Mar. 1, 1999, pp. 1697-1706, vol. 93, No. 5.;;Das, D. S. et al. “A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells” Leukemia, 2016, pp. 2187-2197, vol. 30, No. 11.;;Davis, H. et al. “Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche” Nat Med., Jan. 2015, pp. 62-70, vol. 21, No. 1, Online Methods, pp. 1-3.;;Devereux, J. et al. “A comprehensive set of sequence analysis programs for the VAX” Nucleic Acids Research, 1984, pp. 387-395, vol. 12, No. 1.;;Diamond, P. et al. “Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss” J Bone Miner Res, 2009, pp. 1150-1161, vol. 24, No. 7.;;Dubowchik, G. M. et al. “Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs” Pharmacology and Therapeutics, 1999, pp. 67-123, vol. 83.;;Einhorn, T. A. et al. “Fracture healing: mechanisms and interventions” Nat. Rev. Rheumatol., Jan. 2015, pp. 45-54, vol. 11.;;Emsley, P. et al. “Features and development of Coot” Acta Crystallographica Section D: Biological Crystallography, 2010, pp. 486-501, D66, No. 4.;;Farber, H. W. et al. “Pulmonary Arterial Hypertension” The New England Journal of Medicine, 2004, pp. 1655-1665, vol. 351.;;Ferguson, C. et al. “Does adult fracture repair recapitulate embryonic skeletal formation?” Mechanisms of Development, 1999, pp. 57-66, vol. 87.;;Fowler, J. A. et al. “Bone Marrow Stromal Cells Create a Permissive Microenvironment for Myeloma Development: A New Stromal Role for Wnt Inhibitor Dkk1” Cancer Research, 2012, pp. 2183-2189, vol. 72, No. 9.;;Gasteiger, E. et al. “Protein Identification and Analysis Tools on the ExPASy Server” The Proteomics Protocols Handbook, Humana Press, ed. J. M. Walker, 2005, pp. 571-607.;;Gazzerro, E. et al. “Conditional Deletion of Gremlin Causes a Transient Increase in Bone Formation and Bone Mass” J. Biol. Chem., Oct. 26, 2007, pp. 31549-31557, vol. 282, No. 43.;;Ghobrial, I. M. “Myeloma as a model for the process of metastasis: implications for therapy” Blood, Jul. 5, 2012, pp. 20-30, vol. 120, No. 1.;;Gilbane, A. J. et al. “Impaired Bone Morphogenetic Protein Receptor II Signaling in a Transforming Growth Factor-β-Dependent Mouse Model of Pulmonary Hypertension and in Systemic Sclerosis” Am J Respir Crit Care Med., Mar. 15, 2015, pp. 665-677, vol. 191, Issue 6.;;Goulet, J. A. et al. “Autogenous Iliac Crest Bone Graft. Complications and Functional Assessment” Clinical Orthopaedics and Related Research, Jun. 1997, pp. 76-81, No. 339.;;Guan, Y. et al. “Gremlin1 promotes carcinogenesis of glioma in vitro” Clin Exp Pharmacol Physiol, 2017, pp. 244-256, vol. 44, No. 2.;;Harris, R. J. “Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture” Journal of Chromatography A, 1995, pp. 129-134, vol. 705.;;Hellstrom, K. E. et al. “Antibodies for Drug Delivery” Controlled Drug Delivery, 2nd Ed., Robinson et al., eds., 1987, pp. 623-653.;;Henikoff, S. et al. “Amino acid substitution matrices from protein blocks” Proc. Natl. Acad. Sci. USA, Nov. 1992, pp. 10915-10919, vol. 89.;;Hewett, D. R. et al. “DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment” Neoplasia, Dec. 2017, pp. 972-981, vol. 19, No. 4.;;Hideshima, T. et al. “Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets” Nature Reviews Cancer, Aug. 2007, pp. 585-598, vol. 7, No. 8.;;Hjertner, O. et al. “Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells” Blood, Jan. 15, 2001, pp. 516-522, vol. 97, No. 2.;;Hochleitner, E. O. et al. “Characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometric peptide mapping analysis” Protein Science, 2000, pp. 487-496, vol. 9.;;Holien, T. et al. “Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC” Leukemia, 2012, pp. 1073-1080, vol. 26, No. 5.;;Holliger, P. et al. “Engineered antibody fragments and the rise of single domains” Nature Biotech., Sep. 2005, pp. 1126-1136, vol. 23, No. 9.;;Howe, J. R. et al. “Mutations in the SMAD4/DPC4 Gene in Juvenile Polyposis” Science, May 15, 1998, pp. 1086-1088, vol. 280, No. 5366.;;Howe. J. R. et al. “Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis” Nat Genet., Jun. 2001, pp. 184-187, vol. 28, No. 2.;;Hsu, D. R. et al. “The Xenopus Dorsalizing Factor Gremlin Identifies a Novel Family of Secreted Proteins that Antagonize BMP Activities” Molecular Cell, Apr. 1998, pp. 673-683, vol. 1, No. 5.;;International Search Report and Written Opinion in International Application No. PCT/GB2019/051699, dated Aug. 16, 2019, pp. 1-11.;;Irshad, S. et al. “Bone morphogenetic protein and Notch signalling crosstalk in poorprognosis, mesenchymal-subtype colorectal cancer” J Pathol., 2017, pp. 178-192, vol. 242.;;Isella, C. et al. “Stromal contribution to the colorectal cancer transcriptome” Nat Genet., Apr. 2015, pp. 312-319, vol. 47, No. 4, Online Methods, pp. 1-4.;;Jaeger, E. et al. “Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1” Nat Genet., Jun. 2012, pp. 699-703, vol. 44, No. 6, Online Methods, pp. 1-2.;;Junghans, R. P. et al. “Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders” Cancer Res., Mar. 1, 1990, pp. 1495-1502, vol. 50.;;Kabsch, W. “XDS” Acta Crystallographica Section D, Biological Crystallography, 2010, pp. 125-132, vol. D66.;;Karagiannis, G. S. et al. “Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1” Mol Oncol., 2013, pp. 826-839, vol. 7, No. 4.;;Karagiannis, G. S. et al. “Bone morphogenetic protein antagonist gremlin-1 regulates colon cancer progression” Biol Chem., 2015, pp. 163-183, vol. 396, No. 2.;;Karlin, S. et al. “Applications and statistics for multiple high-scoring segments in molecular sequences” Proc. Natl. Acad. Sci. USA, Jun. 1993, pp. 5873-5877, vol. 90.;;Kashmiri, S. V. S. et al. “SDR grafting—a new approach to antibody humanization” Methods, 2005, pp. 25-34, vol. 36.;;Kettleborough, C. A. et al. “Isolation of tumor cell-specific single-chain Fvfrom immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments” Eur. J. Immunol., 1994, pp. 952-958, vol. 24.;;Kim, M. et al. “Gremlin-1 Induces BMP-Independent Tumor Cell Proliferation, Migration, and Invasion” PloS ONE, Apr. 2012, pp. 1-8, vol. 7, Issue 4, e35100.;;Kim, H. S et al. “GREM1 is expressed in the cancer-associated myofibroblasts of basal cell carcinomas” PloS ONE, 2017, pp. 1-13, vol. 12, No. 3, e0174565.;;Kohler, G. et al. “Continuous cultures of fused cells secreting antibody of predefined specificity” Nature, Aug. 7, 1975, pp. 495-497, vol. 256.;;Koketsu, K. et al. “Gremlin, a Bone Morphogenetic Protein Antagonist, Is a Crucial Angiogenic Factor in Pituitary Adenoma” Int J Endocrinol., 2015, pp. 1-7, Article ID 834137.;;Kozbor, D. et al. “The production of monoclonal antibodies from human lymphocytes” Immunology Today, 1983, pp. 72-79, vol. 4, No. 3.;;Krinner, E.-M. et al. “A human monoclonal lgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF” Mol. Immunol., Feb. 2007, pp. 916-925, vol. 44, No. 5.;;Kyle, R. A. et al. “Multiple Myeloma” N Engl J Med, 2004, pp. 1860-1873, vol. 351, No. 18.;;Laurila, R. et al. “The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues” Int J Clin Exp Pathol., 2013, pp. 1400-1408, vol. 6, No. 7.;;Lavoz, C. et al. “Gremlin regulates renal inflammation via the vascular endothelial growth factor receptor 2 pathway” J Pathol., 2015, pp. 407-420, vol. 236.;;Lawson, M. A. et al. “Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche” Nat Commun., 2015, pp. 1-15, vol. 6, No. 8983.;;Lewis, A. et al. “A Polymorphic Enhancer Near GREM1 Influences Bowel Cancer Risk through Differential CDX2 and TCF7L2 Binding” Cell Rep., Aug. 21, 2014, pp. 983-990, vol. 8, No. 4.;;McCoy, A. J. et al. “Phaser crystallographic software” J Appl Cryst., 2007, pp. 658-674, vol. 40.;;Mitola, S. et al. “Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2” Blood, Nov. 4, 2010, pp. 3677-3680, vol. 116, No. 18.;;Mulvihill, M. S. et al. “Gremlin is Overexpressed in Lung Adenocarcinoma and Increases Cell Growth and Proliferation in Normal Lung Cells” PloS ONE, 2012, pp. 1-8, vol. 7, No. 8, e42264.;;Murshudov, G. N. et al. “REFMAC5 for the refinement of macromolecular crystal structures” Acta Crystallographica Section D: Biological Crystallography, 2011, pp. 355-367, vol. D67.;;Namkoong, H. et al. “The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein” BMC Cancer, 2006, pp. 1-13, vol. 6, No. 74.;;Neufert, C. et al. “An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression” Nat Protoc., 2007, pp. 1998-2004, vol. 2, No. 8.;;Nolan, K. et al. “Structure of Protein Related to Dan and Cerberus: Insights into the Mechanism of Bone Morphogenetic Protein Antagonism” Structure, Aug. 6, 2013, pp. 1417-1429, vol. 21.;;Nolan, K. et al. “Structure of Neuroblastoma Suppressor of Tumorigenicity 1 (NBL1)” J. Biol. Chem., Feb. 20, 2015, pp. 4759-4771, vol. 290, No. 8.;;Noll, J. E. et al. “Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells” Haematologica, 2014, pp. 163-171, vol. 99, No. 1.;;Noll, J. E. et al. “SAMSN1 is a Tumor Suppressor Gene in Multiple Myeloma” Neoplasia, Jul. 2014, pp. 572-585, vol. 16, No. 7.;;Noll, J. E. et al. “PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma” J Hematol Oncol., 2015, pp. 1-16, vol. 8, No. 106.;;Persic, L. et al. “An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries” Gene, 1997, pp. 9-18, vol. 187.;;Plaks, V. et al. “The Cancer Stem Cell Niche: How Essential is the Niche in Regulating Sternness of Tumor Cells?” Cell Stem Cell, Mar. 5, 2015, pp. 225-238, vol. 16, No. 3.;;Ponomarev, V. et al. “A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging” Eur J Nucl Med Mol Imaging, 2004, pp. 740-751, vol. 31, No. 5.;;Reineke, U. “Antibody Epitope Mapping Using Arrays of Synthetic Peptides” Methods Mol Biol, 2004, pp. 443-463, vol. 248.;;Retter, I. et al. “VBASE2, an integrative V gene database” Nucl. Acids Res., 2005, pp. D671-D674, vol. 33.;;Riechmann, L. et al. “Reshaping human antibodies for therapy” Nature, Mar. 24, 1998, pp. 323-327, vol. 332.;;Sato, T. et al. “Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche” Nature, May 14, 2009, pp. 262-265, vol. 459, No. 7244, Methods, p. 1.;;Sato, K. et al. “Establishment of Reproducible, Critical-Sized, Femoral Segmental Bone Defects in Rats” Tissue Eng Part C., 2014, pp. 1037-1041, vol. 20, No. 12.;;Schmid, G. J. et al. “Fibroblast Growth Factor Expression During Skeletal Fracture Healing in Mice” Developmental Dynamics, 2009, pp. 766-774, vol. 238.;;Scoville, D. H. et al. “Current View: Intestinal Stem Cells and Signaling” Gastroenterology, 2008, pp. 849-864, vol. 134, No. 3.;;Search Report for GB1802486.9, dated Oct. 17, 2018, pp. 1-5.;;Sethi, A. et al. “Gremlin utilizes canonical and non-canonical TGFβ signaling to induce lysyl oxidase (LOX) genes in human trabecular meshwork cells” Exp Eye Res., 2013, pp. 117-127, vol. 113.;;Shoshkes-Carmel, M. et al. “Subepithelial telocytes are an important source of Wnts that supports intestinal crypts” Nature, May 10, 2018, pp. 242-246, vol. 557, Supplemental pp. 1-9.;;Simonneau, G. et al. “Updated Clinical Classification of Pulmonary Hypertension” J Am Coll Cardiol., Jun. 30, 2009, pp. S43-S54, vol. 54, No. 1, Suppl S.;;Sneddon, J. B. et al. “Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation” Proc Natl Acad Sci USA, Oct. 3, 2006, pp. 14842-14847, vol. 103, No. 40.;;Tamminen, J.A. et al. “Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug” Oncogenesis, 2013, pp. 1-13, vol. 2, e66.;;Thomas, M. et al. “Activin-like kinase 5 (ALK5) Mediates Abnormal Proliferation of Vascular Smooth Muscle Cells from Patients with Familial Pulmonary Arterial Hypertension and is Involved in the Progression of Experimental Pulmonary Arterial Hypertension Induced by Monocrotaline” Am J Pathol., Feb. 2009, pp. 380-389, vol. 174, No. 2.;;Thorpe, P. E. et al. “The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates” Immunol. Rev., 1982, pp. 119-158, vol. 62.;;Tomlinson, I. P. M. et al. “Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of Colorectal Cancer” PLoS Genet., Jun. 2011, pp. 1-11, vol. 7, No. 6, e1002105.;;Topol, L. Z. et al. “Identification of drm, a Novel Gene Whose Expression is Suppressed in Transformed Cells and Which Can Inhibit Growth of Normal but Not Transformed Cells in Culture” Mol Cell Biol, Aug. 1997, pp. 4801-4810, vol. 17, No. 8.;;United Kingdom Search Report Application No. GB1519083.8, dated Jul. 29, 2016, pp. 1-5.;;Vande Broek, I. et al. “Extravasation and homing mechanisms in multiple myeloma” Clin Exp Metastasis, 2008, pp. 325-334, vol. 25, No. 4.;;Vaughan, T. J. et al. “Human antibodies by design” Nature Biotechnology, Jun. 1998, pp. 535-539, vol. 16.;;Verheyden, J. M. et al. “An Fgf/Gremlin inhibitory feedback loop triggers termination of limb bud outgrowth” Nature, Jul. 31, 2008, pp. 1-12, vol. 454, No. 7204.;;Verma, R. et al. “Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems” Journal of Immunological Methods, 1998, pp. 165-181, vol. 216.;;Wang, D.-J. et al. “The bone morphogenetic protein antagonist Gremlin is overexpressed in human malignant mesothelioma” Oncology Reports, 2012, pp. 58-64, vol. 27, No. 1.;;Worthley, D. L. et al. “Gremlin 1 Identifies a Skeletal Stem Cell with Bone, Cartilage, and Reticular Stromal Potential” Cell, Jan. 15, 2015, pp. 269-284, vol. 160, Nos. 1-2.;;Written Opinion in International Application No. PCT/EP2017/083650, dated Jan. 4, 2019, pp. 1-8.;;Yin, Y. et al. “Overexpression of Gremlin promotes non-small cell lung cancer progression” Tumour Biol, 2016, pp. 2597-2602, vol. 37.;;Yu, Y. Y. et al. “Immunolocalization of BMPs, BMP antagonists, receptors, and effectors during fracture repair” Bone, 2010, pp. 841-851, vol. 46.;;United Kingdom Search Report Application No. GB1809946.5, dated Jan. 24, 2019, pp. 1-4.;;Walsh, D.W. et al. “Extracellular BMP-antagonist regulation in development and disease: tied up in knots” Trends in Cell Biology, Feb. 24, 2010, pp. 244-256, vol. 20, No. 5.;;Torre, L.A et al. “Global Cancer in Women: Burden and Trends” Cancer Epidemiol Biomarkers Prev, Feb. 21, 2017, pp. 444-457, vol. 26, No. 4.;;“Breast Cancer Facts & Figures 2015-2016” American Cancer Society, 2015, 2 cover pages and pp. 1-40.;;Mittal, S. et al. “The breast tumour microenvironment—role in cancer development, progression and response to therapy” Expert Review of Molecular Diagnostics, 2018, pp. 1-34, vol. 18, No. 3.;;Merino, R. et al. “The BMP antagonist Gremlin regulates outgrowth, chondrogenesis and programmed cell death in the developing limb” Development, 1999, pp. 5515-5522, vol. 126.;;Schuetz, C. S. et al. “Progression-Specific Genes Identified by Expression Profiling of Matched Ductal Carcinomas In situ and Invasive Breast Tumors, Combining Laser Capture Microdissection and Oligonucleotide Microarray Analysis” Cancer Research, May 15, 2006, pp. 5278-5286, vol. 66, No. 10.;;Kuchimaru, T. et al. “A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries” Nature Communications, 2018, pp. 1-7, vol. 9, No. 2981.;;Kager, L. et al. “Novel insights and therapeutic interventions for pediatric osteosarcoma” Future Oncol., Sep. 21, 2016, pp. 357-368, vol. 13, No. 4.;;Kresse, S. H. et al. “Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma” PLoS ONE, Nov. 7, 2012, pp. 1-20, vol. 7, Issue 11, e48262.;;Groeneveld, E. H. J. et al. “Bone morphogenetic proteins in human bone regeneration” European Journal of Endocrinology, 2000, pp. 9-21, vol. 142.;;Zysk, A. et al. “Zoledronate Enhances the Cytotoxicity of Gamma Delta T Cell Immunotherapy in an Orthotopic Mouse Model of Osteolytic Osteosarcoma” J Cancer Sci Ther, 2018, pp. 262-266, vol. 10, No. 9.;;Tian, H. et al. “Bone morphogenetic protein-2 and tumor growth: Diverse effects and possibilities for therapy” Cytokine & Growth Factor Reviews, 2017, pp. 73-91, vol. 34.;;Tian, H. et al. “Bone Morphogenetic Protein-2 Promotes Osteosarcoma Growth by Promoting Epithelial-Mesenchymal Transition (EMT) Through the Wnt/β-Catenin Signaling Pathway” Journal of Orthopaedic Research, Jul. 2019, pp. 1638-1648.;;Nguyen, A. et al. “Roles of bone morphogenetic protein signaling in osteosarcoma” International Orthopaedics (SICOT), 2014, pp. 2313-2322, vol. 38.;;Rycaj, K. et al. “Cellular determinants and microenvironmental regulation of prostate cancer metastasis” Semin Cancer Biol., Jun. 2017, pp. 1-35, vol. 44.;;Grillo, E. et al. “Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist” Oncotarget, May 11, 2016, pp. 35353-35368, vol. 7, No. 23.;;Gandaglia, G. et al. “Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer” European Urology, 2015, pp. 325-334, vol. 68.;;Armstrong, A. J. et al. “A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis” Clin Cancer Res, Nov. 1, 2007, pp. 6396-6403, vol. 13, No. 21.;;Van Cutsem, E. et al. “Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up” Annals of Oncology, Sep. 2014, pp. ii1-ii9, vol. 25 (Supplement 3).;;Muñoz, J. et al. “The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent ‘+4’ cell markers” The EMBO Journal, 2012, pp. 3079-3091, vol. 31, No. 14.;;Moser, A. R. et al. “The Min (Multiple Intestinal Neoplasia) Mutation: Its Effect on Gut Epithelial Cell Differentiation and Interaction with a Modifier System” The Journal of Cell Biology, Mar. 1992, pp. 1517-1526, vol. 116, No. 6.;;Shibata, H. et al. “Rapid Colorectal Adenoma Formation Initiated by Conditional Targeting of the Ape Gene” Science, Oct. 3, 1997, pp. 120-123, vol. 278.;;El Marjou, F. et al. “Tissue-Specificand Inducible Cre-Mediated Recombination in the Gut Epithelium” genesis, 2004, pp. 186-193, vol. 39.;;Rudling, R. et al. “A simple device to rapidly prepare whole mounts of murine intestine” Cell Prolif., 2006, pp. 415-420, vol. 39.;;Sato, T. et al. “Long-Term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium” Gastroenterology, Nov. 2011, pp. 1762-1772, vol. 141, No. 5.;;Rudikoff, S. et al. “Single amino acid substitution altering antigen-binding specificity” Proceedings of the National Academy of Sciences of the United States of America, Mar. 1982, pp. 1979-1983, vol. 79, No. 6.;;Janeway, Jr., C. A. et al. Immunology: the immune system in health and disease, 3rd ed., 1997, Garland Publications, Inc., Chapter 3, “Structure of the Antibody Molecule and Immunoglobulin Genes” pp. 3:1-3:11.;;Lederman, S. et al. “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4” Molecular Immunology, 1991, pp. 1171-1181, vol. 28, No. 11.;;Li, J. et al. “Temporal associations between interleukin 22 and the extracellular domains of IL-22R and IL-IOR2” International Immunology, 2004, pp. 693-711, vol. 4.;;Panka, D. J. et al. “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies” Proceedings of the National Academy of Sciences of the United States of America, May 1, 1988, pp. 3080-3084, vol. 85, No. 9.;;Amit, A. G. et al. “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution” Science, Aug. 15, 1986, pp. 747-753, vol. 233, No. 4765.;;Harlow, E. et al. “Antibodies, A Laboratory Manual” Cold Spring Harbor Laboratory, 1988, Chapter 5, pp. 1-2.;;O'Reilly, S. et al. “lnterleukin-6 (IL-6) Trans Signaling Drives a STAT3-dependent Pathway That Leads to Hyperactive Transforming Growth Factor-β (TGF-β) Signaling Promoting SMAD3 Activation and Fibrosis via Gremlin Protein” The Journal of Biological Chemistry, Apr. 4, 2014, pp. 9952-9960, vol. 289, No. 14.;;Sato, M. et al. “Clinical significance of Gremlin 1 in cervical cancer and its effects on cancer stem cell maintenance” Oncology Reports, 2016, pp. 391-397, vol. 35.;;Uchiyama, H. et al. “Adhesion of Human Myeloma-Derived Cell Lines to Bone Marrow Stromal Cells Stimulates Interleukin-6 Secretion” Blood, Dec. 15, 1993, pp. 3712-3720, vol. 82, No. 12.;;Van Vlodrop, I. J. H. et al. “Prognostic Significance of Gremlin1 (GREM1) Promoter CpG Island Hypermethylation in Clear Cell Renal Cell Carcinoma” The American Journal of Pathology, Feb. 2010, pp. 575-584, vol. 176, No. 2.;;Yu, Y. et al. “Overexpression of Gremlin 1 by sonic hedgehog signaling promotes pancreatic cancer progression” International Journal of Oncology, 2018, pp. 2445-2457, vol. 53.;;Clark, K. C. et al. “Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo” Cancers, Aug. 3, 2020, pp. 1-20, vol. 12, No. 2149.",ACTIVE
324,US,A1,US 2014/0039315 A1,049-435-874-614-689,2014-02-06,2014,US 201313962396 A,2013-08-08,US 201313962396 A;;US 201213468939 A;;US 90544707 A;;US 201261681512 P;;US 82745206 P;;US 88428507 P,2006-09-29,Medical devices with visibility-enhancing features,"A method and apparatus are disclosed for a medical device, including a means for enhancing visibility under imaging which, while reducing the local mechanical strength, avoids compromising the overall device effectiveness or safety. Visibility under imaging is increased by a non-uniform distribution of visibility-enhancing features as a function of the local stresses expected during use. One embodiment is for a medical device comprising an elongate member having proximal and distal regions, wherein the distal region comprises: a first echogenic region including a plurality of circumferential first region cuts, each of the first region cuts having a first region cut volume; and a second echogenic region, distal of the first echogenic region, including a plurality of circumferential second region cuts, wherein each of the second region cuts has a second region cut volume greater than said first region cut volume.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;MA ERIC,BAYLIS MEDICAL COMPANY INC (2013-07-26),https://lens.org/049-435-874-614-689,Patent Application,yes,7,10,1,113,0,A61B18/1492;;A61B2018/00011;;A61B2018/00083;;A61B2018/00351;;A61B2018/00839;;A61B2218/002;;A61B18/1477;;A61B10/0233;;A61B2018/00136;;A61B2090/064;;A61B90/37;;A61B2090/3925;;A61B2090/3966;;A61M25/0108;;A61B8/0841;;A61B2018/00011;;A61B2018/00083;;A61B2218/002;;A61B18/1492;;A61B2018/00839;;A61B2018/00351;;A61B18/1477;;A61B10/0233;;A61B2018/00136;;A61B2090/064;;A61B90/37;;A61B2090/3966;;A61B2090/3925,A61B8/08;;A61M25/01,600/439;;604/528,0,0,,,,DISCONTINUED
325,AU,A,AU 2001/067738 A,139-991-281-426-543,2002-02-18,2002,AU 2001/067738 A,2001-07-04,GB 0019552 A;;GB 0103000 W,2000-08-10,Dosing valve,,DAVIES DAVID GARETH HAVARD;;NORMAN EDWARD LESSELS,DAVIES DAVID GARETH HAVARD;;NORMAN EDWARD LESSELS,,https://lens.org/139-991-281-426-543,Patent Application,no,0,0,5,5,0,G05D11/006;;G05D11/006;;Y10T137/2572;;Y10T137/2572,G05D11/00,,0,0,,,,PENDING
326,AU,A1,AU 2019/220407 A1,185-445-995-684-528,2020-08-27,2020,AU 2019/220407 A,2019-02-14,GB 201802486 A;;EP 2019053726 W,2018-02-15,Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect,The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;ROBERTS SCOTT JOHN,,https://lens.org/185-445-995-684-528,Patent Application,no,0,0,22,22,0,C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61P19/00;;A61P19/10;;C07K16/22;;C07K2317/21;;A61K2039/505;;C07K2317/33;;A61P19/00;;C07K2317/24;;C07K2317/92;;C07K2317/76;;A61P19/10;;C07K2299/00;;C07K2317/622;;C07K16/22;;A61P19/00;;A61P19/10;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K2299/00;;A61K2039/505;;A61P19/08;;C07K16/22;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/569;;C07K2317/76;;A61K39/3955,C07K16/22;;A61P19/00;;A61P19/10,,0,0,,,,PENDING
327,GB,A,GB 2586976 A,040-561-084-191-634,2021-03-17,2021,GB 201913002 A,2019-09-10,GB 201913002 A,2019-09-10,Steering torque assist method and apparatus,"A control system (1, Figure 1) with one or more controllers (20, Figure 1), is provided to control generation of a steering wheel overlay signal to control a trajectory α of a host vehicle 2. The control system determines a principal axis PD of a lane of travel LT-n and, based on the principal axis PD, determines a target trajectory αT for host vehicle 2. The steering wheel overlay signal is generated, including an intra-lane steering signal (STQ-LA, Figure 2) for aligning trajectory α with target trajectory αT. The intra-lane steering signal is removed when trajectory α is at least substantially aligned with target trajectory αT. The system is particularly suitable for providing lane-keeping assistance, and the principal axis PD may be based on determined lane boundaries RE-n. Also provided are a vehicle 2 and a control method.",JAGUAR LAND ROVER LTD,ROBYN CALDWELL;;GARETH DAVIES;;DENIS FUSCONI;;KIERON STANGER,,https://lens.org/040-561-084-191-634,Patent Application,no,5,0,12,12,0,B62D15/025;;B60W30/12;;B62D15/025;;B60W2552/53;;B60W10/20;;B60W30/12;;B60W2510/202;;B60W2710/202;;B62D15/025;;B62D15/029,B62D15/02;;B60W30/12,,0,0,,,,ACTIVE
328,GB,B,GB 2536658 B,059-724-723-298-459,2017-03-22,2017,GB 201504979 A,2015-03-24,GB 201504979 A,2015-03-24,Controlling data flow between processors in a processing system,,IMAGINATION TECH LTD,PAUL MURRIN;;GARETH JOHN DAVIES;;ADRIAN JOHN ANDERSON,,https://lens.org/059-724-723-298-459,Granted Patent,no,3,0,8,8,0,G06F15/825;;G06F15/167;;G06F15/167;;G06F15/167;;G06F9/30098;;G06F15/76,G06F15/167,,0,0,,,,ACTIVE
329,AU,A1,AU 2021/291788 A1,066-322-505-944-696,2023-01-05,2023,AU 2021/291788 A,2021-05-25,US 202063041319 P;;US 202063051080 P;;IB 2021054539 W,2020-06-19,Deflectable elongated guidewire assembly,"An elongated guidewire assembly has a distal segment configured to be selectively maneuvered, along an elongated introducer assembly. The distal segment is configured to selectively transmit a tenting force from the elongated guidewire assembly to the first biological wall after the distal segment has contacted, at least in part, the first biological wall and the distal segment has been selectively protracted away from the distal introducer assembly.",BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DICICCO MATTHEW;;MORIYAMA EDUARDO;;DAVIES GARETH,,https://lens.org/066-322-505-944-696,Patent Application,no,0,0,9,9,0,A61B2017/00053;;A61B2017/00243;;A61B2090/3966;;A61M25/09;;A61B17/3478;;A61M2025/09175;;A61B2018/00613;;A61B2018/144;;A61B18/1492;;A61B2018/00351;;A61B18/1492;;A61B17/3478;;A61B90/39;;A61M25/09;;A61B2018/00351;;A61B2018/00613;;A61B2018/144;;A61B2017/00243;;A61B2090/3966;;A61M2025/09175;;A61B2090/3966;;A61B5/6851;;A61B5/6885;;A61B5/7455;;A61M2025/09066;;A61M2025/09175,A61B18/14;;A61B17/00;;A61B17/34;;A61B18/00;;A61M25/09,,0,0,,,,PENDING
330,US,A1,US 2022/0104874 A1,067-995-527-104-703,2022-04-07,2022,US 202117465047 A,2021-09-02,US 202117465047 A;;US 202063088514 P,2020-10-07,ELONGATED MEDICAL ASSEMBLY,"An elongated medical assembly includes a first elongated medical device configured to be inserted, at least in part, into the patient, and also configured to be maneuvered proximate to the biological feature. A second elongated medical device is configured to be received, at least in part, in the first elongated medical device, and also configured to be selectively extended, at least in part, from the first elongated medical device toward, and proximate to, the biological feature. A biological-removal device is mounted to the second elongated medical device, and configured to cut a portion of the biological feature after the second elongated medical device has been positioned proximate to the biological feature.",BAYLIS MEDICAL CO INC,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,BAYLIS MEDICAL COMPANY INC (2021-11-25);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/067-995-527-104-703,Patent Application,yes,14,0,1,1,0,A61B18/1492;;A61B2018/00351;;A61B2018/00601;;A61B2018/1475;;A61B18/1445;;A61B18/1492;;A61B18/1206;;A61B2018/00351;;A61B2018/00601;;A61B18/1442;;A61B18/12;;A61B2018/00244;;A61B2018/00577;;A61B2018/00071;;A61B18/1445,A61B18/12;;A61B18/14,,0,0,,,,PENDING
331,US,A1,US 2019/0231424 A1,086-519-244-537-068,2019-08-01,2019,US 201916381102 A,2019-04-11,US 201916381102 A;;US 201514851412 A;;IB 2014059696 W;;US 201361777368 P;;US 201361781231 P,2013-03-12,Medical Device Having a Support Structure,"Embodiments of medical devices and methods are disclosed. The medical devices typically comprises an elongate member with a proximal region and a distal region. The distal region comprises a flexible portion that is more flexible than the proximal region of the medical device. The flexible region includes gaps in the sidewall of the elongate member. Furthermore, the medical device comprises a rigid energy delivery device at the distal end which is configured to deliver energy to tissue when energy is supplied to the energy delivery device. In some embodiments, the medical device comprises a support spine configured to provide support to the flexible portion of the elongate member.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,BAYLIS MEDICAL COMPANY INC (2019-07-15);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/086-519-244-537-068,Patent Application,yes,0,6,10,113,0,A61M25/0041;;A61M25/0054;;A61M2025/0003;;A61M2025/09133;;A61N1/056;;A61B2018/00101;;A61B5/6852;;A61B5/0215;;A61B2090/3966;;A61B18/1492;;A61B2017/00309;;A61B2017/00986;;A61B2018/00077;;A61M25/0138;;A61M25/0144;;A61B2090/3966;;A61B5/6852;;A61B5/0215;;A61N1/056;;A61M25/0054;;A61B2018/00101;;A61M2025/0003;;A61M25/0041;;A61M2025/09133;;A61B18/1492;;A61B2018/00351;;A61B2218/002,A61B18/14,,0,0,,,,ACTIVE
332,EP,A1,EP 4032491 A1,152-194-670-519-822,2022-07-27,2022,EP 22157372 A,2014-03-14,US 201361781231 P;;EP 14764721 A;;IB 2014059830 W,2013-03-14,ELECTROSURGICAL DEVICE HAVING A LUMEN,"In some embodiments, an electrosurgical device comprises: an electrically conductive elongate member for traversing body vasculature wherein electrical energy can flow through the wall of the elongate member; the elongate member defining a hollow lumen with one or more apertures at or near its distal end; and an energy delivery device in electrical communication with the elongate member (i.e. with the wall defining the lumen) at or about the distal end of the elongate member. The energy delivery device includes an electrode for delivering energy and a thermal shield is positioned between the electrode and the elongate member.
",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-05),https://lens.org/152-194-670-519-822,Patent Application,yes,17,0,12,113,0,A61B18/1492;;A61B2018/00029;;A61B2018/00101;;A61B17/3207;;A61B2017/00247;;A61B2017/22094;;A61B2018/00351;;A61B2018/00601;;A61B2018/1417,A61B17/22;;A61B18/12,,0,0,,,,PENDING
333,WO,A1,WO 2023/170273 A1,032-051-974-651-495,2023-09-14,2023,EP 2023056178 W,2023-03-10,US 202263318856 P,2022-03-11,MEDICAL DEVICES,"A method for carrying out a medical procedure includes advancing a medical device towards a puncture site in a patients body and positioning a radiofrequency puncture electrode of the medical device adjacent the puncture site; delivering radiofrequency energy from the radiofrequency puncture electrode to create a puncture in the puncture site; advancing the medical device through the puncture to position an auxiliary electrode of the medical device adjacent a target site in the patients body; and using the auxiliary electrode for diagnosis, mapping, and/or treatment at the target site.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG CHARLENE;;KOON LAUREN;;MORIYAMA EDUARDO;;DAVIES GARETH,,https://lens.org/032-051-974-651-495,Patent Application,yes,7,0,2,2,0,A61B18/1492;;A61B18/1477;;A61B2018/1407;;A61B2018/1422;;A61B2018/1425;;A61B2018/144;;A61B2018/0038;;A61B2018/00351;;A61B2018/00375;;A61B2018/00577;;A61B2018/00267;;A61B2018/0022;;A61B2017/00867;;A61B2017/00053;;A61B18/1492;;A61B2017/00247;;A61B2018/00279;;A61B2018/00601;;A61B2018/00839;;A61M2025/0042,A61B18/14;;A61B17/00;;A61B18/00,,0,0,,,,PENDING
334,US,B2,US 7828796 B2,101-852-835-385-781,2010-11-09,2010,US 52075406 A,2006-09-14,US 52075406 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 59629705 P,2003-01-21,Method for creating a channel through an occlusion and apparatus therefor,"A method for creating a channel through an occlusion located in a substantially elongated body vessel of a patient, The method uses a channel creating apparatus defining an apparatus distal end portion insertable into the body vessel, the channel creating apparatus including an energy delivery component operatively coupled to the apparatus distal end portion for delivering energy substantially adjacent the apparatus distal end portion. The method includes: inserting the apparatus distal end portion into the body vessel; creating a channel first portion through the occlusion harder section using, at least in part, a delivery of energy into the occlusion harder portion; and creating a channel second portion through the occlusion softer portion by pushing the apparatus distal end portion through at least a portion of the occlusion softer portion substantially without delivering energy into the occlusion softer portion.",BAYLIS MEDICAL CO INC,WONG CHRISTINE;;DAVIES GARETH;;LEUNG RAMSEY;;MOSLEY MARK,BAYLIS MEDICAL COMPANY INC (2008-05-12);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/101-852-835-385-781,Granted Patent,yes,5,22,2,113,0,A61B18/24;;A61B18/24;;A61B18/1492;;A61B18/1492,A61B18/12,606/45;;606/41;;606/46;;607/101,1,1,090-845-072-200-001,10.1007/bf00595842,"Suhonen M. et al. Recanalization of arterial occlusions using a specially designed steering catheter. European Radiology: 2, 264-265(1992).",ACTIVE
335,US,A1,US 2022/0297756 A1,100-156-975-213-409,2022-09-22,2022,US 202017753619 A,2020-09-09,GB 201913002 A;;EP 2020075244 W,2019-09-10,STEERING WHEEL OVERLAY SIGNAL METHOD AND APPARATUS,"The present disclosure relates to a control system for controlling generation of a steering wheel overlay signal to control a trajectory of a host vehicle. The control system includes one or more controllers. The control system is configured to determine a principal axis of a lane of travel. A target trajectory is determined for the host vehicle in dependence on the determined principal axis. The steering wheel overlay signal is generated, including an intra-lane steering signal for aligning the trajectory of the host vehicle with the target trajectory. The intra-lane steering signal is removed when the trajectory is at least substantially aligned with the target trajectory. The present disclosure also relates to a vehicle; and a method of controlling generation of a steering wheel overlay signal.",JAGUAR LAND ROVER LTD,CALDWELL ROBYN;;DAVIES GARETH;;FUSCONI DENIS;;STANGER KIERON,JAGUAR LAND ROVER LIMITED (2022-03-10),https://lens.org/100-156-975-213-409,Patent Application,yes,0,4,12,12,0,B62D15/025;;B60W30/12;;B62D15/025;;B60W2552/53;;B60W10/20;;B60W30/12;;B60W2510/202;;B60W2710/202;;B62D15/025;;B62D15/029,B62D15/02;;B60W10/20;;B60W30/12,,0,0,,,,PENDING
336,GB,B,GB 2590951 B,111-974-580-891-807,2023-03-15,2023,GB 202000257 A,2020-01-09,GB 202000257 A,2020-01-09,Vehicle control system and method,,JAGUAR LAND ROVER LTD,ROBYN CALDWELL;;DENIS FUSCONI;;GARETH DAVIES;;KIERON STANGER,,https://lens.org/111-974-580-891-807,Granted Patent,no,3,0,8,10,0,B62D15/025;;G06V20/588;;G06V20/58;;B60W30/12;;B62D15/025;;B60W2552/53;;B60W2554/801;;G06V20/58;;G06V20/588;;B60W30/12;;B60W40/109,B62D15/02;;B60W30/12,,0,0,,,,ACTIVE
337,JP,A,JP 2021074592 A,180-932-151-114-652,2021-05-20,2021,JP 2021016433 A,2021-02-04,US 201361781231 P,2013-03-14,ELECTROSURGICAL DEVICE WITH LUMEN,"To provide an electrosurgical device for applying electric energy for traversing a tissue of a body region of a patient.SOLUTION: In some embodiments, an electrosurgical device is configured so that electric energy can flow through a wall of a slender member, and comprises: the conductive slender member for traversing a blood circulatory system of a body; the slender member for regulating a hollow lumen having one or more apertures on a distal end or the vicinity thereof; and an energy delivery device (namely, wall for regulating a lumen) for electrically coupling to the slender member on the distal end or the surrounding thereof. The energy delivery device includes an electrode for providing energy, and a thermal shield is arranged between the electrode and the slender member.SELECTED DRAWING: Figure 1",BAYLIS MEDICAL CO INC,GARETH DAVIES;;JOHN PAUL URBANSKI;;RUND ABOU-MARIE,,https://lens.org/180-932-151-114-652,Patent Application,no,1,0,12,113,0,A61B18/1492;;A61B2018/00029;;A61B2018/00101;;A61B17/3207;;A61B2017/00247;;A61B2017/22094;;A61B2018/00351;;A61B2018/00601;;A61B2018/1417,A61B18/14,,0,0,,,,ACTIVE
338,BR,A2,BR 112016002781 A2,019-351-200-837-003,2017-08-01,2017,BR 112016002781 A,2013-11-20,IB 2013060287 W;;US 201361863265 P;;US 201361863579 P,2013-08-07,métodos e dispositivos para puncionar tecido,"são descritos novos e originais dispositivos médicos e métodos associados, para facilitar uma punção eficiente e repetível de um local de tecido, enquanto que permitindo o acesso vascular a partir de vários locais de de acesso do corpo de um paciente. os dispositivos médicos descritos incluem dilatadores e fios utilizáveis separadamente ou em combinação e configurados para facilitar o acesso ao tecido e a punção em várias localizações anatômicas a partir dos locais de acesso desejados. os dispositivos médicos incluem uma ou mais seções apresentando flexibilidade suficiente para acessar o local do tecido a partir do local de acesso, enquanto que mantendo rigidez suficiente para desempenhar uma ou mais funções adicionais.",BAYLIS MEDICAL CO INC,ALLEY FERRYL;;BECA BOGDAN;;DAVIES GARETH;;URBANSKI JOHN,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (IE) (2023-06-06),https://lens.org/019-351-200-837-003,Patent Application,no,0,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/01;;A61B17/34;;A61B18/14;;A61M25/06;;A61M29/00,,0,0,,,,ACTIVE
339,WO,A3,WO 2012/173809 A3,048-030-228-693-560,2013-04-04,2013,US 2012/0040795 W,2012-06-04,US 201161492783 P,2011-06-02,METHOD OF IDENTIFYING DE NOVO COPY NUMBER VARIANTS (CNV) USING MZ TWINS DISCORDANT FOR ATTENTION PROBLEMS/DISORDERS,The present disclosure relates to methods of identifying copy number variation (CNV) events and sizes that are associated with attention problems (AP) and identifying one or more CNVs which correlate with such disorders.,EHLI ERIK;;DAVIES GARETH;;ABDELLAOUI ABDEL;;HUDZIAK JAMES,EHLI ERIK;;DAVIES GARETH;;ABDELLAOUI ABDEL;;HUDZIAK JAMES,,https://lens.org/048-030-228-693-560,Search Report,yes,5,0,2,2,0,C12Q1/6883;;C12Q2600/156,C12Q1/68,,1,1,004-093-015-843-213,22490988;;pmc3449078;;10.1038/ejhg.2012.49,"ERIK A. EHLI ET AL.: ""De novo and inherited CNVs in MZ twin pairs selected for discordance and concordance on Attention Problems"", EUROPEAN JOURNAL OF HUMAN GENETICS, vol. 20, no. 10, 11 April 2012 (2012-04-11), pages 1037 - 1043",PENDING
340,KR,A,KR 20230002807 A,060-418-247-505-890,2023-01-05,2023,KR 20227040137 A,2021-04-14,US 202063013604 P;;IB 2021053085 W,2020-04-22,"열상 시스템 및 장치, 및 열상을 위한 방법","의료 시술들에 사용하기 위한 열상 장치는 반대편의 근위 및 원위 부분들을 갖는 샤프트를 포함한다. 클램프가 원위 부분으로부터 연장된다. 클램프는 제1 및 제2 클램프 아암들을 갖는다. 클램프는 개방 위치와 폐쇄 위치 사이에서 이동가능하다. 개방 위치에서, 제1 클램프 아암은 제2 클램프 아암으로부터 이격된다. 폐쇄 위치에서, 제1 클램프 아암은 제2 클램프 아암을 향해 이동된다. 클램프 액추에이터가 샤프트를 통해 클램프에 연결되고, 클램프를 개방 위치와 폐쇄 위치 사이에서 이동시키도록 조작가능하다. 고주파 전극(RF)이 제1 클램프 아암과 연관된다. RF 전극은 클램프가 폐쇄 위치에 있을 때 제2 클램프 아암에 대면하도록 위치되는 제1 천공 표면을 갖는다. 전기 커넥터가 전원에의 연결을 위해 RF 전극으로부터 근위방향으로 연장된다.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,,https://lens.org/060-418-247-505-890,Patent Application,no,0,0,9,9,0,A61B18/1445;;A61B2018/00601;;A61B2018/00577;;A61B2018/146;;A61B2018/00613;;A61B18/1445;;A61B90/39;;A61B2018/146;;A61B2018/00178;;A61B2018/00577;;A61B2018/00601;;A61B2018/00613;;A61B2090/3966;;A61B18/1445;;A61B2018/00059;;A61B2018/00601,A61B18/14;;A61B18/00;;A61B90/00,,0,0,,,,PENDING
341,CA,A1,CA 3122822 A1,105-008-629-273-510,2022-01-06,2022,CA 3122822 A,2021-06-21,US 202063048415 P,2020-07-06,MEDICAL ASSEMBLY INCLUDING FORCE-LIMITING DEVICE,"An elongated medical assembly includes a distal section having a distal tip configured to be maneuvered to contact, at least in part, the biological feature of the patient. A force-limiting device is interactable with the distal section. The force-limiting device is configured to limit, at least in part, an amount of a force to be applied from the distal tip of the distal section to the biological feature.",BAYLIS MEDICAL CO INC,BALKOVEC CHRISTIAN;;DAVIES GARETH;;DICICCO MATTHEW;;MORIYAMA EDUARDO,,https://lens.org/105-008-629-273-510,Patent Application,no,0,0,1,1,0,,A61M25/00;;A61M25/01,,0,0,,,,PENDING
342,US,B2,US 11819243 B2,113-991-565-795-873,2023-11-21,2023,US 202016823547 A,2020-03-19,US 202016823547 A,2020-03-19,Medical sheath and related systems and methods,"A medical sheath includes an elongate member having a proximal portion defining a proximal end and a distal portion defining a distal end. A first lumen extends through the elongate member and is open at the proximal and the distal end for passage of a medical device through the lumen. The medical sheath further includes an anchoring mechanism that is deployable from the elongate member. The anchoring mechanism includes an anchor that is removably securable to an anatomical feature to secure the elongate member to the anatomical feature, and a connector securing the anchor to the elongate member.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LAU KAYLIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;BALKOVEC CHRISTIAN,BAYLIS MEDICAL COMPANY INC (2020-03-10);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/113-991-565-795-873,Granted Patent,yes,304,0,2,2,0,A61B17/3478;;A61B2017/00247;;A61B2017/003;;A61B2017/3488;;A61B2017/0417;;A61B17/3478;;A61B2017/3488;;A61B2017/003;;A61B2017/00247,A61B17/34;;A61B17/00,,0,0,,,,ACTIVE
343,EP,B1,EP 2967714 B1,148-855-064-227-492,2022-05-11,2022,EP 14764721 A,2014-03-14,US 201361781231 P;;IB 2014059830 W,2013-03-14,ELECTROSURGICAL DEVICE HAVING A LUMEN,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,"BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-19);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2022-12-06)",https://lens.org/148-855-064-227-492,Granted Patent,yes,10,0,12,113,0,A61B18/1492;;A61B2018/00029;;A61B2018/00101;;A61B17/3207;;A61B2017/00247;;A61B2017/22094;;A61B2018/00351;;A61B2018/00601;;A61B2018/1417,A61B18/12;;A61B17/22,,0,0,,,,ACTIVE
344,US,B2,US 10792096 B2,184-234-146-155-211,2020-10-06,2020,US 201514851412 A,2015-09-11,US 201514851412 A;;IB 2014059696 W;;US 201361777368 P;;US 201361781231 P;;US 92629210 A;;US 201113286041 A,2010-11-08,Medical device having a support structure,"Embodiments of medical devices and methods are disclosed. The medical devices typically comprise a flexible elongate member defining a lumen, and a support spine affixed to the distal end and extending proximally therefrom within the elongate member lumen. In some embodiments, the support spine is configured to support at least a portion of the elongate member when the elongate member is bent or curved. Some embodiments include apertures at or near the distal end for enabling fluid communication between the lumen and the outside environment. In some embodiments, the support wire extends proximally from the distal end within a distal portion of the lumen such that a proximal portion of the lumen is substantially unobstructed, thereby reducing turbulence of fluid flowing through the lumen.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,BAYLIS MEDICAL COMPANY INC (2015-09-08);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/184-234-146-155-211,Granted Patent,yes,64,0,4,113,0,A61B2218/002;;A61B2090/3966;;A61B18/1492;;A61B2018/00351;;A61B2018/00029;;A61B2018/00101;;A61B2018/00357;;A61B2018/0041;;A61B2018/00601;;A61B2018/1472;;A61B18/1492;;A61B2018/00351;;A61B2218/002;;A61B2090/3966;;A61B2018/00029;;A61B2018/00101;;A61B2018/00357;;A61B2018/0041;;A61B2018/00601;;A61B2018/1472,A61B18/14;;A61B18/00;;A61B90/00,,3,0,,,"European Supplementary Search Report for Application No. EP 14763003 completed on Sep. 9, 2016.;;International Search Report of International Application No. PCT/IB2014/059696 dated May 7, 2014.;;Japanese Office Action for counterpart Japanese Application No. 2015-562497, dated, Dec. 26, 2017.",ACTIVE
345,US,A1,US 2023/0143116 A1,000-931-413-775-070,2023-05-11,2023,US 202117917640 A,2021-04-07,US 202117917640 A;;US 202063007703 P;;IB 2021052907 W,2020-04-09,MEDICAL ASSEMBLIES HAVING SENSOR DEVICES,"A primary elongated medical assembly is configured to be positioned in, and movable along, a patient. A secondary elongated medical assembly is configured to be positioned in, and movable along, the patient. The primary elongated medical assembly has a primary sensor device. The secondary elongated medical assembly has a secondary sensor device. The primary elongated medical assembly and the secondary elongated medical assembly are each configured to be movable relative to each other; this is done in such a way that the primary sensor device and the secondary sensor device are movable relative to each other.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/000-931-413-775-070,Patent Application,yes,0,0,3,3,0,A61B5/367;;A61B5/287;;A61B18/1492;;A61B2018/00577;;A61B2018/00357;;A61B2018/00839;;A61B2034/2051;;A61B2090/397;;A61B2090/0811;;A61B5/6852;;A61B5/743;;A61B5/06;;A61B2505/05;;A61B5/367;;A61B5/287;;A61B5/065;;A61B2505/05;;A61B2562/0209;;A61B2562/043,A61B5/287;;A61B5/06;;A61B5/367,,0,0,,,,PENDING
346,US,A1,US 2021/0000536 A1,037-868-462-541-047,2021-01-07,2021,US 202016935533 A,2020-07-22,US 202016935533 A;;US 201514851353 A;;IB 2014059830 W;;IB 2014059696 W;;US 201361781231 P;;US 201361777368 P,2013-03-12,Electrosurgical Device Having a Lumen,"An electrosurgical device comprises an electrically conductive elongate member for traversing body vasculature defining a hollow lumen with one or more apertures at or near its distal end, wherein electrical energy can flow through the wall of the elongate member; and an energy delivery device in electrical communication with the elongate member is located distal to the end of the elongate member. The energy delivery device includes an electrode for delivering energy. Methods of using the electrosurgical device include cutting through occlusions and creating transseptal punctures.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,BAYLIS MEDICAL COMPANY INC (2021-09-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/037-868-462-541-047,Patent Application,yes,1,9,1,113,0,A61B2018/00029;;A61B2018/00386;;A61B2018/00982;;A61B2018/1472;;A61B18/1492;;A61B2562/0247;;A61B2018/0038;;A61B2090/064;;A61B18/1492;;A61B2018/00077;;A61B2018/00083;;A61B2562/0247;;A61B2018/00773;;A61B2018/00351;;A61B2218/001;;A61B2018/0022,A61B18/14,,0,0,,,,PENDING
347,US,A1,US 2021/0330355 A1,031-908-720-228-48X,2021-10-28,2021,US 202117231077 A,2021-04-15,US 202117231077 A;;US 202063013617 P,2020-04-22,PUNCTURE DEVICE ASSOCIATED WITH MEDICAL ASSEMBLY,"An elongated medical assembly has a distal-assembly tip. The distal-assembly tip is, at least in part, selectively maneuverable along an assembly-tip movement path terminating proximate to a first biological feature of a biological structure of a patient. An elongated puncture device has a distal puncture tip. The distal puncture tip is, at least in part, selectively deployable along a puncture-tip movement path extending from the elongated medical assembly and into, at least in part, the first biological feature, and also extending from the first biological feature toward a second biological feature of the patient.",BAYLIS MEDICAL CO INC,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,BAYLIS MEDICAL COMPANY INC (2021-10-12);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/031-908-720-228-48X,Patent Application,yes,0,2,1,1,0,A61B2017/00247;;A61B2017/00867;;A61B2017/00358;;A61B2017/22097;;A61B2017/22044;;A61B17/3478;;A61B17/221;;A61B2017/2217;;A61F2/24;;A61B2018/00577;;A61B2018/00601;;A61B18/1477;;A61B17/3478;;A61B2017/00247;;A61B17/00234;;A61B18/14;;A61B18/1206;;A61B2017/00318;;A61B2017/06071;;A61B2018/00601;;A61B2018/1452;;A61B2018/1475;;A61F2/0022;;A61B2017/0237;;A61B2017/00296;;A61B17/221;;A61B2018/1432;;A61B2018/00071;;A61B2018/00279;;A61B2018/00577;;A61B18/1492;;A61B2017/00026;;A61B2017/00243;;A61B2017/2212;;A61B2018/00273;;A61B2017/00017;;A61B2017/003;;A61B17/06066;;A61B2018/00184;;A61B18/1477;;A61B2018/144;;A61B2018/1412;;A61B2018/1407;;A61B2018/1425,A61B17/34;;A61B17/00,,0,0,,,,PENDING
348,WO,A1,WO 2021/140236 A1,035-387-454-179-877,2021-07-15,2021,EP 2021050322 W,2021-01-10,GB 202000257 A,2020-01-09,VEHICLE CONTROL SYSTEM AND METHOD,"Aspects of the present invention relate to a control system (1) for controlling generation of a steering overlay signal (SOV) to control a trajectory of a host vehicle (2). The control system (1) includes one or more controllers (20) and is configured to identify a lateral boundary (BD-n) of the host-vehicle lane of travel (LT-n). The control system (1) monitors a position of the host vehicle in relation to the lateral boundary (BD-n) of the host-vehicle lane of travel (LT-n). A lateral velocity (VLAT) of the host vehicle (2) is determined by the control system (1). The steering overlay signal is generated in dependence on a determination that the host vehicle is approaching or traversing the lateral boundary (BD-n) of the host-vehicle lane of travel (LT-n) and that the determined lateral velocity (VLAT) is greater than or equal to a first lateral velocity threshold (THV). In an alternative arrangement, the control system (1) determines a lateral separation (DLAT) between the host vehicle (2) and an object (27). Aspects of the present invention also relate to a vehicle (2) having a control system (1) for controlling trajectory; and a method of controlling a trajectory of a host vehicle (2).",JAGUAR LAND ROVER LTD,CALDWELL ROBYN;;FUSCONI DENIS;;DAVIES GARETH;;STANGER KIERON,,https://lens.org/035-387-454-179-877,Patent Application,yes,5,0,8,10,0,B62D15/025;;G06V20/588;;G06V20/58;;B60W30/12;;B62D15/025;;B60W2552/53;;B60W2554/801;;G06V20/58;;G06V20/588;;B60W30/12;;B60W40/109,B62D15/02;;B60W30/12;;G05D1/02;;G06K9/00,,0,0,,,,PENDING
349,EP,A4,EP 2967714 A4,136-670-216-322-098,2016-10-19,2016,EP 14764721 A,2014-03-14,US 201361781231 P;;IB 2014059830 W,2013-03-14,ELECTROSURGICAL DEVICE HAVING A LUMEN,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,"BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-19);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2022-12-06)",https://lens.org/136-670-216-322-098,Search Report,no,5,0,12,113,0,A61B18/1492;;A61B2018/00029;;A61B2018/00101;;A61B17/3207;;A61B2017/00247;;A61B2017/22094;;A61B2018/00351;;A61B2018/00601;;A61B2018/1417,A61B18/12;;A61B17/22,,0,0,,,,ACTIVE
350,US,A1,US 2016/0000501 A1,179-285-911-297-807,2016-01-07,2016,US 201514851412 A,2015-09-11,US 201514851412 A;;IB 2014059696 W;;US 201361777368 P;;US 201361781231 P;;US 92629210 A;;US 201113286041 A,2010-11-08,Medical Device Having a Support Structure,"Embodiments of medical devices and methods are disclosed. The medical devices typically comprise a flexible elongate member defining a lumen, and a support spine affixed to the distal end and extending proximally therefrom within the elongate member lumen. In some embodiments, the support spine is configured to support at least a portion of the elongate member when the elongate member is bent or curved. Some embodiments include apertures at or near the distal end for enabling fluid communication between the lumen and the outside environment. In some embodiments, the support wire extends proximally from the distal end within a distal portion of the lumen such that a proximal portion of the lumen is substantially unobstructed, thereby reducing turbulence of fluid flowing through the lumen.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,BAYLIS MEDICAL COMPANY INC (2015-09-08);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/179-285-911-297-807,Patent Application,yes,16,5,4,113,0,A61B2218/002;;A61B2090/3966;;A61B18/1492;;A61B2018/00351;;A61B2018/00029;;A61B2018/00101;;A61B2018/00357;;A61B2018/0041;;A61B2018/00601;;A61B2018/1472;;A61B18/1492;;A61B2018/00351;;A61B2218/002;;A61B2090/3966;;A61B2018/00029;;A61B2018/00101;;A61B2018/00357;;A61B2018/0041;;A61B2018/00601;;A61B2018/1472,A61B18/14,,0,0,,,,ACTIVE
351,CA,A1,CA 3171215 A1,191-343-946-901-688,2021-09-23,2021,CA 3171215 A,2021-03-15,US 202062992250 P;;IB 2021052142 W,2020-03-20,"LACERATION SYSTEM AND DEVICE, AND METHODS FOR LACERATION","A laceration device for use in medical procedures includes a shaft having a proximal portion defining a proximal end, and an opposed distal portion defining a distal end. A perforation electrode is at the distal end, and a first electrical connector extends proximally from the perforation electrode for connection to a power source. An outwardly extending barb is positioned proximal of the distal end. The barb has an inner end proximate the shaft and an outer end opposite the inner end. A laceration electrode is proximal of and adjacent the inner end of the barb, and a second electrical connector extends proximally from the laceration electrode for connection to the power source.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,,https://lens.org/191-343-946-901-688,Patent Application,no,0,0,9,9,0,A61B18/14;;A61B2018/00357;;A61B18/1206;;A61B2018/1425;;A61B2090/036;;A61B2018/00571;;A61B2090/374;;A61B18/14;;A61B18/1477;;A61B18/1206;;A61B2018/1425;;A61B2018/1465;;A61B2018/00357;;A61B2018/00613;;A61B2018/00083;;A61B18/1206;;A61B18/1477;;A61B2018/00369;;A61B2018/00577,A61B17/34;;A61B18/00;;A61B18/14,,0,0,,,,PENDING
352,WO,A1,WO 2009/013526 A1,028-340-754-515-340,2009-01-29,2009,GB 2008050590 W,2008-07-17,GB 0714344 A,2007-07-24,BIOMETRIC ATTENDANCE VERIFICATION,"A biometric attendance system comprises a portable device (11) (such as a personal digital assistant (PDA), laptop computer or a mobile phone) comprises a database (19), a GPS receiver (16) and a biometric sensor (17) arranged to monitor a person's voice, fingerprint, face, iris or other unique personal characteristic. The device (11) is arranged to biometrically verify the identify of a user from user records on the database (19) and to generate an event record containing the identity of a verified user, the time at which the verification occurred and the global position where the verification occurred. The event records can be downloaded onto a remote database (13) for analysis and storage. User records can also be downloaded onto the remote database (13) or uploaded.",UNIV WALES SWANSEA;;CLEMENT ROBERT MARC;;CHEN BIN;;DAVIES GARETH HUW,CLEMENT ROBERT MARC;;CHEN BIN;;DAVIES GARETH HUW,,https://lens.org/028-340-754-515-340,Patent Application,yes,4,73,5,5,0,G07C1/10;;G07C2209/63;;G07C9/26;;G07C9/257;;G07C9/27;;G07C9/28;;G07C1/10;;G07C9/257;;G07C9/27;;G07C9/28;;G07C9/27,G07C1/10;;G07C9/00,,0,0,,,,PENDING
353,AU,A1,AU 2021/260978 A1,053-882-569-546-13X,2022-10-06,2022,AU 2021/260978 A,2021-04-14,US 202063013604 P;;IB 2021053085 W,2020-04-22,"Laceration system and device, and methods for laceration","A laceration device for use in medical procedures includes a shaft having opposed proximal and distal portions. A clamp extends from the distal portion. The clamp has first and second clamp arms. The clamp is movable between an open and closed positions. In the open position, the first clamp arm is spaced apart from the second clamp arm. In the closed position, the first clamp arm is moved towards the second clamp arm. A clamp actuator is connected to the clamp via the shaft and is manipulatable to move the clamp between the open and closed positions. A radiofrequency electrode (RF) is associated with the first clamp arm. The RF electrode has a first perforation surface that is positioned to face the second clamp arm when the clamp is in the closed position. An electrical connector extends proximally from the RF electrode for connection to a power source.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,,https://lens.org/053-882-569-546-13X,Patent Application,no,0,0,9,9,0,A61B18/1445;;A61B2018/00601;;A61B2018/00577;;A61B2018/146;;A61B2018/00613;;A61B18/1445;;A61B90/39;;A61B2018/146;;A61B2018/00178;;A61B2018/00577;;A61B2018/00601;;A61B2018/00613;;A61B2090/3966;;A61B18/1445;;A61B2018/00059;;A61B2018/00601,A61B18/14;;A61B17/00;;A61B18/00;;A61B18/12,,0,0,,,,PENDING
354,US,A1,US 2023/0285074 A1,064-574-904-785-192,2023-09-14,2023,US 202318181935 A,2023-03-10,US 202318181935 A;;US 202263318856 P,2022-03-11,MEDICAL DEVICES AND METHODS FOR CARRYING OUT A MEDICAL PROCEDURE,"A method for carrying out a medical procedure includes advancing a medical device towards a puncture site in a patient's body and positioning a radiofrequency puncture electrode of the medical device adjacent the puncture site; delivering radiofrequency energy from the radiofrequency puncture electrode to create a puncture in the puncture site; advancing the medical device through the puncture to position an auxiliary electrode of the medical device adjacent a target site in the patient's body; and using the auxiliary electrode for diagnosis, mapping, and/or treatment at the target site.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG CHARLENE;;KOON LAUREN;;MORIYAMA EDUARDO;;DAVIES GARETH,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2023-03-09),https://lens.org/064-574-904-785-192,Patent Application,yes,0,0,2,2,0,A61B18/1492;;A61B18/1477;;A61B2018/1407;;A61B2018/1422;;A61B2018/1425;;A61B2018/144;;A61B2018/0038;;A61B2018/00351;;A61B2018/00375;;A61B2018/00577;;A61B2018/00267;;A61B2018/0022;;A61B2017/00867;;A61B2017/00053;;A61B18/1492;;A61B2017/00247;;A61B2018/00279;;A61B2018/00601;;A61B2018/00839;;A61M2025/0042,A61B18/14,,0,0,,,,PENDING
355,US,A1,US 2021/0166487 A1,151-003-952-977-29X,2021-06-03,2021,US 202017108609 A,2020-12-01,US 202017108609 A;;US 201962942583 P,2019-12-02,DECOUPLED CONTENT MANAGEMENT SYSTEM FOR AUGMENTED REALITY,"Methods, systems, and platforms for generating and deploying an augmented reality (AR) experience using a decoupled content management system is described herein. A method for providing an AR experience can include selecting a plurality of digital content associated with the AR experience from a content database at a decoupled CMS, defining one or more triggering mechanisms for actuating the AR experience, selecting one or more augmented reality assets based on a selected media asset type, generating an AR bundle comprised of at least one of the selected plurality of digital content, the one or more triggering mechanisms and the one or more augmented reality assets, and publishing the AR bundle to an end user application.",BUNDLAR,WREN MATTHEW;;DAVIES GARETH;;GARDNER LEWIS;;MARTIN JOHN,,https://lens.org/151-003-952-977-29X,Patent Application,yes,2,4,1,1,0,H04L67/131;;G06T19/006;;G06F9/547;;H04L67/131,G06T19/00;;G06F9/54;;H04L29/06,,1,0,,,"Toole J., ‘Combining artificial intelligence and augmented reality in mobile apps’, [online, downloaded 02 December 2023], https://heartbeat.comet.ml/combining-artificial-intelligence-and-augmented-reality-in-mobile-apps-e0e0ad2cfddc, 07 June. (Year: 2019)",PENDING
356,BR,B1,BR 122021016202 B1,128-572-846-020-853,2022-09-06,2022,BR 122021016202 A,2013-11-20,IB 2013060287 W;;US 201361863265 P;;US 201361863579 P,2013-08-07,DISPOSITIVO MÉDICO E SISTEMA PARA PUNCIONAR TECIDOS,"São descritos novos e originais dispositivos médicos (300) e métodos associados, para facilitar uma punção eficiente e repetível de um local de tecido, enquanto que permitindo o acesso vascular a partir de vários locais de acesso do corpo de um paciente. Os dispositivos médicos descritos (300) incluem dilatadores (100) e fios utilizáveis separadamente ou em combinação e configurados para facilitar o acesso ao tecido e a punção em várias localizações anatômicas a partir dos locais de acesso desejados. Os dispositivos médicos (300) incluem uma ou mais seções apresentando flexibilidade suficiente para acessar o local do tecido a partir do local de acesso, enquanto que mantendo rigidez suficiente para desempenhar uma ou mais funções adicionais.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN;;BECA BOGDAN;;ALLEY FERRYL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (IE) (2023-06-06),https://lens.org/128-572-846-020-853,Granted Patent,no,0,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/01;;A61B17/34;;A61B18/14;;A61M25/06;;A61M29/00,,0,0,,,,ACTIVE
357,EP,A1,EP 4120944 A1,160-074-505-353-738,2023-01-25,2023,EP 21772575 A,2021-03-15,US 202062992250 P;;IB 2021052142 W,2020-03-20,"LACERATION SYSTEM AND DEVICE, AND METHODS FOR LACERATION",,BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,,https://lens.org/160-074-505-353-738,Patent Application,yes,0,0,9,9,0,A61B18/14;;A61B2018/00357;;A61B18/1206;;A61B2018/1425;;A61B2090/036;;A61B2018/00571;;A61B2090/374;;A61B18/14;;A61B18/1477;;A61B18/1206;;A61B2018/1425;;A61B2018/1465;;A61B2018/00357;;A61B2018/00613;;A61B2018/00083;;A61B18/1206;;A61B18/1477;;A61B2018/00369;;A61B2018/00577,A61B18/14;;A61B17/34;;A61B18/00,,0,0,,,,PENDING
358,US,A1,US 2023/0309929 A1,187-587-128-273-065,2023-10-05,2023,US 202117928947 A,2021-05-25,US 202117928947 A;;US 202063051080 P;;US 202063041319 P;;IB 2021054539 W,2020-06-19,DEFLECTABLE ELONGATED GUIDEWIRE ASSEMBLY,"An elongated guidewire assembly has a distal segment configured to be selectively maneuvered, along an elongated Introducer assembly. The distal segment is configured to selectively transmit a tenting force from the elongated guidewire assembly to the first biological wall after the distal segment has contacted, at least in part, the first biological wall and the distal segment has been selectively protracted away from the distal introducer assembly.",BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DICICCO MATTHEW;;MORIYAMA EDUARDO;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2021-09-07);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/187-587-128-273-065,Patent Application,yes,0,0,9,9,0,A61B2017/00053;;A61B2017/00243;;A61B2090/3966;;A61M25/09;;A61B17/3478;;A61M2025/09175;;A61B2018/00613;;A61B2018/144;;A61B18/1492;;A61B2018/00351;;A61B18/1492;;A61B17/3478;;A61B90/39;;A61M25/09;;A61B2018/00351;;A61B2018/00613;;A61B2018/144;;A61B2017/00243;;A61B2090/3966;;A61M2025/09175;;A61B2090/3966;;A61B5/6851;;A61B5/6885;;A61B5/7455;;A61M2025/09066;;A61M2025/09175,A61B5/00,,0,0,,,,PENDING
359,EP,A1,EP 4087771 A1,027-569-347-709-622,2022-11-16,2022,EP 21700399 A,2021-01-10,GB 202000257 A;;EP 2021050322 W,2020-01-09,VEHICLE CONTROL SYSTEM AND METHOD,,JAGUAR LAND ROVER LTD,CALDWELL ROBYN;;FUSCONI DENIS;;DAVIES GARETH;;STANGER KIERON,,https://lens.org/027-569-347-709-622,Patent Application,yes,0,0,8,10,0,B62D15/025;;G06V20/588;;G06V20/58;;B60W30/12;;B62D15/025;;B60W2552/53;;B60W2554/801;;G06V20/58;;G06V20/588;;B60W30/12;;B60W40/109,B62D15/02;;B60W30/12;;G05D1/02;;G06K9/00,,0,0,,,,PENDING
360,US,A1,US 2021/0307783 A1,140-132-320-729-564,2021-10-07,2021,US 202117223122 A,2021-04-06,US 202117223122 A;;US 202063006427 P,2020-04-07,ELONGATED MEDICAL ASSEMBLY,An elongated medical assembly is configured to be maneuverable proximate to a first biological feature of a patient. The elongated medical assembly is also configured to facilitate movement along an elongated length of the elongated medical assembly of a first medical device and a second medical device.,BAYLIS MEDICAL CO INC,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,BAYLIS MEDICAL COMPANY INC (2021-10-12);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/140-132-320-729-564,Patent Application,yes,24,1,2,2,0,A61B2017/00867;;A61B2017/00247;;A61B2018/00601;;A61B18/14;;A61B2018/00369;;A61B17/3478;;A61B2017/22044;;A61B17/3478;;A61B17/00234;;A61B2017/00336;;A61B2017/00247;;A61B2017/3488,A61B17/34;;A61B17/00,,0,0,,,,ACTIVE
361,US,A1,US 2008/0208121 A1,029-840-559-320-06X,2008-08-28,2008,US 90544807 A,2007-10-01,US 90544807 A;;US 82744606 P,2006-09-29,Method for creating a channel through a foreign material,"A method for creating a channel through a foreign material located in a body of a patient, the foreign material defining a material first surface and a substantially opposed material second surface, the channel extending through the foreign material between the material first and second surfaces, the method using an apparatus including a substantially elongated member defining a proximal end region and a substantially longitudinally opposed distal end region, the apparatus including an electrode located about the distal end region, the method comprising: introducing the distal end region into the body of the patient; positioning the electrode substantially adjacent to the material first surface; energizing the electrode with a radiofrequency current; and using the electrode energized with the radiofrequency current to deliver energy into the foreign material to create the channel.",YOUSSEF BIADILLAH;;AMANDA HARTLEY;;DAVIES GARETH;;VISRAM NAHEED,YOUSSEF BIADILLAH;;AMANDA HARTLEY;;DAVIES GARETH;;VISRAM NAHEED,BAYLIS MEDICAL COMPANY INC (2008-04-30);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/029-840-559-320-06X,Patent Application,yes,6,31,2,2,0,A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00875;;A61B2018/00898;;A61B18/1492;;A61B2018/00702;;A61B8/12;;A61B2018/00083;;A61B2018/00875;;A61B2018/00214;;A61B2018/00898,A61B18/14,604/114,0,0,,,,ACTIVE
362,US,B2,US 8048071 B2,081-201-139-308-798,2011-11-01,2011,US 90544807 A,2007-10-01,US 90544807 A;;US 82744606 P,2006-09-29,Method for creating a channel through a foreign material,"A method for creating a channel through a foreign material located in a body of a patient, the foreign material defining a material first surface and a substantially opposed material second surface, the channel extending through the foreign material between the material first and second surfaces, the method using an apparatus including a substantially elongated member defining a proximal end region and a substantially longitudinally opposed distal end region, the apparatus including an electrode located about the distal end region, the method comprising: introducing the distal end region into the body of the patient; positioning the electrode substantially adjacent to the material first surface; energizing the electrode with a radiofrequency current; and using the electrode energized with the radiofrequency current to deliver energy into the foreign material to create the channel.",BAYLIS MEDICAL CO INC,YOUSSEF BIADILLAH;;AMANDA HARTLEY;;DAVIES GARETH;;VISRAM NAHEED,BAYLIS MEDICAL COMPANY INC (2008-04-30);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/081-201-139-308-798,Granted Patent,yes,12,18,2,2,0,A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00875;;A61B2018/00898;;A61B18/1492;;A61B2018/00702;;A61B8/12;;A61B2018/00083;;A61B2018/00875;;A61B2018/00214;;A61B2018/00898,A61B18/18,606/41;;606/40;;128/898,9,9,016-249-543-201-808;;043-109-600-839-627;;104-863-760-253-161;;013-298-075-588-774;;027-249-765-633-859;;035-621-526-377-948;;023-749-888-124-005;;030-041-321-743-550;;026-941-827-483-484,10.1583/09-2903c.1;;20426637;;10.1583/09-2903.1;;20426636;;10.1583/1545-1550(2001)008<0003:eagwra>2.0.co;2;;11220465;;10.1177/152660280100800102;;10.1583/1545-1550(2007)14[158:ivafoa]2.0.co;2;;17484531;;10.1177/152660280701400207;;16473163;;10.1016/j.jvs.2005.10.059;;15056015;;10.1583/03-1180.1;;14656175;;10.1583/1545-1550(2003)010<0946:rfoegf>2.0.co;2;;10.1177/152660280301000518;;10.1583/1545-1550(2001)008<0016:fiegfa>2.0.co;2;;10.1177/152660280100800103;;11220463;;10.1177/152660280100800101;;10.1583/1545-1550(2001)008<0001:sbpdea>2.0.co;2;;11220462,"Frank R. Arko III, ""In Pursuit of an Off-the-Shelf Fenestrated Stent-Graft: Radiofrequency Perforation for in Vivo Antegrade Fenestration"", ""Journal of Endovascular Therapy"", Apr. 2010, pp. 199-200, vol. 17, No. 2, Publisher. Journal of Endovascular Therapy, Published in: US.;;Leonard W. H. Tse et al., ""Radiofrequency Perforation System for in Vivo Antegrade Fenestration of Aortic Stent-Grafts"", ""Journal of Endovascular Therapy"", Apr. 2010, pp. 192-198, vol. 17, No. 2, Publisher: Journal of Endovascular Therapy, Published in: US.;;John Lennon Anderson et al., ""Endoluminal Aortic Grafting with Renal and Superior Mesenteric Artery Incorporation by Graft Fenestration"", ""Journal of Endovascular Therapy"", Feb. 2001, pp. 3-15, No. 8, Publisher: Journal of Endovascular Therapy, Published in: US.;;Abstract of Leonard W.H. Tse et al., ""In Vivo Antegrade Fenestration of Abdominal Aortic Stent-Grafts"", ""Journal of Endovascular Therapy"", Apr. 2007, pp. 158-167, vol. 14, No. 2, Publisher: Joumal of Endovascular Therapy, Published in: US.;;Timothy A.M. Chuter, ""Branched and Fenestrated Stent Grafts for Endovascular Repair of Thoracic Aortic Aneurysms"", Oct. 27, 2005, pp. 111A-115A, vol. 43, No. A, Publisher: The Society for Vascular Sugery, Published in: US.;;Abstract of Richard G. McWilliams et al., ""In Situ Stent-Graft Fenestration to Preserve the Left Subclavian Artery"", ""Journal of Endovascular Therapy"", Apr. 2004, pp. 170-174, vol. 11, No. 2, Publisher: Journal of Endovascular Therapy, Published in: US.;;Abstract of Richard G. McWilliams et al., ""Retrograde Fenestration of Endoluminal Grafts From Target Vessels: Feasibility, Technique, and Potential Usage"", ""Journal of Endovascular Therapy"", Oct. 2003, pp. 946-952, vol. 10, No. 5, Publisher: Journal of Endovascular Therapy, Published in: US.;;Brendan M. Stanley et al., ""Fenestration in Endovascular Grafts for Aortic Aneurysm Repair: New Horizons for Preserving Blood Flow in Branch Vessels"", ""Journal of Endovascular Therapy"", Feb. 2001, pp. 16-24, vol. 8, Publisher: Journal of Endovascular Therapy, Published in: US.;;Edward B. Diethrich, ""Side Branch Preservation During Endovascular Aortic Aneurysm Repair"", ""Journal of Endovascular Therapy"", Feb. 2001, pp. 1-2, vol. 8, Publisher: Journal of Endovascular Therapy, Published in: US.",ACTIVE
363,US,A1,US 2023/0165627 A1,114-666-947-523-053,2023-06-01,2023,US 202117905982 A,2021-03-15,US 202117905982 A;;US 202062992250 P;;IB 2021052142 W,2020-03-20,"LACERATION SYSTEM AND DEVICE, AND METHODS FOR LACERATION","A laceration device for use in medical procedures includes a shaft having a proximal portion defining a proximal end, and an opposed distal portion defining a distal end. A perforation electrode is at the distal end, and a first electrical connector extends proximally from the perforation electrode for connection to a power source. An outwardly extending barb is positioned proximal of the distal end. The barb has an inner end proximate the shaft and an outer end opposite the inner end. A laceration electrode is proximal of and adjacent the inner end of the barb, and a second electrical connector extends proximally from the laceration electrode for connection to the power source.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,BAYLIS MEDICAL COMPANY INC (2021-09-09);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/114-666-947-523-053,Patent Application,yes,0,0,9,9,0,A61B18/14;;A61B2018/00357;;A61B18/1206;;A61B2018/1425;;A61B2090/036;;A61B2018/00571;;A61B2090/374;;A61B18/14;;A61B18/1477;;A61B18/1206;;A61B2018/1425;;A61B2018/1465;;A61B2018/00357;;A61B2018/00613;;A61B2018/00083;;A61B18/1206;;A61B18/1477;;A61B2018/00369;;A61B2018/00577,A61B18/14;;A61B18/12,,0,0,,,,PENDING
364,US,B2,US 11419676 B2,149-856-059-883-373,2022-08-23,2022,US 201916381102 A,2019-04-11,US 201916381102 A;;US 201514851412 A;;IB 2014059696 W;;US 201361777368 P;;US 201361781231 P,2013-03-12,Medical device having a support structure,"Embodiments of medical devices and methods are disclosed. The medical devices typically comprises an elongate member with a proximal region and a distal region. The distal region comprises a flexible portion that is more flexible than the proximal region of the medical device. The flexible region includes gaps in the sidewall of the elongate member. Furthermore, the medical device comprises a rigid energy delivery device at the distal end which is configured to deliver energy to tissue when energy is supplied to the energy delivery device. In some embodiments, the medical device comprises a support spine configured to provide support to the flexible portion of the elongate member.",BAYLIS MEDICAL CO INC;;BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,BAYLIS MEDICAL COMPANY INC (2019-07-15);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/149-856-059-883-373,Granted Patent,yes,3,0,10,113,0,A61M25/0041;;A61M25/0054;;A61M2025/0003;;A61M2025/09133;;A61N1/056;;A61B2018/00101;;A61B5/6852;;A61B5/0215;;A61B2090/3966;;A61B18/1492;;A61B2017/00309;;A61B2017/00986;;A61B2018/00077;;A61M25/0138;;A61M25/0144;;A61B2090/3966;;A61B5/6852;;A61B5/0215;;A61N1/056;;A61M25/0054;;A61B2018/00101;;A61M2025/0003;;A61M25/0041;;A61M2025/09133;;A61B18/1492;;A61B2018/00351;;A61B2218/002,A61B18/14;;A61B5/00;;A61B5/0215;;A61B18/00;;A61B90/00;;A61M25/00;;A61M25/09;;A61N1/05,,0,0,,,,ACTIVE
365,WO,A1,WO 2021/205370 A1,173-019-465-501-459,2021-10-14,2021,IB 2021052907 W,2021-04-07,US 202063007703 P,2020-04-09,MEDICAL ASSEMBLIES HAVING SENSOR DEVICES,"A primary elongated medical assembly is configured to be positioned in, and movable along, a patient. A secondary elongated medical assembly is configured to be positioned in, and movable along, the patient. The primary elongated medical assembly has a primary sensor device. The secondary elongated medical assembly has a secondary sensor device. The primary elongated medical assembly and the secondary elongated medical assembly are each configured to be movable relative to each other; this is done in such a way that the primary sensor device and the secondary sensor device are movable relative to each other.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,,https://lens.org/173-019-465-501-459,Patent Application,yes,7,0,3,3,0,A61B5/367;;A61B5/287;;A61B18/1492;;A61B2018/00577;;A61B2018/00357;;A61B2018/00839;;A61B2034/2051;;A61B2090/397;;A61B2090/0811;;A61B5/6852;;A61B5/743;;A61B5/06;;A61B2505/05;;A61B5/367;;A61B5/287;;A61B5/065;;A61B2505/05;;A61B2562/0209;;A61B2562/043,A61B5/367;;A61B5/00;;A61B5/287;;A61B18/00;;A61B18/14,,0,0,,,,PENDING
366,WO,A3,WO 2015/107506 A3,191-721-962-564-357,2015-11-19,2015,IB 2015050396 W,2015-01-19,US 201461929158 P;;US 201461932891 P,2014-01-20,COLLAPSIBLE TIP RE-ENTRY CATHETER,"A method and apparatus are disclosed for a catheter having a side-port through which a wire may be advanced. The catheter comprises a catheter body, the catheter body defining at least a primary catheter lumen and at least one side-port in communication with the primary catheter lumen, and a distal portion of the catheter extending distal to the at least one side-port, the side-port being configured to allow travel 5 of a wire or other component therethrough, wherein the distal portion of the catheter is radially collapsible.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DAVIES GARETH;;STRACHAN ANNA;;LEUNG LINUS;;UHM YUN,,https://lens.org/191-721-962-564-357,Search Report,yes,5,0,6,12,0,A61M25/0169;;A61M2025/0025;;A61M2025/0183;;A61L29/06;;A61L29/14;;A61M25/008;;A61M25/0169;;A61M2025/0025;;A61M2025/0183;;A61L29/14;;A61L29/06;;A61M25/008;;A61B17/320783;;A61B2017/320056;;A61F2/844;;A61M25/0021;;A61M25/005;;A61M25/0054;;A61M25/007;;A61M25/0108,A61M25/16;;A61M25/00,,0,0,,,,PENDING
367,WO,A1,WO 2014/141197 A1,003-460-299-260-153,2014-09-18,2014,IB 2014059830 W,2014-03-14,US 201361781231 P,2013-03-14,ELECTROSURGICAL DEVICE HAVING A LUMEN,"In some embodiments, an electrosurgical device comprises: an electrically conductive elongate member for traversing body vasculature wherein electrical energy can flow through the wall of the elongate member; the elongate member defining a hollow lumen with one or more apertures at or near its distal end; and an energy delivery device in electrical communication with the elongate member (i.e. with the wall defining the lumen) at or about the distal end of the elongate member. The energy delivery device includes an electrode for delivering energy and a thermal shield is positioned between the electrode and the elongate member.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,,https://lens.org/003-460-299-260-153,Patent Application,yes,5,10,12,113,0,A61B18/1492;;A61B2018/00029;;A61B2018/00101;;A61B17/3207;;A61B2017/00247;;A61B2017/22094;;A61B2018/00351;;A61B2018/00601;;A61B2018/1417,A61B17/22;;A61B18/12,,0,0,,,,PENDING
368,WO,A1,WO 2021/214603 A1,009-733-451-068-887,2021-10-28,2021,IB 2021053085 W,2021-04-14,US 202063013604 P,2020-04-22,"LACERATION SYSTEM AND DEVICE, AND METHODS FOR LACERATION","A laceration device for use in medical procedures includes a shaft having opposed proximal and distal portions. A clamp extends from the distal portion. The clamp has first and second clamp arms. The clamp is movable between an open and closed positions. In the open position, the first clamp arm is spaced apart from the second clamp arm. In the closed position, the first clamp arm is moved towards the second clamp arm. A clamp actuator is connected to the clamp via the shaft and is manipulatable to move the clamp between the open and closed positions. A radiofrequency electrode (RF) is associated with the first clamp arm. The RF electrode has a first perforation surface that is positioned to face the second clamp arm when the clamp is in the closed position. An electrical connector extends proximally from the RF electrode for connection to a power source.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,,https://lens.org/009-733-451-068-887,Patent Application,yes,5,0,9,9,0,A61B18/1445;;A61B2018/00601;;A61B2018/00577;;A61B2018/146;;A61B2018/00613;;A61B18/1445;;A61B90/39;;A61B2018/146;;A61B2018/00178;;A61B2018/00577;;A61B2018/00601;;A61B2018/00613;;A61B2090/3966;;A61B18/1445;;A61B2018/00059;;A61B2018/00601,A61B18/14;;A61B17/00;;A61B18/00;;A61B18/12,,0,0,,,,PENDING
369,GB,A,GB 2468213 A,063-310-303-680-058,2010-09-01,2010,GB 201003295 A,2010-02-26,GB 0903390 A;;GB 0912085 A,2009-02-27,A gasket for use in installing a sanitary fitting to a wall,"The invention relates to a gasket 7 for use in installing a sanitary fitting 1 to a wall 3 and comprises a gasket element which has an outer edge pre-shaped to correspond to at least a perimeter portion of a rear face of the sanitary fitting that faces the wall when the fitting is installed, such the gasket prevents water from running down between the sanitary fitting and the wall. The gasket may comprise a sheet of resilient material such as silicon rubber material or similar. The gasket may comprise cut-outs through which pipes may pass. The gasket may be adhered to the rear of the fitting by an adhesive. Later embodiments relate to a sanitary fitting with an elongate cut-out (71 figure 5) in which a rope type gasket (70 figure 5) is received, a method of installing a sanitary fitting comprising said gasket, and apparatus comprising a sanitary fitting comprising said gasket.",SWIFT INVENT LTD,DAVIES THOMAS WILLIAM GARETH;;MAINWARING WILLIAM HUGH KYNASTON,,https://lens.org/063-310-303-680-058,Patent Application,no,4,0,4,6,0,A47K3/008;;E03C1/322;;E03D11/14;;E03D11/16;;E03C1/322,E03C1/322;;A47K3/00;;E03D11/14,,0,0,,,,DISCONTINUED
370,US,B2,US 11324548 B2,071-797-130-023-179,2022-05-10,2022,US 201615242191 A,2016-08-19,US 201615242191 A;;US 201562208404 P;;US 201562208138 P,2015-08-21,Transvascular electrosurgical devices and systems and methods of using the same,"A system, apparatus, and method of using the same are disclosed for carrying out a transvascular procedure such as a Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure using energy to create a tract between the hepatic vein and the portal vein. The present invention provides a flexible puncturing solution to effectively perform a transvascular procedure such as a TIPS procedure while minimizing damage to the liver and surrounding soft tissues or organs.",BAYLIS MEDICAL CO INC,UHM YUN;;DAVIES GARETH;;WOO JASON;;MATHUR PRATEEK,BAYLIS MEDICAL COMPANY INC (2016-08-18);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/071-797-130-023-179,Granted Patent,yes,21,0,3,3,0,A61B2018/144;;A61B2218/007;;A61B2017/00026;;A61B18/1492;;A61B2018/00428;;A61B2018/00529;;A61B2018/00642;;A61B2017/003;;A61B18/1492;;A61B2018/00529;;A61B2018/00642;;A61B2018/144;;A61B2218/007;;A61B2017/00026;;A61B2018/00404;;A61B2018/00196,A61B18/14;;A61B17/00;;A61B18/00,,2,2,004-151-912-578-539;;011-454-482-337-699,10.1007/s00270-014-0931-0;;24934737;;1515726;;10.1016/s1051-0443(92)72010-7,"Tsauo, Jiaywei; Luo, Xuefeng; Ye, Linchao; Three-Dimensional Path Planning Software-Assisted Transjugular Intrahepatic Portosystemic Shunt: A Technical Modification, (Jun. 17, 2015), Cardiovasc Intervent Radiol. 38:742-746 https://doi.org/10.1007/S00270-014-0931-0.;;Harman, et al. Localization of the Portal Vein for Transjugular Catheterization: Percutaneous Placement ofa Metallic Marker with Real-Time US Guidance. J. Vascular and Interventional Radiology, vol. 3, Iss. 3, Aug. 1992, pp. 545-547. doi.org/10.1016/S1051-0443(92)72010-7 (Year: 1992).",ACTIVE
371,US,A1,US 2017/0049511 A1,102-260-600-432-667,2017-02-23,2017,US 201615242191 A,2016-08-19,US 201615242191 A;;US 201562208404 P;;US 201562208138 P,2015-08-21,Transvascular Electrosurgical Devices and Systems and Methods of using the same,"A system, apparatus, and method of using the same are disclosed for carrying out a transvascular procedure such as a Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure using energy to create a tract between the hepatic vein and the portal vein. The present invention provides a flexible puncturing solution to effectively perform a transvascular procedure such as a TIPS procedure while minimizing damage to the liver and surrounding soft tissues or organs.",BAYLIS MEDICAL CO INC,UHM YUN;;DAVIES GARETH;;WOO JASON;;MATHUR PRATEEK,BAYLIS MEDICAL COMPANY INC (2016-08-18);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/102-260-600-432-667,Patent Application,yes,4,9,3,3,0,A61B2018/144;;A61B2218/007;;A61B2017/00026;;A61B18/1492;;A61B2018/00428;;A61B2018/00529;;A61B2018/00642;;A61B2017/003;;A61B18/1492;;A61B2018/00529;;A61B2018/00642;;A61B2018/144;;A61B2218/007;;A61B2017/00026;;A61B2018/00404;;A61B2018/00196,A61B18/14;;A61B6/00;;A61B6/12;;A61B8/12,,1,1,004-151-912-578-539,10.1007/s00270-014-0931-0;;24934737,"Tsauo, Jiaywei; Luo, Xuefeng; Ye, Linchao; Three-Dimensional Path Planning Software-Assisted Transjugular Intrahepatic Portosystemic Shunt: A Technical Modification, (06/17/2015), Cardiovasc Intervent Radiol. 38:742-746 https://doi.org/10.1007/S00270-014-0931-0",ACTIVE
372,GB,A,GB 2615203 A,135-786-755-567-586,2023-08-02,2023,GB 202301824 A,2020-01-09,GB 202301824 A;;GB 202000257 A,2020-01-09,Vehicle control system and method,"A control system is provided for controlling generation of a steering overlay signal to control a trajectory of a host vehicle 2. The control system includes one or more controllers and identifies an object 27, such as a vehicle, external to host vehicle 2. A lateral separation (DLAT, Figure 3A) is determined between host vehicle 2 and object 27, and a lateral velocity (VLAT, Figure 3A) of host vehicle 2 is determined by the control system. The steering overlay signal is generated dependent on a determination that the lateral separation is less than or equal to a lateral separation threshold and that the determined lateral velocity is greater than or equal to a lateral velocity threshold, which may be 0.1 m/s. The system may suppress generation of the overlay signal if the lateral velocity exceeds a second threshold, for example 0.7 m/s, and hysteresis may also be provided. Also provided are a vehicle 2, a method of controlling a trajectory of a vehicle 2 and corresponding software.",JAGUAR LAND ROVER LTD,ROBYN CALDWELL;;DENIS FUSCONI;;GARETH DAVIES;;KIERON STANGER,,https://lens.org/135-786-755-567-586,Patent Application,no,5,0,2,10,0,B62D15/0265;;B60W10/20;;B60W2540/20;;B60W2540/18;;B60W2710/202;;B60W2552/53;;B60W30/12;;B60W2554/801;;B60W2520/12;;B62D15/0265;;B60W30/09;;B60W30/10,B62D15/02;;B60W30/09;;B60W30/10,,0,0,,,,PENDING
373,CA,A1,CA 3172695 A1,065-866-507-684-567,2021-10-28,2021,CA 3172695 A,2021-04-14,US 202063013604 P;;IB 2021053085 W,2020-04-22,"LACERATION SYSTEM AND DEVICE, AND METHODS FOR LACERATION","A laceration device for use in medical procedures includes a shaft having opposed proximal and distal portions. A clamp extends from the distal portion. The clamp has first and second clamp arms. The clamp is movable between an open and closed positions. In the open position, the first clamp arm is spaced apart from the second clamp arm. In the closed position, the first clamp arm is moved towards the second clamp arm. A clamp actuator is connected to the clamp via the shaft and is manipulatable to move the clamp between the open and closed positions. A radiofrequency electrode (RF) is associated with the first clamp arm. The RF electrode has a first perforation surface that is positioned to face the second clamp arm when the clamp is in the closed position. An electrical connector extends proximally from the RF electrode for connection to a power source.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,,https://lens.org/065-866-507-684-567,Patent Application,no,0,0,9,9,0,A61B18/1445;;A61B2018/00601;;A61B2018/00577;;A61B2018/146;;A61B2018/00613;;A61B18/1445;;A61B90/39;;A61B2018/146;;A61B2018/00178;;A61B2018/00577;;A61B2018/00601;;A61B2018/00613;;A61B2090/3966;;A61B18/1445;;A61B2018/00059;;A61B2018/00601,A61B17/00;;A61B18/00;;A61B18/12;;A61B18/14,,0,0,,,,PENDING
374,EP,A1,EP 4028310 A1,076-097-951-557-578,2022-07-20,2022,EP 20768041 A,2020-09-09,GB 201913002 A;;EP 2020075244 W,2019-09-10,STEERING WHEEL OVERLAY SIGNAL METHOD AND APPARATUS,,JAGUAR LAND ROVER LTD,CALDWELL ROBYN;;DAVIES GARETH;;FUSCONI DENIS;;STANGER KIERON,,https://lens.org/076-097-951-557-578,Patent Application,yes,0,0,12,12,0,B62D15/025;;B60W30/12;;B62D15/025;;B60W2552/53;;B60W10/20;;B60W30/12;;B60W2510/202;;B60W2710/202;;B62D15/025;;B62D15/029,B62D15/02;;B60W30/12,,0,0,,,,PENDING
375,US,A1,US 2016/0066989 A1,074-197-732-763-721,2016-03-10,2016,US 201514851353 A,2015-09-11,US 201514851353 A;;IB 2014059830 W;;IB 2014059696 W;;US 201361777368 P;;US 201361781231 P;;US 92629210 A;;US 201113286041 A,2010-11-08,Electrosurgical Device Having a Lumen,"In some embodiments, an electrosurgical device comprises an electrically conductive elongate member for traversing body vasculature defining a hollow lumen with one or more apertures at or near its distal end, wherein electrical energy can flow through the wall of the elongate member; and an energy delivery device in electrical communication with the elongate member located at or about the distal end of the elongate member. The energy delivery device includes an electrode for delivering energy, and a thermal shield positioned between the electrode and the elongate member.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,BAYLIS MEDICAL COMPANY INC (2015-09-08);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/074-197-732-763-721,Patent Application,yes,15,6,4,113,0,A61B2218/002;;A61B2090/3966;;A61B18/1492;;A61B2018/00351;;A61B2018/00029;;A61B2018/00101;;A61B2018/00357;;A61B2018/0041;;A61B2018/00601;;A61B2018/1472;;A61B18/1492;;A61B2018/00351;;A61B2218/002;;A61B2090/3966;;A61B2018/00029;;A61B2018/00101;;A61B2018/00357;;A61B2018/0041;;A61B2018/00601;;A61B2018/1472,A61B18/14,,0,0,,,,ACTIVE
376,US,A1,US 2023/0149076 A1,066-674-079-227-502,2023-05-18,2023,US 202318155478 A,2023-01-17,US 202318155478 A;;IB 2021056368 W;;US 202063052999 P,2020-07-17,SYSTEM AND METHOD FOR PERICARDIAL PUNCTURE,"A method for pericardial puncture includes contacting a pericardium of a heart of a patient with an electrode of a medical device, and while the heart is in a contracted state, delivering radiofrequency energy from the electrode to puncture the pericardium. A stimulus signal can be delivered to the heart to force contraction and transient standstill of the heart in the contracted state. Electrocardiography monitoring and/or medical imaging can be used to determine when the heart is in the contracted state.",BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DAVIES GARETH;;DICICCO MATTHEW;;MORIYAMA EDUARDO,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2023-01-10),https://lens.org/066-674-079-227-502,Patent Application,yes,0,0,4,4,0,A61B2017/00247;;A61B2018/00601;;A61B18/1492;;A61B2018/00708;;A61B2018/00839;;A61B2090/378;;A61B2090/376;;A61N1/362;;A61B17/00234;;A61B18/1492;;A61B2017/00247;;A61B2018/00708;;A61B2018/00839;;A61N1/362,A61B18/14;;A61B17/00;;A61N1/362,,0,0,,,,PENDING
377,EP,A4,EP 3096830 A4,125-044-172-907-774,2018-02-14,2018,EP 15737506 A,2015-01-19,US 201461929158 P;;US 201461932891 P;;IB 2015050396 W,2014-01-20,COLLAPSIBLE TIP RE-ENTRY CATHETER,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;STRACHAN ANNA;;LEUNG LINUS;;UHM YUN,BAYLIS MEDICAL COMPANY INC. (2022-07-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-05),https://lens.org/125-044-172-907-774,Search Report,no,10,0,6,12,0,A61M25/0169;;A61M2025/0025;;A61M2025/0183;;A61L29/06;;A61L29/14;;A61M25/008;;A61M25/0169;;A61M2025/0025;;A61M2025/0183;;A61L29/14;;A61L29/06;;A61M25/008;;A61B17/320783;;A61B2017/320056;;A61F2/844;;A61M25/0021;;A61M25/005;;A61M25/0054;;A61M25/007;;A61M25/0108,A61M25/00;;A61B17/32;;A61B17/3207;;A61F2/844;;A61L29/06;;A61L29/14;;A61M25/01;;A61M25/16,,0,0,,,,PENDING
378,AU,A1,AU 2021/238999 A1,168-771-139-326-442,2022-09-22,2022,AU 2021/238999 A,2021-03-15,US 202062992250 P;;IB 2021052142 W,2020-03-20,"Laceration system and device, and methods for laceration","A laceration device for use in medical procedures includes a shaft having a proximal portion defining a proximal end, and an opposed distal portion defining a distal end. A perforation electrode is at the distal end, and a first electrical connector extends proximally from the perforation electrode for connection to a power source. An outwardly extending barb is positioned proximal of the distal end. The barb has an inner end proximate the shaft and an outer end opposite the inner end. A laceration electrode is proximal of and adjacent the inner end of the barb, and a second electrical connector extends proximally from the laceration electrode for connection to the power source.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,,https://lens.org/168-771-139-326-442,Patent Application,no,0,0,9,9,0,A61B18/14;;A61B2018/00357;;A61B18/1206;;A61B2018/1425;;A61B2090/036;;A61B2018/00571;;A61B2090/374;;A61B18/14;;A61B18/1477;;A61B18/1206;;A61B2018/1425;;A61B2018/1465;;A61B2018/00357;;A61B2018/00613;;A61B2018/00083;;A61B18/1206;;A61B18/1477;;A61B2018/00369;;A61B2018/00577,A61B18/14;;A61B17/34;;A61B18/00,,0,0,,,,PENDING
379,US,B2,US 10765473 B2,192-917-365-840-203,2020-09-08,2020,US 201514851353 A,2015-09-11,US 201514851353 A;;IB 2014059830 W;;IB 2014059696 W;;US 201361777368 P;;US 201361781231 P;;US 92629210 A;;US 201113286041 A,2010-11-08,Electrosurgical device having a lumen,"In some embodiments, an electrosurgical device comprises an electrically conductive elongate member for traversing body vasculature defining a hollow lumen with one or more apertures at or near its distal end, wherein electrical energy can flow through the wall of the elongate member; and an energy delivery device in electrical communication with the elongate member located at or about the distal end of the elongate member. The energy delivery device includes an electrode for delivering energy, and a thermal shield positioned between the electrode and the elongate member.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,BAYLIS MEDICAL COMPANY INC (2015-09-08);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/192-917-365-840-203,Granted Patent,yes,65,0,4,113,0,A61B2218/002;;A61B2090/3966;;A61B18/1492;;A61B2018/00351;;A61B2018/00029;;A61B2018/00101;;A61B2018/00357;;A61B2018/0041;;A61B2018/00601;;A61B2018/1472;;A61B18/1492;;A61B2018/00351;;A61B2218/002;;A61B2090/3966;;A61B2018/00029;;A61B2018/00101;;A61B2018/00357;;A61B2018/0041;;A61B2018/00601;;A61B2018/1472,A61B18/14;;A61B18/00,,6,0,,,"International Search Report of International Application No. PCT/IB2014/059830 dated Aug. 27, 2014.;;European Search Report for European Application No. 14764721.8 dated Sep. 16, 2016.;;Patent Cooperation Treaty, International Search Report Written Opinion of the International Search Authority for International Application No. PCT/IB2014/059830, dated Aug. 27, 2014.;;Patent Cooperation Treaty, International Preliminary Report on Patentability, dated Sep. 15, 2015.;;Japanese Office Action for corresponding Application No. JP2015-562534 dated Dec. 26, 2017.;;JP Office Action dated Aug. 14, 2018.",ACTIVE
380,KR,A,KR 20220166277 A,008-840-928-309-375,2022-12-16,2022,KR 20227034272 A,2021-03-15,US 202062992250 P;;IB 2021052142 W,2020-03-20,"열상 시스템 및 장치, 및 열상을 위한 방법","의료 시술들에 사용하기 위한 열상 장치는 근위 단부를 한정하는 근위 부분 및 원위 단부를 한정하는 반대편의 원위 부분을 갖는 샤프트를 포함한다. 천공 전극이 원위 단부에 있고, 제1 전기 커넥터가 전원에의 연결을 위해 천공 전극으로부터 근위방향으로 연장된다. 외향 연장 미늘이 원위 단부의 근위에 위치된다. 미늘은 샤프트에 근접한 내측 단부 및 내측 단부의 반대편에 있는 외측 단부를 갖는다. 열상 전극이 미늘의 내측 단부의 근위에 있고 내측 단부에 인접하며, 제2 전기 커넥터가 전원에의 연결을 위해 열상 전극으로부터 근위방향으로 연장된다.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,,https://lens.org/008-840-928-309-375,Patent Application,no,0,0,9,9,0,A61B18/14;;A61B2018/00357;;A61B18/1206;;A61B2018/1425;;A61B2090/036;;A61B2018/00571;;A61B2090/374;;A61B18/14;;A61B18/1477;;A61B18/1206;;A61B2018/1425;;A61B2018/1465;;A61B2018/00357;;A61B2018/00613;;A61B2018/00083;;A61B18/1206;;A61B18/1477;;A61B2018/00369;;A61B2018/00577,A61B18/14;;A61B18/00;;A61B18/12,,0,0,,,,PENDING
381,US,A1,US 2022/0226043 A1,017-917-778-573-734,2022-07-21,2022,US 202217716020 A,2022-04-08,US 202217716020 A;;US 201615242191 A;;US 201562208404 P;;US 201562208138 P,2015-08-21,Transvascular Electrosurgical Devices and Systems and Methods of using the same,"A system, apparatus, and method of using the same are disclosed for carrying out a transvascular procedure such as a Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure using energy to create a tract between the hepatic vein and the portal vein. The present invention provides a method using a flexible radiofrequency (RF) catheter having a lumen therethrough. The method involves the steps of advancing the flexible RF catheter into a first vessel; advancing a guiding sheath overtop of the flexible RF catheter; steering the guiding sheath to direct a distal tip of the RF catheter towards a second vessel; and, delivering RF energy via the flexible RF catheter, forming a tract from the first vessel and entering the second vessel.",BAYLIS MEDICAL CO INC,UHM YUN;;DAVIES GARETH;;WOO JASON;;MATHUR PRATEEK,BAYLIS MEDICAL COMPANY INC (2016-08-18);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/017-917-778-573-734,Patent Application,yes,5,0,3,3,0,A61B2018/144;;A61B2218/007;;A61B2017/00026;;A61B18/1492;;A61B2018/00428;;A61B2018/00529;;A61B2018/00642;;A61B2017/003;;A61B18/1492;;A61B2018/00529;;A61B2018/00642;;A61B2018/144;;A61B2218/007;;A61B2017/00026;;A61B2018/00404;;A61B2018/00196,A61B18/14,,0,0,,,,PENDING
382,GB,A,GB 2590951 A,067-958-905-112-549,2021-07-14,2021,GB 202000257 A,2020-01-09,GB 202000257 A,2020-01-09,Vehicle control system and method,"A control system is provided to generate a steering overlay signal for controlling a trajectory of a vehicle 2. The control system includes controllers 20 and identifies a lateral boundary BDn of a lane of travel LT-n. The control system also monitors a position of the vehicle in relation to lateral boundary BD-n, and determines a lateral velocity VLAT of the vehicle. The steering overlay signal is generated when the vehicle is approaching or traversing lateral boundary BD-n and the determined lateral velocity VLAT is greater than or equal to a first lateral velocity threshold, which may suitably be 0.1 m/s. The system may suppress generating the steering overlay signal if the lateral velocity exceeds an upper threshold, which may be 0.7 m/s. An alternative arrangement has the control system determine a lateral separation between the vehicle 2 and an object 27, for example another vehicle. A vehicle, method and software are also provided.",JAGUAR LAND ROVER LTD,ROBYN CALDWELL;;DENIS FUSCONI;;GARETH DAVIES;;KIERON STANGER,,https://lens.org/067-958-905-112-549,Patent Application,no,3,0,8,10,0,B62D15/025;;G06V20/588;;G06V20/58;;B60W30/12;;B62D15/025;;B60W2552/53;;B60W2554/801;;G06V20/58;;G06V20/588;;B60W30/12;;B60W40/109,B62D15/02;;B60W30/12,,0,0,,,,ACTIVE
383,EP,A2,EP 3096830 A2,092-661-614-633-263,2016-11-30,2016,EP 15737506 A,2015-01-19,US 201461929158 P;;US 201461932891 P;;IB 2015050396 W,2014-01-20,COLLAPSIBLE TIP RE-ENTRY CATHETER,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;STRACHAN ANNA;;LEUNG LINUS;;UHM YUN,BAYLIS MEDICAL COMPANY INC. (2022-07-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-05),https://lens.org/092-661-614-633-263,Patent Application,yes,0,0,6,12,0,A61M25/0169;;A61M2025/0025;;A61M2025/0183;;A61L29/06;;A61L29/14;;A61M25/008;;A61M25/0169;;A61M2025/0025;;A61M2025/0183;;A61L29/14;;A61L29/06;;A61M25/008;;A61B17/320783;;A61B2017/320056;;A61F2/844;;A61M25/0021;;A61M25/005;;A61M25/0054;;A61M25/007;;A61M25/0108,A61M25/00;;A61M25/16,,0,0,,,,PENDING
384,CA,A1,CA 3172993 A1,109-628-823-587-33X,2021-10-14,2021,CA 3172993 A,2021-04-07,US 202063007703 P;;IB 2021052907 W,2020-04-09,MEDICAL ASSEMBLIES HAVING SENSOR DEVICES,"A primary elongated medical assembly is configured to be positioned in, and movable along, a patient. A secondary elongated medical assembly is configured to be positioned in, and movable along, the patient. The primary elongated medical assembly has a primary sensor device. The secondary elongated medical assembly has a secondary sensor device. The primary elongated medical assembly and the secondary elongated medical assembly are each configured to be movable relative to each other; this is done in such a way that the primary sensor device and the secondary sensor device are movable relative to each other.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,,https://lens.org/109-628-823-587-33X,Patent Application,no,0,0,3,3,0,A61B5/367;;A61B5/287;;A61B18/1492;;A61B2018/00577;;A61B2018/00357;;A61B2018/00839;;A61B2034/2051;;A61B2090/397;;A61B2090/0811;;A61B5/6852;;A61B5/743;;A61B5/06;;A61B2505/05;;A61B5/367;;A61B5/287;;A61B5/065;;A61B2505/05;;A61B2562/0209;;A61B2562/043,A61B5/367;;A61B5/287,,0,0,,,,PENDING
385,US,A1,US 2021/0290268 A1,117-349-845-181-208,2021-09-23,2021,US 202016823547 A,2020-03-19,US 202016823547 A,2020-03-19,MEDICAL SHEATH AND RELATED SYSTEMS AND METHODS,"A medical sheath includes an elongate member having a proximal portion defining a proximal end and a distal portion defining a distal end. A first lumen extends through the elongate member and is open at the proximal and the distal end for passage of a medical device through the lumen. The medical sheath further includes an anchoring mechanism that is deployable from the elongate member. The anchoring mechanism includes an anchor that is removably securable to an anatomical feature to secure the elongate member to the anatomical feature, and a connector securing the anchor to the elongate member.",BAYLIS MEDICAL CO INC,LAU KAYLIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;BALKOVEC CHRISTIAN,BAYLIS MEDICAL COMPANY INC (2020-03-10);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/117-349-845-181-208,Patent Application,yes,1,0,2,2,0,A61B17/3478;;A61B2017/00247;;A61B2017/003;;A61B2017/3488;;A61B2017/0417;;A61B17/3478;;A61B2017/3488;;A61B2017/003;;A61B2017/00247,A61B17/34,,0,0,,,,ACTIVE
386,US,A1,US 2022/0354572 A1,043-513-626-887-795,2022-11-10,2022,US 202217873734 A,2022-07-26,US 202217873734 A;;US 201916381102 A;;US 201514851412 A;;IB 2014059696 W;;US 201361777368 P;;US 201361781231 P,2013-03-12,Medical Device Having a Support Structure,"Embodiments of medical devices and methods are disclosed. The medical devices typically comprise a flexible elongate member defining a lumen, and a support spine affixed to the distal end and extending proximally therefrom within the elongate member lumen. In some embodiments, the support spine is pre-shaped such that the support spine biases the distal region of the elongate member to adopt a straight configuration, or the support spine biases at least a portion of the distal region of the elongate member to adopt a curved shape to form a curved portion. Some embodiments include apertures at or near the distal end for enabling fluid communication between the lumen and the outside environment. In some embodiments, the support wire extends proximally from the distal end within a distal portion of the lumen such that a proximal portion of the lumen is substantially unobstructed.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,BAYLIS MEDICAL COMPANY INC (2019-07-15);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/043-513-626-887-795,Patent Application,yes,0,0,10,113,0,A61M25/0041;;A61M25/0054;;A61M2025/0003;;A61M2025/09133;;A61N1/056;;A61B2018/00101;;A61B5/6852;;A61B5/0215;;A61B2090/3966;;A61B18/1492;;A61B2017/00309;;A61B2017/00986;;A61B2018/00077;;A61M25/0138;;A61M25/0144;;A61B2090/3966;;A61B5/6852;;A61B5/0215;;A61N1/056;;A61M25/0054;;A61B2018/00101;;A61M2025/0003;;A61M25/0041;;A61M2025/09133;;A61B18/1492;;A61B2018/00351;;A61B2218/002,A61B18/14;;A61B5/00;;A61B5/0215;;A61N1/05,,0,0,,,,PENDING
387,CA,A1,CA 3181848 A1,053-328-798-830-611,2021-12-23,2021,CA 3181848 A,2021-05-25,US 202063041319 P;;US 202063051080 P;;IB 2021054539 W,2020-06-19,DEFLECTABLE ELONGATED GUIDEWIRE ASSEMBLY,"An elongated guidewire assembly has a distal segment configured to be selectively maneuvered, along an elongated introducer assembly. The distal segment is configured to selectively transmit a tenting force from the elongated guidewire assembly to the first biological wall after the distal segment has contacted, at least in part, the first biological wall and the distal segment has been selectively protracted away from the distal introducer assembly.",BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DICICCO MATTHEW;;MORIYAMA EDUARDO;;DAVIES GARETH,,https://lens.org/053-328-798-830-611,Patent Application,no,0,0,9,9,0,A61B2017/00053;;A61B2017/00243;;A61B2090/3966;;A61M25/09;;A61B17/3478;;A61M2025/09175;;A61B2018/00613;;A61B2018/144;;A61B18/1492;;A61B2018/00351;;A61B18/1492;;A61B17/3478;;A61B90/39;;A61M25/09;;A61B2018/00351;;A61B2018/00613;;A61B2018/144;;A61B2017/00243;;A61B2090/3966;;A61M2025/09175;;A61B2090/3966;;A61B5/6851;;A61B5/6885;;A61B5/7455;;A61M2025/09066;;A61M2025/09175,A61B17/00;;A61B17/34;;A61B18/00;;A61B18/14;;A61M25/09,,0,0,,,,PENDING
388,WO,A2,WO 2012/173809 A2,085-945-631-591-756,2012-12-20,2012,US 2012/0040795 W,2012-06-04,US 201161492783 P,2011-06-02,METHOD OF IDENTIFYING DE NOVO COPY NUMBER VARIANTS (CNV) USING MZ TWINS DISCORDANT FOR ATTENTION PROBLEMS/DISORDERS,The present disclosure relates to methods of identifying copy number variation (CNV) events and sizes that are associated with attention problems (AP) and identifying one or more CNVs which correlate with such disorders.,EHLI ERIK;;DAVIES GARETH;;ABDELLAOUI ABDEL;;HUDZIAK JAMES,EHLI ERIK;;DAVIES GARETH;;ABDELLAOUI ABDEL;;HUDZIAK JAMES,,https://lens.org/085-945-631-591-756,Patent Application,yes,0,3,2,2,0,C12Q1/6883;;C12Q2600/156,C12Q1/68,,0,0,,,,PENDING
389,EP,B1,EP 2968846 B1,073-776-218-074-798,2022-05-04,2022,EP 14763003 A,2014-03-12,US 201361777368 P;;US 201361781231 P;;IB 2014059696 W,2013-03-12,MEDICAL DEVICE HAVING A SUPPORT STRUCTURE,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,"BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-19);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2022-12-06)",https://lens.org/073-776-218-074-798,Granted Patent,yes,1,0,10,113,0,A61M25/0041;;A61M25/0054;;A61M2025/0003;;A61M2025/09133;;A61N1/056;;A61B2018/00101;;A61B5/6852;;A61B5/0215;;A61B2090/3966;;A61B18/1492;;A61B2017/00309;;A61B2017/00986;;A61B2018/00077;;A61M25/0138;;A61M25/0144;;A61B2090/3966;;A61B5/6852;;A61B5/0215;;A61N1/056;;A61M25/0054;;A61B2018/00101;;A61M2025/0003;;A61M25/0041;;A61M2025/09133;;A61B18/1492;;A61B2018/00351;;A61B2218/002,A61B18/12;;A61B17/22,,0,0,,,,ACTIVE
390,US,A1,US 2023/0190360 A1,089-802-497-563-080,2023-06-22,2023,US 202117996238 A,2021-04-14,US 202117996238 A;;US 202063013604 P;;IB 2021053085 W,2020-04-22,"LACERATION SYSTEM AND DEVICE, AND METHODS FOR LACERATION","A laceration device for use in medical procedures includes a shaft having opposed proximal and distal portions. A clamp extends from the distal portion. The clamp has first and second clamp arms. The clamp is movable between an open and closed positions. In the open position, the first clamp arm is spaced apart from the second clamp arm. In the closed position, the first clamp arm is moved towards the second clamp arm. A clamp actuator is connected to the clamp via the shaft and is manipulatable to move the clamp between the open and closed positions. A radiofrequency electrode (RF) is associated with the first clamp arm. The RF electrode has a first perforation surface that is positioned to face the second clamp arm when the clamp is in the closed position. An electrical connector extends proximally from the RF electrode for connection to a power source.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/089-802-497-563-080,Patent Application,yes,0,0,9,9,0,A61B18/1445;;A61B2018/00601;;A61B2018/00577;;A61B2018/146;;A61B2018/00613;;A61B18/1445;;A61B90/39;;A61B2018/146;;A61B2018/00178;;A61B2018/00577;;A61B2018/00601;;A61B2018/00613;;A61B2090/3966;;A61B18/1445;;A61B2018/00059;;A61B2018/00601,A61B18/14,,0,0,,,,PENDING
391,WO,A2,WO 2015/107506 A2,107-288-906-618-444,2015-07-23,2015,IB 2015050396 W,2015-01-19,US 201461929158 P;;US 201461932891 P,2014-01-20,COLLAPSIBLE TIP RE-ENTRY CATHETER,"A method and apparatus are disclosed for a catheter having a side-port through which a wire may be advanced. The catheter comprises a catheter body, the catheter body defining at least a primary catheter lumen and at least one side-port in communication with the primary catheter lumen, and a distal portion of the catheter extending distal to the at least one side-port, the side-port being configured to allow travel 5 of a wire or other component therethrough, wherein the distal portion of the catheter is radially collapsible.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DAVIES GARETH;;STRACHAN ANNA;;LEUNG LINUS;;UHM YUN,,https://lens.org/107-288-906-618-444,Patent Application,yes,0,0,6,12,0,A61M25/0169;;A61M2025/0025;;A61M2025/0183;;A61L29/06;;A61L29/14;;A61M25/008;;A61M25/0169;;A61M2025/0025;;A61M2025/0183;;A61L29/14;;A61L29/06;;A61M25/008;;A61B17/320783;;A61B2017/320056;;A61F2/844;;A61M25/0021;;A61M25/005;;A61M25/0054;;A61M25/007;;A61M25/0108,A61M25/16;;A61M25/00,,0,0,,,,PENDING
392,BR,A2,BR 112022020988 A2,165-269-794-309-718,2022-12-06,2022,BR 112022020988 A,2021-04-14,IB 2021053085 W;;US 202063013604 P,2020-04-22,SISTEMA E DISPOSITIVO DE LACERAÇÃO E MÉTODOS PARA LACERAÇÃO,"SISTEMA E DISPOSITIVO DE LACERAÇÃO E MÉTODOS PARA LACERAÇÃO. Um dispositivo de laceração para uso em procedimentos médicos inclui um eixo de acionamento que tem porções proximal e distal opostas. Uma garra se estende a partir da porção distal. A garra tem um primeiro e um segundo braços de aperto. A garra é móvel entre as posições aberta e fechada. Na posição aberta, o primeiro braço de aperto é espaçado do segundo braço de aperto. Na posição fechada, o primeiro braço de aperto é movido em direção ao segundo braço de aperto. Um atuador de aperto é conectado à garra através do eixo de acionamento e é manipulável para mover a garra entre as posições aberta e fechada. Um eletrodo de radiofrequência (RF) está associado ao primeiro braço de aperto. O eletrodo de RF tem uma primeira superfície de perfuração que é posicionada para ficar voltada para o segundo braço de aperto quando a garra está na posição fechada. Um conector elétrico se estende proximalmente a partir do eletrodo de RF para conexão a uma fonte de energia.",BOSTON SCIENT MEDICAL DEVICE LIMITED,JACKIE LEUNG;;EDUARDO MORIYAMA;;GARETH DAVIES;;KAYLIE LAU,,https://lens.org/165-269-794-309-718,Patent Application,no,0,0,9,9,0,A61B18/1445;;A61B2018/00601;;A61B2018/00577;;A61B2018/146;;A61B2018/00613;;A61B18/1445;;A61B90/39;;A61B2018/146;;A61B2018/00178;;A61B2018/00577;;A61B2018/00601;;A61B2018/00613;;A61B2090/3966;;A61B18/1445;;A61B2018/00059;;A61B2018/00601,A61B18/14;;A61B17/00;;A61B18/00;;A61B18/12,,0,0,,,,PENDING
393,US,A1,US 2007/0066975 A1,166-738-028-552-554,2007-03-22,2007,US 52075406 A,2006-09-14,US 52075406 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 59629705 P,2003-01-21,Method for creating a channel through an occlusion and apparatus therefor,"A method for creating a channel through an occlusion located in a substantially elongated body vessel of a patient, The method uses a channel creating apparatus defining an apparatus distal end portion insertable into the body vessel, the channel creating apparatus including an energy delivery component operatively coupled to the apparatus distal end portion for delivering energy substantially adjacent the apparatus distal end portion. The method includes: inserting the apparatus distal end portion into the body vessel; creating a channel first portion through the occlusion harder section using, at least in part, a delivery of energy into the occlusion harder portion; and creating a channel second portion through the occlusion softer portion by pushing the apparatus distal end portion through at least a portion of the occlusion softer portion substantially without delivering energy into the occlusion softer portion.",WONG CHRISTINE;;DAVIES GARETH;;LEUNG RAMSEY;;MOSLEY MARK,WONG CHRISTINE;;DAVIES GARETH;;LEUNG RAMSEY;;MOSLEY MARK,BAYLIS MEDICAL COMPANY INC (2008-05-12);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/166-738-028-552-554,Patent Application,yes,5,37,2,113,0,A61B18/24;;A61B18/24;;A61B18/1492;;A61B18/1492,A61B18/18,606/45,0,0,,,,EXPIRED
394,US,B2,US 10857329 B2,025-771-350-125-405,2020-12-08,2020,US 201615214084 A,2016-07-19,US 201615214084 A;;IB 2015050396 W;;US 201461932891 P;;US 201461929158 P,2014-01-20,Collapsible tip re-entry catheter,"A method and apparatus are disclosed for a catheter having a side-port through which a wire may be advanced. The catheter comprises a catheter body, the catheter body defining at least a primary catheter lumen and at least one side-port in communication with the primary catheter lumen, and a distal portion of the catheter extending distal to the at least one side-port, the side-port being configured to allow travel of a wire or other component therethrough, wherein the distal portion of the catheter is radially collapsible.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;STRACHAN ANNA;;LEUNG LINUS;;UHM YUN,BAYLIS MEDICAL COMPANY INC (2016-07-12);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/025-771-350-125-405,Granted Patent,yes,44,2,6,12,0,A61M25/0169;;A61M2025/0025;;A61M2025/0183;;A61L29/06;;A61L29/14;;A61M25/008;;A61M25/0169;;A61M2025/0025;;A61M2025/0183;;A61L29/14;;A61L29/06;;A61M25/008;;A61B17/320783;;A61B2017/320056;;A61F2/844;;A61M25/0021;;A61M25/005;;A61M25/0054;;A61M25/007;;A61M25/0108,A61B17/32;;A61M25/00;;A61B17/3207;;A61F2/844;;A61L29/06;;A61L29/14;;A61M25/01,,4,0,,,"European Patent Office Supplementary Search Report, European Application No. 15737506.4, dated Jan. 15, 2018.;;Patent Cooperation Treaty, International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/IB2015/050396, dated Jul. 9, 2015.;;Patent Cooperation Treaty, Preliminary Report on Patentability, for International Application No PCT/IB2015/050396, dated Jul. 26, 2016.;;European Patent Office Supplementary Search Report, European Application No. 15743285.7, dated Aug. 29, 2017.",ACTIVE
395,JP,A,JP 2023076660 A,044-706-329-236-90X,2023-06-01,2023,JP 2023061895 A,2023-04-06,JP 2021016433 A;;US 201361781231 P,2013-03-14,ELECTROSURGICAL DEVICE WITH LUMEN,"To provide an electrosurgical device for applying electric energy for traversing a tissue of a body region of a patient.SOLUTION: In some embodiments, an electrosurgical device is configured so that electric energy can flow through a wall of a slender member, and comprises: the conductive slender member for traversing a blood circulatory system of a body; the slender member for regulating a hollow lumen having one or more apertures on a distal end or the vicinity thereof; and an energy delivery device (namely, wall for regulating a lumen) for electrically coupling to the slender member on the distal end or the surrounding thereof. The energy delivery device includes an electrode for providing energy, and a thermal shield is arranged between the electrode and the slender member.SELECTED DRAWING: Figure 1",BOSTON SCIENT MEDICAL DEVICE LTD,GARETH DAVIES;;JOHN PAUL URBANSKI;;RUND ABOU-MARIE,,https://lens.org/044-706-329-236-90X,Patent Application,no,0,0,12,113,0,A61B18/1492;;A61B2018/00029;;A61B2018/00101;;A61B17/3207;;A61B2017/00247;;A61B2017/22094;;A61B2018/00351;;A61B2018/00601;;A61B2018/1417,A61B18/14,,0,0,,,,PENDING
396,GB,A,GB 2536658 A,061-704-627-298-030,2016-09-28,2016,GB 201504979 A,2015-03-24,GB 201504979 A,2015-03-24,Controlling data flow between processors in a processing system,"The program processor uses an interfacing module and a group of two or more register banks to offload operations of the particular type to the dedicated processor for execution thereon. Whilst the dedicated processor is accessing one register bank for executing a current operation, the interfacing module can concurrently load data for a subsequent operation into a different one of the register banks. The use of multiple register banks allows the dedicated processor to spend a greater proportion of its time executing operations, toggling or switching between registers. The dedicated processor may for executing operations of a particular type (e.g. data parallel operations such as vector processing operations). This allows for a time saving in processing operations based on serial write and read from a single register bank, where the interfacing module indicates which memory addresses are valid addresses to write to, so that data is loaded into a register bank, whilst in parallel the other register bank is used for processing.",IMAGINATION TECH LTD,PAUL MURRIN;;GARETH JOHN DAVIES;;ADRIAN JOHN ANDERSON,,https://lens.org/061-704-627-298-030,Patent Application,no,3,0,8,8,0,G06F15/825;;G06F15/167;;G06F15/167;;G06F15/167;;G06F9/30098;;G06F15/76,G06F15/167,,0,0,,,,ACTIVE
397,BR,A2,BR 112022025387 A2,108-261-100-346-554,2023-01-24,2023,BR 112022025387 A,2021-05-25,IB 2021054539 W;;US 202063051080 P;;US 202063041319 P,2020-06-19,CONJUNTO DE FIO-GUIA ALONGADO DEFLETÍVEL,"CONJUNTO DE FIO-GUIA ALONGADO DEFLETÍVEL Trata-se de um conjunto de fio-guia alongado que tem um segmento distal configurado para ser seletivamente manobrado, ao longo de um conjunto introdutor alongado. O segmento distal é configurado para transmitir seletivamente uma força de penetração a partir do conjunto de fio-guia alongado para a primeira parede biológica após o segmento distal entrar em contato, ao menos em parte, com a primeira parede biológica e o segmento distal ter sido seletivamente projetado na direção oposta ao conjunto introdutor alongado.",BOSTON SCIENT MEDICAL DEVICE LIMITED,CHRISTIAN BALKOVEC;;MATTHEW DICICCO;;EDUARDO MORIYAMA;;GARETH DAVIES,,https://lens.org/108-261-100-346-554,Patent Application,no,0,0,9,9,0,A61B2017/00053;;A61B2017/00243;;A61B2090/3966;;A61M25/09;;A61B17/3478;;A61M2025/09175;;A61B2018/00613;;A61B2018/144;;A61B18/1492;;A61B2018/00351;;A61B18/1492;;A61B17/3478;;A61B90/39;;A61M25/09;;A61B2018/00351;;A61B2018/00613;;A61B2018/144;;A61B2017/00243;;A61B2090/3966;;A61M2025/09175;;A61B2090/3966;;A61B5/6851;;A61B5/6885;;A61B5/7455;;A61M2025/09066;;A61M2025/09175,A61B18/14;;A61B17/00;;A61B17/34;;A61B18/00;;A61M25/09,,0,0,,,,PENDING
398,GB,B,GB 2586976 B,123-313-712-995-737,2022-08-03,2022,GB 201913002 A,2019-09-10,GB 201913002 A,2019-09-10,Steering torque assist method and apparatus,,JAGUAR LAND ROVER LTD,ROBYN CALDWELL;;GARETH DAVIES;;DENIS FUSCONI;;KIERON STANGER,,https://lens.org/123-313-712-995-737,Granted Patent,no,0,0,12,12,0,B62D15/025;;B60W30/12;;B62D15/025;;B60W2552/53;;B60W10/20;;B60W30/12;;B60W2510/202;;B60W2710/202;;B62D15/025;;B62D15/029,B62D15/02;;B60W30/12,,0,0,,,,ACTIVE
399,EP,A4,EP 2968846 A4,166-992-122-478-710,2016-10-19,2016,EP 14763003 A,2014-03-12,US 201361777368 P;;US 201361781231 P;;IB 2014059696 W,2013-03-12,MEDICAL DEVICE HAVING A SUPPORT STRUCTURE,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,"BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-19);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2022-12-06)",https://lens.org/166-992-122-478-710,Search Report,no,6,0,10,113,0,A61M25/0041;;A61M25/0054;;A61M2025/0003;;A61M2025/09133;;A61N1/056;;A61B2018/00101;;A61B5/6852;;A61B5/0215;;A61B2090/3966;;A61B18/1492;;A61B2017/00309;;A61B2017/00986;;A61B2018/00077;;A61M25/0138;;A61M25/0144;;A61B2090/3966;;A61B5/6852;;A61B5/0215;;A61N1/056;;A61M25/0054;;A61B2018/00101;;A61M2025/0003;;A61M25/0041;;A61M2025/09133;;A61B18/1492;;A61B2018/00351;;A61B2218/002,A61B18/12;;A61B17/22,,1,0,,,See also references of WO 2014141105A1,ACTIVE
400,WO,A1,WO 2021/048234 A1,175-658-141-410-554,2021-03-18,2021,EP 2020075244 W,2020-09-09,GB 201913002 A,2019-09-10,STEERING WHEEL OVERLAY SIGNAL METHOD AND APPARATUS,"The present disclosure relates to a control system (1) for controlling generation of a steering wheel overlay signal to control a trajectory (α) of a host vehicle (2). The control system (1) includes one or more controllers (20). The control system (1) is configured to determine a principal axis (PD) of a lane of travel (LT-n). A target trajectory (αT) is determined for the host vehicle (2) in dependence on the determined principal axis (PD). The steering wheel overlay signal is generated, including an intra- lane steering signal (STQ-LA) for aligning the trajectory (α) of the host vehicle (2) with the target trajectory (αT). The intra-lane steering signal (STQ-LA) is removed when the trajectory (α) is at least substantially aligned with the target trajectory (αT). The present disclosure also relates to a vehicle (2); and a method of controlling generation of a steering wheel overlay signal.",JAGUAR LAND ROVER LTD,CALDWELL ROBYN;;DAVIES GARETH;;FUSCONI DENIS;;STANGER KIERON,,https://lens.org/175-658-141-410-554,Patent Application,yes,5,0,12,12,0,B62D15/025;;B60W30/12;;B62D15/025;;B60W2552/53;;B60W10/20;;B60W30/12;;B60W2510/202;;B60W2710/202;;B62D15/025;;B62D15/029,B62D15/02;;B60W30/12,,0,0,,,,PENDING
401,EP,A1,EP 4167888 A1,186-164-734-332-431,2023-04-26,2023,EP 21825504 A,2021-05-25,US 202063041319 P;;US 202063051080 P;;IB 2021054539 W,2020-06-19,DEFLECTABLE ELONGATED GUIDEWIRE ASSEMBLY,,BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DICICCO MATTHEW;;MORIYAMA EDUARDO;;DAVIES GARETH,,https://lens.org/186-164-734-332-431,Patent Application,yes,0,0,9,9,0,A61B2017/00053;;A61B2017/00243;;A61B2090/3966;;A61M25/09;;A61B17/3478;;A61M2025/09175;;A61B2018/00613;;A61B2018/144;;A61B18/1492;;A61B2018/00351;;A61B18/1492;;A61B17/3478;;A61B90/39;;A61M25/09;;A61B2018/00351;;A61B2018/00613;;A61B2018/144;;A61B2017/00243;;A61B2090/3966;;A61M2025/09175;;A61B2090/3966;;A61B5/6851;;A61B5/6885;;A61B5/7455;;A61M2025/09066;;A61M2025/09175,A61B18/14;;A61B17/00;;A61B17/34;;A61B18/00;;A61M25/09,,0,0,,,,PENDING
402,EP,A1,EP 4052673 A1,002-259-718-591-897,2022-09-07,2022,EP 22157635 A,2014-03-12,US 201361777368 P;;US 201361781231 P;;EP 14763003 A;;IB 2014059696 W,2013-03-12,MEDICAL DEVICE FOR PUNCTURING TISSUE,"A medical device for puncturing tissue is disclosed and includes an elongate member with a proximal region and a distal region, wherein the distal region has a flexible portion which is more flexible than the proximal region. The elongate member has a tubular configuration and includes a metallic layer which is electrically conductive. A rigid energy delivery device is provided at a distal end of the elongate member which is electrically connected to the metallic layer of the elongate member, wherein the rigid energy delivery device is configured to deliver electrical energy to tissue when electrical energy is supplied to the rigid energy delivery device through the metallic layer. The flexible portion includes at least one gap in a sidewall of the elongate member wherein the at least one gap comprises at least one cut in the sidewall.
",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-05),https://lens.org/002-259-718-591-897,Patent Application,yes,17,0,10,113,0,A61M25/0041;;A61M25/0054;;A61M2025/0003;;A61M2025/09133;;A61N1/056;;A61B2018/00101;;A61B5/6852;;A61B5/0215;;A61B2090/3966;;A61B18/1492;;A61B2017/00309;;A61B2017/00986;;A61B2018/00077;;A61M25/0138;;A61M25/0144;;A61B2090/3966;;A61B5/6852;;A61B5/0215;;A61N1/056;;A61M25/0054;;A61B2018/00101;;A61M2025/0003;;A61M25/0041;;A61M2025/09133;;A61B18/1492;;A61B2018/00351;;A61B2218/002,A61B18/12;;A61B17/22,,0,0,,,,PENDING
403,US,A1,US 2023/0037472 A1,085-114-490-431-152,2023-02-09,2023,US 202117758565 A,2021-01-10,GB 202000257 A;;EP 2021050322 W,2020-01-09,VEHICLE CONTROL SYSTEM AND METHOD,A control system for controlling generation of a steering overlay signal to control a trajectory of a host vehicle can include one or more controllers and is configured to identify a lateral boundary of the host-vehicle lane of travel. The control system monitors a position of the host vehicle in relation to the lateral boundary of the host-vehicle lane of travel. A lateral velocity of the host vehicle is determined by the control system. The steering overlay signal is generated based on a determination that the host vehicle is approaching or traversing the lateral boundary of the host-vehicle lane of travel and that the determined lateral velocity is greater than or equal to a first lateral velocity threshold. The control system can determine a lateral separation between the host vehicle and an object.,JAGUAR LAND ROVER LTD,CALDWELL ROBYN;;FUSCONI DENIS;;DAVIES GARETH;;STANGER KIERON,JAGUAR LAND ROVER LIMITED (2022-08-04),https://lens.org/085-114-490-431-152,Patent Application,yes,0,3,8,10,0,B62D15/025;;G06V20/588;;G06V20/58;;B60W30/12;;B62D15/025;;B60W2552/53;;B60W2554/801;;G06V20/58;;G06V20/588;;B60W30/12;;B60W40/109,B60W30/12;;B60W40/109;;G06V20/56;;G06V20/58,,0,0,,,,PENDING
404,EP,A1,EP 4181809 A1,101-615-636-065-778,2023-05-24,2023,EP 21841252 A,2021-07-14,US 202063052999 P;;IB 2021056368 W,2020-07-17,SYSTEM AND METHOD FOR PERICARDIAL PUNCTURE,,BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DAVIES GARETH;;DICICCO MATTHEW;;MORIYAMA EDUARDO,,https://lens.org/101-615-636-065-778,Patent Application,yes,0,0,4,4,0,A61B2017/00247;;A61B2018/00601;;A61B18/1492;;A61B2018/00708;;A61B2018/00839;;A61B2090/378;;A61B2090/376;;A61N1/362;;A61B17/00234;;A61B18/1492;;A61B2017/00247;;A61B2018/00708;;A61B2018/00839;;A61N1/362,A61B18/14;;A61B17/00;;A61B18/00;;A61B18/12,,0,0,,,,PENDING
405,EP,A1,EP 2968846 A1,104-750-990-494-939,2016-01-20,2016,EP 14763003 A,2014-03-12,US 201361777368 P;;US 201361781231 P;;IB 2014059696 W,2013-03-12,MEDICAL DEVICE HAVING A SUPPORT STRUCTURE,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,"BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-19);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2022-12-06)",https://lens.org/104-750-990-494-939,Patent Application,yes,0,3,10,113,0,A61M25/0041;;A61M25/0054;;A61M2025/0003;;A61M2025/09133;;A61N1/056;;A61B2018/00101;;A61B5/6852;;A61B5/0215;;A61B2090/3966;;A61B18/1492;;A61B2017/00309;;A61B2017/00986;;A61B2018/00077;;A61M25/0138;;A61M25/0144;;A61B2090/3966;;A61B5/6852;;A61B5/0215;;A61N1/056;;A61M25/0054;;A61B2018/00101;;A61M2025/0003;;A61M25/0041;;A61M2025/09133;;A61B18/1492;;A61B2018/00351;;A61B2218/002,A61B18/12;;A61B17/22,,0,0,,,,ACTIVE
406,US,B2,US 11826075 B2,104-129-344-438-283,2023-11-28,2023,US 202117223122 A,2021-04-06,US 202117223122 A;;US 202063006427 P,2020-04-07,Elongated medical assembly,An elongated medical assembly is configured to be maneuverable proximate to a first biological feature of a patient. The elongated medical assembly is also configured to facilitate movement along an elongated length of the elongated medical assembly of a first medical device and a second medical device.,BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,BAYLIS MEDICAL COMPANY INC (2021-10-12);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/104-129-344-438-283,Granted Patent,yes,337,0,2,2,0,A61B2017/00867;;A61B2017/00247;;A61B2018/00601;;A61B18/14;;A61B2018/00369;;A61B17/3478;;A61B2017/22044;;A61B17/3478;;A61B17/00234;;A61B2017/00336;;A61B2017/00247;;A61B2017/3488,A61B17/34;;A61B17/00,,0,0,,,,ACTIVE
407,WO,A1,WO 2014/141105 A1,129-739-973-925-215,2014-09-18,2014,IB 2014059696 W,2014-03-12,US 201361777368 P;;US 201361781231 P,2013-03-12,MEDICAL DEVICE HAVING A SUPPORT STRUCTURE,"Embodiments of medical devices and methods are disclosed. The medical devices typically comprise a flexible elongate member defining a lumen, and a support spine affixed to the distal end and extending proximally therefrom within the elongate member lumen. In some embodiments, the support spine is configured to support at least a portion of the elongate member, for example when the elongate member is bent or curved. Some embodiments include: apertures at or near the distal end for enabling fluid communication between the lumen and the outside environment; the support wire extending proximally from the distal end within a distal portion of the lumen such that a proximal portion of the lumen is substantially unobstructed, thereby reducing turbulence of fluid flowing through the lumen.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,,https://lens.org/129-739-973-925-215,Patent Application,yes,5,1,10,113,0,A61M25/0041;;A61M25/0054;;A61M2025/0003;;A61M2025/09133;;A61N1/056;;A61B2018/00101;;A61B5/6852;;A61B5/0215;;A61B2090/3966;;A61B18/1492;;A61B2017/00309;;A61B2017/00986;;A61B2018/00077;;A61M25/0138;;A61M25/0144;;A61B2090/3966;;A61B5/6852;;A61B5/0215;;A61N1/056;;A61M25/0054;;A61B2018/00101;;A61M2025/0003;;A61M25/0041;;A61M2025/09133;;A61B18/1492;;A61B2018/00351;;A61B2218/002,A61M25/01,,1,0,,,See also references of EP 2968846A4,PENDING
408,EP,A2,EP 2224068 A2,002-781-724-853-330,2010-09-01,2010,EP 10154933 A,2010-02-26,GB 0903390 A;;GB 0912085 A,2009-02-27,Method and apparatus for use in the installation of sanitary fittings,"A gasket for use in installing a sanitary fitting to a wall comprises a gasket element which has an outer edge that is pre-shaped to correspond to at least a perimeter portion of a rear face of the sanitary fitting that faces the wall when the fitting is installed, such that in use the gasket prevents water from running down between the sanitary fitting and the wall. A method of installing the sanitary fitting comprises locating the gasket between the fitting and the wall prior to final fixing of the fitting, the gasket being so arranged as to prevent or at least reduce the amount of water running down from above the fitting into a space between the rear of the fitting and the wall. A sanitary fitting may be provided for use with the gasket which has a rear face which in use faces a wall, an upper face which meets the rear face at an interface, and in which the rear face includes an elongate cut-out within which a rope type gasket can be received, the cut-out extending over at least a peripheral portion of the rear face that corresponds to the interface.
 
 
",SWIFT INVENT LTD,MAINWARING WILLIAM HUGH KYNASTON;;DAVIES THOMAS WILLIAM GARETH,,https://lens.org/002-781-724-853-330,Patent Application,yes,0,0,4,6,0,A47K3/008;;E03C1/322;;E03D11/14;;E03D11/16;;E03C1/322,E03D11/16;;E03D11/14,,0,0,,,,DISCONTINUED
409,EP,A1,EP 2967714 A1,041-669-706-074-215,2016-01-20,2016,EP 14764721 A,2014-03-14,US 201361781231 P;;IB 2014059830 W,2013-03-14,ELECTROSURGICAL DEVICE HAVING A LUMEN,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ABOU-MARIE RUND,"BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-19);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2022-12-06)",https://lens.org/041-669-706-074-215,Patent Application,yes,0,0,12,113,0,A61B18/1492;;A61B2018/00029;;A61B2018/00101;;A61B17/3207;;A61B2017/00247;;A61B2017/22094;;A61B2018/00351;;A61B2018/00601;;A61B2018/1417,A61B18/12;;A61B17/22,,0,0,,,,ACTIVE
410,US,A1,US 2016/0325073 A1,069-205-560-011-334,2016-11-10,2016,US 201615214084 A,2016-07-19,US 201615214084 A;;IB 2015050396 W;;US 201461932891 P;;US 201461929158 P,2014-01-20,Collapsible Tip Re-entry Catheter,"A method and apparatus are disclosed for a catheter having a side-port through which a wire may be advanced. The catheter comprises a catheter body, the catheter body defining at least a primary catheter lumen and at least one side-port in communication with the primary catheter lumen, and a distal portion of the catheter extending distal to the at least one side-port, the side-port being configured to allow travel of a wire or other component therethrough, wherein the distal portion of the catheter is radially collapsible.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;STRACHAN ANNA;;LEUNG LINUS;;UHM YUN,BAYLIS MEDICAL COMPANY INC (2016-07-12);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/069-205-560-011-334,Patent Application,yes,17,5,6,12,0,A61M25/0169;;A61M2025/0025;;A61M2025/0183;;A61L29/06;;A61L29/14;;A61M25/008;;A61M25/0169;;A61M2025/0025;;A61M2025/0183;;A61L29/14;;A61L29/06;;A61M25/008;;A61B17/320783;;A61B2017/320056;;A61F2/844;;A61M25/0021;;A61M25/005;;A61M25/0054;;A61M25/007;;A61M25/0108,A61M25/00;;A61B17/3207;;A61F2/844;;A61M25/01,,0,0,,,,ACTIVE
411,KR,A,KR 20230029758 A,059-753-626-387-647,2023-03-03,2023,KR 20237000306 A,2021-05-25,US 202063041319 P;;US 202063051080 P;;IB 2021054539 W,2020-06-19,편향가능 세장형 가이드와이어 조립체,"세장형 가이드와이어 조립체는 세장형 도입기 조립체를 따라 선택적으로 조종되도록 구성된 원위 세그먼트를 갖는다. 원위 세그먼트는, 원위 세그먼트가 제1 생체 벽과 적어도 부분적으로 접촉하고 원위 세그먼트가 원위 도입기 조립체로부터 멀어지게 선택적으로 연장된 후에, 세장형 가이드와이어 조립체로부터 제1 생체 벽으로 텐팅 힘을 선택적으로 전달하도록 구성된다.",BOSTON SCIENT MEDICAL DEVICE LIMITED,BALKOVEC CHRISTIAN;;DICICCO MATTHEW;;MORIYAMA EDUARDO;;DAVIES GARETH,,https://lens.org/059-753-626-387-647,Patent Application,no,0,0,9,9,0,A61B2017/00053;;A61B2017/00243;;A61B2090/3966;;A61M25/09;;A61B17/3478;;A61M2025/09175;;A61B2018/00613;;A61B2018/144;;A61B18/1492;;A61B2018/00351;;A61B18/1492;;A61B17/3478;;A61B90/39;;A61M25/09;;A61B2018/00351;;A61B2018/00613;;A61B2018/144;;A61B2017/00243;;A61B2090/3966;;A61M2025/09175;;A61B2090/3966;;A61B5/6851;;A61B5/6885;;A61B5/7455;;A61M2025/09066;;A61M2025/09175,A61B18/14;;A61B17/00;;A61B17/34;;A61B18/00;;A61B90/00;;A61M25/09,,0,0,,,,PENDING
412,GB,A,GB 2464903 A,058-768-552-050-325,2010-05-05,2010,GB 201004145 A,2008-07-17,GB 2008050590 W;;GB 0714344 A,2007-07-24,Biometric attendance verification,"A biometric attendance system comprises a portable device (11) (such as a personal digital assistant (PDA), laptop computer or a mobile phone) comprises a database (19), a GPS receiver (16) and a biometric sensor (17) arranged to monitor a person's voice, fingerprint, face, iris or other unique personal characteristic. The device (11) is arranged to biometrically verify the identify of a user from user records on the database (19) and to generate an event record containing the identity of a verified user, the time at which the verification occurred and the global position where the verification occurred. The event records can be downloaded onto a remote database (13) for analysis and storage. User records can also be downloaded onto the remote database (13) or uploaded.",LAING O ROURKE PLC,CLEMENT ROBERT MARC;;CHEN BIN;;DAVIES GARETH HUW,,https://lens.org/058-768-552-050-325,Patent Application,no,4,6,5,5,0,G07C1/10;;G07C2209/63;;G07C9/26;;G07C9/257;;G07C9/27;;G07C9/28;;G07C1/10;;G07C9/257;;G07C9/27;;G07C9/28;;G07C9/27,G07C1/10;;G07C9/00,,0,0,,,,INACTIVE
413,WO,A1,WO 2021/186329 A1,067-463-123-894-641,2021-09-23,2021,IB 2021052142 W,2021-03-15,US 202062992250 P,2020-03-20,"LACERATION SYSTEM AND DEVICE, AND METHODS FOR LACERATION","A laceration device for use in medical procedures includes a shaft having a proximal portion defining a proximal end, and an opposed distal portion defining a distal end. A perforation electrode is at the distal end, and a first electrical connector extends proximally from the perforation electrode for connection to a power source. An outwardly extending barb is positioned proximal of the distal end. The barb has an inner end proximate the shaft and an outer end opposite the inner end. A laceration electrode is proximal of and adjacent the inner end of the barb, and a second electrical connector extends proximally from the laceration electrode for connection to the power source.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,,https://lens.org/067-463-123-894-641,Patent Application,yes,5,0,9,9,0,A61B18/14;;A61B2018/00357;;A61B18/1206;;A61B2018/1425;;A61B2090/036;;A61B2018/00571;;A61B2090/374;;A61B18/14;;A61B18/1477;;A61B18/1206;;A61B2018/1425;;A61B2018/1465;;A61B2018/00357;;A61B2018/00613;;A61B2018/00083;;A61B18/1206;;A61B18/1477;;A61B2018/00369;;A61B2018/00577,A61B18/14;;A61B17/34;;A61B18/00,,0,0,,,,PENDING
414,US,A1,US 2021/0393925 A1,090-038-566-097-488,2021-12-23,2021,US 202117346422 A,2021-06-14,US 202117346422 A;;US 202063040037 P,2020-06-17,STOP-MOVEMENT DEVICE FOR ELONGATED MEDICAL ASSEMBLY,"A stop-movement device is configured to be mounted to a first elongated medical assembly and a second elongated medical assembly. The stop-movement device has a body configured to stop, at least in part, relative movement between the second elongated medical assembly and the first elongated medical assembly.",BAYLIS MEDICAL CO INC,LAU KAYLIE;;DAVIES GARETH;;MORIYAMA EDUARDO;;BALKOVEC CHRISTIAN,BAYLIS MEDICAL COMPANY INC (2021-09-09);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/090-038-566-097-488,Patent Application,yes,3,0,1,1,0,A61B17/3478;;A61B2090/08021;;A61B2090/034;;A61B2017/003;;A61B2017/00247;;A61M29/00;;A61M25/09041;;A61M25/09;;A61B17/00234;;A61B17/3478;;A61M2025/09116;;A61B2017/003;;A61M2025/09175;;A61B2017/00243;;A61B2017/347,A61B17/00;;A61M25/09;;A61B17/34,,0,0,,,,PENDING
415,JP,A,JP 2019072522 A,106-466-892-131-944,2019-05-16,2019,JP 2018243930 A,2018-12-27,US 201361781231 P,2013-03-14,ELECTROSURGICAL DEVICE HAVING LUMEN,"To provide a device for taking efficient measures to recanalize CTO (chronic total occlusion).SOLUTION: An electrosurgical device comprises: an electrically conductive elongate member 6 for traversing body vasculature in which electrical energy can flow through the wall of the elongate member, the elongate member defining a hollow lumen 26 with one or more apertures 25 at or near its distal end; and an energy delivery device 15 in electrical communication with the elongate member (i.e. with the wall defining the lumen) at or about the distal end of the elongate member. The energy delivery device includes an electrode 19 for delivering energy and a thermal shield 3 is positioned between the electrode and the elongate member.SELECTED DRAWING: Figure 2",BAYLIS MEDICAL CO INC,GARETH DAVIES;;JOHN PAUL URBANSKI;;RUND ABOU-MARIE,,https://lens.org/106-466-892-131-944,Patent Application,no,8,2,12,113,0,A61B18/1492;;A61B2018/00029;;A61B2018/00101;;A61B17/3207;;A61B2017/00247;;A61B2017/22094;;A61B2018/00351;;A61B2018/00601;;A61B2018/1417,A61B18/14;;A61B17/32;;A61B18/18,,0,0,,,,ACTIVE
416,EP,A1,EP 4138696 A1,112-117-409-975-357,2023-03-01,2023,EP 21792385 A,2021-04-14,US 202063013604 P;;IB 2021053085 W,2020-04-22,"LACERATION SYSTEM AND DEVICE, AND METHODS FOR LACERATION",,BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG JACKIE;;MORIYAMA EDUARDO;;DAVIES GARETH;;LAU KAYLIE,,https://lens.org/112-117-409-975-357,Patent Application,yes,0,0,9,9,0,A61B18/1445;;A61B2018/00601;;A61B2018/00577;;A61B2018/146;;A61B2018/00613;;A61B18/1445;;A61B90/39;;A61B2018/146;;A61B2018/00178;;A61B2018/00577;;A61B2018/00601;;A61B2018/00613;;A61B2090/3966;;A61B18/1445;;A61B2018/00059;;A61B2018/00601,A61B18/14;;A61B17/00;;A61B18/00;;A61B18/12,,0,0,,,,PENDING
417,GB,B,GB 2464903 B,132-478-944-287-31X,2012-12-12,2012,GB 201004145 A,2008-07-17,GB 2008050590 W;;GB 0714344 A,2007-07-24,Biometric verification system and method,,AWENID LTD,CLEMENT ROBERT MARC;;CHEN BIN;;DAVIES GARETH HUW,,https://lens.org/132-478-944-287-31X,Granted Patent,no,5,0,5,5,0,G07C1/10;;G07C2209/63;;G07C9/26;;G07C9/257;;G07C9/27;;G07C9/28;;G07C1/10;;G07C9/257;;G07C9/27;;G07C9/28;;G07C9/27,G07C1/10;;G07C9/00,,0,0,,,,INACTIVE
418,WO,A1,WO 2022/013791 A1,023-834-295-847-482,2022-01-20,2022,IB 2021056368 W,2021-07-14,US 202063052999 P,2020-07-17,SYSTEM AND METHOD FOR PERICARDIAL PUNCTURE,"A method for pericardial puncture includes contacting a pericardium of a heart of a patient with an electrode of a medical device, and while the heart is in a contracted state, delivering radiofrequency energy from the electrode to puncture the pericardium. A stimulus signal can be delivered to the heart to force contraction and transient standstill of the heart in the contracted state. Electrocardiography monitoring and/or medical imaging can be used to determine when the heart is in the contracted state.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,BALKOVEC CHRISTIAN;;DAVIES GARETH;;DICICCO MATTHEW;;MORIYAMA EDUARDO,,https://lens.org/023-834-295-847-482,Patent Application,yes,5,0,4,4,0,A61B2017/00247;;A61B2018/00601;;A61B18/1492;;A61B2018/00708;;A61B2018/00839;;A61B2090/378;;A61B2090/376;;A61N1/362;;A61B17/00234;;A61B18/1492;;A61B2017/00247;;A61B2018/00708;;A61B2018/00839;;A61N1/362,A61B18/14;;A61B17/00;;A61B18/00;;A61B18/12,,0,0,,,,PENDING
419,BR,A2,BR 112022018390 A2,053-726-260-571-164,2022-11-08,2022,BR 112022018390 A,2021-03-15,IB 2021052142 W;;US 202062992250 P,2020-03-20,SISTEMA E DISPOSITIVO DE LACERAÇÃO E MÉTODOS PARA LACERAÇÃO,"SISTEMA E DISPOSITIVO DE LACERAÇÃO E MÉTODOS PARA LACERAÇÃO. A presente invenção se refere a um dispositivo de laceração para uso em procedimentos médicos, que inclui uma haste tendo uma porção proximal que define uma extremidade proximal, e uma porção distal oposta que define uma extremidade distal. Um eletrodo de perfuração está na extremidade distal, e um primeiro conector elétrico se estende proximalmente a partir do eletrodo de perfuração para conexão a uma fonte de energia. Uma barbela que se estende para fora está em posição proximal à extremidade distal. A barbela tem uma extremidade interna próxima à haste e uma extremidade externa oposta à extremidade interna. Um eletrodo de laceração é proximal e adjacente à extremidade interna da barbela, e um segundo conector elétrico se estende proximalmente a partir do eletrodo de laceração para conexão à fonte de energia.",BOSTON SCIENT MEDICAL DEVICE LIMITED,JACKIE LEUNG;;EDUARDO MORIYAMA;;GARETH DAVIES;;KAYLIE LAU,,https://lens.org/053-726-260-571-164,Patent Application,no,0,0,9,9,0,A61B18/14;;A61B2018/00357;;A61B18/1206;;A61B2018/1425;;A61B2090/036;;A61B2018/00571;;A61B2090/374;;A61B18/14;;A61B18/1477;;A61B18/1206;;A61B2018/1425;;A61B2018/1465;;A61B2018/00357;;A61B2018/00613;;A61B2018/00083;;A61B18/1206;;A61B18/1477;;A61B2018/00369;;A61B2018/00577,A61B18/14;;A61B17/34;;A61B18/00,,0,0,,,,PENDING
420,WO,A1,WO 2021/255553 A1,063-008-364-137-342,2021-12-23,2021,IB 2021054539 W,2021-05-25,US 202063041319 P;;US 202063051080 P,2020-06-19,DEFLECTABLE ELONGATED GUIDEWIRE ASSEMBLY,"An elongated guidewire assembly has a distal segment configured to be selectively maneuvered, along an elongated introducer assembly. The distal segment is configured to selectively transmit a tenting force from the elongated guidewire assembly to the first biological wall after the distal segment has contacted, at least in part, the first biological wall and the distal segment has been selectively protracted away from the distal introducer assembly.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,BALKOVEC CHRISTIAN;;DICICCO MATTHEW;;MORIYAMA EDUARDO;;DAVIES GARETH,,https://lens.org/063-008-364-137-342,Patent Application,yes,5,0,9,9,0,A61B2017/00053;;A61B2017/00243;;A61B2090/3966;;A61M25/09;;A61B17/3478;;A61M2025/09175;;A61B2018/00613;;A61B2018/144;;A61B18/1492;;A61B2018/00351;;A61B18/1492;;A61B17/3478;;A61B90/39;;A61M25/09;;A61B2018/00351;;A61B2018/00613;;A61B2018/144;;A61B2017/00243;;A61B2090/3966;;A61M2025/09175;;A61B2090/3966;;A61B5/6851;;A61B5/6885;;A61B5/7455;;A61M2025/09066;;A61M2025/09175,A61B18/14;;A61B17/00;;A61B17/34;;A61B18/00;;A61M25/09,,0,0,,,,PENDING
421,EP,A3,EP 2224068 A3,125-012-566-160-056,2012-07-25,2012,EP 10154933 A,2010-02-26,GB 0903390 A;;GB 0912085 A,2009-02-27,Method and apparatus for use in the installation of sanitary fittings,"A gasket for use in installing a sanitary fitting to a wall comprises a gasket element which has an outer edge that is pre-shaped to correspond to at least a perimeter portion of a rear face of the sanitary fitting that faces the wall when the fitting is installed, such that in use the gasket prevents water from running down between the sanitary fitting and the wall. A method of installing the sanitary fitting comprises locating the gasket between the fitting and the wall prior to final fixing of the fitting, the gasket being so arranged as to prevent or at least reduce the amount of water running down from above the fitting into a space between the rear of the fitting and the wall. A sanitary fitting may be provided for use with the gasket which has a rear face which in use faces a wall, an upper face which meets the rear face at an interface, and in which the rear face includes an elongate cut-out within which a rope type gasket can be received, the cut-out extending over at least a peripheral portion of the rear face that corresponds to the interface.
 
 
",SWIFT INVENT LTD,MAINWARING WILLIAM HUGH KYNASTON;;DAVIES THOMAS WILLIAM GARETH,,https://lens.org/125-012-566-160-056,Search Report,yes,4,0,4,6,0,A47K3/008;;E03C1/322;;E03D11/14;;E03D11/16;;E03C1/322,E03D11/16;;E03D11/14,,0,0,,,,DISCONTINUED
422,GB,B,GB 2346892 B,052-188-324-004-707,2002-10-09,2002,GB 9903380 A,1999-02-16,GB 9903380 A,1999-02-16,Grease for constant velocity joints,,GKN TECHNOLOGY LTD;;GKN AUTOMOTIVE AG;;GKN AUTOMOTIVE GMBH,FISH GARETH;;DAVIES TREVOR DAVID;;COOPER JENNIFER SARAH;;E JISHENG;;ISAAC ROBERT GARETH,,https://lens.org/052-188-324-004-707,Granted Patent,no,2,1,15,15,0,C10M169/00;;C10M169/00;;C10M101/02;;C10M101/02;;C10M105/36;;C10M105/36;;C10M107/02;;C10M107/02;;C10M117/02;;C10M117/02;;C10M117/04;;C10M117/04;;C10M117/06;;C10M117/06;;C10M125/26;;C10M125/26;;C10M133/12;;C10M133/12;;C10M135/10;;C10M135/10;;C10M135/18;;C10M135/18;;C10M137/08;;C10M137/08;;C10M137/10;;C10M137/10;;C10M2201/087;;C10M2201/087;;C10M2201/10;;C10M2201/10;;C10M2201/102;;C10M2201/102;;C10M2201/105;;C10M2201/105;;C10M2203/1006;;C10M2203/1006;;C10M2203/1025;;C10M2203/1025;;C10M2203/1045;;C10M2203/1045;;C10M2203/1065;;C10M2203/1065;;C10M2203/1085;;C10M2203/1085;;C10M2205/0206;;C10M2205/0206;;C10M2207/1225;;C10M2207/1225;;C10M2207/123;;C10M2207/123;;C10M2207/1245;;C10M2207/1245;;C10M2207/125;;C10M2207/125;;C10M2207/1265;;C10M2207/1265;;C10M2207/1285;;C10M2207/1285;;C10M2207/129;;C10M2207/129;;C10M2207/166;;C10M2207/166;;C10M2207/186;;C10M2207/186;;C10M2207/206;;C10M2207/206;;C10M2207/22;;C10M2207/22;;C10M2207/246;;C10M2207/246;;C10M2207/282;;C10M2207/282;;C10M2207/2825;;C10M2207/2825;;C10M2207/2855;;C10M2207/2855;;C10M2207/34;;C10M2207/34;;C10M2215/06;;C10M2215/06;;C10M2215/064;;C10M2215/064;;C10M2215/065;;C10M2215/065;;C10M2215/066;;C10M2215/066;;C10M2215/067;;C10M2215/067;;C10M2215/068;;C10M2215/068;;C10M2219/022;;C10M2219/022;;C10M2219/044;;C10M2219/044;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2223/043;;C10M2223/043;;C10M2223/045;;C10M2223/045;;C10N2010/02;;C10N2010/02;;C10N2010/04;;C10N2010/04;;C10N2010/12;;C10N2010/12;;C10N2040/02;;C10N2040/02,C10M101/02;;C10M105/04;;C10M105/32;;C10M105/36;;C10M107/02;;C10M117/02;;C10M133/12;;C10M135/10;;C10M137/10;;C10M159/18;;C10M169/00;;C10N10/02;;C10N10/04;;C10N10/12;;C10N30/06;;C10N30/10;;C10N30/12;;C10N40/04;;C10N50/10,C5F FLC           FLC;;C5F F104          FLC;;C5F F111          FLC;;C5F F113          FLC;;C5F F114          FLC;;U1S S1364,0,0,,,,EXPIRED
423,DE,T1,DE 10084148 T1,188-764-071-623-335,2002-01-03,2002,DE 10084148 T,2000-02-08,GB 9903380 A;;GB 0000360 W,1999-02-16,Schmierfettzusammensetzung für Gleichlaufgelenke,,GKN AUTOMOTIVE GMBH,FISH GARETH;;COOPER JENNIFER SARAH;;JISHENG E;;DAVIES TREVOR DAVID;;ISAAC ROBERT GARETH,"GKN DRIVELINE INTERNATIONAL GMBH, 53797 LOHMAR, DE (2004-07-29)",https://lens.org/188-764-071-623-335,Patent Application,no,0,0,15,15,0,C10M169/00;;C10M169/00;;C10M101/02;;C10M101/02;;C10M105/36;;C10M105/36;;C10M107/02;;C10M107/02;;C10M117/02;;C10M117/02;;C10M117/04;;C10M117/04;;C10M117/06;;C10M117/06;;C10M125/26;;C10M125/26;;C10M133/12;;C10M133/12;;C10M135/10;;C10M135/10;;C10M135/18;;C10M135/18;;C10M137/08;;C10M137/08;;C10M137/10;;C10M137/10;;C10M2201/087;;C10M2201/087;;C10M2201/10;;C10M2201/10;;C10M2201/102;;C10M2201/102;;C10M2201/105;;C10M2201/105;;C10M2203/1006;;C10M2203/1006;;C10M2203/1025;;C10M2203/1025;;C10M2203/1045;;C10M2203/1045;;C10M2203/1065;;C10M2203/1065;;C10M2203/1085;;C10M2203/1085;;C10M2205/0206;;C10M2205/0206;;C10M2207/1225;;C10M2207/1225;;C10M2207/123;;C10M2207/123;;C10M2207/1245;;C10M2207/1245;;C10M2207/125;;C10M2207/125;;C10M2207/1265;;C10M2207/1265;;C10M2207/1285;;C10M2207/1285;;C10M2207/129;;C10M2207/129;;C10M2207/166;;C10M2207/166;;C10M2207/186;;C10M2207/186;;C10M2207/206;;C10M2207/206;;C10M2207/22;;C10M2207/22;;C10M2207/246;;C10M2207/246;;C10M2207/282;;C10M2207/282;;C10M2207/2825;;C10M2207/2825;;C10M2207/2855;;C10M2207/2855;;C10M2207/34;;C10M2207/34;;C10M2215/06;;C10M2215/06;;C10M2215/064;;C10M2215/064;;C10M2215/065;;C10M2215/065;;C10M2215/066;;C10M2215/066;;C10M2215/067;;C10M2215/067;;C10M2215/068;;C10M2215/068;;C10M2219/022;;C10M2219/022;;C10M2219/044;;C10M2219/044;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2223/043;;C10M2223/043;;C10M2223/045;;C10M2223/045;;C10N2010/02;;C10N2010/02;;C10N2010/04;;C10N2010/04;;C10N2010/12;;C10N2010/12;;C10N2040/02;;C10N2040/02,C10M101/02;;C10M105/04;;C10M105/32;;C10M105/36;;C10M107/02;;C10M117/02;;C10M133/12;;C10M135/10;;C10M137/10;;C10M159/18;;C10M169/00;;C10N10/02;;C10N10/04;;C10N10/12;;C10N30/06;;C10N30/10;;C10N30/12;;C10N40/04;;C10N50/10,,0,0,,,,EXPIRED
424,US,B1,US 6656890 B1,153-121-155-152-113,2003-12-02,2003,US 91356602 A,2002-01-16,GB 9903380 A;;GB 0000360 W,1999-02-16,Grease composition for constant velocity joints,"
    A lubricating grease composed of a base oil combination comprising 10 to 35% of one or more poly -olefins, 3 to 15% of one or more synthetic organic esters, 20 to 30% of one or more naphthenic oils, the remainder of the combination being one or more paraffinic oils, the percentages being by weight of the total base oil combination and the ratio of the weight of the ester(s) in the combination to the weight of the poly -olefin(s) therein being not greater than 1:3; between 2 and 15 % by weight of the total grease of a lithium soap thickener, between 1 and 5% by weight of the total grease of a molybdenum dithiophospbate; between 1 and 5% by weight of the total grease of a zinc dialkyldithiophosphate; between 1 and 5% by weight of the total grease of a sulphur-free friction modifier, and some or all of the normal grease additives such as anti-oxidants, corrosion inhibitors, extreme pressure additives and tackiness agents. 
",GKN AUTOMOTIVE GMBH,FISH GARETH;;COOPER JENNIFER SARAH;;E JISHENG;;DAVIES TREVOR DAVID;;ISAAC GARETH ROBERT,,https://lens.org/153-121-155-152-113,Granted Patent,yes,11,24,15,15,0,C10M169/00;;C10M169/00;;C10M101/02;;C10M101/02;;C10M105/36;;C10M105/36;;C10M107/02;;C10M107/02;;C10M117/02;;C10M117/02;;C10M117/04;;C10M117/04;;C10M117/06;;C10M117/06;;C10M125/26;;C10M125/26;;C10M133/12;;C10M133/12;;C10M135/10;;C10M135/10;;C10M135/18;;C10M135/18;;C10M137/08;;C10M137/08;;C10M137/10;;C10M137/10;;C10M2201/087;;C10M2201/087;;C10M2201/10;;C10M2201/10;;C10M2201/102;;C10M2201/102;;C10M2201/105;;C10M2201/105;;C10M2203/1006;;C10M2203/1006;;C10M2203/1025;;C10M2203/1025;;C10M2203/1045;;C10M2203/1045;;C10M2203/1065;;C10M2203/1065;;C10M2203/1085;;C10M2203/1085;;C10M2205/0206;;C10M2205/0206;;C10M2207/1225;;C10M2207/1225;;C10M2207/123;;C10M2207/123;;C10M2207/1245;;C10M2207/1245;;C10M2207/125;;C10M2207/125;;C10M2207/1265;;C10M2207/1265;;C10M2207/1285;;C10M2207/1285;;C10M2207/129;;C10M2207/129;;C10M2207/166;;C10M2207/166;;C10M2207/186;;C10M2207/186;;C10M2207/206;;C10M2207/206;;C10M2207/22;;C10M2207/22;;C10M2207/246;;C10M2207/246;;C10M2207/282;;C10M2207/282;;C10M2207/2825;;C10M2207/2825;;C10M2207/2855;;C10M2207/2855;;C10M2207/34;;C10M2207/34;;C10M2215/06;;C10M2215/06;;C10M2215/064;;C10M2215/064;;C10M2215/065;;C10M2215/065;;C10M2215/066;;C10M2215/066;;C10M2215/067;;C10M2215/067;;C10M2215/068;;C10M2215/068;;C10M2219/022;;C10M2219/022;;C10M2219/044;;C10M2219/044;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2223/043;;C10M2223/043;;C10M2223/045;;C10M2223/045;;C10N2010/02;;C10N2010/02;;C10N2010/04;;C10N2010/04;;C10N2010/12;;C10N2010/12;;C10N2040/02;;C10N2040/02,C10M101/02;;C10M105/04;;C10M105/32;;C10M105/36;;C10M107/02;;C10M117/02;;C10M133/12;;C10M135/10;;C10M137/10;;C10M159/18;;C10M169/00;;C10N10/02;;C10N10/04;;C10N10/12;;C10N30/06;;C10N30/10;;C10N30/12;;C10N40/04;;C10N50/10,508/570;;508/577;;508/579,0,0,,,,EXPIRED
425,WO,A8,WO 2000/049112 A8,008-487-665-998-150,2000-12-07,2000,GB 0000360 W,2000-02-08,GB 9903380 A,1999-02-16,GREASE COMPOSITION FOR CONSTANT VELOCITY JOINTS,"A lubricating grease composed of a base oil combination comprising 10 to 35 % of one or more poly alpha -olefins, 3 to 15 % of one or more synthetic organic esters, 20 to 30 % of one or more naphthenic oils, the remainder of the combination being one or more paraffinic oils, the percentages being by weight of the total base oil combination and the ratio of the weight of the ester(s) in the combination to the weight of the poly alpha -olefin(s) therein being not greater than 1:3; between 2 and 15 % by weight of the total grease of a lithium soap thickener; between 1 and 5 % by weight of the total grease of a molybdenum dithiophosphate; between 1 and 5 % by weight of the total grease of a zinc dialkyldithiophosphate; between 1 and 5 % by weight of the total grease of a sulphur-free friction modifier; and some or all of the normal grease additives such as anti-oxidants, corrosion inhibitors, extreme pressure additives and tackiness agents.",GKN AUTOMOTIVE AG;;FISH GARETH;;COOPER JENNIFER SARAH;;JISHENG E;;DAVIES TREVOR DAVID;;ISAAC ROBERT GARETH,FISH GARETH;;COOPER JENNIFER SARAH;;E JISHENG;;DAVIES TREVOR DAVID;;ISAAC ROBERT GARETH,,https://lens.org/008-487-665-998-150,Patent Application,no,0,0,15,15,0,C10M169/00;;C10M169/00;;C10M101/02;;C10M101/02;;C10M105/36;;C10M105/36;;C10M107/02;;C10M107/02;;C10M117/02;;C10M117/02;;C10M117/04;;C10M117/04;;C10M117/06;;C10M117/06;;C10M125/26;;C10M125/26;;C10M133/12;;C10M133/12;;C10M135/10;;C10M135/10;;C10M135/18;;C10M135/18;;C10M137/08;;C10M137/08;;C10M137/10;;C10M137/10;;C10M2201/087;;C10M2201/087;;C10M2201/10;;C10M2201/10;;C10M2201/102;;C10M2201/102;;C10M2201/105;;C10M2201/105;;C10M2203/1006;;C10M2203/1006;;C10M2203/1025;;C10M2203/1025;;C10M2203/1045;;C10M2203/1045;;C10M2203/1065;;C10M2203/1065;;C10M2203/1085;;C10M2203/1085;;C10M2205/0206;;C10M2205/0206;;C10M2207/1225;;C10M2207/1225;;C10M2207/123;;C10M2207/123;;C10M2207/1245;;C10M2207/1245;;C10M2207/125;;C10M2207/125;;C10M2207/1265;;C10M2207/1265;;C10M2207/1285;;C10M2207/1285;;C10M2207/129;;C10M2207/129;;C10M2207/166;;C10M2207/166;;C10M2207/186;;C10M2207/186;;C10M2207/206;;C10M2207/206;;C10M2207/22;;C10M2207/22;;C10M2207/246;;C10M2207/246;;C10M2207/282;;C10M2207/282;;C10M2207/2825;;C10M2207/2825;;C10M2207/2855;;C10M2207/2855;;C10M2207/34;;C10M2207/34;;C10M2215/06;;C10M2215/06;;C10M2215/064;;C10M2215/064;;C10M2215/065;;C10M2215/065;;C10M2215/066;;C10M2215/066;;C10M2215/067;;C10M2215/067;;C10M2215/068;;C10M2215/068;;C10M2219/022;;C10M2219/022;;C10M2219/044;;C10M2219/044;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2223/043;;C10M2223/043;;C10M2223/045;;C10M2223/045;;C10N2010/02;;C10N2010/02;;C10N2010/04;;C10N2010/04;;C10N2010/12;;C10N2010/12;;C10N2040/02;;C10N2040/02,C10M101/02;;C10M105/04;;C10M105/32;;C10M105/36;;C10M107/02;;C10M117/02;;C10M133/12;;C10M135/10;;C10M137/10;;C10M159/18;;C10M169/00;;C10N10/02;;C10N10/04;;C10N10/12;;C10N30/06;;C10N30/10;;C10N30/12;;C10N40/04;;C10N50/10,,0,0,,,,PENDING
426,BR,B1,BR 0008308 B1,121-513-385-466-339,2011-02-22,2011,BR 0008308 A,2000-02-08,GB 9903380 A;;GB 0000360 W,1999-02-16,composição de graxa para juntas de velocidade constante.,,,FISH GARETH;;COOPER JENNIFER SARAH;;JISHENG E;;DAVIES TREVOR DAVID;;ISAAC ROBERT GARETH,,https://lens.org/121-513-385-466-339,Granted Patent,no,0,0,15,15,0,C10M169/00;;C10M169/00;;C10M101/02;;C10M101/02;;C10M105/36;;C10M105/36;;C10M107/02;;C10M107/02;;C10M117/02;;C10M117/02;;C10M117/04;;C10M117/04;;C10M117/06;;C10M117/06;;C10M125/26;;C10M125/26;;C10M133/12;;C10M133/12;;C10M135/10;;C10M135/10;;C10M135/18;;C10M135/18;;C10M137/08;;C10M137/08;;C10M137/10;;C10M137/10;;C10M2201/087;;C10M2201/087;;C10M2201/10;;C10M2201/10;;C10M2201/102;;C10M2201/102;;C10M2201/105;;C10M2201/105;;C10M2203/1006;;C10M2203/1006;;C10M2203/1025;;C10M2203/1025;;C10M2203/1045;;C10M2203/1045;;C10M2203/1065;;C10M2203/1065;;C10M2203/1085;;C10M2203/1085;;C10M2205/0206;;C10M2205/0206;;C10M2207/1225;;C10M2207/1225;;C10M2207/123;;C10M2207/123;;C10M2207/1245;;C10M2207/1245;;C10M2207/125;;C10M2207/125;;C10M2207/1265;;C10M2207/1265;;C10M2207/1285;;C10M2207/1285;;C10M2207/129;;C10M2207/129;;C10M2207/166;;C10M2207/166;;C10M2207/186;;C10M2207/186;;C10M2207/206;;C10M2207/206;;C10M2207/22;;C10M2207/22;;C10M2207/246;;C10M2207/246;;C10M2207/282;;C10M2207/282;;C10M2207/2825;;C10M2207/2825;;C10M2207/2855;;C10M2207/2855;;C10M2207/34;;C10M2207/34;;C10M2215/06;;C10M2215/06;;C10M2215/064;;C10M2215/064;;C10M2215/065;;C10M2215/065;;C10M2215/066;;C10M2215/066;;C10M2215/067;;C10M2215/067;;C10M2215/068;;C10M2215/068;;C10M2219/022;;C10M2219/022;;C10M2219/044;;C10M2219/044;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2223/043;;C10M2223/043;;C10M2223/045;;C10M2223/045;;C10N2010/02;;C10N2010/02;;C10N2010/04;;C10N2010/04;;C10N2010/12;;C10N2010/12;;C10N2040/02;;C10N2040/02,C10M169/00;;C10M101/02;;C10M105/04;;C10M105/32;;C10M105/36;;C10M107/02;;C10M117/02;;C10M133/12;;C10M135/10;;C10M137/10;;C10M159/18;;C10N10/02;;C10N10/04;;C10N10/12;;C10N30/06;;C10N30/10;;C10N30/12;;C10N40/04;;C10N50/10,,0,0,,,,EXPIRED
427,GB,A,GB 2346892 A,196-645-628-937-39X,2000-08-23,2000,GB 9903380 A,1999-02-16,GB 9903380 A,1999-02-16,Grease for constant velocity joints,"A lubricating grease composed of a base oil combination comprising 10 to 35% of one or more poly a -olefins, 3 to 15% of one or more synthetic organic esters, 20 to 30% of one or more naphthenic oils, the remainder of the combination being one or more paraffinic oils, the percentages being by weight of the total base oil combination and the ratio of the weight of the ester(s) in the combination to the weight of the poly a -olefin(s) therein being not greater than 1:3; between 2 and 15% by weight of the total grease of a lithium soap thickener; between 1 and 5% by weight of the total grease of a molybdenum dithiophosphate; between 1 and 5% by weight of the total grease of a zinc dialkyldithiophosphate; between 1 and 5% by weight of the total grease of a sulphur-free friction modifier; and some or all of the normal grease additives such as anti-oxidants, corrosion inhibitors, extreme pressure additives and tackiness agents.",GKN TECHNOLOGY LTD;;GKN AUTOMOTIVE AG,FISH GARETH;;DAVIES TREVOR DAVID;;COOPER JENNIFER SARAH;;E JISHENG;;ISAAC ROBERT GARETH,,https://lens.org/196-645-628-937-39X,Patent Application,no,1,4,15,15,0,C10M169/00;;C10M169/00;;C10M101/02;;C10M101/02;;C10M105/36;;C10M105/36;;C10M107/02;;C10M107/02;;C10M117/02;;C10M117/02;;C10M117/04;;C10M117/04;;C10M117/06;;C10M117/06;;C10M125/26;;C10M125/26;;C10M133/12;;C10M133/12;;C10M135/10;;C10M135/10;;C10M135/18;;C10M135/18;;C10M137/08;;C10M137/08;;C10M137/10;;C10M137/10;;C10M2201/087;;C10M2201/087;;C10M2201/10;;C10M2201/10;;C10M2201/102;;C10M2201/102;;C10M2201/105;;C10M2201/105;;C10M2203/1006;;C10M2203/1006;;C10M2203/1025;;C10M2203/1025;;C10M2203/1045;;C10M2203/1045;;C10M2203/1065;;C10M2203/1065;;C10M2203/1085;;C10M2203/1085;;C10M2205/0206;;C10M2205/0206;;C10M2207/1225;;C10M2207/1225;;C10M2207/123;;C10M2207/123;;C10M2207/1245;;C10M2207/1245;;C10M2207/125;;C10M2207/125;;C10M2207/1265;;C10M2207/1265;;C10M2207/1285;;C10M2207/1285;;C10M2207/129;;C10M2207/129;;C10M2207/166;;C10M2207/166;;C10M2207/186;;C10M2207/186;;C10M2207/206;;C10M2207/206;;C10M2207/22;;C10M2207/22;;C10M2207/246;;C10M2207/246;;C10M2207/282;;C10M2207/282;;C10M2207/2825;;C10M2207/2825;;C10M2207/2855;;C10M2207/2855;;C10M2207/34;;C10M2207/34;;C10M2215/06;;C10M2215/06;;C10M2215/064;;C10M2215/064;;C10M2215/065;;C10M2215/065;;C10M2215/066;;C10M2215/066;;C10M2215/067;;C10M2215/067;;C10M2215/068;;C10M2215/068;;C10M2219/022;;C10M2219/022;;C10M2219/044;;C10M2219/044;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2223/043;;C10M2223/043;;C10M2223/045;;C10M2223/045;;C10N2010/02;;C10N2010/02;;C10N2010/04;;C10N2010/04;;C10N2010/12;;C10N2010/12;;C10N2040/02;;C10N2040/02,C10M101/02;;C10M105/04;;C10M105/32;;C10M105/36;;C10M107/02;;C10M117/02;;C10M133/12;;C10M135/10;;C10M137/10;;C10M159/18;;C10M169/00;;C10N10/02;;C10N10/04;;C10N10/12;;C10N30/06;;C10N30/10;;C10N30/12;;C10N40/04;;C10N50/10,C5F FLC           FLC;;C5F F104          FLC;;C5F F111          FLC;;C5F F113          FLC;;C5F F114          FLC;;U1S S1364,0,0,,,,EXPIRED
428,FR,A1,FR 2790265 A1,006-247-925-936-947,2000-09-01,2000,FR 0001858 A,2000-02-15,GB 9903380 A,1999-02-16,GRAISSE POUR JOINTS A DOUBLE CARDAN,"<P>L'invention propose une graisse lubrifiante constituée de : une combinaison d'huile de base comprenant 10-35 % d'une ou plusieurs poly (alpha-oléfines), 3-15 % d'un ou plusieurs esters organiques synthétiques, 20-30 % d'une ou plusieurs huiles naphténiques, et pour le reste d'une ou plusieurs huiles paraffiniques, les pourcentages étant en poids de la combinaison d'huile de base totale, et le rapport pondéral ester (s) / poly (alpha-oléfine) (s) dans la combinaison ne dépassant pas 1/ 3; 2-15 %, en poids de la graisse totale, d'un épaississant savon de lithium; 1-5 %, en poids de la graisse totale, d'un dithiophosphate de molybdène; 1-5 %, en poids de la graisse totale, d'un dialkyltidhiophosphate de zinc; 15 %, en poids de la graisse totale, d'un agent modifiant le frottement exempt de soufre; et tout ou partie des additifs pour graisse normaux, tels qu'antioxydants, inhibiteurs de corrosion, additifs extrême pression et agents de pégosité.</P>",GKN AUTOMOTIVE AG,FISH GARETH;;DAVIES TREVOR DAVID;;COOPER JENNIFER SARAH;;JISHENG E;;ISAAC ROBERT GARETH,,https://lens.org/006-247-925-936-947,Patent Application,no,4,0,15,15,0,C10M169/00;;C10M169/00;;C10M101/02;;C10M101/02;;C10M105/36;;C10M105/36;;C10M107/02;;C10M107/02;;C10M117/02;;C10M117/02;;C10M117/04;;C10M117/04;;C10M117/06;;C10M117/06;;C10M125/26;;C10M125/26;;C10M133/12;;C10M133/12;;C10M135/10;;C10M135/10;;C10M135/18;;C10M135/18;;C10M137/08;;C10M137/08;;C10M137/10;;C10M137/10;;C10M2201/087;;C10M2201/087;;C10M2201/10;;C10M2201/10;;C10M2201/102;;C10M2201/102;;C10M2201/105;;C10M2201/105;;C10M2203/1006;;C10M2203/1006;;C10M2203/1025;;C10M2203/1025;;C10M2203/1045;;C10M2203/1045;;C10M2203/1065;;C10M2203/1065;;C10M2203/1085;;C10M2203/1085;;C10M2205/0206;;C10M2205/0206;;C10M2207/1225;;C10M2207/1225;;C10M2207/123;;C10M2207/123;;C10M2207/1245;;C10M2207/1245;;C10M2207/125;;C10M2207/125;;C10M2207/1265;;C10M2207/1265;;C10M2207/1285;;C10M2207/1285;;C10M2207/129;;C10M2207/129;;C10M2207/166;;C10M2207/166;;C10M2207/186;;C10M2207/186;;C10M2207/206;;C10M2207/206;;C10M2207/22;;C10M2207/22;;C10M2207/246;;C10M2207/246;;C10M2207/282;;C10M2207/282;;C10M2207/2825;;C10M2207/2825;;C10M2207/2855;;C10M2207/2855;;C10M2207/34;;C10M2207/34;;C10M2215/06;;C10M2215/06;;C10M2215/064;;C10M2215/064;;C10M2215/065;;C10M2215/065;;C10M2215/066;;C10M2215/066;;C10M2215/067;;C10M2215/067;;C10M2215/068;;C10M2215/068;;C10M2219/022;;C10M2219/022;;C10M2219/044;;C10M2219/044;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2223/043;;C10M2223/043;;C10M2223/045;;C10M2223/045;;C10N2010/02;;C10N2010/02;;C10N2010/04;;C10N2010/04;;C10N2010/12;;C10N2010/12;;C10N2040/02;;C10N2040/02,C10M101/02;;C10M105/04;;C10M105/32;;C10M105/36;;C10M107/02;;C10M117/02;;C10M133/12;;C10M135/10;;C10M137/10;;C10M159/18;;C10M169/00;;C10N10/02;;C10N10/04;;C10N10/12;;C10N30/06;;C10N30/10;;C10N30/12;;C10N40/04;;C10N50/10,,0,0,,,,EXPIRED
429,AU,A,AU 2000/023100 A,166-898-702-640-947,2000-09-04,2000,AU 2000/023100 A,2000-02-08,GB 9903380 A;;GB 0000360 W,1999-02-16,Grease composition for constant velocity joints,,GKN AUTOMOTIVE AG,FISH GARETH;;COOPER JENNIFER SARAH;;JISHENG E;;DAVIES TREVOR DAVID;;ISAAC ROBERT GARETH,,https://lens.org/166-898-702-640-947,Patent Application,no,0,0,15,15,0,C10M169/00;;C10M169/00;;C10M101/02;;C10M101/02;;C10M105/36;;C10M105/36;;C10M107/02;;C10M107/02;;C10M117/02;;C10M117/02;;C10M117/04;;C10M117/04;;C10M117/06;;C10M117/06;;C10M125/26;;C10M125/26;;C10M133/12;;C10M133/12;;C10M135/10;;C10M135/10;;C10M135/18;;C10M135/18;;C10M137/08;;C10M137/08;;C10M137/10;;C10M137/10;;C10M2201/087;;C10M2201/087;;C10M2201/10;;C10M2201/10;;C10M2201/102;;C10M2201/102;;C10M2201/105;;C10M2201/105;;C10M2203/1006;;C10M2203/1006;;C10M2203/1025;;C10M2203/1025;;C10M2203/1045;;C10M2203/1045;;C10M2203/1065;;C10M2203/1065;;C10M2203/1085;;C10M2203/1085;;C10M2205/0206;;C10M2205/0206;;C10M2207/1225;;C10M2207/1225;;C10M2207/123;;C10M2207/123;;C10M2207/1245;;C10M2207/1245;;C10M2207/125;;C10M2207/125;;C10M2207/1265;;C10M2207/1265;;C10M2207/1285;;C10M2207/1285;;C10M2207/129;;C10M2207/129;;C10M2207/166;;C10M2207/166;;C10M2207/186;;C10M2207/186;;C10M2207/206;;C10M2207/206;;C10M2207/22;;C10M2207/22;;C10M2207/246;;C10M2207/246;;C10M2207/282;;C10M2207/282;;C10M2207/2825;;C10M2207/2825;;C10M2207/2855;;C10M2207/2855;;C10M2207/34;;C10M2207/34;;C10M2215/06;;C10M2215/06;;C10M2215/064;;C10M2215/064;;C10M2215/065;;C10M2215/065;;C10M2215/066;;C10M2215/066;;C10M2215/067;;C10M2215/067;;C10M2215/068;;C10M2215/068;;C10M2219/022;;C10M2219/022;;C10M2219/044;;C10M2219/044;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2223/043;;C10M2223/043;;C10M2223/045;;C10M2223/045;;C10N2010/02;;C10N2010/02;;C10N2010/04;;C10N2010/04;;C10N2010/12;;C10N2010/12;;C10N2040/02;;C10N2040/02,C10M101/02;;C10M105/04;;C10M105/32;;C10M105/36;;C10M107/02;;C10M117/02;;C10M133/12;;C10M135/10;;C10M137/10;;C10M159/18;;C10M169/00;;C10N10/02;;C10N10/04;;C10N10/12;;C10N30/06;;C10N30/10;;C10N30/12;;C10N40/04;;C10N50/10,,0,0,,,,DISCONTINUED
430,DE,B4,DE 10084148 B4,110-970-837-710-967,2005-04-14,2005,DE 10084148 T,2000-02-08,GB 9903380 A;;GB 0000360 W,1999-02-16,Schmierfettzusammensetzung für Gleichlaufgelenke,,GKN DRIVELINE INT GMBH,FISH GARETH;;COOPER JENNIFER SARAH;;JISHENG E;;DAVIES TREVOR DAVID;;ISAAC ROBERT GARETH,"GKN DRIVELINE INTERNATIONAL GMBH, 53797 LOHMAR, DE (2004-07-29)",https://lens.org/110-970-837-710-967,Granted Patent,no,3,0,15,15,0,C10M169/00;;C10M169/00;;C10M101/02;;C10M101/02;;C10M105/36;;C10M105/36;;C10M107/02;;C10M107/02;;C10M117/02;;C10M117/02;;C10M117/04;;C10M117/04;;C10M117/06;;C10M117/06;;C10M125/26;;C10M125/26;;C10M133/12;;C10M133/12;;C10M135/10;;C10M135/10;;C10M135/18;;C10M135/18;;C10M137/08;;C10M137/08;;C10M137/10;;C10M137/10;;C10M2201/087;;C10M2201/087;;C10M2201/10;;C10M2201/10;;C10M2201/102;;C10M2201/102;;C10M2201/105;;C10M2201/105;;C10M2203/1006;;C10M2203/1006;;C10M2203/1025;;C10M2203/1025;;C10M2203/1045;;C10M2203/1045;;C10M2203/1065;;C10M2203/1065;;C10M2203/1085;;C10M2203/1085;;C10M2205/0206;;C10M2205/0206;;C10M2207/1225;;C10M2207/1225;;C10M2207/123;;C10M2207/123;;C10M2207/1245;;C10M2207/1245;;C10M2207/125;;C10M2207/125;;C10M2207/1265;;C10M2207/1265;;C10M2207/1285;;C10M2207/1285;;C10M2207/129;;C10M2207/129;;C10M2207/166;;C10M2207/166;;C10M2207/186;;C10M2207/186;;C10M2207/206;;C10M2207/206;;C10M2207/22;;C10M2207/22;;C10M2207/246;;C10M2207/246;;C10M2207/282;;C10M2207/282;;C10M2207/2825;;C10M2207/2825;;C10M2207/2855;;C10M2207/2855;;C10M2207/34;;C10M2207/34;;C10M2215/06;;C10M2215/06;;C10M2215/064;;C10M2215/064;;C10M2215/065;;C10M2215/065;;C10M2215/066;;C10M2215/066;;C10M2215/067;;C10M2215/067;;C10M2215/068;;C10M2215/068;;C10M2219/022;;C10M2219/022;;C10M2219/044;;C10M2219/044;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2223/043;;C10M2223/043;;C10M2223/045;;C10M2223/045;;C10N2010/02;;C10N2010/02;;C10N2010/04;;C10N2010/04;;C10N2010/12;;C10N2010/12;;C10N2040/02;;C10N2040/02,C10M101/02;;C10M105/04;;C10M105/32;;C10M105/36;;C10M107/02;;C10M117/02;;C10M133/12;;C10M135/10;;C10M137/10;;C10M159/18;;C10M169/00;;C10N10/02;;C10N10/04;;C10N10/12;;C10N30/06;;C10N30/10;;C10N30/12;;C10N40/04;;C10N50/10,,0,0,,,,EXPIRED
431,FR,B1,FR 2790265 B1,112-771-143-783-601,2002-05-24,2002,FR 0001858 A,2000-02-15,GB 9903380 A,1999-02-16,GRAISSE POUR JOINTS A DOUBLE CARDAN,,GKN AUTOMOTIVE AG,FISH GARETH;;DAVIES TREVOR DAVID;;COOPER JENNIFER SARAH;;JISHENG E;;ISAAC ROBERT GARETH,,https://lens.org/112-771-143-783-601,Granted Patent,no,0,0,15,15,0,C10M169/00;;C10M169/00;;C10M101/02;;C10M101/02;;C10M105/36;;C10M105/36;;C10M107/02;;C10M107/02;;C10M117/02;;C10M117/02;;C10M117/04;;C10M117/04;;C10M117/06;;C10M117/06;;C10M125/26;;C10M125/26;;C10M133/12;;C10M133/12;;C10M135/10;;C10M135/10;;C10M135/18;;C10M135/18;;C10M137/08;;C10M137/08;;C10M137/10;;C10M137/10;;C10M2201/087;;C10M2201/087;;C10M2201/10;;C10M2201/10;;C10M2201/102;;C10M2201/102;;C10M2201/105;;C10M2201/105;;C10M2203/1006;;C10M2203/1006;;C10M2203/1025;;C10M2203/1025;;C10M2203/1045;;C10M2203/1045;;C10M2203/1065;;C10M2203/1065;;C10M2203/1085;;C10M2203/1085;;C10M2205/0206;;C10M2205/0206;;C10M2207/1225;;C10M2207/1225;;C10M2207/123;;C10M2207/123;;C10M2207/1245;;C10M2207/1245;;C10M2207/125;;C10M2207/125;;C10M2207/1265;;C10M2207/1265;;C10M2207/1285;;C10M2207/1285;;C10M2207/129;;C10M2207/129;;C10M2207/166;;C10M2207/166;;C10M2207/186;;C10M2207/186;;C10M2207/206;;C10M2207/206;;C10M2207/22;;C10M2207/22;;C10M2207/246;;C10M2207/246;;C10M2207/282;;C10M2207/282;;C10M2207/2825;;C10M2207/2825;;C10M2207/2855;;C10M2207/2855;;C10M2207/34;;C10M2207/34;;C10M2215/06;;C10M2215/06;;C10M2215/064;;C10M2215/064;;C10M2215/065;;C10M2215/065;;C10M2215/066;;C10M2215/066;;C10M2215/067;;C10M2215/067;;C10M2215/068;;C10M2215/068;;C10M2219/022;;C10M2219/022;;C10M2219/044;;C10M2219/044;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2223/043;;C10M2223/043;;C10M2223/045;;C10M2223/045;;C10N2010/02;;C10N2010/02;;C10N2010/04;;C10N2010/04;;C10N2010/12;;C10N2010/12;;C10N2040/02;;C10N2040/02,C10M101/02;;C10M105/04;;C10M105/32;;C10M105/36;;C10M107/02;;C10M117/02;;C10M133/12;;C10M135/10;;C10M137/10;;C10M159/18;;C10M169/00;;C10N10/02;;C10N10/04;;C10N10/12;;C10N30/06;;C10N30/10;;C10N30/12;;C10N40/04;;C10N50/10,,0,0,,,,EXPIRED
432,WO,A1,WO 2000/049112 A1,147-470-073-726-222,2000-08-24,2000,GB 0000360 W,2000-02-08,GB 9903380 A,1999-02-16,GREASE COMPOSITION FOR CONSTANT VELOCITY JOINTS,"A lubricating grease composed of a base oil combination comprising 10 to 35 % of one or more poly α-olefins, 3 to 15 % of one or more synthetic organic esters, 20 to 30 % of one or more naphthenic oils, the remainder of the combination being one or more paraffinic oils, the percentages being by weight of the total base oil combination and the ratio of the weight of the ester(s) in the combination to the weight of the poly α-olefin(s) therein being not greater than 1:3; between 2 and 15 % by weight of the total grease of a lithium soap thickener; between 1 and 5 % by weight of the total grease of a molybdenum dithiophosphate; between 1 and 5 % by weight of the total grease of a zinc dialkyldithiophosphate; between 1 and 5 % by weight of the total grease of a sulphur-free friction modifier; and some or all of the normal grease additives such as anti-oxidants, corrosion inhibitors, extreme pressure additives and tackiness agents.",GKN AUTOMOTIVE AG;;FISH GARETH;;COOPER JENNIFER SARAH;;JISHENG E;;DAVIES TREVOR DAVID;;ISAAC ROBERT GARETH,FISH GARETH;;COOPER JENNIFER SARAH;;E JISHENG;;DAVIES TREVOR DAVID;;ISAAC ROBERT GARETH,,https://lens.org/147-470-073-726-222,Patent Application,yes,4,4,15,15,0,C10M169/00;;C10M169/00;;C10M101/02;;C10M101/02;;C10M105/36;;C10M105/36;;C10M107/02;;C10M107/02;;C10M117/02;;C10M117/02;;C10M117/04;;C10M117/04;;C10M117/06;;C10M117/06;;C10M125/26;;C10M125/26;;C10M133/12;;C10M133/12;;C10M135/10;;C10M135/10;;C10M135/18;;C10M135/18;;C10M137/08;;C10M137/08;;C10M137/10;;C10M137/10;;C10M2201/087;;C10M2201/087;;C10M2201/10;;C10M2201/10;;C10M2201/102;;C10M2201/102;;C10M2201/105;;C10M2201/105;;C10M2203/1006;;C10M2203/1006;;C10M2203/1025;;C10M2203/1025;;C10M2203/1045;;C10M2203/1045;;C10M2203/1065;;C10M2203/1065;;C10M2203/1085;;C10M2203/1085;;C10M2205/0206;;C10M2205/0206;;C10M2207/1225;;C10M2207/1225;;C10M2207/123;;C10M2207/123;;C10M2207/1245;;C10M2207/1245;;C10M2207/125;;C10M2207/125;;C10M2207/1265;;C10M2207/1265;;C10M2207/1285;;C10M2207/1285;;C10M2207/129;;C10M2207/129;;C10M2207/166;;C10M2207/166;;C10M2207/186;;C10M2207/186;;C10M2207/206;;C10M2207/206;;C10M2207/22;;C10M2207/22;;C10M2207/246;;C10M2207/246;;C10M2207/282;;C10M2207/282;;C10M2207/2825;;C10M2207/2825;;C10M2207/2855;;C10M2207/2855;;C10M2207/34;;C10M2207/34;;C10M2215/06;;C10M2215/06;;C10M2215/064;;C10M2215/064;;C10M2215/065;;C10M2215/065;;C10M2215/066;;C10M2215/066;;C10M2215/067;;C10M2215/067;;C10M2215/068;;C10M2215/068;;C10M2219/022;;C10M2219/022;;C10M2219/044;;C10M2219/044;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2223/043;;C10M2223/043;;C10M2223/045;;C10M2223/045;;C10N2010/02;;C10N2010/02;;C10N2010/04;;C10N2010/04;;C10N2010/12;;C10N2010/12;;C10N2040/02;;C10N2040/02,C10M101/02;;C10M105/04;;C10M105/32;;C10M105/36;;C10M107/02;;C10M117/02;;C10M133/12;;C10M135/10;;C10M137/10;;C10M159/18;;C10M169/00;;C10N10/02;;C10N10/04;;C10N10/12;;C10N30/06;;C10N30/10;;C10N30/12;;C10N40/04;;C10N50/10,,0,0,,,,PENDING
433,BR,A,BR 0008308 A,166-409-836-631-931,2002-02-05,2002,BR 0008308 A,2000-02-08,GB 9903380 A;;GB 0000360 W,1999-02-16,Graxa,"""GRAXA"". Graxa lubrificante composta de combinação de óleo base compreendendo 10 a 35 % de uma ou mais poli <244>-olefinas, 3 a 15% de um ou mais ésteres orgânicos sintéticos, 20 a 30% de um ou mais óleos naftênicos, o restante da combinação sendo um ou mais óleos para-fínicos, as percentagens sendo em peso do total da combinação de óleo base e a proporção do peso do éster(s) na combinação para o peso da poli <244>-olefina(s) nesse meio sendo não maior do que 1:3; entre 2 e 15% em peso da graxa total do espessador de sabão de lítio; entre 1 e 5% em peso da graxa total do ditiofosfato de molibdênio; entre 1 e 5% em peso da graxa total do dialquilditiofosfato de zinco; entre 1 e 5% em peso da graxa total do modificador de fricção livre de enxofre; e alguns ou todos os aditivos normais de graxa tais como antioxidantes, inibidores de corrosão, aditivos de pressão extrema e agentes de pegajosidade.",GKN AUTOMOTIVE GMBH,FISH GARETH;;COOPER JENNIFER SARAH;;JISHENG E;;DAVIES TREVOR DAVID;;ISAAC ROBERT GARETH,,https://lens.org/166-409-836-631-931,Patent Application,no,0,0,15,15,0,C10M169/00;;C10M169/00;;C10M101/02;;C10M101/02;;C10M105/36;;C10M105/36;;C10M107/02;;C10M107/02;;C10M117/02;;C10M117/02;;C10M117/04;;C10M117/04;;C10M117/06;;C10M117/06;;C10M125/26;;C10M125/26;;C10M133/12;;C10M133/12;;C10M135/10;;C10M135/10;;C10M135/18;;C10M135/18;;C10M137/08;;C10M137/08;;C10M137/10;;C10M137/10;;C10M2201/087;;C10M2201/087;;C10M2201/10;;C10M2201/10;;C10M2201/102;;C10M2201/102;;C10M2201/105;;C10M2201/105;;C10M2203/1006;;C10M2203/1006;;C10M2203/1025;;C10M2203/1025;;C10M2203/1045;;C10M2203/1045;;C10M2203/1065;;C10M2203/1065;;C10M2203/1085;;C10M2203/1085;;C10M2205/0206;;C10M2205/0206;;C10M2207/1225;;C10M2207/1225;;C10M2207/123;;C10M2207/123;;C10M2207/1245;;C10M2207/1245;;C10M2207/125;;C10M2207/125;;C10M2207/1265;;C10M2207/1265;;C10M2207/1285;;C10M2207/1285;;C10M2207/129;;C10M2207/129;;C10M2207/166;;C10M2207/166;;C10M2207/186;;C10M2207/186;;C10M2207/206;;C10M2207/206;;C10M2207/22;;C10M2207/22;;C10M2207/246;;C10M2207/246;;C10M2207/282;;C10M2207/282;;C10M2207/2825;;C10M2207/2825;;C10M2207/2855;;C10M2207/2855;;C10M2207/34;;C10M2207/34;;C10M2215/06;;C10M2215/06;;C10M2215/064;;C10M2215/064;;C10M2215/065;;C10M2215/065;;C10M2215/066;;C10M2215/066;;C10M2215/067;;C10M2215/067;;C10M2215/068;;C10M2215/068;;C10M2219/022;;C10M2219/022;;C10M2219/044;;C10M2219/044;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2223/043;;C10M2223/043;;C10M2223/045;;C10M2223/045;;C10N2010/02;;C10N2010/02;;C10N2010/04;;C10N2010/04;;C10N2010/12;;C10N2010/12;;C10N2040/02;;C10N2040/02,C10M101/02;;C10M105/04;;C10M105/32;;C10M105/36;;C10M107/02;;C10M117/02;;C10M133/12;;C10M135/10;;C10M137/10;;C10M159/18;;C10M169/00;;C10N10/02;;C10N10/04;;C10N10/12;;C10N30/06;;C10N30/10;;C10N30/12;;C10N40/04;;C10N50/10,,0,0,,,,EXPIRED
434,EP,A1,EP 2587384 A1,006-369-313-839-930,2013-05-01,2013,EP 12189414 A,2012-10-22,GB 201118534 A,2011-10-26,Configurable data transfer in a digital signal processing system,"A technique for transferring data in a digital signal processing system is described. In one example, the digital signal processing system comprises a number of hardware peripherals, each connected to a memory access controller and each configured to read data from a memory device, perform one or more operations on the data, and write data to the memory device. To avoid hardwiring the hardware peripherals together, and to provide a configurable digital signal processing system, a multi-threaded processor controls the transfer of data between the hardware peripherals and the memory. Each processor thread is allocated to a memory access channel, and the threads are configured to detect an occurrence of an event and, responsive to this, control the memory access controller to enable a selected hardware peripheral to read data from or write data to the memory device via its memory access channel.
",IMAGINATION TECH LTD,ANDERSON ADRIAN JOHN;;WASS GARY CHRISTOPHER;;DAVIES GARETH JOHN,,https://lens.org/006-369-313-839-930,Patent Application,yes,2,0,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F13/28;;G06F9/30;;G06F9/38;;G06F9/50;;G06F9/54;;G06F12/10;;G06F12/1081;;G06F15/167,,4,0,,,"JUERGEN MATHES: ""How to Approach Inter-Core Communication on TMS320C6474"", 1 January 2009 (2009-01-01), XP055049737, Retrieved from the Internet <URL:http://www.ti.com/lit/an/sprab25/sprab25.pdf> [retrieved on 20130115];;NIKOLIC-POPOVIC J: ""Using TMS320C6416 Coprocessors: Viterbi Coprocessor (VCP)"", 1 September 2003 (2003-09-01), pages 1 - 24, XP002591629, Retrieved from the Internet <URL:http://focus.ti.com.cn/cn/lit/an/spra750d/spra750d.pdf> [retrieved on 20030930];;""TMS320C6474 DSP Enhanced DMA (EDMA3) Controller"", 1 July 2011 (2011-07-01), XP055049608, Retrieved from the Internet <URL:http://www.ti.com/lit/ug/sprug11b/sprug11b.pdf> [retrieved on 20130115];;DAVID BELL ET AL: ""Multicore Programming Guide"", 1 August 2009 (2009-08-01), XP055049589, Retrieved from the Internet <URL:http://www.polyscope.ch/dlCenter/ps/2010_15/15_10.05.pdf> [retrieved on 20130115]",ACTIVE
435,AU,B2,AU 2021/212088 B2,043-102-828-289-404,2023-08-03,2023,AU 2021/212088 A,2021-08-05,AU 2021/212088 A;;AU 2019/213413 A;;AU 2013/397477 A;;US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,Methods and Devices for Puncturing Tissue,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-22),https://lens.org/043-102-828-289-404,Granted Patent,no,3,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/01;;A61B17/34;;A61B18/14;;A61M25/06;;A61M29/00,,0,0,,,,ACTIVE
436,JP,A,JP 2013093026 A,072-955-882-563-044,2013-05-16,2013,JP 2012232839 A,2012-10-22,GB 201118534 A,2011-10-26,DIGITAL SIGNAL PROCESSING DATA TRANSFER,"PROBLEM TO BE SOLVED: To provide a technology of transferring data in a digital signal processing system.SOLUTION: A digital signal processing system comprises a plurality of hardware peripherals, each connected to a memory access controller and configured to read data from a memory device, perform one or more operations on the data, and write data to the memory device. To avoid hardwiring the hardware peripherals together, and to provide a configurable digital signal processing system, a multi-threaded processor controls data transfer between the hardware peripherals and the memory. Each processor thread is allocated to a memory access channel. The thread detects an event and, responsive thereto, controls the memory access controller in order to enable a selected hardware peripheral to read data from or write data to the memory device via its memory access channel.",IMAGINATION TECH LTD,ADRIAN JOHN ANDERSON;;GARY CHRISTOPHER WASS;;GARETH J DAVIES,,https://lens.org/072-955-882-563-044,Patent Application,no,11,1,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F12/00;;G06F12/1081,,0,0,,,,ACTIVE
437,US,B1,US 6187804 B1,104-328-144-641-465,2001-02-13,2001,US 16829398 A,1998-10-08,US 16829398 A;;GB 9202298 A;;US 83305697 A;;US 46203795 A,1992-02-04,Antibiotic compounds,"The present invention relates to carbapenems and provides a compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl; R.sup.4 and R.sup.5 are the same or different and are selected from hydrogen, halo, cyano, C.sub.1-4 alkyl, nitro, hydroxy, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 alkoxycarbonyl, aminosulphonyl, C.sub.1-4 alkylaminosulphonyl, di-C.sub.1-4 -alkylaminosulphonyl, carbamoyl, C.sub.1-4 alkylcarbamoyl, di-C.sub.1-4 alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C.sub.1-4 alkylamino, di-C 1.sub.4 alkylamino, C.sub.1-4 alkanoylamino, C.sub.1-4 alkanoyl(H-C.sub.1-4 alkyl)amino, C.sub.1-4 alkanesulphonamido and C.sub.1-4 alkylS(O).sub.n -- wherein n is zero, one or two: with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to --NR.sup.3 --. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.",ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,ASTRAZENECA UK LIMITED (2004-05-20);;SYNGENTA LIMITED (2002-05-27);;ZENECA LTD (1995-01-06),https://lens.org/104-328-144-641-465,Granted Patent,yes,34,5,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,514/414,2,0,,,"Betts, CA 118(9)=80721d (1992).;;Betts, CA 118(7)=59495y (1992).",EXPIRED
438,EP,B1,EP 2967746 B1,130-745-900-026-071,2019-05-08,2019,EP 14763885 A,2014-03-11,US 201361787617 P;;IB 2014059641 W,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD,,https://lens.org/130-745-900-026-071,Granted Patent,yes,9,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14;;A61B18/00;;A61B90/00,,0,0,,,,ACTIVE
439,AU,A,AU 1993/034574 A,173-895-860-803-676,1993-09-01,1993,AU 1993/034574 A,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,"Carbapenems containing a carboxy substituted phenyl group, processes for their preparation, intermediates and use as antibiotics",,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,ASTRAZENECA AB (2001-02-01),https://lens.org/173-895-860-803-676,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
440,US,B2,US 9575900 B2,002-958-578-235-251,2017-02-21,2017,US 201514625719 A,2015-02-19,US 201514625719 A;;GB 201118534 A;;US 201213646649 A,2011-10-26,Digital signal processing data transfer,"A technique for transferring data in a digital signal processing system is described. In one example, the digital signal processing system comprises a number of fixed function accelerators, each connected to a memory access controller and each configured to read data from a memory device, perform one or more operations on the data, and write data to the memory device. To avoid hardwiring the fixed function accelerators together, and to provide a configurable digital signal processing system, a multi-threaded processor controls the transfer of data between the fixed function accelerators and the memory. Each processor thread is allocated to a memory access channel, and the threads are configured to detect an occurrence of an event and, responsive to this, control the memory access controller to enable a selected fixed function accelerator to read data from or write data to the memory device via its memory access channel.",IMAGINATION TECH LTD,ANDERSON ADRIAN J;;WASS GARY C;;DAVIES GARETH J,NORDIC SEMICONDUCTOR ASA (2020-12-31),https://lens.org/002-958-578-235-251,Granted Patent,yes,37,0,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F9/30;;G06F9/38;;G06F9/50;;G06F9/54;;G06F12/10;;G06F12/1081;;G06F13/28,,4,0,,,"TMS320C6474 DSP Enhanced DMA (EDMA3) Controller, Jul. 1, 2011 (Jul. 1, 2011), XP055049608, Retrieved from the Internet: URL:http://www.ti.com/litJug/sprug11b/sprugllb.pdf, pp. 13, 21, 23, 46, table 2.6.;;Bell et al., ""Multicore Programming Guide"", Aug. 1, 2009 (Aug. 1, 2009), XP055049589, Retrieved from the Internet: URL:http://www.polyscope.ch/d1Center/ps/2010 15/1510.05.pdf.;;Mathes, ""How to Approach Inter-Core Communication on TMS320C6474"", Jan. 1, 2009 (Jan. 1, 2009), XP055049737, Retrieved from the Internet: URL:http:/lwww.ti.com/lit/an/sprab25/sprab25.pdf.;;Nikolic-Popovic, ""Using TMS320C6416 Coprocessors: Viterbi Coprocessor (VCP)"", Texas Instruments Application Report, Dallas, TX, USA, Sep. 1, 2003 (Sep. 1, 2003), pp. 1-24, XP002591629, Retrieved from the Internet: URL:http://focus.ti-com-cn/cn/lit/antspra750d/ spra750d.pdf pp. 11-13.",ACTIVE
441,JO,B1,JO 1740 B1,062-357-852-172-314,1993-06-15,1993,JO P19931740 A,1993-04-10,JO P19931740 A,1993-04-10,ANTIBIOTIC COMPOUNDS,"Abstract of corresponding document: WO 9315078 (A1) The present invention relates to carbapenems and provides a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R<1> is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R<2> is hydrogen or C1-4alkyl; R<3> is hydrogen or C1-4alkyl; R<4> and R<5> are the same or different and are selected from hydrogen, halo, cyano, C1-4alkyl, nitro, hydroxy, carboxy, C1-4alkoxy, C1-4alkoxycarbonyl, aminosulphonyl, C1-4alkylaminosulphonyl, di-C1-4alkylaminosulphonyl, carbamoyl, C1-4alkylcarbamoyl, di-C1-4alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C1-4alkylamino, di-C1-4alkylamino, C1-4alkanoylamino, C1-4alkanoyl(N-C1-4alkyl)amino, C1-4alkanesulphonamido and C1-4alkylS(O)n- wherein n is zero, one or two; with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to -NR<3>-. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.",ASTRAZENECA UK LTD,MICHAEL JOHN BETTS;;MICHAEL LINGARD SWAIN;;GARETH MORSE DAVIES,,https://lens.org/062-357-852-172-314,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
442,WO,A1,WO 2022/069962 A1,070-045-756-248-988,2022-04-07,2022,IB 2021057728 W,2021-09-09,US 202063084749 P,2020-09-29,SURGICAL PERFORATION BETWEEN THE AORTA AND LEFT ATRIUM,"Apparatuses and methods are disclosed for the perforation of a communication between the aorta and left atrium. The method includes introducing the apparatus, positioning the apparatus at a location along the aorta, and energizing the apparatus to create a perforation. For example, one method may include: introducing a flexible wire into the left atrium, advancing a dilator along the flexible wire to position the flexible wire adjacent a selected location along the aorta and energizing the flexible wire to create a perforation from the left atrium into the aorta.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,MORIYAMA EDUARDO;;DAVIES GARETH;;DICICCO MATTHEW;;URBANSKI JOHN PAUL,,https://lens.org/070-045-756-248-988,Patent Application,yes,5,0,2,2,0,A61M29/00;;A61B2018/00601;;A61B2018/00351;;A61B2018/00357;;A61B90/39;;A61B2090/397;;A61B2090/3925;;A61B2090/3966;;A61B2090/3762;;A61B2090/3784;;A61B18/1492;;A61B18/04;;A61B2018/1425;;A61M25/0082;;A61M25/0105;;A61M2025/0002;;A61M2025/0166;;A61B2017/00022;;A61B2017/00358;;A61B2017/22044;;A61B2090/064;;A61B2018/0038;;A61B18/1492;;A61B2018/00351;;A61B2018/00601,A61B18/14;;A61B17/00;;A61B18/00;;A61B18/08;;A61B18/18;;A61M29/00,,0,0,,,,PENDING
443,EP,B1,EP 2587384 B1,063-536-152-174-693,2017-07-12,2017,EP 12189414 A,2012-10-22,GB 201118534 A,2011-10-26,Configurable data transfer in a digital signal processing system,,IMAGINATION TECH LTD,ANDERSON ADRIAN JOHN;;WASS GARY CHRISTOPHER;;DAVIES GARETH JOHN,,https://lens.org/063-536-152-174-693,Granted Patent,yes,2,0,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F13/28;;G06F9/30;;G06F9/38;;G06F9/50;;G06F9/54;;G06F12/10;;G06F12/1081;;G06F15/167,,4,0,,,"Juergen Mathes: ""How to Approach Inter-Core Communication on TMS320C6474"", , 1 January 2009 (2009-01-01), XP055049737, Retrieved from the Internet: URL:http://www.ti.com/lit/an/sprab25/sprab 25.pdf [retrieved on 2013-01-15];;NIKOLIC-POPOVIC J: ""Using TMS320C6416 Coprocessors: Viterbi Coprocessor (VCP)"", TEXAS INSTRUMENTS APPLICATION REPORT, DALLAS, TX, USA , 1 September 2003 (2003-09-01), pages 1-24, XP002591629, Retrieved from the Internet: URL:http://focus.ti.com.cn/cn/lit/an/spra7 50d/spra750d.pdf [retrieved on 2003-09-30];;""TMS320C6474 DSP Enhanced DMA (EDMA3) Controller"", , 1 July 2011 (2011-07-01), XP055049608, Retrieved from the Internet: URL:http://www.ti.com/lit/ug/sprug11b/spru g11b.pdf [retrieved on 2013-01-15];;David Bell ET AL: ""Multicore Programming Guide"", , 1 August 2009 (2009-08-01), XP055049589, Retrieved from the Internet: URL:http://www.polyscope.ch/dlCenter/ps/20 10_15/15_10.05.pdf [retrieved on 2013-01-15]",ACTIVE
444,WO,A2,WO 2002/102471 A2,058-724-034-458-860,2002-12-27,2002,EP 0206498 W,2002-06-12,GB 0114510 A,2001-06-14,EXERCISE MACHINES,"An exercise machine, such as an exercise bicycle, has an adjustable saddle (24) and an adjustable rest (40) for the forearms of a user. The saddle (24) is linked to the rest (40) so that adjustment of the saddle (24) causes adjustment of the rest (40). The forearm rest (40) is provided with adjacent space for the hands of a user so that a person using the machine can manually manipulate an electronic controller (48) on a lead to playa game displayed on a monitor (43) in front of the rest (40).",EXERTRIS LTD;;DAVIES GARETH;;DRAGE KARL JOHN;;WILLS ANDREW;;PRICE OLIVER,DAVIES GARETH;;DRAGE KARL JOHN;;WILLS ANDREW;;PRICE OLIVER,,https://lens.org/058-724-034-458-860,Patent Application,yes,4,0,6,9,0,A63B71/0622;;A63B22/0605;;A63B2071/0641;;A63B2230/06,A63B22/06;;A63B21/00;;A63B22/08;;A63B23/04;;A63B24/00,,0,0,,,,PENDING
445,EP,B1,EP 3623001 B1,139-062-936-787-408,2022-07-27,2022,EP 19204215 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;EP 13891200 A;;IB 2013060287 W,2013-08-07,DEVICES FOR PUNCTURING TISSUE AND SUPPORTING PLACEMENT OF ANCILLARY DEVICES,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,"BAYLIS MEDICAL COMPANY INC. (2022-07-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2023-03-28)",https://lens.org/139-062-936-787-408,Granted Patent,yes,5,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/09;;A61B17/00;;A61B17/22;;A61B17/34;;A61B18/00;;A61B18/14;;A61B90/00;;A61M25/00,,0,0,,,,ACTIVE
446,SI,B,SI 9300056 B,138-215-828-750-323,2000-02-29,2000,SI 9300056 A,1993-02-02,GB 9202298 A,1992-02-04,CARBAPENEMS ANTIBIOTICS,,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;MORSE DAVIES GARETH;;LINGARD SWAIN MICHAEL,ASTRAZENECA UK LIMITED; GB (2005-04-21),https://lens.org/138-215-828-750-323,Amended Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
447,DK,T3,DK 0579826 T3,158-712-166-348-169,1999-07-26,1999,DK 93914514 T,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,"Carbapenemer, der indeholder en carboxysubstitueret phenylgruppe, fremgangsmåder til deres fremstilling, mellemprodukter og",,ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/158-712-166-348-169,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
448,SG,A1,SG 48817 A1,165-810-471-950-423,1998-05-18,1998,SG 1996001979 A,1993-02-02,GB 9202298 A,1992-02-04,Antibiotic compounds,,ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/165-810-471-950-423,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,PENDING
449,US,A,US 5527791 A,192-505-916-268-40X,1996-06-18,1996,US 12399893 A,1993-09-21,EP 92402648 A,1992-09-28,Carbapenem antibiotic compounds,"The present invention provides a compound of the formula: ##STR1## or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: A is a group of the formula (IA) or (IB): ##STR2## R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl; R.sup.3 and R.sup.4 are the same or different and are a variety of substituents X is alkanediyl containing 1-6 carbon atoms optionally interrupted by O, S(O).sub.x (wherein x is zero, one or two), --CONR.sup.5 -- or --NR.sup.5 -- or wherein R.sup.5 is hydrogen or C.sub.1-4 alkyl; or X is alkenediyl containing 1-6 carbon atoms optionally interrupted by O, S(O).sub.x or --NR.sup.5 --.",ZENECA LTD,BETTS MICHAEL J;;DAVIES GARETH M;;JUNG FREDERIC H,ZENECA PHARMA S.A (1993-09-06);;ASTRAZENECA UK LIMITED (2004-08-31);;SYNGENTA LIMITED (2002-08-27),https://lens.org/192-505-916-268-40X,Granted Patent,yes,13,9,9,11,0,C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07D477/20;;C07F9/568;;A61P31/04;;C07D487/04;;C07D477/20;;C07D207/16;;C07D403/12;;C07D409/14;;C07D409/12;;C07F9/568,A61K31/397;;A61P31/04;;A61K31/40;;C07D205/08;;C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07D477/00;;C07D477/20;;C07F9/568,514/210;;540/350,0,0,,,,EXPIRED
450,US,A1,US 2020/0345410 A1,011-437-362-716-462,2020-11-05,2020,US 202016929270 A,2020-07-15,US 202016929270 A;;US 201514850545 A;;IB 2014059641 W;;US 201361787617 P,2013-03-15,Electrosurgical Device having a distal aperture,"A method and apparatus are disclosed for providing forward fluid delivery through an energy delivery device that avoids coring when it delivers energy to a tissue. The device has a distal face defining an opening, with the distal face including at least one electrically exposed portion and at least one electrically insulated portion. An embodiment of the energy delivery device includes an elongate member defining a lumen structured to receive a fluid, and a distal face defining an aperture in communication with the lumen. The distal face includes an electrically exposed conductive portion and an electrically insulated portion. The electrically exposed conductive portion is configured such that the energy it delivers while the energy delivery device is advanced into a tissue punctures the tissue without the tissue substantially occluding the lumen and without creating embolic particles.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;MIRZA MAHMOOD;;HARFIELD ELLEN,BAYLIS MEDICAL COMPANY INC (2015-09-10);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/011-437-362-716-462,Patent Application,yes,0,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14,,0,0,,,,ACTIVE
451,US,A1,US 2021/0401463 A1,018-956-654-145-840,2021-12-30,2021,US 202117474415 A,2021-09-14,US 202117474415 A;;US 201916445790 A;;US 201614910525 A;;IB 2013060287 W;;US 201361863579 P;;US 201361863265 P,2013-08-07,Methods and Devices for Puncturing Tissue,"Novel and unique medical devices and associated methods are disclosed, for a medical device for puncturing tissue at a tissue site. The medical device is an elongate member having a proximal section, a distal section, and a rail section therebetween. The medical device includes an active tip at a distal end of the distal section and is operable to deliver energy to create a puncture through the tissue. The rail section is configured to both act as a rail for supporting installation of one or more tubular members thereupon, as well as be maneuverable for enabling access to the tissue site.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ALLEY FERRYL;;BECA BOGDAN,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/018-956-654-145-840,Patent Application,yes,9,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61B18/14;;A61B17/34;;A61B90/00,,0,0,,,,PENDING
452,US,A1,US 2019/0239924 A1,025-601-564-154-55X,2019-08-08,2019,US 201916387732 A,2019-04-18,US 201916387732 A;;US 201615160737 A;;US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 88428507 P;;US 82745206 P,2006-09-29,Transseptal needle,"Embodiments of medical devices and methods are disclosed. The medical devices typically comprises a needle with a rigid proximal shaft, a flexible distal shaft and a distal tip. The distal tip includes an electrode for delivering energy to puncture a tissue. In some embodiments, the distal shaft comprises a superelastic material. In other embodiments, the distal shaft is comprised of both a superelastic material and a non-superelastic material.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;DAVIES GARETH;;MIRZA MAHMOOD;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2016-05-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/025-601-564-154-55X,Patent Application,yes,0,5,3,113,0,Y10T29/49826;;A61B17/3478;;A61B2017/00867;;A61B2018/00351;;A61B2018/00577;;A61B2018/00613;;A61B18/1492;;A61B2017/00309;;A61B2018/1425;;A61B5/0215;;A61B2018/00601;;A61B18/1477;;A61B2218/002;;A61B2218/007;;A61M5/3286;;A61M5/329;;A61B2090/3966;;A61M3/0283;;A61M1/77;;A61B17/3476;;A61B17/3478;;A61M5/007;;A61M39/08;;A61B18/1477;;A61B5/0215;;A61M3/0283;;A61M5/32;;A61B5/6848;;A61B2017/00867;;A61B2017/00862;;A61B6/12;;A61B2218/007;;A61B2018/00357;;A61B18/1492;;A61B2090/3966;;A61B2090/0811;;A61B2090/3983;;A61B90/02;;A61B2090/064;;Y10T29/49826;;A61B2018/00136;;A61B2018/00297;;A61B2018/00375;;A61B2018/00404;;A61B2017/00247;;A61B2018/00083;;A61B2218/002;;A61B2018/00577;;A61B2018/00351;;A61B2018/00613;;A61M1/77,A61B17/34;;A61B5/00;;A61B5/0215;;A61B18/14;;A61M1/00;;A61M3/02;;A61M5/00;;A61M5/32;;A61M39/08,,0,0,,,,ACTIVE
453,CN,A,CN 110974368 A,045-323-586-479-919,2020-04-10,2020,CN 201911330878 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;CN 201380078846 A;;IB 2013060287 W,2013-08-07,Wires and systems for puncturing tissue at tissue site,"The invention discloses wires and systems for puncturing tissue at a tissue site. The wire includes an elongate member having a proximal end, a distal end, and a track portion between the proximal endand the distal end; a movable tip at a distal end of the distal portion. The movable tip is operable to deliver energy to create a perforation through the tissue; and the track portion is configuredto be operable to bend at least 180 degrees to enable access to the tissue site. The track portion has a stiffness of about 150 N/m to about 600 N/m such that the track portion can be bent at least 180 degrees and can function to support a track on which one or more tubular members are mounted. The wire facilitates access and piercing of tissue at different anatomical locations from a desired access site.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,,https://lens.org/045-323-586-479-919,Patent Application,no,9,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61B17/34;;A61B18/14;;A61B90/00,,0,0,,,,ACTIVE
454,US,A,US 5652233 A,075-022-364-357-392,1997-07-29,1997,US 46203795 A,1995-06-05,US 46203795 A;;GB 9202298 A;;US 12905693 A,1992-02-04,Antibiotic compounds,"The present invention relates to carbapenems and provides a compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl; R.sup.4 and R.sup.5 are the same or different and are selected from hydrogen, halo, cyano, C.sub.1-4 alkyl, nitro, hydroxy, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 alkoxycarbonyl, aminosulphonyl, C.sub.1-4 alkylaminosulphonyl, di-C.sub.1-4 -alkylaminosulphonyl, carbamoyl, C.sub.1-4 alkylcarbamoyl, di-C.sub.1-4 alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.1-4 alkanoylamino, C.sub.1-4 alkanoyl(N-C.sub.1-4 alkyl)amino, C.sub.1-4 alkanesulphonamido and C.sub.1-4 alkylS(O)n- wherein n is zero, one or two: with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to --NR.sup.3 --. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.",ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,ASTRAZENECA UK LIMITED (2004-05-20);;SYNGENTA LIMITED (2002-05-27),https://lens.org/075-022-364-357-392,Granted Patent,yes,20,15,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,514/210;;540/200;;540/350;;548/413;;548/537,2,0,,,"Betts, CA 118(9): 80721d (1992).;;Betts, CA 118(7): 59495aj (1992).",EXPIRED
455,WO,A1,WO 2014/141077 A1,075-526-815-273-323,2014-09-18,2014,IB 2014059641 W,2014-03-11,US 201361787617 P,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,"A method and apparatus are disclosed for providing forward fluid delivery through an energy delivery device, while avoiding coring when energy is delivered to the energy delivery device. The device has a distal face defining an opening, with the distal face including at least one electrically exposed portion and at least one electrically insulated portion. An embodiment of the energy delivery device includes an elongate member defining a lumen structured to receive a fluid and a distal face defining an aperture in communication with the lumen, the distal face including an electrically exposed conductive portion and an electrically insulated portion, where the electrically exposed conductive portion is configured such that energy delivered by the electrically exposed conductive portion, while the energy delivery device is advanced into a tissue, punctures the tissue without the tissue substantially occluding the lumen and without creating embolic particles.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD,,https://lens.org/075-526-815-273-323,Patent Application,yes,6,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/18;;A61M37/00,,1,0,,,See also references of EP 2967746A4,PENDING
456,CN,A,CN 116847797 A,076-527-022-492-551,2023-10-03,2023,CN 202180090732 A,2021-01-14,IB 2021050266 W,2021-01-14,"Medical dilator and system, method and kit for medical dilation","A medical dilator includes an elongate member having a proximal end, an opposite distal end, and a lumen extending through the elongate member from the proximal end to the distal end. The dilation tip is located at the distal end. The dilation tip has a first end with an increasing cross-sectional area and tapers in a distal direction to a second end with a decreasing cross-sectional area. At least a first electrode is associated with the dilation tip. An electrical conductor is electrically connected to the first electrode and extends proximally from the first electrode toward the proximal end for electrical connection with an electroanatomical mapping system.",BOSTON SCIENT SCIMED EQUIPMENT INC,DAVIES GARETH;;KWAN LAUREN;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO,,https://lens.org/076-527-022-492-551,Patent Application,no,0,0,5,5,0,A61B5/283;;A61B18/1477;;A61B2018/00357;;A61B2018/00601;;A61B2018/00839;;A61B18/1492;;A61M29/00;;A61B5/287;;A61B5/287;;A61M29/00,A61B18/14,,0,0,,,,PENDING
457,TW,B,TW 408124 B,077-596-156-719-403,2000-10-11,2000,TW 82100868 A,1993-02-09,GB 9202298 A,1992-02-04,"Antibiotic compounds, preparation process thereof and composition comprising same","The present invention relates to carbapenems and provides a compound of the formula (I): or a pharmaceutically acceptable salt or in vivo hydrolysable ester comprising C1-6 alkyl or C1-6 alkenyl thereof wherein: R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4 alkyl; R3 is hydrogen or C1-4 alkyl; R4 and R5 are the same or different and are selected form hydrogen, halo, cyano, C1-4 alkyl, nitro, hydroxy, carboxy, C1-4 alkoxy, C1-4 alkoxycarbonyl, aminosulphonyl, C1-4 alkylaminosulphonyl, di-C1-4-alkylaminosulphonyl, carbamoyl, C1-4 alkylcarbamoyl, di-C1-4-alkylcarbamoryl, trifluoromethyl, sulphonic acid, amino, C1-4 alkylamino, di-C1-4 alkylamino, C1-4 alkanoylamino, C1-4 alkanoyl (N-C1-4alkyl) amino, C1-4 alkanesulphonamido and C1-4 alkylS(O)n-wherein n is zero, one or two: with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to -NR3-. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/077-596-156-719-403,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
458,AU,B2,AU 2019/213413 B2,096-318-319-260-430,2021-05-06,2021,AU 2019/213413 A,2019-08-09,AU 2019/213413 A;;AU 2013/397477 A;;US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,Methods and Devices for Puncturing Tissue,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions. WO 2015/019132 PCT/1B2013/060287 ~~C)",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-22),https://lens.org/096-318-319-260-430,Granted Patent,no,6,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/01;;A61B17/34;;A61B18/14;;A61M25/06;;A61M29/00,,0,0,,,,ACTIVE
459,US,A1,US 2005/0209212 A1,119-532-247-917-551,2005-09-22,2005,US 12633105 A,2005-05-11,US 12633105 A;;GB 9202298 A;;US 29356102 A;;US 78155601 A;;US 16829398 A;;US 83305697 A;;US 46203795 A;;US 12905693 A;;GB 9300217 W,1992-02-04,Antibiotic compounds,"The present invention relates to carbapenems and provides a compound of the formula (I): or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R 1 is 1 -hydroxyethyl, 1 -fluoroethyl or hydroxymethyl;R 2 is hydrogen or C 1-4 alkyl;R 3 is hydrogen or C 1-4 alkyl;R 4 and R 5 are the same or different and are selected from hydrogen, halo, cyano, C 1-4 alkyl, nitro, hydroxy, carboxy, C 1-4 alkoxy, C 1-4 alkoxycarbonyl, aminosulphonyl, C 1-4 alkylaminosulphonyl, di-C 1-4 -alkylaminosulphonyl, carbamoyl, C 1-4 alkylcarbamoyl, di-C 1-4 alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C 1-4 alkylamino, di-C 1-4 alkylamino, C 1-4 alkanoylamino, C 1-4 alkanoyl( N —C 1-4 alkyl)amino, C 1-4 alkanesulphonamido and C 1-4 alkylS(O) n — wherein n is zero; one or two:with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to —NR 3 —. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.",ASTRAZENECA UK LTD,BETTS MICHAEL J;;DAVIES GARETH M;;SWAIN MICHAEL L,,https://lens.org/119-532-247-917-551,Patent Application,yes,30,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,514/210.13;;540/350,0,0,,,,INACTIVE
460,EP,A1,EP 3623001 A1,128-947-769-496-943,2020-03-18,2020,EP 19204215 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;EP 13891200 A;;IB 2013060287 W,2013-08-07,DEVICES FOR PUNCTURING TISSUE AND SUPPORTING PLACEMENT OF ANCILLARY DEVICES,"A medical device for puncturing tissue at a tissue site is disclosed. The medical device comprises an elongate member having a proximal section (206), a distal section (202) and a rail section (204) between the proximal and distal sections; and an active tip at a distal end of the distal section, the active tip operable to deliver energy to create a puncture through the tissue. The rail section is configured to both act as a rail for supporting installation of one or more tubular members thereupon as well as to be maneuverable for enabling access to the tissue site. Also, a system for puncturing tissue at a tissue site is disclosed. The system comprises such a medical device and an electrosurgical generator for coupling to the at least one medical device for delivering energy to puncture the tissue at the tissue site.
",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,"BAYLIS MEDICAL COMPANY INC. (2022-07-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2023-03-28)",https://lens.org/128-947-769-496-943,Patent Application,yes,5,1,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61B17/00;;A61M25/09;;A61B17/22;;A61B17/34;;A61B18/00;;A61B18/14;;A61B90/00;;A61M25/00,,0,0,,,,ACTIVE
461,PL,B1,PL 174649 B1,156-644-529-211-758,1998-08-31,1998,PL 30076893 A,1993-02-02,GB 9300217 W;;GB 9202298 A,1992-02-04,"CARBAPHENEMES CONTAINING CARBOXYLIC GROUP SUBSTITUTED PHENYL GROUP, METHODS OF OBTAINING SAMES, SEMIPRODUCTS THEREFOR AND THEIR APPLICATION AS ANTIBIOTICS",,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL J;;DAVIES GARETH M;;SWAIN MICHAEL L,,https://lens.org/156-644-529-211-758,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
462,CA,A1,CA 3117171 A1,150-262-541-589-591,2015-02-12,2015,CA 3117171 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;CA 2920683 A,2013-08-07,METHODS AND DEVICES FOR PUNCTURING TISSUE,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;ALLEY FERRYL;;DAVIES GARETH;;BECA BOGDAN,,https://lens.org/150-262-541-589-591,Patent Application,no,0,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,,,0,0,,,,PENDING
463,CA,A1,CA 2106370 A1,163-434-614-059-322,1993-08-05,1993,CA 2106370 A,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,ANTIBIOTIC COMPOUNDS,"2106370 9315078 PCTABS00024 The present invention relates to carbapenems and provides a compound of formula (I) or a pharmaceutically acceptable salt or in vivo) hydrolysable ester thereof wherein: R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4alkyl; R3 is hydrogen or C1-4alkyl; R4 and R5 are the same or different and are selected from hydrogen, halo, cyano, C1-4alkyl, nitro, hydroxy, carboxy, C1-4alkoxy, C1-4alkoxycarbonyl, aminosulphonyl, C1-4alkylaminosulphonyl, di-C1-4alkylaminosulphonyl, carbamoyl, C1-4alkylcarbamoyl, di-C1-4alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C1-4alkylamino, di-C1-4alkylamino, C1-4alkanoylamino, C1-4alkanoyl(N-C1-4alkyl)amino, C1-4alkanesulphonamido and C1-4alkylS(O)n- wherein n is zero, one or two; with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to -NR3-. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL J;;DAVIES GARETH M;;SWAIN MICHAEL L,,https://lens.org/163-434-614-059-322,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
464,WO,A1,WO 2001/053295 A1,178-374-266-844-449,2001-07-26,2001,GB 0100161 W,2001-01-17,GB 0001346 A,2000-01-21,BICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF THE INTERACTION BETWEEN THE INTEGRIN ALPHA4BETA1 RECEPTOR AND VCAM-1 AND/OR FIBRONECTIN,A compound of formual (I) or pharmaceutically acceptable salts or derivatives thereof; wherein variables are as defined in the specification. The compounds are useful in the treatment of disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor α4β1. Pharmaceutical compositions and methods of use or treatment are also described and claimed.,ASTRAZENECA AB;;ASTRAZENECA UK LTD;;BRITTAIN DAVID ROBERT;;LARGE MICHAEL STEWART;;DAVIES GARETH MORSE,BRITTAIN DAVID ROBERT;;LARGE MICHAEL STEWART;;DAVIES GARETH MORSE,,https://lens.org/178-374-266-844-449,Patent Application,yes,4,8,6,6,0,C07D413/12;;A61P1/04;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P29/00;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D413/12,A61K31/423;;A61K31/4439;;A61K31/513;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P29/00;;A61P37/06;;A61P43/00;;C07D413/12,,0,0,,,,PENDING
465,AP,A,AP 398 A,018-943-898-837-429,1995-08-29,1995,AP 9300480 A,1993-01-21,GB 9202298 A,1992-02-04,"Carbapenems derivatives, their preparation and their use in pharmaceutical compositions.",The present invention relates to carbapenems and provides a compound of the,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/018-943-898-837-429,Granted Patent,no,1,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
466,FI,A,FI 930474 A,040-810-938-600-775,1993-08-05,1993,FI 930474 A,1993-02-03,GB 9202298 A,1992-02-04,ANTIBIOTISKA FOERENINGAR,,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/040-810-938-600-775,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
467,CA,C,CA 3117171 C,047-534-232-569-768,2024-02-20,2024,CA 3117171 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;CA 2920683 A,2013-08-07,METHODS AND DEVICES FOR PUNCTURING TISSUE,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;ALLEY FERRYL;;DAVIES GARETH;;BECA BOGDAN,,https://lens.org/047-534-232-569-768,Granted Patent,no,0,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/01;;A61B17/34;;A61B18/14;;A61M25/06,,0,0,,,,PENDING
468,US,A1,US 2016/0262795 A1,067-848-350-081-111,2016-09-15,2016,US 201615160737 A,2016-05-20,US 201615160737 A;;US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 82745206 P;;US 88428507 P;;US 201113113326 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 52275304 P,2003-01-21,Transseptal needle,"Methods and apparatus are disclosed for a needle comprising a distal shaft and a proximal shaft joined at a junction, the needle having a distal tip which includes an electrode for delivering energy to puncture a tissue, wherein the distal shaft is comprised of a superelastic material. In typical embodiments, the needle includes a lumen for delivering and withdrawing fluids from a treatment site. In some embodiments the junction is comprised of a superelastic material.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;DAVIES GARETH;;MIRZA MAHMOOD;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2016-05-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/067-848-350-081-111,Patent Application,yes,9,8,2,113,0,A61M5/007;;A61B18/1492;;A61M39/08;;A61B2017/00247;;A61B2018/00083;;A61B2218/002;;Y10T29/49826;;A61B2090/064;;A61B90/02;;A61B2090/3983;;A61B2090/0811;;A61B2090/3966;;A61B18/1477;;A61B2018/00357;;A61B2218/007;;A61B5/0215;;A61B5/6848;;A61B6/12;;A61B17/3478;;A61B2017/00867;;A61B2018/00136;;A61B2018/00297;;A61B2018/00375;;A61B2018/00404;;A61M1/77;;A61B17/3476;;A61M5/32;;A61B2017/00862;;A61B2018/00083;;A61B2090/0811;;A61B90/02;;A61B2017/00247;;A61B2218/007;;A61B18/1492;;Y10T29/49826;;A61B18/1477;;A61M39/08;;A61B2090/3983;;A61B2090/064;;A61B2090/3966;;A61M5/007;;A61B2218/002;;A61B5/6848;;A61B2018/00357;;A61B5/0215;;A61B17/3478;;A61B6/12;;A61B2018/00404;;A61B2017/00867;;A61B2018/00375;;A61B2018/00297;;A61B2018/00136;;A61M1/77,A61B17/34;;A61M1/00;;A61M3/02;;A61M5/32,,0,0,,,,ACTIVE
469,NZ,A,NZ 272038 A,072-339-074-157-727,1997-07-27,1997,NZ 27203893 A,1993-02-02,GB 9202298 A;;NZ 24691793 A,1992-02-04,TREATMENT OF INFECTIONS USING 2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)CARBAPENEM-3-CARBOXYLIC ACID DERIVATIVES,,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/072-339-074-157-727,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,DISCONTINUED
470,JP,A,JP 2019005628 A,109-682-551-648-65X,2019-01-17,2019,JP 2018188335 A,2018-10-03,US 201361787617 P,2013-03-15,ELECTROSURGICAL DEVICE HAVING DISTAL OPENING,To provide a device delivering fluid forward without scooping when delivering energy to an energy delivery device.SOLUTION: A device has a distal surface which includes at least one part electrically exposed and at least one part electrically insulated and defines an opening. The embodiment of an energy delivery device includes a long and narrow member defining a lumen. The long and narrow member includes a lumen receiving fluid and a distal surface defining an opening communicated with the lumen. The distal surface includes an electrically exposed conductive part and the electric insulation part. The electrically exposed conductive part punctures a tissue without energy delivered by the electrically exposed conductive part virtually closing the lumen or without creating embolization particles while the energy delivery device is progressing in the tissue.SELECTED DRAWING: Figure 1,BAYLIS MEDICAL CO INC,GARETH DAVIES;;JOHN PAUL URBANSKI;;ELLEN HARFIELD;;MAHMOOD MIRZA,,https://lens.org/109-682-551-648-65X,Patent Application,no,2,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14;;A61B18/12,,0,0,,,,ACTIVE
471,CA,C,CA 2920683 C,099-780-366-914-766,2021-06-22,2021,CA 2920683 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,METHODS AND DEVICES FOR PUNCTURING TISSUE,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,,https://lens.org/099-780-366-914-766,Granted Patent,no,0,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/01;;A61B17/34;;A61B18/14;;A61M25/06,,0,0,,,,ACTIVE
472,DE,D1,DE 69322007 D1,126-444-639-281-066,1998-12-17,1998,DE 69322007 T,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,"CARBOXY SUBSTITUIERTE PHENYLGRUPPE ENTHALTENDE CARBAPENEME; VERFAHREN ZU DEREN HERSTELLUNG, ZWISCHENPRODUKTE UND VERWENDUNG ALS ANTIBIOTIKA",,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/126-444-639-281-066,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
473,NO,B1,NO 304315 B1,122-961-666-420-375,1998-11-30,1998,NO 933530 A,1993-10-01,GB 9202298 A;;GB 9300217 W,1992-02-04,"Karbapenemer inneholdene en karboksysubstituert fenylgruppe, mellomprodukter for fremstilling derav, og farmas°ytiske preparater inneholdende dem",,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/122-961-666-420-375,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
474,EP,A2,EP 3581132 A2,162-465-008-886-972,2019-12-18,2019,EP 19167716 A,2014-03-11,US 201361787617 P;;EP 14763885 A;;IB 2014059641 W,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,"A method and apparatus are disclosed for providing forward fluid delivery through an energy delivery device, while avoiding coring when energy is delivered to the energy delivery device. The device has a distal face defining an opening, with the distal face including at least one electrically exposed portion and at least one electrically insulated portion. An example of the energy delivery device includes an elongate member defining a lumen structured to receive a fluid and a distal face defining an aperture in communication with the lumen, the distal face including an electrically exposed conductive portion and an electrically insulated portion, where the electrically exposed conductive portion is configured such that energy delivered by the electrically exposed conductive portion, while the energy delivery device is advanced into a tissue, punctures the tissue without the tissue substantially occluding the lumen and without creating embolic particles.
",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD,"BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2023-03-28);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED; IE (2023-04-14)",https://lens.org/162-465-008-886-972,Patent Application,yes,18,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14;;A61B18/00;;A61B90/00,,0,0,,,,ACTIVE
475,US,B2,US 10820925 B2,193-281-157-466-355,2020-11-03,2020,US 201615160737 A,2016-05-20,US 201615160737 A;;US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 82745206 P;;US 88428507 P;;US 201113113326 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 52275304 P,2003-01-21,Transseptal needle,"Methods and apparatus are disclosed for a needle comprising a distal shaft and a proximal shaft joined at a junction, the needle having a distal tip which includes an electrode for delivering energy to puncture a tissue, wherein the distal shaft is comprised of a superelastic material. In typical embodiments, the needle includes a lumen for delivering and withdrawing fluids from a treatment site. In some embodiments the junction is comprised of a superelastic material.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;DAVIES GARETH;;MIRZA MAHMOOD;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2016-05-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/193-281-157-466-355,Granted Patent,yes,14,3,2,113,0,A61M5/007;;A61B18/1492;;A61M39/08;;A61B2017/00247;;A61B2018/00083;;A61B2218/002;;Y10T29/49826;;A61B2090/064;;A61B90/02;;A61B2090/3983;;A61B2090/0811;;A61B2090/3966;;A61B18/1477;;A61B2018/00357;;A61B2218/007;;A61B5/0215;;A61B5/6848;;A61B6/12;;A61B17/3478;;A61B2017/00867;;A61B2018/00136;;A61B2018/00297;;A61B2018/00375;;A61B2018/00404;;A61M1/77;;A61B17/3476;;A61M5/32;;A61B2017/00862;;A61B2018/00083;;A61B2090/0811;;A61B90/02;;A61B2017/00247;;A61B2218/007;;A61B18/1492;;Y10T29/49826;;A61B18/1477;;A61M39/08;;A61B2090/3983;;A61B2090/064;;A61B2090/3966;;A61M5/007;;A61B2218/002;;A61B5/6848;;A61B2018/00357;;A61B5/0215;;A61B17/3478;;A61B6/12;;A61B2018/00404;;A61B2017/00867;;A61B2018/00375;;A61B2018/00297;;A61B2018/00136;;A61M1/77,A61B18/18;;A61B5/00;;A61B5/0215;;A61B6/12;;A61B17/00;;A61B17/34;;A61B18/00;;A61B18/14;;A61B90/00;;A61M1/00;;A61M3/02;;A61M5/00;;A61M5/32;;A61M39/08,,0,0,,,,ACTIVE
476,NO,L,NO 933530 L,012-509-754-076-35X,1993-10-04,1993,NO 933530 A,1993-10-01,GB 9202298 A;;GB 9300217 W,1992-02-04,"KARBAPENEMER INNEHOLDENE EN KARBOKSYSUBSTITUERT FENYLGRUPPE, FREMGANGSMAATE FOR DERES FREMSTILLING, MELLOMPRODUKETEROG ANVENDELSE SOM ANTIBIOTIKA",,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/012-509-754-076-35X,Abstract,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
477,AU,A1,AU 2019/213413 A1,018-685-562-331-775,2019-08-29,2019,AU 2019/213413 A,2019-08-09,AU 2019/213413 A;;AU 2013/397477 A;;US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,Methods and Devices for Puncturing Tissue,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions. WO 2015/019132 PCT/1B2013/060287 ~~C)",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-22),https://lens.org/018-685-562-331-775,Patent Application,no,0,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/01;;A61B17/34;;A61B18/14;;A61M25/06;;A61M29/00,,0,0,,,,ACTIVE
478,WO,A1,WO 2023/194584 A1,037-529-260-623-494,2023-10-12,2023,EP 2023059271 W,2023-04-06,GB 202205200 A,2022-04-08,COMBINATION OF A GREMLIN-1 ANTAGONIST WITH A CYTIDINE ANALOGUE OR DEOXYCYTIDINE ANALOGUE,The invention relates to an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer in combination with a proliferation-dependent cytotoxic agent.,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;JONES PAUL;;MORTON JENNIFER PATRICIA,,https://lens.org/037-529-260-623-494,Patent Application,yes,47,0,2,2,37,C07K16/22;;C07K2317/24;;A61K39/395;;A61K2039/505;;A61P35/00;;A61K31/7068;;A61K31/706;;A61K31/555;;A61K31/337;;A61K31/519;;A61K31/513;;A61K31/4745,C07K16/22;;A61K31/7068;;A61K39/395;;A61P35/00,,40,27,026-322-432-065-074;;044-958-492-431-511;;088-935-349-526-045;;013-425-185-904-685;;001-638-134-018-871;;106-753-778-592-300;;020-026-345-586-213;;087-448-981-335-707;;055-542-669-483-094;;064-741-687-897-846;;035-081-115-342-527;;077-532-829-551-519;;148-647-852-252-502;;025-662-361-226-516;;042-623-879-457-954;;064-667-501-146-970;;054-899-454-772-257;;030-797-864-869-467;;045-649-831-754-663;;010-655-350-435-62X;;037-436-870-995-452;;113-446-080-346-814;;066-141-497-990-023;;080-856-085-597-555;;056-201-471-905-934;;023-907-179-348-058;;019-779-601-634-917,35117769;;pmc8797889;;10.21037/tcr-20-682;;10.1073/pnas.0606857103;;17003113;;pmc1578503;;10.1371/journal.pone.0035100;;22514712;;pmc3325980;;10.3390/biomedicines10020301;;35203511;;pmc8869528;;10.1007/s00534-006-1166-5;;17520196;;pmc2666331;;1172191;;10.1038/256495a0;;25291284;;10.1016/0167-5699(83)90123-8;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1002/eji.1830240426;;8149964;;10.1016/s0378-1119(96)00627-0;;10.1016/s0065-2776(08)60674-4;;7872158;;10.1038/nbt1142;;16151406;;10.2174/1567269053828800;;10.1016/s0022-1759(98)00077-5;;9760222;;9624683;;10.1038/nbt0698-535;;15848072;;10.1016/j.ymeth.2005.01.003;;15608286;;10.1093/nar/gki088;;pmc540042;;10.1016/0021-9673(94)01255-d;;7620566;;10.1134/s0006297906060150;;10.1385/1-59259-666-5:443;;14970513;;10.1110/ps.9.3.487;;pmc2144561;;10752610;;2406013;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1007/bf00160485;;8483166;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;pmc46825;;8390686;;10.1073/pnas.90.12.5873,"CHENG ZIQI ET AL: ""A review of research progress of antitumor drugs based on tubulin targets"", TRANSLATIONAL CANCER RESEARCH, vol. 9, no. 6, 1 June 2020 (2020-06-01), pages 4020 - 4027, XP093048872, ISSN: 2218-676X, DOI: 10.21037/tcr-20-682;;J. B. SNEDDON ET AL: ""Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 103, no. 40, 3 October 2006 (2006-10-03), pages 14842 - 14847, XP055121828, ISSN: 0027-8424, DOI: 10.1073/pnas.0606857103;;MINSOO KIM ET AL: ""Gremlin-1 Induces BMP-Independent Tumor Cell Proliferation, Migration, and Invasion"", PLOS ONE, vol. 7, no. 4, 13 April 2012 (2012-04-13), pages e35100, XP055121712, DOI: 10.1371/journal.pone.0035100;;ELEMAM NOHA MOUSAAD ET AL: ""Insights into the Role of Gremlin-1, a Bone Morphogenic Protein Antagonist, in Cancer Initiation and Progression"", BIOMEDICINES, vol. 10, no. 2, 28 January 2022 (2022-01-28), pages 301, XP093048642, DOI: 10.3390/biomedicines10020301;;FELDMANN ET AL., J HEPATOBILIARY PANCREAT SURG., vol. 14, no. 3, 2007, pages 224 - 32;;GUINNEY ET AL., NAT MED, 2015;;TOMLINSON ET AL., PLOS GENET, 2011;;""UniProt"", Database accession no. 060565;;""NCBI"", Database accession no. NM_001191323.1;;""Handbook of Experimental Immunology"", vol. 4, 1986, BLACKWELL SCIENTIFIC PUBLISHERS;;KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497;;KOZBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 72;;COLE ET AL.: ""Monoclonal Antibodies and Cancer Therapy"", 1985, ALAN R LISS, INC., pages: 77 - 96;;BABCOOK, J. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, no. 15, 1996, pages 7843 - 78481;;BRINKMAN ET AL., J. IMMUNOL. METHODS, vol. 184, 1995, pages 177 - 186;;KETTLEBOROUGH, EUR. J. IMMUNOL., vol. 24, 1994, pages 952 - 958;;PERSIC ET AL., GENE, vol. 187, 1997, pages 9 - 18;;BURTON, ADVANCES IN IMMUNOLOGY, vol. 57, 1994, pages 191 - 280;;HOLLIGERHUDSON, NATURE BIOTECH., vol. 23, no. 9, 2005, pages 1126 - 1136;;ADAIRLAWSON, DRUG DESIGN REVIEWS, vol. 2, no. 3, 2005, pages 209 - 217;;VERMA ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 216, 1998, pages 165 - 181;;VAUGHAN ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 535 - 539;;KASHMIRI ET AL., METHODS, vol. 36, 2005, pages 25 - 34;;RETTER ET AL., NUCL. ACIDS RES., vol. 33, 2005, pages D671 - D674;;REICHMANN ET AL., NATURE, vol. 332, 1998, pages 323 - 324;;HARRIS, RJ, JOURNAL OF CHROMATOGRAPHY, vol. 705, 1995, pages 129 - 134;;WALKER: ""The Proteomics Protocols Handbook"", 2005, HUMANA PRESS, pages: 571 - 607;;REINEKE, METHODS MOL BIOL, vol. 248, 2004, pages 443 - 63;;TOMER, PROTEIN SCIENCE, vol. 9, 2000, pages 487 - 496;;JUNGHANS ET AL., CANCER RES, vol. 50, 1990, pages 1495 - 1502;;KRINNER ET AL., MOL. IMMUNOL., vol. 44, no. 5, 11 May 2006 (2006-05-11), pages 916 - 25;;DEVEREUX ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 387 - 395;;ALTSCHUL S.F., J MOL EVOL, vol. 36, 1993, pages 290 - 300;;ALTSCHUL, S, F ET AL., J MOL BIOL, vol. 215, 1990, pages 403 - 10;;HENIKOFFHENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 - 10919;;KARLINALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5787;;""Current Protocols in Molecular Biology"", 1995, GREENE PUBLISHING AND WILEY-LNTERSCIENCE;;SAMBROOK ET AL.: ""Molecular Cloning: a laboratory manual"", 2001, COLD SPRING HARBOUR LABORATORY PRESS;;""Remington's Pharmaceutical Sciences"", 2000, LIPPINCOTT, WILLIAMS & WILKINS;;VAN CUTSEM, ANNALS OF ONCOLOGY, vol. 25, 2014",PENDING
479,DE,I1,DE 10299041 I1,053-978-632-118-768,2003-02-20,2003,DE 10299041 C,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,Carboxy substituierte Phenylgruppe enthaltende Carbapeneme Verfahren zu deren Herstellung Zwischenprodukte und Verwendung als Antibiotika,,ASTRAZENECA UL LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/053-978-632-118-768,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,PENDING
480,US,B2,US 11154324 B2,112-133-963-081-81X,2021-10-26,2021,US 201916445790 A,2019-06-19,US 201916445790 A;;US 201614910525 A;;IB 2013060287 W;;US 201361863579 P;;US 201361863265 P,2013-08-07,Methods and devices for puncturing tissue,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ALLEY FERRYL;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2016-02-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/112-133-963-081-81X,Granted Patent,yes,15,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61B18/14;;A61B17/00;;A61B17/22;;A61B17/34;;A61B18/00;;A61B90/00,,2,0,,,Search Report for corresponding European patent application EP19204215.;;Search Report for corresponding Japanese patent application 2018211611.,ACTIVE
481,EP,B1,EP 3030306 B1,122-250-882-873-706,2020-03-04,2020,EP 13891200 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,DEVICES FOR PUNCTURING TISSUE,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,"BAYLIS MEDICAL COMPANY INC. (2019-11-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2022-11-14)",https://lens.org/122-250-882-873-706,Granted Patent,yes,2,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61B17/34;;A61B17/00;;A61B17/22;;A61B18/00;;A61B18/14;;A61B90/00,,0,0,,,,ACTIVE
482,EP,A4,EP 2967746 A4,169-341-326-098-568,2016-11-09,2016,EP 14763885 A,2014-03-11,US 201361787617 P;;IB 2014059641 W,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD,,https://lens.org/169-341-326-098-568,Search Report,no,3,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14;;A61B18/00;;A61B90/00,,1,0,,,See also references of WO 2014141077A1,ACTIVE
483,US,B2,US 10751115 B2,196-676-286-463-025,2020-08-25,2020,US 201514850545 A,2015-09-10,US 201514850545 A;;IB 2014059641 W;;US 201361787617 P,2013-03-15,Electrosurgical device having a distal aperture,"A method and apparatus are disclosed for providing forward fluid delivery through an energy delivery device that avoids coring when it delivers energy to a tissue. The device has a distal face defining an opening, with the distal face including at least one electrically exposed portion and at least one electrically insulated portion. An embodiment of the energy delivery device includes an elongate member defining a lumen structured to receive a fluid, and a distal face defining an aperture in communication with the lumen. The distal face includes an electrically exposed conductive portion and an electrically insulated portion. The electrically exposed conductive portion is configured such that the energy it delivers while the energy delivery device is advanced into a tissue punctures the tissue without the tissue substantially occluding the lumen and without creating embolic particles.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;MIRZA MAHMOOD;;HARFIELD ELLEN,BAYLIS MEDICAL COMPANY INC (2015-09-10);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/196-676-286-463-025,Granted Patent,yes,34,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14;;A61B18/00;;A61B90/00,,15,0,,,"International Search Report for International Application No. PCT/IB2014/059641 with International Filing Date Mar. 11, 2014 dated Jun. 27, 2014.;;International Search Report for International Application No. PCT/IB2014/064600 with International Filing Date Sep. 17, 2014 dated Dec. 31, 2014.;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2014/064600, dated Sep. 13, 2016.;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2014/059641, dated Sep. 15, 2015.;;Japanese Office Action for counterpart Japanese Application No. 2015-562485, dated Jan. 23, 2018.;;European Patent Office, Communication pursuant to Rules 161(2) and 162 EPC, for counterpart European Application No. 147885380.7, dated Oct. 25, 2016.;;Applicant's Reply to Communication pursuant to Rules 161 and 162 for counterpart European Application No. 147885380.7, dated Apr. 30, 2017.;;European Patent Office, Communication pursuant to Rule 70(2) and 70a(2) EPC for counterpart European Application No. 14763885.2, dated Oct. 27, 2016.;;Applicant's Reply to Communication pursuant to Rule 70 EPC for counterpart European Application No. 14763885.2, dated May 8, 2017.;;European Patent Office, Communication pursuant to Rules 161(2) and 162 EPC, for counterpart European Application No. 14763885.2, dated Oct. 22, 2015.;;Applicant's Reply to Communication pursuant to Rules 161 and 162 for counterpart European Application No. 14763885.2, dated Apr. 21, 2016.;;Supplementary European Search Report for European Application No. 14763885.2, dated Sep. 28, 2016.;;Supplementary European Search Report for European Application No. 14885380.7, dated Oct. 18, 2017.;;European Patent Office, Communication pursuant to Rule 70(2) and 70a(2) EPC for counterpart European Application No. 147885380.7, dated Nov. 7, 2017.;;Applicant's Reply to Communication pursuant to Rule 70 EPC for counterpart European Application No. 147885380.7, dated May 17, 2018.",ACTIVE
484,US,A1,US 2003/0181498 A1,006-875-133-475-377,2003-09-25,2003,US 16839602 A,2002-11-25,GB 0001346 A,2000-01-21,Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin,"
    A compound of formual (I) or pharmaceutically acceptable salts or derivatives thereof; wherein variables are as defined in the specification. The compounds are useful in the treatment of disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor ₄ ₁ . Pharmaceutical compositions and methods of use or treatment are also described and claimed. 
",ASTRAZENECA AB,BRITTAIN DAVID ROBERT;;LARGE MICHAEL STEWART;;DAVIES GARETH MORSE,ASTRAZENECA AB (2002-05-29),https://lens.org/006-875-133-475-377,Patent Application,yes,0,2,6,6,0,C07D413/12;;A61P1/04;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P29/00;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D413/12,A61K31/423;;A61K31/4439;;A61K31/513;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P29/00;;A61P37/06;;A61P43/00;;C07D413/12,514/375;;548/217,0,0,,,,DISCONTINUED
485,EP,A1,EP 0590885 A1,018-260-781-379-601,1994-04-06,1994,EP 93307551 A,1993-09-23,EP 93307551 A;;EP 92402648 A,1992-09-28,Antibiotic carbapenem compounds.,"The present invention provided a compound of the formula:
  
 or a pharmaceutically acceptable salt or  in   vivo  hydrolysable ester thereof wherein: 
A is a group of the formula (IA) or (IB):
  
 R¹ is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; 
R² is hydrogen or C₁₋₄alkyl; 
R³ and R⁴ are the same or different and are a variety of substituents X is alkanediyl containing 1-6 carbon atoms optionally interrupted by O, S(O) x  (wherein x is zero, one or two), -CONR⁵- or -NR⁵- wherein R⁵ is hydrogen or C₁₋₄alkyl; 
or X is alkenediyl containing 2-6 carbon atoms optionally interrupted by O, S(O) x  or -NR⁵- wherein x and R⁵ are as hereinbefore defined; with the provisos that:
 i) the interrupting function (O,S(O) x ,NR⁵,-CONR⁵-) may be directly linked to the ring A, but is not directly linked to the -COOH function or to any carbon-carbon double bond in X; and (ii) when the interrupting function is -SO- or -SO₂- it is not β to the COOH function or δ if there is an intervening carbon-carbon double bond in X.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;JUNG FREDERIC HENRI,,https://lens.org/018-260-781-379-601,Patent Application,yes,3,6,2,11,0,C07D477/20;;C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07F9/568,C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07D477/20;;C07F9/568,,0,0,,,,EXPIRED
486,ES,T3,ES 2144446 T3,069-804-187-854-038,2000-06-16,2000,ES 93307551 T,1993-09-23,EP 92402648 A,1992-09-28,COMPUESTOS DE CARBAPENEM ANTIBIOTICOS.,"The present invention provides a compound of the formula: <IMAGE> (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: A is a group of the formula (IA) or (IB): <IMAGE> (IA) <IMAGE> (IB) R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4alkyl; R3 and R4 are the same or different and are a variety of substituents X is alkanediyl containing 1-6 carbon atoms optionally interrupted by O, S(O)x (wherein x is zero, one or two), -CONR5- or -NR5- or wherein R5 is hydrogen or C1-4alkyl; or X is alkenediyl containing 1-6 carbon atoms optionally interrupted by O, S(O)x or -NR5-.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;JUNG FREDERIC HENRI,,https://lens.org/069-804-187-854-038,Granted Patent,no,0,0,9,11,0,C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07D477/20;;C07F9/568;;A61P31/04;;C07D487/04;;C07D477/20;;C07D207/16;;C07D403/12;;C07D409/14;;C07D409/12;;C07F9/568,A61K31/397;;A61P31/04;;C07D205/08;;C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;A61K31/40;;C07D477/00;;C07D477/20;;C07F9/568,,0,0,,,,EXPIRED
487,EP,A1,EP 1272487 A1,065-528-940-591-319,2003-01-08,2003,EP 01900550 A,2001-01-17,GB 0100161 W;;GB 0001346 A,2000-01-21,BICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF THE INTERACTION BETWEEN THE INTEGRIN ALPHA4BETA1 RECEPTOR AND VCAM-1 AND/OR FIBRONECTIN,,ASTRAZENECA AB,BRITTAIN DAVID ROBERT;;LARGE MICHAEL STEWART;;DAVIES GARETH MORSE,,https://lens.org/065-528-940-591-319,Patent Application,yes,0,0,6,6,0,C07D413/12;;A61P1/04;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P29/00;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D413/12,A61K31/423;;A61K31/4439;;A61K31/513;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P29/00;;A61P37/06;;A61P43/00;;C07D413/12,,0,0,,,,DISCONTINUED
488,DE,T2,DE 68920474 T2,086-708-022-190-495,1995-06-01,1995,DE 68920474 T,1989-05-08,GB 8811055 A,1988-05-10,"Cephalosporine, Verfahren zu ihrer Herstellung und pharmazeutische Präparate.",,ZENECA LTD;;ZENECA PHARMA SA,DAVIES GARETH MORSE;;STRAWSON COLIN JOHN;;LOHMANN JEAN JAQUES,"ZENECA LTD., LONDON, GB ZENECA PHARMA S.A., CERGY, (1995-03-30)",https://lens.org/086-708-022-190-495,Granted Patent,no,0,0,9,10,0,C07D501/46;;C07D501/46,A01N43/90;;A61K31/545;;C07D501/18;;C07D501/38;;C07D501/42;;C07D501/44;;C07D501/46;;C07D501/52;;C07D501/54;;C07D501/56,,0,0,,,,EXPIRED
489,US,A1,US 2003/0144264 A1,081-864-433-078-273,2003-07-31,2003,US 29356102 A,2002-11-14,US 29356102 A;;GB 9202298 A;;US 78155601 A;;US 16829398 A;;US 83305697 A;;US 46203795 A;;US 12905693 A;;GB 9300217 W,1992-02-04,Antibiotic compounds,"
    The present invention relates to carbapenems and provides a compound of the formula (I): 

   or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: 

    R ¹ is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; 

    R ² is hydrogen or C ₁₋₄ alkyl; 

    R ³ is hydrogen or C ₁₋₄ alkyl; 

    R ⁴ and R ⁵ are the same or different and are selected from hydrogen, halo, cyano, C ₁₋₄ alkyl, nitro, hydroxy, carboxy, C ₁₋₄ alkoxy, C ₁₋₄ alkoxycarbonyl, aminosulphonyl, C ₁₋₄ alkylaminosulphonyl, di-C ₁₋₄ -alkylaminosulphonyl, carbamoyl, C ₁₋₄ alkylcarbamoyl, di-C ₁₋₄ -alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C ₁₋₄ alkylamino, di-C ₁₋₄ alkylamino, C ₁₋₄ alkanoylamino, C ₁₋₄ alkanoyl(NC ₁₋₄ alkyl)amino, C ₁₋₄ alkanesulphonamido and C ₁₋₄ alkylS(O) ₙ wherein n is zero, one or two: 

    with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to NR ³ . Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them. 
",ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,ASTRAZENECA UK LIMITED (2004-05-20);;SYNGENTA LIMITED (2002-05-27),https://lens.org/081-864-433-078-273,Patent Application,yes,16,3,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,514/210.13;;X54035,0,0,,,,EXPIRED
490,CN,A,CN 107066408 A,091-108-451-038-979,2017-08-18,2017,CN 201710078663 A,2012-10-26,GB 201118534 A;;CN 201210418444 A,2011-10-26,Configurable data transfer in a digital signal processing system,"A technique for transferring data in a digital signal processing system is described. In one example, the digital signal processing system comprises a number of hardware peripherals, each connected to a memory access controller and each configured to read data from a memory device, perform one or more operations on the data, and write data to the memory device. To avoid hardwiring the hardware peripherals together, and to provide a configurable digital signal processing system, a multi-threaded processor controls the transfer of data between the hardware peripherals and the memory. Each processor thread is allocated to a memory access channel, and the threads are configured to detect an occurrence of an event and, responsive to this, control the memory access controller to enable a selected hardware peripheral to read data from or write data to the memory device via its memory access channel.",IMAGINATION TECH LTD,ADRIAN J ANDERSON;;GARY C WASS;;GARETH J DAVIES,,https://lens.org/091-108-451-038-979,Patent Application,no,7,1,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F13/28;;G06F9/38;;G06F9/54;;G06F12/1081,,1,0,,,"TEXAS INSTRUMENTS: ""“How to Approach Inter-Core Communication on TMS320C6474”"", 《WWW.TI.COM/LIT/AN/SPRAB25/SPRAB25.PDF》",ACTIVE
491,US,B2,US 11147614 B2,124-278-916-162-96X,2021-10-19,2021,US 202016929270 A,2020-07-15,US 202016929270 A;;US 201514850545 A;;IB 2014059641 W;;US 201361787617 P,2013-03-15,Electrosurgical device having a distal aperture,"A method and apparatus are disclosed for providing forward fluid delivery through an energy delivery device that avoids coring when it delivers energy to a tissue. The device has a distal face defining an opening, with the distal face including at least one electrically exposed portion and at least one electrically insulated portion. An embodiment of the energy delivery device includes an elongate member defining a lumen structured to receive a fluid, and a distal face defining an aperture in communication with the lumen. The distal face includes an electrically exposed conductive portion and an electrically insulated portion. The electrically exposed conductive portion is configured such that the energy it delivers while the energy delivery device is advanced into a tissue punctures the tissue without the tissue substantially occluding the lumen and without creating embolic particles.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;MIRZA MAHMOOD;;HARFIELD ELLEN,BAYLIS MEDICAL COMPANY INC (2015-09-10);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/124-278-916-162-96X,Granted Patent,yes,13,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14;;A61B18/00;;A61B90/00,,15,0,,,"Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2014/064600, dated Sep. 13, 2016.;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2014/059641, dated Sep. 15, 2015.;;Japanese Office Action for counterpart to parent Japanese Application No. 2015-562485, dated Jan. 23, 2018.;;European Patent Office, Communication pursuant to Rules 161(2) and 162 EPC, for counterpart to parent European Application No. 147885380.7, dated Oct. 25, 2016.;;Applicant's Reply to Communication pursuant to Rules 161 and 162 for counterpart to parent European Application No. 147885380.7, dated Apr. 30, 2017.;;European Patent Office, Communication pursuant to Rule 70(2) and 70a(2) EPC for counterpart to parent European Application No. 14763885.2, dated Oct. 27, 2016.;;Applicant's Reply to Communication pursuant to Rule 70 EPC for counterpart to parent European Application No. 14763885.2, dated May 8, 2017.;;European Patent Office, Communication pursuant to Rules 161(2) and 162 EPC, for counterpart to parent European Application No. 14763885.2, dated Oct. 22, 2015.;;Applicant's Reply to Communication pursuant to Rules 161 and 162 for counterpart to parent European Application No. 14763885.2, dated Apr. 21, 2016.;;Supplementary European Search Report for European Application No. 14763885.2, dated Sep. 28, 2016.;;Supplementary European Search Report for European Application No. 14885380.7, dated Oct. 18, 2017.;;European Patent Office, Communication pursuant to Rule 70(2) and 70a(2) EPC for counterpart to parent European Application No. 147885380.7, dated Nov. 7, 2017.;;Applicant's Reply to Communication pursuant to Rule 70 EPC for counterpart to parent European Application No. 147885380.7, dated May 17, 2018.;;Japanese Search Report for counterpart to parent Japanese Application No. 2015-562485, dated Jan. 26, 2018.;;Japanese Search Report Translation for counterpart to parent Japanese Application No. 2015-562485, dated, Jan. 26, 2018.",ACTIVE
492,KR,A,KR 20210069122 A,146-254-521-035-853,2021-06-10,2021,KR 20217016786 A,2013-11-20,IB 2013060287 W;;US 201361863265 P;;US 201361863579 P;;KR 20167005714 A,2013-08-07,METHODS AND DEVICES FOR PUNCTURING TISSUE,환자 신체의 다양한 접근 부위로부터 혈관 접근을 허용하면서 조직 부위의 효과적이고 반복가능한 천공을 돕는 신규하고 고유한 의료 장치 및 연계 방법이 개시된다. 개시된 의료 장치는 원하는 접근 부위로부터 다양한 해부학적 위치에서 천공 및 조직 접근을 돕도록 구성되고 단독으로 또는 조합하여 사용가능한 확장기 및 와이어를 포함한다. 의료 장치 각각은 하나 이상의 추가 기능을 수행하기에 충분한 강성을 보유하면서 접근 부위로부터 조직 부위로 접근을 위해 충분한 가요성을 갖는 하나 이상의 섹션을 포함한다.,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,,https://lens.org/146-254-521-035-853,Patent Application,no,5,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61B17/34;;A61B17/00;;A61B17/22;;A61B18/00;;A61B18/14;;A61B90/00,,0,0,,,,ACTIVE
493,US,B2,US 11372546 B2,153-274-264-097-843,2022-06-28,2022,US 201916363587 A,2019-03-25,US 201916363587 A;;GB 201118534 A;;US 201715433888 A;;US 201514625719 A;;US 201213646649 A,2011-10-26,Digital signal processing data transfer,"A technique for transferring data in a digital signal processing system is described. In one example, the digital signal processing system comprises a number of fixed function accelerators, each connected to a memory access controller and each configured to read data from a memory device, perform one or more operations on the data, and write data to the memory device. To avoid hardwiring the fixed function accelerators together, and to provide a configurable digital signal processing system, a multi-threaded processor controls the transfer of data between the fixed function accelerators and the memory. Each processor thread is allocated to a memory access channel, and the threads are configured to detect an occurrence of an event and, responsive to this, control the memory access controller to enable a selected fixed function accelerator to read data from or write data to the memory device via its memory access channel.",NORDIC SEMICONDUCTOR ASA,ANDERSON ADRIAN J;;WASS GARY C;;DAVIES GARETH J,NORDIC SEMICONDUCTOR ASA (2020-12-31),https://lens.org/153-274-264-097-843,Granted Patent,yes,55,0,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F9/54;;G06F3/06;;G06F9/30;;G06F9/38;;G06F9/50;;G06F12/1081;;G06F13/28,,6,0,,,"TMS320C6474 DSP Enhanced DMA (EDMA3) Controller, Jul. 1, 2011 (Jul. 1, 2011), XP055049608, Retrieved from the Internet: URL:http://www.ti.com/litJug/sprug11b/sprugllb.pdf, pp. 13, 21, 23, 46, table 2.6.;;Bell et al., “Multicore Programming Guide”, Aug. 1, 2009 (Aug. 1, 2009), XP055049589, Retrieved from the Internet: URL:http://www.polyscope.ch/d1Center/ps/2010 15/1510.05.pdf.;;Mathes, “How to Approach Inter-Core Communication on TMS320C6474”, Jan. 1, 2009 (Jan. 1, 2009), XP055049737, Retrieved from the Internet: URL:http:/lwww.ti.com/lit/an/sprab25/sprab25.pdf.;;Nikolic-Popovic, “Using TMS320C6416 Coprocessors: Viterbi Coprocessor (VCP)”, Texas Instruments Application Report, Dallas, TX, USA, Sep. 1, 2003 (Sep. 1, 2003), pp. 1-24, XP002591629, Retrieved from the Internet: URL:http://focus.ti.sub.--com.sub.—cn/cn/lit/antspra750d/ spra750d.pdf pp. 11-13.;;(*note: copies of NPL in parent appn*).;;EP12189414.1 EPO Extended Search Report dated Jan. 30, 2013.",ACTIVE
494,AU,B2,AU 2013/397477 B2,165-737-445-477-312,2019-05-16,2019,AU 2013/397477 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,Methods and devices for puncturing tissue,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-22),https://lens.org/165-737-445-477-312,Granted Patent,no,3,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/01;;A61B17/34;;A61B18/14;;A61M25/06;;A61M29/00,,0,0,,,,ACTIVE
495,AU,A1,AU 2021/212088 A1,167-165-705-744-248,2021-08-26,2021,AU 2021/212088 A,2021-08-05,AU 2021/212088 A;;AU 2019/213413 A;;AU 2013/397477 A;;US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,Methods and Devices for Puncturing Tissue,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-22),https://lens.org/167-165-705-744-248,Patent Application,no,0,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/01;;A61B17/34;;A61B18/14;;A61M25/06;;A61M29/00,,0,0,,,,ACTIVE
496,FI,A0,FI 930474 A0,001-011-393-419-654,1993-02-03,1993,FI 930474 A,1993-02-03,GB 9202298 A,1992-02-04,ANTIBIOTISKA FOERENINGAR,,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/001-011-393-419-654,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
497,EP,A2,EP 0341948 A2,074-430-673-911-058,1989-11-15,1989,EP 89304621 A,1989-05-08,GB 8811055 A,1988-05-10,"Cephalosporins, process for their preparation and pharmaceutical compositions.","Cephalosporin antibiotics having a 3-position substituent of the formula: 
-CH₂NR¹-Y-A-Z-Q 
are described, wherein R¹ is hydrogen or certain optionally substituted alkyl groups; Y is -CO- or -SO₂-; 
A is optionally substituted phenylene or heterocyclylene; 
Z is a linking group and Q is a catechol or related ring system. 
Processes for their preparation and use are described.  ",ICI PLC;;ICI PHARMA,DAVIES GARETH MORSE;;STRAWSON COLIN JOHN;;LOHMANN JEAN JAQUES,ZENECA PHARMA S.A. (1995-02-01);;ZENECA LIMITED (1995-02-01),https://lens.org/074-430-673-911-058,Patent Application,yes,0,4,9,10,0,C07D501/46;;C07D501/46,A01N43/90;;A61K31/545;;C07D501/18;;C07D501/38;;C07D501/42;;C07D501/44;;C07D501/46;;C07D501/52;;C07D501/54;;C07D501/56,,0,0,,,,EXPIRED
498,AU,A1,AU 2013/397477 A1,074-768-346-326-773,2016-02-11,2016,AU 2013/397477 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,Methods and devices for puncturing tissue,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-22),https://lens.org/074-768-346-326-773,Patent Application,no,0,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/01;;A61B17/34;;A61B18/14;;A61M25/06;;A61M29/00,,0,0,,,,ACTIVE
499,CN,A,CN 103218329 A,065-585-921-083-969,2013-07-24,2013,CN 201210418444 A,2012-10-26,GB 201118534 A,2011-10-26,Digital signal processing data transfer,"A technique for transferring data in a digital signal processing system is described. In one example, the digital signal processing system comprises a number of hardware peripherals, each connected to a memory access controller and each configured to read data from a memory device, perform one or more operations on the data, and write data to the memory device. To avoid hardwiring the hardware peripherals together, and to provide a configurable digital signal processing system, a multi-threaded processor controls the transfer of data between the hardware peripherals and the memory. Each processor thread is allocated to a memory access channel, and the threads are configured to detect an occurrence of an event and, responsive to this, control the memory access controller to enable a selected hardware peripheral to read data from or write data to the memory device via its memory access channel. When disclosed, Figure 3 is as a summary attached drawing.",IMAGINATION TECH LTD,ANDERSON ADRIAN J;;WASS GARY C;;DAVIES GARETH J,,https://lens.org/065-585-921-083-969,Patent Application,no,0,9,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F13/38;;G06F12/1081,,0,0,,,,ACTIVE
500,EP,A1,EP 0579826 A1,119-725-259-082-564,1994-01-26,1994,EP 93914514 A,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,"CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS.","La présente invention se rapporte à des carbapénèmes et décrit un composé répondant à la formule (I) ou un sel pharmaceutiquement acceptable ou un ester hydrolysable in vivo de ce composé: formule dans laquelle: R1 représente 1-hydroxyéthyle, 1-fluoroéthyle ou hydroxyméthyle; R2 représente hydrogène ou C1-4alkyle; R3 représente hydrogène ou C1-4alkyle; R4 et R5 sont identiques ou différents et sont choisis parmi hydrogène, halo, cyano, C1-4alkyle, nitro, hydroxy, carboxy, C1-4alcoxy, C1-4alcoxycarbonyle, aminosulfonyle, C1-4alkylaminosulfonyle, di-C1-4alkylaminosulfonyle, carbamoyle, C1-4alkylcarbamoyle, di-C1-4alkylcarbamoyle, trifluorométhyle, acide sulfonique, amino, C1-4 alkylamino, di-C1-4alkylamino, C1-4alcanoylamino, C1-4alcanoyl(N-C1-4alkyl)amino, C1-4alcanesulfonamido et C1-4alkylS(O)n-, n valant zéro, un ou deux, à condition qu'il n'y ait pas de substituant hydroxy ou carboxy en une position ortho par rapport à la liaison avec -NR3-. L'invention décrit également des procédés de préparation de ces composés, des intermédiaires utilisés dans leur préparation, leur utilisation comme agents thérapeutiques et des compositions pharmaceutiques les contenant.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,"ZENECA LIMITED (1998-06-03);;ASTRAZENECA AB (2008-06-25);;ASTRAZENECA UK LIMITED (2002-12-02);;SYNGENTA LIMITED (2002-12-02);;ASTRAZENECA UK LTD., LONDON, GB (2003-03-27);;ZENECA LIMITED TRANSFER- ASTRAZENECA AB (2001-01-31)",https://lens.org/119-725-259-082-564,Patent Application,yes,0,2,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
501,US,A1,US 2022/0240979 A1,119-542-271-239-489,2022-08-04,2022,US 202217723629 A,2022-04-19,US 202217723629 A;;US 201916387732 A;;US 201615160737 A;;US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 82745206 P;;US 88428507 P,2006-09-29,MEDICAL DEVICE AND TREATMENT METHOD,"Medical devices and methods for puncturing tissue in a patient. The devices include a needle with a rigid proximal shaft, a flexible distal shaft, and a distal tip. The distal tip includes an electrode for delivering energy to puncture a tissue. In some embodiments, the distal shaft includes a superelastic material. In other embodiments, the distal shaft includes both a superelastic material and a non-superelastic material. The distal shaft includes shape memory enabling formation of an anchor within the patient.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;DAVIES GARETH;;MIRZA MAHMOOD;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2016-05-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/119-542-271-239-489,Patent Application,yes,0,0,3,113,0,Y10T29/49826;;A61B17/3478;;A61B2017/00867;;A61B2018/00351;;A61B2018/00577;;A61B2018/00613;;A61B18/1492;;A61B2017/00309;;A61B2018/1425;;A61B5/0215;;A61B2018/00601;;A61B18/1477;;A61B2218/002;;A61B2218/007;;A61M5/3286;;A61M5/329;;A61B2090/3966;;A61M3/0283;;A61M1/77;;A61B17/3476;;A61B17/3478;;A61M5/007;;A61M39/08;;A61B18/1477;;A61B5/0215;;A61M3/0283;;A61M5/32;;A61B5/6848;;A61B2017/00867;;A61B2017/00862;;A61B6/12;;A61B2218/007;;A61B2018/00357;;A61B18/1492;;A61B2090/3966;;A61B2090/0811;;A61B2090/3983;;A61B90/02;;A61B2090/064;;Y10T29/49826;;A61B2018/00136;;A61B2018/00297;;A61B2018/00375;;A61B2018/00404;;A61B2017/00247;;A61B2018/00083;;A61B2218/002;;A61B2018/00577;;A61B2018/00351;;A61B2018/00613;;A61M1/77,A61B17/34;;A61B5/00;;A61B5/0215;;A61B18/14;;A61M1/00;;A61M3/02;;A61M5/00;;A61M5/32;;A61M39/08,,0,0,,,,PENDING
502,AU,B2,AU 668133 B2,147-484-789-638-233,1996-04-26,1996,AU 1993/034574 A,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,"Carbapenems containing a carboxy substituted phenyl group, processes for their preparation, intermediates and use as antibiotics",,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,ASTRAZENECA AB (2001-02-01),https://lens.org/147-484-789-638-233,Granted Patent,no,2,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
503,US,A1,US 2016/0175009 A1,158-719-707-036-89X,2016-06-23,2016,US 201314910525 A,2013-11-20,US 201314910525 A;;US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,Methods and Devices for Puncturing Tissue,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ALLEY FERRYL;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2016-02-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/158-719-707-036-89X,Patent Application,yes,6,46,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61B17/34;;A61B18/14;;A61B90/00,,0,0,,,,ACTIVE
504,EP,B1,EP 0341948 B1,194-917-453-584-345,1995-01-11,1995,EP 89304621 A,1989-05-08,GB 8811055 A,1988-05-10,"Cephalosporins, process for their preparation and pharmaceutical compositions.",,ICI PLC;;ICI PHARMA,DAVIES GARETH MORSE;;STRAWSON COLIN JOHN;;LOHMANN JEAN JAQUES,ZENECA PHARMA S.A. (1995-02-01);;ZENECA LIMITED (1995-02-01),https://lens.org/194-917-453-584-345,Granted Patent,yes,5,0,9,10,0,C07D501/46;;C07D501/46,A01N43/90;;A61K31/545;;C07D501/18;;C07D501/38;;C07D501/42;;C07D501/44;;C07D501/46;;C07D501/52;;C07D501/54;;C07D501/56,,0,0,,,,EXPIRED
505,US,B2,US 7041836 B2,192-360-610-442-888,2006-05-09,2006,US 29356102 A,2002-11-14,US 29356102 A;;GB 9202298 A;;US 78155601 A;;US 16829398 A;;US 83305697 A;;US 46203795 A;;US 12905693 A;;GB 9300217 W,1992-02-04,Antibiotic compounds,"The present invention relates to carbapenems and provides a compound of the formula (I): or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R 1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl;R 2 is hydrogen or C 1-4 alkyl;R 3 is hydrogen or C 1-4 alkyl;R 4 and R 5 are the same or different and are selected from hydrogen, halo, cyano, C 1-4 alkyl, nitro, hydroxy, carboxy, C 1-4 alkoxy, C 1-4 alkoxycarbonyl, aminosulphonyl, C 1-4 alkylaminosulphonyl, di-C 1-4 -alkylaminosulphonyl, carbamoyl, C 1-4 alkylcarbamoyl, di-C 1-4 -alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C 1-4 alkylamino, di-C 1-4 alkylamino, C 1-4 alkanoylamino, C 1-4 alkanoyl( N —C 1-4 alkyl)amino, C 1-4 alkanesulphonamido and C 1-4 alkylS(O) n — wherein n is zero, one or two: with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to —NR 3 —. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.",ASTRAZENECA UK LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,ASTRAZENECA UK LIMITED (2004-05-20);;SYNGENTA LIMITED (2002-05-27),https://lens.org/192-360-610-442-888,Granted Patent,yes,38,2,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,C07D411/00;;A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K31/55;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,548/465;;548/453;;548/537;;514/210;;514/210.11;;514/210.13;;514/414;;540/200;;540/302;;540/350,2,0,,,"Betts, CA 118(9)=80721d (1992).;;Betts, CA 118(7)=59495y (1992).",INACTIVE
506,AT,T1,AT E190615 T1,011-561-672-694-551,2000-04-15,2000,AT 93307551 T,1993-09-23,EP 92402648 A,1992-09-28,ANTIBIOTISCHE CARBAPENEMVERBINDUNGEN,"The present invention provides a compound of the formula: <IMAGE> (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: A is a group of the formula (IA) or (IB): <IMAGE> (IA) <IMAGE> (IB) R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4alkyl; R3 and R4 are the same or different and are a variety of substituents X is alkanediyl containing 1-6 carbon atoms optionally interrupted by O, S(O)x (wherein x is zero, one or two), -CONR5- or -NR5- or wherein R5 is hydrogen or C1-4alkyl; or X is alkenediyl containing 1-6 carbon atoms optionally interrupted by O, S(O)x or -NR5-.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;JUNG FREDERIC HENRI,,https://lens.org/011-561-672-694-551,Granted Patent,no,0,0,9,11,0,C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07D477/20;;C07F9/568;;A61P31/04;;C07D487/04;;C07D477/20;;C07D207/16;;C07D403/12;;C07D409/14;;C07D409/12;;C07F9/568,A61K31/40;;A61K31/397;;A61P31/04;;C07D205/08;;C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07D477/00;;C07D477/20;;C07F9/568,,0,0,,,,DISCONTINUED
507,PL,B1,PL 174601 B1,012-811-589-566-896,1998-08-31,1998,PL 31744793 A,1993-02-02,GB 9300217 W;;GB 9202298 A,1992-02-04,CARBAPENEMES CONTAINING PHENYL GROUP I AND METHOD OF OBTAINING THEM,,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL J;;DAVIES GARETH M;;SWAIN MICHAEL L,,https://lens.org/012-811-589-566-896,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
508,HR,A2,HR P930103 A2,028-092-749-536-737,1994-12-31,1994,HR P930103 A,1993-02-03,GB 9202298 A,1992-02-04,ANTIBIOTIC COMPOUNDS,,ZENECA LIMITED IMPERIAL CHEMIC;;ZENECA PHARMA S A LE GALIEN,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,"ASTRAZENECA SAS, FR (2005-10-05);;SYNGENTA LIMITED, GB (2005-10-05);;ASTRAZENECA SA, FR (2005-10-05);;ASTRAZENECA UK LIMITED, GB (2005-10-05)",https://lens.org/028-092-749-536-737,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
509,SK,B6,SK 280890 B6,060-780-649-415-654,2000-09-12,2000,SK 106393 A,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,"CARBAPENEM COMPOUNDS WITH 2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO GROUP IN THE POSITION 2, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM","There are disclosed carbapenem compounds of the general formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R1 is 1-hydroxyethyl; R2 is hydrogen or C1-4alkyl; R3 is hydrogen or C1-4alkyl; R4 and R5 are the same or different and are selected from hydrogen, halo, cyano, C1-4alkyl, nitro, hydroxy, carboxy, C1-4alkoxy, C1-4alkoxycarbonyl, aminosulphonyl, C1-4alkylaminosulphonyl, di-C1-4alkylaminosulphonyl, carbamoyl, C1-4alkylcarbamoyl, di-C1-4alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C1-4alkylamino, di-C1-4alkylamino, C1-4alkanoylamino, C1-4alkanoyl(N-C1-4alkyl)amino, C1-4alkanesulphonamido and C1-4alkylS(O)n- wherein n is zero, one or two; with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to -NR3-. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/060-780-649-415-654,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
510,US,A1,US 2022/0355087 A1,092-310-010-875-347,2022-11-10,2022,US 202217813945 A,2022-07-21,US 202217813945 A;;US 201816068589 A;;IB 2017050065 W;;US 201662275907 P,2016-01-07,Hybrid Transseptal Dilator and Methods of Using the Same,"An apparatus is disclosed for an optimized transseptal procedure that reduces the number of devices that are used in order to minimize procedural time, complexity and cost. The apparatus comprises a hybrid dilator that comprises the combined functionality of a transseptal sheath and dilator assembly. The hybrid dilator comprises: a dilator shaft defining a lumen for receiving a crossing device therethrough, a distal tip having an outer diameter which tapers down to an outer diameter of the crossing device for providing a smooth transition and a hub coupled with a side arm coupled to the dilator shaft.",BOSTON SCIENT MEDICAL DEVICE LIMITED,THOMPSON SMITH MELANIE;;DAVIES GARETH;;LEUNG LINUS HOI CHE,BAYLIS MEDICAL COMPANY INC (2017-01-04);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/092-310-010-875-347,Patent Application,yes,9,0,10,10,0,A61B17/3478;;A61M25/06;;A61B2017/00247;;A61B2017/22038;;A61B2017/22042;;A61B2017/22047;;A61B2090/033;;A61B2090/062;;A61B2090/0807;;A61M29/00;;A61B2017/22038;;A61B2017/22047;;A61B17/3478;;A61B2017/00247;;A61B2017/22042;;A61M25/06;;A61B2090/062;;A61B2090/0807;;A61B2090/033;;A61M29/00;;A61B17/3415;;A61B18/1477;;A61B2018/00351;;A61B2018/1425;;A61M25/09;;A61M2205/32;;A61M2205/582,A61M29/00;;A61B17/34;;A61B18/14;;A61M25/06;;A61M25/09,,0,0,,,,PENDING
511,DE,T2,DE 69328061 T2,122-676-090-805-113,2000-09-28,2000,DE 69328061 T,1993-09-23,EP 92402648 A,1992-09-28,Antibiotische Carbapenemverbindungen,"The present invention provides a compound of the formula: <IMAGE> (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: A is a group of the formula (IA) or (IB): <IMAGE> (IA) <IMAGE> (IB) R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4alkyl; R3 and R4 are the same or different and are a variety of substituents X is alkanediyl containing 1-6 carbon atoms optionally interrupted by O, S(O)x (wherein x is zero, one or two), -CONR5- or -NR5- or wherein R5 is hydrogen or C1-4alkyl; or X is alkenediyl containing 1-6 carbon atoms optionally interrupted by O, S(O)x or -NR5-.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;JUNG FREDERIC HENRI,,https://lens.org/122-676-090-805-113,Granted Patent,no,0,0,9,11,0,C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07D477/20;;C07F9/568;;A61P31/04;;C07D487/04;;C07D477/20;;C07D207/16;;C07D403/12;;C07D409/14;;C07D409/12;;C07F9/568,A61K31/40;;A61K31/397;;A61P31/04;;C07D205/08;;C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07D477/00;;C07D477/20;;C07F9/568,,0,0,,,,EXPIRED
512,US,A1,US 2021/0259732 A1,133-231-303-099-855,2021-08-26,2021,US 202117185202 A,2021-02-25,US 202117185202 A;;US 202062981434 P,2020-02-25,Methods and Devices for Creation of Communication Between Aorta and Left Atrium,"Methods and devices are disclosed for the formation of a communication between the aorta and left atrium. The method includes introducing a puncturing device, positioning the device at a location along the aorta, and advancing the puncturing device to create a pathway. The method may include: a. via an inferior artery, advancing a perforating tip of the puncturing device towards the aorta; b. positioning the perforating tip adjacent a wall of the aorta, proximate the left atrium; and c. advancing the perforating tip to perforate through the wall of the aorta and then through a wall of the left atrium, to create a pathway between the aorta and the left atrium, wherein the creation of the pathway can be confirmed with at least one of fluoroscopy, electro-anatomical mapping, pressure measurement, contrast injection, and echocardiograph.",BAYLIS MEDICAL CO INC,DICICCO MATTHEW;;DAVIES GARETH;;MORIYAMA EDUARDO;;URBANSKI JOHN PAUL,BAYLIS MEDICAL COMPANY INC (2021-10-14);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/133-231-303-099-855,Patent Application,yes,4,4,1,1,0,A61B2017/00247;;A61B17/3478;;A61B18/1492;;A61B2017/00358;;A61B2090/3966;;A61B2090/3925;;A61B2090/3784;;A61B2090/376;;A61B2018/00601;;A61B2018/00351;;A61B17/3423;;A61B2017/00053;;A61B2017/3425;;A61B17/3476,A61B17/34,,0,0,,,,PENDING
513,US,B2,US 7342005 B2,134-613-234-622-867,2008-03-11,2008,US 12633105 A,2005-05-11,US 12633105 A;;GB 9202298 A;;US 29356102 A;;US 78155601 A;;US 16829398 A;;US 83305697 A;;US 46203795 A;;US 12905693 A;;GB 9300217 W,1992-02-04,Antibiotic compounds,"The present invention relates to carbapenems and provides a compound of the formula (I): or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R 1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl;R 2 is hydrogen or C 1-4 alkyl;R 3 is hydrogen or C 1-4 alkyl;R 4 and R 5 are the same or different and are selected from hydrogen, halo, cyano, C 1-4 alkyl, nitro, hydroxy, carboxy, C 1-4 alkoxy, C 1-4 alkoxycarbonyl, aminosulphonyl, C 1-4 alkylaminosulphonyl, di-C 1-4 -alkylaminosulphonyl, carbamoyl, C 1-4 alkylcarbamoyl, di-C 1-4 alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C 1-4 alkylamino, di-C 1-4 alkylamino, C 1-4 alkanoylamino, C 1-4 alkanoyl(N—C 1-4 alkyl)amino, C 1-4 alkanesulphonamido and C 1-4 alkylS(O) n —wherein n is zero, one or two; with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to —NR 3 —; processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.",ASTRAZENECA UK LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/134-613-234-622-867,Granted Patent,yes,37,2,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/395;;A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,514/210;;540/350;;540/351,2,0,,,"Betts, CA 118(9)=80721d (1992).;;Betts, CA 118(7)=59495y (1992).",INACTIVE
514,US,S,US D0786430 S,168-866-832-510-928,2017-05-09,2017,US 201529533914 F,2015-07-23,US 201529533914 F,2015-07-23,Medical device handle,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;THOMPSON SMITH MELANIE;;COPELAND STEVE;;LIBERTY JONATHAN,BAYLIS MEDICAL COMPANY INC (2015-07-29);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/168-866-832-510-928,Design Right,no,0,23,1,1,0,,,2402;;D24/144,0,0,,,,ACTIVE
515,AT,T1,AT E116986 T1,155-803-936-221-274,1995-01-15,1995,AT 89304621 T,1989-05-08,GB 8811055 A,1988-05-10,"CEPHALOSPORINE, VERFAHREN ZU IHRER HERSTELLUNG UND PHARMAZEUTISCHE PRÄPARATE.",,ICI PLC;;ICI PHARMA,DAVIES GARETH MORSE;;STRAWSON COLIN JOHN;;LOHMANN JEAN JAQUES,,https://lens.org/155-803-936-221-274,Granted Patent,no,0,0,9,10,0,C07D501/46;;C07D501/46,A01N43/90;;A61K31/545;;C07D501/18;;C07D501/38;;C07D501/42;;C07D501/44;;C07D501/46;;C07D501/52;;C07D501/54;;C07D501/56,,0,0,,,,DISCONTINUED
516,KR,A,KR 20220153116 A,189-856-707-553-390,2022-11-17,2022,KR 20227038648 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;KR 20217016786 A;;IB 2013060287 W,2013-08-07,METHODS AND DEVICES FOR PUNCTURING TISSUE,환자 신체의 다양한 접근 부위로부터 혈관 접근을 허용하면서 조직 부위의 효과적이고 반복가능한 천공을 돕는 신규하고 고유한 의료 장치 및 연계 방법이 개시된다. 개시된 의료 장치는 원하는 접근 부위로부터 다양한 해부학적 위치에서 천공 및 조직 접근을 돕도록 구성되고 단독으로 또는 조합하여 사용가능한 확장기 및 와이어를 포함한다. 의료 장치 각각은 하나 이상의 추가 기능을 수행하기에 충분한 강성을 보유하면서 접근 부위로부터 조직 부위로 접근을 위해 충분한 가요성을 갖는 하나 이상의 섹션을 포함한다.,BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,,https://lens.org/189-856-707-553-390,Patent Application,no,0,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61B18/14;;A61B17/00;;A61B17/22;;A61B17/34;;A61B18/00;;A61B90/00,,0,0,,,,ACTIVE
517,MX,A,MX 9300553 A,193-178-190-862-370,1993-09-01,1993,MX 9300553 A,1993-02-02,GB 9202298 A;;GB 9300456 A,1992-02-04,COMPUESTOS ANTIBIOTICOS.,"La presente invención se refiere a los carbapems y se proporciona un compuesto que contienen al grupo de fenilo substituído oncarboxi. La invención además se refiere a los procedimientos para su preparación, a los compuestos intermedios para su preparación, a su uso como agentes terapéuticos, y a las composiciones farmacéuticas que contienen a los mismos. Los compuestos de la invención son antibióticos, y se pueden usar para el tratamiento de cualquier enfermedad que está tratada convencionalmente con los antibióticos, por ejemplo, en el tratamiento de infecciones bacteriales, en mamíferos, incluyendo a los humanos.",ZENECA LIMITED Y ZENECA PHARMA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,ASTRAZENECA UK LIMITED (2005-08-16);;NOVO NORDISK HEALTH CARE AG (2005-08-16),https://lens.org/193-178-190-862-370,Patent Application,no,0,0,1,76,0,,A61K31/33,,0,0,,,,EXPIRED
518,US,B2,US 6521612 B2,037-440-114-242-158,2003-02-18,2003,US 78155601 A,2001-02-13,US 78155601 A;;GB 9202298 A;;US 16829398 A;;US 83305697 A;;US 46203795 A;;US 12905693 A,1992-02-04,Antibiotic compounds,"
    The present invention relates to carbapenems and provides a compound of the formula (I): 

    or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: 

    R ^{ 1 } is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; 

    R ^{ 2 } is hydrogen or C _{ 1-4 } alkyl; 

    R ^{ 3 } is hydrogen or C _{ 1-4 } alkyl; 

    R ^{ 4 } and R ^{ 5 } are the same or different and are selected from hydrogen, halo, cyano, C _{ 1-4 } alkyl, nitro, hydroxy, carboxy, C _{ 1-4 } alkoxy, C _{ 1-4 } alkoxycarbonyl, aminosulphonyl, C _{ 1-4 } alkylaminosulphonyl, di-C _{ 1-4 } -alkylaminosulphonyl, carbamoyl, C _{ 1-4 } alkylcarbamoyl, di-C _{ 1-4 } alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C _{ 1-4 } alkylamino, di-C _{ 1-4 } alkylamino, C _{ 1-4 } alkanoylamino, C _{ 1-4 } alkanoyl(NC _{ 1-4 } alkyl)amino, C _{ 1-4 } alkanesulphonamido and C _{ 1-4 } alkylS(O) _{ n } wherein n is zero; one or two: 

    with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to NR ^{ 3 } . Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them. 
",ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,ASTRAZENECA UK LIMITED (2004-05-20);;SYNGENTA LIMITED (2002-05-27);;ZENECA LTD (1995-01-06),https://lens.org/037-440-114-242-158,Granted Patent,yes,35,4,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,514/210.13;;514/414;;514/210.05;;514/210.09;;514/210.11,2,0,,,"Betts, CA 118(9) = 80721d (1992).;;Betts, CA 118(7) = 59495y (1992).",EXPIRED
519,PL,B1,PL 174936 B1,049-754-500-811-424,1998-10-30,1998,PL 31744893 A,1993-02-02,GB 9300217 W;;GB 9202298 A,1992-02-04,PHARMACEUTIC AGENT CONTAINING NOVEL CARBAPENEMES,,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL J;;DAVIES GARETH M;;SWAIN MICHAEL L,,https://lens.org/049-754-500-811-424,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
520,AT,T1,AT E173262 T1,048-741-477-320-555,1998-11-15,1998,AT 93914514 T,1993-02-02,GB 9202298 A,1992-02-04,"CARBOXY SUBSTITUIERTE PHENYLGRUPPE ENTHALTENDE CARBAPENEME; VERFAHREN ZU DEREN HERSTELLUNG, ZWISCHENPRODUKTE UND VERWENDUNG ALS ANTIBIOTIKA",,ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/048-741-477-320-555,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
521,US,A1,US 2019/0220199 A1,065-638-885-563-434,2019-07-18,2019,US 201916363587 A,2019-03-25,US 201916363587 A;;GB 201118534 A;;US 201715433888 A;;US 201514625719 A;;US 201213646649 A,2011-10-26,Digital Signal Processing Data Transfer,"A technique for transferring data in a digital signal processing system is described. In one example, the digital signal processing system comprises a number of fixed function accelerators, each connected to a memory access controller and each configured to read data from a memory device, perform one or more operations on the data, and write data to the memory device. To avoid hardwiring the fixed function accelerators together, and to provide a configurable digital signal processing system, a multi-threaded processor controls the transfer of data between the fixed function accelerators and the memory. Each processor thread is allocated to a memory access channel, and the threads are configured to detect an occurrence of an event and, responsive to this, control the memory access controller to enable a selected fixed function accelerator to read data from or write data to the memory device via its memory access channel.",IMAGINATION TECH LTD,ANDERSON ADRIAN J;;WASS GARY C;;DAVIES GARETH J,NORDIC SEMICONDUCTOR ASA (2020-12-31),https://lens.org/065-638-885-563-434,Patent Application,yes,7,1,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F3/06;;G06F9/30;;G06F9/38;;G06F9/50;;G06F9/54;;G06F12/1081;;G06F13/28,,0,0,,,,ACTIVE
522,US,A1,US 2002/0042408 A1,085-636-729-423-030,2002-04-11,2002,US 78155601 A,2001-02-13,US 78155601 A;;GB 9202298 A;;US 16829398 A;;US 83305697 A;;US 46203795 A;;US 12905693 A,1992-02-04,Antibiotic compounds,"
    The present invention relates to carbapenems and provides a compound of the formula (I): 

   or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: 

    R ¹ is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; 

    R ² is hydrogen or C ₁₋₄ alkyl; 

    R ³ is hydrogen or C ₁₋₄ alkyl; 

    R ⁴ and R ⁵ are the same or different and are selected from hydrogen, halo, cyano, C ₁₋₄ alkyl, nitro, hydroxy, carboxy, C ₁₋₄ alkoxy, C ₁₋₄ alkoxycarbonyl, aminosulphonyl, C ₁₋₄ alkylaminosulphonyl, di-C ₁₋₄ -alkylaminosulphonyl, carbamoyl, C ₁₋₄ alkylcarbamoyl, di-C ₁₋₄ alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C ₁₋₄ alkylamino, di-C ₁₋₄ alkylamino, C ₁₋₄ alkanoylamino, C ₁₋₄ alkanoyl(NC ₁₋₄ alkyl)amino, C ₁₋₄ alkanesulphonamido and C ₁₋₄ alkylS(O) ₙ wherein n is zero; one or two: 

    with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to NR ³ . Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them. 
",ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,ASTRAZENECA UK LIMITED (2004-05-20);;SYNGENTA LIMITED (2002-05-27);;ZENECA LTD (1995-01-06),https://lens.org/085-636-729-423-030,Patent Application,yes,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,514/210.13;;540/353,0,0,,,,EXPIRED
523,CA,C,CA 2106370 C,088-046-318-315-421,2003-11-25,2003,CA 2106370 A,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,ANTIBIOTIC COMPOUNDS,"The present invention relates to carbapenems and provides a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R1 is 1-hydroxyethyl, 1- fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4alkyl; R3 is hydrogen or C1-4alkyl; R4 and R5 are the same or different and are selected from hydrogen, halo, cyano, C1-4alkyl, nitro, hydroxy, carboxy, C1-4alkoxy, C1-4alkoxycarbonyl, aminosulphonyl, C1-4alkylaminosulphonyl, di-C1-4alky- laminosulphonyl, carbamoyl, C1-4alkylcarbamoyl, di-C1-4alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C1-4alky- laxnino, di-C1-4alkylamino, C1-4alkanoylamino, C1-4alkanoyl(N C1-4alkyl)amin o, C1-4alkanesulphonamido and C1-4al- kylS(O)n; wherein n is zero, one or two; with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to -NR3-. Processes for their preparation, intermediates in thei r preparation, their use as therapeutic agents and pharmaceutical compositions containing them.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL J;;DAVIES GARETH M;;SWAIN MICHAEL L,,https://lens.org/088-046-318-315-421,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
524,FI,B,FI 104074 B,098-619-147-095-820,1999-11-15,1999,FI 930474 A,1993-02-03,GB 9202298 A,1992-02-04,Menetelmä terapeuttisesti käyttökelpoisten 2-£2-(3-karboksifenyylikarbamoyyli)pyrrolidin-4-yylitio|karbapeneemijohdannaisten valmistamiseksi,,ASTRAZENECA UK LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/098-619-147-095-820,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
525,HU,A9,HU 211840 A9,122-467-898-101-628,1995-12-28,1995,HU 9500201 P,1995-06-14,GB 9202298 A,1992-02-04,ANTIBIOTIC COMPOUNDS,,ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,"ASTRAZENECA AB, SE (2001-03-28)",https://lens.org/122-467-898-101-628,Unknown,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,PENDING
526,US,A,US 5478820 A,141-149-106-463-096,1995-12-26,1995,US 12905693 A,1993-10-04,GB 9202298 A;;GB 9300217 W,1992-02-04,Antibiotic compounds,"The present invention relates to carbapenems and provides a compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl; R.sup.4 and R.sup.5 are the same or different and are selected from hydrogen, halo, cyano, C.sub.1-4 alkyl, nitro, hydroxy, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 alkoxycarbonyl, aminosulphonyl, C.sub.1-4 alkylaminosulphonyl, di-C.sub.1-4 alkylaminosulphonyl, carbamoyl, C.sub.1-4 alkylcarbamoyl, di-C.sub.1-4 alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.1-4 alkanoylamino, C.sub.1-4 alkanoyl(N-C.sub.1-4 alkyl)amino, C.sub.1-4 alkanesulphonamido and C.sub.1-4 alkylS(O).sub.n -- wherein n is zero, one or two: with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the --NR.sup.2 --. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.",ZENECA LTD,BETTS MICHAEL J;;DAVIES GARETH M;;SWAIN MICHAEL L,ZENECA PHARMA S.A (1993-09-09);;ASTRAZENECA UK LIMITED (2004-05-20);;SYNGENTA LIMITED (2002-05-27);;ZENECA LTD (1995-01-06),https://lens.org/141-149-106-463-096,Granted Patent,yes,17,55,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,514/210;;540/200;;540/350;;548/413;;548/537,2,0,,,"Betts, CA 118(9):80721d (1992).;;Betts, CA 118(7):59495y (1992).",EXPIRED
527,US,B2,US 10368911 B2,175-821-569-557-44X,2019-08-06,2019,US 201314910525 A,2013-11-20,US 201314910525 A;;US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,Methods and devices for puncturing tissue,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ALLEY FERRYL;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2016-02-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/175-821-569-557-44X,Granted Patent,yes,27,2,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/00;;A61B17/00;;A61B17/22;;A61B17/34;;A61B18/00;;A61B18/14;;A61B90/00,,4,0,,,"Japanese Patent Office Examination Report for counterpart Japanese Application No. 2016-532745, dated Oct. 3, 2017.;;International Search Report for International Application No. PCT/IB2013/060287 dated Mar. 6, 2014.;;Supplementary European Search Report for European Application No. 13891200.1 dated Feb. 7, 2017.;;European Search Opinion for European Application No. 13891200.1 dated Feb. 7, 2017.",ACTIVE
528,JP,A,JP 2019048118 A,030-860-446-207-427,2019-03-28,2019,JP 2018211611 A,2018-11-09,US 201361863265 P;;US 201361863579 P,2013-08-07,METHODS AND DEVICES FOR PUNCTURING TISSUE,To provide devices and associated methods used to access the left side of a heart via puncturing tissue.SOLUTION: Systems 50 include dilators 100 and wires 200 usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The systems each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.SELECTED DRAWING: Figure 1,BAYLIS MEDICAL CO INC,GARETH DAVIES;;JOHN PAUL URBANSKI;;BOGDAN BECA;;FERRYL ALLEY,,https://lens.org/030-860-446-207-427,Patent Application,no,4,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/00;;A61M25/09,,0,0,,,,ACTIVE
529,DE,D1,DE 68920474 D1,042-054-140-812-850,1995-02-23,1995,DE 68920474 T,1989-05-08,GB 8811055 A,1988-05-10,"Cephalosporine, Verfahren zu ihrer Herstellung und pharmazeutische Präparate.",,ICI PLC;;ICI PHARMA,DAVIES GARETH MORSE;;STRAWSON COLIN JOHN;;LOHMANN JEAN JAQUES,"ZENECA LTD., LONDON, GB ZENECA PHARMA S.A., CERGY, (1995-03-30)",https://lens.org/042-054-140-812-850,Granted Patent,no,0,0,9,10,0,C07D501/46;;C07D501/46,A01N43/90;;A61K31/545;;C07D501/18;;C07D501/38;;C07D501/42;;C07D501/44;;C07D501/46;;C07D501/52;;C07D501/54;;C07D501/56,,0,0,,,,EXPIRED
530,CZ,B6,CZ 286878 B6,069-000-747-935-52X,2000-07-12,2000,CZ 206793 A,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,"Carbapenems, process of their preparation, intermediates for their preparation, those carbapenems used for treating infections and pharmaceutical preparations","In the present invention there are disclosed carbapenems of the general formula I in which Re1 represents 1-hydroxyethyl group, 1-fluoroethyl group or hydroxymethyl group, Re2 represents a hydrogen atom or alkyl group containing 1 to 4 carbon atoms, Re3 represents a hydrogen atom or alkyl group containing 1 to 4 carbon atoms, Re4 and Re5 that can be the same or different are selected from a group comprising a hydrogen atom, a halogen atom, a cyano group, an alkyl group containing 1 to 4 carbon atoms, a nitro group, a hydroxy group a carboxyl group an alkoxyl group containing 1 to 4 carbon atoms, an alkoxycarbonyl group containing 1 to 4 carbon atoms in the alkoxy moiety, an aminosulfonyl group, an alkylaminosulfonyl group containing 1 to 4 carbon atoms in the alkyl moiety, dialkylaminosulfonyl group containing 1 to 4 carbon atoms in the alkyl moiety, a carbamoyl group, alkylcarbamoyl group containing 1 to 4 carbon atoms in the alkyl moiety, dialkylcarbamoyl group containing 1 to 4 carbon atoms in the alkyl moiety, a trifluoromethyl group, a sulfonic acid group, an amino group, an alkylamino group containing 1 to 4 carbon atoms in the alkyl moiety, dialkylamino group containing 1 to 4 carbon atoms in the alkyl moiety, an alkanoylamino group containing 1 to 4 carbon atoms in the alkanoyl moiety, alkanoyl-A-alkylamino group containing 1 to 4 carbon atoms in the alkanoyl moiety and 1 to 4 carbon atoms in the alkyl moiety, an alkanesulfonamide group containing 1 to 4 carbon atoms in the alkane moiety and alkyl-S-(O)in group containing 1 to 4 carbon atoms in the alkyl moiety, wherein a is 0, 1 or 2 with the proviso consisting in that in position ortho to the bond to -NRe3- neither hydroxy group nor carboxyl group is present, or pharmaceutically acceptable salt or in vivo hydrolyzable ester thereof. In the present invention there are also claimed a process for preparing the above specified compounds, intermediates used in their preparation, their use as therapeutic agents as well as pharmaceutical compositions in which these compounds are comprised.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/069-000-747-935-52X,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
531,ES,T3,ES 2123654 T3,159-366-350-283-016,1999-01-16,1999,ES 93914514 T,1993-02-02,GB 9202298 A,1992-02-04,"CARBAPENEMS QUE CONTIENEN UN GRUPO FENILO SUBSTITUIDO CON CARBOXI, PROCESOS PARA SU PREPARACION, PRODUCTOS INTERMEDIOS Y USO COMO ANTIBIOTICOS.","LA INVENCION DESCRIBE UNAS CARBAPENEMONAS Y OFRECE UN COMPUESTO DE FORMULA (I), UNA SAL FARMACEUTICAMENTE ACEPTABLE O ESTERES HIDROLIZABLES EN VIVO, DONDE: R1 ES 1-HIDROXIETILO, 1-FLUOROETILO O HIDROXIMETILO; R2 ES HIDROGENO O ALQUILO C1-4; R3 ES H O ALQUILO C14; R4 Y R5 SON IGUALES O NO Y SELECCIONADOS DE H, HALO, CIANO, ALQUILO C1-4, NITRO, HIDROXILO, CARBOXILO, ALCOXILO C1-4, ALCOXICARBONILO C1-4, TRIFLUOROMETILO, ACIDO SULFONICO, AMINO, ALQILAMINO C1-4, DIALQUILAMINO C1-4 ALCANOILAMINO C1-4 ALCANOIL(ALQUILON-C-14)AMINOC1-4, ALCANESULFONAMIDOC1-4 Y ALQUILS(O)N-C1-4, DONDE N ES 0,1 O 2; CON LA PREVISION DE QUE NO HAY HIDROXILO O CARBOXILO SUSTITUYENTE EN UNA POSICION ""ORTO"" A EL ENLACE -NR3-. PROCESOS PARA SU PREPARACION, INTERMEDIARIOS, SU USO COMO AGENTE TERAPEUTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.",ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/159-366-350-283-016,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
532,TW,A,TW 201333711 A,185-897-851-475-660,2013-08-16,2013,TW 101137694 A,2012-10-12,GB 201118534 A,2011-10-26,Digital signal processing data transfer,"A technique for transferring data in a digital signal processing system is described. In one example, the digital signal processing system comprises a number of hardware peripherals, each connected to a memory access controller and each configured to read data from a memory device, perform one or more operations on the data, and write data to the memory device. To avoid hardwiring the hardware peripherals together, and to provide a configurable digital signal processing system, a multi-threaded processor controls the transfer of data between the hardware peripherals and the memory. Each processor thread is allocated to a memory access channel, and the threads are configured to detect an occurrence of an event and, responsive to this, control the memory access controller to enable a selected hardware peripheral to read data from or write data to the memory device via its memory access channel.",IMAGINATION TECH LTD,ANDERSON ADRIAN JOHN;;WASS GARY CHRISTOPHER;;DAVIES GARETH JOHN,,https://lens.org/185-897-851-475-660,Patent of Addition,no,0,0,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F13/28;;G06F9/38;;G06F9/54;;G06F12/1081;;G06F13/38,,0,0,,,,ACTIVE
533,US,S,US D0683016 S,195-784-865-880-28X,2013-05-21,2013,US 201129407710 F,2011-12-01,US 201129407710 F,2011-12-01,Medical device with lateral aperture,,MIRZA MAHMOOD;;HARFIELD ELLEN;;URBANSKI JOHN PAUL;;DAVIES GARETH;;BAYLIS MEDICAL CO INC,MIRZA MAHMOOD;;HARFIELD ELLEN;;URBANSKI JOHN PAUL;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2011-12-01);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/195-784-865-880-28X,Design Right,no,0,17,1,1,0,,,2402;;D24/112,0,0,,,,ACTIVE
534,HU,A,HU T64764 A,000-709-762-562-607,1994-02-28,1994,HU 9302777 A,1993-02-02,GB 9202298 A,1992-02-04,CARBAPENEM-DERIVATIVES WITH ANTIBIOTIC EFFECT AND MEDICAL PREPARATIVES CONTAINING THEM AND PROCESS FOR THE PRODUCTION THEREOF,,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,"ASTRAZENECA AB, SE (2001-03-28)",https://lens.org/000-709-762-562-607,Unknown,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
535,US,A1,US 2023/0355155 A1,073-133-403-503-719,2023-11-09,2023,US 202318351704 A,2023-07-13,IB 2021050266 W,2021-01-14,"MEDICAL DILATOR, AND SYSTEMS, METHODS, AND KITS FOR MEDICAL DILATION","A medical dilator includes an elongate member having a proximal end portion, an opposed distal end portion, and a lumen extending through the elongate member from the proximal end portion to the distal end portion. A dilating tip is at the distal end portion. The dilating tip has a first end of enlarged cross-sectional area and tapers going in the distal direction to a second end of reduced cross-sectional area. At least a first electrode is associated with the dilating tip. An electrical conductor is electrically connected to the first electrode and extends proximally from the first electrode towards the proximal end portion for electrical connection with an electroanatomical mapping system.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;KOON LAUREN;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2023-07-13),https://lens.org/073-133-403-503-719,Patent Application,yes,0,0,5,5,0,A61B5/283;;A61B18/1477;;A61B2018/00357;;A61B2018/00601;;A61B2018/00839;;A61B18/1492;;A61M29/00;;A61B5/287;;A61B5/287;;A61M29/00,A61B5/287;;A61M29/00,,0,0,,,,PENDING
536,US,A1,US 2017/0160947 A1,083-445-585-299-362,2017-06-08,2017,US 201715433888 A,2017-02-15,US 201715433888 A;;GB 201118534 A;;US 201514625719 A;;US 201213646649 A,2011-10-26,Digital Signal Processing Data Transfer,"A technique for transferring data in a digital signal processing system is described. In one example, the digital signal processing system comprises a number of fixed function accelerators, each connected to a memory access controller and each configured to read data from a memory device, perform one or more operations on the data, and write data to the memory device. To avoid hardwiring the fixed function accelerators together, and to provide a configurable digital signal processing system, a multi-threaded processor controls the transfer of data between the fixed function accelerators and the memory. Each processor thread is allocated to a memory access channel, and the threads are configured to detect an occurrence of an event and, responsive to this, control the memory access controller to enable a selected fixed function accelerator to read data from or write data to the memory device via its memory access channel.",IMAGINATION TECH LTD,ANDERSON ADRIAN J;;WASS GARY C;;DAVIES GARETH J,NORDIC SEMICONDUCTOR ASA (2020-12-31),https://lens.org/083-445-585-299-362,Patent Application,yes,32,0,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F3/06;;G06F12/1081,,0,0,,,,ACTIVE
537,US,A1,US 2015/0161058 A1,100-639-813-758-349,2015-06-11,2015,US 201514625719 A,2015-02-19,US 201514625719 A;;GB 201118534 A;;US 201213646649 A,2011-10-26,Digital Signal Processing Data Transfer,"A technique for transferring data in a digital signal processing system is described. In one example, the digital signal processing system comprises a number of fixed function accelerators, each connected to a memory access controller and each configured to read data from a memory device, perform one or more operations on the data, and write data to the memory device. To avoid hardwiring the fixed function accelerators together, and to provide a configurable digital signal processing system, a multi-threaded processor controls the transfer of data between the fixed function accelerators and the memory. Each processor thread is allocated to a memory access channel, and the threads are configured to detect an occurrence of an event and, responsive to this, control the memory access controller to enable a selected fixed function accelerator to read data from or write data to the memory device via its memory access channel.",IMAGINATION TECH LTD,ANDERSON ADRIAN J;;WASS GARY C;;DAVIES GARETH J,NORDIC SEMICONDUCTOR ASA (2020-12-31),https://lens.org/100-639-813-758-349,Patent Application,yes,29,0,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F12/10;;G06F9/30;;G06F9/50;;G06F12/1081,,0,0,,,,ACTIVE
538,KR,A,KR 20160041955 A,115-742-610-313-083,2016-04-18,2016,KR 20167005714 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,METHODS AND DEVICES FOR PUNCTURING TISSUE,환자 신체의 다양한 접근 부위로부터 혈관 접근을 허용하면서 조직 부위의 효과적이고 반복가능한 천공을 돕는 신규하고 고유한 의료 장치 및 연계 방법이 개시된다. 개시된 의료 장치는 원하는 접근 부위로부터 다양한 해부학적 위치에서 천공 및 조직 접근을 돕도록 구성되고 단독으로 또는 조합하여 사용가능한 확장기 및 와이어를 포함한다. 의료 장치 각각은 하나 이상의 추가 기능을 수행하기에 충분한 강성을 보유하면서 접근 부위로부터 조직 부위로 접근을 위해 충분한 가요성을 갖는 하나 이상의 섹션을 포함한다.,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,,https://lens.org/115-742-610-313-083,Patent Application,no,4,2,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61B17/00;;A61B17/22;;A61B18/00;;A61B18/14;;A61B90/00,,0,0,,,,ACTIVE
539,US,B2,US 11331121 B2,129-481-771-436-194,2022-05-17,2022,US 201916387732 A,2019-04-18,US 201916387732 A;;US 201615160737 A;;US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 88428507 P;;US 82745206 P,2006-09-29,Transseptal needle,"Embodiments of medical devices and methods are disclosed. The medical devices typically comprises a needle with a rigid proximal shaft, a flexible distal shaft and a distal tip. The distal tip includes an electrode for delivering energy to puncture a tissue. In some embodiments, the distal shaft comprises a superelastic material. In other embodiments, the distal shaft is comprised of both a superelastic material and a non-superelastic material.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;DAVIES GARETH;;MIRZA MAHMOOD;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2016-05-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/129-481-771-436-194,Granted Patent,yes,28,0,3,113,0,Y10T29/49826;;A61B17/3478;;A61B2017/00867;;A61B2018/00351;;A61B2018/00577;;A61B2018/00613;;A61B18/1492;;A61B2017/00309;;A61B2018/1425;;A61B5/0215;;A61B2018/00601;;A61B18/1477;;A61B2218/002;;A61B2218/007;;A61M5/3286;;A61M5/329;;A61B2090/3966;;A61M3/0283;;A61M1/77;;A61B17/3476;;A61B17/3478;;A61M5/007;;A61M39/08;;A61B18/1477;;A61B5/0215;;A61M3/0283;;A61M5/32;;A61B5/6848;;A61B2017/00867;;A61B2017/00862;;A61B6/12;;A61B2218/007;;A61B2018/00357;;A61B18/1492;;A61B2090/3966;;A61B2090/0811;;A61B2090/3983;;A61B90/02;;A61B2090/064;;Y10T29/49826;;A61B2018/00136;;A61B2018/00297;;A61B2018/00375;;A61B2018/00404;;A61B2017/00247;;A61B2018/00083;;A61B2218/002;;A61B2018/00577;;A61B2018/00351;;A61B2018/00613;;A61M1/77,A61B18/14;;A61B5/00;;A61B5/0215;;A61B6/12;;A61B17/00;;A61B17/34;;A61B18/00;;A61B90/00;;A61M1/00;;A61M3/02;;A61M5/00;;A61M5/32;;A61M39/08,,0,0,,,,ACTIVE
540,EP,A3,EP 3581132 A3,144-396-091-863-704,2020-04-29,2020,EP 19167716 A,2014-03-11,US 201361787617 P;;EP 14763885 A;;IB 2014059641 W,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,"A method and apparatus are disclosed for providing forward fluid delivery through an energy delivery device, while avoiding coring when energy is delivered to the energy delivery device. The device has a distal face defining an opening, with the distal face including at least one electrically exposed portion and at least one electrically insulated portion. An example of the energy delivery device includes an elongate member defining a lumen structured to receive a fluid and a distal face defining an aperture in communication with the lumen, the distal face including an electrically exposed conductive portion and an electrically insulated portion, where the electrically exposed conductive portion is configured such that energy delivered by the electrically exposed conductive portion, while the energy delivery device is advanced into a tissue, punctures the tissue without the tissue substantially occluding the lumen and without creating embolic particles.
",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD,"BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2023-03-28);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED; IE (2023-04-14)",https://lens.org/144-396-091-863-704,Search Report,yes,3,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14;;A61B18/00;;A61B90/00,,0,0,,,,ACTIVE
541,US,A1,US 2013/0111159 A1,153-319-804-833-271,2013-05-02,2013,US 201213646649 A,2012-10-05,GB 201118534 A,2011-10-26,Digital Signal Processing Data Transfer,"A technique for transferring data in a digital signal processing system is described. In one example, the digital signal processing system comprises a number of fixed function accelerators, each connected to a memory access controller and each configured to read data from a memory device, perform one or more operations on the data, and write data to the memory device. To avoid hardwiring the fixed function accelerators together, and to provide a configurable digital signal processing system, a multi-threaded processor controls the transfer of data between the fixed function accelerators and the memory. Each processor thread is allocated to a memory access channel, and the threads are configured to detect an occurrence of an event and, responsive to this, control the memory access controller to enable a selected fixed function accelerator to read data from or write data to the memory device via its memory access channel.",IMAGINATION TECH LTD;;IMAGINATION TECH LTD,ANDERSON ADRIAN J;;WASS GARY C;;DAVIES GARETH J,NORDIC SEMICONDUCTOR ASA (2020-12-31);;IMAGINATION TECHNOLOGIES LTD (2012-09-12),https://lens.org/153-319-804-833-271,Patent Application,yes,5,2,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F12/1081;;G06F12/08,711/158;;X711E12016,0,0,,,,ACTIVE
542,WO,A1,WO 2014/013257 A1,166-713-503-091-873,2014-01-23,2014,GB 2013051921 W,2013-07-18,GB 201212813 A,2012-07-19,FIELD-OFFSET COIL FOR USE WITH AN OPEN MRI SCANNER,"Apparatus for use with an open magnetic resonance imaging (MRI) scanner (1). The MRI scanner (1) generates a primary magnetic field (19) within its scanning region. The apparatus comprises an insert unit (9) comprising a magnetic coil (12) for generating a secondary magnetic field (20) and a support (3-6) for supporting the insert unit (9) in an elevated position within the scanning region of the MRI scanner (1). In use, the secondary magnetic field (20) alters the primary magnetic field (19) for generating an altered magnetic field region (21).",UNIV ABERDEEN,LURIE DAVID JOHN;;DAVIES GARETH REYNOLD;;PINE KERRIN JAMES,,https://lens.org/166-713-503-091-873,Patent Application,yes,1,32,2,2,0,G01R33/3802;;G01R33/3804;;G01R33/3806;;G01R33/381;;G01R33/445;;G01R33/50,G01R33/38;;G01R33/381;;G01R33/44;;G01R33/50,,3,0,,,"PINE K.J. ET AL.: ""A field offset coil for spatially localised in vivo field-cycling relaxometry"", PROCEEDINGS OF THE INTERNATIONAL SOCIETY FOR MAGNETIC RESONANCE IN MEDICINE, 19TH ANNUAL MEETING PROCEEDINGS, 9 May 2011 (2011-05-09), Montréal, Canada, pages 1833, XP040618492;;MORGAN P.N. ET AL.: ""Signal-to-Noise Ratio Gain in Prepolarized MRI"", PROCEEDINGS OF THE INTERNATIONAL SOCIETY FOR MAGNETIC RESONANCE IN MEDICINE, EIGHTH MEETING PROCEEDINGS, 1 April 2000 (2000-04-01), Denver, USA, XP040580530;;LURIE D.J. ET AL.: ""Human Relaxometry and MRI using Fast Field-Cycling"", PROCEEDINGS OF THE AMPERE NMR SCHOOL, 24 June 2012 (2012-06-24), Poznan, Poland, pages 22, XP002715427, Retrieved from the Internet <URL:http://homepages.abdn.ac.uk/d.lurie/pages/pdf/abstract%20-%20Lurie%20AMPERE%20school%202012.pdf> [retrieved on 20131025]",PENDING
543,EP,A1,EP 3030306 A1,021-606-912-111-837,2016-06-15,2016,EP 13891200 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,DEVICES FOR PUNCTURING TISSUE,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,"BAYLIS MEDICAL COMPANY INC. (2019-11-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2022-11-14)",https://lens.org/021-606-912-111-837,Patent Application,yes,0,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61B17/00;;A61B17/34;;A61B17/22;;A61B18/00;;A61B18/14;;A61B90/00,,0,0,,,,ACTIVE
544,US,S,US D0753302 S,037-663-550-397-250,2016-04-05,2016,US 201529517221 F,2015-02-11,US 201529517221 F,2015-02-11,Electrosurgical device with a curve,,BAYLIS MEDICAL CO INC,ALLEY FERRYL;;URBANSKI JOHN PAUL;;DAVIES GARETH;;SHAH KRISHAN,BAYLIS MEDICAL COMPANY INC (2015-02-10);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/037-663-550-397-250,Design Right,no,0,3,1,1,0,,,2402;;D24/144,0,0,,,,ACTIVE
545,EP,B1,EP 0590885 B1,046-161-888-113-557,2000-03-15,2000,EP 93307551 A,1993-09-23,EP 93307551 A;;EP 92402648 A,1992-09-28,Antibiotic carbapenem compounds,,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;JUNG FREDERIC HENRI,,https://lens.org/046-161-888-113-557,Granted Patent,yes,0,1,2,11,0,C07D477/20;;C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07F9/568,C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07D477/20;;C07F9/568,,2,0,,,"BOWMAN ET AL.: ""Textbook of Pharmacology"", 1969, BLACKWELL SCIENTIFIC PUBLICATIONS, ENGLAND;;ANTIINFECTIVE DRUGS AND CHEMOTHERAPY, vol. 13, no. 3, 1995, pages 169 - 175",EXPIRED
546,US,A,US 5149803 A,083-057-375-303-787,1992-09-22,1992,US 73247891 A,1991-07-18,US 73247891 A;;GB 8811055 A;;US 34966289 A,1988-05-10,Intermediates for cephalosporin compounds,"Cephalosporin antibiotics having a 3-position substituent of the formula: --CH.sub.2 NR.sup.1 --Y--A--Z--Q are described, wherein R.sup.1 is hydrogen or certain optionally substituted alkyl groups; Y is --CO-- or --SO.sub.2 --; A is optionally substituted phenylene or heterocyclylene; Z is a linking group and Q is a catechol or related ring system. Processes for their preparation and use are described.",ICI PLC;;ICI PHARMA,DAVIES GARETH M;;STRAWSON COLIN J;;LOHMANN JEAN J,,https://lens.org/083-057-375-303-787,Granted Patent,yes,3,8,1,10,0,C07D501/46;;C07D501/46,C07D501/18;;C07D501/46,540/225;;540/215;;540/221;;540/222,0,0,,,,EXPIRED
547,NZ,A,NZ 246917 A,153-785-148-851-380,1995-09-26,1995,NZ 24691793 A,1993-02-02,GB 9202298 A,1992-02-04,"CARBAPENEMS; DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS",,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/153-785-148-851-380,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,DISCONTINUED
548,SA,B1,SA 93130419 B1,174-976-386-368-515,2006-01-31,2006,SA 93130419 A,1993-03-10,SA 93130419 A,1993-03-10,مركبات مضادات حيوية Antibiotic compounds,"الملخص: يتعلق هذا الاختراع بكربابينيمات carbapenems ويقدم مركب له الصيغة (١):أو ملح مقبول صيدليا أو استر ester هذه قابل للتحلل المائي داخل الجسم in vivo hydrolysable حيث: تكون R1 هى ١- هيدروكسى اثيل l-hydroxyethyl أو ١-فلورو اثيل l-flouroethyl أو هيدروكسي مثيل hydroxymethyl؛ وتكون R2 هى هيدروجين أو الكيل C1-4alkyl) C1-4)؛ وتكون R3 هى هيدروجين أو الكيل C1-4alhyl) c1-4)؛ وتتماثل r4 و R5 أو تختلفا ويتم اختيارهما من هيدروجين، وهالو halo، وسيانو cyano، والكيل C1-4 (C1-4alkyl), ونيترو nitro، وهيدروكسي hydroxy، وكربوكسي carboxy، والكوكسي C1- C1-4) (4 alkoxy، والكوكسي كربونيل (C1-4 C1-4 (alkoxycarbonyl ، وأمينو سلفونيلaminosulphonyl، والكيل أمينو سلفونيل C1-4 C1-4) (alkylaminosulphonyl، وثنائي الكيل أمينو سلفونيل di- C1-4 alkylaminosulphonyl) C1-4)، وكربامويل carbamoyl، والكيل كربامويل C1-4 C1-4) (alkylcarbamoyl، وثنائي الكيل كربامويل (di- C1-4 C1-4 alkylcarbamoyl)، وثلاثي فلورو مثيل triflouromethyl، وحمض سلفونيك ،sulphonic acid وأمينو amino، والكيل أمينو ،(C1-4 alkylamino) C1-4 وثنائي الكيل أمينو di- C1-4 alkylamino) C1-4)، والكانويل أمينو C1-4 alkanoylamino) C1-4)، و-N 4) C1-alkanoyl C1-4alkyl) amino، والكان سلفوناميدو C1-4 alkanesulphonamido) C1-4) و C1-4alkylS(O)n- حيث تدل n على صفر أو واحد أو اثنين؛وبشرط عدم وجود بديل هيدروكسى أو كربوكسي فى موضع ارثو ortho للرابطة إلى NR3-. ويتعلق بطرق تحضيرها، والمواد الوسيطة في تحضيرها واستخدامها كعوامل علاجية والمستحضرات الصيدلية pharmaceutical composition التي تحتوى عليها.",ASTRA ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/174-976-386-368-515,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
549,US,B2,US 11426565 B2,176-714-015-469-985,2022-08-30,2022,US 201716068589 A,2017-01-06,US 201716068589 A;;US 201662275907 P;;IB 2017050065 W,2016-01-07,Hybrid transseptal dilator and methods of using the same,"A method and apparatus are disclosed for an optimized transseptal procedure for providing left heart access, that reduces the number of devices that are used in order to minimize procedural time, complexity and cost. The apparatus comprises a hybrid dilator that comprises the combined functionality of a transseptal sheath and dilator assembly. The hybrid dilator comprises: a dilator shaft defining a lumen for receiving a crossing device therethrough, the dilator shaft being structured to provide support for the crossing device when the crossing device is used to create a puncture in a tissue; and a distal tip having an outer diameter which tapers down to an outer diameter of the crossing device for providing a smooth transition between the crossing device and the distal tip when the crossing device is inserted through the lumen and protrudes beyond the distal tip.",BAYLIS MEDICAL CO INC;;BOSTON SCIENT MEDICAL DEVICE LIMITED,THOMSPON SMITH MELANIE;;DAVIES GARETH;;LEUNG LINUS HOI CHE,BAYLIS MEDICAL COMPANY INC (2017-01-04);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/176-714-015-469-985,Granted Patent,yes,23,3,10,10,0,A61B17/3478;;A61M25/06;;A61B2017/00247;;A61B2017/22038;;A61B2017/22042;;A61B2017/22047;;A61B2090/033;;A61B2090/062;;A61B2090/0807;;A61M29/00;;A61B2017/22038;;A61B2017/22047;;A61B17/3478;;A61B2017/00247;;A61B2017/22042;;A61M25/06;;A61B2090/062;;A61B2090/0807;;A61B2090/033;;A61M29/00;;A61B17/3415;;A61B18/1477;;A61B2018/00351;;A61B2018/1425;;A61M25/09;;A61M2205/32;;A61M2205/582,A61M29/00;;A61B17/00;;A61B17/22;;A61B17/34;;A61B18/00;;A61B18/14;;A61B90/00;;A61M25/06;;A61M25/09,,7,0,,,"Patent Corporation Treaty, International Search Report dated Apr. 18, 2017.;;Patent Corporation Treaty, Written Opinion dated Apr. 18, 2017.;;Patent Corporation Treaty, International Preliminary Report on Patentability, dated Jul. 10, 2018.;;Corresponding European Application, Supplementary European Search Report dated Sep. 18, 2019.;;Corresponding European Application, European Search Opinion dated Sep. 18, 2019.;;Corresponding Japanese Application, Office Action dated Jan. 5, 2021.;;Corresponding Japanese Application, Decision of Refusal dated Aug. 3, 2021.",ACTIVE
550,EP,A1,EP 3909535 A1,188-374-400-714-059,2021-11-17,2021,EP 21177886 A,2014-03-11,US 201361787617 P;;EP 19167716 A;;EP 14763885 A;;IB 2014059641 W,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,"A method and apparatus are disclosed for providing forward fluid delivery through an energy delivery device, while avoiding coring when energy is delivered to the energy delivery device. The device has a distal face defining an opening, with the distal face including at least one electrically exposed portion and at least one electrically insulated portion. An example of the energy delivery device includes an elongate member defining a lumen structured to receive a fluid and a distal face defining an aperture in communication with the lumen, the distal face including an electrically exposed conductive portion and an electrically insulated portion, where the electrically exposed conductive portion is configured such that energy delivered by the electrically exposed conductive portion, while the energy delivery device is advanced into a tissue, punctures the tissue without the tissue substantially occluding the lumen and without creating embolic particles.
",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD,BAYLIS MEDICAL COMPANY INC. (2022-07-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-05),https://lens.org/188-374-400-714-059,Patent Application,yes,23,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14;;A61B18/00;;A61B90/00,,0,0,,,,PENDING
551,US,A1,US 2023/0233254 A1,029-225-199-829-553,2023-07-27,2023,US 202318192378 A,2023-03-29,US 202318192378 A;;IB 2021057728 W;;US 202063084749 P,2020-09-29,SURGICAL PERFORATION BETWEEN THE AORTA AND LEFT ATRIUM,"Apparatuses and methods are disclosed for the perforation of a communication between the aorta and left atrium. The method includes introducing the apparatus, positioning the apparatus at a location along the aorta, and energizing the apparatus to create a perforation. For example, one method may include: introducing a flexible wire into the left atrium, advancing a dilator along the flexible wire to position the flexible wire adjacent a selected location along the aorta and energizing the flexible wire to create a perforation from the left atrium into the aorta.",BOSTON SCIENT MEDICAL DEVICE LIMITED,MORIYAMA EDUARDO;;DAVIES GARETH;;DICICCO MATTHEW;;URBANSKI JOHN PAUL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2023-03-23),https://lens.org/029-225-199-829-553,Patent Application,yes,0,0,2,2,0,A61M29/00;;A61B2018/00601;;A61B2018/00351;;A61B2018/00357;;A61B90/39;;A61B2090/397;;A61B2090/3925;;A61B2090/3966;;A61B2090/3762;;A61B2090/3784;;A61B18/1492;;A61B18/04;;A61B2018/1425;;A61M25/0082;;A61M25/0105;;A61M2025/0002;;A61M2025/0166;;A61B2017/00022;;A61B2017/00358;;A61B2017/22044;;A61B2090/064;;A61B2018/0038;;A61B18/1492;;A61B2018/00351;;A61B2018/00601,A61B18/14,,0,0,,,,PENDING
552,EP,B1,EP 3581132 B1,046-571-104-642-349,2021-06-16,2021,EP 19167716 A,2014-03-11,US 201361787617 P;;EP 14763885 A;;IB 2014059641 W,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD,"BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2023-03-28);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED; IE (2023-04-14)",https://lens.org/046-571-104-642-349,Granted Patent,yes,1,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14;;A61B18/00;;A61B90/00,,0,0,,,,ACTIVE
553,CN,A,CN 105682726 A,090-994-532-426-941,2016-06-15,2016,CN 201380078846 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,Methods and devices for puncturing tissue,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,,https://lens.org/090-994-532-426-941,Patent Application,no,2,8,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/01;;A61B17/34;;A61B18/14;;A61M25/06;;A61M29/00,,0,0,,,,ACTIVE
554,CA,A1,CA 2905589 A1,112-397-037-106-589,2014-09-18,2014,CA 2905589 A,2014-03-11,US 201361787617 P;;IB 2014059641 W,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,"A method and apparatus are disclosed for providing forward fluid delivery through an energy delivery device, while avoiding coring when energy is delivered to the energy delivery device. The device has a distal face defining an opening, with the distal face including at least one electrically exposed portion and at least one electrically insulated portion. An embodiment of the energy delivery device includes an elongate member defining a lumen structured to receive a fluid and a distal face defining an aperture in communication with the lumen, the distal face including an electrically exposed conductive portion and an electrically insulated portion, where the electrically exposed conductive portion is configured such that energy delivered by the electrically exposed conductive portion, while the energy delivery device is advanced into a tissue, punctures the tissue without the tissue substantially occluding the lumen and without creating embolic particles.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD,,https://lens.org/112-397-037-106-589,Patent Application,no,0,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/18;;A61M37/00,,0,0,,,,PENDING
555,CA,A1,CA 2920683 A1,143-212-822-376-227,2015-02-12,2015,CA 2920683 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,METHODS AND DEVICES FOR PUNCTURING TISSUE,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,,https://lens.org/143-212-822-376-227,Patent Application,no,0,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/01;;A61B17/34;;A61B18/14;;A61M25/06;;A61M29/00,,0,0,,,,ACTIVE
556,DE,D1,DE 69328061 D1,175-722-684-823-690,2000-04-20,2000,DE 69328061 T,1993-09-23,EP 92402648 A,1992-09-28,Antibiotische Carbapenemverbindungen,"The present invention provides a compound of the formula: <IMAGE> (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: A is a group of the formula (IA) or (IB): <IMAGE> (IA) <IMAGE> (IB) R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4alkyl; R3 and R4 are the same or different and are a variety of substituents X is alkanediyl containing 1-6 carbon atoms optionally interrupted by O, S(O)x (wherein x is zero, one or two), -CONR5- or -NR5- or wherein R5 is hydrogen or C1-4alkyl; or X is alkenediyl containing 1-6 carbon atoms optionally interrupted by O, S(O)x or -NR5-.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;JUNG FREDERIC HENRI,,https://lens.org/175-722-684-823-690,Granted Patent,no,0,0,9,11,0,C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07D477/20;;C07F9/568;;A61P31/04;;C07D487/04;;C07D477/20;;C07D207/16;;C07D403/12;;C07D409/14;;C07D409/12;;C07F9/568,A61K31/40;;A61K31/397;;A61P31/04;;C07D205/08;;C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07D477/00;;C07D477/20;;C07F9/568,,0,0,,,,EXPIRED
557,WO,A1,WO 2015/019132 A1,197-398-138-915-48X,2015-02-12,2015,IB 2013060287 W,2013-11-20,US 201361863265 P;;US 201361863579 P,2013-08-07,METHODS AND DEVICES FOR PUNCTURING TISSUE,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,,https://lens.org/197-398-138-915-48X,Patent Application,yes,7,15,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61B17/34;;A61M25/01;;A61B18/14;;A61M25/06;;A61M29/00,,1,0,,,See also references of EP 3030306A4,PENDING
558,TW,B,TW I571744 B,026-265-675-151-534,2017-02-21,2017,TW 101137694 A,2012-10-12,GB 201118534 A,2011-10-26,Digital signal processing data transfer,,IMAGINATION TECH LTD,ANDERSON ADRIAN JOHN;;WASS GARY CHRISTOPHER;;DAVIES GARETH JOHN,,https://lens.org/026-265-675-151-534,Granted Patent,no,4,0,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F12/1081,,0,0,,,,ACTIVE
559,EP,A4,EP 3030306 A4,041-144-149-552-576,2017-03-08,2017,EP 13891200 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;IB 2013060287 W,2013-08-07,METHODS AND DEVICES FOR PUNCTURING TISSUE,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,"BAYLIS MEDICAL COMPANY INC. (2019-11-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED, IE (2022-11-14)",https://lens.org/041-144-149-552-576,Search Report,no,5,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/01;;A61B17/34;;A61B18/14;;A61M25/06;;A61M29/00,,1,0,,,See also references of WO 2015019132A1,ACTIVE
560,HU,B,HU 213675 B,055-158-723-470-344,1997-09-29,1997,HU 9302777 A,1993-02-02,GB 9202298 A,1992-02-04,"PROCESS FOR PRODUCING CARBAPENEM DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES",,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,"ASTRAZENECA AB, SE (2001-03-28)",https://lens.org/055-158-723-470-344,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
561,WO,A1,WO 2022/153082 A1,061-079-515-465-307,2022-07-21,2022,IB 2021050266 W,2021-01-14,IB 2021050266 W,2021-01-14,"MEDICAL DILATOR, AND SYSTEMS, METHODS, AND KITS FOR MEDICAL DILATION","A medical dilator includes an elongate member having a proximal end portion, an opposed distal end portion, and a lumen extending through the elongate member from the proximal end portion to the distal end portion. A dilating tip is at the distal end portion. The dilating tip has a first end of enlarged cross-sectional area and tapers going in the distal direction to a second end of reduced cross-sectional area. At least a first electrode is associated with the dilating tip. An electrical conductor is electrically connected to the first electrode and extends proximally from the first electrode towards the proximal end portion for electrical connection with an electroanatomical mapping system.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DAVIES GARETH;;KOON LAUREN;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO,,https://lens.org/061-079-515-465-307,Patent Application,yes,5,0,5,5,0,A61B5/283;;A61B18/1477;;A61B2018/00357;;A61B2018/00601;;A61B2018/00839;;A61B18/1492;;A61M29/00;;A61B5/287;;A61B5/287;;A61M29/00,A61B18/14;;A61B5/283;;A61B18/00;;A61M29/02,,0,0,,,,PENDING
562,HU,A,HU T66514 A,121-738-469-394-413,1994-12-28,1994,HU 9302777 D,1993-02-02,GB 9202298 A,1992-02-04,"CARBAPENEM DERIVATIVES WITH ANTIBIOTIC EFFECT, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THE PRODUCTION OF THEREOF",,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/121-738-469-394-413,Unknown,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,PENDING
563,HK,A1,HK 1013998 A1,156-921-050-767-60X,1999-09-17,1999,HK 98115416 A,1998-12-24,GB 9202298 A;;GB 9300217 W,1992-02-04,Carbapenems containing a carboxy substituted phenyl group processes for their preparation intermediates and use as antibiotics,,ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/156-921-050-767-60X,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
564,GB,A,GB 2495959 A,002-537-340-202-155,2013-05-01,2013,GB 201118534 A,2011-10-26,GB 201118534 A,2011-10-26,Multi-threaded memory access processor,"Technique for transferring data in a digital signal processing system (DSP) such as digital broadcast streams, digital television, and digital radio. The DSP comprises hardware peripherals 108, each connected to a memory access controller and configured to read data from a memory device, perform operations on the data, and write data to the memory device. To avoid hardwiring the hardware peripherals together, and to provide a configurable DSP, a multi-threaded processor 302 controls the transfer of data between the hardware peripherals and the memory. Each processor thread is allocated to a memory access channel. The thread detects an event, such as the completion of an operation by hardware peripherals or a digital signal processor, and, responsive thereto, controls the memory access controller, such as a direct-memory-access controller (DMA), to enable a selected peripheral to read data from or write data to the memory device via its access channel. An event flag engine 304 combines flag states from a plurality of queues 306 and provides an output using logic gates when an event occurs. The inputs to the logic gates are allocated a priority. The peripherals can be accelerators and can comprise Fast-Fourier-Transform (FFT), equalization demapping, deinterleaving, Viterbi or Reed-Solomon decoding.",IMAGINATION TECH LTD,ANDERSON ADRIAN JOHN;;WASS GARY CHRISTOPHER;;DAVIES GARETH JOHN,,https://lens.org/002-537-340-202-155,Patent Application,no,4,4,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F13/28;;G06F12/1081;;G06F13/38,,0,0,,,,DISCONTINUED
565,WO,A1,WO 1993/015078 A1,009-088-432-444-112,1993-08-05,1993,GB 9300217 W,1993-02-02,GB 9202298 A,1992-02-04,"CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS","The present invention relates to carbapenems and provides a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C¿1-4?alkyl; R?3¿ is hydrogen or C¿1-4?alkyl; R?4 and R5¿ are the same or different and are selected from hydrogen, halo, cyano, C¿1-4?alkyl, nitro, hydroxy, carboxy, C1-4alkoxy, C1-4alkoxycarbonyl, aminosulphonyl, C1-4alkylaminosulphonyl, di-C1-4alkylaminosulphonyl, carbamoyl, C1-4alkylcarbamoyl, di-C1-4alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C1-4alkylamino, di-C1-4alkylamino, C1-4alkanoylamino, C1-4alkanoyl(N-C1-4alkyl)amino, C1-4alkanesulphonamido and C1-4alkylS(O)n- wherein n is zero, one or two; with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to -NR?3¿-. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/009-088-432-444-112,Patent Application,yes,2,32,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,PATENTED
566,EP,A2,EP 1409084 A2,036-232-350-036-812,2004-04-21,2004,EP 02767150 A,2002-06-12,EP 0206498 W;;GB 0114510 A,2001-06-14,EXERCISE MACHINES,,EXERTRIS LTD,DAVIES GARETH;;DRAGE KARL JOHN;;WILLS ANDREW;;PRICE OLIVER,,https://lens.org/036-232-350-036-812,Patent Application,yes,0,0,6,9,0,A63B71/0622;;A63B22/0605;;A63B2071/0641;;A63B2230/06,A63B22/06;;A63B21/00;;A63B22/08;;A63B23/04;;A63B24/00,,1,0,,,See references of WO 02102471A2,DISCONTINUED
567,US,A,US 5856321 A,054-327-519-262-378,1999-01-05,1999,US 83305697 A,1997-04-03,US 83305697 A;;GB 9202298 A;;GB 9300217 W;;US 46203795 A;;US 12905693 A,1992-02-04,Antibiotic compounds,"The present invention relates to carbapenems and provides a compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl; R.sup.4 and R.sup.5 are the same or different and are selected from hydrogen, halo, cyano, C.sub.1-4 alkyl, nitro, hydroxy, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 alkoxycarbonyl, aminosulphonyl, C.sub.1-4 alkylaminosulphonyl, di-C.sub.1-4 -alkylaminosulphonyl, carbamoyl, C.sub.1-4 alkylcarbamoyl, di-C.sub.1-4 alkylcarbamoyl, trifluoromethyl, sulphonic acid, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.1-4 alkanoylamino, C.sub.1-4 alkanoyl(N--C.sub.1-4 alkyl)amino, C.sub.1-4 alkanesulphonamido and C.sub.1-4 alkylS(O).sub.n -- wherein n is zero, one or two: with the proviso that there is no hydroxy or carboxy substituent in a position ortho to the link to --NR.sup.3 --. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.",ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,ASTRAZENECA UK LIMITED (2004-05-20);;SYNGENTA LIMITED (2002-05-27),https://lens.org/054-327-519-262-378,Granted Patent,yes,34,10,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,514/210;;540/350;;540/302,2,0,,,"Betts, CA 118(9) 80721d (1992).;;Betts, CA 118(7) 59495y (1992).",EXPIRED
568,MY,A,MY 111685 A,047-599-390-265-273,2000-11-30,2000,MY PI19930120 A,1993-01-27,GB 9202298 A,1992-02-04,ANTIBIOTIC COMPOUNDS.,"THE PRESENT INVENTION RELATES TO CARBAPENEMS AND PROVIDES A COMPOUND OF THE FORMULA (1):@@( FORMULA 1 )@@OR A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF WHEREIN:@R1 IS 1-HYDROXYETHYL, 1-FLUOROETHYL OR HYDROXYMETHYL;@R2 IS HYDROGEN OR C1-4 ALKYL;@R3 IS HYDROGEN OR C1-4 ALKYL;@R4 AND R5 ARE THE SAME OR DIFFERENT AND ARE SELECTED FROM HYDROGEN, HALO, CYANO, C1-4ALKYL, NITRO, HYDROXY, CARBOXY, C1-4 ALKOXY, C1-4ALKOXYCARBONYL, AMINOSULPHONYL, C1-4ALKYLAMINOSULPHONYL, DI-C1-4-ALKYLAMINOSULPHONYL, CARBAMOYL, C1-4ALKYLCARBAMOYL, DI-C1-4 ALKYCARBAMOYL, TRIFLUOROMETHYL, SULPHONIC ACID, AMINO, C1-4 ALKYLAMINO, DI-C1-4 ALKYLAMINO, C1-4 ALKANOYLAMINO, C1-4 ALKANOYL(N-C1-4ALKYL)AMINO, C1-4ALKANESULPHONAMIDO AND C1-4 ALKYLS(0)N-WHEREIN N IS ZERO, ONE OR TWO:@WITH THE PRIVISO THAT THERE IS NO HYDROXY OR CARBOXY SUBSTITUENT IN A POSITION ORTHO TO THE LINK TO -NR3-. PROCESSES FOR THEIR PREPARATION, INTERMEDIATES IN THEIR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.",ASTRAZENECA UK LTD;;ASTRAZENECA SAS,MICHAEL JOHN BETTS;;MICHAEL LINGARD SWAIN;;GARETH MORSE DAVIES,,https://lens.org/047-599-390-265-273,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,C07D403/12;;A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
569,SK,A3,SK 106393 A3,070-002-283-579-364,1994-04-06,1994,SK 106393 A,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,ANTIBIOTIC COMPOUNDS,,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL J;;DAVIES GARETH M;;SWAIN MICHAEL L,,https://lens.org/070-002-283-579-364,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
570,WO,A3,WO 2002/102471 A3,066-060-239-289-563,2003-10-30,2003,EP 0206498 W,2002-06-12,GB 0114510 A,2001-06-14,EXERCISE MACHINES,"An exercise machine, such as an exercise bicycle, has an adjustable saddle (24) and an adjustable rest (40) for the forearms of a user. The saddle (24) is linked to the rest (40) so that adjustment of the saddle (24) causes adjustment of the rest (40). The forearm rest (40) is provided with adjacent space for the hands of a user so that a person using the machine can manually manipulate an electronic controller (48) on a lead to playa game displayed on a monitor (43) in front of the rest (40).",EXERTRIS LTD;;DAVIES GARETH;;DRAGE KARL JOHN;;WILLS ANDREW;;PRICE OLIVER,DAVIES GARETH;;DRAGE KARL JOHN;;WILLS ANDREW;;PRICE OLIVER,,https://lens.org/066-060-239-289-563,Search Report,yes,11,0,6,9,0,A63B71/0622;;A63B22/0605;;A63B2071/0641;;A63B2230/06,A63B22/06;;A63B21/00;;A63B22/08;;A63B23/04;;A63B24/00,,0,0,,,,PENDING
571,EP,A1,EP 4088771 A1,067-286-028-429-050,2022-11-16,2022,EP 22174723 A,2013-11-20,US 201361863265 P;;US 201361863579 P;;EP 19204215 A;;EP 13891200 A;;IB 2013060287 W,2013-08-07,DEVICES FOR PUNCTURING TISSUE,"A medical device for puncturing tissue at a tissue site is disclosed. The medical device comprises an elongate member having a proximal section, a distal section, and a rail section between the proximal and distal sections. An active tip is provided at a distal end of the distal section, the active tip is operable to deliver energy to create a puncture through the tissue. The rail section is configured to both act as a rail for supporting installation of one or more tubular members thereupon, as well as to be maneuverable for enabling access to the tissue site.
",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;BECA BOGDAN;;ALLEY FERRYL,,https://lens.org/067-286-028-429-050,Patent Application,yes,5,0,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61M25/09;;A61B17/00;;A61B17/22;;A61B17/34;;A61B18/00;;A61B18/14;;A61B90/00;;A61M25/00,,0,0,,,,PENDING
572,EP,A1,EP 2967746 A1,072-252-824-113-191,2016-01-20,2016,EP 14763885 A,2014-03-11,US 201361787617 P;;IB 2014059641 W,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD,,https://lens.org/072-252-824-113-191,Patent Application,yes,0,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14;;A61B18/00;;A61B90/00,,0,0,,,,ACTIVE
573,DE,T2,DE 69322007 T2,075-604-932-251-140,1999-04-01,1999,DE 69322007 T,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,"CARBOXY SUBSTITUIERTE PHENYLGRUPPE ENTHALTENDE CARBAPENEME; VERFAHREN ZU DEREN HERSTELLUNG, ZWISCHENPRODUKTE UND VERWENDUNG ALS ANTIBIOTIKA",,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/075-604-932-251-140,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
574,ZA,B,ZA 93453 B,076-595-744-907-696,1993-08-05,1993,ZA 93453 A,1993-01-21,GB 9202298 A,1992-02-04,Antibiotic compounds,,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/076-595-744-907-696,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
575,YU,B,YU 48998 B,094-842-915-189-157,2003-04-30,2003,YU 5493 A,1993-01-29,GB 9202298 A,1992-02-04,ANTIBIOTIC COMPOUNDS,"Jedinjenje, naznačeno time, što ima formulu (I): ili so tog jedinjenja ili ""in vivo"" hidrolizujući estar, pri čemu je u formuli (I): R1 hidroksietil, 1-fluoroetil ili hidroksimetil; R2 vodonik ili C1-4alkil; R3 vodonik ili C1-4alkil; R4 i R5 su isti ili različiti i izabrani iz grupe: vodonik, halo-, cijano-, C1-4alkil, nitro, hidroksi, karboksi, C1-4 alkoksi, C1-4 alkoksikarbonil, aminosulfonil, C1-4 alkilaminosulfonil, di-C1-4 -alkilaminosulfonil, karbamoil, C1-4 alkilkarbamoil, di-C1-4 alkilkarbamoil, trifluorometil, sulfonska kiselina, amino-, C1-4 alkilamino, di-C1-4 alkilamino, C1-4 alkanoilamino, C1-4 alkanoil(N-C-1-4 alkil)amino, C1-4 alkansulfonamido i -S(O)nC1-4 alkil, gde je n nula, jedan ili dva: pod uslovom da ne postoji supstituent hidroksi ili karboksi u položaju orto u odnosu na vezu sa -NR3-. Prijava sadrži još 3 nezavisna i 13 zavisnih zahteva.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/094-842-915-189-157,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
576,EP,A3,EP 0341948 A3,092-529-726-004-949,1991-05-22,1991,EP 89304621 A,1989-05-08,GB 8811055 A,1988-05-10,"CEPHALOSPORINS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS","Cephalosporin antibiotics having a 3-position substituent of the formula: 
-CH₂NR¹-Y-A-Z-Q 
are described, wherein R¹ is hydrogen or certain optionally substituted alkyl groups; Y is -CO- or -SO₂-; 
A is optionally substituted phenylene or heterocyclylene; 
Z is a linking group and Q is a catechol or related ring system. 
Processes for their preparation and use are described.  ",IMPERIAL CHEMICAL INDUSTRIES PLC;;I.C.I.- PHARMA,"DAVIES, GARETH MORSE;;STRAWSON, COLIN JOHN;;LOHMANN, JEAN JAQUES",ZENECA PHARMA S.A. (1995-02-01);;ZENECA LIMITED (1995-02-01),https://lens.org/092-529-726-004-949,Search Report,yes,5,0,9,10,0,C07D501/46;;C07D501/46,A01N43/90;;A61K31/545;;C07D501/18;;C07D501/38;;C07D501/42;;C07D501/44;;C07D501/46;;C07D501/52;;C07D501/54;;C07D501/56,,0,0,,,,EXPIRED
577,US,A1,US 2019/0298411 A1,112-703-271-847-118,2019-10-03,2019,US 201916445790 A,2019-06-19,US 201916445790 A;;US 201614910525 A;;IB 2013060287 W;;US 201361863579 P;;US 201361863265 P,2013-08-07,Methods and Devices for Puncturing Tissue,"Novel and unique medical devices and associated methods are disclosed, for facilitating efficient and repeatable puncture of a tissue site while allowing vascular access from various access sites of a patient's body. Disclosed medical devices include dilators and wires usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The medical devices each include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;ALLEY FERRYL;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2016-02-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/112-703-271-847-118,Patent Application,yes,0,8,37,37,0,A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61M25/09;;A61B2017/22044;;A61B2018/00363;;A61B2018/00601;;A61B2018/144;;A61M25/0041;;A61B17/3478;;A61B18/1492;;A61B2017/00247;;A61B2017/003;;A61B2090/3966;;A61B2017/22042;;A61B2018/00351;;A61B90/39;;A61B2018/00601;;A61B2018/144;;A61B2017/00247;;A61B2017/003;;A61B2017/22042;;A61B18/1492;;A61B2018/00351;;A61B2090/3966;;A61B17/3478;;A61B90/39;;A61B2017/3488,A61B17/34;;A61B18/14;;A61B90/00,,0,0,,,,ACTIVE
578,US,A,US 5055462 A,133-321-317-345-526,1991-10-08,1991,US 34966289 A,1989-05-10,GB 8811055 A,1988-05-10,CEPHALOSPORIN COMPOUNDS,"Cephalosporin antibiotics having a 3-position substituent of the formula: --CH.sub.2 NR.sup.1 --Y--A--Z--Q are described, wherein R.sup.1 is hydrogen or certain optionally substituted alkyl groups; Y is --CO-- or --SO.sub.2 --; A is optionally substituted phenylene or heterocyclylene; Z is a linking group and Q is a catechol or related ring system. Processes for their preparation and use are described.",ICI PLC;;ICI PHARMA,DAVIES GARETH M;;STRAWSON COLIN J;;LOHMANN JEAN J,IMPERIAL CHEMICAL INDUSTRIES PLC. A BRITISH CO (1989-04-27),https://lens.org/133-321-317-345-526,Granted Patent,yes,2,6,9,10,0,C07D501/46;;C07D501/46,A01N43/90;;A61K31/545;;C07D501/18;;C07D501/38;;C07D501/42;;C07D501/44;;C07D501/46;;C07D501/52;;C07D501/54;;C07D501/56,514/202;;514/201;;514/206;;540/221;;540/222;;540/225,0,0,,,,EXPIRED
579,US,A1,US 2019/0015644 A1,165-191-014-787-405,2019-01-17,2019,US 201716068589 A,2017-01-06,US 201716068589 A;;US 201662275907 P;;IB 2017050065 W,2016-01-07,Hybrid Transseptal Dilator and Methods of Using the Same,"A method and apparatus are disclosed for an optimized transseptal procedure for providing left heart access, that reduces the number of devices that are used in order to minimize procedural time, complexity and cost. The apparatus comprises a hybrid dilator that comprises the combined functionality of a transseptal sheath and dilator assembly. The hybrid dilator comprises: a dilator shaft defining a lumen for receiving a crossing device therethrough, the dilator shaft being structured to provide support for the crossing device when the crossing device is used to create a puncture in a tissue; and a distal tip having an outer diameter which tapers down to an outer diameter of the crossing device for providing a smooth transition between the crossing device and the distal tip when the crossing device is inserted through the lumen and protrudes beyond the distal tip.",BAYLIS MEDICAL CO INC,THOMSPON SMITH MELANIE;;DAVIES GARETH;;LEUNG LINUS HOI CHE,BAYLIS MEDICAL COMPANY INC (2017-01-04);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/165-191-014-787-405,Patent Application,yes,0,15,10,10,0,A61B17/3478;;A61M25/06;;A61B2017/00247;;A61B2017/22038;;A61B2017/22042;;A61B2017/22047;;A61B2090/033;;A61B2090/062;;A61B2090/0807;;A61M29/00;;A61B2017/22038;;A61B2017/22047;;A61B17/3478;;A61B2017/00247;;A61B2017/22042;;A61M25/06;;A61B2090/062;;A61B2090/0807;;A61B2090/033;;A61M29/00;;A61B17/3415;;A61B18/1477;;A61B2018/00351;;A61B2018/1425;;A61M25/09;;A61M2205/32;;A61M2205/582,A61B17/34;;A61M29/00;;A61B18/14;;A61M25/09,,0,0,,,,ACTIVE
580,CA,A1,CA 2106141 A1,175-564-519-249-882,1994-03-29,1994,CA 2106141 A,1993-09-14,EP 92402648 A,1992-09-28,ANTIBIOTIC COMPOUNDS,"ANTIBIOTIC COMPOUNDS The present invention provided a compound of the formula: <IMG> (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: A is a group of the formula (IA) or (IB): <IMG> (IA) <IMG> (IB) R1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R2 is hydrogen or C1-4alkyl; R3 and R4 are the same or different and are a variety of substituents X is alkanediyl containing 1-6 carbon atoms optionally interrupted by O, S(O)x (wherein x is zero, one or two), -CONR5- or -NR5- wherein R5 is hydrogen or C1-4alkyl; or X is alkenediyl containing 2-6 carbon atoms optionally interrupted by O, S(O)x or -NR5- wherein x and R5 are as hereinbefore defined, with the provisos that: i) the interrupting function (O,S(O)x,NR5,-CONR5-) may be directly linked to the ring A, but is not directly linked to the -COOH function or to any carbon-carbon double bond in X; and (ii) when the interrupting function is -SO- or -SO2- it is not .beta. to the COOH function or .delta. if there is an intervening carbon-carbon double bond in X.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL J;;DAVIES GARETH M;;JUNG FREDERIC H,,https://lens.org/175-564-519-249-882,Patent Application,no,0,0,9,11,0,C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07D477/20;;C07F9/568;;A61P31/04;;C07D487/04;;C07D477/20;;C07D207/16;;C07D403/12;;C07D409/14;;C07D409/12;;C07F9/568,A61K31/40;;A61K31/397;;A61P31/04;;C07D205/08;;C07D207/16;;C07D403/12;;C07D409/12;;C07D409/14;;C07D477/00;;C07D477/20;;C07F9/568,,0,0,,,,DISCONTINUED
581,GE,B,GE P20022694 B,001-593-466-051-321,2002-05-10,2002,GE AP2001004468 A,2001-08-31,EP 93914514 A;;GB 9202298 A,1992-02-04,"Carbapenems Containing a Carboxy Substituted Phenyl Group, Processes for Their Preparation, Intermediates and Use as Antibiotics","(57) 1. Technical Result Increase in assortment of antibiotic means. 2. Essence Compounds of the formula wherein the values of R1, R2, R3, R4, R5 are defined in the specification. 3. Field of Application Medicine.",ASTRAZENECA LTD,BETTS MICHAEL J;;DAVIES GARETH M;;SWAIN MICHAEL L,,https://lens.org/001-593-466-051-321,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,C07D477/00;;A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
582,NO,D0,NO 933530 D0,045-388-096-180-487,1993-10-01,1993,NO 933530 A,1993-10-01,GB 9202298 A;;GB 9300217 W,1992-02-04,"KARBAPENEMER INNEHOLDENE EN KARBOKSYSUBSTITUERT FENYLGRUPPE, FREMGANGSMAATE FOR DERES FREMSTILLING, MELLOMPRODUKETEROG ANVENDELSE SOM ANTIBIOTIKA",,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/045-388-096-180-487,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
583,CZ,A3,CZ 206793 A3,057-231-709-621-207,1994-04-13,1994,CZ 206793 A,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,ANTIBIOTIC COMPOUNDS,,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/057-231-709-621-207,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
584,US,B2,US 8990522 B2,059-682-878-224-072,2015-03-24,2015,US 201213646649 A,2012-10-05,GB 201118534 A,2011-10-26,Digital signal processing data transfer,"A technique for transferring data in a digital signal processing system is described. In one example, the digital signal processing system comprises a number of fixed function accelerators, each connected to a memory access controller and each configured to read data from a memory device, perform one or more operations on the data, and write data to the memory device. To avoid hardwiring the fixed function accelerators together, and to provide a configurable digital signal processing system, a multi-threaded processor controls the transfer of data between the fixed function accelerators and the memory. Each processor thread is allocated to a memory access channel, and the threads are configured to detect an occurrence of an event and, responsive to this, control the memory access controller to enable a selected fixed function accelerator to read data from or write data to the memory device via its memory access channel.",IMAGINATION TECH LTD,ANDERSON ADRIAN J;;WASS GARY C;;DAVIES GARETH J,NORDIC SEMICONDUCTOR ASA (2020-12-31);;IMAGINATION TECHNOLOGIES LTD (2012-09-12),https://lens.org/059-682-878-224-072,Granted Patent,yes,11,1,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F12/08;;G06F9/38;;G06F9/54;;G06F12/1081;;G06F13/28,711/158;;711/133;;711/6;;711/163;;711/154,6,0,,,"GB1118534.5 Search Report Feb. 17, 2012.;;""TMS320C6474 DSP Enhanced DMA (EDMA3) Controller"", Jul. 1, 2011, XP055049608, Retrieved from the Internet: URL:http://www.ti.com/lit/ug/sprug11b/spru gllb.pdf [retrieved on Jan. 1, 2013] pp. 13, 21, 23, 46, table 2.6.;;David Bell et al ""Multicore Programming Guide"", Aug. 1, 2009, XP055049589, Retrieved from the Internet: URL:http://www.polyscope.ch/d1Center/ps/2010 15/15 10.05.pdf [retrieved on Jan. 15, 2013].;;EP12189414.1 EPO Extended Search Report Jan. 30, 2013.;;Juergen Mathes ""How to Approach Inter-Core Communication on TMS320C6474"", Jan. 1, 2009, XP055049737, Retrieved from the Internet: URL:http://www.ti.com/lit/an/sprab25/sprab25.pdf.;;Nikolic-Popovic J: ""Using TMS320C6416 Coprocessors: Viterbi Coprocessor (VCP)"", Texas Instruments Application Report, Dallas, TX, USA, Sep. 1, 2003, pp. 1-24, XP002591629, Retrieved from the Internet: URL:http://focus.ti.com.cn/cn/lit/an/spra750d/ spra750d.pdf pp. 11-13.",ACTIVE
585,HU,D0,HU 9302777 D0,072-470-538-718-232,1993-12-28,1993,HU 9302777 A,1993-02-02,GB 9202298 A,1992-02-04,COMPOUNDS WITH ANTIBIOTIC EFFECT,,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,"ASTRAZENECA AB, SE (2001-03-28)",https://lens.org/072-470-538-718-232,Patent Application,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
586,EP,A1,EP 4277554 A1,083-603-907-836-820,2023-11-22,2023,EP 21919211 A,2021-01-14,IB 2021050266 W,2021-01-14,"MEDICAL DILATOR, AND SYSTEMS, METHODS, AND KITS FOR MEDICAL DILATION",,BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;KOON LAUREN;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO,,https://lens.org/083-603-907-836-820,Patent Application,yes,0,0,5,5,0,A61B5/283;;A61B18/1477;;A61B2018/00357;;A61B2018/00601;;A61B2018/00839;;A61B18/1492;;A61M29/00;;A61B5/287;;A61B5/287;;A61M29/00,A61B18/14;;A61B5/283;;A61B18/00;;A61M29/02,,0,0,,,,PENDING
587,DE,I2,DE 10299041 I2,101-170-026-067-750,2003-06-12,2003,DE 10299041 C,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,"Carboxy substituierte Phenylgruppe enthaltende Carbapeneme; Verfahren zu deren Herstellung, Zwischenprodukte und Verwendung als Antibiotika.",,ASTRAZENECA UK LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/101-170-026-067-750,Supplementary Protection Certificate,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,PENDING
588,EP,B1,EP 0579826 B1,116-169-209-979-02X,1998-11-11,1998,EP 93914514 A,1993-02-02,GB 9202298 A;;GB 9300217 W,1992-02-04,"CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS",,ZENECA LTD,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,"ZENECA LIMITED (1998-06-03);;ASTRAZENECA AB (2008-06-25);;ASTRAZENECA UK LIMITED (2002-12-02);;SYNGENTA LIMITED (2002-12-02);;ASTRAZENECA UK LTD., LONDON, GB (2003-03-27);;ZENECA LIMITED TRANSFER- ASTRAZENECA AB (2001-01-31)",https://lens.org/116-169-209-979-02X,Granted Patent,yes,2,3,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
589,KR,B1,KR 100200986 B1,146-964-489-829-835,1999-06-15,1999,KR 930702942 A,1993-09-28,GB 9202298 A;;GB 9300217 W,1992-02-04,"CARBAPENEMS CONTAINING CARBOXY SUBSTITUTED PHENYL GROUP, PROCESS FOR THEIR PREPARATION, INTERMEDIATES AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME","본 발명은 카르바페넴에 관한 것이며 하기 일반식 (I)의 화합물 또는 그것의 약학적으로 허용염 또는 그것의 생체내 가수 분해성 에스테르에 관한 것이다: 상기 식 중, R1 은 1-히드록시에틸, 1-플루오로에틸 또는 히드록시메틸이고; R2 는 수소 또는 C1-C4알킬이고; R3 는 수소 또는 C1-C4알킬이며; R4 및 R5는 동일하거나 다른 것으로서 수소, 할로, 시아노, C1-C4알킬, 니트로, 히드록시, 카르복시, C1-C4알콕시, C1-C4알콕시카르보닐, 아미노설포닐, C1-C4알킬아미노설포닐, 디-C1-C4알킬아미노설포닐, 카르바모일, C1-C4알킬카르바모일, 디-C1-C4알킬카르바모일, 트리플루오로메틸, 설폰산, 아미노, C1-C4알킬아미노, 디-C1-4알킬아미노, C1-4알카노일아미노, C1-4알카노일(N-C1-4알킬)아미노, C1-4알칸설폰아미도 및 C1-4알킬 -S(O)n (식 중, n은 0, 1 또는 2임) 중에서 선택되는데, 단 -NR3-에는 오토 위치의 히드록시 또는 카르복시 치환체가 결합되지 않는다. 본 발명은 또한 그것을 제조하는 방법, 그 제조시 중간물질, 그것을 치료제로서 사용하는 방법 및 그것을 함유한 약학적 조성물에 관한 것이기도 하다.",ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/146-964-489-829-835,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
590,FI,B1,FI 104074 B1,160-359-356-227-381,1999-11-15,1999,FI 930474 A,1993-02-03,GB 9202298 A,1992-02-04,Menetelmä terapeuttisesti käyttökelpoisten 2-[2-(3-karboksifenyylikarbamoyyli)pyrrolidin-4-yylitio]karbapeneemijohdannaisten valmistamiseksi,,ZENECA LTD;;ZENECA PHARMA SA,BETTS MICHAEL JOHN;;DAVIES GARETH MORSE;;SWAIN MICHAEL LINGARD,,https://lens.org/160-359-356-227-381,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
591,US,B2,US 10268377 B2,191-236-158-924-279,2019-04-23,2019,US 201715433888 A,2017-02-15,US 201715433888 A;;GB 201118534 A;;US 201514625719 A;;US 201213646649 A,2011-10-26,Digital signal processing data transfer,"A technique for transferring data in a digital signal processing system is described. In one example, the digital signal processing system comprises a number of fixed function accelerators, each connected to a memory access controller and each configured to read data from a memory device, perform one or more operations on the data, and write data to the memory device. To avoid hardwiring the fixed function accelerators together, and to provide a configurable digital signal processing system, a multi-threaded processor controls the transfer of data between the fixed function accelerators and the memory. Each processor thread is allocated to a memory access channel, and the threads are configured to detect an occurrence of an event and, responsive to this, control the memory access controller to enable a selected fixed function accelerator to read data from or write data to the memory device via its memory access channel.",IMAGINATION TECH LTD,ANDERSON ADRIAN J;;WASS GARY C;;DAVIES GARETH J,NORDIC SEMICONDUCTOR ASA (2020-12-31),https://lens.org/191-236-158-924-279,Granted Patent,yes,48,0,20,20,0,G06F9/3851;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F13/28;;G06F13/385;;G06F9/542;;G06F9/544;;G06F13/28;;G06F9/3851;;G06F9/3009;;G06F9/5016;;G06F12/1081;;G06F2212/251;;G06F3/0607;;G06F3/0629;;G06F3/0658;;G06F3/0673,G06F3/06;;G06F9/30;;G06F9/38;;G06F9/50;;G06F9/54;;G06F12/1081;;G06F13/28,,3,0,,,"TMS320C6474 DSP Enhanced DMA (EDMA3) Controller, Jul. 1, 2011 (Jul. 1, 2011), XP055049608, Retrieved from the Internet: URL:http://www.ti.com/litJug/sprugllb/sprugllb.pdf, pp. 1.;;Bell et al., “Multicore Programming Guide”, Aug. 1, 2009 (Aug. 1, 2009), XP055049589, Retrieved from the Internet: URL:http://www.polyscope.ch/d1Center/ps/2010 15/1510.05.pdf.;;Mathes, “How to Approach Inter-Core Communication on TMS320C6474”, Jan. 1, 2009 (Jan. 1, 2009), XP055049737, Retrieved from the Internet: URL:http:/lwww.ti.com/lit/an/sprab25/.",ACTIVE
592,SI,A,SI 9300056 A,189-929-174-535-396,1993-09-30,1993,SI 9300056 A,1993-02-02,GB 9202298 A,1992-02-04,CARBAPENEMS ANTIBIOTICS,,ZENECA LIMITED;;ZENECA-PHARMA S.A.,BETTS MICHAEL JOHN;;MORSE DAVIES GARETH;;LINGARD SWAIN MICHAEL,ASTRAZENECA UK LIMITED; GB (2005-04-21),https://lens.org/189-929-174-535-396,Granted Patent,no,0,0,75,76,0,A61K31/40;;A61K31/407;;A61K31/41;;C07D207/16;;C07D403/12;;C07D477/20;;C07F9/568;;A61P31/04;;C07D477/20;;A61K31/407;;A61K31/40;;A61K31/41;;C07D207/16;;C07D403/12;;C07F9/568,A61K31/397;;A61K31/40;;A61K31/407;;A61K31/41;;A61K38/40;;A61P31/04;;C07C233/00;;C07D205/00;;C07D207/00;;C07D207/16;;C07D403/12;;C07D477/00;;C07D477/20;;C07D487/04;;C07F9/568;;C07F9/572;;C07F9/6574,,0,0,,,,EXPIRED
593,NO,D0,NO 20004830 D0,081-279-907-209-494,2000-09-26,2000,NO 20004830 A,2000-09-26,GB 9806492 A;;GB 9900941 W,1998-03-27,Overflateaktivt basert gelblanding for brønnhulls- behandlingsfluid,,SCHLUMBERGER TECHNOLOGY BV,DAVIES STEPHEN NIGEL;;JONES TIMOTHY GARETH JOHN;;TUSTIN GARY JOHN,,https://lens.org/081-279-907-209-494,Patent Application,no,0,0,8,8,0,C09K8/5753;;C09K8/5756;;C09K8/5756;;C09K8/5753,C09K8/575,,0,0,,,,DISCONTINUED
594,WO,A1,WO 1999/050529 A1,003-256-439-081-926,1999-10-07,1999,GB 9900941 W,1999-03-25,GB 9806492 A,1998-03-27,SURFACTANT BASED GELLING COMPOSITION FOR WELLBORE SERVICE FLUIDS,"A composition, in particular a wellbore service fluid, comprising monomeric surfactants, preferably viscoelastic surfactants, in combination with a polymerization agent. Additionally, the fluid may contain a cross-linking agent to cross-link the polymerized surfactants.",SOFITECH NV;;SCHLUMBERGER CIE DOWELL;;SCHLUMBERGER CA LTD;;DAVIES STEPHEN NIGEL;;JONES TIMOTHY GARETH JOHN;;TUSTIN GARY JOHN,DAVIES STEPHEN NIGEL;;JONES TIMOTHY GARETH JOHN;;TUSTIN GARY JOHN,,https://lens.org/003-256-439-081-926,Patent Application,yes,7,16,8,8,0,C09K8/5753;;C09K8/5756;;C09K8/5756;;C09K8/5753,C09K8/575,,0,0,,,,PENDING
595,US,A1,US 2017/0360498 A1,097-314-681-741-120,2017-12-21,2017,US 201515532402 A,2015-12-03,US 201515532402 A;;US 201462087141 P;;IB 2015059337 W,2014-12-03,Devices and Methods for Electrosurgical Navigation,"A method and apparatus or system are disclosed for a procedure with minimal or no fluoroscopy, for example an electrosurgical procedure, and which uses a three dimensional mapping system. The procedure typically involves electrical measurement of the electrode of a needle to determine its position. Some embodiments further include intracardiac echocardiography (ICE) for tracking devices. The apparatus includes a needle with a tip electrode, an electroanatomical mapping (EAM) system, and an electrical generator, wherein a switching device is used to restrictively electrically connect the needle to only one of the mapping system or generator at a given time.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;HARFIELD ELLEN;;HORTON RODNEY;;WELLS DAVID;;WOO JASON,BAYLIS MEDICAL COMPANY INC (2015-11-27),https://lens.org/097-314-681-741-120,Patent Application,yes,13,9,3,3,0,A61B18/1477;;A61B18/1492;;A61B2018/00357;;A61B2018/00577;;A61B2018/00601;;A61B2018/00791;;A61B2018/00827;;A61B2018/00839;;A61B2018/00875;;A61B2018/00892;;A61B2218/002;;A61B2218/007;;A61B34/20;;A61B2034/2051;;A61B18/1233;;A61B18/1477;;A61B18/1492;;A61B2018/00357;;A61B2018/00577;;A61B2018/00601;;A61B2018/00791;;A61B2018/00827;;A61B2018/00839;;A61B2018/00875;;A61B2018/00892;;A61B2218/002;;A61B2218/007;;A61B34/20;;A61B2034/2051;;A61B5/304;;A61B5/283;;A61B5/361;;A61B18/1233;;A61B5/0536;;A61B2017/00053;;A61B2018/00172;;A61B2018/00178;;A61B2018/0091,A61B18/12;;A61B5/308;;A61B5/361;;A61B17/00;;A61B18/00;;A61B18/14;;A61B34/20,,0,0,,,,DISCONTINUED
596,GB,A,GB 2335679 A,121-097-469-503-694,1999-09-29,1999,GB 9806492 A,1998-03-27,GB 9806492 A,1998-03-27,Wellbore service fluids,"A wellbore service fluid comprises a monomeric surfactant, preferably a viscoelastic surfactant, and an agent for polymerizing the surfactant. The polymerising agent may be a radical, a cationic, or an anionic initiator. Additionally, the fluid may contain a cross linking agent to cross link the polymerized surfactants.",SOFITECH NV,DAVIES STEPHEN NIGEL;;JONES TIMOTHY GARETH JOHN;;TUSTIN GARY JOHN,,https://lens.org/121-097-469-503-694,Patent Application,no,3,3,8,8,0,C09K8/5753;;C09K8/5756;;C09K8/5756;;C09K8/5753,C09K8/575,E1F FGP           FGP;;E1F FPA           FPA;;E1F FPC           FPC,0,0,,,,EXPIRED
597,US,A1,US 2007/0245745 A1,011-127-715-009-250,2007-10-25,2007,US 78873307 A,2007-04-20,US 78873307 A;;US 79373806 P,2006-04-20,Method and device for optimizing a light-up procedure of a gas turbine engine,"An aspect of the invention is directed towards a method and device for optimizing a light-up procedure of a gas turbine engine. An aspect of the method comprises repeating an engine start attempt with amended light-up parameter values or range of light-up parameter values, where the values are amended by a predefined scheme including recording the light-up parameter value or the range of light-up parameter values of each start attempt together with the light-up success rate achieved in the respective start attempts, and optimizing the light-up parameter value or range of parameter values by analyzing the recorded data after the start attempts have been finished. An aspect of the device is to provide a control unit that implements the inventive method.",SIEMENS POWER GENERATION INC,DAVIES GARETH;;NODEN RICHARD;;SKIPPER DORIAN;;WILKINSON JOHN;;WOODS RICHARD,SIEMENS AKTIENGESELLSCHAFT (2007-03-26);;SIEMENS ENERGY GLOBAL GMBH & CO. KG (2021-02-28),https://lens.org/011-127-715-009-250,Patent Application,yes,7,16,2,2,0,F02C7/26;;F02C7/26;;F02C7/22;;F02C7/22;;F02C7/262;;F02C7/262,F02C7/26;;F02C7/22,60/778;;60/786,0,0,,,,ACTIVE
598,US,B2,US 9345509 B2,023-311-866-677-067,2016-05-24,2016,US 201314135656 A,2013-12-20,US 201314135656 A;;US 28037908 A;;CA 2007000285 W;;US 77532706 P;;US 201361773878 P,2006-02-22,Guide-wire dilation device for facilitation of lesion crossing,"Devices and methods are disclosed for widening a channel in a treatment site, the channel containing a guide-wire. The channel is widened by advancing an elongated dilation device, which is configured to fit tightly over the guide-wire at the distal tip of the dilation device and to provide a distal dilating surface, over the guide-wire and at least partially through the treatment site. The dilation device comprises a tubular metallic shaft, typically a metal inner tube, for providing sufficient stiffness and column strength for the dilator to be advanced at least partially through the channel, and a flexible sleeve providing a tapered distal tip. The distal end of the dilator defines a leading surface that is shaped to force away portions of a lesion surrounding the guide-wire away from the guide-wire as the distal end is advanced over the guide-wire through the lesion, whereby a channel through the lesion is at least partially dilated.",BAYLIS MEDICAL CO INC;;STRAUSS BRADLEY H,DAVIES GARETH;;LUK MARIA;;WARAM THOMAS C;;STRAUSS BRADLEY H,BAYLIS MEDICAL COMPANY INC (2013-12-04);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01);;STRAUSS BRADLEY H (2008-09-10),https://lens.org/023-311-866-677-067,Granted Patent,yes,79,0,2,8,0,A61B17/3207;;A61M29/00;;A61B2017/320044;;A61B2017/320056;;A61M25/0021;;A61M25/0045;;A61M2025/0047;;A61M25/0051;;A61M2025/0183;;A61B17/320725;;A61B17/3207;;A61M29/00;;A61B2017/320044;;A61B2017/320056;;A61M25/0021;;A61M25/0045;;A61M2025/0047;;A61M25/0051;;A61M2025/0183,A61B17/22;;A61B17/32;;A61B17/3207;;A61M25/00;;A61M25/01;;A61M29/00,,2,0,,,"European Search Report of Application No. 07710640.9 mailed on Aug. 16, 2013.;;Total across brochure. Medtronic, Inc. Published in 2013.",ACTIVE
599,NO,L,NO 20004830 L,067-965-646-755-86X,2000-11-20,2000,NO 20004830 A,2000-09-26,GB 9806492 A;;GB 9900941 W,1998-03-27,Gelblanding basert pa overflateaktivt middel for bronnhulls-behandlingsfluider,,SCHLUMBERGER TECHNOLOGY BV,DAVIES STEPHEN NIGEL;;JONES TIMOTHY GARETH JOHN;;TUSTIN GARY JOHN,,https://lens.org/067-965-646-755-86X,Abstract,no,0,0,8,8,0,C09K8/5753;;C09K8/5756;;C09K8/5756;;C09K8/5753,C09K8/575,,0,0,,,,DISCONTINUED
600,US,A1,US 2012/0046657 A1,199-692-557-813-111,2012-02-23,2012,US 201113286041 A,2011-10-31,US 201113286041 A;;US 90544807 A;;US 201161448578 P,2007-10-01,Stent Graft Fenestration,"A method for creating a channel through a foreign material located in a body of a patient, the foreign material defining a material first surface and a substantially opposed material second surface, the channel extending through the foreign material between the material first and second surfaces, the method using an apparatus including an electrode, the method comprising: positioning the electrode substantially adjacent to the material first surface; energizing the electrode with a radiofrequency current; and using the electrode energized with the radiofrequency current to deliver energy into the foreign material to create the channel, wherein the foreign material is included in a stent graft.",BIADILLAH YOUSSEF;;HARTLEY AMANDA;;DAVIES GARETH;;VISRAM NAHEED;;JUZKIW TARAS;;BAYLIS MEDICAL COMPANY,BIADILLAH YOUSSEF;;HARTLEY AMANDA;;DAVIES GARETH;;VISRAM NAHEED;;JUZKIW TARAS,BAYLIS MEDICAL COMPANY INC (2011-10-31);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/199-692-557-813-111,Patent Application,yes,3,9,4,113,0,A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00827;;A61B2018/00875;;A61B2018/00898;;A61B2090/3966;;A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00827;;A61B2018/00875;;A61B2018/00898;;A61B2090/3966;;A61B18/04,A61B18/18,606/33,0,0,,,,ACTIVE
601,US,A1,US 2011/0224666 A1,129-224-300-549-611,2011-09-15,2011,US 201113113326 A,2011-05-23,US 201113113326 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 52275304 P,2003-01-21,METHOD OF SURGICAL PERFORATION VIA THE DELIVERY OF ENERGY,"Apparatuses and methods for the perforation of heart tissue of a patient when an inferior approach to the heart is contraindicated are disclosed. The method includes using a superior approach to introduce the apparatus, positioning the apparatus at a tissue location and delivering a controlled amount of non-mechanical energy to the tissue to create a perforation. For example, a method of surgical perforation via the delivery of electrical, radiant or thermal energy may include: introducing an apparatus comprising an energy delivery device into a patient's heart via the patient's superior vena cava; positioning the energy delivery device at a first location adjacent material to be perforated; and perforating the material by delivering energy via the energy delivery device; wherein the energy is selected from the group consisting of electrical energy, radiant energy and thermal energy.",DAVIES GARETH;;HARTLEY AMANDA;;VISRAM NAHEED;;SHAH KRISHAN;;BAYLLS FRANK,DAVIES GARETH;;HARTLEY AMANDA;;VISRAM NAHEED;;SHAH KRISHAN;;BAYLLS FRANK,BAYLIS MEDICAL COMPANY INC (2011-04-18);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/129-224-300-549-611,Patent Application,yes,59,11,2,113,0,A61B18/1206;;A61B18/24;;A61B2018/00351;;A61B2018/00839;;A61B2090/064;;A61B2090/3966;;A61B18/1492;;A61B18/1206;;A61B18/24;;A61B2018/00351;;A61B2018/00839;;A61B2090/064;;A61B2090/3966;;A61B18/1492,A61B18/14;;A61B18/18,606/33;;606/41,0,0,,,,EXPIRED
602,US,A1,US 2014/0100560 A1,044-861-761-504-758,2014-04-10,2014,US 201314100468 A,2013-12-09,US 201314100468 A;;US 201113286041 A;;US 90544807 A;;US 82746606 P;;US 201161448578 P,2006-09-29,Fenestration through foreign material,"Described herein is a method for creating a channel through a foreign material located in a body of a patient. The foreign material defines a material first surface and a substantially opposed material second surface and the channel extends through the foreign material between the material first and second surfaces. The method uses an apparatus including an electrode, and includes the steps of: positioning the electrode substantially adjacent to the material first surface; energizing the electrode with a radiofrequency current; and using the electrode energized with the radiofrequency current to deliver energy into the foreign material to create the channel. In some embodiments, the patient's body includes a heart defining a septum, the septum defines an aperture extending there-through and the foreign material extends across the aperture to cover the aperture.",BAYLIS MEDICAL CO INC,BIADILLAH YOUSSEF;;HARTLEY AMANDA;;DAVIES GARETH;;VISRAM NAHEED;;JUZKIW TARAS,BAYLIS MEDICAL COMPANY INC (2013-12-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/044-861-761-504-758,Patent Application,yes,3,2,4,113,0,A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00827;;A61B2018/00875;;A61B2018/00898;;A61B2090/3966;;A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00827;;A61B2018/00875;;A61B2018/00898;;A61B2090/3966;;A61B18/04,A61B18/04,606/33,0,0,,,,ACTIVE
603,US,B2,US 8623005 B2,192-268-307-886-951,2014-01-07,2014,US 201113286041 A,2011-10-31,US 201113286041 A;;US 90544807 A;;US 201161448578 P,2007-10-01,Stent graft fenestration,"A method for creating a channel through a foreign material located in a body of a patient, the foreign material defining a material first surface and a substantially opposed material second surface, the channel extending through the foreign material between the material first and second surfaces, the method using an apparatus including an electrode, the method comprising: positioning the electrode substantially adjacent to the material first surface; energizing the electrode with a radiofrequency current; and using the electrode energized with the radiofrequency current to deliver energy into the foreign material to create the channel, wherein the foreign material is included in a stent graft.",BIADILLAH YOUSSEF;;HARTLEY AMANDA;;DAVIES GARETH;;VISRAM NAHEED;;JUZKIW TARAS;;BAYLIS MEDICAL CO INC,BIADILLAH YOUSSEF;;HARTLEY AMANDA;;DAVIES GARETH;;VISRAM NAHEED;;JUZKIW TARAS,BAYLIS MEDICAL COMPANY INC (2011-10-31);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/192-268-307-886-951,Granted Patent,yes,19,0,4,113,0,A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00827;;A61B2018/00875;;A61B2018/00898;;A61B2090/3966;;A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00827;;A61B2018/00875;;A61B2018/00898;;A61B2090/3966;;A61B18/04,A61B18/18,606/33;;606/41;;606/45,9,8,016-249-543-201-808;;043-109-600-839-627;;104-863-760-253-161;;013-298-075-588-774;;027-249-765-633-859;;035-621-526-377-948;;030-041-321-743-550;;023-749-888-124-005,10.1583/09-2903c.1;;20426637;;10.1583/09-2903.1;;20426636;;10.1583/1545-1550(2001)008<0003:eagwra>2.0.co;2;;11220465;;10.1177/152660280100800102;;10.1583/1545-1550(2007)14[158:ivafoa]2.0.co;2;;17484531;;10.1177/152660280701400207;;16473163;;10.1016/j.jvs.2005.10.059;;15056015;;10.1583/03-1180.1;;10.1583/1545-1550(2001)008<0016:fiegfa>2.0.co;2;;10.1177/152660280100800103;;11220463;;14656175;;10.1583/1545-1550(2003)010<0946:rfoegf>2.0.co;2;;10.1177/152660280301000518,"Frank R. Arko III, ""In Pursuit of an Off-the Shelf Fenestrated Stent-Graft: Radiofrequency Perforation for In Vivo Antegrade Fenestration"", ""Journal of Endovascular Therapy"", Apr. 2010, pp. 199-200, vol. 17, No. 2, Publisher: Journal of Endovascular Therapy, Published in: US.;;Leonard W. H. Tse et al., ""Radiofrequency Perforation System for an In Vivo Antegrade Fenestration of Aortic Stent-Grafts"", ""Journal of Endovascular Therapy"", Apr. 2010, pp. 192-198, vol. 17, No. 2, Publisher: Journal of Endovascular Therapy, Published in: US.;;John Lennon Anderson et al., ""Endoluminal Aortic Grafting with Renal and Superior Mesenteric Artery Incorporation by Graft Fenestration"", ""Journal of Endovascular Therapy"", Feb. 2001, pp. 3-15, No. 8, Publisher: Journal of Endovascular Therapy, Published in: US.;;Abstract of Leonard W.H. Tse et al., ""In Vivo Antegrade Fenestration of Abdominal Aortic Stent-Grafts"", Journal of Endovascular Therapy, Apr. 2007, pp. 158-167, vol. 14, No. 2, Publisher: Journal of Endovascular Therapy, Published in: US.;;Timothy A.M. Chuter, ""Branched and Fenestrated Stent Grafts for Endovascular Repair of Thoracic Aortic Aneurysms"". Oct. 27, 2005, pp. 111A-115A, vol. 43, No. A, Publisher: The Society for Vascular Surgery, Published in: US.;;Abstract of Richard G. McWilliams et al., ""In Situ Stent-Graft Fenestration to Preserve the Left Subclavian Artery"", ""Journal of Endovascular Therapy"", Apr. 2004, pp. 170-174, vol. 11, No. 2, Publisher: Journal of Endovascular Therapy, Published in: US.;;Brendan M. Stanley et al., ""Fenestration in Endovascular Grafts for Aortic Aneurysm Repair: New Horizons for Preserving Blood Flow in Branch Vessels"", ""Journal of Endovascular Therapy"", Feb. 2001, pp. 16-24, vol. 8, Publisher: Journal of Endovascular Therapy, Published in: US.;;Entire prosecution history of U.S. Appl. No. 11/905,448 from Oct. 1, 2007 to Aug. 22, 2012; Inventor: Biadillah, Youssef et al.;;Abstract of Richard G. McWilliams et al., ""Retrograde Fenestration of Endoluminal Grafts From Target Vessels: Feasibility, Technique, and Potential Usage"", ""Journal of Endovascular Therapy"", Oct. 2003, pp. 946-952, vol. 10, No. 5, Publisher: Journal of Endovascular Therapy, Published in: US.",ACTIVE
604,US,A1,US 2014/0107681 A1,106-315-956-892-526,2014-04-17,2014,US 201314135656 A,2013-12-20,US 201314135656 A;;US 28037908 A;;CA 2007000285 W;;US 77532706 P;;US 201361773878 P,2006-02-22,Guide-Wire Dilation Device for Facilitation of Lesion Crossing,"Devices and methods are disclosed for widening a channel in a treatment site, the channel containing a guide-wire. The channel is widened by advancing an elongated dilation device, which is configured to fit tightly over the guide-wire at the distal tip of the dilation device and to provide a distal dilating surface, over the guide-wire and at least partially through the treatment site. The dilation device comprises a tubular metallic shaft, typically a metal inner tube, for providing sufficient stiffness and column strength for the dilator to be advanced at least partially through the channel, and a flexible sleeve providing a tapered distal tip. The distal end of the dilator defines a leading surface that is shaped to force away portions of a lesion surrounding the guide-wire away from the guide-wire as the distal end is advanced over the guide-wire through the lesion, whereby a channel through the lesion is at least partially dilated.",STRAUSS BRADLEY H;;BAYLIS MEDICAL CO INC,DAVIES GARETH;;LUK MARIA;;WARAM THOMAS C;;STRAUSS BRADLEY H,BAYLIS MEDICAL COMPANY INC (2013-12-04);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01);;STRAUSS BRADLEY H (2008-09-10),https://lens.org/106-315-956-892-526,Patent Application,yes,69,13,2,8,0,A61B17/3207;;A61M29/00;;A61B2017/320044;;A61B2017/320056;;A61M25/0021;;A61M25/0045;;A61M2025/0047;;A61M25/0051;;A61M2025/0183;;A61B17/320725;;A61B17/3207;;A61M29/00;;A61B2017/320044;;A61B2017/320056;;A61M25/0021;;A61M25/0045;;A61M2025/0047;;A61M25/0051;;A61M2025/0183,A61B17/3207,606/159,0,0,,,,ACTIVE
605,US,B2,US 8077314 B2,137-370-787-084-427,2011-12-13,2011,US 24130308 A,2008-09-30,US 24130308 A;;US 97988007 P,2007-10-15,Measuring a characteristic of a multimode optical fiber,"To measure a characteristic of a multimode optical fiber, a light pulse source produces a light pulse for transmission into the multimode optical fiber. A spatial filter passes a portion of Brillouin backscattered light from the multimode optical fiber that is responsive to the light pulse. Optical detection equipment detects the portion of the Brillouin backscattered light passed by the spatial filter.",DAVIES DYLAN;;HARTOG ARTHUR H;;HILTON GRAEME;;LEES GARETH P;;SCHLUMBERGER TECHNOLOGY CORP,DAVIES DYLAN;;HARTOG ARTHUR H;;HILTON GRAEME;;LEES GARETH P,SCHLUMBERGER TECHNOLOGY CORPORATION (2008-10-06),https://lens.org/137-370-787-084-427,Granted Patent,yes,33,13,5,5,0,G01B11/16;;G01D5/353;;G01K11/32;;G01L1/242;;G01K11/32;;G01K11/32;;G01D5/35364;;G01D5/35364;;G01M11/319;;G01M11/319,G01N21/00,356/344;;385/12;;356/73.1,8,7,185-722-547-023-745;;087-488-281-092-464;;042-044-419-083-254;;043-606-542-126-799;;053-074-585-407-003;;112-201-577-882-864;;017-323-613-294-958,10.1088/0957-0233/12/7/315;;10.1109/68.651134;;18084418;;10.1364/ol.23.000079;;10.1364/ol.25.000695;;18064154;;10.1109/68.920768;;10.1364/ol.30.001276;;15981505;;10.1109/50.293961,"Maughan, Sally M., Huai H Kee, Trevor P Newson. Simultaneous distributed fibre temperature and strain sensor using microwave coherent detection of spontaneous Brillouin backscatter. Measurement Science and Technology; 2001, pp. 834-842, vol. 12, Institute of Physics Publishing.;;Lees, Gareth P. , Peter C Wait, Martin J Cole, Trevor P Newson. Advances in Optical Fiber Distributed Temperature Sensing Using the Landau-Placzek Ratio. IEEE Photonics Technology Letters, Jan. 1, 1998, pp. 126-128, vol. 10.;;Feced R., T .R. Parker, M. Farhadiroushan, V. A. Handerek, A. J. Rogers. Power measurement of noise-initiated Brillouin scattering in optical fibers for sensing applications. Optics Letters Jan. 1, 1998, pp. 79-81, vol. 23, No. 1. 1998. Optical Society of America.;;Kee, Huai H., Gareth P. Lees, Trevor P. Newson. All-fiber system for simultaneous interrogation of distributed strain and temperature sensing by spontaneous Brillouin scattering. Optics Letters, May 15, 2000, pp. 695-697, vol. 25, No. 10. 2000 Optical Society of America.;;Wait, P. C. and A.H. Hartog, Spontaneous Brillouin-Based Distributed Temperature Sensor Utilizing a Fiber Bragg Grating Notch Filter for the Separation of the Brillouin Signal. IEEE Photonics Technology Letters, May 2001, pp. 508-510, vol. 13, No. 5. 2001 IEEE.;;Alahbabi, M.N., Y.T. Cho, T. P. Newson. Simultaneous temperature and strain measurement with combined spontaneous Raman and Brillouin scattering. Optics Letters Jun. 1, 2005, pp. 1276-1278, vol. 30, No. 11. 2005 Optical Society of America.;;Shimizu, Kaoru, Tsuneo Horiguchi, Yahei Koyamada, Toshio Kurashima. Coherent Self-Heterodyne Brillouin OTDR for Measurement of Brillouin Frequency Shift Distribution in Optical Fibers. Journal of Lightwave Technology, May 1994, pp. 730-736, vol. 12, No. 5. 1994 IEEE.;;OFC 1998 Technical Digest, pp. 181-182.",ACTIVE
606,US,A1,US 2022/0405841 A1,003-330-149-301-786,2022-12-22,2022,US 202217829360 A,2022-06-01,US 202217829360 A;;US 202217741426 A;;US 202263347564 P;;US 202163186180 P,2021-05-10,METHOD AND SYSTEM OF ALGORITHMIC METALS TESTING AND COMPOSITION RISK ALGORITHMS,"A computerized system for metals trading comprising: a commodity trading and risk management (CTRM) enterprise system comprising: a firewall comprising a network security system that monitors and controls incoming and outgoing network traffic based on a set of predetermined security rules, a gateway comprising a network node configured for interfacing with another network that uses different communication protocols; wherein the CTRM enterprise system is configured to implement a set of trade capture and pricing requirements for a metals commodity, wherein the CTRM enterprise system is configured to use a plurality of application server nodes to perform a plurality of tasks comprising: managing a complex quality-based contract pricing for the metals commodity; calculating and managing a complex formula-based contract penalty with respect to the quality-based contract pricing of the metals commodity; and implement a set of microservice modules that independently perform a set of microservice related to the quality-based contract pricing and the complex formula-based contract penalty of the metals commodity.",PENDHARKAR SHRIRANG;;SARAF ANAND;;DAVIES GARETH;;SHINDE PRASAD;;VAGHASIA SAGAR,PENDHARKAR SHRIRANG;;SARAF ANAND;;DAVIES GARETH;;SHINDE PRASAD;;VAGHASIA SAGAR,,https://lens.org/003-330-149-301-786,Patent Application,yes,0,1,1,2,0,G06Q40/04;;G06Q30/0206;;G06Q30/0206;;G06Q40/04,G06Q40/04;;G06Q30/02,,0,0,,,,PENDING
607,ES,T3,ES 2359187 T3,029-240-185-160-727,2011-05-19,2011,ES 08750663 T,2008-05-21,GB 0710121 A,2007-05-25,"DERIVADOS DE 2-OXO-2-(2-FENIL-5,6,7,8-TETRAHIDRO-INDOLIZIN-3-IL)-ACETAMINDA Y COMPUESTOS REALCIONADOS COMO AGENTES ANTIFUNGICOS.","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,PAYNE LLOYD;;DOWNHAM ROBERT;;SIBLEY GRAHAM;;EDWARDS PHILIP;;DAVIES GARETH,,https://lens.org/029-240-185-160-727,Granted Patent,no,0,0,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A61K31/437;;A61P31/10,,0,0,,,,ACTIVE
608,GB,A,GB 2470298 A,074-803-930-744-510,2010-11-17,2010,GB 201008102 A,2010-05-14,GB 0908448 A,2009-05-16,Safety system incorporating safety helmet.,"A safety system comprises a safety helmet assembly 110, 120, 130, 140 to be worn by a user comprising a hard shell; a communications device secured to or integral with the helmet which comprises a processing unit, a receiver and a transducer to output an audio signal to a wearer of the helmet, and a base unit 210, 220, 230, 240 located at fixed position which comprises a processing unit, and a transmitter. The base unit is arranged to transmit a data signal to the communication device which contains at least one safety message, and the processing unit of the helmet assembly communication device is arranged to receive the safety message received by the associated receiver and to cause the drive circuit to actuate the transducer so as to relay the received safety message from the base station to the wearer of the safety helmet. The system can be used to deliver health and safety messages to workers and form part of a personnel auditing system. The system may also be used to monitor the location of workers on a site and warn if a lone worker is present.",SWIFT INVENT LTD,LAVERY ROD;;MAINWARING WILLIAM HUGH KYNASTON;;DAVIES THOMAS WILLIAM GARETH,,https://lens.org/074-803-930-744-510,Patent Application,no,5,2,3,3,0,A42B3/00;;A42B3/30;;H04B1/385,A42B3/00;;H04B1/38,,0,0,,,,DISCONTINUED
609,WO,A1,WO 2016/088084 A1,090-229-492-986-638,2016-06-09,2016,IB 2015059337 W,2015-12-03,US 201462087141 P,2014-12-03,DEVICES AND METHODS FOR ELECTROSURGICAL NAVIGATION,"A method and apparatus or system are disclosed for a procedure with minimal or no fluoroscopy, for example an electrosurgical procedure, and which uses a three dimensional mapping system. The procedure typically involves electrical measurement of the electrode of a needle to determine its position. Some embodiments further include intracardiac echocardiography (ICE) for tracking devices. The apparatus includes a needle with a tip electrode, an electroanatomical mapping (EAM) system, and an electrical generator, wherein a switching device is used to restrictively electrically connect the needle to only one of the mapping system or generator at a given time.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DAVIES GARETH;;HARFIELD ELLEN;;HORTON RODNEY;;WELLS DAVID;;WOO JASON,,https://lens.org/090-229-492-986-638,Patent Application,yes,5,9,3,3,0,A61B18/1477;;A61B18/1492;;A61B2018/00357;;A61B2018/00577;;A61B2018/00601;;A61B2018/00791;;A61B2018/00827;;A61B2018/00839;;A61B2018/00875;;A61B2018/00892;;A61B2218/002;;A61B2218/007;;A61B34/20;;A61B2034/2051;;A61B18/1233;;A61B18/1477;;A61B18/1492;;A61B2018/00357;;A61B2018/00577;;A61B2018/00601;;A61B2018/00791;;A61B2018/00827;;A61B2018/00839;;A61B2018/00875;;A61B2018/00892;;A61B2218/002;;A61B2218/007;;A61B34/20;;A61B2034/2051;;A61B5/304;;A61B5/283;;A61B5/361;;A61B18/1233;;A61B5/0536;;A61B2017/00053;;A61B2018/00172;;A61B2018/00178;;A61B2018/0091,A61B34/00;;A61B5/308;;A61B5/361;;A61B18/00,,0,0,,,,PENDING
610,GB,B,GB 2335679 B,082-216-449-719-187,2000-09-13,2000,GB 9806492 A,1998-03-27,GB 9806492 A,1998-03-27,Gelling composition based on monomeric viscoelastic surfactants for wellbore service fluids,,SOFITECH NV,DAVIES STEPHEN NIGEL;;JONES TIMOTHY GARETH JOHN;;TUSTIN GARY JOHN,,https://lens.org/082-216-449-719-187,Granted Patent,no,3,6,8,8,0,C09K8/5753;;C09K8/5756;;C09K8/5756;;C09K8/5753,C09K8/575,E1F FGP           FGP;;E1F FPA           FPA;;E1F FPC           FPC,0,0,,,,EXPIRED
611,US,B2,US 7878004 B2,136-251-456-003-209,2011-02-01,2011,US 78873307 A,2007-04-20,US 78873307 A;;US 79373806 P,2006-04-20,Method and device for optimizing a light-up procedure of a gas turbine engine,"An aspect of the invention is directed towards a method and device for optimizing a light-up procedure of a gas turbine engine. An aspect of the method comprises repeating an engine start attempt with amended light-up parameter values or range of light-up parameter values, where the values are amended by a predefined scheme including recording the light-up parameter value or the range of light-up parameter values of each start attempt together with the light-up success rate achieved in the respective start attempts, and optimizing the light-up parameter value or range of parameter values by analyzing the recorded data after the start attempts have been finished. An aspect of the device is to provide a control unit that implements the inventive method.",SIEMENS AG,DAVIES GARETH;;NODEN RICHARD;;SKIPPER DORIAN;;WILKINSON JOHN;;WOODS RICHARD,SIEMENS AKTIENGESELLSCHAFT (2007-03-26);;SIEMENS ENERGY GLOBAL GMBH & CO. KG (2021-02-28),https://lens.org/136-251-456-003-209,Granted Patent,yes,8,11,2,2,0,F02C7/26;;F02C7/26;;F02C7/22;;F02C7/22;;F02C7/262;;F02C7/262,F02C7/22;;F02C7/26,60/778;;60/39.13;;60/790,0,0,,,,ACTIVE
612,AT,T1,AT E495174 T1,170-990-468-845-317,2011-01-15,2011,AT 08750663 T,2008-05-21,GB 0710121 A;;GB 2008001738 W,2007-05-25,"2-OXO-2-(2-PHENYL-5,6,7,8-TETRAHYDROINDOLIZIN-3 YL)ACETAMIDDERIVATE UND VERWANDTE VERBINDUNGEN ALS ANTIPILZMITTEL","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,PAYNE LLOYD;;DOWNHAM ROBERT;;SIBLEY GRAHAM;;EDWARDS PHILIP;;DAVIES GARETH,,https://lens.org/170-990-468-845-317,Granted Patent,no,0,0,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,,,0,0,,,,INACTIVE
613,US,B2,US 9597146 B2,024-669-551-455-091,2017-03-21,2017,US 201113113326 A,2011-05-23,US 201113113326 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 52275304 P,2003-01-21,Method of surgical perforation via the delivery of energy,"Apparatuses and methods for the perforation of heart tissue of a patient when an inferior approach to the heart is contraindicated are disclosed. The method includes using a superior approach to introduce the apparatus, positioning the apparatus at a tissue location and delivering a controlled amount of non-mechanical energy to the tissue to create a perforation. For example, a method of surgical perforation via the delivery of electrical, radiant or thermal energy may include: introducing an apparatus comprising an energy delivery device into a patient's heart via the patient's superior vena cava; positioning the energy delivery device at a first location adjacent material to be perforated; and perforating the material by delivering energy via the energy delivery device; wherein the energy is selected from the group consisting of electrical energy, radiant energy and thermal energy.",DAVIES GARETH;;HARTLEY AMANDA;;VISRAM NAHEED;;SHAH KRISHAN;;BAYLLS FRANK;;BAYLIS MEDICAL CO INC,DAVIES GARETH;;HARTLEY AMANDA;;VISRAM NAHEED;;SHAH KRISHAN;;BAYLLS FRANK,BAYLIS MEDICAL COMPANY INC (2011-04-18);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/024-669-551-455-091,Granted Patent,yes,54,11,2,113,0,A61B18/1206;;A61B18/24;;A61B2018/00351;;A61B2018/00839;;A61B2090/064;;A61B2090/3966;;A61B18/1492;;A61B18/1206;;A61B18/24;;A61B2018/00351;;A61B2018/00839;;A61B2090/064;;A61B2090/3966;;A61B18/1492,A61B18/14;;A61B18/00;;A61B18/12;;A61B18/24,,39,21,007-454-134-946-40X;;012-647-127-487-753;;015-569-231-826-071;;006-495-373-391-557;;126-172-010-773-649;;053-709-812-994-938;;022-286-573-136-47X;;061-080-657-413-13X;;079-220-343-462-372;;102-284-308-414-898;;087-966-302-747-022;;020-214-294-476-433;;113-591-253-296-335;;022-127-515-170-102;;066-004-459-025-109;;038-743-504-882-104;;056-565-923-253-058;;044-496-843-651-986;;064-062-639-916-470;;003-336-720-517-736;;096-535-125-477-640,11733820;;10.1590/s0066-782x2001001100008;;11979539;;10.1002/ccd.10213;;8504569;;10.1002/clc.4960160502;;11553955;;10.1002/ccd.1244;;10.1023/a:1009870227401;;11248781;;9768726;;10.1016/s0735-1097(98)00357-x;;11094817;;10.1007/bf02345756;;10.1017/s1047951103000398;;12887081;;12885744;;10.1161/01.cir.0000084548.44131.d1;;10.1002/ccd.10602;;12929108;;12929107;;10.1002/ccd.10605;;12838844;;10.1136/heart.86.5.e11;;11602562;;pmc1729980;;1764747;;10.1002/ccd.1810240318;;10700071;;10.1002/(sici)1522-726x(200003)49:3<335::aid-ccd24>3.0.co;2-n;;12410514;;10.1002/ccd.10358;;10.1002/(sici)1097-0304(199710)42:2<219::aid-ccd30>3.0.co;2-g;;9328715;;12772256;;10.1002/ccd.10560;;12772255;;10.1002/ccd.10506;;10216007;;10.1002/(sici)1522-726x(199904)46:4<425::aid-ccd7>3.0.co;2-r;;12112899;;10.1002/ccd.10222,"CA Pedra, LN De Sousa, SR Pedra, WP Ferreira, SL Braga, CA Esteves, MV Santant, JE Sousa, VF Fontes. ""New Percutaneous Techniques for Perforating the Pulmonary Valve in Pulmonary Atresia with Intact Ventricular Septum"". Arq. Bras Cariol. 77(5):471-478 (2001).;;DG Nykanen, J Phikala, GP Taylor, LN Benson. ""Radiofrequency Assisted Perforation of the Atrial septum in a Swine Model: Feasibility, Biophysical and Histological Characteristics"". Circulation. 100(Suppl 1):1-804 (1999).;;Baylis Medical Company Inc. ""Radio Frequency Perforation System"". Product Brochure, Published in Canada. 2001.;;Benson, Lee N., David Nykanen, Amanda Collison. ""Radiofrequency Perforation in the Treatment of Congenital Heart Disease"". Catheterizations and Cardiovascular Interventions. 56: 72-82 Jan. 2002.;;Conti C.R. ""Transseptal Left Heart Catheterization for Radiofrequency Ablation of Accessory Pathways"". Clinical Cardiology. 16: 367-368 (1993).;;Justino, Henri, Lee N. Benson, David G. Nykanen. ""Transcatheter Creation of an Atrial Septal Defect Using Radiofrequency Perforation"". Catheterization and Cardiovascular Interventions. 56: 412-415 May 2002.;;Kamal K. Sethi, Jagdish C. Mohan. ""Editorial Comment: Transseptal Catheterization for the Electrophysiologist: Modification with a 'View'"". Journal of Interventional Cardian Physiology. 5: 97-99 (2001).;;Christodoulos Stefanadis. ""Retrograde Nontransseptal Balloon Mitral Valvuloplasty: Immediate Results and Intermediate Long-term Outcome in 441 Cases-A Multicentre Experience"". Journal of the American College of Cardiology. 32(4):1009-16 (1998).;;N. Shimko, P. Savard, K. Shah. ""Radiofrequency Perforation of Cardiac Tissue: Modeling and Experimental Results"". Med. Biol. Eng. comput. 38:575-582 (2000).;;Boston Scientific Corporation. ""http://www.bostonscientific.com/med-specialty/deviceDetail.sp?task=tskBasicDevice.jsp&sectionid=4&relld=1,20,21,22&deviceid=1888&uniqueid=MP0858"". Explorer ST Catheters. 2 pages. (Date of Printing-Jun. 2005).;;Boston Scientific Corporation. ""http://www.bostonscientific.com/med-specialty/deviceDetail.sp?task=tskBasicDevice.jsp&sectionid=4&relld=2,74,75,76&deviceid=556&uniqueid=MPDB4320"". Impulse Angiographic Catheter. 2 pages. (Date of Printing-Jun. 2005).;;Boston Scientific Corporation. ""http://www.bostonscientific.com/med-specialty/deviceDetail.sp?task=tskBasicDevice.jsp&sectionid=4&relld=2,74,75,76&deviceid=11026&uniqueid=MPDB2799"". PT2 Guidewires. 2 pages. (Date of Printing-Jun. 2005).;;IntraLuminal Therapeutics, Inc. ""http://www.intraluminal.com/products/catheter.html"". Safe Cross Support Catheter. 1 page. (Date of Printing-Jun. 2005).;;Lake Region Manufacturing, Inc. ""http://www.lakergn.com/jmc.htm"". Paragon Guidewire. 2 pages (Date of Printing-Jun. 2005).;;Medtronic Inc. ""http://www.medtronic.com/epsystems/diagnostic-catheters.html"". Diagnostic Catheters. 7 pages (Date of Printing-Apr. 2005).;;Johnson & Johnson Gateway, LLC. ""http://www.jnjgateway.com/home.html?loc=USENG&page=viewcontent&contentid=ic0de00100001135&nodekey=/prod-info/Specialty/arrhythmia-management/electrophysiology/EP-diagnostic-catheters"". EP Diagnostic Catheters. 2 pages. (Date of printing-Jun. 2005).;;Johnson & Jonhson Gateway, LLC. ""http://www.jnjgateway.com/home.html.sessionid=JNSFHTWOAOIC0CQPCCECPJYKB2WNSC?loc=USENGA&page=viewcontent&contentid=ic0de00100000524&nodekey=/prod-info/specialty/cardiovascular-and-thoracic/cardiac-diagnosis-interventions/diagnostic-wires&request=228905"". Diagnostic Guidewires. 4 pages (Date of Printing-Jun. 2005).;;T Abdel-Massih, Y Boudjemline, P Bonhoeffer. ""Unusual Interventional Management in an Adult with Tetraogy of Fallot"". Cardiol Young. 13(2):2003-2005. Apr. 2003.;;T Humpl, B Soderberg, BW McCrindle, DG Nykanen, RM Freedom, WG Williams, LN Benson. ""Percutaneous Balloon Valvotomy in Pulmonary Atresia with Intact Ventricular Septum: Impact on Patient Care"". Circulation. 108(7): 826-832 (Aug. 2003).;;CA Pedra, RM Filho, RS Arrieta, R Tellez, VF Fontes. ""Recanalizationof a discrete atretic right pulmonary artery segment with a new radiofrequency system"". Catheter Cardiovasc. Interv. 60(1):82-87 (Sep. 2003).;;HW Kort, DT Balzer. ""Radiofrequency perforation in the treatment of acquired left pulmonary atresia following repair of tetralogy of fallot"". Catheter Cardiovasc. Interv. 60(1): 79-81 (Sep. 2003).;;G. Veldtman, A Peirone, LN Benson. ""Radiofrequency perforation of the atrial system: Preliminary experimental evaluation and development."" PICS VII Abstracts. Catheter Cardiovasc. Interv. 60(1):132 (Sep. 2003).;;F. Godart, C. Francart, GM Breviere, C Rey. ""Pulmonary valvulotomy with the Nykanen Radiofrequency guide in pulmonary atresia with intact interventricular septum"". Arch Mal Couer Vaiss. 86(5):517-520 (May 2003). Article is in French with English Summary.;;T. Szili-Torok, G.P. Kimman, D. Theuns, J. Res, J.R.T.C. Roelandt, L.J. Jordaens. ""Transseptal Left heart Catheterization Guided by Intracardiac Echocardiography"". Heart 2001; 86: e11.;;Hector Biddogia, Juan P. Maciel, Jose A. Alvarez et al. ""Transseptal Left Heart Catheterization: Usefulness of the Intracavitary Electrocardiogram in the Localization of the Fossa Ovalis"". Catheterization and Cardiovascular Diagnosis 24: 221-225 (1991).;;George Joseph,G. Rajendiran, K. Abhaichand Rajpal. ""Transjugular Approach to Concurrent Mitral-Aortic and Mitral-Tricuspid Balloon Valvuloplasty"". Catheterization and Cardiovascular Interventions 49:335-341 (2000).;;George Joseph, Oommen K. George, Asishkumar Mandalay, Sunil Sathe. ""Transjugular Approach to Balloon Mitral Valvuloplasty Helps Overcome Impediments Caused by Anatomical Alterations"". Catheterization and Cardiovascular Interventions 57:353-362 Mar. 2002.;;George Joseph, Dibya K. Baruah, Sajy V. Kuruttukulam, Sunil Thomas Chandy, Shanker Krishnaswami. ""Transjugular Approach to Transseptal Balloon Mitral Valvuloplasty"". Catheterization and Cardiovascular Diagnosis 42:219-226 (1997).;;Tsung O. Cheng. ""All Roads Lead to Rome:Transjugular or Transfemoral Approach to Percutaneous Transseptal Balloon Mitral Valvuloplasty?"". Catheterization and Cardiovascular Interventions 59:266-267 (Jun. 2003).;;J. Thompson Sullebarger, Humberto Coto, Enrique Lopez, Dany Sayad, Hector L. Fontanet.""Transjugular Percutaneous Inoue Balloon Mitral Commissurotomy in a Patient With Inferior Vena Cava Obstruction After Liver Transplantation"". Catheterization and Cardiovascular Interventions 59:261-265 (Jun. 2003).;;George Joseph, K.P. Suresh Kumar, Paul V. George, Subodh Dhanawade. ""Right Internal Jugular Vein Approach as an Alternative in Balloon Pulmonary Valvuloplasty"". Catheterization and Cardiovascular Interventions 46:425-429 (1999).;;Pressure Products, Inc. http://www.pressure-products.com/Downloads/Education-PDFs/Using-CSG-v2.pdf. 4 pages. (first printed Mar. 2005).;;Gideon J. Du Marchie Sarvaas, MD, Kalyani R. Trivedi, MD, Lisa K. Hornberger, MD, K. Jin Lee, MD, Joel A. Kirsh, MD and Lee N. Benson, MD. ""Radiofrequency-Assisted Atrial Septoplasty for an Intact Atrial Septum in Complex Congenital Heart Disease"". Catheterization and Cardiovascular Interventions 56:412-415 Feb. 2002.;;U.S. Appl. No. 11/265,304 Non Final Action Jul. 22, 2010, ""Mailed on Jul. 22, 2010"".;;U.S. Appl. No. 11/265,304 Non Final Action Jun. 26, 2009, ""Mailed on Jun. 26, 2009"".;;U.S. Appl. No. 11/265,304 Non Final Action Feb. 5, 2010, ""Mailed on Feb. 5, 2010"".;;U.S. Appl. No. 11/265,304 Response to Office Action Oct. 19, 2010, ""Mailed on Oct. 19, 2010"".;;U.S. Appl. No. 11/265,304 Response to Office Action Oct. 26, 2009, ""Mailed on Oct. 26, 2009"".;;U.S. Appl. No. 11/265,304 Response to Office Action May 17, 2010, ""Mailed on May 17, 2010"".",ACTIVE
614,US,B2,US 9226788 B2,109-215-967-961-380,2016-01-05,2016,US 201314100468 A,2013-12-09,US 201314100468 A;;US 201113286041 A;;US 90544807 A;;US 82746606 P;;US 201161448578 P,2006-09-29,Fenestration through foreign material,"Described herein is a method for creating a channel through a foreign material located in a body of a patient. The foreign material defines a material first surface and a substantially opposed material second surface and the channel extends through the foreign material between the material first and second surfaces. The method uses an apparatus including an electrode, and includes the steps of: positioning the electrode substantially adjacent to the material first surface; energizing the electrode with a radiofrequency current; and using the electrode energized with the radiofrequency current to deliver energy into the foreign material to create the channel. In some embodiments, the patient's body includes a heart defining a septum, the septum defines an aperture extending there-through and the foreign material extends across the aperture to cover the aperture.",BAYLIS MEDICAL CO INC,BIADILLAH YOUSSEF;;HARTLEY AMANDA;;DAVIES GARETH;;VISRAM NAHEED;;JUZKIW TARAS,BAYLIS MEDICAL COMPANY INC (2013-12-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/109-215-967-961-380,Granted Patent,yes,3,0,4,113,0,A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00827;;A61B2018/00875;;A61B2018/00898;;A61B2090/3966;;A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00827;;A61B2018/00875;;A61B2018/00898;;A61B2090/3966;;A61B18/04,A61B18/18;;A61B8/12;;A61B18/00;;A61B18/04;;A61B18/14,,0,0,,,,ACTIVE
615,US,A1,US 2009/0097015 A1,170-567-714-472-192,2009-04-16,2009,US 24130308 A,2008-09-30,US 24130308 A;;US 97988007 P,2007-10-15,MEASURING A CHARACTERISTIC OF A MULTIMODE OPTICAL FIBER,"To measure a characteristic of a multimode optical fiber, a light pulse source produces a light pulse for transmission into the multimode optical fiber. A spatial filter passes a portion of Brillouin backscattered light from the multimode optical fiber that is responsive to the light pulse. Optical detection equipment detects the portion of the Brillouin backscattered light passed by the spatial filter.",SCHLUMBERGER TECHNOLOGY CORP,DAVIES DYLAN;;HARTOG ARTHUR H;;HILTON GRAEME;;LEES GARETH P,SCHLUMBERGER TECHNOLOGY CORPORATION (2008-10-06),https://lens.org/170-567-714-472-192,Patent Application,yes,18,45,5,5,0,G01B11/16;;G01D5/353;;G01K11/32;;G01L1/242;;G01K11/32;;G01K11/32;;G01D5/35364;;G01D5/35364;;G01M11/319;;G01M11/319,G01N21/17,356/73.1,0,0,,,,ACTIVE
616,US,A1,US 2022/0000537 A1,137-939-969-906-704,2022-01-06,2022,US 202117480804 A,2021-09-21,US 202117480804 A;;US 201715532402 A;;IB 2015059337 W;;US 201462087141 P,2014-12-03,Devices and Methods for Electrosurgical Navigation,"A method and apparatus or system are disclosed for a procedure with minimal or no fluoroscopy, for example an electrosurgical procedure, and which uses a three dimensional mapping system. The procedure typically involves electrical measurement of the electrode of a needle to determine its position. Some embodiments further include intracardiac echocardiography (ICE) for tracking devices. The apparatus includes a needle with a tip electrode, an electroanatomical mapping (EAM) system, and an electrical generator, wherein a switching device is used to restrictively electrically connect the needle to only one of the mapping system or generator at a given time.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;HARFIELD ELLEN;;HORTON RODNEY;;WELLS DAVID;;WOO JASON,BAYLIS MEDICAL COMPANY INC (2015-12-08);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/137-939-969-906-704,Patent Application,yes,0,0,3,3,0,A61B18/1477;;A61B18/1492;;A61B2018/00357;;A61B2018/00577;;A61B2018/00601;;A61B2018/00791;;A61B2018/00827;;A61B2018/00839;;A61B2018/00875;;A61B2018/00892;;A61B2218/002;;A61B2218/007;;A61B34/20;;A61B2034/2051;;A61B18/1233;;A61B18/1477;;A61B18/1492;;A61B2018/00357;;A61B2018/00577;;A61B2018/00601;;A61B2018/00791;;A61B2018/00827;;A61B2018/00839;;A61B2018/00875;;A61B2018/00892;;A61B2218/002;;A61B2218/007;;A61B34/20;;A61B2034/2051;;A61B5/304;;A61B5/283;;A61B5/361;;A61B18/1233;;A61B5/0536;;A61B2017/00053;;A61B2018/00172;;A61B2018/00178;;A61B2018/0091,A61B18/12;;A61B5/304;;A61B5/308;;A61B5/361;;A61B34/20,,0,0,,,,PENDING
617,AT,T1,AT E420639 T1,054-173-122-391-367,2009-01-15,2009,AT 06743919 T,2006-05-18,GB 0510190 A;;GB 0607841 A,2005-05-18,ANTIMYKOTISCHE MITTEL,"Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: R1, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,THOMSON SAMANTHA PATRICIA;;EDWARDS PHILIP NEIL;;DAVIES GARETH;;KUVSHINOV ALEXANDRE;;ALLANSON NIGEL MARK;;DAVIES RHIAN TERESA,,https://lens.org/054-173-122-391-367,Granted Patent,no,0,0,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,,,0,0,,,,INACTIVE
618,US,A1,US 2021/0275246 A1,136-291-290-707-13X,2021-09-09,2021,US 202117316229 A,2021-05-10,US 202117316229 A;;US 201916346404 A;;IB 2017056777 W;;US 202063022793 P;;US 201662415913 P,2016-11-01,Methods and Devices for Puncturing Tissue,"Methods and devices are disclosed for delivering a therapy device during a cardiology procedure. The method includes a step of advancing a radiofrequency guidewire into a right atrium of the heart of a patient. A sheath and dilator are advanced over the radiofrequency guidewire. The distal tip of the radiofrequency guidewire is then positioned on the septum. The septum is then punctured by energizing the radiofrequency guidewire and advancing it through the septum. The dilator is then advanced across the septum, overtop the guidewire, dilating the septum. The radiofrequency guidewire and dilator are withdrawn, and an end therapy device is inserted.",BAYLIS MEDICAL CO INC,MORIYAMA EDUARDO;;URBANSKI JOHN PAUL;;LEUNG CHARLENE;;LEUNG JACKIE;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC (2021-10-12);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/136-291-290-707-13X,Patent Application,yes,7,1,1,17,0,A61B2017/00247;;A61B2090/378;;A61B2090/376;;A61B18/1492;;A61B2018/00839;;A61B2018/00601;;A61B2018/00357;;A61B2090/065;;A61B2090/3966;;A61B2017/00243;;A61B2090/3925;;A61B17/3478;;A61B2017/22079;;A61B2017/308;;A61B2017/22044;;A61M29/00;;A61B18/1492;;A61M29/00;;A61B2017/00247;;A61B17/3468;;A61B2090/064;;A61B2090/376;;A61B2090/378;;A61M2025/09183;;A61B2018/00357;;A61B2018/00839,A61B18/14;;A61M29/00,,0,0,,,,PENDING
619,WO,A3,WO 2000/005224 A3,171-378-151-453-230,2001-08-09,2001,GB 9902342 W,1999-07-20,GB 9815971 A;;GB 9815973 A,1998-07-23,HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITOR,"Compound of formula (I) wherein: A is a bicyclic heteroaryl, optionally substituted with one or more substituents; B is linker group connecting group A to group D and comprising a 3 or 4 atom linker where each atom is independently selected from carbon, oxygen, nitrogen and sulphur and is optionally subsituted with one or more C1-6 alkyl groups or two of such adjacent alkyl substituents may form a ring; C is aryl or a mono or bicyclic heteroaryl, each of which can be optionally substituted; D is an aryl or heteroaryl, both of which are optionally substituted R1 is hydrogen, C¿1-5? alkyl, C1-3 alkanoyl or C1-3 alkoxycarbonyl; R?2 to R5¿ are each independently selected from hydrogen, C¿1-6? alkyl, aryl and heteroaryl containing up to 2 heteroatoms chosen from oxygen, sulphur and nitrogen, the aryl and heteroaryl optionally substituted with C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 alkoxy, C1-4 alkanoyl, C1-6 alkylamino, C1-4alkylC1-6alkyoxyl, C1-6alkylaminoC1-6alkyl, nitro, cyano, halogeno, trifluoromethyl, hydroxy, (CH2)pOH where p is 1 or 2, -CO2R?a¿, and -CONRaRb, where R?a and Rb¿ are independently selected from hydrogen and C¿1-6? alkyl or two of R?2 to R5¿ can be taken together to form a 3 to 7 membered ring; R6 is an acidic functional group; r and s are each independently 0 or 1 with the proviso that r and s cannot both be 0; or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof.",ASTRAZENECA AB;;BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,,https://lens.org/171-378-151-453-230,Search Report,yes,4,0,12,14,0,C07D263/58;;C07D413/04;;A61P1/00;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D263/58;;C07D413/04,A61K31/423;;A61K31/428;;A61K31/4427;;C07D277/82;;A61P1/00;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;C07D263/58;;C07D413/04;;C07D413/12,,0,0,,,,PATENTED
620,BR,A2,BR 112015006265 A2,065-088-503-502-49X,2017-07-04,2017,BR 112015006265 A,2013-09-24,US 2013/0061468 W;;US 201261705711 P,2012-09-26,"enrijecedor à flexão, método para preparar uma luva de enrijecedor à flexão flexível e método para ligar um cano flexível","resumo enrijecedor à flexão, método para preparar uma luva de enrijecedor à flexão flexível e método para ligar um cano flexível um enrijecedor à flexão que compreende: (i) uma luva polimérica flexível tendo um orifício axial para receber um membro flexível alongado e (ii) meios de ligação para ligar a luva a um suporte. pelo menos uma porção da luva polimérica flexível é um elastômero de poliuretano produzido em uma reação de um pré-polímero com terminação isocianato e um agente de cura a um índice de isocianato de 90 a 120. o pré-polímero com terminação isocianato tem um teor de isocianato de 7 a 15% em peso, sendo um produto de reação de pelo menos um poliisocianato aromático e pelo menos um poliéter poliol tendo um peso equivalente de hidroxila de 350 a 2000 e uma funcionalidade nominal de 2 a 2,3. o agente de cura é um ou mais extensores de cadeia tendo um peso equivalente por grupo reativo com isocianato de até 125 ou uma mistura contendo um ou mais desses extensores de cadeia e um ou mais poliéter polióis tendo um peso equivalente de hidroxila de 350 a 2000 e uma funcionalidade nominal de 2 a 2,3. o teor de segmento duro do elastômero de poliuretano tem de 40 a 60% em peso.",DOW GLOBAL TECHNOLOGIES LLC,ANDREW MARTIN DAVIES;;GARETH ROBERTS;;IAN ROBERT MYCOCK;;ROBERT M MOSS,,https://lens.org/065-088-503-502-49X,Patent Application,no,0,0,11,11,0,C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;C08G18/10;;C08G18/3206;;C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;B29C31/10;;B29K2075/00,C08G18/10;;C08G18/32;;C08G18/48;;C08G18/76;;E21B17/01;;H02G15/20,,0,0,,,,PENDING
621,US,A1,US 2006/0142756 A1,070-555-419-865-31X,2006-06-29,2006,US 26530405 A,2005-11-03,US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 52275304 P,2003-01-21,Method of surgical perforation via the delivery of energy,"A method of surgical perforation via the delivery of electrical, radiant or thermal energy comprising the steps of: introducing an apparatus comprising an energy delivery device into a patient's heart via the patient's superior vena cava; positioning the energy delivery device at a first location adjacent material to be perforated; and perforating the material by delivering energy via the energy delivery device; wherein the energy is selected from the group consisting of electrical energy, radiant energy and thermal energy.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;HARTLEY AMANDA A;;VISRAM NAHEED;;SHAH KRISHAN;;BAYLIS FRANK,BAYLIS MEDICAL COMPANY INC (2006-03-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/070-555-419-865-31X,Patent Application,yes,47,72,2,113,0,A61B18/1492;;A61B18/1492;;A61B18/24;;A61B18/24;;A61B2018/00351;;A61B2018/00351,A61B18/18,606/45,0,0,,,,EXPIRED
622,EP,A3,EP 1144393 A3,000-244-537-745-063,2002-09-11,2002,EP 99934897 A,1999-07-20,GB 9902342 W;;GB 9815971 A;;GB 9815973 A,1998-07-23,HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITOR,"Compound of formula (I) wherein: A is a bicyclic heteroaryl, optionally substituted with one or more substituents; B is linker group connecting group A to group D and comprising a 3 or 4 atom linker where each atom is independently selected from carbon, oxygen, nitrogen and sulphur and is optionally subsituted with one or more C1-6 alkyl groups or two of such adjacent alkyl substituents may form a ring; C is aryl or a mono or bicyclic heteroaryl, each of which can be optionally substituted; D is an aryl or heteroaryl, both of which are optionally substituted R1 is hydrogen, C1-5 alkyl, C1-3 alkanoyl or C1-3 alkoxycarbonyl; R2 to R5 are each independently selected from hydrogen, C1-6 alkyl, aryl and heteroaryl containing up to 2 heteroatoms chosen from oxygen, sulphur and nitrogen, the aryl and heteroaryl optionally substituted with C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 alkoxy, C1-4 alkanoyl, C1-6 alkylamino, C1-4alkylC1-6alkyoxyl, C1-6alkylaminoC1-6alkyl, nitro, cyano, halogeno, trifluoromethyl, hydroxy, (CH2)pOH where p is 1 or 2, -CO2Ra, and -CONRaRb, where Ra and Rb are independently selected from hydrogen and C1-6 alkyl or two of R2 to R5 can be taken together to form a 3 to 7 membered ring; R6 is an acidic functional group; r and s are each independently 0 or 1 with the proviso that r and s cannot both be 0; or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof.",ASTRAZENECA AB,BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,,https://lens.org/000-244-537-745-063,Search Report,yes,0,0,12,14,0,C07D263/58;;C07D413/04;;A61P1/00;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D263/58;;C07D413/04,C07D277/82;;A61K31/423;;A61K31/428;;A61K31/4427;;A61P1/00;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;C07D263/58;;C07D413/04;;C07D413/12,,0,0,,,,EXPIRED
623,EP,B1,EP 2900720 B1,024-044-698-286-579,2017-03-08,2017,EP 13771742 A,2013-09-24,US 201261705711 P;;US 2013/0061468 W,2012-09-26,POLYURETHANE BEND STIFFENER,,DOW GLOBAL TECHNOLOGIES LLC,MOSS ROBERT M;;MYCOCK IAN ROBERT;;ROBERTS GARETH;;DAVIES ANDREW MARTIN,,https://lens.org/024-044-698-286-579,Granted Patent,yes,2,0,11,11,0,C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;C08G18/10;;C08G18/3206;;C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;B29C31/10;;B29K2075/00,C08G18/48;;C08G18/10;;C08G18/32;;C08G18/76;;E21B17/01;;H02G15/20,,0,0,,,,ACTIVE
624,US,B2,US 9339948 B2,119-826-904-734-012,2016-05-17,2016,US 201314427250 A,2013-09-24,US 201314427250 A;;US 201261705711 P;;US 2013/0061468 W,2012-09-26,Polyurethane bend stiffener,A bend stiffener comprises a (i) a flexible polymeric sleeve having an axial bore for receiving an elongated flexible member and (ii) attachment means for attaching the sleeve to a support. At least a portion of the flexible polymeric sleeve is a polyurethane elastomer produced in a reaction of an isocyanate-terminated prepolymer and a curing agent at an isocyanate index of 90 to 120. The isocyanate-terminated prepolymer has an isocyanate content of 7 to 15% by weight and is a reaction product of at least one aromatic polyisocyanate and at least one polyether polyol having a hydroxyl equivalent weight of 350 to 2000 and a nominal functionality of 2 to 2.3. The curing agent is one or more chain extenders having an equivalent weight per isocyanate-reactive group of up to 125 or a mixture of one or more such chain extenders and one or more polyether polyols having a hydroxyl equivalent weight of 350 to 2000 and a nominal functionality of 2 to 2.3. The hard segment content of the polyurethane elastomer is from 40 to 60% by weight.,MOSS ROBERT M;;MYCOCK IAN ROBERT;;ROBERTS GARETH;;DAVIES ANDREW MARTIN;;DOW GLOBAL TECHNOLOGIES LLC,MOSS ROBERT M;;MYCOCK IAN ROBERT;;ROBERTS GARETH;;DAVIES ANDREW MARTIN,HYPERLAST LIMITED (2013-01-29);;THE DOW CHEMICAL COMPANY (2013-04-10);;DOW GLOBAL TECHNOLOGIES INC (2013-04-26),https://lens.org/119-826-904-734-012,Granted Patent,yes,16,1,11,11,0,C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;C08G18/10;;C08G18/3206;;C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;B29C31/10;;B29K2075/00,E21B17/01;;B29C31/10;;B29K75/00;;C08G18/48;;C08G18/76;;H02G9/02;;H02G9/12,,1,0,,,"Hepburn, ""Trends in Polyurethane Elastomer Technology"", Iranian J. Polym. Sci. and Technol. vol. 1. Aug. 1992.",ACTIVE
625,US,A1,US 2015/0246465 A1,116-863-271-790-535,2015-09-03,2015,US 201314427250 A,2013-09-24,US 201314427250 A;;US 201261705711 P;;US 2013/0061468 W,2012-09-26,Polyurethane Bend Stiffener,A bend stiffener comprises a (i) a flexible polymeric sleeve having an axial bore for receiving an elongated flexible member and (ii) attachment means for attaching the sleeve to a support. At least a portion of the flexible polymeric sleeve is a poly-urethane elastomer produced in a reaction of an isocyanate- terminated prepolymer and a curing agent at an isocyanate index of 90 to 120. The isocyanate-terminated prepolymer has an isocyanate content of 7 to 15% by weight and is a reaction product of at least one aromatic polyisocyanate and at least one polyether polyol having a hydroxyl equivalent weight of 350 to 2000 and a nominal functionality of 2 to 2.3. The curing agent is one or more chain extenders having an equivalent weight per isocyanate-reactive group of up to 125 or a mixture of one or more such chain extenders and one or more polyether polyols having a hydroxyl equivalent weight of 350 to 2000 and a nominal functionality of 2 to 2.3. The hard segment content of the polyurethane elastomer is from 40 to 60% by weight.,DOW GLOBAL TECHNOLOGIES LLC,MOSS ROBERT M;;MYCOCK IAN ROBERT;;ROBERTS GARETH;;DAVIES ANDREW MARTIN,HYPERLAST LIMITED (2013-01-29);;THE DOW CHEMICAL COMPANY (2013-04-10);;DOW GLOBAL TECHNOLOGIES INC (2013-04-26),https://lens.org/116-863-271-790-535,Patent Application,yes,7,1,11,11,0,C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;C08G18/10;;C08G18/3206;;C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;B29C31/10;;B29K2075/00,E21B17/01;;B29C31/10,,0,0,,,,ACTIVE
626,CN,A,CN 104822723 A,042-260-539-362-502,2015-08-05,2015,CN 201380061332 A,2013-09-24,US 2013/0061468 W;;US 201261705711 P,2012-09-26,Polyurethane bend stiffener,A bend stiffener comprises a (i) a flexible polymeric sleeve having an axial bore for receiving an elongated flexible member and (ii) attachment means for attaching the sleeve to a support. At least a portion of the flexible polymeric sleeve is a polyurethane elastomer produced in a reaction of an isocyanate- terminated prepolymer and a curing agent at an isocyanate index of 90 to 120. The isocyanate-terminated prepolymer has an isocyanate content of 7 to 15% by weight and is a reaction product of at least one aromatic polyisocyanate and at least one polyether polyol having a hydroxyl equivalent weight of 350 to 2000 and a nominal functionality of 2 to 2.3. The curing agent is one or more chain extenders having an equivalent weight per isocyanate-reactive group of up to 125 or a mixture of one or more such chain extenders and one or more polyether polyols having a hydroxyl equivalent weight of 350 to 2000 and a nominal functionality of 2 to 2.3. The hard segment content of the polyurethane elastomer is from 40 to 60% by weight.,DOW GLOBAL TECHNOLOGIES INC,MOSS ROBERT M;;MYCOCK IAN ROBERT;;ROBERTS GARETH;;DAVIES ANDREW MARTIN,,https://lens.org/042-260-539-362-502,Patent Application,no,4,1,11,11,0,C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;C08G18/10;;C08G18/3206;;C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;B29C31/10;;B29K2075/00,C08G18/48;;C08G18/10;;C08G18/32;;C08G18/76;;E21B17/01;;H02G15/20,,0,0,,,,INACTIVE
627,WO,A2,WO 2014/052331 A2,157-303-597-298-286,2014-04-03,2014,US 2013/0061468 W,2013-09-24,US 201261705711 P,2012-09-26,POLYURETHANE BEND STIFFENER,A bend stiffener comprises a (i) a flexible polymeric sleeve having an axial bore for receiving an elongated flexible member and (ii) attachment means for attaching the sleeve to a support. At least a portion of the flexible polymeric sleeve is a polyurethane elastomer produced in a reaction of an isocyanate- terminated prepolymer and a curing agent at an isocyanate index of 90 to 120. The isocyanate-terminated prepolymer has an isocyanate content of 7 to 15% by weight and is a reaction product of at least one aromatic polyisocyanate and at least one polyether polyol having a hydroxyl equivalent weight of 350 to 2000 and a nominal functionality of 2 to 2.3. The curing agent is one or more chain extenders having an equivalent weight per isocyanate-reactive group of up to 125 or a mixture of one or more such chain extenders and one or more polyether polyols having a hydroxyl equivalent weight of 350 to 2000 and a nominal functionality of 2 to 2.3. The hard segment content of the polyurethane elastomer is from 40 to 60% by weight.,DOW GLOBAL TECHNOLOGIES LLC,MOSS ROBERT M;;MYCOCK IAN ROBERT;;ROBERTS GARETH;;DAVIES ANDREW MARTIN,,https://lens.org/157-303-597-298-286,Patent Application,yes,0,3,11,11,0,C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;C08G18/10;;C08G18/3206;;C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;B29C31/10;;B29K2075/00,C08L75/08,,0,0,,,,PENDING
628,EP,B1,EP 1144393 B1,183-627-908-257-400,2004-02-11,2004,EP 99934897 A,1999-07-20,GB 9902342 W;;GB 9815971 A;;GB 9815973 A,1998-07-23,BENZOXAZOLE DERIVATIVES FOR USE AS INTEGRIN INHIBITORS,"Compound of formula (I) wherein: A is a bicyclic heteroaryl, optionally substituted with one or more substituents; B is linker group connecting group A to group D and comprising a 3 or 4 atom linker where each atom is independently selected from carbon, oxygen, nitrogen and sulphur and is optionally subsituted with one or more C1-6 alkyl groups or two of such adjacent alkyl substituents may form a ring; C is aryl or a mono or bicyclic heteroaryl, each of which can be optionally substituted; D is an aryl or heteroaryl, both of which are optionally substituted R1 is hydrogen, C1-5 alkyl, C1-3 alkanoyl or C1-3 alkoxycarbonyl; R2 to R5 are each independently selected from hydrogen, C1-6 alkyl, aryl and heteroaryl containing up to 2 heteroatoms chosen from oxygen, sulphur and nitrogen, the aryl and heteroaryl optionally substituted with C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 alkoxy, C1-4 alkanoyl, C1-6 alkylamino, C1-4alkylC1-6alkyoxyl, C1-6alkylaminoC1-6alkyl, nitro, cyano, halogeno, trifluoromethyl, hydroxy, (CH2)pOH where p is 1 or 2, -CO2Ra, and -CONRaRb, where Ra and Rb are independently selected from hydrogen and C1-6 alkyl or two of R2 to R5 can be taken together to form a 3 to 7 membered ring; R6 is an acidic functional group; r and s are each independently 0 or 1 with the proviso that r and s cannot both be 0; or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof.",ASTRAZENECA AB,BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,,https://lens.org/183-627-908-257-400,Granted Patent,yes,4,0,12,14,0,C07D263/58;;C07D413/04;;A61P1/00;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D263/58;;C07D413/04,C07D277/82;;A61K31/423;;A61K31/428;;A61K31/4427;;A61P1/00;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;C07D263/58;;C07D413/04;;C07D413/12,,0,0,,,,EXPIRED
629,WO,A2,WO 2000/005224 A2,007-375-543-975-601,2000-02-03,2000,GB 9902342 W,1999-07-20,GB 9815971 A;;GB 9815973 A,1998-07-23,CHEMICAL COMPOUNDS,"Compound of formula (I) wherein: A is a bicyclic heteroaryl, optionally substituted with one or more substituents; B is linker group connecting group A to group D and comprising a 3 or 4 atom linker where each atom is independently selected from carbon, oxygen, nitrogen and sulphur and is optionally subsituted with one or more C1-6 alkyl groups or two of such adjacent alkyl substituents may form a ring; C is aryl or a mono or bicyclic heteroaryl, each of which can be optionally substituted; D is an aryl or heteroaryl, both of which are optionally substituted R1 is hydrogen, C¿1-5? alkyl, C1-3 alkanoyl or C1-3 alkoxycarbonyl; R?2 to R5¿ are each independently selected from hydrogen, C¿1-6? alkyl, aryl and heteroaryl containing up to 2 heteroatoms chosen from oxygen, sulphur and nitrogen, the aryl and heteroaryl optionally substituted with C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 alkoxy, C1-4 alkanoyl, C1-6 alkylamino, C1-4alkylC1-6alkyoxyl, C1-6alkylaminoC1-6alkyl, nitro, cyano, halogeno, trifluoromethyl, hydroxy, (CH2)pOH where p is 1 or 2, -CO2R?a¿, and -CONRaRb, where R?a and Rb¿ are independently selected from hydrogen and C¿1-6? alkyl or two of R?2 to R5¿ can be taken together to form a 3 to 7 membered ring; R6 is an acidic functional group; r and s are each independently 0 or 1 with the proviso that r and s cannot both be 0; or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof.",ZENECA LTD;;BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,,https://lens.org/007-375-543-975-601,Patent Application,yes,0,14,12,14,0,C07D263/58;;C07D413/04;;A61P1/00;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D263/58;;C07D413/04,A61K31/423;;C07D277/82;;A61K31/428;;A61K31/4427;;A61P1/00;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;C07D263/58;;C07D413/04;;C07D413/12,,0,0,,,,PATENTED
630,EP,A2,EP 1133484 A2,054-903-362-456-248,2001-09-19,2001,EP 99934885 A,1999-07-20,GB 9902330 W;;GB 9815970 A;;GB 9815972 A;;GB 9914441 A,1998-07-23,HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS,,ASTRAZENECA AB,BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,,https://lens.org/054-903-362-456-248,Patent Application,yes,0,0,5,9,0,C04B41/009;;C04B41/4572;;C04B41/81;;C07D263/58;;C07D277/82;;C07D405/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;A61P1/04;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/00;;A61P37/06;;A61P9/10;;A61P3/10,A61K31/423;;A61K31/428;;A61K31/4439;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/00;;A61P37/06;;C04B41/45;;C04B41/81;;C07D263/58;;C07D277/82;;C07D405/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14,,0,0,,,,DISCONTINUED
631,EP,A2,EP 1144393 A2,057-419-924-592-087,2001-10-17,2001,EP 99934897 A,1999-07-20,GB 9902342 W;;GB 9815971 A;;GB 9815973 A,1998-07-23,BENZOXAZOLE DERIVATIVES FOR USE AS INTEGRIN INHIBITORS,"Compound of formula (I) wherein: A is a bicyclic heteroaryl, optionally substituted with one or more substituents; B is linker group connecting group A to group D and comprising a 3 or 4 atom linker where each atom is independently selected from carbon, oxygen, nitrogen and sulphur and is optionally subsituted with one or more C1-6 alkyl groups or two of such adjacent alkyl substituents may form a ring; C is aryl or a mono or bicyclic heteroaryl, each of which can be optionally substituted; D is an aryl or heteroaryl, both of which are optionally substituted R1 is hydrogen, C1-5 alkyl, C1-3 alkanoyl or C1-3 alkoxycarbonyl; R2 to R5 are each independently selected from hydrogen, C1-6 alkyl, aryl and heteroaryl containing up to 2 heteroatoms chosen from oxygen, sulphur and nitrogen, the aryl and heteroaryl optionally substituted with C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 alkoxy, C1-4 alkanoyl, C1-6 alkylamino, C1-4alkylC1-6alkyoxyl, C1-6alkylaminoC1-6alkyl, nitro, cyano, halogeno, trifluoromethyl, hydroxy, (CH2)pOH where p is 1 or 2, -CO2Ra, and -CONRaRb, where Ra and Rb are independently selected from hydrogen and C1-6 alkyl or two of R2 to R5 can be taken together to form a 3 to 7 membered ring; R6 is an acidic functional group; r and s are each independently 0 or 1 with the proviso that r and s cannot both be 0; or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof.",ASTRAZENECA AB,BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,,https://lens.org/057-419-924-592-087,Patent Application,yes,0,0,12,14,0,C07D263/58;;C07D413/04;;A61P1/00;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D263/58;;C07D413/04,C07D277/82;;A61K31/423;;A61K31/428;;A61K31/4427;;A61P1/00;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;C07D263/58;;C07D413/04;;C07D413/12,,0,0,,,,EXPIRED
632,EP,A1,EP 0986278 A1,018-186-185-645-579,2000-03-15,2000,EP 98307489 A,1998-09-15,EP 98307489 A,1998-09-15,Cellular radio network and method for increasing capacity,"The present invention relates generally to the field of cellular radio networks and a method for increasing capacity of the cellular radio networks, particularly a cellular radio network and a method for increasing capacity by use of concentric zones and an optimised handover algorithm which executes a handover from an outer zone to a more inner zone based on a carrier to interference criterion, whilst a handover from an inner zone to a more outer zone is based on a quality criterion for an active call.",LUCENT TECHNOLOGIES INC,DAVIES GARETH;;FLEWITT ANDRIAN ROBERT;;GUNREBEN PETER;;HERPERS MARTINE;;PAMPEL HOLGER,,https://lens.org/018-186-185-645-579,Patent Application,yes,2,11,1,1,0,H04W16/32;;H04W36/04;;H04W36/324,H04W16/32;;H04W36/04;;H04W36/32,,0,0,,,,DISCONTINUED
633,WO,A2,WO 2000/005223 A2,009-601-413-520-540,2000-02-03,2000,GB 9902330 W,1999-07-20,GB 9815970 A;;GB 9815972 A;;GB 9914441 A,1998-07-23,CHEMICAL COMPOUNDS,"Compound of formula (I) wherein: A is a bicyclic heteroaryl, optionally substituted with one or more substituents; B is aryl or a mono or bicyclic heteroaryl, each of which can be optionally subsituted with one or more subsituents; Z is -X(CRaRb)aCO, -NH, -CO or the group X-(CH2)bCONH (CH2)cNH where X is oxygen, sulphur, amino, alkylamino or a direct bond, R?a and Rb¿ are independently hydrogen or C¿1-4? alkyl, a is an integer from 1 to 4, b is 1 or 2 and c is from 2 to 5, and; W is -NHCH(R?w¿)CO- or OC(Rw)CHNH where Rw is -CH¿2?CH(CH3)2-CH2CH2S(CH3) or CH2CH2S(O2)(CH3); q is 0 or 1 and when q is 0 Z is linked to the group W by the formation of an amide bond between Z and Y, and when q is 1 Z is linked to the group W by the formation of an amide bond between Z and W and W is linked to the group Y by the formation of an amide bond between W and Y; Y is a fragment derived from the C-terminus of a compound which inhibits the interaction between the integrin αIIbβ3 and its ligand fibrinogen; R?1¿ is hydrogen, C¿1-5?alkyl, C1-3 alkanoyl or C1-3 alkoxycarbonyl; or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof.",ZENECA LTD;;BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,,https://lens.org/009-601-413-520-540,Patent Application,yes,0,37,5,9,0,C04B41/009;;C04B41/4572;;C04B41/81;;C07D263/58;;C07D277/82;;C07D405/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;A61P1/04;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/00;;A61P37/06;;A61P9/10;;A61P3/10,A61K31/423;;A61K31/428;;A61K31/4439;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/00;;A61P37/06;;C04B41/45;;C04B41/81;;C07D263/58;;C07D277/82;;C07D405/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14,,0,0,,,,PENDING
634,US,B1,US 6441012 B1,038-229-397-731-068,2002-08-27,2002,US 74433101 A,2001-01-23,GB 9815971 A;;GB 9815973 A;;GB 9902342 W,1998-07-23,Chemical compounds,"
   

    Compound of formula (I) wherein: A is a bicyclic heteroaryl, optionally substituted with one or more substituents; B is linker group connecting group A to group D and comprising a 3 or 4 atom linker where each atom is independently selected from carbon, oxygen, nitrogen and sulphur and is optionally subsituted with one or more C _{ 1-6 } alkyl groups or two of such adjacent alkyl substituents may form a ring; C is aryl or a mono or bicyclic heteroaryl, each of which can be optionally substituted; D is an aryl or heteroaryl, both of which are optionally substituted R ^{ 1 } is hydrogen, C _{ 1-5 } alkyl, C _{ 1-3 } alkanoyl or C _{ 1-3 } alkoxycarbonyl; R ^{ 2 } to R ^{ 5 } are each independently selected from hydrogen, C _{ 1-6 } alkyl, aryl and heteroaryl containing up to 2 heteroatoms chosen from oxygen, sulphur and nitrogen, the aryl and heteroaryl optionally substituted with C _{ 1-6 } alkyl, C _{ 2-6 } alkenyl, C _{ 2-6 } alkynyl, C _{ 1-4 } alkoxy, C _{ 1-4 } alkanoyl, C _{ 1-6 } alkylamino, C _{ 1-4 } alkylC _{ 1-6 } alkyoxyl, C _{ 1-6 } alkylaminoC _{ 1-6 } alkyl, nitro, cyano, halogeno, trifluoromethyl, hydroxy, (CH _{ 2 } ) _{ p } OH where p is 1 or 2, CO _{ 2 } R ^{ a } , and CONR ^{ a } R ^{ b } , where R ^{ a } and R ^{ b } are independently selected from hydrogen and C _{ 1-6 } alkyl or two of R ^{ 2 } to R ^{ 5 } can be taken together to form a 3 to 7 membered ring; R ^{ 6 } is an acidic functional group; r and s are each independently 0 or 1 with the proviso that r and s cannot both be 0; or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof. 
",ASTRAZENECA AB,BRITTAIN DAVID R;;JOHNSTONE CRAIG;;LARGE MICHAEL S;;DAVIES GARETH M,ASTRAZENECA AB (2000-12-15),https://lens.org/038-229-397-731-068,Granted Patent,yes,6,0,12,14,0,C07D263/58;;C07D413/04;;A61P1/00;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D263/58;;C07D413/04,A61K31/423;;A61K31/428;;A61K31/4427;;C07D277/82;;A61P1/00;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;C07D263/58;;C07D413/04;;C07D413/12,514/375;;514/367;;548/161;;548/222,1,0,,,"Bundgaard, Hans, 1985, Design of Prodrugs, Elsvier, p. 1.",EXPIRED
635,WO,A3,WO 2014/052331 A3,002-464-071-591-548,2014-06-26,2014,US 2013/0061468 W,2013-09-24,US 201261705711 P,2012-09-26,POLYURETHANE BEND STIFFENER,A bend stiffener comprises a (i) a flexible polymeric sleeve having an axial bore for receiving an elongated flexible member and (ii) attachment means for attaching the sleeve to a support. At least a portion of the flexible polymeric sleeve is a polyurethane elastomer produced in a reaction of an isocyanate- terminated prepolymer and a curing agent at an isocyanate index of 90 to 120. The isocyanate-terminated prepolymer has an isocyanate content of 7 to 15% by weight and is a reaction product of at least one aromatic polyisocyanate and at least one polyether polyol having a hydroxyl equivalent weight of 350 to 2000 and a nominal functionality of 2 to 2.3. The curing agent is one or more chain extenders having an equivalent weight per isocyanate-reactive group of up to 125 or a mixture of one or more such chain extenders and one or more polyether polyols having a hydroxyl equivalent weight of 350 to 2000 and a nominal functionality of 2 to 2.3. The hard segment content of the polyurethane elastomer is from 40 to 60% by weight.,DOW GLOBAL TECHNOLOGIES LLC,MOSS ROBERT M;;MYCOCK IAN ROBERT;;ROBERTS GARETH;;DAVIES ANDREW MARTIN,,https://lens.org/002-464-071-591-548,Search Report,yes,2,0,11,11,0,C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;C08G18/10;;C08G18/3206;;C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;B29C31/10;;B29K2075/00,C08G18/10;;C08G18/48;;C08G18/32;;C08G18/76;;E21B17/01;;H02G15/20,,0,0,,,,PENDING
636,US,B2,US 7947040 B2,132-766-930-024-232,2011-05-24,2011,US 26530405 A,2005-11-03,US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 52275304 P,2003-01-21,Method of surgical perforation via the delivery of energy,"A method of surgical perforation via the delivery of electrical, radiant or thermal energy comprising the steps of: introducing an apparatus comprising an energy delivery device into a patient's heart via the patient's superior vena cava; positioning the energy delivery device at a first location adjacent material to be perforated; and perforating the material by delivering energy via the energy delivery device; wherein the energy is selected from the group consisting of electrical energy, radiant energy and thermal energy.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;HARTLEY AMANDA APRIL;;VISRAM NAHEED;;SHAH KRISHAN;;BAYLIS FRANK,BAYLIS MEDICAL COMPANY INC (2006-03-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/132-766-930-024-232,Granted Patent,yes,53,53,2,113,0,A61B18/1492;;A61B18/1492;;A61B18/24;;A61B18/24;;A61B2018/00351;;A61B2018/00351,A61B18/18,606/45;;606/34;;606/41,33,21,007-454-134-946-40X;;012-647-127-487-753;;015-569-231-826-071;;006-495-373-391-557;;126-172-010-773-649;;053-709-812-994-938;;022-286-573-136-47X;;061-080-657-413-13X;;079-220-343-462-372;;102-284-308-414-898;;087-966-302-747-022;;020-214-294-476-433;;113-591-253-296-335;;022-127-515-170-102;;066-004-459-025-109;;038-743-504-882-104;;056-565-923-253-058;;044-496-843-651-986;;064-062-639-916-470;;003-336-720-517-736;;096-535-125-477-640,11733820;;10.1590/s0066-782x2001001100008;;11979539;;10.1002/ccd.10213;;8504569;;10.1002/clc.4960160502;;11553955;;10.1002/ccd.1244;;10.1023/a:1009870227401;;11248781;;9768726;;10.1016/s0735-1097(98)00357-x;;11094817;;10.1007/bf02345756;;10.1017/s1047951103000398;;12887081;;12885744;;10.1161/01.cir.0000084548.44131.d1;;10.1002/ccd.10602;;12929108;;12929107;;10.1002/ccd.10605;;12838844;;10.1136/heart.86.5.e11;;11602562;;pmc1729980;;1764747;;10.1002/ccd.1810240318;;10700071;;10.1002/(sici)1522-726x(200003)49:3<335::aid-ccd24>3.0.co;2-n;;12410514;;10.1002/ccd.10358;;10.1002/(sici)1097-0304(199710)42:2<219::aid-ccd30>3.0.co;2-g;;9328715;;12772256;;10.1002/ccd.10560;;12772255;;10.1002/ccd.10506;;10216007;;10.1002/(sici)1522-726x(199904)46:4<425::aid-ccd7>3.0.co;2-r;;12112899;;10.1002/ccd.10222,"CA Pedra, LN De Sousa, SR Pedra, WP Ferreira, SL Braga, CA Esteves, MV Santant, JE Sousa, VF Fontes. ""New Percutaneous Techniques for Perforating the Pulmonary Valve in Pulmonary Atresia with Intact Ventricular Septum"". Arq. Bras Cariol. 77(5):471-478 (2001).;;DG Nykanen, J Phikala, GP Taylor, LN Benson. ""Radiofrequency Assisted Perforation of the Atrial septum in a Swine Model: Feasibility, Biophysical and Histological Characteristics"". Circulation. 100(Suppl 1):1-804 (1999).;;Baylis Medical Company Inc. ""Radio Frequency Perforation System"". 2001.;;""Abstract of European Patent No. 0315730 to Osypka"". (1989).;;Benson, Lee N., David Nykanen, Amanda Collison. ""Radiofrequency Perforation in the Treatment of Congenital Heart Disease"". Catheterizations and Cardiovascular Interventions. 56: 72-82 (2002).;;Conti C.R. ""Transseptal Left Heart Catheterization for Radiofrequency Ablation of Accessory Pathways"". Clinical Cardiology. 16: 367-368 (1993).;;Justino, Henri, Lee N. Benson, David G. Nykanen. ""Transcatheter Creation of an Atrial Septal Defect Using Radiofrequency Perforation"". Catheterization and Cardiovascular Interventions. 56: 412-415 (2002).;;Kamal K. Sethi, Jagdish C. Mohan. ""Editorial Comment: Transseptal Catheterization for the Electrophysiologist: Modification with a 'View'"". Journal of Interventional Cardian Physiology. 5: 97-99 (2001).;;Christodoulos Stefanadis. ""Retrograde Nontransseptal Balloon Mitral Valvuloplasty: Immediate Results and Intermediate Long-term Outcome in 441 Cases-A Multicentre Experience"". Journal of the American College of Cardiology. 32(4):1009-16 (1998).;;N. Shimko, P. Savard, K. Shah. ""Radiofrequency Perforation of Cardiac Tissue: Modeling and Experimental Results"". Med. Biol. Eng. comput. 38:575-582 (2000).;;Boston Scientific Corporation. ""http://www.bostonscientific.com/med-specialty/deviceDetail.sp?task=tskBasicDevice.jsp&sectionid=4&relld=1, 20,21,22&deviceid=1888&uniqueid=MP0858"". Explorer ST Catheters. 2 pages. (Date of Printing-Jun. 2005).;;Boston Scientific Corporation. ""http://www.bostonscientific.com/med-specialty/deviceDetail.sp?task=tskBasicDevice.jsp&sectionid=4&relld=2, 74,75,76&deviceid=11026&uniqueid=MPDB2799"". PT2 Guidewires. 2 pages. (Date of Printing-Jun. 2005).;;IntraLuminal Therapeutics, Inc. ""http://www.intraluminal.com/products/catheter.html"". Safe Cross Support Catheter. 1 page. (Date of Printing-Jun. 2005).;;Lake Region Manufacturing, Inc. ""http://www.lakergn.com/jmc.htm"". Paragon Guidewire. 2 pages (Date of Printing-Jun. 2005).;;Medtronic Inc. ""http://www.medtronic.com/epsystems/diagnostic-catheters.html"". Diagnostic Catheters. 7 pages (Date of Printing-Apr. 2005).;;Johnson & Johnson Gateway, LLC. ""http://www.jnjgateway.com/home.html?loc=USENG&page=viewcontent&contentid=ic0de00100001135&nodekey=/prod-info/Specialty/arrhyth mia-management/electrophysiology/EP-diagnostic-catheters"". EP Diagnostic Catheters. 2 pages. (Date of printing-Jun. 2005).;;Johnson & Jonhson Gateway, LLC. ""http//www.jnjgateway.com/home.html.sessionid=JNSFHTWOAOIC0CQPCCECPJYKB2WNSC?loc=USENGA&page=viewcontent &contentid=ic0de00100000524&nodekey=/prod-info/specialty/cardiovascular-and-thoracic/cardiac-diagnosis-interventions/diagnostic-wires&-request=228905"". Diagnostic Guidewires. 4 pages (Date of Printing-Jun. 2005).;;T Abdel-Massih, Y Boudjemline, p. Bonhoeffer. ""Unusual Interventional Management in an Adult with Tetraogy of Fallot"". Cardiol Young. 13(2):2003-2005. Apr. 2003.;;T Humpl, B Soderberg, BW McCrindle, DG Nykanen, RM Freedom, WG Williams, LN Benson. ""Percutaneous Balloon Valvotomy in Pulmonary Atresia with Intact Ventricular Septum: Impact on Patient Care"". Circulation. 108(7): 826-832 (Aug. 2003).;;CA Pedra, RM Filho, RS Arrieta, R Tellez, VF Fontes. ""Recanalizationof a discrete atretic right pulmonary artery segment with a new radiofrequency system"". Catheter Cardiovasc. Interv. 60(1):82-87 (Sep. 2003).;;HW Kort, DT Balzer. ""Radiofrequency perforation in the treatment of acquired left pulmonary atresia following repair of tetralogy of fallot"". Catheter Cardiovasc. Interv. 60(1): 79-81 (Sep. 2003).;;G. Veldtman, A Peirone, LN Benson. ""Radiofrequency perforation of the atrial system: Preliminary experimental evaluation and development."" PICS VII Abstracts. Catheter Cardiovasc. Interv. 60(1):132 (Sep. 2003).;;F. Godart, C. Francart, GM Breviere, C Rey. ""Pulmonary valvulotomy with the Nykanen Radiofrequency guide in pulmonary atresia with intact interventricular septum"". Arch Mal Couer Vaiss. 86(5):517-520 (May 2003). Article is in French with English Summary.;;T. Szili-Torok, G.P. Kimman, D. Theuns, J. Res, J.R.T.C. Roelandt, L.J. Jordaens. ""Transseptal Left heart Catheterization Guided by Intracardiac Echocardiography"". Heart 2001; 86: e11.;;Hector Biddogia, Juan P. Maciel, Jose A. Alvarez et al. ""Transseptal Left Heart Catheterization: Usefulness of the Intracavitary Electrocardiogram in the Localization of the Fossa Ovalis"". Catheterization and Cardiovascular Diagnosis 24: 221-225 (1991).;;George Joseph, G. Rajendiran, K. Abhaichand Rajpal. ""Transjugular Approach to Concurrent Mitral-Aortic and Mitral-Tricuspid Balloon Valvuloplasty"". Catheterization and Cardiovascular Interventions 49:335-341 (2000).;;George Joseph, Oommen K. George, Asishkumar Mandalay, Sunil Sathe. ""Transjugular Approach to Balloon Mitral Valvuloplasty Helps Overcome Impediments Caused by Anatomical Alterations"". Catheterization and Cardiovascular Interventions 57:353-362 (2002).;;George Joseph, Dibya K. Baruah, Sajy V. Kuruttukumlam, Sunil Thomas Chandy, Shanker Krishnaswami. ""Transjugular Approach toTransseptal Balloon Mitral Valvuloplasty"". Catheterization and Cardiovascular Diagnosis 42:219-226 (1997).;;Tsung O. Cheng. ""All Roads Lead to Rome:Transjugular or Transfemoral Approach to Percutaneous Transseptal Balloon Mitral Valvuloplasty?"". Catheterization and Cardiovascular Interventions 59:266-267 (2003).;;J. Thompson Sullebarger, Humberto Coto, Enrique Lopez, Dany Sayad, Hector L. Fontanet. ""Transjugular Percutaneous Inoue Balloon Mitral Commissurotomy in a Patient With Inferior Vena Cava Obstruction After Liver Transplantation"". Catheterization and Cardiovascular Interventions 59:261-265 (2003).;;Georgejoseph, K.P. Suresh Kumar, Paul V. George, Subodh Dhanawade. ""Right Internal Jugular Vein Approach as an Alternative in Balloon Pulmonary Valvuloplasty"". Catheterization and Cardiovascular Interventions 46:425-429 (1999).;;Pressure Products, Inc. http://www.pressure-products.com/Downloads/Education-PDFs/Using-CSG-v2.pdf. 4 pages. 2005.;;Gideon J. DU Marchie Sarvaas, MD, Kalyani R. Trivedi, MD, Lisa K. Hornberger, MD, K. Jin Lee, MD, Joel A. Kirsh, MD, and Lee N. Benson, MD. ""Radiofrequency-Assisted Atrial Septoplasty for an Intact Atrial Septum in Complex Congenital Heart Disease"". Catheterization and Cardiovascular Interventions 56:412-415 (2002).",ACTIVE
637,WO,A3,WO 2000/005223 A3,139-953-521-630-686,2001-07-12,2001,GB 9902330 W,1999-07-20,GB 9815970 A;;GB 9815972 A;;GB 9914441 A,1998-07-23,HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS,"Compound of formula (I) wherein: A is a bicyclic heteroaryl, optionally substituted with one or more substituents; B is aryl or a mono or bicyclic heteroaryl, each of which can be optionally subsituted with one or more subsituents; Z is -X(CRaRb)aCO, -NH, -CO or the group X-(CH2)bCONH (CH2)cNH where X is oxygen, sulphur, amino, alkylamino or a direct bond, R?a and Rb¿ are independently hydrogen or C¿1-4? alkyl, a is an integer from 1 to 4, b is 1 or 2 and c is from 2 to 5, and; W is -NHCH(R?w¿)CO- or OC(Rw)CHNH where Rw is -CH¿2?CH(CH3)2-CH2CH2S(CH3) or CH2CH2S(O2)(CH3); q is 0 or 1 and when q is 0 Z is linked to the group W by the formation of an amide bond between Z and Y, and when q is 1 Z is linked to the group W by the formation of an amide bond between Z and W and W is linked to the group Y by the formation of an amide bond between W and Y; Y is a fragment derived from the C-terminus of a compound which inhibits the interaction between the integrin αIIbβ3 and its ligand fibrinogen; R?1¿ is hydrogen, C¿1-5?alkyl, C1-3 alkanoyl or C1-3 alkoxycarbonyl; or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof.",ASTRAZENECA AB;;BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,,https://lens.org/139-953-521-630-686,Search Report,yes,4,0,5,9,0,C04B41/009;;C04B41/4572;;C04B41/81;;C07D263/58;;C07D277/82;;C07D405/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;A61P1/04;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/00;;A61P37/06;;A61P9/10;;A61P3/10,A61K31/423;;A61K31/428;;A61K31/4439;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/00;;A61P37/06;;C04B41/45;;C04B41/81;;C07D263/58;;C07D277/82;;C07D405/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14,,0,0,,,,PENDING
638,AU,A,AU 1999/050530 A,025-964-839-443-629,2000-02-14,2000,AU 1999/050530 A,1999-07-20,GB 9815971 A;;GB 9815973 A;;GB 9902342 W,1998-07-23,Chemical compounds,"Compound of formula (I) wherein: A is a bicyclic heteroaryl, optionally substituted with one or more substituents; B is linker group connecting group A to group D and comprising a 3 or 4 atom linker where each atom is independently selected from carbon, oxygen, nitrogen and sulphur and is optionally subsituted with one or more C1-6 alkyl groups or two of such adjacent alkyl substituents may form a ring; C is aryl or a mono or bicyclic heteroaryl, each of which can be optionally substituted; D is an aryl or heteroaryl, both of which are optionally substituted R1 is hydrogen, C1-5 alkyl, C1-3 alkanoyl or C1-3 alkoxycarbonyl; R2 to R5 are each independently selected from hydrogen, C1-6 alkyl, aryl and heteroaryl containing up to 2 heteroatoms chosen from oxygen, sulphur and nitrogen, the aryl and heteroaryl optionally substituted with C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 alkoxy, C1-4 alkanoyl, C1-6 alkylamino, C1-4alkylC1-6alkyoxyl, C1-6alkylaminoC1-6alkyl, nitro, cyano, halogeno, trifluoromethyl, hydroxy, (CH2)pOH where p is 1 or 2, -CO2Ra, and -CONRaRb, where Ra and Rb are independently selected from hydrogen and C1-6 alkyl or two of R2 to R5 can be taken together to form a 3 to 7 membered ring; R6 is an acidic functional group; r and s are each independently 0 or 1 with the proviso that r and s cannot both be 0; or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof.",ZENECA LTD,BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,,https://lens.org/025-964-839-443-629,Patent Application,no,0,0,12,14,0,C07D263/58;;C07D413/04;;A61P1/00;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D263/58;;C07D413/04,C07D277/82;;A61K31/423;;A61K31/428;;A61K31/4427;;A61P1/00;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;C07D263/58;;C07D413/04;;C07D413/12,,0,0,,,,DISCONTINUED
639,EP,A2,EP 2900720 A2,111-462-902-795-553,2015-08-05,2015,EP 13771742 A,2013-09-24,US 201261705711 P;;US 2013/0061468 W,2012-09-26,POLYURETHANE BEND STIFFENER,,DOW GLOBAL TECHNOLOGIES LLC,MOSS ROBERT M;;MYCOCK IAN ROBERT;;ROBERTS GARETH;;DAVIES ANDREW MARTIN,,https://lens.org/111-462-902-795-553,Patent Application,yes,0,1,11,11,0,C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;C08G18/10;;C08G18/3206;;C08G18/4854;;C08G18/7671;;E21B17/017;;H02G9/02;;H02G9/12;;B29C31/10;;B29K2075/00,C08G18/48;;C08G18/10;;C08G18/32;;C08G18/76;;E21B17/01;;H02G15/20,,0,0,,,,ACTIVE
640,AT,T1,AT E259359 T1,141-207-099-576-959,2004-02-15,2004,AT 99934897 T,1999-07-20,GB 9815971 A;;GB 9815973 A;;GB 9902342 W,1998-07-23,BENZOXAZOL-DERIVATE ZUR VERWENDUNG ALS INTEGRIN- INHIBITOREN,"Compound of formula (I) wherein: A is a bicyclic heteroaryl, optionally substituted with one or more substituents; B is linker group connecting group A to group D and comprising a 3 or 4 atom linker where each atom is independently selected from carbon, oxygen, nitrogen and sulphur and is optionally subsituted with one or more C1-6 alkyl groups or two of such adjacent alkyl substituents may form a ring; C is aryl or a mono or bicyclic heteroaryl, each of which can be optionally substituted; D is an aryl or heteroaryl, both of which are optionally substituted R1 is hydrogen, C1-5 alkyl, C1-3 alkanoyl or C1-3 alkoxycarbonyl; R2 to R5 are each independently selected from hydrogen, C1-6 alkyl, aryl and heteroaryl containing up to 2 heteroatoms chosen from oxygen, sulphur and nitrogen, the aryl and heteroaryl optionally substituted with C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 alkoxy, C1-4 alkanoyl, C1-6 alkylamino, C1-4alkylC1-6alkyoxyl, C1-6alkylaminoC1-6alkyl, nitro, cyano, halogeno, trifluoromethyl, hydroxy, (CH2)pOH where p is 1 or 2, -CO2Ra, and -CONRaRb, where Ra and Rb are independently selected from hydrogen and C1-6 alkyl or two of R2 to R5 can be taken together to form a 3 to 7 membered ring; R6 is an acidic functional group; r and s are each independently 0 or 1 with the proviso that r and s cannot both be 0; or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof.",ASTRAZENECA AB,BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,,https://lens.org/141-207-099-576-959,Granted Patent,no,0,0,12,14,0,C07D263/58;;C07D413/04;;A61P1/00;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D263/58;;C07D413/04,C07D277/82;;A61K31/423;;A61K31/428;;A61K31/4427;;A61P1/00;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/14;;A61P29/00;;A61P37/06;;A61P43/00;;C07D263/58;;C07D413/04;;C07D413/12,,0,0,,,,DISCONTINUED
641,AU,A,AU 1999/050521 A,187-566-803-155-271,2000-02-14,2000,AU 1999/050521 A,1999-07-20,GB 9815970 A;;GB 9815972 A;;GB 9914441 A;;GB 9902330 W,1998-07-23,Chemical compounds,,ZENECA LTD,BRITTAIN DAVID ROBERT;;JOHNSTONE CRAIG;;DAVIES GARETH MORSE;;LARGE MICHAEL STEWART,,https://lens.org/187-566-803-155-271,Patent Application,no,0,1,5,9,0,C04B41/009;;C04B41/4572;;C04B41/81;;C07D263/58;;C07D277/82;;C07D405/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;A61P1/04;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/00;;A61P37/06;;A61P9/10;;A61P3/10,A61K31/423;;A61K31/428;;A61K31/4439;;A61P1/04;;A61P3/10;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P25/00;;A61P37/06;;C04B41/45;;C04B41/81;;C07D263/58;;C07D277/82;;C07D405/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14,,0,0,,,,DISCONTINUED
642,US,A1,US 2008/0161302 A1,004-513-037-023-185,2008-07-03,2008,US 91451606 A,2006-05-18,GB 0510190 A;;GB 0607841 A;;GB 2006001820 W,2005-05-18,Antifungal Agents,"Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: R1, R2, R3, R4, R5, R6, R7, X and X 1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,THOMSON SAMANTHA PATRICIA;;DAVIES RHIAN TERESA;;ALLANSON NIGEL MARK;;KUVSHINOV ALEXANDRE;;DAVIES GARETH MORSE;;EDWARDS PHILIP NEIL,F2G LTD (2007-11-14),https://lens.org/004-513-037-023-185,Patent Application,yes,1,1,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,A61K31/437;;A61K31/496;;A61K31/5377;;A61P31/10;;C07D471/04,514/233.2;;546/112;;514/299;;514/253.04,0,0,,,,ACTIVE
643,DK,T3,DK 1888063 T3,119-714-257-418-315,2009-05-11,2009,DK 06743919 T,2006-05-18,GB 0510190 A;;GB 0607841 A;;GB 2006001820 W,2005-05-18,Antimykotiske midler,"Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: R1, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,THOMSON SAMANTHA PATRICIA;;EDWARDS PHILIP NEIL;;DAVIES GARETH MORSE;;KUVSHINOV ALEXANDRE;;ALLANSON NIGEL MARK;;DAVIES RHIAN TERESA,,https://lens.org/119-714-257-418-315,Granted Patent,no,0,0,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,A61K31/437;;A61P31/12,,0,0,,,,ACTIVE
644,NZ,A,NZ 563397 A,037-025-969-202-575,2010-04-30,2010,NZ 56339706 A,2006-05-18,GB 0510190 A;;GB 0607841 A;;GB 2006001820 W,2005-05-18,Antifungal agents comprising indolizinyl derivatives,"Use of a compound which is an indolizinyl derivative formula (I), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of a fungal disease, wherein the variables are defined in the specification. Also disclosed is a method of controlling a fungal disease in a plant, comprising applying said derivative, compounds of formula (I) and a pharmaceutical composition comprising compounds of formula (I).",F2G LTD,THOMSON SAMANTHA PATRICIA;;DAVIES RHIAN TERESA;;ALLANSON NIGEL MARK;;KUVSHINOV ALEXANDRE;;DAVIES GARETH MORSE;;EDWARDS PHILIP NEIL,,https://lens.org/037-025-969-202-575,Patent Application,no,0,0,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,A61K31/437;;A61P31/12,,0,0,,,,PENDING
645,DE,D1,DE 602006004865 D1,080-922-766-476-743,2009-03-05,2009,DE 602006004865 T,2006-05-18,GB 0510190 A;;GB 0607841 A;;GB 2006001820 W,2005-05-18,ANTIMYKOTISCHE MITTEL,"Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: R1, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,THOMSON SAMANTHA PATRICIA;;EDWARDS PHILIP NEIL;;DAVIES GARETH MORSE;;KUVSHINOV ALEXANDRE;;ALLANSON NIGEL MARK;;DAVIES RHIAN TERESA,,https://lens.org/080-922-766-476-743,Granted Patent,no,0,0,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,A61K31/437;;A61P31/12,,0,0,,,,ACTIVE
646,AU,A1,AU 2006/248812 A1,048-481-208-024-987,2006-11-23,2006,AU 2006/248812 A,2006-05-18,GB 0607841 A;;GB 0510190 A;;GB 2006001820 W,2005-05-18,Antifungal agents,"Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: R1, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,EDWARDS PHILIP NEIL;;ALLANSON NIGEL MARK;;THOMSON SAMANTHA PATRICIA;;KUVSHINOV ALEXANDRE;;DAVIES GARETH MORSE;;DAVIES RHIAN TERESA,,https://lens.org/048-481-208-024-987,Patent Application,no,0,1,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,A61K31/437;;A61P31/12,,0,0,,,,ACTIVE
647,AU,B2,AU 2006/248812 B2,128-982-921-268-384,2012-02-16,2012,AU 2006/248812 A,2006-05-18,GB 0607841 A;;GB 0510190 A;;GB 2006001820 W,2005-05-18,Antifungal agents,"Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: Rl, R2, R3, R4, R5, R6, R7, X and X are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,EDWARDS PHILIP NEIL;;ALLANSON NIGEL MARK;;THOMSON SAMANTHA PATRICIA;;KUVSHINOV ALEXANDRE;;DAVIES GARETH MORSE;;DAVIES RHIAN TERESA,,https://lens.org/128-982-921-268-384,Granted Patent,no,4,0,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,A61K31/437;;A61P31/10,,1,1,125-190-663-181-256,8809154;;10.1021/jm960395q,"Hagishita, S. et al, Journal of Medicinal Chemistry, 1996, 39(19):3636-3658",ACTIVE
648,ES,T3,ES 2321230 T3,092-928-862-370-810,2009-06-03,2009,ES 06743919 T,2006-05-18,GB 0510190 A;;GB 0607841 A,2005-05-18,AGENTES ANTIFUNGICOS.,"Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: R1, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,THOMSON SAMANTHA PATRICIA;;EDWARDS PHILIP NEIL;;DAVIES GARETH MORSE;;KUVSHINOV ALEXANDRE;;ALLANSON NIGEL MARK;;DAVIES RHIAN TERESA,,https://lens.org/092-928-862-370-810,Granted Patent,no,0,0,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,A61K31/437;;A61P31/12,,0,0,,,,ACTIVE
649,US,B2,US 8486962 B2,161-161-204-298-976,2013-07-16,2013,US 91451606 A,2006-05-18,GB 0510190 A;;GB 0607841 A;;GB 2006001820 W,2005-05-18,Antifungal agents,"Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: R1, R2, R3, R4, R5, R6, R7, X and X 1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",THOMSON SAMANTHA PATRICIA;;DAVIES RHIAN TERESA;;ALLANSON NIGEL MARK;;KUVSHINOV ALEXANDRE;;DAVIES GARETH MORSE;;EDWARDS PHILIP NEIL;;F2G LTD,THOMSON SAMANTHA PATRICIA;;DAVIES RHIAN TERESA;;ALLANSON NIGEL MARK;;KUVSHINOV ALEXANDRE;;DAVIES GARETH MORSE;;EDWARDS PHILIP NEIL,F2G LTD (2007-11-14),https://lens.org/161-161-204-298-976,Granted Patent,yes,4,0,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,A61K31/437;;A01N43/52;;A01P3/00,514/299;;514/233.2;;514/253.04;;546/112;;424/405,11,8,082-524-780-121-593;;095-630-841-364-590;;157-368-878-373-980;;060-908-101-548-398;;125-190-663-181-256;;064-843-742-303-148;;017-365-412-179-713;;018-491-364-581-321,10.1039/jr9590000620;;10.1039/p19810003150;;10.1021/ja01463a046;;8842991;;10.1016/s0163-4453(96)92700-0;;8809154;;10.1021/jm960395q;;10.1039/jr9550001504;;10064251;;10.1086/515116;;14249429;;10.1002/jps.2600531007,"Ames et al., ""The preparation of aminoalkylpyrrocolines"", Chem. Soc., 1959, 620-622.;;Blondeau et al., ""Synthesis of New Phenols. Part 1. Derivatives of 8-hydroxy-2-phenylindolizine"", J. Chem. Research (S), 1981, 366-367.;;Dick et al., ""Heterocyclic compounds with bridgehead nitrogen atoms. Part 9. Synthesis in the pyrrolo[2,1,5-de]quinolizine ([2.3.3]cyclazine) series starting from indolizines"", J. Chem. Soc., Perkin Trans. 1, 1981, 3150-3157.;;Galbraith et al., ""The Formation of Cycl[3.2.2]azine Derivatives via the Reaction of Pyrrocoline with Dimethyl Acetylenedicarboxylate"", J. of the American Chemical Society, Jan. 20, 1961, 453-458, vol. 83.;;Groll et al., ""Trends in the postmortem epidemiology of invasive fungal infections at a university hospital"", J Infect., Jul. 1996; 23-32; vol. 33(1).;;Guet et al., ""Synthesis of New Phenols. Part 2. Derivatives of 6-hydroxy-2-phenylindolizine"", J. Chem Research (S), 1982, 245.;;Hagishita et al., ""Potent Inhibitors of Secretory Phospholipase A2: Synthesis and Inhibitory Activities of Indolizine and Indene Derivatives"", J. Med. Chem., 1996, 3636-3658, vol. 39(19).;;Holland et al., ""The chemistry of the pyrrocolines. Part VII. Further experiments with 2-methylpyrrocoline"", J. Chem. Soc., 1955, 1504-1511.;;Ribaud et al., ""Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation"", Clin Infect Dis. Feb. 1999; 322-30; vol. 28(2).;;Shipman, ""Product Class 16: Indolizines"", Science of Synthesis, 2001, 745-787, 10.16.;;Venturella, ""Arylindolizines III. Methoxyl and glyoxyl derivatives of several substituted phenylindolizines"", Journal of Pharmaceutical Sciences, 1166-1169, vol. 53(10).",ACTIVE
650,CA,A1,CA 2608977 A1,053-303-362-782-216,2006-11-23,2006,CA 2608977 A,2006-05-18,GB 0510190 A;;GB 0607841 A;;GB 2006001820 W,2005-05-18,ANTIFUNGAL AGENTS,"Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: R1, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,ALLANSON NIGEL MARK;;KUVSHINOV ALEXANDRE;;DAVIES RHIAN TERESA;;THOMSON SAMANTHA PATRICIA;;EDWARDS PHILIP NEIL;;DAVIES GARETH MORSE,,https://lens.org/053-303-362-782-216,Patent Application,no,0,1,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,A61K31/437;;A61P31/12,,0,0,,,,ACTIVE
651,CA,C,CA 2608977 C,153-846-398-845-65X,2014-09-23,2014,CA 2608977 A,2006-05-18,GB 0510190 A;;GB 0607841 A;;GB 2006001820 W,2005-05-18,ANTIFUNGAL AGENTS,"Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: Rl, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,THOMSON SAMANTHA PATRICIA;;DAVIES RHIAN TERESA;;ALLANSON NIGEL MARK;;KUVSHINOV ALEXANDRE;;DAVIES GARETH MORSE;;EDWARDS PHILIP NEIL,,https://lens.org/153-846-398-845-65X,Granted Patent,no,0,0,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,A61K31/437,,0,0,,,,ACTIVE
652,WO,A1,WO 2006/123145 A1,044-330-647-413-067,2006-11-23,2006,GB 2006001820 W,2006-05-18,GB 0510190 A;;GB 0607841 A,2005-05-18,ANTIFUNGAL AGENTS,"Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: Rl, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD;;THOMSON SAMANTHA PATRICIA;;DAVIES RHIAN TERESA;;ALLANSON NIGEL MARK;;KUVSHINOV ALEXANDRE;;DAVIES GARETH MORSE;;EDWARDS PHILIP NEIL,THOMSON SAMANTHA PATRICIA;;DAVIES RHIAN TERESA;;ALLANSON NIGEL MARK;;KUVSHINOV ALEXANDRE;;DAVIES GARETH MORSE;;EDWARDS PHILIP NEIL,,https://lens.org/044-330-647-413-067,Patent Application,yes,4,41,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,A61K31/437;;A61P31/12,,1,1,125-190-663-181-256,8809154;;10.1021/jm960395q,"HAGISHITA, SANJI ET AL: ""Potent Inhibitors of Secretory Phospholipase A2: Synthesis and Inhibitory Activities of Indolizine and Indene Derivatives"", JOURNAL OF MEDICINAL CHEMISTRY , 39(19), 3636-3658 CODEN: JMCMAR; ISSN: 0022-2623, 1996, XP002395282",PENDING
653,EP,A1,EP 1888063 A1,162-048-880-506-023,2008-02-20,2008,EP 06743919 A,2006-05-18,GB 2006001820 W;;GB 0510190 A;;GB 0607841 A,2005-05-18,ANTIFUNGAL AGENTS,"Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: R1, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,THOMSON SAMANTHA PATRICIA;;EDWARDS PHILIP NEIL;;DAVIES GARETH MORSE;;KUVSHINOV ALEXANDRE;;ALLANSON NIGEL MARK;;DAVIES RHIAN TERESA,,https://lens.org/162-048-880-506-023,Patent Application,yes,0,0,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,A61K31/437;;A61P31/12,,0,0,,,,ACTIVE
654,CO,A2,CO 2023004379 A2,123-356-776-952-111,2023-04-27,2023,CO 2023004379 A,2023-04-05,EP 2021075005 W;;US 202063077207 P,2020-09-11,Moléculas de unión a b7-h4 terapéuticas,"La presente invención se refiere a moléculas de unión (por ejemplo, anticuerpos) para el tratamiento del cáncer, y a conjugados de anticuerpo-fármaco relacionados.",MEDIMMUNE LTD,KINNEER KRISTA LYNNE;;DAVIES GARETH CHARLES;;REES DAVID GARETH;;PERCIVAL-ALWYN JENNIFER LOUISE;;ANDREWS JOHN EDWARD;;CHESEBROUGH JON,,https://lens.org/123-356-776-952-111,Patent Application,no,0,0,18,18,0,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,C07K16/28;;A61K31/00;;A61K39/00;;A61K47/68;;A61P35/00;;C07K16/30;;G01N33/574,,0,0,,,,PENDING
655,CR,A,CR 20230146 A,052-096-160-535-940,2023-06-07,2023,CR 20230146 A,2021-09-10,US 202063077207 P;;EP 2021075005 W,2020-09-11,MOLÉCULAS DE UNIÓN A B7-H4 TERAPÉUTICAS,"La presente invención se refiere a moléculas de unión (por ejemplo, anticuerpos) para el tratamiento del cáncer, y a conjugados de anticuerpo-fármaco relacionados.",MEDIMMUNE LTD,REES DAVID GARETH;;DAVIES GARETH CHARLES;;KINNEER KRISTA LYNNE;;ANDREWS JOHN EDWARD;;CHESEBROUGH JON;;PERCIVAL-ALWYN JENNIFER LOUISE,,https://lens.org/052-096-160-535-940,Patent Application,no,0,0,18,18,0,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,C07K16/28;;A61K31/00;;A61K35/00;;A61K39/00;;C07K16/30;;G01N33/574,,0,0,,,,PENDING
656,US,B2,US 11795225 B2,127-845-235-436-248,2023-10-24,2023,US 202117471723 A,2021-09-10,US 202117471723 A;;US 202063077207 P,2020-09-11,Therapeutic binding molecules,"The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.",MEDIMMUNE LTD,KINNEER KRISTA LYNNE;;DAVIES GARETH CHARLES;;REES DAVID GARETH;;PERCIVAL-ALWYN JENNIFER LOUISE;;ANDREWS JOHN EDWARD;;CHESEBROUGH JON,MEDIMMUNE LIMITED (2021-11-23);;MEDIMMUNE LLC (2021-12-01),https://lens.org/127-845-235-436-248,Granted Patent,yes,3,0,18,18,55,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,C07K16/28;;A61K47/68;;A61P35/00;;C07K16/30,,9,8,048-162-849-704-175;;092-937-594-026-371;;003-946-445-440-073;;147-120-641-354-907;;038-077-544-535-228;;034-523-716-361-183;;152-341-119-821-429;;085-628-827-415-050,26217160;;10.1016/s1359-6349(13)70001-6;;pmc4048039;;21818998;;pmc5630270;;28258701;;10.1111/imr.12530;;36007632;;10.1016/j.cbi.2022.110116;;10.1016/j.jim.2018.10.005;;30321550;;10.1007/s12038-018-9772-3;;30207312;;pmc4066406;;10.1016/j.ygyno.2014.03.553;;24657487;;30737243;;10.1158/1078-0432.ccr-17-3123,"Hakan Mellstedt, EJC Supplements II 2013, 3, pp. 1-11 (Year: 2013).;;Joshi SR. Biosimilar peptides: need for pharmacovigilance. J Assoc Physicians India. Apr. 2011;59 Suppl:44-7. (Year: 2011).;;Podojil JR, Miller SD. Potential targeting of B7-H4 for the treatment of cancer. Immunol Rev. Mar. 2017;276(1):40-51. (Year: 2017).;;Goli Var, Butreddy A. Biosimilar monoclonal antibodies: Challenges and approaches towards formulation. Chem Biol Interact. Oct. 1, 2022;366:110116. (Year: 2022).;;Murphy et al. Journal of Immunological Methods, vol. 463, p. 127-133, 2018 (Year: 2018).;;Ji, et al., Construction, expression and functional analysis of anti-B7—H4—scFv—CH3 recombinant antibody, J. of Biosciences, 2018, 43:4, pp. 661-671.;;Smith et al., B7—H4 as a potential target for immunotherapy for gynecologic cancers: A closer look, Gynecol Oncol., 2014, 134, pp. 181-189.;;Iizuka et al., A T-cell-engaging B7—H4/CD3-bispecific Fab—scFv Antibody Targets Human Breast Cancer, Clin. Cancer Res., 2019, 25:9, pp. 2925-2934.;;International Search Report and Written Opinion for PCT/EP2021/075005 dated Dec. 1, 2021.",ACTIVE
657,AR,A1,AR 123480 A1,131-826-997-164-42X,2022-12-07,2022,AR P210102516 A,2021-09-10,US 202063077207 P,2020-09-11,MOLÉCULAS DE UNIÓN TERAPÉUTICAS,"La presente invención se refiere a moléculas de unión (por ejemplo, anticuerpos) para el tratamiento del cáncer, y a conjugados de anticuerpo-fármaco relacionados. Reivindicación 1: Un anticuerpo o fragmento de unión al antígeno de este que se une a B7-H4, que comprende: i. una CDR1 de cadena pesada (HCDR1), una CDR2 de cadena pesada (HCDR2), una CDR3 de cadena pesada (HCDR3), una CDR1 de cadena ligera (LCDR1), una CDR2 de cadena ligera (LCDR2) y una CDR3 de cadena ligera (LCDR3) que comprenden la secuencia de aminoácidos de SEQ ID Nº 7, SEQ ID Nº 8, SEQ ID Nº 9, SEQ ID Nº 10, SEQ ID Nº 11 y la SEQ ID Nº 12, respectivamente, o una variante funcional de la misma; ii. una HCDR1, una HCDR2, una HCDR3, una LCDR1, una LCDR2 y una LCDR3 que comprenden la secuencia de aminoácidos de SEQ ID Nº 1, SEQ ID Nº 2, SEQ ID Nº 3, SEQ ID Nº 4, SEQ ID Nº 5 y la SEQ ID Nº 6, respectivamente, o una variante funcional de la misma; iii. una HCDR1, una HCDR2, una HCDR3, una LCDR1, una LCDR2 y una LCDR3 que comprenden la secuencia de aminoácidos de SEQ ID Nº 13, SEQ ID Nº 14, SEQ ID Nº 15, SEQ ID Nº 16, SEQ ID Nº 17 y la SEQ ID Nº 18, respectivamente, o una variante funcional de la misma; iv. una HCDR1, una HCDR2, una HCDR3, una LCDR1, una LCDR2 y una LCDR3 que comprenden la secuencia de aminoácidos de SEQ ID Nº 19, SEQ ID Nº 20, SEQ ID Nº 21, SEQ ID Nº 22, SEQ ID Nº 23 y la SEQ ID Nº 24, respectivamente, o una variante funcional de la misma; o v. una HCDR1, una HCDR2, una HCDR3, una LCDR1, una LCDR2 y una LCDR3 que comprenden la secuencia de aminoácidos de SEQ ID Nº 25, SEQ ID Nº 26, SEQ ID Nº 27, SEQ ID Nº 28, SEQ ID Nº 29 y la SEQ ID Nº 30, respectivamente, o una variante funcional de la misma. Reivindicación 20: Una composición farmacéutica que comprende un anticuerpo o fragmento de unión a antígeno de este de acuerdo con una cualquiera de las reivindicaciones anteriores. Reivindicación 21: Un polinucleótido que codifica el anticuerpo o fragmento de unión al antígeno de este de acuerdo con una cualquiera de las reivindicaciones 1 - 19. Reivindicación 22: Una célula huésped que comprende el polinucleótido de la reivindicación 21. Reivindicación 23: Un método para producir un anticuerpo o fragmento de unión al antígeno de este que se une a B7-H4, que comprende expresar un polinucleótido de acuerdo con la reivindicación 22 en una célula huésped. Reivindicación 24: Un anticuerpo o fragmento de unión al antígeno de este que puede obtenerse mediante el método de la reivindicación 23. Reivindicación 26: Un anticuerpo o fragmento de unión al antígeno de este de acuerdo con una cualquiera de las reivindicaciones 1 - 19 ó 24, o la composición farmacéutica de la reivindicación 20, para su uso para tratar un cáncer, en el que dicho cáncer comprende una célula cancerosa que expresa B7-H4.",MEDIMMUNE LTD,KINNEER KRISTA LYNNE;;CHESEBROUGH JON;;DAVIES GARETH CHARLES;;REES DAVID GARETH;;PERCIVAL-ALWYN JENNIFER LOUISE;;ANDREWS JOHN EDWARD,,https://lens.org/131-826-997-164-42X,Patent Application,no,0,0,18,18,0,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,A61K47/68;;A61P35/00;;C07K16/28;;C07K16/30,,0,0,,,,PENDING
658,EP,A1,EP 4211166 A1,047-675-257-668-008,2023-07-19,2023,EP 21782448 A,2021-09-10,US 202063077207 P;;EP 2021075005 W,2020-09-11,THERAPEUTIC B7-H4 BINDING MOLECULES,,MEDIMMUNE LTD,KINNEER KRISTA LYNNE;;DAVIES GARETH CHARLES;;REES DAVID GARETH;;PERCIVAL-ALWYN JENNIFER LOUISE;;ANDREWS JOHN EDWARD;;CHESEBROUGH JON,,https://lens.org/047-675-257-668-008,Patent Application,yes,0,0,18,18,0,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,C07K16/28;;A61K31/00;;A61K39/00;;A61K47/68;;A61P35/00;;C07K16/30;;G01N33/574,,0,0,,,,PENDING
659,TW,A,TW 202233670 A,143-457-677-361-445,2022-09-01,2022,TW 110133915 A,2021-09-11,US 202063077207 P,2020-09-11,Therapeutic binding molecules,"The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.",MEDIMMUNE LTD,KINNEER KRISTA LYNNE;;CHESEBROUGH JON;;DAVIES GARETH CHARLES;;REES DAVID GARETH;;PERCIVAL-ALWYN JENNIFER LOUISE;;ANDREWS JOHN EDWARD,,https://lens.org/143-457-677-361-445,Patent of Addition,no,0,0,18,18,0,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,C07K16/28;;A61K47/68;;A61P35/00;;G01N33/68,,0,0,,,,PENDING
660,US,A1,US 2022/0098308 A1,079-534-355-477-098,2022-03-31,2022,US 202117471723 A,2021-09-10,US 202117471723 A;;US 202063077207 P,2020-09-11,THERAPEUTIC BINDING MOLECULES,"The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.",MEDIMMUNE LTD,KINNEER KRISTA LYNNE;;DAVIES GARETH CHARLES;;REES DAVID GARETH;;PERCIVAL-ALWYN JENNIFER LOUISE;;ANDREWS JOHN EDWARD;;CHESEBROUGH JON,MEDIMMUNE LIMITED (2021-11-23);;MEDIMMUNE LLC (2021-12-01),https://lens.org/079-534-355-477-098,Patent Application,yes,1,1,18,18,55,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,C07K16/28;;A61K47/68;;A61P35/00;;C07K16/30,,5,5,048-162-849-704-175;;092-937-594-026-371;;003-946-445-440-073;;147-120-641-354-907;;038-077-544-535-228,26217160;;10.1016/s1359-6349(13)70001-6;;pmc4048039;;21818998;;pmc5630270;;28258701;;10.1111/imr.12530;;36007632;;10.1016/j.cbi.2022.110116;;10.1016/j.jim.2018.10.005;;30321550,"Hakan Mellstedt, EJC Supplements II 2013, 3, pp 1-11 (Year: 2013);;Joshi SR. Biosimilar peptides: need for pharmacovigilance. J Assoc Physicians India. 2011 Apr;59 Suppl:44-7. (Year: 2011);;Podojil JR, Miller SD. Potential targeting of B7-H4 for the treatment of cancer. Immunol Rev. 2017 Mar;276(1):40-51. (Year: 2017);;Goli VAR, Butreddy A. Biosimilar monoclonal antibodies: Challenges and approaches towards formulation. Chem Biol Interact. 2022 Oct 1;366:110116. (Year: 2022);;Murphy et al. Journal of Immunological Methods, Vol. 463, Pg. 127-133, 2018 (Year: 2018)",ACTIVE
661,CL,A1,CL 2023000683 A1,040-840-576-013-975,2023-08-11,2023,CL 2023000683 A,2023-03-09,US 202063077207 P,2020-09-11,Moléculas de unión a b7-h4 terapéuticas,"La presente invención se refiere a moléculas de unión (por ejemplo, anticuerpos) para el tratamiento del cáncer, y a conjugados de anticuerpo-fármaco relacionados.",MEDIMMUNE LTD,KRISTA LYNNE KINNEER;;GARETH CHARLES DAVIES;;DAVID GARETH REES;;JENNIFER LOUISE PERCIVAL-ALWYN;;JOHN EDWARD ANDREWS;;JON CHESEBROUGH,,https://lens.org/040-840-576-013-975,Patent Application,no,0,0,18,18,0,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,A61K31/00;;A61K39/00;;A61K47/68;;A61P35/00;;C07K16/28;;C07K16/30;;G01N33/574,,0,0,,,,PENDING
662,KR,A,KR 20230084497 A,028-993-050-877-325,2023-06-13,2023,KR 20237011802 A,2021-09-10,US 202063077207 P;;EP 2021075005 W,2020-09-11,치료용 B7-H4 결합 분자,"본 발명은 암 치료를 위한 결합 분자(예를 들어, 항체) 및 관련 항체-약물 접합체에 관한 것이다.",MEDIMMUNE LTD,KINNEER KRISTA LYNNE;;DAVIES GARETH CHARLES;;REES DAVID GARETH;;PERCIVAL ALWYN JENNIFER LOUISE;;ANDREWS JOHN EDWARD;;CHESEBROUGH JON,,https://lens.org/028-993-050-877-325,Patent Application,no,0,0,18,18,106,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,C07K16/28;;A61K39/00;;A61K47/68;;A61P35/00;;C07K16/30;;G01N33/574,,0,0,,,,PENDING
663,BR,A2,BR 112023004415 A2,141-604-865-804-199,2023-05-09,2023,BR 112023004415 A,2021-09-10,EP 2021075005 W;;US 202063077207 P,2020-09-11,MOLÉCULAS TERAPÊUTICAS DE LIGAÇÃO A B7-H4,"MOLÉCULAS TERAPÊUTICAS DE LIGAÇÃO A B7-H4. A presente invenção refere-se a moléculas de ligação (p. ex., anticorpos) para o tratamento de câncer e conjugados anticorpo-fármaco relacionados.",MEDIMMUNE LTD,KRISTA LYNNE KINNEER;;GARETH CHARLES DAVIES;;DAVID GARETH REES;;JENNIFER LOUISE PERCIVAL-ALWYN;;JOHN EDWARD ANDREWS;;JON CHESEBROUGH,,https://lens.org/141-604-865-804-199,Patent Application,no,0,0,18,18,0,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,C07K16/28;;A61K31/00;;A61K39/00;;A61K47/68;;A61P35/00;;C07K16/30;;G01N33/574,,0,0,,,,PENDING
664,MX,A,MX 2023002940 A,043-582-241-039-17X,2023-04-11,2023,MX 2023002940 A,2021-09-10,US 202063077207 P;;EP 2021075005 W,2020-09-11,THERAPEUTIC B7-H4 BINDING MOLECULES.,"The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.",MEDIMMUNE LTD,KINNEER KRISTA LYNNE;;DAVIES GARETH CHARLES;;REES DAVID GARETH;;PERCIVAL-ALWYN JENNIFER LOUISE;;ANDREWS JOHN EDWARD;;CHESEBROUGH JON,,https://lens.org/043-582-241-039-17X,Patent Application,no,0,0,18,18,0,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,A61K47/68;;A61K31/00;;A61K39/00;;A61P35/00;;C07K16/28;;C07K16/30;;G01N33/574,,0,0,,,,PENDING
665,CA,A1,CA 3193594 A1,080-210-262-985-805,2022-03-17,2022,CA 3193594 A,2021-09-10,US 202063077207 P;;EP 2021075005 W,2020-09-11,THERAPEUTIC B7-H4 BINDING MOLECULES,"The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.",MEDIMMUNE LTD,KINNEER KRISTA LYNNE;;DAVIES GARETH CHARLES;;REES DAVID GARETH;;PERCIVAL-ALWYN JENNIFER LOUISE;;ANDREWS JOHN EDWARD;;CHESEBROUGH JON,,https://lens.org/080-210-262-985-805,Patent Application,no,0,0,18,18,55,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,A61K31/00;;A61K39/00;;A61K47/68;;A61P35/00;;C07K16/28;;C07K16/30;;G01N33/574,,0,0,,,,PENDING
666,US,A,US 5164382 A,013-063-325-014-997,1992-11-17,1992,US 50980290 A,1990-04-17,GB 8908700 A,1989-04-18,"6-FLUORO-SHIKIMIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USE AS ANTIBACTERIALS AND FUNGICIDES","6-Fluoroshikimic acid derivatives of the formula (I): ##STR1## wherein R.sup.1 is hydroxy or a moiety biotransformable thereto and R.sup.2 is hydrogen or --P(O)(OH).sub.2 have antibacterial, antifungal, and herbicidal activity. Their preparation and use are described as are pharmaceutical compositions containing them.",ICI PLC,SUTHERLAND JAMES K;;WATKINS WILLIAM J;;SNOW GEORGE A;;DAVIES GARETH M,ZENECA LIMITED (1993-11-02);;IMPERIAL CHEMICAL INDUSTRIES PLC (1990-04-04),https://lens.org/013-063-325-014-997,Granted Patent,yes,0,8,11,12,0,A01N37/40;;A01N57/14;;C07C62/32;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/65507;;C07D493/04;;A01N37/40;;C07D303/40;;C07F9/65507;;C07C62/32;;A01N57/14;;C07F9/117,A01N37/40;;A01N41/06;;A01N57/12;;A01N57/14;;A01N37/10;;A61K31/19;;A61K31/215;;C07C51/00;;C07C51/363;;C07C51/367;;C07C62/04;;C07C62/10;;C07C62/32;;C07C67/00;;C07C69/757;;C07D303/38;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/12;;C07F9/655,514/120;;514/529;;514/557;;558/198;;560/125;;562/507,8,4,029-298-171-604-114;;019-461-815-000-522;;126-725-839-414-194;;118-669-091-831-006,10.1016/0040-4020(78)80222-1;;10.1016/s0300-9084(86)80066-9;;3098305;;10.1021/bi00669a018;;11811;;10.1039/p19900001281,"Ganem, B. Tetrahedron 1978, 34(23), 3353 83.;;Bowles, S. et al. Tetrahedron Lett. 1989, 30(28), 3711 14.;;Bundgaard Design of Prodrugs: Bioreversible Derivatives for Various Functional Groups and Chemical Entities , pp. 1 and 2, Design of Prodrugs, Bundgaard, ed. (1985) Elsevier Amsterdam.;;Le Marechal, Contribution to the Study of the Mechanism of Action of an Enzyme of the Aromatic Amino Acid Biosynthetic Pathway; 3 Dehydroquinate Synthetase from Escherichia coil, Preparation and use of Analogues of 3 desoxy D arabino heptulosonate 7 phosphate, its substrate . Thesis submitted at the University of Paris XI, Centre D Orsay to obtain the degree of Doctor of Natural Sciences by Pierre Le Marechal.;;Le Marechal et al., The Shikimate Pathway V, Flourine containing Analogues of 3 deoxy D arabino hept 2 ulosonate 7 phosphate (DAHP), Research Article, pp. 1211 1215.;;Pilch et al., Fluorine Containing Analogues of Intermediates in the Shikimate, Biochemistry, vol. 15, No. 24, pp. 5315 5320, (1976).;;Leroy et al., Stereospecific Synthesis of Racemic cis and trans 6 Trifluoromethylshikimic Acids, J. Chem. Soc. Perkin Trans. I, pp. 1281 1287, (1990).;;Le Marechal, Pierre, A L Universite Paris XI Centre D Orsay (1981).",EXPIRED
667,UA,C2,UA 126025 C2,002-965-883-445-322,2022-08-03,2022,UA A201906847 A,2017-12-19,GB 201621635 A;;EP 2017083650 W,2016-12-19,GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,,https://lens.org/002-965-883-445-322,Limited Patent,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,,,0,0,,,,ACTIVE
668,MA,A,MA 47669 A,021-322-005-018-28X,2020-01-08,2020,MA 47669 A,2017-12-19,GB 201621635 A,2016-12-19,STRUCTURE CRISTALLINE DE GREMLIN-1 ET ANTICORPS INHIBITEUR,,UCB BIOPHARMA SRL,DAVIES GARETH;;DEDI NEESHA;;MCMILLAN DAVID JAMES;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN,,https://lens.org/021-322-005-018-28X,Unknown,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,A61K39/395;;C07K16/22,,0,0,,,,PENDING
669,EP,A1,EP 4148250 A1,033-894-362-428-323,2023-03-15,2023,EP 22192762 A,2022-08-30,GB 202112775 A;;GB 202116766 A,2021-09-08,AN IMPROVED GAS TURBINE ENGINE,"A gas turbine engine for an aircraft comprises, in axial flow sequence, a heat exchanger module, and a core engine. The core engine comprises, in axial flow sequence, an intermediate-pressure compressor, a high-pressure compressor, a high pressure turbine, and a low-pressure turbine. The high-pressure compressor is rotationally connected to the high-pressure turbine by a first shaft, and the intermediate-pressure compressor is rotationally connected to the low-pressure turbine by a second shaft. The heat exchanger module is in fluid communication with the core engine by an inlet duct. The heat exchanger module comprises a central hub and a plurality of heat transfer elements extending radially outwardly from the central hub and spaced in a circumferential array, for transfer of heat energy from a first fluid contained within the heat transfer elements to an inlet airflow passing over a surface of the heat transfer elements prior to entry of the airflow into an inlet to the core engine. The gas turbine engine further comprises a first electric machine. The first electric machine is rotationally connected to the first shaft, the first electric machine is positioned downstream of the heat exchanger module, the first electric machine has a maximum electrical power output of between 180kW and 500kW, the first electric machine has an axial length in the range of between 0.20m and 0.45m, and the first electric machine has a maximum diameter in the range of between 0.15m and 0.39m.
",ROLLS ROYCE PLC,DAVIES PAUL;;MOORE GARETH;;HUSBAND STEPHEN;;TRAINER DAVID;;SCOTHERN DAVID;;GEORGE LUKE,,https://lens.org/033-894-362-428-323,Patent Application,yes,4,0,3,14,0,F02C7/18;;F02C7/32;;F05D2220/766;;F05D2240/12;;F05D2260/213;;F01D15/10;;F01D9/065;;F01D25/12;;Y02T50/60;;F01D15/10;;F02C7/141;;F02K3/06;;F05D2220/323;;F05D2220/36;;F05D2260/213;;F05D2260/606,F02C7/18;;F01D9/06;;F01D15/10;;F02C7/32,,0,0,,,,PENDING
670,GB,B,GB 2605673 B,110-868-060-864-21X,2023-11-15,2023,GB 202116766 A,2021-11-22,GB 202112775 A,2021-09-08,An improved gas turbine engine,,ROLLS ROYCE PLC,PAUL DAVIES;;GARETH MOORE;;STEPHEN HUSBAND;;DAVID TRAINER;;DAVID SCOTHERN;;LUKE GEORGE,,https://lens.org/110-868-060-864-21X,Granted Patent,no,4,0,9,14,0,F02C7/14;;F02C7/18;;F02C7/32;;F01D15/10;;F05D2240/12;;F05D2260/213;;F05D2220/76;;F05D2220/766;;F02K3/04;;F05D2260/42;;Y02T50/60;;F01D15/10;;F02C7/32;;F02C7/14;;F01D9/06;;F02C7/18;;F02C6/20;;F02C7/12;;F02C7/32;;F05D2220/323;;F05D2220/76;;F05D2260/213,F02C7/00;;F02C7/047;;F02C7/12;;F02C7/14;;F02K3/02,,0,0,,,,ACTIVE
671,GB,B,GB 2335680 B,060-459-726-956-737,2000-05-17,2000,GB 9806493 A,1998-03-27,GB 9806493 A,1998-03-27,Method for water control,,SOFITECH NV,DAVIES STEPHEN NIGEL;;JONES TIMOTHY GARETH JOHN;;OLTHOFF SILKE;;TUSTIN GARY JOHN,,https://lens.org/060-459-726-956-737,Granted Patent,no,0,6,9,9,0,C09K8/512;;C09K8/512;;E21B43/32;;E21B43/32,C09K8/512;;E21B43/32,E1F FPC           FPC,0,0,,,,EXPIRED
672,EP,A2,EP 0301725 A2,187-971-450-318-862,1989-02-01,1989,EP 88306310 A,1988-07-11,GB 8717566 A,1987-07-24,Organo metallic compounds of ruthenium iron or cobalt and their use.,"Langmuir Blodgett films are provided having second order molecular hyperpolarizability of at least 30.10⁻⁵⁰c³m³J⁻². combined with chemical stability and a melting point of over 70°. They also have desirable pyroelectric properties shown by a static pyroelectric coefficient of at least 0.0039 nCcm²k⁻¹. The films comprise compounds of the following formula:-
   wherein M is ruthenium, iron or cobalt; 
R¹ is cyclopentadienyl, methylcyclopentadienyl, pentamethylcyclopentadienyl or indenyl; 
Q¹ is (R²)₃Z or carbonyl; 
Q² is (R²)₃Z or carbonyl; 
Z is phosphorus or arsenic; 
R² is an aryl or alkyl radical; 
A is
   Y is a straight chain alkyl or alkoxy radical comprising from 3 to 17 carbon atoms, or, when A is
   N(R³)₂; 
R³ is a lower alkyl radical comprising up to 5 carbon atoms; and 
X is PF₆ or BF₄.   ",EMI PLC THORN,DAVIES STEPHEN GRAHAM;;RICHARDSON TIMOTHY;;ROBERTS GARETH GWYNN;;POLWKA MARION EUGENIO COSIMINO,,https://lens.org/187-971-450-318-862,Patent Application,yes,0,13,5,5,0,C07F15/0046;;Y10T428/31504;;H10N15/15;;Y10T428/31504;;C07F15/0046;;H10N15/15,C09K3/00;;C07F15/00;;C07F15/02;;C07F15/06;;H01L37/02,,0,0,,,,DISCONTINUED
673,WO,A3,WO 2018/115017 A3,060-671-371-256-157,2019-02-07,2019,EP 2017083650 W,2017-12-19,GB 201621635 A,2016-12-19,GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SPRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,,https://lens.org/060-671-371-256-157,Search Report,yes,2,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22;;A61K39/395,,1,1,002-880-498-827-946,10.1016/s1097-2765(00)80067-2;;9660951,"HSU DAVID R ET AL: ""TheXenopusDorsalizing Factor Gremlin Identifies a Novel Family of Secreted Proteins that Antagonize BMP Activities"", MOLECULAR CELL, vol. 1, no. 5, April 1998 (1998-04-01), pages 673 - 683, XP085039240, ISSN: 1097-2765, DOI: 10.1016/S1097-2765(00)80067-2",PENDING
674,GB,A,GB 2335680 A,167-478-953-274-027,1999-09-29,1999,GB 9806493 A,1998-03-27,GB 9806493 A,1998-03-27,Water control in subterranean formations,"A method to reduce water influx into a producing well is described comprising the steps of pumping a chemical composition into a production interval and into surrounding formation ; said composition being capable of forming, firstly, a physically stabilized structure and, secondly, a chemically stabilized structure, wherein said physically stabilized structure being dissolvable by hydrocarbon containing fluids; letting said composition form said physically stabilized structure within the formation surrounding said production interval,; changing pressure condition in said production interval such that the fluid flow within the surrounding formation is reversed; letting thereby in some portions of the formation hydrocarbon containing fluids dissolve said physically stabilized structure and chemically stabilize said structure in the remaining portions by a cross-linking reaction. The time constants of the two stabilizing reactions are selected such that the physical stabilization is essentially completed before the pumping direction is reversed and the chemical stabilization is essentially completed after the pump-out/cleaning operation.",SOFITECH NV,DAVIES STEPHEN NIGEL;;JONES TIMOTHY GARETH JOHN;;OLTHOFF SILKE;;TUSTIN GARY JOHN,,https://lens.org/167-478-953-274-027,Patent Application,no,0,2,9,9,0,C09K8/512;;C09K8/512;;E21B43/32;;E21B43/32,C09K8/512;;E21B43/32,E1F FPC           FPC,0,0,,,,EXPIRED
675,EP,A2,EP 3555129 A2,196-116-211-865-235,2019-10-23,2019,EP 17825499 A,2017-12-19,GB 201621635 A;;EP 2017083650 W,2016-12-19,GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY,,UCB BIOPHARMA SPRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,UCB BIOPHARMA SRL (2020-01-08),https://lens.org/196-116-211-865-235,Patent Application,yes,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22;;A61K39/395,,0,0,,,,PENDING
676,CO,A2,CO 2019006073 A2,036-227-323-780-121,2019-06-19,2019,CO 2019006073 A,2019-06-11,EP 2017083650 W;;GB 201621635 A,2016-12-19,Estructura cristalina de gremlina 1 y anticuerpo inhibidor,"RESUMEN Esta invención se refiere a cristales de la proteína gremlina 1 humana y a la proteína de gremlina 1 humana en la forma de un complejo con un anticuerpo inhibidor. La invención también se refiere a la estructura de gremlina 1 humana (por sí misma, o en un complejo con el anticuerpo) y a los usos de estas estructuras en la selección de agentes que modulan la actividad de gremlina 1. La invención proporciona además anticuerpos que se unen a un sitio inhibidor alostérico en la gremlina 1, junto con las composiciones farmacéuticas y a los usos médicos de tales anticuerpos y agentes identificados por los métodos de selección.",UCB BIOPHARMA SPRL,MCMILLAN DAVID JAMES;;WRIGHT MICHAEL JOHN;;DEDI NEESHA;;TWOMEY BREDA;;DAVIES GARETH,,https://lens.org/036-227-323-780-121,Patent Application,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22;;A61K39/395,,0,0,,,,PENDING
677,EP,A3,EP 0301725 A3,055-141-663-420-343,1991-04-03,1991,EP 88306310 A,1988-07-11,GB 8717566 A,1987-07-24,ORGANO METALLIC COMPOUNDS OF RUTHENIUM IRON OR COBALT AND THEIR USE,"Langmuir Blodgett films are provided having second order molecular hyperpolarizability of at least 30.10⁻⁵⁰c³m³J⁻². combined with chemical stability and a melting point of over 70°. They also have desirable pyroelectric properties shown by a static pyroelectric coefficient of at least 0.0039 nCcm²k⁻¹. The films comprise compounds of the following formula:-
   wherein M is ruthenium, iron or cobalt; 
R¹ is cyclopentadienyl, methylcyclopentadienyl, pentamethylcyclopentadienyl or indenyl; 
Q¹ is (R²)₃Z or carbonyl; 
Q² is (R²)₃Z or carbonyl; 
Z is phosphorus or arsenic; 
R² is an aryl or alkyl radical; 
A is
   Y is a straight chain alkyl or alkoxy radical comprising from 3 to 17 carbon atoms, or, when A is
   N(R³)₂; 
R³ is a lower alkyl radical comprising up to 5 carbon atoms; and 
X is PF₆ or BF₄.",THORN EMI PLC,"DAVIES, STEPHEN GRAHAM;;RICHARDSON, TIMOTHY;;ROBERTS, GARETH GWYNN;;POLWKA, MARION EUGENIO COSIMINO",,https://lens.org/055-141-663-420-343,Search Report,yes,0,0,5,5,0,C07F15/0046;;Y10T428/31504;;H10N15/15;;Y10T428/31504;;C07F15/0046;;H10N15/15,C09K3/00;;C07F15/00;;C07F15/02;;C07F15/06;;H01L37/02,,5,1,063-062-393-417-244,10.1071/ch9791003,"PATENT ABSTRACTS OF JAPAN vol. 9, no. 96 (C-278)(1819), 25 April 1985; & JP - A - 59227893 (RIKAGAKU KENKYUSHO) 21.12.1984;;CHEMICAL ABSTRACTS vol. 107, September/October 1987, page 532, abstract no. 104752r, Columbus, Ohio, US; K. TOKUDA: ""Electrochemistry of Langmuir-Blodgett (LB) monomolecular layer coated electrodes & Hyomen 1987, vol. 25, no. 6, pages 334-353, (Japan);;CHEMICAL ABSTRACTS vol 104, no. 26, 30 June 1986, page 748, abstract no. 235946t, Columbus, Ohio, US; & JP - A - 60216515 (KOKAI TOKKYO KOHO) 30.10.1985;;CHEMICAL ABSTRACTS vol. 91, no. 23, 3 December 1979, page 658, abstract no. 193399x, Columbus, Ohio, US; S.G. ASHBY et al.: ""Cyclopentadienyl-ruthenium and -osmium chemistry. VII. Complexes containing nitriles, tertiaryphosphines or phosphites formed by addition or displacement reactions"" & Aust. J. Chem. 1979, vol. 32, no. 5, 1003-16, (Eng);;JOURNAL OF THE CHEMICAL SOCIETY (A) vol. 14, 1971, pages 2376-2382, London, GB; T. BLACKMORE et al.: ""Some New -Cyclopentadienylruthenium Complexes""",DISCONTINUED
678,ZA,B,ZA 98702 B,053-569-841-190-507,1998-07-29,1998,ZA 98702 A,1998-01-28,EP 97400207 A,1997-01-29,Chemical compounds,,ZENECA LTD;;ZENECA PHARMA SA,ARNOULD JEAN-CLAUDE;;BOYLE FRANCIS THOMAS;;DAVIES GARETH MORSE;;WARDLEWORTH JAMES MICHAEL,,https://lens.org/053-569-841-190-507,Granted Patent,no,0,0,7,7,0,C07D231/12;;C07D233/56;;C07D233/64;;C07D249/08;;C07D233/64;;C07D233/56;;C07D249/08;;C07D231/12,A61K31/415;;A61K31/4168;;C07D233/60;;A61K31/4178;;A61K31/427;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D233/54;;C07D233/61;;C07D233/64;;C07D401/10;;C07D401/12;;C07D409/12;;C07D413/12;;C07D417/06;;C07D417/14;;C07D521/00,,0,0,,,,EXPIRED
679,ES,T3,ES 2060029 T3,125-802-734-881-108,1994-11-16,1994,ES 90303935 T,1990-04-11,GB 8908700 A,1989-04-18,DERIVADOS DE ACIDO 6-FLUOROSIQUIMICO.,"6-Fluoroshikimic acid derivatives of the formula (I): <CHEM> wherein R<1> is hydroxy or a moiety biotransformable thereto and R<2> is hydrogen or -P(O)(OH)2 have antibacterial, antifungal and herbicidal activity. Their preparation and use are described as are pharmaceutical compositions containing them.",ZENECA LTD,SUTHERLAND JAMES KENNETH;;WATKINS WILLIAM JOHN;;SNOW GEORGE ALAN;;DAVIES GARETH MORSE,,https://lens.org/125-802-734-881-108,Granted Patent,no,0,0,11,12,0,A01N37/40;;A01N57/14;;C07C62/32;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/65507;;C07D493/04;;A01N37/40;;C07D303/40;;C07F9/65507;;C07C62/32;;A01N57/14;;C07F9/117,A01N37/40;;A01N41/06;;A01N57/12;;A01N57/14;;A61K31/19;;A61K31/215;;C07C51/00;;C07C51/363;;C07C51/367;;A01N37/10;;C07C62/04;;C07C62/10;;C07C62/32;;C07C67/00;;C07C69/757;;C07D303/38;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/12;;C07F9/655,,0,0,,,,EXPIRED
680,CA,A1,CA 2014622 A1,163-278-710-395-973,1990-10-18,1990,CA 2014622 A,1990-04-17,GB 8908700 A,1989-04-18,COMPOUNDS,"6-FLUOROSHIKIMIC ACID DERIVATIVES 6-Fluoroshikimic acid derivatives of the formula (I): . wherein R1 is hydroxy or a moiety biotransformable thereto and R2 is: hydrogen or -P(O)(OH)2 have antibacterial, antifungal and herbicidal activity. Their preparation and use are described as are pharmaceutical compositions containing them.",ICI PLC,SUTHERLAND JAMES K;;WATKINS WILLIAM J;;SNOW GEORGE A;;DAVIES GARETH M,,https://lens.org/163-278-710-395-973,Patent Application,no,0,0,11,12,0,A01N37/40;;A01N57/14;;C07C62/32;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/65507;;C07D493/04;;A01N37/40;;C07D303/40;;C07F9/65507;;C07C62/32;;A01N57/14;;C07F9/117,A01N37/10;;A01N37/40;;A01N41/06;;A01N57/12;;A01N57/14;;A61K31/19;;A61K31/215;;C07C51/00;;C07C51/363;;C07C51/367;;C07C62/04;;C07C62/10;;C07C62/32;;C07C67/00;;C07C69/757;;C07D303/38;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/12;;C07F9/655,D126005183   M;;1670016    S;;16700197   S;;1670246    S;;071000865  S;;26003511   S;;26003692   S;;26004605   S;;26004795   S,0,0,,,,DISCONTINUED
681,WO,A1,WO 1998/032741 A1,187-706-776-300-93X,1998-07-30,1998,GB 9800230 W,1998-01-27,EP 97400207 A,1997-01-29,INHIBITORS OF FARNESYL PROTEIN TRANSFERASE,"The present invention relates to inhibitors of ras farnesylation of Formula (I), wherein T is of Formula (1) or (2) or (3); A is aryl or heteroaryl; B is aryl or heteroaryl; X and Y represent hydrogen, or both X and Y can represent a single bond (so as to form a double bond); R1 represents a group of Formula (II) or (III), the group of Formula (II) or Formula (III) (having L or D configuration at the chiral alpha carbon in the corresponding free amino acid); R2 represents hydrogen, aryl or heteroaryl; Z represents a direct bond, methylene, ethylene, vinylene, oxy, -CH¿2?-O- or -O-CH2-; and R?3-R4¿, p and r are as defined in the specification or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them. A particular use is in cancer therapy.",ZENECA LTD;;ZENECA PHARMA SA;;ARNOULD JEAN CLAUDE;;BOYLE FRANCIS THOMAS;;DAVIES GARETH MORSE;;WARDLEWORTH JAMES MICHAEL,ARNOULD JEAN-CLAUDE;;BOYLE FRANCIS THOMAS;;DAVIES GARETH MORSE;;WARDLEWORTH JAMES MICHAEL,,https://lens.org/187-706-776-300-93X,Patent Application,yes,2,18,7,7,0,C07D231/12;;C07D233/56;;C07D233/64;;C07D249/08;;C07D233/64;;C07D233/56;;C07D249/08;;C07D231/12,A61K31/415;;A61K31/4168;;A61K31/4178;;A61K31/427;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D233/54;;C07D233/60;;C07D233/61;;C07D233/64;;C07D401/10;;C07D401/12;;C07D409/12;;C07D413/12;;C07D417/06;;C07D417/14;;C07D521/00,,0,0,,,,PENDING
682,US,A1,US 2021/0163586 A1,105-835-099-269-571,2021-06-03,2021,US 202117172109 A,2021-02-10,US 202117172109 A;;GB 201621635 A;;US 201916470996 A;;EP 2017083650 W,2016-12-19,GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,CELLTECH R&D LIMITED (2017-12-04);;UCB BIOPHARMA SRL (2017-06-12),https://lens.org/105-835-099-269-571,Patent Application,yes,0,1,36,36,35,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22;;A61P9/12;;C07K14/51;;G01N33/68,,0,0,,,,ACTIVE
683,US,B1,US 6414145 B1,123-715-528-009-628,2002-07-02,2002,US 35544099 A,1999-07-28,EP 97400207 A;;GB 9800230 W,1997-01-29,Imidazolyl compounds as inhibitors of farnesyl-protein tranferase,"
   

    The present invention relates to inhibitors of ras farnesylation of Formula (I), wherein T is of Formula (1) or (2) or (3); A is aryl or heteroaryl; B is aryl or heteroaryl; X and Y represent hydrogen, or both X and Y can represent a single bond (so as to form a double bond); R ^{ 1 } represents a group of Formula (II) or (III), the group of Formula (II) or Formula (III) (having L or D configuration at the chiral alpha carbon in the corresponding free amino acid); R ^{ 2 } represents hydrogen, aryl or heteroaryl; Z represents a direct bond, methylene, ethylene, vinylene, oxy, CH _{ 2 } O or OCH _{ 2 } ; and R ^{ 3 } R ^{ 4 } , p and r are as defined in the specification or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them. A particular use is in cancer therapy 
",ZENECA LTD;;ZENECA PHARMA SA,BOYLE FRANCIS THOMAS;;DAVIES GARETH MORSE;;WARDLEWORTH JAMES MICHAEL;;ARNOULD JEAN-CLAUDE,ASTRAZENECA SAS (1999-06-02);;ASTRAZENECA UK LIMITED (2000-01-04);;SYNGENTA LIMITED (2002-05-27),https://lens.org/123-715-528-009-628,Granted Patent,yes,7,50,7,7,0,C07D231/12;;C07D233/56;;C07D233/64;;C07D249/08;;C07D233/64;;C07D233/56;;C07D249/08;;C07D231/12,A61K31/415;;A61K31/4168;;A61K31/4178;;A61K31/427;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D233/54;;C07D233/60;;C07D233/61;;C07D233/64;;C07D401/10;;C07D401/12;;C07D409/12;;C07D413/12;;C07D417/06;;C07D417/14;;C07D521/00,544/139;;514/235.8;;514/236.8;;514/326;;514/341;;514/342;;514/365;;514/399;;514/400;;546/209;;546/210;;546/269.7;;546/275.1;;548/204;;548/338.1,0,0,,,,EXPIRED
684,DE,D1,DE 69004143 D1,072-718-720-920-759,1993-12-02,1993,DE 69004143 T,1990-04-11,GB 8908700 A,1989-04-18,6-Fluorshikiminsäurederivate.,"6-Fluoroshikimic acid derivatives of the formula (I): <CHEM> wherein R<1> is hydroxy or a moiety biotransformable thereto and R<2> is hydrogen or -P(O)(OH)2 have antibacterial, antifungal and herbicidal activity. Their preparation and use are described as are pharmaceutical compositions containing them.",ZENECA LTD,SUTHERLAND JAMES KENNETH;;WATKINS WILLIAM JOHN;;SNOW GEORGE ALAN;;DAVIES GARETH MORSE,,https://lens.org/072-718-720-920-759,Granted Patent,no,0,0,11,12,0,A01N37/40;;A01N57/14;;C07C62/32;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/65507;;C07D493/04;;A01N37/40;;C07D303/40;;C07F9/65507;;C07C62/32;;A01N57/14;;C07F9/117,A01N37/40;;A01N41/06;;A01N57/12;;A01N57/14;;A61K31/19;;A61K31/215;;C07C51/00;;C07C51/363;;C07C51/367;;A01N37/10;;C07C62/04;;C07C62/10;;C07C62/32;;C07C67/00;;C07C69/757;;C07D303/38;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/12;;C07F9/655,,0,0,,,,EXPIRED
685,GB,A,GB 2605673 A,077-482-417-498-149,2022-10-12,2022,GB 202116766 A,2021-11-22,GB 202112775 A,2021-09-08,An improved gas turbine engine,"A gas turbine engine 100 for an aircraft comprises a heat exchanger module 120 and a core engine. The core engine comprises a low-pressure compressor connected to a low pressure turbine by a low pressure shaft 140, and a high-pressure compressor connected to a high pressure turbine by a high pressure shaft 162. The heat exchanger module comprises a central hub 122 and a plurality of heat transfer elements 124 extending radially outwardly from the central hub, for transfer of heat energy between a coolant and the inlet airflow 112. The gas turbine engine further comprises an electric machine 210. The electric machine is rotationally connected to the HP shaft and is positioned downstream of the heat exchanger module. The electric machine has a maximum electrical power output of between 180kW and 500kW. The electric machine has an axial length in the range of between 0.20m and 0.45m, and a maximum diameter in the range of between 0.15m and 0.39m.",ROLLS ROYCE PLC,PAUL DAVIES;;GARETH MOORE;;STEPHEN HUSBAND;;DAVID TRAINER;;DAVID SCOTHERN;;LUKE GEORGE,,https://lens.org/077-482-417-498-149,Patent Application,no,4,0,9,14,0,F02C7/14;;F02C7/18;;F02C7/32;;F01D15/10;;F05D2240/12;;F05D2260/213;;F05D2220/76;;F05D2220/766;;F02K3/04;;F05D2260/42;;Y02T50/60;;F01D15/10;;F02C7/32;;F02C7/14;;F01D9/06;;F02C7/18;;F02C6/20;;F02C7/12;;F02C7/32;;F05D2220/323;;F05D2220/76;;F05D2260/213,F02C7/00;;F02C7/047;;F02C7/12;;F02C7/14;;F02K3/02,,0,0,,,,ACTIVE
686,NO,B1,NO 328619 B1,168-061-594-872-123,2010-04-06,2010,NO 20004829 A,2000-09-26,GB 9806493 A;;GB 9900942 W,1998-03-27,Fremgangsmate for a redusere vannproduksjonen i en hydrokarbonbronn,,SCHLUMBERGER TECHNOLOGY BV,JONES TIMOTHY GARETH JOHN;;DAVIES STEPHEN NIGEL;;TUSTIN GARY JOHN;;OLTHOFF SILKE,,https://lens.org/168-061-594-872-123,Granted Patent,no,0,0,9,9,0,C09K8/512;;C09K8/512;;E21B43/32;;E21B43/32,E21B43/32;;C09K8/512,,0,0,,,,EXPIRED
687,US,S,US D0758590 S,184-930-696-190-491,2016-06-07,2016,US 201429510292 F,2014-11-26,US 201429510292 F,2014-11-26,Switch box,,BAYLIS MEDICAL CO INC,BURACHYNSKY NATALIA;;DAVIES GARETH;;SHAH KRISHAN;;STEPHENSON LYNDSAY;;WELLS DAVID;;WOO JASON,BAYLIS MEDICAL COMPANY INC (2014-11-26);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/184-930-696-190-491,Design Right,no,0,7,1,1,0,,,2400;;D24/170,0,0,,,,ACTIVE
688,CA,A1,CA 3045742 A1,006-811-816-870-269,2018-06-28,2018,CA 3045742 A,2017-12-19,GB 201621635 A;;EP 2017083650 W,2016-12-19,GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SPRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,,https://lens.org/006-811-816-870-269,Patent Application,no,0,0,36,36,35,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22;;A61K39/395,,0,0,,,,PENDING
689,TN,A1,TN 2019000188 A1,060-776-932-973-756,2020-10-05,2020,TN 2019000188 A,2017-12-19,GB 201621635 A;;EP 2017083650 W,2016-12-19,GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SPRL,TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DEDI NEESHA;;DAVIES GARETH;;MCMILLAN DAVID JAMES,,https://lens.org/060-776-932-973-756,Patent Application,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,A61K39/395;;C07K16/22,,0,0,,,,PENDING
690,CN,A,CN 110099924 A,132-221-167-047-720,2019-08-06,2019,CN 201780079116 A,2017-12-19,GB 201621635 A;;EP 2017083650 W,2016-12-19,GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SPRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,,https://lens.org/132-221-167-047-720,Patent Application,no,2,2,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22;;A61K39/395,,1,0,,,"DAVID R.HSU等: ""The xenopus dorsalizing factor gremlin identifies a novel family of secreted proteins that antagonize BMP activities"", 《MOLECULAR CELL》",ACTIVE
691,DK,T3,DK 0393923 T3,146-614-257-567-717,1993-12-06,1993,DK 90303935 T,1990-04-11,GB 8908700 A,1989-04-18,"Shikiminsyre og farmaceutisk acceptable salte deraf, deres anvendelse til fremstilling af et lægemiddel, farmaceutisk middel omfattende syren eller et salt deraf, deres anvendelse som fungicid eller herbicid samt fremgangsmåde til fremstilling af syren eller et salt deraf","6-Fluoroshikimic acid derivatives of the formula (I): <CHEM> wherein R<1> is hydroxy or a moiety biotransformable thereto and R<2> is hydrogen or -P(O)(OH)2 have antibacterial, antifungal and herbicidal activity. Their preparation and use are described as are pharmaceutical compositions containing them.",ZENECA LTD,SUTHERLAND JAMES KENNETH;;WATKINS WILLIAM JOHN;;SNOW GEORGE ALAN;;DAVIES GARETH MORSE,,https://lens.org/146-614-257-567-717,Granted Patent,no,0,0,11,12,0,A01N37/40;;A01N57/14;;C07C62/32;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/65507;;C07D493/04;;A01N37/40;;C07D303/40;;C07F9/65507;;C07C62/32;;A01N57/14;;C07F9/117,A01N37/40;;A01N41/06;;A01N57/12;;A01N57/14;;A61K31/19;;A61K31/215;;C07C51/00;;C07C51/363;;C07C51/367;;A01N37/10;;C07C62/04;;C07C62/10;;C07C62/32;;C07C67/00;;C07C69/757;;C07D303/38;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/12;;C07F9/655,,0,0,,,,EXPIRED
692,GB,A,GB 2610656 A,126-759-395-110-231,2023-03-15,2023,GB 202115763 A,2021-11-03,GB 202112773 A,2021-09-08,An improved gas turbine engine,"A gas turbine engine for an aircraft comprises a compressor, a combustor, and a turbine, with a first electric machine 210 being rotationally connected to the turbine. The ratio of the maximum power in Watts (W) generated by the first electrical machine to the maximum dry thrust in Newtons (N) of the gas turbine engine is between 2.0 and 10.0. A fan assembly 130 may comprise a fan with a diameter between 0.3m and 1.4m. The fan assembly may have two or more fan stages with a plurality of blades. The first electrical machine may be positioned axially between the fan assembly and the compressor. A second electric machine 220 may be rotationally connected to the fan assembly, the ratio of the maximum power in Watts (W) generated by the second electrical machine to the maximum dry thrust in Newtons (N) of the gas turbine engine is between 4.0 and 19.0. At least one of the first electric machine and second electric machine may have an axial length and a diameter, wherein a ratio of the axial length to the diameter is between 0.5 and 2.0. An associated method of operation is also disclosed.",ROLLS ROYCE PLC,PAUL DAVIES;;GARETH MOORE;;STEPHEN HUSBAND;;DAVID TRAINER;;DAVID SCOTHERN;;LUKE GEORGE,,https://lens.org/126-759-395-110-231,Patent Application,no,3,0,8,12,0,F02K5/00;;F02K3/06;;F05D2220/76;;B64D27/24;;Y02T50/60;;B64D27/026;;F02K5/00;;F02C6/00;;F02C6/20;;F02C7/12;;F02C7/32;;F05D2220/323;;F05D2220/76;;F05D2260/213,F02C7/32;;F01D15/10;;F02C3/04,,0,0,,,,PENDING
693,KR,A,KR 20190093658 A,174-916-574-020-845,2019-08-09,2019,KR 20197020545 A,2017-12-19,GB 201621635 A;;EP 2017083650 W,2016-12-19,그렘린-1 결정 구조 및 억제 항체,"본 발명은 인간 그렘린-1 단백질의 결정 및 억제 항체와 복합체를 이루는 인간 그렘린-1 단백질에 관한 것이다. 또한, 본 발명은 인간 그렘린-1(그 자체로 또는 항체와의 복합체로서)의 구조 및 그렘린-1 활성을 조절하는 작용제의 스크리닝에서의 상기 구조의 용도에 관한 것이다. 본 발명은 추가로 그렘린-1 상의 알로스테릭 억제 부위에 결합하는 항체, 및 상기 항체 및 스크리닝 방법에 의해 확인된 작용제의 약제학적 조성물 및 의학적 용도를 제공한다.",UCB BIOPHARMA SPRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,,https://lens.org/174-916-574-020-845,Patent Application,no,3,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22;;A61K39/00;;A61P11/00,,0,0,,,,ACTIVE
694,TW,A,TW 201837052 A,056-597-607-670-34X,2018-10-16,2018,TW 106144629 A,2017-12-19,GB 201621635 A,2016-12-19,GREMLIN-1 crystal structure and inhibitory antibody,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SPRL,DAVIES GARETH;;DEDI NEESHA;;MCMILLAN DAVID JAMES;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN,,https://lens.org/056-597-607-670-34X,Patent of Addition,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/18;;A61K39/395;;A61P9/12;;A61P35/00;;A61P43/00,,0,0,,,,ACTIVE
695,AU,A1,AU 2017/384471 A1,154-534-116-399-342,2019-06-13,2019,AU 2017/384471 A,2017-12-19,GB 201621635 A;;EP 2017083650 W,2016-12-19,Gremlin-1 crystal structure and inhibitory antibody,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,UCB BIOPHARMA SRL (2021-12-02),https://lens.org/154-534-116-399-342,Patent Application,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22;;A61K39/395,,0,0,,,,PENDING
696,NO,D0,NO 20004829 D0,139-734-289-993-086,2000-09-26,2000,NO 20004829 A,2000-09-26,GB 9806493 A;;GB 9900942 W,1998-03-27,FremgangsmÕte og blandinger for vannkontroll,,SCHLUMBERGER TECHNOLOGY BV,DAVIES STEPHEN NIGEL;;JONES TIMOTHY GARETH JOHN;;OLTHOFF SILKE;;TUSTIN GARY JOHN,,https://lens.org/139-734-289-993-086,Patent Application,no,0,0,9,9,0,C09K8/512;;C09K8/512;;E21B43/32;;E21B43/32,C09K8/512;;E21B43/32,,0,0,,,,EXPIRED
697,AR,A1,AR 110394 A1,181-965-012-547-893,2019-03-27,2019,AR P170103569 A,2017-12-19,GB 201621635 A,2016-12-19,ESTRUCTURA DEL CRISTAL DE GREMLIN-1 Y ANTICUERPO INHIBIDOR,"Esta solicitud se refiere a cristales de la proteína Gremlin-1 humana y a la proteína Gremlin-1 humana en complejo con un anticuerpo inhibidor. La solicitud también se refiere a la estructura de Gremlin-1 humana (por sí mismo, o en complejo con el anticuerpo) y a los usos de estas estructuras en la prueba de agentes que modulan la actividad de Gremlin-1. La solicitud proporciona además anticuerpos que se unen a un sitio inhibitorio alostérico en Gremlin-1, junto con composiciones farmacéuticas y usos médicos de tales anticuerpos y agentes identificados por los métodos de prueba. Reivindicación 1: Un anticuerpo que se une a un epítopo de Gremlin-1 caracterizado porque comprende al menos un residuo seleccionado de Ile131, Lys147, Lys148, Phe149, Thr150, Thr151, Arg169, Lys174 y Gln175, donde la numeración del residuo está de acuerdo con la SEQ ID Nº 1.",UCB BIOPHARMA SPRL,WRIGHT MICHAEL JOHN;;TWOMEY BREDA;;MMILLAN DAVID JAMES;;DEDI NEESHA;;DAVIES GARETH,,https://lens.org/181-965-012-547-893,Patent Application,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22;;C12N5/22;;C12N15/13,,0,0,,,,PENDING
698,DE,T2,DE 69004143 T2,068-075-762-692-861,1994-03-03,1994,DE 69004143 T,1990-04-11,GB 8908700 A,1989-04-18,6-Fluorshikiminsäurederivate.,"6-Fluoroshikimic acid derivatives of the formula (I): <CHEM> wherein R<1> is hydroxy or a moiety biotransformable thereto and R<2> is hydrogen or -P(O)(OH)2 have antibacterial, antifungal and herbicidal activity. Their preparation and use are described as are pharmaceutical compositions containing them.",ZENECA LTD,SUTHERLAND JAMES KENNETH;;WATKINS WILLIAM JOHN;;SNOW GEORGE ALAN;;DAVIES GARETH MORSE,,https://lens.org/068-075-762-692-861,Granted Patent,no,0,0,11,12,0,A01N37/40;;A01N57/14;;C07C62/32;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/65507;;C07D493/04;;A01N37/40;;C07D303/40;;C07F9/65507;;C07C62/32;;A01N57/14;;C07F9/117,A01N37/40;;A01N41/06;;A01N57/12;;A01N57/14;;A61K31/19;;A61K31/215;;C07C51/00;;C07C51/363;;C07C51/367;;A01N37/10;;C07C62/04;;C07C62/10;;C07C62/32;;C07C67/00;;C07C69/757;;C07D303/38;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/12;;C07F9/655,,0,0,,,,EXPIRED
699,WO,A2,WO 2018/115017 A2,102-983-637-809-260,2018-06-28,2018,EP 2017083650 W,2017-12-19,GB 201621635 A,2016-12-19,GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SPRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,,https://lens.org/102-983-637-809-260,Patent Application,yes,40,7,36,36,35,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22,,51,40,106-753-778-592-300;;020-026-345-586-213;;087-448-981-335-707;;181-448-152-035-827;;055-542-669-483-094;;064-741-687-897-846;;035-081-115-342-527;;077-532-829-551-519;;148-647-852-252-502;;025-662-361-226-516;;042-623-879-457-954;;064-667-501-146-970;;054-899-454-772-257;;030-797-864-869-467;;045-649-831-754-663;;113-446-080-346-814;;057-051-348-154-974;;066-141-497-990-023;;080-856-085-597-555;;056-201-471-905-934;;023-907-179-348-058;;019-779-601-634-917;;010-655-350-435-62X;;037-436-870-995-452;;047-308-646-101-537;;040-363-636-264-022;;082-151-267-963-934;;050-133-270-638-85X;;148-750-828-583-42X;;042-222-591-554-811;;061-154-078-727-141;;076-897-757-672-092;;020-958-411-146-428;;008-583-847-621-717;;053-699-924-523-691;;010-735-642-089-466;;081-004-119-263-171;;028-450-274-279-585;;017-537-377-374-676;;001-135-333-260-455,1172191;;10.1038/256495a0;;25291284;;10.1016/0167-5699(83)90123-8;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;7658022;;10.1016/0022-1759(95)00086-p;;10.1002/eji.1830240426;;8149964;;10.1016/s0378-1119(96)00627-0;;10.1016/s0065-2776(08)60674-4;;7872158;;10.1038/nbt1142;;16151406;;10.2174/1567269053828800;;10.1016/s0022-1759(98)00077-5;;9760222;;9624683;;10.1038/nbt0698-535;;15848072;;10.1016/j.ymeth.2005.01.003;;15608286;;10.1093/nar/gki088;;pmc540042;;10.1016/0021-9673(94)01255-d;;7620566;;10.1134/s0006297906060150;;2406013;;10.1016/j.molimm.2006.03.020;;16697465;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1007/bf00160485;;8483166;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;10.1385/1-59259-666-5:443;;14970513;;10.1110/ps.9.3.487;;pmc2144561;;10752610;;20124692;;pmc2815665;;10.1107/s0907444909047337;;19461840;;pmc2483472;;10.1107/s0021889807021206;;20383002;;pmc2852313;;10.1107/s0907444910007493;;pmc3069751;;10.1107/s0907444911001314;;21460454;;10.1107/s0907444909042073;;20057044;;10.1107/97809553602060000884;;pmc2803126;;10.1016/j.str.2013.06.005;;pmc3749838;;23850456;;pmc4335214;;25561725;;10.1074/jbc.m114.628412;;10.1016/j.jacc.2009.04.011;;19555859;;10.1016/j.pharmthera.2012.06.001;;22722064;;22247494;;10.1161/circulationaha.111.038125;;24160323;;10.1016/j.ajpath.2013.07.017;;pmc5691347;;10.1164/rccm.201206-1028oc;;23087024;;10.1056/nejmra035488;;15483284;;10.1164/rccm.201408-1464oc;;25606692;;10.1016/j.jacc.2009.04.012;;19555858;;10.2353/ajpath.2009.080565;;pmc2630548;;19116361,"""Handbook of Experimental Immunology"", vol. 4, 1986, BLACKWELL SCIENTIFIC PUBLISHERS;;KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497;;KOZBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 72;;COLE ET AL.: ""Monoclonal Antibodies and Cancer Therapy"", 1985, ALAN R LISS, INC., pages: 77 - 96;;BABCOOK, J. ET AL., PROC. NATL. ACAD. SCI., vol. 93, no. 15, 1996, pages 7843 - 78481;;BRINKMAN ET AL., J. IMMUNOL. METHODS, vol. 182, 1995, pages 41 - 50;;AMES ET AL., J. IMMUNOL. METHODS, vol. 184, 1995, pages 177 - 186;;KETTLEBOROUGH ET AL., EUR. J. IMMUNOL., vol. 24, 1994, pages 952 - 958;;PERSIC ET AL., GENE, vol. 187, 1997, pages 9 - 18;;BURTON ET AL., ADVANCES IN IMMUNOLOGY, vol. 57, 1994, pages 191 - 280;;HOLLIGER; HUDSON, NATURE BIOTECH., vol. 23, no. 9, 2005, pages 1126 - 1136;;ADAIR; LAWSON, DRUG DESIGN REVIEWS - ONLINE, vol. 2, no. 3, 2005, pages 209 - 217;;VERMA ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 216, 1998, pages 165 - 181;;VAUGHAN ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 535 - 539;;KASHMIRI ET AL., METHODS, vol. 36, 2005, pages 25 - 34;;RETTER, NUCL. ACIDS RES., vol. 33, no. 1, 2005, pages D671 - D674;;REICHMANN ET AL., NATURE, vol. 332, 1998, pages 323 - 324;;HARRIS, RJ., JOURNAL OF CHROMATOGRAPHY, vol. 705, 1995, pages 129 - 134;;WALKER: ""The Proteomics Protocols Handbook"", 2005, HUMANA PRESS, pages: 571 - 607;;JUNGHANS ET AL., CANCER RES, vol. 50, 1990, pages 1495 - 1502;;KRINNER ET AL., MOL. IMMUNOL., vol. 44, no. 5, February 2007 (2007-02-01), pages 916 - 25;;DEVEREUX, NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 387 - 395;;ALTSCHUL S.F., J MOL EVOL, vol. 36, 1993, pages 290 - 300;;ALTSCHUL, S, F, J MOL BIOL, vol. 215, 1990, pages 403 - 10;;HENIKOFF, PROC. NATL. ACAD. SCI., vol. 89, 1992, pages 10915 - 10919;;KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI., vol. 90, 1993, pages 5873 - 5787;;""Current Protocols in Molecular Biology"", 1999, WILEY INTERSCIENCE;;HARLOW; LANE: ""Antibodies"", COLD SPRING HARBOR PRESS;;REINEKE, METHODS MOL BIOL, vol. 248, 2004, pages 443 - 63;;TOMER, PROTEIN SCIENCE, vol. 9, 2000, pages 487 - 496;;KABSCH, WOLFGANG, ACTA CRYSTALLOGRAPHICA SECTION D, vol. 66, 2010, pages 125 - 132;;MCCOY ET AL., J APPL CRYST, vol. 40, 2007, pages 658 - 674;;EMSLEY ET AL., ACTA CRYSTALLOGRAPHICA SECTION D: BIOLOGICAL CRYSTALLOGRAPHY, vol. 66, no. 4, pages 486 - 501;;MURSHUDOV ET AL.: ""REFMAC5 for the refinement of macromolecular crystal structures"", ACTA CRYSTALLOGRAPHICA SECTION D: BIOLOGICAL CRYSTALLOGRAPHY, vol. 67, 2011, pages 355 - 367;;CHEN ET AL.: ""MolProbity: all-atom structure validation for macromolecular crystallography"", ACTA CRYSTALLOGRAPHICA, vol. D66, 2010, pages 12 - 21;;NOLAN ET AL., STRUCTURE, vol. 21, 2013, pages 1417 - 1429;;NOLAN ET AL., J. BIOL. CHEM., vol. 290, 2014, pages 4759 - 4771;;BUDD & HOLMES PHARM THER, 2012;;THOMAS ET AL., AJP, 2009;;CIUCLAN ET AL., AJP, 2013;;CAHILL ET AL., CIRC, 2012;;CIUCLAN ET AL., AJRCCM, 2013;;BADESCH DB; CHAMPION HC; SANCHEZ MA; HOEPER MM; LOYD JE; MANES A; MCGOON M; NAEIJE R; OLSCHEWSKI H; OUDIZ RJ: ""Diagnosis and assessment of pulmonary arterial hypertension"", J AM COLL CARDIOL., vol. 54, no. 1, 30 June 2009 (2009-06-30), pages S55 - 66, XP026218349, DOI: doi:10.1016/j.jacc.2009.04.011;;BUDD DC; HOLMES AM: ""Targeting TGFP superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders"", PHARMACOL THER., vol. 135, no. 3, September 2012 (2012-09-01), pages 279 - 91;;CAHILL E; COSTELLO CM; ROWAN SC; HARKIN S; HOWELL K; LEONARD MO; SOUTHWOOD M; CUMMINS EP; FITZPATRICK SF; TAYLOR CT: ""Gremlin plays a key role in the pathogenesis of pulmonary hypertension"", CIRCULATION, vol. 125, no. 7, 21 February 2012 (2012-02-21), pages 920 - 30, XP055279199, DOI: doi:10.1161/CIRCULATIONAHA.111.038125;;CIUCLAN L; SHEPPARD K; DONG L; SUTTON D; DUGGAN N; HUSSEY M; SIMMONS J; MORRELL NW; JARAI G; EDWARDS M: ""Treatment with anti-gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice"", AM J PATHOL., vol. 183, no. 5, November 2013 (2013-11-01), pages 1461 - 73, XP055205055, DOI: doi:10.1016/j.ajpath.2013.07.017;;CIUCLAN L; HUSSEY MJ; BURTON V; GOOD R; DUGGAN N; BEACH S; JONES P; FOX R; CLAY I; BONNEAU O: ""Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression"", AM J RESPIR CRIT CARE MED., vol. 187, no. 1, 1 January 2013 (2013-01-01), pages 78 - 89;;FARBER HW; LOSCALZO J: ""Pulmonary arterial hypertension"", N ENGL J MED., vol. 351, no. 16, 14 October 2004 (2004-10-14), pages 1655 - 65;;GILBANE AJ; DERRETT-SMITH E; TRINDER SL; GOOD RB; PEARCE A; DENTON CP; HOLMES AM: ""Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor- 0-dependent mouse model of pulmonary hypertension and in systemic sclerosis"", AM J RESPIR CRIT CARE MED., vol. 191, no. 6, 15 March 2015 (2015-03-15), pages 665 - 77;;SIMONNEAU G; ROBBINS IM; BEGHETTI M; CHANNICK RN; DELCROIX M; DENTON CP; ELLIOTT CG; GAINE SP; GLADWIN MT; JING ZC: ""Updated clinical classification of pulmonary hypertension"", J AM COLL CARDIOL., vol. 54, no. 1, 30 June 2009 (2009-06-30), pages S43 - 54, XP026218348, DOI: doi:10.1016/j.jacc.2009.04.012;;THOMAS M; DOCX C; HOLMES AM; BEACH S; DUGGAN N; ENGLAND K; LEBLANC C; LEBRET C; SCHINDLER F; RAZA F: ""Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline"", AM J PATHOL., vol. 174, no. 2, February 2009 (2009-02-01), pages 380 - 9",PENDING
700,EP,A1,EP 4148263 A1,139-325-675-527-967,2023-03-15,2023,EP 22192758 A,2022-08-30,GB 202112773 A;;GB 202115763 A,2021-09-08,AN IMPROVED GAS TURBINE ENGINE,"A gas turbine engine for an aircraft comprises, in axial flow sequence, a compressor module, a combustor module, and a turbine module, with a first electric machine being rotationally connected to the turbine module. The first electrical machine is configured to generate a maximum electrical power P EM1  (W), and the gas turbine engine is configured to generate a maximum dry thrust T (N); and a ratio S of:    is in a range of between 2.0 and 10.0.
",ROLLS ROYCE PLC,DAVIES PAUL;;MOORE GARETH;;HUSBAND STEPHEN;;TRAINER DAVID;;SCOTHERN DAVID;;GEORGE LUKE,,https://lens.org/139-325-675-527-967,Patent Application,yes,5,0,2,12,0,F02K5/00;;F02K3/06;;F05D2220/76;;B64D27/24;;B64D27/10;;Y02T50/60;;B64D27/026;;F01D15/10;;F02K3/06;;F05D2220/323;;F05D2220/36,F02K5/00,,1,0,,,"ANONYMOUS: ""GE - Aviation: CF6"", 21 November 2008 (2008-11-21), pages 1 - 2, XP093016034, Retrieved from the Internet <URL:https://web.archive.org/web/20081121124612/http://www.geaviation.com/engines/commercial/cf6/cf6-80c2.html> [retrieved on 20230120]",DISCONTINUED
701,AT,T1,AT E96418 T1,134-596-228-354-032,1993-11-15,1993,AT 90303935 T,1990-04-11,GB 8908700 A,1989-04-18,6-FLUORSHIKIMINSAEUREDERIVATE.,"6-Fluoroshikimic acid derivatives of the formula (I): <CHEM> wherein R<1> is hydroxy or a moiety biotransformable thereto and R<2> is hydrogen or -P(O)(OH)2 have antibacterial, antifungal and herbicidal activity. Their preparation and use are described as are pharmaceutical compositions containing them.",ZENECA LTD,SUTHERLAND JAMES KENNETH;;WATKINS WILLIAM JOHN;;SNOW GEORGE ALAN;;DAVIES GARETH MORSE,,https://lens.org/134-596-228-354-032,Granted Patent,no,0,0,11,12,0,A01N37/40;;A01N57/14;;C07C62/32;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/65507;;C07D493/04;;A01N37/40;;C07D303/40;;C07F9/65507;;C07C62/32;;A01N57/14;;C07F9/117,A01N37/10;;A01N37/40;;A01N41/06;;A01N57/12;;A01N57/14;;A61K31/19;;A61K31/215;;C07C51/00;;C07C51/363;;C07C51/367;;C07C62/04;;C07C62/10;;C07C62/32;;C07C67/00;;C07C69/757;;C07D303/38;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/12;;C07F9/655,,0,0,,,,DISCONTINUED
702,ZA,B,ZA 201903810 B,016-145-747-853-799,2020-12-23,2020,ZA 201903810 A,2019-06-12,GB 201621635 A;;EP 2017083650 W,2016-12-19,GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY,,UCB BIOPHARMA SPRL,NEESHA DEDI;;BREDA TWOMEY;;MICHAEL JOHN WRIGHT;;GARETH DAVIES;;DAVID JAMES MCMILLAN,,https://lens.org/016-145-747-853-799,Granted Patent,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,,,0,0,,,,ACTIVE
703,AU,A,AU 1998/057726 A,144-328-197-263-649,1998-08-18,1998,AU 1998/057726 A,1998-01-27,EP 97400207 A;;GB 9800230 W,1997-01-29,Inhibitors of farnesyl protein transferase,,ZENECA LTD,ARNOULD JEAN-CLAUDE;;BOYLE FRANCIS THOMAS;;DAVIES GARETH MORSE;;WARDLEWORTH JAMES MICHAEL,,https://lens.org/144-328-197-263-649,Patent Application,no,0,0,7,7,0,C07D231/12;;C07D233/56;;C07D233/64;;C07D249/08;;C07D233/64;;C07D233/56;;C07D249/08;;C07D231/12,C07D233/60;;A61K31/415;;A61K31/4168;;A61K31/4178;;A61K31/427;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D233/54;;C07D233/61;;C07D233/64;;C07D401/10;;C07D401/12;;C07D409/12;;C07D413/12;;C07D417/06;;C07D417/14;;C07D521/00,,0,0,,,,PENDING
704,PE,A1,PE 20191542 A1,022-813-101-673-981,2019-10-23,2019,PE 2019001251 A,2017-12-19,GB 201621635 A;;EP 2017083650 W,2016-12-19,ESTRUCTURA CRISTALINA DE GREMLINA 1 Y ANTICUERPO INHIBIDOR,"Referido a un anticuerpo, el cual se une a un epitopo sobre gremlina 1, que comprende al menos un residuo seleccionado de Ile131, Lys147, Lys148, Phe149, Thr150, Thrl51, Argl69, Lysl74 y Gin 175, donde la numeracion de los residuos es de conformidad con la SEQ ID NO: 1. Dichos anticuerpos se unen a un sitio inhibidor alosterico en la gremlina 1 y son utiles en el tratamiento y prevencion de la fibrosis renal como nefropatia diabetica, fibrosis pulmonar idiopatica, hipertension, entre otras. Ademas, se refiere a un polinucleotido, un vector, una celula huesped que codifica dicho anticuerpo, una forma cristalina de gremlina 1 y una composicion farmaceutica que comprende dichos anticuerpos",UCB BIOPHARMA SPRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,,https://lens.org/022-813-101-673-981,Patent Application,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22;;A61K39/395,,0,0,,,,PENDING
705,EP,A1,EP 4148264 A1,010-371-077-118-329,2023-03-15,2023,EP 22192759 A,2022-08-30,GB 202112773 A;;GB 202115764 A,2021-09-08,AN IMPROVED GAS TURBINE ENGINE,"A gas turbine engine for an aircraft comprises, in axial flow sequence, a compressor module, a combustor module, and a turbine module, with a first electric machine being rotationally connected to the turbine module. The first electrical machine is configured to generate a maximum electrical power P EM1  (W), and the gas turbine engine is configured to generate a maximum shaft power P SHAFT  (W); and a ratio R of:    is in a range of between 0.005 and 0.020.
",ROLLS ROYCE PLC,DAVIES PAUL;;MOORE GARETH;;HUSBAND STEPHEN;;TRAINER DAVID;;SCOTHERN DAVID;;GEORGE LUKE,,https://lens.org/010-371-077-118-329,Patent Application,yes,5,0,2,12,0,F02K5/00;;F02K3/06;;F05D2220/76;;B64D27/24;;B64D27/10;;Y02T50/60;;B64D27/026;;F02C6/20;;F02C7/32;;F02C7/36;;F05D2220/323;;F05D2220/70,F02K5/00,,1,0,,,"ANONYMOUS: ""The LM6000 Engine | GE Aviation"", 1 January 2021 (2021-01-01), XP055924308, Retrieved from the Internet <URL:https://www.geaviation.com/propulsion/marine/lm6000> [retrieved on 20220523]",DISCONTINUED
706,BR,A2,BR 112019010903 A2,021-818-272-428-688,2019-10-01,2019,BR 112019010903 A,2017-12-19,EP 2017083650 W;;GB 201621635 A,2016-12-19,estrutura de cristal de gremlin-1 e anticorpo inibidor,"a presente invenção se refere a cristais da proteína de gremlin-1 humana, e a proteína de gremlin-1 humana em complexo com um anticorpo inibidor. a invenção também se refere à estrutura de gremlin-1 humana (sozinha ou em complexo com o anticorpo) e faz uso dessas estruturas na triagem quanto a agentes que modulam a atividade de gremlin-1. a invenção fornece adicionalmente os anticorpos que se ligam a um sítio inibidor alostérico em gremlin-1, juntamente com composições farmacêuticas e usos medicinais de tais anticorpos e agentes identificados pelos métodos de triagem.",UCB BIOPHARMA SPRL,BREDA TWOMEY;;DAVID JAMES MCMILLAN;;GARETH DAVIES;;MICHAEL JOHN WRIGHT;;NEESHA DEDI,UCB BIOPHARMA SRL (BE) (2020-07-21),https://lens.org/021-818-272-428-688,Patent Application,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,A61K39/395;;C07K16/22,,0,0,,,,PENDING
707,US,A1,US 2003/0220495 A1,061-654-145-818-483,2003-11-27,2003,US 7109802 A,2002-02-11,US 7109802 A;;EP 97400207 A;;US 35544099 A,1997-01-29,Inhibitors of farnesyl protein transferase,"
    The present invention relates to inhibitors of ras farnesylation of Formula (1), wherein T is of Formula (1) or (2) or (3), A is aryl or heteroaryl; B is aryl or heteroaryl; X and Y represent hydrogen, or both X and Y can represent a single bond (so as to form a double bond); R ¹ represents a group of Formula (II) or (III), the group of Formula (II) or Formula (III) (having L or D configuration at the chiral alpha carbon in the corresponding free amino acid); R ² represents hydrogen, aryl or heteroaryl; Z represents a direct bond, methylene, ethylene, vinylene, oxy, CH ₂ O or OCH ₂ ; and R ³ R ⁴ , p and r are as defined in the specification or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them. A particular use is in cancer therapy. 
",ZENECA LTD AND ZENECA PHARMA S,BOYLE FRANCIS THOMAS;;DAVIES GARETH MORSE;;WARDLEWORTH JAMES MICHAEL;;ARNOULD JEAN-CLAUDE,,https://lens.org/061-654-145-818-483,Patent Application,yes,0,4,7,7,0,C07D231/12;;C07D233/56;;C07D233/64;;C07D249/08;;C07D233/64;;C07D233/56;;C07D249/08;;C07D231/12,A61K31/415;;C07D233/60;;A61K31/4168;;A61K31/4178;;A61K31/427;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D233/54;;C07D233/61;;C07D233/64;;C07D401/10;;C07D401/12;;C07D409/12;;C07D413/12;;C07D417/06;;C07D417/14;;C07D521/00,544/106,0,0,,,,DISCONTINUED
708,CL,A1,CL 2019001715 A1,121-376-600-303-80X,2019-11-29,2019,CL 2019001715 A,2019-06-19,GB 201621635 A,2016-12-19,Estructura cristalina de gremlina 1 y anticuerpo inhibidor.,"ESTA INVENCIÓN SE REFIERE A CRISTALES DE LA PROTEÍNA GREMLINA 1 HUMANA Y A LA PROTEÍNA DE GREMLINA 1 HUMANA EN LA FORMA DE UN COMPLEJO CON UN ANTICUERPO INHIBIDOR. LA INVENCIÓN TAMBIÉN SE REFIERE A LA ESTRUCTURA DE GREMLINA 1 HUMANA (POR SÍ MISMA, O EN UN COMPLEJO CON EL ANTICUERPO) Y A LOS USOS DE ESTAS ESTRUCTURAS EN LA SELECCIÓN DE AGENTES QUE MODULAN LA ACTIVIDAD DE GREMLINA 1. LA INVENCIÓN PROPORCIONA ADEMÁS ANTICUERPOS QUE SE UNEN A UN SITIO INHIBIDOR ALOSTÉRICO EN LA GREMLINA 1, JUNTO CON LAS COMPOSICIONES FARMACÉUTICAS Y A LOS USOS MÉDICOS DE TALES ANTICUERPOS Y AGENTES IDENTIFICADOS POR LOS MÉTODOS DE SELECCIÓN.",UCB BIOPHARMA SPRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,,https://lens.org/121-376-600-303-80X,Patent Application,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22,,0,0,,,,PENDING
709,PH,A1,PH 12019501319 A1,166-498-380-809-523,2020-03-02,2020,PH 12019501319 A,2019-06-11,GB 201621635 A;;EP 2017083650 W,2016-12-19,GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SPRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,,https://lens.org/166-498-380-809-523,Patent Application,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,A61K39/395;;C07K16/22,,0,0,,,,PENDING
710,EP,A1,EP 0393923 A1,157-948-600-016-357,1990-10-24,1990,EP 90303935 A,1990-04-11,GB 8908700 A,1989-04-18,6-Fluoroshikimic acid derivatives.,"6-Fluoroshikimic acid derivatives of the formula (I):
   wherein R¹ is hydroxy or a moiety biotransformable thereto and R² is hydrogen or -P(O)(OH)₂ have antibacterial, antifungal and herbicidal activity. Their preparation and use are described as are pharmaceutical compositions containing them.  ",ICI PLC,SUTHERLAND JAMES KENNETH;;WATKINS WILLIAM JOHN;;SNOW GEORGE ALAN;;DAVIES GARETH MORSE,ZENECA LIMITED (1993-10-20);;CESSIONE;ZENECA LIMITED (1994-04-03),https://lens.org/157-948-600-016-357,Patent Application,yes,0,3,11,12,0,A01N37/40;;A01N57/14;;C07C62/32;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/65507;;C07D493/04;;A01N37/40;;C07D303/40;;C07F9/65507;;C07C62/32;;A01N57/14;;C07F9/117,A01N37/40;;A01N41/06;;A01N57/12;;A01N57/14;;A61K31/19;;A61K31/215;;C07C51/00;;C07C51/363;;C07C51/367;;A01N37/10;;C07C62/04;;C07C62/10;;C07C62/32;;C07C67/00;;C07C69/757;;C07D303/38;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/12;;C07F9/655,,2,0,,,"CHEMICAL ABSTRACTS, vol. 112, no. 7, February 12, 1980 Columbus, Ohio, USA S.BOWLES et al. ""Reactivity studies in the shikimic acid series"" page 726, column 2, abstract- no. 55 429h;;CHEMICAL ABSTRACTS, vol.90, no. 23, June 4, 1990 Columbus, Ohio, USA B.GANEM ""From glucose to aromatics: recent develop- ments in natural products of the shikimic acid path"" page 615, column 1, abstract -no. 186 420y",EXPIRED
711,EC,A,EC SP19051912 A,025-402-160-240-433,2019-07-31,2019,EC DI201951912 A,2019-07-19,GB 201621635 A,2016-12-19,ESTRUCTURA CRISTALINA DE GREMLINA 1 Y ANTICUERPO INHIBIDOR,"Esta invención se refiere a cristales de la proteína gremlina 1 humana y a la proteína de gremlina 1 humana en la forma de un complejo con un anticuerpo inhibidor. La invención también se refiere a la estructura de gremlina 1 humana (por sí misma, o en un complejo con el anticuerpo) y a los usos de estas estructuras en la selección de agentes que modulan la actividad de gremlina 1. La invención proporciona además anticuerpos que se unen a un sitio inhibidor alostérico en la gremlina 1, junto con las composiciones farmacéuticas y a los usos médicos de tales anticuerpos y agentes identificados por los métodos de selección.",UCB BIOPHARMA SPRL,TWOMEY BREDA;;DAVIES GARETH;;WRIGHT MICHAEL JOHN;;DEDI NEESHA;;MCMILLAN DAVID JAMES,,https://lens.org/025-402-160-240-433,Patent Application,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22,,0,0,,,,PENDING
712,EP,B1,EP 0393923 B1,098-952-449-448-619,1993-10-27,1993,EP 90303935 A,1990-04-11,GB 8908700 A,1989-04-18,6-Fluoroshikimic acid derivatives.,"6-Fluoroshikimic acid derivatives of the formula (I): <CHEM> wherein R<1> is hydroxy or a moiety biotransformable thereto and R<2> is hydrogen or -P(O)(OH)2 have antibacterial, antifungal and herbicidal activity. Their preparation and use are described as are pharmaceutical compositions containing them.",ZENECA LTD,SUTHERLAND JAMES KENNETH;;WATKINS WILLIAM JOHN;;SNOW GEORGE ALAN;;DAVIES GARETH MORSE,ZENECA LIMITED (1993-10-20);;CESSIONE;ZENECA LIMITED (1994-04-03),https://lens.org/098-952-449-448-619,Granted Patent,yes,0,0,11,12,0,A01N37/40;;A01N57/14;;C07C62/32;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/65507;;C07D493/04;;A01N37/40;;C07D303/40;;C07F9/65507;;C07C62/32;;A01N57/14;;C07F9/117,A01N37/40;;A01N41/06;;A01N57/12;;A01N57/14;;A61K31/19;;A61K31/215;;C07C51/00;;C07C51/363;;C07C51/367;;A01N37/10;;C07C62/04;;C07C62/10;;C07C62/32;;C07C67/00;;C07C69/757;;C07D303/38;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/12;;C07F9/655,,2,0,,,"CHEMICAL ABSTRACTS, vol. 112, no. 7, February 12, 1980, Columbus, Ohio, USA; S .BOWLES et al, ""Reactivity studies in the shikimic acid series"", page 726, column 2, abstract no. 55 429h;;CHEMICAL ABSTRACTS, vol. 90, no. 23, June 4, 1990, Columbus, Ohio, USA; B. GANEM, ""From glucose to aromatics: recent developments in natural products of the shikimic acid path"", page 615, column 1, abstract no. 186 420y",EXPIRED
713,US,B2,US 10947304 B2,170-027-598-477-318,2021-03-16,2021,US 201716470996 A,2017-12-19,GB 201621635 A;;EP 2017083650 W,2016-12-19,Gremlin-1 antibody,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,CELLTECH R&D LIMITED (2017-12-04);;UCB BIOPHARMA SRL (2017-06-12),https://lens.org/170-027-598-477-318,Granted Patent,yes,65,2,36,36,35,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22;;A61K39/00;;A61P9/12;;C07K14/51;;G01N33/68,,131,120,027-477-313-726-928;;020-367-308-901-689;;046-845-561-202-870;;062-761-744-997-508;;075-555-351-927-589;;042-222-591-554-811;;002-880-498-827-946;;148-647-852-252-502;;056-201-471-905-934;;080-856-085-597-555;;181-448-152-035-827;;033-401-440-963-789;;011-553-054-044-973;;098-724-633-703-400;;087-448-981-335-707;;076-897-757-672-092;;043-729-032-107-483;;041-863-374-864-841;;035-081-115-342-527;;012-007-448-024-359;;008-583-847-621-717;;041-701-093-712-495;;001-646-542-312-05X;;148-750-828-583-42X;;095-834-903-970-444;;000-769-593-092-070;;008-061-699-775-635;;067-024-105-019-398;;010-735-642-089-466;;053-699-924-523-691;;013-703-966-633-758;;097-901-796-209-229;;029-486-847-477-02X;;070-238-365-351-890;;071-630-416-006-425;;066-141-497-990-023;;111-604-378-852-726;;075-789-057-546-584;;056-289-795-899-023;;082-151-267-963-934;;098-322-700-973-135;;081-004-119-263-171;;060-522-017-672-204;;008-017-695-084-433;;051-036-594-306-992;;060-126-066-099-876;;077-587-097-220-826;;076-252-023-764-678;;060-918-425-739-173;;008-693-687-336-286;;030-797-864-869-467;;006-574-942-364-256;;023-907-179-348-058;;018-280-468-055-668;;063-266-551-840-350;;046-951-095-213-650;;037-436-870-995-452;;038-728-499-086-588;;077-532-829-551-519;;023-860-693-372-071;;018-199-486-626-091;;027-840-251-594-854;;020-398-976-665-441;;034-499-526-956-496;;040-842-346-948-061;;113-446-080-346-814;;047-308-646-101-537;;029-970-218-339-139;;092-175-386-389-524;;019-779-601-634-917;;064-667-501-146-970;;055-542-669-483-094;;088-935-349-526-045;;013-337-877-638-381;;106-753-778-592-300;;024-205-497-164-000;;020-026-345-586-213;;057-051-348-154-974;;037-310-319-433-702;;028-671-261-063-506;;026-361-471-680-127;;083-861-682-427-488;;001-062-843-030-532;;040-363-636-264-022;;016-392-744-492-623;;082-522-923-505-342;;050-133-270-638-85X;;095-576-636-997-853;;064-781-969-527-647;;061-154-078-727-141;;028-188-258-692-969;;072-971-856-375-322;;099-142-413-754-43X;;064-741-687-897-846;;028-716-741-713-711;;007-711-535-660-589;;010-655-350-435-62X;;054-899-454-772-257;;042-204-626-457-327;;012-113-132-303-756;;026-553-044-527-677;;034-489-784-615-708;;036-648-857-259-985;;080-784-865-336-364;;053-688-298-868-719;;017-537-377-374-676;;044-958-492-431-511;;044-380-745-789-522;;001-135-333-260-455;;101-640-792-825-42X;;015-238-057-914-589;;017-186-900-863-545;;067-290-214-184-650;;042-623-879-457-954;;051-322-618-006-677;;025-662-361-226-516;;065-274-506-678-30X;;012-265-598-126-264;;016-507-178-023-87X;;021-221-160-658-727,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;1961196;;10.1016/0161-5890(91)90003-3;;10.1016/j.intimp.2004.01.010;;15120653;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;10.1126/science.2426778;;2426778;;10.1016/j.str.2013.06.005;;pmc3749838;;23850456;;10.1016/s1097-2765(00)80067-2;;9660951;;10.2174/1567269053828800;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1007/bf00160485;;8483166;;7658022;;10.1016/0022-1759(95)00086-p;;8417368;;10.1016/0161-5890(93)90432-b;;10.1002/mc.22378;;26293751;;10.1182/blood-2011-09-380410;;pmc3382938;;22394600;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1016/j.jacc.2009.04.011;;19555859;;18751803;;10.1007/s11420-005-0111-5;;pmc2504134;;10.1016/0022-1759(95)00016-4;;7769243;;10.1016/s0065-2776(08)60674-4;;7872158;;pmc5119705;;10.11138/ccmbm/2016.13.2.101;;27920804;;22247494;;10.1161/circulationaha.111.038125;;25706628;;10.1038/ng.3225;;pmc3132213;;10.1002/jcp.22730;;21412775;;10.1107/s0907444909042073;;20057044;;10.1107/97809553602060000884;;pmc2803126;;10.1007/s00535-012-0614-z;;22706573;;10.1038/cddis.2017.533;;pmc5775406;;29095438;;25637218;;10.1016/j.yexcr.2015.01.006;;pmc3398763;;22451422;;10.1182/blood-2012-02-412783;;10.1164/rccm.201206-1028oc;;23087024;;24160323;;10.1016/j.ajpath.2013.07.017;;pmc5691347;;22182508;;10.1016/j.cellsig.2011.12.008;;10029599;;10.1182/blood.v93.5.1697;;10.1182/blood.v93.5.1697.405a17_1697_1706;;pmc5093055;;27118403;;10.1038/leu.2016.96;;25419707;;10.1038/nm.3750;;pmc4594755;;20298438;;pmc2871998;;10.1111/j.1469-7580.2010.01214.x;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;19335218;;10.1359/jbmr.090210;;10511457;;10.1016/s0163-7258(99)00018-2;;25266456;;pmc4464690;;10.1038/nrrheum.2014.164;;20383002;;pmc2852313;;10.1107/s0907444910007493;;10.1007/s11999-009-0981-9;;pmc2772945;;19597895;;10.1056/nejmra035488;;15483284;;10495271;;10.1016/s0925-4773(99)00142-2;;pmc3775476;;22374979;;10.1158/0008-5472.can-11-2067;;10.1385/1-59259-890-0:571;;15539560;;10.1210/en.2004-0766;;17785465;;10.1074/jbc.m701317200;;10.1182/blood-2012-01-379024;;pmc3390959;;22535658;;10.1097/00003086-199706000-00011;;9186204;;27862197;;10.1111/1440-1681.12697;;10.1016/0021-9673(94)01255-d;;7620566;;10.1201/b14193-19;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1016/j.neo.2017.09.004;;pmc5678743;;29091798;;10.1038/nrc2189;;17646864;;11154231;;10.1182/blood.v97.2.516;;10.1110/ps.9.3.487;;pmc2144561;;10752610;;10.1038/leu.2011.263;;21941367;;10.1038/nbt1142;;16151406;;10.1126/science.280.5366.1086;;9582123;;09582123;;10.1038/88919;;11381269;;10.3892/mmr.2017.6253;;pmc5364878;;28260028;;28299802;;10.1002/path.4891;;pmc5488238;;25706627;;10.1038/ng.3224;;22561515;;pmc4594751;;10.1038/ng.2263;;2406013;;20124692;;pmc2815665;;10.1107/s0907444909047337;;23659962;;pmc5528431;;10.1016/j.molonc.2013.04.002;;25153376;;10.1515/hsz-2014-0221;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;15848072;;10.1016/j.ymeth.2005.01.003;;10.1002/eji.1830240426;;8149964;;10.1371/journal.pone.0035100;;22514712;;pmc3325980;;10.1371/journal.pone.0174565;;pmc5367809;;28346486;;1172191;;10.1038/256495a0;;25834571;;pmc4365323;;10.1155/2015/834137;;25291284;;10.1016/0167-5699(83)90123-8;;10.1016/j.molimm.2006.03.020;;16697465;;15509819;;10.1056/nejmra041875;;pmc3693206;;23826422;;10.1002/path.4537;;25810250;;26632274;;10.1038/ncomms9983;;pmc4686867;;10.1016/j.celrep.2014.07.020;;pmc4471812;;25131200;;19461840;;pmc2483472;;10.1107/s0021889807021206;;20660291;;10.1182/blood-2010-06-291930;;22870311;;pmc3411619;;10.1371/journal.pone.0042264;;pmc3069751;;10.1107/s0907444911001314;;21460454;;10.1186/1471-2407-6-74;;16545136;;pmc1459871;;10.1038/nprot.2007.279;;17703211;;pmc4335214;;25561725;;10.1074/jbc.m114.628412;;pmc4007935;;10.3324/haematol.2013.090977;;23935020;;25117979;;pmc4198825;;10.1016/j.neo.2014.07.002;;pmc4595141;;10.1186/s13045-015-0209-2;;26445238;;10.1016/s0378-1119(96)00627-0;;10.1016/j.stem.2015.02.015;;pmc4355577;;25748930;;15014901;;10.1007/s00259-003-1441-5;;10.1385/1-59259-666-5:443;;14970513;;15608286;;10.1093/nar/gki088;;pmc540042;;3127726;;10.1038/332323a0;;10.1038/nature07935;;19329995;;10.1089/ten.tec.2013.0612;;24738624;;pmc2688661;;10.1002/dvdy.21882;;19235733;;10.1053/j.gastro.2008.01.079;;18325394;;10.1016/j.actbio.2012.06.036;;22750247;;10.1038/s41586-018-0084-4;;pmc5966331;;29720649;;10.1016/j.jacc.2009.04.012;;19555858;;10.1073/pnas.0606857103;;17003113;;pmc1578503;;pmc3759128;;23978876;;10.1038/oncsis.2013.29;;10.2353/ajpath.2009.080565;;pmc2630548;;19116361;;7042536;;10.1111/j.1600-065x.1982.tb00392.x;;21655089;;pmc3107194;;10.1371/journal.pgen.1002105;;pmc232332;;10.1128/mcb.17.8.4801;;9234736;;10.1007/s10585-007-9108-4;;17952614;;9624683;;10.1038/nbt0698-535;;18594511;;10.1038/nature07085;;pmc2840222;;10.1016/s0022-1759(98)00077-5;;9760222;;10.3892/or.2011.1463;;21935575;;25594183;;10.1016/j.cell.2014.11.042;;pmc4436082;;10.1007/s13277-015-4093-8;;26392110;;10.1016/j.bone.2009.11.005;;19913648,"Rudikoff et al. Proc. Natl. Acad. Sci. USA vol. 79, pp. 1979-1983 (Mar. 1982). (Year: 1982).;;Janeway et al. Immunology, 3rd ed., 1997, Garland Publications, Inc., pp. 3:1-3:11. (Year: 1997).;;Lederman et al (1991), Molecular Immunology, vol. 28, No. 11, pp. 1171-1181.;;Li et al. (2004), International Immunology, vol. 4, pp. 693-708.;;Panka et al. Proc. Natl. Acad. Sci. USA vol. 85, pp. 3080-3084 (May 1988).;;Amit et al. Science, Vot. 233, pp. 747-753, (Aug. 1986).;;Harlow et al., Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, 1988, p. 76).;;Nolan, K. et al. “Structure of Protein Related to Dan and Cerberus: Insights into the Mechanism of Bone Morphogenetic Protein Antagonism” Structure, Aug. 6, 2013, pp. 1417-1429, vol. 21.;;United Kingdom Search Report Application No. GB1519083.8, dated Jul. 29, 2016, pp. 1-5.;;Hsu, D. R. et al. “The Xenopus Dorsalizing Factor Gremlin Identifies a Novel Family of Secreted Proteins that Antagonize BMP Activities” Molecular Cell, Apr. 1998, pp. 673-683, vol. 1, No. 5.;;Written Opinion in International Application No. PCT/EP2017/083650, dated Jan. 4, 2019, pp. 1-8.;;Adair, J. R. et al. “Therapeutic Antibodies” Drug Design Reviews, 2005, pp. 1-11.;;Altschul, S. F. et al. “Basic Local Alignment Search Tool” J Mol Biol., 1990, pp. 403-410, vol. 215.;;Altschul, S.F. “A Protein Alignment Scoring System Sensitive at All Evolutionary Distances” J Mol Evol., 1993, pp. 290-300, vol. 36.;;Ames, R. S. et al. “Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins” Journal of Immunological Methods, 1995, pp. 177-186, vol. 184.;;Angal, S. et al. “A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody” Molecular Immunology, 1993, pp. 105-108, vol. 30, No. 1.;;Attar-Schneider, O. et al. “Multiple Myeloma and Bone Marrow Mesenchymal Stem Cells' Crosstalk: Effect on Translation Initiation” Molecular Carcinogenesis, 2016, pp. 1343-1354, vol. 55.;;Azab, A. K. et al. “Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features” Blood, Jun. 14, 2012, pp. 5782-5794, vol. 119, No. 24.;;Babcook, J. et al. “A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities” Proc. Natl. Acad. Sci. USA, Jul. 1996, pp. 7843-7848, vol. 93, No. 15.;;Badesch, D. B. et al. “Diagnosis and Assessment of Pulmonary Arterial Hypertension” J Am Coll Cardiol., Jun. 30, 2009, pp. S55-S66, vol. 54, No. 1, Suppl. S.;;Bostrom, M. P. G. et al. “The Clinical Use of Allografts, Demineralized Bone Matrices, Synthetic Bone Graft Substitutes and Osteoinductive Growth Factors: A Survey Study” HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery, 2005, pp. 9-18, vol. 1.;;Brinkmann, U. et al. “Phage display of disulfide-stabilized Fv fragments” Journal of Immunological Methods, 1995, pp. 41-50, vol. 182.;;Budd, D. C. et al. “Targeting TGFβ superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders” Pharmacology & Therapeutics, 2012, pp. 279-291, vol. 135.;;Burton, D. R. et al. “Human Antibodies from Combinatorial Libraries” Advances in Immunology, 1994, pp. 191-280, vol. 57.;;Buza, J. A. et al. “Bone healing in 2016” Clinical Cases in Mineral and Bone Metabolism, 2016, pp. 101-105, vol. 13, No. 2.;;Cahill, E. et al. “Gremlin Plays a Key Role in the Pathogenesis of Pulmonary Hypertension” Circulation, Feb. 21, 2012, pp. 920-930, vol. 125, No. 7.;;Calon, A. et al. “Stromal gene expression defines poor-prognosis subtypes in colorectal cancer” Nat Genet., Apr. 2015, pp. 320-329, vol. 47, No. 4, Online Methods, pp. 1-3.;;Canalis, E. et al. “Gremlin1 is Required for Skeletal Development and Postnatal Skeletal Homeostasis” J. Cell Physiol., 2012, pp. 269-277, vol. 227.;;Chen, V. B. et al. “MolProbity: all-atom structure validation for macromolecular crystallography” Acta Crystallographica Section D, 2010, pp. 12-21, D66.;;Chen, M.-H. et al. “Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors” J Gastroenterol, 2013, pp. 101-108, vol. 48.;;Chen, J. et al. “BAFF is involved in macrophage-induced bortezomib resistance in myeloma” Cell Death Dis, 2017, pp. 1-12, vol. 8, No. 11, e3161.;;Cheong, C. M. et al. “Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo” Exp Cell Res, 2015, pp. 24-38, vol. 332.;;Chesi, M. et al. “Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy” Blood, Jul. 12, 2012, pp. 376-385, vol. 120, No. 2.;;Cho, T.-J. et al. “Differential Temporal Expression of Members of the Transforming Growth Factor β Superfamily During Murine Fracture Healing” Journal of Bone and Mineral Research, Nov. 3, 2002, pp. 513-520, vol. 17, No. 3.;;Ciuclan, L. et al. “Imatinib Attenuates Hypoxia-induced Pulmonary Arterial Hypertension Pathology via Reduction in 5-Hydroxytryptamine through Inhibition of Tryptophan Hydroxylase 1 Expression” Am J Respir Crit Care Med., 2013, pp. 78-89, vol. 187, Issue 1.;;Ciuclan, L, et al. “Treatment with Anti-Gremlin 1 Antibody Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension in Mice” Am J Pathol., Nov. 2013, pp. 1461-1473, vol. 183, No. 5.;;Curran, S. P. et al. “Deletion of Gremlin1 increases cell proliferation and migration responses in mouse embryonic fibroblasts” Cellular Signalling, 2012, pp. 889-898, vol. 24, No. 4.;;Dallas, S. L. et al. “Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease” Blood, Mar. 1, 1999, pp. 1697-1706, vol. 93, No. 5.;;Das, D. S. et al. “A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells” Leukemia, 2016, pp. 2187-2197, vol. 30, No. 11.;;Davis, H. et al. “Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche” Nat Med., Jan. 2015, pp. 62-70, vol. 21, No. 1, Online Methods, pp. 1-3.;;Dean, D. B. et al. “Distinct functionalities of bone morphogenetic protein antagonists during fracture healing in mice” Journal of Anatomy, 2010, pp. 625-630, vol. 216, No. 5.;;Devereux, J. et al. “A comprehensive set of sequence analysis programs for the VAX” Nucleic Acids Research, 1984, pp. 387-395, vol. 12, No. 1.;;Diamond, P. et al. “Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss” J Bone Miner Res, 2009, pp. 1150-1161, vol. 24, No. 7.;;Dubowchik, G. M. et al. “Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs” Pharmacology and Therapeutics, 1999, pp. 67-123, vol. 83.;;Einhorn, T. A. et al. “Fracture healing: mechanisms and interventions” Nat. Rev. Rheumatol., Jan. 2015, pp. 45-54, vol. 11.;;Emsley, P. et al. “Features and development of Coot” Acta Crystallographica Section D: Biological Crystallography, 2010, pp. 486-501, D66, No. 4.;;Fajardo, M. et al. “Levels of Expression for BMP-7 and Several BMP Antagonists May Play an Integral Role in a Fracture Nonunion: A Pilot Study” Clinical Orthopaedics and Related Research, Jul. 14, 2009, pp. 3071-3078, vol. 467, No. 12.;;Farber, H. W. et al. “Pulmonary Arterial Hypertension” The New England Journal of Medicine, 2004, pp. 1655-1665, vol. 351.;;Ferguson, C. et al. “Does adult fracture repair recapitulate embryonic skeletal formation?” Mechanisms of Development, 1999, pp. 57-66, vol. 87.;;Fowler, J. A. et al. “Bone Marrow Stromal Cells Create a Permissive Microenvironment for Myeloma Development: A New Stromal Role for Wnt Inhibitor Dkk1” Cancer Research, 2012, pp. 2183-2189, vol. 72, No. 9.;;Gasteiger, E. et al. “Protein Identification and Analysis Tools on the ExPASy Server” The Proteomics Protocols Handbook, Humana Press, ed. J. M. Walker, 2005, pp. 571-607.;;Gazzerro, E. et al. “Skeletal Overexpression of Gremlin Impairs Bone Formation and Causes Osteopenia” Endocrinology, Feb. 1, 2005, pp. 655-665, vol. 146, No. 2.;;Gazzerro, E. et al. “Conditional Deletion of Gremlin Causes a Transient Increase in Bone Formation and Bone Mass” J. Biol. Chem., Oct. 26, 2007, pp. 31549-31557, vol. 282, No. 43.;;Ghobrial, I. M. “Myeloma as a model for the process of metastasis: implications for therapy” Blood, Jul. 5, 2012, pp. 20-30, vol. 120, No. 1.;;Gilbane, A. J. et al. “Impaired Bone Morphogenetic Protein Receptor II Signaling in a Transforming Growth Factor-β-Dependent Mouse Model of Pulmonary Hypertension and in Systemic Sclerosis” Am J Respir Crit Care Med., Mar. 15, 2015, pp. 665-677, vol. 191, Issue 6.;;Goulet, J. A. et al. “Autogenous Iliac Crest Bone Graft. Complications and Functional Assessment” Clinical Orthopaedics and Related Research, Jun. 1997, pp. 76-81, No. 339.;;Guan, Y. et al. “Gremlin1 promotes carcinogenesis of glioma in vitro” Clin Exp Pharmacol Physiol, 2017, pp. 244-256, vol. 44, No. 2.;;Harris, R. J. “Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture” Journal of Chromatography A, 1995, pp. 129-134, vol. 705.;;Hellstrom, K. E. et al. “Antibodies for Drug Delivery” Controlled Drug Delivery, 2nd Ed., Robinson et al., eds., 1987, pp. 623-653.;;Henikoff, S. et al. “Amino acid substitution matrices from protein blocks” Proc. Natl. Acad. Sci. USA, Nov. 1992, pp. 10915-10919, vol. 89.;;Hewett, D. R. et al. “DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment” Neoplasia, Dec. 2017, pp. 972-981, vol. 19, No. 4.;;Hideshima, T. et al. “Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets” Nature Reviews Cancer, Aug. 2007, pp. 585-598, vol. 7, No. 8.;;Hjertner, O. et al. “Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells” Blood, Jan. 15, 2001, pp. 516-522, vol. 97, No. 2.;;Hochleitner, E. O. et al. “Characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometric peptide mapping analysis” Protein Science, 2000, pp. 487-496, vol. 9.;;Holien, T. et al. “Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC” Leukemia, 2012, pp. 1073-1080, vol. 26, No. 5.;;Holliger, P. et al. “Engineered antibody fragments and the rise of single domains” Nature Biotech., Sep. 2005, pp. 1126-1136, vol. 23, No. 9.;;Howe, J. R. et al. “Mutations in the SMAD4/DPC4 Gene in Juvenile Polyposis” Science, May 15, 1998, pp. 1086-1088, vol. 280, No. 5366.;;Howe, J. R. et al. “Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis” Nat Genet., Jun. 2001, pp. 184-187, vol. 28, No. 2.;;Hu, K. et al. “Gremlin-1 suppression increases BMP-2-induced osteogenesis of human mesenchymal stem cells” Molecular Medicine Reports, 2017, pp. 2186-2194, vol. 15.;;International Search Report and Written Opinion in International Application No. PCT/EP2019/053726, dated May 17, 2019, pp. 1-19.;;International Search Report and Written Opinion in International Application No. PCT/GB2019/051699, dated Aug. 16, 2019, pp. 1-11.;;Irshad, S. et al. “Bone morphogenetic protein and Notch signalling crosstalk in poor-prognosis, mesenchymal-subtype colorectal cancer” J Pathol., 2017, pp. 178-192, vol. 242.;;Isella, C. et al. “Stromal contribution to the colorectal cancer transcriptome” Nat Genet., Apr. 2015, pp. 312-319, vol. 47, No. 4, Online Methods, pp. 1-4.;;Jaeger, E. et al. “Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1” Nat Genet., Jun. 2012, pp. 699-703, vol. 44, No. 6, Online Methods, pp. 1-2.;;Junghans, R. P. et al. “Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders” Cancer Res., Mar. 1, 1990, pp. 1495-1502, vol. 50.;;Kabsch, W. “XDS” Acta Crystallographica Section D, Biological Crystallography, 2010, pp. 125-132, vol. D66.;;Karagiannis, G. S. et al. “Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1” Mol Oncol., 2013, pp. 826-839, vol. 7, No. 4.;;Karagiannis, G. S. et al. “Bone morphogenetic protein antagonist gremlin-1 regulates colon cancer progression” Biol Chem., 2015, pp. 163-183, vol. 396, No. 2.;;Karlin, S. et al. “Applications and statistics for multiple high-scoring segments in molecular sequences” Proc. Natl. Acad. Sci. USA, Jun. 1993, pp. 5873-5877, vol. 90.;;Kashmiri, S. V. S. et al. “SDR grafting—a new approach to antibody humanization” Methods, 2005, pp. 25-34, vol. 36.;;Kettleborough, C. A. et al. “Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments” Eur. J. Immunol., 1994, pp. 952-958, vol. 24.;;Kim, M. et al. “Gremlin-1 Induces BMP-Independent Tumor Cell Proliferation, Migration, and Invasion” PloS ONE, Apr. 2012, pp. 1-8, vol. 7, Issue 4, e35100.;;Kim, H. S. et al. “GREM1 is expressed in the cancer-associated myofibroblasts of basal cell carcinomas” PloS ONE, 2017, pp. 1-13, vol. 12, No. 3, e0174565.;;Kohler, G. et al. “Continuous cultures of fused cells secreting antibody of predefined specificity” Nature, Aug. 7, 1975, pp. 495-497, vol. 256.;;Koketsu, K. et al. “Gremlin, a Bone Morphogenetic Protein Antagonist, Is a Crucial Angiogenic Factor in Pituitary Adenoma” Int J Endocrinol., 2015, pp. 1-7, Article ID 834137.;;Kozbor, D. et al. “The production of monoclonal antibodies from human lymphocytes” Immunology Today, 1983, pp. 72-79, vol. 4, No. 3.;;Krinner, E.-M. et al. “A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF” Mol. Immunol., Feb. 2007, pp. 916-925, vol. 44, No. 5.;;Kyle, R. A. et al. “Multiple Myeloma” N Engl J Med, 2004, pp. 1860-1873, vol. 351, No. 18.;;Laurila, R. et al. “The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues” Int J Clin Exp Pathol., 2013, pp. 1400-1408, vol. 6, No. 7.;;Lavoz, C. et al. “Gremlin regulates renal inflammation via the vascular endothelial growth factor receptor 2 pathway” J Pathol., 2015, pp. 407-420, vol. 236.;;Lawson, M. A. et al. “Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche” Nat Commun., 2015, pp. 1-15, vol. 6, No. 8983.;;Lewis, A. et al. “A Polymorphic Enhancer Near GREM1 Influences Bowel Cancer Risk through Differential CDX2 and TCF7L2 Binding” Cell Rep., Aug. 21, 2014, pp. 983-990, vol. 8, No. 4.;;McCoy, A. J. et al. “Phaser crystallographic software” J Appl Cryst ., 2007, pp. 658-674, vol. 40.;;Mitola, S. et al. “Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2” Blood, Nov. 4, 2010, pp. 3677-3680, vol. 116, No. 18.;;Mulvihill, M. S. et al. “Gremlin is Overexpressed in Lung Adenocarcinoma and Increases Cell Growth and Proliferation in Normal Lung Cells” PloS ONE, 2012, pp. 1-8, vol. 7, No. 8, e42264.;;Murshudov, G. N. et al. “REFMAC5 for the refinement of macromolecular crystal structures” Acta Crystallographica Section D: Biological Crystallography, 2011, pp. 355-367, vol. D67.;;Namkoong, H. et al. “The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein” BMC Cancer, 2006, pp. 1-13, vol. 6, No. 74.;;Neufert, C. et al. “An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression” Nat Protoc., 2007, pp. 1998-2004, vol. 2, No. 8.;;Nolan, K. et al. “Structure of Neuroblastoma Suppressor of Tumorigenicity 1 (NBL1)” J. Biol. Chem., Feb. 20, 2015, pp. 4759-4771, vol. 290, No. 8.;;Noll, J. E. et al. “Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells” Haematologica, 2014, pp. 163-171, vol. 99, No. 1.;;Noll, J. E. et al. “SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma” Neoplasia, Jul. 2014, pp. 572-585, vol. 16, No. 7.;;Noll, J. E. et al. “PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma” J Hematol Oncol., 2015, pp. 1-16, vol. 8, No. 106.;;Persic, L. et al. “An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries” Gene, 1997, pp. 9-18, vol. 187.;;Plaks, V. et al. “The Cancer Stem Cell Niche: How Essential Is The Niche in Regulating Sternness of Tumor Cells?” Cell Stem Cell, Mar. 5, 2015, pp. 225-238, vol. 16, No. 3.;;Ponomarev, V. et al. “A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging” Eur J Nucl Med Mol Imaging, 2004, pp. 740-751, vol. 31, No. 5.;;Reineke, U. “Antibody Epitope Mapping Using Arrays of Synthetic Peptides” Methods Mol Biol, 2004, pp. 443-463, vol. 248.;;Retter, I. et al. “VBASE2, an integrative V gene database” Nucl. Acids Res., 2005, pp. D671-D674, vol. 33.;;Riechmann, L. et al. “Reshaping human antibodies for therapy” Nature, Mar. 24, 1988, pp. 323-327, vol. 332.;;Sato, T. et al. “Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche” Nature, May 14, 2009, pp. 262-265, vol. 459, No. 7244, Methods, p. 1.;;Sato, K. et al. “Establishment of Reproducible, Critical-Sized, Femoral Segmental Bone Defects in Rats” Tissue Eng Part C., 2014, pp. 1037-1041, vol. 20, No. 12.;;Schmid, G. J. et al. “Fibroblast Growth Factor Expression During Skeletal Fracture Healing in Mice” Developmental Dynamics, 2009, pp. 766-774, vol. 238.;;Scoville, D. H. et al. “Current View: Intestinal Stem Cells and Signaling” Gastroenterology, 2008, pp. 849-864, vol. 134, No. 3.;;Search Report for GB1802486.9, dated Oct. 17, 2018, pp. 1-5.;;Sebald, H.-J. et al. “Inhibition of endogenous antagonists with an engineered BMP-2 variant increases BMP-2 efficacy in rat femoral defect healing” Acta Biomaterialia, Oct. 10, 2012, pp. 3816-3820, vol. 8, No. 10.;;Sethi, A. et al. “Gremlin utilizes canonical and non-canonical TGFβ signaling to induce lysyl oxidase (LOX) genes in human trabecular meshwork cells” Exp Eye Res., 2013, pp. 117-127, vol. 113.;;Shoshkes-Carmel, M. et al. “Subepithelial telocytes are an important source of Wnts that supports intestinal crypts” Nature, May 10, 2018, pp. 242-246, vol. 557, Supplemental pp. 1-9.;;Simonneau, G. et al. “Updated Clinical Classification of Pulmonary Hypertension” J Am Coll Cardiol., Jun. 30, 2009, pp. S43-S54, vol. 54, No. 1, Suppl S.;;Sneddon, J. B. et al. “Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation” Proc Natl Acad Sci USA, Oct. 3, 2006, pp. 14842-14847, vol. 103, No. 40.;;Tamminen, J.A. et al. “Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug” Oncogenesis, 2013, pp. 1-13, vol. 2, e66.;;Thomas, M. et al. “Activin-like kinase 5 (ALK5) Mediates Abnormal Proliferation of Vascular Smooth Muscle Cells from Patients with Familial Pulmonary Arterial Hypertension and Is Involved in the Progression of Experimental Pulmonary Arterial Hypertension Induced by Monocrotaline” Am J Pathol., Feb. 2009, pp. 380-389, vol. 174, No. 2.;;Thorpe, P. E. et al. “The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates” Immunol. Rev., 1982, pp. 119-158, vol. 62.;;Tomlinson, I. P. M. et al. “Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of Colorectal Cancer” PLoS Genet., Jun. 2011, pp. 1-11, vol. 7, No. 6, e1002105.;;Topol, L. Z. et al. “Identification of drm, a Novel Gene Whose Expression Is Suppressed in Transformed Cells and Which Can Inhibit Growth of Normal but Not Transformed Cells in Culture” Mol Cell Biol, Aug. 1997, pp. 4801-4810, vol. 17, No. 8.;;Vande Broek, I. et al. “Extravasation and homing mechanisms in multiple myeloma” Clin Exp Metastasis, 2008, pp. 325-334, vol. 25, No. 4.;;Vaughan, T. J. et al. “Human antibodies by design” Nature Biotechnology, Jun. 1998, pp. 535-539, vol. 16.;;Verheyden, J. M. et al. “An Fgf/Gremlin inhibitory feedback loop triggers termination of limb bud outgrowth” Nature, Jul. 31, 2008, pp. 1-12, vol. 454, No. 7204.;;Verma, R. et al. “Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems” Journal of Immunological Methods, 1998, pp. 165-181, vol. 216.;;Wang, D.-J. et al. “The bone morphogenetic protein antagonist Gremlin is overexpressed in human malignant mesothelioma” Oncology Reports, 2012, pp. 58-64, vol. 27, No. 1.;;Worthley, D. L. et al. “Gremlin 1 Identifies a Skeletal Stem Cell with Bone, Cartilage, and Reticular Stromal Potential” Cell, Jan. 15, 2015, pp. 269-284, vol. 160, Nos. 1-2.;;Yin, Y. et al. “Overexpression of Gremlin promotes non-small cell lung cancer progression” Tumour Biol, 2016, pp. 2597-2602, vol. 37.;;Yu, Y. Y. et al. “Immunolocalization of BMPs, BMP antagonists, receptors, and effectors during fracture repair” Bone, 2010, pp. 841-851, vol. 46.",ACTIVE
714,WO,A1,WO 1999/050530 A1,194-396-556-660-864,1999-10-07,1999,GB 9900942 W,1999-03-25,GB 9806493 A,1998-03-27,METHOD AND COMPOSITIONS FOR WATER CONTROL,"A method to reduce water influx into a producing well is described comprising the steps of pumping a chemical composition into a production interval and into surrounding formation; said composition being capable of forming, firstly, a physically stabilized structure and, secondly, a chemically stabilized structure, wherein said physically stabilized structure being dissolvable by hydrocarbon containing fluids; letting said composition form said physically stabilized structure within the formation surrounding said production interval; changing pressure condition in said production interval such that the fluid flow within the surrounding formation is reversed; letting thereby in some portions of the formation hydrocarbon containing fluids dissolve said physically stabilized structure and chemically stabilize said structure in the remaining portions by a cross-linking reaction. The time constants of the two stabilizing reactions are selected such that the physical stabilization is essentially completed before the pumping direction is reversed and the chemical stabilization is essentially completed after the pump-out/cleaning operation.",SOFITECH NV;;SCHLUMBERGER CIE DOWELL;;SCHLUMBERGER CA LTD;;DAVIES STEPHEN NIGEL;;JONES TIMOTHY GARETH JOHN;;OLTHOFF SILKE;;TUSTIN GARY JOHN,DAVIES STEPHEN NIGEL;;JONES TIMOTHY GARETH JOHN;;OLTHOFF SILKE;;TUSTIN GARY JOHN,,https://lens.org/194-396-556-660-864,Patent Application,yes,5,22,9,9,0,C09K8/512;;C09K8/512;;E21B43/32;;E21B43/32,C09K8/512;;E21B43/32,,0,0,,,,PENDING
715,EP,A1,EP 0975603 A1,057-439-433-335-041,2000-02-02,2000,EP 98901389 A,1998-01-27,EP 98901389 A;;EP 97400207 A;;GB 9800230 W,1997-01-29,INHIBITORS OF FARNESYL PROTEIN TRANSFERASE,,ZENECA LTD;;ZENECA PHARMA SA,ARNOULD JEAN-CLAUDE;;BOYLE FRANCIS THOMAS;;DAVIES GARETH MORSE;;WARDLEWORTH JAMES MICHAEL,ZENECA PHARMA S.A. (2000-05-17);;ASTRAZENECA AB (2000-09-13);;ASTRAZENECA UK LIMITED (2000-05-17),https://lens.org/057-439-433-335-041,Patent Application,yes,0,0,7,7,0,C07D231/12;;C07D233/56;;C07D233/64;;C07D249/08;;C07D233/64;;C07D233/56;;C07D249/08;;C07D231/12,C07D233/60;;A61K31/415;;A61K31/4168;;A61K31/4178;;A61K31/427;;A61K31/4439;;A61K31/454;;A61K31/5377;;C07D233/54;;C07D233/61;;C07D233/64;;C07D401/10;;C07D401/12;;C07D409/12;;C07D413/12;;C07D417/06;;C07D417/14;;C07D521/00,,0,0,,,,DISCONTINUED
716,NO,L,NO 20004829 L,061-732-915-277-021,2000-11-20,2000,NO 20004829 A,2000-09-26,GB 9806493 A;;GB 9900942 W,1998-03-27,Fremgangsmate og blandinger for vannkontroll,,SCHLUMBERGER TECHNOLOGY BV,JONES TIMOTHY GARETH JOHN;;DAVIES STEPHEN NIGEL;;TUSTIN GARY JOHN;;OLTHOFF SILKE,,https://lens.org/061-732-915-277-021,Abstract,no,0,0,9,9,0,C09K8/512;;C09K8/512;;E21B43/32;;E21B43/32,E21B43/32;;C09K8/512,,0,0,,,,EXPIRED
717,US,A,US 5214165 A,069-333-429-324-665,1993-05-25,1993,US 93382792 A,1992-08-24,US 93382792 A;;GB 8908700 A;;US 50980290 A,1989-04-18,Compounds useful as intermediates in the synthesis of shikimic acid derivatives,"6-Fluoroshikimic acid derivatives of the formula (I): ##STR1## wherein R.sup.1 is hydroxy or a moiety biotransformable thereto and R.sup.2 is hydrogen or --P(O)(OH).sub.2 have antibacterial, antifungal and herbicidal activity. Their preparation and use are described as are pharmaceutical compositions containing them.",ICI PLC,SUTHERLAND JAMES K;;WATKINS WILLIAM J;;SNOW GEORGE A;;DAVIES GARETH M,ZENECA LIMITED (1993-11-02),https://lens.org/069-333-429-324-665,Granted Patent,yes,0,3,1,12,0,A01N37/40;;A01N37/40;;A01N57/14;;A01N57/14;;C07D493/04;;C07D493/04;;C07C62/32;;C07C62/32;;C07D303/40;;C07D303/40;;C07F9/117;;C07F9/117;;C07F9/65507;;C07F9/65507,A01N37/40;;A01N57/14;;C07C62/32;;C07D303/40;;C07D493/04;;C07F9/117;;C07F9/655,549/433;;549/546,7,5,126-725-839-414-194;;118-669-091-831-006;;029-298-171-604-114;;090-652-281-462-20X;;019-461-815-000-522,10.1021/bi00669a018;;11811;;10.1039/p19900001281;;10.1016/0040-4020(78)80222-1;;10.1016/s0040-4039(01)80490-1;;10.1016/s0300-9084(86)80066-9;;3098305,"Pilch et al, Fluorine Containing Analogues of Intermediates in the Shikimate, Biochemistry, vol. 15, No. 24, pp. 5315 5320, (1976).;;Leroy et al, Stereospecific Synthesis of Racemic cis and trans 6 Trifluoromethylshikimic Acids, J. Chem. Soc. Perkin Trans. 1, pp. 1281 1287, (1990).;;Bundgarrd Design of Prodrugs: Bioreversible Derivatives for Various Functional Groups and Chemical Entities , pp. 1 and; 2, Design of Prodrugs, Bungaard, ed. (1985) Elsevier Amsterdam.;;Le Marechal, Contribution to the Study of the Mechanism of Action of an Enzyme of the Aromatic Amino Acid biosynthetic Pathway; 3 Dehydroguinate Synthetase from Escherichia coli. Preparation and use of Analogues of 3 dexosy D arabino heptulosonate 7 phosphate, its substrate. , Thesis submitted at the University of Paris XI, Dentre D Orsay to obtain the degree of Doctor of Natural Sciences by Pierre Le Marechal (1981).;;Ganem, B. Tetrahedron 1978, 34 (23), 3353 83.;;Bowles et al, Reactivity Studies in the Shikimic Acid Series , Tetrahedron Letters, vol. 30, No. 28, pp. 3711 3714, 1989.;;Le Marechal et al, The Shikimate Pathway V, Flourine containing Analogues of 3 deoxy D arabino hept 2 ulsonate 7 phosphate (DAHP) Biochemie 1986, 68, 1211 1215.",EXPIRED
718,EP,A1,EP 4148265 A1,109-023-258-636-351,2023-03-15,2023,EP 22192760 A,2022-08-30,GB 202112775 A;;GB 202116765 A,2021-09-08,AN IMPROVED GAS TURBINE ENGINE,"A gas turbine engine for an aircraft comprises, in axial flow sequence, a compressor module, a combustor module, and a turbine module. The gas turbine engine further comprises a first electric machine that is rotationally connected to the turbine module, and an electrical energy storage unit. The gas turbine engine is configured to generate a maximum dry thrust T (N). The first electric machine is configured to generate a maximum electrical power P EM1  (W). The electrical energy storage unit has an energy storage capacity E (Wh), a maximum charge rate C (h -1 ), and a maximum discharge rate D (h -1 ). The electrical energy storage unit is configured to store electrical energy that may be generated by the first electric machine.
",ROLLS ROYCE PLC,DAVIES PAUL;;MOORE GARETH;;HUSBAND STEPHEN;;TRAINER DAVID;;SCOTHERN DAVID;;GEORGE LUKE,,https://lens.org/109-023-258-636-351,Patent Application,yes,5,0,2,14,0,F02K3/06;;F02C6/14;;F02K5/00;;F05D2220/76;;F05D2260/42;;B64D27/24;;B64D27/10;;Y02T50/60;;B64D27/026;;F05D2200/13;;F05D2200/14;;F05D2220/323;;F05D2260/213;;F05D2260/232;;F05D2260/42;;F02C7/36,F02K5/00;;B64D27/24;;F02C6/14;;F02K3/06,,0,0,,,,DISCONTINUED
719,UY,A,UY 37528 A,136-630-872-829-368,2018-07-31,2018,UY 37528 A,2017-12-19,GB 201621635 A,2016-12-19,ESTRUCTURA DEL CRISTAL DE GREMLIN-1 Y ANTICUERPO INHIBIDOR,"Esta invención se refiere a cristales de la proteína Gremlin-1 humana y a la proteína Gremlin-1 humana en complejo con un anticuerpo inhibidor. La invención también se refiere a la estructura de Gremlin-1 humana (por sí mismo, o en complejo con el anticuerpo) y a los usos de estas estructuras en la prueba de agentes que modulan la actividad de Gremlin-1. La invención proporciona además anticuerpos que se unen a un sitio inhibitorio alostérico en Gremlin-1, junto con composiciones farmacéuticas y usos médicos de tales anticuerpos y agentes identificados por los métodos de prueba.",UCB BIOPHARMA SPRL,DAVIES GARETH;;DEDI NEESHA;;DAVID JAMES MCMILLAN;;TWOMEY BREDA;;MICHAEL JOHN WRIGHT,,https://lens.org/136-630-872-829-368,Patent Application,no,0,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,A61P13/12;;A61K39/395;;A61P9/12;;A61P35/00;;C07K14/435;;C07K16/18;;C12N5/10;;C12N15/13;;C12N15/85;;C12P21/08,,0,0,,,,PENDING
720,US,A1,US 2019/0330323 A1,141-101-021-524-600,2019-10-31,2019,US 201716470996 A,2017-12-19,GB 201621635 A;;EP 2017083650 W,2016-12-19,GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SPRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH;;MCMILLAN DAVID JAMES,CELLTECH R&D LIMITED (2017-12-04);;UCB BIOPHARMA SRL (2017-06-12),https://lens.org/141-101-021-524-600,Patent Application,yes,1,1,36,36,35,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22;;A61P9/12;;C07K14/51;;G01N33/68,,0,0,,,,ACTIVE
721,US,A,US 4981984 A,167-448-776-284-680,1991-01-01,1991,US 22305088 A,1988-07-22,GB 8717566 A,1987-07-24,Organic compounds,"Langmuir Blodgett films are provided having second order molecular hyperpolarizability of at least 30.10.sup.-50 C.sup.3 m.sup.3 J.sup.-2. combined with chemical stability and a melting point of over 70.degree.. They also have desirable pyroelectric properties shown by a static pyroelectric coefficient of at least 0.0039 nCcm.sup.2 k.sup.-1. The films comprise compounds of the following formula: ##STR1## wherein M is ruthenium, iron or cobalt; R.sup.1 is cyclopentadienyl, methylcyclopentadienyl, pentamethylcyclopentadienyl or indenyl; A.sup.1 is (R.sup.2).sub.3 Z or carbonyl; Q.sup.2 is (R.sup.2).sub.3 Z or carbonyl; Z is phosphorus or arsenic; R.sup.2 is an aryl of alkyl radical; A is ##STR2## Y is a straight chain alkyl or alkoxy radical comprising from 3 to 17 carbon atoms, or, when A is ##STR3## N(R.sup.3).sub.2 ; R.sup.3 is a lower alkyl radical comprising up to 5 carbon atoms; and X is PF.sub.6 or BF.sub.4.",EMI PLC THORN,DAVIES STEPHEN G;;RICHARDSON TIMOTHY;;ROBERTS GARETH G;;POLYWKA MARIO E C,,https://lens.org/167-448-776-284-680,Granted Patent,yes,1,1,5,5,0,C07F15/0046;;Y10T428/31504;;H10N15/15;;Y10T428/31504;;C07F15/0046;;H10N15/15,C09K3/00;;C07F15/00;;C07F15/02;;C07F15/06;;H01L37/02,556/22;;556/7;;556/13;;556/14;;556/16;;556/30;;427/434.3;;428/411.1;;428/688;;428/690;;428/704,3,1,089-727-912-109-313,10.1016/0040-6090(83)90351-6,"On the History of Langmuir Blodgett Films , by G. Gaines, Jr. Thin Solid Films 99 (1983), pp. 4 8.;;1986 Proc. Int. Symp. on the Applications of Ferroelectric Materials, Philadelphia, by D. Neal et al.;;J. Chem. Soc. (1), 1971, 2376, by T. Blackmore et al.",EXPIRED
722,WO,A3,WO 2007/090075 A3,171-560-386-323-01X,2007-12-21,2007,US 2007/0061203 W,2007-01-29,US 74318106 P;;US 82745806 P;;US 62740607 A,2006-01-27,MAGNETICALLY GUIDABLE ENERGY DELIVERY APPARATUS AND METHOD OF USING SAME,"An energy delivery apparatus (10) for delivering electrical energy at a target location, the energy delivery apparatus (10) being usable in combination with a magnetic field. The energy delivery apparatus (10) includes an electrical conductor (16), the electrical conductor (16) having a substantially elongated configuration; an electrode (22) for delivering the electrical energy at the target location, the electrode (22) being electrically coupled to the electrical conductor (16) and located at a predetermined location therealong; and a guiding element (26) mounted to the electrical conductor (16) in a substantially spaced apart relationship relative to the electrode (22), the guiding element (26) including a magnetically responsive material. The energy delivery apparatus (10) is constructed such that a movement of the guiding element (26) causes a corresponding movement of the electrode (22). The magnetic field is used to move the guiding element (26) in order to position the electrode (22) substantially adjacent to the target location.",BAYLIS MEDICAL CO INC;;STEREOTAXIS INC;;DAVIES GARETH;;ALBERT KELLY;;MUNGER GARETH TORREY;;PANDEY ASHWINI;;VISWANATHAN RAJU;;ESKURI ALAN D;;VONGPHAKDY KHAMLA;;MINAR CHRISTOPHER D,DAVIES GARETH;;ALBERT KELLY;;MUNGER GARETH TORREY;;PANDEY ASHWINI;;VISWANATHAN RAJU;;ESKURI ALAN D;;VONGPHAKDY KHAMLA;;MINAR CHRISTOPHER D,,https://lens.org/171-560-386-323-01X,Search Report,yes,4,0,5,113,0,A61B5/062;;A61B18/1492;;A61B2017/00252;;A61M25/0127;;A61N1/05;;A61B34/73;;A61N1/05;;A61B5/062;;A61B2017/00252;;A61B18/1492;;A61M25/0127;;A61B34/73,A61B18/14,,0,0,,,,PENDING
723,EP,B1,EP 1888063 B1,107-892-265-467-412,2009-01-14,2009,EP 06743919 A,2006-05-18,GB 2006001820 W;;GB 0510190 A;;GB 0607841 A,2005-05-18,ANTIFUNGAL AGENTS,"Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: R1, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,THOMSON SAMANTHA PATRICIA F G;;EDWARDS PHILIP NEIL;;DAVIES GARETH MORSE;;KUVSHINOV ALEXANDRE;;ALLANSON NIGEL MARK;;DAVIES RHIAN TERESA,,https://lens.org/107-892-265-467-412,Granted Patent,yes,0,0,16,18,0,A61K31/437;;A61P11/00;;A61P11/06;;A61P15/02;;A61P17/00;;A61P27/16;;A61P31/10;;A61P31/12;;A61P37/08;;A61K31/437,A61K31/437;;A61P31/12,,2,1,095-630-841-364-590,10.1039/p19810003150,"DICK ET AL.: ""Heterocyclic Compounds with Bridgehead Nitrogen Atoms. Part 9. Synthesis in the Pyrrolo[2,1,2-de]quinolizine ([2.3.3]Cyclazine) Series starting from Indolizines"", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN 1 (1972-1999), vol. 12, 1981, pages 3510 - 3517;;AMES ET AL.: ""The Preparation of Aminoalkylpyrrocolines"", JOURNAL OF THE CHEMICAL SOCIETY, ABSTRACTS, 1959, pages 620 - 622",ACTIVE
724,WO,A1,WO 1994/020833 A1,006-438-810-348-282,1994-09-15,1994,GB 9400431 W,1994-03-07,GB 9304545 A,1993-03-05,METHOD AND APPARATUS FOR POSITIONAL MANIPULATION AND ANALYSIS OF SUSPENDED PARTICLES,"In a method of particle handling, a source of acoustic oscillations is applied to a conduit through which a particulate fluid suspension passes, creating acoustic standing waves in the suspension thereby forming local inhomogeneities in the positional distribution of particles in said suspension which may be used to improve the signal-to-noise characteristics of an interrogating optical beam.",UNIV LONDON;;HOLWILL IAN LESLIE JOHN;;DAVIES GARETH BOWEN;;TITCHENER HOOKER NIGEL JOHN;;HOARE MICHAEL,HOLWILL IAN LESLIE JOHN;;DAVIES GARETH BOWEN;;TITCHENER-HOOKER NIGEL JOHN;;HOARE MICHAEL,,https://lens.org/006-438-810-348-282,Patent Application,yes,4,9,2,2,0,B01D21/283;;B01D43/00;;G01N15/0205;;G01N30/02,B01D21/00;;B01D43/00;;G01N15/02;;G01N30/02,,3,1,011-508-213-574-312,18290232;;10.1109/58.31799,"P. BRODEUR ET AL.: ""fiber characterization in a stationary ultrasonic field"", IEEE TRANSACTIONS ON ULTRASONICS, FERROELECTRICS AND FREQUENCY CONTROL, vol. 36, no. 5, September 1989 (1989-09-01), NEW YORK US, pages 549 - 553;;""D.F.PARSONS"", INTERNATIONAL LABORATORY, vol. 22, no. 8, September 1992 (1992-09-01), FAIRFIELD CT US, pages 28 - 32;;PATENT ABSTRACTS OF JAPAN vol. 10, no. 232 (P - 486) 12 August 1986 (1986-08-12)",PENDING
725,CA,C,CA 2943463 C,034-118-045-110-738,2023-07-18,2023,CA 2943463 A,2015-03-23,US 201414222909 A;;IB 2015052118 W,2014-03-24,MEDICAL APPARATUS FOR FLUID COMMUNICATION,"This disclosure describes embodiments of a kit and its constituent components which together form an apparatus in which fluid communication between a medical device's lumen and the surrounding environment is provided by a conduit cooperatively defined by the medical device and a tubular member into which the device is inserted. The medical device and tubular member are configured to fit together such that an outer surface of the distal region of the medical device cooperates with an inner surface of the tubular member to define the conduit between the side- port of the medical device and a distal end of the tubular member. The conduit is operable to be used for injecting fluid, withdrawing fluid, and measuring pressure, for example. Methods of assembling and using the apparatus are described as well.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;SHAH KRISHAN;;MIRZA MAHMOOD;;VISRAM NAHEED;;HARTLEY AMANDA;;DAVIES GARETH,,https://lens.org/034-118-045-110-738,Granted Patent,no,0,0,21,113,0,A61M39/08;;A61B5/0215;;A61B18/1492;;A61B2018/00357;;A61B2018/1475;;A61B2218/002;;A61B2218/007;;A61B2090/064;;A61B2090/3966;;A61B5/065;;A61M25/0068;;A61M25/007;;A61M29/00;;A61M2025/0008;;A61M25/0108;;A61M39/08;;A61M29/02;;A61M5/00;;A61B18/1492;;A61B5/0215;;A61B5/06;;A61B2018/00357;;A61B2018/1475;;A61B2090/064;;A61B2090/3966;;A61B2218/002,A61M39/08;;A61B5/06;;A61B5/103;;A61B18/14;;A61M5/00;;A61M29/02,,0,0,,,,PENDING
726,AU,A1,AU 2021/339953 A1,078-750-968-093-011,2023-05-18,2023,AU 2021/339953 A,2021-09-10,US 202063077207 P;;EP 2021075005 W,2020-09-11,THERAPEUTIC B7-H4 BINDING MOLECULES,"The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.",MEDIMMUNE LTD,KINNEER KRISTA;;DAVIES GARETH;;REES DAVID;;PERCIVAL-ALWYN JENNIFER;;ANDREWS JOHN;;CHESEBROUGH JON,,https://lens.org/078-750-968-093-011,Patent Application,no,0,0,18,18,0,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,C07K16/28;;A61K31/00;;A61K39/00;;A61K47/68;;A61P35/00;;C07K16/30;;G01N33/574,,0,0,,,,PENDING
727,US,B2,US 10493259 B2,059-537-314-776-372,2019-12-03,2019,US 201414222909 A,2014-03-24,US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 201113113326 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 82745206 P;;US 88428507 P;;US 52275304 P,2003-01-21,Medical apparatus for fluid communication,"This disclosure describes embodiments of a kit and its constituent components which together form an apparatus in which fluid communication between a medical device's lumen and the surrounding environment is provided by a conduit cooperatively defined by the medical device and a tubular member into which the device is inserted. The medical device and tubular member are configured to fit together such that an outer surface of the distal region of the medical device cooperates with an inner surface of the tubular member to define the conduit between the side-port of the medical device and a distal end of the tubular member. The conduit is operable to be used for injecting fluid, withdrawing fluid, and measuring pressure, for example. Methods of assembling and using the apparatus are described as well.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;SHAH KRISHAN;;DAVIES GARETH;;MIRZA MAHMOOD;;VISRAM NAHEED;;HARTLEY AMANDA,BAYLIS MEDICAL COMPANY INC (2014-03-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/059-537-314-776-372,Granted Patent,yes,32,4,2,113,0,A61B18/1482;;A61B18/1492;;A61B2018/00011;;A61B2018/00083;;A61B2018/00351;;A61B2018/00839;;A61B2218/002;;A61B2017/00247;;A61B2090/3983;;A61B2090/064;;A61B90/02;;A61B2090/0811;;A61B2090/3966;;Y10T29/49826;;A61M39/08;;A61B5/065;;A61M5/007;;A61B5/103;;A61M29/02;;Y10T29/49826;;A61B2018/00011;;A61B2018/00351;;A61B18/1492;;A61B2018/00083;;A61B2218/002;;A61B18/1482;;A61B2018/00839;;A61B2017/00247;;A61B2090/3983;;A61B2090/0811;;A61B90/02;;A61B2090/3966;;A61B2090/064,A61B18/18;;A61B5/06;;A61B5/103;;A61B17/00;;A61B18/00;;A61B18/14;;A61B90/00;;A61M5/00;;A61M29/02;;A61M39/08,,8,0,,,"Entire Prosecution History of U.S. Appl. No. 13/468,939 from May 10, 2012 to Mar. 5, 2014.;;Patent Cooperation Treaty, International Search Report for International Application No. PCT/IB2015/052118, dated Jun. 26, 2015.;;Patent Cooperation Treaty, Written Opinion of the International Search Authority for International Application No. PCT/IB2015/052118, dated Jun. 26, 2015.;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2015/052118, dated Sep. 27, 2016.;;First Office Action for Chinese Application, Application/Patent No. 2015800262435, Issue Serial No. 2018122001954460, dated Dec. 25, 2018.;;Supplementary European Search Report, EP 15 76 8911, search completed on Nov. 1, 2017.;;Search Opinion for Application No. 15 768 911.8.;;Translation of above listed First Office Action for Chinese Application, Application/Patent No. 2015800262435, Issue Serial No. 2018122001954460, dated Dec. 25, 2018.",ACTIVE
728,US,B2,US 9101375 B2,155-564-324-001-304,2015-08-11,2015,US 201314100576 A,2013-12-09,US 201314100576 A;;US 201113286041 A;;US 90544807 A;;US 82746606 P;;US 201161448578 P,2006-09-29,Fenestration through foreign material,"Described herein is a method for creating a channel through a foreign material located in a septum of a heart at the site of a septal defect. The foreign material defines a material first surface and a substantially opposed material second surface, and the channel extends through the foreign material at least partially between the material first and second surfaces. The method uses an apparatus including an electrode and includes the steps of: positioning the electrode substantially adjacent to the material first surface; energizing the electrode with a radiofrequency current; and using the electrode energized with the radiofrequency current to deliver energy into the foreign material to create the channel.",BAYLIS MEDICAL CO INC,BIADILLAH YOUSSEF;;HARTLEY AMANDA;;DAVIES GARETH;;VISRAM NAHEED;;JUZKIW TARAS;;URBANSKI JOHN PAUL,BAYLIS MEDICAL COMPANY INC (2013-12-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/155-564-324-001-304,Granted Patent,yes,3,3,2,113,0,A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00827;;A61B2018/00875;;A61B2018/00898;;A61B2018/00351;;A61F2002/061;;A61B2034/2055;;A61B2090/3788;;A61B90/02;;A61B34/76;;A61B2090/065;;A61B2090/3966;;A61B18/18;;A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00827;;A61B2018/00875;;A61B2018/00898;;A61B2018/00351;;A61F2002/061;;A61B2034/2055;;A61B2090/3788;;A61B2090/065;;A61B2090/3966;;A61B90/02;;A61B34/76,A61B18/18;;A61B8/12;;A61B18/00;;A61B18/14;;A61B19/00;;A61F2/06,,0,0,,,,ACTIVE
729,CA,A1,CA 2941953 A1,070-474-335-937-668,2015-09-17,2015,CA 2941953 A,2014-09-17,IB 2014059641 W;;IB 2014064600 W;;US 201361787617 P,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,"A method and apparatus are disclosed for providing forward fluid delivery through an electrosurgical device, while avoiding coring when energy is delivered to the electrosurgical device. The device has a distal face defining an opening, with the distal face including at least one cutting portion and at least one non-cutting portion. An embodiment of the electrosurgical device for puncturing tissue includes an elongate member defining a lumen for receiving a fluid; a distal face defining at least one aperture; and the distal face including at least one cutting portion and at least one non-cutting portion cooperating to produce an elongated cut in a tissue when electrical energy is delivered to the distal face while avoiding coring of the tissue.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD;;UHM YUN;;LEUNG LINUS,,https://lens.org/070-474-335-937-668,Patent Application,no,0,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/12,,0,0,,,,PENDING
730,EP,B1,EP 1692844 B1,084-523-861-283-699,2016-07-20,2016,EP 04808879 A,2004-12-13,NO 2004000385 W;;US 52847503 P;;US 53321603 P;;US 62854804 P,2003-12-11,Methods and devices for traversing firewalls and network address translation (nat) installations,,CISCO SYSTEMS INT SARL,ADAMS GREG;;CORDELL PETER;;DAVIES STEVEN GARETH;;GRAY STEVEN;;REED STEVEN;;SCOTT BARRY,CISCO SYSTEMS INTERNATIONAL SARL (2012-01-11),https://lens.org/084-523-861-283-699,Granted Patent,yes,3,0,9,9,0,H04L61/2528;;H04L61/2564;;H04L61/2578;;H04L63/0272;;H04L63/029;;H04L63/166;;H04L61/00;;H04L63/0272;;H04L63/029;;H04L61/2528;;H04L63/166;;H04L61/2564;;H04L61/2578;;H04L61/00;;H04L65/1101,H04L29/12;;H04L9/00;;H04L29/06,,2,0,,,"ROSENBERG J ET AL: ""SIP Traversal through Residential and Enterprise NATs and Firewalls"" INTERNET DRAFT, 2 March 2001 (2001-03-02), XP002245049;;ROSENBERG J ET AL: ""NAT and Firewall Scenarios and Solutions for SIP"" INTERNET DRAFT, December 2002 (2002-12), XP015003441",ACTIVE
731,EP,A3,EP 4233961 A3,121-775-892-574-262,2023-11-08,2023,EP 23170810 A,2015-03-23,US 201414222909 A;;EP 15768911 A;;IB 2015052118 W,2014-03-24,MEDICAL APPARATUS FOR FLUID COMMUNICATION,"This disclosure describes embodiments of a kit and its constituent components which together form an apparatus in which fluid communication between a medical device's lumen and the surrounding environment is provided by a conduit cooperatively defined by the medical device and a tubular member into which the device is inserted. The medical device and tubular member are configured to fit together such that an outer surface of the distal region of the medical device cooperates with an inner surface of the tubular member to define the conduit between the side- port of the medical device and a distal end of the tubular member. The conduit is operable to be used for injecting fluid, withdrawing fluid, and measuring pressure, for example. Methods of assembling and using the apparatus are described as well.
",BOSTON SCIENT MEDICAL DEVICE LIMITED,URBANSKI JOHN PAUL;;SHAH KRISHAN;;MIRZA MAHMOOD;;VISRAM NAHEED;;HARTLEY AMANDA;;DAVIES GARETH,,https://lens.org/121-775-892-574-262,Search Report,yes,5,0,21,113,0,A61M39/08;;A61B5/0215;;A61B18/1492;;A61B2018/00357;;A61B2018/1475;;A61B2218/002;;A61B2218/007;;A61B2090/064;;A61B2090/3966;;A61B5/065;;A61M25/0068;;A61M25/007;;A61M29/00;;A61M2025/0008;;A61M25/0108;;A61M39/08;;A61M29/02;;A61M5/00;;A61B18/1492;;A61B5/0215;;A61B5/06;;A61B2018/00357;;A61B2018/1475;;A61B2090/064;;A61B2090/3966;;A61B2218/002,A61M29/00;;A61B5/0215;;A61B5/06;;A61B18/00;;A61B18/14;;A61B90/00;;A61M25/00;;A61M39/08,,0,0,,,,PENDING
732,GB,B,GB 2453838 B,125-394-302-491-894,2011-12-21,2011,GB 0818084 A,2008-10-03,US 97988007 P,2007-10-15,Measuring a characteristic of a multimode optical fiber,,SCHLUMBERGER HOLDINGS,DAVIES DYLAN H;;HARTOG ARTHUR H;;HILTON GRAEME;;LEES GARETH P;;KADER KAMAL,,https://lens.org/125-394-302-491-894,Granted Patent,no,3,0,5,5,0,G01B11/16;;G01D5/353;;G01K11/32;;G01L1/242;;G01K11/32;;G01K11/32;;G01D5/35364;;G01D5/35364;;G01M11/319;;G01M11/319,G01M11/00;;G01B11/16;;G01D5/353;;G01K11/32;;G01L1/24,,0,0,,,,ACTIVE
733,US,A1,US 2014/0206987 A1,167-829-959-650-97X,2014-07-24,2014,US 201414222909 A,2014-03-24,US 201414222909 A;;US 201213468939 A;;US 90544707 A;;US 201113113326 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 82745206 P;;US 88428507 P;;US 52275304 P,2003-01-21,Medical apparatus for fluid communication,"This disclosure describes embodiments of a kit and its constituent components which together form an apparatus in which fluid communication between a medical device's lumen and the surrounding environment is provided by a conduit cooperatively defined by the medical device and a tubular member into which the device is inserted. The medical device and tubular member are configured to fit together such that an outer surface of the distal region of the medical device cooperates with an inner surface of the tubular member to define the conduit between the side-port of the medical device and a distal end of the tubular member. The conduit is operable to be used for injecting fluid, withdrawing fluid, and measuring pressure, for example. Methods of assembling and using the apparatus are described as well.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;SHAH KRISHAN;;DAVIES GARETH;;MIRZA MAHMOOD;;VISRAM NAHEED;;HARTLEY AMANDA,BAYLIS MEDICAL COMPANY INC (2014-03-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/167-829-959-650-97X,Patent Application,yes,26,29,2,113,0,A61B18/1482;;A61B18/1492;;A61B2018/00011;;A61B2018/00083;;A61B2018/00351;;A61B2018/00839;;A61B2218/002;;A61B2017/00247;;A61B2090/3983;;A61B2090/064;;A61B90/02;;A61B2090/0811;;A61B2090/3966;;Y10T29/49826;;A61M39/08;;A61B5/065;;A61M5/007;;A61B5/103;;A61M29/02;;Y10T29/49826;;A61B2018/00011;;A61B2018/00351;;A61B18/1492;;A61B2018/00083;;A61B2218/002;;A61B18/1482;;A61B2018/00839;;A61B2017/00247;;A61B2090/3983;;A61B2090/0811;;A61B90/02;;A61B2090/3966;;A61B2090/064,A61M39/08;;A61B5/06;;A61B5/103;;A61B18/14;;A61M5/00;;A61M29/02,600/424;;29/428;;600/431;;606/41;;600/587;;606/192,0,0,,,,EXPIRED
734,EP,A4,EP 3116429 A4,012-611-244-189-187,2017-11-15,2017,EP 14885380 A,2014-09-17,IB 2014059641 W;;IB 2014064600 W;;US 201361787617 P,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD;;UHM YUN;;LEUNG LINUS,BAYLIS MEDICAL COMPANY INC. (2022-08-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-08-31),https://lens.org/012-611-244-189-187,Search Report,no,4,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/12;;A61B18/00;;A61B18/14;;A61B90/00,,1,0,,,See also references of WO 2015136338A1,ACTIVE
735,AU,B2,AU 2015/237836 B2,004-481-916-710-228,2019-09-19,2019,AU 2015/237836 A,2015-03-23,US 201414222909 A;;IB 2015052118 W,2014-03-24,Medical apparatus for fluid communication,"This disclosure describes embodiments of a kit and its constituent components which together form an apparatus in which fluid communication between a medical device's lumen and the surrounding environment is provided by a conduit cooperatively defined by the medical device and a tubular member into which the device is inserted. The medical device and tubular member are configured to fit together such that an outer surface of the distal region of the medical device cooperates with an inner surface of the tubular member to define the conduit between the side- port of the medical device and a distal end of the tubular member. The conduit is operable to be used for injecting fluid, withdrawing fluid, and measuring pressure, for example. Methods of assembling and using the apparatus are described as well.",BOSTON SCIENT MEDICAL DEVICE LIMITED,URBANSKI JOHN PAUL;;SHAH KRISHAN;;MIRZA MAHMOOD;;VISRAM NAHEED;;HARTLEY AMANDA;;DAVIES GARETH,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-22),https://lens.org/004-481-916-710-228,Granted Patent,no,3,0,21,113,0,A61M39/08;;A61B5/0215;;A61B18/1492;;A61B2018/00357;;A61B2018/1475;;A61B2218/002;;A61B2218/007;;A61B2090/064;;A61B2090/3966;;A61B5/065;;A61M25/0068;;A61M25/007;;A61M29/00;;A61M2025/0008;;A61M25/0108;;A61M39/08;;A61M29/02;;A61M5/00;;A61B18/1492;;A61B5/0215;;A61B5/06;;A61B2018/00357;;A61B2018/1475;;A61B2090/064;;A61B2090/3966;;A61B2218/002,A61M39/08;;A61B5/06;;A61B5/103;;A61B18/14;;A61M5/00;;A61M29/02,,0,0,,,,ACTIVE
736,ES,T3,ES 2930657 T3,188-161-592-056-628,2022-12-20,2022,ES 14885380 T,2014-09-17,IB 2014059641 W;;IB 2014064600 W;;US 201361787617 P,2013-03-15,Dispositivo electroquirúrgico que tiene una abertura distal,"Se describen un método y un aparato para proporcionar el suministro de fluido hacia adelante a través de un dispositivo electroquirúrgico, al tiempo que se evita la formación de núcleos cuando se suministra energía al dispositivo electroquirúrgico. El dispositivo tiene una cara distal que define una abertura, incluyendo la cara distal al menos una parte cortante y al menos una parte no cortante. Una realización del dispositivo electroquirúrgico para perforar tejido incluye un miembro alargado que define un lumen para recibir un fluido; una cara distal que define al menos una abertura; e incluyendo la cara distal al menos una parte cortante y al menos una parte no cortante que cooperan para producir un corte alargado en un tejido cuando se suministra energía eléctrica a la cara distal mientras se evita la formación de núcleos en el tejido. (Traducción automática con Google Translate, sin valor legal)",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD;;UHM YUN;;LEUNG LINUS,,https://lens.org/188-161-592-056-628,Granted Patent,no,0,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/12;;A61B18/00;;A61B18/14;;A61B90/00,,0,0,,,,ACTIVE
737,CA,C,CA 2941953 C,194-516-910-617-556,2024-01-02,2024,CA 2941953 A,2014-09-17,IB 2014059641 W;;IB 2014064600 W;;US 201361787617 P,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,"A method and apparatus are disclosed for providing forward fluid delivery through an electrosurgical device, while avoiding coring when energy is delivered to the electrosurgical device. The device has a distal face defining an opening, with the distal face including at least one cutting portion and at least one non-cutting portion. An embodiment of the electrosurgical device for puncturing tissue includes an elongate member defining a lumen for receiving a fluid; a distal face defining at least one aperture; and the distal face including at least one cutting portion and at least one non-cutting portion cooperating to produce an elongated cut in a tissue when electrical energy is delivered to the distal face while avoiding coring of the tissue.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD;;UHM YUN;;LEUNG LINUS,,https://lens.org/194-516-910-617-556,Granted Patent,no,0,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/12,,0,0,,,,PENDING
738,EP,A1,EP 4122412 A1,003-116-082-432-134,2023-01-25,2023,EP 22175683 A,2014-09-17,EP 14885380 A;;IB 2014059641 W;;IB 2014064600 W;;US 201361787617 P,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,"A method and apparatus are disclosed for providing forward fluid delivery through an electrosurgical device, while avoiding coring when energy is delivered to the electrosurgical device. The device has a distal face defining an opening, with the distal face including at least one cutting portion and at least one non-cutting portion. An embodiment of the electrosurgical device for puncturing tissue includes an elongate member defining a lumen for receiving a fluid; a distal face defining at least one aperture; and the distal face including at least one cutting portion and at least one non-cutting portion cooperating to produce an elongated cut in a tissue when electrical energy is delivered to the distal face while avoiding coring of the tissue.
",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD;;UHM YUN;;LEUNG LINUS,,https://lens.org/003-116-082-432-134,Patent Application,yes,23,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/12;;A61B18/00;;A61B18/14;;A61B90/00,,0,0,,,,PENDING
739,EP,B1,EP 3122416 B1,033-931-652-954-487,2023-06-07,2023,EP 15768911 A,2015-03-23,US 201414222909 A;;IB 2015052118 W,2014-03-24,MEDICAL APPARATUS FOR FLUID COMMUNICATION,,BOSTON SCIENT MEDICAL DEVICE LIMITED,URBANSKI JOHN PAUL;;SHAH KRISHAN;;MIRZA MAHMOOD;;VISRAM NAHEED;;HARTLEY AMANDA;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC. (2022-07-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-05),https://lens.org/033-931-652-954-487,Granted Patent,yes,4,0,21,113,0,A61M39/08;;A61B5/0215;;A61B18/1492;;A61B2018/00357;;A61B2018/1475;;A61B2218/002;;A61B2218/007;;A61B2090/064;;A61B2090/3966;;A61B5/065;;A61M25/0068;;A61M25/007;;A61M29/00;;A61M2025/0008;;A61M25/0108;;A61M39/08;;A61M29/02;;A61M5/00;;A61B18/1492;;A61B5/0215;;A61B5/06;;A61B2018/00357;;A61B2018/1475;;A61B2090/064;;A61B2090/3966;;A61B2218/002,A61B18/14;;A61B5/0215;;A61B5/06;;A61B18/00;;A61B90/00;;A61M25/00;;A61M29/02;;A61M39/08,,0,0,,,,ACTIVE
740,EP,A1,EP 3116429 A1,093-546-555-563-674,2017-01-18,2017,EP 14885380 A,2014-09-17,IB 2014059641 W;;IB 2014064600 W;;US 201361787617 P,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,,BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD;;UHM YUN;;LEUNG LINUS,BAYLIS MEDICAL COMPANY INC. (2022-08-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-08-31),https://lens.org/093-546-555-563-674,Patent Application,yes,0,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/12,,0,0,,,,ACTIVE
741,EP,A1,EP 3122416 A1,163-821-459-640-896,2017-02-01,2017,EP 15768911 A,2015-03-23,US 201414222909 A;;IB 2015052118 W,2014-03-24,MEDICAL APPARATUS FOR FLUID COMMUNICATION,,BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;SHAH KRISHAN;;MIRZA MAHMOOD;;VISRAM NAHEED;;HARTLEY AMANDA;;DAVIES GARETH,BAYLIS MEDICAL COMPANY INC. (2022-07-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-05),https://lens.org/163-821-459-640-896,Patent Application,yes,0,0,21,113,0,A61M39/08;;A61B5/0215;;A61B18/1492;;A61B2018/00357;;A61B2018/1475;;A61B2218/002;;A61B2218/007;;A61B2090/064;;A61B2090/3966;;A61B5/065;;A61M25/0068;;A61M25/007;;A61M29/00;;A61M2025/0008;;A61M25/0108;;A61M39/08;;A61M29/02;;A61M5/00;;A61B18/1492;;A61B5/0215;;A61B5/06;;A61B2018/00357;;A61B2018/1475;;A61B2090/064;;A61B2090/3966;;A61B2218/002,A61M39/08;;A61B5/06;;A61B5/103;;A61B18/14;;A61M5/00;;A61M29/02,,0,0,,,,ACTIVE
742,JP,A,JP 2019177150 A,170-163-325-835-980,2019-10-17,2019,JP 2019095726 A,2019-05-22,IB 2014059641 W;;US 201361787617 P,2013-03-15,ELECTROSURGICAL DEVICE HAVING DISTAL APERTURE,"To provide a method and a device that can be used for energy delivery into a patient body.SOLUTION: A method and an apparatus are disclosed for providing forward fluid delivery through an electrosurgical device 120, while avoiding coring when energy is delivered to the electrosurgical device. The device has a distal face 104 defining an opening, with the distal face including at least one cutting portion 103a and at least one non-cutting portion 105a. The electrosurgical device for puncturing tissue includes an elongate member 102 defining a lumen for receiving a fluid, and a distal face defining at least one aperture, where the distal face includes at least one cutting portion and at least one non-cutting portion that cooperate to produce an elongated cut in a tissue when electrical energy is delivered to the distal face while avoiding coring of the tissue.SELECTED DRAWING: Figure 1",BAYLIS MEDICAL CO INC,GARETH DAVIES;;JOHN PAUL URBANSKI;;ELLEN HARFIELD;;MAHMOOD MIRZA;;YUN UHM;;LINUS LEUNG,,https://lens.org/170-163-325-835-980,Patent Application,no,6,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14,,0,0,,,,ACTIVE
743,EC,A,EC SP23025680 A,159-715-552-557-487,2023-05-31,2023,EC DI202325680 A,2023-04-10,US 202063077207 P,2020-09-11,MOLÉCULAS DE UNIÓN A B7-H4 TERAPÉUTICAS,"La presente invención se refiere a moléculas de unión (por ejemplo, anticuerpos) para el tratamiento del cáncer, y a conjugados de anticuerpo-fármaco relacionados.",MEDIMMUNE LTD,PERCIVAL-ALWYN JENNIFER;;KINNEER KRISTA;;DAVIES GARETH;;ANDREWS JOHN;;CHESEBROUGH JON;;REES DAVID,,https://lens.org/159-715-552-557-487,Patent Application,no,0,0,18,18,0,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,C07K16/28;;A61K31/00;;A61K39/00;;A61K47/68;;A61P35/00;;C07K16/30;;G01N33/574,,0,0,,,,PENDING
744,WO,A1,WO 2005/057882 A1,168-732-980-155-557,2005-06-23,2005,NO 2004000385 W,2004-12-13,US 52847503 P;;US 53321603 P;;US 62854804 P,2003-12-11,COMMUNICATION SYSTEMS FOR TRAVERSING FIREWALLS AND NETWORK ADDRESS TRANSLATION (NAT) INSTALLATIONS,"Methods, systems, and mediums for enabling clients to traverse firewall and Network Address Translation (NAT) installations by using probe packets between servers and clients to communication the addresses modified by the NAT.",TANDBERG TELECOM AS;;ADAMS GREG;;CORDELL PETER;;DAVIES STEVEN GARETH;;GREY STEVEN;;REED STEVEN;;SCOTT BARRY,ADAMS GREG;;CORDELL PETER;;DAVIES STEVEN GARETH;;GREY STEVEN;;REED STEVEN;;SCOTT BARRY,,https://lens.org/168-732-980-155-557,Patent Application,yes,3,10,9,9,0,H04L61/2528;;H04L61/2564;;H04L61/2578;;H04L63/0272;;H04L63/029;;H04L63/166;;H04L61/00;;H04L63/0272;;H04L63/029;;H04L61/2528;;H04L63/166;;H04L61/2564;;H04L61/2578;;H04L61/00;;H04L65/1101,H04L9/00;;H04L29/06;;H04L29/12,,2,0,,,"ROSENBERG J ET AL: ""SIP Traversal through Residential and Enterprise NATs and Firewalls"", INTERNET DRAFT, 2 March 2001 (2001-03-02), XP002245049;;ROSENBERG J ET AL: ""NAT and Firewall Scenarios and Solutions for SIP"", INTERNET DRAFT, December 2002 (2002-12-01), XP015003441",PENDING
745,DE,D1,DE 602008004540 D1,001-848-393-698-731,2011-02-24,2011,DE 602008004540 T,2008-05-21,GB 0710121 A;;GB 2008001738 W,2007-05-25,"2-OXO-2-(2-PHENYL-5,6,7,8-TETRAHYDROINDOLIZIN-3-YL)ACETAMIDDERIVATE UND VERWANDTE VERBINDUNGEN ALS ANTIPILZMITTEL","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/001-848-393-698-731,Granted Patent,no,0,0,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A61K31/437;;A61P31/10,,0,0,,,,ACTIVE
746,JP,A,JP 2021010765 A,103-716-742-714-386,2021-02-04,2021,JP 2020173733 A,2020-10-15,IB 2014059641 W;;US 201361787617 P,2013-03-15,ELECTROSURGICAL DEVICE HAVING DISTAL APERTURE,"To provide a method and an apparatus which provide forward fluid delivery through an electrosurgical device, while avoiding coring when energy is delivered to the electrosurgical device.SOLUTION: The device has a distal face defining an aperture, the distal face including at least one cutting portion and at least one non-cutting portion. The electrosurgical device for puncturing a tissue includes an elongate member defining a lumen for receiving a fluid, and a distal face defining at least one aperture, where the distal face includes at least one cutting portion and at least one non-cutting portion that cooperate to produce an elongated cut in the tissue when electrical energy is delivered to the distal face while avoiding coring of the tissue.SELECTED DRAWING: Figure 1",BAYLIS MEDICAL CO INC,GARETH DAVIES;;JOHN PAUL URBANSKI;;ELLEN HARFIELD;;MAHMOOD MIRZA;;YUN UHM;;LINUS LEUNG,,https://lens.org/103-716-742-714-386,Patent Application,no,6,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/14,,0,0,,,,ACTIVE
747,CN,B,CN 1890945 B,163-230-586-975-563,2012-08-15,2012,CN 200480036723 A,2004-12-13,NO 2004000385 W;;US 52847503 P;;US 53321603 P;;US 62854804 P,2003-12-11,Communication systems for traversing firewalls and network address translation (NAT) installations,"Methods, systems, and mediums for enabling clients to traverse firewall and Network Address Translation (NAT) installations by using probe packets between servers and clients to communication the addresses modified by the NAT.",CISCO SYSTEMS INT SARL,STEVEN GRAY;;GREG ADAMS;;PETER CORDELL;;STEVEN REED;;BARRY SCOTT;;GARETH DAVIES STEVEN,CISCO SYSTEMS INTERNATIONAL BV (2012-04-05),https://lens.org/163-230-586-975-563,Granted Patent,no,0,0,9,9,0,H04L61/2528;;H04L61/2564;;H04L61/2578;;H04L63/0272;;H04L63/029;;H04L63/166;;H04L61/00;;H04L63/0272;;H04L63/029;;H04L61/2528;;H04L63/166;;H04L61/2564;;H04L61/2578;;H04L61/00;;H04L65/1101,H04L29/12;;H04L9/00;;H04L29/06,,0,0,,,,INACTIVE
748,CA,A1,CA 3220441 A1,162-778-364-319-189,2015-09-17,2015,CA 3220441 A,2014-09-17,IB 2014059641 W;;CA 2941953 A;;US 201615262715 A;;US 201361787617 P,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERATURE,,BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD;;UHM YUN;;LEUNG LINUS,,https://lens.org/162-778-364-319-189,Patent Application,no,0,0,3,36,0,A61B2018/00297;;A61B2018/1427;;A61B2018/1497;;A61B2218/002;;A61B2090/3966;;A61B2018/1412;;A61B2018/1467;;A61B18/1477;;A61B2018/00601;;A61B2018/00351;;A61B2018/00083;;A61B2018/00077;;A61B18/1477;;A61B2018/00601;;A61B2018/00351;;A61B2018/00083;;A61B2018/00077;;A61B2090/3966;;A61B2018/00297;;A61B2018/1497;;A61B2090/392;;A61B2018/1427;;A61B2018/1412;;A61B2018/1467;;A61B2218/002,,,0,0,,,,PENDING
749,EP,A2,EP 4233961 A2,096-661-655-744-942,2023-08-30,2023,EP 23170810 A,2015-03-23,US 201414222909 A;;EP 15768911 A;;IB 2015052118 W,2014-03-24,MEDICAL APPARATUS FOR FLUID COMMUNICATION,"This disclosure describes embodiments of a kit and its constituent components which together form an apparatus in which fluid communication between a medical device's lumen and the surrounding environment is provided by a conduit cooperatively defined by the medical device and a tubular member into which the device is inserted. The medical device and tubular member are configured to fit together such that an outer surface of the distal region of the medical device cooperates with an inner surface of the tubular member to define the conduit between the side- port of the medical device and a distal end of the tubular member. The conduit is operable to be used for injecting fluid, withdrawing fluid, and measuring pressure, for example. Methods of assembling and using the apparatus are described as well.
",BOSTON SCIENT MEDICAL DEVICE LIMITED,URBANSKI JOHN PAUL;;SHAH KRISHAN;;MIRZA MAHMOOD;;VISRAM NAHEED;;HARTLEY AMANDA;;DAVIES GARETH,,https://lens.org/096-661-655-744-942,Patent Application,yes,10,0,21,113,0,A61M39/08;;A61B5/0215;;A61B18/1492;;A61B2018/00357;;A61B2018/1475;;A61B2218/002;;A61B2218/007;;A61B2090/064;;A61B2090/3966;;A61B5/065;;A61M25/0068;;A61M25/007;;A61M29/00;;A61M2025/0008;;A61M25/0108;;A61M39/08;;A61M29/02;;A61M5/00;;A61B18/1492;;A61B5/0215;;A61B5/06;;A61B2018/00357;;A61B2018/1475;;A61B2090/064;;A61B2090/3966;;A61B2218/002,A61M25/00,,0,0,,,,PENDING
750,GB,A,GB 2453838 A,033-617-682-772-929,2009-04-22,2009,GB 0818084 A,2008-10-03,US 97988007 P,2007-10-15,Measuring a characteristic of a multimode optical fibre,"Method and apparatus to measure a characteristic (e.g. temperature, strain) of a multimode optical fibre 102 deployed in a well or along an electrical cable comprises: transmitting a light pulse from a light source 104 into the fibre; passing Brillouin backscattered light that is responsive to the light pulse, from the fibre through a spatial filter 108 (e.g. near or far field spatial filter respectively connected to, and spaced apart from, a proximal end 120 of the fibre), wherein a portion of Brillouin backscattered light is passed through the spatial filter; and directing this portion (e.g. via on optical coupler 504) to optical detection equipment 110 (e.g. optical filter 112 and detector 114) for processing. The spatial filter may be positioned between the fibre and the detection equipment and may include: at least one aperture to pass a portion of a respective speckle pattern; a single mode optical fibre (200); or an opaque layer (300) with a hole (302) therein. A beam combiner (508) may be used to combine light from an optical local oscillator and the Brillouin backscattered light portion. Raman detection equipment may also be incorporated to process Raman backscattered light.",SCHLUMBERGER HOLDINGS,DAVIES DYLAN H;;HARTOG ARTHUR H;;HILTON GRAEME;;LEES GARETH P;;KADER KAMAL,,https://lens.org/033-617-682-772-929,Patent Application,no,3,4,5,5,0,G01B11/16;;G01D5/353;;G01K11/32;;G01L1/242;;G01K11/32;;G01K11/32;;G01D5/35364;;G01D5/35364;;G01M11/319;;G01M11/319,G01K11/32;;G01B11/16;;G01D5/353;;G01L1/24;;G01M11/00,,0,0,,,,ACTIVE
751,EP,B1,EP 3116429 B1,150-728-291-762-153,2022-09-21,2022,EP 14885380 A,2014-09-17,IB 2014059641 W;;IB 2014064600 W;;US 201361787617 P,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,,BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD;;UHM YUN;;LEUNG LINUS,BAYLIS MEDICAL COMPANY INC. (2022-08-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-08-31),https://lens.org/150-728-291-762-153,Granted Patent,yes,2,0,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/12;;A61B18/00;;A61B18/14;;A61B90/00,,0,0,,,,ACTIVE
752,US,A1,US 2014/0100561 A1,196-111-483-803-473,2014-04-10,2014,US 201314100576 A,2013-12-09,US 201314100576 A;;US 201113286041 A;;US 90544807 A;;US 82746606 P;;US 201161448578 P,2006-09-29,Fenestration through foreign material,"Described herein is a method for creating a channel through a foreign material located in a septum of a heart at the site of a septal defect. The foreign material defines a material first surface and a substantially opposed material second surface, and the channel extends through the foreign material at least partially between the material first and second surfaces. The method uses an apparatus including an electrode and includes the steps of: positioning the electrode substantially adjacent to the material first surface; energizing the electrode with a radiofrequency current; and using the electrode energized with the radiofrequency current to deliver energy into the foreign material to create the channel.",BAYLIS MEDICAL CO INC,BIADILLAH YOUSSEF;;HARTLEY AMANDA;;DAVIES GARETH;;VISRAM NAHEED;;JUZKIW TARAS;;URBANSKI JOHN PAUL,BAYLIS MEDICAL COMPANY INC (2013-12-06);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/196-111-483-803-473,Patent Application,yes,3,11,2,113,0,A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00827;;A61B2018/00875;;A61B2018/00898;;A61B2018/00351;;A61F2002/061;;A61B2034/2055;;A61B2090/3788;;A61B90/02;;A61B34/76;;A61B2090/065;;A61B2090/3966;;A61B18/18;;A61B8/12;;A61B18/1492;;A61B2018/00083;;A61B2018/00214;;A61B2018/00702;;A61B2018/00827;;A61B2018/00875;;A61B2018/00898;;A61B2018/00351;;A61F2002/061;;A61B2034/2055;;A61B2090/3788;;A61B2090/065;;A61B2090/3966;;A61B90/02;;A61B34/76,A61B18/18,606/33,0,0,,,,ACTIVE
753,WO,A1,WO 2015/136338 A1,072-028-968-321-444,2015-09-17,2015,IB 2014064600 W,2014-09-17,IB 2014059641 W;;US 201361787617 P,2013-03-15,ELECTROSURGICAL DEVICE HAVING A DISTAL APERTURE,"A method and apparatus are disclosed for providing forward fluid delivery through an electrosurgical device, while avoiding coring when energy is delivered to the electrosurgical device. The device has a distal face defining an opening, with the distal face including at least one cutting portion and at least one non-cutting portion. An embodiment of the electrosurgical device for puncturing tissue includes an elongate member defining a lumen for receiving a fluid; a distal face defining at least one aperture; and the distal face including at least one cutting portion and at least one non-cutting portion cooperating to produce an elongated cut in a tissue when electrical energy is delivered to the distal face while avoiding coring of the tissue.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD;;UHM YUN;;LEUNG LINUS,,https://lens.org/072-028-968-321-444,Patent Application,yes,6,2,32,36,0,A61B2018/1427;;A61B2218/002;;A61B2090/392;;A61B2090/3966;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497;;A61B2018/1427;;A61B2218/002;;A61B2090/3966;;A61B2090/392;;A61B18/1477;;A61B2018/00083;;A61B2018/00297;;A61B2018/00351;;A61B2018/1497,A61B18/12,,1,0,,,See also references of EP 3116429A4,PENDING
754,WO,A1,WO 2022/053650 A1,093-964-285-533-185,2022-03-17,2022,EP 2021075005 W,2021-09-10,US 202063077207 P,2020-09-11,THERAPEUTIC B7-H4 BINDING MOLECULES,"The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.",MEDIMMUNE LTD,KINNEER KRISTA;;DAVIES GARETH;;REES DAVID;;PERCIVAL-ALWYN JENNIFER;;ANDREWS JOHN;;CHESEBROUGH JON,,https://lens.org/093-964-285-533-185,Patent Application,yes,78,3,18,18,55,C07K16/2827;;C07K16/3015;;C07K2317/92;;C07K2317/90;;C07K2317/732;;G01N33/57492;;A61K2039/505;;G01N33/574;;C07K2317/21;;C07K2317/33;;C07K2317/73;;A61P35/00;;C07K2317/77;;A61K47/6803;;A61K47/6849;;A61K47/6855;;G01N33/68;;C07K16/2827;;A61P35/00;;C07K2317/77;;A61K47/6849;;G01N33/57492;;G01N33/574;;C07K2317/90;;A61K2039/505;;C07K2317/92;;C07K16/3015;;C07K2317/73;;A61K47/6803;;A61K47/6855;;C07K2317/732;;C07K2317/21;;C07K2317/33;;G01N33/68;;C07K16/2827;;C07K16/3015;;A61K47/6803;;A61K47/6849;;A61K47/6855;;A61P35/00;;G01N33/57492;;C07K2317/92;;C07K2317/90;;C07K2317/732;;C07K2317/21;;C07K2317/33;;C07K2317/77;;A61K2039/505;;A61K47/6803;;A61K47/6855;;A61P35/00;;C07K16/2827;;C07K16/3015,C07K16/28;;A61K31/00;;A61K39/00;;A61K47/68;;A61P35/00;;C07K16/30;;G01N33/574,,62,49,034-523-716-361-183;;152-341-119-821-429;;085-628-827-415-050;;095-843-764-156-972;;011-375-997-307-135;;003-338-632-019-904;;007-603-263-950-700;;023-115-865-713-224;;049-134-753-209-354;;074-817-300-512-106;;002-264-966-090-625;;010-916-105-450-247;;006-574-964-805-278;;042-204-626-457-327;;021-693-018-511-818;;039-515-794-348-090;;078-432-639-041-575;;008-083-146-934-082;;106-753-778-592-300;;005-530-610-119-448;;030-630-100-818-462;;034-331-211-704-877;;020-855-322-534-259;;053-665-131-053-807;;043-558-136-070-327;;047-193-486-795-201;;069-144-826-896-138;;023-907-179-348-058;;005-112-559-456-657;;007-364-858-655-289;;039-676-361-532-623;;000-789-841-460-564;;038-340-513-777-764;;128-630-976-527-604;;021-798-842-753-904;;074-582-134-846-704;;110-094-292-858-47X;;007-816-444-939-69X;;038-497-994-577-370;;077-066-325-033-341;;005-779-577-361-278;;009-176-538-189-711;;021-301-666-722-431;;046-475-261-047-666;;023-969-505-910-047;;056-456-509-029-170;;016-273-136-051-718;;097-970-813-772-582;;007-454-016-910-916,10.1007/s12038-018-9772-3;;30207312;;pmc4066406;;10.1016/j.ygyno.2014.03.553;;24657487;;30737243;;10.1158/1078-0432.ccr-17-3123;;10.1158/1078-0432.ccr-04-0789;;15501986;;10.1158/1078-0432.843.11.2;;15701875;;10.1038/nbt.1480;;18641636;;10.1182/blood-2009-02-205500;;19633198;;12121142;;10.1021/bc025536j;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/341544a0;;2677748;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1038/nbt0792-779;;1368267;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1126/science.3388019;;3388019;;10.1016/s0145-305x(02)00039-3;;12477501;;10.1074/jbc.m604292200;;16793771;;10.1128/aac.01285-13;;pmc3837853;;24080653;;1172191;;10.1038/256495a0;;10.1016/s0092-8240(86)90010-8;;3580642;;10.1007/bf02462326;;10.1038/348552a0;;2247164;;10.1038/352624a0;;1907718;;1748994;;10.1016/0022-2836(91)90498-u;;9630891;;10.1038/nbt0396-309;;10.1073/pnas.95.11.6157;;pmc27609;;9600934;;10.1016/j.jmb.2007.12.018;;18191144;;8360482;;10.4049/jimmunol.151.5.2623;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1126/science.3925553;;3925553;;10.1002/jps.2600660104;;833720;;10.1093/nar/22.22.4673;;pmc308517;;7984417;;8980688;;10.1006/jmbi.1996.0679;;1422884;;10.1093/bioinformatics/8.5.501;;8211139;;10.1126/science.8211139;;10.1093/bioinformatics/bth116;;14962914;;10.1021/ja00007a055;;10.1016/0076-6879(91)02017-4;;1784180;;8430333;;10.1126/science.8430333;;10.1073/pnas.90.21.10145;;pmc47730;;8234268;;10.1074/jbc.271.33.19991;;8702716;;8003512;;10.1021/bi00189a055;;pmc2142390;;8453377;;10.1002/pro.5560020311;;1549776;;10.1126/science.1549776;;1569578;;10.1016/0022-2836(92)90457-u;;1511746;;10.1016/0014-5793(92)80739-4;;10.1073/pnas.86.7.2152;;2928323;;pmc286869;;10.1016/0378-1119(86)90398-7;;3803923;;10.1089/dna.1988.7.127;;3282853;;pmc2467532;;10.2210/pdb3c2s/pdb;;18560159;;10.1107/s0907444908007877,"JI HONGSHUAI ET AL: ""Construction, expression and functional analysis of anti-B7-H4-scFv-CH3 recombinant antibody"", JOURNAL OF BIOSCIENCES, SPRINGER INDIA, NEW DELHI, vol. 43, no. 4, 10 July 2018 (2018-07-10), pages 661 - 671, XP036579959, ISSN: 0250-5991, [retrieved on 20180710], DOI: 10.1007/S12038-018-9772-3;;SMITH JENESSA B ET AL: ""B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look"", GYNECOLOGIC ONCOLOGY, vol. 134, no. 1, 20 March 2014 (2014-03-20), pages 181 - 189, XP028874738, ISSN: 0090-8258, DOI: 10.1016/J.YGYNO.2014.03.553;;IIZUKA AKIRA ET AL: ""A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer"", CLINICAL CANCER RESEARCH, vol. 25, no. 9, 1 May 2019 (2019-05-01), pages 2925 - 2934, XP055811280, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-17-3123;;HAMBLETT ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 7063 - 7070;;SANDERSON ET AL., CLIN. CANCER RES., vol. 11, 2005, pages 843 - 852;;JUNUTULA ET AL., NATURE BIOTECH, vol. 26, no. 8, 2008, pages 925 - 932;;DORNAN ET AL., BLOOD, vol. 114, no. 13, 2009, pages 2721 - 2729;;DUBOWCHIK ET AL., BIOCONJUGATE CHEMISTRY, vol. 13, 2002, pages 855 - 869;;""Organic Synthesis, Fourth"", 2007, JOHN WILEY & SONS, pages: 696 - 871;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", NATIONAL INSTITUTES OF HEALTH, 1991;;CHOTHIA, C. ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE LAL-ATI-AIØ, 1988;;HUSTON ET AL., PROC. NATL. ACAD. SCL USA, vol. 85, 1988, pages 5879 - 5883;;BERZOFSKY ET AL.: ""Antibody-Antigen Interactions, In Fundamental Immunology"", 1984, MCGRAW-HILL;;MARKS ET AL., BIOTECHNOLOGY, vol. 10, 1992, pages 779 - 783;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327;;REIDHAAR-OLSONSAUER, SCIENCE, vol. 241, 1988, pages 1534 - 1536;;KABAT ET AL.: ""Sequences of Immunological Interest"", NATIONAL INSTITUTES OF HEALTH, BETHESDA, 1991;;LEFRANC, M.P. ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", U.S. PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH, 1991;;DALL'ACQUA ET AL., J. BIOL. CHEM., vol. 281, 2006, pages 23514 - 24;;ROBBIE ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 57, 2013, pages 6147 - 6153;;KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495;;ALTSCHUL ET AL., BULL. MATH. BIO., vol. 48, 1986, pages 603 - 16;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;HOOGENBOOMWINTER, J. MOL. BIOL., vol. 222, 1991, pages 581 - 597;;COLE ET AL., MONOCLONAL ANTIBODIES AND CANCER THERAPY, 1985, pages 77;;BOEMER ET AL., J. IMMUNOL., vol. 147, no. 1, 1991, pages 86 - 95;;VAUGHAN ET AL., NAT. BIOTECH., vol. 14, 1996, pages 309 - 314;;SHEETS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 6157 - 6162;;ROTHE ET AL., J. MOLEC. BIOL., vol. 376, 2008, pages 1182 - 1200;;PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623;;HENIKOFFHENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 - 19;;MORIMOTO ET AL., J. BIOCHEM. BIOPHYS. METH., vol. 24, 1993, pages 107 - 117;;BRENNAN ET AL., SCIENCE, vol. 229, no. 81, 1985;;CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1281;;BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;JULIE D. THOMPSON ET AL.: ""CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position- Specific Gap Penalties and Weight Matrix Choice"", NUCLEIC ACIDS RESEARCH, vol. 22, no. 22, 1994, pages 4673 - 4680, XP002956304;;OSAMU GOTOH: ""Significant Improvement in Accuracy of Multiple Protein. Sequence Alignments by Iterative Refinement as Assessed by Reference to Structural Alignments"", J. MOL. BIOL., vol. 264, no. 4, 1996, pages 823 - 838;;ERIC DEPIEREUXERNEST FEYTMANS: ""Match-Box: A Fundamentally New Algorithm for the Simultaneous Alignment of Several Protein Sequences"", CABIOS, vol. 8, no. 5, 1992, pages 501 - 509;;C. E. LAWRENCE ET AL.: ""Detecting Subtle Sequence Signals: A Gibbs Sampling Strategy for Multiple Alignment"", SCIENCE, vol. 262, no. 5131, 1993, pages 208 - 214, XP001152872, DOI: 10.1126/science.8211139;;IVO VAN WALLE ET AL.: ""Align-M - A New Algorithm for Multiple Alignment of Highly Divergent Sequences"", BIOINFORMATICS, vol. 20, no. 9, 2004, pages 1428 - 1435;;ROBERTSON ET AL., J. AM. CHEM. SOC., vol. 113, 1991, pages 2722;;ELLMAN ET AL., METHODS ENZYMOL., vol. 202, 1991, pages 301;;CHUNG ET AL., SCIENCE, vol. 259, 1993, pages 806 - 9;;CHUNG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 10145 - 9;;TURCATTI ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 19991 - 8;;KOIDE ET AL., BIOCHEM., vol. 33, 1994, pages 7470 - 6;;WYNNRICHARDS, PROTEIN SCI, vol. 2, 1993, pages 395 - 403;;DE VOS ET AL., SCIENCE, vol. 255, 1992, pages 306 - 12;;SMITH ET AL., J. MOL. BIOL., vol. 224, 1992, pages 899 - 904;;WLODAVER ET AL., FEBS LETT, vol. 309, 1992, pages 59 - 64;;BOWIESAUER, PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 2152 - 6;;LOWMAN ET AL., BIOCHEM., vol. 30, 1991, pages 10832 - 7;;DERBYSHIRE ET AL., GENE, vol. 46, 1986, pages 145;;NER ET AL., DNA, vol. 7, 1988, pages 127;;SINGLETON ET AL.: ""DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY"", 1994, JOHN WILEY AND SONS;;HALEMARHAM: ""THE HARPER COLLINS DICTIONARY OF BIOLOGY"", 1991, HARPER PERENNIAL;;ACTA CRYSTALLOGR D BIOL CRYSTALLOGR., vol. 64, 1 June 2008 (2008-06-01), pages 700 - 704",PENDING
755,CA,A1,CA 3190740 A1,127-197-830-378-369,2015-10-01,2015,CA 3190740 A,2015-03-23,US 201414222909 A;;CA 2943463 A,2014-03-24,MEDICAL APPARATUS FOR FLUID COMMUNICATION,"This disclosure describes embodiments of a kit and its constituent components which together form an apparatus in which fluid communication between a medical device's lumen and the surrounding environment is provided by a conduit cooperatively defined by the medical device and a tubular member into which the device is inserted. The medical device and tubular member are configured to fit together such that an outer surface of the distal region of the medical device cooperates with an inner surface of the tubular member to define the conduit between the side-port of the medical device and a distal end of the tubular member. The conduit is operable to be used for injecting fluid, withdrawing fluid, and measuring pressure, for example. Methods of assembling and using the apparatus are described as well.",BOSTON SCIENT MEDICAL DEVICE LIMITED,URBANSKI JOHN PAUL;;MIRZA MAHMOOD;;VISRAM NAHEED;;HARTLEY AMANDA;;DAVIES GARETH;;SHAH KRISHAN,,https://lens.org/127-197-830-378-369,Patent Application,no,0,0,21,113,0,A61M39/08;;A61B5/0215;;A61B18/1492;;A61B2018/00357;;A61B2018/1475;;A61B2218/002;;A61B2218/007;;A61B2090/064;;A61B2090/3966;;A61B5/065;;A61M25/0068;;A61M25/007;;A61M29/00;;A61M2025/0008;;A61M25/0108;;A61M39/08;;A61M29/02;;A61M5/00;;A61B18/1492;;A61B5/0215;;A61B5/06;;A61B2018/00357;;A61B2018/1475;;A61B2090/064;;A61B2090/3966;;A61B2218/002,,,0,0,,,,PENDING
756,US,B2,US 7694127 B2,026-204-683-577-886,2010-04-06,2010,US 815004 A,2004-12-10,US 815004 A;;US 62854804 P;;US 53321603 P;;US 52847503 P,2003-12-11,Communication systems for traversing firewalls and network address translation (NAT) installations,"Methods, systems, and mediums for enabling clients to traverse firewall and Network Address Translation (NAT) installations by using probe packets between servers and clients to communication the addresses modified by the NAT.",TANDBERG TELECOM AS,ADAMS GREG;;CORDELL PETER;;DAVIES STEVEN GARETH;;GRAY STEVEN;;REED STEVEN;;SCOTT BARRY,CISCO TECHNOLOGY INC (2011-11-10);;TANDBERG TELECOM AS (2005-01-26),https://lens.org/026-204-683-577-886,Granted Patent,yes,45,46,9,9,0,H04L61/2528;;H04L61/2564;;H04L61/2578;;H04L63/0272;;H04L63/029;;H04L63/166;;H04L61/00;;H04L63/0272;;H04L63/029;;H04L61/2528;;H04L63/166;;H04L61/2564;;H04L61/2578;;H04L61/00;;H04L65/1101,H04L29/06;;H04L9/00;;H04L29/12,713/151;;713/182;;726/5,6,0,,,"Rosenberg, J. et al., ""SIP Traversal Through Residential and Enterprise NATS and Firewalls"", Internet Engineering Task Force, Internet Draft, Mar. 2, 2001, pp. 1-21.;;Rosenberg, J. et al., ""NAT and Firewall Scenarios and Solutions for SIP"", Internet Engineering Task Force, Internet Draft, Dec. 2002, pp. 1-60.;;Davies, S. et al., ""Traversal of Non-Protocol Aware Firewalls & NATS"", Internet Engineering Task Force, Internet Draft, Oct. 12, 2001, pp. 1-23.;;Davies, S. et al., ""Traversal of Non-Protocol Aware Firewalls & NATS"", Internet Engineering Task Force, Internet Draft, Mar. 18, 2001, pp. 1-30.;;Rosenberg, J et al., ""Interactive Connectivity Establishment (ICE): A Methodology for Network Address Translator (NAT) Traversal for the Session Initiation Protocol (SIP) Draft-Rosenberg-Sipping-Ice-01"", Internet Draft, Dec. 29, 2003, pp. 1-77.;;Press Release, Tandberg Acquires Ridgeway Systems & Software Ltd., May 19, 2004, http://www.tandberg.com/press-room/viewPressRelease.do?id=68.",INACTIVE
757,US,A1,US 2010/0293960 A1,146-097-015-184-251,2010-11-25,2010,US 22747007 A,2007-02-27,EP 06010534 A;;EP 2007051822 W,2006-05-22,Gas Turbine Engine Starting Method and Control Device,A method of starting a gas turbine engine by use of a start sequence is provided. Turbine speed and fuel delivery are coordinated so as to provide a fuel/air mixture at an ignition device allowing a successful ignition. If a successful ignition has not occurred by end of the start sequence the gas turbine engine is purged and the start sequence is repeated after the purging of the gas turbine engine.,DAVIES GARETH HUW;;WILKINSON JOHN;;WILKINSON STUART;;WILKINSON MARIA HELEN KATHAKIN;;WOODS RICHARD,DAVIES GARETH HUW;;WILKINSON JOHN;;WILKINSON STUART;;WILKINSON MARIA HELEN KATHAKIN;;WOODS RICHARD,SIEMENS AKTIENGESELLSCHAFT (2009-03-27);;SIEMENS ENERGY GLOBAL GMBH & CO. KG (2021-02-28),https://lens.org/146-097-015-184-251,Patent Application,yes,5,7,8,8,0,F01D19/00;;F02C7/26;;F02C9/26;;F05D2260/85;;F02C7/26;;F01D19/00;;F02C9/26;;F05D2260/85,F02C7/26,60/778;;60/786,0,0,,,,ACTIVE
758,EP,A1,EP 1692844 A1,058-877-545-407-712,2006-08-23,2006,EP 04808879 A,2004-12-13,NO 2004000385 W;;US 52847503 P;;US 53321603 P;;US 62854804 P,2003-12-11,Methods and devices for traversing firewalls and network address translation (nat) installations,,TANDBERG TELECOM AS,ADAMS GREG;;CORDELL PETER;;DAVIES STEVEN GARETH;;GRAY STEVEN;;REED STEVEN;;SCOTT BARRY,CISCO SYSTEMS INTERNATIONAL SARL (2012-01-11),https://lens.org/058-877-545-407-712,Patent Application,yes,0,0,9,9,0,H04L61/2528;;H04L61/2564;;H04L61/2578;;H04L63/0272;;H04L63/029;;H04L63/166;;H04L61/00;;H04L63/0272;;H04L63/029;;H04L61/2528;;H04L63/166;;H04L61/2564;;H04L61/2578;;H04L61/00;;H04L65/1101,H04L29/12;;H04L9/00;;H04L29/06,,0,0,,,,ACTIVE
759,US,B2,US 8524705 B2,009-844-885-510-873,2013-09-03,2013,US 60128408 A,2008-05-21,GB 0710121 A;;GB 2008001738 W,2007-05-25,"2-oxo-2-(2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl)-acetamide derivatives and related compounds as antifungal agents","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP;;DAVIES GARETH MORSE;;F2G LTD BRITISH BODY CORPORATE,PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP;;DAVIES GARETH MORSE,F2G LIMITED BRITISH BODY CORPORATE (2010-02-26),https://lens.org/009-844-885-510-873,Granted Patent,yes,5,9,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,A61K31/437;;A01N43/90;;A61K31/496;;A61K31/5377;;A61K31/551,514/218;;514/253.04;;514/299;;514/233.2;;546/112;;544/362;;544/121;;540/575,7,7,157-368-878-373-980;;046-015-969-792-277;;028-494-421-159-044;;157-368-878-373-980;;060-908-101-548-398;;017-365-412-179-713;;032-838-088-052-630,10.1021/ja01463a046;;10.1128/jcm.01550-06;;17021057;;pmc1698398;;10.1002/jps.2600660230;;839424;;10.1021/ja01463a046;;8842991;;10.1016/s0163-4453(96)92700-0;;10064251;;10.1086/515116;;10.1021/jo981505z,"Galbraith et al., Journal of the American Chemical Society (1961), 83, 453-8.;;Isham et al., Journal of clinical microbiology, (2006), vol. 44(12), pp. 4342-4344.;;Cardellini et al., ""Indolizine derivatives with biological activity I: N'-substituted hydrazides of indolizine-2-carboxylic acid,"" J Pharm Sci., 66(2):259-262, 1977.;;Galbraith et al., ""The formation of Cycl[3,2,2] azine derivatives via the reaction of pyrrocoline with dimethyl acetylenedicarboxylate,"" Journal of the American Chemical Society, 83:453-458, 1961.;;Groll et al., ""Trends in the postmortem epidemiology of invasive fungal infections at a university hospital,"" J Infect., 33:23-32, 1996.;;Ribaud et al., ""Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation,"" Clin. Infect. Dis., 28:322-330, 1999.;;Savage et al., ""Efficient synthesis of 4-, 5-, and 6-methyl-2,2'-bipyridine by a negishi cross-coupling strategy followed by high-yield conversion to bromo- and chloromethy1-2,2'-bipyridines,"" J. Org. Chem., 63:10048-10051, 1998.",ACTIVE
760,ES,T3,ES 2451659 T3,045-207-048-540-42X,2014-03-28,2014,ES 07824661 T,2007-11-21,GB 0623209 A;;GB 2007004449 W,2006-11-21,Derivados de 2-[(2-sustituido)-indolizin-3-il]-2-oxo-acetamida como agentes antifúngicos,"Un compuesto que es un derivado de indolizinilo de fórmula (I), o una sal farmacéuticamente aceptable delmismo:**Fórmula** donde: X es un enlace, -NR8-, -O-, -S-, -SO- o -SO2-; 10 X1 es O o NOR9, donde R9 es hidrógeno o un grupo alquilo C1-C4 sin sustituir o sustituido; R1 representa -A3-L3-A4, -A3-L1-(A4)p-(A11)q-L3-A5, -A6-L1-A7, -A3-L4-A8, -A3-W, -A9, -A3-L1-A9 o -A10,donde p y q son iguales o diferentes y representan cero o 1; R8 representa hidrógeno, o un grupo sin sustituir o sustituido seleccionado entre arilo C6-C10, un grupoheterociclilo de 5 a 12 miembros, alquilo C1-C8, alquenilo C2-C8, alquinilo C2-C8, cicloalquilo C3-C6, -A1-L1-A2,-L2-A2, -COR' y -Y-Z; L1 es un enlace, -NR'-, -O-, -CO-, -OCO-, -OCONR'R'' o -CONR'R''-; L2 es un grupo alquileno C1-C4 o alquenileno C2-C4 sin sustituir o sustituido; L3 es un enlace o un grupo de fórmula -(Het)r-Alq1-(Het)s-, -(Alq2)m-C(>=O)-Het-(Alq3)n-, -Alq4- o -SO2-, donde Alq1,Alq2, Alq3 y Alq4 son iguales o diferentes y representan grupos alquileno C1-C4 sin sustituir, m, n, r y s soniguales o diferentes y representan cero o 1, y Het representa -O- o -NR9-, donde R9 es hidrógeno o alquilo C1-C4 sin sustituir; L4 es un grupo imino -N>=, donde el doble enlace está unido al grupo A8; A1 es un grupo arileno C6-C10 sin sustituir o sustituido; A2, A3, A4, A5, A7 y A11 son iguales o diferentes y son arilo C6-C10 sin sustituir o sustituido o gruposheterociclilo de 5 a 12 miembros; A6 es un arilo C6-C10 o un grupo heterociclilo 5 a 12 miembros que está sustituido con al menos un arilo C6-C10o un grupo heterociclilo de 5 a 12 miembros que está sin sustituir o sustituido; A8 es un grupo heterociclilo de 5 a 12 miembros sin sustituir o sustituido; A9 es un grupo heterociclilo de 5 a 12 miembros sin sustituir o sustituido donde 1 ó 2 átomos de carbono en elanillo se reemplazan por un grupo seleccionado entre >C(>=O), >S(>=O)2, >C(>=NOR11), donde R11 es hidrógenoo un grupo alquilo C1-C4, >C>=CH2 o >C(-OCH2CH2O-); A10 es un grupo heterociclilo de 13 a 15 miembros tricíclico sin sustituir o sustituido; W es un grupo de fórmula -C(>=O)-NR10-S(>=O)2-R''' donde R10 y R''' son iguales o diferentes y representanhidrógeno o alquilo C1-C4; R2 es un grupo sin sustituir o sustituido seleccionado entre arilo C6-C10, un grupo heterociclilo de 5 a 12miembros, alquilo C1-C8 y cicloalquilo C3-C6, halógeno o un grupo de fórmula -B1-B2 o -B3; B1 es un grupo arilo C6-C10 sin sustituir o sustituido; B2 es un grupo arilo C6-C10 o heterociclilo de 5 a 12 miembros sin sustituir o sustituido; B3 es un grupo heterociclilo de 5 a 12 miembros sin sustituir o sustituido, donde 1 ó 2 átomos de carbono en elanillo se reemplazan por un grupo seleccionado entre >C(>=O), >S(>=O)2, >C(>=NOR11), donde R11 es hidrógenoo un grupo alquilo C1-C4, >C>=CH2 o >C(-OCH2CH2O-); (i) R3 representa arilo C6-C10, un grupo heterociclilo de 5 a 12 miembros, -(alquileno C1-C4)-(arilo C6-C10), -(alquileno C1-C4)-(heterociclilo de 5 a 12 miembros), hidrógeno, halógeno, alquilo C1-C8, alquenilo C2-C8,alquinilo C2-C8, -OR', -CO2R', -CONR'R'', -COR', -CN, -NO2, -NR'R'', CF3 o -Y-Z, y R4 representa arilo C6-C10,un grupo heterociclilo de 5 a 12 miembros, -(alquileno C1-C4)-(arilo C6-C10), -(alquileno C1-C4)-(heterociclilo de5 a 12 miembros), hidrógeno, halógeno, alquilo C1-C8, alquenilo C2-C8, alquinilo C2-C8, -OR', -CO2R', -CONR'R'', -COR', -CN, -NO2, -NR'R'', CF3, -Y-Z o un grupo de fórmula -Het-Alq5-A11, donde Het es -NR12 o -OsiendoR12 hidrógeno o alquilo C1-C4, Alq5 es alquileno C1-C6 y A11 es arilo C6-C10 o un grupo heterociclilo de5 a 12 miembros, o (ii) R3 y R4, junto con los átomos de carbono del anillo a los que están unidos, forman ungrupo arilo C6-C10 o heterociclilo de 5 a 12 miembros sin sustituir o sustituido.",F2G LTD,DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;PAYNE LLOYD JAMES;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/045-207-048-540-42X,Granted Patent,no,0,0,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/90;;A61K31/437;;A61P33/00,,0,0,,,,ACTIVE
761,SG,A,SG 11202012312U A,069-483-685-320-093,2021-01-28,2021,SG 11202012312U A,2019-06-18,GB 201809946 A;;GB 201815694 A;;GB 2019051699 W,2018-06-18,GREMLIN-1 ANTAGONIST FOR THE PREVENTION AND TREATMENT OF CANCER,,UCB BIOPHARMA SRL;;UNIV OXFORD INNOVATION LTD;;UNIV ADELAIDE,DAVIES GARETH CHARLES GLYNDWR;;LEEDHAM SIMON;;ZANNETTINO ANDREW;;CLARK KIMBERLEY;;HEWETT DUNCAN;;PANAGOPOULOS VASILIOS,,https://lens.org/069-483-685-320-093,Unknown,no,0,0,14,17,0,C07K16/18;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K16/18;;A61P35/00;;C12Q1/6886;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12Q2600/158;;C12Q2600/118;;C12Q2600/106;;A61P35/00;;A61K45/06;;A61K2039/505;;C07K16/24;;C07K16/2803;;C07K16/2896;;G01N33/5748;;G01N2800/52,A61K39/395;;A61P35/00,,0,0,,,,PENDING
762,EP,A1,EP 3806898 A1,093-855-363-090-218,2021-04-21,2021,EP 19734460 A,2019-06-18,GB 201809946 A;;GB 201815694 A;;GB 2019051699 W,2018-06-18,GREMLIN-1 ANTAGONIST FOR THE PREVENTION AND TREATMENT OF CANCER,,UCB BIOPHARMA SRL;;UNIV OXFORD INNOVATION LTD;;UNIV ADELAIDE,DAVIES GARETH CHARLES GLYNDWR;;LEEDHAM SIMON;;ZANNETTINO ANDREW;;CLARK KIMBERLEY;;HEWETT DUNCAN;;PANAGOPOULOS VASILIOS,,https://lens.org/093-855-363-090-218,Patent Application,yes,0,0,14,17,0,C07K16/18;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K16/18;;A61P35/00;;C12Q1/6886;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12Q2600/158;;C12Q2600/118;;C12Q2600/106;;A61P35/00;;A61K45/06;;A61K2039/505;;C07K16/24;;C07K16/2803;;C07K16/2896;;G01N33/5748;;G01N2800/52,A61K39/395;;A61P35/00,,0,0,,,,PENDING
763,CA,A1,CA 2670165 A1,126-140-646-877-172,2008-05-29,2008,CA 2670165 A,2007-11-21,GB 0623209 A;;GB 2007004449 W,2006-11-21,2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS,"The invention provides compounds of formula (I), and pharmaceutically acc eptable salts thereof wherein: Rl, R2, R3, R4, R5, R6, R7, X and X1 are as d efined herein. These compounds are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of for mula (I), and agriculturally acceptable salts thereof, may also be used as a gricultural fungicides.",F2G LTD,DAVIES GARETH MORSE;;PAYNE LLOYD JAMES;;EDWARDS PHILIP;;SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT,,https://lens.org/126-140-646-877-172,Patent Application,no,0,0,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/90;;A61K31/437;;A61P33/00,,0,0,,,,ACTIVE
764,WO,A1,WO 2008/145963 A1,184-555-938-367-578,2008-12-04,2008,GB 2008001738 W,2008-05-21,GB 0710121 A,2007-05-25,"2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: Rl, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD;;PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP;;DAVIES GARETH MORSE,PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/184-555-938-367-578,Patent Application,yes,1,22,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A61K31/437;;A61P31/10,,1,0,,,"JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2",PENDING
765,WO,A1,WO 2015/092768 A1,020-396-231-354-631,2015-06-25,2015,IB 2014067173 W,2014-12-19,US 201361918800 P;;US 201361918848 P,2013-12-20,STEERABLE MEDICAL DEVICE HANDLE,"A steerable catheter control handle and method are provided for bi- directional control of a steerable catheter, the catheter including at least two control wires, a distal end of each of the control wires being coupled to the catheter at a distal region thereof. The control system comprises a housing. A wire actuation mechanism is disposed within the housing and is operably coupled to at least two control wires for enabling actuation of the at least two control wires. The steerable catheter control handle additionally comprises a proximal control knob that is operably coupled to the wire actuation mechanism to enable actuation of the at least two control wires. The control knob is positioned proximal to the wire actuation mechanism to enhance ease of use of the steerable catheter control handle. The rotation of the proximal knob causes movement of the wire actuation mechanism within the housing for tensioning one of the at least two control wires for causing a distal end deflection of the steerable catheter.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DAVIES GARETH;;THOMPSON MELANIE;;GORAPALLI DEEPTHI;;COPELAND STEVE;;DICKIE ROBERT;;LEFLER AMY;;BECA BOGDAN,,https://lens.org/020-396-231-354-631,Patent Application,yes,5,4,6,6,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/092;;A61M25/09,,0,0,,,,PENDING
766,US,A1,US 2021/0253688 A1,080-382-086-251-458,2021-08-19,2021,US 201917253660 A,2019-06-18,GB 201809946 A;;GB 201815694 A;;GB 2019051699 W,2018-06-18,GREMLIN-1 ANTAGONIST FOR THE PREVENTION AND TREATMENT OF CANCER,The invention relates to an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer.,UCB BIOPHARMA SRL;;UNIV OXFORD INNOVATION LTD;;UNIV ADELAIDE,DAVIES GARETH CHARLES GLYNDWR;;LEEDHAM SIMON;;ZANNETTINO ANDREW;;CLARK KIMBERLEY;;HEWETT DUNCAN;;PANAGOPOULOS VASILIOS,OXFORD UNIVERSITY INNOVATION LIMITED (2021-04-13);;CELLTECH R&D LIMITED (2019-06-17);;UCB BIOPHARMA SRL (2019-06-17);;THE UNIVERSITY OF ADELAIDE (2021-01-11),https://lens.org/080-382-086-251-458,Patent Application,yes,0,2,14,17,43,C07K16/18;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K16/18;;A61P35/00;;C12Q1/6886;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12Q2600/158;;C12Q2600/118;;C12Q2600/106;;A61P35/00;;A61K45/06;;A61K2039/505;;C07K16/24;;C07K16/2803;;C07K16/2896;;G01N33/5748;;G01N2800/52,C07K16/24;;A61K45/06;;A61P35/00;;C07K16/28;;G01N33/574,,0,0,,,,PENDING
767,EP,A3,EP 4198286 A3,133-444-615-981-66X,2023-07-05,2023,EP 22208025 A,2022-11-17,GB 202118044 A,2021-12-14,RESTARTING A GAS TURBINE ENGINE,"Aircraft power and propulsion systems 100, aircraft 1 comprising such power and propulsion systems 100, and methods of restarting a gas turbine engine 110 of such power and propulsion systems 100 during flight are provided. One such aircraft power and propulsion system 100 comprises: a propulsive gas turbine engine 110 comprising a plurality of spools 14, 19, 26; 15, 17, 27, combustion equipment 16, one or more electric machines 111, 112 mechanically coupled with one or more of the spools 14, 19, 26; 15, 17, 27, and an electrically-powered fuel pump 115 for delivering fuel to the combustion equipment 16; an electrical system 120 connected with the one or more electric machines 111, 112 and the electrically-powered fuel pump 115, the electrical system comprising an energy storage system 130; and a control system 140 configured to: responsive to a determination to the effect that a flame in the combustion equipment 16 has been extinguished, control the electrical system 120 to supply electrical power from the energy storage system 130 to the fuel pump 115 during an engine restart attempt.
",ROLLS ROYCE PLC,HUSBAND STEPHEN;;MOORE GARETH;;DAVIES PAUL;;TRAINER DAVID;;SCOTHERN DAVID;;GEORGE LUKE;;HERBERT DOUGLAS,,https://lens.org/133-444-615-981-66X,Search Report,yes,3,0,5,5,0,F02C7/262;;F02C6/14;;F02K5/00;;F05D2220/76;;F02C9/46;;Y02T50/60;;F02C7/262;;B64D37/32;;F02C9/46;;F01D15/10;;F02C7/32,F02C7/262;;F02K5/00,,0,0,,,,PENDING
768,TW,B,TW I787223 B,103-600-844-172-405,2022-12-21,2022,TW 106144629 A,2017-12-19,GB 201621635 A,2016-12-19,Gremlin-1 crystal structure and inhibitory antibody,,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;DEDI NEESHA;;MCMILLAN DAVID JAMES;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN,,https://lens.org/103-600-844-172-405,Granted Patent,no,1,0,36,36,0,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,,,0,0,,,,ACTIVE
769,WO,A1,WO 2019/243801 A1,142-176-799-421-402,2019-12-26,2019,GB 2019051699 W,2019-06-18,GB 201809946 A;;GB 201815694 A,2018-06-18,GREMLIN-1 ANTAGONIST FOR THE PREVENTION AND TREATMENT OF CANCER,The invention relates to an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer.,UCB BIOPHARMA SRL;;UNIV OXFORD INNOVATION LTD;;UNIV ADELAIDE,DAVIES GARETH CHARLES GLYNDWR;;LEEDHAM SIMON;;ZANNETTINO ANDREW;;CLARK KIMBERLEY;;HEWETT DUNCAN;;PANAGOPOULOS VASILIOS,,https://lens.org/142-176-799-421-402,Patent Application,yes,51,9,14,17,43,C07K16/18;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K16/18;;A61P35/00;;C12Q1/6886;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12Q2600/158;;C12Q2600/118;;C12Q2600/106;;A61P35/00;;A61K45/06;;A61K2039/505;;C07K16/24;;C07K16/2803;;C07K16/2896;;G01N33/5748;;G01N2800/52,A61K39/395;;A61P35/00,,110,98,088-935-349-526-045;;106-753-778-592-300;;020-026-345-586-213;;087-448-981-335-707;;055-542-669-483-094;;064-741-687-897-846;;035-081-115-342-527;;077-532-829-551-519;;148-647-852-252-502;;025-662-361-226-516;;042-623-879-457-954;;064-667-501-146-970;;054-899-454-772-257;;030-797-864-869-467;;043-729-032-107-483;;010-655-350-435-62X;;037-436-870-995-452;;113-446-080-346-814;;057-051-348-154-974;;066-141-497-990-023;;080-856-085-597-555;;056-201-471-905-934;;023-907-179-348-058;;019-779-601-634-917;;046-951-095-213-650;;047-308-646-101-537;;040-363-636-264-022;;082-151-267-963-934;;050-133-270-638-85X;;148-750-828-583-42X;;042-222-591-554-811;;061-154-078-727-141;;007-711-535-660-589;;011-553-054-044-973;;098-724-633-703-400;;012-007-448-024-359;;041-701-093-712-495;;001-646-542-312-05X;;000-769-593-092-070;;095-834-903-970-444;;008-061-699-775-635;;067-024-105-019-398;;070-834-347-340-232;;053-699-924-523-691;;013-703-966-633-758;;097-901-796-209-229;;029-486-847-477-02X;;070-238-365-351-890;;111-604-378-852-726;;056-289-795-899-023;;060-522-017-672-204;;008-017-695-084-433;;060-126-066-099-876;;077-587-097-220-826;;076-252-023-764-678;;060-918-425-739-173;;018-280-468-055-668;;063-266-551-840-350;;038-728-499-086-588;;018-199-486-626-091;;023-860-693-372-071;;002-880-498-827-946;;034-499-526-956-496;;020-398-976-665-441;;040-842-346-948-061;;092-175-386-389-524;;029-970-218-339-139;;088-935-349-526-045;;013-337-877-638-381;;024-205-497-164-000;;037-310-319-433-702;;028-671-261-063-506;;026-361-471-680-127;;083-861-682-427-488;;001-062-843-030-532;;016-392-744-492-623;;082-522-923-505-342;;095-576-636-997-853;;064-781-969-527-647;;028-188-258-692-969;;099-142-413-754-43X;;072-971-856-375-322;;028-716-741-713-711;;012-113-132-303-756;;034-489-784-615-708;;036-648-857-259-985;;057-475-663-409-518;;053-688-298-868-719;;044-958-492-431-511;;044-380-745-789-522;;015-238-057-914-589;;017-186-900-863-545;;067-290-214-184-650;;051-322-618-006-677;;065-274-506-678-30X;;012-265-598-126-264;;016-507-178-023-87X;;021-221-160-658-727,10.1371/journal.pone.0035100;;22514712;;pmc3325980;;1172191;;10.1038/256495a0;;25291284;;10.1016/0167-5699(83)90123-8;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1002/eji.1830240426;;8149964;;10.1016/s0378-1119(96)00627-0;;10.1016/s0065-2776(08)60674-4;;7872158;;10.1038/nbt1142;;16151406;;10.2174/1567269053828800;;10.1016/s0022-1759(98)00077-5;;9760222;;9624683;;10.1038/nbt0698-535;;15848072;;10.1016/j.ymeth.2005.01.003;;15608286;;10.1093/nar/gki088;;pmc540042;;10.1016/0021-9673(94)01255-d;;7620566;;18751803;;10.1007/s11420-005-0111-5;;pmc2504134;;10.1385/1-59259-666-5:443;;14970513;;10.1110/ps.9.3.487;;pmc2144561;;10752610;;2406013;;10.1016/j.molimm.2006.03.020;;16697465;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1007/bf00160485;;8483166;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;11154231;;10.1182/blood.v97.2.516;;20124692;;pmc2815665;;10.1107/s0907444909047337;;19461840;;pmc2483472;;10.1107/s0021889807021206;;20383002;;pmc2852313;;10.1107/s0907444910007493;;pmc3069751;;10.1107/s0907444911001314;;21460454;;10.1107/s0907444909042073;;20057044;;10.1107/97809553602060000884;;pmc2803126;;10.1016/j.str.2013.06.005;;pmc3749838;;23850456;;pmc4335214;;25561725;;10.1074/jbc.m114.628412;;15014901;;10.1007/s00259-003-1441-5;;10.1002/mc.22378;;26293751;;10.1182/blood-2011-09-380410;;pmc3382938;;22394600;;pmc5119705;;10.11138/ccmbm/2016.13.2.101;;27920804;;25706628;;10.1038/ng.3225;;pmc3132213;;10.1002/jcp.22730;;21412775;;10.1038/cddis.2017.533;;pmc5775406;;29095438;;10.1007/s00535-012-0614-z;;22706573;;25637218;;10.1016/j.yexcr.2015.01.006;;pmc3398763;;22451422;;10.1182/blood-2012-02-412783;;10.1359/jbmr.2002.17.3.513;;11874242;;24160323;;10.1016/j.ajpath.2013.07.017;;pmc5691347;;22182508;;10.1016/j.cellsig.2011.12.008;;10029599;;10.1182/blood.v93.5.1697;;10.1182/blood.v93.5.1697.405a17_1697_1706;;pmc5093055;;27118403;;10.1038/leu.2016.96;;25419707;;10.1038/nm.3750;;pmc4594755;;19335218;;10.1359/jbmr.090210;;25266456;;pmc4464690;;10.1038/nrrheum.2014.164;;10495271;;10.1016/s0925-4773(99)00142-2;;pmc3775476;;22374979;;10.1158/0008-5472.can-11-2067;;15539560;;10.1210/en.2004-0766;;17785465;;10.1074/jbc.m701317200;;10.1182/blood-2012-01-379024;;pmc3390959;;22535658;;10.1097/00003086-199706000-00011;;9186204;;10.1016/j.neo.2017.09.004;;pmc5678743;;29091798;;10.1038/nrc2189;;17646864;;10.1038/leu.2011.263;;21941367;;10.1038/88919;;11381269;;10.1126/science.280.5366.1086;;9582123;;09582123;;10.1016/s1097-2765(00)80067-2;;9660951;;25706627;;10.1038/ng.3224;;28299802;;10.1002/path.4891;;pmc5488238;;22561515;;pmc4594751;;10.1038/ng.2263;;25153376;;10.1515/hsz-2014-0221;;23659962;;pmc5528431;;10.1016/j.molonc.2013.04.002;;10.1371/journal.pone.0035100;;22514712;;pmc3325980;;10.1371/journal.pone.0174565;;pmc5367809;;28346486;;25834571;;pmc4365323;;10.1155/2015/834137;;15509819;;10.1056/nejmra041875;;pmc3693206;;23826422;;10.1002/path.4537;;25810250;;26632274;;10.1038/ncomms9983;;pmc4686867;;10.1016/j.celrep.2014.07.020;;pmc4471812;;25131200;;20660291;;10.1182/blood-2010-06-291930;;22870311;;pmc3411619;;10.1371/journal.pone.0042264;;10.1186/1471-2407-6-74;;16545136;;pmc1459871;;10.1038/nprot.2007.279;;17703211;;pmc4007935;;10.3324/haematol.2013.090977;;23935020;;pmc4595141;;10.1186/s13045-015-0209-2;;26445238;;25117979;;pmc4198825;;10.1016/j.neo.2014.07.002;;10.1016/j.stem.2015.02.015;;pmc4355577;;25748930;;10.1038/nature07935;;19329995;;pmc2688661;;10.1002/dvdy.21882;;19235733;;10.1053/j.gastro.2008.01.079;;18325394;;10.1016/j.exer.2013.05.011;;pmc3809843;;23748100;;10.1038/s41586-018-0084-4;;pmc5966331;;29720649;;10.1073/pnas.0606857103;;17003113;;pmc1578503;;pmc3759128;;23978876;;10.1038/oncsis.2013.29;;21655089;;pmc3107194;;10.1371/journal.pgen.1002105;;pmc232332;;10.1128/mcb.17.8.4801;;9234736;;10.1007/s10585-007-9108-4;;17952614;;18594511;;10.1038/nature07085;;pmc2840222;;10.3892/or.2011.1463;;21935575;;25594183;;10.1016/j.cell.2014.11.042;;pmc4436082;;10.1007/s13277-015-4093-8;;26392110;;10.1016/j.bone.2009.11.005;;19913648,"MINSOO KIM ET AL: ""Gremlin-1 Induces BMP-Independent Tumor Cell Proliferation, Migration, and Invasion"", PLOS ONE, vol. 7, no. 4, 13 April 2012 (2012-04-13), pages e35100, XP055121712, DOI: 10.1371/journal.pone.0035100;;GUINNEY ET AL., NAT MED, 2015;;TOMLINSON ET AL., PLOS GENET, 2011;;""UniProt"", Database accession no. 060565;;""NCBI"", Database accession no. NM_001191322.1;;""Handbook of Experimental Immunology"", vol. 4, 1986, BLACKWELL SCIENTIFIC PUBLISHERS;;KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497;;KOZBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 72;;COLE ET AL.: ""Monoclonal Antibodies and Cancer Therapy"", 1985, ALAN R LISS, INC., pages: 77 - 96;;BABCOOK, J. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, no. 15, 1996, pages 7843 - 78481;;BRINKMAN ET AL., J. IMMUNOL. METHODS, vol. 184, 1995, pages 177 - 186;;KETTLEBOROUGH ET AL., EUR. J. IMMUNOL., vol. 24, 1994, pages 952 - 958;;PERSIC ET AL., GENE, vol. 187, 1997, pages 9 - 18;;BURTON ET AL., ADVANCES IN IMMUNOLOGY, vol. 57, 1994, pages 191 - 280;;HOLLIGERHUDSON, NATURE BIOTECH, vol. 23, no. 9, 2005, pages 1126 - 1136;;ADAIRLAWSON, DRUG DESIGN REVIEWS - ONLINE, vol. 2, no. 3, 2005, pages 209 - 217;;VERMA ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 216, 1998, pages 165 - 181;;VAUGHAN ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 535 - 539;;KASHMIRI ET AL., METHODS, vol. 36, 2005, pages 25 - 34;;RETTER ET AL., NUCL. ACIDS RES., vol. 33, no. 1, 2005, pages D671 - D674;;REICHMANN ET AL., NATURE, vol. 332, 1998, pages 323 - 324;;HARRIS, RJ, JOURNAL OF CHROMATOGRAPHY, vol. 705, 1995, pages 129 - 134;;BOSTROM, M. P.SEIGERMAN, D. A.: ""The clinical use of allografts, demineralized bone matrices, synthetic bone graft substitutes and osteoinductive growth factors: a survey study"", HSS JOURNAL: THE MUSCULOSKELETAL JOURNAL OF HOSPITAL FOR SPECIAL SURGERY, vol. 1, 2005, pages 571 - 607;;REINEKE, METHODS MOL BIOL, vol. 248, 2004, pages 443 - 63;;TOMER, PROTEIN SCIENCE, vol. 9, 2000, pages 487 - 496;;JUNGHANS ET AL., CANCER RES, vol. 50, 1990, pages 1495 - 1502;;KRINNER ET AL., MOL. IMMUNOL., vol. 44, no. 5, February 2007 (2007-02-01), pages 916 - 25;;DEVEREUX ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 387 - 395;;ALTSCHUL S.F., J MOL EVOL, vol. 36, 1993, pages 290 - 300;;ALTSCHUL, S, F ET AL., J MOL BIOL, vol. 215, 1990, pages 403 - 10;;HENIKOFFHENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 - 10919;;KARLINALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5787;;""Current Protocols in Molecular Biology"", 1995, GREENE PUBLISHING AND WILEY-LNTERSCIENCE;;HJERTNER, O. ET AL.: ""Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells"", BLOOD, vol. 97, no. 2, 2001, pages 516 - 22;;""Remington's Pharmaceutical Sciences"", 2000, LIPPINCOTT, WILLIAMS & WILKINS;;VAN CUTSEM, ANNALS OF ONCOLOGY, vol. 25, no. 3, 2014;;KABSCHWOLFGANG, ACTA CRYSTALLOGRAPHICA SECTION D, vol. 66, 2010, pages 125 - 132;;MCCOY ET AL., APPL CRYST, vol. 40, 2007, pages 658 - 674;;EMSLEY ET AL., ACTA CRYSTALLOGRAPHIC A SECTION D: BIOLOGICAL CRYSTALLOGRAPHY, vol. 66, no. 4, pages 486 - 501;;MURSHUDOV ET AL.: ""REFMAC5 for the refinement of macromolecular crystal structures"", ACTA CRYSTALLOGRAPHICA SECTION D: BIOLOGICAL CRYSTALLOGRAPHY, vol. 67, no. 4, 2011, pages 355 - 367;;CHEN ET AL.: ""MolProbity: all-atom structure validation for macromolecular crystallography"", ACTA CRYSTALLOGRAPHICA, vol. D66, 2010, pages 12 - 21;;NOLAN ET AL., STRUCTURE, vol. 21, 2013, pages 1417 - 1429;;NOLAN ET AL., J. BIOL. CHEM., vol. 290, 2014, pages 4759 - 4771;;PONOMAREV, V. ET AL.: ""A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging"", EUR J NUCL MED MOL IMAGING, vol. 31, no. 5, 2004, pages 740 - 51, XP002557951, doi:10.1007/s00259-003-1441-5;;ATTAR-SCHNEIDER, O. ET AL.: ""Multiple myeloma and bone marrow mesenchymal stem cells' crosstalk: Effect on translation initiation"", MOL CARCINOG, 2015;;AZAB, A.K. ET AL.: ""Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features"", BLOOD, vol. 119, no. 24, 2012, pages 5782 - 94;;BUZA, J. A., 3RDEINHORN, T., CLINICAL CASES IN MINERAL AND BONE METABOLISM: THE OFFICIAL JOURNAL OF THE ITALIAN SOCIETY OF OSTEOPOROSIS, MINERAL METABOLISM, AND SKELETAL DISEASES, vol. 13, 2016, pages 101 - 105;;CALON ALONARDO EBERENGUER-LLERGO AESPINET EHERNANDO-MOMBLONA XIGLESIAS M ET AL.: ""Stromal gene expression defines poor-prognosis subtypes in colorectal cancer"", NAT GENET, vol. 47, no. 4, 2015, pages 320 - 9, XP055297456, doi:10.1038/ng.3225;;CANALIS, E.PARKER, K.ZANOTTI, S.: ""Gremlinl is required for skeletal development and postnatal skeletal homeostasis"", J.CELL PHYSIOL, vol. 227, 2012, pages 269 - 277;;CHEN, J. ET AL.: ""BAFF is involved in macrophage-induced bortezomib resistance in myeloma"", CELL DEATH DIS, vol. 8, no. 11, 2017, pages e3161;;CHEN, M.H. ET AL.: ""Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors"", J GASTROENTEROL, vol. 48, no. 1, 2013, pages 101 - 8, XP035162725, doi:10.1007/s00535-012-0614-z;;CHEONG, C.M. ET AL.: ""Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo"", EXP CELL RES, vol. 332, no. 1, 2015, pages 24 - 38;;CHESI, M. ET AL.: ""Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy"", BLOOD, vol. 120, no. 2, 2012, pages 376 - 85, XP055235331, doi:10.1182/blood-2012-02-412783;;CHO, T. J.GERSTENFELD, L. C.EINHORN, T. A., JOURNAL OF BONE AND MINERAL RESEARCH: THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH, vol. 17, 2002, pages 513 - 520;;CIUCLAN, L. ET AL.: ""Treatment with anti-gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice"", AM J PATHOL, vol. 183, no. 5, 2013, pages 1461 - 73, XP055205055, doi:10.1016/j.ajpath.2013.07.017;;CURRAN, S.P ET AL.: ""Deletion of Gremlinl increases cell proliferation and migration responses in mouse embryonic fibroblasts"", CELLULAR SIGNALLING, vol. 24, no. 4, 2012, pages 889 - 98, XP055205193, doi:10.1016/j.cellsig.2011.12.008;;DALLAS, S.L. ET AL.: ""Ibandronate reduces osteolytic lesions but not tumour burden in a murine model of myeloma bone disease"", BLOOD, vol. 93, no. 5, 1999, pages 1697 - 706, XP003024844;;DAS, D.S. ET AL.: ""A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells"", LEUKEMIA, vol. 30, no. 11, 2016, pages 2187 - 2197;;DAVIS HIRSHAD SBANSAL MRAFFERTY HBOITSOVA TBARDELLA C ET AL.: ""Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche"", NAT MED., vol. 21, no. 1, 2015, pages 62 - 70;;DIAMOND, P. ET AL.: ""Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss"", J BONE MINER RES, vol. 24, no. 7, 2009, pages 1150 - 61;;EINHORN, T. A.GERSTENFELD, L. C.: ""Fracture healing: mechanisms and interventions"", NAT. REV. RHEUMATOL., vol. 11, 2015, pages 45 - 54;;FERGUSON, C.ALPERN, E.MICLAU, T.HELMS, J. A.: ""Does adult fracture repair recapitulate embryonic skeletal formation?"", MECHANISMS OF DEVELOPMENT, vol. 87, 1999, pages 57 - 66, XP027424262, doi:10.1016/S0925-4773(99)00142-2;;FOWLER, J.A. ET AL.: ""Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkkl"", CANCER RESEARCH, vol. 72, no. 9, 2012, pages 2183 - 9;;GAZZERRO, E. ET AL.: ""Skeletal overexpression of gremlin impairs bone formation and causes osteopenia"", ENDOCRINOLOGY, vol. 146, 2005, pages 655 - 665, XP055576723, doi:10.1210/en.2004-0766;;GAZZERRO, E. ET AL.: ""Conditional deletion of gremlin causes a transient increase in bone formation and bone mass"", J.BIOL.CHEM., vol. 282, 2007, pages 31549 - 31557;;GHOBRIAL, I.M.: ""Myeloma as a model for the process of metastasis: implications for therapy"", BLOOD, vol. 120, no. 1, 2012, pages 20 - 30, XP055476873, doi:10.1182/blood-2012-01-379024;;GOULET, J. A.SENUNAS, L. E.DESILVA, G. L.GREENFIELD, M. L.: ""Autogenous iliac crest bone graft. Complications and functional assessment"", CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 1997, pages 76 - 81;;GUAN ET AL.: ""Gremlinl promotes carcinogensis of glimona in vitro"", EXP PHARMACOL PHYSIOL, vol. 44, no. 2, 2017, pages 244 - 256;;HEWETT, D.R. ET AL.: ""DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment"", NEOPLASIA (NEW YORK, N.Y., vol. 19, no. 12, 2017, pages 972 - 981;;HIDESHIMA, T. ET AL.: ""Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets"", NATURE REVIEWS CANCER, vol. 7, no. 8, 2007, pages 585 - 98;;HOLIEN, T. ET AL.: ""Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC"", LEUKEMIA, vol. 26, no. 5, 2012, pages 1073 - 80;;HOWE JRBAIR JLSAYED MGANDERSON MEMITROS FAPETERSEN GM ET AL.: ""Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis"", NAT GENET, vol. 28, no. 2, 2001, pages 184 - 7, XP002961964, doi:10.1038/88919;;HOWE JROTH SRINGOLD JSUMMERS RJARVINEN HSISTONEN P ET AL.: ""Mutations in the SMAD4/DPC4 gene in juvenile polyposis"", SCIENCE, vol. 280, no. 5366, 1998, pages 1086 - 8;;HSU, D. R.ECONOMIDES, A. N.WANG, X.EIMON, P. M.HARLAND, R. M.: ""The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities"", MOL. CELL, vol. 1, 1998, pages 673 - 683, XP002066230, doi:10.1016/S1097-2765(00)80067-2;;ISELLA CTERRASI ABELLOMO SEPETTI CGALATOLA GMURATORE A ET AL.: ""Stromal contribution to the colorectal cancer transcriptome"", NAT GENET, vol. 47, no. 4, 2015, pages 312 - 9;;IRSHAD SBANSAL MGUARNIERI PDAVIS HAL HAJ ZEN ABARAN B ET AL.: ""Bone morphogenetic protein and Notch signalling crosstalk in poor-prognosis, mesenchymal-subtype colorectal cancer"", J PATHOL., 2017;;JAEGER ELEEDHAM SLEWIS ASEGDITSAS SBECKER MCUADRADO PR ET AL.: ""Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1"", NAT GENET, vol. 45, no. l, January 2012 (2012-01-01), pages 2 - 3;;KARAGIANNIS, G.S. ET AL.: ""Bone morphogenetic protein antagonist gremlin-1 regulates colon cancer progression"", BIOL CHEM, vol. 396, no. 2, 2015, pages 163 - 83;;KARAGIANNIS, G.S. ET AL.: ""Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1"", MOL ONCOL, vol. 7, no. 4, 2013, pages 826 - 39, XP028683907, doi:10.1016/j.molonc.2013.04.002;;KIM, M. ET AL.: ""Gremlin-1 induces BMP-independent tumor cell proliferation, migration, and invasion"", PLOS ONE, vol. 7, no. 4, 2012, pages e35100, XP055121712, doi:10.1371/journal.pone.0035100;;KIM, H.S. ET AL.: ""GREM1 is expressed in the cancer-associated myofibroblasts of basal cell carcinomas"", PLOS ONE, vol. 12, no. 3, 2017, pages e0174565;;KOKETSU, K. ET AL.: ""Gremlin, a bone morphogenetic protein antagonist, is a crucial angiogenic factor in pituitary adenoma"", INT J ENDOCRINOL, vol. 2015, 2015, pages 834137;;KYLE, R.A.S.V. RAJKUMAR: ""Multiple myeloma"", N ENGL J MED, vol. 351, no. 18, 2004, pages 1860 - 73;;LAURILA, R. ET AL.: ""The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues"", INT J CLIN EXP PATHOL, vol. 6, no. 7, 2013, pages 1400 - 8;;LAVOZ, C. ET AL.: ""Gremlin regulates renal inflammation via vascular endothelial growth factor receptor 2 pathway"", J PATHOL, 2015;;LAWSON, M.A. ET AL.: ""Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche"", NAT COMMUN, vol. 6, 2015, pages 8983;;LEWIS AFREEMAN-MILLS LDE LA CALLE-MUSTIENES EGIRALDEZ-PEREZ RMDAVIS HJAEGER E ET AL.: ""A polymorphic enhancer near GREM1 influences bowel cancer risk through differential CDX2 and TCF7L2 binding"", CELL REP., vol. 8, no. 4, 2014, pages 983 - 90;;MITOLA SRAVELLI CMORONI ESALVI VLEALI DBALLMER-HOFER K ET AL.: ""Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2"", BLOOD, vol. 116, no. 18, 2010, pages 3677 - 80, XP055121628, doi:10.1182/blood-2010-06-291930;;MULVIHILL, M.S. ET AL.: ""Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells"", PLOS ONE, vol. 7, no. 8, 2012, pages e42264, XP055121719, doi:10.1371/journal.pone.0042264;;NAMKOONG, H. ET AL.: ""The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein"", BMC CANCER, vol. 6, 2006, pages 74, XP021016278, doi:10.1186/1471-2407-6-74;;NEUFERT, C.BECKER, C.NEURATH, M. F.: ""An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression"", NAT PROTOC, vol. 2, 2007, pages 1998 - 2004;;NOLL, J. ET AL.: ""Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells"", HAEMATOLOGICA, vol. 99, no. 1, 2014;;NOLL, J.E. ET AL.: ""PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma"", J HEMATOL ONCOL, vol. 8, 2015, pages 106, XP021229408, doi:10.1186/s13045-015-0209-2;;NOLL, J.E. ET AL.: ""SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma"", NEOPLASIA, vol. 16, no. 7, 2014, pages 572 - 85;;PLAKS VKONG NWERB Z.: ""The cancer stem cell niche: how essential is the niche in regulating sternness of tumor cells?"", CELL STEM CELL, vol. 16, no. 3, 2015, pages 225 - 38;;SATO TVRIES RGSNIPPERT HJVAN DE WETERING MBARKER NSTANGE DE ET AL.: ""Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche"", NATURE, vol. 459, no. 7244, 2009, pages 262 - 5;;SCHMID, G. J.KOBAYASHI, C.SANDELL, L. JORNITZ, D. M.: ""Fibroblast growth factor expression during skeletal fracture healing in mice"", DEVELOPMENTAL DYNAMICS: AN OFFICIAL PUBLICATION OF THE AMERICAN ASSOCIATION OF ANATOMISTS, vol. 238, 2009, pages 766 - 774;;SCOVILLE DSATO THE XLI L, CURRENT VIEW: INTESTINAL STEM CELLS AND SIGNALING GASTROENTEROLOGY, vol. 134, no. 3, 2008, pages 849 - 64;;SETHI AWORDINGER RJCLARK AF: ""Gremlin utilizes canonical and non-canonical TGFbeta signaling to induce lysyl oxidase (LOX) genes in human trabecular meshwork cells"", EXP EYE RES., vol. 113, 2013, pages 117 - 27;;SHOSHKES-CARMEL, M. ET AL.: ""Subepithelial telocytes are an important source of Wnts that supports intestinal crypts"", NATURE, vol. 557, 2018, pages 242 - 246, XP036540317, doi:10.1038/s41586-018-0084-4;;SNEDDON, J.B. ET AL.: ""Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation"", PROC NATL ACAD SCI USA, vol. 103, no. 40, 2006, pages 14842 - 7, XP055121828, doi:10.1073/pnas.0606857103;;TAMMINEN, J.A. ET AL.: ""Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug"", ONCOGENESIS, vol. 2, 2013, pages e66;;TOMLINSON IPCARVAJAL-CARMONA LGDOBBINS SETENESA AJONES AMHOWARTH K ET AL.: ""Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of Colorectal Cancer"", PLOS GENET, vol. 7, no. 6, 2011, pages el002105;;TOPOL, L.Z. ET AL.: ""Identification of drm, a novel gene whose expression is suppressed in transformed cells and which can inhibit growth of normal but not transformed cells in culture"", MOL CELL BIOL, vol. 17, no. 8, 1997, pages 4801 - 10, XP002066577;;VANDE BROEK, I. ET AL.: ""Extravasation and homing mechanisms in multiple myeloma"", CLIN EXP METASTASIS, vol. 25, no. 4, 2008, pages 325 - 34, XP019601759;;VERHEYDEN, J.MX. SUN: ""An Fgf/Gremlin inhibitory feedback loop triggers termination of limb bud outgrowth"", NATURE, vol. 454, no. 7204, 2008, pages 638 - 41;;WANG, D.J. ET AL.: ""The bone morphogenetic protein antagonist Gremlin is overexpressed in human malignant mesothelioma"", ONCOLOGY REPORTS, vol. 27, no. 1, 2012, pages 58 - 64;;WORTHLEY, D.L. ET AL.: ""Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential"", CELL, vol. 160, no. 1-2, 2015, pages 269 - 84, XP029132639, doi:10.1016/j.cell.2014.11.042;;YIN, Y. ET AL.: ""Overexpression of Gremlin promotes non-small cell lung cancer progression"", TUMOUR BIOL, 2015;;YU, Y. Y. ET AL.: ""Immunolocalization of BMPs, BMP antagonists, receptors, and effectors during fracture repair"", BONE, vol. 46, 2010, pages 841 - 851, XP026904341, doi:10.1016/j.bone.2009.11.005",PENDING
770,CN,A,CN 101743246 A,159-351-716-489-499,2010-06-16,2010,CN 200880023077 A,2008-05-21,GB 2008001738 W;;GB 0710121 A,2007-05-25,"2-oxo-2- (2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl) -acetamide derivatives and related compounds as antifungal agents","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: Rl, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,JAMES PAYNE LLOYD;;ROBERT DOWNHAM;;MORRIS SIBLEY GRAHAM EDWARD;;PHILIP EDWARDS;;MORSE DAVIES GARETH,,https://lens.org/159-351-716-489-499,Patent Application,no,0,7,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A61K31/437;;A61P31/10,,0,0,,,,ACTIVE
771,ES,T3,ES 2535516 T3,128-756-113-388-155,2015-05-12,2015,ES 09734928 T,2009-04-23,GB 0807532 A;;GB 0819696 A;;GB 2009001058 W,2008-04-24,Agentes antifúngicos de pirrol,"Un compuesto que es un derivado de pirrol de formula (I), o una sal farmaceuticamente aceptable del mismo, para su uso en la prevencion o tratamiento de una enfermedad fungica:**Fórmula** donde: R1 representa hidrogeno, alquilo C1-C8, alquenilo C2-C8, 10 alquinilo C2-C8, -COR' o -SO2(alquilo C1-C4) sin sustituir o sustituidos, o un grupo -A2, -L2-A2, -L3-A2, -A2-L3-A3 o -A4; A1 representa un enlace o un grupo fenilo, naftilo, grupo heterociclilo de 5 o 6 miembros o heterociclilo de 8 a miembros sin sustituir o sustituido; A2 y A3 son iguales o diferentes y representan cicloalquilo C3-C6 o un grupo arilo C6-C10 o heterociclilo de 5 a 12 miembros sin sustituir o sustituido; A4 es un grupo heterociclilo de 5 a 12 miembros sin sustituir o sustituido en el que 1 o 2 atomos de carbono del anillo estan sustituidos con un grupo seleccionado de >C(>=O), >S(>=O)2, >C(>=NOR7) en el que R7 es hidrogeno o un grupo alquilo C1-C4, >C>=CH2 o >C(-OCH2CH2O-); L1 representa un enlace, un grupo alquileno C1-C6 en el que ninguno, uno o dos grupos -CH2- estan independientemente sustituidos con -O- o -NR'-, o un grupo heterociclilo de 5 a 7 miembros en el que R' es hidrogeno, alquilo C1-C4 sin sustituir o alquilo C1-C4 sustituido con un grupo alcoxi C1-C4 sin sustituir; L2 representa -NR'-, -O-, -CO-, -OCO-, -OCONR'R""-, -CONR'R""- o -SO2-, en la que R' y R"" representan independientemente hidrogeno, alquilo C1-C8, alquenilo C2-C8 o alquinilo C2-C8; L3 representa un enlace o un grupo alquileno C1-C4 en el que ninguno, uno o dos grupos -CH2- estan independientemente sustituidos con -O-, -S- o -NR'-, en la que R' representa hidrogeno, alquilo C1-C8, alquenilo C2-C8 o alquinilo C2-C8; n es 1; R6 representa hidrogeno o alquilo C1-C4; R5 representa un grupo sin sustituir o sustituido seleccionado de arilo C6-C10, un grupo heterociclilo de 5 a 12 miembros, alquilo C1-C8 y cicloalquilo C3-C6, hidrogeno, halogeno o un grupo de formula -B1-B2 o -B3; B1 representa un grupo arilo C6-C10 sin sustituir o sustituido; B2 representa un grupo arilo C6-C10 o heterociclilo de 5 a 12 miembros sin sustituir o sustituido; B3 es un grupo heterociclilo de 5 a 12 miembros sin sustituir o sustituido en el que 1 o 2 atomos de carbono del anillo estan sustituidos con un grupo seleccionado de >C(>=O), >S(>=O)2, >C(>=NOR11) en la que R11 es hidrogeno o un grupo alquilo C1-C4, >C>=CH2 o >C(-OCH2CH2O-); R2 representa arilo C6-C10, un grupo heterociclilo de 5 a 12 miembros, cicloalquilo C3-C6, hidrogeno, halogeno, alquilo C1-C8, alquenilo C2-C8, alquinilo C2-C8, cicloalquilo C3-C6, -OR', -SR', -SOR', -SO2R', - SO2NR'R"", -SO3H, -NR'R"", -NR'COR',-CO2R', -CONR'R"", -COR', -OCOR', -CF3, -NSO2R' u -OCONR'R"", un grupo alquil (C1-4) -A5, en el que ninguno, uno o dos grupos -CH2- estan reemplazados independientemente por -O-,-S- o -NR'- y en el que A5 representa arilo C6-10 o un grupo heterociclilo de 5 a 12 miembros, en el que R' y R"" representan independientemente hidrogeno, alquilo C1-C8, alquenilo C2-C8 o alquinilo C2-C8, o un grupo de formula -Alk1-X-R', en el que Alk1 es un grupo alquileno C1-C6 sin sustituir o sustituido, X es un grupo -O-, -S-, -NR""-, -CO2-, -CONR""-, -OCO-, -OCONR""- o -SO2-, y R' y R"" se seleccionan independientemente entre hidrogeno y alquilo C1-C4 sin sustituir o sustituido; R3 representa arilo C6-C10, un grupo heterociclilo de 5 a 12 miembros, cicloalquilo C3-C6, hidrogeno, halogeno, alquilo C1-C8, alquenilo C2-C8, alquinilo C2-C8, cicloalquilo C3-C6, -OR', -SR', -SOR', -SO2R', - SO2NR'R"", -SO3H, -NR'R"", -NR'COR', -CO2R', -CONR'R"", -COR', -OCOR', -CF3, -NSO2R' u -OCONR'R"", o un grupo alquil (C1-4)-A5, en el que ninguno, uno o dos grupos -CH2- estan reemplazados independientemente por -O-,-S- o -NR'- y en el que A5 representa arilo C6-10 o un grupo heterociclilo de 5 a 12 miembros, en el que R' y R"" representan independientemente hidrogeno, alquilo C1-C8, alquenilo C2-C8 o alquinilo C2-C8; R4 representa hidrogeno, halogeno, fenilo, alquilo C1-C4, alquenilo C2-C4, alquinilo C2-C4, -OR', -CO2R', - CONR'R"", -COR', -CN, -NO2, -NR'R"" o CF3 en las que R' y R"" son independientemente hidrogeno o alquilo C1- C4; Y representa alquileno C1-C8, alquenileno C2-C8 o alquinileno C2-C8;",F2G LTD,SIBLEY GRAHAM;;DOWNHAM ROBERT;;PAYNE LLOYD;;LAW DEREK;;OLIVER JASON;;BIRCH MIKE;;DAVIES GARETH,,https://lens.org/128-756-113-388-155,Granted Patent,no,0,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D401/12;;A01N43/40;;A01N43/42;;A61P31/10,,0,0,,,,ACTIVE
772,EP,B1,EP 2173749 B1,164-069-886-355-292,2011-01-12,2011,EP 08750663 A,2008-05-21,GB 2008001738 W;;GB 0710121 A,2007-05-25,"2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/164-069-886-355-292,Granted Patent,yes,1,0,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A61K31/437;;A61P31/10,,0,0,,,,ACTIVE
773,JP,A,JP 2014074025 A,191-434-913-679-447,2014-04-24,2014,JP 2013192491 A,2013-09-18,GB 0623209 A,2006-11-21,2-[(2-SUBSTITUTED)-INDOLIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS,"PROBLEM TO BE SOLVED: To provide novel compounds useful as antifungal agents, and pharmaceutical compositions and agrochemical compositions containing the compounds.SOLUTION: Provided are indolizine based compounds represented by the specified formula, and pharmaceutical compositions and agrochemical compositions containing the compounds. [In the formula, X is NR, Ris hydrogen or an unsubstituted C1-C4 alkyl, Rrepresents -A3-L3-A4, L3 is a direct coupling or the like, A3 is phenyl or pyridyl, A4 is an unsubstituted or substituted 5-12 membered heterocyclyl group, Ris a C6-C10 aryl, 5-12 membered heterocyclyl group or the like, and Ris hydrogen or halogen.]",F2G LTD,ROBERT DOWNHAM;;GRAHAM EDWARD MORRIS SIBLEY;;LLOYD JAMES PAYNE;;EDWARDS PHILIP;;GARETH MORSE DAVIES,,https://lens.org/191-434-913-679-447,Patent Application,no,3,1,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/90;;A01P3/00;;A61K31/437;;A61K31/438;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/506;;A61K31/5377;;A61K31/541;;A61K31/551;;A61P11/00;;A61P11/06;;A61P17/00;;A61P31/10;;A61P37/08;;C07D519/00,,2,0,,,"JPN5009020022; ＶＥＮＴＵＲＥＬＬＡ， ＶＩＮＣＥＮＴ Ｓ．: ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ ＳＣＩＥＮＣＥＳ Ｖ５３ Ｎ１０, 196410, Ｐ１１６６-１１６９;;JPN5009020022; ＶＥＮＴＵＲＥＬＬＡ， ＶＩＮＣＥＮＴ Ｓ．: ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ ＳＣＩＥＮＣＥＳ Ｖ５３ Ｎ１０, 196410, Ｐ１１６６-１１６９",ACTIVE
774,MX,A,MX 2020013808 A,121-231-521-548-000,2021-05-27,2021,MX 2020013808 A,2019-06-18,GB 201809946 A;;GB 201815694 A;;GB 2019051699 W,2018-06-18,GREMLIN-1 ANTAGONIST FOR THE PREVENTION AND TREATMENT OF CANCER.,The invention relates to an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer.,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;LEEDHAM SIMON;;ZANNETTINO ANDREW;;CLARK KIMBERLEY;;HEWETT DUNCAN;;PANAGOPOULOS VASILIOS,,https://lens.org/121-231-521-548-000,Patent Application,no,0,0,14,17,0,C07K16/18;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K16/18;;A61P35/00;;C12Q1/6886;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12Q2600/158;;C12Q2600/118;;C12Q2600/106;;A61P35/00;;A61K45/06;;A61K2039/505;;C07K16/24;;C07K16/2803;;C07K16/2896;;G01N33/5748;;G01N2800/52,A61K39/395;;A61P35/00,,0,0,,,,PENDING
775,NZ,A,NZ 577072 A,187-858-999-034-205,2011-10-28,2011,NZ 57707207 A,2007-11-21,GB 0623209 A;;GB 2007004449 W,2006-11-21,2-[(2-SUBSTITUTED)-INDOLIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS,"Disclosed is an indolizinyl compound of formula (I) where the substituents are as disclosed in the specification. Also disclosed is a pharmaceutical composition comprising a compound of formula (I), the use of a compound of formula (I) in the manufacture of a medicament to treat fungal disease especially an agricultural fungicide and a method of controlling a fungal disease in a plant using a compound of formula (I). Examples of compounds of formula (I) are N-[ 4-(2-Morpholin-4-yl-ethoxy)-phenyl]-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; 2-Hydroxy-4-[2-oxo-2-(2-phenyl-indolizin-3-yl)-acetylamino ]-benzoic acid tetrahydropyran-4-yl ester and 2-Isopropyl-4-[2-oxo-2-(2-phenyl-indolizin-3-yl )-acetylamino ]-benzoic acid 2-(2-isopropyl-imidazol-1-yl)-ethyl ester.",F2G LTD,DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;PAYNE LLOYD JAMES;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/187-858-999-034-205,Patent Application,no,0,0,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/90;;A61K31/437;;A61P33/00,,0,0,,,,PENDING
776,AR,A1,AR 115575 A1,025-786-942-865-329,2021-02-03,2021,AR P190101686 A,2019-06-18,GB 201809946 A,2018-06-18,ANTAGONISTA GREMLIN-1 PARA LA PREVENCIÓN Y TRATAMIENTO DEL CÁNCER,La presente se refiere a un antagonista anti-GREM1 para uso en un método para el tratamiento o prevención de un cáncer.,UCB BIOPHARMA SRL;;UNIV OXFORD INNOVATION LTD;;UNIV ADELAIDE,DAVIES GARETH CHARLES GLYNDWR;;LEEDHAM SIMON;;ZANNETTINO ANDREW;;CLARK KIMBERLEY;;HEWETT DUNCAN;;PANAGOPOULOS VASILIOS,,https://lens.org/025-786-942-865-329,Patent Application,no,0,0,2,17,0,,C07K16/18;;A61K39/395;;A61P35/00,,0,0,,,,PENDING
777,EP,B1,EP 2097413 B1,035-923-745-083-791,2013-12-25,2013,EP 07824661 A,2007-11-21,GB 2007004449 W;;GB 0623209 A,2006-11-21,2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS,,F2G LTD,DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;PAYNE LLOYD JAMES;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/035-923-745-083-791,Granted Patent,yes,1,0,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/90;;A61K31/437;;A61P33/00,,2,0,,,"GUET, CHANTAL ET AL: ""Synthesis of new phenols. Part 2. Derivatives of 6-hydroxy-2- phenylindolizine"" JOURNAL OF CHEMICAL RESEARCH, SYNOPSES , (9), 245 CODEN: JRPSDC; ISSN: 0308-2342, 1982, XP009097209;;VENTURELLA, VINCENT S.: ""Arylindolizines. III. Methoxyl and glyoxyl derivatives of several phenylindolizines"" JOURNAL OF PHARMACEUTICAL SCIENCES , 53(10), 1166-9 CODEN: JPMSAE; ISSN: 0022-3549, 1964, XP002449258",ACTIVE
778,CO,A2,CO 2020015923 A2,088-328-881-397-513,2021-05-10,2021,CO 2020015923 A,2020-12-17,GB 2019051699 W;;GB 201809946 A;;GB 201815694 A,2018-06-18,Antagonista de gremlin-1 para la prevención y tratamiento del cáncer,ANTAGONISTA DE GREMLIN-1 PARA LA PREVENCIÓN Y TRATAMIENTO DEL CÁNCER La invención se refiere a un antagonista anti-GREM1 para uso en un método para el tratamiento o prevención de un cáncer.,UCB BIOPHARMA SRL;;UNIV OXFORD INNOVATION LTD;;UNIV ADELAIDE,DAVIES GARETH CHARLES GLYNDWR;;LEEDHAM SIMON;;ZANNETTINO ANDREW;;CLARK KIMBERLEY;;HEWETT DUNCAN;;PANAGOPOULOS VASILIOS,,https://lens.org/088-328-881-397-513,Patent Application,no,0,0,14,17,0,C07K16/18;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K16/18;;A61P35/00;;C12Q1/6886;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12Q2600/158;;C12Q2600/118;;C12Q2600/106;;A61P35/00;;A61K45/06;;A61K2039/505;;C07K16/24;;C07K16/2803;;C07K16/2896;;G01N33/5748;;G01N2800/52,A61K39/395;;A61P35/00,,0,0,,,,PENDING
779,US,A1,US 2010/0056511 A1,109-431-967-277-454,2010-03-04,2010,US 51535407 A,2007-11-21,GB 0623209 A;;GB 2007004449 W,2006-11-21,2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS,"The invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof wherein: R1, R2, R3, R4, R5, R6, R7, X and X 1 are as defined herein. These compounds are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,DOWNHAM ROBERT;;MORRIS EDWARD SIBLEY;;PAYNE LLOYD JAMES;;EDWARDS PHILIP NEIL;;DAVIES GARETH MORSE,F2G LTD BRITISH BODY CORPORATE (2009-07-07),https://lens.org/109-431-967-277-454,Patent Application,yes,1,1,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,A61K31/437;;A01N43/90;;A61K31/438;;A61K31/496;;A61K31/5377;;A61P31/10;;C07D471/04;;C07D491/107,514/233.2;;546/112;;546/94;;544/127;;544/362;;546/16;;540/575;;514/299;;514/253.04;;514/278,1,0,,,"Chemical Abstracts Registry Database (compounds corresponding to answer numbers 1-258, as accessed May 7, 2012, p. 1-125).",ACTIVE
780,EP,A2,EP 4198285 A2,035-890-269-823-251,2023-06-21,2023,EP 22208022 A,2022-11-17,GB 202118041 A,2021-12-14,RESTARTING A GAS TURBINE ENGINE,"Multi-engine aircraft power and propulsion systems 100 and methods 300 of restarting an engine 110b of a multi-engine aircraft 1 during fight are provided. One such method 300 comprises: determining a condition to the effect that a flame in the combustion equipment of the second gas turbine engine has been extinguished; responsive to the determination, supplying electrical power from the electrical energy storage system to one or more of the electric machines of the second gas turbine engine and operating said one or more electric machines as motors to limit a reduction in a speed of the one or more spools of the second gas turbine engine following extinguishment of the flame in its combustion equipment; and restarting the second gas turbine engine 110b by relighting the combustion equipment 16 of the second gas turbine engine 110b.
",ROLLS ROYCE PLC,MOORE GARETH;;DAVIES PAUL;;HUSBAND STEPHEN;;TRAINER DAVID;;SCOTHERN DAVID;;GEORGE LUKE;;HERBERT DOUGLAS,,https://lens.org/035-890-269-823-251,Patent Application,yes,0,0,5,5,0,F02C7/262;;F02C7/268;;F02K5/00;;F05D2220/76;;Y02T50/60;;F05D2270/092;;F05D2270/093;;F01D15/10;;F02C7/262;;F05D2220/323;;F05D2220/76;;F05D2260/85;;F05D2270/092;;F05D2270/093,F02C7/262;;F02C7/268;;F02K5/00,,0,0,,,,PENDING
781,EP,A3,EP 4198285 A3,101-700-910-349-404,2023-08-16,2023,EP 22208022 A,2022-11-17,GB 202118041 A,2021-12-14,RESTARTING A GAS TURBINE ENGINE,"Multi-engine aircraft power and propulsion systems 100 and methods 300 of restarting an engine 110b of a multi-engine aircraft 1 during fight are provided. One such method 300 comprises: determining a condition to the effect that a flame in the combustion equipment of the second gas turbine engine has been extinguished; responsive to the determination, supplying electrical power from the electrical energy storage system to one or more of the electric machines of the second gas turbine engine and operating said one or more electric machines as motors to limit a reduction in a speed of the one or more spools of the second gas turbine engine following extinguishment of the flame in its combustion equipment; and restarting the second gas turbine engine 110b by relighting the combustion equipment 16 of the second gas turbine engine 110b.
",ROLLS ROYCE PLC,MOORE GARETH;;DAVIES PAUL;;HUSBAND STEPHEN;;TRAINER DAVID;;SCOTHERN DAVID;;GEORGE LUKE;;HERBERT DOUGLAS,,https://lens.org/101-700-910-349-404,Search Report,yes,7,0,5,5,0,F02C7/262;;F02C7/268;;F02K5/00;;F05D2220/76;;Y02T50/60;;F05D2270/092;;F05D2270/093;;F01D15/10;;F02C7/262;;F05D2220/323;;F05D2220/76;;F05D2260/85;;F05D2270/092;;F05D2270/093,F02C7/262;;F02C7/268;;F02K5/00,,0,0,,,,PENDING
782,US,A1,US 2011/0009390 A1,189-190-372-096-221,2011-01-13,2011,US 60128408 A,2008-05-21,GB 0710121 A;;GB 2008001738 W,2007-05-25,"2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP;;DAVIES GARETH MORSE,F2G LIMITED BRITISH BODY CORPORATE (2010-02-26),https://lens.org/189-190-372-096-221,Patent Application,yes,0,1,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,A61K31/437;;A01N43/90;;A01P3/00;;A61K31/496;;A61K31/5377;;A61K31/551;;A61P11/06;;A61P31/10;;C07D471/04,514/218;;544/362;;540/575;;546/112;;544/121;;514/253.04;;514/299;;514/233.2,2,2,157-368-878-373-980;;046-015-969-792-277,10.1021/ja01463a046;;10.1128/jcm.01550-06;;17021057;;pmc1698398,"Galbraith et al., Journal of the American Chemical Society (1961), 83, 453-8.;;Isham et al., Journal of clinical microbiology, (2006), vol. 44(12), pages 4342-4344.",ACTIVE
783,CA,A1,CA 3102743 A1,182-200-123-839-583,2019-12-26,2019,CA 3102743 A,2019-06-18,GB 201809946 A;;GB 201815694 A;;GB 2019051699 W,2018-06-18,GREMLIN-1 ANTAGONIST FOR THE PREVENTION AND TREATMENT OF CANCER,The invention relates to an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer.,UCB BIOPHARMA SRL;;UNIV OXFORD INNOVATION LTD;;UNIV ADELAIDE,DAVIES GARETH CHARLES GLYNDWR;;LEEDHAM SIMON;;ZANNETTINO ANDREW;;CLARK KIMBERLEY;;HEWETT DUNCAN;;PANAGOPOULOS VASILIOS,,https://lens.org/182-200-123-839-583,Patent Application,no,0,0,14,17,0,C07K16/18;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K16/18;;A61P35/00;;C12Q1/6886;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12Q2600/158;;C12Q2600/118;;C12Q2600/106;;A61P35/00;;A61K45/06;;A61K2039/505;;C07K16/24;;C07K16/2803;;C07K16/2896;;G01N33/5748;;G01N2800/52,A61K39/395;;A61P35/00,,0,0,,,,PENDING
784,NZ,A,NZ 581143 A,025-992-203-694-164,2011-07-29,2011,NZ 58114308 A,2008-05-21,GB 0710121 A;;GB 2008001738 W,2007-05-25,"2-OXO-2-(2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL)-ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS","Disclosed are tetrahydroindolizine derivatives of formula (1), or pharmaceutically or agriculturally acceptable salts thereof, wherein the substituents are as defined in the specification. The compounds are useful in the treatment of fungal diseases including those caused by Aspergillus or Candida species and fungal dermatophytes, allergic bronchopulmonary aspergillosis (ABPA) and asthma.",F2G LTD,PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/025-992-203-694-164,Patent Application,no,0,0,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A61K31/437;;A61P31/10,,0,0,,,,PENDING
785,KR,A,KR 20100033383 A,028-459-480-724-644,2010-03-29,2010,KR 20097026994 A,2008-05-21,GB 0710121 A,2007-05-25,"2-OXO-2-(2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL)-ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: Rl, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/028-459-480-724-644,Patent Application,no,1,0,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A01P3/00;;A61K31/437,,0,0,,,,ACTIVE
786,EP,A1,EP 2173749 A1,157-871-622-604-421,2010-04-14,2010,EP 08750663 A,2008-05-21,GB 2008001738 W;;GB 0710121 A,2007-05-25,"2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/157-871-622-604-421,Patent Application,yes,0,0,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A61K31/437;;A61P31/10,,0,0,,,,ACTIVE
787,AU,A1,AU 2008/257196 A1,038-598-444-835-745,2008-12-04,2008,AU 2008/257196 A,2008-05-21,GB 0710121 A;;GB 2008001738 W,2007-05-25,"2-oxo-2- (2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl) -acetamide derivatives and related compounds as antifungal agents","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DAVIES GARETH MORSE;;EDWARDS PHILIP;;PAYNE LLOYD JAMES;;DOWNHAM ROBERT,,https://lens.org/038-598-444-835-745,Patent Application,no,0,0,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A61K31/437;;A61P31/10,,0,0,,,,ACTIVE
788,AU,B2,AU 2008/257196 B2,053-517-195-451-623,2013-06-20,2013,AU 2008/257196 A,2008-05-21,GB 0710121 A;;GB 2008001738 W,2007-05-25,"2-oxo-2- (2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl) -acetamide derivatives and related compounds as antifungal agents","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: Rl, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,PAYNE LLOYD JAMES;;SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;DAVIES GARETH MORSE;;EDWARDS PHILIP,,https://lens.org/053-517-195-451-623,Granted Patent,no,1,0,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A61K31/437;;A61P31/10,,0,0,,,,ACTIVE
789,DK,T3,DK 2173749 T3,063-682-462-093-165,2011-05-02,2011,DK 08750663 T,2008-05-21,GB 0710121 A;;GB 2008001738 W,2007-05-25,"2-oxo-2-(2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl)-acetamidderivater og beslægtede forbindelser som antisvampemidler","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/063-682-462-093-165,Granted Patent,no,0,0,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A61K31/437;;A61P31/10,,0,0,,,,ACTIVE
790,KR,A,KR 20090093998 A,084-176-071-856-524,2009-09-02,2009,KR 20097012867 A,2007-11-21,GB 0623209 A;;GB 2007004449 W,2006-11-21,2-[(2-SUBSTITUTED)-INDOLIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS,"The invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof wherein: Rl, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. These compounds are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;PAYNE LLOYD JAMES;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/084-176-071-856-524,Patent Application,no,0,0,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/90;;A61K31/437;;A61P33/00,,0,0,,,,ACTIVE
791,CN,A,CN 101679410 A,089-335-664-918-011,2010-03-24,2010,CN 200780050132 A,2007-11-21,GB 2007004449 W;;GB 0623209 A,2006-11-21,2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents,"The invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof wherein: Rl, R2, R3, R4, R5, R6, R7, X and X<1> are as defined herein. These compounds are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,ROBERT DOWNHAM;;MORRIS SIBLEY GRAHAM EDWARD;;JAMES PAYNE LLOYD;;PHILIP EDWARDS;;MORSE DAVIES GARETH,,https://lens.org/089-335-664-918-011,Patent Application,no,1,8,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/90;;A61K31/437;;A61P33/00,,0,0,,,,ACTIVE
792,US,A1,US 2024/0076365 A1,112-974-136-596-568,2024-03-07,2024,US 18502188,2023-11-06,GB 1621635.0,2016-12-19,GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SRL,NEESHA DEDI;;BREDA TWOMEY;;MICHAEL JOHN WRIGHT;;GARETH CHARLES GLYNDWR DAVIES;;DAVID JAMES MCMILLAN,,https://lens.org/112-974-136-596-568,Patent Application,yes,0,0,1,1,0,C07K16/22;;A61P9/12;;C07K14/51;;G01N33/6854;;A61K2039/505,C07K16/22;;A61P9/12;;C07K14/51;;G01N33/68,,0,0,,,,UNKNOWN
793,DK,T3,DK 2097413 T3,119-398-987-413-063,2014-03-24,2014,DK 07824661 T,2007-11-21,GB 0623209 A;;GB 2007004449 W,2006-11-21,2-[(2-substitueret)-indolizin-3-yl]-2-oxoacetamidderivater som antisvampemidler,,F2G LTD,DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;EDWARDS PHILIP;;DAVIES GARETH MORSE;;SIBLEY GRAHAM EDWARD MORRIS,,https://lens.org/119-398-987-413-063,Granted Patent,no,0,0,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/90;;A61K31/437;;A61P33/00,,0,0,,,,ACTIVE
794,US,B2,US 11807680 B2,132-540-214-055-319,2023-11-07,2023,US 202117172109 A,2021-02-10,US 202117172109 A;;GB 201621635 A;;US 201916470996 A;;EP 2017083650 W,2016-12-19,Gremlin-1 crystal structure and inhibitory antibody,"This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.",UCB BIOPHARMA SRL,DEDI NEESHA;;TWOMEY BREDA;;WRIGHT MICHAEL JOHN;;DAVIES GARETH CHARLES GLYNDWR;;MCMILLAN DAVID JAMES,CELLTECH R&D LIMITED (2017-12-04);;UCB BIOPHARMA SRL (2017-06-12),https://lens.org/132-540-214-055-319,Granted Patent,yes,69,0,36,36,35,A61K2039/505;;A61P9/12;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/6854;;C07K16/22;;A61K2039/505;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61P11/00;;A61P13/12;;A61P35/00;;A61P43/00;;A61P9/12;;C07K16/22;;A61P11/00;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/76;;C07K2317/92;;A61K2039/505;;A61K39/3955;;A61P9/12;;C07K16/2863;;C12N15/63;;A61P9/12;;A61K2039/505;;C07B2200/13;;C07K14/51;;C07K16/22;;C07K2317/21;;C07K2317/34;;C07K2317/55;;C07K2317/565;;C07K2317/76;;G01N33/6854,C07K16/22;;A61K39/00;;A61P9/12;;C07K14/51;;G01N33/68,,167,152,127-732-134-407-287;;056-344-332-419-766;;049-928-993-608-092;;002-880-498-827-946;;042-222-591-554-811;;148-647-852-252-502;;056-201-471-905-934;;080-856-085-597-555;;181-448-152-035-827;;033-401-440-963-789;;011-553-054-044-973;;098-724-633-703-400;;087-448-981-335-707;;076-897-757-672-092;;043-729-032-107-483;;041-863-374-864-841;;020-958-411-146-428;;035-081-115-342-527;;012-007-448-024-359;;008-583-847-621-717;;041-701-093-712-495;;001-646-542-312-05X;;148-750-828-583-42X;;095-834-903-970-444;;000-769-593-092-070;;008-061-699-775-635;;067-024-105-019-398;;010-735-642-089-466;;053-699-924-523-691;;013-703-966-633-758;;097-901-796-209-229;;029-486-847-477-02X;;070-238-365-351-890;;071-630-416-006-425;;066-141-497-990-023;;111-604-378-852-726;;075-789-057-546-584;;056-289-795-899-023;;082-151-267-963-934;;098-322-700-973-135;;081-004-119-263-171;;060-522-017-672-204;;008-017-695-084-433;;051-036-594-306-992;;060-126-066-099-876;;077-587-097-220-826;;076-252-023-764-678;;060-918-425-739-173;;008-693-687-336-286;;030-797-864-869-467;;006-574-942-364-256;;023-907-179-348-058;;018-280-468-055-668;;063-266-551-840-350;;046-951-095-213-650;;037-436-870-995-452;;038-728-499-086-588;;077-532-829-551-519;;023-860-693-372-071;;018-199-486-626-091;;027-840-251-594-854;;020-398-976-665-441;;034-499-526-956-496;;040-842-346-948-061;;113-446-080-346-814;;047-308-646-101-537;;029-970-218-339-139;;092-175-386-389-524;;019-779-601-634-917;;064-667-501-146-970;;055-542-669-483-094;;088-935-349-526-045;;013-337-877-638-381;;106-753-778-592-300;;024-205-497-164-000;;020-026-345-586-213;;057-051-348-154-974;;037-310-319-433-702;;028-671-261-063-506;;026-361-471-680-127;;083-861-682-427-488;;001-062-843-030-532;;040-363-636-264-022;;016-392-744-492-623;;082-522-923-505-342;;050-133-270-638-85X;;095-576-636-997-853;;064-781-969-527-647;;061-154-078-727-141;;028-188-258-692-969;;072-971-856-375-322;;099-142-413-754-43X;;064-741-687-897-846;;028-716-741-713-711;;007-711-535-660-589;;010-655-350-435-62X;;054-899-454-772-257;;042-204-626-457-327;;012-113-132-303-756;;026-553-044-527-677;;034-489-784-615-708;;036-648-857-259-985;;080-784-865-336-364;;053-688-298-868-719;;017-537-377-374-676;;044-958-492-431-511;;044-380-745-789-522;;001-135-333-260-455;;101-640-792-825-42X;;015-238-057-914-589;;017-186-900-863-545;;067-290-214-184-650;;042-623-879-457-954;;051-322-618-006-677;;025-662-361-226-516;;065-274-506-678-30X;;012-265-598-126-264;;016-507-178-023-87X;;021-221-160-658-727;;027-477-313-726-928;;020-367-308-901-689;;046-845-561-202-870;;062-761-744-997-508;;075-555-351-927-589;;013-332-497-462-190;;023-512-772-502-769;;121-507-867-661-339;;051-621-009-816-906;;139-263-323-698-622;;020-469-639-093-468;;038-014-138-403-715;;006-335-336-242-955;;027-348-187-303-025;;083-455-473-700-78X;;051-782-236-917-368;;020-290-815-800-919;;012-276-537-847-635;;013-047-685-206-757;;085-551-195-221-254;;010-638-827-530-479;;015-637-470-440-119;;029-618-245-313-265;;039-435-352-120-718;;098-133-538-052-633;;029-090-460-937-086;;109-846-005-988-815;;049-744-251-457-065;;047-464-834-398-90X;;052-497-936-393-263;;049-595-479-088-060;;026-297-055-190-870;;021-868-921-062-221,20098328;;10.1097/gim.0b013e3181cd68ed;;33923907;;10.3390/ijms22084255;;pmc8074005;;10656818;;10.1006/jmbi.1999.3444;;10.1016/s1097-2765(00)80067-2;;9660951;;10.1016/j.str.2013.06.005;;pmc3749838;;23850456;;10.2174/1567269053828800;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1007/bf00160485;;8483166;;7658022;;10.1016/0022-1759(95)00086-p;;8417368;;10.1016/0161-5890(93)90432-b;;10.1002/mc.22378;;26293751;;10.1182/blood-2011-09-380410;;pmc3382938;;22394600;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1016/j.jacc.2009.04.011;;19555859;;18751803;;10.1007/s11420-005-0111-5;;pmc2504134;;10.1016/0022-1759(95)00016-4;;7769243;;10.1016/j.pharmthera.2012.06.001;;22722064;;10.1016/s0065-2776(08)60674-4;;7872158;;pmc5119705;;10.11138/ccmbm/2016.13.2.101;;27920804;;22247494;;10.1161/circulationaha.111.038125;;25706628;;10.1038/ng.3225;;pmc3132213;;10.1002/jcp.22730;;21412775;;10.1107/s0907444909042073;;20057044;;10.1107/97809553602060000884;;pmc2803126;;10.1007/s00535-012-0614-z;;22706573;;10.1038/cddis.2017.533;;pmc5775406;;29095438;;25637218;;10.1016/j.yexcr.2015.01.006;;pmc3398763;;22451422;;10.1182/blood-2012-02-412783;;10.1164/rccm.201206-1028oc;;23087024;;24160323;;10.1016/j.ajpath.2013.07.017;;pmc5691347;;22182508;;10.1016/j.cellsig.2011.12.008;;10029599;;10.1182/blood.v93.5.1697;;10.1182/blood.v93.5.1697.405a17_1697_1706;;pmc5093055;;27118403;;10.1038/leu.2016.96;;25419707;;10.1038/nm.3750;;pmc4594755;;20298438;;pmc2871998;;10.1111/j.1469-7580.2010.01214.x;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;19335218;;10.1359/jbmr.090210;;10511457;;10.1016/s0163-7258(99)00018-2;;25266456;;pmc4464690;;10.1038/nrrheum.2014.164;;20383002;;pmc2852313;;10.1107/s0907444910007493;;10.1007/s11999-009-0981-9;;pmc2772945;;19597895;;10.1056/nejmra035488;;15483284;;10495271;;10.1016/s0925-4773(99)00142-2;;pmc3775476;;22374979;;10.1158/0008-5472.can-11-2067;;10.1385/1-59259-890-0:571;;15539560;;10.1210/en.2004-0766;;17785465;;10.1074/jbc.m701317200;;10.1182/blood-2012-01-379024;;pmc3390959;;22535658;;10.1097/00003086-199706000-00011;;9186204;;27862197;;10.1111/1440-1681.12697;;10.1016/0021-9673(94)01255-d;;7620566;;10.1201/b14193-19;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1016/j.neo.2017.09.004;;pmc5678743;;29091798;;10.1038/nrc2189;;17646864;;11154231;;10.1182/blood.v97.2.516;;10.1110/ps.9.3.487;;pmc2144561;;10752610;;10.1038/leu.2011.263;;21941367;;10.1038/nbt1142;;16151406;;10.1126/science.280.5366.1086;;9582123;;09582123;;10.1038/88919;;11381269;;10.3892/mmr.2017.6253;;pmc5364878;;28260028;;28299802;;10.1002/path.4891;;pmc5488238;;25706627;;10.1038/ng.3224;;22561515;;pmc4594751;;10.1038/ng.2263;;2406013;;20124692;;pmc2815665;;10.1107/s0907444909047337;;23659962;;pmc5528431;;10.1016/j.molonc.2013.04.002;;25153376;;10.1515/hsz-2014-0221;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;15848072;;10.1016/j.ymeth.2005.01.003;;10.1002/eji.1830240426;;8149964;;10.1371/journal.pone.0035100;;22514712;;pmc3325980;;10.1371/journal.pone.0174565;;pmc5367809;;28346486;;1172191;;10.1038/256495a0;;25834571;;pmc4365323;;10.1155/2015/834137;;25291284;;10.1016/0167-5699(83)90123-8;;10.1016/j.molimm.2006.03.020;;16697465;;15509819;;10.1056/nejmra041875;;pmc3693206;;23826422;;10.1002/path.4537;;25810250;;26632274;;10.1038/ncomms9983;;pmc4686867;;10.1016/j.celrep.2014.07.020;;pmc4471812;;25131200;;19461840;;pmc2483472;;10.1107/s0021889807021206;;20660291;;10.1182/blood-2010-06-291930;;22870311;;pmc3411619;;10.1371/journal.pone.0042264;;pmc3069751;;10.1107/s0907444911001314;;21460454;;10.1186/1471-2407-6-74;;16545136;;pmc1459871;;10.1038/nprot.2007.279;;17703211;;pmc4335214;;25561725;;10.1074/jbc.m114.628412;;pmc4007935;;10.3324/haematol.2013.090977;;23935020;;25117979;;pmc4198825;;10.1016/j.neo.2014.07.002;;pmc4595141;;10.1186/s13045-015-0209-2;;26445238;;10.1016/s0378-1119(96)00627-0;;10.1016/j.stem.2015.02.015;;pmc4355577;;25748930;;15014901;;10.1007/s00259-003-1441-5;;10.1385/1-59259-666-5:443;;14970513;;15608286;;10.1093/nar/gki088;;pmc540042;;3127726;;10.1038/332323a0;;10.1038/nature07935;;19329995;;10.1089/ten.tec.2013.0612;;24738624;;pmc2688661;;10.1002/dvdy.21882;;19235733;;10.1053/j.gastro.2008.01.079;;18325394;;10.1016/j.actbio.2012.06.036;;22750247;;10.1038/s41586-018-0084-4;;pmc5966331;;29720649;;10.1016/j.jacc.2009.04.012;;19555858;;10.1073/pnas.0606857103;;17003113;;pmc1578503;;pmc3759128;;23978876;;10.1038/oncsis.2013.29;;10.2353/ajpath.2009.080565;;pmc2630548;;19116361;;7042536;;10.1111/j.1600-065x.1982.tb00392.x;;21655089;;pmc3107194;;10.1371/journal.pgen.1002105;;pmc232332;;10.1128/mcb.17.8.4801;;9234736;;10.1007/s10585-007-9108-4;;17952614;;9624683;;10.1038/nbt0698-535;;18594511;;10.1038/nature07085;;pmc2840222;;10.1016/s0022-1759(98)00077-5;;9760222;;10.3892/or.2011.1463;;21935575;;25594183;;10.1016/j.cell.2014.11.042;;pmc4436082;;10.1007/s13277-015-4093-8;;26392110;;10.1016/j.bone.2009.11.005;;19913648;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;1961196;;10.1016/0161-5890(91)90003-3;;10.1016/j.intimp.2004.01.010;;15120653;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;10.1126/science.2426778;;2426778;;26530461;;10.3892/or.2015.4367;;10.1182/blood.v82.12.3712.bloodjournal82123712;;8260708;;10.1182/blood.v82.12.3712.3712;;20042676;;10.2353/ajpath.2010.090442;;pmc2808066;;30272371;;pmc6203161;;10.3892/ijo.2018.4573;;10.3390/cancers12082149;;32756430;;pmc7464474;;10.1016/j.tcb.2010.01.008;;20188563;;28223433;;10.1158/1055-9965.epi-16-0858;;10.1080/14737159.2018.1439382;;29424261;;10556075;;10.1242/dev.126.23.5515;;16707453;;10.1158/0008-5472.can-05-4610;;10.1038/s41467-018-05366-3;;pmc6065368;;30061695;;27651036;;10.2217/fon-2016-0261;;pmc3492335;;10.1371/journal.pone.0048262;;23144859;;10633215;;10.1530/eje.0.1420009;;10.4172/1948-5956.1000554;;28109670;;10.1016/j.cytogfr.2017.01.002;;25209345;;10.1007/s00264-014-2512-x;;pmc5491097;;10.1016/j.semcancer.2017.03.009;;28408152;;10.18632/oncotarget.9286;;pmc5085234;;27174917;;25108577;;10.1016/j.eururo.2014.07.020;;10.1158/1078-0432.ccr-07-1036;;17975152;;10.1093/annonc/mdu260;;25190710;;pmc3400017;;22692129;;10.1038/emboj.2012.166;;pmc2289373;;1541640;;10.1083/jcb.116.6.1517;;9311916;;10.1126/science.278.5335.120;;10.1002/gene.20042;;15282745;;10.1111/j.1365-2184.2006.00391.x;;16987142;;pmc6495875;;21889923;;10.1053/j.gastro.2011.07.050,"Cao, A. et al. “Beta-thalassemia” Genetics In Medicine, Feb. 2010, pp. 61-76, vol. 12, No. 2.;;Dabrowski, M. et al. “Diffuse Idiopathic Skeletal Hyperostosis of Cervical Spine with Dysphagia-Molecular and Clinical Aspects” International Journal of Molecular Sciences, 2021, pp. 1-12, vol. 22, No. 4255.;;Knappik, A. et al. “Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides” J. Mol. Biol., 2000, pp. 57-86, vol. 296, No. 1.;;Park, S.-A. et al. “Gremlin-1 augments the oestrogen-related receptor α signalling through EGFR activation: implications for the progression of breast cancer” British Journal of Cancer, published online Jun. 23, 2020, pp. 988-999, vol. 123, No. 6.;;Hsu, D. R. et al. “The Xenopus Dorsalizing Factor Gremlin Identifies a Novel Family of Secreted Proteins that Antagonize BMP Activities” Molecular Cell, Apr. 1998, pp. 673-683, vol. 1, No. 5.;;Written Opinion in International Application No. PCT/EP2017/083650, dated Jan. 4, 2019, pp. 1-8.;;Nolan, K. et al. “Structure of Protein Related to Dan and Cerberus: Insights into the Mechanism of Bone Morphogenetic Protein Antagonism” Structure, Aug. 6, 2013, pp. 1417-1429, vol. 21.;;United Kingdom Search Report Application No. GB1519083.8, dated Jul. 29, 2016, pp. 1-5.;;Adair, J. R. et al. “Therapeutic Antibodies” Drug Design Reviews, 2005, pp. 1-11.;;Altschul, S. F. et al. “Basic Local Alignment Search Tool” J Mol Biol., 1990, pp. 403-410, vol. 215.;;Altschul, S.F. “A Protein Alignment Scoring System Sensitive at All Evolutionary Distances” J Mol Evol., 1993, pp. 290-300, vol. 36.;;Ames, R. S. et al. “Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins” Journal of Immunological Methods, 1995, pp. 177-186, vol. 184.;;Angal, S. et al. “A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody” Molecular Immunology, 1993, pp. 105-108, vol. 30, No. 1.;;Attar-Schneider, O. et al. “Multiple Myeloma and Bone Marrow Mesenchymal Stem Cells' Crosstalk: Effect on Translation Initiation” Molecular Carcinogenesis, 2016, pp. 1343-1354, vol. 55.;;Azab, A. K. et al. “Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features” Blood, Jun. 14, 2012, pp. 5782-5794, vol. 119, No. 24.;;Babcook, J. et al. “A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities” Proc. Natl. Acad. Sci. USA, Jul. 1996, pp. 7843-7848, vol. 93, No. 15.;;Badesch, D. B. et al. “Diagnosis and Assessment of Pulmonary Arterial Hypertension” J Am Coll Cardiol., Jun. 30, 2009, pp. S55-S66, vol. 54, No. 1, Suppl. S.;;Bostrom, M. P. G. et al. “The Clinical Use of Allografts, Demineralized Bone Matrices, Synthetic Bone Graft Substitutes and Osteoinductive Growth Factors: A Survey Study” HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery, 2005, pp. 9-18, vol. 1.;;Brinkmann, U. et al. “Phage display of disulfide-stabilized Fv fragments” Journal of Immunological Methods, 1995, pp. 41-50, vol. 182.;;Budd, D. C. et al. “Targeting TGF superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders” Pharmacology & Therapeutics, 2012, pp. 279-291, vol. 135.;;Burton, D. R. et al. “Human Antibodies from Combinatorial Libraries” Advances in Immunology, 1994, pp. 191-280, vol. 57.;;Buza, J. A. et al. “Bone healing in 2016” Clinical Cases in Mineral and Bone Metabolism, 2016, pp. 101-105, vol. 13, No. 2.;;Cahill, E. et al. “Gremlin Plays a Key Role in the Pathogenesis of Pulmonary Hypertension” Circulation, Feb. 21, 2012, pp. 920-930, vol. 125, No. 7.;;Calon, A. et al. “Stromal gene expression defines poor-prognosis subtypes in colorectal cancer” Nat Genet., Apr. 2015, pp. 320-329, vol. 47, No. 4, Online Methods, pp. 1-3.;;Canalis, E. et al. “Gremlin1 is Required for Skeletal Development and Postnatal Skeletal Homeostasis” J. Cell Physiol., 2012, pp. 269-277, vol. 227.;;Chen, V. B. et al. “MolProbity: all-atom structure validation for macromolecular crystallography” Acta Crystallographica Section D, 2010, pp. 12-21, D66.;;Chen, M.-H. et al. “Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors” J Gastroenterol, 2013, pp. 101-108, vol. 48.;;Chen, J. et al. “BAFF is involved in macrophage-induced bortezomib resistance in myeloma” Cell Death Dis, 2017, pp. 1-12, vol. 8, No. 11, e3161.;;Cheong, C. M. et al. “Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo” Exp Cell Res, 2015, pp. 24-38, vol. 332.;;Chesi, M. et al. “Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy” Blood, Jul. 12, 2012, pp. 376-385, vol. 120, No. 2.;;Cho, T.-J. et al. “Differential Temporal Expression of Members of the Transforming Growth Factor β Superfamily During Murine Fracture Healing” Journal of Bone and Mineral Research, Nov. 3, 2002, pp. 513-520, vol. 17, No. 3.;;Ciuclan, L. et al. “Imatinib Attenuates Hypoxia-induced Pulmonary Arterial Hypertension Pathology via Reduction in 5-Hydroxytryptamine through Inhibition of Tryptophan Hydroxylase 1 Expression” Am J Respir Crit Care Med., 2013, pp. 78-89, vol. 187, Issue 1.;;Ciuclan, L, et al. “Treatment with Anti-Gremlin 1 Antibody Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension in Mice” Am J Pathol., Nov. 2013, pp. 1461-1473, vol. 183, No. 5.;;Curran, S. P. et al. “Deletion of Gremlin1 increases cell proliferation and migration responses in mouse embryonic fibroblasts” Cellular Signalling, 2012, pp. 889-898, vol. 24, No. 4.;;Dallas, S. L. et al. “Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease” Blood, Mar. 1, 1999, pp. 1697-1706, vol. 93, No. 5.;;Das, D. S. et al. “A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells” Leukemia, 2016, pp. 2187-2197, vol. 30, No. 11.;;Davis, H. et al. “Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche” Nat Med., Jan. 2015, pp. 62-70, vol. 21, No. 1, Online Methods, pp. 1-3.;;Dean, D. B. et al. “Distinct functionalities of bone morphogenetic protein antagonists during fracture healing in mice” Journal of Anatomy, 2010, pp. 625-630, vol. 216, No. 5.;;Devereux, J. et al. “A comprehensive set of sequence analysis programs for the VAX” Nucleic Acids Research, 1984, pp. 387-395, vol. 12, No. 1.;;Diamond, P. et al. “Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss” J Bone Miner Res, 2009, pp. 1150-1161, vol. 24, No. 7.;;Dubowchik, G. M. et al. “Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs” Pharmacology and Therapeutics, 1999, pp. 67-123, vol. 83.;;Einhorn, T. A. et al. “Fracture healing: mechanisms and interventions” Nat. Rev. Rheumatol., Jan. 2015, pp. 45-54, vol. 11.;;Emsley, P. et al. “Features and development of Coot” Acta Crystallographica Section D: Biological Crystallography, 2010, pp. 486-501, D66, No. 4.;;Fajardo, M. et al. “Levels of Expression for BMP-7 and Several BMP Antagonists May Play an Integral Role in a Fracture Nonunion: A Pilot Study” Clinical Orthopaedics and Related Research, Jul. 14, 2009, pp. 3071-3078, vol. 467, No. 12.;;Farber, H. W. et al. “Pulmonary Arterial Hypertension” The New England Journal of Medicine, 2004, pp. 1655-1665, vol. 351.;;Ferguson, C. et al. “Does adult fracture repair recapitulate embryonic skeletal formation?” Mechanisms of Development, 1999, pp. 57-66, vol. 87.;;Fowler, J. A. et al. “Bone Marrow Stromal Cells Create a Permissive Microenvironment for Myeloma Development: A New Stromal Role for Wnt Inhibitor Dkk1” Cancer Research, 2012, pp. 2183-2189, vol. 72, No. 9.;;Gasteiger, E. et al. “Protein Identification and Analysis Tools on the ExPASy Server” The Proteomics Protocols Handbook, Humana Press, ed. J. M. Walker, 2005, pp. 571-607.;;Gazzerro, E. et al. “Skeletal Overexpression of Gremlin Impairs Bone Formation and Causes Osteopenia” Endocrinology, Feb. 1, 2005, pp. 655-665, vol. 146, No. 2.;;Gazzerro, E. et al. “Conditional Deletion of Gremlin Causes a Transient Increase in Bone Formation and Bone Mass” J. Biol. Chem., Oct. 26, 2007, pp. 31549-31557, vol. 282, No. 43.;;Ghobrial, I. M. “Myeloma as a model for the process of metastasis: implications for therapy” Blood, Jul. 5, 2012, pp. 20-30, vol. 120, No. 1.;;Gilbane, A. J. et al. “Impaired Bone Morphogenetic Protein Receptor II Signaling in a Transforming Growth Factor-β-Dependent Mouse Model of Pulmonary Hypertension and in Systemic Sclerosis” Am J Respir Crit Care Med., Mar. 15, 2015, pp. 665-677, vol. 191, Issue 6.;;Goulet, J. A. et al. “Autogenous Iliac Crest Bone Graft. Complications and Functional Assessment” Clinical Orthopaedics and Related Research, Jun. 1997, pp. 76-81, No. 339.;;Guan, Y. et al. “Gremlin1 promotes carcinogenesis of glioma in vitro” Clin Exp Pharmacol Physiol, 2017, pp. 244-256, vol. 44, No. 2.;;Harris, R. J. “Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture” Journal of Chromatography A, 1995, pp. 129-134, vol. 705.;;Hellstrom, K. E. et al. “Antibodies for Drug Delivery” Controlled Drug Delivery, 2nd Ed., Robinson et al., eds., 1987, pp. 623-653.;;Henikoff, S. et al. “Amino acid substitution matrices from protein blocks” Proc. Natl. Acad. Sci. USA, Nov. 1992, pp. 10915-10919, vol. 89.;;Hewett, D. R. et al. “DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment” Neoplasia, Dec. 2017, pp. 972-981, vol. 19, No. 4.;;Hideshima, T. et al. “Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets” Nature Reviews Cancer, Aug. 2007, pp. 585-598, vol. 7, No. 8.;;Hjertner, O. et al. “Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells” Blood, Jan. 15, 2001, pp. 516-522, vol. 97, No. 2.;;Hochleitner, E. O. et al. “Characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometric peptide mapping analysis” Protein Science, 2000, pp. 487-496, vol. 9.;;Holien, T. et al. “Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC” Leukemia, 2012, pp. 1073-1080, vol. 26, No. 5.;;Holliger, P. et al. “Engineered antibody fragments and the rise of single domains” Nature Biotech., Sep. 2005, pp. 1126-1136, vol. 23, No. 9.;;Howe, J. R. et al. “Mutations in the SMAD4/DPC4 Gene in Juvenile Polyposis” Science, May 15, 1998, pp. 1086-1088, vol. 280, No. 5366.;;Howe, J. R. et al. “Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis” Nat Genet., Jun. 2001, pp. 184-187, vol. 28, No. 2.;;Hu, K. et al. “Gremlin-1 suppression increases BMP-2-induced osteogenesis of human mesenchymal stem cells” Molecular Medicine Reports, 2017, pp. 2186-2194, vol. 15.;;International Search Report and Written Opinion in International Application No. PCT/EP2019/053726, dated May 17, 2019, pp. 1-19.;;International Search Report and Written Opinion in International Application No. PCT/GB2019/051699, dated Aug. 16, 2019, pp. 1-11.;;Irshad, S. et al. “Bone morphogenetic protein and Notch signalling crosstalk in poor-prognosis, mesenchymal-subtype colorectal cancer” J Pathol., 2017, pp. 178-192, vol. 242.;;Isella, C. et al. “Stromal contribution to the colorectal cancer transcriptome” Nat Genet., Apr. 2015, pp. 312-319, vol. 47, No. 4, Online Methods, pp. 1-4.;;Jaeger, E. et al. “Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1” Nat Genet., Jun. 2012, pp. 699-703, vol. 44, No. 6, Online Methods, pp. 1-2.;;Junghans, R. P. et al. “Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders” Cancer Res., Mar. 1, 1990, pp. 1495-1502, vol. 50.;;Kabsch, W. “XDS” Acta Crystallographica Section D, Biological Crystallography, 2010, pp. 125-132, vol. D66.;;Karagiannis, G. S. et al. “Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1” Mol Oncol., 2013, pp. 826-839, vol. 7, No. 4.;;Karagiannis, G. S. et al. “Bone morphogenetic protein antagonist gremlin-1 regulates colon cancer progression” Biol Chem., 2015, pp. 163-183, vol. 396, No. 2.;;Karlin, S. et al. “Applications and statistics for multiple high-scoring segments in molecular sequences” Proc. Natl. Acad. Sci. USA, Jun. 1993, pp. 5873-5877, vol. 90.;;Kashmiri, S. V. S. et al. “SDR grafting—a new approach to antibody humanization” Methods, 2005, pp. 25-34, vol. 36.;;Kettleborough, C. A. et al. “Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments” Eur. J. Immunol., 1994, pp. 952-958, vol. 24.;;Kim, M. et al. “Gremlin-1 Induces BMP-Independent Tumor Cell Proliferation, Migration, and Invasion” PloS ONE, Apr. 2012, pp. 1-8, vol. 7, Issue 4, e35100.;;Kim, H. S. et al. “GREM1 is expressed in the cancer-associated myofibroblasts of basal cell carcinomas” PloS ONE, 2017, pp. 1-13, vol. 12, No. 3, e0174565.;;Kohler, G. et al. “Continuous cultures of fused cells secreting antibody of predefined specificity” Nature, Aug. 7, 1975, pp. 495-497, vol. 256.;;Koketsu, K. et al. “Gremlin, a Bone Morphogenetic Protein Antagonist, Is a Crucial Angiogenic Factor in Pituitary Adenoma” Int J Endocrinol., 2015, pp. 1-7, Article ID 834137.;;Kozbor, D. et al. “The production of monoclonal antibodies from human lymphocytes” Immunology Today, 1983, pp. 72-79, vol. 4, No. 3.;;Krinner, E.-M. et al. “A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF” Mol. Immunol., Feb. 2007, pp. 916-925, vol. 44, No. 5.;;Kyle, R. A. et al. “Multiple Myeloma” N Engl J Med, 2004, pp. 1860-1873, vol. 351, No. 18.;;Laurila, R. et al. “The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues” Int J Clin Exp Pathol., 2013, pp. 1400-1408, vol. 6, No. 7.;;Lavoz, C. et al. “Gremlin regulates renal inflammation via the vascular endothelial growth factor receptor 2 pathway” J Pathol., 2015, pp. 407-420, vol. 236.;;Lawson, M. A. et al. “Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche” Nat Common., 2015, pp. 1-15, vol. 6, No. 8983.;;Lewis, A. et al. “A Polymorphic Enhancer Near GREM1 Influences Bowel Cancer Risk through Differential CDX2 and TCF7L2 Binding” Cell Rep., Aug. 21, 2014, pp. 983-990, vol. 8, No. 4.;;McCoy, A. J. et al. “Phaser crystallographic software” J Appl Cryst., 2007, pp. 658-674, vol. 40.;;Mitola, S. et al. “Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2” Blood, Nov. 4, 2010, pp. 3677-3680, vol. 116, No. 18.;;Mulvihill, M. S. et al. “Gremlin is Overexpressed in Lung Adenocarcinoma and Increases Cell Growth and Proliferation in Normal Lung Cells” PloS ONE, 2012, pp. 1-8, vol. 7, No. 8, e42264.;;Murshudov, G. N. et al. “REFMAC5 for the refinement of macromolecular crystal structures” Acta Crystallographica Section D: Biological Crystallography, 2011, pp. 355-367, vol. D67.;;Namkoong, H. et al. “The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein” BMC Cancer, 2006, pp. 1-13, vol. 6, No. 74.;;Neufert, C. et al. “An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression” Nat Protoc., 2007, pp. 1998-2004, vol. 2, No. 8.;;Nolan, K. et al. “Structure of Neuroblastoma Suppressor of Tumorigenicity 1 (NBL1)” J. Biol. Chem., Feb. 20, 2015, pp. 4759-4771, vol. 290, No. 8.;;Noll, J. E. et al. “Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells” Haematologica, 2014, pp. 163-171, vol. 99, No. 1.;;Noll, J. E. et al. “SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma” Neoplasia, Jul. 2014, pp. 572-585, vol. 16, No. 7.;;Noll, J. E. et al. “PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma” J Hematol Oncol., 2015, pp. 1-16, vol. 8, No. 106.;;Persic, L. et al. “An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries” Gene, 1997, pp. 9-18, vol. 187.;;Plaks, V. et al. “The Cancer Stem Cell Niche: How Essential Is The Niche in Regulating Sternness of Tumor Cells?” Cell Stem Cell, Mar. 5, 2015, pp. 225-238, vol. 16, No. 3.;;Ponomarev, V. et al. “A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging” Eur J Nucl Med Mol Imaging, 2004, pp. 740-751, vol. 31, No. 5.;;Reineke, U. “Antibody Epitope Mapping Using Arrays of Synthetic Peptides” Methods Mol Biol, 2004, pp. 443-463, vol. 248.;;Retter, I. et al. “VBASE2, an integrative V gene database” Nucl. Acids Res., 2005, pp. D671-D674, vol. 33.;;Riechmann, L. et al. “Reshaping human antibodies for therapy” Nature, Mar. 24, 1988, pp. 323-327, vol. 332.;;Sato, T. et al. “Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche” Nature, May 14, 2009, pp. 262-265, vol. 459, No. 7244, Methods, p. 1.;;Sato, K. et al. “Establishment of Reproducible, Critical-Sized, Femoral Segmental Bone Defects in Rats” Tissue Eng Part C., 2014, pp. 1037-1041, vol. 20, No. 12.;;Schmid, G. J. et al. “Fibroblast Growth Factor Expression During Skeletal Fracture Healing in Mice” Developmental Dynamics, 2009, pp. 766-774, vol. 238.;;Scoville, D. H. et al. “Current View: Intestinal Stem Cells and Signaling” Gastroenterology, 2008, pp. 849-864, vol. 134, No. 3.;;Search Report for GB1802486.9, dated Oct. 17, 2018, pp. 1-5.;;Sebald, H.-J. et al. “Inhibition of endogenous antagonists with an engineered BMP-2 variant increases BMP-2 efficacy in rat femoral defect healing” Acta Biomaterialia, Oct. 10, 2012, pp. 3816-3820, vol. 8, No. 10.;;Sethi, A. et al. “Gremlin utilizes canonical and non-canonical TGFβ signaling to induce lysyl oxidase (LOX) genes in human trabecular meshwork cells” Exp Eye Res., 2013, pp. 117-127, vol. 113.;;Shoshkes-Carmel, M. et al. “Subepithelial telocytes are an important source of Wnts that supports intestinal crypts” Nature, May 10, 2018, pp. 242-246, vol. 557, Supplemental pp. 1-9.;;Simonneau, G. et al. “Updated Clinical Classification of Pulmonary Hypertension” J Am Coll Cardiol., Jun. 30, 2009, pp. S43-S54, vol. 54, No. 1, Suppl S.;;Sneddon, J. B. et al. “Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation” Proc Natl Acad Sci USA, Oct. 3, 2006, pp. 14842-14847, vol. 103, No. 40.;;Tamminen, J.A. et al. “Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug” Oncogenesis, 2013, pp. 1-13, vol. 2, e66.;;Thomas, M. et al. “Activin-like kinase 5 (ALK5) Mediates Abnormal Proliferation of Vascular Smooth Muscle Cells from Patients with Familial Pulmonary Arterial Hypertension and Is Involved in the Progression of Experimental Pulmonary Arterial Hypertension Induced by Monocrotaline” Am J Pathol., Feb. 2009, pp. 380-389, vol. 174, No. 2.;;Thorpe, P. E. et al. “The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates” Immunol. Rev., 1982, pp. 119-158, vol. 62.;;Tomlinson, I. P. M. et al. “Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of Colorectal Cancer” PLoS Genet., Jun. 2011, pp. 1-11, vol. 7, No. 6, e1002105.;;Topol, L. Z. et al. “Identification of drm, a Novel Gene Whose Expression Is Suppressed in Transformed Cells and Which Can Inhibit Growth of Normal but Not Transformed Cells in Culture” Mol Cell Biol, Aug. 1997, pp. 4801-4810, vol. 17, No. 8.;;Vande Broek, I. et al. “Extravasation and homing mechanisms in multiple myeloma” Clin Exp Metastasis, 2008, pp. 325-334, vol. 25, No. 4.;;Vaughan, T. J. et al. “Human antibodies by design” Nature Biotechnology, Jun. 1998, pp. 535-539, vol. 16.;;Verheyden, J. M. et al. “An Fgf/Gremlin inhibitory feedback loop triggers termination of limb bud outgrowth” Nature, Jul. 31, 2008, pp. 1-12, vol. 454, No. 7204.;;Verma, R. et al. “Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems” Journal of Immunological Methods, 1998, pp. 165-181, vol. 216.;;Wang, D.-J. et al. “The bone morphogenetic protein antagonist Gremlin is overexpressed in human malignant mesothelioma” Oncology Reports, 2012, pp. 58-64, vol. 27, No. 1.;;Worthley, D. L. et al. “Gremlin 1 Identifies a Skeletal Stem Cell with Bone, Cartilage, and Reticular Stromal Potential” Cell, Jan. 15, 2015, pp. 269-284, vol. 160, Nos. 1-2.;;Yin, Y. et al. “Overexpression of Gremlin promotes non-small cell lung cancer progression” Tumour Biol, 2016, pp. 2597-2602, vol. 37.;;Yu, Y. Y. et al. “Immunolocalization of BMPs, BMP antagonists, receptors, and effectors during fracture repair” Bone, 2010, pp. 841-851, vol. 46.;;Rudikoff, S. et al. “Single amino acid substitution altering antigen-binding specificity” Proceedings of the National Academy of Sciences of the United States of America, Mar. 1982, pp. 1979-1983, vol. 79, No. 6.;;Janeway, Jr., C. A. et al. Immunology: the immune system in health and disease, 3rd ed., 1997, Garland Publications, Inc., Chapter 3, “Structure of the Antibody Molecule and Immunoglobulin Genes” pp. 3:1-3:11.;;Lederman, S. et al. “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4” Molecular Immunology, 1991, pp. 1171-1181, vol. 28, No. 11.;;Li, J. et al. “Temporal associations between interleukin 22 and the extracellular domains of IL-22R and IL-IOR2” International Immunology, 2004, pp. 693-711, vol. 4.;;Panka, D. J. et al. “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies” Proceedings of the National Academy of Sciences of the United States of America, May 1, 1988, pp. 3080-3084, vol. 85, No. 9.;;Amit, A. G. et al. “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Ø Resolution” Science, Aug. 15, 1986, pp. 747-753, vol. 233, No. 4765.;;Harlow, E. et al. “Antibodies, A Laboratory Manual” Cold Spring Harbor Laboratory, 1988, Chapter 5, pp. 1-2.;;O'Reilly, S. et al. “Interleukin-6 (IL-6) Trans Signaling Drives a STAT3-dependent Pathway That Leads to Hyperactive Transforming Growth Factor-β (TGF-β) Signaling Promoting SMAD3 Activation and Fibrosis via Gremlin Protein” The Journal of Biological Chemistry, Apr. 4, 2014, pp. 9952-9960, vol. 289, No. 14.;;Sato, M. et al. “Clinical significance of Gremlin 1 in cervical cancer and its effects on cancer stem cell maintenance” Oncology Reports, 2016, pp. 391-397, vol. 35.;;Uchiyama, H. et al. “Adhesion of Human Myeloma-Derived Cell Lines to Bone Marrow Stromal Cells Stimulates Interleukin-6 Secretion” Blood, Dec. 15, 1993, pp. 3712-3720, vol. 82, No. 12.;;Van Vlodrop, I. J. H. et al. “Prognostic Significance of Gremlin1 (GREM1) Promoter CpG Island Hypermethylation in Clear Cell Renal Cell Carcinoma” The American Journal of Pathology, Feb. 2010, pp. 575-584, vol. 176, No. 2.;;Yu, Y. et al. “Overexpression of Gremlin 1 by sonic hedgehog signaling promotes pancreatic cancer progression” International Journal of Oncology, 2018, pp. 2445-2457, vol. 53.;;Clark, K. C. et al. “Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo” Cancers, Aug. 3, 2020, pp. 1-20, vol. 12, No. 2149.;;United Kingdom Search Report Application No. GB1809946.5, dated Jan. 24, 2019, pp. 1-4.;;Walsh, D.W. et al. “Extracellular BMP-antagonist regulation in development and disease: tied up in knots” Trends in Cell Biology, Feb. 24, 2010, pp. 244-256, vol. 20, No. 5.;;Torre, L.A. et al. “Global Cancer in Women: Burden and Trends” Cancer Epidemiol Biomarkers Prev, Feb. 21, 2017, pp. 444-457, vol. 26, No. 4.;;“Breast Cancer Facts & Figures 2015-2016” American Cancer Society, 2015, 2 cover pages and pp. 1-40.;;Mittal, S. et al. “The breast tumour microenvironment—role in cancer development, progression and response to therapy” Expert Review of Molecular Diagnostics, 2018, pp. 1-34, vol. 18, No. 3.;;Merino, R. et al. “The BMP antagonist Gremlin regulates outgrowth, chondrogenesis and programmed cell death in the developing limb” Development, 1999, pp. 5515-5522, vol. 126.;;Schuetz, C. S. et al. “Progression-Specific Genes Identified by Expression Profiling of Matched Ductal Carcinomas In situ and Invasive Breast Tumors, Combining Laser Capture Microdissection and Oligonucleotide Microarray Analysis” Cancer Research, May 15, 2006, pp. 5278-5286, vol. 66, No. 10.;;Kuchimaru, T. et al. “A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries” Nature Communications, 2018, pp. 1-7, vol. 9, No. 2981.;;Kager, L. et al. “Novel insights and therapeutic interventions for pediatric osteosarcoma” Future Oncol., Sep. 21, 2016, pp. 357-368, vol. 13, No. 4.;;Kresse, S. H. et al. “Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma” PLoS ONE, Nov. 7, 2012, pp. 1-20, vol. 7, Issue 11, e48262.;;Groeneveld, E. H. J. et al. “Bone morphogenetic proteins in human bone regeneration” European Journal of Endocrinology, 2000, pp. 9-21, vol. 142.;;Zysk, A. et al. “Zoledronate Enhances the Cytotoxicity of Gamma Delta T Cell Immunotherapy in an Orthotopic Mouse Model of Osteolytic Osteosarcoma” J Cancer Sci Ther, 2018, pp. 262-266, vol. 10, No. 9.;;Tian, H. et al. “Bone morphogenetic protein-2 and tumor growth: Diverse effects and possibilities for therapy” Cytokine & Growth Factor Reviews, 2017, pp. 73-91, vol. 34.;;Tian, H. et al. “Bone Morphogenetic Protein-2 Promotes Osteosarcoma Growth by Promoting Epithelial-Mesenchymal Transition (EMT) Through the Wnt/β-Catenin Signaling Pathway” Journal of Orthopaedic Research, Jul. 2019, pp. 1638-1648.;;Nguyen, A. et al. “Roles of bone morphogenetic protein signaling in osteosarcoma” International Orthopaedics (SICOT), 2014, pp. 2313-2322, vol. 38.;;Rycaj, K. et al. “Cellular determinants and microenvironmental regulation of prostate cancer metastasis” Semin Cancer Biol., Jun. 2017, pp. 1-35, vol. 44.;;Grillo, E. et al. “Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist” Oncotarget, May 11, 2016, pp. 35353-35368, vol. 7, No. 23.;;Gandaglia, G. et al. “Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer” European Urology, 2015, pp. 325-334, vol. 68.;;Armstrong, A. J. et al. “A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis” Clin Cancer Res, Nov. 1, 2007, pp. 6396-6403, vol. 13, No. 21.;;Van Cutsem, E. et al. “Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up” Annals of Oncology, Sep. 2014, pp. ii1-ii9, vol. 25 (Supplement 3).;;Muñoz, J. et al. “The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent ‘+4’ cell markers” The EMBO Journal, 2012, pp. 3079-3091, vol. 31, No. 14.;;Moser, A. R. et al. “The Min (Multiple Intestinal Neoplasia) Mutation: Its Effect on Gut Epithelial Cell Differentiation and Interaction with a Modifier System” The Journal of Cell Biology, Mar. 1992, pp. 1517-1526, vol. 116, No. 6.;;Shibata, H. et al. “Rapid Colorectal Adenoma Formation Initiated by Conditional Targeting of the Apc Gene” Science, Oct. 3, 1997, pp. 120-123, vol. 278.;;El Marjou, F. et al. “Tissue-Specificand Inducible Cre-Mediated Recombination in the Gut Epithelium” genesis, 2004, pp. 186-193, vol. 39.;;Rudling, R. et al. “A simple device to rapidly prepare whole mounts of murine intestine” Cell Prolif., 2006, pp. 415-420, vol. 39.;;Sato, T. et al. “Long-Term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium” Gastroenterology, Nov. 2011, pp. 1762-1772, vol. 141, No. 5.",ACTIVE
795,WO,A1,WO 2015/040424 A1,123-486-487-837-809,2015-03-26,2015,GB 2014052875 W,2014-09-22,GB 201316823 A,2013-09-23,TETRAHYDROISOQUINOLINE COMPOUNDS AND THEIR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS,"A compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: R 1 is H, Cl, F, CH 3 or CF 3 ; R 2 is H, C 1 -C 6 alkyl or optionally substituted heteroaryl or optionally substituted aryl; and R 3 is (Alk) n -R n -(Alk) n -R n -(Alk) n -X. The compounds are useful as tetrahydroisoquinoline (THQ) compounds, which are suitable for use as PDK inhibitors, for example for inhibition of cancer cell proliferation.",VERNALIS R&D LTD,BROUGH PAUL ANDREW;;MACIAS ALBA;;ROUGHLEY STEPHEN DAVID;;STOKES STEPHEN;;DAVIES NICHOLAS GARETH MORSE,,https://lens.org/123-486-487-837-809,Patent Application,yes,0,7,2,2,0,C07D401/14;;C07D413/14;;C07D215/14;;C07D401/04;;C07D401/06;;C07D401/12;;C07D405/04;;C07D405/12;;C07D409/12;;C07D409/14;;C07D417/04;;C07D487/04;;C07D491/048;;C07D491/052;;C07D495/04;;A61P35/00,C07D215/14;;A61K31/47;;A61K31/4709;;A61P35/00;;C07D401/04;;C07D401/06;;C07D401/12;;C07D401/14;;C07D405/04;;C07D405/12;;C07D409/12;;C07D409/14;;C07D413/14;;C07D417/04;;C07D487/04,,3,2,021-159-190-609-673;;036-989-400-889-368,23448267;;10.1021/jm4000227;;10.1016/j.str.2007.07.001;;pmc2871385;;17683942,"JESÚS R. MEDINA: ""Selective 3-Phosphoinositide-Dependent Kinase 1 (PDK1) Inhibitors: Dissecting the Function and Pharmacology of PDK1"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 7, 11 April 2013 (2013-04-11), pages 2726 - 2737, XP055156409, ISSN: 0022-2623, DOI: 10.1021/jm4000227;;KATO ET AL: ""Distinct Structural Mechanisms for Inhibition of Pyruvate Dehydrogenase Kinase Isoforms by AZD7545, Dichloroacetate, and Radicicol"", STRUCTURE, CURRENT BIOLOGY LTD., PHILADELPHIA, PA, US, vol. 15, no. 8, 14 August 2007 (2007-08-14), pages 992 - 1004, XP022192478, ISSN: 0969-2126, DOI: 10.1016/J.STR.2007.07.001;;DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 June 2014 (2014-06-07), XP002733269",PENDING
796,CN,B,CN 101743246 B,141-080-999-621-537,2013-07-17,2013,CN 200880023077 A,2008-05-21,GB 2008001738 W;;GB 0710121 A,2007-05-25,"2-oxo-2- (2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl) -acetamide derivatives and related compounds as antifungal agents","The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/141-080-999-621-537,Granted Patent,no,0,0,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A61K31/437;;A61P31/10,,0,0,,,,ACTIVE
797,CN,A,CN 112533632 A,029-417-819-967-225,2021-03-19,2021,CN 201980041089 A,2019-06-18,GB 201809946 A;;GB 201815694 A;;GB 2019051699 W,2018-06-18,GREMLIN-1 ANTAGONIST FOR THE PREVENTION AND TREATMENT OF CANCER,The invention relates to an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer.,UCB BIOPHARMA SPRL;;UNIV OXFORD INNOVATION LTD;;UNIV ADELAIDE,DAVIES GARETH CHARLES GLYNDWR;;LEEDHAM SIMON;;ZANNETTINO ANDREW;;CLARK KIMBERLEY;;HEWETT DUNCAN;;PANAGOPOULOS VASILIOS,,https://lens.org/029-417-819-967-225,Patent Application,no,8,0,14,17,0,C07K16/18;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K16/18;;A61P35/00;;C12Q1/6886;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12Q2600/158;;C12Q2600/118;;C12Q2600/106;;A61P35/00;;A61K45/06;;A61K2039/505;;C07K16/24;;C07K16/2803;;C07K16/2896;;G01N33/5748;;G01N2800/52,A61K39/395;;A61P35/00,,0,0,,,,PENDING
798,CA,C,CA 2670165 C,081-889-760-666-284,2014-11-18,2014,CA 2670165 A,2007-11-21,GB 0623209 A;;GB 2007004449 W,2006-11-21,2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS,"The invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof wherein: Rl, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. These compounds are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;PAYNE LLOYD JAMES;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/081-889-760-666-284,Granted Patent,no,0,0,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/90;;A61K31/437;;A61P33/00,,0,0,,,,ACTIVE
799,AU,B2,AU 2007/324385 B2,128-779-285-250-461,2013-03-21,2013,AU 2007/324385 A,2007-11-21,GB 0623209 A;;GB 2007004449 W,2006-11-21,2- [ (2-substituted) -indolizin-3-yl] -2-oxo-acetamide derivatives as antifungal agents,"The invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof wherein: Rl, R2, R3, R4, R5, R6, R7, X and X",F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP;;DAVIES GARETH MORSE;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES,,https://lens.org/128-779-285-250-461,Granted Patent,no,2,0,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/90;;A61K31/437;;A61P33/00,,1,1,018-491-364-581-321,14249429;;10.1002/jps.2600531007,"Venturella, J. Pharm. Sci., 53(10), 1166-1169 (October 1964)",ACTIVE
800,EP,A1,EP 4197913 A1,156-202-609-677-621,2023-06-21,2023,EP 22208027 A,2022-11-17,GB 202118045 A,2021-12-14,AIRCRAFT POWER AND PROPULSION SYSTEMS AND METHODS OF OPERATING AIRCRAFT POWER AND PROPULSION SYSTEMS,"Aircraft power and propulsion systems 100 and methods 300 of operating such power and propulsion systems 100 are provided. One such method 300 comprises: operating one or more electric machines 111, 112 of one or more gas turbine engines 110; 110a, 110b as generators to extract mechanical power from one or more of spools 16, 19, 26; 15, 17, 27 and generating electrical power therefrom; meeting an electrical power demand, P D , of a plurality of electrical loads 115, 116, 150 connected with an electrical system 120 by supplying the plurality of electrical loads with electrical power generated by the one or more electric machines 111, 112; determining a condition to the effect that there is a fault in the electrical system 120 and/or one or more of the one or more gas turbine engines 110; 110a, 110b and that an amount of electrical power being generated by the power and propulsion system 100 has reduced to a lower level, P fault ; and responsive to the determination: during a time period ΔT, controlling the plurality of electrical loads 115, 116, 150 to reduce the electrical power demand; and during the time period ΔT, meeting at least part of the electrical power demand of the plurality of electrical loads 115, 116, 150 by discharging the electrical energy storage system 130.
",ROLLS ROYCE PLC,MOORE GARETH;;DAVIES PAUL;;HUSBAND STEPHEN;;TRAINER DAVID;;SCOTHERN DAVID;;GEORGE LUKE;;HERBERT DOUGLAS,,https://lens.org/156-202-609-677-621,Patent Application,yes,3,0,3,3,0,B64D2221/00;;F02C7/32;;H02J7/1446;;F02C9/00;;F02K5/00;;F02C6/14;;F05D2220/76;;F02C6/20;;B64D31/06;;H02J2310/44;;H02J2310/58;;H02J2310/60;;H02J2310/62;;H02J2207/50;;H02J7/143;;H02J7/1438;;H02J7/1492;;H02J9/061;;H02J2310/52;;Y02T50/60;;B64D27/026;;B64D27/10;;B64D27/24;;B64D31/06;;B64D2041/002;;F01D15/10;;F05D2220/323;;F05D2220/76;;F05D2270/091;;B64D27/026,B64D25/00;;B64D31/00;;F02C7/32;;H02J7/14,,0,0,,,,PENDING
801,AU,A1,AU 2007/324385 A1,012-209-972-523-504,2008-05-29,2008,AU 2007/324385 A,2007-11-21,GB 0623209 A;;GB 2007004449 W,2006-11-21,2- [ (2-substituted) -ind0lizin-3-yl] -2-oxo-acetamide derivatives as antifungal agents,,F2G LTD,DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;DAVIES GARETH MORSE;;PAYNE LLOYD JAMES;;EDWARDS PHILIP,,https://lens.org/012-209-972-523-504,Patent Application,no,0,0,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/90;;A61K31/437;;A61P33/00,,0,0,,,,ACTIVE
802,WO,A1,WO 2008/062182 A1,020-935-952-586-790,2008-05-29,2008,GB 2007004449 W,2007-11-21,GB 0623209 A,2006-11-21,2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS,"The invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof wherein: Rl, R2, R3, R4, R5, R6, R7, X and X 1 are as defined herein. These compounds are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;PAYNE LLOYD JAMES;;EDWARDS PHILIP;;DAVIES GARETH MORSE,DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;PAYNE LLOYD JAMES;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/020-935-952-586-790,Patent Application,yes,5,49,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,A01N43/90;;C07D471/04;;A61K31/437;;A61P33/00,,3,2,018-491-364-581-321;;125-190-663-181-256,14249429;;10.1002/jps.2600531007;;8809154;;10.1021/jm960395q,"GUET, CHANTAL ET AL: ""Synthesis of new phenols. Part 2. Derivatives of 6-hydroxy-2- phenylindolizine"", JOURNAL OF CHEMICAL RESEARCH, SYNOPSES , (9), 245 CODEN: JRPSDC; ISSN: 0308-2342, 1982, XP009097209;;VENTURELLA, VINCENT S.: ""Arylindolizines. III. Methoxyl and glyoxyl derivatives of several phenylindolizines"", JOURNAL OF PHARMACEUTICAL SCIENCES , 53(10), 1166-9 CODEN: JPMSAE; ISSN: 0022-3549, 1964, XP002449258;;J. MED. CHEM., vol. 39, no. 19, 1996, pages 3636",PENDING
803,US,B2,US 8604029 B2,050-195-229-588-700,2013-12-10,2013,US 51535407 A,2007-11-21,GB 0623209 A;;GB 2007004449 W,2006-11-21,2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents,"The invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof wherein: R1, R2, R3, R4, R5, R6, R7, X and X 1 are as defined herein. These compounds are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;PAYNE LLOYD JAMES;;EDWARDS PHILIP;;DAVIES GARETH MORSE;;F2G LTD BRITISH BODY CORPORATE,DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;PAYNE LLOYD JAMES;;EDWARDS PHILIP;;DAVIES GARETH MORSE,F2G LTD BRITISH BODY CORPORATE (2009-07-07),https://lens.org/050-195-229-588-700,Granted Patent,yes,5,0,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,A61K31/437;;A01N43/90;;A61K31/438;;A61K31/496;;A61K31/5377;;A61P31/10;;C07D471/04;;C07D491/107,514/233.2;;514/299;;514/253.04;;514/278;;546/112;;546/94;;546/127;;546/16;;544/362,17,7,095-630-841-364-590;;157-368-878-373-980;;060-908-101-548-398;;125-190-663-181-256;;064-843-742-303-148;;017-365-412-179-713;;018-491-364-581-321,10.1039/p19810003150;;10.1021/ja01463a046;;8842991;;10.1016/s0163-4453(96)92700-0;;8809154;;10.1021/jm960395q;;10.1039/jr9550001504;;10064251;;10.1086/515116;;14249429;;10.1002/jps.2600531007,"Chemical Abstracts Registry Database (compounds corresponding to answer Nos. 1-258, as accessed May 7, 2012, p. 1-125).;;Ames et al., ""The Preparation of Aminoalkylpyrrocolines""; Journal of the Chemistry Society; Abstracts; 1959; pp. 620-622.;;Blondeau et al., ""Synthesis of New Phenols. Part 1. Derivatives of 8-Hydroxy-indolizine""; Journal of Chemical Research; 1981; pp. 366-367; 12; France.;;Dick et al., ""Heterocyclic Compounds with Bridgehead Nitrogen Atoms. Part 9. Synthesis in the Pyrrolo[2,1,5-de] Quinolizine ([2.3.3] Cyclazine) Series Starting from Indolizines""; Journal of Chemical Society; Perkin Trans. 1; 1981; pp. 3150-3157.;;Galbraith et al., ""The Formation of Cycl[3.2.2]azine Derivatives Via the Reaction of Pyrrocoline with Dimethyl Acetylenedicarboxylate""; Journal American Chemistry Society; 1961; pp. 453-458; vol. 83(2).;;Groll et al., ""Trends in the Postmortem Epidemiology of Invasive Fungal Infections at a University Hospital""; The Journal of infection; 1996; pp. 23-32; vol. 33.;;Guet et al., ""Synthesis of New Phenols, Part 2. Derivatives of 6-Hydroxy-2-Phenylindolizine""; Journal of Chemical Research; 1982; p. 245; vol. 9; France.;;Hagishita et al., ""Potent Inhibitors of Secretory Phospholipase A2: Synthesis and Inhibitory Activities of Indolizine and Indene Derivatives""; J. Med. Chem.; 1996; pp. 3636-3658; vol. 39(19).;;Holland et al., ""The Chemistry of the Pyrrocolines. Part VII. Further Experiments with 2-Methylpyrrocoline""; Journal of the Chemical Society; 1955; pp. 1504-1511; London; W.C.I.;;Ribaud et al., ""Survival and Prognostic Factors of Invasive Aspergillosis After Allogeneic Bone Marrow Transplantation""; Clinical Infectious Diseases 1999; pp. 322-330; vol. 28.;;Shipman, ""Product Class 16: Indolizines, Science of Synthesis""; 2001; pp. 745-787; vol. 10.;;Venturella et al., ""Arylindolizines III. Methoxyl and Glyoxyl Derivatives of Several Substituted Phenylindolizines""; Journal of Pharmaceutical Sciences; 1964; pp. 1166-1169; vol. 53(10).;;International Search Report issued Apr. 15, 2008 (published May 29, 2008) during the prosecution of International Application No. PCT/GB2007/004449.;;Written Opinion issued Apr. 15, 2008 (published May 21, 2009) during the prosecution of International Application No. PCT/GB2007/004449.;;International Preliminary Report on Patentability issued May 26, 2009 (published May 26, 2009) during the prosecution of International Application No. PCT/GB2007/004449.;;Australian Examination Report, issued Jan. 13, 2013 (published Jan. 13, 2013) during the prosecution of Australian Patent Application No. 2007324385.;;Series of compounds taken from the Chemical Abstract Registry Copyright 2012 ACS on STN cited in a Japanese Office Action, issued Dec. 18, 2012 (published Dec. 18, 2012) during the prosecution of Japanese Application No. 2009-537692.",ACTIVE
804,US,A1,US 2009/0163490 A1,148-153-430-731-917,2009-06-25,2009,US 28252607 A,2007-03-09,GB 0604944 A;;GB 0617789 A;;GB 2007000831 W,2006-03-11,Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors,"Compounds of formula (I) have HSP90 inhibitory activity and are therefore useful in the treatment of, inter alia, cancer: Formula (I) wherein R i is hydrogen, fluoro, chloro, bromo, or a radical of formula -X-Alk 1 -(Z) m -(Alk 2 )n-Q wherein X is —O—, —S— —S(O)—, SO 2 —, or —NH—, Z is —O—, —S—, —(C═O)—, —(C═S)—, —S(O)—, —SO 2 —, —NR A —, or, in either orientation —C(═O)O—, —C(═O)NR A —, —C(═S)NR A —, —SO 2 NR A —, —NR A C(═O)—, or —NR A SO 2 — wherein R A is hydrogen or C 1 -C 6 alkyl AIk 1 and AIk 2 are optionally substituted divalent C 1 -C 3 alkylene or C 2 -C 3 alkenylene radicals, m, n and p are independently 0 or 1, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R 2 is a radical of formula —(Ar 1 ) p -(Alk 1 ) q -(Z) r -(Alk 2 ) s -Q wherein Ar 1 is an optionally substituted aryl or heteroaryl radical, Alk 1 , Alk 2 , Z, and Q are as defined above, and p, q, r and s are independently 0 or 1; and R 3 is cyano (—CN), fluoro, chloro, bromo, methyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, ethyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, cyclopropyl, —OH, —CH 2 OH, —C(O)NH 2 , —C(O)CH 3 , Or —NH 2 .",VERNALIS R&D LTD,BROUGH PAUL ANDREW;;DRYSDALE MARTIN JAMES;;DAVIES NICHOLAS GARETH;;FOLOPPE NICOLAS NOEL;;STOKES STEPHEN,,https://lens.org/148-153-430-731-917,Patent Application,yes,3,0,12,16,0,C07D487/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P31/12;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D487/04;;A61K31/517;;C07D487/04,A61K31/5377;;A61K31/519;;A61P31/12;;C07D487/04,514/234.2;;544/280;;514/265.1;;544/117,0,0,,,,DISCONTINUED
805,EP,A1,EP 4198287 A1,147-916-915-561-326,2023-06-21,2023,EP 22208019 A,2022-11-17,GB 202118039 A,2021-12-14,AIRCRAFT POWER AND PROPULSION SYSTEM,"Twin-engine aircraft power and propulsion systems 100 and methods 300 of operating such systems 100 are provided. One such aircraft power and propulsion system 100 comprises: first and second propulsive gas turbine engines 110a, 110b, each comprising combustion equipment 16 and a plurality of spools including a first spool 14, 19, 26 and a second spool 15, 17, 27; a first electrical power generation sub-system 111a comprising a first electric machine mechanically coupled with the first spool 14, 19, 26 of the first propulsive gas turbine engine 110a; a second electrical power generation sub-system 112a comprising a second electric machine mechanically coupled with the second spool 15, 17, 27 of the first propulsive gas turbine engine 110a; a third electrical power generation sub-system 111b comprising a third electric machine mechanically coupled with the first spool 14, 19, 26 of the second propulsive gas turbine engine 110b; a fourth electrical power generation sub-system 112b comprising a fourth electric machine mechanically coupled with the second spool 15, 17, 27 of the second propulsive gas turbine engine 110b; a first power channel 123a connected with a distribution side of the first electric machine of the first electrical power generation sub-system 111a; a second power channel 124a connected with a distribution side of the second electric machine of the second electrical power generation sub-system 112a; a third power channel 123b connected with a distribution side of the third electric machine of the third electrical power generation sub-system 111b; and a fourth power channel 124b connected with a distribution side of the fourth electric machine of the fourth electrical power generation sub-system 112b.
",ROLLS ROYCE PLC,MOORE GARETH;;DAVIES PAUL;;HUSBAND STEPHEN;;TRAINER DAVID;;SCOTHERN DAVID;;GEORGE LUKE;;HERBERT DOUGLAS,,https://lens.org/147-916-915-561-326,Patent Application,yes,5,0,4,4,0,F01D15/10;;F02C7/32;;F02C7/36;;F02K5/00;;F05D2220/76;;F05D2220/766;;F05D2220/762;;F02C6/00;;Y02T50/60;;F02C7/32;;F01D15/10;;B64D27/10;;B64D27/24;;B64D31/06;;B64D35/02;;B64D2041/002;;B64D2221/00;;B64D27/026,F02C7/36,,0,0,,,,PENDING
806,EP,A1,EP 4206453 A1,179-761-239-742-750,2023-07-05,2023,EP 22208020 A,2022-11-17,GB 202118040 A,2021-12-14,STARTING GAS TURBINE ENGINES,"Multi-engine aircraft power and propulsion systems 100 and methods 300 of starting the engines 110a, 110b of multi-engine aircraft 1 are provided. One such method 300 comprises: supplying electrical power from an electrical power source 130 to one or more electric machines 111a, 112aof the a first gas turbine engine 110a and operating said one or more electric machines 111a, 112a as motors to drive rotation of one or more spools 14, 19, 26; 15, 17, 27 of the first gas turbine engine 110a; starting the first gas turbine engine 110a by lighting combustion equipment 16 of the first gas turbine engine 110a; operating one or more of the electric machines 111a, 112a of the first gas turbine engine 110a as generators to extract mechanical power and generate electrical power from one or more spools 14, 19, 26; 15, 17, 27 of the first gas turbine engine 110a; transferring, via an electrical system 120, electrical power generated by the one or more electric machines 111a, 112a of the first gas turbine engine 110a to one or more electric machines 111b, 112b of a second gas turbine 110b engine and operating said one or more electric machines 111b, 112b as motors to drive rotation of one or more spools 14, 19, 26; 15, 17, 27 of the second gas turbine engine 110b; and starting the second gas turbine engine 110b by lighting combustion equipment 16 of the second gas turbine engine 110b.
",ROLLS ROYCE PLC,MOORE GARETH;;DAVIES PAUL;;HUSBAND STEPHEN;;TRAINER DAVID;;SCOTHERN DAVID;;GEORGE LUKE;;HERBERT DOUGLAS,,https://lens.org/179-761-239-742-750,Patent Application,yes,10,0,4,4,0,F02C7/268;;F02C6/14;;F02K5/00;;F05D2220/76;;F01D15/10;;Y02T50/60;;F02C7/268;;B64D31/02;;B64D35/08;;F02C6/14;;B64D2221/00;;B64D27/10;;B64D27/24;;B64D31/06;;B64D2041/002;;B64D2221/00;;F01D15/10;;F05D2220/323;;F05D2220/76;;F05D2260/85;;B64D27/026,F02C7/268;;F02K5/00,,0,0,,,,PENDING
807,KR,A,KR 20210028191 A,130-377-720-952-59X,2021-03-11,2021,KR 20217001142 A,2019-06-18,GB 201809946 A;;GB 201815694 A;;GB 2019051699 W,2018-06-18,암을 예방 및 치료하기 위한 GREMLIN-1 길항제,본 발명은 암 치료 또는 예방 방법에 사용하기 위한 항-GREM1 길항제에 관한 것이다.,UCB BIOPHARMA SRL;;UNIV ADELAIDE;;UNIV OXFORD INNOVATION LTD,DAVIES GARETH CHARLES GLYNDWR;;LEEDHAM SIMON;;ZANNETTINO ANDREW;;CLARK KIMBERLEY;;HEWETT DUNCAN;;PANAGOPOULOS VASILIOS,,https://lens.org/130-377-720-952-59X,Patent Application,no,0,0,14,17,86,C07K16/18;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K16/18;;A61P35/00;;C12Q1/6886;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12Q2600/158;;C12Q2600/118;;C12Q2600/106;;A61P35/00;;A61K45/06;;A61K2039/505;;C07K16/24;;C07K16/2803;;C07K16/2896;;G01N33/5748;;G01N2800/52,C07K16/18;;A61K39/00;;A61P35/00;;C12Q1/6886,,74,69,011-553-054-044-973;;098-724-633-703-400;;043-729-032-107-483;;012-007-448-024-359;;041-701-093-712-495;;001-646-542-312-05X;;000-769-593-092-070;;095-834-903-970-444;;008-061-699-775-635;;067-024-105-019-398;;070-834-347-340-232;;053-699-924-523-691;;013-703-966-633-758;;097-901-796-209-229;;029-486-847-477-02X;;070-238-365-351-890;;111-604-378-852-726;;056-289-795-899-023;;060-522-017-672-204;;008-017-695-084-433;;060-126-066-099-876;;077-587-097-220-826;;076-252-023-764-678;;060-918-425-739-173;;008-693-687-336-286;;018-280-468-055-668;;063-266-551-840-350;;046-951-095-213-650;;038-728-499-086-588;;018-199-486-626-091;;023-860-693-372-071;;002-880-498-827-946;;034-499-526-956-496;;020-398-976-665-441;;040-842-346-948-061;;092-175-386-389-524;;029-970-218-339-139;;088-935-349-526-045;;013-337-877-638-381;;024-205-497-164-000;;037-310-319-433-702;;028-671-261-063-506;;026-361-471-680-127;;083-861-682-427-488;;001-062-843-030-532;;016-392-744-492-623;;082-522-923-505-342;;095-576-636-997-853;;064-781-969-527-647;;028-188-258-692-969;;099-142-413-754-43X;;072-971-856-375-322;;028-716-741-713-711;;007-711-535-660-589;;012-113-132-303-756;;034-489-784-615-708;;036-648-857-259-985;;057-475-663-409-518;;053-688-298-868-719;;044-958-492-431-511;;044-380-745-789-522;;015-238-057-914-589;;017-186-900-863-545;;067-290-214-184-650;;051-322-618-006-677;;065-274-506-678-30X;;012-265-598-126-264;;016-507-178-023-87X;;021-221-160-658-727,10.1002/mc.22378;;26293751;;10.1182/blood-2011-09-380410;;pmc3382938;;22394600;;18751803;;10.1007/s11420-005-0111-5;;pmc2504134;;pmc5119705;;10.11138/ccmbm/2016.13.2.101;;27920804;;25706628;;10.1038/ng.3225;;pmc3132213;;10.1002/jcp.22730;;21412775;;10.1038/cddis.2017.533;;pmc5775406;;29095438;;10.1007/s00535-012-0614-z;;22706573;;25637218;;10.1016/j.yexcr.2015.01.006;;pmc3398763;;22451422;;10.1182/blood-2012-02-412783;;10.1359/jbmr.2002.17.3.513;;11874242;;24160323;;10.1016/j.ajpath.2013.07.017;;pmc5691347;;22182508;;10.1016/j.cellsig.2011.12.008;;10029599;;10.1182/blood.v93.5.1697;;10.1182/blood.v93.5.1697.405a17_1697_1706;;pmc5093055;;27118403;;10.1038/leu.2016.96;;25419707;;10.1038/nm.3750;;pmc4594755;;19335218;;10.1359/jbmr.090210;;25266456;;pmc4464690;;10.1038/nrrheum.2014.164;;10495271;;10.1016/s0925-4773(99)00142-2;;pmc3775476;;22374979;;10.1158/0008-5472.can-11-2067;;15539560;;10.1210/en.2004-0766;;17785465;;10.1074/jbc.m701317200;;10.1182/blood-2012-01-379024;;pmc3390959;;22535658;;10.1097/00003086-199706000-00011;;9186204;;27862197;;10.1111/1440-1681.12697;;10.1016/j.neo.2017.09.004;;pmc5678743;;29091798;;10.1038/nrc2189;;17646864;;11154231;;10.1182/blood.v97.2.516;;10.1038/leu.2011.263;;21941367;;10.1038/88919;;11381269;;10.1126/science.280.5366.1086;;9582123;;09582123;;10.1016/s1097-2765(00)80067-2;;9660951;;25706627;;10.1038/ng.3224;;28299802;;10.1002/path.4891;;pmc5488238;;22561515;;pmc4594751;;10.1038/ng.2263;;25153376;;10.1515/hsz-2014-0221;;23659962;;pmc5528431;;10.1016/j.molonc.2013.04.002;;10.1371/journal.pone.0035100;;22514712;;pmc3325980;;10.1371/journal.pone.0174565;;pmc5367809;;28346486;;25834571;;pmc4365323;;10.1155/2015/834137;;15509819;;10.1056/nejmra041875;;pmc3693206;;23826422;;10.1002/path.4537;;25810250;;26632274;;10.1038/ncomms9983;;pmc4686867;;10.1016/j.celrep.2014.07.020;;pmc4471812;;25131200;;20660291;;10.1182/blood-2010-06-291930;;22870311;;pmc3411619;;10.1371/journal.pone.0042264;;10.1186/1471-2407-6-74;;16545136;;pmc1459871;;10.1038/nprot.2007.279;;17703211;;pmc4007935;;10.3324/haematol.2013.090977;;23935020;;pmc4595141;;10.1186/s13045-015-0209-2;;26445238;;25117979;;pmc4198825;;10.1016/j.neo.2014.07.002;;10.1016/j.stem.2015.02.015;;pmc4355577;;25748930;;15014901;;10.1007/s00259-003-1441-5;;10.1038/nature07935;;19329995;;pmc2688661;;10.1002/dvdy.21882;;19235733;;10.1053/j.gastro.2008.01.079;;18325394;;10.1016/j.exer.2013.05.011;;pmc3809843;;23748100;;10.1038/s41586-018-0084-4;;pmc5966331;;29720649;;10.1073/pnas.0606857103;;17003113;;pmc1578503;;pmc3759128;;23978876;;10.1038/oncsis.2013.29;;21655089;;pmc3107194;;10.1371/journal.pgen.1002105;;pmc232332;;10.1128/mcb.17.8.4801;;9234736;;10.1007/s10585-007-9108-4;;17952614;;18594511;;10.1038/nature07085;;pmc2840222;;10.3892/or.2011.1463;;21935575;;25594183;;10.1016/j.cell.2014.11.042;;pmc4436082;;10.1007/s13277-015-4093-8;;26392110;;10.1016/j.bone.2009.11.005;;19913648,"WO-2014159010 (Priority: 14 Mar, 2013) Regeneron Pharmaceuticals Inc. ""Human antibodies to GREM 1"".;;WO-2013137686 (Priority: 15 Mar, 2012) Seoul National University and Db foundation, Korea ""Gremlinl antibody"".;;US 2009041757A1 (Priority: 16 Mar, 2007) Stanford University, ""Bone morphogenetic protein antagonist and uses thereof'.;;WO2007124486 (Priority: 21 Apr, 2007) Children's Hospital Los Angeles, ""BMP4 inhibitors"".;;W02002054940 (Priority: 12 Jan 2001) University of Medicine and Dentistry of New Jersey, ""Bone morphogenetic protein-2 in the treatment and diagnosis of cancer"".;;Attar-Schneider, O., et al., Multiple myeloma and bone marrow mesenchymal stem cells' crosstalk: Effect on translation initiation. Mol Carcinog, 2015.;;Azab, A.K., et al., Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood, 2012. 119(24): p. 5782-94.;;Bostrom, M. P. & Seigerman, D. A. (2005), HSS journal: The Musculoskeletal Journal of Hospital for Special Surgery 1, 9-18. The clinical use of allografts, demineralized bone matrices, synthetic bone graft substitutes and osteoinductive growth factors: a survey study.;;Buza, J. A., 3rd & Einhorn, T. (2016), Clinical cases in mineral and bone metabolism: The Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases 13, 101-105. Bone healing in 2016.;;Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47(4):320-9.;;Canalis, E., Parker, K. & Zanotti, S. (2012), J.Cell Physiol 227, 269-277. Gremlin1 is required for skeletal development and postnatal skeletal homeostasis.;;Chen, J., et al., BAFF is involved in macrophage-induced bortezomib resistance in myeloma. Cell Death Dis, 2017. 8(11): p. e3161.;;Chen, M.H., et al., Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors. J Gastroenterol, 2013. 48(1): p. 101-8.;;Cheong, C.M., et al., Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Exp Cell Res, 2015. 332(1): p. 24-38.;;Chesi, M., et al., Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood, 2012. 120(2): p. 376-85.;;Cho, T. J., Gerstenfeld, L. C. & Einhorn, T. A. (2002), Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research 17, 513-520. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing.;;Ciuclan, L., et al., Treatment with anti-gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice. Am J Pathol, 2013. 183(5): p. 1461-73.;;Curran, S.P., et al., Deletion of Gremlin1 increases cell proliferation and migration responses in mouse embryonic fibroblasts. Cellular Signalling, 2012. 24(4): p. 889-98.;;Dallas, S.L., et al., Ibandronate reduces osteolytic lesions but not tumour burden in a murine model of myeloma bone disease. Blood, 1999. 93(5): p. 1697-706.;;Das, D.S., et al., A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia, 2016. 30(11): p. 2187-2197.;;Davis H, Irshad S, Bansal M, Rafferty H, Boitsova T, Bardella C, et al. Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche. Nat Med. 2015;21(1):62-70.;;Diamond, P., et al., Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res, 2009. 24(7): p. 1150-61.;;Einhorn, T. A. & Gerstenfeld, L. C. (2015), Nat. Rev. Rheumatol. 11, 45-54. Fracture healing: mechanisms and interventions.;;Ferguson, C., Alpern, E., Miclau, T. & Helms, J. A. (1999), Mechanisms of development 87, 57-66. Does adult fracture repair recapitulate embryonic skeletal formation?;;Fowler, J.A., et al., Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Research, 2012. 72(9): p. 2183-9.;;Gazzerro, E. et al. (2005), Endocrinology 146, 655-665. Skeletal overexpression of gremlin impairs bone formation and causes osteopenia.;;Gazzerro, E. et al. (2007), J.Biol.Chem. 282, 31549-31557. Conditional deletion of gremlin causes a transient increase in bone formation and bone mass.;;Ghobrial, I.M., Myeloma as a model for the process of metastasis: implications for therapy. Blood, 2012. 120(1): p. 20-30.;;Goulet, J. A., Senunas, L. E., DeSilva, G. L. & Greenfield, M. L. (1997), Clinical Orthopaedics and Related Research, 76-81. Autogenous iliac crest bone graft. Complications and functional assessment.;;Guan et al. (2017). Gremlin1 promotes carcinogensis of glimona in vitro. Exp Pharmacol Physiol, 44 (2): 244-256;;Hewett, D.R., et al., DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment. Neoplasia (New York, N.Y.), 2017. 19(12): p. 972-981.;;Hideshima, T., et al., Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer, 2007. 7(8): p. 585-98.;;Hjertner, O., et al., Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood, 2001. 97(2): p. 516-22.;;Holien, T., et al., Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia, 2012. 26(5): p. 1073-80.;;Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet. 2001;28(2):184-7.;;Howe J, Roth S, Ringold J, Summers R, Jarvinen H, Sistonen P, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science. 1998;280(5366):1086-8.;;Hsu, D. R., Economides, A. N., Wang, X., Eimon, P. M. & Harland, R. M. (1998), Mol. Cell 1, 673-683. The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities.;;Isella C, Terrasi A, Bellomo SE; Petti C, Galatola G, Muratore A, et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet. 2015;47(4):312-9.;;Irshad S, Bansal M, Guarnieri P, Davis H, Al Haj Zen A, Baran B, et al. Bone morphogenetic protein and Notch signalling crosstalk in poor-prognosis, mesenchymal-subtype colorectal cancer. J Pathol. 2017.;;Jaeger E, Leedham S, Lewis A, Segditsas S, Becker M, Cuadrado PR, et al. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat Genet. 2012;Jan;45(l):2-3.;;Karagiannis, G.S., et al., Bone morphogenetic protein antagonist gremlin-1 regulates colon cancer progression. Biol Chem, 2015. 396(2): p. 163-83.;;Karagiannis, G.S., et al., Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1. Mol Oncol, 2013. 7(4): p. 826-39.;;Kim, M., et al., Gremlin-1 induces BMP-independent tumor cell proliferation, migration, and invasion. Plos One, 2012. 7(4): p. e35100.;;Kim, H.S., et al., GREM1 is expressed in the cancer-associated myofibroblasts of basal cell carcinomas. Plos One, 2017. 12(3): p. e0174565.;;Koketsu, K., et al., Gremlin, a bone morphogenetic protein antagonist, is a crucial angiogenic factor in pituitary adenoma. Int J Endocrinol, 2015. 2015: p. 834137.;;Kyle, R.A. and S.V. Rajkumar, Multiple myeloma. N Engl J Med, 2004. 351(18): p. 1860-73.;;Laurila, R., et al., The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues. Int J Clin Exp Pathol, 2013. 6(7): p. 1400-8.;;Lavoz, C., et al., Gremlin regulates renal inflammation via vascular endothelial growth factor receptor 2 pathway. J Pathol, 2015.;;Lawson, M.A., et al., Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun, 2015. 6: p. 8983.;;Lewis A, Freeman-Mills L, de la Calle-Mustienes E, Giraldez-Perez RM, Davis H, Jaeger E, et al. A polymorphic enhancer near GREM1 influences bowel cancer risk through differential CDX2 and TCF7L2 binding. Cell Rep. 2014;8(4):983-90.;;Mitola S, Ravelli C, Moroni E, Salvi V, Leali D, Ballmer-Hofer K, et al. Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood. 2010;116(18):3677-80.;;Mulvihill, M.S., et al., Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells. Plos One, 2012. 7(8): p. e42264.;;Namkoong, H., et al., The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC Cancer, 2006. 6: p. 74.;;Neufert, C., Becker, C. & Neurath, M. F. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2, 1998-2004, (2007).;;Noll, J., et al., Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica, 2014. 99(1).;;Noll, J.E., et al., PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. J Hematol Oncol, 2015. 8: p. 106.;;Noll, J.E., et al., SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma. Neoplasia, 2014. 16(7): p. 572-85.;;Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating sternness of tumor cells? Cell Stem Cell. 2015;16(3):225-38.;;Ponomarev, V., et al., A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging, 2004. 31(5): p. 740-51.;;Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459(7244):262-5.;;Schmid, G. J., Kobayashi, C., Sandell, L. J. & Ornitz, D. M. (2009), Developmental Dynamics: An Official Publication of the American Association of Anatomists 238, 766-774. Fibroblast growth factor expression during skeletal fracture healing in mice.;;Scoville D, Sato T, He X, Li L. Current view: intestinal stem cells and signaling Gastroenterology. 2008;134(3):849-64.;;Sethi A, Wordinger RJ, Clark AF. Gremlin utilizes canonical and non-canonical TGFbeta signaling to induce lysyl oxidase (LOX) genes in human trabecular meshwork cells. Exp Eye Res. 2013;113:117-27.;;Shoshkes-Carmel, M. et al. Subepithelial telocytes are an important source of Wnts that supports intestinal crypts. Nature 557, 242-246, (2018).;;Sneddon, J.B., et al., Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A, 2006. 103(40): p. 14842-7.;;Tamminen, J.A., et al., Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug. Oncogenesis, 2013. 2: p. e66.;;Tomlinson IP, Carvajal-Carmona LG, Dobbins SE, Tenesa A, Jones AM, Howarth K, et al. Multiple Common Susceptibility Variants near BMP Pathway Loci GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of Colorectal Cancer. PLoS Genet. 2011;7(6):el002105.;;Topol, L.Z., et al., Identification of drm, a novel gene whose expression is suppressed in transformed cells and which can inhibit growth of normal but not transformed cells in culture. Mol Cell Biol, 1997. 17(8): p. 4801-10.;;Vande Broek, I., et al., Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis, 2008. 25(4): p. 325-34.;;Verheyden, J.M. and X. Sun, An Fgf/Gremlin inhibitory feedback loop triggers termination of limb bud outgrowth. Nature, 2008. 454(7204): p. 638-41.;;Wang, D.J., et al., The bone morphogenetic protein antagonist Gremlin is overexpressed in human malignant mesothelioma. Oncology Reports, 2012. 27(1): p. 58-64.;;Worthley, D.L., et al., Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell, 2015. 160(1-2): p. 269-84.;;Yin, Y., et al., Overexpression of Gremlin promotes non-small cell lung cancer progression. Tumour Biol, 2015.;;Yu, Y. Y. et al. (2010), Bone 46, 841-851. Immunolocalization of BMPs, BMP antagonists, receptors, and effectors during fracture repair.",PENDING
808,WO,A1,WO 2023/194583 A1,030-149-763-251-46X,2023-10-12,2023,EP 2023059270 W,2023-04-06,GB 202205203 A,2022-04-08,COMBINATION OF A GREMLIN-1 ANTAGONIST WITH AN INHIBITOR OF RAS-RAF-MEK-ERK SIGNALLING,The invention relates to an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer in combination with an inhibitor of Ras-Raf-MEK-ERK signalling.,UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;JONES PAUL;;VAN DE SANDE BRAM JEROEN;;MORTON JENNIFER PATRICIA,,https://lens.org/030-149-763-251-46X,Patent Application,yes,47,0,2,2,37,A61P35/00;;A61K31/4184;;A61K39/395;;C07K16/22;;C07K2317/24;;A61K45/06;;A61K31/7088;;A61K31/4365;;G01N2800/52;;G01N2333/51;;G01N33/57496,A61K31/4184;;C07K16/22;;A61K39/395;;A61P35/00,,46,31,070-569-467-189-528;;119-090-531-389-092;;017-545-394-154-368;;001-638-134-018-871;;045-330-077-561-450;;070-569-467-189-528;;106-753-778-592-300;;020-026-345-586-213;;087-448-981-335-707;;055-542-669-483-094;;064-741-687-897-846;;035-081-115-342-527;;077-532-829-551-519;;148-647-852-252-502;;025-662-361-226-516;;042-623-879-457-954;;064-667-501-146-970;;030-797-864-869-467;;107-204-146-558-440;;010-655-350-435-62X;;037-436-870-995-452;;113-446-080-346-814;;066-141-497-990-023;;080-856-085-597-555;;056-201-471-905-934;;023-907-179-348-058;;019-779-601-634-917;;045-594-667-407-954;;011-613-768-232-45X;;031-207-171-819-313;;051-621-009-816-906,10.1371/journal.pone.0185687;;pmc5619833;;28957417;;pmc3878225;;24359404;;10.1186/1478-811x-11-97;;pmc7017232;;10.3390/cells9010198;;31941155;;10.1007/s00534-006-1166-5;;17520196;;pmc2666331;;pmc3425446;;10.1158/2159-8290.cd-11-0347;;22628411;;10.1371/journal.pone.0185687;;pmc5619833;;28957417;;1172191;;10.1038/256495a0;;25291284;;10.1016/0167-5699(83)90123-8;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1002/eji.1830240426;;8149964;;10.1016/s0378-1119(96)00627-0;;10.1016/s0065-2776(08)60674-4;;7872158;;10.1038/nbt1142;;16151406;;10.2174/1567269053828800;;10.1016/s0022-1759(98)00077-5;;9760222;;9624683;;10.1038/nbt0698-535;;15848072;;10.1016/j.ymeth.2005.01.003;;10.1016/0021-9673(94)01255-d;;7620566;;10.1016/j.ccr.2005.04.023;;15894267;;10.1385/1-59259-666-5:443;;14970513;;10.1110/ps.9.3.487;;pmc2144561;;10752610;;2406013;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1007/bf00160485;;8483166;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;10.1016/j.semcancer.2019.11.011;;31874279;;30776401;;10.1016/j.bbcan.2019.02.002;;10.1016/j.ctrv.2016.12.001;;28073102;;30272371;;pmc6203161;;10.3892/ijo.2018.4573,"DIÁNA BRAUSWETTER ET AL: ""Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers"", PLOS ONE, vol. 12, no. 9, 28 September 2017 (2017-09-28), pages e0185687, XP055572028, DOI: 10.1371/journal.pone.0185687;;CARL-HENRIK HELDIN: ""Targeting the PDGF signaling pathway in tumor treatment"", CELL COMMUNICATION AND SIGNALING, BIOMED CENTRAL, LONDON, GB, vol. 11, no. 1, 20 December 2013 (2013-12-20), pages 97, XP021171368, ISSN: 1478-811X, DOI: 10.1186/1478-811X-11-97;;DEGIRMENCI UFUK ET AL: ""Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy"", CELLS, vol. 9, no. 1, 13 January 2020 (2020-01-13), pages 198, XP093049226, DOI: 10.3390/cells9010198;;FELDMANN ET AL., J HEPATOBILIARY PANCREAT SURG, vol. 14, no. 3, 2007, pages 224 - 32;;COLLISSON EA ET AL.: ""A central role for RAF—>MEK—>ERK signaling in the genesis of pancreatic ductal adenocarcinoma"", CANCER DISCOV, vol. 2, no. 8, 2012, pages 685 - 93;;BRAUSWETTER ET AL.: ""Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers"", PLOS ONE, vol. 12, no. 9, 2017, pages 0185687, XP055572028, DOI: 10.1371/journal.pone.0185687;;GUINNEY ET AL., NAT MED, 2015;;TOMLINSON ET AL., PLOS GENET, 2011;;""UniProt"", Database accession no. 060565;;""NCBI"", Database accession no. NM_001191322.1;;""Handbook of Experimental Immunology"", vol. 4, 1986, BLACKWELL SCIENTIFIC PUBLISHERS;;KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497;;KOZBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 72;;COLE ET AL.: ""Monoclonal Antibodies and Cancer Therapy"", 1985, ALAN R LISS, INC, pages: 77 - 96;;BABCOOK, J ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, no. 15, 1996, pages 7843 - 78481;;BRINKMAN ET AL., J. IMMUNOL. METHODS, vol. 184, 1995, pages 177 - 186;;KETTLEBOROUGH, EUR. J. IMMUNOL., vol. 24, 1994, pages 952 - 958;;PERSIC ET AL., GENE, vol. 187, 1997, pages 9 - 18;;BURTON, ADVANCES IN IMMUNOLOGY, vol. 57, 1994, pages 191 - 280;;HOLLIGERHUDSON, NATURE BIOTECH, vol. 23, no. 9, 2005, pages 1126 - 1136;;ADAIRLAWSON, DRUG DESIGN REVIEWS - ONLINE, vol. 2, no. 3, 2005, pages 209 - 217;;VERMA ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 216, 1998, pages 165 - 181;;VAUGHAN ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 535 - 539;;KASHMIRI ET AL., METHODS, vol. 36, 2005, pages 25 - 34;;RETTER ET AL., NUCL. ACIDS RES., vol. 33, 2005, pages 671 - 674;;REICHMANN ET AL., NATURE, vol. 332, 1998, pages 323 - 324;;HARRIS, RJ, JOURNAL OF CHROMATOGRAPHY, vol. 705, 1995, pages 129 - 134;;HINGORANI, S.R.L. WANGA.S. MULTANIC. COMBST.B. DERAMAUDTR.H. HRUBAN ET AL.: ""Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice"", CANCER CELL, vol. 7, 2005, pages 469 - 607;;REINEKE, METHODS MOL BIOL, vol. 248, 2004, pages 443 - 63;;TOMER, PROTEIN SCIENCE, vol. 9, 2000, pages 487 - 496;;JUNGHANS ET AL., CANCER RES, vol. 50, 1990, pages 1495 - 1502;;KRINNER ET AL., MOL. IMMUNOL., vol. 44, no. 5, 11 May 2006 (2006-05-11), pages 916 - 25;;DEVEREUX ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 387 - 395;;ALTSCHUL S.F., J MOL EVOL, vol. 36, 1993, pages 290 - 300;;ALTSCHUL, S, F ET AL., J MOL BIOL, vol. 215, 1990, pages 403 - 10;;HENIKOFFHENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 - 10919;;KARLINALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5787;;""Current Protocols in Molecular Biology"", 1995, GREENE PUBLISHING AND WILEY-LNTERSCIENCE;;SAMBROOK ET AL.: ""Molecular Cloning: a laboratory manual"", 2001, COLD SPRING HARBOUR LABORATORY PRESS;;""Remington's Pharmaceutical Sciences"", 2000, LIPPINCOTT, WILLIAMS & WILKINS;;VAN CUTSEM, ANNALS OF ONCOLOGY, vol. 25, 2014;;""Uniprot"", Database accession no. O60565;;KOBAYASHI, YS. O. LIMH. YAMAGUCHI: ""Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer"", SEMIN CANCER BIOL, vol. 65, 2020, pages 51 - 64, XP086230337, DOI: 10.1016/j.semcancer.2019.11.011;;KOZAR, IC. MARGUES. ROTHENGATTER ET AL.: ""Many ways to resistance: How melanoma cells evade targeted therapies"", BIOCHIM BIOPHYS ACTA REV CANCER, vol. 1871, no. 2, 2019, pages 313 - 322, XP085692942, DOI: 10.1016/j.bbcan.2019.02.002;;MARTINELLI, EF. MORGILLOT. TROIANI ET AL.: ""Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK"", CANCER TREAT REV, vol. 53, 2017, pages 61 - 69, XP029903741, DOI: 10.1016/j.ctrv.2016.12.001;;YU, YL. CHENGB. YAN ET AL.: ""Overexpression of Gremlin 1 by sonic hedgehog signaling promotes pancreatic cancer progression"", INT J ONCOL, vol. 53, no. 6, 2018, pages 2445 - 2457",PENDING
809,CL,A1,CL 2020003249 A1,043-572-637-244-947,2021-07-09,2021,CL 2020003249 A,2020-12-15,GB 201809946 A;;GB 201815694 A,2018-06-18,Antagonista gremlin-1 para la prevención y tratamiento del cáncer,La invención se refiere a un antagonista anti-GREM1 para su uso en un método para el tratamiento o la prevención de un cáncer.,UCB BIOPHARMA SRL;;UNIV OXFORD INNOVATION LTD;;UNIV ADELAIDE,DAVIES GARETH CHARLES GLYNDWR;;LEEDHAM SIMON;;ZANNETTINO ANDREW;;CLARK KIMBERLEY;;HEWETT DUNCAN;;PANAGOPOULOS VASILIOS,,https://lens.org/043-572-637-244-947,Patent Application,no,0,0,14,17,0,C07K16/18;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K16/18;;A61P35/00;;C12Q1/6886;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12Q2600/158;;C12Q2600/118;;C12Q2600/106;;A61P35/00;;A61K45/06;;A61K2039/505;;C07K16/24;;C07K16/2803;;C07K16/2896;;G01N33/5748;;G01N2800/52,A61K39/395;;A61P35/00,,0,0,,,,PENDING
810,BR,A2,BR 112020025661 A2,067-578-159-233-466,2021-03-23,2021,BR 112020025661 A,2019-06-18,GB 2019051699 W;;GB 201809946 A;;GB 201815694 A,2018-06-18,"antagonista anti-grem1, agente anticâncer, métodos de tratamento de um câncer e de prognosticar um câncer, composição ou kit, métodos para a detecção de câncer, para determinar se um paciente com ou com suspeita de ter ou com risco de desenvolver câncer é ou não susceptível de responder ao tratamento com um agente quimioterápico, e para determinar se um paciente com ou com suspeita de ter ou com risco de desenvolver câncer tem probabilidade de responder ao tratamento com um antagonista de grem1","antagonista anti-grem1, agente anticâncer, métodos de tratamento de um câncer e de prognosticar um câncer, composição ou kit, métodos para a detecção de câncer, para determinar se um paciente com ou com suspeita de ter ou com risco de desenvolver câncer é ou não susceptível de responder ao tratamento com um agente quimioterápico, e para determinar se um paciente com ou com suspeita de ter ou com risco de desenvolver câncer tem probabilidade de responder ao tratamento com um antagonista de grem1. a invenção refere-se a um antagonista anti-grem1 para uso em um método para o tratamento ou prevenção de um câncer.",UNIV OXFORD INNOVATION LTD;;UNIV ADELAIDE;;UCB BIOPHARMA SRL,ANDREW ZANNETTINO;;DUNCAN HEWETT;;GARETH CHARLES GLYNDWR DAVIES;;KIMBERLEY CLARK;;SIMON LEEDHAM;;VASILIOS PANAGOPOULOS,,https://lens.org/067-578-159-233-466,Patent Application,no,0,0,14,17,0,C07K16/18;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K16/18;;A61P35/00;;C12Q1/6886;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12Q2600/158;;C12Q2600/118;;C12Q2600/106;;A61P35/00;;A61K45/06;;A61K2039/505;;C07K16/24;;C07K16/2803;;C07K16/2896;;G01N33/5748;;G01N2800/52,A61K39/395;;A61P35/00,,0,0,,,,PENDING
811,CN,B,CN 101679410 B,072-169-372-428-450,2013-11-27,2013,CN 200780050132 A,2007-11-21,GB 2007004449 W;;GB 0623209 A,2006-11-21,2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents,,F2G LTD,DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;PAYNE LLOYD JAMES;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/072-169-372-428-450,Granted Patent,no,0,0,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/90;;A61K31/437;;A61P33/00,,0,0,,,,ACTIVE
812,CA,C,CA 2687790 C,096-663-533-639-991,2014-11-18,2014,CA 2687790 A,2008-05-21,GB 0710121 A;;GB 2008001738 W,2007-05-25,ANTIFUNGAL AGENTS,"The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically accept-able salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/096-663-533-639-991,Granted Patent,no,0,0,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A61K31/437;;A61P31/10,,0,0,,,,ACTIVE
813,CN,A,CN 116390692 A,160-995-994-486-107,2023-07-04,2023,CN 202180070279 A,2021-10-15,US 202063091997 P;;IB 2021059484 W,2020-10-15,Electrosurgical device with automatic severing,A puncture device configured to create a puncture in tissue includes an elongate member including a proximal end portion defining a longitudinal axis along a length of the elongate member. The elongate member also includes a flexible distal portion that bends away from the longitudinal axis and a distal tip configured to deliver energy to tissue. A sensing element placed on the flexible distal end portion of the elongate member detects curvature of the distal end portion such that energy is delivered to the distal tip when the flexible distal end portion of the elongate member is straightened and energy is not delivered to the distal tip when the flexible distal end portion of the elongate member bends.,BOSTON SCIENT SCIMED INC,MO DANIEL YONGHUI;;DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;DICICCO MATTHEW,,https://lens.org/160-995-994-486-107,Patent Application,no,0,0,5,5,0,A61B2034/2061;;A61B2018/00875;;A61B18/1482;;A61B18/1492;;A61B2090/064;;A61B18/1492;;A61B2018/00077;;A61B2018/00083;;A61B2018/00357;;A61B2018/00625;;A61B2018/00708;;A61B2018/00773;;A61B2018/144,A61B18/12,,0,0,,,,PENDING
814,AU,A1,AU 2019/289176 A1,119-605-388-079-357,2020-12-24,2020,AU 2019/289176 A,2019-06-18,GB 201815694 A;;GB 201809946 A;;GB 2019051699 W,2018-06-18,Gremlin-1 antagonist for the prevention and treatment of cancer,The invention relates to an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer.,UNIV OXFORD INNOVATION LTD;;UNIV ADELAIDE;;UCB BIOPHARMA SRL,DAVIES GARETH CHARLES GLYNDWR;;LEEDHAM SIMON;;ZANNETTINO ANDREW;;CLARK KIMBERLEY;;HEWETT DUNCAN;;PANAGOPOULOS VASILIOS,,https://lens.org/119-605-388-079-357,Patent Application,no,0,0,14,17,0,C07K16/18;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C07K16/18;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;C07K16/18;;A61P35/00;;C12Q1/6886;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/55;;C07K2317/622;;C07K2317/76;;C07K2317/92;;A61K2039/505;;C12Q2600/158;;C12Q2600/118;;C12Q2600/106;;A61P35/00;;A61K45/06;;A61K2039/505;;C07K16/24;;C07K16/2803;;C07K16/2896;;G01N33/5748;;G01N2800/52,A61K39/395;;A61P35/00,,0,0,,,,PENDING
815,CA,A1,CA 2687790 A1,114-839-142-680-628,2008-12-04,2008,CA 2687790 A,2008-05-21,GB 0710121 A;;GB 2008001738 W,2007-05-25,ANTIFUNGAL AGENTS,"The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: Rl, R2, R3, R4, R5, R6, R 7, R8, A1, L1 and n are as defined herein. These compounds and their pharmac eutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agric ultural fungicides.",F2G LTD,PAYNE LLOYD JAMES;;DAVIES GARETH MORSE;;DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;EDWARDS PHILIP,,https://lens.org/114-839-142-680-628,Patent Application,no,0,3,21,21,0,C07D471/04;;A61P11/00;;A61P11/06;;A61P31/10;;C07D471/04;;A01N43/40;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/40;;A61K31/437;;A61P31/10,,0,0,,,,ACTIVE
816,EP,A2,EP 4198286 A2,132-689-017-593-148,2023-06-21,2023,EP 22208025 A,2022-11-17,GB 202118044 A,2021-12-14,RESTARTING A GAS TURBINE ENGINE,"Aircraft power and propulsion systems 100, aircraft 1 comprising such power and propulsion systems 100, and methods of restarting a gas turbine engine 110 of such power and propulsion systems 100 during flight are provided. One such aircraft power and propulsion system 100 comprises: a propulsive gas turbine engine 110 comprising a plurality of spools 14, 19, 26; 15, 17, 27, combustion equipment 16, one or more electric machines 111, 112 mechanically coupled with one or more of the spools 14, 19, 26; 15, 17, 27, and an electrically-powered fuel pump 115 for delivering fuel to the combustion equipment 16; an electrical system 120 connected with the one or more electric machines 111, 112 and the electrically-powered fuel pump 115, the electrical system comprising an energy storage system 130; and a control system 140 configured to: responsive to a determination to the effect that a flame in the combustion equipment 16 has been extinguished, control the electrical system 120 to supply electrical power from the energy storage system 130 to the fuel pump 115 during an engine restart attempt.
",ROLLS ROYCE PLC,MOORE GARETH;;DAVIES PAUL;;HUSBAND STEPHEN;;TRAINER DAVID;;SCOTHERN DAVID;;GEORGE LUKE;;HERBERT DOUGLAS,,https://lens.org/132-689-017-593-148,Patent Application,yes,0,0,5,5,0,F02C7/262;;F02C6/14;;F02K5/00;;F05D2220/76;;F02C9/46;;Y02T50/60;;F02C7/262;;B64D37/32;;F02C9/46;;F01D15/10;;F02C7/32,F02C7/262;;F02K5/00,,0,0,,,,PENDING
817,EP,A1,EP 2097413 A1,198-922-831-267-921,2009-09-09,2009,EP 07824661 A,2007-11-21,GB 2007004449 W;;GB 0623209 A,2006-11-21,2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS,,F2G LTD,DOWNHAM ROBERT;;SIBLEY GRAHAM EDWARD MORRIS;;PAYNE LLOYD JAMES;;EDWARDS PHILIP;;DAVIES GARETH MORSE,,https://lens.org/198-922-831-267-921,Patent Application,yes,0,0,21,21,0,C07D471/04;;A61P1/02;;A61P11/00;;A61P11/06;;A61P17/00;;A61P27/16;;A61P31/10;;A61P33/00;;A61P37/08;;A61P3/10;;C07D471/04;;A01N43/90;;A61K31/437;;C07D471/04,C07D471/04;;A01N43/90;;A61K31/437;;A61P33/00,,0,0,,,,ACTIVE
818,US,A1,US 2011/0152285 A1,161-258-948-766-948,2011-06-23,2011,US 98941009 A,2009-04-23,GB 0807532 A;;GB 0819696 A;;GB 2009001058 W,2008-04-24,PYRROLE ANTIFUNGAL AGENTS,"The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE;;DAVIES PATRICIA SULING,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE;;DAVIES PATRICIA SULING,F2G LTD (2010-10-12),https://lens.org/161-258-948-766-948,Patent Application,yes,15,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,A61K31/497;;A61P31/10;;C07D409/14,514/253.01;;544/364,4,3,168-449-788-313-849;;073-424-137-358-597;;101-312-400-123-101,10.1016/s0040-4020(01)00525-7;;10.1016/s0223-5234(98)80009-3;;9880479;;pmc88911;;10.1128/cmr.12.1.147,"Yavari et al. (Tetrahedron (2001), 57(27), 5873-5878).;;Dumoulin et al. (European Journal of Medicinal Chemistry (1998), 33(3), 201-207);;McDonnell et al. (Clinical Microbiology Reviews, Jan. 1999, p. 147-179; Vol. 12, Issue 1;;http://www.merckmillipore.com/chemicals/diethyl-ether/MDA_CHEM-100926/p_NgGb.s1Lay4AAAEW8uEfVhTl- (2012)",ACTIVE
819,CN,A,CN 101432287 A,114-668-417-697-67X,2009-05-13,2009,CN 200780015649 A,2007-03-09,GB 0604944 A,2006-03-11,Pyrrolopyrimidine derivatives used as HSP90 inhibitors,"Compounds of formula (I) have HSP90 inhibitory activity and are therefore useful in the treatment of, inter alia, cancer: Formula (I) wherein Ri is hydrogen, fluoro, chloro, bromo, or a radical of formula -X-Alk<1>-(Z)m-(Alk<2>)n-Q wherein X is -O-, -S- -S(O)-, -SO2-, or -NH-, Z is -O-, -S-, -(C=O)-, -(C=S)-, -S(O)-, -SO2-, -NR<A>-, or, in either orientation -C(=O)O-, -C(=O)NR<A>- , -C(=S)NR<A>-, -SO2NR<A>-, -NR<A>C(=O)-, or -NR<A>SO2- wherein R<A> is hydrogen or C1-C6 alkyl AIk<1> and AIk<2> are optionally substituted divalent C1-C3 alkylene or C2-C3 alkenylene radicals, m, n and p are independently 0 or 1 , and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is a radical of formula -(Ar<1>)p-(Alk<1>)q-(Z)r-(Alk<2>)s-Q wherein Ar<1> is an optionally substituted aryl or heteroaryl radical, Alk<1>, Alk<2>, Z, and Q are as defined above, and p, q, r and s are independently 0 or 1 ; and R3 is cyano (-CN), fluoro, chloro, bromo, methyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, ethyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, cyclopropyl, -OH, -CH2OH, -C(O)NH2, -C(O)CH3, Or -NH2.",VERNALIS R&D LTD,ANDREW BROUGH PAUL;;JAMES DRYSDALE MARTIN;;MORSE DAVIES NICHOLAS GARETH;;NOEL FOLOPPE NICOLAS;;STEPHAN STOKES,,https://lens.org/114-668-417-697-67X,Patent Application,no,0,3,3,16,0,,C07D487/04;;A61K31/517;;A61P35/00,,0,0,,,,DISCONTINUED
820,US,A1,US 2015/0231366 A1,144-613-977-909-941,2015-08-20,2015,US 201314409662 A,2013-06-18,US 201314409662 A;;US 201261661664 P;;IB 2013055013 W,2012-06-19,Steerable Medical Device Handle,"A control system and method are provided for control of a steerable catheter, the catheter including at least two control wires, a distal end of each of the control wires being coupled to the catheter at a distal region thereof, the control system comprising: a housing coupled to the catheter; a slide assembly positioned within the housing and operable to translate linearly therein; a proximal portion of each of the at least two control wires being positioned through the slide assembly; and a control knob rotatably coupled to the housing for linearly translating the slide assembly, thereby enabling the slide assembly to separately manipulate each of said at least two control wires to effect a change in a deflection of said catheter. Rotation of the control knob in a first rotational direction causes distal movement of the slide assembly in a first linear direction causing the slide assembly to tension one of said at least two control wires thereby effecting a change in the deflection of said catheter in a first deflection direction and wherein rotation of the knob in a second rotational direction causes proximal movement of the slide assembly in a second linear direction causing the slide assembly to tension the other of said at least two control wires thereby effecting a change in the deflection of said catheter in a second deflection direction.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;THOMPSON MELANIE;;GORAPALLI DEEPTHI;;COPELAND STEVE;;DICKIE ROBERT G;;LEFLER AMY;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2014-12-11);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/144-613-977-909-941,Patent Application,yes,6,24,16,16,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/01,,0,0,,,,ACTIVE
821,US,A1,US 2020/0324082 A1,174-342-852-266-782,2020-10-15,2020,US 202016848926 A,2020-04-15,US 202016848926 A;;US 201615106584 A;;IB 2014067173 W;;US 201361918800 P;;US 201361918848 P,2013-12-20,Steerable Medical Device Handle,"Embodiments of a steerable catheter control system and methods are disclosed. The steerable catheter control system comprises a housing which defines an inner housing and a slide assembly which linearly translates within the inner housing. At least two control wires are positioned through the slide assembly wherein one of the at least two controls wires are indirectly coupled to the slide assembly via the direction reversing element. The steerable catheter control system further comprises a slack limiting element, coupled to at least one of the at least two control wires. The slack limiting element allows for frictional engagement of the control wire to limit slack. The control system includes a control knob for linearly translating the slide assembly, enabling the slide assembly to manipulate the control wires which causes a change in deflection of the steerable catheter.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;THOMPSON SMITH MELANIE;;GORAPALLI DEEPTHI;;COPELAND STEVE;;DICKIE ROBERT;;LEFLER AMY;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2016-06-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/174-342-852-266-782,Patent Application,yes,1,0,6,6,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/01,,0,0,,,,ACTIVE
822,EP,B1,EP 2007767 B1,194-085-298-841-508,2011-11-02,2011,EP 07712872 A,2007-03-09,GB 2007000831 W;;GB 0604944 A;;GB 0617789 A,2006-03-11,PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS,,VERNALIS R&D LTD,BROUGH PAUL ANDREW;;DRYSDALE MARTIN JAMES;;DAVIES NICHOLAS GARETH MORSE;;FOLOPPE NICOLAS NOEL;;STOKES STEPHAN,VERNALIS (R&D) LTD (2011-06-01),https://lens.org/194-085-298-841-508,Granted Patent,yes,3,0,12,16,0,C07D487/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P31/12;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D487/04;;A61K31/517;;C07D487/04,C07D487/04;;A61K31/517;;A61P35/00,,1,0,,,"SEELA F ET AL: ""RIBOSIDIERUNG VON PYRROLO2,3-CPYRIMIDINEN IN GEGENWART STARKER BASEN RIBOSIDATION OF PYRROLO2,3-DPYRIMIDINES IN THE PRESENCE OF STRONGBASES"" CHEMISCHE BERICHTE, VERLAG CHEMIE GMBH. WEINHEIM, DE, vol. 113, no. 8, 1980, pages 2808-2813, XP000995468 ISSN: 0009-2940",ACTIVE
823,WO,A3,WO 2013/190475 A3,052-232-765-720-237,2014-03-13,2014,IB 2013055013 W,2013-06-18,US 201261661664 P,2012-06-19,STEERABLE MEDICAL DEVICE HANDLE,"A control system and method are provided for control of a steerable catheter, the catheter including at least two control wires, a distal end of each of the control wires being coupled to the catheter at a distal region thereof, the control system comprising: a housing coupled to the catheter; a slide assembly positioned within the housing and operable to translate linearly therein; a proximal portion of each of the at least two control wires being positioned through the slide assembly; and a control knob rotatably coupled to the housing for linearly translating the slide assembly, thereby enabling the slide assembly to separately manipulate each of said at least two control wires to effect a change in a deflection of said catheter. Rotation of the control knob in a first rotational direction causes distal movement of the slide assembly in a first linear direction causing the slide assembly to tension one of said at least two control wires thereby effecting a change in the deflection of said catheter in a first deflection direction and wherein rotation of the knob in a second rotational direction causes proximal movement of the slide assembly in a second linear direction causing the slide assembly to tension the other of said at least two control wires thereby effecting a change in the deflection of said catheter in a second deflection direction.",BAYLIS MEDICAL CO INC;;DAVIES GARETH,DAVIES GARETH;;THOMPSON MELANIE;;GORAPALLI DEEPTHI;;COPELAND STEVE;;DICKIE ROBERT G;;LEFLER AMY;;BECA BOGDAN,,https://lens.org/052-232-765-720-237,Search Report,yes,8,0,16,16,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/01,,0,0,,,,PENDING
824,EP,A1,EP 4236848 A1,131-834-139-461-970,2023-09-06,2023,EP 21885461 A,2021-10-25,US 202063105975 P;;IB 2021059823 W,2020-10-27,ELECTROSURGICAL DEVICE WITH SENSING,,BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;DICICCO MATTHEW;;MOK DANIEL WING FAI,,https://lens.org/131-834-139-461-970,Patent Application,yes,0,0,5,5,0,A61B2018/00351;;A61B2018/0038;;A61B2018/00601;;A61B2018/00875;;A61B2018/00827;;A61B18/1477;;A61B18/1492;;A61B2218/002;;A61B2018/00702;;A61B2090/065;;A61B17/3478;;A61B18/1233;;A61B18/1492;;A61B2017/00247;;A61B2018/00083;;A61B2018/0038;;A61B2018/00642;;A61B2018/00708;;A61B2018/00833;;A61B2018/00875,A61B18/14;;A61B18/00;;A61B18/12,,0,0,,,,PENDING
825,CN,A,CN 116528784 A,004-952-564-209-760,2023-08-01,2023,CN 202180080032 A,2021-10-25,US 202063105975 P;;IB 2021059823 W,2020-10-27,Electrosurgical device with sensing,"A system includes a generator capable of supplying energy and a current of a known voltage to a punctured tissue, where the current of the known voltage is capable of passing through the tissue without damaging the tissue. The system also includes a piercing device including an elongate member. The distal tip of the elongate member includes an energy delivery device and two electrodes, the energy delivery device configured to deliver energy for puncturing, and two electrodes configured to deliver a current of a known voltage from one electrode to the other through a material in contact with the distal tip. The system also includes a sensor capable of detecting a current value between the two electrodes. The generator includes a generator switch for disabling the energy delivery tip based on the current value detected by the sensor.",BOSTON SCIENT SCIMED EQUIPMENT INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;DICICCO MATTHEW;;MO DANIEL WING FAI,,https://lens.org/004-952-564-209-760,Patent Application,no,0,0,5,5,0,A61B2018/00351;;A61B2018/0038;;A61B2018/00601;;A61B2018/00875;;A61B2018/00827;;A61B18/1477;;A61B18/1492;;A61B2218/002;;A61B2018/00702;;A61B2090/065;;A61B17/3478;;A61B18/1233;;A61B18/1492;;A61B2017/00247;;A61B2018/00083;;A61B2018/0038;;A61B2018/00642;;A61B2018/00708;;A61B2018/00833;;A61B2018/00875,A61B18/12,,0,0,,,,PENDING
826,JP,A,JP 2023145712 A,117-506-753-664-874,2023-10-11,2023,JP 2023127097 A,2023-08-03,JP 2021176101 A;;US 201261661664 P;;JP 2018172033 A;;JP 2015517905 A,2012-06-19,STEERABLE MEDICAL DEVICE HANDLE,"To provide a control system that enables steering of a medical device inside a body.SOLUTION: A catheter includes at least two control wires. Each control wire has a tip connected to the catheter in a tip area thereof. A control system includes: a housing coupled to the catheter; a slide assembly positioned within the housing and operable to translate linearly in the housing; a base end part of each of the at least two control wires positioned within the slide assembly; and a control knob rotatably coupled to the housing for linearly translating the slide assembly, thereby enabling the slide assembly to individually manipulate each of the at least two control wires, effecting a change in deflection of the catheter.SELECTED DRAWING: Figure 1",BOSTON SCIENT MEDICAL DEVICE LTD,GARETH DAVIES;;MELANIE THOMPSON;;DEEPTHI GORAPALLI;;STEVE COPELAND;;ROBERT G DICKIE;;AMY LEFLER;;BOGDAN BECA,,https://lens.org/117-506-753-664-874,Patent Application,no,0,0,16,16,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/092,,0,0,,,,PENDING
827,CA,A1,CA 2645343 A1,177-075-371-324-537,2007-09-20,2007,CA 2645343 A,2007-03-09,GB 0604944 A;;GB 0617789 A;;GB 2007000831 W,2006-03-11,PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS,,VERNALIS R&D LTD,BROUGH PAUL ANDREW;;FOLOPPE NICOLAS NOEL;;STOKES STEPHAN;;DRYSDALE MARTIN JAMES;;DAVIES NICHOLAS GARETH MORSE,,https://lens.org/177-075-371-324-537,Patent Application,no,0,0,12,16,0,C07D487/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P31/12;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D487/04;;A61K31/517;;C07D487/04,C07D487/04;;A61K31/517;;A61P35/00,,0,0,,,,DISCONTINUED
828,US,A1,US 2016/0374751 A1,003-193-593-615-505,2016-12-29,2016,US 201615262715 A,2016-09-12,US 201615262715 A;;IB 2014064600 W;;IB 2014059641 W;;US 201514850545 A;;US 201361787617 P,2013-03-15,Electrosurgical Device having a distal aperture,"A method and apparatus are disclosed for providing forward fluid delivery through an electrosurgical device, while avoiding coring when energy is delivered to the electrosurgical device. The device has a distal face defining an opening, with the distal face including at least one cutting portion and at least one non-cutting portion. An embodiment of the electrosurgical device for puncturing tissue includes an elongate member defining a lumen for receiving a fluid; a distal face defining at least one aperture; and the distal face including at least one cutting portion and at least one non-cutting portion cooperating to produce an elongated cut in a tissue when electrical energy is delivered to the distal face while avoiding coring of the tissue.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD;;UHM YUN;;LEUNG LINUS;;ALLEY FERRYL,BAYLIS MEDICAL COMPANY INC (2016-09-12);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/003-193-593-615-505,Patent Application,yes,24,5,3,36,0,A61B2018/00297;;A61B2018/1427;;A61B2018/1497;;A61B2218/002;;A61B2090/3966;;A61B2018/1412;;A61B2018/1467;;A61B18/1477;;A61B2018/00601;;A61B2018/00351;;A61B2018/00083;;A61B2018/00077;;A61B18/1477;;A61B2018/00601;;A61B2018/00351;;A61B2018/00083;;A61B2018/00077;;A61B2090/3966;;A61B2018/00297;;A61B2018/1497;;A61B2090/392;;A61B2018/1427;;A61B2018/1412;;A61B2018/1467;;A61B2218/002,A61B18/14,,1,0,,,wo2010135793a1,ACTIVE
829,BR,A2,BR 112014031843 A2,047-818-490-803-793,2021-05-25,2021,BR 112014031843 A,2013-06-18,IB 2013055013 W;;US 201261661664 P,2012-06-19,cabo de dispositivo médico orientável,"sistema e dispositivo de controle de um cateter orientável, dispositivo de cateter orientável e método de utilização do dito sistema de controle. são providos um sistema e método de controle (40,42) para controlar um cateter (90) orientável, o cateter (90) incluindo pelo menos dois fios de controle, uma extremidade distal de cada um dos fios de controle (40,42) sendo acoplada ao cateter (90) em uma região distal deste, o sistema de controle (100) compreendendo: um alojamento (20) acoplado ao cateter; uma montagem deslizante (30) posicionada no interior do alojamento (20) e operável para se deslocar linearmente em seu interior; uma parte proximal de cada um dos pelo menos dois fios de controle (40,42) sendo posicionada através da montagem deslizante (30); e um botão (10) de controle acoplado de forma rotativa ao alojamento (20) para deslocar linearmente a montagem deslizante, possibilitando assim que a montagem deslizante (30) manipule separadamente cada um dos ditos pelo menos dois fios de controle (40,42) para efetuar uma alteração em uma deflexão do dito cateter. a rotação do botão (10) de controle em uma primeira direção de rotação provoca o deslocamento distal da montagem deslizante (30) em uma primeira direção linear fazendo com que a montagem deslizante (30) aplique uma tensão em um dos ditos pelo menos dois fios de controle (40,42) efetuando assim uma alteração na deflexão do dito cateter (90) em uma primeira direção de deflexão e onde a rotação do botão (10) em uma segunda direção de rotação provoca o deslocamento proximal da montagem deslizante (30) em uma segunda direção linear fazendo com que a montagem deslizante (30) aplique uma tensão no outro dos ditos pelo menos dois fios de controle (40,42) efetuando assim uma alteração na deflexão do dito cateter (90) em uma segunda direção de deflexão.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;THOMPSON MELANIE;;GORAPALLI DEEPTHI;;COPELAND STEVE;;DICKIE ROBERT G;;LEFLER AMY;;BECA BOGDAN,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (IE) (2023-06-06),https://lens.org/047-818-490-803-793,Patent Application,no,0,0,16,16,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/01,,0,0,,,,ACTIVE
830,US,B2,US 11020173 B2,043-363-798-532-164,2021-06-01,2021,US 201615262715 A,2016-09-12,US 201615262715 A;;IB 2014064600 W;;IB 2014059641 W;;US 201514850545 A;;US 201361787617 P,2013-03-15,Electrosurgical device having a distal aperture,"A method and apparatus are disclosed for providing forward fluid delivery through an electrosurgical device, while avoiding coring when energy is delivered to the electrosurgical device. The device has a distal face defining an opening, with the distal face including at least one cutting portion and at least one non-cutting portion. An embodiment of the electrosurgical device for puncturing tissue includes an elongate member defining a lumen for receiving a fluid; a distal face defining at least one aperture; and the distal face including at least one cutting portion and at least one non-cutting portion cooperating to produce an elongated cut in a tissue when electrical energy is delivered to the distal face while avoiding coring of the tissue.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD;;UHM YUN;;LEUNG LINUS;;ALLEY FERRYL,BAYLIS MEDICAL COMPANY INC (2016-09-12);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/043-363-798-532-164,Granted Patent,yes,32,2,3,36,0,A61B2018/00297;;A61B2018/1427;;A61B2018/1497;;A61B2218/002;;A61B2090/3966;;A61B2018/1412;;A61B2018/1467;;A61B18/1477;;A61B2018/00601;;A61B2018/00351;;A61B2018/00083;;A61B2018/00077;;A61B18/1477;;A61B2018/00601;;A61B2018/00351;;A61B2018/00083;;A61B2018/00077;;A61B2090/3966;;A61B2018/00297;;A61B2018/1497;;A61B2090/392;;A61B2018/1427;;A61B2018/1412;;A61B2018/1467;;A61B2218/002,A61B18/14;;A61B18/00;;A61B90/00,,14,0,,,"International Search Report of International Application No. PCT/IB2014/064600 dated Dec. 31, 2014.;;Patent Cooperation Treaty, International Search Report and Written Opinion of the International Search Authority for International Application No. PCT/IB2014/064600, dated Dec. 31, 2014.;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2014/064600, dated Sep. 13, 2016.;;Patent Cooperation Treaty, International Search Report and Written Opinion of the International Search Authority for International Application No. PCT/IB2014/059641, dated Jun. 27, 2014.;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2014/059641, dated Sep. 15, 2015.;;Japanese Office Action for counterpart Japanese Application No. 2015-562485, dated Jan. 23, 2018.;;European Patent Office, Communication pursuant to Rules 161(2) and 162 EPC, for counterpart European Application No. 147885380.7, dated Oct. 25, 2016.;;Applicant's Reply to Communication pursuant to Rules 161 and 162 for counterpart European Application No. 147885380.7, dated Apr. 30, 2017.;;European Patent Office, Communication pursuant to Rule 70(2) and 70a(2) EPC for counterpart European Application No. 14763885.2, dated Oct. 27, 2016.;;Applicant's Reply to Communication pursuant to Rule 70 EPC for counterpart European Application No. 14763885.2, dated May 8, 2017.;;European Patent Office, Communication pursuant to Rules 161(2) and 162 EPC, for counterpart European Application No. 14763885.2, dated Oct. 22, 2015.;;Applicant's Reply to Communication pursuant to Rules 161 and 162 for counterpart European Application No. 14763885.2, dated Apr. 21, 2016.;;Supplementary European Search Report for European Application No. 14763885.2, dated Sep. 28, 2016.;;Supplementary European Search Report for European Application No. 14885380.7, dated Oct. 18, 2017.",ACTIVE
831,US,A1,US 2023/0218862 A1,009-704-774-286-149,2023-07-13,2023,US 202318164042 A,2023-02-03,US 202318164042 A;;US 202016848926 A;;US 201615106584 A;;IB 2014067173 W;;US 201361918800 P;;US 201361918848 P,2013-12-20,Steerable Medical Device Handle,"A steerable catheter control handle and method are provided for bi-directional control of a steerable catheter, the catheter including at least two control wires, a distal end of each of the control wires being coupled to the catheter at a distal region thereof. The control system comprises a housing. A wire actuation mechanism is disposed within the housing and is operably coupled to at least two control wires for enabling actuation of the at least two control wires. The steerable catheter control handle additionally comprises a proximal control knob that is operably coupled to the wire actuation mechanism to enable actuation of the at least two control wires for causing a distal end deflection of the steerable catheter.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;THOMPSON SMITH MELANIE;;GORAPALLI DEEPTHI;;COPELAND STEVE;;DICKIE ROBERT;;LEFLER AMY;;BECA BOGDAN,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2016-02-21),https://lens.org/009-704-774-286-149,Patent Application,yes,0,0,6,6,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/01,,0,0,,,,PENDING
832,US,A1,US 2023/0172594 A1,134-110-318-313-872,2023-06-08,2023,US 202318154183 A,2023-01-13,US 202318154183 A;;IB 2021056256 W;;US 202063051106 P,2020-07-13,PUNCTURING DEVICE COMPRISING A DISTAL BALLOON FEATURE,A method and apparatus are disclosed for a device for creating a puncture in a tissue. The puncturing device comprising an elongate member having a puncturing portion at the distal tip. The puncturing device further includes at least one inflatable feature positioned around the outer circumference and at a distal portion of the elongate member. The puncturing device includes a lumen extending from a proximal end of the elongate member to the inflatable feature. The inflatable feature is in a fluid communication with the lumen and can be inflated to dilate the puncture in the tissue or anchor the puncturing device in a heart structure.,BOSTON SCIENT MEDICAL DEVICE LIMITED,DICICCO MATTHEW;;DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;MOK DANIEL WING FAI,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2023-01-09),https://lens.org/134-110-318-313-872,Patent Application,yes,0,0,4,4,0,A61B18/1492;;A61B2017/00247;;A61B2018/00285;;A61B2018/00357;;A61B2018/00601;;A61B2090/3966;;A61M2025/1079;;A61M25/04;;A61M2025/1004;;A61B90/39;;A61B2090/3966;;A61B17/00234;;A61B2017/00247,A61B17/00;;A61B90/00,,0,0,,,,PENDING
833,US,A1,US 2017/0071667 A1,177-331-818-078-249,2017-03-16,2017,US 201615359881 A,2016-11-23,US 201615359881 A;;US 92629210 A;;US 62740607 A;;US 74318106 P;;US 82745806 P,2006-01-27,Electrosurgical Device for Creating a Channel through a Region of Tissue and Methods of Use thereof,"A method and apparatus are disclosed for an RF guidewire for applying RF energy to create a channel through a region of tissue within a patient's body. The RF guidewire is configured to have a hydrophilic coating disposed thereon to reduce friction to facilitate traversal through vasculature while maintaining its mechanical, electrical and thermal properties.",BAYLIS MEDICAL CO INC,LEUNG LINUS HOI CHE;;SAMIEE-ZAFARGHANDY MAHBAN;;JUZKIW TARAS;;DAVIES GARETH;;LUK MARIA;;ALBERT KELLY,BAYLIS MEDICAL COMPANY INC (2016-11-22);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/177-331-818-078-249,Patent Application,yes,7,6,2,113,0,A61B2017/00867;;C08L2201/12;;A61B18/1492;;A61B90/39;;A61B2018/00136;;A61B2018/00083;;A61B2018/00101;;A61B2018/0041;;A61B2018/1213;;C08L2203/206;;A61B2090/3966;;A61B18/1492;;A61B90/39;;A61B2018/00601;;A61B2018/00136;;A61B2018/00083;;A61B2018/00101;;A61B2018/0041;;A61B18/1206;;A61B2018/1213;;A61B2090/3966,A61B18/14;;A61B90/00,,0,0,,,,ACTIVE
834,WO,A2,WO 2013/190475 A2,187-388-223-452-705,2013-12-27,2013,IB 2013055013 W,2013-06-18,US 201261661664 P,2012-06-19,STEERABLE MEDICAL DEVICE HANDLE,"A control system and method are provided for control of a steerable catheter, the catheter including at least two control wires, a distal end of each of the control wires being coupled to the catheter at a distal region thereof, the control system comprising: a housing coupled to the catheter; a slide assembly positioned within the housing and operable to translate linearly therein; a proximal portion of each of the at least two control wires being positioned through the slide assembly; and a control knob rotatably coupled to the housing for linearly translating the slide assembly, thereby enabling the slide assembly to separately manipulate each of said at least two control wires to effect a change in a deflection of said catheter. Rotation of the control knob in a first rotational direction causes distal movement of the slide assembly in a first linear direction causing the slide assembly to tension one of said at least two control wires thereby effecting a change in the deflection of said catheter in a first deflection direction and wherein rotation of the knob in a second rotational direction causes proximal movement of the slide assembly in a second linear direction causing the slide assembly to tension the other of said at least two control wires thereby effecting a change in the deflection of said catheter in a second deflection direction.",BAYLIS MEDICAL CO INC;;DAVIES GARETH,DAVIES GARETH;;THOMPSON MELANIE;;GORAPALLI DEEPTHI;;COPELAND STEVE;;DICKIE ROBERT G;;LEFLER AMY;;BECA BOGDAN,,https://lens.org/187-388-223-452-705,Patent Application,yes,2,14,16,16,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/01,,0,0,,,,PENDING
835,AU,A1,AU 2007/226344 A1,191-677-963-949-587,2007-09-20,2007,AU 2007/226344 A,2007-03-09,GB 0617789 A;;GB 0604944 A;;GB 2007000831 W,2006-03-11,Pyrrolopyrimidine derivatives used as HSP90 inhibitors,,VERNALIS R&D LTD,DAVIES NICHOLAS GARETH MORSE;;BROUGH PAUL ANDREW;;FOLOPPE NICOLAS NOEL;;DRYSDALE MARTIN JAMES;;STOKES STEPHAN,,https://lens.org/191-677-963-949-587,Patent Application,no,0,0,12,16,0,C07D487/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P31/12;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D487/04;;A61K31/517;;C07D487/04,C07D487/04;;A61K31/517;;A61P35/00,,0,0,,,,DISCONTINUED
836,US,A1,US 2023/0329771 A1,029-054-456-946-07X,2023-10-19,2023,US 202318308415 A,2023-04-27,US 202318308415 A;;IB 2021059823 W;;US 202063105975 P,2020-10-27,ELECTROSURGICAL DEVICE WITH SENSING,"A system comprising a generator which is capable of supplying energy for puncturing a tissue and an electrical current of known voltage, wherein the electrical current of known voltage can pass through the tissue without damaging the tissue. The system also includes a puncturing device comprising an elongate member. A distal tip of the elongate member comprises an energy delivery device which is configured for delivering the energy for puncturing and two electrodes which are configured for delivering the electrical current of known voltage from one electrode to the other through a material which is in contact with the distal tip. The system further includes a sensor which is capable of detecting a value of the electrical current between the two electrodes. The generator comprises a generator switch for disabling energy delivery tip based on the value of the electric current detected by the sensor.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;DICICCO MATTHEW;;MOK DANIEL WING FAI,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2023-04-04),https://lens.org/029-054-456-946-07X,Patent Application,yes,0,0,5,5,0,A61B2018/00351;;A61B2018/0038;;A61B2018/00601;;A61B2018/00875;;A61B2018/00827;;A61B18/1477;;A61B18/1492;;A61B2218/002;;A61B2018/00702;;A61B2090/065;;A61B17/3478;;A61B18/1233;;A61B18/1492;;A61B2017/00247;;A61B2018/00083;;A61B2018/0038;;A61B2018/00642;;A61B2018/00708;;A61B2018/00833;;A61B2018/00875,A61B18/12;;A61B18/14,,0,0,,,,PENDING
837,EP,A1,EP 4178478 A1,014-797-352-722-736,2023-05-17,2023,EP 21842522 A,2021-07-12,US 202063051106 P;;IB 2021056256 W,2020-07-13,A PUNCTURING DEVICE COMPRISING A DISTAL BALLOON FEATURE,,BOSTON SCIENT MEDICAL DEVICE LIMITED,DICICCO MATTHEW;;DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;MOK DANIEL WING FAI,,https://lens.org/014-797-352-722-736,Patent Application,yes,0,0,4,4,0,A61B18/1492;;A61B2017/00247;;A61B2018/00285;;A61B2018/00357;;A61B2018/00601;;A61B2090/3966;;A61M2025/1079;;A61M25/04;;A61M2025/1004;;A61B90/39;;A61B2090/3966;;A61B17/00234;;A61B2017/00247,A61B18/14;;A61B18/00;;A61M25/10,,0,0,,,,PENDING
838,KR,A,KR 20090007319 A,097-173-227-492-201,2009-01-16,2009,KR 20087024851 A,2008-10-10,GB 0604944 A;;GB 0617789 A,2006-03-11,PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS,"Compounds of formula (I) have HSP90 inhibitory activity and are therefore useful in the treatment of, inter alia, cancer: Formula (I) wherein Ri is hydrogen, fluoro, chloro, bromo, or a radical of formula-X-Alk1-(Z)m-(Alk2)n-Q wherein X is-O-,-S--S(O)-,-SO2-, or-NH-, Z is-O-,-S-,-(C=O)-,-(C=S)-,-S(O)-,-SO2-,-NRA-, or, in either orientation-C(=O)O-,-C(=O)NRA-,-C(=S)NRA-,-SO2NRA-,-NRAC(=O)-, or-NRASO2-wherein RA is hydrogen or C1-C6 alkyl AIk1 and AIk2 are optionally substituted divalent C1-C3 alkylene or C2-C3 alkenylene radicals, m, n and p are independently 0 or 1, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is a radical of formula-(Ar1)p-(Alk1)q-(Z)r -(Alk2)s-Q wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1, Alk2, Z, and Q are as defined above, and p, q, r and s are independently 0 or 1 ; and R3 is cyano (-CN), fluoro, chloro, bromo, methyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, ethyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, cyclopropyl,-OH,-CH2OH,-C(O)NH2,-C(O)CH3, Or-NH2.",VERNALIS R&D LTD,BROUGH PAUL ANDREW;;DRYSDALE MARTIN JAMES;;DAVIES NICHOLAS GARETH MORSE;;FOLOPPE NICOLAS NOEL;;STOKES STEPHAN,,https://lens.org/097-173-227-492-201,Patent Application,no,0,0,12,16,0,C07D487/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P31/12;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D487/04;;A61K31/517;;C07D487/04,A61K31/517;;A61P35/00,,0,0,,,,DISCONTINUED
839,WO,A1,WO 2022/013714 A1,009-188-920-035-818,2022-01-20,2022,IB 2021056256 W,2021-07-12,US 202063051106 P,2020-07-13,A PUNCTURING DEVICE COMPRISING A DISTAL BALLOON FEATURE,A method and apparatus are disclosed for a device for creating a puncture in a tissue. The puncturing device comprising an elongate member having a puncturing portion at the distal tip. The puncturing device further includes at least one inflatable feature positioned around the outer circumference and at a distal portion of the elongate member. The puncturing device includes a lumen extending from a proximal end of the elongate member to the inflatable feature. The inflatable feature is in fluid communication with the lumen and can be inflated to dilate the puncture in the tissue or anchor the puncturing device in a heart structure.,BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DICICCO MATTHEW;;DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;MOK DANIEL WING FAI,,https://lens.org/009-188-920-035-818,Patent Application,yes,5,0,4,4,0,A61B18/1492;;A61B2017/00247;;A61B2018/00285;;A61B2018/00357;;A61B2018/00601;;A61B2090/3966;;A61M2025/1079;;A61M25/04;;A61M2025/1004;;A61B90/39;;A61B2090/3966;;A61B17/00234;;A61B2017/00247,A61B18/14;;A61B18/00;;A61M25/10,,0,0,,,,PENDING
840,ZA,B,ZA 200808598 B,080-809-850-361-880,2009-12-30,2009,ZA 200808598 A,2008-10-08,GB 0604944 A,2006-03-11,Pyrrolopyrimidine derivatives used as HSP90 inhibitors,,VERNALIS R&D LTD,BROUGH PAUL ANDREW;;DRYSDALE MARTIN JAMES;;DAVIES NICHOLAS GARETH MORSE;;FOLOPPE NICOLAS NOEL;;STOKES STEPHAN,,https://lens.org/080-809-850-361-880,Granted Patent,no,0,0,3,16,0,,A61K/;;A61P/;;C07D/,,0,0,,,,ACTIVE
841,US,B2,US 10806896 B2,080-985-205-609-938,2020-10-20,2020,US 201314409662 A,2013-06-18,US 201314409662 A;;US 201261661664 P;;IB 2013055013 W,2012-06-19,Steerable medical device handle,"A control system and method are provided for control of a steerable catheter, the catheter including at least two control wires, a distal end of each of the control wires being coupled to the catheter at a distal region thereof, the control system comprising: a housing coupled to the catheter; a slide assembly positioned within the housing and operable to translate linearly therein; a proximal portion of each of the at least two control wires being positioned through the slide assembly; and a control knob rotatably coupled to the housing for linearly translating the slide assembly, thereby enabling the slide assembly to separately manipulate each of said at least two control wires to effect a change in a deflection of said catheter.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;THOMPSON MELANIE;;GORAPALLI DEEPTHI;;COPELAND STEVE;;DICKIE ROBERT G;;LEFLER AMY;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2014-12-11);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/080-985-205-609-938,Granted Patent,yes,54,2,16,16,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/01,,9,0,,,"Patent Cooperation Treaty, International Search Report and Written Opinion of the International Search Authority for International Application No. PCT/IB2013/055013, dated Jan. 20, 2014.;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2013/055013, dated Dec. 23, 2014.;;Japanese Office Action for counterpart Japanese Application No. 2015-517905, dated Aug. 1, 2017.;;European Patent Office, Communication pursuant to Rules 161 and 162, for counterpart European Application No. 13752677.8, dated Jan. 27, 2015.;;Applicant's Reply to Communication pursuant to Rules 161 and 162 for counterpart European Application No. 13752677.8, dated Jul. 31, 2015.;;Related Japanese Application, Office Action, dated Jul. 29, 2017.;;Related Japanese Application, Office Action, dated May 8, 2018.;;Related Japanese Application, Office Action, dated May 11, 2020.;;Related Japanese Application, Office Action, dated Aug. 6, 2019.",ACTIVE
842,US,B2,US 11571547 B2,108-963-293-602-716,2023-02-07,2023,US 202016848926 A,2020-04-15,US 202016848926 A;;US 201615106584 A;;IB 2014067173 W;;US 201361918800 P;;US 201361918848 P,2013-12-20,Steerable medical device handle,"Embodiments of a steerable catheter control system and methods are disclosed. The steerable catheter control system comprises a housing which defines an inner housing and a slide assembly which linearly translates within the inner housing. At least two control wires are positioned through the slide assembly wherein one of the at least two controls wires are indirectly coupled to the slide assembly via the direction reversing element. The steerable catheter control system further comprises a slack limiting element, coupled to at least one of the at least two control wires. The slack limiting element allows for frictional engagement of the control wire to limit slack. The control system includes a control knob for linearly translating the slide assembly, enabling the slide assembly to manipulate the control wires which causes a change in deflection of the steerable catheter.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DAVIES GARETH;;SMITH MELANIE THOMPSON;;GORAPALLI DEEPTHI;;COPELAND STEVE;;DICKIE ROBERT;;LEFLER AMY;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2016-06-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/108-963-293-602-716,Granted Patent,yes,81,0,6,6,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/01,,12,0,,,"International Search Report for related PCT Application No. PCT/IB2013/055013 dated Jan. 20, 2014.;;IPRP for related PCT Application No. PCT/IB2013/055013 dated Dec. 31, 2014.;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2013/055013, dated Dec. 23, 2014.;;Patent Cooperation Treaty, International Preliminary Report on Patentability, for corresponding International Application No. PCT/IB2013/055013, dated Dec. 23, 2014.;;Japanese Office Action for corresponding Japanese Application No. 2015-517905, dated Aug. 1, 2017.;;European Patent Office, Communication pursuant to Rules 161 and 162, for corresponding European Application No. 13752677.8, dated Jan. 27, 2015.;;Corresponding Japanese Application, Office Action, dated Aug. 6, 2019.;;Corresponding Japanese Application, Office Action, dated Jul. 29, 2017.;;Corresponding Japanese Application, Office Action, dated May 9, 2018.;;Corresponding Japanese Application, Office Action, dated May 11, 2020.;;Patent Cooperation Treaty, International Preliminary Report on Patentability, International Application No. PCT/IB2014/067173, dated Mar. 23, 2015.;;Patent Cooperation Treaty, Written Opinion, International Application No. PCT/IB2014/067173, dated Mar. 23, 2015.",ACTIVE
843,US,A1,US 2023/0255685 A1,109-002-805-940-756,2023-08-17,2023,US 202318300972 A,2023-04-14,US 202318300972 A;;IB 2021059484 W;;US 202063091997 P,2020-10-15,ELECTROSURGICAL DEVICE WITH AUTOMATIC SHUT-OFF,"A puncturing device configured to create a puncture in a tissue comprising an elongate member comprising a proximal portion defining a longitudinal axis along the length of the elongate member. The elongate member further comprises a flexible distal portion of the that curves away from the longitudinal axis and a distal tip configured to deliver energy to the tissue. A sensing element placed on the flexible distal portion of the elongate member detects the curvature of the distal portion such that when the flexible distal portion of the elongate member is straightened, energy is delivered to the distal tip and when the flexible distal portion of the elongate member is curved, energy is not delivered to the distal tip.",BOSTON SCIENT MEDICAL DEVICE LIMITED,MOK DANIEL WING FAI;;DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;DICICCO MATTHEW,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2023-04-04),https://lens.org/109-002-805-940-756,Patent Application,yes,0,0,5,5,0,A61B2034/2061;;A61B2018/00875;;A61B18/1482;;A61B18/1492;;A61B2090/064;;A61B18/1492;;A61B2018/00077;;A61B2018/00083;;A61B2018/00357;;A61B2018/00625;;A61B2018/00708;;A61B2018/00773;;A61B2018/144,A61B18/14,,0,0,,,,PENDING
844,BR,B1,BR 122020010829 B1,161-527-120-368-563,2022-03-29,2022,BR 122020010829 A,2013-06-18,IB 2013055013 W;;US 201261661664 P;;BR 112014031843 A,2012-06-19,Sistema de controle compreendendo um cabo de controle de cateter orientável e sistema de controle de cateter orientável para controle bidirecional de um cateter orientável,"são providos um sistema e um método para o controle de um cateter orientável, o cateter incluindo pelo menos dois fios de controle, uma extremidade distal de cada um dos fios de controle sendo acoplada ao cateter em uma região distal deste, o sistema de controle compreendendo: um alojamento acoplado ao cateter que define um alojamento interno. uma montagem deslizante é posicionada e operável para ser deslocada linearmente no interior do alojamento interno. uma parte proximal dos pelo menos dois fios de controle sendo posicionada através da montagem deslizante, onde um dos pelo menos dois fios de controle é indiretamente acoplado à montagem deslizante por meio de um elemento reversor de direção. a montagem deslizante inclui adicionalmente um mecanismo limitante de deslizamento para restringir o deslocamento linear da montagem deslizante. o sistema de controle inclui um botão de controle acoplado de forma rotativa ao alojamento para deslocar linearmente a montagem deslizante, possibilitando assim que a montagem deslizante manipule cada um dos pelo menos dois fios de controle, efetuando uma alteração na deflexão do dito cateter.",BAYLIS MEDICAL CO INC,LEFLER AMY;;BECA BOGDAN;;GORAPALLI DEEPTHI;;DAVIES GARETH;;THOMPSON MELANIE;;ROBERT G DICKIE;;COPELAND STEVE,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (IE) (2023-06-06),https://lens.org/161-527-120-368-563,Granted Patent,no,0,0,16,16,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/01,,0,0,,,,ACTIVE
845,WO,A1,WO 2007/104944 A1,157-603-702-451-743,2007-09-20,2007,GB 2007000831 W,2007-03-09,GB 0604944 A;;GB 0617789 A,2006-03-11,PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS,"Compounds of formula (I) have HSP90 inhibitory activity and are therefore useful in the treatment of, inter alia, cancer: Formula (I) wherein R i is hydrogen, fluoro, chloro, bromo, or a radical of formula -X-Alk 1 -(Z) m -(Alk 2 )n-Q wherein X is -O-, -S- -S(O)-, -SO 2 -, or -NH-, Z is -O-, -S-, -(C=O)-, -(C=S)-, -S(O)-, -SO 2 -, -NR A -, or, in either orientation -C(=O)O-, -C(=O)NR A - , -C(=S)NR A -, -SO 2 NR A -, -NR A C(=O)-, or -NR A SO 2 - wherein R A is hydrogen or C 1 -C 6 alkyl AIk 1 and AIk 2 are optionally substituted divalent C 1 -C 3 alkylene or C 2 -C 3 alkenylene radicals, m, n and p are independently 0 or 1 , and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R 2 is a radical of formula -(Ar 1 ) p -(Alk 1 ) q -(Z) r -(Alk 2 ) s -Q wherein Ar 1 is an optionally substituted aryl or heteroaryl radical, Alk 1 , Alk 2 , Z, and Q are as defined above, and p, q, r and s are independently 0 or 1 ; and R 3 is cyano (-CN), fluoro, chloro, bromo, methyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, ethyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, cyclopropyl, -OH, -CH 2 OH, -C(O)NH 2 , -C(O)CH 3 , Or -NH 2 .",VERNALIS R&D LTD;;BROUGH PAUL ANDREW;;DRYSDALE MARTIN JAMES;;DAVIES NICHOLAS GARETH MORSE;;FOLOPPE NICOLAS NOEL;;STOKES STEPHAN,BROUGH PAUL ANDREW;;DRYSDALE MARTIN JAMES;;DAVIES NICHOLAS GARETH MORSE;;FOLOPPE NICOLAS NOEL;;STOKES STEPHAN,,https://lens.org/157-603-702-451-743,Patent Application,yes,3,20,12,16,0,C07D487/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P31/12;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D487/04;;A61K31/517;;C07D487/04,C07D487/04;;A61K31/517;;A61P35/00,,9,9,113-427-238-550-273;;054-994-580-275-556;;019-207-592-027-029;;061-949-440-742-061;;006-399-230-168-526;;114-860-801-874-175;;063-668-547-661-28X;;011-985-021-286-211;;026-811-232-106-393,10.1002/cber.19801130826;;10.1517/13543784.14.6.569;;16004589;;11772336;;10.1517/14712598.2.1.3;;16175177;;10.1038/nrc1716;;16302791;;10.1021/jm050759r;;16199163;;10.1016/j.tcb.2005.09.003;;10597632;;10.1006/scdb.1999.0320;;10.1091/mbc.11.5.1585;;10793137;;pmc14869;;pmc1572305;;10960063;;10.1038/sj.bjp.0703549,"SEELA F ET AL: ""RIBOSIDIERUNG VON PYRROLO2,3-CPYRIMIDINEN IN GEGENWART STARKER BASEN RIBOSIDATION OF PYRROLO2,3-DPYRIMIDINES IN THE PRESENCE OF STRONGBASES"", CHEMISCHE BERICHTE, VERLAG CHEMIE GMBH. WEINHEIM, DE, vol. 113, no. 8, 1980, pages 2808 - 2813, XP000995468, ISSN: 0009-2940;;ISAACS JS: ""Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up"", EXPERT OPIN. INVESTIQ. DRUGS, vol. 14, 2005, pages 569 - 589;;MALONEY A; WORKMAN P.: ""Hsp90 as a new therapeutic target for cancer therapy: the story unfolds"", EXPERT OPIN. BIOL. THER., vol. 2, 2002, pages 3 - 24;;WHITESELL L; LINDQUIST SL.: ""Hsp90 and the chaperoning of cancer"", NATURE REV. CANCER, vol. 5, 2005, pages 761 - 772;;JANIN Y: ""Heat Shock Protein 90 Inhibitors. A Text Book Example of Medicinal Chemistry"", J. MED. CHEM., vol. 48, 2005, pages 7503;;AOYAGI S; ARCHER TK.: ""Modulating molecular chaperone Hsp90 functions through reversible acetylation"", TRENDS CELL BIOL., vol. 15, 2005, pages 565 - 7;;ARGON Y; SIMEN BB.: ""Grp94, an ER chaperone with protein and peptide binding properties"", SEMIN. CELL DEV. BIOL., vol. 10, 1999, pages 495 - 505;;BIJLMAKERS M-JJE; MARSH M.: ""Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src- kinase p561ck"", MOLECULAR BIOLOGV OF THE CELL, vol. 11, 2000, pages 1585 - 1595;;BUCCI M; ROVIEZZO F; CICALA C; SESSA WC; CIRINO G.: ""Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo"", BRIT. J. PHARMACOL., vol. 131, 2000, pages 13 - 16",PENDING
846,JP,A,JP 2019013777 A,005-740-775-070-350,2019-01-31,2019,JP 2018172033 A,2018-09-14,JP 2015517905 A;;US 201261661664 P,2012-06-19,STEERABLE MEDICAL DEVICE HANDLE,"To provide a control system and a method for controlling a steerable catheter.SOLUTION: A handle 100 includes: a housing 20 coupled to a catheter 90; a slide assembly positioned within the housing and operable to translate linearly therein; a proximal portion of each of at least two control wires being positioned through the slide assembly; and a knob 10 rotatably coupled to the housing for linearly translating the slide assembly, thereby enabling the slide assembly to separately manipulate each of the at least two control wires to effect a change in a deflection of the catheter.SELECTED DRAWING: Figure 1",BAYLIS MEDICAL CO INC,GARETH DAVIES;;MELANIE THOMPSON;;DEEPTHI GORAPALLI;;STEVE COPELAND;;ROBERT G DICKIE;;AMY LEFLER;;BOGDAN BECA,,https://lens.org/005-740-775-070-350,Patent Application,no,5,0,16,16,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/092,,0,0,,,,ACTIVE
847,WO,A1,WO 2022/090896 A1,031-902-607-235-963,2022-05-05,2022,IB 2021059823 W,2021-10-25,US 202063105975 P,2020-10-27,ELECTROSURGICAL DEVICE WITH SENSING,"A system comprising a generator which is capable of supplying energy for puncturing a tissue and an electrical current of known voltage, wherein the electrical current of known voltage can pass through the tissue without damaging the tissue. The system also includes a puncturing device comprising an elongate member. A distal tip of the elongate member comprises an energy delivery device which is configured for delivering the energy for puncturing and two electrodes which are configured for delivering the electrical current of known voltage from one electrode to the other through a material which is in contact with the distal tip. The system further includes a sensor which is capable of detecting a value of the electrical current between the two electrodes. The generator comprises a generator switch for disabling energy delivery tip based on the value of the electric current detected by the sensor.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;DICICCO MATTHEW;;MOK DANIEL WING FAI,,https://lens.org/031-902-607-235-963,Patent Application,yes,5,1,5,5,0,A61B2018/00351;;A61B2018/0038;;A61B2018/00601;;A61B2018/00875;;A61B2018/00827;;A61B18/1477;;A61B18/1492;;A61B2218/002;;A61B2018/00702;;A61B2090/065;;A61B17/3478;;A61B18/1233;;A61B18/1492;;A61B2017/00247;;A61B2018/00083;;A61B2018/0038;;A61B2018/00642;;A61B2018/00708;;A61B2018/00833;;A61B2018/00875,A61B18/00;;A61B18/14;;A61B18/12,,0,0,,,,PENDING
848,WO,A1,WO 2022/079672 A1,055-061-611-677-980,2022-04-21,2022,IB 2021059484 W,2021-10-15,US 202063091997 P,2020-10-15,AN ELECTROSURGICAL DEVICE WITH AUTOMATIC SHUT-OFF,"A puncturing device configured to create a puncture in a tissue comprising an elongate member comprising a proximal portion defining a longitudinal axis along the length of the elongate member. The elongate member further comprises a flexible distal portion of the that curves away from the longitudinal axis and a distal tip configured to deliver energy to the tissue. A sensing element placed on the flexible distal portion of the elongate member detects the curvature of the distal portion such that when the flexible distal portion of the elongate member is straightened, energy is delivered to the distal tip and when the flexible distal portion of the elongate member is curved, energy is not delivered to the distal tip.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,MOK DANIEL WING FAI;;DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;DICICCO MATTHEW,,https://lens.org/055-061-611-677-980,Patent Application,yes,5,0,5,5,0,A61B2034/2061;;A61B2018/00875;;A61B18/1482;;A61B18/1492;;A61B2090/064;;A61B18/1492;;A61B2018/00077;;A61B2018/00083;;A61B2018/00357;;A61B2018/00625;;A61B2018/00708;;A61B2018/00773;;A61B2018/144,A61B18/14;;A61B18/00;;A61B18/12,,0,0,,,,PENDING
849,US,A1,US 2021/0001087 A1,039-349-561-483-231,2021-01-07,2021,US 202017022936 A,2020-09-16,US 202017022936 A;;US 201414409662 A;;IB 2013055013 W;;US 201261661664 P,2012-06-19,Steerable Medical Device Handle,"Apparatus and systems are disclosed that incorporate a steerable catheter control handle for bi-directional control of a steerable catheter. The steerable catheter control handle includes a slide assembly positioned within the inner housing and operable to translate linearly therein. The control handle further includes a proximal portion of at least two control wires being positioned through the slide assembly wherein one of the at least two control wires is indirectly coupled to the slide assembly via a direction reversing element. The steerable catheter control handle has a control knob rotatably coupled to the housing for linearly translating the slide assembly, thereby enabling the slide assembly to manipulate each of the at least two control wires, effecting a change in deflection of said catheter. The slide assembly further comprises a slide limiting mechanism to restrict linear translation of the slide assembly.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;THOMPSON MELANIE;;GORAPALLI DEEPTHI;;COPELAND STEVE;;DICKIE ROBERT G;;LEFLER AMY;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2014-12-11);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/039-349-561-483-231,Patent Application,yes,7,1,16,16,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/01,,0,0,,,,PENDING
850,EP,A1,EP 4228538 A1,096-295-388-135-554,2023-08-23,2023,EP 21879641 A,2021-10-15,US 202063091997 P;;IB 2021059484 W,2020-10-15,AN ELECTROSURGICAL DEVICE WITH AUTOMATIC SHUT-OFF,,BOSTON SCIENT MEDICAL DEVICE LIMITED,MOK DANIEL WING FAI;;DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;DICICCO MATTHEW,,https://lens.org/096-295-388-135-554,Patent Application,yes,0,0,5,5,0,A61B2034/2061;;A61B2018/00875;;A61B18/1482;;A61B18/1492;;A61B2090/064;;A61B18/1492;;A61B2018/00077;;A61B2018/00083;;A61B2018/00357;;A61B2018/00625;;A61B2018/00708;;A61B2018/00773;;A61B2018/144,A61B18/14;;A61B18/00;;A61B18/12,,0,0,,,,PENDING
851,US,A1,US 2019/0274754 A1,115-839-641-962-183,2019-09-12,2019,US 201916423092 A,2019-05-27,US 201916423092 A;;US 201615262715 A,2016-09-12,Electrosurgical device having a distal aperture,"A method and apparatus are disclosed for providing forward fluid delivery through an electrosurgical device, while avoiding coring when energy is delivered to the electrosurgical device. The device has a distal face defining an opening, with the distal face including at least one cutting portion and at least one non-cutting portion. An embodiment of the electrosurgical device for puncturing tissue includes an elongate member defining a lumen for fluid; a distal portion including an electrode and the distal face which defines at least one aperture. The portion of the at least one cutting portion defines a leading portion partially surrounding a circumference of the at least one aperture wherein the outer diameter of the at least one of the distal portion of the electrosurgical device or the electrode decreases towards a distal tip of the electrosurgical device.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;URBANSKI JOHN PAUL;;HARFIELD ELLEN;;MIRZA MAHMOOD;;UHM YUN;;LEUNG LINUS;;ALLEY FERRYL,BAYLIS MEDICAL COMPANY INC (2016-09-12);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/115-839-641-962-183,Patent Application,yes,3,0,1,36,0,A61B18/1477;;A61B2018/00297;;A61B2018/00351;;A61B2018/00601;;A61B2018/1412;;A61B2018/1427;;A61B2018/1467;;A61B2018/1497;;A61B2218/002;;A61B18/1206;;A61B2090/3966;;A61B18/1477;;A61B2018/1467;;A61B2018/1412;;A61B2090/3966;;A61B2090/392;;A61B2218/002;;A61B2018/1497;;A61B2018/1427;;A61B2018/00297;;A61B2018/00077;;A61B2018/00083;;A61B2018/00351;;A61B2018/00601;;A61B18/1206,A61B18/14,,0,0,,,,PENDING
852,BR,A2,BR PI0708779 A2,116-159-572-503-350,2011-06-14,2011,BR PI0708779 A,2007-03-09,GB 0604944 A;;GB 0617789 A;;GB 2007000831 W,2006-03-11,derivados de pirrolopirimidina utilizados como inibidores de hsp90,"DERIVADOS DE PIRROLOPIRIMIDINA UTILIZADOS COMO INIBIDORES DE HSP9O. A presente invenção refere-se a compostos de fórmula (I) que possuem atividade inibidora HSP9O e são, portanto, úteis no tratamento de, inter alia, câncer: em que R~ 1~ é hidrogênio, flúor, cloro, bromo, ou um radical de fórmula -X-Alq^ 1^-(Z)~ m~-(Alq^ 2^)~ n~-Q em que X é -O-, -S- -S(O)-, -SO~ 2~-, ou -NH-, Z é -O-, -S-, -(C=O)-, -(C=S)-, -S(O)-, -S0~ 2-~-, -NR^ A-^~, ou, em cada orientação - C(=O)O-, -C(=O)NR^ A-^, ~C(=S)NR^A-^, -SO~ 2~NR^ A-^, -NR^ A^C(=O)-, ou ~NR^ A^SO~ 2~- em que R^ A^ é hidrogênio ou C~ 1~-C~ 6~ alquila AIq^ 1^ e Alq^ 2^ são radicais de C~ 1~-C~ 3~ alquileno ou C~ 2~-C~ 3~ alquenileno divalentes opcionalmente substituidos, m, n e p são independentemente 0 ou 1, e Q é hidrogênio ou um radical carbocíclico ou heterocíclico opcionalmente substituído; R~ 2~ é um radical de fórmula -(Ar^ 1^)p-(Alq^ 1^)q-(Z)r-(Alq^ 2^)~ s~-Q em que Ar^ 1^ é um radical de arila ou heteroarila opcionalmente substituído, Alq^ 1^, Alq^ 2^, Z, e Q são como definidos acima, e p, q, r e s são independentemente 0 ou 1; e R~ 3~ é ciano (-CN), flúor, cloro, bromo, metila em que um ou mais átomos de hidrogênio são opcionalmente substituidos por átomos de flúor, etila em que um ou mais átomos de hidrogênio são opcionalmente substituidos por átomos de flúor, ciclopropila, -OH, -CH~ 2~OH, -C(O)NH~ 2~, -C(O)CH~ 3~ ou -NH~ 2~.",VERNALIS R&D LTD,BROUGH PAUL ANDREW;;DRYSDALE MARTIN JAMES;;DAVIES NICHOLAS GARETH MORSE;;FOLOPPE NICOLAS NOEL;;STOKES STEPHAN,,https://lens.org/116-159-572-503-350,Patent Application,no,0,0,12,16,0,C07D487/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P31/12;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D487/04;;A61K31/517;;C07D487/04,C07D487/04;;A61K31/517;;A61P35/00,,0,0,,,,DISCONTINUED
853,EP,A1,EP 2007767 A1,193-425-981-130-737,2008-12-31,2008,EP 07712872 A,2007-03-09,GB 2007000831 W;;GB 0604944 A;;GB 0617789 A,2006-03-11,PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS,,VERNALIS R&D LTD,BROUGH PAUL ANDREW;;DRYSDALE MARTIN JAMES;;DAVIES NICHOLAS GARETH MORSE;;FOLOPPE NICOLAS NOEL;;STOKES STEPHAN,VERNALIS (R&D) LTD (2011-06-01),https://lens.org/193-425-981-130-737,Patent Application,yes,0,0,12,16,0,C07D487/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P31/12;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D487/04;;A61K31/517;;C07D487/04,C07D487/04;;A61K31/517;;A61P35/00,,0,0,,,,ACTIVE
854,US,A1,US 2021/0016786 A1,188-402-039-743-734,2021-01-21,2021,US 202017032294 A,2020-09-25,GB 201804886 A;;GB 201804888 A;;GB 201808881 A;;EP 2019057638 W,2018-03-27,Predictive Vehicle Diagnostics Method,"A computer-implemented method of predicting vehicle failures comprises: receiving, at a processing stage: i) a vehicle diagnostics dataset, which records historic diagnostic warning events and an associated timing for each diagnostic warning event, and ii) a vehicle fault dataset, which records historic vehicle fault events and an associated timing for each vehicle fault event, wherein the diagnostic warning events and vehicle fault events are associated in their respective datasets with cooperating vehicle identifiers; wherein a predictive algorithm executed at the data processing stage determines whether or not each diagnostic warning event of a target type is time-associated with a diagnostic warning event in that its associated timing is within a predetermined time window relative to that of any vehicle fault event associated with a matching vehicle identifier, and computes, based thereon, a significance value for the target type of diagnostic warning event, the significance value denoting the likelihood of a vehicle fault event occurring should a diagnostic warning event of the target type occur.",WE PREDICT LTD,GRIFFITHS ANTHONY PETER;;DAVIES CHRISTOPHER LEE;;DAVIES JAMES GARETH;;NORRIS STEPHEN DAVID;;TUDOR PATRICK JAMES;;DAVIS TIMOTHY PETER;;NOCK KELLY MARIE;;REES STEFFAN,WE PREDICT LIMITED (2020-11-12),https://lens.org/188-402-039-743-734,Patent Application,yes,5,18,7,9,0,G05B23/024;;G05B23/0283;;G07C5/0808;;G07C5/0825;;G05B2219/2637;;G05B23/0221;;G05B23/0224;;G05B23/0267;;B60W50/0205;;B60W50/0225;;B60W50/14;;B60W2050/143;;B60W2050/146;;G06N20/00;;B60R16/0234;;G06N5/04;;G07C5/0808;;G07C5/0841,B60W50/02;;B60W50/14,,0,0,,,,DISCONTINUED
855,WO,A1,WO 2019/185659 A1,149-541-906-648-221,2019-10-03,2019,EP 2019057640 W,2019-03-26,GB 201804886 A;;GB 201804888 A;;GB 201808881 A,2018-03-27,PREDICTIVE VEHICLE DIAGNOSTIC METHOD,"A computer-implemented method of predicting vehicle faults, the method comprising, at a data processing stage: receiving: i) sets of telematics data each associated with a vehicle identifier, and ii) a vehicle fault dataset, which records historic vehicle fault events, wherein the vehicle fault events are associated in the datasets with cooperating vehicle identifiers; for each of the vehicle identifiers, determining i) a feature object by processing the associated set of telematics data to determine at least one driving style parameter therefrom, the feature object comprising the at least one driving style parameter, and ii) a training label for the feature object based on one or more of the vehicle fault events associated with that vehicle identifier; and using the feature objects and their training labels to train a predictive component, executed at the data processing stage, to learn causal associations between the driving style parameters and the vehicle fault events, such that a feature object comprising at least one target driving style parameter, associated with a target vehicle, inputted to the trained predictive component causes the predictive component to output a corresponding vehicle fault prediction.",WE PREDICT LTD,GRIFFITHS ANTHONY PETER;;DAVIES CHRISTOPHER LEE;;DAVIES JAMES GARETH;;NORRIS STEPHEN DAVID;;TUDOR PATRICK JAMES;;DAVIS TIMOTHY PETER;;NOCK KELLY MARIE;;REES STEFFAN,,https://lens.org/149-541-906-648-221,Patent Application,yes,4,5,7,9,0,G05B23/024;;G05B23/0283;;G07C5/0808;;G07C5/0825;;G05B2219/2637;;G05B23/0221;;G05B23/0224;;G05B23/0267;;B60W50/0205;;B60W50/0225;;B60W50/14;;B60W2050/143;;B60W2050/146;;G06N20/00;;B60R16/0234;;G06N5/04;;G07C5/0808;;G07C5/0841,G07C5/08;;G05B23/02,,0,0,,,,PENDING
856,EP,A1,EP 3776494 A1,107-458-925-980-077,2021-02-17,2021,EP 19714594 A,2019-03-26,GB 201804888 A;;GB 201804886 A;;GB 201808881 A;;EP 2019057638 W,2018-03-27,PREDICTIVE VEHICLE DIAGNOSTICS METHOD,,WE PREDICT LTD,GRIFFITHS ANTHONY PETER;;DAVIES CHRISTOPHER LEE;;DAVIES JAMES GARETH;;NORRIS STEPHEN DAVID;;TUDOR PATRICK JAMES;;DAVIS TIMOTHY PETER;;NOCK KELLY MARIE;;REES STEFFAN,,https://lens.org/107-458-925-980-077,Patent Application,yes,0,1,7,9,0,G05B23/024;;G05B23/0283;;G07C5/0808;;G07C5/0825;;G05B2219/2637;;G05B23/0221;;G05B23/0224;;G05B23/0267;;B60W50/0205;;B60W50/0225;;B60W50/14;;B60W2050/143;;B60W2050/146;;G06N20/00;;B60R16/0234;;G06N5/04;;G07C5/0808;;G07C5/0841,G07C5/08;;G05B23/02,,0,0,,,,DISCONTINUED
857,EP,A1,EP 3776495 A1,112-996-019-636-425,2021-02-17,2021,EP 19714595 A,2019-03-26,GB 201804886 A;;GB 201804888 A;;GB 201808881 A;;EP 2019057640 W,2018-03-27,PREDICTIVE VEHICLE DIAGNOSTIC METHOD,,WE PREDICT LTD,GRIFFITHS ANTHONY PETER;;DAVIES CHRISTOPHER LEE;;DAVIES JAMES GARETH;;NORRIS STEPHEN DAVID;;TUDOR PATRICK JAMES;;DAVIS TIMOTHY PETER;;NOCK KELLY MARIE;;REES STEFFAN,,https://lens.org/112-996-019-636-425,Patent Application,yes,0,0,7,9,0,B60W50/0205;;B60R16/0234;;B60W50/0225;;B60W50/14;;B60W2050/143;;B60W2050/146;;G07C5/0808;;G05B23/0221;;G05B23/0224;;G05B23/024;;G05B23/0267;;G05B23/0283;;G05B2219/2637;;G06N5/04;;G06N20/00;;G07C5/0808;;G07C5/0825;;G07C5/0841,G07C5/08;;G05B23/02,,1,0,,,See references of WO 2019185659A1,PENDING
858,WO,A1,WO 2019/185657 A1,124-136-815-282-918,2019-10-03,2019,EP 2019057638 W,2019-03-26,GB 201804888 A;;GB 201804886 A;;GB 201808881 A,2018-03-27,PREDICTIVE VEHICLE DIAGNOSTICS METHOD,"A computer-implemented method of predicting vehicle failures comprises: receiving, at a processing stage: i) a vehicle diagnostics dataset, which records historic diagnostic warning events and an associated timing for each diagnostic warning event, and ii) a vehicle fault dataset, which records historic vehicle fault events and an associated timing for each vehicle fault event, wherein the diagnostic warning events and vehicle fault events are associated in their respective datasets with cooperating vehicle identifiers; wherein a predictive algorithm executed at the data processing stage determines whether or not each diagnostic warning event of a target type is time-associated with a diagnostic warning event in that its associated timing is within a predetermined time window relative to that of any vehicle fault event associated with a matching vehicle identifier, and computes, based thereon, a significance value for the target type of diagnostic warning event, the significance value denoting the likelihood of a vehicle fault event occurring should a diagnostic warning event of the target type occur.",WE PREDICT LTD,GRIFFITHS ANTHONY PETER;;DAVIES CHRISTOPHER LEE;;DAVIES JAMES GARETH;;NORRIS STEPHEN DAVID;;TUDOR PATRICK JAMES;;DAVIS TIMOTHY PETER;;NOCK KELLY MARIE;;REES STEFFAN,,https://lens.org/124-136-815-282-918,Patent Application,yes,4,8,7,9,0,G05B23/024;;G05B23/0283;;G07C5/0808;;G07C5/0825;;G05B2219/2637;;G05B23/0221;;G05B23/0224;;G05B23/0267;;B60W50/0205;;B60W50/0225;;B60W50/14;;B60W2050/143;;B60W2050/146;;G06N20/00;;B60R16/0234;;G06N5/04;;G07C5/0808;;G07C5/0841,G07C5/08;;G05B23/02,,0,0,,,,PENDING
859,US,A1,US 2021/0090359 A1,174-497-611-295-407,2021-03-25,2021,US 202017032271 A,2020-09-25,GB 201804886 A;;GB 201804888 A;;GB 201808881 A;;EP 2019057640 W,2018-03-27,PREDICTIVE VEHICLE DIAGNOSTIC METHOD,"A computer-implemented method of predicting vehicle faults, the method comprising, at a data processing stage: receiving: i) sets of telematics data each associated with a vehicle identifier, and ii) a vehicle fault dataset, which records historic vehicle fault events, wherein the vehicle fault events are associated in the datasets with cooperating vehicle identifiers; for each of the vehicle identifiers, determining i) a feature object by processing the associated set of telematics data to determine at least one driving style parameter therefrom, the feature object comprising the at least one driving style parameter, and ii) a training label for the feature object based on one or more of the vehicle fault events associated with that vehicle identifier; and using the feature objects and their training labels to train a predictive component, executed at the data processing stage, to learn causal associations between the driving style parameters and the vehicle fault events, such that a feature object comprising at least one target driving style parameter, associated with a target vehicle, inputted to the trained predictive component causes the predictive component to output a corresponding vehicle fault prediction.",WE PREDICT LTD,GRIFFITHS ANTHONY PETER;;DAVIES CHRISTOPHER LEE;;DAVIES JAMES GARETH;;NORRIS STEPHEN DAVID;;TUDOR PATRICK JAMES;;DAVIS TIMOTHY PETER;;NOCK KELLY MARIE;;REES STEFFAN,WE PREDICT LIMITED (2021-01-22),https://lens.org/174-497-611-295-407,Patent Application,yes,0,4,7,9,0,B60W50/0205;;B60R16/0234;;B60W50/0225;;B60W50/14;;B60W2050/143;;B60W2050/146;;G07C5/0808;;G05B23/0221;;G05B23/0224;;G05B23/024;;G05B23/0267;;G05B23/0283;;G05B2219/2637;;G06N5/04;;G06N20/00;;G07C5/0808;;G07C5/0825;;G07C5/0841,G07C5/08;;B60R16/023;;G06N5/04;;G06N20/00,,0,0,,,,PENDING
860,WO,A1,WO 2015/107356 A1,126-741-952-933-965,2015-07-23,2015,GB 2015050092 W,2015-01-16,GB 201400753 A,2014-01-16,GAMING APPARATUS,"A gaming apparatus comprising: a plurality of concentric wheels adapted to independently rotate around a common axis of rotation, each of the concentric wheels having a plurality of sections for selection; and wheel control means adapted to apply a force to at least one of the concentric wheels so as to alter a rotational speed of the at least one concentric wheels. The wheel control means are adapted to vary the applied force.",CENTRAL GAMING LTD;;RANDOM GAMES LTD,MEDDICK LESLIE DOUGLAS;;DAVIES ANDREW GEORGE;;ANDREWS GARETH;;CHALK ROBERT CLIFFORD;;ANDREWS MATTHEW LEWIS;;CHALMERS RONALD,,https://lens.org/126-741-952-933-965,Patent Application,yes,4,4,3,3,0,A63F5/043;;A63F5/043;;A63F5/00;;A63F5/0052;;A63F5/0082;;A63F5/04;;A63F2009/2447,A63F5/04,,0,0,,,,PENDING
861,MX,A,MX 2008011559 A,178-282-555-153-769,2008-11-25,2008,MX 2008011559 A,2007-03-09,GB 0604944 A;;GB 0617789 A;;GB 2007000831 W,2006-03-11,PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS.,"Compounds of formula (I) have HSP90 inhibitory activity and are therefore useful in the treatment of, inter alia, cancer: Formula (I) wherein Ri is hydrogen, fluoro, chloro, bromo, or a radical of formula -X-Alk1-(Z)m-(Alk2)n-Q wherein X is -O-, -S- -S(O)-, -SO2-, or -NH-, Z is -O-, -S-, -(C=O)-, -(C=S)-, -S(O)-, -SO2-, -NRA-, or, in either orientation -C(=O)O-, -C(=O)NRA- , -C(=S)NRA-, -SO2NRA-, -NRAC(=O)-, or -NRASO2- wherein RA is hydrogen or C1-C6 alkyl AIk1 and AIk2 are optionally substituted divalent C1-C3 alkylene or C2-C3 alkenylene radicals, m, n and p are independently 0 or 1 , and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is a radical of formula -(Ar1)p-(Alk1)q-(Z) r-(Alk2)s-Q wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1, Alk2, Z, and Q are as defined above, and p, q, r and s are independently 0 or 1 ; and R3 is cyano (-CN), fluoro, chloro, bromo, methyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, ethyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, cyclopropyl, -OH, -CH2OH, -C(O)NH2, -C(O)CH3, Or -NH2.",VERNALIS R&D LTD,DRYSDALE MARTIN JAMES;;BROUGH PAUL ANDREW;;DAVIES NICHOLAS GARETH MORSE;;FOLOPPE NICOLAS NOEL ANDRE;;STOKES STEPHEN,,https://lens.org/178-282-555-153-769,Patent Application,no,0,0,12,16,0,C07D487/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P31/12;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D487/04;;A61K31/517;;C07D487/04,A61K31/517;;C07D487/04;;A61P35/00,,0,0,,,,DISCONTINUED
862,US,A1,US 2016/0331932 A1,053-689-783-155-370,2016-11-17,2016,US 201415106584 A,2014-12-19,US 201415106584 A;;US 201361918800 P;;US 201361918848 P;;IB 2014067173 W,2013-12-20,Steerable Medical Device Handle,"A steerable catheter control handle and method are provided for bi-directional control of a steerable catheter, the catheter including at least two control wires, a distal end of each of the control wires being coupled to the catheter at a distal region thereof. The control system comprises a housing. A wire actuation mechanism is disposed within the housing and is operably coupled to at least two control wires for enabling actuation of the at least two control wires. The steerable catheter control handle additionally comprises a proximal control knob that is operably coupled to the wire actuation mechanism to enable actuation of the at least two control wires. The control knob is positioned proximal to the wire actuation mechanism to enhance ease of use of the steerable catheter control handle. The rotation of the proximal knob causes movement of the wire actuation mechanism within the housing for tensioning one of the at least two control wires for causing a distal end deflection of the steerable catheter.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;THOMPSON SMITH MELANIE;;GORAPALLI DEEPTHI;;COPELAND STEVE;;DICKIE ROBERT G;;LEFLER AMY;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2016-06-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/053-689-783-155-370,Patent Application,yes,6,4,6,6,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/01,,0,0,,,,ACTIVE
863,US,A1,US 2022/0265966 A1,199-810-506-509-456,2022-08-25,2022,US 202217740431 A,2022-05-10,US 202217740431 A;;US 201715851942 A;;US 201662437916 P,2016-12-22,Feedback Mechanisms for a Steerable Medical Device,"An apparatus and method are disclosed for providing feedback for a steerable medical device assembly for deflecting a device, the assembly comprising a control handle comprising an actuation mechanism. The assembly additionally comprises a device coupled to the control handle and operable to be deflected upon actuation of the actuation mechanism, and a feedback mechanism for providing an indication of the deflection of the device, wherein the feedback mechanism is associated with the actuation mechanism for deflecting the device.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;THOMPSON SMITH MELANIE;;CHEN JAN-HUNG;;ALNABELSEYA AHMED;;CHAN AUDREY;;PEQUEGNAT ANDREW;;CHEHADE MOUSSA,BAYLIS MEDICAL COMPANY INC (2019-02-07);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/199-810-506-509-456,Patent Application,yes,3,0,3,9,0,A61M25/0136;;A61B2090/0811;;A61M2205/582;;A61M2205/583;;A61M2205/581;;A61M25/0136;;A61M25/0147;;A61B2090/0811;;A61M2205/582;;A61M2205/583;;A61M2205/581,A61M25/01,,0,0,,,,PENDING
864,IL,A,IL 281979 A,037-834-352-028-618,2021-05-31,2021,IL 28197921 A,2021-04-01,GB 201816210 A;;EP 2019076772 W,2018-10-04,Humanised anti-n-truncated amyloid beta monoclonal antibody field,,GEORG AUGUST UNIVERSIT?T G?TTINGEN STIFTUNG ?FFENTLICHEN RECHTS UNIVERSIT?TSMEDIZIN;;LIFEARC;;BAYER THOMAS;;BAKRANIA PREETI;;DAVIES SARAH;;BROWN ALEX;;MPAMHANGA CHIDO;;MATTHEWS DAVID;;CARR MARK;;HALL GARETH,BAYER THOMAS;;BAKRANIA PREETI;;DAVIES SARAH;;BROWN ALEX;;MPAMHANGA CHIDO;;MATTHEWS DAVID;;CARR MARK;;HALL GARETH,,https://lens.org/037-834-352-028-618,Patent Application,no,0,0,14,14,0,C07K16/18;;C07K2317/24;;A61P25/28;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/567;;A61K2039/505;;A61P25/28;;C07K16/18;;C07K2317/24;;C07K2317/567;;C07K2317/92;;C07K2317/94;;C07K16/18;;A61P25/28;;C07K2317/56;;C07K2317/567;;C07K2317/92;;C07K2317/94;;A61K2039/505;;A61P25/28;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/567,,,0,0,,,,PENDING
865,KR,A,KR 20210080400 A,040-012-616-741-552,2021-06-30,2021,KR 20217012796 A,2019-10-02,GB 201816210 A;;EP 2019076772 W,2018-10-04,인간화 항-N-절단 아밀로이드 베타 단일 클론 항체,"본 발명은 아밀로이드 펩티드에 결합하는 인간화 항체에 관한 것으로, 상기 항체는 중쇄 및/또는 경쇄 가변 도메인에 돌연변이를 포함하고, 이 돌연변이는 결합 활성을 향상시킨다. 상기 항체는 알츠하이머병 (AD) 치료에 유용할 수 있다.",GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN;;LIFEARC,BAYER THOMAS;;BAKRANIA PREETI;;DAVIES SARAH;;BROWN ALEX;;MPAMHANGA CHIDO;;MATTHEWS DAVID;;CARR MARK;;HALL GARETH,,https://lens.org/040-012-616-741-552,Patent Application,no,0,0,14,14,136,C07K16/18;;C07K2317/24;;A61P25/28;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/567;;A61K2039/505;;A61P25/28;;C07K16/18;;C07K2317/24;;C07K2317/567;;C07K2317/92;;C07K2317/94;;C07K16/18;;A61P25/28;;C07K2317/56;;C07K2317/567;;C07K2317/92;;C07K2317/94;;A61K2039/505;;A61P25/28;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/567,C07K16/18;;A61K39/00;;A61P25/28,,0,0,,,,PENDING
866,CA,A1,CA 3114669 A1,054-971-225-714-217,2020-04-09,2020,CA 3114669 A,2019-10-02,GB 201816210 A;;EP 2019076772 W,2018-10-04,HUMANISED ANTI-N-TRUNCATED AMYLOID BETA MONOCLONAL ANTIBODY,"The present invention relates to humanised antibodies that bind amyloid peptides, which antibodies comprise mutations in the heavy chain and/or light chain variable domains, which mutations improve the binding activity. The antibodies may be useful in the treatment of Alzheimer's disease (AD).",GEORG AUGUST UNIV GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS UNIVSMEDIZIN;;LIFEARC,BAYER THOMAS;;BAKRANIA PREETI;;DAVIES SARAH;;BROWN ALEX;;MPAMHANGA CHIDO;;MATTHEWS DAVID;;CARR MARK;;HALL GARETH,,https://lens.org/054-971-225-714-217,Patent Application,no,0,0,14,14,68,C07K16/18;;C07K2317/24;;A61P25/28;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/567;;A61K2039/505;;A61P25/28;;C07K16/18;;C07K2317/24;;C07K2317/567;;C07K2317/92;;C07K2317/94;;C07K16/18;;A61P25/28;;C07K2317/56;;C07K2317/567;;C07K2317/92;;C07K2317/94;;A61K2039/505;;A61P25/28;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/567,C07K16/18;;A61K39/00;;A61K39/395;;A61P25/28,,0,0,,,,PENDING
867,MX,A,MX 2021003867 A,178-012-417-906-574,2021-09-08,2021,MX 2021003867 A,2019-10-02,GB 201816210 A;;EP 2019076772 W,2018-10-04,HUMANISED ANTI-N-TRUNCATED AMYLOID BETA MONOCLONAL ANTIBODY.,"The present invention relates to humanised antibodies that bind amyloid peptides, which antibodies comprise mutations in the heavy chain and/or light chain variable domains, which mutations improve the binding activity. The antibodies may be useful in the treatment of Alzheimer's disease (AD).",GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN,BAYER THOMAS;;BAKRANIA PREETI;;DAVIES SARAH;;BROWN ALEX;;MPAMHANGA CHIDO;;MATTHEWS DAVID;;CARR MARK;;HALL GARETH,,https://lens.org/178-012-417-906-574,Patent Application,no,0,0,14,14,0,C07K16/18;;C07K2317/24;;A61P25/28;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/567;;A61K2039/505;;A61P25/28;;C07K16/18;;C07K2317/24;;C07K2317/567;;C07K2317/92;;C07K2317/94;;C07K16/18;;A61P25/28;;C07K2317/56;;C07K2317/567;;C07K2317/92;;C07K2317/94;;A61K2039/505;;A61P25/28;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/567,A61K39/00;;C07K16/18;;A61K39/395;;A61P25/28,,0,0,,,,PENDING
868,US,B2,US 10661057 B2,168-932-932-352-587,2020-05-26,2020,US 201415106584 A,2014-12-19,US 201415106584 A;;US 201361918800 P;;US 201361918848 P;;IB 2014067173 W,2013-12-20,Steerable medical device handle,"A steerable catheter control handle and method are provided for bi-directional control of a steerable catheter, the catheter including at least two control wires, a distal end of each of the control wires being coupled to the catheter at a distal region thereof. The control system comprises a housing. A wire actuation mechanism is disposed within the housing and is operably coupled to at least two control wires for enabling actuation of the at least two control wires. The steerable catheter control handle additionally comprises a proximal control knob that is operably coupled to the wire actuation mechanism to enable actuation of the at least two control wires. The control knob is positioned proximal to the wire actuation mechanism to enhance ease of use of the steerable catheter control handle. The rotation of the proximal knob causes movement of the wire actuation mechanism within the housing for tensioning one of the at least two control wires for causing a distal end deflection of the steerable catheter.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;THOMPSON SMITH MELANIE;;GORAPALLI DEEPTHI;;COPELAND STEVE;;DICKIE ROBERT G;;LEFLER AMY;;BECA BOGDAN,BAYLIS MEDICAL COMPANY INC (2016-06-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/168-932-932-352-587,Granted Patent,yes,32,1,6,6,0,A61M25/0147;;A61M25/0136;;A61M25/0147;;A61M25/0136,A61M25/01,,3,0,,,"International Search Report for PCT Application No. PCT/IB2013/055013 dated Jan. 20, 2014.;;IPRP for PCT Application No. PCT/IB2013/055013 dated Dec. 31, 2014.;;IDS filed in related U.S. Appl. No. 14/409,662, dated Feb. 12, 2018.",ACTIVE
869,US,A1,US 2021/0347867 A1,048-040-418-911-257,2021-11-11,2021,US 201917282592 A,2019-10-02,GB 201816210 A;;EP 2019076772 W,2018-10-04,HUMANISED ANTI-N-TRUNCATED AMYLOID BETA MONOCLONAL ANTIBODY,"The present invention relates to humanised antibodies that bind amyloid peptides, which antibodies comprise mutations in the heavy chain and/or light chain variable domains, which mutations improve the binding activity. The antibodies may be useful in the treatment of Alzheimer's disease (AD).",GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN;;LIFEARC,BAYER THOMAS;;BAKRANIA PREETI;;DAVIES SARAH;;BROWN ALEX;;MPAMHANGA CHIDO;;MATTHEWS DAVID;;CARR MARK;;HALL GARETH,LIFEARC (2021-04-12);;GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS UNIVERSITÄTSMEDIZIN (2021-04-12),https://lens.org/048-040-418-911-257,Patent Application,yes,0,0,14,14,68,C07K16/18;;C07K2317/24;;A61P25/28;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/567;;A61K2039/505;;A61P25/28;;C07K16/18;;C07K2317/24;;C07K2317/567;;C07K2317/92;;C07K2317/94;;C07K16/18;;A61P25/28;;C07K2317/56;;C07K2317/567;;C07K2317/92;;C07K2317/94;;A61K2039/505;;A61P25/28;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/567,C07K16/18;;A61P25/28,,0,0,,,,PENDING
870,SG,A,SG 11202102765R A,127-043-804-613-378,2021-04-29,2021,SG 11202102765R A,2019-10-02,GB 201816210 A;;EP 2019076772 W,2018-10-04,HUMANISED ANTI-N-TRUNCATED AMYLOID BETA MONOCLONAL ANTIBODY,,GEORG AUGUST UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVERSITAETSMEDIZIN;;LIFEARC,BAYER THOMAS;;BAKRANIA PREETI;;DAVIES SARAH;;BROWN ALEX;;MPAMHANGA CHIDO;;MATTHEWS DAVID;;CARR MARK;;HALL GARETH,,https://lens.org/127-043-804-613-378,Unknown,no,0,0,14,14,0,C07K16/18;;C07K2317/24;;A61P25/28;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/567;;A61K2039/505;;A61P25/28;;C07K16/18;;C07K2317/24;;C07K2317/567;;C07K2317/92;;C07K2317/94;;C07K16/18;;A61P25/28;;C07K2317/56;;C07K2317/567;;C07K2317/92;;C07K2317/94;;A61K2039/505;;A61P25/28;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/567,C07K16/18;;A61K39/00;;A61K39/395;;A61P25/28,,0,0,,,,PENDING
871,US,A9,US 2023/0203140 A9,160-546-883-550-010,2023-06-29,2023,US 201917282592 A,2019-10-02,GB 201816210 A;;EP 2019076772 W,2018-10-04,HUMANISED ANTI-N-TRUNCATED AMYLOID BETA MONOCLONAL ANTIBODY,"The present invention relates to humanised antibodies that bind amyloid peptides, which antibodies comprise mutations in the heavy chain and/or light chain variable domains, which mutations improve the binding activity. The antibodies may be useful in the treatment of Alzheimer's disease (AD).",GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN;;LIFEARC,BAYER THOMAS;;BAKRANIA PREETI;;DAVIES SARAH;;BROWN ALEX;;MPAMHANGA CHIDO;;MATTHEWS DAVID;;CARR MARK;;HALL GARETH,LIFEARC (2021-04-12);;GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS UNIVERSITÄTSMEDIZIN (2021-04-12),https://lens.org/160-546-883-550-010,Amended Application,yes,0,0,14,14,68,C07K16/18;;C07K2317/24;;A61P25/28;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/567;;A61K2039/505;;A61P25/28;;C07K16/18;;C07K2317/24;;C07K2317/567;;C07K2317/92;;C07K2317/94;;C07K16/18;;A61P25/28;;C07K2317/56;;C07K2317/567;;C07K2317/92;;C07K2317/94;;A61K2039/505;;A61P25/28;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/567,C07K16/18;;A61P25/28,,0,0,,,,PENDING
872,AU,A1,AU 2019/354714 A1,004-178-706-369-963,2021-04-29,2021,AU 2019/354714 A,2019-10-02,GB 201816210 A;;EP 2019076772 W,2018-10-04,Humanised anti-N-truncated amyloid beta monoclonal antibody,"The present invention relates to humanised antibodies that bind amyloid peptides, which antibodies comprise mutations in the heavy chain and/or light chain variable domains, which mutations improve the binding activity. The antibodies may be useful in the treatment of Alzheimer's disease (AD).",GEORG AUGUST UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVERSITAETSMEDIZIN;;LIFEARC,BAYER THOMAS;;BAKRANIA PREETI;;DAVIES SARAH;;BROWN ALEX;;MPAMHANGA CHIDO;;MATTHEWS DAVID;;CARR MARK;;HALL GARETH,,https://lens.org/004-178-706-369-963,Patent Application,no,0,0,14,14,0,C07K16/18;;C07K2317/24;;A61P25/28;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/567;;A61K2039/505;;A61P25/28;;C07K16/18;;C07K2317/24;;C07K2317/567;;C07K2317/92;;C07K2317/94;;C07K16/18;;A61P25/28;;C07K2317/56;;C07K2317/567;;C07K2317/92;;C07K2317/94;;A61K2039/505;;A61P25/28;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/567,C07K16/18;;A61K39/00;;A61K39/395;;A61P25/28,,0,0,,,,PENDING
873,EP,A1,EP 3861023 A1,103-224-240-084-387,2021-08-11,2021,EP 19782593 A,2019-10-02,GB 201816210 A;;EP 2019076772 W,2018-10-04,HUMANISED ANTI-N-TRUNCATED AMYLOID BETA MONOCLONAL ANTIBODY,,GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN;;LIFEARC,BAYER THOMAS;;BAKRANIA PREETI;;DAVIES SARAH;;BROWN ALEX;;MPAMHANGA CHIDO;;MATTHEWS DAVID;;CARR MARK;;HALL GARETH,,https://lens.org/103-224-240-084-387,Patent Application,yes,0,0,14,14,0,C07K16/18;;C07K2317/24;;A61P25/28;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/567;;A61K2039/505;;A61P25/28;;C07K16/18;;C07K2317/24;;C07K2317/567;;C07K2317/92;;C07K2317/94;;C07K16/18;;A61P25/28;;C07K2317/56;;C07K2317/567;;C07K2317/92;;C07K2317/94;;A61K2039/505;;A61P25/28;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/567,A61K39/00;;C07K16/18;;A61K39/395;;A61P25/28,,0,0,,,,PENDING
874,GB,A,GB 2522221 A,123-522-101-719-611,2015-07-22,2015,GB 201400753 A,2014-01-16,GB 201400753 A,2014-01-16,Gaming apparatus,"A gaming apparatus, for example a roulette wheel, comprises a plurality of concentric wheels adapted to independently rotate around a common axis of rotation, each of the concentric wheels has a plurality of sections for selection; and wheel control means adapted to apply a force to at least one of the concentric wheels so as to alter a rotational speed of the at least one concentric wheels. The wheel control means are adapted to vary the applied force.",CENTRAL GAMING LTD;;RANDOM GAMES LTD,MEDDICK LESLIE DOUGLAS;;DAVIES ANDREW GEORGE;;ANDREWS GARETH;;CHALK ROBERT CLIFFORD;;ANDREWS MATTHEW LEWIS;;CHALMERS RONALD,,https://lens.org/123-522-101-719-611,Patent Application,no,2,0,3,3,0,A63F5/043;;A63F5/043;;A63F5/00;;A63F5/0052;;A63F5/0082;;A63F5/04;;A63F2009/2447,A63F5/04;;A63F5/00,,0,0,,,,DISCONTINUED
875,BG,B1,BG 64989 B1,122-090-123-224-852,2006-11-30,2006,BG 10515201 A,2001-01-15,GB 9813576 A,1998-06-24,"A SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVE, PHARMACEUTICAL COMPOSITIONS MADE THEREFROM","7-(1,1-Dimethylethyl)-6-(2-ethyl-2(H)-, 1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-i(b)]pyridazine, and pharmaceutically acceptable salts thereof, are selective ligands of GABAAreceptors, in particular having high affinity for the alpha2 and/or alpha3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.",MERCK SHARP & DOHME,CARLING WILLIAM;;CASTRO BERTRAND;;COWDEN CAMERON;;DAVIES ANTONY;;MADIN ANDREW;;MCCABE JAMES;;PEARCE GARETH;;STREET LESLIE,,https://lens.org/122-090-123-224-852,Granted Patent,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/50;;A61K31/5025;;A61P25/00;;A61P25/22,,0,0,,,,EXPIRED
876,WO,A1,WO 2020/070225 A1,193-155-069-783-310,2020-04-09,2020,EP 2019076772 W,2019-10-02,GB 201816210 A,2018-10-04,HUMANISED ANTI-N-TRUNCATED AMYLOID BETA MONOCLONAL ANTIBODY,"The present invention relates to humanised antibodies that bind amyloid peptides, which antibodies comprise mutations in the heavy chain and/or light chain variable domains, which mutations improve the binding activity. The antibodies may be useful in the treatment of Alzheimer's disease (AD).",GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN;;LIFEARC,BAYER THOMAS;;BAKRANIA PREETI;;DAVIES SARAH;;BROWN ALEX;;MPAMHANGA CHIDO;;MATTHEWS DAVID;;CARR MARK;;HALL GARETH,,https://lens.org/193-155-069-783-310,Patent Application,yes,8,1,14,14,68,C07K16/18;;C07K2317/24;;A61P25/28;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/567;;A61K2039/505;;A61P25/28;;C07K16/18;;C07K2317/24;;C07K2317/567;;C07K2317/92;;C07K2317/94;;C07K16/18;;A61P25/28;;C07K2317/56;;C07K2317/567;;C07K2317/92;;C07K2317/94;;A61K2039/505;;A61P25/28;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/567,A61K39/00;;C07K16/18;;A61K39/395;;A61P25/28,,25,20,014-454-911-548-136;;054-283-017-164-24X;;004-768-996-498-068;;014-454-911-548-136;;040-577-067-037-463;;104-212-297-137-759;;083-633-544-126-594;;066-081-654-645-396;;002-569-552-152-58X;;045-149-256-448-908;;138-344-087-704-67X;;025-446-329-734-602;;035-881-005-963-336;;002-364-381-558-702;;019-982-436-313-59X;;016-499-498-557-662;;072-057-233-458-24X;;041-012-440-911-39X;;014-454-911-548-136;;054-302-965-100-511,pmc4667289;;26626428;;10.1038/srep17338;;24252153;;10.1186/2051-5960-1-56;;pmc3893517;;10.1007/s00401-015-1489-x;;26467270;;pmc4667289;;26626428;;10.1038/srep17338;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1007/978-1-4757-1770-9;;10.4161/mabs.2.2.11158;;pmc2840237;;20150767;;pmc3722453;;23685882;;10.1007/s00401-013-1129-2;;2218494;;10.1126/science.2218494;;10.1016/s0169-409x(97)00053-7;;10837567;;10.1038/36014;;9495336;;10.1002/eji.1830251248;;8566048;;10.1016/s0005-2736(97)00177-6;;9459598;;11397087;;10.1006/jmbi.2001.4662;;17021169;;pmc6674618;;10.1523/jneurosci.1202-06.2006;;10.1016/0165-0270(84)90007-4;;6471907;;19823761;;pmc2789212;;10.1007/s00702-009-0314-x;;pmc4667289;;26626428;;10.1038/srep17338;;22267726;;10.1074/jbc.m111.308601;;pmc3318696,"GREGORY ANTONIOS ET AL: ""Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X"", SCIENTIFIC REPORTS, vol. 5, no. 1, 2 December 2015 (2015-12-02), pages 1 - 14, XP055638852, DOI: 10.1038/srep17338;;GREGORY ANTONIOS ET AL: ""N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody"", ACTA NEUROPATHOLOGICA COMMUNICATIONS, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. 1, 6 September 2013 (2013-09-06), pages 56, XP021162782, ISSN: 2051-5960, DOI: 10.1186/2051-5960-1-56;;BOUTER YVONNE ET AL: ""Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models"", ACTA NEUROPATHOLOGICA, SPRINGER VERLAG, BERLIN, DE, vol. 130, no. 5, 14 October 2015 (2015-10-14), pages 713 - 729, XP035572431, ISSN: 0001-6322, [retrieved on 20151014], DOI: 10.1007/S00401-015-1489-X;;ANTONIOS ET AL., ACTA NEUROPATHOL. COMMUN., vol. 6 1, 2013, pages 56;;ANTONIOS ET AL., SCIENTIFIC REPORTS, vol. 5, 2015, pages 17338;;KABAT, E.A.WU, T.T.PERRY, H.M.GOTTESMANN, K.SFOELLER, C.: ""Sequences of Proteins of Immunological Interest"", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, pages: 1 - 3242;;SONGSIVILAILACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1149 - 1553;;WINNACKER: ""From Genes to Clones"", 1987, VCH PUBLISHERS;;JAWHAR, S. ET AL., NEUROBIOLAGING, vol. 33, 2012;;SCOPES: ""Protein Purification"", 1982, SPRINGER-VERLAG;;MOORE ET AL., MABS, vol. 2, no. 2, 2010, pages 181 - 189;;BOUTER, Y. ET AL., ACTA NEUROPATHOL, vol. 126, 2013, pages 189 - 205;;LANGER, SCIENCE, vol. 249, 1990, pages 1527;;HANES, ADVANCED DRUG DELIVERY REVIEWS, vol. 28, 1997, pages 97;;GLENN ET AL., NATURE, vol. 391, 1998, pages 851;;PAUL ET AL., EUR. J. IMMUNOL., vol. 25, 1995, pages 3521;;CEVC ET AL., BIOCHEM. BIOPHYS. ACTA, vol. 1368, 1998, pages 201 - 15;;HONEGGER, APLUCKTHUN A., J. MOL. BIOL, vol. 309, 2001, pages 657 - 67;;OAKLEY, H. ET AL., J NEUROSCI, vol. 26, 2006, pages 10129 - 10140;;MORRIS, R., J NEUROSCI METHODS, vol. 11, 1984, pages 47 - 60;;WIRTHS, O. ET AL., J NEURAL TRANSM, vol. 117, 2010, pages 85 - 96;;ANTONIOS, G. ET AL., SCIENTIFIC REPORTS, vol. 5, 2015, pages 17338;;WITTNAM, J.L. ET AL., J BIOI CHEM, vol. 287, 2012, pages 8154 - 8162;;LEFRANC, M.-P. ET AL., NUCL. ACIDS RES., vol. 43, no. D1, 2015, pages D413 - D422",PENDING
877,US,B2,US 11357953 B2,080-796-432-956-523,2022-06-14,2022,US 201715851942 A,2017-12-22,US 201715851942 A;;US 201662437916 P,2016-12-22,Feedback mechanisms for a steerable medical device,"An apparatus and method are disclosed for providing feedback for a steerable medical device assembly for deflecting a device, the assembly comprising a control handle comprising an actuation mechanism. The assembly additionally comprises a device coupled to the control handle and operable to be deflected upon actuation of the actuation mechanism, and a feedback mechanism for providing an indication of the deflection of the device, wherein the feedback mechanism is associated with the actuation mechanism for deflecting the device.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;THOMPSON SMITH MELANIE;;CHEN JAN-HUNG;;ALNABELSEYA AHMED;;CHAN AUDREY;;PEQUEGNAT ANDREW;;CHEHADE MOUSSA,BAYLIS MEDICAL COMPANY INC (2019-02-07);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/080-796-432-956-523,Granted Patent,yes,83,1,3,9,0,A61M25/0136;;A61B2090/0811;;A61M2205/582;;A61M2205/583;;A61M2205/581;;A61M25/0136;;A61M25/0147;;A61B2090/0811;;A61M2205/582;;A61M2205/583;;A61M2205/581,A61M25/01;;A61B90/00,,0,0,,,,ACTIVE
878,US,A1,US 2018/0214669 A1,002-703-409-713-043,2018-08-02,2018,US 201715851942 A,2017-12-22,US 201715851942 A;;US 201662437916 P,2016-12-22,Feedback Mechanisms for a Steerable Medical Device,"An apparatus and method are disclosed for providing feedback for a steerable medical device assembly for deflecting a device, the assembly comprising a control handle comprising an actuation mechanism. The assembly additionally comprises a device coupled to the control handle and operable to be deflected upon actuation of the actuation mechanism, and a feedback mechanism for providing an indication of the deflection of the device, wherein the feedback mechanism is associated with the actuation mechanism for deflecting the device.",BAYLIS MEDICAL CO INC,DAVIES GARETH;;THOMPSON SMITH MELANIE;;CHEN JAN-HUNG;;ALNABELSEYA AHMED;;CHAN AUDREY;;PEQUEGNAT ANDREW;;CHEHADE MOUSSA,BAYLIS MEDICAL COMPANY INC (2019-02-07);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/002-703-409-713-043,Patent Application,yes,2,6,3,9,0,A61M25/0136;;A61B2090/0811;;A61M2205/582;;A61M2205/583;;A61M2205/581;;A61M25/0136;;A61M25/0147;;A61B2090/0811;;A61M2205/582;;A61M2205/583;;A61M2205/581,A61M25/01,,0,0,,,,ACTIVE
879,BR,A2,BR 112021006153 A2,016-355-453-750-263,2021-06-29,2021,BR 112021006153 A,2019-10-02,EP 2019076772 W;;GB 201816210 A,2018-10-04,anticorpo monoclonal beta amiloide anti-n-truncado humanizado,"a presente invenção refere-se a anticorpos humanizados que ligam peptídeos amiloides, cujos anticorpos compreendem mutações nos domínios variáveis de cadeia pesada e/ou cadeia leve, cujas mutações melhoram a atividade de ligação. os anticorpos podem ser úteis no tratamento da doença de alzheimer (ad).",GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN;;LIFEARC,ALEX BROWN;;CHIDO MPAMHANGA;;DAVID MATTHEWS;;GARETH HALL;;MARK CARR;;PREETI BAKRANIA;;SARAH DAVIES;;THOMAS BAYER,,https://lens.org/016-355-453-750-263,Patent Application,no,0,0,14,14,0,C07K16/18;;C07K2317/24;;A61P25/28;;A61K2039/505;;C07K2317/92;;C07K2317/94;;C07K2317/567;;A61K2039/505;;A61P25/28;;C07K16/18;;C07K2317/24;;C07K2317/567;;C07K2317/92;;C07K2317/94;;C07K16/18;;A61P25/28;;C07K2317/56;;C07K2317/567;;C07K2317/92;;C07K2317/94;;A61K2039/505;;A61P25/28;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/567,A61K39/395;;A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,PENDING
880,US,A1,US 2023/0338082 A1,023-760-885-899-224,2023-10-26,2023,US 202117918656 A,2021-05-06,US 202117918656 A;;US 202063022842 P;;IB 2021053876 W,2020-05-11,An Electrosurgical Device with Automatic Shut-Off,"A method and apparatus are disclosed for creating a puncture in a tissue. The assembly includes a puncturing device having a distal tip configured to deliver energy to the tissue, creating the puncture. The puncturing device further includes a marker positioned along the puncturing device. The assembly further includes a dilator which has a lumen extending from a proximal portion to a distal portion and configured to receive the puncturing device. The dilator further comprises a sensor positioned along a length of the dilator. When the marker and the sensor are aligned, energy is delivered to the distal tip of the puncturing device.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DICICCO MATTHEW;;DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;MOK DANIEL WING FAI;;TYLER BRANDON,BAYLIS MEDICAL COMPANY INC (2021-09-13);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/023-760-885-899-224,Patent Application,yes,0,0,5,5,0,A61B90/00;;A61B18/1492;;A61B2018/00357;;A61B2018/00601;;A61B2018/0038;;A61B18/1233;;A61B2018/00642;;A61B2018/00708;;A61B2090/062;;A61B18/1492;;A61B2018/00083;;A61B2018/00107;;A61B2018/00357;;A61B2018/00625,A61B18/14,,0,0,,,,PENDING
881,EP,A1,EP 4149379 A1,064-443-942-354-588,2023-03-22,2023,EP 21804972 A,2021-05-06,US 202063022842 P;;IB 2021053876 W,2020-05-11,AN ELECTROSURGICAL DEVICE WITH AUTOMATIC SHUT-OFF,,BOSTON SCIENT MEDICAL DEVICE LIMITED,DICICCO MATTHEW;;DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;MOK DANIEL WING FAI;;TYLER BRANDON,,https://lens.org/064-443-942-354-588,Patent Application,yes,0,0,5,5,0,A61B90/00;;A61B18/1492;;A61B2018/00357;;A61B2018/00601;;A61B2018/0038;;A61B18/1233;;A61B2018/00642;;A61B2018/00708;;A61B2090/062;;A61B18/1492;;A61B2018/00083;;A61B2018/00107;;A61B2018/00357;;A61B2018/00625,A61B18/14;;A61B17/00;;A61B17/34;;A61B18/00;;A61B18/12;;A61B90/00,,0,0,,,,PENDING
882,GB,A,GB 2610657 A,097-674-220-944-784,2023-03-15,2023,GB 202115764 A,2021-11-03,GB 202112773 A,2021-09-08,An improved gas turbine engine,"A gas turbine engine for an aircraft comprises a compressor, a combustor, and a turbine, with a first electric machine 210 being rotationally connected to the turbine. The ratio of the maximum power generated by the first electrical machine to the maximum shaft power of the gas turbine engine is between 0.005 and 0.020. A fan assembly 130 may comprise a fan with a diameter between 0.3m and 1.4m. The fan assembly may have two or more fan stages with a plurality of blades. The first electrical machine may be positioned axially between the fan assembly and the compressor. A second electric machine 220 may be rotationally connected to the fan assembly, the ratio of the maximum power generated by the second electrical machine to the maximum shaft power of the gas turbine engine being between 0.005 and 0.035. At least one of the first electric machine and second electric machine may have an axial length and a diameter, wherein a ratio of the axial length to the diameter is between 0.5 and 2.0. An associated method of operation is also disclosed.",ROLLS ROYCE PLC,R PAUL DAVIES;;E GARETH MOORE;;M STEPHEN HUSBAND;;R DAVID TRAINER;;P DAVID SCOTHERN;;LUKE GEORGE,,https://lens.org/097-674-220-944-784,Patent Application,no,3,0,8,12,0,F02K5/00;;F02K3/06;;F05D2220/76;;B64D27/24;;Y02T50/60;;B64D27/026;;F02K5/00;;F02C6/00;;F02C6/20;;F02C7/12;;F02C7/32;;F05D2220/323;;F05D2220/76;;F05D2260/213,F02C7/32;;F01D15/10;;F02C3/04,,0,0,,,,PENDING
883,CA,A1,CA 3173440 A1,054-406-545-992-038,2021-11-18,2021,CA 3173440 A,2021-05-06,US 202063022842 P;;IB 2021053876 W,2020-05-11,AN ELECTROSURGICAL DEVICE WITH AUTOMATIC SHUT-OFF,"A method and apparatus are disclosed for creating a puncture in a tissue. The assembly includes a puncturing device having a distal tip configured to deliver energy to the tissue, creating the puncture. The puncturing device further includes a marker positioned along the puncturing device. The assembly further includes a dilator which has a lumen extending from a proximal portion to a distal portion and configured to receive the puncturing device. The dilator further comprises a sensor positioned along a length of the dilator. When the marker and the sensor are aligned, energy is delivered to the distal tip of the puncturing device.",BOSTON SCIENT MEDICAL DEVICE LIMITED,DICICCO MATTHEW;;DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;MOK DANIEL WING FAI;;TYLER BRANDON,,https://lens.org/054-406-545-992-038,Patent Application,no,0,0,5,5,0,A61B90/00;;A61B18/1492;;A61B2018/00357;;A61B2018/00601;;A61B2018/0038;;A61B18/1233;;A61B2018/00642;;A61B2018/00708;;A61B2090/062;;A61B18/1492;;A61B2018/00083;;A61B2018/00107;;A61B2018/00357;;A61B2018/00625,A61B17/00;;A61B17/34;;A61B18/00;;A61B18/12;;A61B18/14;;A61B90/00,,0,0,,,,PENDING
884,GB,A,GB 2610658 A,076-272-172-734-489,2023-03-15,2023,GB 202116765 A,2021-11-22,GB 202112775 A,2021-09-08,An improved gas turbine engine,"A gas turbine engine for an aircraft comprises a compressor, a combustor, and a turbine, with a first electric machine 210 being rotationally connected to the turbine configured to generate electrical energy and an electrical storage unit 230 to store the generated energy. The product of the energy storage capacity (Wh) and the maximum generated electrical power (W) divided by the maximum dry thrust (N) may be 20,000-300,000. The product of the maximum charge rate (h-1) and the maximum generated electrical power (W) divided by the maximum dry thrust (N) may be 20-400. The product of the maximum discharge rate (h-1) and the maximum generated electrical power (W) divided by the maximum dry thrust (N) may be 40-400. A fan assembly 130 may comprise a fan with a diameter between 0.3m and 2.0m and may have two or more fan stages with a plurality of blades. A second electric machine 220 may be rotationally connected to the fan assembly. The electrical storage unit may be a battery or capacitor. A heat exchanger 120 in fluid communication with the engine may comprise a hub and plurality of heat transfer elements extending radially outward. An associated method of operation is also disclosed.",ROLLS ROYCE PLC,PAUL R DAVIES;;GARETH E MOORE;;STEPHEN MARK HUSBAND;;DAVID R TRAINER;;DAVID P SCOTHERN;;LUKE GEORGE,,https://lens.org/076-272-172-734-489,Patent Application,no,8,0,9,14,0,F02C7/14;;F02C7/18;;F02C7/32;;F01D15/10;;F05D2240/12;;F05D2260/213;;F05D2220/76;;F05D2220/766;;F02K3/04;;F05D2260/42;;Y02T50/60;;F01D15/10;;F02C7/32;;F02C7/14;;F01D9/06;;F02C7/18;;F02C6/20;;F02C7/12;;F02C7/32;;F05D2220/323;;F05D2220/76;;F05D2260/213,F01D15/10;;F02C6/14;;F02C7/32;;H02K7/18,,0,0,,,,PENDING
885,US,A1,US 2023/0184128 A1,147-758-413-781-31X,2023-06-15,2023,US 202217940614 A,2022-09-08,GB 202112775 A;;GB 202116765 A,2021-09-08,IMPROVED GAS TURBINE ENGINE,"A gas turbine engine for an aircraft comprises, in axial flow sequence, a compressor module, a combustor module, and a turbine module. The gas turbine engine further comprises a first electric machine that is rotationally connected to the turbine module, and an electrical energy storage unit. The gas turbine engine is configured to generate a maximum dry thrust T (N). The first electric machine is configured to generate a maximum electrical power P EM1 (W). The electrical energy storage unit has an energy storage capacity E (Wh), a maximum charge rate C (h −1 ), and a maximum discharge rate D (h −1 ). The electrical energy storage unit is configured to store electrical energy that may be generated by the first electric machine.",ROLLS ROYCE PLC,DAVIES PAUL R;;MOORE GARETH E;;HUSBAND STEPHEN M;;TRAINER DAVID R;;SCOTHERN DAVID P;;GEORGE LUKE,ROLLS-ROYCE PLC (2021-11-22),https://lens.org/147-758-413-781-31X,Patent Application,yes,3,0,2,14,0,F02K3/06;;F02C6/14;;F02K5/00;;F05D2220/76;;F05D2260/42;;B64D27/24;;B64D27/10;;Y02T50/60;;B64D27/026;;F05D2200/13;;F05D2200/14;;F05D2220/323;;F05D2260/213;;F05D2260/232;;F05D2260/42;;F02C7/36,F01D15/10;;F02K3/06,,0,0,,,,PENDING
886,US,A1,US 2023/0184163 A1,147-898-446-372-146,2023-06-15,2023,US 202217940748 A,2022-09-08,GB 202112773 A;;GB 202115764 A,2021-09-08,IMPROVED GAS TURBINE ENGINE,"A gas turbine engine for an aircraft comprises, in axial flow sequence, a compressor module, a combustor module, and a turbine module, with a first electric machine being rotationally connected to the turbine module. The first electrical machine is configured to generate a maximum electrical power P EM1 (W), and the gas turbine engine is configured to generate a maximum shaft power P SHAFT (W); and a ratio R of: is in a range of between 0.005 and 0.020.",ROLLS ROYCE PLC,DAVIES PAUL R;;MOORE GARETH E;;HUSBAND STEPHEN M;;TRAINER DAVID R;;SCOTHERN DAVID P;;GEORGE LUKE,ROLLS-ROYCE PLC (2021-11-25),https://lens.org/147-898-446-372-146,Patent Application,yes,5,0,2,12,0,F02K5/00;;F02K3/06;;F05D2220/76;;B64D27/24;;B64D27/10;;Y02T50/60;;B64D27/026;;F02C6/20;;F02C7/32;;F02C7/36;;F05D2220/323;;F05D2220/70,F02C6/20;;F02C7/32;;F02C7/36,,1,1,015-760-271-604-065,10.1155/2018/9237907,"Chen et al., “Performance Analysis of a Three-Stream Adaptive Cycle Engine during Throttling”, 22 April 2018, Hindawi International Journal of Aerospace Engineering, Volume 2018, Article ID 9237907, 16 pages, https://doi.org/10.1155/2018/9237907 (Year: 2018)",PENDING
887,CN,A,CN 116157174 A,170-376-543-594-571,2023-05-23,2023,CN 202180059626 A,2021-07-19,US 202063053930 P;;US 202063085517 P;;IB 2021056514 W,2020-07-20,Hybrid transseptal dilator and method of use thereof,"A method and apparatus for optimizing a transseptal procedure to provide left heart access is disclosed that reduces the number of devices used to minimize procedure time, complexity, and cost. In some embodiments, the apparatus includes a reformable hybrid dilator that includes a combined function of a transseptal sheath and a dilator assembly. A hybrid dilator includes: a dilator shaft defining a lumen for receiving a penetrating device therethrough, the dilator shaft including a reinforcing member and a deflectable portion configured to provide support for the penetrating device when the penetrating device is used to create a puncture in tissue; and a distal tip having an outer diameter tapering to the outer diameter of the pass-through device for providing a smooth transition between the pass-through device and the distal tip when the pass-through device is inserted through the lumen and projects beyond the distal tip.",BOSTON SCIENT SCIMED INC,LIANG SHALIN;;MO DANIEL YONGHUI;;MORIYAMA EDUARDO;;DAVIES GARETH;;OLIVIA LAFIDE;;SULLIVAN DERMOT;;LEUNG LINUS;;BARD RYAN,,https://lens.org/170-376-543-594-571,Patent Application,no,0,0,6,6,0,A61B90/00;;A61M29/00;;A61B2017/00243;;A61B17/3478;;A61B2018/00107;;A61B2018/00196;;A61B2018/00357;;A61B2018/00982;;A61B2018/1425;;A61B2018/144;;A61B18/1487;;A61B18/1492;;A61B2090/3925;;A61B2090/3966;;A61B2090/376;;A61B2017/00327;;A61M25/0147;;A61M25/0136;;A61M25/0054;;A61M25/0136;;A61M25/0147;;A61M25/0606;;A61M29/02,A61M29/00,,0,0,,,,PENDING
888,US,A1,US 2023/0167786 A1,194-282-139-642-926,2023-06-01,2023,US 202217940480 A,2022-09-08,GB 202112775 A;;GB 202116766 A,2021-09-08,IMPROVED GAS TURBINE ENGINE,"An aircraft gas turbine engine includes a heat exchanger module, and a core engine. The core engine includes an intermediate-pressure compressor, high-pressure compressor, and high and low-pressure turbines. The high-pressure compressor rotationally connects to the high-pressure turbine by a first shaft, and the intermediate-pressure compressor rotationally connects to the low-pressure turbine by a second shaft. The heat exchanger module fluidly communicates with the core engine by an inlet duct. The heat exchanger module includes a central hub and multiple heat transfer elements extending radially from the hub and spaced in a circumferential array, for heat energy transfer from a first fluid within the elements to an inlet airflow passing over a surface of the elements prior to airflow entry into an inlet to the core engine. The gas turbine engine further includes a first electric machine rotationally connected to the first shaft, and positioned downstream of the heat exchanger module.",ROLLS ROYCE PLC,DAVIES PAUL R;;MOORE GARETH E;;HUSBAND STEPHEN M;;TRAINER DAVID R;;SCOTHERN DAVID P;;GEORGE LUKE,ROLLS-ROYCE PLC (2021-11-22),https://lens.org/194-282-139-642-926,Patent Application,yes,11,0,3,14,0,F02C7/18;;F02C7/32;;F05D2220/766;;F05D2240/12;;F05D2260/213;;F01D15/10;;F01D9/065;;F01D25/12;;Y02T50/60;;F01D15/10;;F02C7/141;;F02K3/06;;F05D2220/323;;F05D2220/36;;F05D2260/213;;F05D2260/606,F02K3/06;;F01D15/10;;F02C7/141,,0,0,,,,ACTIVE
889,WO,A1,WO 2021/229383 A1,147-412-863-976-212,2021-11-18,2021,IB 2021053876 W,2021-05-06,US 202063022842 P,2020-05-11,AN ELECTROSURGICAL DEVICE WITH AUTOMATIC SHUT-OFF,"A method and apparatus are disclosed for creating a puncture in a tissue. The assembly includes a puncturing device having a distal tip configured to deliver energy to the tissue, creating the puncture. The puncturing device further includes a marker positioned along the puncturing device. The assembly further includes a dilator which has a lumen extending from a proximal portion to a distal portion and configured to receive the puncturing device. The dilator further comprises a sensor positioned along a length of the dilator. When the marker and the sensor are aligned, energy is delivered to the distal tip of the puncturing device.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,DICICCO MATTHEW;;DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;MOK DANIEL WING FAI;;TYLER BRANDON,,https://lens.org/147-412-863-976-212,Patent Application,yes,5,0,5,5,0,A61B90/00;;A61B18/1492;;A61B2018/00357;;A61B2018/00601;;A61B2018/0038;;A61B18/1233;;A61B2018/00642;;A61B2018/00708;;A61B2090/062;;A61B18/1492;;A61B2018/00083;;A61B2018/00107;;A61B2018/00357;;A61B2018/00625,A61B18/14;;A61B17/00;;A61B17/34;;A61B18/00;;A61B18/12;;A61B90/00,,0,0,,,,PENDING
890,US,A1,US 2011/0118735 A1,116-206-773-094-345,2011-05-19,2011,US 92629210 A,2010-11-08,US 92629210 A;;US 52075406 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 62740607 A;;US 59629705 P;;US 74318106 P;;US 82745806 P,2003-01-21,Electrosurgical device for creating a channel through a region of tissue and methods of use thereof,"An electrosurgical device and methods are disclosed for creating a channel through a region of tissue. The device comprises an elongate member for receiving the energy from an electrical energy source. An electrical insulation layer surrounds the elongate member along the device proximal region. An electrode tip is coupled to the distal end of the elongate member for delivering the energy, the electrode tip being configured and sized for delivering the energy in a manner such that electrical arcing is generated in the region of tissue in order to create a channel through at least a portion of the region of tissue. An electrically insulative thermal shield is disposed between the electrode tip and the device proximal region for preventing arcing therebetween during the delivery of the energy and for thermally protecting the device proximal region from heat produced by the delivery of the energy through the electrode tip.",BAYLIS MEDICAL COMPANY,ABOU-MARIE RUND;;JUZKIW TARAS;;DAVIES GARETH;;LUK MARIA;;LEUNG RAMSEY;;MOSLEY MARK;;WONG CHRISTINE;;ALBERT KELLY,BAYLIS MEDICAL COMPANY INC (2011-03-18);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/116-206-773-094-345,Patent Application,yes,32,80,2,113,0,A61B18/1492;;A61B18/1492;;A61B90/39;;A61B90/39;;A61B2017/00867;;A61B2017/00867;;A61B2018/00083;;A61B2018/00083;;A61B2018/00101;;A61B2018/00101;;A61B2018/00136;;A61B2018/00136;;A61B2018/0041;;A61B2018/1213;;A61B2018/1213;;C08L2201/12;;C08L2201/12,A61B18/14,606/45,0,0,,,,EXPIRED
891,US,A1,US 2023/0167785 A1,177-653-124-231-722,2023-06-01,2023,US 202217940421 A,2022-09-08,GB 202112773 A;;GB 202115763 A,2021-09-08,AN IMPROVED GAS TURBINE ENGINE,"A gas turbine engine for an aircraft comprises, in axial flow sequence, a compressor module, a combustor module, and a turbine module, with a first electric machine being rotationally connected to the turbine module. The first electrical machine is configured to generate a maximum electrical power P EM1 (W), and the gas turbine engine is configured to generate a maximum dry thrust T (N); and a ratio S of: S =(Maximum Electrical Power Generated= P EM1 )/(Maximum Dry Thrust= T ) is in a range of between 2.0 and 10.0.",ROLLS ROYCE PLC,DAVIES PAUL R;;MOORE GARETH E;;HUSBAND STEPHEN M;;TRAINER DAVID R;;SCOTHERN DAVID P;;GEORGE LUKE,ROLLS-ROYCE PLC (2021-11-25),https://lens.org/177-653-124-231-722,Patent Application,yes,13,4,2,12,0,F02K5/00;;F02K3/06;;F05D2220/76;;B64D27/24;;B64D27/10;;Y02T50/60;;B64D27/026;;F01D15/10;;F02K3/06;;F05D2220/323;;F05D2220/36,F02K3/06;;F01D15/10,,0,0,,,,PENDING
892,US,B2,US 11879413 B2,194-476-555-097-328,2024-01-23,2024,US 202217940480 A,2022-09-08,GB 202112775 A;;GB 202116766 A,2021-09-08,Gas turbine engine,"An aircraft gas turbine engine includes a heat exchanger module, and a core engine. The core engine includes an intermediate-pressure compressor, high-pressure compressor, and high and low-pressure turbines. The high-pressure compressor rotationally connects to the high-pressure turbine by a first shaft, and the intermediate-pressure compressor rotationally connects to the low-pressure turbine by a second shaft. The heat exchanger module fluidly communicates with the core engine by an inlet duct. The heat exchanger module includes a central hub and multiple heat transfer elements extending radially from the hub and spaced in a circumferential array, for heat energy transfer from a first fluid within the elements to an inlet airflow passing over a surface of the elements prior to airflow entry into an inlet to the core engine. The gas turbine engine further includes a first electric machine rotationally connected to the first shaft, and positioned downstream of the heat exchanger module.",ROLLS ROYCE PLC,DAVIES PAUL R;;MOORE GARETH E;;HUSBAND STEPHEN M;;TRAINER DAVID R;;SCOTHERN DAVID P;;GEORGE LUKE,ROLLS-ROYCE PLC (2021-11-22),https://lens.org/194-476-555-097-328,Granted Patent,yes,52,0,3,14,0,F02C7/18;;F02C7/32;;F05D2220/766;;F05D2240/12;;F05D2260/213;;F01D15/10;;F01D9/065;;F01D25/12;;Y02T50/60;;F01D15/10;;F02C7/141;;F02K3/06;;F05D2220/323;;F05D2220/36;;F05D2260/213;;F05D2260/606,F02K3/06;;F01D15/10;;F02C7/141,,18,1,015-760-271-604-065,10.1155/2018/9237907,"U.S. Appl. No. 17/940,748, filed Sep. 8, 2022 in the name of Davies et al.;;U.S. Appl. No. 17/940,614, filed Sep. 8, 2022 in the name of Davies et al.;;U.S. Appl. No. 17/940,421, filed Sep. 8, 2022 in the name of Davies et al.;;May 3, 2022 Combined Examination and Search Report issued in British Patent Application No. GB2115764.9.;;Jun. 16, 2022 Search Report issued in British Patent Application No. GB2112773.3.;;Apr. 29, 2022 Search Report issued in British Patent Application No. GB2115763.1.;;GE Aviation. “The LM6000 Engine,” https://www.geaviation.com/propulsion/marine/lm6000, Jun. 21, 2022, 4 pages.;;May 24, 2022 Combined Examination and Search Report issued in British Patent Application No. GB2116765.5.;;May 11, 2022 Search Report issued in British Patent Application No. GB2116766.3.;;Jun. 16, 2022 Search Report issued in British Patent Application No. GB2112775.8.;;Feb. 1, 2023 Search Report issued in EP Patent Application No. 22192759.3.;;Feb. 8, 2023 Search Report issued in EP Patent Application No. 22192760.1.;;Feb. 15, 2023 Search Report issued in EP Patent Application No. 22192762.7.;;“GE—Aviation: CF6-80C2,” https://web.archive.org/web/20081121124612/https://www.geaviation.com/engines/commercial/cf6/cf6-80c2.html, Nov. 21, 2008, 2 pages.;;Feb. 1, 2023 Search Report issued in EP Patent Application No. 22192758.5.;;May 22, 2023 Office Action issued in U.S. Appl. No. 17/940,421.;;Chen et al., “Performance Analysis of a Three-Stream Adaptive Cycle Engine during Throttling”, Apr. 22, 2018, Hindawi International Journal of Aerospace Engineering vol. 2018, Article ID 9237907, 16 pages, https://doi.org/10.1155/2018/9237907 (Year: 2018).;;Jun. 2, 2023 Office Action issued in U.S. Appl. No. 17/940,748.",ACTIVE
893,US,B2,US 9510900 B2,163-535-283-120-805,2016-12-06,2016,US 92629210 A,2010-11-08,US 92629210 A;;US 52075406 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 62740607 A;;US 59629705 P;;US 74318106 P;;US 82745806 P,2003-01-21,Electrosurgical device for creating a channel through a region of tissue and methods of use thereof,"An electrosurgical device and methods are disclosed for creating a channel through a region of tissue. The device comprises an elongate member for receiving the energy from an electrical energy source. An electrical insulation layer surrounds the elongate member along the device proximal region. An electrode tip is coupled to the distal end of the elongate member for delivering the energy, the electrode tip being configured and sized for delivering the energy in a manner such that electrical arcing is generated in the region of tissue in order to create a channel through at least a portion of the region of tissue. An electrically insulative thermal shield is disposed between the electrode tip and the device proximal region for preventing arcing therebetween during the delivery of the energy and for thermally protecting the device proximal region from heat produced by the delivery of the energy through the electrode tip.",ABOU-MARIE RUND;;JUZKIW TARAS;;DAVIES GARETH;;LUK MARIA;;LEUNG RAMSEY;;MOSLEY MARK;;WONG CHRISTINE;;ALBERT KELLY;;BAYLIS MEDICAL CO INC,ABOU-MARIE RUND;;JUZKIW TARAS;;DAVIES GARETH;;LUK MARIA;;LEUNG RAMSEY;;MOSLEY MARK;;WONG CHRISTINE;;ALBERT KELLY,BAYLIS MEDICAL COMPANY INC (2011-03-18);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/163-535-283-120-805,Granted Patent,yes,32,4,2,113,0,A61B18/1492;;A61B18/1492;;A61B90/39;;A61B90/39;;A61B2017/00867;;A61B2017/00867;;A61B2018/00083;;A61B2018/00083;;A61B2018/00101;;A61B2018/00101;;A61B2018/00136;;A61B2018/00136;;A61B2018/0041;;A61B2018/1213;;A61B2018/1213;;C08L2201/12;;C08L2201/12,A61B18/14;;A61B17/00;;A61B18/00;;A61B18/12,,24,0,,,"J. E Della, ""Non-Final rejection in the case of U.S. Appl. No. 11/520,754"",Aug. 19, 2009.;;J. E Della, ""Notice of Allowance in the case of U.S. Appl. No. 11/520,754"", Jul. 2, 2010.;;R. D Gibson, ""Non-final rejection in the case of U.S. Appl. No. 11/265,304"", Jun. 26, 2009.;;R. D Gibson, ""Non-final rejection in the case of U.S. Appl. No. 11/265,304"", Feb. 5, 2010.;;R. D Gibson, ""Non-final rejection in the case of U.S. Appl. No. 11/265,304"", Jul. 22, 2010.;;R. D Gibson, ""Notice of allowance in the case of U.S. Appl. No. 11/265,304"", Jan. 14, 2011.;;M. F Peffley, ""Final rejection in the case of U.S. Appl. No. 10/666,301"", Sep. 16, 2005.;;M. F Peffley, ""Notice of Allowance in the case of U.S. Appl. No. 10/666,301"", Dec. 23, 2005.;;P. J Vrettakos, ""Non-final rejection in the case of U.S. Appl. No. 10/760,479"",Feb. 14, 2006.;;P. J Vrettakos, ""Final rejection in the case of U.S. Appl. No. 10/760,479"", Oct. 5, 2006.;;P. J Vrettakos, ""Notice of allowance in the case of U.S. Appl. No. 10/760,479"", May 2, 2007.;;P. J Vrettakos, ""Notice of allowance in the case of U.S. Appl. No. 10/760,479"", Jul. 19, 2007.;;P. J Vrettakos, ""Non-final rejection in the case of U.S. Appl. No. 10/666,288"", Nov. 2, 2005.;;P. J Vrettakos, ""Final rejection in the case of U.S. Appl. No. 10/666,288"", Jun. 27, 2006.;;P. J Vrettakos, ""Non-final rejection in the case of U.S. Appl. No. 10/666,288"", Sep. 13, 2006.;;P. J Vrettakos, ""Final rejection in the case of U.S. Appl. No. 10/666,288"", May 21, 2007.;;P. J Vrettakos, ""Notice of abandonment in the case of U.S. Appl. No. 10/666,288"", Dec. 10, 2007.;;M. P Straightiff, ""Non-final rejection in the case of U.S. Appl. No. 10/347,366"", Oct. 4, 2004.;;M. P Straightiff, ""Final rejection in the case of U.S. Appl. No. 10/347,366"", Mar. 21, 2005.;;M. P Straightiff, ""Non-final rejection in the case of U.S. Appl. No. 10/347,366"", Sep. 26, 2005.;;M. P Straightiff, ""Notice of Allowance U.S. Appl. No. 10/347,366"", Feb. 27, 2006.;;A. L Scott, ""Non-final rejection in the case of U.S. Appl. No. 10/627,406"", Oct. 5, 2010.;;A. L Scott, ""Final rejection in the case of U.S. Appl. No. 10/627,406"", Apr. 25, 2011.;;A. L Scott, ""Notice of Allowance in the case of U.S. Appl. No. 10/627,406"", Aug. 17, 2011.",ACTIVE
894,DE,D1,DE 69612084 D1,164-284-276-270-605,2001-04-19,2001,DE 69612084 T,1996-01-12,GB 9500660 A;;GB 9600052 W,1995-01-13,ANALOGE EINES WACHSTUMSFAKTORS,,SECR DEFENCE,ANDERSON WILLIAM;;MELLOR MACRAE;;RICHARDS GORDON;;SARGOOD JANE;;TURNER LESLIE;;SHARMA PRAKASH;;DAVIES ELIZABETH;;CHAMBERLIN GARETH;;RICHTER AUDREY,,https://lens.org/164-284-276-270-605,Granted Patent,no,0,0,9,9,0,A61K38/00;;A61K38/00;;C07K14/495;;C07K14/495,A61K38/00;;C07K14/495,,0,0,,,,EXPIRED
895,CA,A1,CA 3189765 A1,078-670-980-009-660,2022-01-27,2022,CA 3189765 A,2021-07-19,US 202063053930 P;;US 202063085517 P;;IB 2021056514 W,2020-07-20,HYBRID TRANSSEPTAL DILATOR AND METHODS OF USING THE SAME,"A method and apparatus are disclosed for an optimized transseptal procedure for providing left heart access, that reduces the number of devices that are used in order to minimize procedural time, complexity and cost. The apparatus comprises a reshapeable hybrid dilator that comprises the combined functionality of a transseptal sheath and dilator assembly. The hybrid dilator comprises: a dilator shaft defining a lumen for receiving a crossing device therethrough, the dilator shaft comprising a stiffening member and a deflectable portion, being structured to provide support for the crossing device when the crossing device is used to create a puncture in a tissue; and a distal tip having an outer diameter which tapers down to an outer diameter of the crossing device for providing a smooth transition between the crossing device and the distal tip when the crossing device is inserted through the lumen and protrudes beyond the distal tip.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG CHARLENE;;MOK DANIEL WING FAI;;MORIYAMA EDUARDO;;DAVIES GARETH;;LOUGHEED OLIVIA;;SULLIVAN DERMOT;;LEUNG LINUS;;BUDD RYAN,,https://lens.org/078-670-980-009-660,Patent Application,no,0,0,6,6,0,A61B90/00;;A61M29/00;;A61B2017/00243;;A61B17/3478;;A61B2018/00107;;A61B2018/00196;;A61B2018/00357;;A61B2018/00982;;A61B2018/1425;;A61B2018/144;;A61B18/1487;;A61B18/1492;;A61B2090/3925;;A61B2090/3966;;A61B2090/376;;A61B2017/00327;;A61M25/0147;;A61M25/0136;;A61M25/0054;;A61M25/0136;;A61M25/0147;;A61M25/0606;;A61M29/02,A61B17/00;;A61B17/34;;A61B18/00;;A61B18/14;;A61B90/00;;A61M25/09;;A61M29/00,,0,0,,,,PENDING
896,CA,A1,CA 3114776 A1,134-443-935-356-793,2021-10-21,2021,CA 3114776 A,2021-04-13,US 202063012971 P,2020-04-21,STEERABLE ELECTROSURGICAL PUNCTURE DEVICE,"A puncturing device configured to create a puncture in a tissue having a maneuverable distal portion which is connected to a distal tip. A handle with an actuation mechanism is at the proximal portion of the puncturing device. The maneuverable distal portion is coupled to the actuation mechanism, where upon actuation of the actuation mechanism manipulates the maneuverable distal portion, thereby manipulating the distal tip of the puncturing device.",BAYLIS MEDICAL CO INC,MOK DANIEL WING FAI;;DAVIES GARETH;;URBANSKI JOHN PAUL;;MORIYAMA EDUARDO;;RYAN PATRICK;;DICICCO MATTHEW;;DELL TREVOR JAMES,,https://lens.org/134-443-935-356-793,Patent Application,no,0,1,1,1,0,,A61B18/14;;A61B17/94,,0,0,,,,PENDING
897,US,S,US D0478135 S,169-570-517-006-071,2003-08-05,2003,US 15653302 F,2002-03-04,GB 2104559 F,2001-09-04,Exercise bike,,EXTERIS LTD,MIVAL NICHOLAS;;WALL BRYAN;;HAWLEY MILES;;WILLS ANDREW;;MANSON TIM;;LEDDY JAMES;;PRICE OLIVER;;DRAGE KARL;;DAVIES GARETH,EXERTRIS LTD (2002-05-24),https://lens.org/169-570-517-006-071,Design Right,no,0,6,1,1,0,,,D21/663,0,0,,,,EXPIRED
898,US,A1,US 2022/0151681 A1,194-611-315-512-624,2022-05-19,2022,US 202217574815 A,2022-01-13,US 202217574815 A;;US 201615359881 A;;US 92629210 A;;US 62740607 A;;US 74318106 P;;US 82745806 P,2006-01-27,Electrosurgical Device for Creating a Channel through a Region of Tissue and Methods of Use thereof,"A method and apparatus are disclosed for an RF guidewire for applying RF energy to create a channel through a region of tissue within a patient's body. The RF guidewire is configured to have a hydrophilic coating disposed thereon to reduce friction to facilitate traversal through vasculature while maintaining its mechanical, electrical and thermal properties. The RF guidewire includes an electrode tip at a distal end of the guidewire for delivering the energy and an electrically insulative thermal shield between the electrode tip and electrical insulation for thermally protecting the electrical insulation from heat produced by delivering the energy. Some embodiments include electrical insulation inside of the electrically insulative thermal shield.",BAYLIS MEDICAL CO INC,LEUNG LINUS HOI CHE;;SAMIEE-ZAFARGHANDY MAHBAN;;ABOU-MARIE RUND;;JUZKIW TARAS;;DAVIES GARETH;;LUK MARIA;;ALBERT KELLY,BAYLIS MEDICAL COMPANY INC (2022-01-26);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/194-611-315-512-624,Patent Application,yes,0,0,1,113,0,A61B2018/00083;;A61B2018/00345;;A61B2018/1417;;A61B2018/00101;;A61B2018/00136;;A61B18/1492;;A61B18/14;;A61B2018/00107;;A61B2018/00345;;A61B2018/1417;;A61B2018/00083;;A61B2018/144;;A61B2018/00077,A61B18/14,,0,0,,,,PENDING
899,US,B2,US 11234761 B2,116-190-456-786-336,2022-02-01,2022,US 201615359881 A,2016-11-23,US 201615359881 A;;US 92629210 A;;US 62740607 A;;US 74318106 P;;US 82745806 P,2006-01-27,Electrosurgical device for creating a channel through a region of tissue and methods of use thereof,"A method and apparatus are disclosed for an RF guidewire for applying RF energy to create a channel through a region of tissue within a patient's body. The RF guidewire is configured to have a hydrophilic coating disposed thereon to reduce friction to facilitate traversal through vasculature while maintaining its mechanical, electrical and thermal properties.",BAYLIS MEDICAL CO INC,LEUNG LINUS HOI CHE;;SAMIEE-ZAFARGHANDY MAHBAN;;ABOU-MARIE RUND;;JUZKIW TARAS;;DAVIES GARETH;;LUK MARIA;;ALBERT KELLY,BAYLIS MEDICAL COMPANY INC (2016-11-22);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/116-190-456-786-336,Granted Patent,yes,8,1,2,113,0,A61B2017/00867;;C08L2201/12;;A61B18/1492;;A61B90/39;;A61B2018/00136;;A61B2018/00083;;A61B2018/00101;;A61B2018/0041;;A61B2018/1213;;C08L2203/206;;A61B2090/3966;;A61B18/1492;;A61B90/39;;A61B2018/00601;;A61B2018/00136;;A61B2018/00083;;A61B2018/00101;;A61B2018/0041;;A61B18/1206;;A61B2018/1213;;A61B2090/3966,A61B18/14;;A61B17/00;;A61B18/00;;A61B18/12;;A61B90/00,,0,0,,,,ACTIVE
900,US,A1,US 2023/0149675 A1,115-477-815-290-79X,2023-05-18,2023,US 202318157569 A,2023-01-20,US 202318157569 A;;IB 2021056514 W;;US 202063053930 P;;US 202063085517 P,2020-07-20,HYBRID TRANSSEPTAL DILATOR AND METHODS OF USING THE SAME,"A method and apparatus are disclosed for an optimized transseptal procedure for providing left heart access, that reduces the number of devices that are used in order to minimize procedural time, complexity and cost. The apparatus comprises a reshapeable hybrid dilator that comprises the combined functionality of a transseptal sheath and dilator assembly. The hybrid dilator comprises: a dilator shaft defining a lumen for receiving a crossing device therethrough, the dilator shaft comprising a stiffening member and a deflectable portion, being structured to provide support for the crossing device when the crossing device is used to create a puncture in a tissue; and a distal tip having an outer diameter which tapers down to an outer diameter of the crossing device for providing a smooth transition between the crossing device and the distal tip when the crossing device is inserted through the lumen and protrudes beyond the distal tip.",BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG CHARLENE;;MOK DANIEL WING FAI;;MORIYAMA EDUARDO;;DAVIES GARETH;;LOUGHEED OLIVIA;;SULLIVAN DERMOT;;LEUNG LINUS;;BUDD RYAN,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2023-01-18),https://lens.org/115-477-815-290-79X,Patent Application,yes,0,0,6,6,0,A61B90/00;;A61M29/00;;A61B2017/00243;;A61B17/3478;;A61B2018/00107;;A61B2018/00196;;A61B2018/00357;;A61B2018/00982;;A61B2018/1425;;A61B2018/144;;A61B18/1487;;A61B18/1492;;A61B2090/3925;;A61B2090/3966;;A61B2090/376;;A61B2017/00327;;A61M25/0147;;A61M25/0136;;A61M25/0054;;A61M25/0136;;A61M25/0147;;A61M25/0606;;A61M29/02,A61M29/02;;A61M25/00;;A61M25/01;;A61M25/06,,0,0,,,,PENDING
901,DE,T2,DE 69612084 T2,136-500-916-021-614,2001-07-19,2001,DE 69612084 T,1996-01-12,GB 9500660 A;;GB 9600052 W,1995-01-13,Wachstumsfaktor-Analoga,,SECR DEFENCE,ANDERSON WILLIAM;;MELLOR MACRAE;;RICHARDS GORDON;;SARGOOD JANE;;TURNER LESLIE;;SHARMA PRAKASH;;DAVIES ELIZABETH;;CHAMBERLIN GARETH;;RICHTER AUDREY,,https://lens.org/136-500-916-021-614,Granted Patent,no,0,0,9,9,0,A61K38/00;;A61K38/00;;C07K14/495;;C07K14/495,A61K38/00;;C07K14/495,,0,0,,,,EXPIRED
902,EP,A1,EP 4181810 A1,198-355-761-699-420,2023-05-24,2023,EP 21845872 A,2021-07-19,US 202063053930 P;;US 202063085517 P;;IB 2021056514 W,2020-07-20,HYBRID TRANSSEPTAL DILATOR AND METHODS OF USING THE SAME,,BOSTON SCIENT MEDICAL DEVICE LIMITED,LEUNG CHARLENE;;MOK DANIEL WING FAI;;MORIYAMA EDUARDO;;DAVIES GARETH;;LOUGHEED OLIVIA;;SULLIVAN DERMOT;;LEUNG LINUS;;BUDD RYAN,,https://lens.org/198-355-761-699-420,Patent Application,yes,0,0,6,6,0,A61B90/00;;A61M29/00;;A61B2017/00243;;A61B17/3478;;A61B2018/00107;;A61B2018/00196;;A61B2018/00357;;A61B2018/00982;;A61B2018/1425;;A61B2018/144;;A61B18/1487;;A61B18/1492;;A61B2090/3925;;A61B2090/3966;;A61B2090/376;;A61B2017/00327;;A61M25/0147;;A61M25/0136;;A61M25/0054;;A61M25/0136;;A61M25/0147;;A61M25/0606;;A61M29/02,A61B18/14;;A61B17/00;;A61B17/34;;A61B18/00;;A61B90/00;;A61M25/09;;A61M29/00,,0,0,,,,PENDING
903,WO,A1,WO 2022/018617 A1,178-208-522-383-108,2022-01-27,2022,IB 2021056514 W,2021-07-19,US 202063053930 P;;US 202063085517 P,2020-07-20,HYBRID TRANSSEPTAL DILATOR AND METHODS OF USING THE SAME,"A method and apparatus are disclosed for an optimized transseptal procedure for providing left heart access, that reduces the number of devices that are used in order to minimize procedural time, complexity and cost. The apparatus comprises a reshapeable hybrid dilator that comprises the combined functionality of a transseptal sheath and dilator assembly. The hybrid dilator comprises: a dilator shaft defining a lumen for receiving a crossing device therethrough, the dilator shaft comprising a stiffening member and a deflectable portion, being structured to provide support for the crossing device when the crossing device is used to create a puncture in a tissue; and a distal tip having an outer diameter which tapers down to an outer diameter of the crossing device for providing a smooth transition between the crossing device and the distal tip when the crossing device is inserted through the lumen and protrudes beyond the distal tip.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,LEUNG CHARLENE;;MOK DANIEL WING FAI;;MORIYAMA EDUARDO;;DAVIES GARETH;;LOUGHEED OLIVIA;;SULLIVAN DERMOT;;LEUNG LINUS;;BUDD RYAN,,https://lens.org/178-208-522-383-108,Patent Application,yes,5,0,6,6,0,A61B90/00;;A61M29/00;;A61B2017/00243;;A61B17/3478;;A61B2018/00107;;A61B2018/00196;;A61B2018/00357;;A61B2018/00982;;A61B2018/1425;;A61B2018/144;;A61B18/1487;;A61B18/1492;;A61B2090/3925;;A61B2090/3966;;A61B2090/376;;A61B2017/00327;;A61M25/0147;;A61M25/0136;;A61M25/0054;;A61M25/0136;;A61M25/0147;;A61M25/0606;;A61M29/02,A61B18/14;;A61B17/00;;A61B17/34;;A61B18/00;;A61B90/00;;A61M25/09;;A61M29/00,,0,0,,,,PENDING
904,ZA,B,ZA 200902826 B,036-209-340-834-268,2010-04-28,2010,ZA 200902826 A,2009-04-23,GB 0621720 A,2006-11-01,IKK-B Serine-Threonine protein kinase inhibitors,,CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/036-209-340-834-268,Granted Patent,no,0,0,3,29,0,,A61K/;;C07D/,,0,0,,,,ACTIVE
905,ZA,B,ZA 201008026 B,120-714-454-128-312,2011-07-27,2011,ZA 201008026 A,2010-11-09,GB 2008001434 W,2008-04-23,INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE,,CHROMA THERAPEUTICS LTD,ONIONS STUART THOMAS;;WILLIAMS JONATHAN GARETH;;HIRST SIMON CHRISTOPHER;;CHARLTON MICHAEL HUGH;;MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN,,https://lens.org/120-714-454-128-312,Granted Patent,no,0,0,14,15,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,,,0,0,,,,ACTIVE
906,BR,A2,BR PI0822522 A2,120-557-912-910-330,2018-06-05,2018,BR PI0822522 A,2008-04-23,GB 2008001434 W,2008-04-23,inibidores da proteína quinase ikk-beta serina-treonina,,CHROMA THERAPEUTICS LTD,DAVID FESTUS CHARLES MOFFAT;;JONATHON GARETH WILLIAMS;;MICHAEL HUGH CHARLTON;;SIMON CHRISTOPHER HIRST;;STEPHEN JOHN DAVIES;;STUART THOMAS ONIONS,,https://lens.org/120-557-912-910-330,Patent Application,no,0,0,14,15,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,C07D333/38;;A61K31/381;;A61P25/28;;A61P37/00,,0,0,,,,DISCONTINUED
907,US,A1,US 2010/0069473 A1,123-716-288-613-491,2010-03-18,2010,US 44727107 A,2007-10-29,GB 0621720 A;;GB 0715469 A;;GB 2007004117 W,2006-11-01,Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: wherein R 7 is hydrogen or optionally substituted (C 1 -C 6 )alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is a radical of formula R-L 1 -Y 1 —(CH 2 ) z —, wherein: z is 0 or 1; R is a radical of formula (X) or (Y) R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R 6 is hydrogen, or optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl or heteroaryl or —(C═O)R 3 , —(C═O)OR 3 , or —(C═O)NR 3 wherein R 3 is hydrogen or optionally substituted (C 1 -C 6 )alkyl; Y 1 is a bond, —(C═O)—, —S(O 2 )—, —C(═O)O—, —OC(═O)—, —(C═O)NR 3 —, —NR 3 (C═O)—, —S(O 2 )NR 3 —, —NR 3 S(O 2 )—, or —NR 3 (C═O)NR 4 —, wherein R 3 and R 4 are independently hydrogen or optionally substituted (C 1 -C 6 )alkyl, L 1 is a divalent linker radical of formula -(Alk 1 ) m (Q) n (Alk 2 ) p - wherein m, n, p, Q, Alk 1 and Alk 2 are as defined in the claims.",CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,CHROMA THERAPEUTICS LTD (2009-05-06),https://lens.org/123-716-288-613-491,Patent Application,yes,0,0,7,29,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,A61K31/381;;A61P3/10;;A61P11/00;;A61P17/00;;A61P29/00;;A61P35/00;;A61P37/00;;C07D333/36;;C12N9/99,514/447;;549/69;;435/184,0,0,,,,INACTIVE
908,WO,A1,WO 2009/130434 A1,127-495-266-310-122,2009-10-29,2009,GB 2008001434 W,2008-04-23,GB 2008001434 W,2008-04-23,INHIBITORS OF IKK-ß SERINE-THREONINE PROTEIN KINASE,"Cyclopentyl (2S,4 E )-2-amino-5-{3-[4-carbamoyl-5 (carbamoylamino)-2-thienyl]phenyl}pent-4-enoate; Cyclopentyl 5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-norvalinate; Cyclopentyl (2S,4 E )-2-amino-5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-5-methylphenyl}pent-4-enoate; Cyclopentyl (2S,4 E )-2-amino-5-{5-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-2-methylphenyl}pent-4-enoate; Cyclopentyl O -{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-homoserinate; Cyclopentyl O -{3-[4-carbamoyl-5-(carbamoylamino)-2-thienylJphenyl}-L-homoserinate; Cyclopentyl N -{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate; and tert -Butyl N -{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate are hydrolysed to the corresponding carboxylic acids by intracellular carboxylesterases, and are useful for the inhibition of IKKβ activity.",CHROMA THERAPEUTICS LTD;;MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/127-495-266-310-122,Patent Application,yes,3,1,14,15,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,C07D333/38;;A61K31/381;;A61P25/28;;A61P37/00,,0,0,,,,PENDING
909,EP,B1,EP 2086956 B1,123-192-431-596-985,2011-09-14,2011,EP 07824361 A,2007-10-29,GB 2007004117 W;;GB 0621720 A;;GB 0715469 A,2006-11-01,INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is a radical of formula R-L1-Y1—(CH2)z—, wherein: z is 0 or 1; R is a radical of formula (X) or (Y) R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R6 is hydrogen, or optionally substituted C1-C6 alkyl, C3-C7 cycloalkyl, aryl or heteroaryl or —(C═O)R3, —(C═O)OR3, or —(C═O)NR3 wherein R3 is hydrogen or optionally substituted (C1-C6)alkyl; Y1 is a bond, —(C═O)—, —S(O2)—, —C(═O)O—, —OC(═O)—, —(C═O)NR3—, —NR3(C═O)—, —S(O2)NR3—, —NR3S(O2)—, or —NR3(C═O)NR4—, wherein R3 and R4 are independently hydrogen or optionally substituted (C1-C6)alkyl, L1 is a divalent linker radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n, p, Q, Alk1 and Alk2 are as defined in the claims.",CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/123-192-431-596-985,Granted Patent,yes,2,0,7,29,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,C07D333/38;;A61K31/381,,0,0,,,,ACTIVE
910,EP,B1,EP 2283006 B1,145-056-972-437-276,2015-02-25,2015,EP 09734928 A,2009-04-23,GB 2009001058 W;;GB 0807532 A;;GB 0819696 A,2008-04-24,PYRROLE ANTIFUNGAL AGENTS,,F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,,https://lens.org/145-056-972-437-276,Granted Patent,yes,1,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D401/12;;A01N43/40;;A01N43/42;;A61P31/10,,0,0,,,,ACTIVE
911,DK,T3,DK 2283006 T3,152-936-846-249-88X,2015-05-26,2015,DK 09734928 T,2009-04-23,GB 0807532 A;;GB 0819696 A;;GB 2009001058 W,2008-04-24,Pyrrolbaserede antisvampemidler,,F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,,https://lens.org/152-936-846-249-88X,Granted Patent,no,0,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D401/12;;A01N43/40;;A01N43/42;;A61P31/10,,0,0,,,,ACTIVE
912,CA,C,CA 2721944 C,164-177-796-914-634,2016-06-07,2016,CA 2721944 A,2009-04-23,GB 0807532 A;;GB 0819696 A;;GB 2009001058 W,2008-04-24,PYRROLE ANTIFUNGAL AGENTS,"The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, Al, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,,https://lens.org/164-177-796-914-634,Granted Patent,no,0,0,24,26,0,A01N43/36;;A01N43/60;;A01N43/76;;C07D498/04;;A01N43/40;;A01N43/42;;A01N43/84;;A01N43/90;;A61K31/4025;;A61K31/4439;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/4985;;A61K31/5377;;C07D487/04;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;A01N43/36;;A01N43/60;;A01N43/76;;C07D498/04;;A01N43/40;;A01N43/42;;A01N43/84;;A01N43/90;;C07D487/04;;A61K31/4025;;A61K31/4439;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/4985;;A61K31/5377;;A61K45/06,C07D401/12;;A01N43/40;;A01N43/42;;A61P31/10,,0,0,,,,ACTIVE
913,CA,A1,CA 2721944 A1,081-956-613-679-402,2009-10-29,2009,CA 2721944 A,2009-04-23,GB 0807532 A;;GB 0819696 A;;GB 2009001058 W,2008-04-24,PYRROLE ANTIFUNGAL AGENTS,"The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,,https://lens.org/081-956-613-679-402,Patent Application,no,0,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D401/12;;A01N43/40;;A01N43/42;;A61P31/10,,0,0,,,,ACTIVE
914,AU,B2,AU 2009/239778 B2,198-570-334-526-420,2014-03-13,2014,AU 2009/239778 A,2009-04-23,GB 0819696 A;;GB 0807532 A;;GB 2009001058 W,2008-04-24,Pyrrole antifungal agents,"The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,DAVIES GARETH MORSE;;BIRCH MIKE;;LAW DEREK;;SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;OLIVER JASON DAVID;;PAYNE LLOYD JAMES,,https://lens.org/198-570-334-526-420,Granted Patent,no,2,0,24,26,0,A01N43/36;;A01N43/60;;A01N43/76;;C07D498/04;;A01N43/40;;A01N43/42;;A01N43/84;;A01N43/90;;A61K31/4025;;A61K31/4439;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/4985;;A61K31/5377;;C07D487/04;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;A01N43/36;;A01N43/60;;A01N43/76;;C07D498/04;;A01N43/40;;A01N43/42;;A01N43/84;;A01N43/90;;C07D487/04;;A61K31/4025;;A61K31/4439;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/4985;;A61K31/5377;;A61K45/06,C07D401/12;;A01N43/40;;A01N43/42;;A61P31/10,,5,4,168-449-788-313-849;;076-227-872-906-787;;073-424-137-358-597;;153-633-274-519-255,10.1016/s0040-4020(01)00525-7;;7944906;;10.1002/ardp.19943270808;;10.1016/s0223-5234(98)80009-3;;10.1002/jhet.5570040304,"Yavari, I., et al, Tetrahedron, 2001, 57(27), 5873-8;;Dannhardt, G., et al, Archiv der Pharmazie (1994), 8(327), 509-14;;Dumoulin, H., et al, European Journal of Medicinal Chemistry, 1998, 33(3), 201-7;;Dannhardt, G., et al, Chemiker-Zeitung (1986), 110(3), 124-7;;Archibald, J. L., et al, Journal of Heterocyclic Chemistry, 1967, 4, 335-8",ACTIVE
915,US,B2,US 9452168 B2,155-623-500-422-851,2016-09-27,2016,US 201514625532 A,2015-02-18,US 201514625532 A;;GB 0807532 A;;GB 0819696 A;;US 98941011 A;;GB 2009001058 W,2008-04-24,Pyrrole antifungal agents,"The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MICHAEL;;DAVIES GARETH MORSE,F2G LTD (2010-11-01),https://lens.org/155-623-500-422-851,Granted Patent,yes,51,5,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,A01N43/36;;A01N43/40;;A01N43/42;;A01N43/60;;A01N43/76;;A01N43/84;;A01N43/90;;A61K31/4025;;A61K31/4439;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/4985;;A61K31/5377;;A61K45/06;;C07D487/04;;C07D498/04,,101,40,179-007-856-363-671;;082-524-780-121-593;;153-633-274-519-255;;005-101-078-984-914;;001-238-456-156-836;;069-163-075-034-476;;000-168-006-302-253;;033-970-842-208-903;;031-088-884-898-454;;091-580-409-839-448;;059-936-365-638-63X;;060-766-148-116-567;;028-494-421-159-044;;082-832-526-455-955;;091-792-125-882-107;;139-917-414-896-675;;074-022-163-901-658;;076-227-872-906-787;;073-424-137-358-597;;097-337-103-019-912;;004-694-871-327-186;;157-368-878-373-980;;060-908-101-548-398;;125-190-663-181-256;;062-214-858-572-249;;107-812-744-328-804;;078-668-787-190-32X;;031-312-429-278-02X;;099-799-234-674-203;;101-312-400-123-101;;061-072-347-279-836;;017-365-412-179-713;;073-622-770-770-672;;094-225-106-312-625;;014-769-575-719-552;;032-838-088-052-630;;018-067-402-237-562;;059-965-899-863-228;;092-933-020-902-40X;;000-575-008-415-735,10.1016/s0040-4039(00)00755-3;;10.1039/jr9590000620;;10.1002/jhet.5570040304;;10.1021/jm00253a016;;4151968;;10.1039/p19920002175;;10.1002/ijch.196400006;;10.1139/v71-151;;10.1016/0040-4020(96)00441-3;;10.1021/ja960803f;;10.1016/s0040-4020(00)00774-2;;10.1021/jm0102203;;11754575;;4197003;;10.1002/jps.2600660230;;839424;;38816;;10.1039/jr9490003007;;10.1039/jr9570002931;;10.1002/ardp.19793121104;;7944906;;10.1002/ardp.19943270808;;10.1016/s0223-5234(98)80009-3;;10.1016/s0040-4020(01)93611-7;;10.1021/jo01287a016;;10.1021/ja01463a046;;8842991;;10.1016/s0163-4453(96)92700-0;;8809154;;10.1021/jm960395q;;10.1021/jm049161u;;16451085;;10.3998/ark.5550190.0009.905;;17531483;;10.1016/j.bmcl.2007.04.071;;10.1016/j.tet.2004.11.026;;18385843;;10.1039/b719776d;;9880479;;pmc88911;;10.1128/cmr.12.1.147;;10.1016/j.dyepig.2004.10.003;;10064251;;10.1086/515116;;10.1039/jr9350001796;;10.1039/jr9360001098;;10.1080/14756360701811379;;18608761;;10.1021/jo981505z;;7473547;;10.1021/jm00021a009;;10.1073/pnas.0307953101;;pmc387369;;15051887;;10.1016/s0960-894x(00)00322-x;;10937729;;10.1002/chin.200443161,"Types of Fungal Diseases-www.cdc.gov/fungal/diseases/index.html [Nov. 16, 2015].;;(CDC ""Aspergillosis Risk and Prevention""-www.cdc.fungal/diseases/aspergillosis/risk-prevention.html [Nov. 16, 2015].;;Alvarez, M. et al. (1999). ""Synthesis of 1,2-Dihydropyrrolo[1,2-c]Pyrimidin-1-Ones,"" Journal of Chemical Society 249-255.;;Alves, M.J. et al. (2000). ""Novel Aziridine Esters by the Addition of Aromatic Nitrogen Heterocycles to a 2H-Azirine-3-Carboxylic Ester,"" Tetrahedron Letters 41:4991-4995.;;Ames, D.E. et al. (1959, e-published Jan. 1, 1959). ""The Preparation of Aminoalkylpyrrocolines,"" Journal of Chemical Society 124:620-622.;;Anonymous. (Mar. 2006-Nov. 2013). ""Anacor Pharmaceuticals Scientific Presentations"", 7 pages.;;Anonymous. (2012). ""Diethyl Ether,"" Located at <http:www.merckmillipore.com/chemicals/diethyl-ether/MDA-CHEM-100926/p-NgGb.s1Lay4AAAEW8uEfVhTl>, last visited on Jul. 11, 2012, 4 pages.;;Archibald, J.L. et al. (Sep. 1967). ""New Reactions of Pyrroles. II. Preparation and Reactions of Pyrroleglyoxyloyl Derivatives,"" Journal of Heterocyclic Chemistry 4:335-338.;;Archibald, J.L. et al. (1974). ""Benzamidopiperidines. 2. Heterocyclic Compounds Related to Indoramin,"" Journal of Medicinal Chemistry 17(7):736-739.;;Battersby, A.R. et al. (1992, e-published Jan. 1, 1992). ""Synthetic Studies Relevant to Biosynthetic Research on Vitamin B12. Part 10. Construction of the East and West Building Blocks for Synthesis of Isobacteriochlorins,"" Journal of Chemical Society 17:2175-2187.;;Bentov, M. et al. (1964). ""4-Fluoroindole and Derivatives,"" Israel Journal of Chemistry 2:25-28.;;Birchall, G.R. et al. (1971). ""The Chlorination of Pyrroles. Part II,"" Canadian Journal of Chemistry 49:919-922.;;Black, D.S.C. et al. (1996). ""Reaction of Some 4,6-Dimethoxyindoles with Oxalyl Chloride,"" Tetrahedron 52(26):8925-8936.;;Black, D.S.C. et al. (1996). ""The Indol-2-Ylglyoxylamide Moiety: A New Building Block for the Design and Self-Assembly of Hydrogen Bond Networks,"" Journal of American Chemical Society 118(34):8148-8149.;;Black, D.S.C. et al. (2000). ""Formation of C-Amido-Calix[3]Indoles from 2'- and 7'-Indolylglyoxylamides,"" Tetrahedron 56:8513-8524.;;Bohusch, M. et al. (1991). ""Consequences of a Diminution of the Porphyrin pi-System: Attempted Syntheses of Bacteriophin and Chlorophin,"" Liebigs Annalen der Chemie 67-70. (Abstract Only).;;Borthwick, A.D. et al. (Jan. 3, 2002, e-published Dec. 5, 2001). ""Design and synthesis of Pyrrolidine-5,5-trans-Lactams (5-Oxohexahdropyrrolo[3,2-b]Pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 2. Potency and Chirality,"" Journal of Medicinal Chemistry 45(1):1-18.;;Cameron, B.D. et al. (1973). ""The Synthesis and Metabolic Fate of 14C-Viminol, a New Analgesic, in the Rat and the Dog,"" Arzneimittel-Forshung/Drug Res. 23(5):708-712.;;Cardellini, M. et al. (Feb. 1977). ""Indolizine Derivatives with Biological Activity I: N'-Substituted Hydrazides of Indolizine-2-Carboxylic Acid,"" Journal of Pharmaceutical Sciences 66(2):259-262.;;Chemcats. (Jan. 25, 2008). ""Benzo [b] Thiophene-2-Carboxylic Acid, 3-[2-[[(4-Methoxyphenyl) Amino]Oxoacetyl]-1H-Pyrrol-1-y1]-, Methyl Ester,"" Ryan Scientific Screening Library 5 pages.;;Chemcats. (Feb. 13, 2008). ""1H-Pyrrole-2-Acetamide, N-(4-Bromophenyl)-1-(2-Chloro-4-Nitrophenyl)-alpha-Oxo-,"" Ambinter Stock Screening Collection 5 pages.;;Chemcats. (Feb. 18, 2008). ""1H-Pyrrole-2-Acetamide, N-(2,4-Dichlorophenyl)-1-Methyl-alpha-Oxo-,"" Interchim Intermediates 5 pages.;;Chiarino, D. et al. (1978). ""Stereochemistry of Viminol, a Novel Central Analgesic,"" Arzneimittel-Forshung/Drug Res. 28(11):1554-1561.;;Cook, A.H. et al. (1949, e-published Jan. 1, 1949). ""Studies in the Azole Series. Part XXIV. The Interaction of Carbonyl Compounds and 2-Thio-5-Thiazolidone,"" Journal of Chemical Society 633:3007-3012.;;Crowley, K.J. et al. (1957). ""Intermediates for the Synthesis of Optically Active Methyl-Substituted Long-Chain Acids. Part II,"" Journal of the Chemical Society 2931-2934.;;Dannhardt, G. et al. (1979). ""Synthese und Eigenschaften von 2,3-Dihydro-1H-Pyrrolizinen,"" Arch. Pharm. 312:896-907.;;Dannhardt, G. et al. (1994). ""Nonsteroidal Antiinflammatory Agents, XVIII: C-5 Functionalized 6,7-Diphenyl-2,3-Dihydro-1H-Pyrrolizines as Inhibitors of Bovine Cyclooxygenase and 5-Lipoxygenase,"" Arch Pharm 327:509-514.;;Dannhardt, V.G. et al. (1986). ""Antiphlogistische 2,3-Dihydro-1H-Pyrrolizine, 11. Mitt. Dihydropyrrolizinyl-Substituierte 2-Aminoethanol- und Glykosäure-Derivate,"" Chemiker-Zeitung 110(3):124-127.;;Dumoulin, H. et al. (1998). ""2-Oxo-2-(Pehn-2-Ylpyrrol-2-Yl)Acetamides as Potential Anxiolytic Agents: Synthesis and Affinity at the Central Benzodiazepine Receptor,"" European Journal of Medicinal Chemistry 33:201-207.;;Dyke, S.F. et al. (1978). ""Pavinane and Isopavinane Alkaloids,"" Tetrahedron 34:241-245.;;Fryer, R.I. et al. (Dec. 1967). ""Quinazolines and 1,4-Benzodiazepines. XXXVII. Synthesis and Rearrangements of a Substituted 5-Phenyl-1H-1,4-Benzodiazepine,"" Journal of Organic Chemistry 32:3798-3803.;;Galbraith, A. et al. (Jan. 20, 1961). ""The Formation of Cycl[3,2,2]azine Derivatives via the Reaction of Pyrrocoline with Dimethyl Acetylenedicarboxylate,"" Journal of the American Chemical Society 83:453-458.;;Groll, A.H. et al. (1996). ""Trends in the Postmortem Epidemiology of Invasive Fungal Infections at a University Hospital,"" Journal of Infection 33:23-32.;;Hagishita, S. et al. (1996). ""Potent Inhibitors of Secretory Phospholipase A2: Synthesis and Inhibitory Activities of Indolizine and Indene Derivatives,"" Journal of Medicinal Chemistry 39(19):3636-3658.;;Hudack, R.A. et al. (2006, e-published Jan. 14, 2006). ""Design, Synthesis, and Biological Activity of Novel Polycyclic Aza-Amide FKBP12 Ligands,"" Journal of Medicinal Chemistry 49(3):1202-1206.;;Ignatovich, J. et al. (2008). ""Synthesis of Functionalized Benzyl Amines by the Reductive Alkylation of Heterocyclic and Heteroaromatic Amines with Arylaldehydes and preparation of the Intermediates for New Synthetic Biomolecules,"" ARKAT-USA, Inc. (ix):42-51.;;Islam, I. et al. (2007, e-published Apr. 27, 2007). ""Indolinone Based Phosphoinositide-Dependent Kinase-1 (PDK1) Inhibitors. Part 1: Design, Synthesis and Biological Activity,"" Bioorganic & Medicinal Chemistry Letters 17:3814-3818.;;Keawin, T. et al. (2005, e-published Dec. 10, 2004). ""Reaction of Some 4,6-Dimethoxyindoles with Nitric Acid: Nitration and Oxidative Dimerisation,"" Tetrahedron 61:853-861.;;Mahiout, Z. et al. (2008, e-published Feb. 28, 2008). ""Solvent-Dependent Oxidations of 5- and 6-Azaindoles to Trioxopyrrolopyridines and Functionalised Azaindoles,"" Organic & Biomolecular Chemistry 6:1364-1376.;;Mao, W. et al. (Date Unknown) ""AN2718 Has Broad Spectrum Antifungal Activity Necessary for the Topical Treatment of Skin and Nail Fungal Infections,"" P2422, 7 pages.;;McDonell et al. (Jan. 1999). ""Antiseptics and Disinfectants: Activity, Action, and Resistance"", Clinical Microbiology Reviews 12(1) 147-149.;;Nourmohammadian, F. et al. (2005, e-published Jan. 21, 2005). ""An AB Initio Molecular Orbital Study of Structural Isomers of Diketopyrrolopyrrole,"" Dyes and Pigments 67:15-20.;;Pätzel, M. et al. (2005). ""Product Class 5: alpha-Heteroatom-Substituted Alkanamides,"" Science of Synthesis 21:477-535.;;Plattner, J.J. et al. (Date Unknown). ""Medicinal Chemistry of AN2690, A Novel Broad-Spectrum Antifungal Agent in Development for the Topical Treatment of Onychomycosis,"" Poster #775, Anacor Pharmaceuticals, 1 page.;;Ribaud, P. et al. (1999). ""Survival and Prognostic Factors of Invasive Aspergillosis After Allogeneic Bone Marrow Transplantation,"" Clinical Infectious Diseases 28:322-330.;;Rowe, F.M. et al. (1935, e-published Jan. 1, 1935). ""A Reaction of Certain Diazosulphonates Derived from beta-Naphthol-1-Sulphonic Acid. Part XIII. Fission of the Naphthalene Nucleus and Subsequent Closure in Two Directions,"" Journal of Chemical Society 420:1796-1808.;;Rowe, F.M. et al. (1936, e-published Jan. 1, 1936). ""A Reaction of Certain Diazosulphonates Derived from beta-Naphthol-1-Sulphonic Acid. Part XV. Derivatives of 2'-Nitro-4'-Methyl-Benzene-2-Naphthol-1-Diazosulphonate and Synthesis of 2-(2'-Nitro-4'-Methylphenylamino)Isoindolinone-3-Acetic Acid,"" Journal of Chemical Society 232:1098-1108.;;Roy, K. et al. (Dec. 2008). ""Development of Linear and Nonlinear Predictive QSAR Models and Their External Validation Using Molecular Similarity Principle for Anti-HIV Indolyl Aryl Sulfones,"" Journal of Enzyme Inhibition and Medicinal Chemistry 23(6):980-995.;;Savage, S.A. et al. (1998). ""Efficient Synthesis of 4-, 5-, and 6-Methyl-2,2'-Bipyridine by a Negishi Cross-Coupling Strategy Followed by High-Yield Conversion to Bromo- and Chloromethyl-2,2'-Bipyridines,"" Journal of Organic Chemistry 63(26):10048-10051.;;Scott, M.K. et al. (1995). ""Piperazinylalkyl Heterocycles as Potential Antipsychotic Agents,"" Journal of Medicinal Chemistry 38(21):4198-4210.;;Si, Z. et al. (Apr. 6, 2004). ""Small-Molecule Inhibitors of HIV-1 Entry Block Receptor-Induced Conformational Changes in the Viral Envelope Glycoproteins,"" Proceedings of the National Academy of Sciences 101(14):5036-5041.;;Slassi, A. et al. (2000). ""5-Alkyltryptamine Derivatives as Highly Selective and Potent 5-HT1D Receptor Agonists,"" Bioorganic & Medicinal Chemistry Letters 10:1707-1709.;;Sofan, M.A. et al. (2004). ""Studies on 2,3-Dioxopyrrolidines. Synthesis of Piperazine, Pyrrolo[4,5-b]Indole, Pyrazino [5,6-b]Indole and Arylazo Derivatives of Amino Acids,"" Polish Journal of Chemistry 78:837-842.;;CAS Registry No. 3758-62-1, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 3768-71-6, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 3768-72-7, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 3768-82-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 4380-46-5, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 4595-83-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 6616-51-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 15940-17-7, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 15940-18-8, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 15940-19-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 15940-20-2, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 15940-21-3, created Nov. 16, 1984 last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 15940-22-4, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 15940-23-5, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 15940-24-6, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 15940-25-7, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 23502-48-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 26883-51-2, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 31709-75-8, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 31709-76-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 31709-77-0, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 31710-23-3, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 36793-47-2, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 41596-37-6, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 42060-03-7, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 42060-05-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 42221-74-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 43084-49-7, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 53391-28-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 53391-29-0, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 53391-30-3, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 53391-52-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 53391-63-2, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 65473-58-7, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 68803-72-5, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 81729-69-3, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 81741-58-4, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 83996-64-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 130761-64-7, created Nov. 30, 1990, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 130761-68-1, created Nov. 30, 1990, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 145045-69-8, created Dec. 25, 1992, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 171854-40-3, created Dec. 29, 1995, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 171854-41-4, created Dec. 29, 1995, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 171854-42-5, created Dec. 29, 1995, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 171854-43-6, created Dec. 29, 1995, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 17854-44-7, created Dec. 29, 1995, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 171845-45-8, created Dec. 29, 1995, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 171854-46-9, created Dec. 29, 1995, last accessed Feb. 2, 2012, 1 page.",ACTIVE
916,US,A1,US 2021/0307823 A1,187-403-666-272-968,2021-10-07,2021,US 202117350434 A,2021-06-17,US 202117350434 A;;US 201715463913 A;;US 201113113326 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 52275304 P,2003-01-21,Method of surgical perforation via the delivery of energy,"A method of perforating a tissue of a heart of a patient when an inferior approach to the heart is contraindicated. The method utilizes an electrosurgical apparatus having an energy delivery device which can function as an ECG measuring device at a distal end thereof and a delivery system comprising a dilator. Said method comprises the steps of (a) advancing the dilator through a superior vena cava into the heart of the patient, from a superior approach, until a distal end of the dilator is adjacent the tissue; (b) checking an ECG signal to confirm a position of the energy delivery device; (c) using the electrosurgical apparatus, which is positioned through the dilator, to create a perforation in the tissue by delivering electrical energy to the tissue; (d) advancing the distal end of the electrosurgical apparatus through the perforation; and (e) advancing the dilator over the electrosurgical apparatus.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;DICICCO MATTHEW PAUL JOSEPH;;ACHEM BAHE;;DAVIES GARETH;;HARTLEY AMANDA;;VISRAM NAHEED;;SHAH KRISHAN;;BAYLIS FRANK,BAYLIS MEDICAL COMPANY INC (2017-05-23);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/187-403-666-272-968,Patent Application,yes,0,2,3,113,0,A61B18/1206;;A61B18/24;;A61B2090/064;;A61B2090/3966;;A61B18/1492;;A61B2018/00839;;A61B2018/00601;;A61B2018/00351;;A61B18/1492;;A61B18/16;;A61M29/02;;A61M5/007;;A61B2018/00839;;A61B2018/00601;;A61B2018/00351;;A61B18/24;;A61B2090/3966;;A61B2090/064;;A61B2018/0038,A61B18/14;;A61B18/16;;A61M5/00;;A61M29/02,,0,0,,,,PENDING
917,AU,A1,AU 2008/355333 A1,190-119-685-092-989,2009-10-29,2009,AU 2008/355333 A,2008-04-23,GB 2008001434 W,2008-04-23,Inhibitors of IKK-beta serine-threonine protein kinase,,CHROMA THERAPEUTICS LTD,HIRST SIMON CHRISTOPHER;;MOFFAT DAVID FESTUS CHARLES;;WILLIAMS JONATHON GARETH;;ONIONS STUART THOMAS;;CHARLTON MICHAEL HUGH;;DAVIES STEPHEN JOHN,,https://lens.org/190-119-685-092-989,Patent Application,no,0,0,14,15,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,C07D333/38;;A61K31/381;;A61P25/28;;A61P37/00,,0,0,,,,DISCONTINUED
918,EP,A1,EP 2626361 A1,041-358-519-690-858,2013-08-14,2013,EP 13167337 A,2009-04-23,GB 0807532 A;;GB 0819696 A;;EP 09734928 A,2008-04-24,Pyrrole antifungal agents,"The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof:
  
wherein: 
R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,,https://lens.org/041-358-519-690-858,Patent Application,yes,3,3,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D487/04;;A01N43/36;;A01N43/60;;A01N43/76;;A61P31/10;;C07D498/04,,5,2,060-908-101-548-398;;017-365-412-179-713,8842991;;10.1016/s0163-4453(96)92700-0;;10064251;;10.1086/515116,"GROLL ET AL., JLNFECT, vol. 33, 1996, pages 23 - 32;;RIBAUD ET AL., CLIN INFECT DIS., vol. 28, 1999, pages 322 - 30;;JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2;;J. ORG. CHEM., vol. 63, 1998, pages 10048 - 51;;CROWLEY, J. CHEM. SOC., 1957, pages 2931 - 2934",ACTIVE
919,ES,T3,ES 2526083 T3,058-988-297-636-082,2015-01-05,2015,ES 13167337 T,2009-04-23,GB 0807532 A;;GB 0819696 A,2008-04-24,Agentes antifúngicos de pirrol,"Un compuesto que es un derivado de pirrol de fórmula (I), o una sal farmacéuticamente aceptable del mismo, para su uso en la prevención o tratamiento de una enfermedad fúngica:**Fórmula** en la que: R1 representa hidrógeno, alquilo C1-C8, alquenilo C2-C8, alquinilo C2-10 C8, -COR' o -SO2(alquilo C1-C4) sin sustituir o sustituidos, o un grupo -A2, -L2-A2, -L3-A2, -A2-L3-A3 o -A4; A1 representa un enlace o un grupo fenilo, naftilo, grupo heterociclilo de 5 a 6 miembros o heterociclilo de 8 a miembros sin sustituir o sustituido; A2 y A3 son iguales o diferentes y representan cicloalquilo C3-C6 o un grupo arilo C6-C10 o heterociclilo de 5 a 12 miembros sin sustituir o sustituido; A4 es un grupo heterociclilo de 5 a 12 miembros sin sustituir o sustituido en el que 1 o 2 átomos de carbono del anillo están sustituidos con un grupo seleccionado de >C(>=O), >S(>=O)2, >C(>=NOR7) en el que R7 es hidrógeno o un grupo alquilo C1-C4, >C>=CH2 o >C(-OCH2CH2O-); L1 representa un enlace, un grupo alquileno C1-C6 en el que ninguno, uno o dos grupos -CH2- están independientemente sustituidos con -O- o -NR'-, o un grupo heterociclilo de 5 a 7 miembros en el que R' es hidrógeno, alquilo C1-C4 sin sustituir o alquilo C1-C4 sustituido con un grupo alcoxi C1-C4 sin sustituir; L2 representa -NR'-, -O-, -CO-, -OCO-, -OCONR'R""-, -CONR'R""- o -SO2-; L3 representa un enlace o un grupo alquileno C1-C4 en el que ninguno, uno o dos grupos -CH2- están independientemente sustituidos con -O-, -S- o -NR'-; n es 1; R6 representa hidrógeno o alquilo C1-C4; R5 representa un grupo sin sustituir o sustituido seleccionado de arilo C6-C10, un grupo heterociclilo de 5 a 12 miembros, alquilo C1-C8 y cicloalquilo C3-C6, hidrógeno, halógeno o un grupo de fórmula -B1-B2 o -B3; B1 representa un grupo arilo C6-C10 sin sustituir o sustituido; B2 representa un grupo arilo C6-C10 o heterociclilo de 5 a 12 miembros sin sustituir o sustituido; B3 es un grupo heterociclilo de 5 a 12 miembros sin sustituir o sustituido en el que 1 o 2 átomos de carbono del anillo están sustituidos con un grupo seleccionado de >C(>=O), >S(>=O)2, >C(>=NOR11) en la que R11 es hidrógeno o un grupo alquilo C1-C4, >C>=CH2 o >C(-OCH2CH2O-); R2 y R3, junto con los átomos de anillo a los que están unidos, forman un anillo de piperazinilo, morfolinilo o pirrolidinilo; R4 representa hidrógeno, halógeno, fenilo, alquilo C1-C4, alquenilo C2-C4, alquinilo C2-C4, -OR', -CO2R', - CONR'R"", -COR', -CN, -NO2, -NR'R"" o CF3 en las que R' y R"" son independientemente hidrógeno o alquilo C1- C4; Y representa alquileno C1-C8, alquenileno C2-C8 o alquinileno C2-C8; Z representa halógeno, cicloalquilo C3-C6, -OR', -SR', -SOR', -SO2R', -SO2NR'R"", -SO3H, -NR'R"", -NR'COR', - NO2, -CO2R', -CONR'R"", -COR', -OCOR', -CN, -CF3, -NSO2R', -OCONR'R"" o -CR'>=NOR""; a menos que se especifique de otro modo, R' y R"" representan independientemente hidrógeno, alquilo C1-C8, alquenilo C2-C8 o alquinilo C2-C8; a menos que se especifique de otro modo, un grupo o resto alquilo, alquenilo, alquinilo, cicloalquilo, arilo o heteroarilo puede estar sustituido o sin sustituir; y en la que: un grupo sustituido o resto alquilo, alquenilo o alquinilo es dicho grupo o resto alquilo, alquenilo o alquinilo que está sustituido con hasta tres sustituyentes seleccionados de halógeno, hidroxi, amino, (alquil C1- C4)amino, di(alquil C1-C4)amino, alcoxi C1-C4, -S(alquilo C1-C4), -CO2H, -CO2(alquilo C1-C4), fenilo, heterociclilo de 5 o 6 miembros, -CONR'R' y -NR'CO(alquilo C1-C4) en las que R' y R"" son iguales o diferentes y representan hidrógeno o alquilo C1-C4 sin sustituir, en las que los sustituyentes sobre un grupo o resto alquilo, alquenilo o alquinilo sustituido están ellos mismos sin sustituir o, el caso de sustituyentes alcoxi C1-C4, pueden estar adicionalmente sustituidos con metoxi o etoxi sin sustituir; un grupo cicloalquilo sustituido es dicho grupo cicloalquilo que está sustituido con hasta tres sustituyentes seleccionados de alquilo C1-C8, alquenilo C2-C8, alquinilo C2-C8, Z y -Y-Z en las que Y y Z son como se han definido anteriormente en este documento.",F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,,https://lens.org/058-988-297-636-082,Granted Patent,no,0,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D487/04;;A01N43/36;;A01N43/60;;A01N43/76;;A61P31/10;;C07D498/04,,0,0,,,,ACTIVE
920,EP,A1,EP 2283006 A1,093-920-775-169-422,2011-02-16,2011,EP 09734928 A,2009-04-23,GB 2009001058 W;;GB 0807532 A;;GB 0819696 A,2008-04-24,PYRROLE ANTIFUNGAL AGENTS,,F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,,https://lens.org/093-920-775-169-422,Patent Application,yes,0,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D401/12;;A01N43/40;;A01N43/42;;A61P31/10,,1,0,,,See references of WO 2009130481A1,ACTIVE
921,NZ,A,NZ 589010 A,147-758-713-202-164,2012-11-30,2012,NZ 58901009 A,2009-04-23,GB 0807532 A;;GB 0819696 A;;GB 2009001058 W,2008-04-24,PYRROLE ANTIFUNGAL AGENTS,"Disclosed herein is a pyrrole derivative of formula (I), wherein the substituents are as defined within the specification, processes for its preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as agricultural fungicides. Specifically preferred examples include: · 2-(1,5-Dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{ 4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-1-yl]-phenyl} -2-oxo-acetamide, · N-{ 4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-1-yl]-phenyl} -2-oxo-2-(1-phenyl-1H-pyrrol-2-yl)-acetamide, · N-{ 4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-1-yl]-phenyl} -2-(5-methyl-1-phenyl-1Hpyrrol-2-yl)-2-oxo-acetamide, · N-{ 4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-1-yl]-phenyl} -2-(5-methyl-1H-pyrrol-2-yl)-2-oxo-acetamide, · 2-[3-(4-Chloro-phenyl)-1-(2-methoxy-ethyl)-1H-pyrrol-2-yl]-N-{ 4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-1-yl]-phenyl} -2-oxo-acetamide, · 2-[1-(2-Methoxy-ethyl)-5-methyl-3-phenyl-1H-pyrrol-2-yl]-2-oxo-N-phenyl-1-acetamide, · (2-{ 4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-1-yl]-phenylaminooxalyl} -pyrrol-1-yl)-acetic acid methyl ester,",F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,,https://lens.org/147-758-713-202-164,Patent Application,no,0,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,A61P31/10;;A01N43/36;;C07D207/333,,0,0,,,,PENDING
922,EP,A1,EP 2086956 A1,000-109-588-889-567,2009-08-12,2009,EP 07824361 A,2007-10-29,GB 2007004117 W;;GB 0621720 A;;GB 0715469 A,2006-11-01,INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is a radical of formula R-L1-Y1—(CH2)z—, wherein: z is 0 or 1; R is a radical of formula (X) or (Y) R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R6 is hydrogen, or optionally substituted C1-C6 alkyl, C3-C7 cycloalkyl, aryl or heteroaryl or —(C═O)R3, —(C═O)OR3, or —(C═O)NR3 wherein R3 is hydrogen or optionally substituted (C1-C6)alkyl; Y1 is a bond, —(C═O)—, —S(O2)—, —C(═O)O—, —OC(═O)—, —(C═O)NR3—, —NR3(C═O)—, —S(O2)NR3—, —NR3S(O2)—, or —NR3(C═O)NR4—, wherein R3 and R4 are independently hydrogen or optionally substituted (C1-C6)alkyl, L1 is a divalent linker radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n, p, Q, Alk1 and Alk2 are as defined in the claims.",CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/000-109-588-889-567,Patent Application,yes,0,0,7,29,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,C07D333/38;;A61K31/381,,0,0,,,,ACTIVE
923,PL,T3,PL 2283006 T3,014-495-968-596-447,2015-08-31,2015,PL 09734928 T,2009-04-23,GB 0807532 A;;GB 0819696 A;;EP 09734928 A;;GB 2009001058 W,2008-04-24,PYRROLE ANTIFUNGAL AGENTS,,F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,,https://lens.org/014-495-968-596-447,Patent Application,no,0,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D401/12;;A01N43/40;;A01N43/42;;A61P31/10,,0,0,,,,PENDING
924,WO,A1,WO 2009/130481 A1,127-752-902-770-440,2009-10-29,2009,GB 2009001058 W,2009-04-23,GB 0807532 A;;GB 0819696 A,2008-04-24,PYRROLE ANTIFUNGAL AGENTS,"The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD;;SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,,https://lens.org/127-752-902-770-440,Patent Application,yes,13,38,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D401/12;;A01N43/40;;A01N43/42;;A61P31/10,,11,4,168-449-788-313-849;;078-668-787-190-32X;;179-007-856-363-671;;050-511-615-487-977,10.1016/s0040-4020(01)00525-7;;17531483;;10.1016/j.bmcl.2007.04.071;;10.1016/s0040-4039(00)00755-3;;11922793;;10.1021/ol010297l,"TETRAHEDRON, vol. 57, no. 27, 2001, pages 5873 - 5878;;EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 3, 1998, pages 201 - 207;;BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, no. 14, 2007, pages 3814 - 3818;;PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, vol. 177, no. 3, 2002, pages 545 - 553;;TETRAHEDRON LETTERS, vol. 41, no. 25, 2000, pages 4991 - 4995;;JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY (1972-1999, vol. 17, 1992, pages 2175 - 87;;LIEBIGS ANNALEN DER CHEMIE, vol. 1, 1991, pages 67 - 70;;CANADIAN JOURNAL OF CHEMISTRY, vol. 49, no. 6, 1971, pages 919 - 22;;JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 4, no. 3, 1967, pages 335 - 8;;ORGANIC LETTERS, vol. 4, no. 7, 2002, pages 1103 - 1105;;TETRAHEDRON, vol. 34, no. 2, 1978, pages 241 - 5",PENDING
925,CA,A1,CA 2668338 A1,064-262-794-781-488,2008-05-08,2008,CA 2668338 A,2007-10-29,GB 0621720 A;;GB 0715470 A;;GB 2007004114 W,2006-11-01,IKK-.BETA.SERINE-THREONINE PROTEIN KINASE INHIBITORS,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) acti vity, and are useful in the treatment of autoimmune and inflammatory disease s: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1- C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-1 3 ring atoms; Z is (a) a radical of formula R1R2CHNH-Y-L1-X1-(CH2)Z- wherein : z is 0 or 1; R1 is a carboxylic acid group (-COOH), or an ester group whic h is hydrolysable by one or more intracellular esterase enzymes to a carboxy lic acid group; R2 is the side chain of a natural or non- natural alpha amin o acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(=O)NR3-, - C(=S)-NR3, - C(=NH)-NR3 or -S(=O)2NR3- wherein R3 is hydrogen or optionally substituted C 1-C6 alkyl; L1 is a divalent linker radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.",CHROMA THERAPEUTICS LTD,WILLIAMS JONATHON GARETH;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;DAVIES STEPHEN JOHN;;MOFFAT DAVID FESTUS CHARLES,,https://lens.org/064-262-794-781-488,Patent Application,no,0,0,17,29,0,C07D333/38;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38;;A61K31/381;;C07D333/38,C07D333/38;;A61K31/381,,0,0,,,,DISCONTINUED
926,EP,B1,EP 2297128 B1,181-204-231-857-529,2012-08-15,2012,EP 08737089 A,2008-04-23,GB 2008001434 W,2008-04-23,INHIBITORS OF IKK- SERINE-THREONINE PROTEIN KINASE,,CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/181-204-231-857-529,Granted Patent,yes,3,0,14,15,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,C07D333/38;;A61K31/381;;A61P25/28;;A61P37/00,,0,0,,,,ACTIVE
927,CN,A,CN 102036979 A,008-447-824-321-037,2011-04-27,2011,CN 200880129402 A,2008-04-23,GB 2008001434 W,2008-04-23,Inhibitors of IKK-beta serine-theronine protein kinase,"Cyclopentyl(2S,4E)-2-amino-5-{3-[4-carbamoyl-5(carbamoylamino)-2-thienyl]phenyl}pent-4-enoate; Cyclopentyl 5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-norvalinate; Cyclopentyl(2S,4E)-2-amino-5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-5-methylphenyl}pent-4-enoate; Cyclopentyl(25,4E)-2-amino-5-{5-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-2-methylphenyl}pent-4-enoate; Cyclopentyl O-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-homoserinate; Cyclopentyl O-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-homoserinate; Cyclopentyl N-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate; and tert-Butyl N-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate are hydrolysed to the corresponding carboxylic acids by intracellular carboxylesterases, and are useful for the inhibition of IKK[beta] activity.",CHROMA THERAPEUTICS LTD,CHARLES MOFFAT DAVID FESTUS;;JOHN DAVIES STEPHEN;;HUGH CHARLTON MICHAEL;;CHRISTOPHER HIRST SIMON;;GARETH WILLIAMS JONATHON;;THOMAS ONIONS STUART,,https://lens.org/008-447-824-321-037,Patent Application,no,0,1,14,15,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,C07D333/38;;A61K31/381;;A61P25/28;;A61P37/00,,0,0,,,,DISCONTINUED
928,AU,A1,AU 2007/315943 A1,029-062-530-884-525,2008-05-08,2008,AU 2007/315943 A,2007-10-29,GB 0715470 A;;GB 0621720 A;;GB 2007004114 W,2006-11-01,IKK-beta serine-threonine protein kinase inhibitors,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH—Y-L1-X1—(CH2)z— wherein: z is 0 or 1; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(═O)—, —S(═O)2-, —C(═O)O—, —C(═O)NR3-, —C(═S)—NR3, —C(═NH)—NR3 or —S(═O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent linker radical of formula -(Alk1)m(Q)(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.",CHROMA THERAPEUTICS LTD,HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;MOFFAT DAVID FESTUS CHARLES;;WILLIAMS JONATHON GARETH,,https://lens.org/029-062-530-884-525,Patent Application,no,0,0,17,29,0,C07D333/38;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38;;A61K31/381;;C07D333/38,C07D333/38;;A61K31/381,,0,0,,,,DISCONTINUED
929,EP,B1,EP 2078007 B1,040-136-550-926-822,2011-08-31,2011,EP 07824358 A,2007-10-29,GB 2007004114 W;;GB 0621720 A;;GB 0715470 A,2006-11-01,IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH—Y-L1-X1—(CH2)z— wherein: z is 0 or 1; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(═O)—, —S(═O)2-, —C(═O)O—, —C(═O)NR3-, —C(═S)—NR3, —C(═NH)—NR3 or —S(═O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent linker radical of formula -(Alk1)m(Q)(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.",CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/040-136-550-926-822,Granted Patent,yes,2,0,17,29,0,C07D333/38;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38;;A61K31/381;;C07D333/38,C07D333/38;;A61K31/381,,0,0,,,,ACTIVE
930,KR,A,KR 20110021799 A,061-812-181-474-308,2011-03-04,2011,KR 20107026081 A,2008-04-23,GB 2008001434 W,2008-04-23,INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE,,CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/061-812-181-474-308,Patent Application,no,0,0,14,15,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,A61K31/381;;A61P35/00;;C07D333/36,,0,0,,,,DISCONTINUED
931,AU,A1,AU 2009/239778 A1,167-958-677-474-331,2009-10-29,2009,AU 2009/239778 A,2009-04-23,GB 0819696 A;;GB 0807532 A;;GB 2009001058 W,2008-04-24,Pyrrole antifungal agents,,F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DAVIES GARETH MORSE;;PAYNE LLOYD JAMES;;DOWNHAM ROBERT;;LAW DEREK;;BIRCH MIKE;;OLIVER JASON DAVID,,https://lens.org/167-958-677-474-331,Patent Application,no,0,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D401/12;;A01N43/40;;A01N43/42;;A61P31/10,,0,0,,,,ACTIVE
932,NZ,A,NZ 576705 A,013-287-491-595-005,2011-12-22,2011,NZ 57670507 A,2007-10-29,GB 0621720 A;;GB 0715470 A;;GB 2007004114 W,2006-11-01,IKK-Beta SERINE-THREONINE PROTEIN KINASE INHIBITORS,"Disclosed is a compound of formula (IA) or (IB), or a salt, N-oxide, hydrate or solvate thereof e.g. Cyclopentyl N-{ 4-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl} -L-leucinate, wherein R7 and Z are defined in the specification for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, chronic obstructive pulmonary disease, asthma, multiple sclerosis, diabetes, atopic dermatitis, graft versus host disease, or systemic lupus erythematosus.",CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/013-287-491-595-005,Patent Application,no,0,0,17,29,0,C07D333/38;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38;;A61K31/381;;C07D333/38,C07D333/38;;A61K31/381,,0,0,,,,DISCONTINUED
933,DK,T3,DK 2078007 T3,128-983-408-357-997,2011-12-12,2011,DK 07824358 T,2007-10-29,GB 0621720 A;;GB 0715470 A;;GB 2007004114 W,2006-11-01,Ikk-beta-serin-threonin-proteinkinasehæmmere,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH—Y-L1-X1—(CH2)z— wherein: z is 0 or 1; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(═O)—, —S(═O)2-, —C(═O)O—, —C(═O)NR3-, —C(═S)—NR3, —C(═NH)—NR3 or —S(═O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent linker radical of formula -(Alk1)m(Q)(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.",CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/128-983-408-357-997,Granted Patent,no,0,0,17,29,0,C07D333/38;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38;;A61K31/381;;C07D333/38,C07D333/38;;A61K31/381,,0,0,,,,ACTIVE
934,EP,A1,EP 2297128 A1,152-825-248-305-106,2011-03-23,2011,EP 08737089 A,2008-04-23,GB 2008001434 W,2008-04-23,INHIBITORS OF IKK- SERINE-THREONINE PROTEIN KINASE,,CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/152-825-248-305-106,Patent Application,yes,0,0,14,15,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,C07D333/38;;A61K31/381;;A61P25/28;;A61P37/00,,0,0,,,,ACTIVE
935,US,B2,US 8003695 B2,165-078-828-463-296,2011-08-23,2011,US 51320607 A,2007-10-29,GB 0621720 A;;GB 0715470 A;;GB 2007004114 W,2006-11-01,IKK-beta serine-threonine protein kinase inhibitors,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R 7 is hydrogen or optionally substituted (C 1 -C 6 )alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R 1 R 2 CHNH—Y-L 1 -X 1 —(CH 2 ) z — wherein: z is 0 or 1; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(═O)—, —S(═P)2-, —C(═O)O—, —C(═O)NR3-, —C(═S)—NR 3 , —C(═NH)—NR 3 or —S(═O) 2 NR 3 — wherein R 3 is hydrogen or optionally substituted C 1 -C 6 alkyl; L is a divalent linker radical of formula -(Alk 1 ) m (Q)(Alk 2 ) p - wherein m, n, p, Q, AIk 1 and AIk 2 are as defined in the claims.",CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHAN GARETH,CHROMA THERAPEUTICS LTD (2009-04-16),https://lens.org/165-078-828-463-296,Granted Patent,yes,2,9,17,29,0,C07D333/38;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38;;A61K31/381;;C07D333/38,A61K31/381;;C07D333/38,514/534;;560/42,1,0,,,"International Search Report of PCT/GB2007/004114 dated Feb. 19, 2009.",INACTIVE
936,MX,A,MX 2010011501 A,191-546-175-902-825,2010-11-30,2010,MX 2010011501 A,2008-04-23,GB 2008001434 W,2008-04-23,INHIBITORS OF IKK-Î² SERINE-THREONINE PROTEIN KINASE.,"Cyclopentyl (2S,4E)-2-amino-5-{3-[4-carbamoyl-5 (carbamoylamino)-2-thienyl]phenyl}pent-4-enoate; Cyclopentyl 5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-norval inate; Cyclopentyl (2S,4E)-2-amino-5-{3-[4-carbamoyl-5-(carbamoylamino)-2-t hienyl]-5-methylphenyl}pent-4-enoate; Cyclopentyl (2S,4E)-2-amino-5-{5-[4-carbamoyl-5-(carbamoylamino)-2-t hienyl]-2-methylphenyl}pent-4-enoate; Cyclopentyl O-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L -homoserinate; Cyclopentyl O-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienylJphenyl}-L -homoserinate; Cyclopentyl N-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L -alaninate; and tert-Butyl N-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L -alaninate are hydrolysed to the corresponding carboxylic acids by intracellular carboxylesterases, and are useful for the inhibition of IKKÎ² activity.",CHROMA THERAPEUTICS LTD,DAVIES STEPHEN JOHN;;MOFFAT DAVID FESTUS CHARLES;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/191-546-175-902-825,Patent Application,no,0,0,14,15,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,C07D333/38;;A61K31/381;;A61P25/28;;A61P37/00,,0,0,,,,DISCONTINUED
937,US,B2,US 8993574 B2,078-132-791-690-241,2015-03-31,2015,US 98941009 A,2009-04-23,GB 0807532 A;;GB 0819696 A;;GB 2009001058 W,2008-04-24,Pyrrole antifungal agents,"The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE;;DAVIES PATRICIA SULING;;F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,F2G LTD (2010-10-12),https://lens.org/078-132-791-690-241,Granted Patent,yes,49,6,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D487/04;;A01N43/36;;A01N43/40;;A01N43/42;;A01N43/60;;A01N43/76;;A01N43/84;;A01N43/90;;C07D498/04,514/253.01;;544/364;;514/427,104,42,168-449-788-313-849;;073-424-137-358-597;;101-312-400-123-101;;179-007-856-363-671;;082-524-780-121-593;;153-633-274-519-255;;005-101-078-984-914;;001-238-456-156-836;;069-163-075-034-476;;000-168-006-302-253;;033-970-842-208-903;;031-088-884-898-454;;091-580-409-839-448;;059-936-365-638-63X;;060-766-148-116-567;;028-494-421-159-044;;082-832-526-455-955;;091-792-125-882-107;;139-917-414-896-675;;074-022-163-901-658;;076-227-872-906-787;;073-424-137-358-597;;097-337-103-019-912;;004-694-871-327-186;;157-368-878-373-980;;060-908-101-548-398;;125-190-663-181-256;;062-214-858-572-249;;107-812-744-328-804;;078-668-787-190-32X;;031-312-429-278-02X;;099-799-234-674-203;;061-072-347-279-836;;017-365-412-179-713;;073-622-770-770-672;;094-225-106-312-625;;014-769-575-719-552;;032-838-088-052-630;;018-067-402-237-562;;059-965-899-863-228;;092-933-020-902-40X;;000-575-008-415-735,10.1016/s0040-4020(01)00525-7;;10.1016/s0223-5234(98)80009-3;;9880479;;pmc88911;;10.1128/cmr.12.1.147;;10.1016/s0040-4039(00)00755-3;;10.1039/jr9590000620;;10.1002/jhet.5570040304;;10.1021/jm00253a016;;4151968;;10.1039/p19920002175;;10.1002/ijch.196400006;;10.1139/v71-151;;10.1016/0040-4020(96)00441-3;;10.1021/ja960803f;;10.1016/s0040-4020(00)00774-2;;10.1021/jm0102203;;11754575;;4197003;;10.1002/jps.2600660230;;839424;;38816;;10.1039/jr9490003007;;10.1039/jr9570002931;;10.1002/ardp.19793121104;;7944906;;10.1002/ardp.19943270808;;10.1016/s0223-5234(98)80009-3;;10.1016/s0040-4020(01)93611-7;;10.1021/jo01287a016;;10.1021/ja01463a046;;8842991;;10.1016/s0163-4453(96)92700-0;;8809154;;10.1021/jm960395q;;10.1021/jm049161u;;16451085;;10.3998/ark.5550190.0009.905;;17531483;;10.1016/j.bmcl.2007.04.071;;10.1016/j.tet.2004.11.026;;18385843;;10.1039/b719776d;;10.1016/j.dyepig.2004.10.003;;10064251;;10.1086/515116;;10.1039/jr9350001796;;10.1039/jr9360001098;;10.1080/14756360701811379;;18608761;;10.1021/jo981505z;;7473547;;10.1021/jm00021a009;;10.1073/pnas.0307953101;;pmc387369;;15051887;;10.1016/s0960-894x(00)00322-x;;10937729;;10.1002/chin.200443161,"Yavari et al. (Tetrahedron (2001), 57(27), 5873-5878).;;Dumoulin et al. (European Journal of Medicinal Chemistry (1998), 33(3), 201-207).;;McDonnell et al. Clinical Microbiology Reviews, Jan. 1999, p. 147-179; vol. 12, Issue 1.;;http://www.merckmillipore.com/chemicals/diethyl-ether/MDA-CHEM-100926/p-NgGb.s1Lay4AAAEW8uEfVhTI-(2012).;;Schoichet Laboratory at UCSF (through ZINC database of commercially available small molecules-entered to CHEMCATS Feb. and Mar. 2008; p. 1-64).;;Alvarez, M. et al. (1999). ""Synthesis of 1,2-Dihydropyrrolo[1,2-c]Pyrimidin-1-Ones,"" Journal of Chemical Society 249-255.;;Alves, M.J. et al. (2000). ""Novel Aziridine Esters by the Addition of Aromatic Nitrogen Heterocycles to a 2H-Azirine-3-Carboxylic Ester,"" Tetrahedron Letters 41:4991-4995.;;Ames, D.E. et al. (1959, e-published Jan. 1, 1959). ""The Preparation of Aminoalkylpyrrocolines,"" Journal of Chemical Society 124:620-622.;;Archibald, J.L. et al. (Sep. 1967). ""New Reactions of Pyrroles. II. Preparation and Reactions of Pyrroleglyoxyloyl Derivatives,"" Journal of Heterocyclic Chemistry 4:335-338.;;Archibald, J.L. et al. (1974). ""Benzamidopiperidines. 2. Heterocyclic Compounds Related to Indoramin,"" Journal of Medicinal Chemistry 17(7):736-739.;;Battersby, A.R. et al. (1992, e-published Jan. 1, 1992). ""Synthetic Studies Relevant to Biosynthetic Research on Vitamin B12. Part 10. Construction of the East and West Building Blocks for Synthesis of Isobacteriochlorins,"" Journal of Chemical Society 17:2175-2187.;;Bentov, M. et al. (1964). ""4-Fluoroindole and Derivatives,"" Israel Journal of Chemistry 2:25-28.;;Birchall, G.R. et al. (1971). ""The Chlorination of Pyrroles. Part II,"" Canadian Journal of Chemistry 49:919-922.;;Black, D.S.C. et al. (1996). ""Reaction of Some 4,6-Dimethoxyindoles with Oxalyl Chloride,"" Tetrahedron 52(26):8925-8936.;;Black, D.S.C. et al. (1996). ""The Indol-2-Ylglyoxylamide Moiety: A New Building Block for the Design and Self-Assembly of Hydrogen Bond Networks,"" Journal of American Chemical Society 118(34):8148-8149.;;Black, D.S.C. et al. (2000). ""Formation of C-Amido-Calix[3]Indoles from 2'- and 7'-Indolylglyoxylamides,"" Tetrahedron 56:8513-8524.;;Bohusch, M. et al. (1991). ""Consequences of a Diminution of the Porphyrin pi-System: Attempted Syntheses of Bacteriophin and Chlorophin,"" Liebigs Annalen der Chemie 67-70. (Abstract Only).;;Borthwick, A.D. et al. (Jan. 3, 2002, e-published Dec. 5, 2001). ""Design and synthesis of Pyrrolidine-5,5-trans-Lactams (5-Oxohexahdropyrrolo[3,2-b]Pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 2. Potency and Chirality,"" Journal of Medicinal Chemistry 45(1):1-18.;;Cameron, B.D. et al. (1973). ""The Synthesis and Metabolic Fate of 14C-Viminol, a New Analgesic, in the Rat and the Dog,"" Arzneimittel-Forshung/Drug Res. 23(5):708-712.;;Cardellini, M. et al. (Feb. 1977). ""Indolizine Derivatives with Biological Activity I: N'-Substituted Hydrazides of Indolizine-2-Carboxylic Acid,"" Journal of Pharmaceutical Sciences 66(2):259-262.;;Chemcats. (Jan. 25, 2008). ""Benzo [b] Thiophene-2-Carboxylic Acid, 3-[2-[[(4-Methoxyphenyl) Amino]Oxoacetyl]-1H-Pyrrol-1-y1]-, Methyl Ester,"" Ryan Scientific Screening Library 5 pages.;;Chemcats. (Feb. 13, 2008). ""1H-Pyrrole-2-Acetamide, N-(4-Bromophenyl)-1- (2-Chloro-4-Nitrophenyl) -alpha-Oxo-,"" Ambinter Stock Screening Collection 5 pages.;;Chemcats. (Feb. 18, 2008). ""1H-Pyrrole-2-Acetamide, N- (2,4-Dichlorophenyl)-1-Methyl-alpha-Oxo-,"" Interchim Intermediates 5 pages.;;Chiarino, D. et al. (1978). ""Stereochemistry of Viminol, a Novel Central Analgesic,"" Arzneimittel-Forshung/Drug Res. 28(11):1554-1561.;;Cook, A.H. et al. (1949, e-published Jan. 1, 1949). ""Studies in the Azole Series. Part XXIV. The Interaction of Carbonyl Compounds and 2-Thio-5-Thiazolidone,"" Journal of Chemical Society 633:3007-3012.;;Crowley, K.J. et al. (1957). ""Intermediates for the Synthesis of Optically Active Methyl-Substituted Long-Chain Acids. Part II,"" Journal of the Chemical Society 2931-2934.;;Dannhardt, G. et al. (1979). ""Synthese und Eigenschaften von 2,3-Dihydro-1 H-Pyrrolizinen,"" Arch. Pharm. 312:896-907.;;Dannhardt, G. et al. (1994). ""Nonsteroidal Antiinflammatory Agents, XVIII: C-5 Functionalized 6,7-Diphenyl-2,3-Dihydro-1 H-Pyrrolizines as Inhibitors of Bovine Cyclooxygenase and 5-Lipoxygenase,"" Arch Pharm 327:509-514.;;Dannhardt, V.G. et al. (1986). ""Antiphlogistische 2,3-Dihydro-1H-Pyrrolizine, 11. Mitt. Dihydropyrrolizinyl-Substituierte 2-Aminoethanol- und Glykosäure-Derivate,"" Chemiker-Zeitung 110(3):124-127.;;Dumoulin, H. et al. (1998). ""2-Oxo-2-(Pehn-2-Ylpyrrol-2-Yl)Acetamides as Potential Anxiolytic Agents: Synthesis and Affinity at the Central Benzodiazepine Receptor,"" European Journal of Medicinal Chemistry 33:201-207.;;Dyke, S.F. et al. (1978). ""Pavinane and Isopavinane Alkaloids,"" Tetrahedron 34:241-245.;;Fryer, R.I. et al. (Dec. 1967). ""Quinazolines and 1,4-Benzodiazepines. XXXVII. Synthesis and Rearrangements of a Substituted 5-Phenyl-1 H-1,4-Benzodiazepine,"" Journal of Organic Chemistry 32:3798-3803.;;Galbraith, A. et al. (Jan. 20, 1961). ""The Formation of Cycl[3,2,2]azine Derivatives via the Reaction of Pyrrocoline with Dimethyl Acetylenedicarboxylate,"" Journal of the American Chemical Society 83:453-458.;;Groll, A.H. et al. (1996). ""Trends in the Postmortem Epidemiology of Invasive Fungal Infections at a University Hospital,"" Journal of Infection 33:23-32.;;Hagishita, S. et al. (1996). ""Potent Inhibitors of Secretory Phospholipase A2: Synthesis and Inhibitory Activities of Indolizine and Indene Derivatives,"" Journal of Medicinal Chemistry 39(19):3636-3658.;;Hudack, R.A. et al. (2006, e-published Jan. 14, 2006). ""Design, Synthesis, and Biological Activity of Novel Polycyclic Aza-Amide FKBP12 Ligands,"" Journal of Medicinal Chemistry 49(3):1202-1206.;;Ignatovich, J. et al. (2008). ""Synthesis of Functionalized Benzyl Amines by the Reductive Alkylation of Heterocyclic and Heteroaromatic Amines with Arylaldehydes and preparation of the Intermediates for New Synthetic Biomolecules,"" ARKAT-USA, Inc. (ix):42-51.;;Islam, I. et al. (2007, e-published Apr. 27, 2007). ""Indolinone Based Phosphoinositide-Dependent Kinase-1 (PDK1) Inhibitors. Part 1: Design, Synthesis and Biological Activity,"" Bioorganic & Medicinal Chemistry Letters 17:3814-3818.;;Keawin, T. et al. (2005, e-published Dec. 10, 2004). ""Reaction of Some 4,6-Dimethoxyindoles with Nitric Acid: Nitration and Oxidative Dimerisation,"" Tetrahedron 61:853-861.;;Mahiout, Z. et al. (2008, e-published Feb. 28, 2008). ""Solvent-Dependent Oxidations of 5-and 6-Azaindoles to Trioxopyrrolopyridines and Functionalised Azaindoles,"" Organic & Biomolecular Chemistry6:1364-1376.;;Nourmohammadian, F. et al. (2005, e-published Jan. 21, 2005). ""An AB Initio Molecular Orbital Study of Structural Isomers of Diketopyrrolopyrrole,"" Dyes and Pigments 67:15-20.;;Pätzel, M. et al. (2005). ""Product Class 5: alpha-Heteroatom-Substituted Alkanamides,"" Science of Synthesis 21:477-535.;;Ribaud, P. et al. (1999). ""Survival and Prognostic Factors of Invasive Aspergillosis After Allogeneic Bone Marrow Transplantation,"" Clinical Infectious Diseases 28:322-330.;;Rowe, F.M. et al. (1935, e-published Jan. 1, 1935). ""A Reaction of Certain Diazosulphonates Derived from beta-Naphthol-1-Sulphonic Acid. Part XIII. Fission of the Naphthalene Nucleus and Subsequent Closure in Two Directions,"" Journal of Chemical Society 420:1796-1808.;;Rowe, F.M. et al. (1936, e-published Jan. 1, 1936). ""A Reaction of Certain Diazosulphonates Derived from beta-Naphthol-1-Sulphonic Acid. Part XV. Derivatives of 2'-Nitro-4'-Methyl-Benzene-2-Naphthol-1-Diazosulphonate and Synthesis of 2-(2'-Nitro-4'-Methylphenylamino)Isoindolinone-3-Acetic Acid,"" Journal of Chemical Society 232:1098-1108.;;Roy, K. et al. (Dec. 2008). ""Development of Linear and Nonlinear Predictive QSAR Models and Their External Validation Using Molecular Similarity Principle for Anti-HIV Indolyl Aryl Sulfones,"" Journal of Enzyme Inhibition and Medicinal Chemistry 23(6):980-995.;;Savage, S.A. et al. (1998). ""Efficient Synthesis of 4-, 5-, and 6-Methyl-2,2'-Bipyridine by a Negishi Cross-Coupling Strategy Followed by High-Yield Conversion to Bromo- and Chloromethyl-2,2'-Bipyridines,"" Journal of Organic Chemistry 63(26):10048-10051.;;Scott, M.K. et al. (1995). ""Piperazinylalkyl Heterocycles as Potential Antipsychotic Agents,"" Journal of Medicinal Chemistry 38(21):4198-4210.;;Si, Z. et al. (Apr. 6, 2004). ""Small-Molecule Inhibitors of HIV-1 Entry Block Receptor-Induced Conformational Changes in the Viral Envelope Glycoproteins,"" Proceedings of the National Academy of Sciences 101(14):5036-5041.;;Slassi, A. et al. (2000). ""5-Alkyltryptamine Derivatives as Highly Selective and Potent 5-HT1D Receptor Agonists,"" Bioorganic & Medicinal Chemistry Letters 10:1707-1709.;;Sofan, M.A. et al. (2004). ""Studies on 2,3-Dioxopyrrolidines. Synthesis of Piperazine, Pyrrolo[4,5-b]Indole, Pyrazino [5,6-b]Indole and Arylazo Derivatives of Amino Acids,"" Polish Journal of Chemistry 78:837-842.;;CAS Registry No. 3758-62-1, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 3768-71-6, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 3768-72-7, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 3768-82-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 4380-46-5, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 4595-83-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 6616-51-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 15940-17-7, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 15940-18-8, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 15940-19-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 15940-20-2, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 15940-21-3, created Nov. 16, 1984 last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 15940-22-4, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 15940-23-5, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 15940-24-6, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 15940-25-7, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 23502-48-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 26883-51-2, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 31709-75-8, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 31709-76-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 31709-77-0, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 31710-23-3, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 36793-47-2, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 41596-37-6, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 42060-03-7, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 42060-05-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 42221-74-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 43084-49-7, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 53391-28-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 53391-29-0, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 53391-30-3, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 53391-52-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 53391-63-2, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 65473-58-7, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 68803-72-5, created Nov. 16, 1984, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 81729-69-3, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 81741-58-4, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 83996-64-9, created Nov. 16, 1984, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 130761-64-7, created Nov. 30, 1990, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 130761-68-1, created Nov. 30, 1990, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 145045-69-8, created Dec. 25, 1992, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 171854-40-3, created Dec. 29, 1995, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 171854-41-4, created Dec. 29, 1995, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 171854-42-5, created Dec. 29, 1995, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 171854-43-6, created Dec. 29, 1995, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 17854-44-7, created Dec. 29, 1995, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 171845-45-8, created Dec. 29, 1995, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 171854-46-9, created Dec. 29, 1995, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 171854-47-0, created Dec. 29, 1995, last accessed Feb. 2, 2012, 2 pages.;;CAS Registry No. 185030-21-1, created Jan. 15, 1997, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 208765-70-2, created Jul. 22, 1998, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 208765-71-3, created Jul. 22, 1998, last accessed Feb. 2, 2012, 1 page.;;CAS Registry No. 208765-72-4, created Jul. 22, 1998, last accessed Feb. 2, 2012, 2 pages.",ACTIVE
938,US,B2,US 8106091 B2,056-584-793-070-846,2012-01-31,2012,US 44727107 A,2007-10-29,GB 0621720 A;;GB 0715469 A;;GB 2007004117 W,2006-11-01,Inhibitors of IKK-beta serine-threonine protein kinase,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: wherein R 7 is hydrogen or optionally substituted (C 1 -C 6 )alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is a radical of formula R-L 1 -Y 1 —(CH 2 ) z —, wherein: z is 0 or 1; R is a radical of formula (X) or (Y) R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R 6 is hydrogen, or optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl or heteroaryl or —(C═O)R 3 , —(C═O)OR 3 , or —(C═O)NR 3 wherein R 3 is hydrogen or optionally substituted (C 1 -C 6 )alkyl; Y 1 is a bond, —(C═O)—, —S(O 2 )—, —C(═O)O—, —OC(═O)—, —(C═O)NR 3 —, —NR 3 (C═O)—, —S(O 2 )NR 3 —, —NR 3 S(O 2 )—, or —NR 3 (C═O)NR 4 —, wherein R 3 and R 4 are independently hydrogen or optionally substituted (C 1 -C 6 )alkyl, L 1 is a divalent linker radical of formula -(Alk 1 ) m (Q) n (Alk 2 ) p - wherein m, n, p, Q, Alk 1 and Alk 2 are as defined in the claims.",MOFFAT DAVID CHARLES FESTUS;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH;;CHROMA THERAPEUTICS LTD,MOFFAT DAVID CHARLES FESTUS;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,CHROMA THERAPEUTICS LTD (2009-05-06),https://lens.org/056-584-793-070-846,Granted Patent,yes,2,9,7,29,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,A61K31/381;;C07D333/36,514/447;;549/69,1,0,,,"International Search Report dated Feb. 12, 2008.",INACTIVE
939,US,A1,US 2017/0189113 A1,077-598-196-445-602,2017-07-06,2017,US 201715463913 A,2017-03-20,US 201715463913 A;;US 201113113326 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 52275304 P,2003-01-21,Method of surgical perforation via the delivery of energy,"A method of perforating a tissue of a heart of a patient when an inferior approach to the heart is contraindicated. The method utilizes an electrosurgical apparatus and a delivery system comprising at least two dilators wherein a first dilator is configured for facilitating positioning of the electrosurgical apparatus adjacent the tissue and wherein a second dilator is configured for advancement through a perforation in the tissue. An outer diameter of the second dilator is substantially equal to or less than an outer diameter of the first dilator. The method comprises the steps of: (a) advancing the first dilator into the heart of the patient, from a superior approach, until a distal end of the first dilator is adjacent the tissue; (b) using the electrosurgical apparatus, which is positioned through the first dilator, to create a perforation in the tissue by delivering electrical energy to the tissue; (c) advancing the distal end of the electrosurgical apparatus through the perforation; (d) withdrawing the first dilator; and (e) advancing the second dilator over the electrosurgical apparatus.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;DICICCO MATTHEW PAUL JOSEPH;;HACHEM BAHE;;DAVIES GARETH;;HARTLEY AMANDA;;VISRAM NAHEED;;SHAH KRISHAN;;BAYLIS FRANK,BAYLIS MEDICAL COMPANY INC (2017-05-23);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/077-598-196-445-602,Patent Application,yes,7,5,3,113,0,A61B18/1206;;A61B18/24;;A61B2090/064;;A61B2090/3966;;A61B18/1492;;A61B2018/00839;;A61B2018/00601;;A61B2018/00351;;A61B18/1492;;A61B18/16;;A61M29/02;;A61M5/007;;A61B2018/00839;;A61B2018/00601;;A61B2018/00351;;A61B18/24;;A61B2090/3966;;A61B2090/064;;A61B2018/0038,A61B18/14;;A61B18/16;;A61M5/00;;A61M29/02,,0,0,,,,EXPIRED
940,JP,A,JP 2015051984 A,101-680-376-784-258,2015-03-19,2015,JP 2014208999 A,2014-10-10,GB 0807532 A;;GB 0819696 A,2008-04-24,PYRROLE ANTIFUNGAL AGENTS,"PROBLEM TO BE SOLVED: To provide a compound that is useful in prevention or treatment of a fungal disease and may also be used as agricultural fungicides, and provide a complex in which the compound and a second antifungal agent are formulated for simultaneous or successive administration.SOLUTION: The present invention relates to a pyrrole derivative of the general formula (I) represented by 2-(1,5-dimethyl-3-phenyl-1 H-pyrrole-2-yl)-N-{4-[4-(4,6-dimethyl-pyridine-2-yl)-piperazine-1-yl]-phenyl}-2-oxo-acetamide, and pharmaceutically and agriculturally acceptable salts thereof.",F2G LTD,GRAHAM EDWARD MORRIS SIBLEY;;ROBERT DOWNHAM;;LLOYD JAMES PAYNE;;DEREK LAW;;JASON DAVID OLIVER;;MIKE BIRCH;;GARETH MORSE DAVIES,,https://lens.org/101-680-376-784-258,Patent Application,no,4,1,24,26,0,A01N43/36;;A01N43/60;;A01N43/76;;C07D498/04;;A01N43/40;;A01N43/42;;A01N43/84;;A01N43/90;;A61K31/4025;;A61K31/4439;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/4985;;A61K31/5377;;C07D487/04;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;A01N43/36;;A01N43/60;;A01N43/76;;C07D498/04;;A01N43/40;;A01N43/42;;A01N43/84;;A01N43/90;;C07D487/04;;A61K31/4025;;A61K31/4439;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/4985;;A61K31/5377;;A61K45/06,A61K31/40;;A01N43/60;;A01P3/00;;A61K31/137;;A61K31/4025;;A61K31/404;;A61K31/407;;A61K31/415;;A61K31/4164;;A61K31/4174;;A61K31/4196;;A61K31/422;;A61K31/4439;;A61K31/454;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/4985;;A61K31/505;;A61K31/506;;A61K31/5375;;A61K31/5377;;A61K31/5383;;A61K31/55;;A61K31/7048;;A61K31/7072;;A61K45/00;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D207/333;;C07D207/34;;C07D213/36;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D405/14;;C07D409/14;;C07D413/12;;C07D413/14;;C07D487/04;;C07D498/04,,6,0,,,"JPN6015042983; Ａｒｃｈｉｖ ｄｅｒ Ｐｈａｒｍａｚｉｅ Ｖｏｌ．３２７， Ｎｏ．８, 1994, ｐ．５０９-５１４;;JPN6015042985; Ｃｈｅｍｉｋｅｒ-Ｚｅｉｔｕｎｇ Ｖｏｌ．１１０， Ｎｏ．３, 1986, ｐ．１２４-１２７;;JPN6015042987; Ａｒｃｈｉｖ ｄｅｒ Ｐｈａｒｍａｚｉｅ Ｖｏｌ．３１２， Ｎｏ．１１, 1979, ｐ．８９６-９０７;;JPN6015042983; Ａｒｃｈｉｖ ｄｅｒ Ｐｈａｒｍａｚｉｅ Ｖｏｌ．３２７， Ｎｏ．８, 1994, ｐ．５０９-５１４;;JPN6015042985; Ｃｈｅｍｉｋｅｒ-Ｚｅｉｔｕｎｇ Ｖｏｌ．１１０， Ｎｏ．３, 1986, ｐ．１２４-１２７;;JPN6015042987; Ａｒｃｈｉｖ ｄｅｒ Ｐｈａｒｍａｚｉｅ Ｖｏｌ．３１２， Ｎｏ．１１, 1979, ｐ．８９６-９０７",ACTIVE
941,BR,A2,BR PI0718056 A2,011-919-522-997-323,2013-11-05,2013,BR PI0718056 A,2007-10-29,GB 0621720 A;;GB 0715470 A;;GB 2007004114 W,2006-11-01,INIBIDORES DA PROTEÍNA CINASE IKK-BETA SERINA-TREONINA,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH—Y-L1-X1—(CH2)z— wherein: z is 0 or 1; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(═O)—, —S(═O)2-, —C(═O)O—, —C(═O)NR3-, —C(═S)—NR3, —C(═NH)—NR3 or —S(═O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent linker radical of formula -(Alk1)m(Q)(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.",CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/011-919-522-997-323,Patent Application,no,0,0,17,29,0,C07D333/38;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38;;A61K31/381;;C07D333/38,C07D333/38;;A61K31/381,,0,0,,,,DISCONTINUED
942,US,A1,US 2010/0087515 A1,087-799-266-548-257,2010-04-08,2010,US 51320607 A,2007-10-29,GB 0621720 A;;GB 0715470 A;;GB 2007004114 W,2006-11-01,IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R 7 is hydrogen or optionally substituted (C 1 -C 6 )alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R 1 R 2 CHNH—Y-L 1 -X 1 —(CH 2 ) z — wherein: z is 0 or 1; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(═O)—, —S(═P)2-, —C(═O)O—, —C(═O)NR3-, —C(═S)—NR 3 , —C(═NH)—NR 3 or —S(═O) 2 NR 3 — wherein R 3 is hydrogen or optionally substituted C 1 -C 6 alkyl; L is a divalent linker radical of formula -(Alk 1 ) m (Q)(Alk 2 ) p - wherein m, n, p, Q, AIk 1 and AIk 2 are as defined in the claims.",CHROMA TERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHAN GARETH,CHROMA THERAPEUTICS LTD (2009-04-16),https://lens.org/087-799-266-548-257,Patent Application,yes,0,0,17,29,0,C07D333/38;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38;;A61K31/381;;C07D333/38,A61K31/381;;A61P1/00;;A61P11/00;;A61P29/00;;A61P35/00;;A61P37/00;;C07D333/38;;C12N9/99,514/447;;549/69;;435/184,0,0,,,,INACTIVE
943,MX,A,MX 2009004442 A,086-929-696-140-821,2009-05-22,2009,MX 2009004442 A,2007-10-29,GB 0621720 A;;GB 0715470 A;;GB 2007004114 W,2006-11-01,IKK- Â SERINE-THREONINE PROTEIN KINASE INHIBITORS.,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula(A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH-Y-L1-X1-(CH2)Z-wherein: z is 0 or 1; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non- natural alpha amino acid; Yis a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(=O)NR3-, - C(=S)-NR3,-C(=NH)-NR3 or -S(=O)2NR3- wherein R3is hydrogen or optionally substituted C1-C6 alkyl; L1is a divalent linker radical of formula -(Alk1)m(Q)n(Alk2)p-wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.",CHROMA THERAPEUTICS LTD,DAVIES STEPHEN JOHN;;MOFFAT DAVID FESTUS CHARLES;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/086-929-696-140-821,Patent Application,no,0,0,17,29,0,C07D333/38;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38;;A61K31/381;;C07D333/38,C07D333/38;;A61K31/00,,0,0,,,,ACTIVE
944,EP,B1,EP 2626361 B1,154-654-909-659-964,2014-10-15,2014,EP 13167337 A,2009-04-23,GB 0807532 A;;GB 0819696 A;;EP 09734928 A,2008-04-24,Pyrrole antifungal agents,,F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,,https://lens.org/154-654-909-659-964,Granted Patent,yes,3,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D487/04;;A01N43/36;;A01N43/60;;A01N43/76;;A61P31/10;;C07D498/04,,0,0,,,,ACTIVE
945,NZ,A,NZ 589413 A,052-865-057-095-83X,2012-08-31,2012,NZ 58941308 A,2008-04-23,NZ 58941308 A;;GB 2008001434 W,2008-04-23,INHIBITORS OF IKK-beta SERINE-THREONINE PROTEIN KINASE,"Disclosed herein is a compound of: · Cyclopentyl (2S,4E)-2-amino-5-{ 3-[4-carbamoyl-5 (carbamoylamino )-2-thienyl]phenyl} pent-4-enoate; · Cyclopentyl 5-{ 3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl] phenyl} -L-norvalinate; · Cyclopentyl (2S,4E)-2-amino-5-{ 3-[4-carbamoyl-5-( carbamoylamino )-2-thienyl]-5-methylphenyl} pent-4-enoate; · Cyclopentyl (2S,4E)-2-amino-5-{ 5-[4-carbamoyl-5-( carbamoylamino )-2-thienyl]-2-methYlphenyl} pent-4-enoate; · Cyclopentyl O-{ 3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl} -L-homoserinate; · Cyclopentyl N-{ 3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl} -L-alaninate; · tert-Butyl N-{ 3-[4-carbamoyl-5-( carbamoylamino )-2-thienyl]benzyl} -L-alaninate; · (2S,4E)-2-ami no-5-{ 3-[ 4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl} pent -4-enoic acid; · 5-{ 3-[ 4-carbamoyl-5-( carbamoylamino )-2-thienyl]phenyl} -L-norvaline; · (2S,4E)-2-am ino-5-{ 3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-5-methylphenyl} pent-4-enoic acid; · (2S,4E)-2-amino-5-{ 5-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-2-methylphenyl} pent-4-enoic acid; · O-{ 3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl} -L-homoserine; · N-{ 3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl} -L-alanine; and pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions comprising said compounds and uses thereof. Said compounds are useful as inhibitors of IKK-â serine-Theronine protein kinase as such are useful in the treatment of proliferative disease states such as hepatocellular cancer or cancer, bowel cancer, ovarian cancer, head and neck and cervical squamous cancers, gastric or lung cancers, anaplastic oligodendrogliomas, glioblastoma multiforme or medulloblastomas; autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, chronic obstructive pulmonary disease, asthma, multiple sclerosis, diabetes, atopic dermatitis, graft versus host disease, or systemic lupus erythematosus.",CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,"CHROMA THERAPEUTICS LTD., GB (2011-01-28)",https://lens.org/052-865-057-095-83X,Patent Application,no,0,0,1,15,0,,C07D333/38;;A61K31/381;;A61P25/28;;A61P37/00,,0,0,,,,DISCONTINUED
946,PT,E,PT 2283006 E,077-802-216-339-168,2015-06-29,2015,PT 09734928 T,2009-04-23,GB 0807532 A;;GB 0819696 A,2008-04-24,PYRROLE ANTIFUNGAL AGENTS,,F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,,https://lens.org/077-802-216-339-168,Granted Patent,no,0,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D401/12;;A01N43/40;;A01N43/42;;A61P31/10,,0,0,,,,ACTIVE
947,US,A1,US 2015/0238500 A1,159-135-382-000-043,2015-08-27,2015,US 201514625532 A,2015-02-18,US 201514625532 A;;GB 0807532 A;;GB 0819696 A;;US 98941011 A;;GB 2009001058 W,2008-04-24,PYRROLE ANTIFUNGAL AGENTS,"The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.",F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MICHAEL;;DAVIES GARETH MORSE,F2G LTD (2010-11-01),https://lens.org/159-135-382-000-043,Patent Application,yes,0,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,A61K31/5377;;A01N43/36;;A01N43/40;;A01N43/42;;A01N43/60;;A01N43/84;;A01N43/90;;A61K31/4025;;A61K31/4439;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/4985;;A61K45/06,,2,0,,,"Types of Fungal Diseases""-www.cdc.gov/fungal/diseases/index.html [11/16/2015];;(CDC ""Aspergillosis Risk and Prevention"" -www.cdc.fungal/diseases/aspergillosis/risk-prevention.html [11/16/2015]",ACTIVE
948,WO,A1,WO 2008/053185 A1,150-636-468-031-615,2008-05-08,2008,GB 2007004117 W,2007-10-29,GB 0621720 A;;GB 0715469 A,2006-11-01,INHIBITORS OF IKK-ß SERINE-THREONINE PROTEIN KINASE,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases wherein R 7 is hydrogen or optionally substituted (C 1 C 6 )alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is a radical of formula R-L 1 -Y 1 -(CH 2 ) z -, wherein: z is 0 or 1; R is a radical of formula (X) or (Y) R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R 6 is hydrogen, or optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl or heteroaryl or -(C=O)R 3 , -(C=O)OR 3 , Or -(C=O)NR 3 wherein R 3 is hydrogen.or optionally substituted (C 1 -C 6 )alkyl; Y 1 is a bond, -(C=O)-, -S(O 2 )-, -C(=O)O-, -OC(=O)-, -(C=O)NR 3 -, -NR 3 (C=O)-, -S(O 2 )NR 3 -, -NR 3 S(O 2 )-, or -NR 3 (C=O)NR 4 -, wherein R 3 and R 4 are independently hydrogen or optionally substituted (CrC6)alkyl, L 1 is a divalent linker radical of formula -(Alk 1 ) m (Q) n (Alk 2 ) p - wherein m, n, p, Q, Alk 1 and AIk 2 are as defined in the claims.",CHROMA THERAPEUTICS LTD;;MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/150-636-468-031-615,Patent Application,yes,2,8,7,29,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,A61K31/381;;C07D333/38,,0,0,,,,PENDING
949,CN,A,CN 101541779 A,177-305-505-897-359,2009-09-23,2009,CN 200780040236 A,2007-10-29,GB 0621720 A,2006-11-01,IKK-beta serine-threonine protein kinase inhibitors,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH-Y-L-X-(CH2)Z- wherein: z is 0 or 1; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non- natural alpha amino acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(=O)NR3-, - C(=S)-NR3, -C(=NH)-NR3 or -S(=O)2NR3- wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L is a divalent linker radical of formula -(Alk)m(Q)n(Alk)p- wherein m, n, p, Q, AIk and AIk are as defined in the claims.",CHROMA THERAPEUTICS LTD,CHARLES MOFFAT DAVID FESTUS;;JOHN DAVIES STEPHEN;;HUGH CHARLTON MICHAEL;;CHRISTOPHER HIRST SIMON;;THOMAS ONIONS STUART;;GARETH WILLIAMS JONATHON,,https://lens.org/177-305-505-897-359,Patent Application,no,0,1,3,29,0,,C07D333/38,,0,0,,,,DISCONTINUED
950,EP,A1,EP 2078007 A1,170-087-791-994-864,2009-07-15,2009,EP 07824358 A,2007-10-29,GB 2007004114 W;;GB 0621720 A;;GB 0715470 A,2006-11-01,IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH—Y-L1-X1—(CH2)z— wherein: z is 0 or 1; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(═O)—, —S(═O)2-, —C(═O)O—, —C(═O)NR3-, —C(═S)—NR3, —C(═NH)—NR3 or —S(═O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent linker radical of formula -(Alk1)m(Q)(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.",CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/170-087-791-994-864,Patent Application,yes,0,0,17,29,0,C07D333/38;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38;;A61K31/381;;C07D333/38,C07D333/38;;A61K31/381,,0,0,,,,ACTIVE
951,WO,A1,WO 2008/053182 A1,079-937-422-955-480,2008-05-08,2008,GB 2007004114 W,2007-10-29,GB 0621720 A;;GB 0715470 A,2006-11-01,IKK-ß SERINE-THREONINE PROTEIN KINASE INHIBITORS,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R 7 is hydrogen or optionally substituted (C 1 -C 6 )alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R 1 R 2 CHNH-Y-L 1 -X 1 -(CH 2 ) Z - wherein: z is 0 or 1; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non- natural alpha amino acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(=O)NR3-, - C(=S)-NR 3 , -C(=NH)-NR 3 or -S(=O) 2 NR 3 - wherein R 3 is hydrogen or optionally substituted C 1 -C 6 alkyl; L 1 is a divalent linker radical of formula -(Alk 1 ) m (Q) n (Alk 2 ) p - wherein m, n, p, Q, AIk 1 and AIk 2 are as defined in the claims.",CHROMA THERAPEUTICS LTD;;MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/079-937-422-955-480,Patent Application,yes,2,6,17,29,0,C07D333/38;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38;;A61K31/381;;C07D333/38,A61K31/381;;C07D333/38,,1,1,135-162-118-743-908,10229185;;10.1016/s1074-7613(00)80042-4,"TANAKA, M., IMMUNITY, vol. 10, 1999, pages 421",PENDING
952,DK,T3,DK 2626361 T3,177-728-642-920-281,2015-01-19,2015,DK 13167337 T,2009-04-23,GB 0807532 A;;GB 0819696 A;;EP 09734928 A,2008-04-24,PYRROL-ANTIMYKOTIKA,,F2G LTD,SIBLEY GRAHAM EDWARD MORRIS;;DOWNHAM ROBERT;;PAYNE LLOYD JAMES;;LAW DEREK;;OLIVER JASON DAVID;;BIRCH MIKE;;DAVIES GARETH MORSE,,https://lens.org/177-728-642-920-281,Granted Patent,no,0,0,24,26,0,A61K31/5377;;A61K31/5377;;A01N43/36;;A01N43/36;;A01N43/40;;A01N43/40;;A01N43/42;;A01N43/42;;A01N43/60;;A01N43/60;;A01N43/76;;A01N43/76;;A01N43/84;;A01N43/84;;A01N43/90;;A01N43/90;;A61K31/4025;;A61K31/4025;;A61K31/4439;;A61K31/4439;;A61K31/4709;;A61K31/4709;;A61K31/4725;;A61K31/4725;;A61K31/496;;A61K31/496;;A61K31/4985;;A61K31/4985;;A61K45/06;;A61P11/00;;A61P11/06;;A61P31/10;;A61P43/00;;C07D487/04;;C07D487/04;;C07D498/04;;C07D498/04,C07D487/04;;A01N43/36;;A01N43/60;;A01N43/76;;A61P31/10;;C07D498/04,,0,0,,,,ACTIVE
953,US,A1,US 2011/0039920 A1,012-663-551-057-197,2011-02-17,2011,US 98902208 A,2008-04-23,GB 2008001434 W,2008-04-23,INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE,"Cyclopentyl(2S,4E)-2-amino-5-{3-[4-carbamoyl-5(carbamoylamino)-2-thienyl]phenyl}pent-4-enoate; Cyclopentyl 5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-norvalinate; Cyclopentyl(2S,4E)-2-amino-5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-5-methylphenyl}pent-4-enoate; Cyclopentyl(25,4E)-2-amino-5-{5-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-2-methylphenyl}pent-4-enoate; Cyclopentyl O-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-homoserinate; Cyclopentyl O-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-homoserinate; Cyclopentyl N-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate; and tert-Butyl N-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate are hydrolysed to the corresponding carboxylic acids by intracellular carboxylesterases, and are useful for the inhibition of IKKβ activity.",CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;WILLIAMS JONATHON GARETH;;ONIONS STUART THOMAS,CHROMA THERAPEUTICS LTD (2010-10-08),https://lens.org/012-663-551-057-197,Patent Application,yes,0,5,14,15,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,A61K31/381;;A61P1/04;;A61P3/10;;A61P11/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/06;;C07D333/38;;C12N9/99,514/447;;549/69;;435/184,0,0,,,,DISCONTINUED
954,CA,A1,CA 2722255 A1,018-611-886-349-355,2009-10-29,2009,CA 2722255 A,2008-04-23,GB 2008001434 W,2008-04-23,INHIBITORS OF IKK-.BETA. SERINE-THREONINE PROTEIN KINASE,"Cyclopentyl (2S,4E)-2-amino-5-{3-[4-carbamoyl-5 (carbamoylamino)-2-thienyl]phenyl}pent-4-enoate; Cyclopentyl 5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-norvalinate; Cyclopentyl (2S,4E)-2-amino-5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-5-methylphenyl}pent-4-enoate; Cyclopentyl (2S,4E)-2-amino-5-{5-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-2-methylphenyl}pent-4-enoate; Cyclopentyl O-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-homoserinate; Cyclopentyl O-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienylJphenyl}-L-homoserinate; Cyclopentyl N-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate; and tert-Butyl N-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate are hydrolysed to the corresponding carboxylic acids by intracellular carboxylesterases, and are useful for the inhibition of IKKß activity.",CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/018-611-886-349-355,Patent Application,no,0,0,14,15,0,C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38,C07D333/38;;A61K31/381;;A61P25/28;;A61P37/00,,0,0,,,,DISCONTINUED
955,US,B2,US 11039880 B2,017-521-416-806-501,2021-06-22,2021,US 201715463913 A,2017-03-20,US 201715463913 A;;US 201113113326 A;;US 26530405 A;;US 66630103 A;;US 76047904 A;;US 66628803 A;;US 34736603 A;;US 52275304 P,2003-01-21,Method of surgical perforation via the delivery of energy,"A method of perforating a tissue of a heart of a patient when an inferior approach to the heart is contraindicated. The method utilizes an electrosurgical apparatus and a delivery system comprising at least two dilators wherein a first dilator is configured for facilitating positioning of the electrosurgical apparatus adjacent the tissue and wherein a second dilator is configured for advancement through a perforation in the tissue. An outer diameter of the second dilator is substantially equal to or less than an outer diameter of the first dilator. The method comprises the steps of: (a) advancing the first dilator into the heart of the patient, from a superior approach, until a distal end of the first dilator is adjacent the tissue; (b) using the electrosurgical apparatus, which is positioned through the first dilator, to create a perforation in the tissue by delivering electrical energy to the tissue; (c) advancing the distal end of the electrosurgical apparatus through the perforation; (d) withdrawing the first dilator; and (e) advancing the second dilator over the electrosurgical apparatus.",BAYLIS MEDICAL CO INC,URBANSKI JOHN PAUL;;DICICCO MATTHEW PAUL JOSEPH;;HACHEM BAHE;;DAVIES GARETH;;HARTLEY AMANDA;;VISRAM NAHEED;;SHAH KRISHAN;;BAYLIS FRANK,BAYLIS MEDICAL COMPANY INC (2017-05-23);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/017-521-416-806-501,Granted Patent,yes,8,0,3,113,0,A61B18/1206;;A61B18/24;;A61B2090/064;;A61B2090/3966;;A61B18/1492;;A61B2018/00839;;A61B2018/00601;;A61B2018/00351;;A61B18/1492;;A61B18/16;;A61M29/02;;A61M5/007;;A61B2018/00839;;A61B2018/00601;;A61B2018/00351;;A61B18/24;;A61B2090/3966;;A61B2090/064;;A61B2018/0038,A61B18/04;;A61B18/00;;A61B18/14;;A61B18/16;;A61B18/24;;A61B90/00;;A61M5/00;;A61M29/02,,2,0,,,"Final Office Action of U.S. Appl. No. 13/113,326, dated Jun. 28, 2016.;;Response to Final Office Action of U.S. Appl. No. 13/113,326, dated Jun. 28, 2016.",ACTIVE
956,KR,A,KR 20090077975 A,195-355-881-565-567,2009-07-16,2009,KR 20097011261 A,2007-10-29,GB 0621720 A;;GB 0715470 A,2006-11-01,IKK-beta SERINE-THREONINE PROTEIN KINASE INHIBITORS,"Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH-Y-L1-X1-(CH2 )Z-wherein: z is 0 or 1; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond,-C(=O)-,-S(=O)2-,-C(=O)O-,-C(=O)NR3-,-C(=S)-NR3,-C(=NH)-NR3 or-S(=O)2NR3-wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent linker radical of formula-(Alk1)m(Q)n(Alk2)p-wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.",CHROMA THERAPEUTICS LTD,MOFFAT DAVID FESTUS CHARLES;;DAVIES STEPHEN JOHN;;CHARLTON MICHAEL HUGH;;HIRST SIMON CHRISTOPHER;;ONIONS STUART THOMAS;;WILLIAMS JONATHON GARETH,,https://lens.org/195-355-881-565-567,Patent Application,no,0,0,17,29,0,C07D333/38;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P15/00;;A61P17/00;;A61P17/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P3/10;;C07D333/38;;A61K31/381;;C07D333/38,C07D333/38;;A61K31/381,,0,0,,,,DISCONTINUED
957,US,B1,US 6983263 B1,198-300-895-730-413,2006-01-03,2006,US 71005600 A,2000-11-10,US 71005600 A,2000-11-10,Electronic boardroom,"Methods and systems for organization management using an electronic boardroom to facilitate review of business specific information in a uniform format are described. In one embodiment, the method comprises receiving and storing information relating to a business into databases accessible to authorized users and organizing the information which includes reviewer comments and approvals or disapproval. The information is then reported to a user for further actions. While described in terms of a business deal, the methods and systems described are applicable for other aspects of a business including financial, business development and compliance issues.",GEN ELECTRIC CAPITAL CORP,DEMKO LISA A;;NAYDEN DENIS J;;CARY WILLIAM H;;COLICA JAMES A;;BROKAW FRANK S;;DAVIES GARETH J;;PERRETA CHRISTOPHER P,GE CAPITAL US HOLDINGS INC (2015-12-02);;GENERAL ELECTRIC CAPITAL CORPORATION (2001-05-02),https://lens.org/198-300-895-730-413,Granted Patent,yes,12,10,1,1,0,G06Q10/00;;G06Q10/06312;;G06Q50/188;;G06Q10/00;;G06Q10/06312;;G06Q50/188,,705/80;;705/1;;705/7;;705/8;;705/9;;705/10;;717/100;;703/6;;703/13,0,0,,,,EXPIRED
958,GB,A,GB 2613787 A,145-010-259-623-264,2023-06-21,2023,GB 202118039 A,2021-12-14,GB 202118039 A,2021-12-14,Aircraft power and propulsion system,"An aircraft power and propulsion system 100 comprises first and second gas turbine engines 110a, 110b, each comprising a plurality of spools including a first spool and a second spool. First and second electrical power generation sub-system 111a each comprise an electric machine 111a, 112a mechanically coupled with the first and second spools respectively of the first propulsive gas turbine engine 110a. Third and fourth electrical power generation sub-system 111b each comprise an electric machine 111b, 112b mechanically coupled with the first and second spools respectively of the second propulsive gas turbine engine 110b. Power channels are connected to the distribution side of each electrical machine. Each electrical machine may comprise a first sub-machine 111a’, 112a’ and a second sub-machine 111a’’, 112a’’, wherein the power channels associated with the first and second electric machines connect to a distribution side of both sub-machines. Each power channel may supply DC power and may connect to the electric machine via an AC-DC converter 121, 122. An electrical energy storage system 130 may connect with each of the power channels and may supply power to the electrical machines or fuel pumps 115 during engine restart attempts.",ROLLS ROYCE PLC,GARETH E MOORE;;PAUL R DAVIES;;STEPHEN M HUSBAND;;DAVID R TRAINER;;DAVID P SCOTHERN;;LUKE GEORGE;;DOUGLAS M M HERBERT,,https://lens.org/145-010-259-623-264,Patent Application,no,5,0,4,4,0,F01D15/10;;F02C7/32;;F02C7/36;;F02K5/00;;F05D2220/76;;F05D2220/766;;F05D2220/762;;F02C6/00;;Y02T50/60;;F02C7/32;;F01D15/10;;B64D27/10;;B64D27/24;;B64D31/06;;B64D35/02;;B64D2041/002;;B64D2221/00;;B64D27/026,F02C7/32;;F01D15/10,,0,0,,,,PENDING
959,US,A1,US 2023/0182920 A1,161-586-749-498-728,2023-06-15,2023,US 202217988341 A,2022-11-16,GB 202118039 A,2021-12-14,AIRCRAFT POWER AND PROPULSION SYSTEM,"A twin-engine aircraft power and propulsion system including first and second propulsive gas turbine engines, each having combustion equipment and a first and second spool; first, second, third, and fourth electrical power generation sub-systems including electric machines respectively mechanically coupled with the first spool of the first propulsive gas turbine engine, the second spool of the first propulsive gas turbine engine, the first spool of the second propulsive gas turbine engine, and the second spool of the second propulsive gas turbine engine; and first, second, third, and fourth power channels respectively connected with distribution sides of the first electric machine, second electric machine, third electric machine, and fourth electric machine.",ROLLS ROYCE PLC,MOORE GARETH E;;DAVIES PAUL R;;HUSBAND STEPHEN M;;TRAINER DAVID R;;SCOTHERN DAVID P;;GEORGE LUKE;;HERBERT DOUGLAS M M,ROLLS-ROYCE PLC (2021-12-14),https://lens.org/161-586-749-498-728,Patent Application,yes,0,0,4,4,0,F01D15/10;;F02C7/32;;F02C7/36;;F02K5/00;;F05D2220/76;;F05D2220/766;;F05D2220/762;;F02C6/00;;Y02T50/60;;F02C7/32;;F01D15/10;;B64D27/10;;B64D27/24;;B64D31/06;;B64D35/02;;B64D2041/002;;B64D2221/00;;B64D27/026,B64D35/02;;B64D27/10;;B64D27/24;;B64D31/06,,0,0,,,,PENDING
960,GB,A,GB 2613789 A,116-248-855-071-871,2023-06-21,2023,GB 202118044 A,2021-12-14,GB 202118044 A,2021-12-14,Restarting a gas turbine engine,"An aircraft power and propulsion system 100 has a propulsive gas turbine engine (GTE) 110 with a number of spools, combustion equipment (fig.1,16), one or more electric machines 111,112 mechanically coupled with one or more of the spools, and an electric fuel pump 115. An electrical system 120 is connected with the electric machines and the fuel pump, and also contains an energy storage system 130. A control system 140 is configured to respond when a determination is made that a flame in the combustion equipment 110 has been extinguished to control the electrical system to supply electrical power from the energy storage system to the fuel pump during an engine restart attempt. The control system may supply electrical power to the electric machines and operate them as motors to increase the speed of the spools during the restart attempt, and may also maintain the charge of the storage system above a level sufficient to power the fuel pump and/or the electric machines for at least one restart attempt, prior to a restart attempt this may be by operating the electric machines as generators.",ROLLS ROYCE PLC,GARETH E MOORE;;PAUL R DAVIES;;STEPHEN M HUSBAND;;DAVID R TRAINER;;DAVID P SCOTHERN;;LUKE GEORGE;;DOUGLAS M M HERBERT,,https://lens.org/116-248-855-071-871,Patent Application,no,5,0,5,5,0,F02C7/262;;F02C6/14;;F02K5/00;;F05D2220/76;;F02C9/46;;Y02T50/60;;F02C7/262;;B64D37/32;;F02C9/46;;F01D15/10;;F02C7/32,F02C7/262;;B64D37/32;;F02C9/46,,0,0,,,,PENDING
961,US,A1,US 2023/0182917 A1,072-453-854-508-654,2023-06-15,2023,US 202217988371 A,2022-11-16,GB 202118040 A,2021-12-14,STARTING GAS TURBINE ENGINES,"Multi-engine aircraft power and propulsion systems and methods of starting the engines of multi-engine aircraft disclosed, including supplying electrical power from an electrical power source to electric machines of the a first gas turbine engine and operating electric machines as motors to drive rotation of spools of the first gas turbine engine; starting the first gas turbine engine by lighting combustion equipment of the first gas turbine engine; operating the electric machines of the first gas turbine engine as generators to extract mechanical power and generate electrical power from spools of the first gas turbine engine; transferring the electrical power to electric machines of a second gas turbine engine and operating the electric machines as motors to drive rotation of spools of the second gas turbine engine; and starting the second gas turbine engine by lighting combustion equipment of the second gas turbine engine.",ROLLS ROYCE PLC,MOORE GARETH E;;DAVIES PAUL R;;HUSBAND STEPHEN M;;TRAINER DAVID R;;SCOTHERN DAVID P;;GEORGE LUKE;;HERBERT DOUGLAS M M,ROLLS-ROYCE PLC (2021-12-14),https://lens.org/072-453-854-508-654,Patent Application,yes,0,0,4,4,0,F02C7/268;;F02C6/14;;F02K5/00;;F05D2220/76;;F01D15/10;;Y02T50/60;;F02C7/268;;B64D31/02;;B64D35/08;;F02C6/14;;B64D2221/00;;B64D27/10;;B64D27/24;;B64D31/06;;B64D2041/002;;B64D2221/00;;F01D15/10;;F05D2220/323;;F05D2220/76;;F05D2260/85;;B64D27/026,B64D31/06;;B64D27/10;;B64D27/24;;F01D15/10,,0,0,,,,PENDING
962,US,A1,US 2023/0184130 A1,122-474-076-516-117,2023-06-15,2023,US 202217988393 A,2022-11-16,GB 202118044 A,2021-12-14,RESTARTING A GAS TURBINE ENGINE,"Aircraft power and propulsion systems, aircraft comprising such power and propulsion systems, and methods of restarting a gas turbine engine of such power and propulsion systems during flight are provided. One such aircraft power and propulsion system comprises: a propulsive gas turbine engine comprising a plurality of spools, combustion equipment, one or more electric machines mechanically coupled with one or more of the spools and an electrically-powered fuel pump for delivering fuel to the combustion equipment; an electrical system connected with the one or more electric machines and the electrically-powered fuel pump, the electrical system comprising an energy storage system; and a control system configured to: responsive to a determination to the effect that a flame in the combustion equipment has been extinguished, control the electrical system to supply electrical power from the energy storage system to the fuel pump during an engine restart attempt.",ROLLS ROYCE PLC,MOORE GARETH E;;DAVIES PAUL R;;HUSBAND STEPHEN M;;TRAINER DAVID R;;SCOTHERN DAVID P;;GEORGE LUKE;;HERBERT DOUGLAS M M,ROLLS-ROYCE PLC (2021-12-14),https://lens.org/122-474-076-516-117,Patent Application,yes,2,0,5,5,0,F02C7/262;;F02C6/14;;F02K5/00;;F05D2220/76;;F02C9/46;;Y02T50/60;;F02C7/262;;B64D37/32;;F02C9/46;;F01D15/10;;F02C7/32,F01D15/10;;F02C7/32,,0,0,,,,PENDING
963,GB,A,GB 2613788 A,134-358-804-227-864,2023-06-21,2023,GB 202118040 A,2021-12-14,GB 202118040 A,2021-12-14,Starting gas turbine engines,"Method of starting the engines of a multi-engine aircraft comprising: supplying electrical power from an electrical power source 130 to one or more electric machines 111a, 112a of the a first gas turbine engine 110a and operating them as motors to drive rotation of one or more spools 14, 19, 26; 15, 17, 27 of the first GTE; starting the first gas turbine engine by lighting combustion equipment 16 of the first gas turbine engine ; operating one or more of the electric machines of the first GTE as generators; transferring, via an electrical system 120, electrical power generated by the one or more electric machines of the first GTE to one or more electric machines 111b, 112b of a second GTE and operating them as motors to drive rotation of one or more spools 14, 19, 26; 15, 17, 27 of the second gas turbine engine 110b; and starting the second gas turbine engine 110b by lighting combustion equipment 16 of the second gas turbine engine 110b.",ROLLS ROYCE PLC,GARETH E MOORE;;PAUL R DAVIES;;STEPHEN M HUSBAND;;DAVID R TRAINER;;DAVID P SCOTHERN;;LUKE GEORGE;;DOUGLAS M M HERBERT,,https://lens.org/134-358-804-227-864,Patent Application,no,3,0,4,4,0,F02C7/268;;F02C6/14;;F02K5/00;;F05D2220/76;;F01D15/10;;Y02T50/60;;F02C7/268;;B64D31/02;;B64D35/08;;F02C6/14;;B64D2221/00;;B64D27/10;;B64D27/24;;B64D31/06;;B64D2041/002;;B64D2221/00;;F01D15/10;;F05D2220/323;;F05D2220/76;;F05D2260/85;;B64D27/026,F02C7/268;;B64D31/02;;B64D35/08;;F02C6/14,,0,0,,,,PENDING
964,US,B2,US 11905887 B2,174-785-198-421-92X,2024-02-20,2024,US 202217988504 A,2022-11-16,GB 202118041 A,2021-12-14,Restarting a gas turbine engine,"Multi-engine aircraft power and propulsion systems and methods of restarting an engine of a multi-engine aircraft during fight are provided. One such method comprises: determining a condition to the effect that a flame in the combustion equipment of the second gas turbine engine has been extinguished; responsive to the determination, supplying electrical power from the electrical energy storage system to one or more of the electric machines of the second gas turbine engine and operating said one or more electric machines as motors to limit a reduction in a speed of the one or more spools of the second gas turbine engine following extinguishment of the flame in its combustion equipment; and restarting the second gas turbine engine by relighting the combustion equipment of the second gas turbine engine.",ROLLS ROYCE PLC,MOORE GARETH E;;DAVIES PAUL R;;HUSBAND STEPHEN M;;TRAINER DAVID R;;SCOTHERN DAVID P;;GEORGE LUKE;;HERBERT DOUGLAS M M,,https://lens.org/174-785-198-421-92X,Granted Patent,yes,53,0,5,5,0,F02C7/262;;F02C7/268;;F02K5/00;;F05D2220/76;;Y02T50/60;;F05D2270/092;;F05D2270/093;;F01D15/10;;F02C7/262;;F05D2220/323;;F05D2220/76;;F05D2260/85;;F05D2270/092;;F05D2270/093,F02C7/262;;F01D15/10,,16,0,,,"Jane's Aero-Engines, Issue Seven, Edited by Bill Gunston, Jane's Information Group Inc., Alexandria, Virginia, 2000, pp. 1-47 and 510-512. (Year: 2000) (Year: 2000).;;Noor Zainab Hussain, Rolls-Royce hit by further setback to fixing Boeing 787 engines, Sep. 20, 2019, Reuters, Aerospace and Defense, pp. 1-4, URL: https://www.reuters.com/article/us-rolls-royce-hldg-trent-1000/rolls-royce-hit-by-further-setback-to-fixing-boeing-787-engines-idUSKBN1W50MP (Year: 2019).;;May 9, 2023 Search Report issued in European Patent Application No. 22208027.7.;;May 17, 2023 Extended Search Report issued in European Patent Application No. 22208019.4.;;Jun. 14, 2022 Search Report issued in GB Patent Application No. 2118039.3.;;Jun. 13, 2022 Search Report issued in GB Patent Application No. 2118040.1.;;Jun. 14, 2022 Search Report issued in GB Patent Application No. 2118041.9.;;Jun. 14, 2022 Search Report issued in GB Patent Application No. 2118044.3.;;Jun. 14, 2022 Search Report issued in GB Patent Application No. 2118045.0.;;U.S. Appl. No. 17/988,538, filed Nov. 16, 2022 in the name of Moore et al.;;U.S. Appl. No. 17/988,393, filed Nov. 16, 2022 in the name of Moore et al.;;U.S. Appl. No. 17/988,371, filed Nov. 16, 2022 in the name of Moore et al.;;U.S. Appl. No. 17/988,341, filed Nov. 16, 2022 in the name of Moore et al.;;Jun. 2, 2023 extended Search Report issued in European Patent Application No. 22208020.2.;;Jun. 6, 2023 extended Search Report issued in European Patent Application No. 22208025.1.;;Jul. 14, 2023 Extended Search Report issued in European Patent Application No. 22208022.8.",ACTIVE
965,US,A1,US 2023/0184171 A1,027-048-986-334-835,2023-06-15,2023,US 202217988504 A,2022-11-16,GB 202118041 A,2021-12-14,RESTARTING A GAS TURBINE ENGINE,"Multi-engine aircraft power and propulsion systems and methods of restarting an engine of a multi-engine aircraft during fight are provided. One such method comprises: determining a condition to the effect that a flame in the combustion equipment of the second gas turbine engine has been extinguished; responsive to the determination, supplying electrical power from the electrical energy storage system to one or more of the electric machines of the second gas turbine engine and operating said one or more electric machines as motors to limit a reduction in a speed of the one or more spools of the second gas turbine engine following extinguishment of the flame in its combustion equipment; and restarting the second gas turbine engine by relighting the combustion equipment of the second gas turbine engine.",ROLLS ROYCE PLC,MOORE GARETH E;;DAVIES PAUL R;;HUSBAND STEPHEN M;;TRAINER DAVID R;;SCOTHERN DAVID P;;GEORGE LUKE;;HERBERT DOUGLAS M M,ROLLS-ROYCE PLC (2021-12-14),https://lens.org/027-048-986-334-835,Patent Application,yes,21,0,5,5,0,F02C7/262;;F02C7/268;;F02K5/00;;F05D2220/76;;Y02T50/60;;F05D2270/092;;F05D2270/093;;F01D15/10;;F02C7/262;;F05D2220/323;;F05D2220/76;;F05D2260/85;;F05D2270/092;;F05D2270/093,F02C7/262,,2,0,,,"Jane's Aero-Engines, Issue Seven, Edited by Bill Gunston, Jane's Information Group Inc., Alexandria, Virginia, 2000, pp. 1 - 47 and 510-512. (Year: 2000) (Year: 2000);;Noor Zainab Hussain, Rolls-Royce hit by further setback to fixing Boeing 787 engines, 09/20/2019, Reuters, Aerospace and Defense, pp. 1-4, URL: https://www.reuters.com/article/us-rolls-royce-hldg-trent-1000/rolls-royce-hit-by-further-setback-to-fixing-boeing-787-engines-idUSKBN1W50MP (Year: 2019)",ACTIVE
966,US,A1,US 2023/0182918 A1,003-154-018-177-295,2023-06-15,2023,US 202217988538 A,2022-11-16,GB 202118045 A,2021-12-14,AIRCRAFT POWER AND PROPULSION SYSTEMS AND METHODS OF OPERATING AIRCRAFT POWER AND PROPULSION SYSTEMS,"Aircraft power and propulsion systems and methods of operating the systems, one method includes: operating electric machines of gas turbine engines as generators to extract mechanical power from spools and generating electrical power therefrom; meeting an electrical power demand of a plurality of electrical loads connected with an electrical system by supplying the plurality of electrical loads with electrical power generated by the electric machines; determining when there is an electrical system and/or the gas turbine engine fault and an amount of electrical power generated by the power and propulsion system is reduced to a lower level; and responsive to the determination: during a time period ΔT, controlling the plurality of electrical loads reducing the electrical power demand; and during the time period ΔT, meeting at least part of the electrical power demand of the plurality of electrical loads by discharging the electrical energy storage system.",ROLLS ROYCE PLC,MOORE GARETH E;;DAVIES PAUL R;;HUSBAND STEPHEN M;;TRAINER DAVID R;;SCOTHERN DAVID P;;GEORGE LUKE;;HERBERT DOUGLAS M M,ROLLS-ROYCE PLC (2021-12-14),https://lens.org/003-154-018-177-295,Patent Application,yes,0,1,3,3,0,B64D2221/00;;F02C7/32;;H02J7/1446;;F02C9/00;;F02K5/00;;F02C6/14;;F05D2220/76;;F02C6/20;;B64D31/06;;H02J2310/44;;H02J2310/58;;H02J2310/60;;H02J2310/62;;H02J2207/50;;H02J7/143;;H02J7/1438;;H02J7/1492;;H02J9/061;;H02J2310/52;;Y02T50/60;;B64D27/026;;B64D27/10;;B64D27/24;;B64D31/06;;B64D2041/002;;F01D15/10;;F05D2220/323;;F05D2220/76;;F05D2270/091;;B64D27/026,B64D31/06;;B64D27/10;;B64D27/24;;F01D15/10,,0,0,,,,PENDING
967,EP,A1,EP 4230122 A1,117-790-733-362-028,2023-08-23,2023,EP 23181091 A,2018-08-10,US 201762543635 P;;EP 18843576 A;;IB 2018056059 W,2017-08-10,HEAT EXCHANGE AND TEMPERATURE SENSING DEVICE AND METHOD OF USE,"A method and apparatus are disclosed for regulating a temperature of an esophagus when heat or cold is delivered to a left atrium, the method including altering a heat exchange device from an insertable configuration to a heat exchanging configuration which conforms and corresponds with a cross-section of an inside of the esophagus such that the esophagus is maintained in its natural shape and location. In some embodiments the heat exchange device has a heating/cooling balloon which is inflated to be in the heat exchanging configuration. Some alternative embodiments includes altering the configuration of the balloon to conform to or correspond with the cross section of an esophagus by means other than inflation.
",BOSTON SCIENT MEDICAL DEVICE LIMITED,HARTLEY AMANDA;;DAVIES GARETH;;CENTAZZO-COLELLA AMANDA;;YANG NOAH;;AVARI HAMED;;AL-SAFFAR YASIR;;SHAH KISHAN;;HERBERT-COPLEY ANDREW;;WIERZBICKI RAMUNAS;;GERBER DMITRY,,https://lens.org/117-790-733-362-028,Patent Application,yes,6,0,20,20,0,A61F7/12;;A61F7/123;;A61B18/1492;;A61N1/362;;A61B2018/00005;;A61B2018/00023;;A61B2018/00029;;A61B2018/00035;;A61B2018/0022;;A61B2018/00285;;A61B2018/00291;;A61B2018/00488;;A61B2018/00797;;A61F2007/0054;;A61F2007/0059;;A61F2007/0075;;A61F2007/0096;;A61B2090/065;;A61B2034/2051;;A61B2090/3966;;A61B5/6853;;A61B5/01;;A61B5/25;;A61F7/123;;A61B5/4233;;A61B5/25;;A61F2007/0054;;A61F2007/0086;;A61F2007/0096;;A61B6/487;;A61B6/032;;A61B5/055;;A61B5/28;;A61B90/04;;A61B2090/0418;;A61B2090/0463;;A61B2090/061;;A61B2090/374;;A61B2090/3762;;A61B2090/3966;;A61B2090/3983;;A61B18/04;;A61B2017/00557;;A61B2018/00023;;A61B2018/00035;;A61B2018/00357;;A61B2018/00791;;A61B2018/00839;;A61B2018/0091;;A61B2018/0212;;A61F7/123;;A61F2007/0054;;A61F2007/0056;;A61F2007/0075;;A61F2007/101;;A61M25/1002;;A61M2025/1013;;A61M2025/1084;;A61M2210/105;;A61N1/0517;;A61N1/362;;A61B5/287;;A61B18/02;;A61B2018/00577;;A61B2018/00797;;A61M2025/1043;;A61F7/0085;;A61F7/12;;A61F2007/0091;;A61F2007/0096;;A61F2007/126,A61B5/01;;A61B5/00;;A61B5/25;;A61B18/00;;A61B18/14;;A61B34/20;;A61B90/00;;A61F7/00;;A61F7/12;;A61N1/362,,0,0,,,,PENDING
968,BR,A2,BR 112020011128 A2,023-228-913-179-558,2021-05-04,2021,BR 112020011128 A,2018-08-10,IB 2018056059 W;;US 201762543635 P,2017-08-10,dispositivo de troca de calor e sensor de temperatura e método de uso,"dispositivo de troca de calor e sensor de temperatura e método de uso. um método e aparelho são divulgados para regular uma temperatura de um esôfago quando calor ou frio são distribuídos para um átrio esquerdo, o método incluindo alterar um dispositivo de troca de calor de uma configuração inserível para uma configuração de troca de calor que se conforma e corresponde a uma seção transversal de um interior do esôfago, de modo que o esôfago seja mantido em sua forma e localização naturais. em algumas modalidades, o dispositivo de troca de calor tem um balão de aquecimento/resfriamento que é inflado para estar na configuração de troca de calor. algumas modalidades alternativas incluem alterar a configuração do balão para se conformar ou corresponder à seção transversal de um esôfago por meios que não inflação.",BAYLIS MEDICAL CO INC,WIERZBICKI RAMUNAS;;AL-SAFFAR YASIR;;AVARI HAMED;;CENTAZZO-COLELLA AMANDA;;DAVIES GARETH;;GERBER DMITRY;;HARTLEY AMANDA;;HERBERT-COPLEY ANDREW;;SHAH KISHAN;;YANG NOAH,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (IE) (2023-06-06),https://lens.org/023-228-913-179-558,Patent Application,no,0,0,20,20,0,A61F7/12;;A61F7/123;;A61B18/1492;;A61N1/362;;A61B2018/00005;;A61B2018/00023;;A61B2018/00029;;A61B2018/00035;;A61B2018/0022;;A61B2018/00285;;A61B2018/00291;;A61B2018/00488;;A61B2018/00797;;A61F2007/0054;;A61F2007/0059;;A61F2007/0075;;A61F2007/0096;;A61B2090/065;;A61B2034/2051;;A61B2090/3966;;A61B5/6853;;A61B5/01;;A61B5/25;;A61F7/123;;A61B5/4233;;A61B5/25;;A61F2007/0054;;A61F2007/0086;;A61F2007/0096;;A61B6/487;;A61B6/032;;A61B5/055;;A61B5/28;;A61B90/04;;A61B2090/0418;;A61B2090/0463;;A61B2090/061;;A61B2090/374;;A61B2090/3762;;A61B2090/3966;;A61B2090/3983;;A61B18/04;;A61B2017/00557;;A61B2018/00023;;A61B2018/00035;;A61B2018/00357;;A61B2018/00791;;A61B2018/00839;;A61B2018/0091;;A61B2018/0212;;A61F7/123;;A61F2007/0054;;A61F2007/0056;;A61F2007/0075;;A61F2007/101;;A61M25/1002;;A61M2025/1013;;A61M2025/1084;;A61M2210/105;;A61N1/0517;;A61N1/362;;A61B5/287;;A61B18/02;;A61B2018/00577;;A61B2018/00797;;A61M2025/1043;;A61F7/0085;;A61F7/12;;A61F2007/0091;;A61F2007/0096;;A61F2007/126,A61B5/00;;A61F7/00;;A61F7/12;;A61N1/362,,0,0,,,,DISCONTINUED
969,KR,A,KR 20200030610 A,085-607-978-109-373,2020-03-20,2020,KR 20207006423 A,2018-08-10,US 201762543635 P;;IB 2018056059 W,2017-08-10,열 교환 및 온도 감지 장치 및 사용 방법,"열기 또는 냉기가 좌심방으로 전달될 때 식도의 온도를 조절하기 위한 방법 및 장치가 개시되며, 이때 이러한 방법은 열 교환 장치를 삽입가능 구성으로부터 식도가 그의 자연적인 형상 및 위치로 유지되도록 식도 내부의 단면에 순응하고 대응하는 열 교환 구성으로 변화시키는 단계를 포함한다. 일부 실시형태에서, 열 교환 장치는 열 교환 구성에 있도록 팽창되는 가열/냉각 벌룬을 갖는다. 일부 대안적인 실시형태는 팽창 이외의 수단에 의해 식도의 단면에 순응하거나 대응하도록 벌룬의 구성을 변화시키는 단계를 포함한다.",BAYLIS MEDICAL CO INC,HARTLEY AMANDA;;DAVIES GARETH;;CENTAZZO COLELLA AMANDA;;YANG NOAH;;AVARI HAMED;;AL SAFFAR YASIR;;SHAH KISHAN;;HERBERT COPLEY ANDREW;;WIERZBICKI RAMUNAS;;GERBER DMITRY,,https://lens.org/085-607-978-109-373,Patent Application,no,0,0,20,20,0,A61F7/12;;A61F7/123;;A61B18/1492;;A61N1/362;;A61B2018/00005;;A61B2018/00023;;A61B2018/00029;;A61B2018/00035;;A61B2018/0022;;A61B2018/00285;;A61B2018/00291;;A61B2018/00488;;A61B2018/00797;;A61F2007/0054;;A61F2007/0059;;A61F2007/0075;;A61F2007/0096;;A61B2090/065;;A61B2034/2051;;A61B2090/3966;;A61B5/6853;;A61B5/01;;A61B5/25;;A61F7/123;;A61B5/4233;;A61B5/25;;A61F2007/0054;;A61F2007/0086;;A61F2007/0096;;A61B6/487;;A61B6/032;;A61B5/055;;A61B5/28;;A61B90/04;;A61B2090/0418;;A61B2090/0463;;A61B2090/061;;A61B2090/374;;A61B2090/3762;;A61B2090/3966;;A61B2090/3983;;A61B18/04;;A61B2017/00557;;A61B2018/00023;;A61B2018/00035;;A61B2018/00357;;A61B2018/00791;;A61B2018/00839;;A61B2018/0091;;A61B2018/0212;;A61F7/123;;A61F2007/0054;;A61F2007/0056;;A61F2007/0075;;A61F2007/101;;A61M25/1002;;A61M2025/1013;;A61M2025/1084;;A61M2210/105;;A61N1/0517;;A61N1/362;;A61B5/287;;A61B18/02;;A61B2018/00577;;A61B2018/00797;;A61M2025/1043;;A61F7/0085;;A61F7/12;;A61F2007/0091;;A61F2007/0096;;A61F2007/126,A61F7/12;;A61B5/00;;A61B5/0408;;A61F7/00;;A61N1/362,,0,0,,,,DISCONTINUED
970,EP,A4,EP 3664755 A4,094-454-064-325-397,2021-04-14,2021,EP 18843576 A,2018-08-10,US 201762543635 P;;IB 2018056059 W,2017-08-10,HEAT EXCHANGE AND TEMPERATURE SENSING DEVICE AND METHOD OF USE,,BAYLIS MEDICAL CO INC,HARTLEY AMANDA;;DAVIES GARETH;;CENTAZZO-COLELLA AMANDA;;YANG NOAH;;AVARI HAMED;;AL-SAFFAR YASIR;;SHAH KISHAN;;HERBERT-COPLEY ANDREW;;WIERZBICKI RAMUNAS;;GERBER DMITRY,BAYLIS MEDICAL COMPANY INC. (2022-07-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-05),https://lens.org/094-454-064-325-397,Search Report,no,4,0,20,20,0,A61F7/12;;A61F7/123;;A61B18/1492;;A61N1/362;;A61B2018/00005;;A61B2018/00023;;A61B2018/00029;;A61B2018/00035;;A61B2018/0022;;A61B2018/00285;;A61B2018/00291;;A61B2018/00488;;A61B2018/00797;;A61F2007/0054;;A61F2007/0059;;A61F2007/0075;;A61F2007/0096;;A61B2090/065;;A61B2034/2051;;A61B2090/3966;;A61B5/6853;;A61B5/01;;A61B5/25;;A61F7/123;;A61B5/4233;;A61B5/25;;A61F2007/0054;;A61F2007/0086;;A61F2007/0096;;A61B6/487;;A61B6/032;;A61B5/055;;A61B5/28;;A61B90/04;;A61B2090/0418;;A61B2090/0463;;A61B2090/061;;A61B2090/374;;A61B2090/3762;;A61B2090/3966;;A61B2090/3983;;A61B18/04;;A61B2017/00557;;A61B2018/00023;;A61B2018/00035;;A61B2018/00357;;A61B2018/00791;;A61B2018/00839;;A61B2018/0091;;A61B2018/0212;;A61F7/123;;A61F2007/0054;;A61F2007/0056;;A61F2007/0075;;A61F2007/101;;A61M25/1002;;A61M2025/1013;;A61M2025/1084;;A61M2210/105;;A61N1/0517;;A61N1/362;;A61B5/287;;A61B18/02;;A61B2018/00577;;A61B2018/00797;;A61M2025/1043;;A61F7/0085;;A61F7/12;;A61F2007/0091;;A61F2007/0096;;A61F2007/126,A61B5/01;;A61B5/00;;A61B5/25;;A61B18/00;;A61B18/14;;A61B34/00;;A61B34/20;;A61B90/00;;A61F7/00;;A61F7/12;;A61N1/362,,0,0,,,,ACTIVE
971,US,A1,US 2020/0253682 A1,177-458-913-412-346,2020-08-13,2020,US 201816637315 A,2018-08-10,US 201816637315 A;;US 201762543635 P;;IB 2018056059 W,2017-08-10,HEAT EXCHANGE AND TEMPERATURE SENSING DEVICE AND METHOD OF USE,"A method and apparatus are disclosed for regulating a temperature of an esophagus when heat or cold is delivered to a left atrium, the method including altering a heat exchange device from an insertable configuration to a heat exchanging configuration which conforms and corresponds with a cross-section of an inside of the esophagus such that the esophagus is maintained in its natural shape and location. In some embodiments the heat exchange device has a heating/cooling balloon which is inflated to be in the heat exchanging configuration. Some alternative embodiments includes altering the configuration of the balloon to conform to or correspond with the cross section of an esophagus by means other than inflation.",BAYLIS MEDICAL CO INC,HARTLEY AMANDA;;DAVIES GARETH;;CENTAZZO-COLELLA AMANDA;;YANG NOAH;;AVARI HAMED;;AL-SAFFAR YASIR;;SHAH KISHAN;;HERBERT-COPLEY ANDREW;;WIERZBICKI RAMUNAS;;GERBER DMITRY,BAYLIS MEDICAL COMPANY INC (2021-09-24);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-06-01),https://lens.org/177-458-913-412-346,Patent Application,yes,7,2,20,20,0,A61F7/12;;A61F7/123;;A61B18/1492;;A61N1/362;;A61B2018/00005;;A61B2018/00023;;A61B2018/00029;;A61B2018/00035;;A61B2018/0022;;A61B2018/00285;;A61B2018/00291;;A61B2018/00488;;A61B2018/00797;;A61F2007/0054;;A61F2007/0059;;A61F2007/0075;;A61F2007/0096;;A61B2090/065;;A61B2034/2051;;A61B2090/3966;;A61B5/6853;;A61B5/01;;A61B5/25;;A61F7/123;;A61B5/4233;;A61B5/25;;A61F2007/0054;;A61F2007/0086;;A61F2007/0096;;A61B6/487;;A61B6/032;;A61B5/055;;A61B5/28;;A61B90/04;;A61B2090/0418;;A61B2090/0463;;A61B2090/061;;A61B2090/374;;A61B2090/3762;;A61B2090/3966;;A61B2090/3983;;A61B18/04;;A61B2017/00557;;A61B2018/00023;;A61B2018/00035;;A61B2018/00357;;A61B2018/00791;;A61B2018/00839;;A61B2018/0091;;A61B2018/0212;;A61F7/123;;A61F2007/0054;;A61F2007/0056;;A61F2007/0075;;A61F2007/101;;A61M25/1002;;A61M2025/1013;;A61M2025/1084;;A61M2210/105;;A61N1/0517;;A61N1/362;;A61B5/287;;A61B18/02;;A61B2018/00577;;A61B2018/00797;;A61M2025/1043;;A61F7/0085;;A61F7/12;;A61F2007/0091;;A61F2007/0096;;A61F2007/126,A61B90/00;;A61B18/04;;A61F7/12,,0,0,,,,PENDING
972,AU,A1,AU 2018/315484 A1,131-402-899-346-124,2020-02-27,2020,AU 2018/315484 A,2018-08-10,US 201762543635 P;;IB 2018056059 W,2017-08-10,Heat exchange and temperature sensing device and method of use,"A method and apparatus are disclosed for regulating a temperature of an esophagus when heat or cold is delivered to a left atrium, the method including altering a heat exchange device from an insertable configuration to a heat exchanging configuration which conforms and corresponds with a cross-section of an inside of the esophagus such that the esophagus is maintained in its natural shape and location. In some embodiments the heat exchange device has a heating/cooling balloon which is inflated to be in the heat exchanging configuration. Some alternative embodiments includes altering the configuration of the balloon to conform to or correspond with the cross section of an esophagus by means other than inflation.",BOSTON SCIENT MEDICAL DEVICE LIMITED,HARTLEY AMANDA;;DAVIES GARETH;;CENTAZZO-COLELLA AMANDA;;YANG NOAH;;AVARI HAMED;;AL-SAFFAR YASIR;;SHAH KISHAN;;HERBERT-COPLEY ANDREW;;WIERZBICKI RAMUNAS;;GERBER DMITRY,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-09-22),https://lens.org/131-402-899-346-124,Patent Application,no,0,0,20,20,0,A61F7/12;;A61F7/123;;A61B18/1492;;A61N1/362;;A61B2018/00005;;A61B2018/00023;;A61B2018/00029;;A61B2018/00035;;A61B2018/0022;;A61B2018/00285;;A61B2018/00291;;A61B2018/00488;;A61B2018/00797;;A61F2007/0054;;A61F2007/0059;;A61F2007/0075;;A61F2007/0096;;A61B2090/065;;A61B2034/2051;;A61B2090/3966;;A61B5/6853;;A61B5/01;;A61B5/25;;A61F7/123;;A61B5/4233;;A61B5/25;;A61F2007/0054;;A61F2007/0086;;A61F2007/0096;;A61B6/487;;A61B6/032;;A61B5/055;;A61B5/28;;A61B90/04;;A61B2090/0418;;A61B2090/0463;;A61B2090/061;;A61B2090/374;;A61B2090/3762;;A61B2090/3966;;A61B2090/3983;;A61B18/04;;A61B2017/00557;;A61B2018/00023;;A61B2018/00035;;A61B2018/00357;;A61B2018/00791;;A61B2018/00839;;A61B2018/0091;;A61B2018/0212;;A61F7/123;;A61F2007/0054;;A61F2007/0056;;A61F2007/0075;;A61F2007/101;;A61M25/1002;;A61M2025/1013;;A61M2025/1084;;A61M2210/105;;A61N1/0517;;A61N1/362;;A61B5/287;;A61B18/02;;A61B2018/00577;;A61B2018/00797;;A61M2025/1043;;A61F7/0085;;A61F7/12;;A61F2007/0091;;A61F2007/0096;;A61F2007/126,A61F7/12;;A61B5/00;;A61B5/0408;;A61F7/00;;A61N1/362,,0,0,,,,PENDING
973,EP,A2,EP 3664755 A2,134-088-432-485-100,2020-06-17,2020,EP 18843576 A,2018-08-10,US 201762543635 P;;IB 2018056059 W,2017-08-10,HEAT EXCHANGE AND TEMPERATURE SENSING DEVICE AND METHOD OF USE,,BAYLIS MEDICAL CO INC,HARTLEY AMANDA;;DAVIES GARETH;;CENTAZZO-COLELLA AMANDA;;YANG NOAH;;AVARI HAMED;;AL-SAFFAR YASIR;;SHAH KISHAN;;HERBERT-COPLEY ANDREW;;WIERZBICKI RAMUNAS;;GERBER DMITRY,BAYLIS MEDICAL COMPANY INC. (2022-07-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-05),https://lens.org/134-088-432-485-100,Patent Application,yes,0,0,20,20,0,A61F7/12;;A61F7/123;;A61B18/1492;;A61N1/362;;A61B2018/00005;;A61B2018/00023;;A61B2018/00029;;A61B2018/00035;;A61B2018/0022;;A61B2018/00285;;A61B2018/00291;;A61B2018/00488;;A61B2018/00797;;A61F2007/0054;;A61F2007/0059;;A61F2007/0075;;A61F2007/0096;;A61B2090/065;;A61B2034/2051;;A61B2090/3966;;A61B5/6853;;A61B5/01;;A61B5/25;;A61F7/123;;A61B5/4233;;A61B5/25;;A61F2007/0054;;A61F2007/0086;;A61F2007/0096;;A61B6/487;;A61B6/032;;A61B5/055;;A61B5/28;;A61B90/04;;A61B2090/0418;;A61B2090/0463;;A61B2090/061;;A61B2090/374;;A61B2090/3762;;A61B2090/3966;;A61B2090/3983;;A61B18/04;;A61B2017/00557;;A61B2018/00023;;A61B2018/00035;;A61B2018/00357;;A61B2018/00791;;A61B2018/00839;;A61B2018/0091;;A61B2018/0212;;A61F7/123;;A61F2007/0054;;A61F2007/0056;;A61F2007/0075;;A61F2007/101;;A61M25/1002;;A61M2025/1013;;A61M2025/1084;;A61M2210/105;;A61N1/0517;;A61N1/362;;A61B5/287;;A61B18/02;;A61B2018/00577;;A61B2018/00797;;A61M2025/1043;;A61F7/0085;;A61F7/12;;A61F2007/0091;;A61F2007/0096;;A61F2007/126,A61F7/12;;A61B5/00;;A61B5/0408;;A61F7/00;;A61N1/362,,0,0,,,,ACTIVE
974,WO,A2,WO 2019/030733 A2,185-743-342-537-470,2019-02-14,2019,IB 2018056059 W,2018-08-10,US 201762543635 P,2017-08-10,HEAT EXCHANGE AND TEMPERATURE SENSING DEVICE AND METHOD OF USE,"A method and apparatus are disclosed for regulating a temperature of an esophagus when heat or cold is delivered to a left atrium, the method including altering a heat exchange device from an insertable configuration to a heat exchanging configuration which conforms and corresponds with a cross-section of an inside of the esophagus such that the esophagus is maintained in its natural shape and location. In some embodiments the heat exchange device has a heating/cooling balloon which is inflated to be in the heat exchanging configuration. Some alternative embodiments includes altering the configuration of the balloon to conform to or correspond with the cross section of an esophagus by means other than inflation.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,HARTLEY AMANDA;;DAVIES GARETH;;CENTAZZO-COLELLA AMANDA;;YANG NOAH;;AVARI HAMED;;AL-SAFFAR YASIR;;SHAH KISHAN;;HERBERT-COPLEY ANDREW;;WIERZBICKI RAMUNAS;;GERBER DMITRY,,https://lens.org/185-743-342-537-470,Patent Application,yes,3,1,20,20,0,A61F7/12;;A61F7/123;;A61B18/1492;;A61N1/362;;A61B2018/00005;;A61B2018/00023;;A61B2018/00029;;A61B2018/00035;;A61B2018/0022;;A61B2018/00285;;A61B2018/00291;;A61B2018/00488;;A61B2018/00797;;A61F2007/0054;;A61F2007/0059;;A61F2007/0075;;A61F2007/0096;;A61B2090/065;;A61B2034/2051;;A61B2090/3966;;A61B5/6853;;A61B5/01;;A61B5/25;;A61F7/123;;A61B5/4233;;A61B5/25;;A61F2007/0054;;A61F2007/0086;;A61F2007/0096;;A61B6/487;;A61B6/032;;A61B5/055;;A61B5/28;;A61B90/04;;A61B2090/0418;;A61B2090/0463;;A61B2090/061;;A61B2090/374;;A61B2090/3762;;A61B2090/3966;;A61B2090/3983;;A61B18/04;;A61B2017/00557;;A61B2018/00023;;A61B2018/00035;;A61B2018/00357;;A61B2018/00791;;A61B2018/00839;;A61B2018/0091;;A61B2018/0212;;A61F7/123;;A61F2007/0054;;A61F2007/0056;;A61F2007/0075;;A61F2007/101;;A61M25/1002;;A61M2025/1013;;A61M2025/1084;;A61M2210/105;;A61N1/0517;;A61N1/362;;A61B5/287;;A61B18/02;;A61B2018/00577;;A61B2018/00797;;A61M2025/1043;;A61F7/0085;;A61F7/12;;A61F2007/0091;;A61F2007/0096;;A61F2007/126,A61B5/00;;A61F7/12;;A61B5/0408;;A61F7/00;;A61N1/362,,0,0,,,,PENDING
975,WO,A3,WO 2019/030733 A3,105-207-501-279-501,2019-05-09,2019,IB 2018056059 W,2018-08-10,US 201762543635 P,2017-08-10,HEAT EXCHANGE AND TEMPERATURE SENSING DEVICE AND METHOD OF USE,"A method and apparatus are disclosed for regulating a temperature of an esophagus when heat or cold is delivered to a left atrium, the method including altering a heat exchange device from an insertable configuration to a heat exchanging configuration which conforms and corresponds with a cross-section of an inside of the esophagus such that the esophagus is maintained in its natural shape and location. In some embodiments the heat exchange device has a heating/cooling balloon which is inflated to be in the heat exchanging configuration. Some alternative embodiments includes altering the configuration of the balloon to conform to or correspond with the cross section of an esophagus by means other than inflation.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,HARTLEY AMANDA;;DAVIES GARETH;;CENTAZZO-COLELLA AMANDA;;YANG NOAH;;AVARI HAMED;;AL-SAFFAR YASIR;;SHAH KISHAN;;HERBERT-COPLEY ANDREW;;WIERZBICKI RAMUNAS;;GERBER DMITRY,,https://lens.org/105-207-501-279-501,Search Report,yes,5,0,20,20,0,A61F7/12;;A61F7/123;;A61B18/1492;;A61N1/362;;A61B2018/00005;;A61B2018/00023;;A61B2018/00029;;A61B2018/00035;;A61B2018/0022;;A61B2018/00285;;A61B2018/00291;;A61B2018/00488;;A61B2018/00797;;A61F2007/0054;;A61F2007/0059;;A61F2007/0075;;A61F2007/0096;;A61B2090/065;;A61B2034/2051;;A61B2090/3966;;A61B5/6853;;A61B5/01;;A61B5/25;;A61F7/123;;A61B5/4233;;A61B5/25;;A61F2007/0054;;A61F2007/0086;;A61F2007/0096;;A61B6/487;;A61B6/032;;A61B5/055;;A61B5/28;;A61B90/04;;A61B2090/0418;;A61B2090/0463;;A61B2090/061;;A61B2090/374;;A61B2090/3762;;A61B2090/3966;;A61B2090/3983;;A61B18/04;;A61B2017/00557;;A61B2018/00023;;A61B2018/00035;;A61B2018/00357;;A61B2018/00791;;A61B2018/00839;;A61B2018/0091;;A61B2018/0212;;A61F7/123;;A61F2007/0054;;A61F2007/0056;;A61F2007/0075;;A61F2007/101;;A61M25/1002;;A61M2025/1013;;A61M2025/1084;;A61M2210/105;;A61N1/0517;;A61N1/362;;A61B5/287;;A61B18/02;;A61B2018/00577;;A61B2018/00797;;A61M2025/1043;;A61F7/0085;;A61F7/12;;A61F2007/0091;;A61F2007/0096;;A61F2007/126,A61F7/12;;A61B5/00;;A61B5/0408;;A61F7/00;;A61N1/362,,0,0,,,,PENDING
976,CN,A,CN 111065358 A,085-162-912-151-465,2020-04-24,2020,CN 201880059820 A,2018-08-10,US 201762543635 P;;IB 2018056059 W,2017-08-10,HEAT EXCHANGE AND TEMPERATURE SENSING DEVICE AND METHOD OF USE,"A method and apparatus are disclosed for regulating a temperature of an esophagus when heat or cold is delivered to a left atrium, the method including altering a heat exchange device from an insertable configuration to a heat exchanging configuration which conforms and corresponds with a cross-section of an inside of the esophagus such that the esophagus is maintained in its natural shape and location. In some embodiments the heat exchange device has a heating/cooling balloon which is inflated to be in the heat exchanging configuration. Some alternative embodiments includes altering the configuration of the balloon to conform to or correspond with the cross section of an esophagus by means other than inflation.",BAYLIS MEDICAL CO INC,HARTLEY AMANDA;;DAVIES GARETH;;CENTAZZO-COLELLA AMANDA;;YANG NOAH;;AVARI HAMED;;AL-SAFFAR YASIR;;SHAH KISHAN;;HERBERT-COPLEY ANDREW;;WIERZBICKI RAMUNAS;;GERBER DMITRY,,https://lens.org/085-162-912-151-465,Patent Application,no,7,0,20,20,0,A61F7/12;;A61F7/123;;A61B18/1492;;A61N1/362;;A61B2018/00005;;A61B2018/00023;;A61B2018/00029;;A61B2018/00035;;A61B2018/0022;;A61B2018/00285;;A61B2018/00291;;A61B2018/00488;;A61B2018/00797;;A61F2007/0054;;A61F2007/0059;;A61F2007/0075;;A61F2007/0096;;A61B2090/065;;A61B2034/2051;;A61B2090/3966;;A61B5/6853;;A61B5/01;;A61B5/25;;A61F7/123;;A61B5/4233;;A61B5/25;;A61F2007/0054;;A61F2007/0086;;A61F2007/0096;;A61B6/487;;A61B6/032;;A61B5/055;;A61B5/28;;A61B90/04;;A61B2090/0418;;A61B2090/0463;;A61B2090/061;;A61B2090/374;;A61B2090/3762;;A61B2090/3966;;A61B2090/3983;;A61B18/04;;A61B2017/00557;;A61B2018/00023;;A61B2018/00035;;A61B2018/00357;;A61B2018/00791;;A61B2018/00839;;A61B2018/0091;;A61B2018/0212;;A61F7/123;;A61F2007/0054;;A61F2007/0056;;A61F2007/0075;;A61F2007/101;;A61M25/1002;;A61M2025/1013;;A61M2025/1084;;A61M2210/105;;A61N1/0517;;A61N1/362;;A61B5/287;;A61B18/02;;A61B2018/00577;;A61B2018/00797;;A61M2025/1043;;A61F7/0085;;A61F7/12;;A61F2007/0091;;A61F2007/0096;;A61F2007/126,A61F7/12;;A61B5/00;;A61B5/0408;;A61F7/00;;A61N1/362,,0,0,,,,ACTIVE
977,EP,B1,EP 3664755 B1,189-868-005-527-778,2023-08-02,2023,EP 18843576 A,2018-08-10,US 201762543635 P;;IB 2018056059 W,2017-08-10,HEAT EXCHANGE AND TEMPERATURE SENSING DEVICE,,BOSTON SCIENT MEDICAL DEVICE LIMITED,HARTLEY AMANDA;;DAVIES GARETH;;CENTAZZO-COLELLA AMANDA;;YANG NOAH;;AVARI HAMED;;AL-SAFFAR YASIR;;SHAH KISHAN;;HERBERT-COPLEY ANDREW;;WIERZBICKI RAMUNAS;;GERBER DMITRY,BAYLIS MEDICAL COMPANY INC. (2022-07-20);;BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-10-05),https://lens.org/189-868-005-527-778,Granted Patent,yes,9,0,20,20,0,A61F7/12;;A61F7/123;;A61B18/1492;;A61N1/362;;A61B2018/00005;;A61B2018/00023;;A61B2018/00029;;A61B2018/00035;;A61B2018/0022;;A61B2018/00285;;A61B2018/00291;;A61B2018/00488;;A61B2018/00797;;A61F2007/0054;;A61F2007/0059;;A61F2007/0075;;A61F2007/0096;;A61B2090/065;;A61B2034/2051;;A61B2090/3966;;A61B5/6853;;A61B5/01;;A61B5/25;;A61F7/123;;A61B5/4233;;A61B5/25;;A61F2007/0054;;A61F2007/0086;;A61F2007/0096;;A61B6/487;;A61B6/032;;A61B5/055;;A61B5/28;;A61B90/04;;A61B2090/0418;;A61B2090/0463;;A61B2090/061;;A61B2090/374;;A61B2090/3762;;A61B2090/3966;;A61B2090/3983;;A61B18/04;;A61B2017/00557;;A61B2018/00023;;A61B2018/00035;;A61B2018/00357;;A61B2018/00791;;A61B2018/00839;;A61B2018/0091;;A61B2018/0212;;A61F7/123;;A61F2007/0054;;A61F2007/0056;;A61F2007/0075;;A61F2007/101;;A61M25/1002;;A61M2025/1013;;A61M2025/1084;;A61M2210/105;;A61N1/0517;;A61N1/362;;A61B5/287;;A61B18/02;;A61B2018/00577;;A61B2018/00797;;A61M2025/1043;;A61F7/0085;;A61F7/12;;A61F2007/0091;;A61F2007/0096;;A61F2007/126,A61B5/01;;A61B5/00;;A61B5/25;;A61B18/00;;A61B18/14;;A61B34/00;;A61B34/20;;A61B90/00;;A61F7/00;;A61F7/12;;A61N1/362,,0,0,,,,ACTIVE
978,CN,A,CN 116785068 A,127-721-130-358-242,2023-09-22,2023,CN 202310836581 A,2018-08-10,US 201762543635 P;;CN 201880059820 A;;IB 2018056059 W,2017-08-10,Heat exchange device,"The present invention relates to a heat exchange device configured to regulate the temperature of the esophagus, comprising: an elongate shaft comprising a distal end and a proximal end, the elongate shaft defining at least a first lumen and a second lumen; a handle attached to the proximal end of the elongate shaft; a heat exchanger attached to the distal end of the elongate shaft, the heat exchanger including a distal end, a proximal end, and a cavity therebetween, at least a portion of the cavity being in fluid communication with the first and second cavities of the elongate shaft, the heat exchanger including an insertable configuration, wherein the cross-section of the heat exchanger in the insertable configuration is smaller than the cross-section of the heat exchanger in the heat exchange configuration, and wherein the heat exchanger is expandable and constrained on the axis of the cross-section such that, when expanded to the heat exchange configuration, the heat exchanger has a smaller cross-section than the cross-section of the heat exchanger in the insertable configuration. The cross-sectional shape of the heat exchanger is substantially elliptical in a direction transverse to the longitudinal axis of the heat exchanger.",BOSTON SCIENT SCIMED EQUIPMENT INC,HARTLEY AMANDA;;DAVIES GARETH;;CENTAZZO-COLELLA AMANDA;;YOUNG NOAH;;AVARI HAMID;;AL-SAFFAR YASSER;;SHAH KISHAN;;HERBERT-COPLEY ANDREW;;WIERZBICKI RAMUNAS;;GERBER DMITRY,,https://lens.org/127-721-130-358-242,Patent Application,no,0,0,20,20,0,A61F7/12;;A61F7/123;;A61B18/1492;;A61N1/362;;A61B2018/00005;;A61B2018/00023;;A61B2018/00029;;A61B2018/00035;;A61B2018/0022;;A61B2018/00285;;A61B2018/00291;;A61B2018/00488;;A61B2018/00797;;A61F2007/0054;;A61F2007/0059;;A61F2007/0075;;A61F2007/0096;;A61B2090/065;;A61B2034/2051;;A61B2090/3966;;A61B5/6853;;A61B5/01;;A61B5/25;;A61F7/123;;A61B5/4233;;A61B5/25;;A61F2007/0054;;A61F2007/0086;;A61F2007/0096;;A61B6/487;;A61B6/032;;A61B5/055;;A61B5/28;;A61B90/04;;A61B2090/0418;;A61B2090/0463;;A61B2090/061;;A61B2090/374;;A61B2090/3762;;A61B2090/3966;;A61B2090/3983;;A61B18/04;;A61B2017/00557;;A61B2018/00023;;A61B2018/00035;;A61B2018/00357;;A61B2018/00791;;A61B2018/00839;;A61B2018/0091;;A61B2018/0212;;A61F7/123;;A61F2007/0054;;A61F2007/0056;;A61F2007/0075;;A61F2007/101;;A61M25/1002;;A61M2025/1013;;A61M2025/1084;;A61M2210/105;;A61N1/0517;;A61N1/362;;A61B5/287;;A61B18/02;;A61B2018/00577;;A61B2018/00797;;A61M2025/1043;;A61F7/0085;;A61F7/12;;A61F2007/0091;;A61F2007/0096;;A61F2007/126,A61F7/12;;A61B5/00;;A61B5/283;;A61B5/285;;A61B5/367;;A61B18/00;;A61N1/05;;A61N1/362,,0,0,,,,PENDING
979,NZ,A,NZ 508290 A,160-991-907-925-063,2003-09-26,2003,NZ 50829099 A,1999-06-15,GB 9813576 A;;GB 9901897 W,1998-06-24,"A substituted triazolo-pyridazine derivative, pharmaceutical compostions made therefrom","Disclosed is the compound 7-(1,1-Dimethylethyl)-6-(2- ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)- 1,2,4-triazolo[4,3-b]pyridazine. The above compound is used in the manufacture of medicaments for the treatment and/or prevention of anxiety.",MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;COWDEN CAMERON JOHN;;DAVIES ANTONY JOHN;;MADIN ANDREW;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD STEPHEN;;STREET LESLIE JOSEPH;;CASTROPINEIRO JOSE LUIS,,https://lens.org/160-991-907-925-063,Patent Application,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,PENDING
980,EP,A1,EP 3558436 A1,014-531-699-269-928,2019-10-30,2019,EP 17885285 A,2017-12-19,US 201662437916 P;;US 201662437946 P;;US 201762569055 P;;IB 2017058137 W,2016-12-22,STEERABLE MEDICAL DEVICE,,BAYLIS MEDICAL CO INC,CHEN JAN-HUNG;;LAU KANDICE;;OLDHAM LORRAINE;;THOMPSON SMITH MELANIE;;KUSINS JONATHAN;;DAVIES GARETH;;CHAN AUDREY;;ALNABELSEYA AHMED;;PEQUEGNAT ANDREW;;ALLEY FERRYL;;BRUGHA CATHAL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-08-31),https://lens.org/014-531-699-269-928,Patent Application,yes,0,0,6,9,0,A61M25/0136;;A61M25/0147;;A61B1/0052;;A61B1/00042;;A61M25/0136;;A61B1/00042,A61M25/01,,0,0,,,,PENDING
981,WO,A1,WO 2018/116162 A1,134-403-077-622-947,2018-06-28,2018,IB 2017058137 W,2017-12-19,US 201662437916 P;;US 201662437946 P;;US 201762569055 P,2016-12-22,STEERABLE MEDICAL DEVICE,"A method and apparatus are disclosed for a steerable catheter control handle for deflecting a catheter. The control handle comprises an actuator and a means for deflecting the catheter upon actuation of the actuator, the means for deflecting being coupled to the actuator. The control handle further comprises an inefficiency generator configured to interact with the means for deflecting the catheter, wherein the inefficiency generator provides increasing resistance to actuation, requiring increasing force required to actuate the actuator upon increasing deflection of the catheter.",BAYLIS MEDICAL CO INC;;BAYLIS MEDICAL USA INC,CHEN JAN-HUNG;;LAU KANDICE;;OLDHAM LORRAINE;;THOMPSON SMITH MELANIE;;KUSINS JONATHAN;;DAVIES GARETH;;CHAN AUDREY;;ALNABELSEYA AHMED;;PEQUEGNAT ANDREW;;ALLEY FERRYL;;BRUGHA CATHAL,,https://lens.org/134-403-077-622-947,Patent Application,yes,12,3,6,9,0,A61M25/0136;;A61M25/0147;;A61B1/0052;;A61B1/00042;;A61M25/0136;;A61B1/00042,A61M25/01,,0,0,,,,PENDING
982,CA,A1,CA 3074129 A1,032-612-135-673-666,2019-02-14,2019,CA 3074129 A,2018-08-10,US 201762543635 P;;IB 2018056059 W,2017-08-10,HEAT EXCHANGE AND TEMPERATURE SENSING DEVICE AND METHOD OF USE,"A method and apparatus are disclosed for regulating a temperature of an esophagus when heat or cold is delivered to a left atrium, the method including altering a heat exchange device from an insertable configuration to a heat exchanging configuration which conforms and corresponds with a cross-section of an inside of the esophagus such that the esophagus is maintained in its natural shape and location. In some embodiments the heat exchange device has a heating/cooling balloon which is inflated to be in the heat exchanging configuration. Some alternative embodiments includes altering the configuration of the balloon to conform to or correspond with the cross section of an esophagus by means other than inflation.",BAYLIS MEDICAL CO INC,HARTLEY AMANDA;;DAVIES GARETH;;CENTAZZO-COLELLA AMANDA;;YANG NOAH NUOXU;;AVARI HAMED;;AL-SAFFAR YASIR;;SHAH KISHAN;;HERBERT-COPLEY ANDREW;;WIERZBICKI RAMUNAS;;GERBER DMITRY,,https://lens.org/032-612-135-673-666,Patent Application,no,0,0,20,20,0,A61F7/12;;A61F7/123;;A61B18/1492;;A61N1/362;;A61B2018/00005;;A61B2018/00023;;A61B2018/00029;;A61B2018/00035;;A61B2018/0022;;A61B2018/00285;;A61B2018/00291;;A61B2018/00488;;A61B2018/00797;;A61F2007/0054;;A61F2007/0059;;A61F2007/0075;;A61F2007/0096;;A61B2090/065;;A61B2034/2051;;A61B2090/3966;;A61B5/6853;;A61B5/01;;A61B5/25;;A61F7/123;;A61B5/4233;;A61B5/25;;A61F2007/0054;;A61F2007/0086;;A61F2007/0096;;A61B6/487;;A61B6/032;;A61B5/055;;A61B5/28;;A61B90/04;;A61B2090/0418;;A61B2090/0463;;A61B2090/061;;A61B2090/374;;A61B2090/3762;;A61B2090/3966;;A61B2090/3983;;A61B18/04;;A61B2017/00557;;A61B2018/00023;;A61B2018/00035;;A61B2018/00357;;A61B2018/00791;;A61B2018/00839;;A61B2018/0091;;A61B2018/0212;;A61F7/123;;A61F2007/0054;;A61F2007/0056;;A61F2007/0075;;A61F2007/101;;A61M25/1002;;A61M2025/1013;;A61M2025/1084;;A61M2210/105;;A61N1/0517;;A61N1/362;;A61B5/287;;A61B18/02;;A61B2018/00577;;A61B2018/00797;;A61M2025/1043;;A61F7/0085;;A61F7/12;;A61F2007/0091;;A61F2007/0096;;A61F2007/126,A61F7/12;;A61B5/00;;A61B5/0408;;A61F7/00;;A61N1/362,,0,0,,,,PENDING
983,US,B1,US 6630471 B1,044-477-793-236-990,2003-10-07,2003,US 71918401 A,2001-02-01,GB 9813576 A;;GB 9901897 W,1998-06-24,"Substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom","
    7-(1,1 -Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo4,3-bpyridazine, and pharmaceutically acceptable salts thereof are selective ligands for GABA _{ A } receptors useful in the treatment of disorders of the central nervous system. 
",MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;CASTRO PINEIRO JOSE LUIS;;COWDEN CAMERON JOHN;;DAVIES ANTONY JOHN;;MADIN ANDREW;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD;;STREET LESLIE JOSEPH,MERCK SHARP & DOHME LTD (2000-10-31),https://lens.org/044-477-793-236-990,Granted Patent,yes,1,10,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,514/248;;544/236,4,4,060-878-076-134-948;;062-406-253-175-79X;;051-204-631-537-977;;066-650-394-271-144,8794909;;10.1007/bf02245597;;8539335;;22302946;;10.1177/026988119601000305;;8930150,"K.A. Wafford et al., Molecular Pharmacology, 50: 670-678 (1996).;;G.R. Dawson et al., Pharmacology, 121: 109-117 (1995).;;P.J. Bayley et al., J. Psychopharmacology, 10: 206-213 (1996).;;L.J. Bristow et al., J. Pharmacology and Exp. Ther., 279: 492-501 (1996).",EXPIRED
984,EP,A4,EP 3558436 A4,062-741-521-480-28X,2020-09-09,2020,EP 17885285 A,2017-12-19,US 201662437916 P;;US 201662437946 P;;US 201762569055 P;;IB 2017058137 W,2016-12-22,STEERABLE MEDICAL DEVICE,,BAYLIS MEDICAL CO INC,CHEN JAN-HUNG;;LAU KANDICE;;OLDHAM LORRAINE;;THOMPSON SMITH MELANIE;;KUSINS JONATHAN;;DAVIES GARETH;;CHAN AUDREY;;ALNABELSEYA AHMED;;PEQUEGNAT ANDREW;;ALLEY FERRYL;;BRUGHA CATHAL,BOSTON SCIENTIFIC MEDICAL DEVICE LIMITED (2022-08-31),https://lens.org/062-741-521-480-28X,Search Report,no,1,0,6,9,0,A61M25/0136;;A61M25/0147;;A61B1/0052;;A61B1/00042;;A61M25/0136;;A61B1/00042,A61M25/01;;A61B1/00;;A61B1/005,,0,0,,,,PENDING
985,NO,L,NO 20006576 L,042-299-637-753-45X,2001-02-14,2001,NO 20006576 A,2000-12-21,GB 9813576 A;;GB 9901897 W,1998-06-24,Et substituert triazol-pyridazinderivat og farmasöytiske preparater fremstilt av dette,,MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;PINEIRO JOSE LUIS CASTRO;;COWDEN CAMERON JOHN;;DAVIES ANTHONY JOHN;;MADIN ANDREW;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD STEPHEN;;STREET LESLIE JOSEPH,,https://lens.org/042-299-637-753-45X,Abstract,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,EXPIRED
986,NO,D0,NO 20006576 D0,162-270-662-911-095,2000-12-21,2000,NO 20006576 A,2000-12-21,GB 9813576 A;;GB 9901897 W,1998-06-24,Et substituert triazol-pyridazinderivat og farmasöytiske preparater fremstilt av dette,,MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;PINEIRO JOSE LUIS CASTRO;;COWDEN CAMERON JOHN;;DAVIES ANTHONY JOHN;;MADIN ANDREW;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD STEPHEN;;STREET LESLIE JOSEPH,,https://lens.org/162-270-662-911-095,Patent Application,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,EXPIRED
987,CZ,B6,CZ 291409 B6,024-554-022-291-407,2003-03-12,2003,CZ 20004872 A,1999-06-15,GB 9813576 A,1998-06-24,Substituted triazolo-pyridazine derivative,"In the present invention there is disclosed a substituted triazolo-pyridazine derivative 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,-triazolo[4,3-b]pyridazine and salts thereof. These compounds exhibit anti-anxiety activity and they can be therefore used in the form of a pharmaceutical preparation for treating various anxiety states including panic reactions. In the invention, there are also described processes for preparing specified active substances.",MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;CASTRO PINEIRO JOSE LUIS;;COWDEN CAMERON JOHN;;DAVIES ANTONY JOHN;;MADIN ANDREW;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD STEPHEN;;STREET LESLIE JOSEPH,,https://lens.org/024-554-022-291-407,Granted Patent,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,EXPIRED
988,EE,A,EE 200000767 A,041-465-103-658-540,2002-06-17,2002,EE P200000767 A,1999-06-15,GB 9813576 A;;GB 9901897 W,1998-06-24,"Asendatud triasolopüridasiini derivaat, selle valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon",,MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;STREET LESLIE JOSEPH;;PINEIRO JOSE LUIS CASTRO;;COWDEN CAMERON JOHN;;DAVIES ANTONY JOHN;;MADIN ANDREW;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD STEPHEN,,https://lens.org/041-465-103-658-540,Patent Application,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,PENDING
989,ID,A,ID 27771 A,105-252-445-656-925,2001-04-26,2001,ID 20002717 A,1999-06-15,GB 9813576 A,1998-06-24,"TURUNAN TRIAZOL-PIRIDAZIN TERSUBSTITUSI, KOMPOSISI FARMASI YANG DIBUAT DARI BAHAN ITU",,MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;DAVIES ANTONY JOHN;;PEARCE GARETH EDWARD STEPHEN;;PINEIRO JOSE LUIS CASIRO;;MADIN ANDREW;;SIREET LESLIE JOSEPH;;COWDEN CAMERON JOHN;;MCCABE JAMES FRANCIS,,https://lens.org/105-252-445-656-925,Patent Application,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,PENDING
990,GE,B,GE P20033143 B,028-328-176-453-632,2003-12-25,2003,GE AP1999005726 A,1999-06-15,GB 9813576 A,1998-06-24,"A Substituted Triazolo-Pyridazine Derivative, Method for its Production, Pharmaceutical Compositions Made Therefrom for Treatment of Disorders of the Central Nervous System","1. Technical Result Increase in treatment efficiency of disorders of the central nervous system. 2. Essence 7- (1, 1- Dimethylethyl) -6 - (2-ethyl- 2H- 1, 2, 4- triazol- 3-ylmethoxy) -3- (2-fluorophenyl) - 1,2,4-triazolo[4,3-b]pyridazine, and pharmaceu-tically acceptable salts thereof, are selective ligands for GABAA receptors, in particular having high affinity for the alpha 2 and/or alpha 3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system. Method for its production and pharmaceutical compositions made therefrom for treatment and/or prevention of disorders of the central nervous system. 3. Field of Application Medicine. Tables: 8",MERCK SHARP & DOHME,PEARCE GARETH EDWARD STEPHEN;;MADIN ANDREW;;COWDEN CAMERON JOHN;;STREET LESLIE JOSEPH;;MCCABE JAMES FRANCIS;;DAVIES ANTONY JOHN;;CASTRO PINEIRO JOSE LUIS;;CARLING WILLIAM ROBERT,,https://lens.org/028-328-176-453-632,Granted Patent,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/50;;A61K31/5025;;A61P25/00;;A61P25/22,,0,0,,,,EXPIRED
991,DE,D1,DE 69907675 D1,068-735-701-695-760,2003-06-12,2003,DE 69907675 T,1999-06-15,GB 9813576 A;;GB 9901897 W,1998-06-24,"EIN SUBSTITUIERTES TRIAZOLO-PYRIDAZIN-DERIVAT, DAVON HERGESTELLTE ARZNEIMITTEL",,MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;CASTRO PINEIRO JOSE LUIS;;COWDEN CAMERON JOHN;;DAVIES ANTONY JOHN;;MADIN ANDREW;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD STEPHEN;;STREET LESLIE JOSEPH,,https://lens.org/068-735-701-695-760,Granted Patent,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,EXPIRED
992,WO,A1,WO 1999/067245 A1,093-605-741-683-060,1999-12-29,1999,GB 9901897 W,1999-06-15,GB 9813576 A,1998-06-24,"A SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVE, PHARMACEUTICAL COMPOSITIONS MADE THEREFROM","7- (1, 1- Dimethylethyl) -6 - (2-ethyl- 2H- 1, 2, 4- triazol- 3-ylmethoxy) -3- (2-fluorophenyl) - 1,2,4-triazolo[4,3-b]pyridazine, and pharmaceutically acceptable salts thereof, are selective ligands for GABAA receptors, in particular having high affinity for the α2 and/or α3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.",MERCK SHARP & DOHME;;CARLING WILLIAM ROBERT;;CASTRO PINEIRO JOSE LUIS;;COWDEN CAMERON JOHN;;DAVIES ANTONY JOHN;;MADIN ANDREW;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD STEPHEN;;STREET LESLIE JOSEPH,CARLING WILLIAM ROBERT;;CASTRO PINEIRO JOSE LUIS;;COWDEN CAMERON JOHN;;DAVIES ANTONY JOHN;;MADIN ANDREW;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD STEPHEN;;STREET LESLIE JOSEPH,,https://lens.org/093-605-741-683-060,Patent Application,yes,1,18,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,PATENTED
993,HU,A2,HU P0102894 A2,091-949-323-883-189,2001-11-28,2001,HU P0102894 A,1999-06-15,GB 9813576 A;;GB 9901897 W,1998-06-24,"A SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM","A találmány egy szubsztituált triazolopiridazin-származékra, ezt avegyületet tartalmazó gyógyászati készítményekre, illetve ennek avegyületnek gyógyászati készítmények előállításához való alkalmazásáravonatkozik. Közelebbről a találmány az (I) képletű 7-(1,1-dimetiletil)-6-(2-etil-2H-1,2,4-triazol-3-ilmetoxi)-3-(2-fluorfenil)-1,2,4-triazolo[4,3-b]piridazinra vonatkozik, amely egy GABAA receptorligandum és így felhasználható különböző káros mentális állapotokkezelésére. A találmány értelmében az (I) képletű vegyületet úgyállítják elő, hogy a) valamely (III) általános képletű vegyületet - aképletben L1 jelentése kilépő csoport - a (IV) képletű vegyülettelreagáltatják, vagy b) a (XI) képletű vegyületet vagy 1,2,4-triazolo[4,3-b]piridazin-6-on tautomerjét valamely (XII) általánosképletű vegyülettel - a képletben L3 jelentése kilépő csoport -reagáltatják, vagy c) trimetilecetsavat a (XIII) képletű vegyülettelreagáltatják ezüstnitrát és ammóniumperszulfát jelenlétében, vagy d)valamely (XIV) általános képletű vegyületet - a képletben L4 jelentésekilépő csoport - valamely (XV) általános képletű vegyülettel - aképletben M jelentése -B(OH)2 vagy Sn(Alk)3 általános képletű csoport,és az utóbbiban Alk jelentése 1-6 szénatomot tartalmazó alkilcsoport,jellegzetesen n=butilcsoport - reagáltatnak egy átmenetifémkatalizátor jelenlétében. Ó",MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;CASTRO PINEIRO JOSE LUIS;;COWDEN CAMERON JOHN;;DAVIES ANTONY JOHN;;MADIN ANDREW;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD STEPHEN;;STREET LESLIE JOSEPH,,https://lens.org/091-949-323-883-189,Patent Application,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,PENDING
994,BR,A,BR 9911563 A,014-630-225-429-524,2001-03-20,2001,BR 9911563 A,1999-06-15,GB 9813576 A;;GB 9901897 W,1998-06-24,"Composto, composição farmacêutica, uso de 7- (1,1- dimetiletil) -6- (2- etil - 2h - 1,2,4- triazol -3- ilmetoxi) -3- (2- fluorofenil) - 1,2,4- triazol [4,3b] piridazina, e, processos para a preparação de 7- (1,1- dimetiletil) -6- (2- etil - 2h - 1,2,4- triazol -3- ilmetoxi) -3- (2- fluorofenil) - 1,2,4- triazol [4, 3b] piridazina, e para o tratamento e/ou prevenção de ansiedade","""COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE 7- (1,1- DIMETILETIL)-6-(2- ETIL - 2H - 1,2,4- TRIAZOL -3- ILMETOXI)-3-(2-FLUOROFENIL)- 1,2,4- TRIAZOL [4,3B] PIRIDAZINA, E, PROCESSOS PARA A PREPARAçãO DE 7- (1,1- DIMETILETIL)-6-(2- ETIL - 2H - 1,2,4- TRIAZOL -3- ILMETOXI)-3-(2- FLUOROFENIL)- 1,2,4- TRIAZOL [4,3B] PIRIDAZINA, E PARA O TRATAMENTO E/OU PREVENçãO DE ANSIEDADE"" 7- (1,1- dimetiletil)-6-(2- etil - 1,2,4- triazol -3- ilmetoxi)-3-(2- fluorofenil)- 1,2,4- triazol [4,3b] piridazina, e sais farmaceuticamente aceitáveis do mesmo, são ligandos seletivos para receptores GABA~ A~, particularmente tendo alta afinidade com a subunidade <244>2 e/ou <244>3 dos mesmos, e, consequentemente, são de benefício no tratamento e/ou prevenção de distúrbios do sis>tema nervoso central, incluindo ansiedade e convulsões.",MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;PINEIRO JOSE LUIS CASTRO;;COWDEN CAMERON JOHN;;DAVIES ANTONY JOHN;;MADIN ANDREW;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD STEPHEN;;STREET LESLIE JOSEPH,,https://lens.org/014-630-225-429-524,Patent Application,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,DISCONTINUED
995,YU,A,YU 77800 A,012-563-957-322-378,2003-10-31,2003,YU 77800 A,1999-06-15,GB 9813576 A,1998-06-24,"A SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVE, PHARMACEUTICAL COMPOSITIONS MADE THEREFROM","7- (1, 1- Dimethylethyl) -6 - (2-ethyl- 2i(H)- 1, 2, 4- triazol- 3-ylmethoxy) -3- (2-fluorophenyl) -1,2,4-triazolo[4,3-i(b)]pyridazine, and pharmaceu tically acceptable salts thereof, are selective ligands for GABAA receptors, in particular having high affinity for the α2 and/or α3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.",MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;DAVIES ANTONY JOHN;;PEARCE GARETH EDWARD STEPHEN;;CASTRO PINEIRO JOSE LUIS;;MADIN ANDREW;;STREET LESLIE JOSEPH;;COWDEN CAMERON JOHN;;MCCABE JAMES FRANCIS,,https://lens.org/012-563-957-322-378,Patent Application,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,EXPIRED
996,ZA,B,ZA 200007485 B,043-013-102-036-462,2002-01-07,2002,ZA 200007485 A,2000-12-14,GB 9813576 A,1998-06-24,"A substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom.",,MERCK SHARP & DOHME,ROBERT CARLING WILLIAM;;LUIS CASTRO PINEIRO JOSE;;JOHN COWDEN CAMERON;;JOHN DAVIES ANTONY;;MADIN ANDREW;;FRANCIS MCCABE JAMES;;STEPHEN PEARCE GARETH EDWARD;;JOSEPH STREET LESLIE,,https://lens.org/043-013-102-036-462,Granted Patent,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,EXPIRED
997,PL,B1,PL 204650 B1,152-929-806-328-385,2010-01-29,2010,PL 34533299 A,1999-06-15,GB 9901897 W;;GB 9813576 A,1998-06-24,"A SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVE, PHARMACEUTICAL COMPOSITIONS MADE THEREFROM",,MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;CASTRO PINEIRO JOSE LUIS;;COWDEN CAMERON JOHN;;DAVIES ANTONY JOHN;;MADIN ANDREW;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD STEPHEN;;STREET LESLIE JOSEPH,,https://lens.org/152-929-806-328-385,Granted Patent,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/4196;;A61K31/50;;A61K31/5025;;A61P25/00;;A61P25/22;;C07D237/00;;C07D249/00,,0,0,,,,EXPIRED
998,WO,A1,WO 2023/091461 A1,147-924-934-065-432,2023-05-25,2023,US 2022/0050065 W,2022-11-16,US 202163281140 P,2021-11-19,PYRIDINE COMPOUNDS AS KV7.2 ENHANCERS,"The invention provides new heterocyclic compounds having the general formula (I), or a solvate or a pharmaceutically acceptable salt thereof: Formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.",ICAGEN LLC;;HOFFMANN LA ROCHE;;HOFFMANN LA ROCHE,LEBRETON SYLVAIN;;GERLACH AARON;;REDONDO ROGER;;NORCROSS ROGER;;MOWREY DAVID;;NAIR ANIL;;SAFAROVA ALENA;;SMRCINA MARTIN;;DAVIES NICHOLAS GARETH;;NAGARAJAN KARTHIGEYAN;;CHAPMAN MARK;;MECHIN INGRID,,https://lens.org/147-924-934-065-432,Patent Application,yes,3,0,1,1,0,C07D405/14;;C07D401/12;;C07D213/42,C07D405/14;;A61K31/443;;A61K31/4433;;A61K31/4439;;A61P25/00;;C07D213/42;;C07D401/12,,55,53,011-102-971-425-842;;088-445-410-132-706;;032-939-734-807-157;;035-913-093-166-006;;074-295-960-076-615;;043-275-298-093-839;;011-416-379-106-676;;136-700-130-050-516;;015-913-299-856-744;;154-529-993-520-46X;;025-842-944-152-801;;029-915-258-094-672;;047-245-923-846-487;;022-925-871-868-618;;044-934-736-100-430;;025-410-286-672-848;;091-207-799-320-32X;;045-036-478-119-594;;017-074-297-236-339;;090-048-844-887-201;;003-665-408-103-763;;090-003-826-964-825;;099-464-315-407-751;;029-973-170-994-153;;044-318-116-405-680;;026-387-514-747-05X;;053-751-970-141-42X;;132-213-230-553-416;;012-025-743-566-846;;116-073-860-432-553;;178-118-084-470-375;;000-396-777-979-259;;035-549-067-065-596;;007-179-611-004-738;;041-037-627-402-254;;024-112-888-096-225;;068-476-578-392-807;;061-637-806-242-983;;022-680-621-812-221;;093-852-272-829-140;;028-285-592-286-119;;043-233-200-924-396;;024-585-315-019-10X;;146-343-101-132-563;;027-944-500-763-687;;020-328-035-038-610;;012-484-409-580-549;;072-219-470-256-982;;001-923-944-460-664;;025-212-926-377-605;;006-325-569-600-822;;104-310-480-694-456;;093-649-658-810-262,10.1101/2020.11.27.401570;;10.1093/brain/awab141;;33768249;;pmc8536937;;10.1017/s0012162201002833;;10.1111/j.1469-8749.2002.tb00277.x;;12418611;;pmc2697739;;10.1111/j.1476-5381.2009.00111.x;;19298256;;pmc8114617;;33987468;;10.1515/biol-2020-0003;;26243502;;10.1016/j.ijporl.2015.07.024;;28229394;;10.1007/s11910-017-0720-7;;23563578;;10.1038/nn.3376;;10.1016/j.biopsych.2021.07.018;;pmc8571044;;34538422;;10.1101/286336;;pmc2865483;;20398390;;10.1186/1824-7288-36-31;;10.1016/j.neuron.2017.11.028;;29301104;;10.7554/elife.50333;;31782729;;pmc6905854;;22220513;;10.1111/j.1528-1167.2011.03365.x;;29052611;;10.1038/nrdp.2017.85;;28980624;;10.1038/nrdp.2017.72;;10.1038/nrdp.2017.71;;10.1111/epi.13506;;27554343;;pmc5547884;;10.1159/000158538;;18827480;;pmc3030994;;10.1093/brain/awl024;;16467388;;10.1136/jnnp-2011-301782;;22566594;;23621294;;10.1111/epi.12200;;pmc5364175;;10.3389/fnagi.2017.00071;;28392767;;pmc7324798;;32655623;;10.3389/fgene.2020.00614;;pmc7050516;;10.1111/gbb.12599;;31283873;;10.1124/jpet.105.083923;;15814569;;10.1152/jn.00665.2003;;14523070;;28459436;;10.1038/nm.4330;;pmc5461182;;10.1016/j.neuropharm.2008.04.006;;18474382;;31199083;;pmc6625149;;10.1002/mgg3.816;;10.1073/pnas.1302770110;;23716673;;pmc3683764;;26553995;;pmc4664349;;10.1073/pnas.1515228112;;pmc7347277;;32039504;;10.1096/fj.201902435r;;10.1177/1362361321991255;;33645260;;pmc8264631;;20840535;;pmc3012405;;10.1111/j.1476-5381.2010.01027.x;;10.1016/j.neulet.2011.09.013;;21945947;;10.1016/j.neuron.2007.07.025;;pmc8055171;;17785178;;10.1038/nrn1971;;16924260;;21962519;;10.1016/j.cell.2011.08.040;;pmc3390029;;30254520;;10.5698/1535-7597.18.4.240;;pmc6145379;;10.7554/elife.38617;;30382937;;pmc6211828;;28649286;;pmc5481888;;10.1186/s11689-017-9202-0;;pmc6533171;;10.1038/s41593-018-0080-x;;29403035;;pmc6494706;;10.1038/s41380-018-0283-2;;30385872;;10.1016/j.dcn.2017.04.010;;pmc6987885;;28545994;;pmc4013391;;23835471;;10.1001/jamaneurol.2013.136;;10897150;;10.1111/j.1528-1157.2000.tb00246.x;;pmc4023477;;24703839;;10.1016/j.celrep.2014.03.019;;33226425;;10.1001/jamaneurol.2020.4300;;pmc7684515;;9836639;;10.1126/science.282.5395.1890;;10.1089/neu.2016.4789;;pmc5359643;;28073317;;10.1186/1744-8069-6-49;;20796319;;pmc2936374;;pmc6216232;;10.1093/hmg/ddy292;;30107516;;31642496;;pmc7145562;;10.1093/nar/gkz923;;915158;;10.1021/ja00464a050;;10.1002/anie.199620561;;10.1002/9781118662083,"AIBA, INOEBELS, J. L.: ""Kcnq2/Kv7.2 controls the threshold and bihemispheric symmetry of cortical spreading depolarization"", BRAIN: A JOURNAL OF NEUROLOGY, 2021;;BERRY-KRAVIS, E: ""Developmental medicine and child neurology"", vol. 44, 2002, WILEY ONLINE LIBRARY, article ""Epilepsy in fragile X syndrome"", pages: 724 - 728;;BROWN, D. A.PASSMORE, G. M.: ""Neural KCNQ (Kv7) channels"", BRITISH JOURNAL OF PHARMACOLOGY, vol. 156, no. 8, 2009, pages 1185 - 1195, XP071170581, DOI: 10.1111/j.1476-5381.2009.00111.x;;BUDISTEANU, M. ET AL.: ""Open life sciences"", vol. 15, 2020, WALTER DE GRUYTER GMBH, article ""Treatment of Epilepsy Associated with Common Chromosomal Developmental Diseases"", pages: 21 - 29;;DANESH, A. A. ET AL.: ""Tinnitus and hyperacusis in autism spectrum disorders with emphasis on high functioning individuals diagnosed with Asperger's Syndrome"", INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, vol. 79, no. 10, 2015, pages 1683 - 1688, XP029273251, DOI: 10.1016/j.ijporl.2015.07.024;;VON DEIMLING, M.HELBIG, IMARSH, E. D: ""Epileptic Encephalopathies-Clinical Syndromes and Pathophysiological Concepts"", CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, vol. 17, no. 2, 2017, pages 10, XP036195111, DOI: 10.1007/s11910-017-0720-7;;DOLEV, I. ET AL.: ""Spike bursts increase amyloid-(3 40/42 ratio by inducing a presenilin-1 conformational change"", NATURE NEUROSCIENCE, vol. 16, no. 5, 2013, pages 587 - 595;;FINK, J. J. ET AL.: ""Hyperexcitable phenotypes in iPSC-derived neurons from patients with 15q1 1-q13 duplication syndrome, a genetic form of autism"", BIORXIV, 2018, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/286336v1>;;FIUMARA, A. ET AL.: ""Epilepsy in patients with Angelman syndrome"", ITALIAN JOURNAL OF PEDIATRICS, 2010, pages 31, XP021084914, DOI: 10.1186/1824-7288-36-31;;FRERE, SSLUTSKY, I: ""Alzheimer's Disease: From Firing Instability to Homeostasis Network Collapse"", NEURON, vol. 97, no. 1, 2018, pages 32 - 58, XP085330535, DOI: 10.1016/j.neuron.2017.11.028;;GHATAK, S. ET AL.: ""Mechanisms of hyperexcitability in Alzheimer's disease hiPSC-derived neurons and cerebral organoids vs isogenic controls"", ELIFE, 2019, pages 8;;GUNTHORPE, M. J.LARGE, C. HSANKAR, R: ""The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy"", EPILEPSIA, vol. 53, no. 3, 2012, pages 412 - 424;;HARDIMAN, O. ET AL.: ""Amyotrophic lateral sclerosis"", NATURE REVIEWS. DISEASE PRIMERS, vol. 3, 2017, pages 17071;;HOLDER, J. L., JRQUACH, M. M.: ""The spectrum of epilepsy and electroencephalographic abnormalities due to SHANK3 loss-of-function mutations"", EPILEPSIA, vol. 57, no. 10, 2016, pages 1651 - 1659;;JIN, Z. ET AL.: ""Expression and localization of K channels KCNQ2 and KCNQ3 in the mammalian cochlea"", AUDIOLOGY & NEURO-OTOLOGY, vol. 14, no. 2, 2009, pages 98 - 105;;KANAI, K. ET AL.: ""Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage"", BRAIN: A JOURNAL OF NEUROLOGY, vol. 129, 2006, pages 953 - 962;;KANAI, K ET AL.: ""Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis"", JOURNAL OF NEUROLOGY, NEUROSURGERY, AND PSYCHIATRY, vol. 83, no. 7, 2012, pages 734 - 738;;KATO, M. ET AL.: ""Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation"", EPILEPSIA, vol. 54, no. 7, 2013, pages 1282 - 1287, XP071212289, DOI: 10.1111/epi.12200;;KAZIM, S. F. ET AL.: ""Early-Onset Network Hyperexcitability in Presymptomatic Alzheimer's Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/A(3 Antibody and by mGluR5 Blockade"", FRONTIERS IN AGING NEUROSCIENCE, vol. 9, 2017, pages 71;;KESSI, M. ET AL.: ""Intellectual Disability and Potassium Channelopathies: A Systematic Review"", FRONTIERS IN GENETICS, vol. 11, 2020, pages 614;;KIM, E. C. ET AL.: ""Heterozygous loss of epilepsy gene KCNQ2 alters social, repetitive, and exploratory behaviors"", GENES, BRAIN AND BEHAVIOR, 2019;;KORSGAARD, M. P. G. ET AL.: ""Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels"", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 314, no. 1, 2005, pages 282 - 292;;KUO, J. J. ET AL.: ""Hyperexcitability of cultured spinal motoneurons from presymptomatic ALS mice"", JOURNAL OF NEUROPHYSIOLOGY, vol. 91, no. 1, 2004, pages 571 - 575;;LAM, A. D. ET AL.: ""Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease"", NATURE MEDICINE, vol. 23, no. 6, 2017, pages 678 - 680;;LANG, P. M. ET AL.: ""Retigabine reduces the excitability of unmyelinated peripheral human axons"", NEUROPHARMACOLOGY, vol. 54, no. 8, 2008, pages 1271 - 1278, XP022684543, DOI: 10.1016/j.neuropharm.2008.04.006;;LEE, I.-C. ET AL.: ""KCNQ2 mutations in childhood nonlesional epilepsy: Variable phenotypes and a novel mutation in a case series"", MOLECULAR GENETICS & GENOMIC MEDICINE, vol. 7, no. 7, 2019, pages e00816;;LI, S.CHOI, V.TZOUNOPOULOS, T.: ""Pathogenic plasticity of Kv7.2/3 channel activity is essential for the induction of tinnitus"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 24, 2013, pages 9980 - 9985;;LIU, C.GLOWATZKI, E.FUCHS, P. A.: ""Unmyelinated type II afferent neurons report cochlear damage"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 112, no. 47, 2015, pages 14723 - 14727;;MCCULLAGH, E. A. ET AL.: ""Mechanisms underlying auditory processing deficits in Fragile X syndrome"", FASEB JOURNAL: OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, 2020;;NEUFELD, J. ET AL.: ""A co-twin-control study of altered sensory processing in autism"", AUTISM: THE INTERNATIONAL JOURNAL OF RESEARCH AND PRACTICE, vol. 25, no. 5, 2021, pages 1422 - 1432;;NG, F. L ET AL.: ""Expression and function of the K+ channel KCNQ genes in human arteries"", BRITISH JOURNAL OF PHARMACOLOGY, vol. 162, no. 1, 2011, pages 42 - 53, XP071129772, DOI: 10.1111/j.1476-5381.2010.01027.x;;NODERA, H. ET AL.: ""Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy"", NEUROSCIENCE LETTERS, vol. 505, no. 3, 2011, pages 223 - 227;;PALOP, J. J. ET AL.: ""Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease"", NEURON, vol. 55, no. 5, 2007, pages 697 - 711;;PASINELLI, P.BROWN, R. H.: ""Molecular biology of amyotrophic lateral sclerosis: insights from genetics"", NATURE REVIEWS. NEUROSCIENCE, vol. 7, no. 9, 2006, pages 710 - 723;;PENAGARIKANO, O. ET AL.: ""Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits"", CELL, vol. 147, no. 1, 2011, pages 235 - 246, XP028304231, DOI: 10.1016/j.cell.2011.08.040;;SIMKIN, DKISKINIS, E: ""Modeling Pediatric Epilepsy Through iPSC-Based Technologies"", EPILEPSY CURRENTS / AMERICAN EPILEPSY SOCIETY, vol. 18, no. 4, 2018, pages 240 - 245;;SOH, H. ET AL.: ""Deletion of KCNQ2/3 potassium channels from PV+ interneurons leads to homeostatic potentiation of excitatory transmission"", ELIFE, 2018, pages 7;;SRIVASTAVA, SSAHIN, M: ""Autism spectrum disorder and epileptic encephalopathy: common causes, many questions"", JOURNAL OF NEURODEVELOPMENTAL DISORDERS, vol. 9, 2017, pages 23;;STYR, BSLUTSKY, I: ""Imbalance between firing homeostasis and synaptic plasticity drives early-phase Alzheimer's disease"", NATURE NEUROSCIENCE, vol. 21, no. 4, 2018, pages 463 - 473, XP036468148, DOI: 10.1038/s41593-018-0080-x;;TAN, A. ET AL.: ""Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder"", MOLECULAR PSYCHIATRY, 2018;;THYE, M. D. ET AL.: ""Developmental cognitive neuroscience"", vol. 29, 2018, ELSEVIER, article ""The impact of atypical sensory processing on social impairments in autism spectrum disorder"", pages: 151 - 167;;VOSSEL, K. A. ET AL.: ""Seizures and epileptiform activity in the early stages of Alzheimer disease"", JAMA NEUROLOGY, vol. 70, no. 9, 2013, pages 1158 - 1166;;WAALER, P. E. ET AL.: ""Prevalence, classification, and severity of epilepsy in children in western Norway"", EPILEPSIA, vol. 41, no. 7, 2000, pages 802 - 810, XP071206469, DOI: 10.1111/j.1528-1157.2000.tb00246.x;;WAINGER, B. J. ET AL.: ""Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons"", CELL REPORTS, vol. 7, no. 1, 2014, pages 1 - 11, XP055218701, DOI: 10.1016/j.celrep.2014.03.019;;WAINGER, B. J. ET AL.: ""Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial"", JAMA NEUROLOGY, vol. 78, no. 2, 2021, pages 186 - 196;;WANG, H. S. ET AL.: ""Science"", vol. 282, 1998, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, article ""KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel"", pages: 1890 - 1893;;WU, Z ET AL.: ""Activation of KCNQ Channels Suppresses Spontaneous Activity in Dorsal Root Ganglion Neurons and Reduces Chronic Pain after Spinal Cord Injury"", JOURNAL OF NEUROTRAUMA, vol. 34, no. 6, 2017, pages 1260 - 1270;;XU, W ET AL.: ""Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats"", MOLECULAR PAIN, vol. 6, 2010, pages 49, XP021080422, DOI: 10.1186/1744-8069-6-49;;ZHANG, F. ET AL.: ""Human molecular genetics"", vol. 27, 2018, OXFORD ACADEMIC, article ""Fragile X mental retardation protein modulates the stability of its m6A-marked messenger RNA targets"", pages: 3936 - 3950;;ZHAO, G. ET AL.: ""Nucleic acids research"", vol. 48, 2020, OXFORD ACADEMIC, article ""Gene4Denovo: an integrated database and analytic platform for de novo mutations in humans"", pages: D913 - D926;;""McGraw-Hill Dictionary of Chemical Terms"", 1984, MCGRAW-HILL BOOK COMPANY;;""Stereochemistry of Organic Compounds"", 1994, JOHN WILEY & SONS, INC.;;BARANYR. B. MERRIFIELD, J. AM. CHEM. SOC., vol. 99, 1977, pages 7363;;H. WALDMANN ET AL., ANGEW. CHEM. INT. ED. ENGL., vol. 35, 1996, pages 2056;;RICHARD C. LAROCK: ""Comprehensive Organic Transformations: A Guide to Functional Group Preparations"", 1999, JOHN WILEY & SONS",PENDING
999,IS,A,IS 5730 A,192-842-756-206-425,2000-11-24,2000,IS 5730 A,2000-11-24,GB 9813576 A;;GB 9901897 W,1998-06-24,"Setin tíazóló-pýridazín afleiða, lyfjasamsetningar gerðar úr henni",,MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;PINEIRO JOSE LUIS CASTRO;;MADIN ANDREW;;STREET LESLIE JOSEPH;;COWDEN CAMERON JOHN;;DAVIES ANTONY JOHN;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD STEPHEN,,https://lens.org/192-842-756-206-425,Patent Application,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,EXPIRED
1000,TR,T2,TR 200003789 T2,034-066-561-248-280,2001-04-20,2001,TR 200003789 T,1999-06-15,GB 9813576 A,1998-06-24,İkameli triazolo-piridazin türevi ve bundan yapılan farmasötik bileşimler.,"7-(1,1-Dimetiletil)-6- (2-etil-2H-1,2,4-triazol-3-ilmetoksi) -3-(2-flüorofenil) -1,2,4-triazolo[4,3-b] piridazin ve bunun farmasötik açidan kabul edilen tuzlari olup, GABAA reseptörleri için, özellikle alfa2 ve/veya alfa3 alt ünitesi için yüksek uyum gösteren seçici ligantlardir ve buna uygun olarak, anksiyete ve konvülsiyonu da içeren merkezi sinir sistemi hastaliklarinin tedavisi ve/veya önlenmesinde yararlidir.",MERCK SHARP & DOHME,CARLING WILLIAM ROBERT;;PINEIRO JOSE LUIS CASTRO;;COWDEN CAMERON JOHN;;DAVIES ANTONY JOHN;;MADIN ANDREW;;MCCABE JAMES FRANCIS;;PEARCE GARETH EDWARD STEPHEN;;STREET LESLIE JOSEPH,,https://lens.org/034-066-561-248-280,Patent Application,no,0,0,53,53,0,C07D487/04;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/24;;C07D487/04;;C07D487/04,A61K31/5025;;A61P25/00;;A61P25/22;;C07D487/04,,0,0,,,,PENDING
